Immunostaining	O
and	O
confocal	O
analysis	O
DNA	O
labelling	O
and	O
staining	O
with	O
5	O
-	O
bromo	O
-	O
2	O
'	O
-	O
deoxyuridine	O
(	O
BrdU	O
labelling	O
and	O
detection	O
kit	O
I	O
;	O
Boehringer	O
Mannheim	O
,	O
Germany	O
)	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O
The	O
nucleoli	B-Anatomy
were	O
detected	O
with	O
an	O
anti	O
-	O
nucleolin	O
antibody	O
(	O
clone	O
3G4B2	O
;	O
Upstate	O
biotechnology	O
,	O
Lake	O
Placid	O
,	O
NY	O
)	O
on	O
cells	B-Anatomy
fixed	O
in	O
2	O
%	O
formalin	O
for	O
10	O
min	O
followed	O
by	O
permeabilization	O
with	O
ice	O
-	O
cold	O
methanol	O
for	O
30	O
min	O
.	O
The	O
secondary	O
antibody	O
used	O
for	O
both	O
BrdU	O
and	O
nucleoli	B-Anatomy
staining	O
was	O
a	O
rhodamine	O
(	O
tetra	O
-	O
methyl	O
)	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
antibody	O
(	O
T	O
-	O
2762	O
)	O
from	O
Molecular	O
Probe	O
(	O
Eugene	O
,	O
OR	O
)	O
.	O
The	O
cells	B-Anatomy
were	O
examined	O
in	O
a	O
Zeiss	O
LSM	O
510	O
laser	O
scanning	O
microscope	O
equipped	O
with	O
a	O
Plan	O
-	O
Apochromate	O
63x	O
/	O
1	O
.	O
4	O
oil	O
immersion	O
objective	O
.	O
We	O
used	O
the	O
488	O
nm	O
laser	O
line	O
for	O
excitation	O
of	O
EGFP	O
(	O
detected	O
at	O
505	O
nm	O
<	O
lambdaEGFP	O
<	O
530	O
nm	O
)	O
and	O
the	O
543	O
nm	O
laser	O
line	O
for	O
rhodamine	O
(	O
tetra	O
-	O
methyl	O
)	O
(	O
detected	O
at	O
lambdaRhodamine	O
>	O
560	O
nm	O
)	O
.	O
ECFP	O
fusion	O
protein	O
was	O
excited	O
with	O
a	O
458	O
nm	O
laser	O
line	O
(	O
detected	O
at	O
480	O
nm	O
<	O
lambdaECFP	O
<	O
520	O
nm	O
)	O
,	O
EYFP	O
fusion	O
protein	O
was	O
excited	O
with	O
a	O
514	O
nm	O
laser	O
line	O
(	O
lambdaEGFP	O
>	O
560	O
nm	O
)	O
and	O
HcRed	O
fusion	O
protein	O
was	O
excited	O
with	O
a	O
543	O
nm	O
laser	O
line	O
and	O
detected	O
at	O
>	O
585	O
or	O
650	O
nm	O
.	O
The	O
images	O
were	O
from	O
1	O
mum	O
thick	O
slices	B-Anatomy
of	O
the	O
cells	B-Anatomy
.	O
The	O
images	O
were	O
exported	O
into	O
Adobe	O
Photoshop	O
(	O
Adobe	O
Systems	O
Inc	O
.	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
.	O
Transcripts	O
Upregulated	O
in	O
ST	B-Anatomy
-	I-Anatomy
HSC	I-Anatomy
Compared	O
to	O
LT	B-Anatomy
-	I-Anatomy
HSC	I-Anatomy
(	O
181	O
KB	O
XLS	O
)	O
Results	O
OFTT	O
was	O
given	O
to	O
33	O
men	O
with	O
MetS	O
(	O
defined	O
by	O
the	O
Adult	O
Treatment	O
Panel	O
III	O
)	O
,	O
17	O
HTN	O
and	O
14	O
healthy	O
men	O
.	O
The	O
MetS	O
group	O
was	O
further	O
divided	O
according	O
to	O
fasting	O
triglycerides	O
(	O
TG	O
)	O
into	O
TG	O
>	O
=	O
150	O
[	O
MetS	O
+	O
TG	O
,	O
(	O
n	O
=	O
22	O
)	O
]	O
or	O
<	O
150	O
mg	O
/	O
dl	O
[	O
MetS	O
-	O
TG	O
(	O
n	O
=	O
11	O
)	O
]	O
,	O
and	O
into	O
those	O
with	O
or	O
without	O
hypertension	O
[	O
MetS	O
+	O
HTN	O
(	O
n	O
=	O
24	O
)	O
,	O
MetS	O
-	O
HTN	O
(	O
n	O
=	O
9	O
)	O
,	O
respectively	O
]	O
.	O
TG	O
concentrations	O
were	O
measured	O
before	O
and	O
at	O
4	O
,	O
6	O
and	O
8	O
h	O
after	O
OFTT	O
and	O
the	O
postprandial	O
response	O
was	O
quantified	O
using	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
for	O
TG	O
.	O
The	O
postprandial	O
response	O
was	O
significantly	O
higher	O
in	O
MetS	O
compared	O
to	O
HTN	O
and	O
healthy	O
men	O
[	O
AUC	O
(	O
SD	O
)	O
in	O
mg	O
/	O
dl	O
/	O
h	O
;	O
2534	O
+	O
/	O
-	O
1016	O
vs	O
.	O
1620	O
+	O
/	O
-	O
494	O
and	O
1019	O
+	O
/	O
-	O
280	O
,	O
respectively	O
,	O
p	O
<	O
=	O
0	O
.	O
001	O
]	O
.	O
The	O
TG	O
levels	O
were	O
increased	O
significantly	O
in	O
MetS	O
+	O
TG	O
compared	O
to	O
MetS	O
-	O
TG	O
subjects	O
at	O
4	O
(	O
p	O
=	O
0	O
.	O
022	O
)	O
,	O
6	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
8	O
hours	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
The	O
TG	O
were	O
increased	O
significantly	O
in	O
MetS	O
-	O
TG	O
compared	O
to	O
healthy	O
subjects	O
at	O
4	O
(	O
p	O
=	O
0	O
.	O
011	O
)	O
,	O
6	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
8	O
hours	O
(	O
p	O
=	O
0	O
.	O
015	O
)	O
.	O
In	O
linear	O
regression	O
analysis	O
only	O
fasting	O
TG	O
levels	O
were	O
a	O
significant	O
predictor	O
of	O
the	O
AUC	O
(	O
Coefficient	O
B	O
=	O
8	O
.	O
462	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
Conclusions	O
Only	O
after	O
careful	O
consideration	O
of	O
the	O
biological	O
underpinnings	O
of	O
a	O
truly	O
beneficial	O
response	O
can	O
an	O
exposure	O
be	O
considered	O
for	O
the	O
general	O
population	O
,	O
such	O
as	O
the	O
addition	O
of	O
folic	O
acid	O
to	O
cereals	O
.	O
If	O
a	O
toxic	O
or	O
hazardous	O
pollutant	O
were	O
found	O
to	O
have	O
truly	O
beneficial	O
effects	O
at	O
low	O
dose	O
,	O
then	O
that	O
agent	O
should	O
be	O
tested	O
clinically	O
,	O
go	O
through	O
the	O
U	O
.	O
S	O
.	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
approval	O
process	O
,	O
and	O
be	O
regulated	O
as	O
a	O
pharmaceutical	O
for	O
those	O
who	O
might	O
benefit	O
from	O
its	O
use	O
.	O
Certainly	O
,	O
the	O
general	O
population	O
should	O
not	O
be	O
exposed	O
to	O
chemotherapeutic	O
agents	O
that	O
benefit	O
cancer	B-Anatomy
patients	O
.	O
For	O
pharmaceuticals	O
,	O
it	O
is	O
understood	O
that	O
there	O
are	O
trade	O
offs	O
between	O
benefits	O
and	O
risks	O
.	O
For	O
example	O
,	O
although	O
aspirin	O
is	O
a	O
generally	O
well	O
-	O
tolerated	O
pain	O
reliever	O
and	O
is	O
increasingly	O
advocated	O
as	O
a	O
preventative	O
tool	O
for	O
heart	B-Anatomy
attacks	O
and	O
colorectal	B-Anatomy
cancer	I-Anatomy
(	O
Vainio	O
and	O
Miller	O
2003	O
;	O
Werner	O
et	O
al	O
.	O
2004	O
)	O
,	O
it	O
is	O
also	O
linked	O
to	O
increased	O
risk	O
of	O
gastrointestinal	B-Anatomy
bleeding	O
,	O
cerebral	B-Anatomy
hemorrhage	O
(	O
Werner	O
et	O
al	O
.	O
2004	O
)	O
,	O
and	O
asthma	O
attacks	O
(	O
Jenkins	O
et	O
al	O
.	O
2004	O
)	O
.	O
In	O
addition	O
,	O
aspirin	O
is	O
not	O
recommended	O
for	O
children	O
or	O
teenagers	O
who	O
have	O
or	O
are	O
recovering	O
from	O
chicken	O
pox	O
or	O
flulike	O
symptoms	O
because	O
it	O
can	O
cause	O
debilitating	O
and	O
sometimes	O
lethal	O
Reyes	O
syndrome	O
(	O
U	O
.	O
S	O
.	O
FDA	O
2003	O
)	O
.	O
Individual	O
risks	O
to	O
pharmaceutical	O
agents	O
can	O
be	O
controlled	O
with	O
proper	O
usage	O
;	O
however	O
,	O
increased	O
exposure	O
to	O
environmental	O
toxins	O
presents	O
additional	O
involuntary	O
risks	O
for	O
the	O
general	O
population	O
.	O
Under	O
the	O
latter	O
condition	O
,	O
exposure	O
is	O
inadequately	O
controlled	O
,	O
and	O
there	O
is	O
no	O
mechanism	O
to	O
correct	O
for	O
individual	O
circumstances	O
(	O
e	O
.	O
g	O
.	O
,	O
medical	O
condition	O
or	O
age	O
)	O
that	O
may	O
result	O
in	O
harm	O
.	O
Although	O
hormetic	O
effects	O
may	O
occur	O
in	O
some	O
instances	O
,	O
it	O
is	O
indeed	O
rare	O
that	O
exposures	O
to	O
toxic	O
,	O
mutagenic	O
,	O
teratogenic	O
,	O
and	O
carcinogenic	O
chemicals	O
,	O
even	O
at	O
low	O
exposure	O
levels	O
,	O
would	O
be	O
risk	O
free	O
and	O
provide	O
health	O
benefits	O
for	O
the	O
general	O
public	O
.	O
Portraying	O
chemicals	O
with	O
numerous	O
adverse	O
effects	O
as	O
having	O
benefits	O
while	O
ignoring	O
their	O
hazards	O
is	O
irresponsible	O
and	O
does	O
not	O
provide	O
full	O
and	O
objective	O
disclosure	O
.	O
In	O
the	O
1950s	O
doctors	O
prescribed	O
DES	O
to	O
pregnant	O
women	O
to	O
prevent	O
miscarriage	O
and	O
premature	O
births	O
and	O
to	O
produce	O
""""	O
bigger	O
and	O
stronger	O
babies	O
""""	O
even	O
though	O
DES	O
had	O
been	O
shown	O
to	O
cause	O
damage	O
to	O
reproductive	O
tissues	B-Anatomy
in	O
animals	O
(	O
Dinusson	O
et	O
al	O
.	O
1948	O
;	O
Dunn	O
and	O
Green	O
1963	O
;	O
Takasugi	O
and	O
Bern	O
1964	O
)	O
.	O
Human	O
use	O
of	O
DES	O
was	O
banned	O
in	O
the	O
United	O
States	O
in	O
1971	O
after	O
the	O
discovery	O
of	O
high	O
rates	O
of	O
rare	O
,	O
clear	O
-	O
cell	O
adenocarcinomas	B-Anatomy
of	O
the	O
vagina	B-Anatomy
and	O
cervix	B-Anatomy
in	O
DES	O
-	O
exposed	O
daughters	O
(	O
Herbst	O
1981	O
)	O
,	O
and	O
later	O
studies	O
showed	O
elevated	O
breast	B-Anatomy
cancer	I-Anatomy
risk	O
in	O
women	O
who	O
took	O
DES	O
during	O
pregnancy	O
(	O
Titus	O
-	O
Ernstoff	O
et	O
al	O
.	O
2001	O
)	O
.	O
Certainly	O
,	O
health	O
policy	O
decisions	O
should	O
be	O
based	O
on	O
scientific	O
evidence	O
and	O
not	O
on	O
speculation	O
of	O
health	O
benefits	O
in	O
order	O
for	O
the	O
general	O
population	O
to	O
avoid	O
repeating	O
the	O
mistakes	O
of	O
the	O
past	O
similar	O
to	O
that	O
of	O
the	O
DES	O
tragedy	O
.	O
The	O
claims	O
and	O
projections	O
of	O
health	O
benefits	O
from	O
exposures	O
to	O
environmental	O
toxicants	O
and	O
carcinogens	O
are	O
based	O
on	O
untested	O
assumptions	O
and	O
disregard	O
numerous	O
well	O
-	O
established	O
scientific	O
principles	O
that	O
underpin	O
a	O
public	O
health	O
-	O
protective	O
approach	O
to	O
regulating	O
exposure	O
to	O
toxic	O
substances	O
.	O
If	O
hormesis	O
were	O
used	O
in	O
the	O
decision	O
-	O
making	O
process	O
to	O
allow	O
higher	O
exposures	O
to	O
toxic	O
and	O
carcinogenic	O
agents	O
,	O
this	O
would	O
substantially	O
increase	O
health	O
risks	O
for	O
many	O
,	O
if	O
not	O
most	O
,	O
segments	O
of	O
the	O
general	O
population	O
.	O
Measured	O
analytes	O
in	O
five	O
biologic	O
sample	O
matrices	O
.	O
a	O
Competing	O
interests	O
None	O
declared	O
.	O
This	O
article	O
is	O
the	O
third	O
in	O
an	O
ongoing	O
,	O
educational	O
review	O
series	O
on	O
medical	O
statistics	O
in	O
critical	O
care	O
.	O
Previous	O
articles	O
have	O
covered	O
'	O
presenting	O
and	O
summarising	O
data	O
'	O
[	O
3	O
]	O
and	O
'	O
samples	O
and	O
populations	O
'	O
[	O
4	O
]	O
.	O
Future	O
topics	O
to	O
be	O
covered	O
include	O
power	O
calculations	O
,	O
comparison	O
of	O
means	O
,	O
comparison	O
of	O
proportions	O
,	O
and	O
analysis	O
of	O
survival	O
data	O
to	O
name	O
but	O
a	O
few	O
.	O
If	O
there	O
is	O
a	O
medical	O
statistics	O
topic	O
you	O
would	O
like	O
explained	O
contact	O
us	O
on	O
editorial	O
@	O
ccforum	O
.	O
com	O
.	O
Results	O
The	O
set	O
of	O
E	O
.	O
coli	O
expression	O
vectors	O
,	O
encode	O
for	O
either	O
a	O
hexa	O
-	O
histidine	O
tag	O
or	O
the	O
three	O
most	O
commonly	O
used	O
solubility	O
tags	O
(	O
GST	O
,	O
MBP	O
,	O
NusA	O
)	O
and	O
all	O
with	O
an	O
N	O
-	O
terminal	O
hexa	O
-	O
histidine	O
sequence	O
.	O
The	O
result	O
is	O
two	O
-	O
fold	O
:	O
the	O
His	O
-	O
tag	O
facilitates	O
purification	O
by	O
immobilised	O
metal	O
affinity	O
chromatography	O
,	O
whilst	O
the	O
fusion	O
domains	O
act	O
primarily	O
as	O
solubility	O
aids	O
during	O
expression	O
,	O
in	O
addition	O
to	O
providing	O
an	O
optional	O
purification	O
step	O
.	O
We	O
have	O
also	O
incorporated	O
a	O
TEV	O
recognition	O
sequence	O
following	O
the	O
solubility	O
tag	O
domain	O
,	O
which	O
allows	O
for	O
highly	O
specific	O
cleavage	O
(	O
using	O
TEV	O
protease	O
)	O
of	O
the	O
fusion	O
protein	O
to	O
yield	O
native	O
protein	O
.	O
These	O
vectors	O
are	O
also	O
designed	O
for	O
ligation	O
-	O
independent	O
cloning	O
and	O
they	O
possess	O
a	O
high	O
-	O
level	O
expressing	O
T7	O
promoter	O
,	O
which	O
is	O
suitable	O
for	O
auto	O
-	O
induction	O
.	O
To	O
validate	O
our	O
vector	O
system	O
,	O
we	O
have	O
cloned	O
four	O
different	O
genes	O
and	O
also	O
one	O
gene	O
into	O
all	O
four	O
vectors	O
and	O
used	O
small	O
-	O
scale	O
expression	O
and	O
purification	O
techniques	O
.	O
We	O
demonstrate	O
that	O
the	O
vectors	O
are	O
capable	O
of	O
high	O
levels	O
of	O
expression	O
and	O
that	O
efficient	O
screening	O
of	O
new	O
proteins	O
can	O
be	O
readily	O
achieved	O
at	O
the	O
laboratory	O
level	O
.	O
Inflammation	O
-	O
modulating	O
effect	O
of	O
antithrombin	O
on	O
the	O
endothelium	B-Anatomy
.	O
Ligation	O
of	O
heparan	O
sulfate	O
proteoglycans	O
(	O
HSPGs	O
)	O
of	O
endothelium	B-Anatomy
with	O
antithrombin	O
(	O
AT	O
)	O
induces	O
cellular	B-Anatomy
signalling	O
events	O
that	O
alter	O
the	O
cell	B-Anatomy
'	O
s	O
biochemical	O
and	O
functional	O
responses	O
to	O
inflammatory	O
stimuli	O
(	O
e	O
.	O
g	O
.	O
bacterial	O
lipopolysaccharide	O
[	O
LPS	O
]	O
)	O
.	O
Changes	O
include	O
reduced	O
release	O
of	O
inflammatory	O
and	O
procoagulatory	O
mediators	O
(	O
e	O
.	O
g	O
.	O
interleukin	O
[	O
IL	O
]	O
-	O
1	O
,	O
IL	O
-	O
6	O
,	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
[	O
TNF	O
]	O
)	O
,	O
tissue	O
factor	O
(	O
TF	O
)	O
,	O
adenosine	O
diphosphate	O
(	O
ADP	O
)	O
and	O
cellular	B-Anatomy
adhesion	O
molecules	O
(	O
not	O
shown	O
)	O
,	O
as	O
well	O
as	O
increased	O
release	O
of	O
anticoagulatory	O
prostacyclin	O
(	O
prostaglandin	O
[	O
PG	O
]	O
I	O
)	O
or	O
CD39	O
/	O
ATPDase	O
.	O
In	O
neuronal	B-Anatomy
tissue	I-Anatomy
,	O
protective	O
mechanisms	O
may	O
by	O
mediated	O
via	O
the	O
release	O
of	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
and	O
nitric	O
oxide	O
with	O
the	O
potential	O
to	O
affect	O
prostacyclin	O
release	O
[	O
55	O
]	O
.	O
Background	O
Hallucinations	O
may	O
occur	O
in	O
any	O
sensory	O
modalities	O
.	O
Formed	O
musical	O
hallucinations	O
(	O
i	O
.	O
e	O
.	O
Perception	O
of	O
either	O
vocal	O
or	O
instrumental	O
melodies	O
)	O
reported	O
in	O
English	O
literature	O
to	O
date	O
have	O
typically	O
been	O
associated	O
with	O
marked	O
hearing	O
loss	O
,	O
advanced	O
age	O
,	O
female	O
sex	O
(	O
71	O
%	O
)	O
,	O
lack	O
of	O
response	O
to	O
treatment	O
and	O
associated	O
psychopathology	O
[	O
1	O
]	O
but	O
has	O
been	O
concluded	O
that	O
hearing	O
loss	O
is	O
neither	O
a	O
necessary	O
nor	O
sufficient	O
condition	O
for	O
the	O
occurrence	O
of	O
musical	O
hallucinations	O
[	O
1	O
]	O
.	O
Tumor	B-Anatomy
like	O
Astrocytoma	B-Anatomy
,	O
Temporal	B-Anatomy
lobe	I-Anatomy
epilepsy	O
,	O
raised	O
intra	O
cranial	B-Anatomy
tension	O
,	O
drug	O
induced	O
(	O
tricyclics	O
,	O
Propronolol	O
etc	O
;	O
)	O
,	O
meningitis	O
and	O
psychotic	O
illness	O
were	O
shown	O
to	O
cause	O
palinacousis	O
and	O
musical	O
hallucinations	O
[	O
2	O
,	O
3	O
]	O
.	O
Musical	O
hallucinations	O
are	O
pseudo	O
hallucinations	O
that	O
originate	O
in	O
memory	O
representations	O
and	O
they	O
may	O
undergo	O
a	O
transition	O
to	O
true	O
hallucination	O
.	O
In	O
musical	O
hallucination	O
spatial	O
projection	O
is	O
less	O
definite	O
.	O
Sometimes	O
they	O
are	O
perceived	O
like	O
the	O
tinnitus	O
in	O
patient	O
'	O
s	O
own	O
head	B-Anatomy
.	O
The	O
quality	O
is	O
usually	O
very	O
intense	O
and	O
distinct	O
often	O
very	O
loud	O
.	O
They	O
vary	O
from	O
elementary	O
sounds	O
to	O
instrumental	O
music	O
,	O
vocal	O
music	O
,	O
bird	O
songs	O
,	O
bells	O
,	O
pieces	O
of	O
melodies	O
or	O
sentences	O
,	O
religious	O
music	O
etc	O
:	O
-	O
We	O
report	O
an	O
unusual	O
presentation	O
of	O
an	O
elderly	O
lady	O
who	O
had	O
experienced	O
musical	O
hallucinations	O
whilst	O
being	O
treated	O
with	O
Electro	O
Convulsive	O
Therapy	O
.	O
Though	O
this	O
has	O
never	O
been	O
reported	O
earlier	O
,	O
there	O
seemed	O
to	O
have	O
a	O
good	O
association	O
between	O
the	O
initiation	O
of	O
Electro	O
convulsive	O
therapy	O
and	O
musical	O
hallucination	O
in	O
our	O
patient	O
.	O
Correlation	O
between	O
sperm	B-Anatomy
morphology	O
and	O
seminal	B-Anatomy
plasma	I-Anatomy
NO	O
(	O
a	O
)	O
and	O
TBARS	O
(	O
b	O
)	O
levels	O
in	O
both	O
groups	O
.	O
Conclusion	O
The	O
survey	O
indicated	O
that	O
,	O
the	O
study	O
area	O
has	O
plenty	O
of	O
medicinal	O
plants	O
to	O
treat	O
a	O
wide	O
spectrum	O
of	O
human	O
ailments	O
.	O
Earlier	O
studies	O
on	O
traditional	O
medicinal	O
plants	O
also	O
revealed	O
that	O
the	O
economically	O
backward	O
local	O
and	O
tribal	O
people	O
of	O
Tamil	O
Nadu	O
prefer	O
folk	O
medicine	O
due	O
to	O
low	O
cost	O
and	O
sometimes	O
it	O
is	O
a	O
part	O
of	O
their	O
social	O
life	O
and	O
culture	O
[	O
40	O
-	O
45	O
]	O
.	O
It	O
is	O
evident	O
from	O
the	O
interviews	O
conducted	O
in	O
different	O
villages	O
,	O
knowledge	O
of	O
medicinal	O
plants	O
is	O
limited	O
to	O
traditional	O
healers	O
,	O
herbalists	O
and	O
elderly	O
persons	O
who	O
are	O
living	O
in	O
rural	O
areas	O
.	O
This	O
study	O
also	O
points	O
out	O
that	O
certain	O
species	O
of	O
medicinal	O
plants	O
are	O
being	O
exploited	O
by	O
the	O
local	O
residents	O
who	O
are	O
unaware	O
of	O
the	O
importance	O
of	O
medicinal	O
plants	O
in	O
the	O
ecosystem	O
.	O
This	O
study	O
concluded	O
that	O
even	O
though	O
the	O
accessibility	O
of	O
Western	O
medicine	O
for	O
simple	O
and	O
complicated	O
diseases	O
is	O
available	O
,	O
many	O
people	O
in	O
the	O
studied	O
parts	O
of	O
Kancheepuram	O
district	O
is	O
still	O
continue	O
to	O
depend	O
on	O
medicinal	O
plants	O
,	O
at	O
least	O
for	O
the	O
treatment	O
of	O
some	O
simple	O
diseases	O
such	O
as	O
,	O
cold	O
,	O
cough	O
,	O
fever	O
,	O
headache	O
,	O
poison	B-Anatomy
bites	O
,	O
skin	B-Anatomy
diseases	O
and	O
tooth	B-Anatomy
infections	O
.	O
Well	O
-	O
knowledged	O
healers	O
have	O
good	O
interactions	O
with	O
patients	O
and	O
this	O
would	O
improve	O
the	O
quality	O
of	O
healthcare	O
delivery	O
.	O
The	O
present	O
-	O
day	O
traditional	O
healers	O
are	O
very	O
old	O
.	O
Due	O
to	O
lack	O
of	O
interest	O
among	O
the	O
younger	O
generation	O
as	O
well	O
as	O
their	O
tendency	O
to	O
migrate	O
to	O
cities	O
for	O
lucrative	O
jobs	O
,	O
there	O
is	O
a	O
possibility	O
of	O
losing	O
this	O
wealth	O
of	O
knowledge	O
in	O
the	O
near	O
future	O
.	O
It	O
thus	O
becomes	O
necessary	O
to	O
acquire	O
and	O
preserve	O
this	O
traditional	O
system	O
of	O
medicine	O
by	O
proper	O
documentation	O
and	O
identification	O
of	O
specimens	O
.	O
Figures	O
and	O
Tables	O
Figure	O
1	O
Modular	O
crosstalking	O
in	O
synthetic	O
gene	O
networks	O
.	O
A	O
promoter	O
with	O
binding	O
sites	O
for	O
lambda	O
cI	O
dimers	O
(	O
OR1	O
and	O
OR2	O
)	O
and	O
for	O
the	O
lac	O
repressor	O
(	O
Olac	O
)	O
controls	O
the	O
production	O
of	O
the	O
lac	O
repressor	O
(	O
encoded	O
by	O
lacI	O
)	O
in	O
module	O
1	O
and	O
lambda	O
cI	O
(	O
encoded	O
by	O
cI	O
)	O
in	O
module	O
2	O
.	O
The	O
lac	O
repressor	O
and	O
lambda	O
cI	O
dimers	O
are	O
represented	O
by	O
blue	O
ellipsoids	O
and	O
red	O
circles	O
,	O
respectively	O
.	O
When	O
the	O
two	O
modules	O
are	O
put	O
together	O
,	O
two	O
pairs	O
of	O
lambda	O
cI	O
dimers	O
bound	O
at	O
different	O
operators	O
can	O
loop	O
DNA	O
and	O
octamerize	O
,	O
forming	O
a	O
tetramer	O
of	O
dimers	O
.	O
Comparison	O
of	O
the	O
Predicted	O
Irr	O
Regulon	O
and	O
ICE	O
Motifs	O
with	O
the	O
Published	O
Expression	O
Microarray	O
Data	O
for	O
Iron	O
-	O
and	O
Irr	O
-	O
Affected	O
Genes	O
in	O
Bradyrhizobium	O
japonicum	O
Mass	O
casualty	O
estimation	O
on	O
a	O
geographic	O
basis	O
The	O
Defense	O
Threat	O
Reduction	O
Agency	O
(	O
DTRA	O
)	O
has	O
expended	O
considerable	O
effort	O
to	O
develop	O
models	O
for	O
calculating	O
mass	O
casualties	O
from	O
a	O
nuclear	O
detonation	O
.	O
In	O
order	O
to	O
specifically	O
evaluate	O
urban	O
medical	O
systems	O
vulnerability	O
we	O
are	O
employing	O
the	O
PC	O
based	O
Consequence	O
Assessment	O
Tool	O
Set	O
(	O
CATS	O
)	O
v6	O
,	O
with	O
ESRI	O
'	O
s	O
ArcGIS9	O
[	O
14	O
]	O
,	O
CATS	O
/	O
JACE	O
(	O
Joint	O
Assessment	O
of	O
Catastrophic	O
Events	O
)	O
v5	O
with	O
ESRI	O
'	O
s	O
ArcView	O
3	O
.	O
3	O
,	O
Hazard	O
Prediction	O
and	O
Assessment	O
Capability	O
(	O
HPAC	O
)	O
V4	O
.	O
04SP3	O
[	O
15	O
]	O
,	O
as	O
well	O
as	O
custom	O
GIS	O
and	O
database	O
software	O
applications	O
.	O
HPAC	O
does	O
excellent	O
Chemical	O
Biological	O
and	O
Nuclear	O
(	O
CBN	O
)	O
modeling	O
,	O
although	O
output	O
could	O
provide	O
more	O
flexibility	O
.	O
Additionally	O
,	O
results	O
can	O
be	O
exported	O
to	O
CATS	O
for	O
further	O
analysis	O
and	O
display	O
.	O
All	O
three	O
programs	O
can	O
access	O
the	O
current	O
weather	O
data	O
from	O
both	O
classified	O
and	O
unclassified	O
weather	O
servers	O
.	O
Examples	O
of	O
uses	O
of	O
CATS	O
/	O
HPAC	O
are	O
hurricane	O
,	O
tidal	O
surge	O
and	O
earthquake	O
damage	O
,	O
prediction	O
of	O
the	O
results	O
from	O
nuclear	O
,	O
biological	O
and	O
chemical	O
releases	O
,	O
assessment	O
of	O
persons	O
and	O
infrastructure	O
affected	O
and	O
at	O
risk	O
(	O
e	O
.	O
g	O
.	O
which	O
hospitals	O
and	O
pharmacies	O
are	O
under	O
a	O
CBN	O
plume	O
and	O
are	O
thus	O
out	O
of	O
commission	O
)	O
,	O
and	O
mobilization	O
of	O
surviving	O
and	O
nearby	O
infrastructure	O
outside	O
the	O
plume	O
that	O
would	O
be	O
needed	O
to	O
address	O
healthcare	O
and	O
other	O
emergency	O
response	O
needs	O
of	O
the	O
community	O
.	O
These	O
models	O
have	O
been	O
,	O
and	O
continue	O
to	O
be	O
,	O
developed	O
with	O
a	O
view	O
to	O
better	O
estimating	O
the	O
impact	O
of	O
WMD	O
weapons	O
in	O
an	O
offensive	O
setting	O
.	O
However	O
,	O
recent	O
DTRA	O
enhancements	O
and	O
our	O
modifications	O
have	O
facilitated	O
their	O
use	O
in	O
helping	O
estimate	O
potential	O
casualties	O
from	O
a	O
WMD	O
terrorist	O
incident	O
.	O
One	O
area	O
of	O
intense	O
interest	O
,	O
and	O
somewhat	O
of	O
a	O
vacuum	O
in	O
public	O
health	O
planning	O
,	O
has	O
been	O
the	O
utility	O
of	O
this	O
approach	O
in	O
estimating	O
medical	O
care	O
vulnerabilities	O
in	O
such	O
an	O
attack	O
,	O
and	O
for	O
the	O
calculation	O
of	O
the	O
distribution	O
of	O
surviving	O
medical	O
care	O
resources	O
.	O
While	O
much	O
work	O
has	O
already	O
occurred	O
in	O
estimating	O
the	O
impact	O
of	O
chemical	O
weapons	O
(	O
due	O
to	O
the	O
dual	O
use	O
in	O
chemical	O
spill	O
management	O
from	O
transportation	O
and	O
industrial	O
accidents	O
)	O
,	O
or	O
in	O
nuclear	O
power	O
plant	O
accident	O
management	O
,	O
much	O
less	O
research	O
and	O
development	O
has	O
gone	O
into	O
estimating	O
the	O
impact	O
on	O
our	O
civilian	O
population	O
of	O
a	O
nuclear	O
weapon	O
detonation	O
from	O
a	O
terrorist	O
incident	O
in	O
a	O
large	O
urban	O
area	O
.	O
The	O
models	O
already	O
calculate	O
such	O
factors	O
as	O
the	O
impact	O
of	O
blast	O
,	O
thermal	O
effects	O
and	O
fallout	O
,	O
but	O
results	O
are	O
often	O
not	O
available	O
at	O
the	O
detail	O
level	O
needed	O
for	O
civil	O
defense	O
purposes	O
,	O
casualty	O
management	O
,	O
and	O
planning	O
the	O
use	O
of	O
scarce	O
health	O
resources	O
in	O
response	O
to	O
a	O
nuclear	O
weapon	O
detonation	O
.	O
Furthermore	O
,	O
the	O
models	O
do	O
not	O
readily	O
facilitate	O
the	O
calculation	O
of	O
injuries	O
from	O
multiple	O
effects	O
such	O
as	O
burns	O
and	O
blast	O
with	O
fallout	O
or	O
prompt	O
radiation	O
.	O
The	O
complexity	O
of	O
the	O
urban	O
three	O
-	O
dimensional	O
landscape	O
and	O
its	O
local	O
impact	O
on	O
thermal	O
,	O
blast	O
and	O
radiation	O
is	O
also	O
poorly	O
understood	O
.	O
Additionally	O
,	O
given	O
their	O
traditional	O
world	O
-	O
wide	O
focus	O
,	O
and	O
the	O
increased	O
sensitivity	O
to	O
providing	O
information	O
on	O
the	O
U	O
.	O
S	O
.	O
A	O
.	O
of	O
use	O
to	O
terrorists	O
,	O
the	O
models	O
do	O
not	O
provide	O
detailed	O
or	O
current	O
data	O
that	O
exists	O
for	O
the	O
United	O
States	O
that	O
would	O
help	O
provide	O
better	O
casualty	O
estimates	O
and	O
response	O
.	O
The	O
models	O
can	O
be	O
customized	O
locally	O
and	O
data	O
updated	O
if	O
the	O
user	O
has	O
sufficient	O
expertise	O
.	O
However	O
,	O
there	O
is	O
often	O
a	O
significant	O
duplication	O
of	O
effort	O
due	O
to	O
overlapping	O
jurisdictions	O
and	O
the	O
lack	O
of	O
data	O
sharing	O
due	O
to	O
security	O
and	O
other	O
considerations	O
.	O
CATS	O
and	O
HPAC	O
are	O
also	O
useful	O
for	O
creating	O
realistic	O
scenarios	O
for	O
training	O
and	O
planning	O
before	O
a	O
disaster	O
strikes	O
,	O
thus	O
enabling	O
responders	O
to	O
drill	O
and	O
exercise	O
so	O
they	O
know	O
roughly	O
what	O
to	O
expect	O
and	O
how	O
to	O
react	O
.	O
Contingency	O
plans	O
can	O
be	O
created	O
using	O
comprehensive	O
national	O
and	O
more	O
detailed	O
population	O
and	O
infrastructure	O
data	O
.	O
Should	O
disaster	O
strike	O
,	O
the	O
affected	O
population	O
and	O
the	O
impact	O
on	O
critical	O
facilities	O
can	O
be	O
quickly	O
assessed	O
,	O
although	O
efforts	O
frequently	O
need	O
to	O
be	O
expended	O
to	O
ensure	O
regional	O
and	O
local	O
databases	O
are	O
current	O
and	O
useful	O
.	O
Case	O
Presentation	O
The	O
patient	O
is	O
an	O
80	O
year	O
old	O
male	O
with	O
diabetes	O
mellitus	O
and	O
hypertension	O
,	O
who	O
at	O
age	O
74	O
(	O
March	O
2001	O
)	O
had	O
received	O
a	O
living	O
non	O
-	O
related	O
donor	O
kidney	B-Anatomy
transplant	O
.	O
At	O
that	O
time	O
he	O
was	O
discharged	O
with	O
a	O
double	O
immunosuppressive	O
therapy	O
consisting	O
of	O
prednisone	O
20	O
mg	O
/	O
day	O
and	O
mophetil	O
mycophenolate	O
1	O
.	O
5	O
gr	O
/	O
day	O
.	O
No	O
calcineurin	O
inhibitor	O
was	O
administered	O
.	O
His	O
prednisone	O
dose	O
was	O
further	O
decreased	O
to	O
5	O
mg	O
/	O
day	O
and	O
mophetil	O
mycophenolate	O
doses	O
sustained	O
.	O
In	O
November	O
2001	O
he	O
developed	O
cutaneous	B-Anatomy
purple	I-Anatomy
elevated	I-Anatomy
lesions	I-Anatomy
in	O
his	O
lower	B-Anatomy
limbs	I-Anatomy
that	O
were	O
diagnosed	O
as	O
KS	B-Anatomy
by	O
skin	B-Anatomy
biopsy	O
.	O
He	O
received	O
19	O
administrations	O
of	O
vincristine	O
(	O
1	O
mg	O
)	O
and	O
bleomycin	O
(	O
15	O
mg	O
)	O
weekly	O
that	O
resulted	O
in	O
flattening	O
and	O
fading	O
of	O
the	O
lesions	B-Anatomy
.	O
Treatment	O
was	O
discontinued	O
for	O
two	O
months	O
,	O
and	O
KS	B-Anatomy
recurred	O
,	O
with	O
pain	O
and	O
edema	B-Anatomy
in	O
both	O
legs	B-Anatomy
.	O
On	O
July	O
2002	O
,	O
with	O
an	O
almost	O
100	O
%	O
involvement	O
of	O
his	O
lower	B-Anatomy
limbs	I-Anatomy
skin	I-Anatomy
with	O
KS	B-Anatomy
but	O
no	O
visceral	B-Anatomy
involvement	O
he	O
received	O
50	O
mg	O
of	O
liposomal	O
-	O
adriamycin	O
.	O
In	O
addition	O
,	O
he	O
was	O
then	O
prescribed	O
valganciclovir	O
450	O
mg	O
BID	O
(	O
corrected	O
for	O
creatinine	O
clearance	O
)	O
[	O
7	O
]	O
and	O
three	O
additional	O
administrations	O
of	O
liposomal	O
-	O
adriamycin	O
,	O
up	O
to	O
December	O
2002	O
.	O
He	O
showed	O
40	O
%	O
response	O
again	O
with	O
early	O
relapse	O
.	O
On	O
January	O
2003	O
the	O
patient	O
developed	O
disseminated	O
herpes	O
zoster	O
,	O
which	O
was	O
treated	O
with	O
IV	O
acyclovir	O
.	O
In	O
May	O
2003	O
KS	B-Anatomy
progression	O
was	O
observed	O
and	O
received	O
radiotherapy	O
with	O
no	O
benefit	O
Figure	O
1	O
.	O
In	O
August	O
2003	O
he	O
started	O
oral	B-Anatomy
etoposide	O
at	O
50	O
mg	O
QD	O
for	O
two	O
weeks	O
followed	O
by	O
two	O
weeks	O
off	O
until	O
May	O
2004	O
achieving	O
a	O
very	O
slow	O
50	O
%	O
response	O
.	O
Tolerance	O
was	O
good	O
and	O
serum	B-Anatomy
creatinine	O
remain	O
stable	O
at	O
around	O
1	O
,	O
4	O
mg	O
/	O
dl	O
.	O
Mophetil	O
mycophenolate	O
dose	O
was	O
reduced	O
to	O
1	O
g	O
/	O
day	O
and	O
prednisone	O
to	O
2	O
.	O
5	O
mg	O
/	O
day	O
.	O
Figure	O
1	O
Kaposi	B-Anatomy
'	I-Anatomy
s	I-Anatomy
sarcoma	I-Anatomy
progressions	O
after	O
chemotherapy	O
withdrawal	O
,	O
both	O
lower	B-Anatomy
limbs	I-Anatomy
were	O
completely	O
covered	O
with	O
Kaposi	B-Anatomy
'	I-Anatomy
s	I-Anatomy
Sarcoma	I-Anatomy
(	O
June	O
2003	O
)	O
.	O
On	O
May	O
2004	O
the	O
patient	O
requested	O
a	O
second	O
opinion	O
and	O
was	O
prescribed	O
Imatinib	O
200	O
mg	O
qd	O
for	O
two	O
weeks	O
followed	O
by	O
400	O
mg	O
qd	O
.	O
After	O
four	O
weeks	O
of	O
Imatinib	O
,	O
his	O
health	O
deteriorated	O
rapidly	O
,	O
he	O
developed	O
anasarca	B-Anatomy
,	O
worsening	O
of	O
KS	B-Anatomy
,	O
his	O
serum	B-Anatomy
creatinine	O
increased	O
from	O
1	O
.	O
4	O
mg	O
/	O
dl	O
to	O
2	O
.	O
3	O
mg	O
/	O
dl	O
and	O
he	O
developed	O
grade	O
4	O
granulocytopenia	O
(	O
Figure	O
2	O
)	O
.	O
The	O
patient	O
was	O
hospitalized	O
with	O
fever	O
and	O
was	O
started	O
on	O
IV	O
antibiotics	O
and	O
daily	O
G	O
-	O
CSF	O
for	O
four	O
days	O
after	O
which	O
his	O
WBC	B-Anatomy
count	O
normalized	O
.	O
Two	O
weeks	O
later	O
the	O
creatinine	O
level	O
returned	O
to	O
1	O
.	O
5	O
mg	O
/	O
dl	O
.	O
On	O
February	O
2005	O
he	O
was	O
started	O
on	O
30	O
mg	O
of	O
paclitaxel	O
IV	O
every	O
three	O
weeks	O
.	O
After	O
three	O
courses	O
with	O
no	O
clinical	O
benefit	O
he	O
developed	O
a	O
skin	B-Anatomy
rash	O
that	O
prompted	O
discontinuation	O
.	O
Figure	O
2	O
Patient	O
developed	O
anasarca	B-Anatomy
with	O
rapid	O
progression	O
of	O
Kaposi	B-Anatomy
'	I-Anatomy
s	I-Anatomy
Sarcoma	I-Anatomy
after	O
four	O
weeks	O
of	O
taking	O
Imatinib	O
(	O
June	O
2004	O
)	O
.	O
On	O
April	O
2005	O
,	O
he	O
was	O
started	O
on	O
Sirolimus	O
2	O
mg	O
a	O
day	O
,	O
and	O
after	O
8	O
weeks	O
escalated	O
to	O
4	O
mg	O
a	O
day	O
.	O
Three	O
weeks	O
later	O
mophetil	O
mycophenolate	O
and	O
prednisone	O
were	O
discontinued	O
.	O
Sustained	O
and	O
significant	O
KS	B-Anatomy
regression	O
was	O
evident	O
after	O
16	O
weeks	O
,	O
but	O
he	O
developed	O
a	O
basal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
and	O
pneumonia	O
that	O
required	O
hospital	O
admission	O
;	O
Sirolimus	O
dose	O
was	O
lowered	O
to	O
2	O
mg	O
a	O
day	O
.	O
Thereafter	O
his	O
clinical	O
course	O
has	O
been	O
satisfactory	O
with	O
continuous	O
and	O
progressive	O
regression	O
of	O
KS	B-Anatomy
lesions	I-Anatomy
(	O
Figure	O
3	O
)	O
.	O
His	O
serum	B-Anatomy
creatinine	O
has	O
remained	O
under	O
1	O
.	O
6	O
mg	O
/	O
dl	O
and	O
he	O
has	O
not	O
developed	O
new	O
infectious	O
episodes	O
.	O
Figure	O
3	O
Extensive	O
regression	O
of	O
Kaposi	B-Anatomy
Sarcoma	I-Anatomy
after	O
immune	O
-	O
suppression	O
was	O
changed	O
to	O
Sirolimus	O
,	O
(	O
14	O
months	O
later	O
)	O
,	O
he	O
only	O
has	O
hyperpigmented	O
areas	O
at	O
knee	B-Anatomy
levels	O
,	O
skin	B-Anatomy
looks	O
thin	O
and	O
delicate	O
and	O
easily	O
bruised	O
(	O
July	O
2006	O
)	O
.	O
Hypothetical	O
distribution	O
patterns	O
of	O
the	O
meadow	O
brown	O
Maniola	O
jurtina	O
in	O
Europe	O
during	O
the	O
last	O
glacial	O
maximum	O
(	O
dark	O
hatched	O
areas	O
)	O
.	O
Postglacial	O
expansions	O
are	O
indicated	O
by	O
solid	O
arrows	O
.	O
The	O
postulated	O
actual	O
hybrid	O
zone	O
is	O
shown	O
by	O
the	O
hatched	O
area	O
.	O
Question	O
marks	O
indicate	O
lack	O
of	O
information	O
concerning	O
ancient	O
distribution	O
patterns	O
in	O
the	O
South	O
and	O
present	O
distribution	O
of	O
hybrid	O
populations	O
in	O
the	O
North	O
.	O
Redrawn	O
from	O
Schmitt	O
et	O
.	O
al	O
.	O
[	O
36	O
]	O
;	O
based	O
on	O
Thomson	O
[	O
37	O
]	O
and	O
Schmitt	O
et	O
al	O
.	O
[	O
36	O
]	O
.	O
Supporting	O
Information	O
Alternate	O
Language	O
Article	O
S1	O
Translation	O
of	O
the	O
manuscript	O
into	O
French	O
by	O
EL	O
(	O
201	O
KB	O
DOC	O
)	O
.	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Extrapyramidal	O
symptoms	O
based	O
on	O
Extrapyramidal	O
Symptoms	O
Rating	O
Scale	O
Etiology	O
Anorectal	B-Anatomy
malformations	O
(	O
ARM	O
)	O
represent	O
a	O
spectrum	O
of	O
abnormalities	O
ranging	O
from	O
mild	O
anal	B-Anatomy
anomalies	O
to	O
complex	O
cloacal	O
malformations	O
.	O
The	O
etiology	O
of	O
such	O
malformations	O
remains	O
unclear	O
and	O
is	O
likely	O
multifactorial	O
.	O
There	O
are	O
however	O
reasons	O
to	O
believe	O
there	O
is	O
a	O
genetic	O
componenet	O
.	O
As	O
early	O
as	O
the	O
1950s	O
,	O
it	O
was	O
recognized	O
that	O
there	O
was	O
an	O
increased	O
risk	O
for	O
a	O
sibling	O
of	O
a	O
patient	O
with	O
ARM	O
to	O
be	O
born	O
with	O
a	O
malformation	O
,	O
as	O
much	O
as	O
1	O
in	O
100	O
,	O
compared	O
with	O
the	O
incidence	O
of	O
about	O
1	O
in	O
5000	O
in	O
the	O
general	O
population	O
.	O
Since	O
that	O
time	O
there	O
have	O
been	O
reports	O
of	O
families	O
with	O
2	O
or	O
more	O
affected	O
members	O
and	O
associations	O
of	O
ARMs	O
with	O
multisystem	O
syndromes	O
.	O
In	O
particular	O
,	O
mutations	O
in	O
specific	O
genes	O
encoding	O
transcription	O
factors	O
have	O
been	O
described	O
in	O
patients	O
having	O
Townes	O
-	O
Broks	O
syndrome	O
,	O
Currarino	O
'	O
s	O
syndrome	O
,	O
and	O
Pallister	O
-	O
Hall	O
syndrome	O
,	O
each	O
of	O
which	O
have	O
autosomal	O
dominant	O
modes	O
of	O
inheritance	O
.	O
In	O
addition	O
,	O
it	O
has	O
been	O
found	O
that	O
there	O
is	O
not	O
only	O
an	O
increased	O
incidence	O
of	O
ARM	O
in	O
patient	O
with	O
trisomy	O
21	O
(	O
Down	O
'	O
s	O
syndrome	O
)	O
,	O
but	O
that	O
95	O
%	O
of	O
patients	O
with	O
trisomy	O
21	O
and	O
ARM	O
have	O
imperforate	O
anus	B-Anatomy
without	O
fistula	B-Anatomy
,	O
compared	O
with	O
only	O
5	O
%	O
of	O
all	O
patients	O
with	O
ARM	O
.	O
Based	O
on	O
this	O
evidence	O
,	O
it	O
is	O
likely	O
that	O
the	O
mutation	O
of	O
a	O
variety	O
of	O
different	O
genes	O
can	O
result	O
in	O
ARM	O
,	O
or	O
that	O
the	O
etiology	O
of	O
ARM	O
is	O
multigenic	O
[	O
13	O
]	O
.	O
Images	O
Fig	O
.	O
1	O
Fig	O
.	O
2	O
Fig	O
.	O
3	O
Results	O
Images	O
Figure	O
1	O
Results	O
The	O
observation	O
that	O
AP	O
-	O
3	O
is	O
found	O
in	O
both	O
cytosolic	B-Anatomy
and	O
membrane	B-Anatomy
subcellular	I-Anatomy
fractions	I-Anatomy
,	O
and	O
that	O
membrane	B-Anatomy
-	O
associated	O
AP	O
-	O
3	O
can	O
be	O
extracted	O
with	O
salts	O
(	O
Dell	O
'	O
Angelica	O
et	O
al	O
.	O
,	O
1997a	O
)	O
is	O
consistent	O
with	O
its	O
role	O
as	O
a	O
membrane	B-Anatomy
coat	O
that	O
can	O
be	O
recruited	O
from	O
a	O
cytosolic	B-Anatomy
pool	I-Anatomy
.	O
In	O
addition	O
,	O
the	O
punctate	O
staining	O
of	O
AP	O
-	O
3	O
by	O
immunofluorescence	O
microscopy	O
,	O
its	O
redistribution	O
to	O
the	O
cytosol	B-Anatomy
by	O
BFA	O
,	O
and	O
the	O
reversibility	O
of	O
the	O
BFA	O
effect	O
(	O
Dell	O
'	O
Angelica	O
et	O
al	O
.	O
,	O
1997a	O
;	O
Simpson	O
et	O
al	O
.	O
,	O
1997	O
)	O
also	O
indicate	O
that	O
AP	O
-	O
3	O
can	O
cycle	O
between	O
the	O
cytosol	B-Anatomy
and	O
membranes	B-Anatomy
.	O
The	O
sensitivity	O
of	O
AP	O
-	O
3	O
to	O
BFA	O
in	O
cells	B-Anatomy
suggests	O
that	O
its	O
membrane	B-Anatomy
association	O
may	O
be	O
regulated	O
by	O
ARF1	O
,	O
since	O
BFA	O
inhibits	O
ARF1	O
guanine	O
nucleotide	O
exchange	O
,	O
and	O
has	O
been	O
shown	O
to	O
prevent	O
ARF1	O
membrane	B-Anatomy
binding	O
in	O
vitro	O
(	O
Donaldson	O
et	O
al	O
.	O
,	O
1992	O
;	O
Helms	O
and	O
Rothman	O
,	O
1992	O
;	O
Randazzo	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O
Immunocytochemistry	O
C2C12	B-Anatomy
cells	I-Anatomy
grown	O
in	O
8	O
-	O
chamber	O
slides	O
(	O
Nunc	O
)	O
were	O
fixed	O
in	O
4	O
%	O
PFA	O
/	O
PBS	O
for	O
10	O
min	O
and	O
permeabilized	O
in	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
for	O
20	O
min	O
.	O
In	O
some	O
cases	O
,	O
they	O
were	O
fixed	O
and	O
permeabilized	O
in	O
methanol	O
at	O
-	O
20degreesC	O
for	O
2	O
min	O
.	O
The	O
fixed	O
and	O
permeabilized	O
cells	B-Anatomy
were	O
blocked	O
in	O
PBS	O
containing	O
3	O
%	O
BSA	O
(	O
Jackson	O
ImmunoResearch	O
Laboratories	O
)	O
and	O
incubated	O
overnight	O
at	O
4degreesC	O
with	O
primary	O
antibodies	O
in	O
blocking	O
solution	O
.	O
Immunoreactivity	O
was	O
detected	O
with	O
either	O
Alexa	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
Molecular	O
Probes	O
)	O
or	O
a	O
combination	O
of	O
biotin	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
Vector	O
Laboratories	O
)	O
and	O
Alexa	O
-	O
conjugated	O
streptavidin	O
(	O
Molecular	O
Probes	O
)	O
.	O
Cytology	O
and	O
Histology	O
For	O
semithin	O
sections	B-Anatomy
,	O
embryoid	B-Anatomy
bodies	I-Anatomy
were	O
washed	O
twice	O
in	O
PBS	O
,	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
at	O
4degreesC	O
overnight	O
,	O
and	O
after	O
dehydration	O
in	O
ethanol	O
were	O
embedded	O
in	O
JB	O
-	O
4	O
resin	O
(	O
Polysciences	O
,	O
Inc	O
.	O
)	O
.	O
1	O
-	O
4	O
-	O
mum	O
sections	B-Anatomy
were	O
cut	O
with	O
a	O
glass	O
knife	O
.	O
For	O
cytology	O
,	O
the	O
sections	B-Anatomy
were	O
stained	O
with	O
toluidine	O
blue	O
.	O
In	O
cell	B-Anatomy
mixing	O
experiments	O
,	O
the	O
embryoid	B-Anatomy
bodies	I-Anatomy
were	O
prefixed	O
and	O
stained	O
for	O
beta	O
-	O
galactosidase	O
and	O
the	O
sections	B-Anatomy
were	O
counterstained	O
with	O
neutral	O
red	O
.	O
Teratocarcinomas	O
were	O
fixed	O
in	O
Bouin	O
fixative	O
,	O
embedded	O
in	O
Paraplast	O
,	O
and	O
the	O
sections	B-Anatomy
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
.	O
Microphotography	O
was	O
with	O
a	O
ZEISS	O
Axiomat	O
microscope	O
.	O
Films	O
were	O
scanned	O
and	O
figures	O
were	O
prepared	O
with	O
Photoshop	O
5	O
.	O
5	O
software	O
.	O
Stimulation	O
/	O
Inhibition	O
of	O
iDC	B-Anatomy
Functions	O
by	O
Activated	O
NK	B-Anatomy
Cells	I-Anatomy
.	O
Two	O
previous	O
studies	O
have	O
shown	O
that	O
both	O
resting	O
and	O
activated	O
NK	B-Anatomy
cells	I-Anatomy
partially	O
kill	O
autologous	O
DCs	B-Anatomy
,	O
as	O
measured	O
by	O
3	O
-	O
4	O
-	O
h	O
chromium	O
release	O
assays	O
using	O
high	O
NK	B-Anatomy
/	O
DC	B-Anatomy
ratios	O
(	O
11	O
,	O
12	O
)	O
.	O
However	O
,	O
in	O
our	O
long	O
-	O
term	O
cultures	O
(	O
24	O
-	O
48	O
h	O
)	O
the	O
NK	B-Anatomy
cells	I-Anatomy
stimulated	O
the	O
iDCs	B-Anatomy
rather	O
than	O
lysing	O
them	O
.	O
Based	O
on	O
these	O
conflicting	O
results	O
,	O
we	O
examined	O
in	O
more	O
detail	O
the	O
apparent	O
stimulation	O
of	O
iDCs	B-Anatomy
after	O
contact	O
with	O
NK	B-Anatomy
cells	I-Anatomy
.	O
We	O
reasoned	O
that	O
activated	O
NK	B-Anatomy
cells	I-Anatomy
would	O
be	O
more	O
useful	O
for	O
these	O
experiments	O
because	O
(	O
i	O
)	O
an	O
encounter	O
in	O
vivo	O
between	O
NK	B-Anatomy
cells	I-Anatomy
that	O
normally	O
traffic	O
in	O
the	O
blood	B-Anatomy
(	O
4	O
)	O
and	O
iDCs	B-Anatomy
which	O
reside	O
in	O
the	O
tissues	B-Anatomy
(	O
1	O
,	O
3	O
)	O
,	O
should	O
only	O
occur	O
when	O
both	O
cells	B-Anatomy
are	O
activated	O
;	O
(	O
ii	O
)	O
activated	O
NK	B-Anatomy
cells	I-Anatomy
mediate	O
more	O
potent	O
lysis	O
of	O
iDCs	B-Anatomy
(	O
11	O
-	O
13	O
)	O
,	O
thereby	O
allowing	O
for	O
a	O
more	O
rigorous	O
examination	O
of	O
a	O
potential	O
cytotoxic	O
effect	O
;	O
and	O
(	O
iii	O
)	O
the	O
number	O
of	O
NK	B-Anatomy
cells	I-Anatomy
obtained	O
after	O
short	O
-	O
term	O
in	O
vitro	O
culture	O
would	O
be	O
far	O
greater	O
providing	O
more	O
cells	B-Anatomy
for	O
analysis	O
(	O
9	O
)	O
.	O
The	O
DC	B-Anatomy
maturation	O
induced	O
by	O
resting	O
NK	B-Anatomy
cells	I-Anatomy
we	O
observed	O
was	O
dependent	O
on	O
endogenous	O
TNF	O
-	O
alpha	O
production	O
.	O
Furthermore	O
,	O
TNF	O
-	O
alpha	O
and	O
other	O
proinflammatory	O
cytokines	O
are	O
important	O
amplifiers	O
of	O
immune	O
responses	O
(	O
14	O
)	O
.	O
Therefore	O
,	O
we	O
used	O
TNF	O
-	O
alpha	O
production	O
as	O
a	O
readout	O
for	O
DC	B-Anatomy
stimulation	O
in	O
our	O
culture	O
system	O
.	O
Culturing	O
activated	O
NK	B-Anatomy
cells	I-Anatomy
with	O
DCs	B-Anatomy
at	O
low	O
NK	B-Anatomy
/	O
DC	B-Anatomy
ratios	O
(	O
1	O
:	O
5	O
)	O
led	O
to	O
increases	O
in	O
TNF	O
-	O
alpha	O
production	O
,	O
which	O
were	O
augmented	O
dramatically	O
by	O
the	O
addition	O
of	O
suboptimal	O
doses	O
(	O
10	O
ng	O
/	O
ml	O
)	O
of	O
LPS	O
(	O
Fig	O
.	O
2	O
A	O
)	O
.	O
The	O
increased	O
TNF	O
-	O
alpha	O
production	O
was	O
dependent	O
on	O
cell	B-Anatomy
-	O
to	O
-	O
cell	B-Anatomy
contact	O
because	O
when	O
the	O
two	O
cell	B-Anatomy
types	O
were	O
separated	O
in	O
trans	O
-	O
wells	O
,	O
no	O
stimulation	O
was	O
observed	O
(	O
Fig	O
.	O
2	O
B	O
)	O
.	O
In	O
separate	O
experiments	O
we	O
observed	O
this	O
NK	B-Anatomy
-	O
stimulatory	O
effect	O
on	O
TNF	O
-	O
alpha	O
production	O
at	O
NK	B-Anatomy
/	O
DC	B-Anatomy
ratios	O
as	O
low	O
as	O
1	O
:	O
20	O
and	O
1	O
:	O
40	O
(	O
data	O
not	O
shown	O
)	O
.	O
Raising	O
the	O
NK	B-Anatomy
/	O
DC	B-Anatomy
ratio	O
to	O
5	O
:	O
1	O
changes	O
the	O
interaction	O
from	O
one	O
of	O
potent	O
DC	B-Anatomy
stimulation	O
to	O
that	O
of	O
complete	O
inhibition	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
(	O
Fig	O
.	O
2	O
C	O
)	O
.	O
An	O
identical	O
pattern	O
is	O
seen	O
for	O
IL	O
-	O
12	O
p40	O
production	O
(	O
Fig	O
.	O
2	O
D	O
)	O
.	O
No	O
IL	O
-	O
10	O
production	O
in	O
the	O
cultures	O
was	O
detected	O
under	O
any	O
of	O
the	O
conditions	O
tested	O
(	O
data	O
not	O
shown	O
)	O
.	O
The	O
massive	O
production	O
of	O
TNF	O
-	O
alpha	O
in	O
the	O
cultures	O
at	O
the	O
lowest	O
ratios	O
was	O
mediated	O
primarily	O
by	O
DCs	B-Anatomy
in	O
the	O
culture	O
due	O
to	O
the	O
low	O
number	O
of	O
NK	B-Anatomy
cells	I-Anatomy
(	O
2	O
x	O
104	O
cells	B-Anatomy
per	O
well	O
)	O
used	O
in	O
these	O
experiments	O
.	O
In	O
addition	O
,	O
efforts	O
to	O
stimulate	O
NK	B-Anatomy
cells	I-Anatomy
directly	O
with	O
optimal	O
doses	O
of	O
anti	O
-	O
CD16	O
,	O
rIL	O
-	O
2	O
,	O
rIL	O
-	O
12	O
,	O
and	O
PMA	O
/	O
ionomycin	O
alone	O
or	O
in	O
combination	O
induced	O
only	O
moderate	O
(	O
<	O
500	O
pg	O
/	O
ml	O
)	O
TNF	O
-	O
alpha	O
production	O
by	O
the	O
NK	B-Anatomy
cells	I-Anatomy
alone	O
which	O
were	O
present	O
at	O
2	O
x	O
105	O
cells	B-Anatomy
per	O
well	O
(	O
data	O
not	O
shown	O
)	O
.	O
Figure	O
2	O
.	O
Activated	O
/	O
cultured	O
NK	B-Anatomy
cell	I-Anatomy
-	O
mediated	O
amplification	O
/	O
inhibition	O
of	O
DC	B-Anatomy
cytokine	O
production	O
.	O
Results	O
are	O
presented	O
on	O
log	O
scales	O
.	O
Cultured	O
iDCs	B-Anatomy
were	O
incubated	O
alone	O
or	O
with	O
cultured	O
/	O
purified	O
NK	B-Anatomy
cells	I-Anatomy
for	O
24	O
h	O
(	O
A	O
and	O
B	O
)	O
or	O
48	O
h	O
(	O
C	O
-	O
E	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
indicated	O
concentrations	O
of	O
LPS	O
.	O
After	O
culture	O
the	O
supernatants	B-Anatomy
were	O
removed	O
and	O
analyzed	O
by	O
ELISA	O
for	O
TNF	O
-	O
alpha	O
or	O
IL	O
-	O
12	O
p40	O
.	O
(	O
A	O
)	O
TNF	O
-	O
alpha	O
production	O
was	O
measured	O
in	O
the	O
supernatants	B-Anatomy
from	O
cultures	B-Anatomy
of	O
:	O
DCs	B-Anatomy
alone	O
(	O
gray	O
bars	O
)	O
;	O
NK	B-Anatomy
+	O
DC	B-Anatomy
(	O
1	O
:	O
5	O
)	O
(	O
black	O
bars	O
)	O
.	O
LPS	O
concentrations	O
used	O
were	O
:	O
0	O
,	O
10	O
,	O
and	O
1	O
,	O
000	O
ng	O
/	O
ml	O
(	O
DCs	B-Anatomy
alone	O
only	O
)	O
.	O
(	O
B	O
)	O
Contact	O
-	O
dependent	O
stimulation	O
of	O
iDC	B-Anatomy
TNF	O
-	O
alpha	O
production	O
by	O
NK	B-Anatomy
cells	I-Anatomy
was	O
tested	O
under	O
the	O
following	O
conditions	O
:	O
DCs	B-Anatomy
alone	O
(	O
gray	O
bars	O
)	O
;	O
NK	B-Anatomy
+	O
DC	B-Anatomy
(	O
1	O
:	O
5	O
)	O
(	O
black	O
bars	O
)	O
;	O
NK	B-Anatomy
/	O
DC	B-Anatomy
(	O
1	O
:	O
5	O
)	O
trans	O
-	O
wells	O
(	O
striped	O
bars	O
)	O
.	O
LPS	O
concentrations	O
used	O
were	O
:	O
10	O
ng	O
/	O
ml	O
(	O
donor	O
1	O
)	O
and	O
20	O
ng	O
/	O
ml	O
(	O
donor	O
2	O
)	O
.	O
(	O
C	O
and	O
D	O
)	O
Effect	O
of	O
increasing	O
the	O
NK	B-Anatomy
/	O
DC	B-Anatomy
ratio	O
(	O
DCs	B-Anatomy
alone	O
;	O
NK	B-Anatomy
:	O
DC	B-Anatomy
-	O
1	O
:	O
5	O
;	O
1	O
:	O
1	O
;	O
5	O
:	O
1	O
)	O
on	O
(	O
C	O
)	O
TNF	O
-	O
alpha	O
and	O
(	O
D	O
)	O
IL	O
-	O
12	O
p40	O
production	O
.	O
LPS	O
concentrations	O
used	O
were	O
:	O
0	O
ng	O
/	O
ml	O
(	O
*	O
)	O
;	O
20	O
ng	O
/	O
ml	O
(	O
*	O
)	O
;	O
50	O
ng	O
/	O
ml	O
(	O
^	O
)	O
;	O
and	O
1	O
,	O
000	O
ng	O
/	O
ml	O
-	O
LPS	O
(	O
*	O
)	O
(	O
DCs	B-Anatomy
alone	O
only	O
)	O
.	O
(	O
E	O
)	O
The	O
effect	O
of	O
neutralizing	O
IFN	O
-	O
gamma	O
production	O
was	O
tested	O
under	O
the	O
following	O
conditions	O
:	O
DCs	B-Anatomy
alone	O
(	O
gray	O
bars	O
)	O
;	O
NK	B-Anatomy
+	O
DC	B-Anatomy
(	O
1	O
:	O
5	O
)	O
(	O
black	O
bars	O
)	O
;	O
NK	B-Anatomy
+	O
DC	B-Anatomy
(	O
1	O
:	O
5	O
)	O
and	O
10	O
mug	O
/	O
ml	O
of	O
blocking	O
anti	O
-	O
IFN	O
-	O
gamma	O
mAb	O
(	O
stippled	O
bars	O
)	O
.	O
LPS	O
concentrations	O
used	O
were	O
:	O
0	O
ng	O
/	O
ml	O
(	O
NO	O
LPS	O
)	O
and	O
20	O
ng	O
/	O
ml	O
(	O
LPS	O
20	O
)	O
.	O
Blocking	O
reagents	O
for	O
CD80	O
,	O
CD86	O
,	O
CD154	O
,	O
CD95	O
,	O
CD11a	O
,	O
CD50	O
,	O
or	O
IL	O
-	O
12	O
,	O
had	O
no	O
effect	O
on	O
the	O
NK	B-Anatomy
cell	I-Anatomy
-	O
induced	O
TNF	O
-	O
alpha	O
or	O
IL	O
-	O
12	O
p40	O
production	O
,	O
whereas	O
a	O
neutralizing	O
antibody	O
for	O
IFN	O
-	O
gamma	O
while	O
not	O
affecting	O
TNF	O
-	O
alpha	O
production	O
partially	O
blocked	O
(	O
<	O
20	O
%	O
)	O
IL	O
-	O
12	O
p40	O
production	O
induced	O
by	O
the	O
NK	B-Anatomy
cells	I-Anatomy
(	O
Fig	O
.	O
2	O
E	O
)	O
.	O
This	O
partial	O
inhibition	O
is	O
consistent	O
with	O
numerous	O
previous	O
reports	O
demonstrating	O
a	O
central	O
role	O
for	O
an	O
IL	O
-	O
12	O
/	O
IFN	O
-	O
gamma	O
positive	O
feedback	O
loop	O
active	O
between	O
NK	B-Anatomy
cells	I-Anatomy
and	O
IL	B-Anatomy
-	I-Anatomy
12	I-Anatomy
-	I-Anatomy
producing	I-Anatomy
cells	I-Anatomy
(	O
15	O
-	O
17	O
)	O
.	O
Clearly	O
,	O
however	O
,	O
this	O
well	O
-	O
described	O
cytokine	O
cross	O
-	O
talk	O
mechanism	O
is	O
secondary	O
to	O
the	O
contact	O
-	O
dependent	O
activation	O
of	O
DCs	B-Anatomy
by	O
NK	B-Anatomy
cells	I-Anatomy
described	O
here	O
.	O
Taken	O
together	O
these	O
results	O
indicate	O
that	O
novel	O
mechanisms	O
control	O
cognate	O
interactions	O
between	O
NK	B-Anatomy
cells	I-Anatomy
and	O
DCs	B-Anatomy
and	O
that	O
NK	B-Anatomy
-	O
DC	B-Anatomy
contact	O
has	O
the	O
potential	O
to	O
serve	O
as	O
an	O
important	O
control	O
switch	O
for	O
both	O
amplifying	O
and	O
attenuating	O
innate	O
immune	O
responses	O
in	O
vivo	O
.	O
We	O
next	O
tested	O
directly	O
whether	O
NK	B-Anatomy
cell	I-Anatomy
killing	O
was	O
active	O
in	O
our	O
system	O
using	O
both	O
short	O
-	O
term	O
(	O
4	O
-	O
h	O
)	O
chromium	O
release	O
assays	O
(	O
data	O
not	O
shown	O
)	O
and	O
a	O
flow	O
cytometric	O
assay	O
which	O
allowed	O
us	O
to	O
follow	O
the	O
survival	O
of	O
the	O
autologous	O
iDCs	B-Anatomy
in	O
the	O
presence	O
of	O
NK	B-Anatomy
cells	I-Anatomy
over	O
longer	O
periods	O
(	O
Fig	O
.	O
3	O
)	O
.	O
The	O
results	O
demonstrate	O
that	O
NK	B-Anatomy
cells	I-Anatomy
kill	O
autologous	O
iDCs	B-Anatomy
(	O
Fig	O
.	O
3	O
A	O
)	O
at	O
all	O
NK	B-Anatomy
/	O
DC	B-Anatomy
ratios	O
tested	O
after	O
4	O
h	O
and	O
the	O
level	O
of	O
killing	O
is	O
similar	O
to	O
the	O
lysis	O
of	O
K562	B-Anatomy
cells	I-Anatomy
over	O
the	O
same	O
time	O
(	O
Fig	O
.	O
3	O
B	O
)	O
.	O
After	O
24	O
h	O
,	O
however	O
,	O
the	O
presence	O
of	O
NK	B-Anatomy
cells	I-Anatomy
led	O
to	O
completely	O
divergent	O
effects	O
on	O
the	O
DCs	B-Anatomy
.	O
At	O
the	O
5	O
:	O
1	O
(	O
NK	B-Anatomy
/	O
DC	B-Anatomy
)	O
ratio	O
,	O
NK	B-Anatomy
cell	I-Anatomy
-	O
mediated	O
destruction	O
of	O
the	O
iDCs	B-Anatomy
was	O
the	O
dominant	O
feature	O
,	O
whereas	O
at	O
the	O
low	O
ratio	O
(	O
1	O
:	O
5	O
)	O
the	O
same	O
NK	B-Anatomy
cells	I-Anatomy
promoted	O
iDCs	B-Anatomy
survival	O
compared	O
with	O
iDCs	B-Anatomy
alone	O
over	O
the	O
same	O
period	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O
The	O
equal	O
ratio	O
of	O
NK	B-Anatomy
/	O
DC	B-Anatomy
(	O
1	O
:	O
1	O
)	O
fell	O
between	O
these	O
two	O
extremes	O
.	O
The	O
NK	B-Anatomy
cell	I-Anatomy
-	O
mediated	O
lysis	O
of	O
the	O
K562	B-Anatomy
targets	O
increased	O
at	O
all	O
ratios	O
tested	O
after	O
the	O
24	O
-	O
h	O
incubation	O
.	O
These	O
striking	O
differences	O
between	O
death	O
and	O
survival	O
of	O
DCs	B-Anatomy
upon	O
encountering	O
NK	B-Anatomy
cells	I-Anatomy
correlate	O
precisely	O
with	O
our	O
previous	O
results	O
on	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
12	O
p40	O
production	O
where	O
increasing	O
numbers	O
of	O
NK	B-Anatomy
cells	I-Anatomy
in	O
the	O
culture	O
shifts	O
the	O
NK	B-Anatomy
effect	O
from	O
potent	O
stimulation	O
to	O
complete	O
inhibition	O
(	O
Fig	O
.	O
2	O
)	O
.	O
Figure	O
3	O
.	O
Activated	O
/	O
cultured	O
NK	B-Anatomy
cell	I-Anatomy
-	O
mediated	O
death	O
/	O
survival	O
of	O
DCs	B-Anatomy
and	O
NK	B-Anatomy
-	O
DC	B-Anatomy
conjugate	O
formation	O
.	O
NK	B-Anatomy
cell	I-Anatomy
mediated	O
killing	O
/	O
survival	O
of	O
CFDA	O
.	O
SE	O
-	O
loaded	O
iDCs	B-Anatomy
(	O
A	O
)	O
and	O
K562	B-Anatomy
cells	I-Anatomy
(	O
B	O
)	O
was	O
measured	O
by	O
flow	O
cytometry	O
over	O
4	O
h	O
(	O
*	O
)	O
or	O
24	O
h	O
(	O
*	O
)	O
at	O
the	O
indicated	O
NK	B-Anatomy
/	O
DC	B-Anatomy
ratios	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O
Results	O
are	O
presented	O
as	O
percentage	O
of	O
specific	O
lysis	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
3	O
independent	O
experiments	O
)	O
.	O
NK	B-Anatomy
-	O
DC	B-Anatomy
(	O
C	O
-	O
E	O
)	O
or	O
NK	B-Anatomy
-	O
K562	B-Anatomy
(	O
F	O
-	O
H	O
)	O
conjugate	O
formation	O
was	O
measured	O
by	O
flow	O
cytometry	O
,	O
at	O
the	O
following	O
ratios	O
(	O
NK	B-Anatomy
/	O
DC	B-Anatomy
or	O
NK	B-Anatomy
/	O
K562	B-Anatomy
)	O
:	O
1	O
:	O
5	O
(	O
C	O
and	O
F	O
)	O
;	O
1	O
:	O
1	O
(	O
D	O
and	O
G	O
)	O
;	O
and	O
5	O
:	O
1	O
(	O
E	O
and	O
H	O
)	O
.	O
Snarf	O
-	O
1	O
(	O
FL3	O
)	O
-	O
labeled	O
iDCs	B-Anatomy
or	O
K562	B-Anatomy
cells	I-Anatomy
were	O
incubated	O
(	O
30	O
min	O
)	O
with	O
CFDA	O
.	O
SE	O
(	O
FL1	O
)	O
-	O
labeled	O
NK	B-Anatomy
cells	I-Anatomy
at	O
the	O
different	O
ratios	O
.	O
The	O
percentage	O
of	O
conjugates	O
formed	O
(	O
top	O
right	O
quadrant	O
)	O
was	O
calculated	O
by	O
determining	O
the	O
percentage	O
of	O
FL3	O
+	O
(	O
Snarf	O
-	O
1	O
)	O
events	O
which	O
were	O
also	O
positive	O
for	O
FL1	O
(	O
CFDA	O
.	O
SE	O
)	O
.	O
The	O
results	O
are	O
representative	O
of	O
four	O
experiments	O
performed	O
with	O
activated	O
NK	B-Anatomy
cells	I-Anatomy
.	O
Resting	O
NK	B-Anatomy
cells	I-Anatomy
also	O
readily	O
formed	O
conjugates	O
with	O
autologous	O
iDCs	B-Anatomy
(	O
data	O
not	O
shown	O
)	O
.	O
NK	B-Anatomy
cells	I-Anatomy
can	O
both	O
efficiently	O
kill	O
and	O
potently	O
stimulate	O
DCs	B-Anatomy
in	O
our	O
model	O
system	O
and	O
each	O
of	O
these	O
opposing	O
effects	O
appear	O
dependent	O
on	O
cell	B-Anatomy
-	O
to	O
-	O
cell	B-Anatomy
contact	O
.	O
To	O
quantify	O
these	O
apparent	O
cognate	O
interactions	O
we	O
measured	O
the	O
formation	O
of	O
NK	B-Anatomy
-	O
DC	B-Anatomy
conjugates	O
and	O
compared	O
them	O
to	O
conjugates	O
formed	O
by	O
NK	B-Anatomy
cells	I-Anatomy
and	O
tumor	B-Anatomy
targets	O
.	O
Our	O
analysis	O
revealed	O
that	O
NK	B-Anatomy
cells	I-Anatomy
bound	O
DC	B-Anatomy
(	O
Fig	O
.	O
3	O
C	O
-	O
E	O
)	O
with	O
an	O
efficiency	O
almost	O
equal	O
to	O
that	O
of	O
NK	B-Anatomy
cell	I-Anatomy
binding	O
to	O
the	O
classical	O
NK	B-Anatomy
-	O
target	O
,	O
K562	B-Anatomy
(	O
Fig	O
.	O
3	O
F	O
-	O
H	O
)	O
.	O
Binding	O
was	O
detectable	O
even	O
at	O
the	O
lowest	O
NK	B-Anatomy
/	O
DC	B-Anatomy
ratio	O
tested	O
(	O
1	O
:	O
5	O
)	O
indicating	O
that	O
NK	B-Anatomy
-	O
DC	B-Anatomy
conjugates	O
are	O
formed	O
in	O
our	O
other	O
experiments	O
measuring	O
cytokine	O
production	O
and	O
cell	B-Anatomy
killing	O
.	O
Our	O
initial	O
experiments	O
using	O
resting	O
NK	B-Anatomy
cells	I-Anatomy
(	O
Fig	O
.	O
1	O
)	O
demonstrated	O
a	O
contact	O
-	O
dependent	O
NK	B-Anatomy
effect	O
driving	O
iDCs	B-Anatomy
to	O
mature	O
.	O
Therefore	O
,	O
we	O
tested	O
what	O
effects	O
activated	O
NK	B-Anatomy
cells	I-Anatomy
mediated	O
on	O
DC	B-Anatomy
maturation	O
(	O
Fig	O
.	O
4	O
)	O
.	O
Similar	O
to	O
our	O
previous	O
results	O
with	O
activated	O
NK	B-Anatomy
cells	I-Anatomy
(	O
Figs	O
.	O
2	O
and	O
3	O
)	O
,	O
addition	O
of	O
NK	B-Anatomy
cells	I-Anatomy
to	O
the	O
culture	B-Anatomy
leads	O
to	O
opposing	O
effects	O
on	O
the	O
iDC	B-Anatomy
population	O
depending	O
on	O
the	O
NK	B-Anatomy
/	O
DC	B-Anatomy
ratio	O
.	O
Compared	O
with	O
the	O
untreated	O
DCs	B-Anatomy
(	O
Fig	O
.	O
4	O
A	O
-	O
C	O
)	O
,	O
low	O
NK	B-Anatomy
/	O
DC	B-Anatomy
ratios	O
(	O
1	O
:	O
5	O
or	O
1	O
:	O
1	O
)	O
consistently	O
augmented	O
expression	O
of	O
the	O
maturation	O
markers	O
:	O
CD86	O
(	O
Fig	O
.	O
4	O
D	O
-	O
I	O
)	O
,	O
CD83	O
,	O
and	O
HLA	O
-	O
DR	O
(	O
data	O
not	O
shown	O
)	O
.	O
At	O
a	O
5	O
:	O
1	O
ratio	O
(	O
NK	B-Anatomy
/	O
DC	B-Anatomy
)	O
most	O
of	O
the	O
DCs	B-Anatomy
are	O
nonviable	O
(	O
Fig	O
.	O
4	O
J	O
-	O
L	O
)	O
.	O
Addition	O
of	O
suboptimal	O
doses	O
of	O
LPS	O
(	O
Fig	O
.	O
4	O
C	O
,	O
F	O
,	O
I	O
,	O
and	O
L	O
)	O
augmented	O
the	O
NK	B-Anatomy
-	O
induced	O
maturation	O
at	O
NK	B-Anatomy
/	O
DC	B-Anatomy
ratios	O
of	O
1	O
:	O
5	O
and	O
1	O
:	O
1	O
,	O
but	O
had	O
no	O
effect	O
at	O
the	O
5	O
:	O
1	O
ratio	O
.	O
Again	O
,	O
DC	B-Anatomy
maturation	O
was	O
dependent	O
on	O
NK	B-Anatomy
cell	I-Anatomy
contact	O
and	O
endogenously	O
produced	O
TNF	O
-	O
alpha	O
,	O
because	O
it	O
did	O
not	O
occur	O
when	O
the	O
two	O
cell	B-Anatomy
types	O
were	O
separated	O
in	O
trans	O
-	O
wells	O
or	O
upon	O
the	O
addition	O
of	O
a	O
neutralizing	O
antibody	O
for	O
TNF	O
-	O
alpha	O
(	O
Fig	O
.	O
5	O
)	O
.	O
Moreover	O
,	O
addition	O
of	O
blocking	O
reagents	O
for	O
CD80	O
,	O
CD86	O
,	O
CD154	O
,	O
CD95	O
,	O
CD11a	O
,	O
CD50	O
,	O
IL	O
-	O
12	O
,	O
IFN	O
-	O
gamma	O
,	O
IFN	O
-	O
alpha	O
,	O
or	O
IFN	O
-	O
beta	O
had	O
no	O
effect	O
on	O
the	O
NK	B-Anatomy
-	O
induced	O
maturation	O
(	O
data	O
not	O
shown	O
)	O
.	O
Figure	O
4	O
.	O
Activated	O
/	O
cultured	O
NK	B-Anatomy
cell	I-Anatomy
-	O
mediated	O
maturation	O
/	O
death	O
of	O
DCs	B-Anatomy
.	O
Cultured	O
iDCs	B-Anatomy
were	O
incubated	O
for	O
48	O
h	O
,	O
alone	O
(	O
A	O
-	O
C	O
)	O
,	O
or	O
with	O
NK	B-Anatomy
cells	I-Anatomy
at	O
the	O
following	O
ratios	O
(	O
NK	B-Anatomy
/	O
DC	B-Anatomy
)	O
,	O
1	O
:	O
5	O
(	O
D	O
-	O
F	O
)	O
,	O
1	O
:	O
1	O
(	O
G	O
-	O
I	O
)	O
,	O
and	O
5	O
:	O
1	O
(	O
J	O
-	O
L	O
)	O
.	O
Forward	O
versus	O
side	O
scatter	O
plots	O
(	O
A	O
,	O
D	O
,	O
G	O
,	O
and	O
J	O
)	O
show	O
the	O
gating	O
on	O
the	O
DC	B-Anatomy
subset	O
and	O
demonstrate	O
its	O
disappearance	O
at	O
the	O
5	O
:	O
1	O
(	O
NK	B-Anatomy
/	O
DC	B-Anatomy
)	O
ratio	O
(	O
J	O
)	O
.	O
Propidium	O
iodide	O
staining	O
of	O
the	O
NK	B-Anatomy
/	O
DC	B-Anatomy
(	O
5	O
:	O
1	O
)	O
cultures	O
confirmed	O
the	O
almost	O
complete	O
absence	O
of	O
viable	O
DCs	B-Anatomy
(	O
data	O
not	O
shown	O
)	O
.	O
Staining	O
for	O
CD86	O
expression	O
was	O
performed	O
as	O
described	O
in	O
Fig	O
.	O
1	O
and	O
the	O
histograms	O
are	O
shown	O
for	O
DCs	B-Anatomy
cultured	O
in	O
the	O
presence	O
(	O
C	O
,	O
F	O
,	O
I	O
,	O
and	O
L	O
)	O
or	O
absence	O
(	O
B	O
,	O
E	O
,	O
H	O
,	O
and	O
K	O
)	O
of	O
1	O
ng	O
/	O
ml	O
of	O
LPS	O
.	O
Results	O
are	O
representative	O
of	O
six	O
experiments	O
performed	O
.	O
Figure	O
5	O
.	O
Activated	O
/	O
cultured	O
NK	B-Anatomy
cell	I-Anatomy
-	O
induced	O
DC	B-Anatomy
maturation	O
is	O
dependent	O
on	O
cell	B-Anatomy
-	O
to	O
-	O
cell	B-Anatomy
contact	O
and	O
endogenous	O
TNF	O
-	O
alpha	O
production	O
.	O
Cultured	O
iDCs	B-Anatomy
were	O
incubated	O
alone	O
(	O
A	O
,	O
D	O
,	O
and	O
G	O
)	O
;	O
with	O
activated	O
NK	B-Anatomy
cells	I-Anatomy
at	O
an	O
NK	B-Anatomy
/	O
DC	B-Anatomy
ratio	O
of	O
1	O
:	O
5	O
(	O
B	O
,	O
E	O
,	O
and	O
H	O
)	O
;	O
with	O
activated	O
NK	B-Anatomy
cells	I-Anatomy
(	O
NK	B-Anatomy
/	O
DC	B-Anatomy
;	O
1	O
:	O
5	O
)	O
separated	O
in	O
trans	O
-	O
wells	O
(	O
C	O
and	O
F	O
)	O
;	O
or	O
with	O
activated	O
NK	B-Anatomy
cells	I-Anatomy
and	O
10	O
mug	O
/	O
ml	O
of	O
a	O
neutralizing	O
antibody	O
for	O
TNF	O
-	O
alpha	O
(	O
I	O
)	O
.	O
LPS	O
concentrations	O
used	O
were	O
:	O
0	O
ng	O
/	O
ml	O
(	O
A	O
-	O
C	O
)	O
;	O
10	O
ng	O
/	O
ml	O
(	O
D	O
-	O
F	O
)	O
and	O
50	O
ng	O
/	O
ml	O
(	O
G	O
-	O
I	O
)	O
.	O
CD86	O
staining	O
of	O
the	O
DC	B-Anatomy
subset	O
was	O
performed	O
as	O
in	O
Figs	O
.	O
1	O
and	O
4	O
.	O
Results	O
are	O
representative	O
of	O
four	O
experiments	O
performed	O
.	O
Acknowledgements	O
We	O
would	O
like	O
to	O
thank	O
our	O
colleague	O
Dr	O
.	O
Nikolaos	O
Papathanasiou	O
for	O
his	O
assistance	O
in	O
performing	O
the	O
statistical	O
analysis	O
.	O
Anion	O
to	O
cation	O
selectivity	O
ratio	O
determined	O
from	O
the	O
relative	O
rates	O
of	O
reaction	O
of	O
MTSES	O
-	O
and	O
MTSET	O
+	O
with	O
the	O
water	O
exposed	O
residues	O
in	O
the	O
M6	O
segment	O
.	O
The	O
anion	O
selectivity	O
ratio	O
is	O
calculated	O
as	O
described	O
in	O
Table	O
II	O
,	O
column	O
5	O
.	O
Note	O
the	O
marked	O
increase	O
in	O
anion	O
selectivity	O
at	O
the	O
residues	O
T351C	O
and	O
Q353C	O
.	O
A	O
ratio	O
of	O
1	O
indicates	O
no	O
selectivity	O
between	O
anions	O
and	O
cations	O
.	O
The	O
larger	O
the	O
ratio	O
the	O
greater	O
the	O
anion	O
selectivity	O
.	O
Loss	O
of	O
both	O
apical	B-Anatomy
pathways	I-Anatomy
(	O
bottom	O
)	O
allows	O
astral	B-Anatomy
microtubules	I-Anatomy
(	O
arrows	O
)	O
to	O
form	O
apically	O
and	O
basally	O
in	O
neuroblasts	B-Anatomy
.	O
Authors	O
'	O
contributions	O
All	O
authors	O
contributed	O
to	O
the	O
development	O
of	O
the	O
methodology	O
.	O
CY	O
and	O
NZ	O
led	O
method	O
conceptualization	O
and	O
prepared	O
the	O
original	O
draft	O
,	O
which	O
was	O
revised	O
by	O
JR	O
.	O
CY	O
and	O
VD	O
performed	O
most	O
implementations	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
Background	O
Potato	O
late	O
blight	O
,	O
a	O
disease	O
caused	O
by	O
the	O
oomycete	O
pathogen	O
Phytophthora	O
infestans	O
,	O
is	O
one	O
of	O
the	O
world	O
'	O
s	O
most	O
devastating	O
crop	O
diseases	O
.	O
World	O
-	O
wide	O
losses	O
due	O
to	O
late	O
blight	O
exceed	O
several	O
billion	O
dollars	O
annually	O
[	O
1	O
]	O
.	O
Most	O
of	O
the	O
potato	O
cultivars	O
currently	O
grown	O
in	O
the	O
United	O
States	O
are	O
highly	O
susceptible	O
to	O
late	O
blight	O
and	O
control	O
of	O
this	O
disease	O
relies	O
almost	O
exclusively	O
on	O
fungicide	O
applications	O
.	O
The	O
most	O
effective	O
and	O
environmentally	O
sound	O
way	O
for	O
controlling	O
late	O
blight	O
is	O
to	O
incorporate	O
natural	O
resistance	O
into	O
potato	O
cultivars	O
.	O
The	O
pedigrees	O
of	O
many	O
potato	O
cultivars	O
currently	O
used	O
in	O
different	O
countries	O
include	O
late	O
blight	O
resistant	O
germplasm	O
derived	O
from	O
Solanum	O
demissum	O
,	O
Solanum	O
andigena	O
,	O
and	O
other	O
wild	O
species	O
.	O
However	O
,	O
most	O
of	O
the	O
resistance	O
derived	O
from	O
these	O
wild	O
species	O
is	O
controlled	O
by	O
single	O
dominant	O
resistance	O
genes	O
(	O
R	O
genes	O
)	O
.	O
These	O
R	O
genes	O
are	O
only	O
effective	O
in	O
preventing	O
the	O
development	O
of	O
late	O
blight	O
if	O
the	O
invading	O
P	O
.	O
infestans	O
race	O
contains	O
the	O
corresponding	O
avirulence	O
genes	O
.	O
This	O
R	O
gene	O
-	O
mediated	O
resistance	O
is	O
often	O
short	O
-	O
lived	O
and	O
is	O
rapidly	O
overcome	O
by	O
new	O
races	O
of	O
the	O
late	O
blight	O
pathogen	O
.	O
Solanum	O
bulbocastanum	O
(	O
2n	O
=	O
2x	O
=	O
24	O
)	O
is	O
a	O
diploid	O
species	O
that	O
has	O
adapted	O
in	O
the	O
same	O
environment	O
as	O
the	O
late	O
blight	O
pathogen	O
.	O
This	O
wild	O
species	O
was	O
characterized	O
as	O
possessing	O
durable	O
resistance	O
against	O
P	O
.	O
infestans	O
,	O
even	O
under	O
high	O
disease	O
pressure	O
[	O
2	O
,	O
3	O
]	O
.	O
Two	O
resistance	O
genes	O
,	O
RB	O
(	O
Rpi	O
-	O
blb1	O
)	O
and	O
Rpi	O
-	O
blb2	O
,	O
have	O
been	O
cloned	O
from	O
S	O
.	O
bulbocastanum	O
[	O
4	O
-	O
6	O
]	O
.	O
Both	O
genes	O
confer	O
broad	O
-	O
spectrum	O
resistance	O
against	O
a	O
wide	O
range	O
of	O
known	O
P	O
.	O
infestans	O
races	O
.	O
Transgenic	O
potato	O
lines	O
containing	O
a	O
single	O
RB	O
gene	O
showed	O
a	O
high	O
-	O
level	O
resistance	O
in	O
the	O
Toluca	O
Valley	O
,	O
Mexico	O
,	O
where	O
the	O
potato	O
fields	O
are	O
naturally	O
intensively	O
infested	O
with	O
the	O
most	O
diversified	O
P	O
.	O
infestans	O
populations	O
[	O
7	O
]	O
.	O
Most	O
interestingly	O
,	O
transgenic	O
RB	O
plants	O
did	O
not	O
show	O
total	O
immunity	O
to	O
late	O
blight	O
,	O
but	O
instead	O
showed	O
a	O
marked	O
delay	O
in	O
both	O
onset	O
of	O
symptoms	O
and	O
development	O
of	O
lesions	B-Anatomy
.	O
Such	O
rate	O
-	O
limiting	O
resistance	O
may	O
put	O
less	O
selection	O
pressure	O
on	O
the	O
P	O
.	O
infestans	O
populations	O
and	O
protect	O
the	O
durability	O
of	O
this	O
resistance	O
gene	O
.	O
The	O
RB	O
gene	O
therefore	O
provides	O
an	O
excellent	O
model	O
to	O
study	O
the	O
mechanism	O
of	O
broad	O
-	O
spectrum	O
and	O
rate	O
-	O
limiting	O
disease	O
resistances	O
.	O
An	O
understanding	O
of	O
the	O
underlying	O
mechanism	O
of	O
this	O
type	O
of	O
resistance	O
is	O
important	O
for	O
developing	O
strategies	O
to	O
breed	O
durable	O
and	O
sustainable	O
disease	O
resistance	O
.	O
Several	O
genes	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
R	O
gene	O
function	O
.	O
Of	O
these	O
genes	O
,	O
Rar1	O
and	O
Sgt1	O
are	O
among	O
the	O
most	O
extensively	O
studied	O
genes	O
.	O
The	O
Rar1	O
(	O
required	O
for	O
Mla12	O
resistance	O
)	O
gene	O
was	O
first	O
identified	O
for	O
its	O
essential	O
role	O
in	O
the	O
function	O
of	O
a	O
subset	O
of	O
Mla	O
genes	O
that	O
confer	O
resistance	O
to	O
barley	O
powdery	O
mildew	O
[	O
8	O
]	O
.	O
The	O
RAR1	O
protein	O
contains	O
two	O
highly	O
similar	O
but	O
distinct	O
cysteine	O
-	O
and	O
histidine	O
-	O
rich	O
(	O
CHORD	O
)	O
Zn2	O
+	O
-	O
binding	O
domains	O
and	O
was	O
proposed	O
to	O
play	O
a	O
role	O
in	O
stabilizing	O
R	O
proteins	O
in	O
a	O
confirmation	O
that	O
is	O
implicated	O
in	O
receiving	O
pathogen	O
signals	O
[	O
9	O
]	O
.	O
The	O
Sgt1	O
gene	O
(	O
suppressor	O
of	O
the	O
G2	O
allele	O
of	O
skp1	O
)	O
is	O
an	O
essential	O
gene	O
with	O
multiple	O
functions	O
in	O
yeast	O
.	O
SGT1	O
protein	O
was	O
initially	O
identified	O
as	O
a	O
RAR1	O
-	O
interacting	O
partner	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
[	O
10	O
]	O
.	O
SGT1	O
may	O
play	O
a	O
role	O
in	O
R	O
protein	O
accumulation	O
[	O
11	O
]	O
.	O
Rar1	O
and	O
Sgt1	O
genes	O
are	O
required	O
in	O
various	O
R	O
-	O
gene	O
mediated	O
resistance	O
against	O
viral	O
,	O
bacterial	O
,	O
oomycete	O
or	O
fungal	O
pathogens	O
[	O
12	O
]	O
.	O
However	O
,	O
none	O
of	O
the	O
previously	O
studied	O
R	O
genes	O
showed	O
a	O
race	O
-	O
non	O
-	O
specific	O
and	O
rate	O
-	O
limiting	O
resistance	O
phenotype	O
as	O
the	O
RB	O
gene	O
.	O
In	O
addition	O
,	O
the	O
role	O
the	O
Rar1	O
and	O
Sgt1	O
genes	O
are	O
not	O
universal	O
and	O
these	O
genes	O
are	O
not	O
essential	O
for	O
resistance	O
involving	O
some	O
R	O
genes	O
[	O
12	O
,	O
13	O
]	O
.	O
Besides	O
the	O
two	O
broad	O
-	O
spectrum	O
resistance	O
genes	O
RB	O
and	O
Rpi	O
-	O
blb2	O
,	O
several	O
race	O
-	O
specific	O
late	O
blight	O
resistance	O
genes	O
have	O
also	O
been	O
cloned	O
[	O
14	O
-	O
16	O
]	O
.	O
Numerous	O
late	O
blight	O
resistance	O
genes	O
have	O
recently	O
been	O
mapped	O
in	O
various	O
potato	O
species	O
or	O
populations	O
[	O
17	O
-	O
25	O
]	O
.	O
However	O
,	O
there	O
is	O
almost	O
no	O
information	O
available	O
about	O
the	O
resistance	O
pathways	O
mediated	O
by	O
any	O
of	O
these	O
genes	O
.	O
As	O
an	O
initial	O
effort	O
to	O
understand	O
the	O
RB	O
-	O
mediated	O
late	O
blight	O
resistance	O
pathway	O
,	O
we	O
silenced	O
the	O
Rar1	O
and	O
Sgt1	O
genes	O
using	O
an	O
RNAi	O
-	O
based	O
approach	O
in	O
a	O
potato	O
line	O
containing	O
the	O
RB	O
gene	O
.	O
We	O
demonstrated	O
that	O
SGT1	O
,	O
but	O
not	O
RAR1	O
,	O
is	O
essential	O
for	O
the	O
RB	O
-	O
mediated	O
broad	O
-	O
spectrum	O
resistance	O
to	O
potato	O
late	O
blight	O
.	O
Ovariectomy	O
Based	O
on	O
the	O
uterine	B-Anatomy
weight	O
,	O
we	O
determined	O
seven	O
unsuccessful	O
OVXs	O
.	O
The	O
rats	O
concerned	O
were	O
removed	O
from	O
further	O
analyses	O
,	O
which	O
left	O
nine	O
rats	O
in	O
the	O
control	O
group	O
,	O
five	O
in	O
the	O
OVX	O
group	O
,	O
seven	O
in	O
the	O
OVX	O
and	O
late	O
ZOL	O
group	O
,	O
and	O
eight	O
in	O
the	O
OVX	O
and	O
early	O
ZOL	O
group	O
.	O
For	O
each	O
animal	O
,	O
we	O
determined	O
the	O
percentage	O
change	O
in	O
structural	O
parameters	O
compared	O
to	O
the	O
values	O
at	O
week	O
0	O
.	O
Figure	O
1	O
shows	O
the	O
average	O
percentage	O
change	O
and	O
upper	O
standard	O
deviation	O
for	O
all	O
groups	O
for	O
BV	O
/	O
TV	O
,	O
Conn	O
.	O
D	O
,	O
SMI	O
,	O
Tb	O
.	O
N	O
,	O
Tb	O
.	O
Th	O
,	O
and	O
Tb	O
.	O
Sp	O
.	O
The	O
OVX	O
group	O
without	O
treatment	O
showed	O
large	O
changes	O
in	O
structural	O
parameters	O
,	O
indicating	O
the	O
development	O
of	O
OVX	O
-	O
induced	O
bone	B-Anatomy
loss	O
(	O
Figs	O
.	O
1	O
and	O
2	O
)	O
.	O
Paired	O
Student	O
'	O
s	O
t	O
-	O
test	O
indicated	O
significant	O
changes	O
within	O
2	O
weeks	O
after	O
OVX	O
for	O
all	O
structural	O
parameters	O
.	O
BV	O
/	O
TV	O
,	O
Conn	O
.	O
D	O
,	O
and	O
Tb	O
.	O
N	O
decreased	O
during	O
the	O
experiment	O
and	O
SMI	O
and	O
Tb	O
.	O
Sp	O
increased	O
.	O
Both	O
Tb	O
.	O
Th	O
and	O
Tb	O
.	O
N	O
decreased	O
within	O
2	O
weeks	O
,	O
indicating	O
that	O
both	O
thinning	O
and	O
complete	O
resorption	O
of	O
trabeculae	O
started	O
directly	O
after	O
OVX	O
.	O
The	O
initial	O
rapid	O
loss	O
of	O
bone	B-Anatomy
and	O
connectivity	O
was	O
largely	O
accompanied	O
by	O
trabecular	B-Anatomy
thinning	O
,	O
while	O
secondary	O
,	O
slower	O
loss	O
of	O
bone	B-Anatomy
was	O
concomitant	O
with	O
a	O
decrease	O
in	O
Tb	O
.	O
N	O
.	O
While	O
BV	O
/	O
TV	O
,	O
Conn	O
.	O
D	O
,	O
SMI	O
,	O
Tb	O
.	O
N	O
,	O
and	O
Tb	O
.	O
Sp	O
showed	O
continuous	O
changes	O
in	O
the	O
same	O
direction	O
throughout	O
the	O
experiment	O
,	O
Tb	O
.	O
Th	O
initially	O
decreased	O
significantly	O
until	O
4	O
weeks	O
after	O
OVX	O
and	O
then	O
increased	O
again	O
until	O
after	O
16	O
weeks	O
Tb	O
.	O
Th	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
control	O
group	O
.	O
Fig	O
.	O
1	O
Average	O
percentage	O
change	O
in	O
structural	O
parameters	O
in	O
the	O
metaphyseal	O
proximal	O
tibia	B-Anatomy
and	O
upper	O
standard	O
deviation	O
for	O
all	O
groups	O
at	O
all	O
time	O
points	O
.	O
Brackets	O
indicate	O
P	O
<	O
0	O
.	O
05	O
at	O
week	O
16	O
Fig	O
.	O
2	O
Same	O
slice	O
of	O
an	O
unprocessed	O
CT	O
scan	O
of	O
the	O
same	O
rat	O
in	O
the	O
OVX	O
group	O
taken	O
at	O
weeks	O
0	O
(	O
a	O
)	O
,	O
2	O
(	O
b	O
)	O
,	O
4	O
(	O
c	O
)	O
,	O
8	O
(	O
d	O
)	O
,	O
12	O
(	O
e	O
)	O
,	O
and	O
16	O
(	O
f	O
)	O
.	O
Images	O
show	O
typical	O
trabecular	B-Anatomy
bone	I-Anatomy
loss	O
due	O
to	O
OVX	O
in	O
the	O
metaphysis	O
.	O
Green	O
line	O
shows	O
the	O
analyzed	O
metaphyseal	O
bone	B-Anatomy
The	O
absolute	O
average	O
values	O
and	O
standard	O
deviations	O
for	O
all	O
structural	O
parameters	O
of	O
all	O
measurements	O
are	O
shown	O
in	O
Table	O
1	O
.	O
At	O
the	O
starting	O
point	O
,	O
some	O
differences	O
in	O
the	O
values	O
between	O
the	O
groups	O
were	O
present	O
.	O
This	O
was	O
due	O
to	O
the	O
fact	O
that	O
some	O
animals	O
,	O
which	O
mostly	O
had	O
a	O
relatively	O
low	O
BV	O
/	O
TV	O
,	O
were	O
removed	O
from	O
the	O
study	O
because	O
they	O
did	O
not	O
respond	O
to	O
the	O
OVX	O
.	O
However	O
,	O
since	O
we	O
compared	O
the	O
relative	O
changes	O
in	O
each	O
animal	O
,	O
the	O
results	O
were	O
most	O
likely	O
not	O
affected	O
by	O
the	O
difference	O
in	O
absolute	O
values	O
.	O
Table	O
1	O
Mean	O
values	O
and	O
standard	O
deviation	O
of	O
all	O
structural	O
parameters	O
of	O
all	O
groups	O
at	O
the	O
start	O
of	O
the	O
experiment	O
Group	O
BV	O
/	O
TV	O
(	O
1	O
)	O
Conn	O
.	O
D	O
(	O
1	O
/	O
mm	O
)	O
SMI	O
(	O
1	O
)	O
Tb	O
.	O
N	O
(	O
1	O
/	O
mm	O
)	O
Tb	O
.	O
Th	O
(	O
mum	O
)	O
Tb	O
.	O
Sp	O
(	O
mum	O
)	O
Control	O
0	O
.	O
17	O
(	O
0	O
.	O
056	O
)	O
41	O
(	O
47	O
)	O
1	O
.	O
52	O
(	O
0	O
.	O
53	O
)	O
1	O
.	O
89	O
(	O
1	O
.	O
38	O
)	O
105	O
(	O
49	O
)	O
613	O
(	O
368	O
)	O
OVX	O
0	O
.	O
26	O
(	O
0	O
.	O
055	O
)	O
141	O
(	O
76	O
)	O
1	O
.	O
22	O
(	O
0	O
.	O
39	O
)	O
3	O
.	O
77	O
(	O
1	O
.	O
66	O
)	O
84	O
(	O
10	O
)	O
335	O
(	O
174	O
)	O
OVX	O
+	O
late	O
ZOL	O
0	O
.	O
23	O
(	O
0	O
.	O
062	O
)	O
86	O
(	O
66	O
)	O
1	O
.	O
23	O
(	O
0	O
.	O
34	O
)	O
2	O
.	O
77	O
(	O
1	O
.	O
55	O
)	O
89	O
(	O
13	O
)	O
482	O
(	O
227	O
)	O
OVX	O
+	O
early	O
ZOL	O
0	O
.	O
17	O
(	O
0	O
.	O
056	O
)	O
38	O
(	O
21	O
)	O
1	O
.	O
70	O
(	O
0	O
.	O
39	O
)	O
1	O
.	O
86	O
(	O
0	O
.	O
80	O
)	O
95	O
(	O
7	O
)	O
647	O
(	O
207	O
)	O
3	O
.	O
Results	O
and	O
discussion	O
AbsC	O
was	O
overexpressed	O
and	O
purified	O
with	O
a	O
final	O
yield	O
of	O
approximately	O
10	O
mg	O
of	O
protein	O
from	O
1	O
l	O
culture	O
and	O
was	O
judged	O
to	O
be	O
greater	O
than	O
98	O
%	O
pure	O
by	O
SDS	O
-	O
PAGE	O
analysis	O
.	O
The	O
DLS	O
analysis	O
after	O
gel	O
filtration	O
showed	O
a	O
monomodal	O
distribution	O
,	O
with	O
a	O
polydispersity	O
value	O
of	O
18	O
.	O
9	O
%	O
and	O
a	O
molecular	O
-	O
size	O
estimate	O
of	O
39	O
.	O
6	O
kDa	O
.	O
This	O
was	O
comparable	O
to	O
the	O
value	O
of	O
36	O
kDa	O
estimated	O
from	O
the	O
calibrated	O
gel	O
-	O
filtration	O
column	O
,	O
strongly	O
suggesting	O
that	O
AbsC	O
exists	O
as	O
a	O
homodimer	O
in	O
solution	O
(	O
calculated	O
molecular	O
weight	O
of	O
41	O
.	O
0	O
kDa	O
for	O
the	O
His	O
-	O
tagged	O
dimer	O
)	O
,	O
in	O
agreement	O
with	O
other	O
characterized	O
MarR	O
homologues	O
.	O
Preliminary	O
crystals	O
grew	O
within	O
24	O
h	O
at	O
293	O
K	O
from	O
several	O
different	O
crystallization	O
conditions	O
.	O
Improved	O
crystals	O
were	O
subsequently	O
obtained	O
with	O
a	O
precipitant	O
solution	O
consisting	O
of	O
1	O
M	O
ammonium	O
sulfate	O
,	O
0	O
.	O
55	O
M	O
potassium	O
sodium	O
tartrate	O
in	O
100	O
mM	O
citrate	O
pH	O
5	O
.	O
6	O
,	O
giving	O
crystals	O
with	O
approximate	O
dimensions	O
of	O
700	O
x	O
50	O
x	O
50	O
microm	O
(	O
Fig	O
.	O
1	O
>	O
)	O
.	O
Native	O
X	O
-	O
ray	O
data	O
were	O
collected	O
from	O
a	O
single	O
AbsC	O
crystal	O
:	O
a	O
total	O
of	O
214	O
x	O
0	O
.	O
4degrees	O
oscillation	O
images	O
were	O
recorded	O
in	O
a	O
continuous	O
sweep	O
to	O
a	O
maximum	O
resolution	O
of	O
2	O
.	O
25	O
A	O
.	O
Indexing	O
was	O
consistent	O
with	O
a	O
primitive	O
orthorhombic	O
lattice	O
,	O
with	O
unit	O
-	O
cell	B-Anatomy
parameters	O
a	O
=	O
43	O
.	O
53	O
,	O
b	O
=	O
121	O
.	O
30	O
,	O
c	O
=	O
143	O
.	O
75	O
A	O
.	O
After	O
processing	O
the	O
data	O
in	O
space	O
group	O
P222	O
,	O
pseudo	O
-	O
precession	O
plots	O
were	O
analysed	O
using	O
HKLVIEW	O
(	O
Collaborative	O
Computational	O
Project	O
,	O
Number	O
4	O
,	O
1994	O
>	O
)	O
and	O
the	O
systematic	O
absences	O
were	O
indicative	O
of	O
space	O
group	O
P212121	O
.	O
Reprocessing	O
in	O
this	O
space	O
group	O
yielded	O
a	O
data	O
set	O
that	O
was	O
95	O
.	O
6	O
%	O
complete	O
to	O
2	O
.	O
25	O
A	O
resolution	O
.	O
Data	O
-	O
collection	O
statistics	O
are	O
summarized	O
in	O
Table	O
1	O
>	O
.	O
Estimation	O
of	O
the	O
content	O
of	O
the	O
asymmetric	O
unit	O
(	O
ASU	O
)	O
suggested	O
that	O
three	O
or	O
four	O
His	O
-	O
tagged	O
AbsC	O
subunits	O
were	O
most	O
likely	O
,	O
giving	O
solvent	O
contents	O
of	O
60	O
.	O
3	O
%	O
or	O
47	O
.	O
0	O
%	O
and	O
crystal	O
-	O
packing	O
parameters	O
(	O
V	O
M	O
)	O
of	O
3	O
.	O
09	O
or	O
2	O
.	O
32	O
A3	O
Da	O
-	O
1	O
,	O
respectively	O
.	O
Given	O
that	O
both	O
DLS	O
and	O
gel	O
filtration	O
suggest	O
that	O
AbsC	O
is	O
dimeric	O
and	O
that	O
MarR	O
homologues	O
exist	O
as	O
homodimers	O
(	O
Wilkinson	O
&	O
Grove	O
,	O
2006	O
>	O
)	O
,	O
an	O
even	O
number	O
of	O
subunits	O
per	O
ASU	O
,	O
i	O
.	O
e	O
.	O
four	O
,	O
would	O
seem	O
to	O
be	O
the	O
most	O
probable	O
(	O
Matthews	O
,	O
1968	O
>	O
)	O
.	O
A	O
Patterson	O
function	O
calculated	O
on	O
data	O
in	O
the	O
resolution	O
range	O
10	O
.	O
0	O
-	O
3	O
.	O
0	O
A	O
revealed	O
a	O
significant	O
peak	O
(	O
at	O
24	O
%	O
of	O
the	O
origin	O
peak	O
)	O
with	O
a	O
vector	O
of	O
u	O
=	O
0	O
.	O
0	O
,	O
v	O
=	O
0	O
.	O
5	O
,	O
w	O
=	O
0	O
.	O
014	O
,	O
indicating	O
that	O
one	O
or	O
more	O
molecules	O
in	O
the	O
ASU	O
were	O
similarly	O
orientated	O
.	O
A	O
self	O
-	O
rotation	O
function	O
calculated	O
on	O
data	O
in	O
the	O
resolution	O
range	O
10	O
.	O
0	O
-	O
5	O
.	O
0	O
A	O
using	O
MOLREP	O
(	O
Vagin	O
&	O
Teplyakov	O
,	O
2000	O
>	O
)	O
did	O
not	O
show	O
any	O
clear	O
noncrystallographic	O
symmetry	O
(	O
NCS	O
)	O
,	O
perhaps	O
suggesting	O
that	O
if	O
NCS	O
axes	O
were	O
present	O
they	O
were	O
parallel	O
(	O
or	O
almost	O
parallel	O
)	O
to	O
crystallographic	O
axes	O
.	O
Fold	O
prediction	O
,	O
based	O
on	O
the	O
amino	O
-	O
acid	O
sequence	O
of	O
AbsC	O
,	O
was	O
performed	O
using	O
the	O
FUGUE	O
server	O
(	O
http	O
:	O
/	O
/	O
www	O
-	O
cryst	O
.	O
bioc	O
.	O
cam	O
.	O
ac	O
.	O
uk	O
/	O
~	O
fugue	O
/	O
prfsearch	O
.	O
html	O
;	O
Shi	O
et	O
al	O
.	O
,	O
2001	O
>	O
)	O
.	O
This	O
found	O
eight	O
'	O
certain	O
'	O
hits	O
,	O
with	O
the	O
top	O
three	O
being	O
MarR	O
(	O
PDB	O
code	O
1jgs	O
;	O
Z	O
score	O
21	O
.	O
4	O
;	O
18	O
%	O
sequence	O
identity	O
)	O
,	O
SlyA	O
(	O
PDB	O
code	O
1lj9	O
;	O
Z	O
score	O
18	O
.	O
4	O
;	O
16	O
%	O
sequence	O
identity	O
)	O
and	O
YusO	O
(	O
PDB	O
code	O
1s3j	O
;	O
Z	O
score	O
15	O
.	O
7	O
;	O
16	O
%	O
sequence	O
identity	O
)	O
.	O
All	O
three	O
hits	O
were	O
used	O
as	O
search	O
models	O
for	O
molecular	O
replacement	O
in	O
the	O
program	O
AMoRe	O
(	O
Navaza	O
,	O
1994	O
>	O
)	O
,	O
but	O
none	O
yielded	O
plausible	O
solutions	O
against	O
the	O
2	O
.	O
25	O
A	O
resolution	O
native	O
data	O
set	O
,	O
although	O
this	O
is	O
not	O
too	O
surprising	O
given	O
their	O
very	O
low	O
sequence	O
identities	O
.	O
Thus	O
,	O
we	O
will	O
need	O
to	O
solve	O
the	O
AbsC	O
structure	O
by	O
isomorphous	O
replacement	O
methods	O
.	O
To	O
this	O
end	O
,	O
we	O
are	O
preparing	O
selenomethionine	O
-	O
labelled	O
protein	O
;	O
there	O
are	O
a	O
total	O
of	O
seven	O
methionine	O
residues	O
present	O
in	O
the	O
158	O
-	O
amino	O
-	O
acid	O
sequence	O
of	O
AbsC	O
.	O
Click	O
here	O
for	O
file	O
Aim	O
This	O
study	O
reports	O
the	O
results	O
of	O
a	O
large	O
prospective	O
single	O
-	O
blinded	O
clinical	O
trial	O
of	O
3	O
SSRI	O
(	O
paroxetine	O
,	O
fluoxetine	O
and	O
escitalopram	O
)	O
in	O
PE	O
using	O
a	O
validated	O
questionnaire	O
.	O
Analysis	O
of	O
furAII	O
-	O
katGII	O
region	O
The	O
cDNA	O
from	O
M	O
.	O
fortuitum	O
under	O
the	O
different	O
stresses	O
was	O
analysed	O
by	O
PCR	O
using	O
the	O
primers	O
furAII	O
-	O
Fo	O
and	O
P1	O
.	O
1	O
(	O
Table	O
2	O
)	O
to	O
test	O
the	O
presence	O
of	O
furAII	O
and	O
katGII	O
cotranscripts	O
.	O
PCR	O
cycling	O
was	O
performed	O
as	O
follows	O
:	O
a	O
denaturizing	O
step	O
at	O
95degreesC	O
for	O
5	O
minutes	O
;	O
36	O
cycles	O
of	O
95degreesC	O
for	O
45	O
seconds	O
,	O
54degreesC	O
for	O
45	O
seconds	O
and	O
72degreesC	O
for	O
1	O
minute	O
;	O
and	O
a	O
final	O
extension	O
at	O
72degreesC	O
for	O
10	O
minutes	O
.	O
Summary	O
of	O
studies	O
reporting	O
comorbidities	O
with	O
diabetes	O
.	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Images	O
Figure	O
1	O
Figure	O
5	O
Figure	O
6	O
Characteristics	O
of	O
cases	O
with	O
childhood	B-Anatomy
leukaemia	I-Anatomy
(	O
n	O
=	O
162	O
)	O
and	O
matched	O
controls	O
(	O
n	O
=	O
2125	O
)	O
,	O
all	O
registered	O
within	O
3	O
months	O
of	O
birth	O
Appendix	O
Table	O
Detection	O
of	O
Nipah	O
virus	O
antibody	O
among	O
bat	O
serum	B-Anatomy
samples	I-Anatomy
collected	O
from	O
10	O
provinces	O
in	O
China	O
,	O
2004	O
-	O
2007	O
*	O
Whole	O
-	O
Body	O
gamma	O
-	O
Irradiation	O
To	O
evaluate	O
differential	O
sensitivity	O
to	O
irradiation	O
,	O
mice	O
were	O
exposed	O
to	O
gamma	O
-	O
irradiation	O
(	O
4	O
-	O
10	O
Gy	O
,	O
single	O
dose	O
)	O
and	O
closely	O
monitored	O
throughout	O
the	O
experimentation	O
period	O
.	O
Animals	O
were	O
killed	O
at	O
the	O
first	O
appearance	O
of	O
signs	O
of	O
poor	O
health	O
.	O
Recipients	O
of	O
bone	B-Anatomy
marrow	I-Anatomy
transplants	O
were	O
pre	O
-	O
irradiated	O
with	O
a	O
total	O
dose	O
of	O
10	O
.	O
2	O
Gy	O
(	O
two	O
doses	O
of	O
5	O
.	O
1	O
Gy	O
,	O
3	O
h	O
apart	O
)	O
.	O
For	O
in	O
vivo	O
DNA	O
damage	O
experiments	O
,	O
mice	O
were	O
irradiated	O
with	O
a	O
single	O
dose	O
of	O
5Gy	O
and	O
killed	O
after	O
1	O
,	O
3	O
or	O
6	O
hours	O
.	O
All	O
irradiations	O
were	O
carried	O
out	O
in	O
a	O
Cesium	O
Mark1	O
irradiator	O
(	O
Shepherd	O
Associates	O
)	O
.	O
Background	O
Sealant	O
application	O
criteria	O
for	O
molar	B-Anatomy
fissures	O
Power	O
(	O
Y	O
-	O
axis	O
)	O
as	O
a	O
function	O
of	O
main	O
effects	O
(	O
x	O
-	O
axis	O
)	O
.	O
For	O
a	O
pure	O
main	O
-	O
effects	O
model	O
(	O
x	O
-	O
axis	O
=	O
a1	O
>	O
0	O
;	O
interaction	O
effects	O
a2	O
=	O
a3	O
=	O
0	O
are	O
all	O
zero	O
)	O
,	O
Figure	O
1	O
shows	O
that	O
pattern	O
(	O
solid	O
red	O
line	O
)	O
and	O
single	O
-	O
locus	O
(	O
broken	O
blue	O
line	O
)	O
approaches	O
have	O
virtually	O
the	O
same	O
power	O
.	O
Peptide	O
-	O
BSA	O
conjugates	O
as	O
diagnostic	O
antigens	O
To	O
analyse	O
the	O
potential	O
of	O
the	O
peptides	O
to	O
behave	O
as	O
antigen	O
mimics	O
,	O
their	O
ability	O
to	O
react	O
with	O
IgM	O
antibodies	O
from	O
individuals	O
infected	O
with	O
EBV	O
was	O
assessed	O
.	O
In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
sensitivity	O
of	O
detection	O
was	O
greatly	O
improved	O
when	O
the	O
peptides	O
were	O
coupled	O
to	O
a	O
carrier	O
molecule	O
such	O
as	O
BSA	O
prior	O
to	O
immobilisation	O
onto	O
a	O
solid	O
surface	O
(	O
Casey	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
This	O
strategy	O
was	O
adopted	O
to	O
test	O
peptides	O
Eb1	O
-	O
4	O
and	O
H1	O
.	O
A	O
set	O
of	O
40	O
clinical	O
samples	B-Anatomy
that	O
were	O
classified	O
as	O
EBV	O
seropositive	O
(	O
n	O
=	O
16	O
)	O
,	O
seronegative	O
(	O
n	O
=	O
16	O
)	O
or	O
potentially	O
cross	O
-	O
reactive	O
sera	B-Anatomy
(	O
n	O
=	O
8	O
)	O
were	O
assessed	O
for	O
reactivity	O
with	O
Eb1	O
-	O
4	O
and	O
H1	O
peptides	O
individually	O
.	O
The	O
cut	O
-	O
off	O
level	O
was	O
defined	O
as	O
the	O
mean	O
optical	O
density	O
of	O
the	O
seronegative	O
samples	B-Anatomy
plus	O
3	O
standard	O
deviations	O
shown	O
as	O
a	O
line	O
on	O
the	O
graphs	O
in	O
Fig	O
.	O
5	O
.	O
Readings	O
above	O
this	O
level	O
were	O
defined	O
as	O
positive	O
and	O
below	O
this	O
level	O
negative	O
.	O
The	O
same	O
set	O
of	O
samples	B-Anatomy
were	O
analysed	O
on	O
BSA	O
alone	O
and	O
these	O
values	O
were	O
subtracted	O
from	O
the	O
peptide	O
-	O
BSA	O
conjugate	O
readings	O
and	O
the	O
corrected	O
absorbance	O
readings	O
were	O
plotted	O
individually	O
for	O
our	O
new	O
peptides	O
Eb1	O
-	O
4	O
and	O
H1	O
in	O
Fig	O
.	O
5	O
.	O
There	O
was	O
a	O
clear	O
difference	O
in	O
the	O
detection	O
of	O
seropositive	O
antibodies	O
by	O
all	O
the	O
peptides	O
(	O
Fig	O
.	O
5A	O
-	O
E	O
)	O
compared	O
with	O
the	O
analysis	O
of	O
BSA	O
alone	O
(	O
Fig	O
.	O
5F	O
)	O
,	O
with	O
the	O
majority	O
of	O
absorbance	O
readings	O
above	O
the	O
cut	O
-	O
off	O
level	O
.	O
We	O
compared	O
the	O
ability	O
of	O
our	O
panel	O
of	O
peptide	O
mimotopes	O
to	O
be	O
recognised	O
by	O
antibodies	O
in	O
the	O
same	O
set	O
of	O
seropositive	O
samples	B-Anatomy
in	O
Fig	O
.	O
6A	O
and	O
the	O
sensitivity	O
of	O
detection	O
is	O
shown	O
in	O
Fig	O
.	O
6B	O
.	O
We	O
also	O
included	O
F1	O
and	O
Gp125	O
mimotopes	O
specific	O
for	O
two	O
mAbs	O
in	O
our	O
previous	O
study	O
(	O
Casey	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
Of	O
the	O
peptides	O
identified	O
from	O
polyclonal	O
sera	B-Anatomy
Eb1	O
,	O
Gp125	O
and	O
F1	O
had	O
the	O
highest	O
sensitivity	O
(	O
94	O
%	O
)	O
.	O
Slightly	O
lower	O
sensitivity	O
was	O
observed	O
for	O
Eb2	O
,	O
3	O
and	O
4	O
(	O
88	O
%	O
)	O
and	O
H1	O
peptide	O
had	O
the	O
lowest	O
sensitivity	O
(	O
81	O
%	O
)	O
as	O
summarised	O
in	O
Fig	O
.	O
6B	O
.	O
The	O
sensitivity	O
of	O
F1	O
and	O
Gp125	O
was	O
similar	O
to	O
that	O
produced	O
by	O
the	O
mimotopes	O
selected	O
in	O
our	O
previous	O
study	O
,	O
95	O
%	O
for	O
F1	O
and	O
92	O
%	O
for	O
Gp125	O
.	O
Fig	O
.	O
5	O
Evaluation	O
of	O
peptides	O
Eb1	O
-	O
4	O
and	O
H1	O
coupled	O
to	O
BSA	O
as	O
EBV	O
diagnostic	O
reagents	O
.	O
Human	O
serum	B-Anatomy
(	O
n	O
=	O
40	O
)	O
previously	O
analysed	O
using	O
a	O
diagnostic	O
test	O
for	O
VCA	O
IgM	O
was	O
allowed	O
to	O
react	O
with	O
the	O
peptides	O
and	O
the	O
bound	O
IgM	O
antibodies	O
were	O
detected	O
using	O
anti	O
-	O
human	O
IgM	O
HRP	O
.	O
The	O
absorbance	O
readings	O
for	O
1	O
(	O
positive	O
)	O
,	O
2	O
(	O
negative	O
)	O
and	O
putative	O
cross	O
-	O
reactive	O
sera	B-Anatomy
for	O
3	O
(	O
Parvo	O
)	O
,	O
4	O
(	O
HSV	O
)	O
,	O
5	O
(	O
CMV	O
)	O
and	O
6	O
(	O
RF	O
)	O
are	O
plotted	O
for	O
(	O
A	O
)	O
Eb1	O
,	O
(	O
B	O
)	O
Eb2	O
,	O
(	O
C	O
)	O
Eb3	O
,	O
(	O
D	O
)	O
Eb4	O
,	O
(	O
E	O
)	O
H1	O
and	O
(	O
F	O
)	O
BSA	O
,	O
respectively	O
.	O
The	O
cut	O
-	O
off	O
value	O
is	O
defined	O
as	O
the	O
mean	O
of	O
the	O
negative	O
population	O
+	O
3SD	O
indicated	O
by	O
a	O
solid	O
horizontal	O
line	O
;	O
since	O
there	O
were	O
no	O
false	O
positives	O
,	O
the	O
specificity	O
for	O
each	O
mimotope	O
was	O
100	O
%	O
.	O
Fig	O
.	O
6	O
Comparison	O
of	O
the	O
reactivities	O
of	O
our	O
panel	O
of	O
mimotopes	O
Eb1	O
-	O
4	O
,	O
H1	O
,	O
F1	O
and	O
Gp125	O
conjugated	O
to	O
BSA	O
with	O
EBV	O
IgM	O
-	O
positive	O
sera	B-Anatomy
(	O
n	O
=	O
16	O
)	O
absorbance	O
values	O
are	O
plotted	O
and	O
the	O
cut	O
-	O
off	O
levels	O
are	O
depicted	O
by	O
a	O
horizontal	O
line	O
in	O
(	O
A	O
)	O
.	O
(	O
B	O
)	O
Summary	O
of	O
the	O
false	O
-	O
negative	O
results	O
from	O
the	O
5	O
/	O
16	O
serum	B-Anatomy
samples	I-Anatomy
seropositive	O
for	O
IgM	O
EBV	O
and	O
the	O
overall	O
sensitivity	O
for	O
each	O
mimotope	O
for	O
diagnosis	O
of	O
EBV	O
IgM	O
antibodies	O
.	O
We	O
also	O
considered	O
which	O
seropositive	O
EBV	O
samples	B-Anatomy
contained	O
antibodies	O
that	O
did	O
not	O
recognise	O
the	O
panel	O
of	O
peptides	O
,	O
i	O
.	O
e	O
.	O
false	O
-	O
negative	O
readings	O
,	O
listed	O
in	O
Fig	O
.	O
6B	O
.	O
The	O
antibodies	O
in	O
serum	B-Anatomy
1	O
(	O
s1	O
)	O
were	O
unreactive	O
with	O
all	O
of	O
the	O
peptides	O
identified	O
in	O
this	O
study	O
,	O
s2	O
was	O
not	O
reactive	O
with	O
Eb3	O
,	O
Eb4	O
and	O
H1	O
and	O
s3	O
was	O
unreactive	O
with	O
H1	O
.	O
Gp125	O
and	O
F1	O
that	O
were	O
selected	O
in	O
our	O
previous	O
study	O
were	O
recognised	O
by	O
s1	O
,	O
2	O
and	O
3	O
;	O
however	O
,	O
two	O
different	O
serum	B-Anatomy
samples	I-Anatomy
(	O
s4	O
and	O
5	O
)	O
did	O
not	O
recognise	O
F1	O
or	O
Gp125	O
,	O
respectively	O
.	O
This	O
demonstrates	O
that	O
individual	O
peptides	O
are	O
not	O
recognised	O
by	O
all	O
EBV	O
antibodies	O
and	O
confirms	O
that	O
different	O
peptides	O
are	O
required	O
to	O
represent	O
different	O
epitopes	O
.	O
Therefore	O
,	O
a	O
combination	O
of	O
Eb1	O
peptide	O
F1	O
and	O
Gp125	O
peptides	O
could	O
be	O
recognised	O
by	O
antibodies	O
present	O
in	O
all	O
this	O
set	O
of	O
EBV	O
clinical	O
samples	B-Anatomy
resulting	O
in	O
100	O
%	O
sensitivity	O
.	O
For	O
the	O
samples	B-Anatomy
defined	O
as	O
EBV	O
-	O
seronegative	O
,	O
there	O
were	O
no	O
readings	O
above	O
the	O
cut	O
-	O
off	O
level	O
and	O
therefore	O
no	O
false	O
positives	O
,	O
resulting	O
in	O
100	O
%	O
specificity	O
.	O
In	O
addition	O
,	O
there	O
were	O
no	O
absorbance	O
readings	O
above	O
the	O
cut	O
-	O
off	O
levels	O
for	O
the	O
potentially	O
cross	O
-	O
reactive	O
serum	B-Anatomy
samples	I-Anatomy
,	O
inferring	O
that	O
the	O
peptides	O
identified	O
in	O
this	O
study	O
have	O
high	O
specificity	O
for	O
EBV	O
antibodies	O
.	O
Additional	O
File	O
2	O
Full	O
Model	O
Code	O
.	O
Full	O
model	O
code	O
plus	O
instructions	O
for	O
running	O
in	O
Berkeley	O
Madonna	O
(	O
TM	O
)	O
.	O
Secchi	O
depth	O
in	O
the	O
Baltic	O
Proper	O
,	O
June	O
-	O
August	O
,	O
1957	O
-	O
1998	O
.	O
Number	O
of	O
data	O
:	O
3	O
,	O
452	O
.	O
Nucleotide	O
features	O
of	O
free	O
-	O
standing	O
homing	O
-	O
endonucleases	O
Gene	O
control	O
elements	O
were	O
identified	O
for	O
several	O
members	O
of	O
each	O
type	O
of	O
intervening	O
homing	O
endonuclease	O
genes	O
described	O
in	O
this	O
study	O
.	O
In	O
15	O
out	O
of	O
16	O
,	O
5	O
'	O
untranslated	O
regions	O
of	O
the	O
endonucleases	O
we	O
identified	O
RNA	O
hairpin	O
structures	O
upstream	O
of	O
initiation	O
codons	O
(	O
Figures	O
1	O
and	O
4A	O
)	O
.	O
This	O
may	O
be	O
a	O
translational	O
regulatory	O
hairpin	O
structure	O
known	O
from	O
various	O
phage	O
genes	O
,	O
including	O
homing	O
endonucleases	O
(	O
22	O
,	O
47	O
-	O
49	O
)	O
.	O
The	O
hairpins	O
we	O
found	O
are	O
in	O
fractured	O
gene	O
loci	O
with	O
different	O
protein	O
host	O
types	O
,	O
including	O
gp41	O
,	O
IMPDH	O
,	O
DnaE	O
,	O
NrdJ	O
and	O
NrdA	O
.	O
Ten	O
of	O
these	O
hairpins	O
also	O
include	O
a	O
conserved	O
sequence	O
of	O
Aeh1	O
phage	O
late	O
promoter	O
element	O
(	O
TATAAATA	O
)	O
,	O
which	O
was	O
recently	O
shown	O
to	O
inhibit	O
the	O
translation	O
of	O
a	O
gene	O
-	O
fracturing	O
endonuclease	O
gene	O
,	O
by	O
sequestering	O
its	O
ribosome	B-Anatomy
binding	O
site	O
(	O
22	O
,	O
23	O
)	O
.	O
Analysis	O
of	O
the	O
endonuclease	O
5	O
'	O
untranslated	O
regions	O
revealed	O
two	O
conserved	O
motifs	O
(	O
Figures	O
4A	O
and	O
Supplementary	O
Figure	O
S4	O
)	O
,	O
which	O
usually	O
complement	O
each	O
other	O
on	O
the	O
stem	O
of	O
the	O
conserved	O
hairpin	O
structures	O
.	O
Figure	O
4	O
.	O
Nucleotide	O
features	O
of	O
endonuclease	O
genes	O
.	O
(	O
A	O
)	O
RNA	O
hairpin	O
structures	O
at	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
endonuclease	O
ORFs	O
in	O
the	O
gp41	O
-	O
1	O
(	O
representing	O
the	O
very	O
similar	O
sequences	O
of	O
gp41	O
-	O
1	O
-	O
7	O
)	O
,	O
nrdA	O
-	O
5	O
and	O
DnaE	O
-	O
1	O
gene	O
loci	O
.	O
Initiator	O
codons	O
are	O
marked	O
by	O
arrows	O
,	O
conserved	O
putative	O
T4	O
late	O
promoter	O
elements	O
are	O
boxed	O
,	O
and	O
conserved	O
sequence	O
motifs	O
(	O
Supplementary	O
Figure	O
S4	O
)	O
are	O
highlighted	O
in	O
grey	O
.	O
The	O
expected	O
values	O
for	O
motifs	O
1	O
and	O
2	O
are	O
1	O
.	O
7	O
-	O
10	O
and	O
9	O
.	O
9	O
-	O
3	O
,	O
respectively	O
.	O
RNA	O
structures	O
were	O
calculated	O
using	O
the	O
Vienna	O
package	O
(	O
http	O
:	O
/	O
/	O
rna	O
.	O
tbi	O
.	O
univie	O
.	O
ac	O
.	O
at	O
/	O
cgi	O
-	O
bin	O
/	O
RNAfold	O
.	O
cgi	O
)	O
,	O
and	O
sequence	O
motifs	O
were	O
identified	O
using	O
the	O
MEME	O
program	O
.	O
(	O
B	O
)	O
Overlapping	O
#	O
protein	O
coding	O
regions	O
of	O
endonuclease	O
3	O
'	O
termini	O
and	O
the	O
5	O
'	O
termini	O
of	O
their	O
downstream	O
genes	O
.	O
Additionally	O
,	O
15	O
loci	O
included	O
an	O
overlapping	O
region	O
of	O
6	O
-	O
69	O
bp	O
between	O
the	O
coding	O
regions	O
of	O
the	O
probable	O
endonuclease	O
C	O
-	O
termini	O
and	O
the	O
downstream	O
N	O
-	O
termini	O
of	O
the	O
split	O
-	O
intein	O
part	O
(	O
Figures	O
1	O
and	O
4B	O
)	O
.	O
This	O
overlap	O
is	O
present	O
in	O
both	O
types	O
of	O
endonucleases	O
,	O
and	O
is	O
independent	O
on	O
the	O
presence	O
of	O
a	O
split	O
-	O
intein	O
part	O
in	O
the	O
fractured	O
gene	O
,	O
also	O
occurring	O
in	O
the	O
putative	O
sbcD	O
DNA	O
-	O
repair	O
gene	O
that	O
we	O
found	O
,	O
as	O
well	O
as	O
in	O
the	O
Aeh1	O
fractured	O
nrdA	O
found	O
by	O
Gibb	O
and	O
Edgell	O
(	O
22	O
)	O
.	O
Efficacy	O
of	O
MMF	O
in	O
current	O
immunosuppressive	O
regimens	O
after	O
kidney	B-Anatomy
transplantation	O
Current	O
established	O
immunosuppressive	O
strategies	O
in	O
kidney	B-Anatomy
transplantation	O
often	O
include	O
an	O
induction	O
agent	O
(	O
monoclonal	O
or	O
polyclonal	O
anti	O
-	O
T	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
antibodies	O
)	O
based	O
on	O
the	O
immunologic	O
risk	O
of	O
the	O
recipient	O
,	O
followed	O
by	O
a	O
maintenance	O
regimen	O
combining	O
a	O
CNI	O
and	O
an	O
anti	O
-	O
proliferative	O
agent	O
,	O
with	O
or	O
without	O
corticosteroids	O
.	O
2	O
-	O
4	O
As	O
MMF	O
was	O
the	O
first	O
MPA	O
formulation	O
approved	O
in	O
clinical	O
kidney	B-Anatomy
transplantation	O
,	O
more	O
extensive	O
clinical	O
data	O
are	O
available	O
with	O
this	O
drug	O
in	O
comparison	O
to	O
EC	O
-	O
MPS	O
.	O
Sex	O
and	O
age	O
distributions	O
of	O
confirmed	O
cases	O
Of	O
480	O
confirmed	O
cases	O
,	O
56	O
%	O
(	O
269	O
/	O
480	O
)	O
were	O
male	O
patients	O
and	O
44	O
%	O
(	O
211	O
/	O
480	O
)	O
were	O
female	O
,	O
respectively	O
.	O
The	O
percentage	O
of	O
male	O
cases	O
was	O
higher	O
than	O
that	O
of	O
females	O
in	O
all	O
groups	O
except	O
for	O
the	O
group	O
aged	O
31	O
-	O
40	O
(	O
chi2	O
=	O
42	O
.	O
4	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
278	O
(	O
57	O
.	O
9	O
%	O
)	O
cases	O
were	O
in	O
the	O
group	O
aged	O
21	O
-	O
50	O
,	O
followed	O
by	O
102	O
(	O
21	O
.	O
3	O
%	O
)	O
,	O
79	O
(	O
16	O
.	O
5	O
%	O
)	O
and	O
21	O
(	O
4	O
.	O
4	O
%	O
)	O
cases	O
in	O
the	O
group	O
aged	O
51	O
-	O
70	O
,	O
0	O
-	O
20	O
,	O
and	O
>	O
=	O
71	O
,	O
respectively	O
.	O
The	O
youngest	O
and	O
oldest	O
cases	O
were	O
1	O
.	O
5	O
and	O
81	O
years	O
old	O
,	O
respectively	O
(	O
Table	O
2	O
)	O
.	O
Table	O
2	O
Age	O
and	O
occupational	O
distributions	O
and	O
activities	O
(	O
1	O
-	O
3	O
weeks	O
prior	O
to	O
symptom	O
appearance	O
)	O
of	O
confirmed	O
cases	O
Cases	O
(	O
%	O
)	O
(	O
Male	O
:	O
Female	O
,	O
%	O
)	O
Age	O
(	O
Years	O
)	O
0	O
-	O
10	O
46	O
(	O
9	O
.	O
6	O
)	O
(	O
76	O
:	O
24	O
)	O
11	O
-	O
20	O
33	O
(	O
6	O
.	O
9	O
)	O
(	O
79	O
:	O
21	O
)	O
21	O
-	O
30	O
78	O
(	O
16	O
.	O
3	O
)	O
(	O
51	O
:	O
49	O
)	O
31	O
-	O
40	O
99	O
(	O
20	O
.	O
6	O
)	O
(	O
46	O
:	O
54	O
)	O
41	O
-	O
50	O
101	O
(	O
21	O
.	O
0	O
)	O
(	O
56	O
:	O
44	O
)	O
51	O
-	O
60	O
47	O
(	O
9	O
.	O
8	O
)	O
(	O
55	O
:	O
45	O
)	O
61	O
-	O
70	O
55	O
(	O
11	O
.	O
5	O
)	O
(	O
53	O
:	O
47	O
)	O
>	O
=	O
71	O
21	O
(	O
4	O
.	O
4	O
)	O
(	O
52	O
:	O
48	O
)	O
Occupation	O
Children	O
at	O
preschool	O
age	O
20	O
(	O
4	O
.	O
2	O
)	O
(	O
75	O
:	O
25	O
)	O
Pupils	O
50	O
(	O
10	O
.	O
4	O
)	O
(	O
78	O
:	O
22	O
)	O
Farmers	O
408	O
(	O
85	O
.	O
0	O
)	O
(	O
52	O
:	O
48	O
)	O
Others	O
2	O
(	O
0	O
.	O
4	O
)	O
(	O
50	O
:	O
50	O
)	O
Activities	O
Farm	O
work	O
325	O
(	O
67	O
.	O
7	O
)	O
(	O
53	O
:	O
47	O
)	O
Play	O
on	O
grassland	O
65	O
(	O
13	O
.	O
5	O
)	O
(	O
75	O
:	O
25	O
)	O
Recreation	O
20	O
(	O
4	O
.	O
2	O
)	O
(	O
65	O
:	O
35	O
)	O
Housework	O
25	O
(	O
5	O
.	O
2	O
)	O
(	O
8	O
:	O
92	O
)	O
Unknown	O
45	O
(	O
9	O
.	O
4	O
)	O
(	O
71	O
:	O
29	O
)	O
Discussion	O
Because	O
Netherton	O
syndrome	O
exhibits	O
allergic	O
phenotype	O
,	O
it	O
is	O
reasonable	O
to	O
speculate	O
that	O
SPINK5	O
,	O
which	O
is	O
mutated	O
in	O
Netherton	O
syndrome	O
,	O
may	O
act	O
as	O
a	O
candidate	O
gene	O
for	O
asthma	O
and	O
other	O
allergic	O
diseases	O
[	O
9	O
]	O
.	O
An	O
extensive	O
search	O
for	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
SPINK5	O
led	O
to	O
the	O
identification	O
of	O
a	O
number	O
of	O
SNPs	O
,	O
including	O
six	O
nonsynonymous	O
SNPs	O
in	O
coding	O
region	O
that	O
might	O
perturb	O
its	O
immune	O
function	O
.	O
Subsequent	O
genotyping	O
of	O
three	O
nonsynonymous	O
SNPs	O
,	O
A1103G	O
,	O
G1156A	O
and	O
G1258A	O
in	O
two	O
independent	O
panels	O
of	O
British	O
families	O
showed	O
a	O
significant	O
association	O
between	O
SNP	O
G1258A	O
(	O
Glu420Lys	O
)	O
and	O
atopy	O
,	O
atopic	O
dermatitis	O
,	O
elevated	O
serum	B-Anatomy
IgE	O
levels	O
and	O
asthma	O
[	O
10	O
]	O
.	O
This	O
association	O
was	O
confirmed	O
in	O
a	O
large	O
German	O
population	O
and	O
two	O
Japanese	O
populations	O
[	O
16	O
-	O
18	O
]	O
.	O
Kato	O
et	O
al	O
analyzed	O
eight	O
SNPs	O
in	O
exon	O
13	O
and	O
14	O
of	O
the	O
SPINK5	O
including	O
G1258A	O
(	O
Glu420Lys	O
)	O
,	O
and	O
found	O
a	O
positive	O
association	O
of	O
seven	O
SNPs	O
with	O
atopic	O
dermatitis	O
in	O
a	O
Japanese	O
study	O
sample	O
using	O
a	O
case	O
-	O
control	O
study	O
design	O
[	O
16	O
]	O
.	O
Nishio	O
et	O
al	O
surveyed	O
five	O
of	O
six	O
previously	O
reported	O
nonsynonymous	O
SPINK5	O
SNPs	O
in	O
Japanese	O
atopic	O
families	O
identified	O
through	O
asthmatic	O
children	O
or	O
subjects	O
with	O
atopic	O
dermatitis	O
and	O
found	O
that	O
SPINK5	O
was	O
associated	O
with	O
development	O
of	O
atopic	O
dermatitis	O
but	O
not	O
asthma	O
[	O
17	O
]	O
.	O
Kabesch	O
M	O
et	O
al	O
.	O
analyzed	O
G1258A	O
(	O
Glu420Lys	O
)	O
in	O
a	O
German	O
population	O
of	O
school	O
children	O
,	O
and	O
found	O
its	O
association	O
with	O
asthma	O
as	O
well	O
as	O
a	O
concomitant	O
occurrence	O
of	O
asthma	O
and	O
atopic	O
dermatitis	O
[	O
18	O
]	O
.	O
However	O
,	O
two	O
subsequent	O
studies	O
failed	O
to	O
replicate	O
the	O
original	O
SPINK5	O
findings	O
for	O
allergic	O
diseases	O
[	O
19	O
,	O
20	O
]	O
.	O
Folster	O
-	O
Holst	O
et	O
al	O
genotyped	O
four	O
nonsynonymous	O
SNPs	O
(	O
Asp106Asn	O
,	O
Asn368Ser	O
,	O
Asp386Asn	O
,	O
and	O
Glu420Lys	O
)	O
,	O
and	O
detected	O
no	O
association	O
between	O
SPINK5	O
and	O
atopic	O
dermatitis	O
in	O
populations	O
of	O
Northern	O
German	O
origin	O
[	O
20	O
]	O
.	O
Jongepier	O
H	O
et	O
al	O
.	O
failed	O
to	O
detect	O
any	O
association	O
between	O
SPINK5	O
and	O
asthma	O
,	O
atopic	O
phenotypes	O
and	O
atopic	O
dermatitis	O
in	O
a	O
Dutch	O
population	O
[	O
19	O
]	O
.	O
These	O
discordant	O
findings	O
probably	O
reflect	O
different	O
genetic	O
and	O
environmental	O
backgrounds	O
in	O
various	O
populations	O
.	O
To	O
determine	O
whether	O
nonsynonymous	O
SNPs	O
of	O
the	O
SPINK5	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
in	O
the	O
Chinese	O
Han	O
population	O
,	O
we	O
performed	O
a	O
case	O
-	O
control	O
study	O
by	O
genotyping	O
four	O
nonsynonymous	O
SNPs	O
in	O
the	O
SPINK5	O
.	O
We	O
did	O
not	O
detect	O
any	O
significant	O
association	O
between	O
these	O
nonsynonymous	O
SNPs	O
and	O
asthma	O
in	O
our	O
Chinese	O
samples	O
.	O
With	O
our	O
sample	O
size	O
,	O
we	O
expected	O
a	O
power	O
of	O
at	O
least	O
80	O
%	O
in	O
detecting	O
an	O
effect	O
of	O
OR	O
>	O
=	O
1	O
.	O
3	O
for	O
each	O
of	O
these	O
SNPs	O
.	O
Therefore	O
,	O
our	O
failure	O
to	O
detect	O
an	O
association	O
for	O
these	O
4	O
SNPs	O
was	O
not	O
due	O
to	O
the	O
sample	O
size	O
.	O
These	O
results	O
suggest	O
that	O
the	O
polymorphisms	O
in	O
the	O
coding	O
region	O
of	O
the	O
SPINK5	O
are	O
unlikely	O
to	O
contribute	O
to	O
asthma	O
risk	O
in	O
the	O
Chinese	O
Han	O
population	O
.	O
However	O
,	O
because	O
our	O
patients	O
were	O
ascertained	O
for	O
asthma	O
,	O
we	O
could	O
not	O
exclude	O
a	O
role	O
of	O
the	O
coding	O
SNPs	O
of	O
the	O
SPINK5	O
in	O
atopic	O
dermatitis	O
in	O
our	O
population	O
.	O
The	O
variations	O
in	O
the	O
regulatory	O
sequences	O
of	O
genes	O
may	O
determine	O
risks	O
to	O
common	O
diseases	O
by	O
causing	O
different	O
levels	O
of	O
expression	O
.	O
Therefore	O
,	O
the	O
identification	O
and	O
functional	O
evaluation	O
of	O
polymorphisms	O
in	O
promoter	O
region	O
are	O
of	O
great	O
value	O
in	O
understanding	O
the	O
genetic	O
susceptibility	O
to	O
asthma	O
.	O
In	O
order	O
to	O
determine	O
the	O
role	O
of	O
the	O
SPINK5	O
promoter	O
polymorphism	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
,	O
we	O
genotyped	O
a	O
promoter	O
polymorphism	O
,	O
-	O
206G	O
>	O
A	O
,	O
in	O
422	O
asthma	O
patients	O
and	O
410	O
controls	O
,	O
and	O
found	O
a	O
marginal	O
association	O
.	O
The	O
frequency	O
of	O
allele	O
G	O
was	O
significantly	O
higher	O
in	O
asthmatic	O
patients	O
than	O
that	O
in	O
controls	O
(	O
p	O
=	O
0	O
.	O
022	O
)	O
.	O
To	O
confirm	O
the	O
association	O
,	O
additional	O
267	O
asthma	O
patients	O
and	O
301	O
controls	O
newly	O
recruited	O
from	O
the	O
same	O
hospital	O
were	O
genotyped	O
,	O
and	O
the	O
-	O
206G	O
>	O
A	O
polymorphism	O
remained	O
significantly	O
associated	O
with	O
asthma	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
,	O
even	O
after	O
Bonferroni	O
correction	O
(	O
adjusted	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
association	O
of	O
-	O
206G	O
>	O
A	O
polymorphism	O
with	O
asthma	O
.	O
We	O
further	O
examined	O
the	O
potential	O
functional	O
role	O
of	O
this	O
promoter	O
polymorphism	O
,	O
and	O
found	O
that	O
the	O
G	O
to	O
A	O
substitution	O
at	O
-	O
206	O
generated	O
a	O
GATA	O
-	O
3	O
transcription	O
factor	O
binding	O
site	O
.	O
Major	O
transcription	O
factors	O
controlling	O
Th1	O
and	O
Th2	O
development	O
,	O
such	O
as	O
T	O
-	O
box	O
transcription	O
factor	O
and	O
GATA3	O
,	O
are	O
possibly	O
involved	O
in	O
asthma	O
and	O
atopic	O
diseases	O
.	O
GATA	O
-	O
3	O
,	O
a	O
transcription	O
factor	O
specifically	O
expressed	O
in	O
T	B-Anatomy
helper	I-Anatomy
2	I-Anatomy
(	I-Anatomy
Th2	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
,	O
plays	O
a	O
critical	O
role	O
in	O
the	O
differentiation	O
of	O
Th2	B-Anatomy
cells	I-Anatomy
from	O
uncommitted	O
CD4	B-Anatomy
+	I-Anatomy
lymphocytes	I-Anatomy
.	O
In	O
addition	O
,	O
GATA	O
-	O
3	O
is	O
essential	O
for	O
the	O
expression	O
of	O
the	O
cytokines	O
IL	O
-	O
4	O
,	O
IL	O
-	O
5	O
and	O
IL	O
-	O
13	O
that	O
mediate	O
allergic	O
inflammation	O
[	O
23	O
]	O
.	O
Our	O
luciferase	O
reporter	O
assay	O
confirmed	O
that	O
SNP	O
-	O
206G	O
>	O
A	O
is	O
associated	O
with	O
the	O
transcriptional	O
activity	O
of	O
SPINK5	O
.	O
The	O
G	O
allele	O
was	O
associated	O
with	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
SPINK5	O
.	O
The	O
mechanism	O
by	O
which	O
the	O
-	O
206G	O
>	O
A	O
SNP	O
affects	O
SPINK5	O
expression	O
may	O
be	O
explained	O
by	O
the	O
potential	O
differential	O
transcription	O
factor	O
binding	O
of	O
GATA	O
binding	O
factor	O
,	O
since	O
-	O
206G	O
>	O
A	O
is	O
located	O
at	O
the	O
core	O
sequence	O
of	O
GATA	O
binding	O
factor	O
binding	O
site	O
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
confirmed	O
that	O
the	O
A	O
to	O
G	O
substitution	O
at	O
-	O
206	O
significantly	O
reduced	O
the	O
binding	O
efficiency	O
of	O
nuclear	B-Anatomy
proteins	O
to	O
this	O
element	O
.	O
Our	O
data	O
suggest	O
that	O
loss	O
of	O
GATA	O
transcription	O
factor	O
regulation	O
with	O
the	O
-	O
206G	O
may	O
decrease	O
the	O
SPINK5	O
expression	O
and	O
thereby	O
potentially	O
perturb	O
the	O
immunosuppressive	O
function	O
of	O
LEKTI	O
.	O
Statistical	O
Analysis	O
Mitochondrial	B-Anatomy
DNA	O
haplogroup	O
frequencies	O
were	O
calculated	O
by	O
counting	O
from	O
the	O
observed	O
genotypes	O
.	O
The	O
Pearson	O
chi	O
-	O
square	O
test	O
and	O
the	O
chi	O
-	O
square	O
test	O
for	O
linear	O
-	O
by	O
-	O
linear	O
association	O
were	O
used	O
to	O
analyze	O
the	O
significances	O
between	O
the	O
prevalence	O
of	O
haplogroups	O
and	O
different	O
age	O
groups	O
.	O
SPSS	O
software	O
(	O
version	O
10	O
.	O
0	O
)	O
was	O
used	O
.	O
Duplicated	O
HGT	O
candidates	O
in	O
K	O
.	O
thermotolerans	O
.	O
(	O
A	O
)	O
Part	O
of	O
the	O
conserved	O
synteny	O
block	O
surrounding	O
KLTH0C07700g	O
and	O
KLTH0C07722g	O
tandem	O
genes	O
.	O
Same	O
legend	O
as	O
Figure	O
3A	O
.	O
(	O
B	O
)	O
Part	O
of	O
the	O
conserved	O
synteny	O
block	O
surrounding	O
KLTH0F12276g	O
gene	O
.	O
Same	O
legend	O
as	O
Figure	O
3A	O
.	O
(	O
C	O
)	O
Sequence	O
alignment	O
of	O
proteins	O
from	O
K	O
.	O
thermotolerans	O
and	O
K	O
.	O
waltii	O
.	O
(	O
D	O
)	O
Phylogenetic	O
tree	O
reconstructed	O
from	O
sequence	O
alignment	O
of	O
100	O
sites	O
of	O
K	O
.	O
thermotolerans	O
protein	O
family	O
members	O
,	O
K	O
.	O
waltii	O
gene	O
,	O
bacterial	O
(	O
green	O
)	O
and	O
amoebal	O
(	O
blue	O
)	O
proteins	O
.	O
Bootstrap	O
values	O
are	O
indicated	O
next	O
to	O
the	O
nodes	O
and	O
branch	O
length	O
scale	O
is	O
shown	O
at	O
bottom	O
left	O
.	O
Quantitative	O
reverse	O
transcription	O
PCR	O
Reverse	O
transcription	O
was	O
performed	O
using	O
0	O
.	O
2	O
mug	O
of	O
total	O
RNA	O
from	O
muscle	B-Anatomy
of	O
10	O
week	O
-	O
old	O
and	O
19	O
month	O
-	O
old	O
C57Bl6	O
mice	O
(	O
five	O
animals	O
per	O
group	O
)	O
,	O
a	O
Core	O
kit	O
(	O
RT	O
-	O
RTCK	O
-	O
03	O
,	O
Eurogentec	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
instruction	O
and	O
a	O
mix	O
of	O
random	O
primers	O
(	O
9	O
mers	O
)	O
and	O
oligodT	O
.	O
qPCR	O
was	O
performed	O
on	O
SDS7900HT	O
(	O
Applied	O
Biosystem	O
)	O
using	O
Mesagreen	O
qPCR	O
kit	O
for	O
SYBR	O
(	O
Eurogentec	O
)	O
and	O
the	O
following	O
primers	O
:	O
PPARbeta	O
:	O
5	O
'	O
-	O
AGATGGTGGCAGAGCTATGACC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
TCCTCCTGTGGCTGTTCC	O
-	O
3	O
'	O
.	O
Catalase	O
:	O
5	O
'	O
-	O
GGATCCTGACATGGTCTGGG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
TGGAGAGACTCGGGACGAAG	O
-	O
3	O
'	O
.	O
PDK4	O
:	O
5	O
'	O
-	O
GCATTTCTACTCGGATGCTCAATG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CCAATGTGGCTTGGGTTTCC	O
-	O
3	O
'	O
.	O
36B4	O
:	O
5	O
'	O
-	O
TCCAGGCTTTGGGCATCA	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CTTTATCAGCTGCACATCACTCAGA	O
-	O
3	O
'	O
.	O
Data	O
were	O
all	O
normalised	O
using	O
36B4	O
as	O
housekeeping	O
gene	O
.	O
Chicken	O
CCN3	O
expression	O
in	O
embryonic	B-Anatomy
and	O
extraembryonic	B-Anatomy
tissues	I-Anatomy
Expression	O
of	O
CCN3	O
in	O
axial	B-Anatomy
structure	I-Anatomy
becomes	O
visible	O
in	O
the	O
presegmentation	O
stage	O
and	O
reaches	O
to	O
the	O
highest	O
level	O
at	O
the	O
beginning	O
of	O
somitogenesis	O
(	O
HH	O
stage	O
7	O
,	O
Fig	O
.	O
1a	O
)	O
.	O
Strong	O
similarity	O
between	O
CCN3	O
and	O
Sonic	O
Hedgehog	O
was	O
observed	O
for	O
the	O
expression	O
pattern	O
in	O
axial	B-Anatomy
structure	I-Anatomy
(	O
notochord	B-Anatomy
and	O
floor	B-Anatomy
plate	I-Anatomy
)	O
,	O
in	O
which	O
the	O
left	O
-	O
right	O
asymmetrical	O
pattern	O
in	O
the	O
node	B-Anatomy
area	I-Anatomy
is	O
also	O
conserved	O
(	O
Fig	O
.	O
1b	O
)	O
.	O
However	O
,	O
Sonic	O
Hedgehog	O
expression	O
is	O
slightly	O
broader	O
than	O
that	O
of	O
CCN3	O
.	O
Since	O
CCN3	O
stimulates	O
Notch	O
signaling	O
(	O
Sakamoto	O
et	O
al	O
.	O
2002	O
)	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
Notch	O
signal	O
genes	O
.	O
Among	O
them	O
,	O
Serrate1	O
,	O
a	O
ligand	O
of	O
Notch	O
is	O
unique	O
because	O
its	O
expression	O
is	O
apparently	O
a	O
right	O
deviated	O
pattern	O
in	O
the	O
node	B-Anatomy
area	I-Anatomy
(	O
Fig	O
.	O
1c	O
)	O
.	O
Another	O
Notch	O
ligand	O
,	O
Delta1	O
shows	O
a	O
right	O
deviated	O
pattern	O
,	O
but	O
is	O
more	O
caudal	B-Anatomy
area	I-Anatomy
of	O
the	O
node	B-Anatomy
extending	O
to	O
the	O
primitive	B-Anatomy
streak	I-Anatomy
(	O
data	O
not	O
shown	O
)	O
.	O
The	O
expression	O
of	O
CCN3	O
in	O
axial	B-Anatomy
structure	I-Anatomy
was	O
followed	O
by	O
the	O
presomitic	O
mesoderm	O
although	O
it	O
is	O
diminished	O
(	O
Sakamoto	O
et	O
al	O
.	O
2002	O
)	O
.	O
Fig	O
.	O
1	O
Expression	O
of	O
mRNA	O
in	O
early	O
stage	O
chicken	O
embryo	B-Anatomy
;	O
CCN3	O
(	O
a	O
)	O
,	O
Sonic	O
Hedgehog	O
(	O
b	O
)	O
and	O
Serrate1	O
(	O
c	O
)	O
at	O
the	O
beginning	O
stage	O
of	O
somitogenesis	O
(	O
Hamburger	O
and	O
Hamilton	O
(	O
HH	O
)	O
Stage	O
7	O
)	O
.	O
Arrowheads	O
indicate	O
Hensen	B-Anatomy
'	I-Anatomy
s	I-Anatomy
node	I-Anatomy
.	O
Demonstrates	O
the	O
schematic	O
view	O
of	O
tissue	B-Anatomy
organization	O
at	O
this	O
stage	O
(	O
d	O
)	O
.	O
Expression	O
of	O
CCN3	O
mRNA	O
in	O
blood	B-Anatomy
islands	I-Anatomy
of	O
chicken	O
extraembryonic	B-Anatomy
tissue	I-Anatomy
(	O
HH	O
stage	O
10	O
)	O
(	O
e	O
)	O
.	O
Ventral	B-Anatomy
part	I-Anatomy
of	O
the	O
endothelial	B-Anatomy
precursor	I-Anatomy
cells	I-Anatomy
in	O
blood	B-Anatomy
islands	I-Anatomy
is	O
positive	O
for	O
CCN3	O
expression	O
.	O
Coloration	O
was	O
stopped	O
before	O
the	O
background	O
staining	O
started	O
in	O
sense	O
probes	O
(	O
negative	O
control	O
)	O
There	O
is	O
accumulating	O
evidence	O
of	O
CCN3	O
commitment	O
to	O
hematopoiesis	O
and	O
therefore	O
we	O
investigated	O
the	O
CCN3	O
expression	O
in	O
extraembryonic	B-Anatomy
tissues	I-Anatomy
.	O
Blood	B-Anatomy
islands	I-Anatomy
are	O
formed	O
in	O
the	O
yolk	B-Anatomy
sac	I-Anatomy
mesodermal	I-Anatomy
area	I-Anatomy
just	O
between	O
the	O
visceral	B-Anatomy
endodermal	I-Anatomy
and	O
ectodermal	B-Anatomy
layers	I-Anatomy
,	O
which	O
supply	O
the	O
red	B-Anatomy
blood	I-Anatomy
cells	I-Anatomy
at	O
the	O
primary	O
stage	O
.	O
The	O
cells	B-Anatomy
in	O
blood	B-Anatomy
islands	I-Anatomy
are	O
called	O
hemangioblasts	B-Anatomy
since	O
they	O
also	O
differentiate	O
into	O
the	O
endothelial	B-Anatomy
cells	I-Anatomy
of	O
extraembryonic	B-Anatomy
blood	I-Anatomy
vessel	I-Anatomy
structure	I-Anatomy
.	O
In	O
chicken	O
embryo	B-Anatomy
,	O
differentiating	O
endothelial	B-Anatomy
cells	I-Anatomy
in	O
the	O
ventral	B-Anatomy
part	I-Anatomy
of	O
blood	B-Anatomy
islands	I-Anatomy
express	O
CCN3	O
from	O
the	O
initial	O
stage	O
(	O
Fig	O
.	O
1e	O
)	O
.	O
Erythroblasts	B-Anatomy
in	O
the	O
center	O
of	O
blood	B-Anatomy
islands	I-Anatomy
(	O
spherical	O
cells	B-Anatomy
in	O
Fig	O
.	O
1e	O
)	O
weakly	O
express	O
CCN3	O
and	O
their	O
expression	O
is	O
mildly	O
enhanced	O
in	O
later	O
stage	O
(	O
data	O
not	O
shown	O
)	O
.	O
Conclusions	O
and	O
policy	O
implications	O
Early	O
postnatal	O
home	O
visit	O
is	O
one	O
strategy	O
for	O
providing	O
critical	O
interventions	O
to	O
improve	O
newborn	O
survival	O
.	O
Given	O
the	O
compelling	O
data	O
in	O
this	O
study	O
,	O
we	O
recommend	O
that	O
in	O
developing	O
countries	O
,	O
especially	O
those	O
where	O
home	O
delivery	O
with	O
unskilled	O
attendants	O
is	O
the	O
norm	O
,	O
all	O
newborns	O
should	O
receive	O
a	O
home	O
visit	O
and	O
undergo	O
assessment	O
by	O
a	O
trained	O
worker	O
as	O
soon	O
as	O
possible	O
,	O
preferably	O
on	O
the	O
day	O
of	O
birth	O
but	O
no	O
later	O
than	O
48	O
hours	O
after	O
birth	O
.	O
The	O
impact	O
of	O
this	O
approach	O
is	O
likely	O
to	O
be	O
dependent	O
on	O
the	O
content	O
,	O
quality	O
,	O
and	O
coverage	O
of	O
the	O
technical	O
interventions	O
included	O
.	O
Reaching	O
neonates	O
within	O
first	O
day	O
or	O
first	O
two	O
days	O
of	O
life	O
is	O
a	O
challenge	O
.	O
Given	O
that	O
the	O
community	O
health	O
workers	O
in	O
this	O
study	O
were	O
not	O
skilled	O
birth	O
attendants	O
and	O
attended	O
only	O
about	O
5	O
%	O
of	O
deliveries	O
,	O
a	O
complementary	O
strategy	O
will	O
be	O
to	O
ensure	O
skilled	O
attendance	O
at	O
delivery	O
that	O
is	O
linked	O
to	O
essential	O
obstetric	O
care	O
.	O
31	O
32	O
Further	O
operational	O
research	O
will	O
be	O
needed	O
to	O
develop	O
context	O
specific	O
strategies	O
to	O
reach	O
all	O
newborns	O
as	O
soon	O
as	O
possible	O
after	O
birth	O
.	O
Assessment	O
of	O
various	O
forms	O
of	O
bevavioural	O
addictions	O
A	O
first	O
approach	O
for	O
the	O
comprehensive	O
and	O
standardized	O
assessment	O
of	O
different	O
forms	O
of	O
behavioural	O
addictions	O
(	O
e	O
.	O
g	O
.	O
,	O
pathological	O
gambling	O
,	O
workaholism	O
,	O
compulsive	O
buying	O
)	O
is	O
the	O
German	O
self	O
-	O
assessment	O
questionnaire	O
""""	O
Fragebogen	O
zur	O
Differenzierten	O
Anamnese	O
exzessiver	O
Verhaltensweisen	O
""""	O
(	O
FDAV	O
,	O
Questionnaire	O
on	O
Differentiated	O
Assessment	O
of	O
Excessive	O
Behaviours	O
)	O
[	O
96	O
]	O
.	O
The	O
FDAV	O
is	O
based	O
on	O
the	O
criteria	O
of	O
substance	O
-	O
related	O
addictions	O
,	O
pathological	O
gambling	O
and	O
impulse	O
control	O
disorders	O
of	O
the	O
ICD	O
-	O
10	O
[	O
3	O
]	O
and	O
the	O
DSM	O
-	O
IV	O
-	O
TR	O
[	O
2	O
]	O
.	O
The	O
FDAV	O
is	O
a	O
modified	O
version	O
of	O
the	O
""""	O
Fragebogen	O
zur	O
Differenzierten	O
Drogenanamnese	O
""""	O
(	O
FDDA	O
;	O
Questionnaire	O
on	O
Differentiated	O
Assessment	O
of	O
Addiction	O
,	O
QDAA	O
)	O
[	O
97	O
]	O
.	O
Its	O
seven	O
modules	O
obtain	O
""""	O
sociodemographic	O
information	O
""""	O
(	O
e	O
.	O
g	O
.	O
,	O
age	O
,	O
profession	O
,	O
marital	O
status	O
)	O
,	O
""""	O
history	O
of	O
excessive	O
behaviour	O
""""	O
(	O
e	O
.	O
g	O
.	O
,	O
diagnostic	O
criteria	O
for	O
addictions	O
and	O
impulse	O
control	O
disorder	O
,	O
individual	O
patterns	O
of	O
behaviour	O
,	O
craving	O
symptoms	O
)	O
,	O
""""	O
critical	O
life	O
events	O
""""	O
(	O
stress	O
caused	O
by	O
traumatic	O
events	O
)	O
,	O
""""	O
legal	O
situation	O
""""	O
,	O
""""	O
medical	O
history	O
""""	O
,	O
""""	O
physical	O
and	O
psychological	O
complaints	O
""""	O
,	O
and	O
""""	O
emotional	O
state	O
""""	O
(	O
triggering	O
psychological	O
conditions	O
,	O
or	O
consequences	O
of	O
the	O
addictive	O
behaviour	O
,	O
respectively	O
)	O
.	O
Every	O
module	O
can	O
be	O
administered	O
separately	O
according	O
to	O
the	O
suspected	O
behavioural	O
addiction	O
,	O
thereby	O
making	O
the	O
FDAV	O
an	O
economical	O
tool	O
in	O
assessing	O
behavioural	O
addictions	O
.	O
The	O
FDAV	O
is	O
suitable	O
for	O
diagnostics	O
,	O
evaluation	O
of	O
therapy	O
and	O
follow	O
-	O
up	O
in	O
clinical	O
practice	O
and	O
research	O
.	O
Currently	O
,	O
the	O
FDAV	O
is	O
being	O
validated	O
in	O
clinical	O
and	O
non	O
-	O
clinical	O
samples	O
.	O
Click	O
here	O
for	O
file	O
Authors	O
'	O
contributions	O
PM	O
carried	O
out	O
and	O
analyzed	O
molecular	O
assay	O
and	O
sequencing	O
data	O
and	O
drafted	O
the	O
manuscript	O
.	O
NS	O
participated	O
in	O
study	O
design	O
and	O
in	O
the	O
local	O
coordination	O
during	O
the	O
study	O
.	O
She	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O
MD	O
has	O
made	O
substantial	O
contributions	O
to	O
the	O
acquisition	O
and	O
analysis	O
of	O
data	O
.	O
He	O
participated	O
in	O
design	O
of	O
the	O
study	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O
MO	O
has	O
made	O
substantial	O
contributions	O
to	O
acquisition	O
and	O
analysis	O
of	O
data	O
.	O
GB	O
has	O
made	O
substantial	O
contributions	O
to	O
acquisition	O
and	O
analysis	O
of	O
data	O
.	O
GP	O
carried	O
out	O
microscopy	O
and	O
microbiology	O
analyses	O
in	O
Italy	O
and	O
contributed	O
in	O
drafting	O
the	O
manuscript	O
.	O
GBM	O
has	O
made	O
substantial	O
contributions	O
in	O
conceiving	O
,	O
analysing	O
and	O
writing	O
the	O
manuscript	O
.	O
AM	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O
DMC	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
conceived	O
,	O
and	O
analysed	O
the	O
manuscript	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
Method	O
Results	O
:	O
All	O
fractures	O
united	O
.	O
Individual	O
movement	O
of	O
dorsiflexion	O
,	O
palmar	B-Anatomy
flexion	O
,	O
supination	O
,	O
pronation	O
and	O
radial	B-Anatomy
-	O
ulnar	B-Anatomy
deviation	O
were	O
all	O
significantly	O
better	O
in	O
the	O
dorsiflexed	O
-	O
immobilized	O
group	O
as	O
compared	O
with	O
the	O
palmar	B-Anatomy
flexed	O
immobilized	O
group	O
.	O
Grip	O
strength	O
recovery	O
with	O
subjective	O
assessment	O
was	O
better	O
in	O
the	O
dorsiflexed	O
group	O
(	O
77	O
%	O
)	O
as	O
compared	O
to	O
the	O
palmar	B-Anatomy
flexed	O
group	O
(	O
23	O
%	O
)	O
.	O
Radiological	O
parameters	O
were	O
markedly	O
better	O
in	O
the	O
dorsiflexed	O
group	O
.	O
Ninety	O
-	O
one	O
per	O
cent	O
of	O
patients	O
in	O
the	O
dorsiflexed	O
group	O
had	O
excellent	O
to	O
good	O
results	O
as	O
compared	O
to	O
66	O
%	O
in	O
the	O
palmar	B-Anatomy
flexed	O
group	O
.	O
3	O
.	O
2	O
.	O
Cell	B-Anatomy
line	I-Anatomy
and	O
culture	O
DU145	B-Anatomy
(	I-Anatomy
prostate	I-Anatomy
cancer	I-Anatomy
)	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
was	O
used	O
in	O
this	O
assay	O
.	O
DU145	B-Anatomy
was	O
grown	O
in	O
DMEM	O
/	O
F	O
-	O
12	O
medium	O
(	O
Gibco	O
BRL	O
Life	O
Technologies	O
,	O
San	O
Diego	O
,	O
CA	O
.	O
,	O
USA	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	B-Anatomy
calf	I-Anatomy
serum	I-Anatomy
and	O
kept	O
in	O
a	O
humidified	O
37	O
degreesC	O
,	O
5	O
%	O
CO2	O
incubator	O
.	O
Target	O
volumes	O
'	O
coverage	O
The	O
mean	O
PTV1	O
and	O
PTV2	O
volumes	O
were	O
452	O
cm3	O
(	O
range	O
276	O
-	O
1074	O
cm3	O
)	O
and	O
300	O
cm3	O
(	O
range	O
137	O
-	O
567	O
cm3	O
)	O
respectively	O
.	O
A	O
mean	O
of	O
>	O
98	O
%	O
(	O
range	O
92	O
-	O
100	O
%	O
)	O
of	O
the	O
PTV1	O
received	O
100	O
%	O
of	O
the	O
prescribed	O
dose	O
in	O
all	O
planning	O
methods	O
.	O
A	O
mean	O
of	O
95	O
.	O
5	O
%	O
and	O
95	O
.	O
7	O
%	O
of	O
the	O
PTV2	O
received	O
100	O
%	O
of	O
the	O
prescribed	O
dose	O
with	O
TOMO	O
and	O
IMRT	O
plans	O
respectively	O
.	O
A	O
mean	O
of	O
94	O
%	O
and	O
92	O
%	O
of	O
the	O
PTV2	O
received	O
100	O
%	O
of	O
the	O
prescribed	O
dose	O
with	O
IB	O
and	O
3D	O
treatment	O
plans	O
,	O
respectively	O
.	O
The	O
mean	O
IB	O
and	O
3D	O
plans	O
PTV2	O
coverage	O
was	O
significantly	O
inferior	O
then	O
the	O
IMRT	O
and	O
TOMO	O
plans	O
(	O
p	O
<	O
0	O
.	O
02	O
,	O
for	O
all	O
comparisons	O
)	O
.	O
The	O
mean	O
Inhomogeneity	O
Coefficient	O
(	O
IC	O
)	O
was	O
significantly	O
lower	O
(	O
better	O
)	O
with	O
the	O
TOMO	O
plans	O
,	O
compared	O
to	O
all	O
other	O
plans	O
for	O
both	O
PTV1	O
and	O
PTV2	O
(	O
p	O
<	O
0	O
.	O
0003	O
for	O
all	O
comparisons	O
)	O
(	O
figure	O
3	O
)	O
.	O
The	O
mean	O
IC	O
of	O
the	O
IMRT	O
plans	O
was	O
significantly	O
higher	O
(	O
worse	O
)	O
than	O
the	O
mean	O
IC	O
of	O
the	O
3D	O
plans	O
regarding	O
PTV	O
1	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
and	O
higher	O
(	O
worse	O
)	O
then	O
the	O
mean	O
IC	O
of	O
the	O
IB	O
plans	O
regarding	O
PTV2	O
(	O
p	O
<	O
0	O
.	O
03	O
)	O
(	O
figure	O
3	O
)	O
.	O
No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
means	O
of	O
the	O
IC	O
of	O
the	O
3D	O
and	O
IB	O
plans	O
.	O
Figure	O
3	O
The	O
mean	O
Inhomogeneity	O
Coefficient	O
(	O
IC	O
)	O
achieved	O
by	O
the	O
different	O
planning	O
methods	O
.	O
The	O
mean	O
of	O
the	O
Inhomogeneity	O
Coefficient	O
is	O
a	O
measure	O
of	O
dose	O
inhomogeneity	O
in	O
the	O
target	O
volumes	O
.	O
The	O
closer	O
the	O
IC	O
to	O
zero	O
,	O
the	O
more	O
homogenous	O
the	O
dose	O
is	O
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODS	O
For	O
this	O
study	O
,	O
20	O
individuals	O
(	O
mean	O
age	O
39	O
.	O
5	O
+	O
/	O
-	O
11	O
.	O
1	O
years	O
)	O
with	O
long	O
-	O
standing	O
type	O
1	O
diabetes	O
(	O
21	O
.	O
3	O
+	O
/	O
-	O
10	O
.	O
7	O
years	O
)	O
were	O
enrolled	O
in	O
this	O
prospective	O
open	O
-	O
label	O
crossover	O
trial	O
.	O
After	O
achieving	O
optimal	O
blood	B-Anatomy
glucose	O
control	O
,	O
16	O
subjects	O
were	O
randomized	O
to	O
exenatide	O
with	O
or	O
without	O
daclizumab	O
.	O
Endogenous	O
insulin	O
production	O
was	O
determined	O
by	O
repeatedly	O
measuring	O
serum	B-Anatomy
C	O
-	O
peptide	O
.	O
Subjects	O
and	O
Methods	O
ABPM	O
was	O
conducted	O
for	O
60	O
selected	O
patients	O
who	O
had	O
visited	O
Sunlin	O
Hospital	O
between	O
January	O
2008	O
and	O
August	O
2008	O
.	O
Patients	O
were	O
classified	O
into	O
3	O
groups	O
;	O
an	O
obese	O
group	O
whose	O
body	B-Anatomy
mass	O
index	O
(	O
BMI	O
)	O
was	O
>	O
the	O
95th	O
percentile	O
,	O
an	O
overweight	O
group	O
whose	O
BMI	O
was	O
>	O
the	O
85th	O
percentile	O
but	O
less	O
than	O
the	O
95th	O
percentile	O
,	O
and	O
a	O
normal	O
group	O
whose	O
BMI	O
was	O
below	O
the	O
85th	O
percentile	O
.	O
Overall	O
mean	O
BP	O
,	O
day	O
and	O
night	O
BP	O
and	O
BP	O
load	O
were	O
measured	O
by	O
ABPM	O
.	O
Surgery	O
Trabeculectomy	O
should	O
be	O
considered	O
in	O
all	O
patients	O
,	O
when	O
the	O
'	O
target	O
IOP	O
'	O
is	O
not	O
achieved	O
with	O
glaucoma	B-Anatomy
medications	O
and	O
if	O
the	O
expected	O
rate	O
of	O
visual	O
loss	O
could	O
affect	O
the	O
patient	O
during	O
their	O
lifetime	O
.	O
In	O
this	O
procedure	O
,	O
an	O
opening	O
is	O
made	O
in	O
the	O
trabecular	B-Anatomy
meshwork	O
,	O
so	O
that	O
aqueous	B-Anatomy
humor	I-Anatomy
can	O
drain	O
into	O
the	O
sclera	B-Anatomy
.	O
Many	O
patients	O
can	O
discontinue	O
glaucoma	B-Anatomy
medications	O
after	O
surgery	O
.	O
Approximately	O
one	O
-	O
third	O
of	O
the	O
trabeculectomy	O
patients	O
develop	O
cataract	O
within	O
five	O
years	O
.	O
If	O
trabeculectomy	O
fails	O
,	O
another	O
type	O
of	O
surgery	O
places	O
a	O
drainage	O
tube	O
(	O
Molteno	O
tube	O
)	O
in	O
the	O
eye	B-Anatomy
,	O
between	O
the	O
cornea	B-Anatomy
and	O
iris	B-Anatomy
,	O
which	O
exits	O
at	O
the	O
junction	O
of	O
the	O
cornea	B-Anatomy
and	O
sclera	B-Anatomy
.	O
Cyclodestructive	O
procedures	O
,	O
which	O
lower	O
IOP	O
by	O
destroying	O
the	O
ciliary	B-Anatomy
body	I-Anatomy
,	O
are	O
typically	O
reserved	O
for	O
eyes	B-Anatomy
,	O
which	O
are	O
refractory	O
to	O
all	O
other	O
forms	O
of	O
therapy	O
.	O
These	O
procedures	O
include	O
cyclocryotherapy	O
,	O
cylcodiathermy	O
and	O
laser	O
cyclophotocoagulation	O
.	O
[	O
91	O
-	O
93	O
]	O
Follow	O
-	O
up	O
Patients	O
were	O
followed	O
up	O
at	O
the	O
outpatient	O
clinic	O
at	O
1	O
,	O
4	O
,	O
and	O
7	O
months	O
after	O
the	O
ablation	O
procedure	O
and	O
every	O
6	O
months	O
thereafter	O
.	O
Routine	O
24	O
or	O
48	O
h	O
Holter	O
monitoring	O
was	O
performed	O
before	O
each	O
appointment	O
,	O
and	O
a	O
12	O
-	O
lead	O
electrocardiogram	O
was	O
obtained	O
at	O
each	O
visit	O
.	O
Patients	O
were	O
asked	O
to	O
report	O
to	O
the	O
emergency	O
room	O
or	O
our	O
arrhythmia	O
unit	O
for	O
an	O
ECG	O
if	O
any	O
symptom	O
suggestive	O
of	O
recurrence	O
occurred	O
between	O
scheduled	O
visits	O
.	O
After	O
the	O
ablation	O
procedure	O
,	O
all	O
patients	O
received	O
anti	O
-	O
arrhythmic	O
treatment	O
for	O
at	O
least	O
1	O
month	O
to	O
protect	O
against	O
early	O
recurrences	O
and	O
continued	O
oral	B-Anatomy
anticoagulation	O
for	O
a	O
minimum	O
of	O
2	O
months	O
to	O
maintain	O
an	O
international	O
normalized	O
ratio	O
between	O
2	O
.	O
0	O
and	O
3	O
.	O
0	O
.	O
Additionally	O
,	O
magnetic	O
resonance	O
angiography	O
was	O
repeated	O
at	O
3	O
-	O
6	O
months	O
after	O
the	O
procedure	O
to	O
evaluate	O
the	O
presence	O
of	O
PV	O
stenosis	O
.	O
Arrhythmia	O
recurrence	O
was	O
defined	O
as	O
a	O
documented	O
AF	O
or	O
atrial	B-Anatomy
flutter	O
episode	O
of	O
>	O
30	O
s	O
.	O
Arrhythmic	O
episodes	O
within	O
the	O
first	O
3	O
months	O
after	O
the	O
CPVA	O
(	O
healing	O
period	O
)	O
were	O
not	O
considered	O
in	O
the	O
evaluation	O
of	O
final	O
success	O
rates	O
because	O
they	O
are	O
often	O
described	O
as	O
transient	O
recurrences	O
related	O
to	O
atrial	B-Anatomy
inflammatory	O
processes	O
following	O
RF	O
lesions	O
.	O
26	O
The	O
endpoint	O
of	O
the	O
study	O
was	O
freedom	O
from	O
arrhythmia	O
recurrence	O
after	O
a	O
single	O
CPVA	O
procedure	O
,	O
without	O
anti	O
-	O
arrhythmic	O
medication	O
.	O
A	O
minimum	O
follow	O
-	O
up	O
of	O
3	O
months	O
was	O
required	O
.	O
Background	O
Refractive	O
outcomes	O
have	O
become	O
an	O
increasingly	O
important	O
part	O
of	O
cataract	O
surgery	O
and	O
the	O
limbal	B-Anatomy
relaxing	O
incision	O
(	O
LRI	O
)	O
has	O
been	O
shown	O
to	O
be	O
a	O
safe	O
and	O
effective	O
procedure	O
to	O
reduce	O
astigmatism	O
[	O
1	O
-	O
4	O
]	O
.	O
Currently	O
,	O
ophthalmic	O
surgeons	O
have	O
only	O
two	O
material	O
choices	O
for	O
knives	O
to	O
perform	O
limbal	B-Anatomy
relaxing	O
incision	O
,	O
diamond	O
and	O
metal	O
.	O
BD	O
(	O
Becton	O
,	O
Dickinson	O
and	O
Company	O
)	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
has	O
developed	O
a	O
safety	O
engineered	O
,	O
single	O
use	O
,	O
uni	O
-	O
directional	O
cutting	O
silicon	O
knife	O
for	O
these	O
incisions	O
.	O
Previous	O
research	O
has	O
suggested	O
that	O
the	O
silicon	O
BD	O
Atomic	O
Edge	O
(	O
TM	O
)	O
knife	O
has	O
superior	O
performance	O
characteristics	O
when	O
compared	O
to	O
a	O
metal	O
knife	O
and	O
performance	O
similar	O
to	O
diamond	O
knife	O
when	O
making	O
various	O
incisions	O
[	O
5	O
,	O
6	O
]	O
.	O
This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
performance	O
characteristics	O
of	O
silicon	O
accurate	O
depth	O
knives	O
in	O
comparison	O
to	O
diamond	O
LRI	O
knives	O
and	O
steel	O
accurate	O
depth	O
knives	O
in	O
five	O
performance	O
characteristics	O
.	O
Electrostatic	O
interaction	O
energies	O
between	O
the	O
SNARE	O
complex	O
and	O
fusing	O
membranes	B-Anatomy
.	O
(	O
A	O
)	O
Schematic	O
diagram	O
and	O
definitions	O
of	O
intermolecular	O
interaction	O
energies	O
presented	O
in	O
(	O
B	O
)	O
and	O
(	O
C	O
)	O
.	O
In	O
(	O
A	O
)	O
through	O
(	O
C	O
)	O
,	O
only	O
the	O
SNARE	O
core	O
complex	O
is	O
considered	O
.	O
Interaction	O
free	O
energies	O
are	O
calculated	O
for	O
(	O
B	O
)	O
a	O
series	O
of	O
SNARE	O
/	O
membrane	B-Anatomy
distances	O
and	O
(	O
C	O
)	O
different	O
membrane	B-Anatomy
lipid	O
compositions	O
.	O
Arrow	O
in	O
(	O
B	O
)	O
indicates	O
the	O
most	O
physiologically	O
relevant	O
distance	O
when	O
the	O
closest	O
points	O
between	O
SNARE	O
and	O
membranes	B-Anatomy
are	O
3	O
A	O
,	O
the	O
thickness	O
of	O
a	O
layer	O
of	O
water	O
.	O
[	O
19	O
]	O
In	O
(	O
D	O
)	O
through	O
(	O
F	O
)	O
,	O
TMDs	O
of	O
VAMP	O
and	O
syntaxin	O
are	O
present	O
and	O
embedded	O
in	O
membranes	B-Anatomy
.	O
Furthermore	O
,	O
the	O
C	O
-	O
terminus	O
of	O
the	O
SNARE	O
motif	O
is	O
partially	O
unraveled	O
into	O
individual	O
alpha	O
-	O
helices	O
by	O
molecular	O
dynamics	O
simulations	O
to	O
represent	O
trans	O
-	O
SNARE	O
complex	O
.	O
Interaction	O
free	O
energies	O
are	O
then	O
calculated	O
for	O
(	O
E	O
)	O
a	O
series	O
of	O
SNARE	O
motif	O
C	O
-	O
terminus	O
separation	O
distances	O
and	O
(	O
F	O
)	O
different	O
lipid	O
compositions	O
of	O
the	O
membranes	B-Anatomy
.	O
Conclusions	O
drawn	O
from	O
both	O
groups	O
of	O
studies	O
are	O
essentially	O
the	O
same	O
.	O
V	O
(	O
circles	O
)	O
:	O
Interaction	O
energies	O
between	O
the	O
SNARE	O
complex	O
and	O
the	O
v	B-Anatomy
-	I-Anatomy
membrane	I-Anatomy
.	O
T	O
(	O
squares	O
)	O
:	O
Interaction	O
energies	O
between	O
SNARE	O
and	O
the	O
t	B-Anatomy
-	I-Anatomy
membrane	I-Anatomy
.	O
VT	O
(	O
triangles	O
)	O
:	O
Interaction	O
energies	O
between	O
the	O
v	B-Anatomy
-	I-Anatomy
and	O
the	O
t	B-Anatomy
-	I-Anatomy
membranes	I-Anatomy
if	O
the	O
SNARE	O
complex	O
were	O
extracted	O
.	O
Demographic	O
data	O
of	O
subjects	O
1	O
.	O
Background	O
The	O
United	O
Republic	O
of	O
Tanzania	O
,	O
is	O
among	O
the	O
many	O
countries	O
in	O
sub	O
-	O
Saharan	O
Africa	O
facing	O
a	O
human	O
resources	O
crisis	O
in	O
its	O
health	O
sector	O
,	O
with	O
a	O
small	O
and	O
inequitably	O
distributed	O
health	O
workforce	O
[	O
1	O
]	O
that	O
shoulders	O
a	O
disproportionately	O
high	O
burden	O
of	O
disease	O
[	O
2	O
]	O
.	O
Although	O
all	O
poor	O
countries	O
in	O
the	O
world	O
face	O
a	O
severe	O
human	O
resource	O
crisis	O
in	O
their	O
health	O
sectors	O
[	O
3	O
,	O
4	O
]	O
,	O
the	O
problem	O
is	O
most	O
acute	O
in	O
Sub	O
-	O
Saharan	O
Africa	O
,	O
in	O
which	O
an	O
estimated	O
workforce	O
of	O
750	O
000	O
health	O
workers	O
in	O
the	O
region	O
serves	O
682	O
million	O
people	O
[	O
2	O
]	O
.	O
By	O
comparison	O
,	O
the	O
ratio	O
is	O
10	O
to	O
15	O
times	O
higher	O
in	O
developed	O
countries	O
.	O
Moreover	O
,	O
this	O
estimated	O
workforce	O
of	O
doctors	O
,	O
nurses	O
and	O
allied	O
health	O
workers	O
in	O
Sub	O
-	O
Saharan	O
Africa	O
constitutes	O
1	O
.	O
3	O
%	O
of	O
the	O
world	O
'	O
s	O
health	O
workforce	O
,	O
while	O
Africa	O
suffers	O
from	O
25	O
%	O
of	O
the	O
world	O
'	O
s	O
burden	O
of	O
disease	O
[	O
2	O
]	O
.	O
A	O
minimum	O
level	O
of	O
a	O
health	O
workforce	O
of	O
2	O
.	O
5	O
health	O
workers	O
per	O
1000	O
people	O
is	O
required	O
to	O
achieve	O
the	O
Millennium	O
Development	O
Goals	O
[	O
5	O
]	O
.	O
Africa	O
is	O
far	O
from	O
this	O
level	O
with	O
a	O
health	O
workforce	O
density	O
that	O
only	O
averages	O
0	O
.	O
8	O
worker	O
per	O
1000	O
people	O
,	O
while	O
the	O
world	O
median	O
density	O
of	O
health	O
personnel	O
is	O
5	O
per	O
1000	O
people	O
[	O
5	O
]	O
.	O
There	O
is	O
a	O
positive	O
correlation	O
between	O
health	O
worker	O
density	O
and	O
various	O
health	O
indices	O
,	O
most	O
notably	O
infant	O
mortality	O
rate	O
,	O
maternal	O
mortality	O
rates	O
,	O
and	O
various	O
disease	O
specific	O
mortality	O
and	O
morbidity	O
rates	O
[	O
6	O
,	O
7	O
]	O
.	O
An	O
increase	O
in	O
the	O
number	O
of	O
health	O
workers	O
per	O
capita	O
is	O
associated	O
with	O
a	O
notable	O
decline	O
in	O
the	O
rates	O
mentioned	O
above	O
.	O
As	O
a	O
consequence	O
,	O
it	O
has	O
been	O
argued	O
that	O
health	O
worker	O
shortages	O
have	O
impeded	O
the	O
implementation	O
of	O
development	O
goals	O
in	O
many	O
poor	O
countries	O
[	O
8	O
]	O
.	O
CASE	O
:	O
Here	O
for	O
the	O
first	O
time	O
a	O
case	O
of	O
CDLS	O
from	O
Iran	O
,	O
a	O
15	O
-	O
week	O
-	O
old	O
male	O
infant	O
who	O
was	O
refereed	O
as	O
a	O
case	O
of	O
multiple	O
congenital	O
anomalies	O
.	O
Clinical	O
investigation	O
showed	O
that	O
the	O
child	O
was	O
a	O
case	O
of	O
CDLS	O
.	O
Applying	O
A1C	O
cut	O
offs	O
to	O
the	O
AusDiab	O
population	O
(	O
4	O
.	O
6	O
%	O
undiagnosed	O
diabetes	O
)	O
Applying	O
the	O
same	O
cut	O
offs	O
,	O
a	O
total	O
75	O
.	O
9	O
%	O
of	O
the	O
AusDiab	O
population	O
had	O
diabetes	O
ruled	O
in	O
or	O
ruled	O
out	O
(	O
Fig	O
.	O
1B	O
)	O
,	O
while	O
the	O
remaining	O
24	O
.	O
1	O
%	O
had	O
impaired	O
A1C	O
.	O
From	O
those	O
with	O
impaired	O
A1C	O
,	O
69	O
.	O
3	O
%	O
had	O
abnormal	O
glucose	O
status	O
.	O
For	O
diabetes	O
,	O
A1C	O
at	O
5	O
.	O
5	O
%	O
provided	O
moderate	O
sensitivity	O
(	O
83	O
.	O
5	O
%	O
)	O
but	O
high	O
NPV	O
(	O
99	O
.	O
0	O
%	O
)	O
,	O
since	O
diabetes	O
prevalence	O
was	O
lower	O
in	O
the	O
AusDiab	O
than	O
in	O
the	O
MP	O
population	O
.	O
A1C	O
at	O
7	O
.	O
0	O
%	O
gave	O
100	O
%	O
specificity	O
and	O
100	O
%	O
PPV	O
.	O
By	O
dropping	O
the	O
cut	O
off	O
to	O
6	O
.	O
5	O
%	O
,	O
specificity	O
remained	O
99	O
.	O
9	O
%	O
,	O
with	O
PPV	O
near	O
100	O
%	O
.	O
Calcium	O
intake	O
and	O
effects	O
on	O
QUS	O
T	O
-	O
score	O
Figure	O
5	O
shows	O
the	O
amounts	O
of	O
dietary	O
calcium	O
intake	O
according	O
to	O
menopausal	O
status	O
.	O
Calcium	O
consumption	O
in	O
most	O
groups	O
,	O
like	O
that	O
in	O
the	O
study	O
population	O
as	O
a	O
whole	O
,	O
was	O
inadequate	O
.	O
Fewer	O
than	O
one	O
third	O
of	O
premenopausal	O
and	O
postmenopausal	O
women	O
received	O
more	O
than	O
800	O
mg	O
calcium	O
daily	O
,	O
and	O
fewer	O
than	O
16	O
%	O
of	O
premenopausal	O
women	O
in	O
the	O
50	O
-	O
59	O
age	O
decade	O
(	O
n	O
=	O
38	O
)	O
consumed	O
more	O
than	O
800	O
mg	O
calcium	O
daily	O
.	O
Figure	O
5	O
Daily	O
calcium	O
intake	O
in	O
premenopausal	O
and	O
postmenopausal	O
women	O
.	O
This	O
figure	O
depicts	O
the	O
daily	O
amounts	O
of	O
dietary	O
calcium	O
intake	O
(	O
and	O
percent	O
)	O
according	O
to	O
menopausal	O
status	O
using	O
800	O
mg	O
daily	O
as	O
cut	O
off	O
point	O
.	O
QUS	O
T	O
-	O
score	O
were	O
then	O
calculated	O
according	O
to	O
daily	O
calcium	O
intake	O
in	O
all	O
premenopausal	O
and	O
postmenopausal	O
activity	O
groups	O
using	O
800	O
mg	O
daily	O
calcium	O
as	O
cutoff	O
point	O
.	O
As	O
shown	O
in	O
Tables	O
3	O
and	O
4	O
and	O
Figure	O
6	O
,	O
premenopausal	O
women	O
who	O
were	O
systematically	O
active	O
and	O
consumed	O
more	O
than	O
800	O
mg	O
calcium	O
daily	O
had	O
significantly	O
higher	O
QUS	O
T	O
-	O
scores	O
compared	O
with	O
all	O
other	O
activity	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Among	O
systematically	O
active	O
premenopausal	O
women	O
who	O
received	O
more	O
than	O
800	O
mg	O
calcium	O
per	O
day	O
,	O
this	O
difference	O
was	O
separately	O
significant	O
verses	O
sedentary	O
(	O
p	O
=	O
0	O
.	O
028	O
)	O
and	O
moderately	O
active	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
women	O
.	O
In	O
contrast	O
,	O
postmenopausal	O
women	O
showed	O
no	O
difference	O
in	O
QUS	O
T	O
-	O
scores	O
regardless	O
of	O
the	O
amount	O
of	O
daily	O
calcium	O
intake	O
.	O
Figure	O
6	O
Synergy	O
between	O
physical	O
activity	O
and	O
dietary	O
calcium	O
intake	O
in	O
women	O
consuming	O
calcium	O
amounts	O
greater	O
than	O
800	O
mg	O
/	O
day	O
.	O
This	O
graphic	O
depicts	O
mean	O
QUS	O
T	O
-	O
score	O
values	O
calculated	O
according	O
to	O
daily	O
calcium	O
intake	O
in	O
all	O
premenopausal	O
and	O
postmenopausal	O
activity	O
groups	O
using	O
800	O
mg	O
daily	O
as	O
cut	O
off	O
point	O
(	O
for	O
statistical	O
significant	O
values	O
see	O
text	O
)	O
.	O
CONCLUSIONS	O
The	O
lack	O
of	O
association	O
between	O
depression	O
and	O
glycemic	O
control	O
is	O
not	O
due	O
to	O
the	O
use	O
of	O
a	O
binary	O
measure	O
of	O
depression	O
.	O
Findings	O
further	O
clarify	O
the	O
significant	O
association	O
between	O
distress	O
and	O
A1C	O
.	O
Discussion	O
This	O
is	O
the	O
first	O
study	O
to	O
employ	O
such	O
a	O
large	O
number	O
of	O
replicated	O
samples	O
in	O
order	O
to	O
assess	O
the	O
bacterial	O
communities	B-Anatomy
of	O
healthy	O
and	O
diseased	O
corals	O
,	O
and	O
the	O
first	O
culture	B-Anatomy
-	O
independent	O
assessment	O
of	O
bacterial	O
communities	B-Anatomy
on	O
Acroporid	O
WS	O
corals	O
on	O
the	O
GBR	O
.	O
Despite	O
the	O
potential	O
of	O
not	O
capturing	O
rare	O
or	O
very	O
low	O
abundance	O
bacterial	O
ribotypes	O
,	O
the	O
DGGE	O
analysis	O
used	O
in	O
this	O
study	O
indicated	O
similar	O
results	O
of	O
captured	O
bacterial	O
ribotypes	O
and	O
tentative	O
bacterial	O
species	O
replacement	O
in	O
unhealthy	O
corals	O
to	O
that	O
of	O
less	O
replicated	O
studies	O
using	O
other	O
non	O
-	O
culture	B-Anatomy
based	O
techniques	O
(	O
e	O
.	O
g	O
.	O
[	O
3	O
]	O
,	O
[	O
54	O
]	O
,	O
[	O
69	O
]	O
;	O
Figure	O
4	O
)	O
.	O
The	O
results	O
from	O
this	O
research	O
reinforce	O
,	O
with	O
statistically	O
relevant	O
data	O
,	O
that	O
corals	O
harbour	O
bacterial	O
communities	B-Anatomy
different	O
to	O
the	O
water	O
column	O
[	O
7	O
]	O
,	O
[	O
9	O
]	O
,	O
[	O
42	O
]	O
,	O
corroborate	O
findings	O
that	O
corals	O
associate	O
only	O
with	O
certain	O
specific	O
bacterial	O
groups	O
,	O
and	O
that	O
these	O
coral	O
-	O
associated	O
bacterial	O
communities	B-Anatomy
are	O
'	O
host	O
'	O
species	O
-	O
specific	O
[	O
2	O
]	O
.	O
The	O
data	O
presented	O
here	O
highlight	O
a	O
cluster	O
of	O
bacterial	O
ribotypes	O
frequently	O
associated	O
with	O
corals	O
,	O
and	O
the	O
distribution	O
of	O
these	O
bacterial	O
ribotypes	O
on	O
healthy	O
and	O
diseased	O
corals	O
,	O
which	O
allows	O
for	O
further	O
targeted	O
research	O
into	O
a	O
tentative	O
link	O
between	O
these	O
common	O
coral	O
associates	O
and	O
coral	O
health	O
.	O
This	O
study	O
indicates	O
that	O
coral	O
bacterial	O
community	B-Anatomy
assessments	O
require	O
a	O
number	O
of	O
replicates	O
per	O
coral	O
species	O
and	O
site	O
to	O
accurately	O
describe	O
the	O
diversity	O
present	O
across	O
the	O
population	O
and	O
in	O
order	O
to	O
draw	O
inferences	O
on	O
health	O
-	O
related	O
changes	O
in	O
the	O
community	B-Anatomy
composition	O
.	O
In	O
addition	O
,	O
the	O
comparisons	O
of	O
healthy	O
and	O
diseased	O
Acropora	O
hyacinthus	O
samples	O
showed	O
that	O
bacterial	O
communities	B-Anatomy
can	O
change	O
dramatically	O
in	O
diseased	O
individuals	O
.	O
The	O
DGGE	O
profiles	O
observed	O
for	O
corals	O
displaying	O
signs	O
of	O
White	O
Syndrome	O
comprised	O
a	O
range	O
of	O
bacterial	O
ribotypes	O
not	O
generally	O
found	O
on	O
healthy	O
corals	O
,	O
including	O
close	O
relatives	O
of	O
bacteria	O
previously	O
found	O
on	O
Black	O
Band	O
Diseased	O
corals	O
.	O
However	O
the	O
community	B-Anatomy
profiles	O
across	O
the	O
samples	O
taken	O
from	O
diseased	O
coral	O
colonies	O
were	O
inconsistent	O
and	O
not	O
indicative	O
of	O
a	O
single	O
bacterial	O
causative	O
agent	O
.	O
Comparison	O
of	O
the	O
molecular	O
organisation	O
of	O
the	O
tra	O
-	O
2	O
of	O
A	O
.	O
obliqua	O
(	O
A	O
)	O
,	O
C	O
.	O
capitata	O
(	O
B	O
)	O
and	O
D	O
.	O
melanogaster	O
(	O
C	O
)	O
and	O
their	O
proteins	O
.	O
Exons	O
(	O
boxes	O
)	O
and	O
introns	O
(	O
dashed	O
lines	O
)	O
are	O
not	O
drawn	O
to	O
scale	O
.	O
The	O
numbers	O
inside	O
the	O
boxes	O
indicate	O
the	O
number	O
of	O
the	O
exon	O
.	O
The	O
beginning	O
and	O
the	O
end	O
of	O
the	O
ORF	O
are	O
indicated	O
by	O
ATG	O
and	O
TAA	O
respectively	O
.	O
AAA	O
stands	O
for	O
poly	O
-	O
A	O
(	O
+	O
)	O
.	O
(	O
D	O
)	O
Expression	O
of	O
gene	O
tra	O
-	O
2	O
of	O
A	O
.	O
obliqua	O
.	O
RT	O
-	O
PCR	O
analyses	O
of	O
total	O
RNA	O
from	O
ovaries	B-Anatomy
(	O
O	O
)	O
,	O
embryos	B-Anatomy
(	O
E	O
)	O
,	O
from	O
male	O
and	O
female	O
larvae	O
(	O
L	O
)	O
,	O
male	O
soma	B-Anatomy
(	O
head	B-Anatomy
plus	O
thorax	B-Anatomy
,	O
MS	O
)	O
and	O
female	O
soma	B-Anatomy
(	O
head	B-Anatomy
plus	O
thorax	B-Anatomy
,	O
FS	O
)	O
.	O
(	O
E	O
)	O
Expression	O
of	O
gene	O
tra	O
-	O
2	O
of	O
A	O
.	O
obliqua	O
.	O
RT	O
-	O
PCR	O
analysis	O
of	O
total	O
RNA	O
from	O
A	O
.	O
obliqua	O
testis	B-Anatomy
.	O
Lane	O
1	O
corresponds	O
to	O
PCR	O
with	O
primers	O
PM1	O
and	O
P2	O
;	O
lane	O
2	O
corresponds	O
to	O
PCR	O
with	O
primers	O
P1	O
and	O
P2	O
(	O
see	O
location	O
of	O
primers	O
in	O
Figure	O
1A	O
)	O
.	O
(	O
F	O
)	O
Southern	O
-	O
blot	O
corresponding	O
to	O
the	O
gel	O
shown	O
in	O
(	O
E	O
)	O
and	O
hybridisation	O
with	O
a	O
probe	O
specific	O
for	O
intron	O
3	O
of	O
A	O
.	O
obliqua	O
.	O
The	O
arrow	O
marks	O
the	O
hybridisation	O
to	O
the	O
higher	O
band	O
in	O
lane	O
1	O
of	O
Figure	O
1E	O
.	O
The	O
size	O
of	O
the	O
mRNAs	O
encoding	O
the	O
proteins	O
shown	O
in	O
this	O
figure	O
are	O
:	O
1923	O
bp	O
for	O
A	O
.	O
obliqua	O
mRNA	O
,	O
1113	O
bp	O
for	O
C	O
.	O
capitata	O
mRNA	O
,	O
and	O
960	O
,	O
1583	O
and	O
1391	O
bp	O
for	O
D	O
.	O
melanogaster	O
mRNAs	O
tra2	O
-	O
179	O
,	O
tra2	O
-	O
226	O
and	O
tra2	O
-	O
264	O
,	O
respectively	O
.	O
The	O
eukaryotic	O
parasite	O
Trypanosoma	O
brucei	O
is	O
able	O
to	O
import	O
inositol	O
from	O
the	O
environment	O
or	O
synthesize	O
it	O
de	O
novo	O
.	O
However	O
,	O
according	O
to	O
the	O
current	O
model	O
,	O
inositol	O
imported	O
from	O
the	O
environment	O
is	O
utilized	O
primarily	O
in	O
bulk	O
phosphatidylinositol	O
(	O
red	O
and	O
yellow	O
phospholipid	O
)	O
production	O
via	O
a	O
phosphatidylinositol	O
synthase	O
(	O
PIS	O
)	O
localized	O
to	O
the	O
Golgi	B-Anatomy
complex	I-Anatomy
.	O
Inositol	O
synthesized	O
de	O
novo	O
is	O
primarily	O
used	O
to	O
generate	O
phosphatidylinositol	O
that	O
is	O
used	O
for	O
production	O
of	O
glycosylphosphatidylinositols	O
(	O
GPIs	O
)	O
.	O
The	O
de	O
novo	O
-	O
synthesized	O
inositol	O
is	O
believed	O
to	O
be	O
utilized	O
mostly	O
for	O
GPI	O
production	O
because	O
the	O
IMPase	O
that	O
dephosphorylates	O
inositol	O
3	O
-	O
phosphate	O
to	O
inositol	O
is	O
localized	O
to	O
the	O
ER	B-Anatomy
,	O
where	O
GPI	O
synthesis	O
occurs	O
.	O
Mutants	O
lacking	O
TbINO1	O
are	O
inviable	O
because	O
of	O
diminished	O
GPI	O
production	O
.	O
2	O
.	O
CLINICAL	O
PROTEOMICS	O
AT	O
THE	O
BEDSIDE	O
Clinically	O
-	O
based	O
proteomics	O
has	O
a	O
large	O
potential	O
for	O
the	O
development	O
of	O
strategies	O
which	O
aim	O
to	O
alleviate	O
risk	O
associated	O
with	O
cardiac	B-Anatomy
disease	O
.	O
Biomarkers	O
that	O
are	O
used	O
in	O
clinical	O
practice	O
are	O
highly	O
useful	O
in	O
that	O
they	O
support	O
medical	O
decision	O
making	O
,	O
by	O
complementing	O
other	O
diagnostic	O
tests	O
,	O
such	O
as	O
the	O
medical	O
history	O
,	O
physical	O
examination	O
,	O
and	O
various	O
other	O
special	O
tests	O
.	O
Theoretically	O
,	O
there	O
are	O
three	O
criteria	O
that	O
,	O
if	O
satisfied	O
,	O
would	O
provide	O
an	O
optimal	O
biomarker	O
of	O
the	O
disease	O
state	O
.	O
First	O
,	O
the	O
potential	O
biomarkers	O
must	O
be	O
easily	O
measurable	O
in	O
a	O
short	O
time	O
period	O
at	O
a	O
cost	O
that	O
is	O
practical	O
.	O
Second	O
,	O
elevation	O
of	O
this	O
protein	O
would	O
offer	O
diagnostic	O
information	O
that	O
was	O
not	O
previously	O
present	O
in	O
the	O
absence	O
of	O
the	O
protein	O
.	O
Third	O
,	O
the	O
information	O
obtained	O
would	O
aid	O
in	O
the	O
medical	O
decision	O
making	O
process	O
performed	O
by	O
the	O
clinician	O
[	O
11	O
]	O
.	O
Fulfillment	O
of	O
such	O
criteria	O
encourages	O
follow	O
-	O
up	O
of	O
such	O
a	O
biomarker	O
in	O
other	O
model	O
systems	O
or	O
patient	O
cohort	O
samples	O
.	O
For	O
instance	O
,	O
cardiac	O
troponin	O
I	O
has	O
been	O
previously	O
shown	O
to	O
fulfill	O
such	O
criteria	O
,	O
and	O
further	O
follow	O
-	O
up	O
in	O
patient	O
cohorts	O
is	O
underway	O
.	O
Recently	O
,	O
this	O
approach	O
was	O
utilized	O
to	O
ascertain	O
whether	O
Cardiac	O
Troponin	O
I	O
(	O
CTN	O
I	O
)	O
or	O
Creatine	O
Kinase	O
-	O
Myoglobin	O
(	O
CK	O
-	O
MB	O
)	O
could	O
be	O
used	O
as	O
short	O
-	O
term	O
or	O
long	O
-	O
term	O
markers	O
of	O
risk	O
associated	O
with	O
cardiac	B-Anatomy
surgery	O
[	O
12	O
]	O
.	O
In	O
this	O
study	O
,	O
a	O
patient	O
cohort	O
of	O
252	O
individuals	O
who	O
had	O
undergone	O
cardiac	B-Anatomy
surgery	O
was	O
used	O
to	O
analyze	O
levels	O
of	O
these	O
two	O
proteins	O
in	O
blood	B-Anatomy
.	O
Not	O
only	O
was	O
CTN	O
-	O
I	O
shown	O
to	O
be	O
a	O
strong	O
predictor	O
of	O
mortality	O
,	O
but	O
increases	O
in	O
the	O
levels	O
of	O
this	O
protein	O
also	O
correlated	O
well	O
with	O
increases	O
in	O
mortality	O
.	O
Findings	O
from	O
this	O
study	O
support	O
the	O
utilization	O
of	O
patient	O
cohorts	O
as	O
a	O
means	O
to	O
ease	O
the	O
transition	O
from	O
bench	O
to	O
bedside	O
.	O
Large	O
nodular	B-Anatomy
hepatic	I-Anatomy
flexure	I-Anatomy
lesions	I-Anatomy
as	O
seen	O
on	O
Colonoscopy	O
.	O
Water	O
emerging	O
from	O
the	O
yoke	O
adapter	O
of	O
the	O
nitrous	O
oxide	O
hose	O
Treatment	O
for	O
patients	O
with	O
diabetes	O
It	O
is	O
notable	O
that	O
treatment	O
of	O
diabetes	O
has	O
not	O
been	O
directly	O
monitored	O
by	O
OECD	O
indicators	O
,	O
largely	O
due	O
to	O
complexity	O
in	O
data	O
collection	O
.	O
Treatment	O
is	O
tailored	O
for	O
individuals	O
depending	O
on	O
the	O
patient	O
'	O
s	O
disease	O
status	O
,	O
and	O
plays	O
a	O
crucial	O
role	O
in	O
diabetes	O
management	O
.	O
Clinical	O
trials	O
have	O
found	O
that	O
a	O
one	O
percentage	O
point	O
reduction	O
in	O
HbA1c	O
levels	O
would	O
reduce	O
micro	O
-	O
vascular	B-Anatomy
complications	O
by	O
25	O
%	O
to	O
30	O
%	O
[	O
49	O
,	O
50	O
]	O
and	O
a	O
10	O
mmHg	O
reduction	O
in	O
blood	B-Anatomy
pressure	O
would	O
decrease	O
macro	O
-	O
and	O
micro	O
-	O
vascular	B-Anatomy
complications	O
and	O
death	O
rates	O
by	O
32	O
%	O
[	O
51	O
]	O
.	O
Improved	O
control	O
of	O
blood	B-Anatomy
lipids	O
can	O
reduce	O
risk	O
of	O
coronary	B-Anatomy
heart	B-Anatomy
disease	O
by	O
39	O
%	O
and	O
risk	O
of	O
death	O
by	O
43	O
%	O
[	O
52	O
]	O
.	O
RAND	O
'	O
s	O
Quality	O
Assessment	O
Tools	O
System	O
offers	O
indicators	O
relating	O
to	O
diabetes	O
treatment	O
[	O
53	O
]	O
,	O
and	O
application	O
of	O
these	O
indicators	O
in	O
a	O
national	O
study	O
in	O
the	O
US	O
has	O
provided	O
insight	O
into	O
adherence	O
to	O
recommended	O
treatment	O
regimens	O
.	O
For	O
people	O
with	O
newly	O
diagnosed	O
diabetes	O
56	O
%	O
received	O
dietary	O
and	O
exercise	O
counselling	O
.	O
In	O
type	O
2	O
diabetes	O
patients	O
,	O
use	O
of	O
oral	B-Anatomy
hypoglycaemic	O
agents	O
for	O
those	O
inadequately	O
controlled	O
on	O
dietary	O
therapy	O
was	O
38	O
%	O
and	O
use	O
of	O
insulin	O
for	O
those	O
inadequately	O
controlled	O
on	O
oral	B-Anatomy
hypoglycaemics	O
was	O
39	O
%	O
.	O
Fifty	O
-	O
five	O
percent	O
of	O
diabetics	O
were	O
offered	O
an	O
ACE	O
inhibitor	O
within	O
3	O
months	O
of	O
the	O
notation	O
of	O
proteinuria	B-Anatomy
unless	O
contraindicated	O
.	O
The	O
AusDiab	O
study	O
reported	O
the	O
treatment	O
pattern	O
among	O
Australian	O
adults	O
with	O
type	O
2	O
diabetes	O
[	O
37	O
]	O
.	O
While	O
32	O
%	O
of	O
diabetes	O
patients	O
were	O
on	O
diet	O
regimen	O
only	O
,	O
58	O
%	O
used	O
oral	B-Anatomy
hypoglycaemic	O
agents	O
and	O
diet	O
only	O
,	O
and	O
another	O
10	O
%	O
took	O
insulin	O
.	O
Bailie	O
and	O
colleagues	O
reported	O
pharmaceutical	O
interventions	O
for	O
diabetes	O
patients	O
in	O
remote	O
Aboriginal	O
communities	O
in	O
the	O
Northern	O
Territory	O
[	O
54	O
]	O
.	O
During	O
the	O
3	O
-	O
years	O
study	O
period	O
,	O
75	O
-	O
79	O
%	O
of	O
Aboriginal	O
patients	O
took	O
oral	B-Anatomy
hypoglycaemic	O
agents	O
,	O
and	O
4	O
-	O
7	O
%	O
used	O
insulin	O
.	O
The	O
pedigree	O
of	O
a	O
Korean	O
family	O
with	O
macular	B-Anatomy
dystrophy	O
demonstrating	O
the	O
characteristics	O
of	O
an	O
autosomal	O
dominant	O
inheritance	O
trait	O
.	O
Histological	O
analysis	O
A	O
cross	B-Anatomy
-	I-Anatomy
section	I-Anatomy
of	O
the	O
distal	B-Anatomy
colon	I-Anatomy
(	O
2	O
cm	O
)	O
was	O
fixed	O
in	O
10	O
%	O
paraformaldehyde	O
solution	O
.	O
Afterwards	O
,	O
it	O
was	O
cut	O
into	O
small	O
fragments	B-Anatomy
,	O
dehydrated	O
through	O
an	O
ethanol	O
series	O
(	O
70	O
%	O
-	O
100	O
%	O
)	O
,	O
cleared	O
in	O
xylol	O
and	O
embedded	O
in	O
paraffin	O
.	O
The	O
fragments	B-Anatomy
were	O
sliced	O
into	O
5	O
mum	O
thick	O
sections	B-Anatomy
and	O
stained	O
with	O
hematoxylin	O
-	O
eosin	O
.	O
Histological	O
evaluation	O
was	O
done	O
by	O
a	O
pathologist	O
who	O
was	O
blinded	O
to	O
the	O
experimental	O
groups	O
,	O
and	O
it	O
was	O
based	O
on	O
the	O
intensity	O
of	O
mononuclear	O
and	O
polymorphonuclear	O
infiltrates	O
in	O
the	O
lamina	B-Anatomy
propria	I-Anatomy
,	O
crypt	B-Anatomy
dilation	O
,	O
cellular	B-Anatomy
destruction	O
and	O
mucosal	B-Anatomy
ulceration	O
.	O
Histopathological	O
changes	O
were	O
graded	O
according	O
to	O
the	O
degree	O
of	O
inflammation	O
using	O
the	O
following	O
scale	O
:	O
absent	O
(	O
0	O
)	O
,	O
light	O
(	O
1	O
)	O
,	O
moderate	O
(	O
2	O
)	O
and	O
intense	O
(	O
3	O
)	O
,	O
and	O
the	O
numbers	O
represented	O
the	O
inflammation	O
score	O
(	O
IS	O
)	O
.	O
Results	O
were	O
expressed	O
as	O
mean	O
values	O
of	O
IS	O
+	O
/	O
-	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
for	O
each	O
experimental	O
group	O
.	O
Pteris	O
vittata	O
Intervention	O
Patients	O
'	O
initial	O
introduction	O
to	O
the	O
Wrist	B-Anatomy
Extension	O
Dynasplint	O
(	O
WED	O
)	O
system	O
,	O
[	O
Dynasplint	O
Systems	O
,	O
Inc	O
.	O
,	O
Severna	O
Park	O
,	O
MD	O
,	O
USA	O
]	O
included	O
customized	O
fitting	O
(	O
wrist	B-Anatomy
length	O
,	O
width	O
,	O
and	O
girth	O
so	O
that	O
the	O
force	O
and	O
counter	O
force	O
straps	O
could	O
be	O
properly	O
aligned	O
)	O
and	O
training	O
on	O
donning	O
and	O
doffing	O
of	O
the	O
device	O
.	O
(	O
See	O
figure	O
1	O
.	O
)	O
Verbal	O
and	O
written	O
instructions	O
were	O
provided	O
throughout	O
the	O
duration	O
of	O
treatment	O
for	O
safety	O
,	O
general	O
wear	O
and	O
care	O
,	O
and	O
tension	O
setting	O
goals	O
based	O
on	O
patient	O
tolerance	O
.	O
Figure	O
1	O
Wrist	B-Anatomy
Extension	O
Dynasplint	O
.	O
Each	O
patient	O
initially	O
wore	O
the	O
WED	O
for	O
4	O
-	O
6	O
continuous	O
hours	O
at	O
an	O
initial	O
tension	O
setting	O
of	O
#	O
2	O
(	O
0	O
.	O
1	O
foot	O
pounds	O
of	O
torque	O
)	O
.	O
This	O
duration	O
was	O
for	O
acclimatization	O
to	O
the	O
system	O
;	O
then	O
patients	O
were	O
instructed	O
to	O
wear	O
the	O
WED	O
system	O
at	O
night	O
while	O
sleeping	O
for	O
6	O
-	O
8	O
hours	O
of	O
continuous	O
wear	O
.	O
After	O
each	O
patient	O
was	O
comfortable	O
wearing	O
the	O
unit	O
for	O
one	O
week	O
at	O
tension	O
level	O
#	O
2	O
,	O
they	O
were	O
instructed	O
to	O
increase	O
the	O
tension	O
level	O
to	O
#	O
3	O
(	O
0	O
.	O
3	O
ft	O
lbs	O
.	O
)	O
and	O
make	O
continual	O
increases	O
every	O
two	O
weeks	O
.	O
If	O
prolonged	O
soreness	O
followed	O
a	O
session	O
(	O
soreness	O
for	O
more	O
than	O
15	O
minutes	O
)	O
the	O
patient	O
was	O
instructed	O
to	O
decrease	O
the	O
tension	O
one	O
half	O
a	O
setting	O
for	O
two	O
days	O
until	O
they	O
were	O
comfortable	O
wearing	O
it	O
for	O
6	O
-	O
8	O
hours	O
at	O
the	O
new	O
tension	O
setting	O
.	O
The	O
majority	O
of	O
all	O
patients	O
reached	O
level	O
#	O
5	O
(	O
0	O
.	O
8	O
foot	O
pounds	O
of	O
torque	O
)	O
by	O
the	O
end	O
of	O
two	O
months	O
.	O
All	O
range	O
of	O
motion	O
measurements	O
were	O
recorded	O
by	O
the	O
prescribing	O
clinician	O
.	O
Study	O
Population	O
This	O
prospective	O
longitudinal	O
study	O
was	O
conducted	O
at	O
the	O
University	O
of	O
British	O
Columbia	O
and	O
was	O
approved	O
by	O
the	O
human	O
research	O
ethics	O
board	O
at	O
that	O
institution	O
.	O
All	O
subjects	O
who	O
received	O
a	O
renal	B-Anatomy
transplant	I-Anatomy
from	O
January	O
2005	O
to	O
December	O
2007	O
were	O
invited	O
to	O
participate	O
,	O
and	O
those	O
who	O
agreed	O
and	O
signed	O
consent	O
forms	O
were	O
enrolled	O
in	O
the	O
study	O
.	O
Patients	O
were	O
followed	O
routinely	O
at	O
the	O
transplant	O
center	O
,	O
and	O
blood	B-Anatomy
and	O
urine	B-Anatomy
samples	I-Anatomy
were	O
obtained	O
prior	O
to	O
and	O
serially	O
post	O
-	O
transplant	O
at	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
and	O
26	O
weeks	O
;	O
then	O
every	O
6	O
months	O
through	O
year	O
3	O
;	O
and	O
also	O
at	O
the	O
time	O
of	O
suspected	O
rejection	O
.	O
Graft	B-Anatomy
biopsy	I-Anatomy
tissue	I-Anatomy
was	O
obtained	O
pretransplant	O
and	O
at	O
the	O
time	O
of	O
all	O
biopsies	O
performed	O
post	O
-	O
transplant	O
.	O
Blood	B-Anatomy
samples	I-Anatomy
from	O
normal	O
healthy	O
controls	O
served	O
as	O
reference	O
samples	B-Anatomy
.	O
Samples	B-Anatomy
from	O
cases	O
,	O
controls	O
,	O
and	O
comparators	O
were	O
treated	O
identically	O
.	O
All	O
rejection	O
episodes	O
were	O
diagnosed	O
by	O
conventional	O
clinical	O
and	O
laboratory	O
parameters	O
,	O
confirmed	O
by	O
biopsy	O
,	O
and	O
graded	O
according	O
to	O
the	O
Banff	O
97	O
working	O
classification	O
of	O
renal	B-Anatomy
allograft	I-Anatomy
pathology	O
(	O
28	O
)	O
.	O
Banff	O
categories	O
2	O
and	O
4	O
(	O
antibody	O
-	O
mediated	O
or	O
acute	O
/	O
active	O
cellular	B-Anatomy
rejection	O
)	O
were	O
considered	O
significant	O
.	O
Category	O
3	O
(	O
borderline	O
change	O
)	O
was	O
only	O
considered	O
significant	O
if	O
associated	O
with	O
graft	B-Anatomy
dysfunction	O
and	O
treated	O
for	O
rejection	O
.	O
All	O
baseline	O
demographic	O
and	O
follow	O
-	O
up	O
data	O
were	O
recorded	O
in	O
the	O
transplant	O
program	O
electronic	O
database	O
,	O
and	O
there	O
was	O
no	O
loss	O
to	O
follow	O
-	O
up	O
during	O
the	O
period	O
of	O
study	O
.	O
Animals	O
STOP	O
mice	O
and	O
their	O
WT	O
littermates	O
were	O
generated	O
on	O
a	O
mixed	O
BALBc	O
/	O
129	O
SvPas	O
and	O
on	O
a	O
pure	O
129	O
SvPas	O
background	O
as	O
previously	O
reported	O
by	O
Andrieux	O
et	O
al	O
.	O
[	O
4	O
]	O
.	O
All	O
animals	O
used	O
in	O
the	O
study	O
underwent	O
immunohistochemistry	O
for	O
the	O
detection	O
of	O
STOP	O
protein	O
,	O
resulting	O
in	O
no	O
staining	O
in	O
STOP	O
mice	O
,	O
and	O
genotyping	O
by	O
PCR	O
as	O
described	O
by	O
Andrieux	O
et	O
al	O
.	O
[	O
4	O
]	O
.	O
All	O
mice	O
were	O
kept	O
under	O
standard	O
housing	O
conditions	O
with	O
a	O
12	O
-	O
hour	O
/	O
12	O
-	O
hour	O
dark	O
-	O
light	O
cycle	O
.	O
The	O
experiments	O
were	O
carried	O
out	O
in	O
accordance	O
with	O
the	O
European	O
Communities	O
Council	O
Directive	O
of	O
24	O
November	O
1986	O
(	O
86	O
/	O
609	O
/	O
EEC	O
)	O
,	O
and	O
the	O
French	O
Department	O
of	O
Agriculture	O
(	O
License	O
Ndegrees	O
67	O
-	O
95	O
)	O
.	O
The	O
protocol	O
was	O
approved	O
by	O
the	O
ethical	O
Animal	O
Research	O
Committee	O
of	O
Louis	O
Pasteur	O
University	O
(	O
CREMEAS	O
#	O
AL	O
/	O
01	O
/	O
19	O
/	O
10	O
/	O
07	O
)	O
.	O
In	O
a	O
first	O
experiment	O
,	O
we	O
searched	O
for	O
differences	O
in	O
glomerular	B-Anatomy
ultrastructure	O
and	O
peripheral	O
neurogenesis	O
between	O
WT	O
and	O
STOP	O
mice	O
:	O
a	O
first	O
group	O
of	O
24	O
mice	O
,	O
3	O
-	O
to	O
6	O
-	O
month	O
-	O
old	O
,	O
was	O
used	O
for	O
ultrastructural	O
study	O
of	O
the	O
OBs	O
;	O
a	O
second	O
group	O
of	O
13	O
animals	O
was	O
used	O
to	O
analyse	O
proliferation	O
and	O
apoptosis	O
in	O
the	O
OE	B-Anatomy
and	O
VNE	B-Anatomy
on	O
paraffin	B-Anatomy
sections	I-Anatomy
in	O
3	O
-	O
month	O
-	O
old	O
mice	O
.	O
In	O
a	O
second	O
experiment	O
we	O
analysed	O
,	O
in	O
WT	O
and	O
STOP	O
mice	O
,	O
the	O
effect	O
of	O
OE	B-Anatomy
regeneration	O
on	O
glomeruli	B-Anatomy
structure	O
and	O
ultrastructure	O
and	O
on	O
peripheral	O
neurogenesis	O
at	O
two	O
age	O
times	O
(	O
3	O
and	O
10	O
months	O
)	O
.	O
Effect	O
of	O
the	O
deletion	O
of	O
IRE1alpha	O
on	O
the	O
liver	B-Anatomy
.	O
(	O
A	O
)	O
HE	O
-	O
stained	O
sections	B-Anatomy
of	O
the	O
liver	B-Anatomy
tissue	I-Anatomy
(	O
scale	O
bar	O
:	O
50	O
mum	O
)	O
.	O
(	O
B	O
)	O
Comparison	O
of	O
the	O
serum	B-Anatomy
AST	O
and	O
ALT	O
levels	O
between	O
the	O
IRE1alpha	O
CKO	O
mice	O
and	O
the	O
control	O
mice	O
.	O
Data	O
are	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
(	O
n	O
=	O
5	O
)	O
.	O
(	O
C	O
)	O
Quantitative	O
PCR	O
analysis	O
of	O
lipid	O
synthesis	O
genes	O
in	O
the	O
liver	B-Anatomy
of	O
mice	O
fed	O
normal	O
or	O
high	O
-	O
fructose	O
feed	O
.	O
Columns	O
indicate	O
mean	O
and	O
error	O
bars	O
denote	O
S	O
.	O
E	O
.	O
M	O
(	O
n	O
=	O
3	O
)	O
.	O
All	O
the	O
data	O
were	O
obtained	O
from	O
20	O
weeks	O
old	O
male	O
mice	O
.	O
2	O
.	O
Methods	O
Historical	O
Background	O
of	O
PTSD	O
PTSD	O
gained	O
acceptance	O
in	O
the	O
medical	O
and	O
psychiatric	O
community	O
after	O
a	O
number	O
of	O
studies	O
appeared	O
in	O
prominent	O
medical	O
and	O
psychiatric	O
journals	O
describing	O
the	O
psychiatric	O
symptoms	O
of	O
soldiers	O
who	O
had	O
served	O
and	O
fought	O
in	O
the	O
Vietnam	O
War	O
(	O
Fox	O
1972	O
;	O
Goldsmith	O
and	O
Cretekos	O
1969	O
)	O
.	O
Subsequent	O
publications	O
described	O
the	O
profound	O
psychological	O
and	O
emotional	O
sequelae	O
secondary	O
to	O
being	O
exposed	O
to	O
extremely	O
traumatic	O
events	O
such	O
as	O
fires	O
,	O
explosions	O
,	O
floods	O
,	O
torture	O
,	O
serious	O
motor	O
vehicle	O
accidents	O
(	O
MVAs	O
)	O
,	O
violent	O
crimes	O
,	O
and	O
sexual	O
assault	O
(	O
e	O
.	O
g	O
.	O
,	O
Horowitz	O
1976	O
)	O
.	O
These	O
publications	O
posited	O
that	O
individuals	O
with	O
PTSD	O
no	O
longer	O
felt	O
in	O
control	O
of	O
their	O
lives	O
,	O
viewed	O
the	O
world	O
as	O
an	O
unpredictable	O
and	O
dangerous	O
place	O
,	O
lived	O
in	O
fear	O
,	O
and	O
reported	O
a	O
loss	O
of	O
trust	O
in	O
a	O
""""	O
just	O
world	O
.	O
""""	O
These	O
studies	O
also	O
reported	O
that	O
individuals	O
with	O
PTSD	O
avoided	O
thoughts	O
or	O
situations	O
that	O
might	O
trigger	O
traumatic	O
memories	O
,	O
complained	O
of	O
feelings	O
of	O
emotional	O
numbness	O
,	O
and	O
exhibited	O
symptoms	O
of	O
blunted	O
affect	O
.	O
The	O
conceptual	O
refinements	O
coupled	O
with	O
the	O
empirical	O
information	O
generated	O
by	O
these	O
studies	O
significantly	O
advanced	O
our	O
understanding	O
of	O
individuals	O
who	O
have	O
been	O
exposed	O
to	O
a	O
traumatic	O
stressor	O
.	O
This	O
led	O
in	O
1980	O
to	O
the	O
inclusion	O
of	O
the	O
diagnostic	O
criteria	O
for	O
PTSD	O
in	O
the	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
III	O
(	O
DSM	O
-	O
III	O
;	O
American	O
Psychiatric	O
Association	O
1980	O
)	O
.	O
At	O
that	O
time	O
,	O
PTSD	O
was	O
defined	O
as	O
a	O
syndrome	O
that	O
developed	O
in	O
response	O
to	O
a	O
""""	O
stressor	O
that	O
would	O
evoke	O
significant	O
symptoms	O
of	O
distress	O
in	O
almost	O
everyone	O
""""	O
(	O
p	O
.	O
238	O
)	O
.	O
The	O
DSM	O
-	O
III	O
criteria	O
also	O
required	O
that	O
the	O
individual	O
who	O
developed	O
PTSD	O
had	O
to	O
have	O
been	O
directly	O
exposed	O
to	O
a	O
traumatic	O
event	O
.	O
The	O
DSM	O
-	O
IV	O
criteria	O
(	O
APA	O
1994	O
)	O
significantly	O
broadened	O
the	O
definition	O
of	O
PTSD	O
to	O
include	O
(	O
a	O
)	O
a	O
""""	O
personal	O
experience	O
of	O
an	O
event	O
that	O
involves	O
actual	O
or	O
threatened	O
death	O
or	O
serious	O
injury	O
,	O
or	O
other	O
threat	O
to	O
one	O
'	O
s	O
physical	O
integrity	O
""""	O
(	O
p	O
.	O
463	O
)	O
or	O
(	O
b	O
)	O
witnessing	O
a	O
comparable	O
traumatic	O
event	O
or	O
even	O
""""	O
learning	O
about	O
unexpected	O
or	O
violent	O
death	O
,	O
serious	O
harm	O
,	O
or	O
threat	O
of	O
death	O
or	O
injury	O
experienced	O
by	O
a	O
family	O
member	O
or	O
a	O
close	O
associate	O
""""	O
(	O
p	O
.	O
462	O
)	O
.	O
As	O
a	O
consequence	O
of	O
these	O
modifications	O
,	O
the	O
DSM	O
-	O
IV	O
diagnostic	O
criteria	O
for	O
PTSD	O
have	O
been	O
criticized	O
for	O
failing	O
to	O
discriminate	O
between	O
symptoms	O
of	O
PTSD	O
and	O
normal	O
stress	O
reactions	O
(	O
e	O
.	O
g	O
.	O
,	O
learning	O
about	O
the	O
9	O
/	O
11	O
disaster	O
;	O
Wakefield	O
and	O
Spitzer	O
2002	O
)	O
.	O
Summary	O
of	O
instrument	O
characteristics	O
Additional	O
file	O
2	O
Video	O
S2	O
TTE	O
apical	O
4	O
-	O
chamber	O
view	O
.	O
The	O
vegetation	O
seems	O
located	O
just	O
above	O
the	O
tricuspid	B-Anatomy
septal	I-Anatomy
valve	I-Anatomy
without	O
causing	O
obstruction	O
on	O
it	O
.	O
Histology	O
of	O
the	O
lung	B-Anatomy
The	O
left	B-Anatomy
lung	I-Anatomy
was	O
fixed	O
by	O
gentle	O
infusion	O
of	O
fixative	O
(	O
4	O
%	O
paraformaldehyde	O
)	O
through	O
the	O
tracheal	B-Anatomy
cannula	O
[	O
24	O
]	O
.	O
After	O
excision	O
,	O
the	O
lung	B-Anatomy
was	O
immersed	O
in	O
a	O
fresh	O
fixative	O
for	O
2	O
h	O
.	O
The	O
lung	B-Anatomy
lobe	I-Anatomy
was	O
embedded	O
in	O
paraffin	O
and	O
cut	O
into	O
3	O
mum	O
transverse	O
sections	B-Anatomy
,	O
followed	O
by	O
immunohistochemical	O
and	O
chemical	O
staining	O
.	O
Photomicrographs	O
were	O
captured	O
using	O
KS400	O
image	O
analyze	O
platform	O
(	O
Zeiss	O
,	O
Oberkochen	O
,	O
Germany	O
)	O
and	O
analyzed	O
quantitatively	O
.	O
Data	O
collection	O
:	O
CrystalClear	O
(	O
Rigaku	O
/	O
MSC	O
,	O
2005	O
>	O
)	O
;	O
cell	B-Anatomy
refinement	O
:	O
CrystalClear	O
;	O
data	O
reduction	O
:	O
CrystalClear	O
;	O
program	O
(	O
s	O
)	O
used	O
to	O
solve	O
structure	O
:	O
SHELXS97	O
(	O
Sheldrick	O
,	O
2008	O
>	O
)	O
;	O
program	O
(	O
s	O
)	O
used	O
to	O
refine	O
structure	O
:	O
SHELXL97	O
(	O
Sheldrick	O
,	O
2008	O
>	O
)	O
;	O
molecular	O
graphics	O
:	O
ORTEPII	O
(	O
Johnson	O
,	O
1976	O
>	O
)	O
;	O
software	O
used	O
to	O
prepare	O
material	O
for	O
publication	O
:	O
SHELXL97	O
.	O
Experimental	O
The	O
molecular	O
structure	O
of	O
(	O
I	O
)	O
,	O
showing	O
displacement	O
ellipsoids	O
at	O
the	O
30	O
%	O
probability	O
level	O
for	O
non	O
-	O
H	O
atoms	O
.	O
Discussion	O
Our	O
results	O
indicate	O
beneficial	O
effects	O
of	O
motivational	O
incentives	O
on	O
cognitive	O
performance	O
and	O
alleviating	O
effects	O
on	O
cognitive	O
decline	O
.	O
These	O
beneficial	O
effects	O
were	O
evident	O
in	O
healthy	O
young	O
and	O
older	O
adults	O
and	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
.	O
Young	O
adults	O
showed	O
improved	O
antisaccade	O
preparation	O
when	O
a	O
reward	O
was	O
at	O
stake	O
;	O
older	O
adults	O
and	O
PD	O
patients	O
could	O
utilize	O
reward	O
prospect	O
to	O
improve	O
their	O
impaired	O
antisaccade	O
preparation	O
.	O
Elderly	O
participants	O
and	O
PD	O
patients	O
were	O
not	O
only	O
better	O
prepared	O
by	O
means	O
of	O
commonly	O
used	O
preparatory	O
aids	O
(	O
i	O
.	O
e	O
.	O
,	O
more	O
preparation	O
time	O
and	O
advance	O
information	O
on	O
the	O
upcoming	O
response	O
)	O
but	O
also	O
by	O
means	O
of	O
motivational	O
incentives	O
.	O
These	O
beneficial	O
effects	O
of	O
motivational	O
incentives	O
on	O
cognitive	O
action	O
preparation	O
in	O
healthy	O
and	O
pathological	O
aging	O
further	O
support	O
views	O
that	O
question	O
the	O
notion	O
of	O
monotonic	O
deterioration	O
of	O
cognitive	O
function	O
with	O
age	O
(	O
Allen	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O
They	O
indicate	O
that	O
age	O
-	O
related	O
declines	O
can	O
be	O
modulated	O
by	O
emotion	O
-	O
cognition	O
interactions	O
.	O
In	O
line	O
with	O
the	O
predominant	O
view	O
that	O
cognitive	O
control	O
deteriorates	O
in	O
aging	O
and	O
Parkinson	O
'	O
s	O
disease	O
,	O
and	O
in	O
line	O
with	O
previous	O
findings	O
on	O
age	O
-	O
related	O
changes	O
in	O
antisaccade	O
control	O
specifically	O
(	O
Eenshuistra	O
et	O
al	O
.	O
,	O
2004	O
;	O
Chan	O
et	O
al	O
.	O
,	O
2005	O
;	O
Amador	O
et	O
al	O
.	O
,	O
2006	O
;	O
Abel	O
and	O
Douglas	O
,	O
2007	O
)	O
,	O
the	O
current	O
results	O
showed	O
decline	O
in	O
antisaccade	O
preparation	O
in	O
PD	O
patients	O
with	O
severe	O
motor	O
symptoms	O
as	O
compared	O
to	O
healthy	O
seniors	O
.	O
Mild	O
-	O
symptom	O
patients	O
and	O
healthy	O
elderly	O
did	O
not	O
differ	O
in	O
antisaccade	O
preparation	O
.	O
Healthy	O
seniors	O
showed	O
declining	O
antisaccade	O
preparation	O
as	O
compared	O
to	O
young	O
adults	O
.	O
Decline	O
was	O
evident	O
on	O
several	O
oculomotor	B-Anatomy
parameters	O
and	O
most	O
pronounced	O
on	O
antisaccade	O
onset	O
latencies	O
.	O
In	O
line	O
with	O
the	O
notion	O
that	O
in	O
general	O
,	O
elderly	O
tend	O
to	O
prefer	O
accuracy	O
over	O
speed	O
,	O
elderly	O
showed	O
no	O
decreased	O
antisaccade	O
accuracy	O
as	O
compared	O
to	O
young	O
adults	O
.	O
As	O
compared	O
to	O
the	O
young	O
group	O
,	O
elderly	O
and	O
PD	O
patients	O
exhibited	O
slightly	O
,	O
but	O
not	O
significantly	O
more	O
premature	O
eye	B-Anatomy
movements	O
.	O
Premature	O
eye	B-Anatomy
movements	O
,	O
however	O
significantly	O
increased	O
in	O
elderly	O
and	O
PD	O
patients	O
but	O
only	O
slightly	O
in	O
the	O
young	O
,	O
when	O
more	O
specific	O
information	O
on	O
the	O
upcoming	O
movement	O
was	O
available	O
in	O
advance	O
.	O
Presumably	O
,	O
this	O
increase	O
in	O
premature	O
eye	B-Anatomy
movements	O
reflects	O
difficulties	O
with	O
the	O
inhibition	O
of	O
externally	O
guided	O
movement	O
and	O
/	O
or	O
the	O
suppression	O
of	O
strongly	O
activated	O
prepotent	O
action	O
plans	O
.	O
On	O
the	O
one	O
hand	O
,	O
the	O
choice	O
for	O
medicated	O
PD	O
patients	O
represents	O
a	O
limitation	O
of	O
the	O
current	O
study	O
as	O
we	O
cannot	O
exclude	O
differential	O
effects	O
of	O
medication	O
on	O
behavior	O
.	O
On	O
the	O
other	O
hand	O
,	O
PD	O
patients	O
generally	O
take	O
medication	O
in	O
their	O
daily	O
routine	O
,	O
such	O
that	O
the	O
results	O
can	O
be	O
generalized	O
to	O
clinical	O
practice	O
.	O
Exploratory	O
analysis	O
within	O
the	O
PD	O
patient	O
group	O
revealed	O
that	O
patients	O
with	O
more	O
severe	O
motoric	O
symptoms	O
(	O
as	O
indexed	O
by	O
their	O
motoric	O
subscore	O
on	O
the	O
UPDRS	O
)	O
displayed	O
more	O
signs	O
of	O
antisaccade	O
decline	O
,	O
such	O
as	O
longer	O
antisaccade	O
latencies	O
and	O
lower	O
accuracy	O
compared	O
to	O
mildly	O
affected	O
patients	O
,	O
who	O
initiated	O
saccades	O
equally	O
fast	O
as	O
healthy	O
adults	O
.	O
This	O
suggests	O
that	O
dopaminergic	O
medication	O
was	O
not	O
sufficient	O
to	O
raise	O
the	O
patient	O
'	O
s	O
antisaccadic	O
preparation	O
up	O
to	O
the	O
level	O
of	O
the	O
healthy	O
older	O
adults	O
.	O
One	O
intriguing	O
observation	O
was	O
that	O
despite	O
the	O
different	O
extents	O
of	O
observed	O
antisaccade	O
performance	O
decline	O
in	O
elderly	O
and	O
PD	O
patients	O
,	O
reward	O
prospect	O
led	O
to	O
beneficial	O
effects	O
on	O
antisaccade	O
latency	O
and	O
accuracy	O
in	O
young	O
,	O
elderly	O
,	O
and	O
PD	O
patients	O
alike	O
.	O
Young	O
,	O
elderly	O
and	O
PD	O
patients	O
benefited	O
from	O
reward	O
prospect	O
to	O
the	O
same	O
extent	O
,	O
confirming	O
that	O
the	O
expectancy	O
of	O
reward	O
is	O
a	O
powerful	O
mediator	O
of	O
cognitive	O
control	O
,	O
even	O
if	O
cognitive	O
control	O
suffers	O
from	O
decline	O
.	O
The	O
expectation	O
of	O
rewarding	O
incentives	O
thus	O
seems	O
to	O
support	O
older	O
adults	O
'	O
and	O
PD	O
patients	O
'	O
ability	O
to	O
anticipate	O
,	O
prepare	O
and	O
initiate	O
goal	O
-	O
directed	O
behavior	O
.	O
These	O
findings	O
imply	O
that	O
despite	O
a	O
general	O
decline	O
in	O
the	O
action	O
preparation	O
system	O
as	O
indexed	O
by	O
increased	O
antisaccade	O
latency	O
,	O
action	O
preparation	O
processes	O
remain	O
susceptible	O
to	O
the	O
prospect	O
of	O
future	O
reward	O
.	O
It	O
could	O
thus	O
be	O
argued	O
that	O
the	O
neural	B-Anatomy
representations	O
of	O
upcoming	O
rewards	O
influence	O
neural	B-Anatomy
systems	I-Anatomy
concerned	O
with	O
action	O
preparation	O
and	O
oculomotor	B-Anatomy
control	O
.	O
Although	O
the	O
current	O
behavioral	O
results	O
cannot	O
exclude	O
or	O
confirm	O
neural	B-Anatomy
links	O
between	O
reward	O
anticipation	O
and	O
action	O
preparation	O
systems	O
in	O
the	O
brain	B-Anatomy
,	O
they	O
suggest	O
intact	O
cross	O
-	O
talk	O
among	O
subcortical	B-Anatomy
circuits	O
that	O
allow	O
goal	O
-	O
directed	O
action	O
to	O
be	O
modified	O
by	O
motivational	O
factors	O
.	O
The	O
motivational	O
neural	B-Anatomy
reward	O
anticipation	O
signal	O
presumably	O
activates	O
the	O
reward	O
network	O
including	O
the	O
amygdala	B-Anatomy
,	O
orbitofrontal	B-Anatomy
cortex	I-Anatomy
,	O
the	O
more	O
ventral	B-Anatomy
and	O
dorsal	B-Anatomy
striatum	I-Anatomy
(	O
nucleus	B-Anatomy
accumbens	I-Anatomy
,	O
putamen	B-Anatomy
,	O
and	O
caudate	B-Anatomy
)	O
,	O
leading	O
to	O
an	O
release	O
of	O
caudate	O
/	O
SNr	O
inhibition	O
on	O
the	O
executive	O
oculomotor	B-Anatomy
structure	I-Anatomy
superior	I-Anatomy
colliculus	I-Anatomy
.	O
This	O
transiently	O
decreased	O
inhibitory	O
force	O
on	O
superior	B-Anatomy
colliculus	I-Anatomy
may	O
improve	O
goal	O
-	O
directed	O
oculomotor	B-Anatomy
control	O
.	O
Thus	O
reward	O
anticipation	O
might	O
compensate	O
for	O
the	O
age	O
-	O
and	O
disease	O
-	O
related	O
dopaminergic	O
loss	O
in	O
the	O
SNc	O
projections	O
to	O
the	O
caudate	O
/	O
SNr	O
and	O
may	O
thus	O
play	O
a	O
compensatory	O
role	O
in	O
""""	O
boosting	O
""""	O
the	O
efficiency	O
of	O
interactions	O
between	O
motivational	O
and	O
impaired	O
cognitive	O
control	O
processes	O
.	O
However	O
the	O
reward	O
-	O
related	O
modulation	O
of	O
the	O
oculomotor	B-Anatomy
control	I-Anatomy
system	I-Anatomy
may	O
not	O
only	O
apply	O
to	O
the	O
basal	B-Anatomy
ganglia	I-Anatomy
part	O
of	O
the	O
oculomotor	B-Anatomy
network	I-Anatomy
.	O
Although	O
speculative	O
,	O
it	O
could	O
extend	O
to	O
the	O
cortical	B-Anatomy
eyefields	I-Anatomy
(	O
frontal	B-Anatomy
,	O
supplementary	B-Anatomy
,	O
and	O
parietal	B-Anatomy
eyefields	I-Anatomy
)	O
and	O
to	O
parts	O
of	O
the	O
visual	B-Anatomy
cortex	I-Anatomy
.	O
Human	O
research	O
shows	O
that	O
more	O
preparatory	O
activation	O
in	O
the	O
frontal	B-Anatomy
eyefields	I-Anatomy
leads	O
to	O
a	O
faster	O
antisaccade	O
latency	O
(	O
Connolly	O
et	O
al	O
.	O
,	O
2002	O
,	O
2005	O
)	O
.	O
The	O
compensatory	O
effect	O
on	O
the	O
antisaccade	O
latency	O
,	O
therefore	O
,	O
could	O
theoretically	O
stem	O
from	O
a	O
propagation	O
of	O
reward	O
anticipation	O
signal	O
in	O
the	O
caudate	B-Anatomy
to	O
the	O
frontal	B-Anatomy
eyefields	I-Anatomy
.	O
Complex	O
structural	O
connections	O
enable	O
the	O
striatum	B-Anatomy
to	O
exert	O
a	O
controlling	O
influence	O
over	O
the	O
cerebral	B-Anatomy
cortex	I-Anatomy
via	O
a	O
series	O
of	O
reentrant	B-Anatomy
corticobasal	I-Anatomy
ganglia	I-Anatomy
circuits	O
.	O
Thus	O
reward	O
anticipation	O
may	O
increase	O
the	O
level	O
of	O
preparation	O
in	O
the	O
intact	O
cortical	B-Anatomy
eyefields	I-Anatomy
and	O
thereby	O
compensate	O
for	O
age	O
-	O
and	O
disease	O
-	O
related	O
subcortical	B-Anatomy
decrements	O
in	O
the	O
oculomotor	B-Anatomy
network	I-Anatomy
.	O
Taken	O
together	O
,	O
it	O
seems	O
plausible	O
that	O
motivational	O
reward	O
processes	O
in	O
the	O
caudate	B-Anatomy
enhance	O
preparatory	O
activation	O
in	O
subcortical	B-Anatomy
as	O
well	O
as	O
in	O
cortical	B-Anatomy
nodes	I-Anatomy
of	O
the	O
oculomotor	B-Anatomy
network	I-Anatomy
.	O
Several	O
neurotransmission	O
mechanisms	O
may	O
underlie	O
the	O
remedial	O
effect	O
of	O
positive	O
incentives	O
on	O
declining	O
antisaccadic	O
control	O
.	O
Given	O
the	O
convergence	O
of	O
dopamine	O
and	O
glutamate	O
inputs	O
at	O
the	O
spiny	B-Anatomy
projection	I-Anatomy
neurons	I-Anatomy
in	O
the	O
striatum	B-Anatomy
(	O
Burns	O
et	O
al	O
.	O
,	O
1994	O
)	O
,	O
an	O
interaction	O
between	O
dopamine	O
and	O
glutamate	O
might	O
underlie	O
striatal	B-Anatomy
processes	O
of	O
reward	O
anticipation	O
and	O
action	O
preparation	O
.	O
However	O
,	O
it	O
cannot	O
be	O
fully	O
excluded	O
that	O
alterations	O
in	O
other	O
neurotransmitter	O
systems	O
may	O
also	O
have	O
an	O
effect	O
on	O
declining	O
oculomotor	B-Anatomy
control	O
and	O
on	O
remediating	O
incentive	O
effects	O
.	O
Non	O
-	O
dopaminergic	O
changes	O
such	O
as	O
noradrenergic	O
,	O
serotonergic	O
,	O
and	O
cholinergic	O
deafferentation	O
of	O
the	O
cortex	B-Anatomy
also	O
occur	O
in	O
PD	O
and	O
can	O
inflict	O
cognitive	O
deficits	O
(	O
Agid	O
et	O
al	O
.	O
,	O
1987	O
)	O
.	O
Evidence	O
from	O
non	O
-	O
human	O
primates	O
suggests	O
that	O
basal	B-Anatomy
ganglia	I-Anatomy
dopamine	O
acts	O
to	O
speed	B-Anatomy
motor	I-Anatomy
responding	O
in	O
response	O
to	O
rewarding	O
cues	O
(	O
Niv	O
,	O
2007	O
;	O
Niv	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O
Among	O
at	O
least	O
five	O
types	O
of	O
DA	O
receptors	O
,	O
mainly	O
D1	O
and	O
D2	O
receptors	O
are	O
expressed	O
in	O
caudate	B-Anatomy
projection	I-Anatomy
neurons	I-Anatomy
(	O
Nakamura	O
and	O
Hikosaka	O
,	O
2006	O
)	O
.	O
Tendencies	O
to	O
speed	O
responses	O
to	O
obtain	O
large	O
rewards	O
have	O
been	O
found	O
to	O
be	O
dependent	O
on	O
striatal	B-Anatomy
D1	O
receptors	O
(	O
Dalley	O
et	O
al	O
.	O
,	O
2005	O
;	O
Berridge	O
,	O
2007	O
)	O
.	O
In	O
contrast	O
to	O
this	O
D1	O
modulated	O
speeding	O
in	O
reward	O
-	O
motor	O
tasks	O
,	O
evidence	O
from	O
saccade	O
tasks	O
in	O
non	O
-	O
human	O
primates	O
suggests	O
D2	O
receptor	O
modulation	O
of	O
reward	O
dependent	O
improvements	O
of	O
performance	O
(	O
Nakamura	O
and	O
Hikosaka	O
,	O
2006	O
)	O
.	O
Injections	O
of	O
a	O
D1	O
antagonist	O
and	O
a	O
D2	O
antagonist	O
into	O
the	O
region	O
of	O
the	O
caudate	B-Anatomy
where	O
saccade	O
-	O
related	O
neurons	B-Anatomy
are	O
clustered	O
while	O
the	O
monkey	O
performed	O
a	O
reward	O
-	O
biased	O
saccade	O
task	O
showed	O
that	O
D1	O
antagonists	O
attenuate	O
the	O
reward	O
modulation	O
of	O
saccade	O
behavior	O
whereas	O
D2	O
antagonists	O
into	O
the	O
same	O
region	O
enhanced	O
the	O
reward	O
-	O
dependent	O
changes	O
.	O
Future	O
studies	O
of	O
Parkinson	O
patients	O
on	O
versus	O
off	O
medication	O
,	O
could	O
provide	O
some	O
information	O
on	O
the	O
role	O
of	O
dopaminergic	O
mechanisms	O
in	O
the	O
remedial	O
effects	O
on	O
antisaccadic	O
performance	O
.	O
A	O
recent	O
study	O
of	O
reward	O
learning	O
in	O
Parkinson	O
patients	O
on	O
/	O
off	O
dopaminergic	O
medication	O
showed	O
that	O
patients	O
adapted	O
their	O
behavior	O
to	O
maximize	O
expected	O
reward	O
value	O
dependent	O
on	O
their	O
medication	O
status	O
(	O
Moustafa	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O
Whilst	O
off	O
dopaminergic	O
medication	O
,	O
patients	O
slowed	O
their	O
responses	O
to	O
avoid	O
low	O
expected	O
values	O
,	O
but	O
succeeded	O
less	O
well	O
in	O
speeding	O
responses	O
when	O
a	O
reward	O
was	O
at	O
stake	O
.	O
The	O
opposite	O
pattern	O
emerged	O
when	O
the	O
same	O
patients	O
were	O
on	O
medication	O
;	O
patients	O
showed	O
better	O
response	O
speeding	O
,	O
and	O
worse	O
response	O
slowing	O
,	O
to	O
maximize	O
expected	O
value	O
.	O
The	O
current	O
behavioral	O
findings	O
are	O
in	O
line	O
with	O
neuroimaging	O
research	O
showing	O
intact	O
neural	B-Anatomy
representations	O
of	O
future	O
reward	O
in	O
the	O
aging	O
striatum	B-Anatomy
(	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O
The	O
observation	O
however	O
that	O
older	O
adults	O
and	O
PD	O
patients	O
can	O
use	O
this	O
intact	O
neural	B-Anatomy
representation	O
of	O
reward	O
anticipation	O
(	O
a	O
positive	O
motivational	O
incentive	O
)	O
to	O
optimize	O
their	O
preparatory	O
processes	O
,	O
cannot	O
necessarily	O
be	O
generalized	O
to	O
cognitive	O
contexts	O
with	O
negative	O
motivational	O
incentives	O
.	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
(	O
2010	O
)	O
recently	O
showed	O
that	O
older	O
adults	O
were	O
not	O
able	O
to	O
optimally	O
use	O
their	O
intact	O
neural	B-Anatomy
reward	O
anticipation	O
system	O
in	O
risky	O
financial	O
decision	O
making	O
.	O
Elderly	O
made	O
more	O
suboptimal	O
choices	O
when	O
they	O
were	O
to	O
choose	O
risky	O
assets	O
.	O
The	O
authors	O
deemed	O
it	O
likely	O
that	O
these	O
decrements	O
in	O
value	O
-	O
based	O
decision	O
making	O
are	O
explained	O
by	O
the	O
fact	O
that	O
value	O
-	O
based	O
decision	O
making	O
requires	O
the	O
weighting	O
of	O
behavioral	O
alternatives	O
,	O
that	O
may	O
lead	O
to	O
either	O
gain	O
or	O
loss	O
.	O
During	O
anticipation	O
of	O
rewards	O
older	O
adults	O
show	O
similar	O
neural	B-Anatomy
responses	O
as	O
young	O
adults	O
but	O
they	O
show	O
reduced	O
neural	B-Anatomy
activation	O
during	O
the	O
anticipation	O
of	O
losses	O
(	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O
The	O
latter	O
,	O
together	O
with	O
the	O
observation	O
that	O
older	O
adults	O
tend	O
to	O
shift	O
their	O
attention	O
away	O
from	O
negative	O
stimuli	O
and	O
attend	O
to	O
positive	O
information	O
instead	O
(	O
Mather	O
and	O
Carstensen	O
,	O
2003	O
,	O
2005	O
)	O
,	O
may	O
have	O
led	O
to	O
the	O
underestimation	O
of	O
loss	O
and	O
therefore	O
to	O
more	O
risky	O
and	O
suboptimal	O
decisions	O
.	O
In	O
this	O
respect	O
,	O
one	O
limitation	O
of	O
the	O
current	O
task	O
is	O
that	O
it	O
built	O
solely	O
on	O
reward	O
prospect	O
and	O
not	O
on	O
the	O
prospect	O
of	O
loss	O
,	O
such	O
that	O
the	O
question	O
of	O
how	O
the	O
anticipation	O
of	O
loss	O
influences	O
action	O
preparation	O
was	O
not	O
tested	O
.	O
The	O
impact	O
of	O
negative	O
incentives	O
might	O
be	O
an	O
intriguing	O
question	O
for	O
future	O
research	O
,	O
as	O
due	O
to	O
the	O
decreased	O
activation	O
of	O
the	O
neural	B-Anatomy
loss	O
anticipation	O
system	O
(	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
,	O
2007	O
)	O
together	O
with	O
the	O
observed	O
differential	O
attentional	O
bias	O
for	O
negative	O
and	O
positive	O
information	O
(	O
Mather	O
and	O
Carstensen	O
,	O
2003	O
)	O
,	O
it	O
seems	O
likely	O
that	O
negative	O
motivational	O
incentives	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
prospect	O
of	O
loss	O
,	O
might	O
have	O
a	O
different	O
impact	O
on	O
action	O
preparation	O
in	O
older	O
adults	O
than	O
in	O
the	O
young	O
.	O
Future	O
approaches	O
to	O
the	O
effect	O
of	O
loss	O
anticipation	O
on	O
declining	O
antisaccade	O
control	O
may	O
ideally	O
contain	O
a	O
sequence	O
of	O
experiments	O
,	O
starting	O
with	O
a	O
separate	O
(	O
punishment	O
only	O
)	O
approach	O
before	O
moving	O
to	O
combined	O
reward	O
-	O
punishment	O
designs	O
.	O
This	O
might	O
be	O
necessary	O
as	O
previous	O
evidence	O
(	O
from	O
healthy	O
young	O
adults	O
)	O
suggests	O
that	O
the	O
reward	O
effect	O
on	O
oculomotor	B-Anatomy
control	O
disappears	O
in	O
the	O
presence	O
of	O
punishment	O
trials	O
.	O
The	O
authors	O
deemed	O
it	O
likely	O
that	O
the	O
participants	O
increased	O
caution	O
to	O
all	O
incentive	O
(	O
reward	O
and	O
punishment	O
)	O
trials	O
(	O
Blaukopf	O
and	O
DiGirolamo	O
,	O
2006	O
)	O
.	O
As	O
of	O
yet	O
,	O
age	O
-	O
related	O
changes	O
in	O
neural	B-Anatomy
reward	O
anticipation	O
have	O
mainly	O
been	O
studied	O
in	O
isolation	O
.	O
Recently	O
however	O
,	O
the	O
interaction	O
of	O
neural	B-Anatomy
reward	O
processing	O
with	O
other	O
cognitive	O
functions	O
and	O
their	O
underlying	O
neural	B-Anatomy
systems	I-Anatomy
,	O
such	O
as	O
the	O
action	B-Anatomy
control	I-Anatomy
system	I-Anatomy
,	O
has	O
gained	O
increasing	O
interest	O
(	O
Haber	O
and	O
Knutson	O
,	O
2010	O
)	O
.	O
Initial	O
evidence	O
suggests	O
coordinated	O
activity	O
between	O
distant	O
brain	B-Anatomy
regions	O
responsible	O
for	O
reward	O
processing	O
(	O
Cohen	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
The	O
current	O
results	O
encourage	O
further	O
neural	B-Anatomy
network	I-Anatomy
investigations	O
on	O
the	O
role	O
of	O
coordinated	O
brain	B-Anatomy
network	O
activity	O
in	O
motivated	O
behavior	O
.	O
Behavioral	O
benefits	O
from	O
motivation	O
might	O
be	O
associated	O
with	O
changes	O
in	O
functional	O
brain	B-Anatomy
connectivity	O
on	O
a	O
larger	O
scale	O
,	O
e	O
.	O
g	O
.	O
,	O
between	O
frontostriatal	B-Anatomy
reward	I-Anatomy
and	O
action	B-Anatomy
preparation	I-Anatomy
structures	I-Anatomy
.	O
Another	O
important	O
factor	O
that	O
emerges	O
from	O
the	O
present	O
and	O
previous	O
results	O
,	O
is	O
the	O
importance	O
of	O
the	O
training	O
of	O
the	O
motivational	O
aspects	O
of	O
the	O
instructions	O
that	O
need	O
to	O
be	O
kept	O
in	O
working	O
memory	O
when	O
performing	O
a	O
cognitive	O
task	O
.	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
(	O
2007	O
)	O
found	O
intact	O
neural	B-Anatomy
reward	O
anticipation	O
processes	O
specifically	O
in	O
the	O
absence	O
of	O
learning	O
(	O
after	O
the	O
learning	O
process	O
of	O
reward	O
cue	O
-	O
reward	O
associations	O
was	O
completed	O
)	O
.	O
Therefore	O
it	O
might	O
be	O
important	O
for	O
researchers	O
doing	O
experiments	O
with	O
motivation	O
based	O
instructions	O
to	O
keep	O
in	O
mind	O
that	O
,	O
compared	O
to	O
young	O
adults	O
,	O
elderly	O
and	O
PD	O
patients	O
are	O
generally	O
hampered	O
on	O
stimulus	O
-	O
response	O
learning	O
(	O
Shohamy	O
et	O
al	O
.	O
,	O
2004	O
;	O
Marschner	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
Reward	O
instruction	O
cues	O
,	O
as	O
they	O
were	O
used	O
in	O
the	O
current	O
study	O
require	O
participants	O
to	O
form	O
reward	O
cue	O
-	O
reward	O
associations	O
.	O
Impairments	O
in	O
the	O
learning	O
of	O
associations	O
between	O
the	O
cue	O
signaling	O
reward	O
and	O
the	O
actual	O
reward	O
might	O
conceal	O
intact	O
reward	O
anticipation	O
processes	O
.	O
When	O
the	O
formation	O
of	O
associations	O
is	O
weakened	O
,	O
it	O
could	O
appear	O
as	O
a	O
failure	O
to	O
capitalize	O
on	O
the	O
neural	B-Anatomy
reward	O
anticipation	O
system	O
,	O
whereas	O
it	O
represents	O
an	O
indirect	O
effect	O
of	O
non	O
-	O
available	O
reward	O
associations	O
in	O
working	O
memory	O
when	O
preparing	O
the	O
response	O
.	O
Hence	O
,	O
one	O
might	O
circumvent	O
the	O
effect	O
of	O
potential	O
learning	O
impairments	O
on	O
reward	O
anticipation	O
processes	O
by	O
the	O
training	O
of	O
abstract	O
reward	O
cues	O
(	O
as	O
in	O
the	O
current	O
and	O
in	O
Samanez	O
-	O
Larkin	O
'	O
s	O
study	O
)	O
or	O
by	O
using	O
explicit	O
and	O
concrete	O
rewards	O
.	O
Once	O
the	O
learning	O
of	O
reward	O
cues	O
is	O
accomplished	O
the	O
intact	O
reward	O
anticipation	O
processes	O
might	O
become	O
evident	O
.	O
In	O
sum	O
,	O
the	O
results	O
confirmed	O
that	O
the	O
preparation	O
of	O
goal	O
-	O
directed	O
actions	O
declined	O
in	O
PD	O
patients	O
compared	O
to	O
healthy	O
seniors	O
,	O
and	O
in	O
healthy	O
seniors	O
compared	O
to	O
young	O
adults	O
.	O
Due	O
perhaps	O
to	O
deterioration	O
in	O
dopaminergic	O
striatal	B-Anatomy
circuitry	O
,	O
antisaccade	O
performance	O
is	O
subject	O
to	O
decline	O
in	O
healthy	O
seniors	O
,	O
and	O
even	O
more	O
in	O
individuals	O
with	O
Parkinson	O
'	O
s	O
disease	O
.	O
The	O
prospect	O
of	O
future	O
reward	O
however	O
provided	O
a	O
motivational	O
incentive	O
for	O
optimizing	O
oculomotor	B-Anatomy
preparation	O
in	O
all	O
groups	O
alike	O
.	O
These	O
results	O
suggest	O
that	O
reward	O
-	O
processing	O
networks	O
and	O
oculomotor	B-Anatomy
-	I-Anatomy
control	I-Anatomy
networks	I-Anatomy
in	O
the	O
brain	B-Anatomy
are	O
connected	O
in	O
such	O
a	O
way	O
(	O
presumably	O
with	O
the	O
dorsal	B-Anatomy
striatum	I-Anatomy
as	O
a	O
common	O
nexus	O
)	O
that	O
reward	O
anticipation	O
can	O
facilitate	O
oculomotor	B-Anatomy
control	O
and	O
alleviate	O
the	O
deficiencies	O
experienced	O
by	O
healthy	O
seniors	O
and	O
PD	O
patients	O
.	O
Future	O
investigations	O
should	O
examine	O
whether	O
the	O
observed	O
effects	O
are	O
specific	O
for	O
the	O
current	O
task	O
or	O
generalize	O
to	O
other	O
tasks	O
that	O
show	O
age	O
-	O
and	O
PD	O
-	O
related	O
cognitive	O
decrements	O
(	O
e	O
.	O
g	O
.	O
,	O
in	O
task	O
switching	O
)	O
and	O
have	O
been	O
related	O
to	O
dopaminergic	O
denervation	O
in	O
the	O
caudate	B-Anatomy
(	O
e	O
.	O
g	O
.	O
,	O
impaired	O
verbal	O
episodic	O
memory	O
,	O
attention	O
,	O
and	O
response	O
inhibition	O
;	O
Rinne	O
et	O
al	O
.	O
,	O
2000	O
;	O
Bruck	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
Future	O
studies	O
on	O
network	O
processes	O
may	O
help	O
to	O
localize	O
the	O
neural	B-Anatomy
link	O
between	O
reward	O
prospect	O
and	O
action	O
preparation	O
that	O
enables	O
alleviating	O
effects	O
of	O
motivational	O
incentives	O
on	O
cognitive	O
decline	O
.	O
Atomic	O
displacement	O
parameters	O
(	O
A2	O
)	O
U11	O
U22	O
U33	O
U12	O
U13	O
U23	O
Br	O
0	O
.	O
03555	O
(	O
15	O
)	O
0	O
.	O
05091	O
(	O
17	O
)	O
0	O
.	O
03161	O
(	O
14	O
)	O
-	O
0	O
.	O
01198	O
(	O
11	O
)	O
0	O
.	O
01077	O
(	O
10	O
)	O
-	O
0	O
.	O
00502	O
(	O
11	O
)	O
S	O
0	O
.	O
0273	O
(	O
3	O
)	O
0	O
.	O
0176	O
(	O
2	O
)	O
0	O
.	O
0338	O
(	O
3	O
)	O
0	O
.	O
0016	O
(	O
2	O
)	O
-	O
0	O
.	O
0020	O
(	O
2	O
)	O
0	O
.	O
0026	O
(	O
2	O
)	O
F	O
0	O
.	O
0514	O
(	O
10	O
)	O
0	O
.	O
0486	O
(	O
9	O
)	O
0	O
.	O
0464	O
(	O
9	O
)	O
0	O
.	O
0068	O
(	O
8	O
)	O
0	O
.	O
0279	O
(	O
8	O
)	O
-	O
0	O
.	O
0001	O
(	O
7	O
)	O
O1	O
0	O
.	O
0293	O
(	O
8	O
)	O
0	O
.	O
0186	O
(	O
7	O
)	O
0	O
.	O
0251	O
(	O
7	O
)	O
-	O
0	O
.	O
0030	O
(	O
6	O
)	O
0	O
.	O
0028	O
(	O
6	O
)	O
0	O
.	O
0004	O
(	O
6	O
)	O
O2A	O
0	O
.	O
0417	O
(	O
12	O
)	O
0	O
.	O
0238	O
(	O
9	O
)	O
0	O
.	O
0326	O
(	O
10	O
)	O
-	O
0	O
.	O
0001	O
(	O
8	O
)	O
-	O
0	O
.	O
0051	O
(	O
8	O
)	O
0	O
.	O
0102	O
(	O
7	O
)	O
O2B	O
0	O
.	O
036	O
(	O
11	O
)	O
0	O
.	O
010	O
(	O
7	O
)	O
0	O
.	O
025	O
(	O
9	O
)	O
-	O
0	O
.	O
003	O
(	O
7	O
)	O
0	O
.	O
003	O
(	O
7	O
)	O
0	O
.	O
007	O
(	O
6	O
)	O
C1	O
0	O
.	O
0228	O
(	O
11	O
)	O
0	O
.	O
0192	O
(	O
9	O
)	O
0	O
.	O
0233	O
(	O
10	O
)	O
0	O
.	O
0001	O
(	O
8	O
)	O
-	O
0	O
.	O
0023	O
(	O
8	O
)	O
0	O
.	O
0019	O
(	O
8	O
)	O
C2	O
0	O
.	O
0258	O
(	O
11	O
)	O
0	O
.	O
0199	O
(	O
10	O
)	O
0	O
.	O
0193	O
(	O
9	O
)	O
0	O
.	O
0000	O
(	O
8	O
)	O
-	O
0	O
.	O
0033	O
(	O
8	O
)	O
0	O
.	O
0016	O
(	O
7	O
)	O
C3	O
0	O
.	O
0263	O
(	O
11	O
)	O
0	O
.	O
0229	O
(	O
10	O
)	O
0	O
.	O
0177	O
(	O
9	O
)	O
-	O
0	O
.	O
0020	O
(	O
8	O
)	O
-	O
0	O
.	O
0031	O
(	O
8	O
)	O
0	O
.	O
0008	O
(	O
8	O
)	O
C4	O
0	O
.	O
0294	O
(	O
12	O
)	O
0	O
.	O
0228	O
(	O
10	O
)	O
0	O
.	O
0277	O
(	O
11	O
)	O
-	O
0	O
.	O
0014	O
(	O
9	O
)	O
-	O
0	O
.	O
0008	O
(	O
9	O
)	O
0	O
.	O
0027	O
(	O
8	O
)	O
C5	O
0	O
.	O
0323	O
(	O
13	O
)	O
0	O
.	O
0297	O
(	O
11	O
)	O
0	O
.	O
0285	O
(	O
11	O
)	O
-	O
0	O
.	O
0081	O
(	O
10	O
)	O
-	O
0	O
.	O
0003	O
(	O
9	O
)	O
0	O
.	O
0042	O
(	O
9	O
)	O
C6	O
0	O
.	O
0257	O
(	O
12	O
)	O
0	O
.	O
0389	O
(	O
13	O
)	O
0	O
.	O
0207	O
(	O
10	O
)	O
-	O
0	O
.	O
0049	O
(	O
10	O
)	O
0	O
.	O
0013	O
(	O
8	O
)	O
0	O
.	O
0001	O
(	O
9	O
)	O
C7	O
0	O
.	O
0320	O
(	O
13	O
)	O
0	O
.	O
0304	O
(	O
11	O
)	O
0	O
.	O
0218	O
(	O
10	O
)	O
0	O
.	O
0015	O
(	O
9	O
)	O
0	O
.	O
0009	O
(	O
9	O
)	O
-	O
0	O
.	O
0005	O
(	O
9	O
)	O
C8	O
0	O
.	O
0298	O
(	O
12	O
)	O
0	O
.	O
0257	O
(	O
10	O
)	O
0	O
.	O
0178	O
(	O
9	O
)	O
0	O
.	O
0006	O
(	O
9	O
)	O
-	O
0	O
.	O
0012	O
(	O
8	O
)	O
0	O
.	O
0001	O
(	O
8	O
)	O
C9	O
0	O
.	O
0392	O
(	O
14	O
)	O
0	O
.	O
0205	O
(	O
10	O
)	O
0	O
.	O
0219	O
(	O
10	O
)	O
0	O
.	O
0034	O
(	O
9	O
)	O
0	O
.	O
0031	O
(	O
9	O
)	O
-	O
0	O
.	O
0010	O
(	O
8	O
)	O
C10	O
0	O
.	O
0378	O
(	O
13	O
)	O
0	O
.	O
0184	O
(	O
10	O
)	O
0	O
.	O
0234	O
(	O
10	O
)	O
-	O
0	O
.	O
0017	O
(	O
9	O
)	O
0	O
.	O
0014	O
(	O
9	O
)	O
0	O
.	O
0006	O
(	O
8	O
)	O
C11	O
0	O
.	O
0254	O
(	O
11	O
)	O
0	O
.	O
0227	O
(	O
10	O
)	O
0	O
.	O
0198	O
(	O
10	O
)	O
-	O
0	O
.	O
0024	O
(	O
8	O
)	O
0	O
.	O
0004	O
(	O
8	O
)	O
0	O
.	O
0006	O
(	O
8	O
)	O
C12	O
0	O
.	O
0254	O
(	O
11	O
)	O
0	O
.	O
0187	O
(	O
10	O
)	O
0	O
.	O
0222	O
(	O
10	O
)	O
-	O
0	O
.	O
0003	O
(	O
8	O
)	O
-	O
0	O
.	O
0032	O
(	O
8	O
)	O
-	O
0	O
.	O
0007	O
(	O
7	O
)	O
C13	O
0	O
.	O
0237	O
(	O
11	O
)	O
0	O
.	O
0220	O
(	O
10	O
)	O
0	O
.	O
0222	O
(	O
10	O
)	O
0	O
.	O
0012	O
(	O
8	O
)	O
-	O
0	O
.	O
0008	O
(	O
8	O
)	O
0	O
.	O
0030	O
(	O
8	O
)	O
C14	O
0	O
.	O
0298	O
(	O
12	O
)	O
0	O
.	O
0241	O
(	O
10	O
)	O
0	O
.	O
0286	O
(	O
11	O
)	O
-	O
0	O
.	O
0009	O
(	O
9	O
)	O
-	O
0	O
.	O
0007	O
(	O
9	O
)	O
-	O
0	O
.	O
0006	O
(	O
9	O
)	O
C15	O
0	O
.	O
0408	O
(	O
14	O
)	O
0	O
.	O
0267	O
(	O
11	O
)	O
0	O
.	O
0269	O
(	O
11	O
)	O
0	O
.	O
0049	O
(	O
10	O
)	O
0	O
.	O
0028	O
(	O
10	O
)	O
-	O
0	O
.	O
0031	O
(	O
9	O
)	O
C16	O
0	O
.	O
0353	O
(	O
14	O
)	O
0	O
.	O
0326	O
(	O
12	O
)	O
0	O
.	O
0294	O
(	O
12	O
)	O
0	O
.	O
0094	O
(	O
10	O
)	O
0	O
.	O
0094	O
(	O
10	O
)	O
0	O
.	O
0058	O
(	O
9	O
)	O
C17	O
0	O
.	O
0255	O
(	O
12	O
)	O
0	O
.	O
0281	O
(	O
11	O
)	O
0	O
.	O
0349	O
(	O
12	O
)	O
-	O
0	O
.	O
0001	O
(	O
9	O
)	O
0	O
.	O
0015	O
(	O
9	O
)	O
0	O
.	O
0082	O
(	O
9	O
)	O
C18	O
0	O
.	O
0271	O
(	O
12	O
)	O
0	O
.	O
0231	O
(	O
10	O
)	O
0	O
.	O
0250	O
(	O
11	O
)	O
0	O
.	O
0002	O
(	O
9	O
)	O
-	O
0	O
.	O
0032	O
(	O
9	O
)	O
0	O
.	O
0011	O
(	O
8	O
)	O
C19	O
0	O
.	O
0353	O
(	O
14	O
)	O
0	O
.	O
0251	O
(	O
11	O
)	O
0	O
.	O
0375	O
(	O
13	O
)	O
-	O
0	O
.	O
0045	O
(	O
10	O
)	O
-	O
0	O
.	O
0070	O
(	O
10	O
)	O
-	O
0	O
.	O
0012	O
(	O
9	O
)	O
Different	O
ROC	O
analysis	O
When	O
the	O
true	O
positive	O
peptides	O
are	O
not	O
known	O
a	O
priori	O
,	O
there	O
exist	O
various	O
strategies	O
in	O
classifying	O
hits	O
into	O
true	O
or	O
false	O
positives	O
when	O
making	O
a	O
ROC	O
plot	O
.	O
These	O
strategies	O
,	O
unfortunately	O
,	O
will	O
make	O
a	O
notable	O
difference	O
in	O
retrieval	O
assessment	O
.	O
For	O
example	O
,	O
in	O
a	O
cell	B-Anatomy
lysate	I-Anatomy
experiment	O
of	O
a	O
certain	O
organism	O
,	O
it	O
is	O
customary	O
to	O
estimate	O
the	O
number	O
of	O
false	O
positive	O
hits	O
by	O
introducing	O
a	O
decoy	O
database	O
during	O
the	O
data	O
analysis	O
.	O
The	O
main	O
idea	O
there	O
is	O
to	O
first	O
sort	O
the	O
peptide	O
hits	O
according	O
to	O
their	O
scores	O
.	O
Then	O
for	O
each	O
decoy	O
hit	O
,	O
one	O
assumes	O
that	O
there	O
is	O
just	O
one	O
corresponding	O
false	O
hit	O
in	O
the	O
target	O
database	O
.	O
This	O
strategy	O
has	O
been	O
used	O
extensively	O
[	O
24	O
]	O
.	O
ROC	O
analyses	O
done	O
this	O
way	O
generally	O
count	O
false	O
positives	O
,	O
which	O
are	O
highly	O
homologous	O
to	O
the	O
target	O
peptides	O
,	O
towards	O
true	O
positives	O
.	O
This	O
has	O
two	O
effects	O
:	O
an	O
overcount	O
of	O
true	O
positives	O
and	O
a	O
undercount	O
of	O
false	O
positives	O
.	O
As	O
a	O
consequence	O
,	O
the	O
ROC	O
curves	O
will	O
appear	O
more	O
impressive	O
.	O
To	O
mimick	O
this	O
situation	O
,	O
we	O
used	O
BLAST	O
to	O
find	O
in	O
the	O
NCBI	O
'	O
s	O
nr	O
database	O
highly	O
homologous	O
proteins	O
to	O
the	O
target	O
proteins	O
used	O
in	O
the	O
experiment	O
and	O
include	O
those	O
proteins	O
in	O
our	O
true	O
positive	O
set	O
.	O
This	O
strategy	O
produces	O
ROC	O
curves	O
shown	O
as	O
the	O
solid	O
curves	O
of	O
Figure	O
S8	O
.	O
When	O
compared	O
to	O
Figure	O
6	O
and	O
Figure	O
S6	O
,	O
the	O
ROC	O
curves	O
produced	O
by	O
this	O
strategy	O
seem	O
much	O
more	O
impressive	O
.	O
Not	O
counting	O
highly	O
homologous	O
proteins	O
as	O
false	O
positives	O
would	O
probably	O
be	O
agreeable	O
.	O
However	O
,	O
counting	O
those	O
peptides	O
/	O
proteins	O
as	O
true	O
positives	O
could	O
be	O
exaggerating	O
.	O
Therefore	O
one	O
may	O
use	O
a	O
slightly	O
different	O
strategy	O
:	O
removing	O
from	O
consideration	O
proteins	O
homologous	O
to	O
the	O
target	O
proteins	O
,	O
which	O
is	O
called	O
the	O
cluster	O
removal	O
strategy	O
[	O
11	O
]	O
.	O
The	O
dashed	O
curves	O
of	O
Figure	O
S9	O
are	O
ROC	O
curves	O
obtained	O
this	O
way	O
.	O
This	O
strategy	O
also	O
produces	O
slightly	O
more	O
impressive	O
ROC	O
curves	O
than	O
in	O
Figure	O
6	O
and	O
Figure	O
S6	O
.	O
Apparently	O
,	O
this	O
indicates	O
the	O
highly	O
homologous	O
false	O
positive	O
hits	O
are	O
the	O
ones	O
that	O
degrade	O
the	O
retrieval	O
performance	O
.	O
Thus	O
,	O
it	O
can	O
be	O
useful	O
to	O
remove	O
those	O
false	O
positives	O
from	O
consideration	O
.	O
Keeping	O
only	O
the	O
best	O
hit	O
per	O
spectrum	O
turns	O
out	O
to	O
be	O
one	O
way	O
to	O
achieve	O
this	O
goal	O
.	O
Crystal	O
data	O
C24H21ClN4O2S	O
M	O
r	O
=	O
464	O
.	O
96	O
Triclinic	O
,	O
a	O
=	O
8	O
.	O
6798	O
(	O
18	O
)	O
A	O
b	O
=	O
11	O
.	O
078	O
(	O
2	O
)	O
A	O
c	O
=	O
11	O
.	O
372	O
(	O
2	O
)	O
A	O
alpha	O
=	O
78	O
.	O
984	O
(	O
7	O
)	O
degrees	O
beta	O
=	O
81	O
.	O
867	O
(	O
10	O
)	O
degrees	O
gamma	O
=	O
81	O
.	O
718	O
(	O
11	O
)	O
degrees	O
V	O
=	O
1054	O
.	O
8	O
(	O
4	O
)	O
A3	O
Z	O
=	O
2	O
Cu	O
Kalpha	O
radiation	O
mu	O
=	O
2	O
.	O
78	O
mm	O
-	O
1	O
T	O
=	O
113	O
K	O
0	O
.	O
28	O
x	O
0	O
.	O
24	O
x	O
0	O
.	O
20	O
mm	O
Characteristics	O
of	O
fistula	B-Anatomy
lesions	I-Anatomy
Selective	O
SMA	O
angiography	O
was	O
performed	O
5	O
h	O
from	O
onset	O
.	O
Before	O
therapy	O
,	O
the	O
SMA	O
was	O
completely	O
occluded	O
by	O
an	O
embolus	B-Anatomy
at	O
the	O
proximal	O
portion	O
(	O
a	O
)	O
,	O
and	O
after	O
the	O
bolus	O
infusion	O
of	O
urokinase	O
(	O
600	O
,	O
000	O
IU	O
)	O
into	O
the	O
SMA	O
,	O
peripheral	B-Anatomy
blood	I-Anatomy
flow	O
was	O
improved	O
.	O
However	O
,	O
the	O
thrombus	B-Anatomy
decreased	O
in	O
size	O
,	O
but	O
remained	O
(	O
b	O
)	O
.	O
Asterisks	O
indicate	O
thrombus	B-Anatomy
.	O
Measurement	O
of	O
IgA1	O
content	O
IgA1	O
content	O
in	O
the	O
supernatant	B-Anatomy
from	O
each	O
culture	B-Anatomy
well	O
was	O
measured	O
in	O
duplicate	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O
All	O
incubations	O
were	O
performed	O
at	O
room	O
temperature	O
except	O
for	O
capture	O
antibody	O
coating	O
.	O
Briefly	O
,	O
96	O
-	O
well	O
immunoplates	O
(	O
Thermo	O
Fisher	O
Scientific	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
were	O
coated	O
with	O
5	O
microg	O
/	O
mL	O
of	O
F	O
(	O
ab	O
'	O
)	O
2	O
fragment	O
goat	O
anti	O
-	O
human	O
IgA	O
antibody	O
(	O
Jackson	O
ImmunoResearch	O
Laboratories	O
,	O
West	O
Grove	O
,	O
PA	O
,	O
USA	O
)	O
,	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
at	O
4degreesC	O
overnight	O
.	O
After	O
three	O
washes	O
with	O
PBS	O
containing	O
0	O
.	O
05	O
%	O
Tween	O
-	O
20	O
(	O
PBST	O
)	O
,	O
plates	O
were	O
blocked	O
by	O
adding	O
PBS	O
containing	O
1	O
%	O
bovine	O
serum	B-Anatomy
albumin	O
(	O
BSA	O
)	O
to	O
the	O
wells	O
for	O
90	O
min	O
.	O
Next	O
,	O
50	O
microL	O
of	O
supernatant	B-Anatomy
sample	I-Anatomy
or	O
standard	O
human	O
IgA1	O
(	O
CALBIOCHEM	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
was	O
added	O
to	O
the	O
reaction	O
wells	O
and	O
then	O
incubated	O
for	O
90	O
min	O
.	O
After	O
three	O
washes	O
,	O
0	O
.	O
75	O
microg	O
/	O
mL	O
alkaline	O
phosphatase	O
conjugated	O
goat	O
anti	O
-	O
human	O
IgA	O
(	O
Southern	O
Biotechnology	O
Associates	O
,	O
Birmingham	O
,	O
AL	O
,	O
USA	O
)	O
in	O
1	O
%	O
BSA	O
/	O
PBS	O
was	O
added	O
to	O
the	O
reaction	O
wells	O
and	O
then	O
incubated	O
for	O
90	O
min	O
.	O
Plates	O
were	O
washed	O
three	O
times	O
and	O
developed	O
with	O
a	O
substrate	O
solution	O
of	O
1	O
mg	O
/	O
mL	O
p	O
-	O
nitrophenyl	O
phosphate	O
disodium	O
salt	O
(	O
SIGMA	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
in	O
0	O
.	O
1	O
M	O
glycine	O
buffer	O
containing	O
1	O
mM	O
MgCl2	O
,	O
1	O
mM	O
ZnCl2	O
,	O
pH	O
10	O
.	O
4	O
.	O
The	O
optical	O
density	O
at	O
405	O
nm	O
was	O
determined	O
in	O
a	O
microplate	O
reader	O
(	O
Benchmark	O
PlusTM	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O
IgA1	O
concentration	O
in	O
unknown	O
duplicate	O
samples	B-Anatomy
was	O
determined	O
by	O
interpolation	O
of	O
the	O
respective	O
optical	O
density	O
into	O
the	O
appropriate	O
standard	O
curve	O
.	O
IgG	O
and	O
IgM	O
contents	O
in	O
the	O
supernatant	B-Anatomy
were	O
measured	O
using	O
sandwich	O
ELISA	O
(	O
IMMUNOtek	O
(	O
R	O
)	O
,	O
ZeptoMetrix	O
Corporation	O
,	O
Buffalo	O
,	O
NY	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O
The	O
thickness	O
of	O
the	O
inner	B-Anatomy
retina	I-Anatomy
was	O
established	O
as	O
the	O
distance	O
between	O
retinal	B-Anatomy
nerve	I-Anatomy
fiber	I-Anatomy
layer	I-Anatomy
and	O
inner	B-Anatomy
nuclear	I-Anatomy
layer	I-Anatomy
and	O
was	O
measured	O
using	O
the	O
1	O
,	O
000	O
mum	O
caliper	O
available	O
in	O
the	O
OCT	O
-	O
SLO	O
Spectralis	O
.	O
Ten	O
age	O
-	O
matched	O
normal	O
eyes	B-Anatomy
were	O
used	O
as	O
controls	O
.	O
Observe	O
the	O
decrease	O
in	O
the	O
nasal	B-Anatomy
and	O
temporal	O
inner	B-Anatomy
retinal	I-Anatomy
thickness	O
in	O
the	O
right	B-Anatomy
eye	I-Anatomy
in	O
comparison	O
to	O
the	O
left	B-Anatomy
and	O
normal	O
control	O
eyes	B-Anatomy
.	O
Sensitivity	O
of	O
intervention	O
cost	O
-	O
effectiveness	O
to	O
rates	O
of	O
decay	O
in	O
intervention	O
effectiveness	O
between	O
0	O
%	O
(	O
life	O
-	O
long	O
health	O
benefits	O
from	O
one	O
-	O
off	O
intervention	O
)	O
and	O
100	O
%	O
(	O
no	O
health	O
benefits	O
beyond	O
the	O
end	O
of	O
intervention	O
)	O
.	O
Real	O
time	O
RT	O
-	O
PCR	O
RNA	O
extraction	O
and	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
were	O
performed	O
as	O
we	O
described	O
previously	O
[	O
22	O
]	O
.	O
The	O
sequences	O
of	O
ABCG2	O
primers	O
are	O
5	O
'	O
-	O
GGCTTTCTACCTGCACGAAAACCAGTTGAG	O
-	O
3	O
'	O
(	O
forward	O
)	O
and	O
5	O
'	O
-	O
ATGGCGTTGAGACCAG	O
-	O
3	O
'	O
(	O
reverse	O
)	O
.	O
The	O
sequences	O
of	O
GAPDH	O
primers	O
are	O
5	O
'	O
-	O
AAGGACTCATGACCACAGTCCAT	O
-	O
3	O
'	O
(	O
forward	O
)	O
and	O
5	O
'	O
-	O
CCATCACGCCACAGTTTCC	O
-	O
3	O
'	O
(	O
reverse	O
)	O
.	O
The	O
relative	O
ABCG2	O
RNA	O
level	O
(	O
2DeltaCT	O
)	O
treated	O
with	O
inhibitors	O
was	O
expressed	O
as	O
percentage	O
of	O
the	O
control	O
(	O
in	O
the	O
presence	O
of	O
0	O
.	O
1	O
%	O
DMSO	O
)	O
where	O
DeltaCT	O
(	O
threshold	O
cycle	O
)	O
=	O
(	O
CTABCG2	O
-	O
CTGAPDH	O
)	O
.	O
Introduction	O
Adipose	B-Anatomy
tissue	I-Anatomy
,	O
once	O
viewed	O
as	O
simply	O
a	O
storage	O
and	O
release	O
depot	O
for	O
lipids	O
,	O
is	O
now	O
considered	O
an	O
endocrine	B-Anatomy
tissue	I-Anatomy
[	O
1	O
,	O
2	O
]	O
that	O
secretes	O
various	O
substances	O
(	O
adipokines	O
)	O
,	O
including	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
,	O
interleukin	O
(	O
IL	O
)	O
-	O
6	O
,	O
leptin	O
,	O
adiponectin	O
,	O
resistin	O
,	O
visfatin	O
,	O
and	O
omenetin	O
[	O
3	O
,	O
4	O
]	O
.	O
Among	O
these	O
adipokines	O
,	O
much	O
attention	O
has	O
been	O
paid	O
to	O
adiponectin	O
'	O
s	O
relationship	O
with	O
insulin	O
sensitivity	O
and	O
glucose	O
and	O
lipid	O
metabolism	O
in	O
the	O
past	O
10	O
years	O
.	O
In	O
addition	O
,	O
adiponectin	O
is	O
known	O
to	O
exhibit	O
potent	O
anti	O
-	O
inflammatory	O
[	O
5	O
]	O
,	O
atheroprotective	O
[	O
6	O
]	O
,	O
and	O
antidiabetic	O
[	O
7	O
]	O
effects	O
.	O
Recent	O
findings	O
suggest	O
that	O
adiponectin	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O
Levels	O
of	O
adiponectin	O
in	O
synovial	B-Anatomy
fluid	I-Anatomy
and	O
sera	B-Anatomy
were	O
elevated	O
in	O
patients	O
with	O
RA	O
[	O
8	O
,	O
9	O
]	O
.	O
Adiponectin	O
also	O
induces	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
IL	O
-	O
6	O
,	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-	O
1	O
,	O
and	O
IL	O
-	O
8	O
from	O
RA	O
synovial	B-Anatomy
fibroblasts	I-Anatomy
in	O
vitro	O
[	O
10	O
,	O
11	O
]	O
.	O
Thus	O
,	O
it	O
was	O
suggested	O
that	O
adiponectin	O
can	O
also	O
exert	O
significant	O
proinflammatory	O
and	O
matrix	O
-	O
degrading	O
effects	O
.	O
However	O
,	O
the	O
role	O
of	O
adiponectin	O
in	O
the	O
pathogenesis	O
of	O
RA	O
is	O
still	O
controversial	O
because	O
of	O
conflicting	O
reports	O
about	O
its	O
function	O
[	O
10	O
,	O
12	O
-	O
15	O
]	O
.	O
In	O
particular	O
,	O
adiponectin	O
seems	O
to	O
play	O
an	O
anti	O
-	O
inflammatory	O
role	O
because	O
it	O
significantly	O
inhibited	O
IL	O
-	O
1beta	O
-	O
stimulated	O
synovial	B-Anatomy
cell	I-Anatomy
proliferation	O
in	O
collagen	O
-	O
induced	O
arthritic	O
mice	O
,	O
despite	O
increased	O
IL	O
-	O
6	O
expression	O
[	O
16	O
]	O
.	O
In	O
contrast	O
,	O
high	O
-	O
grade	O
inflammation	O
in	O
RA	O
patients	O
was	O
negatively	O
correlated	O
with	O
circulating	O
adiponectin	O
concentrations	O
[	O
17	O
]	O
.	O
Rather	O
,	O
it	O
was	O
suggested	O
that	O
circulating	O
adiponectin	O
may	O
be	O
involved	O
in	O
cardiovascular	B-Anatomy
disease	O
in	O
RA	O
patients	O
.	O
Although	O
this	O
contradiction	O
was	O
partly	O
explained	O
by	O
the	O
induction	O
of	O
tolerance	O
to	O
inflammatory	O
stimuli	O
by	O
adiponectin	O
[	O
18	O
]	O
,	O
the	O
pro	O
-	O
or	O
anti	O
-	O
inflammatory	O
effects	O
of	O
adiponectin	O
on	O
the	O
pathogenesis	O
of	O
RA	O
remain	O
unknown	O
.	O
With	O
regard	O
to	O
adiponectin	O
'	O
s	O
proinflammatory	O
effects	O
,	O
we	O
wondered	O
whether	O
adiponectin	O
might	O
stimulate	O
the	O
production	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
MMPs	O
as	O
well	O
as	O
proinflammatory	O
mediators	O
like	O
IL	O
-	O
1beta	O
and	O
TNF	O
-	O
alpha	O
do	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
stimulatory	O
effect	O
of	O
adiponectin	O
on	O
the	O
production	O
of	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
VEGF	O
,	O
and	O
MMPs	O
.	O
In	O
addition	O
,	O
the	O
correlation	O
between	O
adiponectin	O
and	O
VEGF	O
or	O
MMPs	O
was	O
investigated	O
by	O
measuring	O
the	O
levels	O
of	O
these	O
three	O
proteins	O
in	O
the	O
joint	B-Anatomy
fluid	I-Anatomy
of	O
patients	O
with	O
RA	O
or	O
osteoarthritis	O
(	O
OA	O
)	O
.	O
Refinement	O
The	O
H	O
-	O
atoms	O
were	O
positioned	O
geometrically	O
(	O
O	O
-	O
H	O
=	O
0	O
.	O
82	O
,	O
C	O
-	O
H	O
=	O
0	O
.	O
93	O
A	O
)	O
and	O
were	O
included	O
in	O
the	O
refinement	O
in	O
the	O
riding	O
model	O
approximation	O
,	O
with	O
Uiso	O
(	O
H	O
)	O
=	O
xUeq	O
(	O
C	O
,	O
O	O
)	O
,	O
where	O
x	O
=	O
1	O
.	O
2	O
for	O
all	O
H	O
-	O
atoms	O
.	O
Reagents	O
and	O
antibodies	O
Maxisorp	O
strips	O
(	O
NunC	O
,	O
Roskilde	O
,	O
Denmark	O
)	O
,	O
GST	O
-	O
PNMA2	O
recombinant	O
protein	O
(	O
Abnova	O
,	O
Taipei	O
,	O
Taiwan	O
)	O
;	O
3	O
,	O
3	O
'	O
,	O
5	O
,	O
5	O
-	O
tetramethylbenzidine	O
(	O
TMB	O
)	O
+	O
substrate	O
(	O
Dako	O
,	O
Glostrup	O
,	O
Denmark	O
)	O
,	O
Peroxidase	O
with	O
dakocytomation	O
peroxidase	O
block	O
(	O
Dako	O
)	O
,	O
Dakocytomation	O
envision	O
(	O
R	O
)	O
system	O
labeled	O
polymer	O
-	O
HRP	O
anti	O
-	O
rabbit	O
kit	O
and	O
3	O
-	O
3	O
'	O
-	O
diaminobenzidine	O
(	O
Dako	O
)	O
,	O
Mayer	O
'	O
s	O
hematoxylin	O
(	O
Histolab	O
Product	O
AB	O
,	O
Gothenburg	O
,	O
Sweden	O
)	O
,	O
Graded	O
alcohol	O
(	O
Kemetyl	O
,	O
Vestby	O
,	O
Norway	O
)	O
,	O
Xylen	O
(	O
Solveco	O
,	O
Rosersberg	O
,	O
Sweden	O
)	O
,	O
Pertex	O
(	O
R	O
)	O
(	O
Histolab	O
,	O
Gothenburg	O
,	O
Sweden	O
)	O
,	O
Tris	O
-	O
Glycine	O
blotting	O
buffer	O
(	O
Amresco	O
,	O
Solon	O
,	O
OH	O
)	O
,	O
Western	O
blotting	O
(	O
WB	O
)	O
reagent	O
and	O
Lumi	O
-	O
Light	O
WB	O
substrate	O
(	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
,	O
EasyTag	O
Methionine	O
-	O
L	O
-	O
35S	O
,	O
NEG709A005MC	O
(	O
PerkinElmer	O
,	O
Waltham	O
,	O
MA	O
)	O
,	O
Full	O
-	O
length	O
cDNA	O
clone	O
for	O
human	O
PNMA2	O
,	O
ID6580976	O
(	O
BioScience	O
Geneservice	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
TnT	O
(	O
R	O
)	O
SP6	O
Quick	O
Coupled	O
Transcription	O
/	O
Translation	O
System	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
,	O
Protein	O
G	O
-	O
Sepharose	O
beads	O
(	O
GE	O
Healthcare	O
,	O
Little	O
Chalfont	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
,	O
Peroxidase	O
(	O
HRP	O
)	O
-	O
conjugated	O
rabbit	O
anti	O
human	O
IgG	O
(	O
anti	O
-	O
IgG	O
)	O
(	O
Dako	O
)	O
,	O
rabbit	O
polyclonal	O
antibody	O
anti	O
-	O
PNMA2	O
(	O
Atlas	O
Antibodies	O
,	O
Stockholm	O
,	O
Sweden	O
)	O
,	O
monoclonal	O
mouse	O
anti	O
-	O
GST	O
,	O
sc	O
-	O
138	O
,	O
polyclonal	O
goat	O
anti	O
-	O
human	O
Ma2	O
,	O
sc	O
-	O
68099	O
,	O
HRP	O
-	O
donkey	O
anti	O
-	O
goat	O
,	O
sc	O
-	O
2020	O
,	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
,	O
HRP	O
-	O
goat	O
anti	O
-	O
rabbit	O
,	O
P0448	O
,	O
(	O
Dako	O
)	O
and	O
Ravo	O
PNS	O
-	O
Blot	O
,	O
(	O
Ravo	O
Diagnostika	O
GmbH	O
,	O
Freiburg	O
,	O
Germany	O
)	O
.	O
Statistical	O
analysis	O
All	O
statistical	O
analyses	O
were	O
performed	O
using	O
SPSS13	O
.	O
0	O
software	O
.	O
The	O
differences	O
between	O
groups	O
were	O
compared	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
,	O
and	O
data	O
were	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SD	O
.	O
Statistical	O
difference	O
was	O
accepted	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O
The	O
importance	O
in	O
identifying	O
genes	O
involved	O
in	O
spinal	B-Anatomy
curvature	O
Spinal	B-Anatomy
curvature	O
is	O
a	O
prevalent	O
and	O
costly	O
deformity	O
among	O
humans	O
and	O
teleosts	O
.	O
The	O
estimated	O
annual	O
cost	O
of	O
treating	O
children	O
hospitalized	O
with	O
idiopathic	O
scoliosis	O
(	O
IS	O
)	O
in	O
the	O
United	O
States	O
alone	O
is	O
over	O
$	O
3	O
billion	O
.	O
This	O
cost	O
estimate	O
does	O
not	O
consider	O
Scheuermann	O
kyphosis	O
,	O
or	O
adults	O
with	O
idiopathic	O
-	O
type	O
spinal	B-Anatomy
curvature	O
who	O
suffer	O
from	O
chronic	O
back	B-Anatomy
pain	O
,	O
contributing	O
to	O
the	O
estimated	O
$	O
849	O
billion	O
cost	O
of	O
treatment	O
and	O
lost	O
wages	O
associated	O
with	O
musculoskeletal	B-Anatomy
disease	O
[	O
24	O
]	O
.	O
Among	O
teleosts	O
,	O
spinal	B-Anatomy
column	I-Anatomy
deformities	O
reduce	O
total	O
production	O
in	O
the	O
aquaculture	O
industry	O
substantially	O
[	O
12	O
]	O
.	O
In	O
contrast	O
to	O
humans	O
,	O
teleost	O
curve	O
phenotypes	O
are	O
less	O
well	O
characterized	O
;	O
although	O
heritable	O
curves	O
are	O
acknowledged	O
to	O
account	O
for	O
many	O
cases	O
among	O
cultured	O
stocks	O
,	O
whether	O
these	O
cases	O
are	O
from	O
congenital	O
defects	O
or	O
are	O
idiopathic	O
-	O
type	O
is	O
often	O
not	O
known	O
.	O
Despite	O
the	O
prevalence	O
and	O
impact	O
of	O
this	O
type	O
of	O
deformity	O
,	O
the	O
genetic	O
architecture	O
and	O
specific	O
genes	O
involved	O
are	O
unknown	O
.	O
The	O
current	O
view	O
is	O
that	O
human	O
idiopathic	O
-	O
type	O
scoliosis	O
is	O
a	O
complex	O
genetic	O
disorder	O
with	O
multiple	O
genes	O
segregating	O
in	O
the	O
population	O
exhibiting	O
complex	O
genotype	O
by	O
environment	O
interactions	O
[	O
25	O
-	O
30	O
]	O
.	O
In	O
aquaculture	O
stocks	O
,	O
inheritance	O
for	O
spinal	B-Anatomy
curvature	O
has	O
been	O
described	O
as	O
Mendelian	O
recessive	O
or	O
dominant	O
,	O
as	O
well	O
as	O
polygenic	O
,	O
depending	O
on	O
how	O
well	O
the	O
phenotype	O
is	O
characterized	O
and	O
what	O
stock	O
is	O
considered	O
(	O
reviewed	O
in	O
[	O
13	O
]	O
,	O
[	O
16	O
]	O
)	O
.	O
The	O
guppy	O
curveback	O
phenotype	O
has	O
been	O
extensively	O
characterized	O
so	O
that	O
the	O
lineage	O
can	O
be	O
applied	O
as	O
a	O
model	O
for	O
understanding	O
the	O
biological	O
context	O
of	O
heritable	O
spinal	B-Anatomy
curvature	O
[	O
1	O
,	O
7	O
-	O
9	O
]	O
.	O
Future	O
studies	O
can	O
use	O
approaches	O
to	O
map	O
QTL	O
affecting	O
shape	O
based	O
on	O
digital	O
photos	O
[	O
31	O
,	O
32	O
]	O
,	O
rather	O
than	O
the	O
qualitative	O
scale	O
used	O
in	O
the	O
present	O
study	O
.	O
The	O
identification	O
of	O
QTL	O
in	O
this	O
study	O
is	O
a	O
first	O
step	O
in	O
understanding	O
the	O
genetics	O
of	O
this	O
type	O
of	O
deformity	O
and	O
will	O
lead	O
to	O
the	O
identification	O
of	O
biological	O
pathways	O
associated	O
with	O
spinal	B-Anatomy
integrity	O
.	O
Intact	O
mass	O
analysis	O
of	O
a	O
mixed	O
population	O
of	O
proteins	O
.	O
A	O
mixture	O
of	O
the	O
membrane	B-Anatomy
protein	O
KCNJ12	O
,	O
the	O
soluble	O
TEV	O
protease	O
used	O
to	O
cleave	O
the	O
fusion	O
tag	O
,	O
and	O
the	O
membrane	B-Anatomy
protein	O
HVCN1	O
,	O
which	O
occurred	O
as	O
a	O
contaminant	O
from	O
an	O
earlier	O
analysis	O
on	O
the	O
same	O
LC	O
column	O
.	O
The	O
asymmetric	O
unit	O
of	O
the	O
title	O
compound	O
with	O
the	O
atomic	O
labelling	O
scheme	O
.	O
Displacement	O
are	O
drawn	O
at	O
the	O
50	O
%	O
probability	O
level	O
.	O
H	O
atoms	O
are	O
represented	O
as	O
small	O
spheres	O
of	O
arbitrary	O
radii	O
.	O
Hydrogen	O
bonds	O
are	O
shown	O
as	O
dashed	O
lines	O
.	O
Modified	O
radiology	O
-	O
guided	O
percutaneous	B-Anatomy
gastrostomy	O
technique	O
.	O
A	O
.	O
21G	O
fine	O
needle	O
punctured	O
localized	O
collection	O
of	O
air	O
,	O
which	O
was	O
visible	O
in	O
collapsed	O
stomach	B-Anatomy
under	O
fluoroscopy	O
-	O
guided	O
gastrostomy	O
.	O
Needle	O
tip	O
is	O
then	O
gradually	O
withdrawn	O
while	O
injecting	O
small	O
amounts	O
of	O
water	O
-	O
soluble	O
contrast	O
medium	O
.	O
Location	O
of	O
stomach	B-Anatomy
is	O
confirmed	O
by	O
visualization	O
of	O
opacified	O
gastric	B-Anatomy
rugae	O
.	O
B	O
.	O
Stomach	B-Anatomy
was	O
inflated	O
with	O
approximately	O
600	O
-	O
800	O
mL	O
of	O
room	O
air	O
through	O
21G	O
fine	O
needle	O
.	O
C	O
.	O
100	O
-	O
cm	O
stainless	O
steel	O
guide	O
wire	O
is	O
inserted	O
through	O
needle	O
,	O
and	O
gastro	B-Anatomy
-	O
percutaneous	B-Anatomy
tract	O
is	O
gradually	O
dilated	O
.	O
D	O
.	O
Insertion	O
of	O
14	O
-	O
Fr	O
pigtail	O
gastrostomy	O
catheter	O
and	O
injection	O
of	O
small	O
amount	O
of	O
water	O
-	O
soluble	O
contrast	O
medium	O
via	O
pigtail	O
catheter	O
confirmed	O
that	O
gastrostomy	O
catheter	O
is	O
correctly	O
placed	O
within	O
stomach	B-Anatomy
.	O
Loss	O
of	O
body	B-Anatomy
weight	O
after	O
challenge	O
-	O
infection	O
with	O
WNV	O
.	O
Mice	O
(	O
n	O
=	O
8	O
)	O
were	O
vaccinated	O
intranasally	B-Anatomy
with	O
Flu	O
-	O
-	O
DIII	O
(	O
*	O
)	O
or	O
Flu	O
-	O
-	O
GFP	O
(	O
o	O
)	O
or	O
by	O
the	O
subcutaneous	B-Anatomy
route	O
(	O
^	O
and	O
^	O
,	O
respectively	O
)	O
.	O
The	O
daily	O
weights	O
of	O
each	O
animal	O
were	O
calculated	O
compared	O
to	O
their	O
respective	O
weight	O
on	O
the	O
day	O
of	O
challenge	O
,	O
and	O
data	O
are	O
shown	O
as	O
the	O
average	O
percentage	O
of	O
initial	O
weight	O
for	O
each	O
group	O
.	O
Error	O
bars	O
represent	O
the	O
standard	O
error	O
for	O
all	O
samples	O
available	O
at	O
that	O
time	O
point	O
.	O
Subsequently	O
,	O
the	O
mice	O
were	O
challenged	O
subcutaneously	B-Anatomy
with	O
106	O
TCID50	O
WNV	O
-	O
NY99	O
and	O
weighed	O
daily	O
.	O
The	O
mean	O
body	B-Anatomy
weight	O
is	O
expressed	O
as	O
the	O
percentage	O
of	O
the	O
body	B-Anatomy
weight	O
before	O
challenge	O
infection	O
(	O
A	O
)	O
.	O
The	O
survival	O
rates	O
of	O
mice	O
after	O
challenge	O
infection	O
with	O
WNV	O
-	O
NY99	O
are	O
depicted	O
as	O
Kaplan	O
-	O
Meier	O
survival	O
curves	O
(	O
B	O
)	O
.	O
The	O
difference	O
in	O
survival	O
rate	O
between	O
Flu	O
-	O
-	O
DIII	O
and	O
Flu	O
-	O
-	O
GFP	O
vaccinated	O
mice	O
was	O
statistically	O
significant	O
as	O
determined	O
by	O
the	O
logrank	O
test	O
.	O
The	O
symbols	O
for	O
the	O
respective	O
groups	O
are	O
the	O
same	O
as	O
in	O
panel	O
A	O
.	O
Representative	O
time	O
histories	O
of	O
the	O
estimated	O
SatO2	O
levels	O
of	O
normal	O
cortex	B-Anatomy
(	O
black	O
)	O
and	O
tumor	B-Anatomy
(	O
grey	O
)	O
from	O
all	O
six	O
patients	O
.	O
Etymology	O
.	O
Professor	O
Stephen	O
Lane	O
Wood	O
worked	O
extensively	O
on	O
collections	O
of	O
Scolytinae	O
preserved	O
in	O
Indian	O
museums	O
,	O
and	O
described	O
a	O
number	O
of	O
new	O
Scolytinae	O
species	O
from	O
India	O
.	O
In	O
this	O
paper	O
we	O
describe	O
one	O
more	O
new	O
bark	O
-	O
beetle	O
species	O
from	O
India	O
kept	O
in	O
the	O
Natural	O
History	O
Museum	O
in	O
Vienna	O
(	O
NHMW	O
)	O
and	O
dedicate	O
this	O
species	O
to	O
the	O
late	O
Professor	O
Stephen	O
Lane	O
Wood	O
.	O
Statistics	O
The	O
survival	O
of	O
mice	O
was	O
analyzed	O
using	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
.	O
All	O
other	O
data	O
were	O
analyzed	O
by	O
one	O
-	O
way	O
ANOVA	O
,	O
followed	O
by	O
the	O
Student	O
-	O
Newman	O
-	O
Keuls	O
test	O
for	O
all	O
pairwise	O
comparisons	O
.	O
Prior	O
to	O
ANOVA	O
,	O
Levene	O
'	O
s	O
Test	O
for	O
Equality	O
of	O
Variances	O
was	O
performed	O
.	O
All	O
statistical	O
analyses	O
were	O
performed	O
using	O
MedCalc	O
software	O
,	O
version	O
11	O
.	O
2	O
.	O
1	O
.	O
0	O
.	O
Background	O
Inflammation	O
plays	O
a	O
critical	O
role	O
in	O
plaque	B-Anatomy
initiation	O
,	O
progression	O
,	O
and	O
disruption	O
.	O
As	O
such	O
,	O
inflammation	O
represents	O
an	O
emerging	O
target	O
for	O
the	O
treatment	O
of	O
atherosclerosis	O
.	O
Acknowledgements	O
The	O
authors	O
gratefully	O
acknowledge	O
the	O
support	O
of	O
DRUID	O
study	O
participants	O
,	O
study	O
staff	O
,	O
members	O
of	O
the	O
Indigenous	O
Steering	O
Group	O
,	O
and	O
partner	O
organisations	O
.	O
The	O
DRUID	O
Study	O
was	O
funded	O
by	O
the	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
(	O
NHMRC	O
Project	O
Grant	O
#	O
236207	O
)	O
,	O
with	O
additional	O
support	O
from	O
the	O
Australian	O
Government	O
Department	O
of	O
Employment	O
and	O
Workplace	O
Relations	O
,	O
the	O
Clive	O
and	O
Vera	O
Ramaciotti	O
Foundation	O
,	O
the	O
Vincent	O
Fairfax	O
Family	O
Foundation	O
,	O
the	O
International	O
Diabetes	O
Institute	O
(	O
AusDiab	O
Partnership	O
)	O
,	O
and	O
Bayer	O
HealthCare	O
.	O
The	O
DRUID	O
Study	O
is	O
an	O
in	O
-	O
kind	O
project	O
of	O
the	O
Cooperative	O
Research	O
Centre	O
for	O
Aboriginal	O
Health	O
.	O
LMB	O
had	O
a	O
NHMRC	O
Scholarship	O
2003	O
-	O
5	O
and	O
is	O
supported	O
by	O
NHMRC	O
Training	O
Fellowship	O
(	O
#	O
605837	O
)	O
,	O
NHMRC	O
#	O
320860	O
and	O
the	O
Centre	O
of	O
Clinical	O
Research	O
Excellence	O
in	O
Clinical	O
Science	O
in	O
Diabetes	O
,	O
University	O
of	O
Melbourne	O
.	O
JC	O
was	O
supported	O
by	O
a	O
NHMRC	O
Career	O
Development	O
Award	O
(	O
#	O
283310	O
)	O
and	O
a	O
NHMRC	O
Research	O
Fellowship	O
(	O
#	O
545200	O
)	O
.	O
AH	O
is	O
supported	O
by	O
NHMRC	O
Fellowship	O
(	O
#	O
520316	O
)	O
.	O
Thank	O
you	O
to	O
Dr	O
Jaquelyne	O
Hughes	O
for	O
comments	O
on	O
the	O
manuscript	O
.	O
Funding	O
sources	O
played	O
no	O
role	O
in	O
the	O
study	O
design	O
,	O
in	O
the	O
collection	O
,	O
analysis	O
and	O
interpretation	O
of	O
the	O
data	O
,	O
in	O
the	O
writing	O
of	O
the	O
manuscript	O
,	O
or	O
in	O
the	O
decision	O
to	O
submit	O
the	O
manuscript	O
for	O
publication	O
.	O
Concurrent	O
disease	O
in	O
33	O
cows	O
with	O
LDA	O
.	O
Parkin	O
regulates	O
the	O
proteasomal	B-Anatomy
degradation	O
of	O
PARIS	O
and	O
PGC	O
-	O
1alpha	O
-	O
dependent	O
mitochondrial	B-Anatomy
biogenesis	O
.	O
(	O
A	O
)	O
Normal	O
physiological	O
conditions	O
that	O
maintain	O
mitochondrial	B-Anatomy
homeostasis	O
:	O
PINK1	O
recruits	O
parkin	O
to	O
the	O
mitochondria	B-Anatomy
,	O
where	O
these	O
two	O
proteins	O
interact	O
to	O
eliminate	O
abnormal	O
mitochondria	B-Anatomy
through	O
mitophagy	O
.	O
Alterations	O
in	O
mitochondrial	B-Anatomy
membrane	I-Anatomy
potential	O
(	O
DeltaPsim	O
;	O
a	O
key	O
indicator	O
of	O
mitochondrial	B-Anatomy
physiology	O
and	O
cell	B-Anatomy
viability	O
)	O
initiate	O
the	O
PINK1	O
-	O
parkin	O
cascade	O
of	O
events	O
that	O
lead	O
to	O
mitophagy	O
.	O
Furthermore	O
,	O
parkin	O
ubiquitylates	O
and	O
thereby	O
promotes	O
proteasomal	B-Anatomy
degradation	O
of	O
PARIS	O
.	O
Because	O
PARIS	O
represses	O
the	O
expression	O
of	O
PGC	O
-	O
1alpha	O
,	O
degradation	O
of	O
PARIS	O
by	O
parkin	O
allows	O
PGC	O
-	O
1alpha	O
-	O
dependent	O
gene	O
expression	O
and	O
enables	O
mitochondrial	B-Anatomy
biogenesis	O
.	O
Parkin	O
seems	O
to	O
be	O
an	O
integral	O
regulator	O
of	O
mitochondrial	B-Anatomy
homeostasis	O
,	O
controlling	O
both	O
degradation	O
and	O
biogenesis	O
.	O
(	O
B	O
)	O
Loss	O
of	O
parkin	O
function	O
as	O
a	O
result	O
of	O
familial	O
mutations	O
(	O
in	O
the	O
case	O
of	O
AR	O
-	O
PD	O
)	O
or	O
aging	O
,	O
environmental	O
or	O
cellular	B-Anatomy
stress	O
(	O
in	O
the	O
case	O
of	O
sporadic	O
PD	O
)	O
leads	O
to	O
the	O
accumulation	O
of	O
abnormal	O
mitochondria	B-Anatomy
,	O
owing	O
to	O
faulty	O
mitophagy	O
.	O
In	O
addition	O
,	O
PARIS	O
accumulates	O
and	O
represses	O
PGC	O
-	O
1alpha	O
,	O
preventing	O
mitochondrial	B-Anatomy
biogenesis	O
.	O
Loss	O
of	O
parkin	O
function	O
does	O
not	O
tip	O
the	O
balance	O
between	O
mitochondrial	B-Anatomy
biogenesis	O
and	O
degradation	O
to	O
either	O
side	O
,	O
but	O
leads	O
to	O
a	O
general	O
breakdown	O
of	O
mitochondrial	B-Anatomy
homeostasis	O
that	O
can	O
ultimately	O
lead	O
to	O
PD	O
.	O
Scheme	O
of	O
the	O
activity	O
of	O
5	O
-	O
HT	O
(	O
A	O
)	O
and	O
norepinephrine	O
(	O
NE	O
)	O
(	O
B	O
)	O
neurotransmission	O
during	O
treatment	O
with	O
milnacipran	O
.	O
A	O
)	O
5	O
-	O
HT	O
system	O
.	O
Acute	O
treatment	O
with	O
milnacipran	O
results	O
in	O
a	O
decreased	O
firing	O
of	O
5	B-Anatomy
-	I-Anatomy
HT	I-Anatomy
neurons	I-Anatomy
from	O
the	O
raphe	B-Anatomy
nucleus	I-Anatomy
possibly	O
due	O
in	O
part	O
to	O
increased	O
stimulation	O
of	O
somatodendritic	B-Anatomy
autoreceptors	O
.	O
Long	O
-	O
term	O
treatment	O
with	O
milnacipran	O
results	O
in	O
a	O
full	O
recovery	O
in	O
the	O
firing	O
rate	O
of	O
5	B-Anatomy
-	I-Anatomy
HT	I-Anatomy
neurons	I-Anatomy
in	O
the	O
presence	O
of	O
milnacipran	O
thereby	O
leading	O
to	O
a	O
net	O
increase	O
in	O
5	O
-	O
HT	O
neurotransmission	O
.	O
Contributing	O
to	O
this	O
enhancement	O
are	O
:	O
1	O
)	O
the	O
normalized	O
firing	O
rate	O
of	O
5	B-Anatomy
-	I-Anatomy
HT	I-Anatomy
neurons	I-Anatomy
in	O
the	O
presence	O
of	O
milnacipran	O
2	O
)	O
the	O
desensitization	O
of	O
the	O
terminal	O
5	O
-	O
HT1B	O
autoreceptor	O
,	O
and	O
3	O
)	O
the	O
desensitization	O
of	O
the	O
alpha2	O
-	O
adrenergic	O
heteroreceptors	O
on	O
5	O
-	O
HT	O
terminals	O
.	O
B	O
)	O
NE	O
system	O
.	O
Acute	O
treatment	O
with	O
milnacipran	O
results	O
in	O
increased	O
synaptic	B-Anatomy
concentrations	O
of	O
NE	O
but	O
decreased	O
firing	O
of	O
the	O
NE	B-Anatomy
neurons	I-Anatomy
of	O
the	O
locus	B-Anatomy
coeruleus	I-Anatomy
due	O
to	O
increased	O
stimulation	O
of	O
the	O
somatodendritic	B-Anatomy
alpha2	O
-	O
adrenergic	O
autoreceptors	O
.	O
Long	O
-	O
term	O
treatment	O
with	O
milnacipran	O
results	O
in	O
a	O
further	O
increase	O
in	O
synaptic	B-Anatomy
concentrations	O
of	O
NE	O
due	O
to	O
desensitization	O
of	O
presynaptic	B-Anatomy
autoreceptors	O
.	O
The	O
somatodendritic	B-Anatomy
alpha2	O
-	O
adrenergic	O
autoreceptors	O
do	O
not	O
desensitize	O
.	O
3	O
.	O
1	O
.	O
Glucose	O
Tolerance	O
Test	O
at	O
Various	O
Times	O
following	O
Dosing	O
DIO	O
mice	O
were	O
treated	O
with	O
a	O
single	O
IV	O
dose	O
of	O
CNTO	O
530	O
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
,	O
and	O
glucose	O
metabolism	O
was	O
monitored	O
using	O
an	O
intraperitoneal	B-Anatomy
glucose	O
tolerance	O
test	O
(	O
IPGTT	O
)	O
at	O
various	O
times	O
following	O
dosing	O
(	O
day	O
1	O
to	O
35	O
)	O
.	O
CNTO	O
530	O
did	O
not	O
influence	O
glucose	O
tolerance	O
24	O
hours	O
after	O
dosing	O
.	O
However	O
,	O
a	O
significant	O
improvement	O
was	O
observed	O
in	O
both	O
fasting	O
glucose	O
(	O
179	O
+	O
/	O
-	O
29	O
versus	O
133	O
+	O
/	O
-	O
19	O
mg	O
/	O
dL	O
for	O
untreated	O
versus	O
treated	O
)	O
and	O
overall	O
glucose	O
tolerance	O
seven	O
days	O
after	O
a	O
single	O
dose	O
of	O
CNTO	O
530	O
(	O
Figure	O
2	O
(	O
b	O
)	O
)	O
.	O
In	O
a	O
separate	O
study	O
,	O
the	O
activity	O
of	O
CNTO	O
530	O
was	O
compared	O
to	O
a	O
control	O
protein	O
that	O
lacked	O
the	O
EMP	O
-	O
1	O
peptides	O
to	O
ensure	O
that	O
the	O
observed	O
effects	O
were	O
due	O
to	O
the	O
peptide	O
and	O
not	O
the	O
Fc	O
.	O
The	O
glucose	O
lowering	O
effect	O
was	O
not	O
observed	O
in	O
the	O
mice	O
treated	O
with	O
the	O
protein	O
lacking	O
the	O
EMP	O
-	O
1	O
peptides	O
(	O
data	O
not	O
shown	O
)	O
.	O
Fasting	O
blood	B-Anatomy
glucose	O
remained	O
improved	O
in	O
the	O
treated	O
animals	O
14	O
and	O
21	O
days	O
after	O
CNTO530	O
treatment	O
,	O
but	O
was	O
similar	O
to	O
the	O
untreated	O
group	O
after	O
35	O
days	O
(	O
data	O
not	O
shown	O
)	O
.	O
The	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
for	O
the	O
glucose	O
tolerance	O
tests	O
showed	O
a	O
significant	O
improvement	O
with	O
CNTO	O
530	O
treatment	O
on	O
days	O
7	O
,	O
14	O
,	O
20	O
,	O
and	O
28	O
(	O
Figure	O
2	O
(	O
b	O
)	O
)	O
.	O
The	O
most	O
dramatic	O
effect	O
on	O
glucose	O
tolerance	O
following	O
CNTO	O
530	O
-	O
treatment	O
was	O
observed	O
on	O
day	O
14	O
where	O
glucose	O
was	O
cleared	O
from	O
circulation	O
by	O
the	O
15	O
-	O
minute	O
time	O
point	O
(	O
Figure	O
2	O
(	O
a	O
)	O
)	O
.	O
CNTO	O
530	O
-	O
mediated	O
acceleration	O
of	O
glucose	O
utilization	O
was	O
diminished	O
but	O
still	O
significant	O
by	O
day	O
28	O
and	O
not	O
seen	O
by	O
day	O
35	O
(	O
Figure	O
2	O
(	O
b	O
)	O
)	O
.	O
Hemoglobin	O
levels	O
followed	O
a	O
similar	O
time	O
-	O
dependent	O
change	O
,	O
showing	O
an	O
increase	O
that	O
peaked	O
on	O
day	O
22	O
and	O
returned	O
to	O
normal	O
levels	O
by	O
day	O
29	O
(	O
Figure	O
2	O
(	O
c	O
)	O
)	O
.	O
Similar	O
studies	O
were	O
completed	O
in	O
lean	O
littermate	O
mice	O
fed	O
a	O
normal	O
chow	O
diet	O
.	O
Mice	O
(	O
n	O
=	O
7	O
)	O
were	O
given	O
a	O
single	O
administration	O
of	O
CNTO	O
530	O
(	O
0	O
.	O
01	O
-	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
,	O
and	O
glucose	O
tolerance	O
tests	O
were	O
completed	O
after	O
1	O
and	O
14	O
days	O
.	O
As	O
we	O
observed	O
in	O
the	O
diabetic	O
rodents	O
,	O
no	O
significant	O
changes	O
were	O
seen	O
in	O
glucose	O
clearance	O
24	O
hours	O
after	O
dosing	O
.	O
However	O
,	O
there	O
were	O
significant	O
improvements	O
in	O
the	O
area	O
under	O
the	O
curve	O
in	O
the	O
glucose	O
tolerance	O
test	O
in	O
animals	O
dosed	O
with	O
0	O
.	O
3	O
and	O
0	O
.	O
1	O
mg	O
/	O
kg	O
CNTO	O
530	O
as	O
compared	O
to	O
PBS	O
(	O
22865	O
.	O
4	O
+	O
/	O
-	O
1900	O
.	O
2	O
,	O
24478	O
.	O
9	O
+	O
/	O
-	O
1093	O
.	O
4	O
,	O
and	O
28773	O
.	O
2	O
+	O
/	O
-	O
1368	O
.	O
3	O
,	O
resp	O
.	O
,	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
.	O
There	O
were	O
no	O
dose	O
-	O
dependent	O
changes	O
in	O
the	O
fasting	O
blood	B-Anatomy
glucose	O
.	O
4	O
.	O
2	O
.	O
Histological	O
Findings	O
Microscopy	O
revealed	O
features	O
of	O
a	O
diffusely	O
growing	O
discohesive	B-Anatomy
carcinoma	I-Anatomy
,	O
exclusively	O
growing	O
in	O
the	O
alveolar	B-Anatomy
interstitium	I-Anatomy
,	O
thus	O
expanding	O
it	O
,	O
while	O
leaving	O
the	O
original	O
alveolar	B-Anatomy
architecture	O
intact	O
(	O
Figure	O
2	O
)	O
.	O
There	O
was	O
local	O
ulceration	O
of	O
the	O
pleura	B-Anatomy
,	O
while	O
,	O
beyond	O
this	O
ulcer	B-Anatomy
,	O
the	O
tumor	B-Anatomy
formed	O
a	O
thick	O
cake	O
of	O
discohesive	B-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
lining	O
the	O
pleural	B-Anatomy
membrane	I-Anatomy
(	O
Figure	O
2	O
(	O
c	O
)	O
)	O
,	O
with	O
only	O
focal	O
,	O
microscopic	O
invasion	O
into	O
the	O
fatty	B-Anatomy
tissue	I-Anatomy
of	O
the	O
parietal	B-Anatomy
pleura	I-Anatomy
.	O
The	O
tumor	B-Anatomy
consisted	O
of	O
atypical	O
,	O
moderately	O
polymorphous	O
,	O
and	O
irregularly	O
shaped	O
tumor	B-Anatomy
cells	I-Anatomy
with	O
marked	O
discohesiveness	O
.	O
They	O
featured	O
scant	O
eosinophilic	B-Anatomy
cytoplasm	I-Anatomy
and	O
irregularly	O
contoured	O
and	O
hyperchromatic	O
nuclei	B-Anatomy
,	O
often	O
containing	O
one	O
or	O
more	O
prominent	O
nucleoli	B-Anatomy
(	O
Figure	O
2	O
(	O
b	O
)	O
)	O
.	O
There	O
were	O
many	O
mitoses	O
and	O
apoptoses	O
present	O
,	O
but	O
necrosis	O
was	O
not	O
observed	O
.	O
No	O
squamous	B-Anatomy
or	O
glandular	B-Anatomy
differentiation	O
was	O
observed	O
,	O
and	O
mucin	O
stains	O
(	O
PAS	O
-	O
D	O
and	O
alcian	O
blue	O
)	O
were	O
negative	O
.	O
Within	O
the	O
tumor	B-Anatomy
,	O
there	O
were	O
multiple	O
small	O
blood	B-Anatomy
-	O
filled	O
clefts	O
and	O
blood	B-Anatomy
lakes	O
.	O
Angioinvasion	O
in	O
medium	O
-	O
sized	O
vessels	B-Anatomy
,	O
including	O
an	O
artery	B-Anatomy
,	O
was	O
demonstrated	O
(	O
Figure	O
2	O
(	O
d	O
)	O
)	O
.	O
Of	O
note	O
,	O
the	O
broadened	O
alveolar	B-Anatomy
septa	I-Anatomy
were	O
lined	O
by	O
markedly	O
atypical	O
epithelial	B-Anatomy
cells	I-Anatomy
,	O
yet	O
less	O
atypical	O
than	O
the	O
interstitial	B-Anatomy
carcinoma	I-Anatomy
(	O
Figures	O
2	O
(	O
a	O
)	O
and	O
2	O
(	O
b	O
)	O
)	O
.	O
The	O
atypia	O
of	O
the	O
lining	B-Anatomy
cells	I-Anatomy
extended	O
beyond	O
the	O
tumor	B-Anatomy
front	I-Anatomy
,	O
showing	O
a	O
sharp	O
demarcation	O
with	O
normal	O
type	B-Anatomy
I	I-Anatomy
pneumocytes	I-Anatomy
(	O
Figure	O
2	O
(	O
a	O
)	O
)	O
,	O
a	O
feature	O
characteristic	O
to	O
nonmucinous	B-Anatomy
adenocarcinoma	I-Anatomy
in	I-Anatomy
situ	I-Anatomy
with	O
lepidic	O
growth	O
pattern	O
(	O
former	O
bronchioloalveolar	B-Anatomy
carcinoma	I-Anatomy
,	O
BAC	B-Anatomy
)	O
[	O
3	O
]	O
.	O
Paederus	O
dermatitis	O
involving	O
the	O
neck	B-Anatomy
Introduction	O
During	O
the	O
weaning	O
period	O
and	O
transition	O
to	O
solid	O
foods	O
in	O
the	O
first	O
year	O
of	O
life	O
,	O
infants	O
take	O
a	O
critical	O
step	O
in	O
their	O
eating	O
behavior	O
and	O
need	O
to	O
meet	O
high	O
nutrient	O
requirements	O
[	O
1	O
,	O
2	O
]	O
.	O
They	O
are	O
exposed	O
to	O
new	O
foods	O
and	O
food	O
combinations	O
,	O
which	O
should	O
ensure	O
a	O
smooth	O
transition	O
to	O
the	O
family	O
diet	O
later	O
in	O
life	O
.	O
At	O
this	O
stage	O
,	O
either	O
homemade	O
or	O
commercially	O
prepared	O
foods	O
may	O
be	O
fed	O
.	O
It	O
is	O
worth	O
noting	O
that	O
in	O
prosperous	O
countries	O
the	O
modern	O
diet	O
differs	O
considerably	O
from	O
that	O
of	O
previous	O
generations	O
,	O
now	O
dominated	O
by	O
products	O
that	O
have	O
been	O
processed	O
,	O
stored	O
,	O
and	O
transported	O
over	O
great	O
distances	O
.	O
Traditional	O
,	O
cold	O
-	O
pressed	O
vegetable	B-Anatomy
oils	I-Anatomy
of	O
the	O
highest	O
nutritional	O
quality	O
,	O
e	O
.	O
g	O
.	O
extra	O
virgin	O
olive	B-Anatomy
oil	I-Anatomy
,	O
may	O
therefore	O
constitute	O
an	O
important	O
part	O
of	O
the	O
modern	O
diet	O
[	O
3	O
,	O
4	O
]	O
.	O
In	O
Poland	O
,	O
many	O
infants	O
do	O
not	O
receive	O
any	O
traditional	O
homemade	O
foods	O
and	O
even	O
fruits	B-Anatomy
come	O
from	O
purchased	O
jars	O
.	O
Commercial	O
baby	O
foods	O
are	O
regarded	O
by	O
some	O
parents	O
and	O
medical	O
professionals	O
to	O
be	O
more	O
appropriate	O
for	O
several	O
reasons	O
:	O
they	O
undergo	O
intense	O
screening	O
for	O
contaminants	O
in	O
comparison	O
to	O
foods	O
sold	O
for	O
the	O
general	O
population	O
,	O
contain	O
no	O
additives	O
of	O
certain	O
types	O
,	O
and	O
are	O
thought	O
to	O
be	O
designed	O
to	O
help	O
infants	O
meet	O
nutrient	O
requirements	O
[	O
5	O
]	O
.	O
The	O
process	O
of	O
peeling	O
,	O
however	O
,	O
was	O
identified	O
as	O
the	O
most	O
effective	O
,	O
and	O
simple	O
,	O
procedure	O
in	O
reducing	O
residues	O
,	O
e	O
.	O
g	O
.	O
pesticides	O
,	O
in	O
fruits	B-Anatomy
and	O
vegetables	B-Anatomy
[	O
6	O
]	O
.	O
Moreover	O
,	O
contrary	O
to	O
homemade	O
food	O
,	O
which	O
does	O
not	O
contain	O
furan	O
,	O
the	O
highest	O
average	O
content	O
of	O
this	O
chemical	O
was	O
found	O
in	O
ready	O
-	O
to	O
-	O
eat	O
baby	O
foods	O
with	O
pasta	O
meals	O
,	O
followed	O
by	O
vegetable	B-Anatomy
meals	O
and	O
meals	O
with	O
meat	B-Anatomy
[	O
7	O
]	O
.	O
Furan	O
is	O
considered	O
to	O
be	O
potentially	O
hazardous	O
chemical	O
and	O
is	O
classified	O
as	O
a	O
possible	O
carcinogen	O
.	O
The	O
problem	O
of	O
this	O
chemical	O
in	O
homemade	O
food	O
may	O
only	O
arise	O
if	O
meals	O
with	O
potatoes	O
are	O
stored	O
and	O
then	O
hardly	O
re	O
-	O
heated	O
[	O
7	O
]	O
.	O
There	O
is	O
a	O
growing	O
body	O
of	O
evidence	O
that	O
flavor	O
experiences	O
and	O
dietary	O
patterns	O
in	O
childhood	O
influence	O
these	O
patterns	O
later	O
in	O
life	O
[	O
1	O
,	O
8	O
,	O
9	O
]	O
.	O
It	O
is	O
most	O
likely	O
early	O
in	O
life	O
that	O
culture	O
-	O
specific	O
flavor	O
preferences	O
are	O
initiated	O
[	O
10	O
,	O
11	O
]	O
.	O
Consequently	O
,	O
exposure	O
to	O
flavors	O
and	O
smells	O
of	O
transitory	O
foods	O
may	O
serve	O
to	O
heighten	O
preferences	O
for	O
""""	O
known	O
tastes	O
""""	O
in	O
the	O
family	O
diet	O
later	O
in	O
adulthood	O
.	O
Moreover	O
,	O
adopting	O
elements	O
of	O
childhood	O
dinner	O
patterns	O
was	O
recognized	O
to	O
be	O
an	O
important	O
part	O
of	O
the	O
social	O
reproduction	O
of	O
family	O
identities	O
across	O
generations	O
[	O
12	O
]	O
.	O
Processing	O
industries	O
have	O
been	O
successful	O
in	O
manufacturing	O
and	O
marketing	O
jarred	O
baby	O
foods	O
on	O
a	O
commercial	O
scale	O
.	O
Available	O
products	O
contain	O
different	O
ingredients	O
and	O
depend	O
on	O
the	O
manufacturer	O
,	O
country	O
,	O
traditional	O
cuisine	O
,	O
income	O
rate	O
,	O
and	O
lastly	O
,	O
personal	O
beliefs	O
and	O
values	O
of	O
parents	O
[	O
9	O
,	O
11	O
]	O
.	O
Jarred	O
foods	O
with	O
vegetables	B-Anatomy
,	O
meats	B-Anatomy
,	O
and	O
desserts	O
may	O
contain	O
added	O
fat	O
from	O
a	O
variety	O
of	O
sources	O
:	O
vegetable	B-Anatomy
oils	I-Anatomy
,	O
cow	O
milk	B-Anatomy
butter	O
,	O
or	O
cream	O
.	O
Manufacturer	O
advertising	O
makes	O
the	O
majority	O
of	O
consumers	O
feel	O
safe	O
,	O
causing	O
them	O
to	O
believe	O
that	O
they	O
are	O
doing	O
the	O
best	O
possible	O
in	O
buying	O
given	O
products	O
[	O
11	O
]	O
.	O
A	O
noteworthy	O
fact	O
is	O
that	O
many	O
types	O
of	O
baby	O
foods	O
produced	O
by	O
international	O
manufacturers	O
are	O
,	O
in	O
essence	O
,	O
the	O
same	O
mixtures	O
with	O
different	O
names	O
;	O
this	O
procedure	O
aims	O
to	O
exploit	O
the	O
specifics	O
of	O
local	O
markets	O
without	O
delivering	O
any	O
new	O
,	O
real	O
value	O
[	O
11	O
]	O
.	O
In	O
the	O
book	O
,	O
How	O
to	O
Eat	O
Well	O
and	O
Stay	O
Well	O
the	O
Mediterranean	O
Way	O
by	O
Keys	O
[	O
13	O
]	O
first	O
used	O
the	O
term	O
""""	O
good	O
Mediterranean	O
diet	O
""""	O
to	O
describe	O
the	O
eating	O
patterns	O
of	O
populations	O
dwelling	O
in	O
southern	O
Europe	O
,	O
where	O
the	O
olive	O
tree	O
(	O
Olea	O
europaea	O
)	O
is	O
an	O
emblematic	O
species	O
[	O
4	O
,	O
14	O
]	O
.	O
There	O
is	O
variation	O
between	O
the	O
exact	O
diet	O
in	O
different	O
parts	O
of	O
the	O
Mediterranean	O
region	O
.	O
However	O
,	O
generalized	O
and	O
distinctive	O
dietary	O
patterns	O
do	O
exist	O
,	O
including	O
olive	B-Anatomy
oil	I-Anatomy
as	O
the	O
main	O
source	O
of	O
visible	O
fat	B-Anatomy
,	O
employed	O
both	O
in	O
cooking	O
and	O
as	O
a	O
dressing	O
,	O
moderate	O
fish	O
and	O
poultry	O
but	O
low	O
red	B-Anatomy
meat	I-Anatomy
consumption	O
,	O
high	O
intake	O
of	O
vegetables	B-Anatomy
,	O
fruits	B-Anatomy
,	O
legumes	B-Anatomy
,	O
nuts	B-Anatomy
,	O
and	O
whole	O
-	O
grain	O
cereals	O
[	O
4	O
,	O
14	O
-	O
16	O
]	O
.	O
When	O
dietary	B-Anatomy
fats	I-Anatomy
are	O
added	O
,	O
in	O
accordance	O
with	O
the	O
traditional	O
Mediterranean	O
diet	O
,	O
olive	B-Anatomy
oil	I-Anatomy
is	O
the	O
choice	O
for	O
children	O
[	O
17	O
]	O
.	O
It	O
has	O
been	O
repeatedly	O
observed	O
that	O
individuals	O
applying	O
the	O
Mediterranean	O
diet	O
have	O
reduced	O
risks	O
of	O
type	O
2	O
diabetes	O
and	O
other	O
diseases	O
associated	O
with	O
the	O
metabolic	O
syndrome	O
,	O
autoimmunological	O
diseases	O
,	O
and	O
certain	O
forms	O
of	O
cancer	B-Anatomy
[	O
18	O
]	O
.	O
Moreover	O
,	O
considerable	O
evidence	O
exists	O
that	O
the	O
Mediterranean	O
diet	O
increases	O
quality	O
of	O
life	O
in	O
the	O
course	O
of	O
ageing	O
,	O
as	O
well	O
as	O
longevity	O
[	O
13	O
,	O
19	O
]	O
.	O
The	O
health	O
benefits	O
of	O
olive	B-Anatomy
oil	I-Anatomy
have	O
been	O
attributed	O
to	O
two	O
main	O
constituents	O
:	O
a	O
high	O
oleic	O
acid	O
(	O
monounsaturated	O
fatty	O
acid	O
,	O
18	O
:	O
1n	O
-	O
9	O
)	O
content	O
(	O
70	O
-	O
85	O
%	O
)	O
and	O
a	O
large	O
amount	O
of	O
antioxidant	O
compounds	O
,	O
which	O
also	O
possess	O
antiviral	O
,	O
antibacterial	O
,	O
and	O
immunomodulating	O
effects	O
[	O
3	O
,	O
4	O
,	O
14	O
,	O
16	O
]	O
.	O
Polyphenols	O
found	O
in	O
virgin	O
olive	B-Anatomy
oil	I-Anatomy
are	O
linked	O
to	O
both	O
its	O
flavor	O
and	O
its	O
remarkable	O
stability	O
[	O
3	O
]	O
.	O
The	O
introduction	O
of	O
solid	O
foods	O
in	O
infancy	O
is	O
one	O
of	O
the	O
primary	O
matters	O
often	O
discussed	O
by	O
parents	O
with	O
their	O
child	O
'	O
s	O
pediatrician	O
.	O
However	O
,	O
many	O
parents	O
do	O
not	O
feel	O
that	O
the	O
diet	O
of	O
their	O
child	O
may	O
be	O
linked	O
to	O
poor	O
health	O
outcomes	O
in	O
the	O
future	O
.	O
Parents	O
should	O
be	O
educated	O
about	O
the	O
interplay	O
of	O
environmental	O
and	O
genetic	O
influences	O
on	O
children	O
,	O
specifically	O
during	O
the	O
early	O
years	O
of	O
development	O
when	O
the	O
child	O
is	O
maturing	O
and	O
taking	O
control	O
of	O
its	O
own	O
diet	O
[	O
11	O
]	O
.	O
Nutrition	O
educators	O
should	O
increase	O
the	O
critical	O
awareness	O
of	O
parents	O
in	O
relation	O
to	O
their	O
child	O
'	O
s	O
solid	O
food	O
choices	O
.	O
It	O
is	O
important	O
to	O
emphasize	O
to	O
parents	O
the	O
fundamental	O
role	O
that	O
the	O
Mediterranean	O
diet	O
and	O
consumption	O
of	O
foods	O
with	O
olive	B-Anatomy
oil	I-Anatomy
play	O
in	O
a	O
healthy	O
life	O
style	O
[	O
14	O
,	O
20	O
]	O
.	O
Parental	O
management	O
of	O
the	O
family	O
food	O
environment	O
may	O
be	O
complicated	O
by	O
numerous	O
mitigating	O
factors	O
,	O
e	O
.	O
g	O
.	O
health	O
literacy	O
,	O
time	O
availability	O
,	O
and	O
financial	O
resources	O
.	O
Considering	O
the	O
role	O
baby	O
food	O
manufacturers	O
play	O
in	O
the	O
infant	O
'	O
s	O
contextual	O
environment	O
,	O
their	O
products	O
,	O
as	O
well	O
as	O
the	O
manufacturers	O
themselves	O
,	O
should	O
also	O
be	O
viewed	O
as	O
key	O
players	O
and	O
central	O
agents	O
in	O
establishing	O
dietary	O
habits	O
.	O
Consequently	O
,	O
we	O
attempted	O
to	O
survey	O
manufacturer	O
claims	O
concerning	O
added	O
fat	O
in	O
jarred	O
infant	O
foods	O
supplied	O
to	O
the	O
Polish	O
market	O
.	O
2	O
.	O
1	O
.	O
3	O
Pixel	O
Classification	O
The	O
feature	O
vector	O
of	O
a	O
grid	O
,	O
which	O
consists	O
of	O
nine	O
features	O
,	O
is	O
normalized	O
to	O
[	O
0	O
,	O
1	O
]	O
,	O
and	O
the	O
position	O
features	O
are	O
scaled	O
by	O
the	O
weighting	O
coefficient	O
wpos	O
.	O
Then	O
,	O
taking	O
the	O
nine	O
dimensional	O
vector	O
of	O
each	O
grid	O
as	O
the	O
input	O
of	O
the	O
classifier	O
,	O
the	O
ROI	O
and	O
non	O
-	O
ROI	O
background	O
in	O
ultrasonic	O
breast	B-Anatomy
tumor	I-Anatomy
images	O
can	O
be	O
distinguished	O
.	O
In	O
this	O
section	O
,	O
the	O
self	O
-	O
organizing	O
feature	O
map	O
neural	O
network	O
(	O
SOMNN	O
)	O
[	O
25	O
]	O
,	O
proposed	O
by	O
Kohonen	O
according	O
to	O
characteristics	O
of	O
the	O
nervous	B-Anatomy
system	I-Anatomy
,	O
is	O
used	O
for	O
the	O
classification	O
of	O
these	O
grids	O
to	O
detect	O
the	O
ROI	O
automatically	O
.	O
The	O
SOM	O
is	O
trained	O
by	O
the	O
unsupervised	O
learning	O
to	O
produce	O
a	O
low	O
-	O
dimensional	O
discretized	O
representation	O
of	O
the	O
input	O
space	O
of	O
the	O
training	O
samples	O
,	O
and	O
it	O
uses	O
a	O
neighborhood	O
function	O
to	O
preserve	O
the	O
topological	O
properties	O
of	O
the	O
input	O
space	O
,	O
which	O
makes	O
it	O
different	O
from	O
other	O
artificial	O
neural	O
networks	O
.	O
In	O
this	O
way	O
,	O
the	O
SOM	O
is	O
able	O
to	O
classify	O
the	O
sub	O
-	O
blocks	O
into	O
n	O
clusters	O
only	O
by	O
the	O
unsupervised	O
learning	O
.	O
In	O
our	O
study	O
,	O
the	O
output	O
layer	O
number	O
n	O
is	O
set	O
to	O
2	O
(	O
ROI	O
and	O
non	O
-	O
ROI	O
output	O
)	O
and	O
the	O
feature	O
vector	O
extracted	O
from	O
each	O
grid	O
is	O
taken	O
as	O
the	O
input	O
.	O
To	O
map	O
the	O
sorted	O
sub	O
-	O
blocks	O
back	O
to	O
the	O
size	O
of	O
the	O
original	O
ultrasonic	O
images	O
,	O
the	O
initial	O
result	O
of	O
ROI	O
detection	O
can	O
be	O
represented	O
by	O
a	O
binary	O
image	O
as	O
shown	O
in	O
Fig	O
.	O
(	O
2d	O
)	O
,	O
where	O
white	O
areas	O
indicate	O
the	O
ROI	O
candidates	O
while	O
black	O
areas	O
the	O
non	O
-	O
ROIs	O
.	O
Materials	O
and	O
Methods	O
:	O
A	O
total	O
of	O
75	O
brain	B-Anatomy
abscess	I-Anatomy
pus	I-Anatomy
specimens	I-Anatomy
were	O
collected	O
during	O
neurosurgery	O
,	O
either	O
by	O
burr	O
hole	O
or	O
by	O
craniotomy	O
.	O
These	O
specimens	B-Anatomy
were	O
further	O
subjected	O
to	O
Gram	O
stain	O
,	O
Ziehl	O
-	O
Neelsen	O
(	O
ZN	O
)	O
stain	O
,	O
and	O
conventional	O
microbiological	O
culture	O
.	O
Only	O
those	O
cases	O
which	O
showed	O
presence	O
of	O
AFB	O
on	O
ZN	O
stain	O
along	O
with	O
the	O
growth	O
of	O
Mycobacterium	O
tuberculosis	O
were	O
considered	O
as	O
TBAs	O
.	O
Such	O
TBA	O
cases	O
were	O
further	O
presented	O
along	O
with	O
their	O
In	O
vitro	O
Proton	O
Magnetic	O
Resonance	O
(	O
MR	O
)	O
Spectroscopic	O
findings	O
.	O
Challenges	O
to	O
creating	O
and	O
implementing	O
a	O
perioperative	O
glycemic	O
control	O
protocol	O
.	O
Parameters	O
derived	O
from	O
normalized	O
averaged	O
data	O
across	O
participants	O
ACKNOWLEDGEMENTS	O
The	O
authors	O
thank	O
Mr	O
.	O
C	O
.	O
Roberto	O
for	O
providing	O
animal	O
care	O
.	O
This	O
research	O
was	O
supported	O
by	O
the	O
State	O
of	O
Rio	O
de	O
Janeiro	O
Carlos	O
Chagas	O
Filho	O
Research	O
Foundation	O
(	O
FAPERJ	O
)	O
and	O
the	O
Coordination	O
for	O
the	O
Enhancement	O
of	O
Higher	O
Education	O
Personnel	O
(	O
CAPES	O
)	O
.	O
Absolute	O
responder	O
rates	O
for	O
medical	O
management	O
recommendations	O
.	O
Conclusions	O
This	O
is	O
the	O
first	O
prospective	O
evaluation	O
of	O
parents	O
'	O
preferences	O
in	O
newly	O
diagnosed	O
juvenile	O
idiopathic	O
arthritis	O
patients	O
participating	O
in	O
the	O
BeSt	O
for	O
Kids	O
trial	O
.	O
Within	O
the	O
limitations	O
of	O
the	O
small	O
amounts	O
,	O
patients	O
clearly	O
preferred	O
initial	O
combination	O
therapy	O
with	O
etanercept	O
and	O
disliked	O
taking	O
prednisone	O
.	O
After	O
actual	O
exposure	O
and	O
follow	O
up	O
,	O
this	O
questionnaire	O
will	O
be	O
repeated	O
to	O
see	O
if	O
preferences	O
remain	O
the	O
same	O
.	O
Patients	O
and	O
Study	O
Design	O
A	O
prospective	O
evaluation	O
of	O
the	O
different	O
CMR	O
parameters	O
for	O
predicting	O
LV	B-Anatomy
segmental	O
and	O
global	O
functional	O
recovery	O
was	O
performed	O
in	O
46	O
patients	O
(	O
63	O
+	O
/	O
-	O
10	O
years	O
old	O
,	O
3	O
with	O
previous	O
CABG	O
,	O
35	O
with	O
three	O
-	O
vessel	O
disease	O
,	O
3	O
with	O
one	O
-	O
vessel	O
disease	O
)	O
with	O
LV	B-Anatomy
systolic	O
dysfunction	O
(	O
LVEF	O
35	O
+	O
/	O
-	O
8	O
%	O
)	O
before	O
they	O
underwent	O
surgical	O
(	O
n	O
=	O
34	O
)	O
or	O
percutaneous	B-Anatomy
(	O
n	O
=	O
12	O
)	O
revascularisation	O
.	O
Sixty	O
patients	O
without	O
contraindications	O
for	O
CMR	O
were	O
screened	O
for	O
the	O
following	O
inclusion	O
criteria	O
:	O
(	O
1	O
)	O
CAD	O
(	O
>	O
70	O
%	O
stenosis	O
in	O
one	O
or	O
more	O
major	O
epicardial	B-Anatomy
vessels	I-Anatomy
)	O
,	O
scheduled	O
for	O
a	O
revascularisation	O
procedure	O
;	O
(	O
2	O
)	O
LVEF	O
<	O
=	O
45	O
%	O
;	O
(	O
3	O
)	O
at	O
least	O
two	O
adjacent	O
segments	O
with	O
wall	B-Anatomy
motion	O
abnormalities	O
at	O
rest	O
;	O
and	O
(	O
4	O
)	O
no	O
infarction	O
or	O
revascularisation	O
within	O
the	O
last	O
two	O
months	O
.	O
Patients	O
were	O
included	O
in	O
the	O
study	O
only	O
after	O
a	O
successful	O
and	O
complete	O
coronary	B-Anatomy
revascularisation	O
.	O
Of	O
the	O
14	O
patients	O
who	O
did	O
not	O
complete	O
the	O
study	O
,	O
3	O
decided	O
not	O
to	O
undergo	O
the	O
repeated	O
CMR	O
scan	O
or	O
were	O
lost	O
during	O
follow	O
-	O
up	O
;	O
7	O
had	O
significant	O
periprocedural	O
injury	O
(	O
new	O
LGE	B-Anatomy
zones	O
on	O
repeated	O
CMR	O
scans	O
and	O
clinically	O
proven	O
periprocedural	O
myocardial	B-Anatomy
infarction	O
(	O
MI	O
)	O
or	O
MI	O
between	O
both	O
scans	O
)	O
;	O
3	O
had	O
pacemakers	O
or	O
defibrillators	O
implanted	O
in	O
the	O
period	O
between	O
the	O
MR	O
scans	O
;	O
and	O
1	O
was	O
excluded	O
because	O
of	O
dilated	O
cardiomyopathy	O
with	O
secondary	O
CAD	O
.	O
None	O
of	O
the	O
patients	O
were	O
excluded	O
from	O
the	O
study	O
for	O
technical	O
reasons	O
or	O
image	O
quality	O
.	O
The	O
mean	O
interval	O
between	O
CMR	O
and	O
revascularisation	O
was	O
12	O
+	O
/	O
-	O
13	O
days	O
,	O
and	O
none	O
of	O
the	O
patients	O
presented	O
clinical	O
evidence	O
of	O
infarction	O
during	O
this	O
period	O
.	O
The	O
mean	O
interval	O
between	O
MI	O
and	O
the	O
first	O
CMR	O
was	O
3	O
.	O
6	O
years	O
.	O
In	O
46	O
patients	O
,	O
the	O
extent	O
of	O
regional	O
contractility	O
and	O
LGE	B-Anatomy
were	O
determined	O
repeatedly	O
by	O
CMR	O
28	O
+	O
/	O
-	O
4	O
weeks	O
(	O
6	O
months	O
)	O
after	O
revascularisation	O
.	O
The	O
study	O
was	O
approved	O
by	O
the	O
Lithuanian	O
Bioethics	O
Committee	O
(	O
Nr	O
.	O
17	O
)	O
,	O
and	O
informed	O
written	O
consent	O
was	O
obtained	O
from	O
each	O
patient	O
prior	O
to	O
inclusion	O
in	O
the	O
study	O
.	O
4	O
.	O
The	O
kinetochore	B-Anatomy
The	O
arguments	O
built	O
in	O
the	O
previous	O
section	O
lead	O
to	O
the	O
conclusion	O
that	O
it	O
is	O
essential	O
to	O
understand	O
error	O
correction	O
and	O
spindle	O
checkpoint	O
signalling	O
in	O
the	O
context	O
of	O
the	O
complex	O
structural	O
organization	O
of	O
the	O
kinetochore	B-Anatomy
.	O
A	O
complete	O
account	O
of	O
kinetochore	B-Anatomy
organization	O
is	O
beyond	O
the	O
scope	O
of	O
this	O
review	O
and	O
several	O
reviews	O
on	O
this	O
topic	O
have	O
been	O
made	O
available	O
recently	O
[	O
21	O
,	O
22	O
]	O
.	O
Suffice	O
to	O
say	O
that	O
kinetochores	B-Anatomy
are	O
thought	O
to	O
consist	O
of	O
an	O
inner	O
plate	O
hosting	O
an	O
interface	O
between	O
the	O
15	O
-	O
subunit	O
constitutive	O
centromere	O
-	O
associated	O
network	O
(	O
CCAN	O
)	O
and	O
specialized	O
centromeric	O
chromatin	B-Anatomy
;	O
and	O
an	O
outer	O
plate	O
containing	O
the	O
10	O
-	O
subunit	O
KMN	O
network	O
(	O
from	O
the	O
initials	O
of	O
its	O
Knl1	O
,	O
Mis12	O
and	O
Ndc80	O
subcomplexes	O
)	O
implicated	O
in	O
microtubule	B-Anatomy
binding	O
.	O
The	O
CCAN	O
and	O
KMN	O
networks	O
are	O
tightly	O
connected	O
.	O
An	O
interaction	O
between	O
CENP	O
-	O
C	O
(	O
CCAN	O
)	O
and	O
the	O
Mis12	O
complex	O
(	O
KMN	O
network	O
)	O
provides	O
an	O
important	O
point	O
of	O
contact	O
[	O
81	O
-	O
83	O
]	O
.	O
The	O
existence	O
of	O
additional	O
points	O
of	O
contact	O
,	O
including	O
one	O
between	O
CENP	O
-	O
T	O
(	O
CCAN	O
)	O
and	O
the	O
Ndc80	O
subcomplex	O
(	O
KMN	O
network	O
)	O
[	O
83	O
,	O
84	O
]	O
,	O
is	O
supported	O
by	O
extensive	O
analyses	O
of	O
localization	O
dependencies	O
of	O
kinetochore	B-Anatomy
proteins	O
and	O
from	O
initial	O
experiments	O
of	O
biochemical	O
reconstitution	O
.	O
Biochemical	O
and	O
structural	O
studies	O
,	O
including	O
super	O
-	O
resolution	O
investigations	O
of	O
kinetochore	B-Anatomy
organization	O
by	O
fluorescence	O
microscopy	O
,	O
have	O
finally	O
resulted	O
in	O
rather	O
precise	O
maps	O
of	O
the	O
relative	O
position	O
of	O
many	O
structural	O
kinetochore	B-Anatomy
proteins	O
and	O
of	O
several	O
checkpoint	O
components	O
[	O
85	O
-	O
88	O
]	O
.	O
For	O
instance	O
,	O
these	O
studies	O
clarified	O
that	O
the	O
highly	O
elongated	O
4	O
-	O
subunit	O
Ndc80	O
complex	O
,	O
conserved	O
in	O
all	O
eukaryotes	O
,	O
orients	O
its	O
approximately	O
60	O
nm	O
long	O
axis	O
at	O
a	O
relatively	O
small	O
angle	O
with	O
the	O
inter	O
-	O
kinetochore	B-Anatomy
axis	O
[	O
85	O
-	O
87	O
]	O
.	O
The	O
kinetochore	B-Anatomy
-	O
binding	O
end	O
of	O
the	O
Ndc80	O
complex	O
was	O
predicted	O
to	O
be	O
positioned	O
near	O
the	O
Mis12	O
and	O
Knl1	O
complexes	O
[	O
87	O
,	O
88	O
]	O
,	O
and	O
this	O
prediction	O
was	O
fully	O
confirmed	O
in	O
experiments	O
of	O
biochemical	O
reconstitution	O
[	O
89	O
]	O
.	O
In	O
prophase	O
Drosophila	O
melanogaster	O
S2	B-Anatomy
cells	I-Anatomy
,	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
Ndc80	O
subunit	O
is	O
located	O
approximately	O
65	O
nm	O
outward	O
(	O
i	O
.	O
e	O
.	O
towards	O
the	O
microtubule	B-Anatomy
)	O
relative	O
to	O
CENP	O
-	O
A	O
,	O
the	O
histone	O
H3	O
variant	O
that	O
marks	O
centromeres	O
from	O
yeast	O
to	O
humans	O
[	O
40	O
]	O
.	O
Remarkably	O
,	O
it	O
was	O
shown	O
that	O
this	O
distance	O
increases	O
to	O
approximately	O
100	O
nm	O
when	O
kinetochores	B-Anatomy
experience	O
microtubule	B-Anatomy
-	O
dependent	O
tension	O
at	O
metaphase	O
[	O
40	O
]	O
.	O
This	O
phenomenon	O
is	O
now	O
known	O
as	O
intra	O
-	O
kinetochore	B-Anatomy
stretch	O
or	O
tension	O
[	O
40	O
,	O
90	O
]	O
.	O
A	O
major	O
task	O
for	O
the	O
future	O
is	O
to	O
understand	O
how	O
intra	O
-	O
kinetochore	B-Anatomy
stretch	O
is	O
generated	O
when	O
microtubules	B-Anatomy
bind	O
the	O
kinetochore	B-Anatomy
.	O
At	O
one	O
extreme	O
,	O
intra	O
-	O
kinetochore	B-Anatomy
stretching	O
might	O
be	O
the	O
result	O
of	O
a	O
discreet	O
conformational	O
change	O
in	O
the	O
kinetochore	B-Anatomy
caused	O
by	O
microtubule	B-Anatomy
binding	O
[	O
22	O
,	O
91	O
]	O
.	O
While	O
this	O
is	O
possible	O
,	O
it	O
seems	O
unlikely	O
when	O
considering	O
the	O
great	O
structural	O
complexity	O
of	O
kinetochores	B-Anatomy
.	O
Each	O
microtubule	B-Anatomy
-	O
binding	O
site	O
contains	O
six	O
to	O
eight	O
copies	O
of	O
the	O
approximately	O
30	O
structural	O
kinetochore	B-Anatomy
components	O
[	O
85	O
]	O
.	O
Furthermore	O
,	O
in	O
most	O
species	O
,	O
kinetochores	B-Anatomy
are	O
designed	O
to	O
bind	O
multiple	O
microtubules	B-Anatomy
.	O
Plausibly	O
,	O
each	O
microtubule	B-Anatomy
-	O
binding	O
site	O
becomes	O
engaged	O
at	O
a	O
different	O
time	O
.	O
Thus	O
,	O
it	O
may	O
be	O
more	O
sensible	O
to	O
interpret	O
intra	O
-	O
kinetochore	B-Anatomy
stretching	O
as	O
a	O
progressive	O
,	O
continuous	O
distortion	O
of	O
the	O
kinetochore	B-Anatomy
when	O
microtubules	B-Anatomy
are	O
added	O
.	O
In	O
agreement	O
with	O
this	O
idea	O
,	O
intermediate	O
levels	O
of	O
stretching	O
are	O
observed	O
when	O
microtubule	B-Anatomy
end	O
dynamics	O
are	O
inhibited	O
through	O
addition	O
of	O
taxol	O
[	O
40	O
]	O
.	O
Importantly	O
,	O
intra	O
-	O
kinetochore	B-Anatomy
stretch	O
was	O
shown	O
to	O
correlate	O
with	O
the	O
status	O
of	O
checkpoint	O
activation	O
,	O
with	O
high	O
stretch	O
being	O
correlated	O
with	O
checkpoint	O
satisfaction	O
.	O
This	O
idea	O
of	O
checkpoint	O
control	O
is	O
alternative	O
to	O
a	O
previous	O
idea	O
that	O
tension	O
might	O
be	O
monitored	O
at	O
the	O
centromere	O
,	O
i	O
.	O
e	O
.	O
between	O
sister	O
kinetochores	B-Anatomy
(	O
inter	O
-	O
kinetochore	B-Anatomy
tension	O
)	O
[	O
46	O
]	O
.	O
A	O
significant	O
theoretical	O
limitation	O
of	O
the	O
idea	O
that	O
the	O
checkpoint	O
sensor	O
monitors	O
tension	O
between	O
sister	O
kinetochores	B-Anatomy
is	O
that	O
it	O
is	O
not	O
applicable	O
to	O
meiosis	O
I	O
,	O
when	O
the	O
sisters	O
co	O
-	O
orient	O
and	O
the	O
homologues	O
pair	O
through	O
the	O
chiasmata	O
.	O
Conversely	O
,	O
the	O
intra	O
-	O
kinetochore	B-Anatomy
tension	O
idea	O
is	O
also	O
applicable	O
to	O
checkpoint	O
control	O
in	O
meiosis	O
I	O
.	O
Discussion	O
In	O
our	O
previous	O
work	O
,	O
we	O
considered	O
in	O
CD	O
families	O
the	O
risk	O
to	O
develop	O
the	O
disease	O
according	O
to	O
a	O
specific	O
HLA	O
haplotypes	O
,	O
obtaining	O
a	O
risk	O
range	O
from	O
0	O
.	O
01	O
to	O
>	O
=	O
0	O
.	O
20	O
[	O
1	O
]	O
.	O
In	O
the	O
present	O
study	O
we	O
evaluated	O
the	O
role	O
of	O
3	O
non	O
-	O
HLA	O
genetic	O
markers	O
to	O
influence	O
the	O
CD	O
risk	O
in	O
first	O
relatives	O
of	O
CD	O
affected	O
children	O
.	O
We	O
collected	O
data	O
on	O
families	O
with	O
at	O
least	O
one	O
CD	O
-	O
affected	O
among	O
offspring	O
.	O
This	O
family	O
set	O
helped	O
to	O
evaluate	O
the	O
association	O
between	O
SNPs	O
and	O
CD	O
(	O
TDT	O
on	O
parents	O
-	O
offspring	O
trios	O
)	O
and	O
to	O
estimate	O
the	O
risk	O
of	O
CD	O
in	O
the	O
other	O
sibs	O
.	O
The	O
TDT	O
design	O
provides	O
robustness	O
to	O
population	O
stratification	O
and	O
mitigation	O
of	O
the	O
possible	O
confounding	O
effect	O
of	O
environmental	O
factors	O
,	O
because	O
all	O
family	O
members	O
share	O
the	O
same	O
environment	O
[	O
16	O
]	O
.	O
Ten	O
SNPs	O
,	O
selected	O
from	O
those	O
previously	O
found	O
to	O
be	O
associated	O
with	O
CD	O
by	O
GWAS	O
[	O
13	O
]	O
,	O
were	O
successfully	O
genotyped	O
.	O
In	O
our	O
population	O
three	O
SNPs	O
resulted	O
significantly	O
associated	O
with	O
CD	O
(	O
those	O
in	O
LPP	O
,	O
RGS1	O
and	O
REL	O
genes	O
)	O
and	O
the	O
other	O
seven	O
investigated	O
SNPs	O
,	O
even	O
if	O
not	O
statistically	O
associated	O
with	O
CD	O
,	O
showed	O
always	O
an	O
higher	O
frequency	O
of	O
the	O
previously	O
reported	O
risk	O
alleles	O
[	O
13	O
]	O
in	O
affected	O
subjects	O
than	O
in	O
controls	O
.	O
The	O
three	O
genes	O
selected	O
appear	O
to	O
be	O
appealing	O
for	O
the	O
pathogenesis	O
of	O
CD	O
.	O
LPP	O
(	O
OR	O
=	O
2	O
.	O
36	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
was	O
reported	O
to	O
be	O
highly	O
expressed	O
in	O
small	B-Anatomy
intestinal	I-Anatomy
mucosa	I-Anatomy
and	O
may	O
have	O
a	O
structural	O
role	O
at	O
sites	B-Anatomy
of	O
cell	B-Anatomy
adhesion	O
in	O
maintaining	O
cell	B-Anatomy
shape	O
and	O
motility	O
[	O
7	O
]	O
.	O
RGS1	O
(	O
OR	O
=	O
1	O
.	O
75	O
;	O
p	O
=	O
0	O
.	O
025	O
)	O
belongs	O
to	O
a	O
family	O
of	O
RGS	O
genes	O
.	O
It	O
attenuates	O
the	O
signaling	O
activity	O
of	O
G	O
-	O
proteins	O
,	O
blocking	O
the	O
homing	O
of	O
Intra	B-Anatomy
Epithelial	I-Anatomy
Lymphocytes	I-Anatomy
(	O
IELs	B-Anatomy
)	O
,	O
and	O
it	O
is	O
specifically	O
expressed	O
both	O
in	O
human	O
small	B-Anatomy
intestinal	I-Anatomy
mucosa	I-Anatomy
and	O
in	O
murine	O
IELs	B-Anatomy
,	O
key	O
players	O
in	O
the	O
development	O
of	O
human	O
CD	O
villous	O
atrophy	O
[	O
7	O
]	O
,	O
[	O
17	O
]	O
.	O
REL	O
(	O
OR	O
=	O
1	O
.	O
66	O
;	O
p	O
=	O
0	O
.	O
034	O
)	O
is	O
a	O
subunit	O
of	O
NF	O
-	O
kB	O
complex	O
,	O
implicated	O
in	O
T	B-Anatomy
cell	I-Anatomy
differentiation	O
[	O
18	O
]	O
and	O
it	O
appears	O
to	O
be	O
a	O
key	O
molecule	O
regulating	O
inflammation	O
and	O
the	O
switch	O
from	O
tolerance	O
to	O
autoimmunity	O
[	O
19	O
]	O
.	O
It	O
is	O
interesting	O
to	O
note	O
that	O
our	O
data	O
confirm	O
previous	O
pathogenetic	O
implications	O
reported	O
in	O
literature	O
of	O
these	O
SNPs	O
with	O
CD	O
as	O
well	O
as	O
with	O
other	O
autoimmune	O
diseases	O
[	O
20	O
]	O
.	O
By	O
the	O
Bayesian	O
approach	O
we	O
calculated	O
a	O
ranking	O
score	O
(	O
BS	O
)	O
among	O
the	O
sibs	O
.	O
However	O
,	O
it	O
should	O
be	O
considered	O
that	O
BS	O
is	O
not	O
a	O
plain	O
disease	O
risk	O
,	O
rather	O
a	O
method	O
to	O
rank	O
different	O
genotypes	O
according	O
to	O
their	O
contribution	O
to	O
make	O
an	O
individual	O
susceptible	O
to	O
CD	O
.	O
For	O
instance	O
,	O
some	O
of	O
our	O
BS	O
are	O
very	O
near	O
to	O
1	O
,	O
nevertheless	O
none	O
of	O
the	O
considered	O
genotypes	O
could	O
give	O
a	O
100	O
%	O
risk	O
to	O
develop	O
the	O
disease	O
.	O
In	O
other	O
terms	O
,	O
we	O
considered	O
the	O
BS	O
as	O
a	O
ranking	O
measure	O
,	O
only	O
stating	O
that	O
a	O
given	O
genotype	O
could	O
assign	O
a	O
higher	O
risk	O
than	O
another	O
genotype	O
but	O
does	O
not	O
allow	O
a	O
quantitative	O
measure	O
of	O
the	O
risk	O
difference	O
(	O
2	O
-	O
fold	O
,	O
3	O
-	O
fold	O
,	O
etc	O
)	O
.	O
However	O
,	O
even	O
if	O
the	O
addition	O
of	O
only	O
3	O
SNPs	O
to	O
HLA	O
could	O
be	O
considered	O
at	O
""""	O
minor	O
effect	O
""""	O
[	O
13	O
]	O
,	O
we	O
demonstrated	O
that	O
they	O
could	O
significantly	O
improve	O
the	O
prediction	O
of	O
CD	O
risk	O
in	O
sibs	O
,	O
in	O
terms	O
of	O
diagnostic	O
sensitivity	O
and	O
negative	O
predictive	O
value	O
.	O
So	O
,	O
in	O
a	O
cohort	O
of	O
CD	O
families	O
,	O
our	O
data	O
confirm	O
that	O
non	O
-	O
HLA	O
SNPs	O
evaluation	O
is	O
an	O
usefull	O
diagnostic	O
tool	O
in	O
CD	O
risk	O
evaluation	O
as	O
a	O
previous	O
study	O
showed	O
in	O
CD	O
unrelated	O
subjects	O
[	O
14	O
]	O
.	O
CD	O
,	O
on	O
the	O
basis	O
of	O
the	O
actual	O
knowledge	O
,	O
cannot	O
be	O
exactly	O
predicted	O
by	O
genetic	O
testing	O
,	O
but	O
a	O
reliable	O
probabilistic	O
method	O
might	O
be	O
associated	O
to	O
careful	O
surveillance	O
of	O
infants	O
carrying	O
the	O
higher	O
risk	O
.	O
This	O
will	O
help	O
to	O
significantly	O
reduce	O
the	O
heavy	O
load	O
of	O
anxiety	O
and	O
pain	O
associated	O
with	O
the	O
appearance	O
of	O
symptoms	O
of	O
CD	O
,	O
by	O
anticipating	O
,	O
with	O
simple	O
serological	O
tests	O
,	O
the	O
clinical	O
appearance	O
of	O
the	O
disease	O
.	O
To	O
improve	O
the	O
possibility	O
to	O
identify	O
high	O
risk	O
patients	O
in	O
CD	O
families	O
we	O
propose	O
in	O
alternative	O
to	O
the	O
classical	O
HLA	O
classification	O
(	O
Fig	O
.	O
4	O
,	O
panel	O
A	O
)	O
a	O
slight	O
improved	O
flow	O
-	O
chart	O
(	O
Fig	O
.	O
4	O
,	O
panel	O
B	O
)	O
:	O
1	O
)	O
HLA	O
genotyping	O
:	O
subjects	O
belonging	O
to	O
the	O
HLA	O
risk	O
groups	O
1	O
and	O
2	O
will	O
be	O
classified	O
as	O
at	O
high	O
CD	O
risk	O
;	O
2	O
)	O
subjects	O
belonging	O
to	O
the	O
HLA	O
risk	O
groups	O
3	O
and	O
4	O
,	O
will	O
be	O
further	O
investigated	O
for	O
our	O
SNPs	O
combination	O
(	O
LPP	O
,	O
REL	O
,	O
RGS1	O
)	O
in	O
order	O
to	O
calculate	O
their	O
BS	O
(	O
Fig	O
.	O
4	O
,	O
panel	O
B	O
)	O
.	O
Among	O
these	O
latter	O
subjects	O
those	O
with	O
a	O
BS	O
>	O
=	O
the	O
median	O
value	O
will	O
be	O
classified	O
at	O
high	O
risk	O
;	O
3	O
)	O
subjects	O
belonging	O
to	O
the	O
HLA	O
risk	O
group	O
5	O
will	O
be	O
considered	O
at	O
low	O
CD	O
risk	O
.	O
All	O
CD	O
familials	O
belonging	O
to	O
the	O
above	O
high	O
risk	O
groups	O
(	O
HLA	O
group	O
1	O
-	O
2	O
and	O
HLA	O
group	O
3	O
-	O
4	O
with	O
BS	O
>	O
=	O
median	O
)	O
will	O
be	O
undergo	O
a	O
strict	O
surveillance	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0026920	O
.	O
g004	O
Figure	O
4	O
Classification	O
flow	O
-	O
chart	O
.	O
In	O
panel	O
A	O
the	O
classical	O
HLA	O
-	O
based	O
classification	O
.	O
In	O
panel	O
B	O
the	O
proposed	O
BS	O
-	O
based	O
classification	O
considering	O
the	O
genotypes	O
of	O
HLA	O
plus	O
LPP	O
,	O
RGS1	O
and	O
REL	O
SNPs	O
.	O
One	O
of	O
the	O
limitation	O
of	O
our	O
cohort	O
family	O
study	O
could	O
be	O
the	O
sample	O
size	O
,	O
which	O
may	O
have	O
not	O
allowed	O
to	O
explore	O
genes	O
at	O
smaller	O
effect	O
,	O
so	O
explaining	O
the	O
lack	O
of	O
association	O
between	O
SNPs	O
in	O
TAGAP	O
,	O
IL2	O
/	O
IL21	O
,	O
OLIG3	O
,	O
CCR	O
,	O
SH2B3	O
,	O
IL12A	O
and	O
IL12A	O
/	O
SCHIP1	O
genes	O
with	O
CD	O
although	O
the	O
trend	O
observed	O
in	O
previous	O
studies	O
in	O
unrelated	O
CD	O
patients	O
was	O
confirmed	O
[	O
13	O
]	O
.	O
In	O
the	O
main	O
time	O
the	O
homogeneity	O
of	O
the	O
genetic	O
and	O
environmental	O
domains	O
in	O
the	O
tested	O
families	O
allows	O
to	O
explore	O
risk	O
factors	O
within	O
a	O
controlled	O
cohort	O
.	O
A	O
second	O
limit	O
of	O
the	O
study	O
is	O
the	O
relatively	O
short	O
(	O
6	O
years	O
)	O
follow	O
up	O
of	O
the	O
sibship	O
,	O
which	O
could	O
cause	O
an	O
underestimation	O
of	O
the	O
disease	O
development	O
at	O
later	O
ages	O
.	O
Our	O
aim	O
is	O
to	O
go	O
on	O
with	O
the	O
monitoring	O
of	O
these	O
families	O
in	O
the	O
next	O
years	O
.	O
In	O
conclusion	O
,	O
the	O
estimate	O
of	O
the	O
CD	O
risk	O
by	O
HLA	O
+	O
SNPs	O
approach	O
,	O
even	O
if	O
not	O
applicable	O
to	O
prevention	O
,	O
could	O
be	O
a	O
precious	O
tool	O
improving	O
CD	O
diagnosis	O
respect	O
to	O
the	O
only	O
HLA	O
(	O
NPV	O
:	O
95	O
%	O
vs	O
91	O
%	O
,	O
and	O
DS	O
:	O
79	O
%	O
vs	O
45	O
%	O
)	O
,	O
in	O
the	O
cohort	O
of	O
first	O
degree	O
relatives	O
.	O
In	O
fact	O
in	O
clinical	O
practice	O
the	O
absence	O
of	O
HLA	O
risk	O
groups	O
1	O
or	O
2	O
,	O
allows	O
to	O
exclude	O
the	O
disease	O
with	O
high	O
probability	O
,	O
while	O
testing	O
the	O
three	O
SNPs	O
in	O
HLA	O
groups	O
3	O
or	O
4	O
could	O
represent	O
a	O
further	O
tool	O
to	O
identify	O
less	O
frequent	O
CD	O
cases	O
.	O
So	O
,	O
an	O
infant	O
with	O
high	O
HLA	O
+	O
SNPs	O
score	O
even	O
if	O
belonging	O
to	O
HLA	O
low	O
risk	O
groups	O
,	O
shall	O
undergo	O
a	O
simple	O
surveillance	O
system	O
to	O
allow	O
proper	O
diagnosis	O
and	O
treatment	O
before	O
the	O
full	O
blow	O
disease	O
appears	O
.	O
Authors	O
'	O
contributions	O
EEKN	O
was	O
responsible	O
for	O
data	O
collection	O
,	O
statistical	O
analysis	O
and	O
drafting	O
the	O
manuscript	O
.	O
SAGN	O
and	O
YW	O
involved	O
in	O
data	O
collection	O
and	O
helped	O
with	O
the	O
data	O
analysis	O
.	O
AS	O
helped	O
in	O
data	O
analysis	O
.	O
EST	O
and	O
JL	O
directed	O
the	O
study	O
and	O
helped	O
in	O
revising	O
the	O
manuscript	O
.	O
RMVD	O
helped	O
in	O
data	O
analysis	O
,	O
interpretation	O
of	O
the	O
results	O
and	O
led	O
writing	O
of	O
the	O
manuscript	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
Figures	O
Fig	O
.	O
1	O
.	O
A	O
view	O
of	O
(	O
I	O
)	O
with	O
displacement	O
ellipsoids	O
drawn	O
at	O
the	O
30	O
%	O
probability	O
level	O
.	O
Fig	O
.	O
2	O
.	O
Stereoview	O
of	O
the	O
sheet	O
formed	O
by	O
C	O
-	O
-	O
H	O
.	O
.	O
.	O
pi	O
interactions	O
.	O
Hydrogen	O
atoms	O
not	O
involved	O
in	O
the	O
motifs	O
are	O
not	O
included	O
.	O
Background	O
Eucalyptus	O
globulus	O
is	O
the	O
most	O
widely	O
planted	O
species	O
for	O
pulpwood	B-Anatomy
production	O
in	O
temperate	O
regions	O
of	O
the	O
world	O
and	O
there	O
are	O
breeding	O
programs	O
in	O
numerous	O
countries	O
.	O
There	O
is	O
interest	O
in	O
molecular	O
approaches	O
to	O
breeding	O
,	O
particularly	O
marker	O
assisted	O
selection	O
of	O
wood	B-Anatomy
properties	O
.	O
QTL	O
analysis	O
has	O
an	O
important	O
role	O
in	O
identifying	O
positional	O
candidate	O
genes	O
responsible	O
for	O
variation	O
in	O
wood	B-Anatomy
properties	O
.	O
This	O
is	O
one	O
approach	O
to	O
targeting	O
genes	O
which	O
may	O
harbour	O
functional	O
allelic	O
variants	O
(	O
SNPs	O
)	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
detect	O
and	O
validate	O
QTL	O
across	O
multiple	O
sites	O
and	O
pedigrees	O
,	O
in	O
order	O
to	O
identify	O
genomic	O
regions	O
and	O
genes	O
affecting	O
growth	O
and	O
wood	B-Anatomy
properties	O
with	O
wide	O
applicability	O
in	O
the	O
species	O
.	O
We	O
also	O
aimed	O
to	O
determine	O
the	O
proportion	O
of	O
QTL	O
which	O
were	O
stable	O
in	O
their	O
expression	O
across	O
sites	O
of	O
contrasting	O
productivity	O
.	O
Such	O
information	O
will	O
be	O
important	O
to	O
exploit	O
the	O
full	O
potential	O
of	O
the	O
impending	O
Eucalyptus	O
genome	O
sequences	O
.	O
The	O
growth	O
in	O
the	O
number	O
of	O
database	O
publications	O
per	O
year	O
.	O
Each	O
bar	O
shows	O
the	O
number	O
of	O
research	O
articles	O
with	O
the	O
keyword	O
'	O
database	O
'	O
appearing	O
in	O
the	O
article	O
title	O
in	O
the	O
given	O
year	O
.	O
The	O
count	O
only	O
covers	O
articles	O
indexed	O
in	O
PubMed	O
.	O
The	O
increase	O
shows	O
an	O
exponential	O
trend	O
that	O
will	O
produce	O
nearly	O
2000	O
database	O
publications	O
per	O
year	O
by	O
2015	O
.	O
Cation	O
binding	O
to	O
yolk	B-Anatomy
platelet	I-Anatomy
phosvitin	O
In	O
addition	O
to	O
non	O
-	O
heme	O
iron	O
[	O
23	O
]	O
,	O
yolk	B-Anatomy
phosvitin	O
also	O
contains	O
Ca2	O
+	O
,	O
Mg2	O
+	O
,	O
Na	O
+	O
and	O
K	O
+	O
[	O
11	O
]	O
.	O
Partially	O
relaxed	O
23Na	O
Fourier	O
transform	O
NMR	O
spectra	O
revealed	O
the	O
existence	O
of	O
at	O
least	O
two	O
major	O
intracellular	B-Anatomy
compartments	I-Anatomy
of	O
NMR	O
-	O
visible	O
Na	O
+	O
[	O
35	O
]	O
.	O
A	O
large	O
fraction	O
of	O
the	O
Rana	O
oocyte	B-Anatomy
Na	O
+	O
was	O
NMR	O
-	O
invisible	O
and	O
could	O
be	O
recovered	O
in	O
the	O
yolk	B-Anatomy
platelets	I-Anatomy
[	O
35	O
]	O
.	O
During	O
the	O
first	O
meiotic	O
division	O
there	O
is	O
a	O
net	O
increase	O
in	O
NMR	O
-	O
visible	O
Na	O
+	O
;	O
by	O
completion	O
of	O
the	O
second	O
meiotic	O
division	O
(	O
following	O
fertilization	O
)	O
,	O
about	O
70	O
%	O
of	O
the	O
total	O
Na	O
+	O
becomes	O
NMR	O
-	O
visible	O
.	O
Thus	O
,	O
phosvitin	O
not	O
only	O
serves	O
as	O
a	O
site	O
for	O
energy	O
storage	O
,	O
but	O
also	O
as	O
a	O
storage	O
site	O
for	O
iron	O
and	O
other	O
ions	O
essential	O
for	O
embryonic	B-Anatomy
development	O
in	O
ponds	O
and	O
streams	O
that	O
contain	O
little	O
dissolved	O
salts	O
and	O
minerals	O
.	O
Predicted	O
methylation	O
level	O
of	O
C	O
.	O
gigas	O
genes	O
categorized	O
by	O
biological	O
processes	O
compared	O
to	O
measured	O
level	O
of	O
DNA	O
methylation	O
.	O
Mean	O
CpG	O
O	O
/	O
E	O
for	O
10	O
,	O
699	O
C	O
.	O
gigas	O
genes	O
categorized	O
according	O
to	O
Biological	O
Process	O
Gene	O
Ontology	O
(	O
GO	O
)	O
Slim	O
terms	O
are	O
plotted	O
on	O
the	O
x	O
-	O
axis	O
(	O
modified	O
from	O
Gavery	O
and	O
Roberts	O
,	O
2010	O
)	O
.	O
DNA	O
methylation	O
was	O
empirically	O
measured	O
by	O
performing	O
MBD	O
-	O
seq	O
on	O
the	O
SOLiD	O
4	O
platform	O
(	O
Applied	O
Biosystems	O
)	O
.	O
Genes	O
identified	O
in	O
the	O
MBD	O
-	O
library	O
were	O
associated	O
with	O
respective	O
GO	O
terms	O
and	O
enrichment	O
analysis	O
was	O
performed	O
based	O
on	O
the	O
entire	O
transcriptome	O
(	O
Fleury	O
et	O
al	O
.	O
,	O
2009	O
)	O
using	O
DAVID	O
(	O
Huang	O
et	O
al	O
.	O
,	O
2009a	O
,	O
b	O
)	O
.	O
Results	O
indicate	O
the	O
most	O
underrepresented	O
genes	O
in	O
the	O
library	O
are	O
involved	O
in	O
cell	B-Anatomy
adhesion	O
and	O
genes	O
involved	O
in	O
DNA	O
and	O
protein	O
metabolism	O
were	O
most	O
prevalent	O
in	O
the	O
MBD	O
-	O
library	O
.	O
Mitochondria	B-Anatomy
in	O
Cardiac	B-Anatomy
Myocyte	I-Anatomy
Apoptosis	O
It	O
has	O
been	O
suggested	O
that	O
activation	O
of	O
the	O
mitochondrial	B-Anatomy
apoptotic	O
pathway	O
leading	O
to	O
executioner	O
casp	O
activation	O
is	O
relevant	O
in	O
heart	B-Anatomy
injury	O
.	O
1	O
The	O
notion	O
of	O
participation	O
of	O
casp	O
activation	O
in	O
adult	B-Anatomy
cardiac	I-Anatomy
myocyte	I-Anatomy
apoptosis	O
emerged	O
from	O
studies	O
using	O
immunofluorescence	O
microscopy16	O
and	O
casp	O
inhibitors	O
.	O
37	O
Bahi	O
et	O
al	O
.	O
38	O
demonstrated	O
that	O
cardiomyocyte	B-Anatomy
levels	O
of	O
all	O
casps	O
decrease	O
with	O
age	O
,	O
and	O
they	O
are	O
very	O
low	O
in	O
adult	B-Anatomy
cardiac	I-Anatomy
cells	I-Anatomy
.	O
Recently	O
,	O
Bae	O
et	O
al	O
.	O
39	O
reported	O
that	O
apoptosis	O
can	O
be	O
induced	O
in	O
the	O
heart	B-Anatomy
lacking	O
casp	O
activation	O
via	O
casp	O
-	O
independent	O
pathways	O
,	O
probably	O
through	O
apoptosis	O
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
.	O
Both	O
the	O
intrinsic	O
and	O
extrinsic	O
pathways	O
can	O
be	O
inhibited	O
by	O
the	O
cytoprotective	O
protein	O
apoptosis	O
repressor	O
with	O
caspase	O
recruitment	O
domain	O
(	O
ARC	O
)	O
.	O
ARC	O
inhibits	O
the	O
extrinsic	O
pathway	O
by	O
interacting	O
with	O
casp	O
8	O
and	O
components	O
of	O
the	O
death	O
-	O
inducing	O
signaling	O
complex	O
,	O
such	O
as	O
FADD	O
,	O
whereas	O
inhibition	O
of	O
the	O
intrinsic	O
pathway	O
is	O
mediated	O
by	O
blocking	O
BAX	O
activation	O
and	O
mitochondria	B-Anatomy
translocation	O
.	O
40	O
AIF	O
is	O
anchored	O
by	O
its	O
N	O
terminus	O
to	O
the	O
mitochondrial	B-Anatomy
inner	I-Anatomy
membrane	I-Anatomy
,	O
with	O
its	O
C	O
terminus	O
oriented	O
toward	O
the	O
intermembrane	B-Anatomy
space	I-Anatomy
.	O
AIF	O
is	O
required	O
for	O
oxidative	O
phosphorylation	O
and	O
for	O
the	O
assembly	O
and	O
/	O
or	O
stabilization	O
of	O
respiratory	O
complex	O
I	O
.	O
41	O
Upon	O
induction	O
of	O
apoptosis	O
,	O
AIF	O
is	O
cleaved	O
and	O
released	O
into	O
the	O
cytosol	B-Anatomy
,	O
where	O
it	O
translocates	O
to	O
the	O
nucleus	B-Anatomy
and	O
mediates	O
chromatin	B-Anatomy
condensation	O
and	O
large	O
-	O
scale	O
DNA	O
fragmentation	O
.	O
41	O
However	O
,	O
this	O
well	O
-	O
known	O
pro	O
-	O
apoptotic	O
action	O
of	O
AIF	O
is	O
in	O
conflict	O
with	O
the	O
observation	O
that	O
AIF	O
is	O
essential	O
for	O
the	O
maintenance	O
of	O
normal	O
heart	B-Anatomy
function	O
and	O
its	O
inactivation	O
results	O
in	O
dilated	O
C	O
.	O
42	O
Moreover	O
,	O
cardiac	B-Anatomy
myocytes	I-Anatomy
isolated	O
from	O
a	O
mouse	O
model	O
with	O
80	O
%	O
reduction	O
in	O
AIF	O
levels	O
manifested	O
increased	O
cell	B-Anatomy
death	O
induced	O
by	O
oxidative	O
stress	O
,	O
and	O
the	O
hearts	B-Anatomy
of	O
these	O
mice	O
displayed	O
enhanced	O
ischemic	O
damage	O
after	O
in	O
vivo	O
I	O
/	O
R	O
.	O
43	O
Although	O
it	O
has	O
been	O
described	O
that	O
AIF	O
is	O
released	O
from	O
cardiac	B-Anatomy
myocyte	I-Anatomy
mitochondria	I-Anatomy
during	O
I	O
/	O
R	O
,	O
its	O
contribution	O
to	O
I	O
/	O
R	O
-	O
induced	O
apoptosis	O
was	O
discounted	O
.	O
38	O
However	O
,	O
AIF	O
has	O
been	O
implicated	O
in	O
cardiac	B-Anatomy
myocyte	I-Anatomy
death	O
induced	O
by	O
oxidative	O
stress	O
and	O
HF	O
.	O
44	O
Endonuclease	O
G	O
(	O
Endo	O
G	O
)	O
is	O
a	O
nuclear	B-Anatomy
-	O
encoded	O
endonuclease	O
localized	O
to	O
the	O
intermembrane	B-Anatomy
space	I-Anatomy
of	O
mitochondria	B-Anatomy
.	O
In	O
cardiac	B-Anatomy
myocyte	I-Anatomy
apoptosis	O
,	O
Endo	O
G	O
translocates	O
to	O
the	O
nucleus	B-Anatomy
,	O
where	O
it	O
cleaves	O
DNA	O
.	O
In	O
heart	B-Anatomy
and	O
cultured	O
cardiac	B-Anatomy
myocytes	I-Anatomy
,	O
Endo	O
G	O
has	O
a	O
role	O
in	O
I	O
/	O
R	O
-	O
mediated	O
cell	B-Anatomy
death	O
.	O
38	O
Activation	O
of	O
the	O
intrinsic	O
pathway	O
by	O
the	O
extrinsic	O
apoptotic	O
pathway	O
can	O
take	O
place	O
through	O
casp	O
-	O
8	O
-	O
dependent	O
cleavage	O
of	O
BCL2	O
-	O
interacting	O
protein	O
(	O
BID	O
)	O
to	O
truncated	O
BID	O
(	O
t	O
-	O
BID	O
)	O
.	O
The	O
C	O
-	O
terminal	O
fragment	O
of	O
t	O
-	O
BID	O
subsequently	O
translocates	O
to	O
the	O
mitochondrial	B-Anatomy
outer	I-Anatomy
membrane	I-Anatomy
,	O
where	O
it	O
presumably	O
activates	O
the	O
intrinsic	O
pathway	O
.	O
This	O
pathway	O
is	O
operative	O
in	O
the	O
heart	B-Anatomy
.	O
1	O
Discussion	O
We	O
estimated	O
the	O
future	O
acceptability	O
of	O
PrEP	O
,	O
examining	O
the	O
attitudes	O
and	O
preferences	O
of	O
potential	O
user	O
groups	O
from	O
different	O
countries	O
towards	O
hypothetical	O
and	O
known	O
PrEP	O
attributes	O
.	O
Our	O
results	O
show	O
that	O
participants	O
were	O
generally	O
willing	O
to	O
accept	O
PrEP	O
and	O
adopt	O
it	O
as	O
soon	O
as	O
it	O
becomes	O
available	O
.	O
Surprisingly	O
,	O
participants	O
were	O
also	O
willing	O
to	O
take	O
PrEP	O
even	O
when	O
reminded	O
of	O
potential	O
side	O
effects	O
,	O
cost	O
,	O
condom	O
use	O
,	O
and	O
frequent	O
HIV	O
testing	O
.	O
These	O
findings	O
indicate	O
participants	O
'	O
motivation	O
to	O
overcome	O
barriers	O
which	O
can	O
have	O
a	O
considerable	O
impact	O
on	O
uptake	O
.	O
In	O
contrast	O
,	O
participants	O
mentioned	O
that	O
the	O
thought	O
of	O
taking	O
PrEP	O
made	O
them	O
feel	O
anxious	O
,	O
although	O
they	O
also	O
indicated	O
that	O
taking	O
PrEP	O
would	O
not	O
be	O
embarrassing	O
and	O
they	O
would	O
want	O
their	O
partner	O
or	O
partners	O
to	O
know	O
.	O
Participants	O
'	O
anxiety	O
may	O
be	O
explained	O
by	O
the	O
hypothetical	O
nature	O
of	O
most	O
of	O
the	O
presented	O
PrEP	O
characteristics	O
,	O
the	O
stigma	O
associated	O
with	O
HIV	O
[	O
34	O
]	O
,	O
and	O
in	O
some	O
settings	O
,	O
the	O
criminalization	O
of	O
sex	O
work	O
,	O
injected	O
drug	O
use	O
and	O
homosexuality	O
[	O
35	O
]	O
.	O
Most	O
participants	O
,	O
nonetheless	O
,	O
subsequently	O
indicated	O
that	O
PrEP	O
would	O
give	O
them	O
hope	O
,	O
which	O
suggests	O
that	O
their	O
initial	O
willingness	O
to	O
take	O
it	O
remained	O
largely	O
unscathed	O
.	O
Female	O
participants	O
indicated	O
a	O
higher	O
level	O
of	O
willingness	O
to	O
take	O
PrEP	O
than	O
male	O
participants	O
,	O
which	O
may	O
be	O
explained	O
by	O
women	O
'	O
s	O
difficulty	O
negotiating	O
the	O
use	O
of	O
condoms	O
and	O
awareness	O
of	O
their	O
and	O
/	O
or	O
their	O
partners	O
'	O
risk	O
of	O
becoming	O
infected	O
with	O
HIV	O
[	O
36	O
]	O
.	O
We	O
also	O
found	O
that	O
younger	O
participants	O
and	O
those	O
with	O
fewer	O
children	O
,	O
those	O
who	O
reported	O
adherence	O
to	O
past	O
medication	O
,	O
more	O
frequent	O
condom	O
usage	O
,	O
having	O
been	O
tested	O
for	O
HIV	O
in	O
the	O
past	O
and	O
never	O
injecting	O
drugs	O
,	O
reported	O
greater	O
willingness	O
to	O
take	O
PrEP	O
.	O
These	O
promising	O
findings	O
suggest	O
that	O
those	O
who	O
are	O
currently	O
bearing	O
the	O
brunt	O
of	O
HIV	O
[	O
1	O
]	O
,	O
have	O
higher	O
perceived	O
risk	O
,	O
and	O
are	O
most	O
likely	O
to	O
adhere	O
to	O
a	O
comprehensive	O
PrEP	O
program	O
,	O
are	O
also	O
the	O
most	O
motivated	O
to	O
enroll	O
.	O
Yet	O
,	O
while	O
participants	O
stated	O
not	O
being	O
interested	O
in	O
selling	O
PrEP	O
,	O
the	O
majority	O
reported	O
intentions	O
to	O
share	O
it	O
.	O
Therefore	O
,	O
information	O
and	O
counseling	O
about	O
the	O
risks	O
of	O
sharing	O
PrEP	O
should	O
be	O
readily	O
available	O
as	O
part	O
of	O
any	O
implementation	O
program	O
.	O
Results	O
from	O
the	O
conjoint	O
analysis	O
reveal	O
trends	O
in	O
participants	O
'	O
preferences	O
which	O
deserve	O
consideration	O
.	O
PrEP	O
route	O
of	O
administration	O
was	O
the	O
most	O
important	O
attribute	O
,	O
and	O
bi	O
-	O
monthly	O
and	O
monthly	O
injections	O
were	O
the	O
preferred	O
alternatives	O
.	O
This	O
finding	O
is	O
encouraging	O
from	O
a	O
policy	O
perspective	O
if	O
such	O
modalities	O
become	O
available	O
;	O
since	O
it	O
may	O
reduce	O
users	O
'	O
likelihood	O
of	O
sharing	O
,	O
selling	O
or	O
forgetting	O
to	O
take	O
PrEP	O
,	O
but	O
it	O
also	O
raises	O
questions	O
regarding	O
participants	O
'	O
willingness	O
to	O
take	O
oral	B-Anatomy
PrEP	O
.	O
HIV	O
testing	O
was	O
the	O
second	O
most	O
important	O
attribute	O
,	O
and	O
a	O
test	O
every	O
six	O
months	O
was	O
,	O
as	O
expected	O
,	O
the	O
preferred	O
alternative	O
.	O
Interestingly	O
,	O
dispensing	O
sites	O
were	O
more	O
important	O
than	O
any	O
other	O
attribute	O
for	O
some	O
groups	O
,	O
particularly	O
in	O
Africa	O
.	O
This	O
may	O
indicate	O
concerns	O
about	O
social	O
stigma	O
and	O
access	O
[	O
37	O
]	O
.	O
However	O
,	O
it	O
is	O
encouraging	O
that	O
most	O
participants	O
were	O
willing	O
to	O
receive	O
PrEP	O
at	O
a	O
healthcare	O
facility	O
,	O
which	O
can	O
facilitate	O
synergies	O
between	O
PrEP	O
and	O
other	O
existing	O
prevention	O
services	O
.	O
Time	O
spent	O
obtaining	O
PrEP	O
and	O
frequency	O
of	O
pick	O
up	O
,	O
which	O
we	O
used	O
as	O
a	O
proxy	O
measure	O
for	O
cost	O
-	O
opportunity	O
,	O
were	O
generally	O
less	O
important	O
,	O
consistent	O
with	O
participants	O
'	O
willingness	O
to	O
pay	O
for	O
PrEP	O
.	O
Our	O
findings	O
are	O
broadly	O
consistent	O
with	O
the	O
work	O
of	O
Guest	O
et	O
al	O
.	O
and	O
Galea	O
et	O
al	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
.	O
However	O
,	O
specific	O
comparisons	O
are	O
not	O
advisable	O
as	O
the	O
composition	O
and	O
size	O
of	O
the	O
samples	O
,	O
recruitment	O
methods	O
,	O
measures	O
and	O
statistical	O
analyses	O
differ	O
greatly	O
.	O
Previous	O
work	O
on	O
PrEP	O
implementation	O
suggests	O
that	O
delivery	O
programs	O
will	O
need	O
to	O
meet	O
a	O
number	O
of	O
requirements	O
in	O
order	O
to	O
be	O
effective	O
,	O
including	O
:	O
prioritization	O
of	O
groups	O
at	O
higher	O
risk	O
of	O
infection	O
;	O
delivery	O
of	O
PrEP	O
in	O
combination	O
with	O
other	O
prevention	O
services	O
,	O
including	O
risk	O
reduction	O
and	O
medication	O
adherence	O
counseling	O
,	O
condoms	O
provision	O
,	O
diagnosis	O
and	O
treatment	O
of	O
other	O
sexually	O
transmitted	O
infections	O
,	O
and	O
frequent	O
HIV	O
testing	O
;	O
and	O
monitoring	O
of	O
side	O
effects	O
,	O
adherence	O
and	O
risk	O
behaviors	O
[	O
8	O
]	O
,	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
,	O
[	O
40	O
]	O
,	O
[	O
41	O
]	O
,	O
[	O
42	O
]	O
.	O
Our	O
results	O
provide	O
valuable	O
clues	O
that	O
can	O
help	O
countries	O
to	O
deliver	O
PrEP	O
more	O
effectively	O
,	O
should	O
they	O
decide	O
to	O
implement	O
it	O
,	O
by	O
focusing	O
their	O
efforts	O
on	O
the	O
aspects	O
that	O
need	O
more	O
attention	O
.	O
This	O
is	O
the	O
first	O
multinational	O
study	O
,	O
to	O
our	O
knowledge	O
,	O
that	O
integrates	O
different	O
disciplines	O
to	O
shed	O
light	O
on	O
a	O
question	O
that	O
we	O
believe	O
is	O
of	O
global	O
importance	O
.	O
Our	O
study	O
complements	O
previous	O
work	O
on	O
PrEP	O
by	O
examining	O
potential	O
users	O
'	O
perspective	O
and	O
offering	O
insights	O
into	O
their	O
attitudes	O
and	O
preferences	O
.	O
We	O
note	O
that	O
it	O
may	O
not	O
be	O
possible	O
to	O
generalize	O
the	O
observed	O
PrEP	O
acceptability	O
to	O
other	O
settings	O
and	O
our	O
results	O
should	O
be	O
considered	O
within	O
the	O
context	O
of	O
this	O
study	O
'	O
s	O
limitations	O
.	O
Given	O
the	O
sensitive	O
nature	O
of	O
the	O
addressed	O
questions	O
,	O
and	O
despite	O
all	O
our	O
efforts	O
to	O
reduce	O
social	O
desirability	O
bias	O
,	O
there	O
is	O
an	O
unavoidable	O
risk	O
that	O
participants	O
may	O
have	O
felt	O
at	O
times	O
compelled	O
to	O
provide	O
what	O
they	O
felt	O
was	O
the	O
""""	O
right	O
""""	O
answer	O
.	O
Additionally	O
,	O
our	O
data	O
collection	O
took	O
place	O
in	O
urban	O
areas	O
,	O
where	O
HIV	O
incidence	O
is	O
normally	O
higher	O
,	O
thus	O
current	O
findings	O
may	O
not	O
be	O
generalizable	O
to	O
rural	O
settings	O
.	O
Finally	O
,	O
examining	O
acceptability	O
among	O
users	O
enrolled	O
in	O
pilot	O
programs	O
is	O
much	O
deserving	O
,	O
as	O
actual	O
acceptability	O
may	O
differ	O
from	O
potential	O
willingness	O
to	O
take	O
PrEP	O
,	O
especially	O
if	O
relevant	O
attributes	O
of	O
a	O
product	O
or	O
program	O
are	O
modified	O
,	O
as	O
observed	O
in	O
other	O
comparable	O
interventions	O
[	O
43	O
]	O
.	O
Origins	O
of	O
Acquired	O
Antibiotic	O
Resistance	O
Mechanisms	O
Recently	O
,	O
D	O
'	O
Costa	O
et	O
al	O
.	O
(	O
2011	O
)	O
have	O
reported	O
a	O
metagenomic	O
analysis	O
of	O
the	O
Beringian	O
permafrost	O
,	O
which	O
is	O
30	O
,	O
000	O
years	O
old	O
.	O
They	O
showed	O
molecular	O
evidences	O
of	O
the	O
ancient	O
origins	O
of	O
antibiotic	O
resistances	O
,	O
detecting	O
beta	O
-	O
lactamases	O
genes	O
,	O
vanX	O
-	O
like	O
,	O
component	O
of	O
the	O
vancomycin	O
resistance	O
operon	O
,	O
and	O
tetM	O
,	O
coding	O
for	O
a	O
protein	O
protecting	O
the	O
ribosomal	B-Anatomy
target	O
from	O
tetracycline	O
.	O
Sequence	O
analysis	O
revealed	O
that	O
the	O
beta	O
-	O
lactamases	O
genes	O
recovered	O
from	O
the	O
permafrost	O
demonstrated	O
an	O
amino	O
-	O
acid	O
homology	O
(	O
53	O
-	O
84	O
%	O
)	O
to	O
known	O
beta	O
-	O
lactamases	O
from	O
beta	O
-	O
lactams	O
producing	O
Streptomyces	O
.	O
The	O
tetM	O
sequences	O
revealed	O
a	O
high	O
similarity	O
to	O
the	O
genes	O
coding	O
for	O
the	O
ribosomal	B-Anatomy
protection	O
protein	O
of	O
actinomycetes	O
.	O
The	O
vanX	O
sequence	O
showed	O
a	O
similarity	O
to	O
the	O
vanX	O
gene	O
recovered	O
in	O
pathogenic	O
vancomycin	O
resistant	O
enterococci	O
(	O
VRE	O
)	O
and	O
to	O
the	O
vanX	O
gene	O
from	O
Amycolatopsis	O
orientalis	O
.	O
This	O
environmental	O
species	O
,	O
belonging	O
to	O
the	O
actinobacteria	O
phylum	O
,	O
is	O
a	O
natural	O
producer	O
of	O
vancomycin	O
,	O
and	O
very	O
likely	O
the	O
progenitor	O
of	O
the	O
van	O
genes	O
operons	O
,	O
responsible	O
for	O
resistance	O
to	O
vancomycin	O
.	O
The	O
integration	O
of	O
the	O
van	O
operons	O
on	O
transposons	O
and	O
on	O
conjugative	B-Anatomy
plasmids	I-Anatomy
has	O
enhanced	O
their	O
spread	O
(	O
Courvalin	O
,	O
2006	O
)	O
.	O
Reports	O
of	O
VRE	O
in	O
freshwater	O
have	O
been	O
provided	O
by	O
several	O
authors	O
(	O
Talebi	O
et	O
al	O
.	O
,	O
2008	O
;	O
Lata	O
et	O
al	O
.	O
,	O
2009	O
;	O
Luczkiewicz	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O
Interestingly	O
,	O
Schwartz	O
et	O
al	O
.	O
(	O
2003	O
)	O
detected	O
vanA	O
genes	O
in	O
the	O
biofilm	B-Anatomy
of	O
drinking	O
water	O
supplies	O
,	O
in	O
the	O
absence	O
of	O
enterococci	O
,	O
demonstrating	O
the	O
lateral	O
transfer	O
of	O
this	O
gene	O
.	O
Notably	O
,	O
the	O
progenitors	O
of	O
these	O
resistance	O
genes	O
are	O
soil	O
bacteria	O
thus	O
most	O
likely	O
,	O
a	O
shuttle	O
has	O
been	O
responsible	O
for	O
the	O
introduction	O
of	O
these	O
genes	O
into	O
the	O
commensal	O
bacterial	O
community	B-Anatomy
and	O
afterward	O
into	O
the	O
pathogenic	O
species	O
.	O
Results	O
Supplementary	O
Material	O
Crystal	O
structure	O
:	O
contains	O
datablock	O
(	O
s	O
)	O
global	O
,	O
I	O
.	O
DOI	O
:	O
10	O
.	O
1107	O
/	O
S1600536812002796	O
/	O
hg5166sup1	O
.	O
cif	O
Structure	O
factors	O
:	O
contains	O
datablock	O
(	O
s	O
)	O
I	O
.	O
DOI	O
:	O
10	O
.	O
1107	O
/	O
S1600536812002796	O
/	O
hg5166Isup2	O
.	O
hkl	O
Additional	O
supplementary	O
materials	O
:	O
crystallographic	O
information	O
;	O
3D	O
view	O
;	O
checkCIF	O
report	O
Results	O
Ventricular	B-Anatomy
fibrillation	O
due	O
to	O
long	O
QT	O
syndrome	O
probably	O
caused	O
by	O
clindamycin	O
.	O
Prolongation	O
of	O
QT	O
time	O
interval	O
may	O
be	O
provoked	O
by	O
a	O
limited	O
number	O
of	O
drugs	O
,	O
especially	O
macrolide	O
antibiotics	O
.	O
We	O
describe	O
a	O
case	O
of	O
QT	O
time	O
interval	O
prolongation	O
induced	O
by	O
clindamycin	O
with	O
subsequent	O
repeated	O
ventricular	B-Anatomy
fibrillation	O
and	O
resuscitation	O
;	O
there	O
is	O
no	O
previous	O
report	O
in	O
the	O
literature	O
of	O
QT	O
time	O
prolongation	O
caused	O
by	O
lincosamides	O
.	O
The	O
TGF	O
-	O
beta	O
type	O
II	O
receptor	O
in	O
chronic	B-Anatomy
myeloid	I-Anatomy
leukemia	I-Anatomy
:	O
analysis	O
of	O
microsatellite	O
regions	O
and	O
gene	O
expression	O
.	O
Genomic	O
instability	O
is	O
one	O
mechanism	O
proposed	O
to	O
play	O
a	O
role	O
in	O
the	O
disease	O
progression	O
of	O
chronic	B-Anatomy
myeloid	I-Anatomy
leukemia	I-Anatomy
(	O
CML	B-Anatomy
)	O
.	O
Microsatellite	O
regions	O
in	O
the	O
type	O
II	O
transforming	O
growth	O
factor	O
-	O
beta	O
receptor	O
(	O
TGF	O
-	O
beta	O
RII	O
)	O
gene	O
appear	O
to	O
be	O
targets	O
for	O
mutation	O
in	O
some	O
cancers	B-Anatomy
displaying	O
microsatellite	O
instability	O
(	O
replication	O
error	O
phenotype	O
,	O
RER	O
+	O
)	O
.	O
Furthermore	O
,	O
TGF	O
-	O
beta	O
RII	O
mutations	O
in	O
RER	B-Anatomy
+	I-Anatomy
tumors	I-Anatomy
have	O
been	O
associated	O
with	O
decreased	O
TGF	O
-	O
beta	O
RII	O
mRNA	O
levels	O
.	O
As	O
TGF	O
-	O
beta	O
is	O
a	O
potent	O
negative	O
growth	O
regulator	O
of	O
hematopoietic	B-Anatomy
cells	I-Anatomy
,	O
investigations	O
were	O
undertaken	O
to	O
determine	O
whether	O
inactivation	O
of	O
the	O
receptor	O
by	O
microsatellite	O
alteration	O
might	O
be	O
involved	O
in	O
the	O
progression	O
of	O
CML	B-Anatomy
.	O
Analysis	O
of	O
TGF	O
-	O
beta	O
RII	O
mRNA	O
expression	O
by	O
RNase	O
protection	O
,	O
with	O
comparison	O
of	O
cells	B-Anatomy
from	O
the	O
chronic	O
,	O
accelerated	O
and	O
blast	O
phases	O
of	O
CML	B-Anatomy
,	O
showed	O
no	O
change	O
in	O
TGF	O
-	O
beta	O
RII	O
transcript	O
levels	O
during	O
disease	O
progression	O
.	O
However	O
,	O
during	O
each	O
phase	O
of	O
the	O
disease	O
,	O
low	O
levels	O
of	O
TGF	O
-	O
beta	O
RII	O
were	O
detected	O
when	O
compared	O
with	O
the	O
hematopoietic	B-Anatomy
cells	I-Anatomy
of	O
normal	O
donors	O
.	O
Furthermore	O
,	O
this	O
decreased	O
expression	O
was	O
also	O
observed	O
in	O
the	O
other	O
myeloproliferative	O
disorders	O
,	O
polycythemia	O
rubra	O
vera	O
(	O
PRV	O
)	O
and	O
essential	O
thrombocythemia	O
(	O
ET	O
)	O
.	O
The	O
leukemia	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
K562	I-Anatomy
and	O
HL	B-Anatomy
-	I-Anatomy
60	I-Anatomy
had	O
no	O
detectable	O
TGF	O
-	O
beta	O
RII	O
mRNA	O
.	O
Two	O
microsatellite	O
regions	O
found	O
altered	O
in	O
RER	B-Anatomy
+	I-Anatomy
colon	I-Anatomy
cancers	I-Anatomy
were	O
analyzed	O
to	O
establish	O
if	O
these	O
sequences	O
were	O
aberrant	O
in	O
CML	B-Anatomy
.	O
No	O
alteration	O
was	O
detected	O
in	O
either	O
of	O
these	O
regions	O
in	O
any	O
phase	O
of	O
the	O
disease	O
.	O
These	O
results	O
suggest	O
that	O
alterations	O
of	O
the	O
microsatellite	O
regions	O
in	O
the	O
TGF	O
-	O
beta	O
RII	O
gene	O
are	O
not	O
involved	O
in	O
the	O
progression	O
of	O
CML	B-Anatomy
.	O
Decreased	O
expression	O
of	O
TGF	O
-	O
beta	O
RII	O
in	O
CML	B-Anatomy
cells	I-Anatomy
and	O
leukemia	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
raises	O
the	O
possibility	O
that	O
altered	O
expression	O
of	O
the	O
receptor	O
may	O
play	O
a	O
role	O
in	O
the	O
initiation	O
and	O
/	O
or	O
maintenance	O
of	O
the	O
disease	O
state	O
.	O
N	O
-	O
glycosylation	O
of	O
glucose	O
transporter	O
-	O
1	O
(	O
Glut	O
-	O
1	O
)	O
is	O
associated	O
with	O
increased	O
transporter	O
affinity	O
for	O
glucose	O
in	O
human	O
leukemic	B-Anatomy
cells	I-Anatomy
.	O
To	O
elucidate	O
the	O
role	O
of	O
N	O
-	O
glycosylation	O
in	O
the	O
functional	O
activity	O
of	O
the	O
universal	O
glucose	O
transporter	O
,	O
Glut	O
-	O
1	O
,	O
we	O
investigated	O
effects	O
of	O
the	O
N	O
-	O
glycosylation	O
inhibitor	O
,	O
tunicamycin	O
,	O
on	O
glucose	O
transport	O
by	O
human	O
leukemic	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
K562	I-Anatomy
,	O
U937	B-Anatomy
and	O
HL60	B-Anatomy
.	O
Treatment	O
with	O
tunicamycin	O
produced	O
a	O
40	O
-	O
50	O
%	O
inhibition	O
of	O
2	O
-	O
deoxyglucose	O
uptake	O
and	O
this	O
was	O
associated	O
with	O
a	O
2	O
-	O
2	O
.	O
5	O
-	O
fold	O
decrease	O
in	O
transporter	O
affinity	O
for	O
glucose	O
(	O
Km	O
)	O
without	O
a	O
change	O
in	O
Vmax	O
.	O
Leukemic	B-Anatomy
K562	I-Anatomy
,	O
U937	B-Anatomy
and	O
HL60	B-Anatomy
cells	I-Anatomy
expressed	O
Glut	O
-	O
1	O
transporter	O
protein	O
.	O
With	O
K562	B-Anatomy
cells	I-Anatomy
Glut	O
-	O
1	O
appeared	O
as	O
a	O
broad	O
band	O
of	O
50	O
-	O
60	O
kDa	O
,	O
whereas	O
with	O
U937	B-Anatomy
and	O
HL60	B-Anatomy
cells	I-Anatomy
a	O
diffuse	O
band	O
was	O
observed	O
at	O
approximately	O
55	O
kDa	O
.	O
Treatment	O
of	O
K562	B-Anatomy
cells	I-Anatomy
with	O
tunicamycin	O
for	O
18	O
h	O
,	O
resulted	O
in	O
extensive	O
loss	O
of	O
the	O
50	O
-	O
60	O
kDa	O
glycoprotein	O
,	O
appearance	O
of	O
a	O
30	O
-	O
40	O
kDa	O
band	O
and	O
increased	O
staining	O
of	O
a	O
45	O
kDa	O
band	O
.	O
With	O
U937	B-Anatomy
cells	I-Anatomy
,	O
tunicamycin	O
treatment	O
resulted	O
in	O
the	O
appearance	O
of	O
a	O
30	O
-	O
40	O
kDa	O
band	O
and	O
increased	O
staining	O
of	O
a	O
45	O
kDa	O
band	O
.	O
With	O
HL60	B-Anatomy
cells	I-Anatomy
loss	O
of	O
the	O
55	O
kDa	O
Glut	O
-	O
1	O
band	O
was	O
observed	O
and	O
a	O
band	O
of	O
45	O
kDa	O
appeared	O
.	O
Tunicamycin	O
-	O
treatment	O
resulted	O
in	O
75	O
-	O
90	O
%	O
inhibition	O
in	O
[	O
3H	O
]	O
mannose	O
incorporation	O
but	O
only	O
20	O
-	O
25	O
%	O
inhibition	O
in	O
[	O
3H	O
]	O
thymidine	O
and	O
[	O
3H	O
]	O
leucine	O
incorporation	O
.	O
In	O
contrast	O
,	O
tunicamycin	O
had	O
little	O
effect	O
on	O
the	O
viability	O
and	O
MTT	O
responses	O
of	O
the	O
cells	B-Anatomy
used	O
.	O
These	O
results	O
suggest	O
that	O
in	O
leukemic	B-Anatomy
cells	I-Anatomy
N	O
-	O
glycosylation	O
of	O
Glut	O
-	O
1	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
its	O
structure	O
and	O
functional	O
integration	O
.	O
Decontamination	O
of	O
medical	O
equipment	O
-	O
-	O
manufacturer	O
'	O
s	O
problems	O
.	O
1	O
.	O
Small	O
items	O
sent	O
via	O
the	O
post	O
present	O
a	O
much	O
greater	O
hidden	O
hazard	O
and	O
a	O
higher	O
potential	O
for	O
catching	O
people	O
unawares	O
.	O
2	O
.	O
Large	O
items	O
accompanied	O
by	O
a	O
Decontamination	O
Certificate	O
need	O
to	O
be	O
treated	O
with	O
caution	O
because	O
only	O
those	O
surfaces	O
which	O
are	O
accessible	O
will	O
have	O
been	O
cleaned	O
;	O
as	O
soon	O
as	O
engineers	O
start	O
dismantling	O
equipment	O
,	O
areas	O
which	O
are	O
still	O
soiled	O
become	O
exposed	O
.	O
3	O
.	O
Total	O
co	O
-	O
operation	O
between	O
hospital	O
staff	O
and	O
service	O
engineers	O
is	O
necessary	O
to	O
resolve	O
these	O
problems	O
-	O
neither	O
can	O
work	O
safely	O
without	O
the	O
assistance	O
of	O
the	O
other	O
.	O
4	O
.	O
Many	O
products	O
in	O
use	O
in	O
hospitals	O
may	O
be	O
up	O
to	O
20	O
years	O
old	O
and	O
clearly	O
were	O
not	O
designed	O
to	O
facilitate	O
decontamination	O
and	O
therefore	O
present	O
far	O
greater	O
risk	O
to	O
all	O
concerned	O
.	O
5	O
.	O
For	O
the	O
future	O
there	O
a	O
clearly	O
a	O
responsibility	O
with	O
manufacturers	O
to	O
give	O
more	O
thought	O
to	O
the	O
design	O
of	O
their	O
equipment	O
so	O
that	O
decontamination	O
can	O
be	O
achieved	O
more	O
effectively	O
.	O
Enterococci	O
at	O
the	O
crossroads	O
of	O
food	O
safety	O
?	O
Enterococci	O
are	O
gram	O
-	O
positive	O
bacteria	O
and	O
fit	O
within	O
the	O
general	O
definition	O
of	O
lactic	O
acid	O
bacteria	O
.	O
Modern	O
classification	O
techniques	O
resulted	O
in	O
the	O
transfer	O
of	O
some	O
members	O
of	O
the	O
genus	O
Streptococcus	O
,	O
notably	O
some	O
of	O
the	O
Lancefield	O
'	O
s	O
group	O
D	O
streptococci	O
,	O
to	O
the	O
new	O
genus	O
Enterococcus	O
.	O
Enterococci	O
can	O
be	O
used	O
as	O
indicators	O
of	O
faecal	B-Anatomy
contamination	O
.	O
They	O
have	O
been	O
implicated	O
in	O
outbreaks	O
of	O
foodborne	O
illness	O
,	O
and	O
they	O
have	O
been	O
ascribed	O
a	O
beneficial	O
or	O
detrimental	O
role	O
in	O
foods	O
.	O
In	O
processed	O
meats	B-Anatomy
,	O
enterococci	O
may	O
survive	O
heat	O
processing	O
and	O
cause	O
spoilage	O
,	O
though	O
in	O
certain	O
cheeses	O
the	O
growth	O
of	O
enterococci	O
contributes	O
to	O
ripening	O
and	O
development	O
of	O
product	O
flavour	O
.	O
Some	O
enterococci	O
of	O
food	O
origin	O
produce	O
bacteriocins	O
that	O
exert	O
anti	O
-	O
Listeria	O
activity	O
.	O
Enterococci	O
are	O
used	O
as	O
probiotics	O
to	O
improve	O
the	O
microbial	O
balance	O
of	O
the	O
intestine	B-Anatomy
,	O
or	O
as	O
a	O
treatment	O
for	O
gastroenteritis	O
in	O
humans	O
and	O
animals	O
.	O
On	O
the	O
other	O
hand	O
,	O
enterococci	O
have	O
become	O
recognised	O
as	O
serious	O
nosocomial	O
pathogens	O
causing	O
bacteraemia	O
,	O
endocarditis	O
,	O
urinary	B-Anatomy
tract	I-Anatomy
and	O
other	O
infections	O
.	O
This	O
is	O
in	O
part	O
explained	O
by	O
the	O
resistance	O
of	O
some	O
of	O
these	O
bacteria	O
to	O
most	O
antibiotics	O
that	O
are	O
currently	O
in	O
use	O
.	O
Resistance	O
is	O
acquired	O
by	O
gene	O
transfer	O
systems	O
,	O
such	O
as	O
conjugative	B-Anatomy
or	O
nonconjugative	B-Anatomy
plasmids	I-Anatomy
or	O
transposons	O
.	O
Virulence	O
of	O
enterococci	O
is	O
not	O
well	O
understood	O
but	O
adhesins	O
,	O
haemolysin	O
,	O
hyaluronidase	O
,	O
aggregation	O
substance	O
and	O
gelatinase	O
are	O
putative	O
virulence	O
factors	O
.	O
It	O
appears	O
that	O
foods	O
could	O
be	O
a	O
source	O
of	O
vancomycin	O
-	O
resistant	O
enterococci	O
.	O
This	O
review	O
addresses	O
the	O
issue	O
of	O
the	O
health	O
risk	O
of	O
foods	O
containing	O
enterococci	O
.	O
Immunohistochemical	O
analysis	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
in	O
node	B-Anatomy
-	O
positive	O
lung	B-Anatomy
cancer	I-Anatomy
and	O
lymph	B-Anatomy
nodes	I-Anatomy
.	O
The	O
nm23	O
-	O
H1	O
gene	O
product	O
has	O
been	O
considered	O
as	O
an	O
anti	O
-	O
metastatic	O
protein	O
and	O
the	O
level	O
of	O
its	O
expression	O
has	O
been	O
reported	O
to	O
correlate	O
inversely	O
with	O
metastatic	O
potential	O
in	O
some	O
cancers	B-Anatomy
.	O
However	O
,	O
the	O
expression	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
in	O
the	O
metastatic	B-Anatomy
sites	I-Anatomy
have	O
not	O
been	O
studied	O
in	O
detail	O
.	O
We	O
examined	O
the	O
expression	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
in	O
surgically	O
resected	O
46	O
pairs	O
of	O
primary	B-Anatomy
lung	I-Anatomy
cancers	I-Anatomy
and	O
metastatic	B-Anatomy
lymph	I-Anatomy
nodes	I-Anatomy
by	O
immunohistochemistry	O
.	O
The	O
positive	O
staining	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
in	O
primary	B-Anatomy
cancers	I-Anatomy
and	O
metastatic	B-Anatomy
lymph	I-Anatomy
nodes	I-Anatomy
were	O
observed	O
in	O
56	O
.	O
5	O
and	O
67	O
.	O
4	O
%	O
,	O
respectively	O
.	O
The	O
heterogeneity	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
expression	O
between	O
primary	B-Anatomy
cancers	I-Anatomy
and	O
metastatic	B-Anatomy
lymph	I-Anatomy
nodes	I-Anatomy
was	O
observed	O
in	O
41	O
.	O
3	O
%	O
.	O
No	O
correlations	O
were	O
found	O
between	O
the	O
nm23	O
-	O
H1	O
gene	O
product	O
expression	O
in	O
lung	B-Anatomy
cancers	I-Anatomy
and	O
the	O
patients	O
survival	O
.	O
No	O
significant	O
association	O
was	O
also	O
observed	O
between	O
nm23	O
-	O
H1	O
gene	O
product	O
expression	O
in	O
lymph	B-Anatomy
nodes	I-Anatomy
and	O
the	O
patients	O
survival	O
.	O
There	O
was	O
,	O
furthermore	O
,	O
no	O
correlation	O
between	O
the	O
heterogeneity	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
expression	O
and	O
the	O
patients	O
survival	O
.	O
In	O
conclusion	O
,	O
the	O
level	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
expression	O
does	O
not	O
significantly	O
reveal	O
prognostic	O
value	O
in	O
node	B-Anatomy
-	O
positive	O
lung	B-Anatomy
cancers	I-Anatomy
.	O
Expression	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
in	O
metastatic	B-Anatomy
lymph	I-Anatomy
nodes	I-Anatomy
was	O
also	O
unrelated	O
to	O
patients	O
survival	O
.	O
Bradycardia	O
-	O
induced	O
coronary	B-Anatomy
angiogenesis	O
is	O
dependent	O
on	O
vascular	O
endothelial	O
growth	O
factor	O
.	O
A	O
marked	O
coronary	B-Anatomy
angiogenesis	O
is	O
known	O
to	O
occur	O
with	O
chronic	O
bradycardia	O
.	O
We	O
tested	O
the	O
hypothesis	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
an	O
endothelial	B-Anatomy
cell	I-Anatomy
mitogen	O
and	O
a	O
major	O
regulator	O
of	O
angiogenesis	O
,	O
is	O
upregulated	O
in	O
response	O
to	O
low	O
heart	B-Anatomy
rate	O
and	O
consequential	O
increased	O
stroke	O
volume	O
.	O
Bradycardia	O
was	O
induced	O
in	O
rats	O
by	O
administering	O
the	O
bradycardic	O
drug	O
alinidine	O
(	O
3	O
mg	O
/	O
kg	O
body	B-Anatomy
weight	O
)	O
twice	O
daily	O
.	O
Heart	B-Anatomy
rate	O
decreased	O
by	O
32	O
%	O
for	O
20	O
to	O
40	O
minutes	O
after	O
injection	O
and	O
was	O
chronically	O
reduced	O
by	O
10	O
%	O
,	O
14	O
%	O
,	O
and	O
18	O
.	O
5	O
%	O
after	O
1	O
,	O
2	O
,	O
and	O
3	O
weeks	O
of	O
treatment	O
,	O
respectively	O
.	O
Arterial	B-Anatomy
pressure	O
and	O
cardiac	B-Anatomy
output	O
were	O
unchanged	O
.	O
Left	B-Anatomy
ventricular	I-Anatomy
capillary	I-Anatomy
length	O
density	O
(	O
mm	O
/	O
mm	O
(	O
3	O
)	O
)	O
increased	O
gradually	O
with	O
alinidine	O
administration	O
;	O
a	O
15	O
%	O
increase	O
after	O
2	O
weeks	O
and	O
a	O
40	O
%	O
increase	O
after	O
3	O
weeks	O
of	O
alinidine	O
treatment	O
were	O
documented	O
.	O
Left	B-Anatomy
ventricular	I-Anatomy
weight	O
,	O
body	B-Anatomy
weight	O
,	O
and	O
their	O
ratio	O
were	O
not	O
significantly	O
altered	O
by	O
alinidine	O
treatment	O
.	O
After	O
1	O
week	O
of	O
treatment	O
,	O
before	O
an	O
increase	O
in	O
capillary	B-Anatomy
length	O
density	O
,	O
VEGF	O
mRNA	O
increased	O
greater	O
than	O
2	O
-	O
fold	O
and	O
then	O
declined	O
to	O
control	O
levels	O
after	O
3	O
weeks	O
of	O
treatment	O
.	O
VEGF	O
protein	O
was	O
higher	O
in	O
alinidine	O
-	O
treated	O
rats	O
than	O
in	O
controls	O
after	O
2	O
weeks	O
and	O
increased	O
further	O
after	O
3	O
weeks	O
of	O
treatment	O
.	O
Injection	O
of	O
VEGF	O
-	O
neutralizing	O
antibodies	O
over	O
a	O
2	O
-	O
week	O
period	O
completely	O
blocked	O
alinidine	O
-	O
stimulated	O
angiogenesis	O
.	O
In	O
contrast	O
,	O
bFGF	O
mRNA	O
was	O
not	O
altered	O
by	O
alinidine	O
treatment	O
.	O
These	O
data	O
suggest	O
that	O
VEGF	O
plays	O
a	O
key	O
role	O
in	O
the	O
angiogenic	O
response	O
that	O
occurs	O
with	O
chronic	O
bradycardia	O
.	O
The	O
mechanism	O
underlying	O
this	O
VEGF	O
-	O
associated	O
angiogenesis	O
may	O
be	O
an	O
increase	O
in	O
stretch	O
due	O
to	O
enhanced	O
diastolic	O
filling	O
.	O
External	O
beam	O
radiotherapy	O
for	O
subretinal	B-Anatomy
neovascularization	O
in	O
age	O
-	O
related	O
macular	B-Anatomy
degeneration	O
:	O
is	O
this	O
treatment	O
efficient	O
?	O
PURPOSE	O
:	O
Control	O
of	O
the	O
natural	O
course	O
of	O
subretinal	B-Anatomy
neovascularization	O
(	O
SRNV	O
)	O
in	O
age	O
-	O
related	O
macular	B-Anatomy
degeneration	O
(	O
AMD	O
)	O
is	O
difficult	O
.	O
Only	O
a	O
subset	O
of	O
patients	O
is	O
suitable	O
for	O
laser	O
coagulation	O
.	O
This	O
prospective	O
study	O
aimed	O
to	O
determine	O
the	O
efficacy	O
and	O
individual	O
benefit	O
of	O
external	O
beam	O
radiotherapy	O
(	O
EBRT	O
)	O
.	O
METHODS	O
AND	O
MATERIALS	O
:	O
The	O
prospective	O
trial	O
included	O
287	O
patients	O
with	O
subfoveal	O
neovascularization	O
due	O
to	O
AMD	O
which	O
was	O
verified	O
by	O
fluorescein	O
angiography	O
.	O
Patients	O
have	O
been	O
treated	O
between	O
January	O
1996	O
and	O
October	O
1997	O
.	O
All	O
patients	O
received	O
a	O
total	O
dose	O
of	O
16	O
Gy	O
in	O
2	O
-	O
Gy	O
daily	O
fractions	O
with	O
5	O
-	O
6	O
MeV	O
photons	O
based	O
on	O
computerized	O
treatment	O
planning	O
in	O
individual	O
head	B-Anatomy
mask	O
fixation	O
.	O
This	O
first	O
analysis	O
is	O
based	O
on	O
73	O
patients	O
(	O
50	O
women	O
,	O
23	O
men	O
,	O
median	O
age	O
74	O
.	O
3	O
years	O
)	O
,	O
with	O
a	O
median	O
follow	O
-	O
up	O
of	O
13	O
.	O
3	O
months	O
and	O
a	O
minimum	O
follow	O
-	O
up	O
of	O
11	O
months	O
.	O
RESULTS	O
:	O
All	O
patients	O
completed	O
therapy	O
and	O
tolerability	O
was	O
good	O
.	O
First	O
clinical	O
control	O
with	O
second	O
angiography	O
was	O
performed	O
6	O
weeks	O
after	O
irradiation	O
,	O
then	O
in	O
3	O
-	O
month	O
intervals	O
.	O
Eighteen	O
patients	O
with	O
SRNV	O
refusing	O
radiotherapy	O
served	O
as	O
a	O
control	O
group	O
and	O
were	O
matched	O
with	O
18	O
irradiated	O
patients	O
.	O
After	O
7	O
months	O
median	O
visual	O
acuity	O
(	O
VA	O
)	O
was	O
20	O
/	O
160	O
for	O
the	O
irradiated	O
and	O
20	O
/	O
400	O
for	O
the	O
untreated	O
patients	O
.	O
One	O
year	O
after	O
radiotherapy	O
final	O
median	O
VA	O
was	O
20	O
/	O
400	O
in	O
both	O
groups	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
16	O
Gy	O
of	O
conventionally	O
fractionated	O
external	O
beam	O
irradiation	O
slows	O
down	O
the	O
visual	O
loss	O
in	O
exudative	O
AMD	O
for	O
only	O
a	O
few	O
months	O
.	O
Patients	O
'	O
reading	O
vision	O
could	O
not	O
be	O
saved	O
for	O
a	O
long	O
-	O
term	O
run	O
.	O
Increased	O
serum	B-Anatomy
levels	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
in	O
patients	O
with	O
renal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
Neovascularization	O
,	O
an	O
essential	O
event	O
for	O
the	O
growth	O
of	O
solid	B-Anatomy
tumors	I-Anatomy
,	O
is	O
regulated	O
by	O
a	O
number	O
of	O
angiogenic	O
factors	O
.	O
One	O
such	O
factor	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
is	O
considered	O
to	O
exert	O
a	O
potent	O
angiogenic	O
activity	O
,	O
as	O
indicated	O
by	O
immunohistochemical	O
and	O
molecular	O
evidence	O
.	O
In	O
this	O
study	O
we	O
investigated	O
the	O
serum	B-Anatomy
VEGF	O
level	O
(	O
s	O
-	O
VEGF	O
)	O
in	O
patients	O
with	O
renal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	O
RCC	B-Anatomy
)	O
.	O
s	O
-	O
VEGF	O
in	O
peripheral	B-Anatomy
blood	I-Anatomy
samples	I-Anatomy
was	O
analyzed	O
in	O
40	O
RCC	B-Anatomy
patients	O
and	O
40	O
patients	O
without	O
cancer	B-Anatomy
(	O
controls	O
)	O
using	O
a	O
sandwich	O
enzyme	O
-	O
linked	O
immunoassay	O
.	O
In	O
20	O
RCC	B-Anatomy
patients	O
,	O
serum	B-Anatomy
samples	I-Anatomy
were	O
obtained	O
separately	O
from	O
the	O
bilateral	B-Anatomy
renal	I-Anatomy
veins	I-Anatomy
.	O
s	O
-	O
VEGF	O
was	O
also	O
measured	O
before	O
,	O
4	O
and	O
8	O
weeks	O
after	O
nephrectomy	O
in	O
11	O
patients	O
.	O
There	O
were	O
significant	O
differences	O
in	O
s	O
-	O
VEGF	O
between	O
the	O
RCC	B-Anatomy
patients	O
and	O
the	O
controls	O
(	O
207	O
.	O
3	O
+	O
/	O
-	O
32	O
.	O
9	O
vs	O
.	O
71	O
.	O
5	O
+	O
/	O
-	O
9	O
.	O
1	O
pg	O
/	O
ml	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
(	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
between	O
the	O
tumor	B-Anatomy
-	O
bearing	O
renal	B-Anatomy
veins	I-Anatomy
and	O
the	O
contralateral	O
ones	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
between	O
the	O
pre	O
-	O
and	O
post	O
-	O
nephrectomy	O
situations	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
among	O
the	O
various	O
parameters	O
of	O
tumor	B-Anatomy
status	O
such	O
as	O
tumor	B-Anatomy
extent	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
existence	O
of	O
metastasis	B-Anatomy
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
s	O
-	O
VEGF	O
significantly	O
correlated	O
with	O
the	O
tumor	B-Anatomy
volume	O
obtained	O
by	O
a	O
three	O
-	O
dimensional	O
measurement	O
(	O
r	O
=	O
0	O
.	O
802	O
,	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O
The	O
sensitivity	O
and	O
specificity	O
of	O
s	O
-	O
VEGF	O
at	O
the	O
cut	O
-	O
off	O
level	O
of	O
100	O
pg	O
/	O
ml	O
,	O
as	O
determined	O
by	O
the	O
receiver	O
-	O
operating	O
-	O
characteristics	O
curve	O
,	O
were	O
80	O
.	O
0	O
%	O
and	O
72	O
.	O
5	O
%	O
,	O
respectively	O
.	O
The	O
results	O
indicate	O
that	O
tumor	B-Anatomy
tissue	I-Anatomy
of	O
RCC	B-Anatomy
liberates	O
VEGF	O
into	O
the	O
systemic	O
blood	B-Anatomy
flow	O
and	O
that	O
s	O
-	O
VEGF	O
is	O
a	O
possible	O
marker	O
for	O
RCC	B-Anatomy
.	O
Insulin	O
-	O
induced	O
vascular	O
endothelial	O
growth	O
factor	O
expression	O
in	O
retina	B-Anatomy
.	O
PURPOSE	O
:	O
Clinical	O
studies	O
have	O
demonstrated	O
that	O
intensive	O
insulin	O
therapy	O
causes	O
a	O
transient	O
worsening	O
of	O
retinopathy	O
.	O
The	O
mechanisms	O
underlying	O
the	O
initial	O
insulin	O
-	O
induced	O
deterioration	O
of	O
retinal	B-Anatomy
status	O
in	O
patients	O
with	O
diabetes	O
remain	O
unknown	O
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
known	O
to	O
be	O
operative	O
in	O
the	O
pathogenesis	O
of	O
diabetic	O
retinopathy	O
.	O
The	O
current	O
study	O
was	O
conducted	O
to	O
characterize	O
the	O
effect	O
of	O
insulin	O
on	O
retinal	B-Anatomy
VEGF	O
gene	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
METHODS	O
:	O
The	O
effect	O
of	O
insulin	O
on	O
VEGF	O
expression	O
in	O
vivo	O
was	O
examined	O
by	O
in	O
situ	O
hybridization	O
studies	O
of	O
rat	O
retinal	B-Anatomy
VEGF	O
transcripts	O
.	O
To	O
examine	O
the	O
mechanisms	O
by	O
which	O
insulin	O
regulates	O
VEGF	O
expression	O
,	O
human	O
retinal	B-Anatomy
pigment	I-Anatomy
epithelial	I-Anatomy
(	I-Anatomy
RPE	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
were	O
exposed	O
to	O
insulin	O
,	O
and	O
VEGF	O
mRNA	O
levels	O
were	O
quantified	O
with	O
RNase	O
protection	O
assays	O
(	O
RPAs	O
)	O
.	O
Conditioned	O
media	O
from	O
insulin	O
-	O
treated	O
RPE	B-Anatomy
cells	I-Anatomy
were	O
assayed	O
for	O
VEGF	O
protein	O
and	O
capillary	B-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
proliferation	O
.	O
The	O
capacity	O
of	O
insulin	O
to	O
stimulate	O
the	O
VEGF	O
promoter	O
linked	O
to	O
a	O
luciferase	O
reporter	O
gene	O
was	O
characterized	O
in	O
transient	O
transfection	O
assays	O
.	O
RESULTS	O
:	O
Insulin	O
increased	O
VEGF	O
mRNA	O
levels	O
in	O
the	O
ganglion	B-Anatomy
,	O
inner	B-Anatomy
nuclear	I-Anatomy
,	O
and	O
RPE	B-Anatomy
cell	I-Anatomy
layers	I-Anatomy
.	O
In	O
vitro	O
,	O
insulin	O
increased	O
VEGF	O
mRNA	O
levels	O
in	O
human	O
RPE	B-Anatomy
cells	I-Anatomy
and	O
enhanced	O
VEGF	O
promoter	O
activity	O
without	O
affecting	O
transcript	O
stability	O
.	O
Insulin	O
treatment	O
also	O
increased	O
VEGF	O
protein	O
levels	O
in	O
conditioned	O
RPE	B-Anatomy
cell	I-Anatomy
media	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
a	O
median	O
effective	O
concentration	O
of	O
5	O
nM	O
.	O
The	O
insulin	O
-	O
conditioned	O
RPE	B-Anatomy
cell	I-Anatomy
media	O
stimulated	O
capillary	B-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
proliferation	O
,	O
an	O
effect	O
that	O
was	O
completely	O
blocked	O
by	O
anti	O
-	O
VEGF	O
neutralizing	O
antibody	O
.	O
CONCLUSIONS	O
:	O
Insulin	O
increases	O
VEGF	O
mRNA	O
and	O
secreted	O
protein	O
levels	O
in	O
RPE	B-Anatomy
cells	I-Anatomy
through	O
enhanced	O
transcription	O
of	O
the	O
VEGF	O
gene	O
.	O
Intensive	O
insulin	O
therapy	O
may	O
cause	O
a	O
transient	O
worsening	O
of	O
retinopathy	O
in	O
patients	O
with	O
diabetes	O
through	O
increased	O
retinal	B-Anatomy
VEGF	O
gene	O
expression	O
.	O
The	O
antiangiogenic	O
agent	O
linomide	O
inhibits	O
the	O
growth	O
rate	O
of	O
von	B-Anatomy
Hippel	I-Anatomy
-	I-Anatomy
Lindau	I-Anatomy
paraganglioma	I-Anatomy
xenografts	I-Anatomy
to	O
mice	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
ascertain	O
the	O
potential	O
usefulness	O
of	O
the	O
antiangiogenic	O
compound	O
linomide	O
for	O
treatment	O
of	O
von	B-Anatomy
Hippel	I-Anatomy
-	I-Anatomy
Lindau	I-Anatomy
(	I-Anatomy
VHL	I-Anatomy
)	I-Anatomy
-	I-Anatomy
related	I-Anatomy
tumors	I-Anatomy
.	O
Paraganglioma	B-Anatomy
tissue	I-Anatomy
fragments	I-Anatomy
obtained	O
at	O
surgery	O
from	O
a	O
VHL	O
type	O
2a	O
patient	O
were	O
transplanted	O
s	O
.	O
c	O
.	O
to	O
male	O
BALB	O
/	O
c	O
nu	O
/	O
nu	O
(	O
nude	O
)	O
mice	O
:	O
(	O
a	O
)	O
2	O
-	O
3	O
-	O
mm	O
fragments	B-Anatomy
for	O
""""	O
prevention	O
""""	O
experiments	O
;	O
and	O
(	O
b	O
)	O
2	O
-	O
3	O
-	O
mm	O
fragments	B-Anatomy
allowed	O
to	O
grow	O
to	O
1	O
cm	O
for	O
""""	O
intervention	O
""""	O
studies	O
.	O
Both	O
groups	O
received	O
either	O
0	O
.	O
5	O
mg	O
/	O
ml	O
linomide	O
in	O
drinking	O
water	O
or	O
acidified	O
water	O
and	O
were	O
followed	O
until	O
tumor	B-Anatomy
diameter	O
reached	O
3	O
cm	O
or	O
for	O
4	O
weeks	O
.	O
In	O
both	O
the	O
prevention	O
and	O
intervention	O
experiments	O
,	O
a	O
significant	O
diminution	O
of	O
tumor	B-Anatomy
size	O
and	O
weight	O
was	O
observed	O
in	O
the	O
drug	O
-	O
treated	O
animals	O
.	O
In	O
vivo	O
nuclear	O
magnetic	O
resonance	O
analysis	O
of	O
tumor	B-Anatomy
blood	B-Anatomy
flow	O
in	O
linomide	O
-	O
treated	O
animals	O
showed	O
localization	O
of	O
blood	B-Anatomy
vessels	I-Anatomy
almost	O
exclusively	O
to	O
the	O
periphery	O
of	O
the	O
poorly	O
vascularized	O
tumors	B-Anatomy
with	O
a	O
significant	O
reduction	O
of	O
both	O
vascular	B-Anatomy
functionality	O
and	O
vasodilation	O
.	O
Histological	O
examination	O
of	O
tumors	B-Anatomy
from	O
linomide	O
-	O
treated	O
animals	O
revealed	O
marked	O
avascularity	O
.	O
Treated	O
animals	O
also	O
displayed	O
a	O
2	O
.	O
4	O
-	O
fold	O
reduction	O
of	O
tumor	B-Anatomy
vascular	O
endothelial	O
growth	O
factor	O
mRNA	O
levels	O
.	O
Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
in	O
VHL	O
disease	O
,	O
therapy	O
directed	O
at	O
inhibition	O
of	O
constitutively	O
expressed	O
VEGF	O
induction	O
of	O
angiogenesis	O
by	O
VHL	B-Anatomy
tumors	I-Anatomy
may	O
constitute	O
an	O
effective	O
medical	O
treatment	O
.	O
Phosphatidyl	O
serine	O
exposure	O
during	O
apoptosis	O
precedes	O
release	O
of	O
cytochrome	O
c	O
and	O
decrease	O
in	O
mitochondrial	B-Anatomy
transmembrane	I-Anatomy
potential	O
.	O
Time	O
kinetics	O
of	O
phosphatidyl	O
serine	O
(	O
PS	O
)	O
exposure	O
were	O
compared	O
to	O
other	O
apoptotic	O
parameters	O
following	O
different	O
apoptotic	O
stimuli	O
.	O
Our	O
data	O
indicate	O
that	O
anti	O
-	O
Fas	O
treatment	O
of	O
L929sAhFas	B-Anatomy
cells	I-Anatomy
results	O
in	O
rapid	O
exposure	O
of	O
PS	O
,	O
which	O
precedes	O
decrease	O
in	O
mitochondrial	B-Anatomy
transmembrane	I-Anatomy
potential	O
(	O
DeltaPsi	O
(	O
m	O
)	O
)	O
and	O
release	O
of	O
cytochrome	O
c	O
,	O
indicating	O
that	O
PS	O
exposure	O
occurs	O
independently	O
of	O
these	O
mitochondrial	B-Anatomy
events	O
.	O
Also	O
during	O
TNF	O
-	O
,	O
etoposide	O
-	O
or	O
staurosporine	O
-	O
mediated	O
apoptosis	O
in	O
PC60	B-Anatomy
RI	I-Anatomy
/	I-Anatomy
RII	I-Anatomy
cells	I-Anatomy
,	O
PS	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
cells	I-Anatomy
were	O
observed	O
before	O
they	O
had	O
a	O
decreased	O
DeltaPsi	O
(	O
m	O
)	O
.	O
However	O
,	O
during	O
growth	O
factor	O
depletion	O
-	O
induced	O
death	O
of	O
32D	B-Anatomy
cells	I-Anatomy
,	O
both	O
phenomena	O
seemed	O
to	O
occur	O
at	O
the	O
same	O
time	O
.	O
LMP1	O
of	O
Epstein	O
-	O
Barr	O
virus	O
induces	O
proliferation	O
of	O
primary	O
mouse	O
embryonic	B-Anatomy
fibroblasts	I-Anatomy
and	O
cooperatively	O
transforms	O
the	O
cells	B-Anatomy
with	O
a	O
p16	O
-	O
insensitive	O
CDK4	O
oncogene	O
.	O
The	O
latent	O
membrane	O
protein	O
LMP1	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
often	O
present	O
in	O
EBV	O
-	O
associated	O
malignancies	B-Anatomy
including	O
nasopharyngeal	B-Anatomy
carcinoma	I-Anatomy
and	O
Hodgkin	B-Anatomy
'	I-Anatomy
s	I-Anatomy
lymphoma	I-Anatomy
.	O
Previous	O
work	O
demonstrates	O
that	O
the	O
LMP1	O
gene	O
of	O
EBV	O
is	O
sufficient	O
to	O
transform	O
certain	O
established	O
rodent	O
fibroblast	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
and	O
to	O
induce	O
the	O
tumorigenicity	O
of	O
some	O
human	O
epithelial	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
In	O
addition	O
,	O
LMP1	O
plays	O
pleiotropic	O
roles	O
in	O
cell	B-Anatomy
growth	O
arrest	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
,	O
depending	O
on	O
the	O
background	O
of	O
the	O
target	O
cells	B-Anatomy
.	O
To	O
examine	O
the	O
roles	O
of	O
LMP1	O
in	O
cell	B-Anatomy
proliferation	O
and	O
growth	O
regulation	O
in	O
primary	O
culture	B-Anatomy
cells	I-Anatomy
,	O
we	O
constructed	O
a	O
recombinant	O
retrovirus	O
containing	O
an	O
LMP1	O
gene	O
.	O
With	O
this	O
retrovirus	O
,	O
LMP1	O
was	O
shown	O
to	O
stimulate	O
the	O
proliferation	O
of	O
primary	O
mouse	O
embryonic	B-Anatomy
fibroblasts	I-Anatomy
(	O
MEF	B-Anatomy
cells	I-Anatomy
)	O
.	O
It	O
has	O
a	O
mitogenic	O
activity	O
for	O
MEF	B-Anatomy
cells	I-Anatomy
,	O
as	O
demonstrated	O
by	O
an	O
immediate	O
induction	O
of	O
cell	B-Anatomy
doubling	O
time	O
.	O
In	O
addition	O
,	O
it	O
significantly	O
extends	O
the	O
passage	O
number	O
of	O
MEF	B-Anatomy
cells	I-Anatomy
to	O
more	O
than	O
30	O
after	O
retroviral	O
infection	O
,	O
compared	O
with	O
less	O
than	O
5	O
for	O
uninfected	O
MEF	B-Anatomy
cells	I-Anatomy
.	O
Furthermore	O
,	O
LMP1	O
cooperates	O
with	O
a	O
p16	O
-	O
insensitive	O
CDK4	O
(	O
R24C	O
)	O
oncogene	O
in	O
transforming	O
MEF	B-Anatomy
cells	I-Anatomy
.	O
Our	O
results	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
abilities	O
of	O
the	O
LMP1	O
gene	O
,	O
acting	O
alone	O
,	O
to	O
effectively	O
induce	O
the	O
proliferation	O
of	O
primary	O
MEF	B-Anatomy
cells	I-Anatomy
and	O
of	O
its	O
cooperativity	O
with	O
another	O
cellular	B-Anatomy
oncogene	O
in	O
transforming	O
primary	O
cells	B-Anatomy
.	O
Obstructive	O
nephropathy	O
:	O
lessons	O
from	O
cystic	B-Anatomy
kidney	B-Anatomy
disease	O
.	O
Obstructive	O
nephropathy	O
is	O
one	O
of	O
the	O
most	O
important	O
causes	O
of	O
renal	B-Anatomy
failure	O
in	O
infants	O
and	O
children	O
,	O
while	O
polycystic	B-Anatomy
kidney	B-Anatomy
disease	O
(	O
PKD	O
)	O
is	O
a	O
major	O
cause	O
of	O
renal	B-Anatomy
failure	O
in	O
the	O
adult	O
population	O
.	O
This	O
review	O
summarizes	O
the	O
evidence	O
that	O
there	O
may	O
be	O
a	O
number	O
of	O
mechanisms	O
common	O
to	O
the	O
pathophysiology	O
of	O
both	O
conditions	O
.	O
In	O
animal	O
models	O
of	O
obstructive	O
nephropathy	O
and	O
PKD	O
,	O
the	O
renal	B-Anatomy
tubular	I-Anatomy
expression	O
of	O
epidermal	O
growth	O
factor	O
is	O
suppressed	O
,	O
and	O
expression	O
of	O
clusterin	O
is	O
increased	O
,	O
both	O
of	O
which	O
suggest	O
arrested	O
maturation	O
or	O
dedifferentiation	O
of	O
the	O
tubular	B-Anatomy
cell	I-Anatomy
.	O
There	O
is	O
a	O
marked	O
increase	O
in	O
apoptosis	O
of	O
epithelial	B-Anatomy
cells	I-Anatomy
in	O
dilated	O
tubules	B-Anatomy
,	O
associated	O
with	O
an	O
increase	O
in	O
apoptotic	O
stimuli	O
.	O
The	O
renin	O
-	O
angiotensin	O
system	O
is	O
activated	O
in	O
both	O
obstructive	O
nephropathy	O
and	O
PKD	O
,	O
which	O
may	O
contribute	O
to	O
tubular	B-Anatomy
atrophy	O
and	O
interstitial	B-Anatomy
fibrosis	O
,	O
which	O
characterize	O
the	O
progression	O
of	O
both	O
conditions	O
.	O
Focal	O
cystic	B-Anatomy
dilatation	O
of	O
the	O
tubule	B-Anatomy
is	O
found	O
in	O
obstructive	O
nephropathy	O
,	O
while	O
tubular	B-Anatomy
obstruction	O
is	O
present	O
in	O
cystic	B-Anatomy
kidney	B-Anatomy
disease	O
.	O
It	O
is	O
therefore	O
likely	O
that	O
elucidation	O
of	O
the	O
effects	O
of	O
mechanical	O
stretch	O
on	O
renal	B-Anatomy
tubular	I-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
will	O
contribute	O
to	O
our	O
understanding	O
of	O
both	O
conditions	O
.	O
Autotaxin	O
(	O
ATX	O
)	O
,	O
a	O
potent	O
tumor	B-Anatomy
motogen	O
,	O
augments	O
invasive	O
and	O
metastatic	O
potential	O
of	O
ras	O
-	O
transformed	O
cells	B-Anatomy
.	O
Autotaxin	O
(	O
ATX	O
)	O
,	O
an	O
exo	O
-	O
nucleotide	O
pyrophosphatase	O
and	O
phosphodiesterase	O
,	O
was	O
originally	O
isolated	O
as	O
a	O
potent	O
stimulator	O
of	O
tumor	B-Anatomy
cell	I-Anatomy
motility	O
.	O
In	O
order	O
to	O
study	O
whether	O
ATX	O
expression	O
affects	O
motility	O
-	O
dependent	O
processes	O
such	O
as	O
invasion	O
and	O
metastasis	O
,	O
we	O
stably	O
transfected	O
full	O
-	O
length	O
ATX	O
cDNA	O
into	O
two	O
non	O
-	O
expressing	O
cell	B-Anatomy
lines	I-Anatomy
,	O
parental	O
and	O
ras	O
-	O
transformed	O
NIH3T3	B-Anatomy
(	I-Anatomy
clone7	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
.	O
The	O
effect	O
of	O
ATX	O
secretion	O
on	O
in	O
vitro	O
cell	B-Anatomy
motility	O
was	O
variable	O
.	O
The	O
ras	O
-	O
transformed	O
,	O
ATX	O
-	O
secreting	O
subclones	B-Anatomy
had	O
enhanced	O
motility	O
to	O
ATX	O
as	O
chemoattractant	O
,	O
but	O
there	O
was	O
little	O
difference	O
in	O
the	O
motility	O
responses	O
of	O
NIH3T3	B-Anatomy
cells	I-Anatomy
transfected	O
with	O
atx	O
,	O
an	O
inactive	O
mutant	O
gene	O
,	O
or	O
empty	O
vector	O
.	O
In	O
MatrigelTM	O
invasion	O
assays	O
,	O
all	O
subclones	B-Anatomy
,	O
which	O
secreted	O
enzymatically	O
active	O
ATX	O
,	O
demonstrated	O
greater	O
spontaneous	O
and	O
ATX	O
-	O
stimulated	O
invasion	O
than	O
appropriate	O
controls	O
.	O
This	O
difference	O
in	O
invasiveness	O
was	O
not	O
caused	O
by	O
differences	O
in	O
gelatinase	O
production	O
,	O
which	O
was	O
constant	O
within	O
each	O
group	O
of	O
transfectants	B-Anatomy
.	O
In	O
vivo	O
studies	O
with	O
athymic	O
nude	O
mice	O
demonstrated	O
that	O
injection	O
of	O
atx	O
-	O
transfected	O
NIH3T3	B-Anatomy
cells	I-Anatomy
resulted	O
in	O
a	O
weak	O
tumorigenic	O
capacity	O
with	O
few	O
experimental	O
metastases	B-Anatomy
.	O
Combination	O
of	O
ATX	O
expression	O
with	O
ras	O
transformation	O
produced	O
cells	B-Anatomy
with	O
greatly	O
amplified	O
tumorigenesis	O
and	O
metastatic	O
potential	O
compared	O
to	O
ras	O
-	O
transformed	O
controls	B-Anatomy
.	O
Thus	O
,	O
ATX	O
appears	O
to	O
augment	O
cellular	B-Anatomy
characteristics	O
necessary	O
for	O
tumor	B-Anatomy
aggressiveness	O
.	O
Oncogenic	O
epidermal	O
growth	O
factor	O
receptor	O
mutants	O
with	O
tandem	O
duplication	O
:	O
gene	O
structure	O
and	O
effects	O
on	O
receptor	O
function	O
.	O
A	O
number	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
deletion	O
mutants	O
have	O
been	O
identified	O
in	O
gliomas	B-Anatomy
,	O
in	O
which	O
the	O
EGFR	O
gene	O
is	O
frequently	O
amplified	O
and	O
rearranged	O
.	O
We	O
have	O
previously	O
characterized	O
the	O
structure	O
of	O
a	O
gene	O
in	O
A	B-Anatomy
-	I-Anatomy
172	I-Anatomy
human	I-Anatomy
glioma	I-Anatomy
cells	I-Anatomy
that	O
encodes	O
a	O
190	O
-	O
kDa	O
EGFR	O
mutant	O
with	O
tandem	O
duplication	O
of	O
the	O
tyrosine	O
kinase	O
(	O
TK	O
)	O
and	O
calcium	O
-	O
mediated	O
internalization	O
(	O
CAIN	O
)	O
domains	O
.	O
Here	O
we	O
describe	O
a	O
185	O
-	O
kDa	O
tandem	O
duplication	O
mutant	O
(	O
TDM	O
)	O
that	O
is	O
expressed	O
in	O
KE	B-Anatomy
and	O
A	B-Anatomy
-	I-Anatomy
1235	I-Anatomy
glioma	I-Anatomy
cells	I-Anatomy
,	O
along	O
with	O
certain	O
functional	O
characteristics	O
of	O
the	O
mutants	O
.	O
The	O
corresponding	O
transcripts	O
in	O
KE	B-Anatomy
and	O
A	B-Anatomy
-	I-Anatomy
1235	I-Anatomy
cells	I-Anatomy
contain	O
1053	O
additional	O
nucleotides	O
representing	O
an	O
in	O
-	O
frame	O
duplication	O
of	O
exons	O
18	O
through	O
25	O
which	O
encode	O
the	O
entire	O
TK	O
region	O
and	O
a	O
portion	O
of	O
the	O
CAIN	O
domain	O
.	O
As	O
with	O
duplication	O
of	O
the	O
entire	O
TK	O
/	O
CAIN	O
region	O
(	O
exons	O
18	O
-	O
26	O
)	O
in	O
A	B-Anatomy
-	I-Anatomy
172	I-Anatomy
cells	I-Anatomy
,	O
duplication	O
of	O
exons	O
18	O
-	O
25	O
is	O
associated	O
with	O
a	O
specific	O
genomic	O
rearrangement	O
between	O
flanking	O
introns	O
.	O
Involved	O
introns	O
contain	O
homology	O
to	O
recombination	O
signal	O
sequence	O
(	O
RSS	O
)	O
heptamers	O
present	O
in	O
the	O
V	O
(	O
D	O
)	O
J	O
region	O
of	O
the	O
T	B-Anatomy
lymphocyte	I-Anatomy
receptor	O
gene	O
.	O
In	O
defined	O
medium	O
,	O
both	O
oncogenic	O
TDM	O
are	O
constitutively	O
autophosphorylated	O
and	O
inefficiently	O
downregulated	O
.	O
High	O
-	O
affinity	O
binding	O
is	O
reduced	O
in	O
EGFR	O
.	O
TDM	O
/	O
18	O
-	O
26	O
,	O
although	O
the	O
t1	O
/	O
2	O
of	O
receptor	O
internalization	O
is	O
not	O
prolonged	O
.	O
Ciprofloxacin	O
mediated	O
cell	B-Anatomy
growth	O
inhibition	O
,	O
S	O
/	O
G2	O
-	O
M	O
cell	B-Anatomy
cycle	O
arrest	O
,	O
and	O
apoptosis	O
in	O
a	O
human	O
transitional	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
of	O
the	O
bladder	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
.	O
The	O
second	O
most	O
prevalent	O
urological	B-Anatomy
malignancy	I-Anatomy
in	O
middle	O
aged	O
and	O
elderly	O
men	O
is	O
bladder	B-Anatomy
cancer	I-Anatomy
,	O
with	O
90	O
%	O
of	O
the	O
cases	O
being	O
transitional	B-Anatomy
cell	I-Anatomy
carcinomas	I-Anatomy
.	O
The	O
success	O
of	O
current	O
systemic	O
and	O
intravesical	O
therapeutic	O
agents	O
,	O
such	O
as	O
cisplatin	O
,	O
thiotepa	O
,	O
Adriamycin	O
,	O
mitomycin	O
C	O
,	O
and	O
bacillus	O
Calmette	O
-	O
Guerin	O
,	O
is	O
limited	O
with	O
recurrence	O
rates	O
reduced	O
to	O
17	O
-	O
44	O
%	O
.	O
In	O
addition	O
,	O
most	O
of	O
these	O
agents	O
require	O
instrumentation	O
of	O
the	O
urinary	B-Anatomy
tract	I-Anatomy
and	O
are	O
delivered	O
at	O
a	O
significant	O
cost	O
and	O
potential	O
morbidity	O
to	O
the	O
patient	O
.	O
Fluroquinolone	O
antibiotics	O
such	O
as	O
ciprofloxacin	O
,	O
which	O
can	O
be	O
administered	O
p	O
.	O
o	O
.	O
,	O
may	O
have	O
a	O
profound	O
effect	O
in	O
bladder	B-Anatomy
cancer	I-Anatomy
management	O
.	O
This	O
is	O
primarily	O
based	O
on	O
limited	O
in	O
vitro	O
studies	O
on	O
tumor	B-Anatomy
cells	I-Anatomy
derived	O
from	O
transitional	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
of	O
the	O
bladder	B-Anatomy
that	O
revealed	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
inhibition	O
of	O
cell	B-Anatomy
growth	O
by	O
ciprofloxacin	O
at	O
concentrations	O
that	O
are	O
easily	O
attainable	O
in	O
the	O
urine	B-Anatomy
of	O
patients	O
.	O
However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
ciprofloxacin	O
elicits	O
its	O
biological	O
effects	O
on	O
bladder	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
is	O
not	O
well	O
documented	O
.	O
Our	O
experimental	O
data	O
confirm	O
previous	O
studies	O
showing	O
the	O
in	O
vitro	O
cell	B-Anatomy
growth	O
inhibition	O
of	O
the	O
transitional	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
of	O
the	O
bladder	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
HTB9	I-Anatomy
and	O
further	O
showed	O
the	O
induction	O
of	O
cell	B-Anatomy
cycle	O
arrest	O
at	O
the	O
S	O
/	O
G2	O
-	O
M	O
checkpoints	O
.	O
In	O
addition	O
,	O
we	O
found	O
down	O
-	O
regulation	O
of	O
cyclin	O
B	O
,	O
cyclin	O
E	O
,	O
and	O
dephosphorylation	O
of	O
cdk2	O
in	O
ciprofloxacin	O
-	O
treated	O
bladder	B-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
.	O
There	O
was	O
also	O
an	O
up	O
-	O
regulation	O
of	O
Bax	O
,	O
which	O
altered	O
the	O
Bax	O
:	O
Bcl	O
-	O
2	O
ratio	O
,	O
which	O
may	O
be	O
responsible	O
for	O
mitochondrial	B-Anatomy
depolarization	O
reported	O
to	O
be	O
involved	O
prior	O
to	O
the	O
induction	O
of	O
apoptosis	O
.	O
The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21WAF1	O
level	O
was	O
found	O
to	O
be	O
decreased	O
within	O
12	O
h	O
of	O
ciprofloxacin	O
treatment	O
and	O
disappeared	O
completely	O
when	O
HTB9	B-Anatomy
cells	I-Anatomy
were	O
treated	O
with	O
200	O
microg	O
/	O
ml	O
ciprofloxacin	O
for	O
24	O
h	O
.	O
The	O
down	O
-	O
regulation	O
of	O
p21WAF1	O
closely	O
correlated	O
with	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
cleavage	O
and	O
CPP32	O
activation	O
.	O
Recent	O
studies	O
revealed	O
that	O
p21WAF1	O
protects	O
cells	B-Anatomy
from	O
apoptosis	O
by	O
arresting	O
them	O
in	O
G1	O
and	O
further	O
binds	O
to	O
pro	O
-	O
caspase	O
-	O
3	O
,	O
preventing	O
its	O
activation	O
and	O
thus	O
,	O
inhibiting	O
the	O
apoptotic	O
cascade	O
.	O
Hence	O
,	O
the	O
down	O
-	O
regulation	O
of	O
p21WAF1	O
,	O
together	O
with	O
the	O
alterations	O
in	O
Bax	O
and	O
cdk2	O
as	O
observed	O
in	O
our	O
studies	O
,	O
may	O
define	O
a	O
novel	O
mechanism	O
by	O
which	O
ciprofloxacin	O
inhibits	O
tumor	B-Anatomy
cell	I-Anatomy
growth	O
and	O
induces	O
apoptotic	O
cell	B-Anatomy
death	O
.	O
The	O
results	O
of	O
our	O
current	O
studies	O
provide	O
strong	O
experimental	O
evidence	O
for	O
the	O
use	O
of	O
ciprofloxacin	O
as	O
a	O
potential	O
preventive	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
the	O
management	O
of	O
transitional	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
of	O
the	O
bladder	B-Anatomy
.	O
Genuine	O
monovalent	O
ligands	O
of	O
TrkA	O
nerve	O
growth	O
factor	O
receptors	O
reveal	O
a	O
novel	O
pharmacological	O
mechanism	O
of	O
action	O
.	O
Developing	O
small	O
molecule	O
agonistic	O
ligands	O
for	O
tyrosine	O
kinase	O
receptors	O
has	O
been	O
difficult	O
,	O
and	O
it	O
is	O
generally	O
thought	O
that	O
such	O
ligands	O
require	O
bivalency	O
.	O
Moreover	O
,	O
multisubunit	O
receptors	O
are	O
difficult	O
to	O
target	O
,	O
because	O
each	O
subunit	O
contributes	O
to	O
ligand	O
affinity	O
,	O
and	O
each	O
subunit	O
may	O
have	O
distinct	O
and	O
sometimes	O
opposing	O
functions	O
.	O
Here	O
,	O
the	O
nerve	O
growth	O
factor	O
receptor	O
subunits	O
p75	O
and	O
the	O
tyrosine	O
kinase	O
TrkA	O
were	O
studied	O
using	O
artificial	O
ligands	O
that	O
bind	O
specifically	O
to	O
their	O
extracellular	B-Anatomy
domain	O
.	O
Bivalent	O
TrkA	O
ligands	O
afford	O
robust	O
signals	O
.	O
However	O
,	O
genuine	O
monomeric	O
and	O
monovalent	O
TrkA	O
ligands	O
afford	O
partial	O
agonism	O
,	O
activate	O
the	O
tyrosine	O
kinase	O
activity	O
,	O
cause	O
receptor	O
internalization	O
,	O
and	O
induce	O
survival	O
and	O
differentiation	O
in	O
cell	B-Anatomy
lines	I-Anatomy
and	O
primary	B-Anatomy
neurons	I-Anatomy
.	O
Monomeric	O
and	O
monovalent	O
TrkA	O
ligands	O
can	O
synergize	O
with	O
ligands	O
that	O
bind	O
the	O
p75	O
subunit	O
.	O
However	O
,	O
the	O
p75	O
ligands	O
used	O
in	O
this	O
study	O
must	O
be	O
bivalent	O
,	O
and	O
monovalent	O
p75	O
ligands	O
have	O
no	O
effect	O
.	O
These	O
findings	O
will	O
be	O
useful	O
in	O
designing	O
and	O
developing	O
screens	O
of	O
small	O
molecules	O
selective	O
for	O
tyrosine	O
kinase	O
receptors	O
and	O
indicate	O
that	O
strategies	O
for	O
designing	O
agonists	O
of	O
multisubunit	O
receptors	O
require	O
consideration	O
of	O
the	O
role	O
of	O
each	O
subunit	O
.	O
Last	O
,	O
the	O
strategy	O
of	O
using	O
anti	O
-	O
receptor	O
mAbs	O
and	O
small	O
molecule	O
hormone	O
mimics	O
as	O
receptor	O
ligands	O
could	O
be	O
applied	O
to	O
the	O
study	O
of	O
many	O
other	O
heteromeric	O
cell	B-Anatomy
surface	I-Anatomy
receptors	O
.	O
Vascular	B-Anatomy
proliferation	O
and	O
enhanced	O
expression	O
of	O
endothelial	O
nitric	O
oxide	O
synthase	O
in	O
human	O
peritoneum	B-Anatomy
exposed	O
to	O
long	O
-	O
term	O
peritoneal	B-Anatomy
dialysis	O
.	O
Long	O
-	O
term	O
peritoneal	B-Anatomy
dialysis	O
(	O
PD	O
)	O
is	O
associated	O
with	O
alterations	O
in	O
peritoneal	B-Anatomy
permeability	O
and	O
loss	O
of	O
ultrafiltration	O
.	O
These	O
changes	O
originate	O
from	O
increased	O
peritoneal	B-Anatomy
surface	I-Anatomy
area	I-Anatomy
,	O
but	O
the	O
morphologic	O
and	O
molecular	O
mechanisms	O
involved	O
remain	O
unknown	O
.	O
The	O
hypothesis	O
that	O
modifications	O
of	O
activity	O
and	O
/	O
or	O
expression	O
of	O
nitric	O
oxide	O
synthase	O
(	O
NOS	O
)	O
isozymes	O
might	O
play	O
a	O
role	O
in	O
these	O
modifications	O
,	O
via	O
enhanced	O
local	O
production	O
of	O
nitric	O
oxide	O
,	O
was	O
tested	O
in	O
this	O
study	O
.	O
NOS	O
activities	O
were	O
measured	O
by	O
the	O
L	O
-	O
citrulline	O
assay	O
in	O
peritoneal	B-Anatomy
biopsies	I-Anatomy
from	O
seven	O
control	O
subjects	O
,	O
eight	O
uremic	O
patients	O
immediately	O
before	O
the	O
onset	O
of	O
PD	O
,	O
and	O
13	O
uremic	O
patients	O
on	O
short	O
-	O
term	O
(	O
less	O
than	O
18	O
mo	O
,	O
n	O
=	O
6	O
)	O
or	O
long	O
-	O
term	O
(	O
greater	O
than	O
18	O
mo	O
,	O
n	O
=	O
7	O
)	O
PD	O
.	O
Peritoneal	B-Anatomy
NOS	O
activity	O
is	O
increased	O
fivefold	O
in	O
long	O
-	O
term	O
PD	O
patients	O
compared	O
with	O
control	O
subjects	O
.	O
In	O
uremic	O
patients	O
,	O
NOS	O
activity	O
is	O
positively	O
correlated	O
with	O
the	O
duration	O
of	O
PD	O
.	O
Increased	O
NOS	O
activity	O
is	O
mediated	O
solely	O
by	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
NOS	O
and	O
,	O
as	O
shown	O
by	O
immunoblotting	O
,	O
an	O
upregulation	O
of	O
endothelial	O
NOS	O
.	O
The	O
biologic	O
relevance	O
of	O
increased	O
NOS	O
in	O
long	O
-	O
term	O
PD	O
was	O
demonstrated	O
by	O
enhanced	O
nitrotyrosine	O
immunoreactivity	O
and	O
a	O
significant	O
increase	O
in	O
vascular	B-Anatomy
density	O
and	O
endothelial	B-Anatomy
area	I-Anatomy
in	O
the	O
peritoneum	B-Anatomy
.	O
Immunoblotting	O
and	O
immunostaining	O
studies	O
demonstrated	O
an	O
upregulation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
mostly	O
along	O
the	O
endothelium	B-Anatomy
lining	O
peritoneal	B-Anatomy
blood	I-Anatomy
vessels	I-Anatomy
in	O
long	O
-	O
term	O
PD	O
patients	O
.	O
In	O
the	O
latter	O
,	O
VEGF	O
colocalized	O
with	O
the	O
advanced	O
glycation	O
end	O
product	O
pentosidine	O
deposits	O
.	O
These	O
data	O
provide	O
a	O
morphologic	O
(	O
angiogenesis	O
and	O
increased	O
endothelial	B-Anatomy
area	I-Anatomy
)	O
and	O
molecular	O
(	O
enhanced	O
NOS	O
activity	O
and	O
endothelial	O
NOS	O
upregulation	O
)	O
basis	O
for	O
explaining	O
the	O
permeability	O
changes	O
observed	O
in	O
long	O
-	O
term	O
PD	O
.	O
They	O
also	O
support	O
the	O
implication	O
of	O
local	O
advanced	O
glycation	O
end	O
product	O
deposits	O
and	O
liberation	O
of	O
VEGF	O
in	O
that	O
process	O
.	O
Active	O
hair	B-Anatomy
growth	O
(	O
anagen	O
)	O
is	O
associated	O
with	O
angiogenesis	O
.	O
After	O
the	O
completion	O
of	O
skin	B-Anatomy
development	O
,	O
angiogenesis	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
growth	O
of	O
new	O
capillaries	B-Anatomy
from	O
pre	O
-	O
existing	O
blood	B-Anatomy
vessels	I-Anatomy
,	O
is	O
held	O
to	O
occur	O
in	O
the	O
skin	B-Anatomy
only	O
under	O
pathologic	O
conditions	O
.	O
It	O
has	O
long	O
been	O
noted	O
,	O
however	O
,	O
that	O
hair	B-Anatomy
follicle	I-Anatomy
cycling	O
is	O
associated	O
with	O
prominent	O
changes	O
in	O
skin	B-Anatomy
perfusion	O
,	O
that	O
the	O
epithelial	B-Anatomy
hair	I-Anatomy
bulbs	I-Anatomy
of	O
anagen	B-Anatomy
follicles	I-Anatomy
display	O
angiogenic	O
properties	O
,	O
and	O
that	O
the	O
follicular	B-Anatomy
dermal	I-Anatomy
papilla	I-Anatomy
can	O
produce	O
angiogenic	O
factors	O
.	O
Despite	O
these	O
suggestive	O
observations	O
,	O
no	O
formal	O
proof	O
is	O
as	O
yet	O
available	O
for	O
the	O
concept	O
that	O
angiogenesis	O
is	O
a	O
physiologic	O
event	O
that	O
occurs	O
all	O
over	O
the	O
mature	O
mammalian	O
integument	O
whenever	O
hair	B-Anatomy
follicles	I-Anatomy
switch	O
from	O
resting	O
(	O
telogen	O
)	O
to	O
active	O
growth	O
(	O
anagen	O
)	O
.	O
This	O
study	O
uses	O
quantitative	O
histomorphometry	O
and	O
double	O
-	O
immunohistologic	O
detection	O
techniques	O
for	O
the	O
demarcation	O
of	O
proliferating	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
to	O
show	O
that	O
synchronized	O
hair	B-Anatomy
follicle	I-Anatomy
cycling	O
in	O
adolescent	O
C57BL	O
/	O
6	O
mice	O
is	O
associated	O
with	O
substantial	O
angiogenesis	O
,	O
and	O
that	O
inhibiting	O
angiogenesis	O
in	O
vivo	O
by	O
the	O
intraperitoneal	B-Anatomy
application	O
of	O
a	O
fumagillin	O
derivative	O
retards	O
experimentally	O
induced	O
anagen	B-Anatomy
development	O
in	O
these	O
mice	O
.	O
Thus	O
,	O
angiogenesis	O
is	O
a	O
physiologic	O
event	O
in	O
normal	O
postnatal	O
murine	O
skin	B-Anatomy
,	O
apparently	O
is	O
dictated	O
by	O
the	O
hair	B-Anatomy
follicle	I-Anatomy
,	O
and	O
appears	O
to	O
be	O
required	O
for	O
normal	O
anagen	B-Anatomy
development	O
.	O
Anagen	O
-	O
associated	O
angiogenesis	O
offers	O
an	O
attractive	O
model	O
for	O
identifying	O
the	O
physiologic	O
controls	O
of	O
cutaneous	B-Anatomy
angiogenesis	O
,	O
and	O
an	O
interesting	O
system	O
for	O
screening	O
the	O
effects	O
of	O
potential	O
antiangiogenic	O
drugs	O
in	O
vivo	O
.	O
Neuroblastoma	B-Anatomy
and	O
hepatocyte	B-Anatomy
coculture	O
conditioned	O
media	O
alter	O
apoptosis	O
.	O
BACKGROUND	O
:	O
Neuroblastoma	B-Anatomy
is	O
a	O
childhood	O
tumor	B-Anatomy
that	O
often	O
displays	O
unusual	O
biological	O
behavior	O
.	O
The	O
tumor	B-Anatomy
may	O
present	O
with	O
widespread	O
metastases	B-Anatomy
that	O
are	O
unresponsive	O
to	O
aggressive	O
treatment	O
.	O
At	O
other	O
times	O
,	O
both	O
the	O
metastases	B-Anatomy
and	O
the	O
primary	B-Anatomy
tumor	I-Anatomy
may	O
spontaneously	O
regress	O
without	O
treatment	O
.	O
Apoptosis	O
,	O
or	O
programmed	O
cell	B-Anatomy
death	O
,	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
the	O
dichotomous	O
behavior	O
of	O
neuroblastoma	B-Anatomy
.	O
We	O
hypothesize	O
that	O
neuroblastoma	B-Anatomy
cells	I-Anatomy
will	O
interact	O
with	O
host	O
tissues	B-Anatomy
to	O
release	O
mediators	O
that	O
affect	O
apoptosis	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
neuroblastoma	B-Anatomy
cells	I-Anatomy
and	O
human	O
Chang	B-Anatomy
hepatocytes	I-Anatomy
are	O
grown	O
in	O
a	O
noncontact	O
,	O
coculture	O
system	O
.	O
After	O
incubation	O
for	O
4	O
days	O
,	O
the	O
medium	O
from	O
the	O
coculture	O
system	O
is	O
collected	O
.	O
Neuroblastoma	B-Anatomy
cells	I-Anatomy
and	O
Chang	B-Anatomy
hepatocytes	I-Anatomy
are	O
then	O
plated	O
separately	O
with	O
the	O
conditioned	O
medium	O
and	O
their	O
own	O
standard	O
growth	O
medium	O
as	O
controls	O
.	O
After	O
4	O
days	O
,	O
these	O
cells	B-Anatomy
are	O
harvested	O
and	O
cytospins	O
made	O
for	O
immunostaining	O
.	O
Tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
,	O
Fas	O
ligand	O
,	O
and	O
Bcl	O
-	O
2	O
,	O
are	O
measured	O
with	O
immunohistochemistry	O
.	O
Apoptosis	O
is	O
detected	O
with	O
the	O
TUNEL	O
method	O
.	O
Immunostaining	O
data	O
are	O
interpreted	O
with	O
computer	O
image	O
analysis	O
and	O
reported	O
as	O
stain	O
index	O
.	O
TUNEL	O
data	O
are	O
reported	O
as	O
percentage	O
apoptotic	O
cells	B-Anatomy
.	O
All	O
data	O
are	O
reported	O
as	O
means	O
+	O
/	O
-	O
SEM	O
.	O
Statistical	O
analysis	O
is	O
performed	O
and	O
P	O
<	O
0	O
.	O
05	O
considered	O
significant	O
.	O
RESULTS	O
:	O
Chang	B-Anatomy
hepatocytes	I-Anatomy
grown	O
in	O
the	O
coculture	O
conditioned	O
media	O
have	O
an	O
increase	O
in	O
TNF	O
-	O
alpha	O
and	O
Fas	O
ligand	O
.	O
The	O
neuroblastoma	B-Anatomy
cells	I-Anatomy
have	O
a	O
significant	O
decrease	O
in	O
Fas	O
ligand	O
.	O
There	O
is	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
apoptotic	O
hepatocytes	B-Anatomy
when	O
they	O
are	O
cultured	O
in	O
the	O
conditioned	O
media	O
.	O
In	O
contrast	O
,	O
the	O
neuroblastoma	B-Anatomy
cells	I-Anatomy
grown	O
in	O
the	O
coculture	O
conditioned	O
media	O
show	O
no	O
increase	O
in	O
apoptosis	O
.	O
Finally	O
,	O
Bcl	O
-	O
2	O
is	O
significantly	O
increased	O
in	O
the	O
neuroblastoma	B-Anatomy
cells	I-Anatomy
cultured	O
in	O
the	O
conditioned	O
media	O
.	O
CONCLUSIONS	O
:	O
Neuroblastoma	B-Anatomy
cells	I-Anatomy
grown	O
in	O
coculture	O
conditioned	O
media	O
show	O
increased	O
expression	O
of	O
Bcl	O
-	O
2	O
and	O
decreased	O
Fas	O
ligand	O
levels	O
.	O
These	O
changes	O
should	O
diminish	O
apoptosis	O
activity	O
in	O
the	O
tumor	B-Anatomy
cells	I-Anatomy
.	O
In	O
contrast	O
,	O
the	O
conditioned	O
media	O
induce	O
elevated	O
levels	O
of	O
proapoptotic	O
mediators	O
in	O
the	O
Chang	B-Anatomy
hepatocytes	I-Anatomy
.	O
A	O
tumor	B-Anatomy
'	O
s	O
ability	O
to	O
successfully	O
metastasize	O
may	O
be	O
dependent	O
on	O
mediators	O
generated	O
in	O
the	O
tumor	B-Anatomy
-	O
host	O
interaction	O
,	O
and	O
may	O
not	O
be	O
just	O
an	O
independent	O
characteristic	O
of	O
the	O
tumor	B-Anatomy
itself	O
.	O
Neoplastic	B-Anatomy
transformation	O
by	O
Notch	O
requires	O
nuclear	B-Anatomy
localization	O
.	O
Notch	O
proteins	O
are	O
plasma	B-Anatomy
membrane	I-Anatomy
-	O
spanning	O
receptors	O
that	O
mediate	O
important	O
cell	B-Anatomy
fate	O
decisions	O
such	O
as	O
differentiation	O
,	O
proliferation	O
,	O
and	O
apoptosis	O
.	O
The	O
mechanism	O
of	O
Notch	O
signaling	O
remains	O
poorly	O
understood	O
.	O
However	O
,	O
it	O
is	O
clear	O
that	O
the	O
Notch	O
signaling	O
pathway	O
mediates	O
its	O
effects	O
through	O
intercellular	B-Anatomy
contact	O
between	O
neighboring	O
cells	B-Anatomy
.	O
The	O
prevailing	O
model	O
for	O
Notch	O
signaling	O
suggests	O
that	O
ligand	O
,	O
presented	O
on	O
a	O
neighboring	O
cell	B-Anatomy
,	O
triggers	O
proteolytic	O
processing	O
of	O
Notch	O
.	O
Following	O
proteolysis	O
,	O
it	O
is	O
thought	O
that	O
the	O
intracellular	B-Anatomy
portion	O
of	O
Notch	O
(	O
N	O
(	O
ic	O
)	O
)	O
translocates	O
to	O
the	O
nucleus	B-Anatomy
,	O
where	O
it	O
is	O
involved	O
in	O
regulating	O
gene	O
expression	O
.	O
There	O
is	O
considerable	O
debate	O
concerning	O
where	O
in	O
the	O
cell	B-Anatomy
Notch	O
functions	O
and	O
what	O
proteins	O
serve	O
as	O
effectors	O
of	O
the	O
Notch	O
signal	O
.	O
Several	O
Notch	O
genes	O
have	O
clearly	O
been	O
shown	O
to	O
be	O
proto	O
-	O
oncogenes	O
in	O
mammalian	B-Anatomy
cells	I-Anatomy
.	O
Activation	O
of	O
Notch	O
proto	O
-	O
oncogenes	O
has	O
been	O
associated	O
with	O
tumorigenesis	O
in	O
several	O
human	O
and	O
other	O
mammalian	B-Anatomy
cancers	I-Anatomy
.	O
Transforming	O
alleles	O
of	O
Notch	O
direct	O
the	O
expression	O
of	O
truncated	O
proteins	O
that	O
primarily	O
consist	O
of	O
N	O
(	O
ic	O
)	O
and	O
are	O
not	O
tethered	O
to	O
the	O
plasma	B-Anatomy
membrane	I-Anatomy
.	O
However	O
,	O
the	O
mechanism	O
by	O
which	O
Notch	O
oncoproteins	O
(	O
generically	O
termed	O
here	O
as	O
N	O
(	O
ic	O
)	O
)	O
induce	O
neoplastic	B-Anatomy
transformation	O
is	O
not	O
known	O
.	O
Previously	O
we	O
demonstrated	O
that	O
N1	O
(	O
ic	O
)	O
and	O
N2	O
(	O
ic	O
)	O
could	O
transform	O
E1A	O
immortalized	O
baby	O
rat	O
kidney	B-Anatomy
cells	I-Anatomy
(	O
RKE	B-Anatomy
)	O
in	O
vitro	O
.	O
We	O
now	O
report	O
direct	O
evidence	O
that	O
N1	O
(	O
ic	O
)	O
must	O
accumulate	O
in	O
the	O
nucleus	B-Anatomy
to	O
induce	O
transformation	O
of	O
RKE	B-Anatomy
cells	I-Anatomy
.	O
In	O
addition	O
,	O
we	O
define	O
the	O
minimal	O
domain	O
of	O
N1	O
(	O
ic	O
)	O
required	O
to	O
induce	O
transformation	O
and	O
present	O
evidence	O
that	O
transformation	O
of	O
RKE	B-Anatomy
cells	I-Anatomy
by	O
N1	O
(	O
ic	O
)	O
is	O
likely	O
to	O
be	O
through	O
a	O
CBF1	O
-	O
independent	O
pathway	O
.	O
Alpha	O
-	O
melanocyte	O
-	O
stimulating	O
hormone	O
modulates	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
and	O
secretion	O
of	O
interleukin	O
-	O
8	O
in	O
human	O
dermal	B-Anatomy
fibroblasts	I-Anatomy
.	O
Alpha	O
-	O
melanocyte	O
-	O
stimulating	O
hormone	O
(	O
alpha	O
-	O
MSH	O
)	O
has	O
evolved	O
as	O
a	O
mediator	O
of	O
diverse	O
biological	O
activities	O
in	O
an	O
ever	O
-	O
growing	O
number	O
of	O
non	B-Anatomy
-	I-Anatomy
melanocytic	I-Anatomy
cell	I-Anatomy
types	O
.	O
One	O
mechanism	O
by	O
which	O
alpha	O
-	O
MSH	O
exerts	O
its	O
effects	O
is	O
modulation	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
.	O
These	O
two	O
transcription	O
factors	O
also	O
play	O
an	O
important	O
role	O
in	O
fibroblasts	B-Anatomy
,	O
in	O
extracellular	B-Anatomy
matrix	I-Anatomy
composition	O
,	O
and	O
in	O
cytokine	O
expression	O
.	O
By	O
use	O
of	O
electric	O
mobility	O
shift	O
assays	O
,	O
we	O
demonstrate	O
that	O
alpha	O
-	O
MSH	O
(	O
10	O
(	O
-	O
6	O
)	O
to	O
10	O
(	O
-	O
14	O
)	O
M	O
)	O
activates	O
AP	O
-	O
1	O
in	O
human	O
dermal	B-Anatomy
fibroblasts	I-Anatomy
,	O
whereas	O
coincubation	O
with	O
interleukin	O
-	O
1	O
beta	O
(	O
IL	O
-	O
1	O
beta	O
)	O
results	O
in	O
suppression	O
of	O
its	O
activation	O
.	O
alpha	O
-	O
MSH	O
also	O
induces	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
but	O
does	O
not	O
modulate	O
DNA	O
binding	O
on	O
costimulation	O
with	O
IL	O
-	O
1	O
beta	O
.	O
Since	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
are	O
key	O
elements	O
in	O
controlling	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
transcription	O
,	O
human	O
fibroblasts	B-Anatomy
were	O
treated	O
with	O
alpha	O
-	O
MSH	O
and	O
IL	O
-	O
1	O
beta	O
for	O
24	O
hours	O
,	O
and	O
cytokine	O
levels	O
in	O
the	O
supernatants	B-Anatomy
were	O
measured	O
by	O
ELISA	O
.	O
alpha	O
-	O
MSH	O
alone	O
had	O
little	O
effect	O
,	O
whereas	O
coincubation	O
with	O
IL	O
-	O
1	O
beta	O
led	O
to	O
marked	O
downregulation	O
of	O
IL	O
-	O
8	O
secretion	O
(	O
at	O
most	O
288	O
+	O
/	O
-	O
152	O
ng	O
/	O
mL	O
)	O
when	O
compared	O
to	O
treatment	O
with	O
IL	O
-	O
1	O
beta	O
alone	O
(	O
919	O
+	O
/	O
-	O
157	O
ng	O
/	O
mL	O
)	O
.	O
Our	O
results	O
indicate	O
that	O
alpha	O
-	O
MSH	O
exerts	O
modulatory	O
effects	O
on	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
,	O
and	O
that	O
it	O
can	O
regulate	O
chemokine	O
secretion	O
in	O
human	O
dermal	B-Anatomy
fibroblasts	I-Anatomy
.	O
These	O
effects	O
of	O
alpha	O
-	O
MSH	O
may	O
have	O
important	O
regulatory	O
functions	O
in	O
extracellular	B-Anatomy
matrix	I-Anatomy
composition	O
,	O
wound	B-Anatomy
healing	O
,	O
or	O
angiogenesis	O
.	O
Application	O
of	O
microsatellite	O
PCR	O
techniques	O
in	O
the	O
identification	O
of	O
mixed	O
up	O
tissue	B-Anatomy
specimens	I-Anatomy
in	O
surgical	O
pathology	O
.	O
A	O
fragment	B-Anatomy
of	O
tumour	B-Anatomy
was	O
erroneously	O
mixed	O
up	O
with	O
an	O
endometrial	B-Anatomy
biopsy	I-Anatomy
.	O
Micro	O
-	O
satellite	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
clearly	O
demonstrated	O
the	O
extraneous	O
nature	O
of	O
the	O
fragment	B-Anatomy
.	O
Micro	O
-	O
satellite	O
PCR	O
may	O
be	O
useful	O
for	O
the	O
identification	O
of	O
mis	O
-	O
labelled	O
or	O
mismatched	O
tissue	B-Anatomy
fragments	I-Anatomy
in	O
surgical	O
pathology	O
specimens	B-Anatomy
.	O
CD40	O
expression	O
on	O
human	O
lung	B-Anatomy
cancer	I-Anatomy
correlates	O
with	O
metastatic	O
spread	O
.	O
PURPOSE	O
:	O
The	O
poor	O
prognosis	O
associated	O
with	O
lung	B-Anatomy
cancer	I-Anatomy
is	O
related	O
to	O
the	O
high	O
incidence	O
of	O
regional	O
and	O
distant	O
metastasis	O
.	O
There	O
is	O
a	O
crucial	O
need	O
to	O
identify	O
parameters	O
that	O
can	O
predict	O
a	O
tendancy	O
to	O
metastatic	O
spread	O
to	O
allow	O
better	O
prognostic	O
evaluation	O
and	O
therapeutic	O
approach	O
.	O
METHODS	O
:	O
Using	O
flow	O
cytometry	O
we	O
evaluated	O
18	O
human	O
lung	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
for	O
the	O
expression	O
of	O
different	O
surface	B-Anatomy
markers	O
on	O
lung	B-Anatomy
cancers	I-Anatomy
suggested	O
to	O
be	O
possible	O
prognostic	O
parameters	O
,	O
including	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
,	O
intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
,	O
Fas	O
and	O
CD40	O
.	O
RESULTS	O
:	O
No	O
correlation	O
was	O
found	O
between	O
tumor	B-Anatomy
prognosis	O
and	O
EGFR	O
,	O
ICAM	O
-	O
1	O
or	O
Fas	O
.	O
However	O
,	O
a	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
the	O
surface	B-Anatomy
expression	O
of	O
CD40	O
and	O
the	O
metastatic	O
spread	O
of	O
the	O
tumor	B-Anatomy
.	O
In	O
this	O
study	O
,	O
14	O
of	O
18	O
lung	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
(	O
78	O
%	O
)	O
expressed	O
CD40	O
on	O
their	O
surface	B-Anatomy
.	O
All	O
of	O
the	O
4	O
tumors	B-Anatomy
that	O
were	O
CD40	O
-	O
negative	O
,	O
were	O
stage	O
I	O
tumors	B-Anatomy
,	O
without	O
any	O
evidence	O
of	O
regional	O
or	O
distant	O
metastasis	O
.	O
Of	O
the	O
14	O
tumors	B-Anatomy
that	O
expressed	O
CD40	O
,	O
all	O
but	O
1	O
(	O
93	O
%	O
)	O
had	O
either	O
nodal	B-Anatomy
or	O
systemic	O
metastasis	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O
Patients	O
whose	O
tumors	B-Anatomy
were	O
CD40	O
-	O
negative	O
showed	O
a	O
significantly	O
better	O
N	O
stage	O
,	O
overall	O
stage	O
at	O
presentation	O
and	O
survival	O
than	O
those	O
patients	O
with	O
CD40	O
-	O
positive	O
patients	O
.	O
No	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
were	O
observed	O
in	O
tumor	B-Anatomy
size	O
,	O
gender	O
,	O
age	O
,	O
histology	O
,	O
differentiation	O
or	O
preoperative	O
therapy	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
CD40	O
expression	O
on	O
lung	B-Anatomy
cancer	I-Anatomy
may	O
play	O
a	O
role	O
in	O
metastatic	O
spread	O
,	O
and	O
also	O
may	O
serve	O
as	O
a	O
prognostic	O
marker	O
and	O
an	O
indicator	O
of	O
advanced	O
disease	O
.	O
Specific	O
subgroup	O
B	O
adenovirus	O
diagnosis	O
by	O
PCR	O
of	O
the	O
fibre	O
gene	O
.	O
OBJECTIVE	O
:	O
A	O
highly	O
sensitive	O
and	O
specific	O
PCR	O
assay	O
targeting	O
regions	O
of	O
the	O
fibre	O
gene	O
was	O
developed	O
for	O
the	O
identification	O
of	O
subgroup	O
B	O
adenovirus	O
strains	O
.	O
This	O
is	O
critical	O
,	O
since	O
these	O
adenovirus	O
strains	O
are	O
frequently	O
associated	O
with	O
severe	O
respiratory	B-Anatomy
infections	O
in	O
infants	O
and	O
new	O
-	O
borns	O
.	O
METHODS	O
:	O
Clinical	O
samples	B-Anatomy
from	O
nasopharyngeal	B-Anatomy
aspirates	I-Anatomy
were	O
analysed	O
by	O
PCR	O
using	O
several	O
sets	O
of	O
primers	O
corresponding	O
to	O
sequences	O
of	O
the	O
gene	O
coding	O
for	O
the	O
fibre	O
protein	O
.	O
RESULTS	O
:	O
The	O
assay	O
allowed	O
the	O
detection	O
and	O
identification	O
of	O
all	O
the	O
genotypes	O
of	O
adenovirus	O
subgroup	O
B	O
,	O
based	O
on	O
the	O
size	O
of	O
the	O
amplified	O
product	O
when	O
analysed	O
on	O
polyacrilamide	O
gel	O
electrophoresis	O
.	O
Specifically	O
,	O
one	O
set	O
of	O
primers	O
was	O
able	O
to	O
amplify	O
DNA	O
of	O
subgroup	O
B	O
but	O
not	O
subgroup	O
C	O
and	O
E	O
viruses	O
.	O
CONCLUSION	O
:	O
The	O
detection	O
of	O
adenovirus	O
and	O
the	O
genotyping	O
can	O
be	O
done	O
on	O
a	O
routine	O
basis	O
by	O
a	O
PCR	O
assay	O
using	O
the	O
fibre	O
gene	O
as	O
a	O
target	O
.	O
The	O
assay	O
allows	O
the	O
identification	O
of	O
ADV	O
subgroup	O
B	O
,	O
including	O
genotype	O
7h	O
,	O
which	O
is	O
the	O
single	O
most	O
important	O
viral	O
pathogen	O
associated	O
with	O
respiratory	B-Anatomy
diseases	O
in	O
infants	O
and	O
young	O
children	O
in	O
the	O
southern	O
part	O
of	O
South	O
America	O
.	O
The	O
value	O
of	O
serum	B-Anatomy
S	O
-	O
100beta	O
and	O
interleukins	O
as	O
tumour	B-Anatomy
markers	O
in	O
advanced	O
melanoma	B-Anatomy
.	O
Recently	O
serum	B-Anatomy
S	O
-	O
100beta	O
has	O
shown	O
promise	O
as	O
a	O
tumour	B-Anatomy
marker	O
in	O
melanoma	B-Anatomy
;	O
however	O
,	O
its	O
use	O
as	O
a	O
prognostic	O
marker	O
in	O
the	O
advanced	O
stage	O
needs	O
to	O
be	O
confirmed	O
.	O
Interleukins	O
(	O
ILs	O
)	O
may	O
mediate	O
regression	O
or	O
progression	O
of	O
cancer	B-Anatomy
.	O
In	O
order	O
to	O
study	O
their	O
relation	O
to	O
the	O
metastatic	O
profile	O
and	O
survival	O
,	O
we	O
evaluated	O
the	O
association	O
between	O
pretreatment	O
serum	B-Anatomy
levels	O
of	O
S	O
-	O
100beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
10	O
and	O
IL	O
-	O
12	O
and	O
metastatic	B-Anatomy
site	I-Anatomy
and	O
survival	O
in	O
50	O
patients	O
with	O
advanced	O
melanoma	B-Anatomy
who	O
were	O
to	O
receive	O
chemoimmunotherapy	O
.	O
Patients	O
with	O
liver	B-Anatomy
and	O
/	O
or	O
bone	B-Anatomy
metastases	I-Anatomy
had	O
significantly	O
higher	O
median	O
concentrations	O
of	O
S	O
-	O
100beta	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
10	O
than	O
those	O
with	O
only	O
skin	B-Anatomy
,	O
nodal	B-Anatomy
and	O
/	O
or	O
lung	B-Anatomy
involvement	O
.	O
The	O
differences	O
in	O
IL	O
-	O
12	O
levels	O
were	O
unremarkable	O
.	O
Using	O
univariate	O
analysis	O
,	O
the	O
S	O
-	O
100beta	O
level	O
and	O
metastatic	O
profile	O
were	O
found	O
to	O
be	O
statistically	O
significant	O
prognostic	O
factors	O
for	O
survival	O
.	O
Using	O
multivariate	O
analysis	O
the	O
S	O
-	O
100beta	O
level	O
was	O
the	O
most	O
powerful	O
prognostic	O
indicator	O
,	O
while	O
the	O
metastatic	O
profile	O
was	O
found	O
to	O
be	O
significant	O
after	O
exclusion	O
of	O
S	O
-	O
100beta	O
.	O
The	O
findings	O
suggest	O
that	O
elevated	O
serum	B-Anatomy
levels	O
of	O
S	O
-	O
100beta	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
10	O
reflect	O
concurrent	O
liver	B-Anatomy
or	O
bone	B-Anatomy
metastases	I-Anatomy
in	O
melanoma	B-Anatomy
.	O
S	O
-	O
100beta	O
is	O
also	O
an	O
independent	O
prognostic	O
marker	O
.	O
Pretreatment	O
IL	O
levels	O
were	O
not	O
associated	O
with	O
outcome	O
.	O
TEL	O
,	O
a	O
putative	O
tumor	B-Anatomy
suppressor	O
,	O
modulates	O
cell	B-Anatomy
growth	O
and	O
cell	B-Anatomy
morphology	O
of	O
ras	O
-	O
transformed	O
cells	B-Anatomy
while	O
repressing	O
the	O
transcription	O
of	O
stromelysin	O
-	O
1	O
.	O
TEL	O
is	O
a	O
member	O
of	O
the	O
ETS	O
family	O
of	O
transcription	O
factors	O
that	O
interacts	O
with	O
the	O
mSin3	O
and	O
SMRT	O
corepressors	O
to	O
regulate	O
transcription	O
.	O
TEL	O
is	O
biallelically	O
disrupted	O
in	O
acute	B-Anatomy
leukemia	I-Anatomy
,	O
and	O
loss	O
of	O
heterozygosity	O
at	O
the	O
TEL	O
locus	O
has	O
been	O
observed	O
in	O
various	O
cancers	B-Anatomy
.	O
Here	O
we	O
show	O
that	O
expression	O
of	O
TEL	O
in	O
Ras	O
-	O
transformed	O
NIH	B-Anatomy
3T3	I-Anatomy
cells	I-Anatomy
inhibits	O
cell	B-Anatomy
growth	O
in	O
soft	O
agar	O
and	O
in	O
normal	O
cultures	B-Anatomy
.	O
Unexpectedly	O
,	O
cells	B-Anatomy
expressing	O
both	O
Ras	O
and	O
TEL	O
grew	O
as	O
aggregates	O
.	O
To	O
begin	O
to	O
explain	O
the	O
morphology	O
of	O
Ras	O
-	O
plus	O
TEL	O
-	O
expressing	O
cells	B-Anatomy
,	O
we	O
demonstrated	O
that	O
the	O
endogenous	O
matrix	O
metalloproteinase	O
stromelysin	O
-	O
1	O
was	O
repressed	O
by	O
TEL	O
.	O
TEL	O
bound	O
sequences	O
in	O
the	O
stromelysin	O
-	O
1	O
promoter	O
and	O
repressed	O
the	O
promoter	O
in	O
transient	O
-	O
expression	O
assays	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
target	O
for	O
TEL	O
-	O
mediated	O
regulation	O
.	O
Mutants	O
of	O
TEL	O
that	O
removed	O
a	O
binding	O
site	O
for	O
the	O
mSin3A	O
corepressor	O
but	O
retained	O
the	O
ETS	O
domain	O
failed	O
to	O
repress	O
stromelysin	O
-	O
1	O
.	O
When	O
BB	O
-	O
94	O
,	O
a	O
matrix	O
metalloproteinase	O
inhibitor	O
,	O
was	O
added	O
to	O
the	O
culture	O
medium	O
of	O
Ras	O
-	O
expressing	O
cells	B-Anatomy
,	O
it	O
caused	O
a	O
cell	B-Anatomy
aggregation	O
phenotype	O
similar	O
to	O
that	O
caused	O
by	O
TEL	O
expression	O
.	O
In	O
addition	O
,	O
TEL	O
inhibited	O
the	O
invasiveness	O
of	O
Ras	O
-	O
transformed	O
cells	B-Anatomy
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Our	O
results	O
suggest	O
that	O
TEL	O
acts	O
as	O
a	O
tumor	B-Anatomy
suppressor	O
,	O
in	O
part	O
,	O
by	O
transcriptional	O
repression	O
of	O
stromelysin	O
-	O
1	O
.	O
Caspase	O
-	O
3	O
is	O
essential	O
for	O
procaspase	O
-	O
9	O
processing	O
and	O
cisplatin	O
-	O
induced	O
apoptosis	O
of	O
MCF	B-Anatomy
-	I-Anatomy
7	I-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
In	O
this	O
study	O
,	O
we	O
sought	O
to	O
investigate	O
in	O
more	O
detail	O
the	O
role	O
of	O
caspase	O
-	O
3	O
in	O
apoptotic	O
processes	O
in	O
cultured	O
cells	B-Anatomy
and	O
in	O
cell	B-Anatomy
-	O
free	O
extracts	B-Anatomy
of	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
We	O
present	O
evidence	O
that	O
apoptosis	O
of	O
caspase	B-Anatomy
-	I-Anatomy
3	I-Anatomy
-	I-Anatomy
deficient	I-Anatomy
MCF	I-Anatomy
-	I-Anatomy
7	I-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
is	O
defective	O
in	O
response	O
to	O
cisplatin	O
treatment	O
,	O
as	O
determined	O
by	O
chromatin	B-Anatomy
condensation	O
,	O
nuclear	B-Anatomy
fragmentation	O
,	O
DNA	O
fragmentation	O
,	O
and	O
release	O
of	O
cytochrome	O
c	O
from	O
the	O
mitochondria	B-Anatomy
.	O
Reconstitution	O
of	O
MCF	B-Anatomy
-	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
by	O
stable	O
transfection	O
of	O
CASP	O
-	O
3	O
cDNA	O
restores	O
all	O
these	O
defects	O
and	O
results	O
in	O
an	O
extensive	O
apoptosis	O
after	O
cisplatin	O
treatment	O
.	O
We	O
further	O
show	O
that	O
in	O
extracts	B-Anatomy
from	O
caspase	B-Anatomy
-	I-Anatomy
3	I-Anatomy
-	I-Anatomy
deficient	I-Anatomy
MCF	I-Anatomy
-	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
,	O
procaspase	O
-	O
9	O
processing	O
is	O
strongly	O
impaired	O
after	O
stimulation	O
with	O
either	O
cytochrome	O
c	O
or	O
recombinant	O
caspase	O
-	O
8	O
.	O
Reconstitution	O
of	O
MCF	B-Anatomy
-	I-Anatomy
7	I-Anatomy
cell	I-Anatomy
extracts	I-Anatomy
with	O
procaspase	O
-	O
3	O
corrects	O
this	O
defect	O
,	O
resulting	O
in	O
an	O
efficient	O
and	O
complete	O
processing	O
of	O
procaspase	O
-	O
9	O
.	O
Together	O
,	O
our	O
data	O
define	O
caspase	O
-	O
3	O
as	O
an	O
important	O
integrator	O
of	O
the	O
apoptotic	O
process	O
in	O
MCF	B-Anatomy
-	I-Anatomy
7	I-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
and	O
reveal	O
an	O
essential	O
function	O
of	O
caspase	O
-	O
3	O
for	O
procaspase	O
-	O
9	O
processing	O
.	O
Vasodilator	O
-	O
stimulated	O
phosphoprotein	O
is	O
involved	O
in	O
stress	B-Anatomy
-	I-Anatomy
fiber	I-Anatomy
and	O
membrane	B-Anatomy
ruffle	I-Anatomy
formation	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
Vasodilator	O
-	O
stimulated	O
phosphoprotein	O
(	O
VASP	O
)	O
is	O
highly	O
expressed	O
in	O
vascular	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
,	O
where	O
it	O
has	O
been	O
implicated	O
in	O
cellular	B-Anatomy
reorganization	O
during	O
angiogenesis	O
,	O
as	O
well	O
as	O
in	O
endothelial	B-Anatomy
retraction	O
and	O
changes	O
in	O
vessel	B-Anatomy
permeability	O
.	O
However	O
,	O
the	O
cellular	B-Anatomy
functions	O
of	O
VASP	O
are	O
not	O
known	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
expressed	O
wild	O
-	O
type	O
and	O
mutant	O
forms	O
of	O
VASP	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
to	O
determine	O
in	O
what	O
aspects	O
of	O
cytoskeletal	B-Anatomy
behavior	O
this	O
protein	O
participates	O
.	O
Expression	O
of	O
wild	O
-	O
type	O
VASP	O
induces	O
marked	O
membrane	B-Anatomy
ruffling	O
and	O
formation	O
of	O
prominent	O
stress	B-Anatomy
fibers	I-Anatomy
in	O
bovine	O
aortic	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
Deletion	O
of	O
the	O
proline	O
-	O
rich	O
domain	O
of	O
VASP	O
abolishes	O
its	O
ability	O
to	O
bind	O
profilin	O
but	O
does	O
not	O
affect	O
ruffling	O
or	O
stress	B-Anatomy
fiber	I-Anatomy
formation	O
.	O
Further	O
deletions	O
reveal	O
a	O
sequence	O
within	O
the	O
carboxy	O
-	O
terminal	O
domain	O
that	O
is	O
responsible	O
for	O
in	O
vivo	O
bundle	B-Anatomy
formation	O
.	O
Ruffling	O
occurs	O
only	O
on	O
the	O
expression	O
of	O
forms	O
of	O
VASP	O
that	O
possess	O
bundling	O
activity	O
and	O
the	O
capacity	O
to	O
bind	O
zyxin	O
/	O
vinculin	O
-	O
derived	O
peptide	O
.	O
The	O
ability	O
of	O
distinct	O
subdomains	O
within	O
VASP	O
to	O
bind	O
adhesion	O
proteins	O
and	O
induce	O
F	O
-	O
actin	O
bundling	O
in	O
vivo	O
suggests	O
that	O
this	O
protein	O
could	O
function	O
in	O
the	O
aggregation	O
and	O
tethering	O
of	O
actin	B-Anatomy
filaments	I-Anatomy
during	O
the	O
formation	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
-	I-Anatomy
substrate	I-Anatomy
and	O
cell	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
contacts	I-Anatomy
.	O
These	O
data	O
provide	O
a	O
mechanism	O
whereby	O
VASP	O
can	O
influence	O
endothelial	B-Anatomy
migration	O
and	O
organization	O
during	O
capillary	B-Anatomy
formation	O
and	O
modulate	O
vascular	B-Anatomy
permeability	O
via	O
effects	O
on	O
endothelial	B-Anatomy
cell	I-Anatomy
contractility	O
.	O
Urokinase	O
receptor	O
:	O
a	O
molecular	O
organizer	O
in	O
cellular	B-Anatomy
communication	O
.	O
In	O
a	O
variety	O
of	O
cell	B-Anatomy
types	O
,	O
the	O
glycolipid	O
-	O
anchored	O
urokinase	O
receptor	O
(	O
uPAR	O
)	O
is	O
colocalized	O
pericellularly	B-Anatomy
with	O
components	O
of	O
the	O
plasminogen	O
activation	O
system	O
and	O
endocytosis	O
receptors	O
.	O
uPAR	O
is	O
also	O
coexpressed	O
with	O
caveolin	O
and	O
members	O
of	O
the	O
integrin	O
adhesion	O
receptor	O
superfamily	O
.	O
The	O
formation	O
of	O
functional	O
units	O
with	O
these	O
various	O
proteins	O
allows	O
the	O
uPAR	O
to	O
mediate	O
the	O
focused	O
proteolysis	O
required	O
for	O
cell	B-Anatomy
migration	O
and	O
invasion	O
and	O
to	O
contribute	O
both	O
directly	O
and	O
indirectly	O
to	O
cell	B-Anatomy
adhesive	O
processes	O
in	O
a	O
non	O
-	O
proteolytic	O
fashion	O
.	O
This	O
dual	O
activity	O
,	O
together	O
with	O
the	O
initiation	O
of	O
signal	O
transduction	O
pathways	O
by	O
uPAR	O
,	O
is	O
believed	O
to	O
influence	O
cellular	B-Anatomy
behaviour	O
in	O
angiogenesis	O
,	O
inflammation	O
,	O
wound	B-Anatomy
repair	O
and	O
tumor	B-Anatomy
progression	O
/	O
metastasis	O
and	O
open	O
up	O
the	O
way	O
for	O
uPAR	O
-	O
based	O
therapeutic	O
approaches	O
.	O
p75	O
mediated	O
apoptosis	O
in	O
neuroblastoma	B-Anatomy
cells	I-Anatomy
is	O
inhibited	O
by	O
expression	O
of	O
TrkA	O
.	O
BACKGROUND	O
:	O
Neurotrophins	O
mediate	O
their	O
effects	O
by	O
binding	O
to	O
members	O
of	O
the	O
Trk	O
family	O
of	O
receptor	O
tyrosine	O
kinases	O
and	O
to	O
the	O
low	O
-	O
affinity	O
nerve	O
growth	O
factor	O
receptor	O
p75	O
.	O
Nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
has	O
been	O
demonstrated	O
to	O
support	O
survival	O
and	O
differentiation	O
of	O
neuroblastoma	B-Anatomy
(	I-Anatomy
NB	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
by	O
activation	O
of	O
the	O
TrkA	O
receptor	O
.	O
The	O
p75	O
receptor	O
belongs	O
to	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
family	O
of	O
death	O
receptors	O
and	O
has	O
been	O
suggested	O
as	O
a	O
receptor	O
that	O
mediates	O
apoptosis	O
in	O
neuronal	B-Anatomy
and	O
NB	B-Anatomy
cells	I-Anatomy
.	O
PROCEDURE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
p75	O
expression	O
in	O
NB	B-Anatomy
,	O
we	O
transfected	O
the	O
p75	O
cDNA	O
into	O
SH	B-Anatomy
-	I-Anatomy
SY5Y	I-Anatomy
cells	I-Anatomy
,	O
an	O
NB	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
lacking	O
expression	O
of	O
both	O
p75	O
and	O
TrkA	O
.	O
RESULTS	O
:	O
Cell	B-Anatomy
clones	I-Anatomy
expressing	O
elevated	O
levels	O
of	O
p75	O
showed	O
a	O
high	O
degree	O
of	O
apoptosis	O
even	O
in	O
10	O
%	O
serum	B-Anatomy
-	O
supplemented	O
medium	O
.	O
Apoptotic	O
signaling	O
by	O
p75	O
was	O
ligand	O
-	O
independent	O
and	O
only	O
partly	O
caspase	O
-	O
dependent	O
.	O
The	O
level	O
of	O
apoptosis	O
correlated	O
directly	O
with	O
the	O
expression	O
level	O
of	O
the	O
receptor	O
,	O
indicating	O
that	O
p75	O
may	O
activate	O
the	O
cell	B-Anatomy
death	O
program	O
directly	O
.	O
However	O
,	O
additional	O
transfection	O
of	O
TrkA	O
into	O
SY5Y	B-Anatomy
-	I-Anatomy
p75	I-Anatomy
cells	I-Anatomy
resulted	O
in	O
a	O
significantly	O
reduced	O
rate	O
of	O
apoptosis	O
even	O
in	O
the	O
absence	O
of	O
NGF	O
.	O
CONCLUSIONS	O
:	O
Thus	O
,	O
expression	O
of	O
the	O
TrkA	O
receptor	O
itself	O
inhibits	O
p75	O
mediated	O
apoptosis	O
in	O
NB	B-Anatomy
cells	I-Anatomy
.	O
RNA	O
damage	O
and	O
inhibition	O
of	O
neoplastic	B-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
growth	O
:	O
effects	O
of	O
human	O
and	O
amphibian	O
ribonucleases	O
.	O
Angiogenesis	O
defines	O
the	O
many	O
steps	O
involved	O
in	O
the	O
growth	O
and	O
migration	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
-	O
derived	O
blood	B-Anatomy
vessels	I-Anatomy
.	O
This	O
process	O
is	O
necessary	O
for	O
the	O
growth	O
and	O
metastasis	O
of	O
tumors	B-Anatomy
,	O
and	O
considerable	O
effort	O
is	O
being	O
expended	O
to	O
find	O
inhibitors	O
of	O
tumor	B-Anatomy
angiogenesis	O
.	O
This	O
usually	O
involves	O
screening	O
of	O
potential	O
anti	O
-	O
angiogenic	O
compounds	O
on	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
To	O
this	O
end	O
,	O
two	O
candidate	O
anti	O
-	O
angiogenic	O
RNA	O
-	O
damaging	O
agents	O
,	O
onconase	O
and	O
(	O
-	O
4	O
)	O
rhEDN	O
,	O
were	O
screened	O
for	O
their	O
effects	O
on	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
using	O
three	O
distinct	O
types	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
in	O
culture	O
:	O
HPV	O
-	O
16	O
E6	O
/	O
E7	O
-	O
immortalized	O
human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
(	O
HUVECs	B-Anatomy
)	O
,	O
a	O
Kras	O
-	O
transformed	O
HPV	O
-	O
16	O
E6	O
/	O
E7	O
HUVEC	B-Anatomy
(	O
Rhim	O
et	O
al	O
.	O
,	O
Carcinogenesis	O
4	O
,	O
673	O
-	O
681	O
,	O
1998	O
)	O
,	O
and	O
primary	O
HUVECs	B-Anatomy
.	O
Onconase	O
similarly	O
inhibited	O
proliferation	O
in	O
all	O
three	O
cell	B-Anatomy
lines	I-Anatomy
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
3	O
-	O
1	O
.	O
0	O
microM	O
)	O
while	O
(	O
-	O
4	O
)	O
rhEDN	O
was	O
more	O
effective	O
on	O
immortalized	O
HUVEC	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
02	O
-	O
0	O
.	O
06	O
microM	O
)	O
than	O
on	O
primary	O
HUVECs	B-Anatomy
(	O
IC	O
(	O
50	O
)	O
>	O
0	O
.	O
1	O
microM	O
)	O
.	O
Differential	O
sensitivity	O
to	O
these	O
agents	O
implies	O
that	O
more	O
than	O
one	O
endothelial	B-Anatomy
cell	I-Anatomy
type	I-Anatomy
must	O
be	O
used	O
in	O
proliferation	O
assays	O
to	O
screen	O
for	O
novel	O
anti	O
-	O
angiogenic	O
compounds	O
.	O
TRADD	O
domain	O
of	O
Epstein	O
-	O
Barr	O
virus	O
transforming	O
protein	O
LMP1	O
is	O
essential	O
for	O
inducing	O
immortalization	O
and	O
suppressing	O
senescence	O
of	O
primary	O
rodent	O
fibroblasts	B-Anatomy
.	O
Mutation	O
analysis	O
of	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
in	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-	O
induced	O
B	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
immortalization	O
revealed	O
two	O
transformation	O
effector	O
sites	O
,	O
TES1	O
and	O
TES2	O
.	O
TES2	O
mediates	O
the	O
interaction	O
with	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
death	O
domain	O
protein	O
(	O
TRADD	O
)	O
and	O
plays	O
a	O
key	O
role	O
in	O
transactivating	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
.	O
Recombinant	O
EBV	O
containing	O
LMP1	O
with	O
TES2	O
deleted	O
induces	O
a	O
limited	O
proliferation	O
of	O
B	B-Anatomy
cells	I-Anatomy
.	O
The	O
present	O
study	O
shows	O
that	O
a	O
mutant	O
with	O
an	O
LMP1	O
site	O
-	O
specific	O
mutation	O
at	O
TES2	O
,	O
LMP1	O
(	O
TRADD	O
)	O
,	O
initially	O
stimulates	O
cell	B-Anatomy
growth	O
and	O
significantly	O
extends	O
the	O
life	O
span	O
of	O
MEF	B-Anatomy
.	O
However	O
,	O
it	O
is	O
not	O
sufficient	O
for	O
the	O
immortalization	O
of	O
MEF	B-Anatomy
,	O
and	O
MEF	B-Anatomy
-	I-Anatomy
LMP1	I-Anatomy
(	I-Anatomy
TRADD	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
eventually	O
enter	O
growth	O
arrest	O
.	O
Further	O
analysis	O
reveals	O
that	O
although	O
LMP1	O
(	O
TRADD	O
)	O
promotes	O
cell	B-Anatomy
growth	O
,	O
it	O
does	O
not	O
prevent	O
the	O
eventual	O
onset	O
of	O
senescence	O
and	O
the	O
expression	O
of	O
tumor	B-Anatomy
suppressor	O
p16	O
(	O
Ink4a	O
)	O
.	O
IL	O
-	O
12	O
inhibition	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
functions	O
and	O
angiogenesis	O
depends	O
on	O
lymphocyte	B-Anatomy
-	O
endothelial	B-Anatomy
cell	I-Anatomy
cross	O
-	O
talk	O
.	O
In	O
vivo	O
IL	O
-	O
12	O
-	O
dependent	O
tumor	B-Anatomy
inhibition	O
rests	O
on	O
the	O
ability	O
of	O
IL	O
-	O
12	O
to	O
activate	O
a	O
CD8	O
-	O
mediated	O
cytotoxicity	O
,	O
inhibit	O
angiogenesis	O
,	O
and	O
cause	O
vascular	B-Anatomy
injury	O
.	O
Although	O
in	O
vivo	O
studies	O
have	O
shown	O
that	O
such	O
inhibition	O
stems	O
from	O
complex	O
interactions	O
of	O
immune	B-Anatomy
cells	I-Anatomy
and	O
the	O
production	O
of	O
IFN	O
-	O
gamma	O
and	O
other	O
downstream	O
angiostatic	O
chemokines	O
,	O
the	O
mechanisms	O
involved	O
are	O
still	O
poorly	O
defined	O
.	O
Here	O
we	O
show	O
that	O
IL	O
-	O
12	O
activates	O
an	O
anti	O
-	O
angiogenic	O
program	O
in	O
Con	O
A	O
-	O
activated	O
mouse	O
spleen	B-Anatomy
cells	I-Anatomy
(	O
activated	O
spc	B-Anatomy
)	O
or	O
human	O
PBMC	B-Anatomy
(	O
activated	O
PBMC	B-Anatomy
)	O
.	O
The	O
soluble	O
factors	O
they	O
release	O
in	O
its	O
presence	O
arrest	O
the	O
cycle	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
(	O
EC	B-Anatomy
)	O
,	O
inhibit	O
in	O
vitro	O
angiogenesis	O
,	O
negatively	O
modulate	O
the	O
production	O
of	O
matrix	O
metalloproteinase	O
-	O
9	O
,	O
and	O
the	O
ability	O
of	O
EC	B-Anatomy
to	O
adhere	O
to	O
vitronectin	O
and	O
up	O
-	O
regulate	O
ICAM	O
-	O
1	O
and	O
VCAM	O
-	O
1	O
expression	O
.	O
These	O
effects	O
do	O
not	O
require	O
direct	O
cell	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
contact	I-Anatomy
,	O
yet	O
result	O
from	O
continuous	O
interaction	O
between	O
activated	O
lymphoid	B-Anatomy
cells	I-Anatomy
and	O
EC	B-Anatomy
.	O
We	O
used	O
neutralizing	O
Abs	O
to	O
show	O
that	O
the	O
IFN	O
-	O
inducible	O
protein	O
-	O
10	O
and	O
monokine	O
-	O
induced	O
by	O
IFN	O
-	O
gamma	O
chemokines	O
are	O
pivotal	O
in	O
inducing	O
these	O
effects	O
.	O
Experiments	O
with	O
nu	O
/	O
nu	O
mice	O
,	O
nonobese	O
diabetic	O
-	O
SCID	O
mice	O
,	O
or	O
activated	O
spc	B-Anatomy
enriched	O
in	O
specific	O
cell	B-Anatomy
subpopulations	O
demonstrated	O
that	O
CD4	B-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
,	O
CD8	B-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
,	O
and	O
NK	B-Anatomy
cells	I-Anatomy
are	O
all	O
needed	O
to	O
mediate	O
the	O
full	O
anti	O
-	O
angiogenetic	O
effect	O
of	O
IL	O
-	O
12	O
.	O
[	O
Study	O
of	O
fungus	O
polysaccharides	O
compounds	O
(	O
FPC	O
)	O
in	O
inducing	O
the	O
apoptosis	O
of	O
liver	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
Bel	I-Anatomy
-	I-Anatomy
7402	I-Anatomy
]	I-Anatomy
.	O
To	O
observe	O
the	O
influence	O
of	O
fungus	O
polysaccharides	O
compounds	O
(	O
FPC	O
)	O
in	O
inducing	O
human	O
liver	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
Bel	I-Anatomy
-	I-Anatomy
7402	I-Anatomy
apoptosis	O
in	O
cell	B-Anatomy
cultivating	O
in	O
vitro	O
,	O
the	O
authors	O
analyzed	O
tumor	B-Anatomy
inhibitive	O
gene	O
P53	O
expression	O
in	O
Bel	B-Anatomy
-	I-Anatomy
7402	I-Anatomy
apoptosis	O
by	O
applying	O
double	O
immuno	O
-	O
marker	O
.	O
The	O
result	O
showed	O
that	O
the	O
multilevel	O
of	O
FPC	O
could	O
all	O
apparently	O
induce	O
Bel	B-Anatomy
-	I-Anatomy
7402	I-Anatomy
apoptosis	O
.	O
With	O
the	O
enhancement	O
of	O
FPC	O
concentration	O
,	O
the	O
authors	O
observed	O
chromatin	B-Anatomy
condensation	O
in	O
some	O
phases	O
companying	O
with	O
the	O
characteristic	O
apoptosis	O
.	O
In	O
the	O
meantime	O
,	O
it	O
could	O
also	O
greatly	O
reduce	O
the	O
G1	O
and	O
S	O
,	O
with	O
obviously	O
dose	O
-	O
response	O
relationship	O
.	O
The	O
percentage	O
of	O
cell	B-Anatomy
apoptosis	O
increased	O
with	O
the	O
enhancing	O
of	O
concentration	O
.	O
In	O
the	O
high	O
-	O
level	O
group	O
the	O
authors	O
found	O
typical	O
DNA	O
ladder	O
eletrophoresis	O
stripe	O
.	O
The	O
result	O
showed	O
that	O
the	O
mechanism	O
of	O
the	O
FPC	O
antineoplastic	B-Anatomy
effect	O
had	O
an	O
intimate	O
relation	O
with	O
its	O
induction	O
to	O
apoptosis	O
and	O
that	O
the	O
result	O
of	O
FPC	O
inducing	O
tumor	B-Anatomy
cell	I-Anatomy
apoptosis	O
had	O
the	O
character	O
of	O
P53	O
independence	O
.	O
Effects	O
of	O
morphological	O
patterning	O
on	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
.	O
The	O
migration	O
of	O
vascular	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
(	O
ECs	B-Anatomy
)	O
plays	O
an	O
important	O
role	O
in	O
vascular	B-Anatomy
remodeling	O
.	O
Here	O
we	O
studied	O
the	O
effects	O
of	O
cell	B-Anatomy
morphology	O
on	O
the	O
migration	O
of	O
bovine	O
aortic	B-Anatomy
ECs	I-Anatomy
by	O
culturing	O
cells	B-Anatomy
on	O
micropatterned	O
strips	O
of	O
collagen	O
matrix	B-Anatomy
(	O
60	O
-	O
,	O
30	O
-	O
,	O
and	O
15	O
-	O
microm	O
wide	O
)	O
.	O
The	O
spreading	O
areas	O
of	O
the	O
cells	B-Anatomy
on	O
15	O
-	O
and	O
30	O
-	O
microm	O
wide	O
strips	O
were	O
30	O
%	O
lower	O
than	O
those	O
on	O
60	O
-	O
microm	O
wide	O
strips	O
and	O
unpatterned	O
collagen	O
.	O
The	O
cells	B-Anatomy
on	O
15	O
-	O
microm	O
wide	O
strips	O
completely	O
aligned	O
in	O
the	O
direction	O
of	O
the	O
strip	O
,	O
and	O
had	O
significantly	O
lower	O
shape	O
index	O
than	O
those	O
in	O
all	O
other	O
groups	O
.	O
On	O
strips	O
of	O
all	O
widths	O
,	O
ECs	B-Anatomy
tended	O
to	O
migrate	O
in	O
the	O
direction	O
of	O
strips	O
.	O
ECs	B-Anatomy
on	O
15	O
-	O
microm	O
wide	O
strips	O
had	O
highest	O
speed	O
,	O
particularly	O
in	O
the	O
direction	O
of	O
the	O
strip	O
.	O
Vinculin	O
staining	O
showed	O
that	O
the	O
leading	O
edge	O
of	O
ECs	B-Anatomy
on	O
15	O
-	O
microm	O
wide	O
strips	O
had	O
focal	B-Anatomy
adhesions	I-Anatomy
that	O
were	O
oriented	O
with	O
their	O
lamellipodial	O
protrusion	O
and	O
the	O
direction	O
of	O
cell	B-Anatomy
migration	O
;	O
this	O
arrangement	O
of	O
the	O
focal	B-Anatomy
adhesions	I-Anatomy
may	O
promote	O
EC	B-Anatomy
migration	O
.	O
The	O
present	O
study	O
provides	O
direct	O
evidence	O
on	O
the	O
role	O
of	O
cell	B-Anatomy
morphology	O
in	O
EC	B-Anatomy
migration	O
,	O
and	O
will	O
help	O
us	O
to	O
understand	O
the	O
mechanisms	O
of	O
EC	B-Anatomy
migration	O
during	O
angiogenesis	O
and	O
wound	B-Anatomy
healing	O
.	O
Thrombospondin	O
-	O
2	O
plays	O
a	O
protective	O
role	O
in	O
multistep	O
carcinogenesis	O
:	O
a	O
novel	O
host	O
anti	O
-	O
tumor	B-Anatomy
defense	O
mechanism	O
.	O
The	O
angiogenic	O
switch	O
during	O
tumorigenesis	O
is	O
thought	O
to	O
be	O
induced	O
by	O
a	O
change	O
in	O
the	O
balance	O
of	O
pro	O
-	O
angiogenic	O
and	O
anti	O
-	O
angiogenic	O
factors	O
.	O
To	O
elucidate	O
the	O
biological	O
role	O
of	O
the	O
endogenous	O
angiogenesis	O
inhibitor	O
thrombospondin	O
-	O
2	O
(	O
TSP	O
-	O
2	O
)	O
during	O
multistep	O
carcinogenesis	O
,	O
we	O
subjected	O
TSP	O
-	O
2	O
-	O
deficient	O
and	O
wild	O
-	O
type	O
mice	O
to	O
a	O
chemical	O
skin	B-Anatomy
carcinogenesis	O
regimen	O
.	O
Surprisingly	O
,	O
TSP	O
-	O
2	O
expression	O
was	O
strongly	O
upregulated	O
in	O
the	O
mesenchymal	B-Anatomy
stroma	I-Anatomy
of	O
wild	O
-	O
type	O
mice	O
throughout	O
the	O
consecutive	O
stages	O
of	O
tumorigenesis	O
whereas	O
the	O
angiogenesis	O
factor	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
was	O
induced	O
predominantly	O
in	O
tumor	B-Anatomy
cells	I-Anatomy
.	O
TSP	O
-	O
2	O
deficiency	O
dramatically	O
enhanced	O
susceptibility	O
to	O
skin	B-Anatomy
carcinogenesis	O
and	O
resulted	O
in	O
accelerated	O
and	O
increased	O
tumor	B-Anatomy
formation	O
.	O
The	O
angiogenic	O
switch	O
occurred	O
in	O
early	O
stages	O
of	O
pre	B-Anatomy
-	I-Anatomy
malignant	I-Anatomy
tumor	I-Anatomy
formation	O
,	O
and	O
tumor	B-Anatomy
angiogenesis	O
was	O
significantly	O
enhanced	O
in	O
TSP	O
-	O
2	O
-	O
deficient	O
mice	O
.	O
While	O
TSP	O
-	O
2	O
deficiency	O
did	O
not	O
affect	O
tumor	B-Anatomy
differentiation	O
or	O
proliferation	O
,	O
tumor	B-Anatomy
cell	I-Anatomy
apoptosis	O
was	O
significantly	O
reduced	O
.	O
These	O
results	O
reveal	O
upregulation	O
of	O
an	O
endogenous	O
angiogenesis	O
inhibitor	O
during	O
multi	O
step	O
tumorigenesis	O
and	O
identify	O
enhanced	O
stromal	B-Anatomy
TSP	O
-	O
2	O
expression	O
as	O
a	O
novel	O
host	O
anti	O
-	O
tumor	B-Anatomy
defense	O
mechanism	O
.	O
Relationship	O
of	O
p53	O
and	O
Helicobacter	O
pylori	O
to	O
clinicopathological	O
features	O
of	O
human	O
remnant	B-Anatomy
stomach	I-Anatomy
cancer	I-Anatomy
after	O
gastric	B-Anatomy
surgery	O
for	O
primary	B-Anatomy
gastric	I-Anatomy
cancer	I-Anatomy
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
biological	O
features	O
of	O
gastric	B-Anatomy
cancer	I-Anatomy
of	O
the	O
remnant	B-Anatomy
stomach	I-Anatomy
(	O
RSC	B-Anatomy
)	O
.	O
Twenty	O
-	O
one	O
patients	O
underwent	O
resection	O
of	O
the	O
remnant	B-Anatomy
stomach	I-Anatomy
for	O
RSC	B-Anatomy
and	O
were	O
divided	O
into	O
two	O
groups	O
:	O
the	O
RSCB	B-Anatomy
group	O
consisted	O
of	O
11	O
patients	O
who	O
underwent	O
distal	O
gastrectomy	O
for	O
benign	B-Anatomy
disease	I-Anatomy
and	O
the	O
RSCM	B-Anatomy
group	O
consisted	O
of	O
10	O
patients	O
who	O
underwent	O
gastrectomy	O
for	O
primary	B-Anatomy
gastric	I-Anatomy
cancer	I-Anatomy
.	O
The	O
interval	O
between	O
primary	O
surgery	O
and	O
the	O
appearance	O
of	O
gastric	B-Anatomy
cancer	I-Anatomy
in	O
the	O
remnant	B-Anatomy
stomach	I-Anatomy
was	O
significantly	O
shorter	O
in	O
the	O
RSCM	B-Anatomy
group	O
than	O
in	O
the	O
RSCB	B-Anatomy
group	O
.	O
Invasion	O
of	O
adjacent	O
organs	B-Anatomy
was	O
more	O
frequent	O
in	O
the	O
RSCM	B-Anatomy
group	O
than	O
in	O
the	O
RSCB	B-Anatomy
group	O
and	O
the	O
Ki	O
-	O
67	O
labeling	O
index	O
of	O
the	O
tumors	B-Anatomy
was	O
significantly	O
higher	O
in	O
the	O
former	O
group	O
.	O
Furthermore	O
,	O
p53	O
overexpression	O
by	O
tumors	B-Anatomy
was	O
almost	O
twice	O
as	O
common	O
in	O
the	O
RSCM	B-Anatomy
group	O
as	O
in	O
the	O
RSCB	B-Anatomy
group	O
.	O
Although	O
there	O
was	O
no	O
significant	O
difference	O
of	O
the	O
H	O
.	O
pylori	O
positivity	O
between	O
the	O
two	O
groups	O
,	O
the	O
rate	O
for	O
both	O
groups	O
was	O
higher	O
than	O
reported	O
in	O
previous	O
studies	O
.	O
Mutation	O
of	O
p53	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
high	O
proliferative	O
activity	O
of	O
tumors	B-Anatomy
in	O
the	O
RSCM	B-Anatomy
group	O
and	O
H	O
.	O
pylori	O
infection	O
may	O
be	O
closely	O
related	O
to	O
carcinogenesis	O
in	O
patients	O
with	O
RSC	B-Anatomy
.	O
Current	O
prospects	O
for	O
controlling	O
cancer	B-Anatomy
growth	O
with	O
non	O
-	O
cytotoxic	O
agents	O
-	O
-	O
nutrients	O
,	O
phytochemicals	O
,	O
herbal	O
extracts	B-Anatomy
,	O
and	O
available	O
drugs	O
.	O
In	O
animal	O
or	O
cell	B-Anatomy
culture	I-Anatomy
studies	O
,	O
the	O
growth	O
and	O
spread	O
of	O
cancer	B-Anatomy
can	O
be	O
slowed	O
by	O
many	O
nutrients	O
,	O
food	O
factors	O
,	O
herbal	O
extracts	B-Anatomy
,	O
and	O
well	O
-	O
tolerated	O
,	O
available	O
drugs	O
that	O
are	O
still	O
rarely	O
used	O
in	O
the	O
clinical	O
management	O
of	O
cancer	B-Anatomy
,	O
in	O
part	O
because	O
they	O
seem	O
unlikely	O
to	O
constitute	O
definitive	O
therapies	O
in	O
themselves	O
.	O
However	O
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
mechanistically	O
complementary	O
combinations	O
of	O
these	O
measures	O
could	O
have	O
a	O
worthwhile	O
impact	O
on	O
survival	O
times	O
and	O
,	O
when	O
used	O
as	O
adjuvants	O
,	O
could	O
improve	O
the	O
cure	O
rates	O
achievable	O
with	O
standard	O
therapies	O
.	O
The	O
therapeutic	O
options	O
available	O
in	O
this	O
regard	O
include	O
measures	O
that	O
:	O
down	O
-	O
regulate	O
serum	B-Anatomy
free	O
IGF	O
-	O
I	O
;	O
suppress	O
the	O
synthesis	O
of	O
mevalonic	O
acid	O
and	O
/	O
or	O
certain	O
derivatives	O
thereof	O
;	O
modulate	O
arachidonate	O
metabolism	O
by	O
inhibiting	O
5	O
-	O
lipoxygenase	O
,	O
12	O
-	O
lipoxygenase	O
,	O
or	O
COX	O
-	O
2	O
;	O
antagonize	O
the	O
activation	O
of	O
AP	O
-	O
1	O
transcription	O
factors	O
;	O
promote	O
the	O
activation	O
of	O
PPAR	O
-	O
gamma	O
transcription	O
factors	O
;	O
and	O
that	O
suppress	O
angiogenesis	O
by	O
additional	O
mechanisms	O
.	O
Many	O
of	O
these	O
measures	O
appear	O
suitable	O
for	O
use	O
in	O
cancer	B-Anatomy
prevention	O
.	O
Oncogenic	O
mechanisms	O
of	O
Evi	O
-	O
1	O
protein	O
.	O
Although	O
Evi	O
-	O
1	O
is	O
thought	O
to	O
promote	O
growth	O
or	O
block	O
differentiation	O
in	O
some	O
cell	B-Anatomy
types	O
,	O
its	O
biological	O
functions	O
have	O
not	O
been	O
elucidated	O
.	O
To	O
explore	O
the	O
mechanisms	O
underlying	O
Evi	O
-	O
1	O
-	O
induced	O
oncogenesis	O
,	O
we	O
investigated	O
whether	O
Evi	O
-	O
1	O
affects	O
the	O
signaling	O
of	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
,	O
which	O
inhibits	O
proliferation	O
of	O
a	O
wide	O
range	O
of	O
cell	B-Anatomy
types	O
and	O
is	O
one	O
of	O
the	O
most	O
studied	O
growth	O
regulatory	O
factors	O
.	O
We	O
demonstrated	O
that	O
Evi	O
-	O
1	O
represses	O
TGF	O
-	O
beta	O
signaling	O
and	O
antagonizes	O
its	O
growth	O
-	O
inhibitory	O
effects	O
.	O
Two	O
separate	O
regions	O
of	O
Evi	O
-	O
1	O
are	O
responsible	O
for	O
this	O
repression	O
,	O
one	O
of	O
which	O
is	O
the	O
first	O
zinc	O
-	O
finger	O
domain	O
.	O
Through	O
this	O
domain	O
,	O
Evi	O
-	O
1	O
physically	O
interacts	O
with	O
Smad3	O
,	O
an	O
intracellular	B-Anatomy
mediator	O
of	O
TGF	O
-	O
beta	O
signaling	O
,	O
thereby	O
suppressing	O
the	O
transcriptional	O
activity	O
of	O
Smad3	O
.	O
These	O
results	O
define	O
a	O
novel	O
function	O
of	O
Evi	O
-	O
1	O
as	O
a	O
repressor	O
of	O
signaling	O
components	O
of	O
TGF	O
-	O
beta	O
.	O
We	O
also	O
demonstrated	O
that	O
Evi	O
-	O
1	O
represses	O
Smad	O
-	O
induced	O
transcriptional	O
activation	O
by	O
recruiting	O
CtBP	O
as	O
a	O
corepressor	O
.	O
Evi	O
-	O
1	O
associates	O
with	O
CtBP1	O
through	O
one	O
of	O
the	O
CtBP	O
-	O
binding	O
consensus	O
motifs	O
within	O
the	O
region	O
from	O
amino	O
acid	O
544	O
to	O
607	O
,	O
and	O
this	O
association	O
is	O
required	O
for	O
the	O
efficient	O
inhibition	O
of	O
TGF	O
-	O
beta	O
signaling	O
.	O
A	O
specific	O
histone	O
deacetylase	O
(	O
HDAc	O
)	O
inhibitor	O
,	O
trichostatin	O
A	O
(	O
TSA	O
)	O
,	O
alleviates	O
Evi	O
-	O
1	O
-	O
mediated	O
repression	O
of	O
TGF	O
-	O
beta	O
signaling	O
,	O
suggesting	O
that	O
HDAc	O
is	O
involved	O
in	O
transcriptional	O
repression	O
by	O
Evi	O
-	O
1	O
.	O
This	O
identifies	O
a	O
novel	O
function	O
of	O
Evi	O
-	O
1	O
as	O
a	O
member	O
of	O
corepressor	O
complexes	O
and	O
suggests	O
that	O
aberrant	O
recruitment	O
of	O
corepressors	O
is	O
one	O
of	O
the	O
mechanisms	O
involved	O
in	O
Evi	O
-	O
1	O
-	O
induced	O
leukemogenesis	O
.	O
These	O
results	O
indicate	O
that	O
specific	O
HDAc	O
inhibitors	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
Evi	O
-	O
1	O
-	O
induced	O
neoplastic	B-Anatomy
tumors	I-Anatomy
,	O
including	O
myeloid	B-Anatomy
leukemias	I-Anatomy
.	O
Antibodies	O
to	O
PAI	O
-	O
1	O
alter	O
the	O
invasive	O
and	O
migratory	O
properties	O
of	O
human	O
tumour	B-Anatomy
cells	I-Anatomy
in	O
vitro	O
.	O
Recent	O
reports	O
suggest	O
that	O
elevated	O
levels	O
of	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
may	O
contribute	O
to	O
tumour	B-Anatomy
progression	O
.	O
The	O
studies	O
reported	O
here	O
were	O
designed	O
to	O
help	O
elucidate	O
PAI	O
-	O
1	O
'	O
s	O
contribution	O
to	O
the	O
invasive	O
and	O
migratory	O
phenotype	O
.	O
Antibodies	O
to	O
PA	O
-	O
1	O
dose	O
-	O
dependently	O
,	O
and	O
significantly	O
,	O
inhibited	O
the	O
invasive	O
and	O
migratory	O
potential	O
of	O
human	O
HT1080	B-Anatomy
fibrosarcoma	I-Anatomy
cells	I-Anatomy
,	O
as	O
did	O
an	O
antibody	O
to	O
uPA	O
and	O
the	O
plasmin	O
inhibitor	O
aprotinin	O
.	O
Invasion	O
of	O
the	O
human	O
melanoma	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
BLM	B-Anatomy
,	O
was	O
also	O
attenuated	O
by	O
the	O
anti	O
-	O
PAI	O
-	O
1	O
monoclonal	O
antibody	O
MAI	O
-	O
12	O
.	O
The	O
non	O
-	O
invasive	O
human	O
melanoma	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
IF6	B-Anatomy
,	O
which	O
does	O
not	O
express	O
uPA	O
,	O
provided	O
further	O
confirmation	O
of	O
PAI	O
-	O
1	O
and	O
uPA	O
'	O
s	O
role	O
as	O
,	O
upon	O
transfection	O
with	O
uPA	O
,	O
this	O
cell	B-Anatomy
line	I-Anatomy
attained	O
an	O
invasive	O
phenotype	O
,	O
which	O
was	O
again	O
attenuated	O
by	O
MAI	O
-	O
12	O
.	O
Although	O
antibodies	O
to	O
PAI	O
-	O
1	O
did	O
not	O
affect	O
the	O
adhesion	O
of	O
HT1080	B-Anatomy
cells	I-Anatomy
to	O
vitronectin	O
,	O
the	O
antibody	O
to	O
uPA	O
reduced	O
their	O
attachment	O
.	O
Addition	O
of	O
exogenous	O
PAI	O
-	O
1	O
,	O
however	O
,	O
prevented	O
HT1080	B-Anatomy
cell	I-Anatomy
adhesion	O
(	O
IC50	O
180	O
nM	O
)	O
and	O
promoted	O
cell	B-Anatomy
detachment	O
from	O
vitronectin	O
.	O
Furthermore	O
melanoma	B-Anatomy
cells	I-Anatomy
transfected	O
with	O
a	O
uPA	O
variant	O
,	O
which	O
had	O
an	O
impaired	O
interaction	O
with	O
PAI	O
-	O
1	O
,	O
were	O
not	O
invasive	O
and	O
had	O
impaired	O
binding	O
to	O
vitronectin	O
.	O
These	O
data	O
highlight	O
the	O
importance	O
of	O
a	O
balanced	O
proteolysis	O
and	O
suggest	O
an	O
additional	O
role	O
for	O
PAI	O
-	O
1	O
distinct	O
from	O
its	O
role	O
in	O
proteolysis	O
.	O
These	O
data	O
also	O
suggest	O
that	O
uPA	O
and	O
PAI	O
-	O
1	O
may	O
co	O
-	O
operate	O
in	O
the	O
migratory	O
process	O
by	O
respectively	O
facilitating	O
the	O
attachment	O
to	O
,	O
and	O
subsequent	O
detachment	O
from	O
,	O
vitronectin	O
in	O
the	O
extracellular	B-Anatomy
matrix	I-Anatomy
.	O
These	O
results	O
support	O
the	O
clinical	O
findings	O
and	O
indicate	O
that	O
modulation	O
of	O
PAI	O
-	O
1	O
activity	O
may	O
be	O
of	O
therapeutic	O
benefit	O
for	O
the	O
treatment	O
of	O
cancer	B-Anatomy
.	O
[	O
Anesthetic	O
management	O
of	O
a	O
patient	O
with	O
Dyggve	O
-	O
Melchior	O
-	O
Clausen	O
syndrome	O
]	O
.	O
The	O
Dyggve	O
-	O
Melchior	O
-	O
Clausen	O
syndrome	O
(	O
DMCS	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
skeletal	B-Anatomy
dysplasia	I-Anatomy
characterized	O
by	O
short	O
-	O
trunk	B-Anatomy
dwarfism	O
and	O
mental	O
retardation	O
.	O
A	O
49	O
-	O
year	O
-	O
old	O
male	O
with	O
DMCS	O
underwent	O
resection	O
arthroplasty	O
for	O
contracture	O
of	O
the	O
right	B-Anatomy
hip	I-Anatomy
joint	I-Anatomy
under	O
general	O
anesthesia	O
using	O
thiamylal	O
,	O
nitrous	O
oxide	O
,	O
sevoflurane	O
,	O
and	O
vecuronium	O
.	O
Although	O
he	O
was	O
assumed	O
to	O
have	O
difficult	O
airway	B-Anatomy
due	O
to	O
short	O
neck	B-Anatomy
,	O
macroglossia	O
,	O
and	O
disturbance	O
of	O
neck	B-Anatomy
flexion	O
,	O
tracheal	B-Anatomy
intubation	O
was	O
not	O
difficult	O
.	O
No	O
complications	O
including	O
malignant	O
hyperthermia	O
were	O
observed	O
during	O
the	O
95	O
min	O
of	O
the	O
operation	O
.	O
Assembly	O
strategies	O
and	O
GTPase	O
regulation	O
of	O
the	O
eukaryotic	O
and	O
Escherichia	O
coil	O
translocons	B-Anatomy
.	O
The	O
translocation	O
of	O
most	O
proteins	O
across	O
the	O
endoplasmic	B-Anatomy
reticulum	I-Anatomy
or	O
bacterial	O
inner	B-Anatomy
membrane	I-Anatomy
occurs	O
through	O
an	O
aqueous	B-Anatomy
pore	I-Anatomy
that	O
spans	O
the	O
membrane	B-Anatomy
.	O
Substrates	O
that	O
are	O
translocated	O
co	O
-	O
translationally	O
across	O
the	O
membrane	B-Anatomy
are	O
directed	O
to	O
the	O
translocation	B-Anatomy
pore	I-Anatomy
via	O
an	O
interaction	O
between	O
the	O
cytosolic	B-Anatomy
signal	O
recognition	O
particle	O
and	O
its	O
membrane	B-Anatomy
-	O
bound	O
receptor	O
.	O
Together	O
the	O
translocation	B-Anatomy
pore	I-Anatomy
and	O
the	O
receptor	O
are	O
referred	O
to	O
as	O
a	O
translocon	B-Anatomy
.	O
By	O
studying	O
the	O
biogenesis	O
of	O
the	O
translocon	B-Anatomy
a	O
number	O
of	O
alternate	O
targeting	O
and	O
membrane	B-Anatomy
-	O
integration	O
pathways	O
have	O
been	O
discovered	O
that	O
operate	O
independently	O
of	O
the	O
signal	O
recognition	O
particle	O
(	O
SRP	O
)	O
pathway	O
.	O
The	O
novel	O
assembly	O
strategies	O
of	O
the	O
translocon	B-Anatomy
and	O
the	O
ways	O
in	O
which	O
these	O
components	O
interact	O
to	O
ensure	O
the	O
fidelity	O
and	O
unidirectionality	O
of	O
the	O
targeting	O
and	O
translocation	O
process	O
are	O
reviewed	O
here	O
.	O
Phonology	O
:	O
a	O
review	O
and	O
proposals	O
from	O
a	O
connectionist	O
perspective	O
.	O
A	O
parallel	O
distributed	O
processing	O
(	O
PDP	O
)	O
model	O
of	O
phonological	O
processing	O
is	O
developed	O
,	O
including	O
components	O
to	O
support	O
repetition	O
,	O
auditory	O
processing	O
,	O
comprehension	O
,	O
and	O
language	O
production	O
.	O
From	O
the	O
performance	O
of	O
the	O
PDP	O
reading	O
model	O
of	O
Plaut	O
,	O
McClelland	O
,	O
Seidenberg	O
,	O
and	O
Patterson	O
(	O
1996	O
)	O
,	O
it	O
is	O
inferred	O
that	O
the	O
acoustic	O
-	O
articulatory	O
motor	O
pattern	O
associator	O
that	O
supports	O
repetition	O
provides	O
the	O
basis	O
for	O
phonological	O
sequence	O
knowledge	O
.	O
From	O
the	O
observation	O
that	O
many	O
patients	O
make	O
phonemic	O
paraphasic	O
errors	O
in	O
language	O
production	O
,	O
as	O
in	O
repetition	O
,	O
it	O
is	O
argued	O
that	O
there	O
must	O
be	O
a	O
direct	O
link	O
between	O
distributed	O
concept	O
representations	O
(	O
lexical	O
semantic	O
knowledge	O
)	O
and	O
this	O
network	O
representation	O
of	O
sequence	O
knowledge	O
.	O
In	O
this	O
way	O
,	O
both	O
lexical	O
semantic	O
and	O
phonotactic	O
constraints	O
are	O
brought	O
to	O
bear	O
on	O
language	O
production	O
.	O
The	O
literature	O
on	O
phonological	O
function	O
in	O
normal	O
subjects	O
(	O
slip	O
-	O
of	O
-	O
the	O
-	O
tongue	O
corpora	O
)	O
and	O
in	O
patients	O
with	O
aphasia	O
is	O
critically	O
reviewed	O
from	O
this	O
perspective	O
.	O
The	O
relationship	O
between	O
acoustic	O
and	O
articulatory	O
motor	O
representations	O
in	O
the	O
process	O
of	O
phonetic	O
perception	O
is	O
considered	O
.	O
Repetition	O
and	O
reproduction	O
conduction	O
aphasia	O
are	O
reviewed	O
in	O
detail	O
and	O
extended	O
consideration	O
is	O
given	O
to	O
the	O
representation	O
of	O
auditory	O
verbal	O
short	O
-	O
term	O
memory	O
in	O
the	O
model	O
.	O
Finally	O
,	O
the	O
PDP	O
model	O
is	O
reconciled	O
with	O
information	O
processing	O
models	O
of	O
phonological	O
processing	O
,	O
including	O
that	O
of	O
Lichtheim	O
,	O
and	O
with	O
current	O
knowledge	O
of	O
the	O
anatomic	O
localization	O
of	O
phonological	O
processing	O
.	O
Although	O
no	O
simulations	O
of	O
the	O
model	O
were	O
run	O
,	O
a	O
number	O
of	O
simulation	O
studies	O
are	O
proposed	O
.	O
Inhibition	O
of	O
PDGF	O
-	O
stimulated	O
and	O
matrix	B-Anatomy
-	O
mediated	O
proliferation	O
of	O
human	O
vascular	B-Anatomy
smooth	I-Anatomy
muscle	I-Anatomy
cells	I-Anatomy
by	O
SPARC	O
is	O
independent	O
of	O
changes	O
in	O
cell	B-Anatomy
shape	O
or	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitors	O
.	O
Interactions	O
among	O
growth	O
factors	O
,	O
cells	B-Anatomy
,	O
and	O
extracellular	B-Anatomy
matrix	I-Anatomy
regulate	O
proliferation	O
during	O
normal	O
development	O
and	O
in	O
pathologies	O
such	O
as	O
atherosclerosis	O
.	O
SPARC	O
(	O
secreted	O
protein	O
,	O
acidic	O
,	O
and	O
rich	O
in	O
cysteine	O
)	O
is	O
a	O
matrix	B-Anatomy
-	O
associated	O
glycoprotein	O
that	O
modulates	O
the	O
adhesion	O
and	O
proliferation	O
of	O
vascular	B-Anatomy
cells	I-Anatomy
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
SPARC	O
inhibits	O
human	O
arterial	B-Anatomy
smooth	I-Anatomy
muscle	I-Anatomy
cell	I-Anatomy
proliferation	O
stimulated	O
by	O
platelet	O
-	O
derived	O
growth	O
factor	O
or	O
by	O
adhesion	O
to	O
monomeric	O
type	O
I	O
collagen	O
.	O
Binding	O
studies	O
with	O
SPARC	O
and	O
SPARC	O
peptides	O
indicate	O
specific	O
and	O
saturable	O
interaction	O
with	O
smooth	B-Anatomy
muscle	I-Anatomy
cells	I-Anatomy
that	O
involves	O
the	O
C	O
-	O
terminal	O
Ca2	O
+	O
-	O
binding	O
region	O
of	O
the	O
protein	O
.	O
We	O
also	O
report	O
that	O
SPARC	O
arrests	O
monomeric	O
collagen	O
-	O
supported	O
smooth	B-Anatomy
muscle	I-Anatomy
cell	I-Anatomy
proliferation	O
in	O
the	O
late	O
G1	O
-	O
phase	O
of	O
the	O
cell	B-Anatomy
cycle	O
in	O
the	O
absence	O
of	O
an	O
effect	O
on	O
cell	B-Anatomy
shape	O
or	O
on	O
levels	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitors	O
.	O
Cyclin	O
-	O
dependent	O
kinase	O
-	O
2	O
activity	O
,	O
p107	O
and	O
cyclin	O
A	O
levels	O
,	O
and	O
retinoblastoma	O
protein	O
phosphorylation	O
are	O
markedly	O
reduced	O
in	O
response	O
to	O
the	O
addition	O
of	O
exogenous	O
SPARC	O
and	O
/	O
or	O
peptides	O
derived	O
from	O
specific	O
domains	O
of	O
SPARC	O
.	O
Thus	O
,	O
SPARC	O
,	O
previously	O
characterized	O
as	O
an	O
inhibitor	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
binding	O
to	O
its	O
receptor	O
,	O
also	O
antagonizes	O
smooth	B-Anatomy
muscle	I-Anatomy
cell	I-Anatomy
proliferation	O
mediated	O
by	O
monomeric	O
collagen	O
at	O
the	O
level	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
-	O
2	O
activity	O
.	O
Prognostic	O
significance	O
of	O
heat	O
shock	O
protein	O
27	O
(	O
HSP27	O
)	O
in	O
patients	O
with	O
oral	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
Heat	O
shock	O
proteins	O
(	O
HSPs	O
)	O
have	O
been	O
defined	O
as	O
proteins	O
induced	O
by	O
heat	O
shock	O
and	O
other	O
environmental	O
and	O
pathophysiologic	O
stress	O
.	O
Heat	O
shock	O
protein	O
27	O
(	O
HSP27	O
)	O
is	O
one	O
of	O
the	O
small	O
heat	O
shock	O
proteins	O
.	O
HSP27	O
is	O
implicated	O
in	O
protein	O
-	O
protein	O
interactions	O
such	O
as	O
folding	O
,	O
translocation	O
,	O
and	O
prevention	O
of	O
inappropriate	O
protein	O
aggregation	O
.	O
Many	O
of	O
their	O
functions	O
suggest	O
that	O
they	O
play	O
important	O
roles	O
in	O
cancers	B-Anatomy
.	O
Archival	B-Anatomy
tissues	I-Anatomy
from	O
40	O
patients	O
with	O
oral	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
who	O
received	O
primary	O
surgical	O
resection	O
were	O
examined	O
for	O
HSP27	O
by	O
immunohistochemistry	O
and	O
correlated	O
with	O
clinical	O
stage	O
,	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
,	O
histological	O
grade	O
and	O
survival	O
period	O
.	O
HSP27	O
expression	O
was	O
positive	O
staining	O
(	O
+	O
)	O
in	O
20	O
(	O
50	O
%	O
)	O
,	O
weak	O
or	O
negative	O
staining	O
(	O
-	O
)	O
in	O
20	O
(	O
50	O
%	O
)	O
of	O
total	O
40	O
cases	O
.	O
There	O
was	O
no	O
correlation	O
between	O
HSP27	O
expression	O
and	O
clinical	O
stage	O
,	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
and	O
histological	O
grade	O
.	O
However	O
,	O
when	O
compared	O
with	O
clinicopathological	O
features	O
,	O
the	O
expression	O
of	O
HSP27	O
correlated	O
inversely	O
with	O
survival	O
period	O
.	O
This	O
study	O
suggests	O
that	O
the	O
expression	O
of	O
HSP27	O
is	O
frequently	O
promoted	O
in	O
patients	O
with	O
oral	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
and	O
should	O
be	O
considered	O
an	O
independent	O
prognostic	O
factor	O
of	O
oral	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
patients	O
.	O
Novel	O
method	O
for	O
multiturn	O
extraction	O
:	O
trapping	O
charged	O
particles	O
in	O
islands	O
of	O
phase	O
space	O
.	O
A	O
novel	O
method	O
for	O
multiturn	O
extraction	O
from	O
a	O
circular	O
particle	O
accelerator	O
is	O
presented	O
,	O
based	O
on	O
trapping	O
particles	O
into	O
islands	O
of	O
phase	O
space	O
generated	O
by	O
nonlinear	O
resonances	O
.	O
By	O
appropriate	O
use	O
of	O
sextupoles	O
and	O
octupoles	O
,	O
stable	O
islands	O
can	O
be	O
created	O
at	O
small	O
amplitude	O
in	O
phase	O
space	O
.	O
By	O
varying	O
the	O
linear	O
tune	O
,	O
particles	O
can	O
be	O
trapped	O
inside	O
these	O
islands	O
and	O
then	O
transported	O
towards	O
higher	O
amplitudes	O
for	O
extraction	O
.	O
Results	O
of	O
numerical	O
simulations	O
are	O
discussed	O
.	O
Upregulation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
is	O
associated	O
with	O
advanced	O
neuroblastoma	B-Anatomy
.	O
BACKGROUND	O
:	O
Angiogenesis	O
is	O
essential	O
for	O
tumor	B-Anatomy
growth	O
and	O
relies	O
on	O
the	O
production	O
of	O
angiogenic	O
factors	O
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
a	O
major	O
regulator	O
of	O
angiogenesis	O
that	O
binds	O
to	O
tyrosine	O
kinase	O
receptors	O
Flt	O
-	O
1	O
and	O
KDR	O
.	O
The	O
interaction	O
of	O
VEGF	O
and	O
its	O
receptors	O
at	O
gene	O
and	O
protein	O
levels	O
in	O
neuroblastoma	B-Anatomy
remains	O
widely	O
unknown	O
.	O
METHODS	O
:	O
Tumor	B-Anatomy
biopsy	I-Anatomy
specimens	I-Anatomy
and	O
serum	B-Anatomy
were	O
obtained	O
from	O
37	O
neuroblastoma	B-Anatomy
patients	O
;	O
adrenal	B-Anatomy
biopsy	I-Anatomy
sections	I-Anatomy
and	O
sera	B-Anatomy
of	O
7	O
normal	O
children	O
served	O
as	O
controls	O
.	O
Biopsy	B-Anatomy
specimens	I-Anatomy
were	O
examined	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
Western	O
blotting	O
;	O
serum	B-Anatomy
was	O
analyzed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O
VEGF	O
-	O
A	O
(	O
165	O
)	O
,	O
B	O
,	O
C	O
,	O
Flt	O
-	O
1	O
,	O
and	O
KDR	O
were	O
analyzed	O
.	O
RESULTS	O
:	O
VEGF	O
isoforms	O
and	O
its	O
receptors	O
'	O
mRNA	O
were	O
expressed	O
in	O
neuroblastoma	B-Anatomy
and	O
control	O
tissues	B-Anatomy
.	O
Whereas	O
the	O
ligands	O
were	O
increased	O
in	O
stages	O
III	O
and	O
IV	O
,	O
the	O
receptors	O
were	O
upregulated	O
in	O
stage	O
III	O
only	O
.	O
At	O
protein	O
level	O
,	O
VEGF	O
-	O
B	O
and	O
C	O
,	O
Flt	O
-	O
1	O
,	O
and	O
KDR	O
were	O
not	O
detectable	O
in	O
tissue	B-Anatomy
lysates	I-Anatomy
,	O
whereas	O
VEGF	O
-	O
A	O
was	O
increased	O
in	O
stages	O
III	O
and	O
IV	O
.	O
Serum	B-Anatomy
VEGF	O
protein	O
levels	O
were	O
upregulated	O
in	O
stage	O
III	O
.	O
CONCLUSIONS	O
:	O
VEGF	O
-	O
A	O
(	O
165	O
)	O
is	O
one	O
of	O
the	O
major	O
angiogenesis	O
regulators	O
among	O
the	O
ligands	O
'	O
family	O
of	O
VEGF	O
,	O
whereas	O
its	O
receptors	O
KDR	O
,	O
and	O
most	O
probably	O
Flt	O
-	O
1	O
,	O
may	O
contribute	O
to	O
a	O
poor	O
prognosis	O
(	O
angiogenic	O
)	O
phenotype	O
,	O
as	O
indicated	O
by	O
their	O
upregulated	O
MRNA	O
levels	O
in	O
stage	B-Anatomy
III	I-Anatomy
neuroblastoma	I-Anatomy
.	O
VEGF	O
-	O
A	O
(	O
165	O
)	O
mainly	O
contributes	O
to	O
increased	O
serum	B-Anatomy
VEGF	O
levels	O
and	O
may	O
serve	O
as	O
a	O
diagnostic	O
tool	O
in	O
advanced	O
-	O
stage	O
neuroblastoma	B-Anatomy
.	O
Hypoxia	O
-	O
inducible	O
factor	O
1	O
activation	O
by	O
aerobic	O
glycolysis	O
implicates	O
the	O
Warburg	O
effect	O
in	O
carcinogenesis	O
.	O
Cancer	B-Anatomy
cells	I-Anatomy
display	O
high	O
rates	O
of	O
aerobic	O
glycolysis	O
,	O
a	O
phenomenon	O
known	O
historically	O
as	O
the	O
Warburg	O
effect	O
.	O
Lactate	O
and	O
pyruvate	O
,	O
the	O
end	O
products	O
of	O
glycolysis	O
,	O
are	O
highly	O
produced	O
by	O
cancer	B-Anatomy
cells	I-Anatomy
even	O
in	O
the	O
presence	O
of	O
oxygen	O
.	O
Hypoxia	O
-	O
induced	O
gene	O
expression	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
has	O
been	O
linked	O
to	O
malignant	O
transformation	O
.	O
Here	O
we	O
provide	O
evidence	O
that	O
lactate	O
and	O
pyruvate	O
regulate	O
hypoxia	O
-	O
inducible	O
gene	O
expression	O
independently	O
of	O
hypoxia	O
by	O
stimulating	O
the	O
accumulation	O
of	O
hypoxia	O
-	O
inducible	O
Factor	O
1alpha	O
(	O
HIF	O
-	O
1alpha	O
)	O
.	O
In	O
human	O
gliomas	B-Anatomy
and	O
other	O
cancer	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
,	O
the	O
accumulation	O
of	O
HIF	O
-	O
1alpha	O
protein	O
under	O
aerobic	O
conditions	O
requires	O
the	O
metabolism	O
of	O
glucose	O
to	O
pyruvate	O
that	O
prevents	O
the	O
aerobic	O
degradation	O
of	O
HIF	O
-	O
1alpha	O
protein	O
,	O
activates	O
HIF	O
-	O
1	O
DNA	O
binding	O
activity	O
,	O
and	O
enhances	O
the	O
expression	O
of	O
several	O
HIF	O
-	O
1	O
-	O
activated	O
genes	O
including	O
erythropoietin	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
glucose	O
transporter	O
3	O
,	O
and	O
aldolase	O
A	O
.	O
Our	O
findings	O
support	O
a	O
novel	O
role	O
for	O
pyruvate	O
in	O
metabolic	O
signaling	O
and	O
suggest	O
a	O
mechanism	O
by	O
which	O
high	O
rates	O
of	O
aerobic	O
glycolysis	O
can	O
promote	O
the	O
malignant	O
transformation	O
and	O
survival	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
Risk	O
of	O
myelodysplastic	O
syndrome	O
and	O
acute	B-Anatomy
myeloid	I-Anatomy
leukemia	I-Anatomy
in	O
congenital	O
neutropenias	O
.	O
Granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
has	O
had	O
a	O
major	O
impact	O
on	O
the	O
management	O
of	O
""""	O
severe	O
chronic	O
neutropenia	O
""""	O
(	O
SCN	O
)	O
,	O
a	O
collective	O
term	O
referring	O
to	O
congenital	O
,	O
idiopathic	O
,	O
or	O
cyclic	O
neutropenia	O
.	O
Almost	O
all	O
patients	O
respond	O
to	O
G	O
-	O
CSF	O
with	O
increased	O
neutrophils	B-Anatomy
,	O
reduced	O
infections	O
,	O
and	O
improved	O
survival	O
.	O
Some	O
responders	O
with	O
congenital	O
neutropenia	O
and	O
Shwachman	O
-	O
Diamond	O
syndrome	O
(	O
SDS	O
)	O
have	O
developed	O
myelodysplastic	O
syndrome	O
and	O
acute	B-Anatomy
myeloid	I-Anatomy
leukemia	I-Anatomy
(	O
MDS	O
/	O
AML	B-Anatomy
)	O
,	O
which	O
raises	O
the	O
question	O
of	O
the	O
role	O
of	O
G	O
-	O
CSF	O
in	O
pathogenesis	O
.	O
The	O
issue	O
is	O
complicated	O
because	O
both	O
disorders	O
have	O
a	O
propensity	O
for	O
MDS	O
or	O
AML	B-Anatomy
as	O
part	O
of	O
their	O
natural	O
history	O
.	O
To	O
address	O
this	O
,	O
the	O
Severe	O
Chronic	O
Neutropenia	O
International	O
Registry	O
(	O
SCNIR	O
)	O
used	O
its	O
large	O
database	O
of	O
chronic	O
neutropenia	O
patients	O
treated	O
with	O
G	O
-	O
CSF	O
to	O
determine	O
the	O
incidence	O
of	O
malignant	B-Anatomy
myeloid	I-Anatomy
transformation	O
in	O
the	O
two	O
disorders	O
,	O
and	O
its	O
relationship	O
to	O
treatment	O
and	O
to	O
other	O
patient	O
characteristics	O
.	O
No	O
statistically	O
significant	O
relationships	O
were	O
found	O
between	O
age	O
at	O
onset	O
of	O
MDS	O
or	O
AML	B-Anatomy
and	O
patient	O
gender	O
,	O
G	O
-	O
CSF	O
dose	O
,	O
or	O
duration	O
of	O
G	O
-	O
CSF	O
therapy	O
.	O
What	O
was	O
observed	O
,	O
however	O
,	O
was	O
the	O
multistep	O
acquisition	O
of	O
aberrant	O
cellular	B-Anatomy
genetic	O
changes	O
in	O
marrow	B-Anatomy
cells	I-Anatomy
from	O
patients	O
who	O
transformed	O
,	O
including	O
activating	O
ras	O
oncogene	O
mutations	O
,	O
clonal	O
cytogenetic	O
abnormalities	O
,	O
and	O
G	O
-	O
CSF	O
receptor	O
mutations	O
.	O
In	O
murine	O
models	O
,	O
the	O
latter	O
produces	O
a	O
hyperproliferative	O
response	O
to	O
G	O
-	O
CSF	O
,	O
confers	O
resistance	O
to	O
apoptosis	O
,	O
and	O
enhances	O
cell	B-Anatomy
survival	O
.	O
Since	O
congenital	O
neutropenia	O
and	O
SDS	O
are	O
inherited	O
forms	O
of	O
bone	B-Anatomy
marrow	I-Anatomy
failure	O
,	O
G	O
-	O
CSF	O
may	O
accelerate	O
the	O
propensity	O
for	O
MDS	O
/	O
AML	B-Anatomy
in	O
the	O
genetically	O
altered	O
stem	B-Anatomy
and	O
progenitor	B-Anatomy
cells	I-Anatomy
,	O
especially	O
in	O
those	O
with	O
G	O
-	O
CSF	O
receptor	O
and	O
ras	O
mutations	O
(	O
82	O
%	O
and	O
50	O
%	O
of	O
patients	O
who	O
transform	O
,	O
respectively	O
)	O
.	O
Alternatively	O
,	O
and	O
equally	O
plausible	O
,	O
G	O
-	O
CSF	O
may	O
simply	O
be	O
an	O
""""	O
innocent	O
bystander	O
""""	O
that	O
corrects	O
neutropenia	O
,	O
prolongs	O
patient	O
survival	O
,	O
and	O
allows	O
time	O
for	O
the	O
malignant	O
predisposition	O
to	O
declare	O
itself	O
.	O
In	O
patients	O
who	O
transform	O
to	O
overt	O
MDS	O
or	O
AML	B-Anatomy
,	O
hematopoietic	B-Anatomy
stem	I-Anatomy
cell	I-Anatomy
transplantation	O
is	O
the	O
only	O
chance	O
for	O
cure	O
.	O
In	O
those	O
with	O
""""	O
soft	O
""""	O
signs	O
of	O
MDS	O
,	O
such	O
as	O
an	O
isolated	O
clonal	O
cytogenetic	O
change	O
but	O
without	O
other	O
evidence	O
of	O
MDS	O
,	O
or	O
with	O
an	O
isolated	O
G	O
-	O
CSF	O
receptor	O
mutation	O
,	O
there	O
is	O
room	O
for	O
conservative	O
management	O
.	O
One	O
option	O
is	O
to	O
reduce	O
the	O
G	O
-	O
CSF	O
dosage	O
as	O
much	O
as	O
possible	O
,	O
and	O
observe	O
the	O
tempo	O
of	O
progression	O
,	O
if	O
any	O
,	O
to	O
more	O
overt	O
signs	O
of	O
malignancy	B-Anatomy
.	O
Stimulation	O
of	O
beta	O
-	O
adrenergic	O
receptors	O
in	O
the	O
pineal	B-Anatomy
gland	I-Anatomy
increases	O
the	O
noradrenaline	O
stores	O
of	O
its	O
sympathetic	B-Anatomy
nerves	I-Anatomy
.	O
The	O
administration	O
of	O
isoproterenol	O
decreases	O
the	O
level	O
of	O
serotonin	O
in	O
the	O
rat	O
pineal	B-Anatomy
gland	I-Anatomy
and	O
at	O
the	O
same	O
time	O
it	O
increases	O
pineal	B-Anatomy
noradrenaline	O
.	O
These	O
effects	O
depend	O
on	O
the	O
stimulation	O
of	O
a	O
beta	O
-	O
adrenergic	O
receptor	O
because	O
they	O
are	O
blocked	O
by	O
pretreatment	O
of	O
the	O
animals	O
with	O
propranolol	O
;	O
this	O
drug	O
by	O
itself	O
does	O
not	O
modify	O
either	O
serotonin	O
or	O
noradrenaline	O
levels	O
in	O
the	O
pineal	B-Anatomy
.	O
The	O
elevation	O
of	O
noradrenaline	O
produced	O
by	O
isoproterenol	O
is	O
selective	O
for	O
the	O
pineal	B-Anatomy
because	O
it	O
is	O
not	O
observed	O
in	O
the	O
salivary	B-Anatomy
gland	I-Anatomy
innervated	O
by	O
postganglionic	B-Anatomy
adrenergic	I-Anatomy
fibers	I-Anatomy
from	O
the	O
same	O
origin	O
as	O
pineal	B-Anatomy
nerves	I-Anatomy
.	O
Pineal	B-Anatomy
serotonin	O
is	O
stored	O
in	O
equilibrium	O
in	O
two	O
compartments	B-Anatomy
,	O
i	O
.	O
e	O
.	O
,	O
the	O
parenchymal	B-Anatomy
cells	I-Anatomy
and	O
the	O
adrenergic	B-Anatomy
nerves	I-Anatomy
and	O
thus	O
is	O
most	O
probably	O
reduced	O
in	O
both	O
sites	B-Anatomy
.	O
Since	O
noradrenaline	O
and	O
serotonin	O
are	O
detected	O
in	O
pineal	B-Anatomy
nerve	I-Anatomy
vesicles	I-Anatomy
and	O
may	O
coexist	O
in	O
them	O
,	O
the	O
diminution	O
of	O
intravesicular	B-Anatomy
serotonin	O
,	O
by	O
making	O
more	O
storage	O
sites	B-Anatomy
available	O
,	O
probably	O
determines	O
the	O
selective	O
increase	O
of	O
pineal	B-Anatomy
noradrenaline	O
.	O
A	O
similar	O
modification	O
in	O
the	O
ratio	O
of	O
intravesicular	B-Anatomy
amines	O
as	O
a	O
result	O
of	O
the	O
physiological	O
stimulation	O
of	O
pineal	B-Anatomy
beta	O
-	O
adrenergic	O
receptors	O
by	O
the	O
adrenergic	O
neurotransmitter	O
may	O
explain	O
some	O
of	O
the	O
changes	O
observed	O
in	O
the	O
content	O
of	O
pineal	B-Anatomy
amines	O
.	O
Simian	O
virus	O
40	O
large	O
T	O
antigen	O
and	O
two	O
independent	O
T	O
-	O
antigen	O
segments	O
sensitize	O
cells	B-Anatomy
to	O
apoptosis	O
following	O
genotoxic	O
damage	O
.	O
The	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
large	O
tumor	O
(	O
T	O
)	O
antigen	O
is	O
sufficient	O
to	O
transform	O
cells	B-Anatomy
in	O
cultures	O
and	O
induce	O
tumors	B-Anatomy
in	O
experimental	O
animals	O
.	O
Transformation	O
of	O
primary	O
cells	B-Anatomy
in	O
cultures	O
requires	O
both	O
overcoming	O
growth	O
arrest	O
by	O
stimulating	O
the	O
cell	B-Anatomy
cycle	O
and	O
blocking	O
cell	B-Anatomy
death	O
activities	O
presumably	O
activated	O
by	O
oncogene	O
-	O
mediated	O
hyperproliferation	O
signals	O
.	O
The	O
study	O
presented	O
here	O
examined	O
the	O
ability	O
of	O
specific	O
regions	O
and	O
activities	O
of	O
T	O
antigen	O
to	O
modulate	O
apoptosis	O
in	O
cells	B-Anatomy
treated	O
with	O
the	O
genotoxic	O
agent	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
.	O
The	O
results	O
showed	O
that	O
the	O
expression	O
of	O
full	O
-	O
length	O
T	O
antigen	O
rendered	O
rat	O
embryo	B-Anatomy
fibroblasts	I-Anatomy
(	O
REF	B-Anatomy
)	O
sensitive	O
to	O
5	O
-	O
FU	O
-	O
induced	O
apoptosis	O
.	O
Thus	O
,	O
neither	O
the	O
p53	O
-	O
binding	O
region	O
nor	O
the	O
Bcl	O
-	O
2	O
homology	O
region	O
of	O
T	O
antigen	O
was	O
sufficient	O
to	O
prevent	O
cell	B-Anatomy
death	O
induced	O
by	O
the	O
DNA	O
-	O
damaging	O
agent	O
.	O
T	O
-	O
antigen	O
-	O
mediated	O
sensitization	O
occurred	O
independently	O
of	O
retinoblastoma	O
protein	O
or	O
p53	O
and	O
p300	O
binding	O
.	O
An	O
N	O
-	O
terminal	O
segment	O
containing	O
the	O
first	O
127	O
T	O
-	O
antigen	O
amino	O
acids	O
(	O
T1	O
-	O
127	O
)	O
was	O
sufficient	O
to	O
sensitize	O
cells	B-Anatomy
.	O
A	O
C	O
-	O
terminal	O
segment	O
consisting	O
of	O
T	O
-	O
antigen	O
amino	O
acids	O
251	O
to	O
708	O
(	O
T251	O
-	O
708	O
)	O
also	O
sensitized	O
cells	B-Anatomy
to	O
5	O
-	O
FU	O
-	O
induced	O
apoptosis	O
.	O
This	O
sensitization	O
did	O
not	O
occur	O
when	O
T251	O
-	O
708	O
was	O
targeted	O
to	O
the	O
nucleus	B-Anatomy
by	O
inclusion	O
of	O
the	O
SV40	O
nuclear	B-Anatomy
localization	O
signal	O
.	O
The	O
introduction	O
of	O
mutations	O
into	O
the	O
T	O
-	O
antigen	O
J	O
domain	O
resulted	O
in	O
mutation	O
-	O
specific	O
and	O
variable	O
inhibition	O
of	O
apoptosis	O
.	O
This	O
result	O
suggested	O
that	O
either	O
the	O
structural	O
or	O
the	O
functional	O
integrity	O
of	O
the	O
J	O
domain	O
is	O
required	O
to	O
sensitize	O
cells	B-Anatomy
to	O
apoptosis	O
.	O
Treatment	O
of	O
REF	B-Anatomy
or	O
REF	B-Anatomy
expressing	O
full	O
-	O
length	O
T	O
antigen	O
,	O
an	O
N	O
-	O
terminal	O
segment	O
,	O
or	O
T251	O
-	O
708	O
resulted	O
in	O
increased	O
expression	O
of	O
the	O
p53	O
-	O
responsive	O
MDM2	O
gene	O
;	O
apoptosis	O
occurred	O
through	O
a	O
p53	O
-	O
dependent	O
pathway	O
,	O
as	O
p53	B-Anatomy
-	I-Anatomy
cells	I-Anatomy
expressing	O
these	O
T	O
antigens	O
were	O
resistant	O
to	O
5	O
-	O
FU	O
-	O
induced	O
apoptosis	O
.	O
Possible	O
mechanisms	O
involved	O
in	O
sensitizing	O
cells	B-Anatomy
to	O
a	O
p53	O
-	O
dependent	O
apoptosis	O
pathway	O
in	O
spite	O
of	O
the	O
ability	O
of	O
T	O
antigen	O
to	O
bind	O
and	O
inactivate	O
the	O
transcriptional	O
transactivating	O
activity	O
of	O
p53	O
are	O
discussed	O
.	O
Optimizing	O
treatment	O
of	O
choroidal	B-Anatomy
neovascularization	O
feeder	B-Anatomy
vessels	I-Anatomy
associated	O
with	O
age	O
-	O
related	O
macular	B-Anatomy
degeneration	O
.	O
PURPOSE	O
:	O
To	O
optimize	O
the	O
method	O
of	O
treating	O
choroidal	B-Anatomy
neovascularization	O
(	O
CNV	O
)	O
associated	O
with	O
age	O
-	O
related	O
macular	B-Anatomy
degeneration	O
(	O
AMD	O
)	O
.	O
DESIGN	O
:	O
Experimental	O
study	O
and	O
interventional	O
case	O
series	O
.	O
METHODS	O
:	O
The	O
parameters	O
associated	O
with	O
locating	O
and	O
then	O
photocoagulating	O
CNV	O
feeder	B-Anatomy
vessels	I-Anatomy
were	O
identified	O
and	O
optimized	O
using	O
published	O
data	O
and	O
data	O
derived	O
from	O
modeling	O
the	O
choroidal	B-Anatomy
vasculature	I-Anatomy
.	O
Based	O
on	O
these	O
optimized	O
parameters	O
,	O
a	O
prototype	O
diagnostic	O
/	O
treatment	O
system	O
was	O
designed	O
that	O
captures	O
high	O
-	O
speed	O
indocyanine	O
green	O
(	O
ICG	O
)	O
angiogram	O
images	O
and	O
facilitates	O
analysis	O
of	O
the	O
images	O
by	O
enhancing	O
visualization	O
of	O
dye	O
movement	O
through	O
CNV	O
feeder	B-Anatomy
vessels	I-Anatomy
(	O
FVs	B-Anatomy
)	O
.	O
The	O
system	O
also	O
permits	O
precise	O
aiming	O
and	O
delivery	O
of	O
810	O
-	O
nm	O
wavelength	O
photocoagulation	O
laser	O
energy	O
to	O
target	O
FVs	B-Anatomy
on	O
a	O
real	O
-	O
time	O
ICG	O
angiogram	O
image	O
of	O
the	O
choroidal	B-Anatomy
vasculature	I-Anatomy
.	O
Target	O
FVs	B-Anatomy
are	O
tracked	O
by	O
a	O
joy	O
-	O
stick	O
controlled	O
laser	O
aiming	O
beam	O
until	O
an	O
intravenously	B-Anatomy
-	O
injected	O
high	O
-	O
concentration	O
ICG	O
dye	O
bolus	O
is	O
observed	O
to	O
enter	O
the	O
target	O
vessel	B-Anatomy
,	O
at	O
which	O
time	O
the	O
laser	O
is	O
fired	O
.	O
Proof	O
of	O
principle	O
of	O
the	O
combined	O
diagnosis	O
/	O
treatment	O
system	O
design	O
for	O
performing	O
dye	O
-	O
enhanced	O
photocoagulation	O
(	O
DEP	O
)	O
in	O
the	O
clinical	O
setting	O
and	O
determination	O
of	O
the	O
minimum	O
DEP	O
laser	O
energy	O
needed	O
to	O
close	O
CNV	O
FVs	B-Anatomy
was	O
made	O
in	O
11	O
AMD	O
patients	O
requiring	O
treatment	O
of	O
CNV	O
,	O
but	O
for	O
whom	O
other	O
treatment	O
was	O
not	O
appropriate	O
.	O
RESULTS	O
:	O
Using	O
ICG	O
-	O
DEP	O
,	O
CNV	O
feeder	B-Anatomy
vessels	I-Anatomy
were	O
closed	O
with	O
single	O
pulse	O
laser	O
energy	O
,	O
delivering	O
as	O
little	O
as	O
0	O
.	O
6	O
to	O
1	O
.	O
8	O
J	O
of	O
energy	O
to	O
the	O
fundus	B-Anatomy
,	O
producing	O
no	O
visible	O
change	O
in	O
the	O
fundus	B-Anatomy
.	O
Successful	O
FV	B-Anatomy
closure	O
was	O
usually	O
indicated	O
immediately	O
by	O
presence	O
of	O
incarcerated	O
ICG	O
dye	O
in	O
the	O
vessel	B-Anatomy
adjacent	O
to	O
the	O
burn	O
site	B-Anatomy
.	O
The	O
prototype	O
system	O
proved	O
relatively	O
easy	O
to	O
operate	O
.	O
After	O
acquiring	O
and	O
interpreting	O
diagnostic	O
angiograms	O
and	O
repositioning	O
a	O
patient	O
in	O
front	O
of	O
the	O
device	O
,	O
feeder	B-Anatomy
vessel	I-Anatomy
DEP	O
and	O
treatment	O
evaluation	O
required	O
15	O
to	O
20	O
minutes	O
.	O
CONCLUSIONS	O
:	O
Indocyanine	O
green	O
dye	O
-	O
enhanced	O
photocoagulation	O
of	O
CNV	O
feeder	B-Anatomy
vessels	I-Anatomy
,	O
facilitated	O
by	O
use	O
of	O
a	O
device	O
that	O
permits	O
real	O
-	O
time	O
visualization	O
of	O
the	O
choroidal	B-Anatomy
circulation	O
while	O
aiming	O
the	O
treatment	O
laser	O
beam	O
,	O
appears	O
to	O
minimize	O
the	O
amount	O
of	O
energy	O
applied	O
to	O
the	O
fundus	B-Anatomy
and	O
the	O
volume	O
of	O
fundus	B-Anatomy
tissue	I-Anatomy
affected	O
by	O
treatment	O
,	O
compared	O
with	O
other	O
treatment	O
modalities	O
.	O
The	O
combination	O
diagnosis	O
/	O
treatment	O
device	O
should	O
be	O
useful	O
in	O
optimizing	O
FV	B-Anatomy
treatment	O
and	O
in	O
refining	O
and	O
evaluating	O
the	O
efficacy	O
of	O
DEP	O
in	O
future	O
clinical	O
trials	O
.	O
Inhibition	O
of	O
angiogenesis	O
by	O
the	O
cancer	B-Anatomy
chemopreventive	O
agent	O
conjugated	O
linoleic	O
acid	O
.	O
Dietary	O
conjugated	O
linoleic	O
acid	O
(	O
CLA	O
)	O
has	O
been	O
shown	O
previously	O
to	O
inhibit	O
rat	O
mammary	B-Anatomy
carcinogenesis	O
.	O
In	O
addition	O
to	O
direct	O
effects	O
on	O
mammary	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
,	O
including	O
decreased	O
proliferation	O
and	O
induction	O
of	O
apoptosis	O
,	O
CLA	O
may	O
exert	O
its	O
effects	O
indirectly	O
by	O
inhibiting	O
the	O
differentiation	O
of	O
mammary	B-Anatomy
stromal	I-Anatomy
cells	I-Anatomy
to	O
an	O
endothelial	B-Anatomy
cell	I-Anatomy
type	I-Anatomy
.	O
Specifically	O
,	O
CLA	O
was	O
found	O
to	O
decrease	O
the	O
ability	O
of	O
mammary	B-Anatomy
stromal	I-Anatomy
cells	I-Anatomy
to	O
form	O
complex	O
anastomosing	O
microcapillary	B-Anatomy
networks	I-Anatomy
in	O
vitro	O
on	O
Engelbreth	O
-	O
Holm	O
-	O
Swarm	O
-	O
derived	O
reconstituted	O
basement	B-Anatomy
membrane	I-Anatomy
.	O
This	O
suggested	O
that	O
CLA	O
might	O
inhibit	O
angiogenesis	O
in	O
vivo	O
.	O
To	O
test	O
this	O
possibility	O
,	O
CD2	O
/	O
F	O
(	O
1	O
)	O
mice	O
were	O
placed	O
on	O
synthetic	O
diets	O
containing	O
0	O
,	O
1	O
,	O
or	O
2	O
%	O
CLA	O
for	O
6	O
weeks	O
,	O
before	O
angiogenic	O
challenge	O
by	O
s	O
.	O
c	O
.	O
injection	O
with	O
an	O
angiogenic	O
gel	O
substrate	O
(	O
Matrigel	O
pellet	O
assay	O
)	O
.	O
After	O
7	O
days	O
,	O
the	O
pellets	O
from	O
animals	O
fed	O
the	O
control	O
diet	O
were	O
infiltrated	O
by	O
abundant	O
branching	O
networks	B-Anatomy
of	I-Anatomy
blood	I-Anatomy
vessels	I-Anatomy
with	O
patent	O
lumen	B-Anatomy
-	O
containing	O
RBCs	B-Anatomy
.	O
In	O
contrast	O
,	O
pellets	O
from	O
the	O
CLA	O
-	O
fed	O
animals	O
contained	O
fewer	O
infiltrating	O
cells	B-Anatomy
,	O
which	O
formed	O
limited	O
branching	O
cellular	B-Anatomy
networks	I-Anatomy
,	O
the	O
majority	O
of	O
which	O
had	O
collapsed	O
lumen	B-Anatomy
and	O
no	O
RBCs	B-Anatomy
.	O
Both	O
levels	O
of	O
dietary	O
CLA	O
showed	O
similar	O
effects	O
,	O
with	O
the	O
number	O
of	O
RBC	B-Anatomy
-	O
containing	O
vessels	B-Anatomy
per	O
20x	O
field	O
decreased	O
to	O
a	O
third	O
of	O
that	O
seen	O
in	O
control	O
.	O
Dietary	O
CLA	O
decreased	O
serum	B-Anatomy
levels	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
whole	O
mammary	B-Anatomy
gland	I-Anatomy
levels	O
of	O
VEGF	O
and	O
its	O
receptor	O
Flk	O
-	O
1	O
.	O
Both	O
cis	O
-	O
9	O
,	O
trans	O
-	O
11	O
and	O
trans	O
-	O
10	O
,	O
cis	O
-	O
12	O
CLA	O
isomers	O
were	O
effective	O
in	O
inhibiting	O
angiogenesis	O
in	O
vitro	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O
The	O
ability	O
of	O
CLA	O
to	O
inhibit	O
angiogenesis	O
may	O
contribute	O
to	O
its	O
efficacy	O
as	O
a	O
chemopreventive	O
agent	O
.	O
Molecular	O
characterization	O
of	O
angiogenic	O
properties	O
of	O
human	O
oral	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
Little	O
is	O
known	O
about	O
the	O
specificity	O
of	O
angiogenic	O
properties	O
of	O
oral	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
and	O
the	O
possible	O
mechanisms	O
.	O
Stimulatory	O
effects	O
on	O
proliferation	O
and	O
migration	O
of	O
human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
(	O
HUVEC	B-Anatomy
)	O
characterized	O
the	O
angiogenic	O
properties	O
of	O
oral	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
but	O
not	O
normal	B-Anatomy
oral	I-Anatomy
keratinocytes	I-Anatomy
(	O
NOK	B-Anatomy
)	O
.	O
ELISA	O
found	O
the	O
presence	O
of	O
vascular	O
endothelial	O
growth	O
factors	O
(	O
VEGF	O
)	O
both	O
in	O
the	O
tested	O
oral	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
and	O
NOK	B-Anatomy
.	O
Attenuation	O
of	O
the	O
proangiogenic	O
effects	O
by	O
neutralizing	O
VEGF	O
antibodies	O
suggests	O
VEGF	O
play	O
a	O
key	O
role	O
in	O
the	O
acquisition	O
of	O
the	O
angiogenic	O
phenotype	O
in	O
oral	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Western	O
blotting	O
of	O
p53	O
and	O
murine	O
double	O
mutant	O
2	O
(	O
Mdm2	O
)	O
together	O
with	O
p53	O
DNA	O
sequencing	O
analysis	O
indicate	O
that	O
p53	O
function	O
loss	O
by	O
mutation	O
or	O
overexpression	O
of	O
Mdm2	O
occurred	O
in	O
all	O
tested	O
oral	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
regardless	O
of	O
their	O
etiology	O
.	O
In	O
summary	O
,	O
the	O
angiogenic	O
property	O
of	O
oral	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
is	O
mediated	O
by	O
many	O
factors	O
in	O
addition	O
to	O
VEGF	O
and	O
the	O
functional	O
status	O
of	O
p53	O
.	O
Impacts	O
of	O
water	O
management	O
options	O
on	O
flows	O
in	O
the	O
Condamine	O
River	O
in	O
Southern	O
Queensland	O
.	O
This	O
paper	O
examines	O
the	O
implications	O
for	O
river	O
flows	O
of	O
a	O
number	O
of	O
water	O
practices	O
and	O
potential	O
management	O
options	O
in	O
the	O
alluvial	O
plains	O
of	O
the	O
Upper	O
Condamine	O
River	O
.	O
It	O
is	O
an	O
intensively	O
cultivated	O
area	O
where	O
irrigation	O
is	O
limited	O
by	O
the	O
availability	O
of	O
water	O
resources	O
.	O
The	O
practice	O
of	O
capturing	O
overland	O
flows	O
was	O
investigated	O
by	O
the	O
development	O
of	O
a	O
model	O
that	O
simulates	O
the	O
performance	O
of	O
clusters	O
of	O
offstream	O
storages	O
up	O
to	O
sub	O
-	O
catchment	O
scale	O
.	O
Management	O
options	O
examined	O
included	O
improvement	O
to	O
on	O
-	O
farm	O
water	O
use	O
efficiency	O
,	O
the	O
suppression	O
of	O
evaporation	O
from	O
open	O
water	O
storages	O
,	O
increasing	O
the	O
depth	O
of	O
those	O
storages	O
,	O
decreasing	O
their	O
number	O
,	O
and	O
improved	O
tailwater	O
return	O
from	O
irrigated	O
land	O
.	O
Impacts	O
of	O
management	O
options	O
were	O
analysed	O
using	O
a	O
catchment	O
scale	O
water	O
allocation	O
model	O
.	O
Male	O
role	O
in	O
fertility	O
decisions	O
in	O
Robertsport	O
,	O
Liberia	O
:	O
an	O
experimental	O
exercise	O
for	O
policy	O
formulation	O
.	O
There	O
is	O
a	O
tendency	O
to	O
believe	O
that	O
in	O
African	O
societies	O
men	O
are	O
the	O
dominant	O
decision	O
makers	O
in	O
the	O
family	O
.	O
In	O
Robertsport	O
,	O
Liberia	O
,	O
there	O
are	O
indications	O
that	O
,	O
with	O
respect	O
to	O
fertility	O
regulation	O
,	O
the	O
dominance	O
of	O
the	O
husband	O
in	O
fertility	O
decisions	O
exists	O
,	O
but	O
it	O
is	O
also	O
apparent	O
that	O
many	O
of	O
these	O
decisions	O
are	O
made	O
jointly	O
by	O
both	O
husband	O
and	O
wife	O
.	O
Education	O
is	O
particularly	O
influential	O
in	O
the	O
joint	O
fertility	O
decision	O
-	O
making	O
process	O
.	O
The	O
100	O
husbands	O
sampled	O
in	O
1982	O
desired	O
a	O
large	O
number	O
of	O
children	O
and	O
had	O
experience	O
with	O
infant	O
and	O
child	O
mortality	O
.	O
If	O
family	O
planning	O
programs	O
should	O
attain	O
their	O
goals	O
,	O
men	O
should	O
be	O
more	O
involved	O
,	O
than	O
at	O
present	O
,	O
in	O
every	O
aspect	O
of	O
the	O
programs	O
.	O
Equally	O
important	O
is	O
the	O
urgency	O
for	O
studies	O
related	O
to	O
the	O
role	O
of	O
men	O
in	O
fertility	O
regulation	O
,	O
using	O
adequately	O
large	O
samples	O
.	O
Act	O
No	O
.	O
16	O
.	O
045	O
of	O
2	O
June	O
1989	O
prohibiting	O
all	O
discrimination	O
that	O
violates	O
the	O
principle	O
of	O
equality	O
of	O
treatment	O
and	O
opportunities	O
for	O
both	O
sexes	O
in	O
all	O
sectors	O
of	O
labor	O
activity	O
.	O
This	O
Uruguayan	O
Act	O
prohibits	O
discrimination	O
in	O
employment	O
with	O
respect	O
to	O
the	O
following	O
areas	O
,	O
among	O
others	O
:	O
1	O
)	O
advertising	O
for	O
the	O
provision	O
of	O
positions	O
;	O
2	O
)	O
selection	O
criteria	O
;	O
3	O
)	O
recruitment	O
and	O
hiring	O
;	O
4	O
)	O
evaluation	O
of	O
performance	O
criteria	O
;	O
5	O
)	O
the	O
right	O
to	O
advancement	O
and	O
promotion	O
;	O
6	O
)	O
labour	O
stability	O
;	O
7	O
)	O
social	O
benefits	O
;	O
8	O
)	O
suspension	O
and	O
dismissal	O
,	O
particularly	O
in	O
cases	O
involving	O
a	O
change	O
of	O
civil	O
status	O
,	O
pregnancy	O
,	O
or	O
nursing	O
;	O
9	O
)	O
possibilities	O
for	O
professional	O
and	O
technical	O
education	O
or	O
retraining	O
;	O
and	O
10	O
)	O
remuneration	O
criteria	O
.	O
Reserving	O
places	O
for	O
one	O
sex	O
because	O
of	O
the	O
presence	O
of	O
activities	O
in	O
which	O
the	O
sex	O
of	O
the	O
employee	O
is	O
essential	O
for	O
performance	O
or	O
to	O
comply	O
with	O
international	O
labor	O
treaties	O
does	O
not	O
constitute	O
discrimination	O
.	O
Nor	O
do	O
compensatory	O
acts	O
designed	O
to	O
promote	O
equality	O
of	O
opportunities	O
and	O
treatment	O
of	O
both	O
sexes	O
in	O
concrete	O
situations	O
.	O
In	O
cases	O
where	O
the	O
provisions	O
of	O
this	O
Act	O
have	O
been	O
violated	O
,	O
specially	O
designated	O
judges	O
will	O
call	O
the	O
parties	O
together	O
and	O
may	O
adopt	O
measures	O
designed	O
to	O
end	O
the	O
situation	O
complained	O
of	O
.	O
If	O
they	O
deem	O
it	O
necessary	O
,	O
the	O
judges	O
may	O
institute	O
more	O
formal	O
proceedings	O
.	O
If	O
the	O
measures	O
adopted	O
are	O
not	O
carried	O
out	O
,	O
the	O
person	O
violating	O
the	O
law	O
is	O
subject	O
to	O
a	O
daily	O
fine	O
,	O
as	O
well	O
as	O
administrative	O
penalties	O
set	O
out	O
in	O
Act	O
15	O
.	O
903	O
of	O
10	O
November	O
1987	O
.	O
Adverse	O
decisions	O
may	O
be	O
appealed	O
.	O
The	O
state	O
is	O
also	O
to	O
undertake	O
educative	O
campaigns	O
to	O
create	O
interest	O
in	O
and	O
understanding	O
of	O
the	O
problems	O
affecting	O
women	O
workers	O
,	O
thus	O
promoting	O
awareness	O
in	O
such	O
workers	O
and	O
their	O
employers	O
of	O
their	O
situation	O
.	O
Enforced	O
expression	O
of	O
tissue	O
inhibitor	O
of	O
matrix	O
metalloproteinase	O
-	O
3	O
affects	O
functional	O
capillary	B-Anatomy
morphogenesis	O
and	O
inhibits	O
tumor	B-Anatomy
growth	O
in	O
a	O
murine	O
tumor	B-Anatomy
model	O
.	O
Homeostasis	O
of	O
the	O
extracellular	B-Anatomy
matrix	I-Anatomy
is	O
a	O
delicate	O
balance	O
between	O
degradation	O
and	O
remodeling	O
,	O
the	O
balance	O
being	O
maintained	O
by	O
the	O
interaction	O
of	O
activated	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
specific	O
tissue	O
inhibitors	O
of	O
matrix	O
metalloproteinases	O
(	O
TIMPs	O
)	O
.	O
Up	O
-	O
regulation	O
of	O
MMP	O
activity	O
,	O
favoring	O
proteolytic	O
degradation	O
of	O
the	O
basement	B-Anatomy
membrane	I-Anatomy
and	O
extracellular	B-Anatomy
matrix	I-Anatomy
,	O
has	O
been	O
linked	O
to	O
tumor	B-Anatomy
growth	O
and	O
metastasis	O
,	O
as	O
well	O
as	O
tumor	B-Anatomy
-	O
associated	O
angiogenesis	O
,	O
whereas	O
inhibition	O
of	O
MMP	O
activity	O
appears	O
to	O
restrict	O
these	O
processes	O
.	O
We	O
have	O
used	O
retroviral	O
-	O
mediated	O
gene	O
delivery	O
to	O
effect	O
sustained	O
autocrine	O
expression	O
of	O
TIMP	O
-	O
3	O
in	O
murine	O
neuroblastoma	B-Anatomy
and	O
melanoma	B-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
in	O
order	O
to	O
further	O
examine	O
the	O
ability	O
of	O
TIMPs	O
to	O
inhibit	O
angiogenesis	O
in	O
vivo	O
.	O
Growth	O
of	O
both	O
histologic	O
types	O
of	O
gene	O
-	O
modified	O
tumor	B-Anatomy
cells	I-Anatomy
in	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
mice	O
was	O
significantly	O
restricted	O
when	O
compared	O
with	O
controls	O
.	O
Grossly	O
,	O
these	O
tumors	B-Anatomy
were	O
small	O
and	O
had	O
few	O
feeding	B-Anatomy
vessels	I-Anatomy
.	O
Histologic	O
evaluation	O
revealed	O
that	O
although	O
tumors	B-Anatomy
overexpressing	O
TIMP	O
-	O
3	O
had	O
an	O
increased	O
number	O
of	O
CD31	B-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
,	O
these	O
endothelial	B-Anatomy
cells	I-Anatomy
had	O
not	O
formed	O
functional	O
tubules	B-Anatomy
,	O
as	O
evidenced	O
by	O
decreased	O
vessel	B-Anatomy
continuity	O
and	O
minimal	O
pericyte	B-Anatomy
recruitment	O
.	O
This	O
effect	O
appears	O
to	O
be	O
mediated	O
,	O
in	O
part	O
,	O
by	O
decreased	O
expression	O
of	O
vascular	O
endothelial	O
(	O
VE	O
)	O
-	O
cadherin	O
by	O
endothelial	B-Anatomy
cells	I-Anatomy
in	O
the	O
presence	O
of	O
TIMP	O
-	O
3	O
as	O
seen	O
both	O
in	O
an	O
in	O
vitro	O
assay	O
and	O
in	O
TIMP	O
-	O
3	O
-	O
overexpressing	O
tumors	B-Anatomy
.	O
Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
overexpression	O
of	O
TIMP	O
-	O
3	O
can	O
inhibit	O
angiogenesis	O
and	O
associated	O
tumor	B-Anatomy
growth	O
,	O
and	O
that	O
the	O
antiangiogenic	O
effects	O
of	O
TIMP	O
-	O
3	O
appear	O
to	O
be	O
mediated	O
through	O
the	O
inhibition	O
of	O
functional	O
capillary	B-Anatomy
morphogenesis	O
.	O
Brn	O
-	O
3a	O
,	O
a	O
neuronal	B-Anatomy
transcription	O
factor	O
of	O
the	O
POU	O
gene	O
family	O
:	O
indications	O
for	O
its	O
involvement	O
in	O
cancer	B-Anatomy
and	O
angiogenesis	O
.	O
Brn	O
-	O
3a	O
,	O
a	O
member	O
of	O
the	O
POU	O
gene	O
family	O
(	O
so	O
-	O
called	O
because	O
of	O
the	O
similarity	O
with	O
the	O
group	O
of	O
transcription	O
factors	O
Pit	O
,	O
Oct	O
,	O
and	O
Unc	O
)	O
,	O
was	O
found	O
in	O
neuronal	B-Anatomy
cells	I-Anatomy
engaged	O
in	O
the	O
transcription	O
activity	O
of	O
the	O
p1	O
and	O
p2	O
promoters	O
of	O
the	O
most	O
powerful	O
antiapoptotic	O
gene	O
,	O
namely	O
,	O
Bcl	O
-	O
2	O
.	O
The	O
alternative	O
splicing	O
of	O
Brn	O
-	O
3a	O
mRNA	O
produces	O
two	O
molecular	O
forms	O
:	O
a	O
longer	O
,	O
Bcl	O
-	O
2	O
transactivating	O
form	O
,	O
and	O
a	O
shorter	O
inactive	O
form	O
,	O
lacking	O
84	O
AA	O
in	O
the	O
aminoterminus	O
.	O
In	O
neuronal	B-Anatomy
cells	I-Anatomy
,	O
following	O
Brn	O
-	O
3a	O
gene	O
transfection	O
and	O
superexpression	O
,	O
an	O
increase	O
of	O
30	O
fold	O
of	O
the	O
Bcl	O
-	O
2	O
protein	O
occurs	O
,	O
leading	O
to	O
apoptosis	O
protection	O
.	O
However	O
,	O
recent	O
works	O
demonstrate	O
that	O
Brn	O
-	O
3a	O
expression	O
is	O
not	O
restricted	O
to	O
neuronal	B-Anatomy
cells	I-Anatomy
,	O
as	O
its	O
activity	O
was	O
detected	O
also	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
of	O
non	O
-	O
neuronal	B-Anatomy
nature	O
.	O
Looking	O
for	O
mechanisms	O
linking	O
Brn	O
-	O
3a	O
to	O
carcinogenesis	O
,	O
we	O
discuss	O
the	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
influencing	O
Bcl	O
-	O
2	O
/	O
p53	O
antagonism	O
and	O
Bcl	O
-	O
2	O
/	O
VEGF	O
induction	O
of	O
tumor	B-Anatomy
angiogenesis	O
,	O
concluding	O
this	O
review	O
with	O
a	O
proposal	O
for	O
the	O
oncogenic	O
nature	O
of	O
Brn	O
-	O
3a	O
.	O
Roles	O
of	O
cell	B-Anatomy
adhesion	O
molecules	O
in	O
tumor	B-Anatomy
angiogenesis	O
induced	O
by	O
cotransplantation	O
of	O
cancer	B-Anatomy
and	O
endothelial	B-Anatomy
cells	I-Anatomy
to	O
nude	O
rats	O
.	O
Roles	O
of	O
cell	B-Anatomy
adhesion	O
molecules	O
mediating	O
the	O
interaction	O
of	O
cancer	B-Anatomy
and	O
endothelial	B-Anatomy
cells	I-Anatomy
in	O
tumor	B-Anatomy
angiogenesis	O
were	O
investigated	O
using	O
new	O
in	O
vitro	O
and	O
in	O
vivo	O
model	O
systems	O
with	O
a	O
cultured	O
murine	O
endothelial	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
(	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
)	O
and	O
human	O
cultured	O
epidermoid	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
(	O
A431	B-Anatomy
)	O
.	O
The	O
A431	B-Anatomy
cells	I-Anatomy
exhibited	O
typical	O
in	O
vitro	O
cell	B-Anatomy
adhesion	O
to	O
the	O
endothelial	B-Anatomy
F	I-Anatomy
-	I-Anatomy
2	I-Anatomy
cells	I-Anatomy
.	O
The	O
initial	O
step	O
of	O
adhesion	O
was	O
mediated	O
by	O
sialyl	O
Lewis	O
(	O
x	O
)	O
(	O
Le	O
(	O
x	O
)	O
)	O
and	O
sialyl	O
Le	O
(	O
a	O
)	O
,	O
the	O
carbohydrate	O
determinants	O
expressed	O
on	O
the	O
cancer	B-Anatomy
cells	I-Anatomy
,	O
and	O
E	O
-	O
selectin	O
expressed	O
constitutively	O
on	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
cells	I-Anatomy
.	O
Prolonged	O
culture	O
led	O
to	O
the	O
implantation	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
into	O
the	O
monolayer	B-Anatomy
of	O
the	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
cells	I-Anatomy
,	O
which	O
was	O
mediated	O
mainly	O
by	O
alpha	O
(	O
3	O
)	O
beta	O
(	O
1	O
)	O
-	O
integrin	O
.	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
cells	I-Anatomy
cultured	O
on	O
Matrigel	O
showed	O
evident	O
tube	B-Anatomy
formation	O
,	O
and	O
coculture	O
of	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
cells	I-Anatomy
with	O
A431	B-Anatomy
cells	I-Anatomy
led	O
to	O
the	O
formation	O
of	O
A431	B-Anatomy
cell	I-Anatomy
nests	O
constantly	O
surrounded	O
by	O
tube	B-Anatomy
-	I-Anatomy
like	I-Anatomy
networks	I-Anatomy
consisting	O
of	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
cells	I-Anatomy
.	O
This	O
in	O
vitro	O
morphogenesis	O
was	O
inhibited	O
by	O
the	O
addition	O
of	O
anti	O
-	O
sialyl	O
Le	O
(	O
x	O
)	O
/	O
Le	O
(	O
a	O
)	O
or	O
anti	O
-	O
beta	O
(	O
1	O
)	O
-	O
integrin	O
antibodies	O
,	O
which	O
led	O
to	O
the	O
formation	O
of	O
cancer	B-Anatomy
cell	I-Anatomy
aggregates	I-Anatomy
that	O
were	O
independent	O
from	O
the	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
cell	I-Anatomy
networks	O
.	O
This	O
in	O
vitro	O
morphological	O
appearance	O
was	O
exactly	O
reproduced	O
in	O
the	O
in	O
vivo	O
tumors	B-Anatomy
,	O
which	O
were	O
formed	O
when	O
the	O
mixture	O
of	O
A431	B-Anatomy
and	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
cells	I-Anatomy
at	O
the	O
ratio	O
of	O
10	O
:	O
1	O
were	O
cotransplanted	O
s	O
.	O
c	O
.	O
into	O
the	O
back	B-Anatomy
of	O
nude	O
rats	O
.	O
The	O
tumors	B-Anatomy
of	O
A431	B-Anatomy
supplemented	O
with	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
cells	I-Anatomy
were	O
profoundly	O
vascularized	O
throughout	O
by	O
the	O
tubular	B-Anatomy
structures	I-Anatomy
formed	O
by	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
cells	I-Anatomy
,	O
the	O
lumen	B-Anatomy
of	O
which	O
contained	O
the	O
host	O
rat	O
blood	B-Anatomy
cells	I-Anatomy
.	O
The	O
tumor	B-Anatomy
mass	I-Anatomy
thus	O
formed	O
was	O
an	O
average	O
5	O
.	O
8	O
-	O
fold	O
as	O
large	O
as	O
control	O
A431	B-Anatomy
tumors	I-Anatomy
that	O
were	O
grown	O
without	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
cells	I-Anatomy
.	O
The	O
co	O
-	O
injection	O
of	O
anti	O
-	O
Le	O
(	O
x	O
)	O
/	O
Le	O
(	O
a	O
)	O
or	O
anti	O
-	O
beta	O
(	O
1	O
)	O
-	O
integrin	O
antibodies	O
produced	O
a	O
marked	O
reduction	O
in	O
the	O
size	O
of	O
A431	B-Anatomy
tumors	I-Anatomy
,	O
which	O
were	O
not	O
vascularized	O
and	O
accompanied	O
an	O
independent	O
tiny	O
remnant	O
clump	O
of	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
cells	I-Anatomy
.	O
The	O
size	O
of	O
these	O
A431	B-Anatomy
tumors	I-Anatomy
did	O
not	O
differ	O
significantly	O
from	O
those	O
of	O
control	O
A431	B-Anatomy
tumors	I-Anatomy
raised	O
without	O
F	B-Anatomy
-	I-Anatomy
2	I-Anatomy
cells	I-Anatomy
.	O
These	O
results	O
indicate	O
that	O
the	O
interaction	O
of	O
tumor	B-Anatomy
cells	I-Anatomy
and	O
endothelial	B-Anatomy
cells	I-Anatomy
in	O
orderly	O
tumor	B-Anatomy
angiomorphogenesis	O
is	O
highly	O
dependent	O
on	O
the	O
action	O
of	O
cell	B-Anatomy
adhesion	O
molecules	O
mediating	O
the	O
adhesion	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
to	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
inhibition	O
of	O
which	O
remarkably	O
retards	O
tumor	B-Anatomy
growth	O
and	O
angiogenesis	O
.	O
Identification	O
of	O
Dss1	O
as	O
a	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
-	O
responsive	O
gene	O
expressed	O
in	O
keratinocyte	B-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
,	O
with	O
possible	O
involvement	O
in	O
early	O
skin	B-Anatomy
tumorigenesis	O
.	O
This	O
study	O
identifies	O
genes	O
expressed	O
early	O
in	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
-	O
induced	O
skin	B-Anatomy
carcinogenesis	O
in	O
genetically	O
initiated	O
Tg	O
.	O
AC	O
v	O
-	O
Ha	O
-	O
ras	O
transgenic	O
mice	O
.	O
Keratinocyte	B-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
from	O
TPA	O
-	O
treated	O
Tg	O
.	O
AC	O
mice	O
were	O
isolated	O
with	O
fluorescence	O
-	O
activated	O
cell	B-Anatomy
sorting	O
and	O
expression	O
was	O
analyzed	O
using	O
cDNA	O
microarray	O
technology	O
.	O
Eleven	O
genes	O
were	O
identified	O
whose	O
expression	O
changed	O
significantly	O
in	O
response	O
to	O
carcinogen	O
treatment	O
.	O
Deleted	O
in	O
split	O
hand	O
/	O
split	O
foot	O
1	O
(	O
Dss1	O
)	O
is	O
a	O
gene	O
associated	O
with	O
a	O
heterogeneous	O
limb	B-Anatomy
developmental	O
disorder	O
called	O
split	O
hand	B-Anatomy
/	O
split	O
foot	B-Anatomy
malformation	O
.	O
cDNA	O
microarray	O
expression	O
analysis	O
showed	O
that	O
the	O
mouse	O
homologue	O
of	O
Dss1	O
is	O
induced	O
by	O
TPA	O
.	O
Dss1	O
overexpression	O
was	O
detected	O
by	O
Northern	O
blot	O
analysis	O
in	O
early	O
TPA	O
-	O
treated	O
hyperplastic	B-Anatomy
skins	I-Anatomy
and	O
in	O
JB6	B-Anatomy
Cl	I-Anatomy
41	I-Anatomy
-	I-Anatomy
5a	I-Anatomy
epidermal	I-Anatomy
cells	I-Anatomy
.	O
Interestingly	O
,	O
Dss1	O
expression	O
was	O
also	O
shown	O
to	O
be	O
elevated	O
in	O
skin	B-Anatomy
papillomas	I-Anatomy
relative	O
to	O
normal	O
skins	B-Anatomy
,	O
and	O
further	O
increased	O
in	O
squamous	B-Anatomy
cell	I-Anatomy
malignancies	I-Anatomy
.	O
Functional	O
studies	O
by	O
ectopically	O
constitutive	O
expression	O
of	O
Dss1	O
in	O
JB6	B-Anatomy
Cl	I-Anatomy
41	I-Anatomy
-	I-Anatomy
5a	I-Anatomy
preneoplastic	I-Anatomy
cells	I-Anatomy
strongly	O
increased	O
focus	B-Anatomy
formation	O
and	O
proliferation	O
of	O
these	O
cells	B-Anatomy
and	O
enhanced	O
efficiency	O
of	O
neoplastic	B-Anatomy
transformation	O
of	O
the	O
cells	B-Anatomy
in	O
soft	O
agar	O
.	O
These	O
results	O
strongly	O
suggest	O
that	O
Dss1	O
is	O
a	O
TPA	O
-	O
inducible	O
gene	O
that	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
early	O
stages	O
of	O
skin	B-Anatomy
carcinogenesis	O
.	O
Downregulation	O
of	O
c	O
-	O
FLIP	O
sensitizes	O
DU145	B-Anatomy
prostate	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
to	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O
Although	O
DU145	B-Anatomy
prostate	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
are	O
resistant	O
to	O
exogenously	O
applied	O
Fas	O
agonist	O
CH	O
-	O
11	O
(	O
anti	O
-	O
Fas	O
monoclonal	O
antibody	O
)	O
,	O
Fas	O
-	O
resistance	O
can	O
be	O
overcome	O
using	O
a	O
FasL	O
expressing	O
adenovirus	O
(	O
AdGFPFasL	O
(	O
TET	O
)	O
)	O
[	O
Hyer	O
et	O
al	O
.	O
,	O
Molecular	O
Therapy	O
,	O
2000	O
;	O
2	O
:	O
348	O
-	O
58	O
(	O
ref	O
.	O
12	O
)	O
]	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
try	O
to	O
understand	O
why	O
DU145	B-Anatomy
cells	I-Anatomy
are	O
resistant	O
to	O
CH	O
-	O
11	O
and	O
determine	O
the	O
signaling	O
pathway	O
utilized	O
by	O
AdGFPFasL	O
(	O
TET	O
)	O
to	O
induce	O
apoptosis	O
in	O
these	O
Fas	O
-	O
resistant	O
cells	B-Anatomy
.	O
Using	O
immunoblot	O
analysis	O
,	O
we	O
show	O
that	O
AdGFPFasL	O
(	O
TET	O
)	O
is	O
capable	O
of	O
initiating	O
the	O
classic	O
Fas	O
-	O
mediated	O
apoptotic	O
pathway	O
in	O
DU145	B-Anatomy
cells	I-Anatomy
,	O
which	O
includes	O
activation	O
of	O
caspases	O
-	O
8	O
,	O
-	O
3	O
,	O
-	O
7	O
,	O
and	O
-	O
9	O
,	O
BID	O
cleavage	O
,	O
cytochrome	O
c	O
release	O
from	O
mitochondria	B-Anatomy
,	O
and	O
PARP	O
cleavage	O
.	O
In	O
contrast	O
,	O
CH	O
-	O
11	O
binds	O
to	O
Fas	O
,	O
but	O
is	O
unable	O
to	O
transmit	O
the	O
death	O
signal	O
beyond	O
the	O
plasma	B-Anatomy
membrane	I-Anatomy
suggesting	O
a	O
block	O
at	O
the	O
DISC	O
(	O
death	O
inducing	O
signaling	O
complex	O
)	O
.	O
The	O
anti	O
-	O
apoptotic	O
protein	O
c	O
-	O
FLIP	O
(	O
cellular	O
Flice	O
-	O
like	O
inhibitory	O
protein	O
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
inhibit	O
Fas	O
-	O
mediated	O
apoptosis	O
at	O
the	O
DISC	O
,	O
was	O
down	O
-	O
regulated	O
following	O
AdGFPFasL	O
(	O
TET	O
)	O
treatment	O
prompting	O
us	O
to	O
investigate	O
its	O
role	O
in	O
inhibiting	O
CH	O
-	O
11	O
-	O
induced	O
cell	B-Anatomy
death	O
.	O
Using	O
c	O
-	O
FLIP	O
anti	O
-	O
sense	O
oligonucleotides	O
to	O
down	O
-	O
regulate	O
c	O
-	O
FLIP	O
we	O
sensitized	O
DU145	B-Anatomy
cells	I-Anatomy
to	O
CH	O
-	O
11	O
-	O
induced	O
apoptosis	O
.	O
These	O
data	O
suggest	O
that	O
c	O
-	O
FLIP	O
may	O
play	O
a	O
critical	O
role	O
in	O
regulating	O
Fas	O
-	O
mediated	O
apoptosis	O
in	O
prostate	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
and	O
that	O
modulation	O
of	O
c	O
-	O
FLIP	O
may	O
enhance	O
Fas	O
signaling	O
based	O
therapies	O
.	O
Topoisomerase	O
I	O
protein	O
expression	O
in	O
primary	B-Anatomy
colorectal	I-Anatomy
cancer	I-Anatomy
and	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
.	O
Topoisomerase	O
I	O
(	O
topo	O
I	O
)	O
is	O
an	O
important	O
target	O
for	O
the	O
treatment	O
of	O
malignant	B-Anatomy
disease	I-Anatomy
,	O
especially	O
colorectal	B-Anatomy
cancer	I-Anatomy
.	O
Because	O
there	O
is	O
little	O
information	O
on	O
the	O
expression	O
of	O
topo	O
I	O
in	O
colorectal	B-Anatomy
tumors	I-Anatomy
,	O
this	O
study	O
evaluated	O
and	O
characterized	O
topo	O
I	O
protein	O
expression	O
in	O
primary	B-Anatomy
colorectal	I-Anatomy
cancer	I-Anatomy
and	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
and	O
studied	O
the	O
association	O
between	O
topo	O
I	O
protein	O
expression	O
and	O
clinicopathologic	O
data	O
,	O
p53	O
status	O
,	O
and	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
)	O
status	O
.	O
Immunohistochemistry	O
assay	O
was	O
performed	O
for	O
topo	O
I	O
protein	O
expression	O
in	O
249	O
primary	B-Anatomy
human	I-Anatomy
colorectal	I-Anatomy
cancer	I-Anatomy
and	O
42	O
paired	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	I-Anatomy
samples	I-Anatomy
.	O
Topo	O
I	O
expression	O
was	O
described	O
as	O
the	O
percentage	O
of	O
cells	B-Anatomy
staining	O
positive	O
for	O
topo	O
I	O
,	O
along	O
with	O
the	O
intensity	O
and	O
localization	O
of	O
the	O
staining	O
.	O
Clinicopathologic	O
data	O
(	O
sex	O
,	O
age	O
,	O
Dukes	O
'	O
stage	O
,	O
differentiation	O
grade	O
,	O
survival	O
status	O
)	O
,	O
p53	O
status	O
,	O
and	O
PCNA	O
status	O
were	O
statistically	O
analyzed	O
for	O
association	O
with	O
topo	O
I	O
protein	O
expression	O
.	O
Topo	O
I	O
expression	O
in	O
paired	O
primary	B-Anatomy
lymph	I-Anatomy
node	I-Anatomy
metastases	I-Anatomy
were	O
studied	O
for	O
concordance	O
.	O
Topo	O
I	O
protein	O
expression	O
was	O
detected	O
in	O
127	O
(	O
51	O
%	O
)	O
samples	B-Anatomy
,	O
including	O
24	O
.	O
4	O
%	O
with	O
>	O
50	O
%	O
positive	O
tumor	B-Anatomy
cells	I-Anatomy
.	O
The	O
majority	O
had	O
nuclear	B-Anatomy
(	O
70	O
.	O
1	O
%	O
)	O
or	O
nuclear	B-Anatomy
and	O
cytoplasmic	B-Anatomy
staining	O
(	O
17	O
.	O
3	O
%	O
)	O
.	O
A	O
higher	O
percentage	O
of	O
cells	B-Anatomy
expressing	O
topo	O
I	O
in	O
primary	B-Anatomy
colorectal	I-Anatomy
cancer	I-Anatomy
was	O
significantly	O
associated	O
with	O
advanced	O
age	O
(	O
P	O
=	O
.	O
040	O
)	O
.	O
Patients	O
with	O
rectal	B-Anatomy
cancer	I-Anatomy
had	O
greater	O
topo	O
I	O
expression	O
than	O
those	O
with	O
colon	B-Anatomy
tumors	I-Anatomy
(	O
P	O
=	O
.	O
029	O
)	O
.	O
No	O
significant	O
correlation	O
was	O
found	O
between	O
topo	O
I	O
protein	O
expression	O
and	O
sex	O
,	O
Dukes	O
'	O
stage	O
,	O
differentiation	O
grade	O
,	O
survival	O
status	O
,	O
p53	O
status	O
,	O
and	O
PCNA	O
status	O
.	O
Concordance	O
in	O
topo	O
I	O
staining	O
between	O
primary	B-Anatomy
and	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
was	O
observed	O
in	O
33	O
of	O
42	O
cases	O
(	O
P	O
=	O
.	O
029	O
)	O
.	O
This	O
suggests	O
that	O
the	O
activity	O
of	O
topo	O
I	O
inhibitors	O
will	O
not	O
differ	O
across	O
various	O
tumor	B-Anatomy
stages	O
,	O
pathology	O
,	O
and	O
patient	O
gender	O
.	O
p53	O
and	O
PCNA	O
status	O
do	O
not	O
appear	O
to	O
influence	O
topo	O
I	O
expression	O
,	O
and	O
topo	O
I	O
has	O
no	O
apparent	O
association	O
with	O
the	O
acquisition	O
of	O
a	O
metastatic	O
phenotype	O
.	O
Topo	O
I	O
expression	O
now	O
needs	O
to	O
be	O
evaluated	O
in	O
patients	O
undergoing	O
topo	O
I	O
-	O
inhibitor	O
therapy	O
,	O
to	O
better	O
define	O
the	O
role	O
of	O
this	O
protein	O
as	O
a	O
predictive	O
marker	O
.	O
CXC	O
chemokine	O
receptors	O
in	O
the	O
central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
:	O
Role	O
in	O
cerebellar	B-Anatomy
neuromodulation	O
and	O
development	O
.	O
Chemokines	O
and	O
their	O
receptors	O
are	O
constitutively	O
present	O
in	O
the	O
central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
(	O
CNS	B-Anatomy
)	O
,	O
expressed	O
in	O
neurons	B-Anatomy
and	O
glial	B-Anatomy
cells	I-Anatomy
.	O
Much	O
evidence	O
suggests	O
that	O
,	O
beyond	O
their	O
involvement	O
in	O
neuroinflammation	O
,	O
these	O
proteins	O
play	O
a	O
role	O
in	O
neurodevelopment	O
and	O
neurophysiological	O
signaling	O
.	O
The	O
goal	O
of	O
this	O
review	O
is	O
to	O
summarize	O
recent	O
information	O
concerning	O
expression	O
,	O
signaling	O
,	O
and	O
function	O
of	O
CXC	O
chemokine	O
receptor	O
in	O
the	O
CNS	B-Anatomy
,	O
with	O
the	O
main	O
focus	O
on	O
the	O
developmental	O
and	O
neuromodulatory	O
actions	O
of	O
chemokines	O
in	O
the	O
cerebellum	B-Anatomy
.	O
Combined	O
tracheal	B-Anatomy
and	O
esophageal	B-Anatomy
stenting	O
for	O
palliation	O
of	O
tracheoesophageal	B-Anatomy
symptoms	O
from	O
mediastinal	B-Anatomy
lymphoma	I-Anatomy
.	O
Mediastinal	B-Anatomy
lymphoma	I-Anatomy
as	O
a	O
cause	O
of	O
tracheobronchial	B-Anatomy
obstruction	O
is	O
uncommon	O
,	O
and	O
a	O
malignant	B-Anatomy
tracheoesophageal	I-Anatomy
fistula	I-Anatomy
in	O
the	O
setting	O
of	O
mediastinal	B-Anatomy
lymphoma	I-Anatomy
is	O
rare	O
.	O
Malignant	B-Anatomy
tracheoesophageal	I-Anatomy
fistulas	I-Anatomy
are	O
associated	O
with	O
pronounced	O
morbidity	O
and	O
mortality	O
.	O
We	O
describe	O
a	O
patient	O
with	O
mediastinal	B-Anatomy
lymphomatous	I-Anatomy
infiltration	O
resulting	O
in	O
tracheal	B-Anatomy
obstruction	O
,	O
esophageal	B-Anatomy
obstruction	O
,	O
and	O
tracheoesophageal	B-Anatomy
fistula	I-Anatomy
that	O
were	O
successfully	O
palliated	O
with	O
combined	O
airway	B-Anatomy
and	O
esophageal	B-Anatomy
stent	O
placement	O
.	O
Regulation	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
signaling	O
and	O
vascular	B-Anatomy
diseases	O
.	O
PURPOSE	O
:	O
Members	O
of	O
the	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
superfamily	O
play	O
critical	O
roles	O
in	O
regulation	O
of	O
various	O
cellular	B-Anatomy
functions	O
.	O
Dysregulation	O
of	O
the	O
signaling	O
mechanisms	O
of	O
the	O
TGF	O
-	O
beta	O
superfamily	O
proteins	O
is	O
associated	O
with	O
clinical	O
diseases	O
such	O
as	O
cancer	B-Anatomy
,	O
fibrotic	O
diseases	O
,	O
and	O
vascular	B-Anatomy
disorders	O
.	O
Therefore	O
,	O
understanding	O
these	O
signaling	O
mechanisms	O
may	O
provide	O
us	O
with	O
novel	O
ways	O
to	O
develop	O
strategies	O
for	O
treating	O
clinical	O
diseases	O
induced	O
by	O
these	O
cytokines	O
.	O
METHODS	O
:	O
This	O
review	O
discusses	O
our	O
current	O
understanding	O
of	O
the	O
mechanisms	O
of	O
TGF	O
-	O
beta	O
signaling	O
,	O
focusing	O
on	O
the	O
roles	O
of	O
TGF	O
-	O
beta	O
in	O
regulation	O
of	O
vascular	B-Anatomy
wall	I-Anatomy
cells	I-Anatomy
and	O
on	O
the	O
regulation	O
of	O
TGF	O
-	O
beta	O
superfamily	O
signals	O
by	O
inhibitory	O
Smads	O
.	O
[	O
Expression	O
and	O
mutation	O
of	O
c	O
-	O
kit	O
gene	O
in	O
gastrointestinal	B-Anatomy
stromal	I-Anatomy
tumor	I-Anatomy
]	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
the	O
expression	O
and	O
mutation	O
of	O
c	O
-	O
kit	O
gene	O
and	O
its	O
relationship	O
with	O
clinical	O
pathology	O
and	O
prognosis	O
of	O
gastrointestinal	B-Anatomy
stromal	I-Anatomy
tumor	I-Anatomy
(	O
GIST	B-Anatomy
)	O
.	O
METHODS	O
:	O
Immunohistochemical	O
and	O
PCR	O
-	O
SSCP	O
techniques	O
were	O
used	O
to	O
detect	O
c	O
-	O
kit	O
protein	O
expression	O
and	O
c	O
-	O
kit	O
gene	O
exon	O
11	O
mutation	O
in	O
82	O
patients	O
with	O
GIST	B-Anatomy
.	O
RESULTS	O
:	O
The	O
positive	O
c	O
-	O
kit	O
protein	O
expression	O
and	O
c	O
-	O
kit	O
gene	O
mutation	O
rates	O
were	O
97	O
.	O
6	O
%	O
(	O
80	O
/	O
82	O
)	O
and	O
41	O
.	O
5	O
%	O
(	O
34	O
/	O
82	O
)	O
.	O
Correlating	O
the	O
results	O
of	O
these	O
two	O
methods	O
and	O
clinicopathological	O
factors	O
,	O
the	O
c	O
-	O
kit	O
expression	O
and	O
c	O
-	O
kit	O
gene	O
mutation	O
rates	O
were	O
95	O
.	O
0	O
%	O
(	O
19	O
/	O
20	O
)	O
and	O
0	O
in	O
benign	B-Anatomy
GIST	I-Anatomy
,	O
and	O
were	O
98	O
.	O
4	O
%	O
(	O
61	O
/	O
62	O
)	O
,	O
54	O
.	O
8	O
%	O
(	O
34	O
/	O
62	O
)	O
in	O
malignant	B-Anatomy
GIST	I-Anatomy
.	O
Mutation	O
positive	O
GIST	B-Anatomy
showed	O
higher	O
frequency	O
of	O
adjacent	O
tissue	B-Anatomy
invasion	O
,	O
metastasis	O
and	O
recurrence	O
as	O
compared	O
with	O
mutation	O
negative	O
ones	O
.	O
CONCLUSION	O
:	O
c	O
-	O
kit	O
protein	O
is	O
an	O
important	O
diagnostic	O
marker	O
of	O
gastrointestinal	B-Anatomy
stromal	I-Anatomy
tumor	I-Anatomy
.	O
c	O
-	O
kit	O
gene	O
mutation	O
may	O
play	O
a	O
significant	O
role	O
in	O
the	O
pathogenesis	O
of	O
GIST	B-Anatomy
and	O
also	O
may	O
be	O
a	O
prognostic	O
marker	O
.	O
Inhibition	O
of	O
glucose	O
metabolism	O
sensitizes	O
tumor	B-Anatomy
cells	I-Anatomy
to	O
death	O
receptor	O
-	O
triggered	O
apoptosis	O
through	O
enhancement	O
of	O
death	O
-	O
inducing	O
signaling	O
complex	O
formation	O
and	O
apical	O
procaspase	O
-	O
8	O
processing	O
.	O
Tumors	B-Anatomy
display	O
a	O
high	O
rate	O
of	O
glucose	O
uptake	O
and	O
glycolysis	O
.	O
We	O
investigated	O
how	O
inhibition	O
of	O
glucose	O
metabolism	O
could	O
affect	O
death	O
receptor	O
-	O
mediated	O
apoptosis	O
in	O
human	O
tumor	B-Anatomy
cells	I-Anatomy
of	O
diverse	O
origin	O
.	O
We	O
show	O
that	O
both	O
substitution	O
of	O
glucose	O
for	O
pyruvate	O
and	O
treatment	O
with	O
2	O
-	O
deoxyglucose	O
enhanced	O
apoptosis	O
induced	O
by	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
,	O
CD95	O
agonistic	O
antibody	O
,	O
and	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
.	O
Inhibition	O
of	O
glucose	O
metabolism	O
enhanced	O
killing	O
of	O
myeloid	B-Anatomy
leukemia	I-Anatomy
U937	I-Anatomy
,	O
cervical	B-Anatomy
carcinoma	I-Anatomy
HeLa	I-Anatomy
,	O
and	O
breast	B-Anatomy
carcinoma	I-Anatomy
MCF	I-Anatomy
-	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
upon	O
death	O
receptor	O
ligation	O
.	O
Caspase	O
activation	O
,	O
mitochondrial	B-Anatomy
depolarization	O
,	O
and	O
cytochrome	O
c	O
release	O
were	O
increased	O
under	O
these	O
conditions	O
.	O
Glucose	O
deprivation	O
-	O
mediated	O
sensitization	O
to	O
apoptosis	O
was	O
prevented	O
in	O
MCF	B-Anatomy
-	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
overexpressing	O
BCL	O
-	O
2	O
.	O
Interestingly	O
,	O
the	O
human	O
B	B-Anatomy
-	I-Anatomy
lymphoblastoid	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
SKW6	I-Anatomy
.	I-Anatomy
4	I-Anatomy
,	O
a	O
prototype	O
for	O
mitochondria	B-Anatomy
-	O
independent	O
death	O
receptor	O
-	O
induced	O
apoptosis	O
,	O
was	O
also	O
sensitized	O
to	O
anti	O
-	O
CD95	O
and	O
TRAIL	O
-	O
induced	O
apoptosis	O
under	O
glucose	O
-	O
free	O
conditions	O
.	O
Changes	O
in	O
c	O
-	O
FLIP	O
(	O
L	O
)	O
and	O
cFLIPs	O
levels	O
were	O
observed	O
in	O
some	O
but	O
not	O
all	O
the	O
cell	B-Anatomy
lines	I-Anatomy
studied	O
following	O
glucose	O
deprivation	O
.	O
Glucose	O
deprivation	O
enhanced	O
death	O
receptor	O
-	O
triggered	O
formation	O
of	O
death	O
-	O
inducing	O
signaling	O
complex	O
and	O
early	O
processing	O
of	O
procaspase	O
-	O
8	O
.	O
Altogether	O
,	O
these	O
results	O
suggest	O
that	O
the	O
glycolytic	O
pathway	O
may	O
be	O
an	O
important	O
target	O
for	O
therapeutic	O
intervention	O
to	O
sensitize	O
tumor	B-Anatomy
cells	I-Anatomy
to	O
selectively	O
toxic	O
soluble	O
death	O
ligands	O
or	O
death	O
ligand	O
-	O
expressing	O
cells	B-Anatomy
of	O
the	O
immune	B-Anatomy
system	I-Anatomy
by	O
facilitating	O
the	O
activation	O
of	O
initiator	O
caspase	O
-	O
8	O
.	O
Rural	O
/	O
urban	O
differences	O
in	O
access	O
to	O
and	O
utilization	O
of	O
services	O
among	O
people	O
in	O
Alabama	O
with	O
sickle	B-Anatomy
cell	I-Anatomy
disease	O
.	O
OBJECTIVE	O
:	O
This	O
study	O
examined	O
relationships	O
between	O
socioeconomic	O
factors	O
and	O
the	O
geographic	O
distribution	O
of	O
662	O
cases	O
of	O
sickle	B-Anatomy
cell	I-Anatomy
disease	O
in	O
Alabama	O
in	O
1999	O
-	O
2001	O
.	O
METHODS	O
:	O
Measures	O
of	O
community	O
distress	O
,	O
physical	O
functioning	O
,	O
and	O
medical	O
problems	O
were	O
used	O
in	O
analyzing	O
utilization	O
differences	O
between	O
individuals	O
with	O
sickle	B-Anatomy
cell	I-Anatomy
disease	O
living	O
in	O
urban	O
and	O
rural	O
areas	O
.	O
RESULTS	O
:	O
Utilization	O
of	O
comprehensive	O
sickle	B-Anatomy
cells	I-Anatomy
disease	O
services	O
was	O
lower	O
for	O
individuals	O
with	O
sickle	B-Anatomy
cell	I-Anatomy
disease	O
living	O
in	O
rural	O
areas	O
than	O
for	O
those	O
living	O
in	O
urban	O
areas	O
.	O
Rural	O
clients	O
reported	O
significantly	O
more	O
limitations	O
than	O
urban	O
clients	O
on	O
several	O
measures	O
of	O
physical	O
functioning	O
.	O
The	O
results	O
also	O
suggest	O
that	O
utilization	O
of	O
services	O
was	O
higher	O
for	O
those	O
with	O
more	O
medical	O
problems	O
and	O
those	O
who	O
lived	O
in	O
high	O
distress	O
areas	O
,	O
although	O
these	O
findings	O
did	O
not	O
meet	O
the	O
criterion	O
for	O
statistical	O
significance	O
.	O
CONCLUSIONS	O
:	O
Conclusions	O
based	O
on	O
statistical	O
evidence	O
that	O
geographic	O
location	O
and	O
socioeconomic	O
factors	O
relate	O
to	O
significantly	O
different	O
health	O
care	O
service	O
experience	O
bear	O
important	O
implications	O
for	O
medical	O
and	O
health	O
care	O
support	O
systems	O
,	O
especially	O
on	O
the	O
community	O
level	O
.	O
Arteriogenesis	O
:	O
the	O
development	O
and	O
growth	O
of	O
collateral	B-Anatomy
arteries	I-Anatomy
.	O
In	O
patients	O
with	O
atherosclerotic	O
vascular	B-Anatomy
diseases	O
,	O
collateral	B-Anatomy
vessels	I-Anatomy
bypassing	O
major	O
arterial	B-Anatomy
obstructions	I-Anatomy
have	O
frequently	O
been	O
observed	O
.	O
This	O
may	O
explain	O
why	O
some	O
patients	O
remain	O
without	O
symptoms	O
or	O
signs	O
of	O
ischemia	O
.	O
The	O
term	O
""""	O
arteriogenesis	O
""""	O
was	O
introduced	O
to	O
differentiate	O
the	O
formation	O
of	O
collateral	B-Anatomy
arteries	I-Anatomy
from	O
angiogenesis	O
,	O
which	O
mainly	O
occurs	O
in	O
the	O
ischemic	O
,	O
collateral	O
flow	O
-	O
dependent	O
tissue	B-Anatomy
.	O
Many	O
observations	O
in	O
various	O
animal	O
models	O
and	O
humans	O
support	O
that	O
the	O
remodeling	O
of	O
preexisting	O
collateral	B-Anatomy
vessels	I-Anatomy
is	O
the	O
mechanism	O
of	O
collateral	B-Anatomy
artery	I-Anatomy
formation	O
.	O
This	O
remodeling	O
process	O
seems	O
to	O
be	O
mainly	O
flow	O
-	O
mediated	O
.	O
It	O
involves	O
endothelial	B-Anatomy
cell	I-Anatomy
activation	O
,	O
basal	B-Anatomy
membrane	I-Anatomy
degradation	O
,	O
leukocyte	B-Anatomy
invasion	O
,	O
proliferation	O
of	O
vascular	B-Anatomy
cells	I-Anatomy
,	O
neointima	B-Anatomy
formation	O
(	O
in	O
most	O
species	O
studied	O
)	O
,	O
and	O
changes	O
of	O
the	O
extracellular	B-Anatomy
matrix	I-Anatomy
.	O
The	O
contribution	O
of	O
ischemia	O
to	O
arteriogenesis	O
is	O
still	O
unclear	O
,	O
but	O
arteriogenesis	O
clearly	O
can	O
occur	O
in	O
the	O
absence	O
of	O
any	O
significant	O
ischemia	O
.	O
It	O
is	O
questionable	O
,	O
whether	O
collateral	B-Anatomy
arteries	I-Anatomy
also	O
form	O
de	O
novo	O
in	O
ischemic	O
vascular	B-Anatomy
diseases	O
.	O
A	O
better	O
understanding	O
of	O
the	O
mechanisms	O
of	O
arteriogenesis	O
will	O
be	O
important	O
for	O
the	O
design	O
of	O
more	O
effective	O
strategies	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
ischemic	O
vascular	B-Anatomy
diseases	O
.	O
Bee	O
venom	B-Anatomy
induces	O
apoptosis	O
and	O
inhibits	O
expression	O
of	O
cyclooxygenase	O
-	O
2	O
mRNA	O
in	O
human	O
lung	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
NCI	I-Anatomy
-	I-Anatomy
H1299	I-Anatomy
.	O
To	O
investigate	O
whether	O
bee	O
venom	B-Anatomy
(	O
BV	B-Anatomy
)	O
induces	O
apoptosis	O
,	O
the	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
2	O
,	O
5	O
-	O
diphenyltetrazolium	O
bromide	O
assay	O
,	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
nick	O
end	O
-	O
labeling	O
assay	O
,	O
4	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenylindole	O
staining	O
,	O
flow	O
cytometric	O
analysis	O
,	O
and	O
DNA	O
fragmentation	O
assay	O
were	O
performed	O
on	O
NCI	B-Anatomy
-	I-Anatomy
H1299	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
treated	O
with	O
BV	B-Anatomy
.	O
Through	O
morphological	O
and	O
biochemical	O
analyses	O
,	O
it	O
was	O
demonstrated	O
that	O
NCI	B-Anatomy
-	I-Anatomy
H1299	I-Anatomy
cells	I-Anatomy
treated	O
with	O
BV	B-Anatomy
exhibit	O
several	O
features	O
of	O
apoptosis	O
.	O
In	O
addition	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
prostaglandin	O
E	O
(	O
2	O
)	O
(	O
PGE	O
(	O
2	O
)	O
)	O
immunoassay	O
were	O
performed	O
to	O
verify	O
whether	O
BV	B-Anatomy
possesses	O
an	O
inhibitory	O
effect	O
on	O
the	O
expression	O
of	O
cyclooxygenase	O
(	O
COX	O
)	O
and	O
PGE	O
(	O
2	O
)	O
synthesis	O
.	O
Expression	O
of	O
COX	O
-	O
2	O
mRNA	O
and	O
synthesis	O
of	O
PGE	O
(	O
2	O
)	O
were	O
inhibited	O
by	O
BV	B-Anatomy
.	O
These	O
results	O
suggest	O
the	O
possibility	O
that	O
BV	B-Anatomy
may	O
exert	O
an	O
anti	O
-	O
tumor	B-Anatomy
effect	O
on	O
human	O
lung	B-Anatomy
cancer	I-Anatomy
.	O
Prenatal	O
aspects	O
of	O
ascorbic	O
acid	O
metabolism	O
in	O
the	O
albino	O
rat	O
.	O
Transfer	O
of	O
ascorbic	O
acid	O
and	O
/	O
or	O
its	O
derivatives	O
from	O
maternal	O
blood	B-Anatomy
into	O
the	O
fetus	B-Anatomy
was	O
studied	O
during	O
the	O
last	O
week	O
of	O
gestation	O
in	O
the	O
rat	O
.	O
Rats	O
were	O
injected	O
intravenously	B-Anatomy
with	O
[	O
1	O
-	O
14C	O
]	O
-	O
ascorbic	O
acid	O
and	O
the	O
rate	O
of	O
transfer	O
estimated	O
by	O
the	O
concentration	O
and	O
content	O
of	O
label	O
present	O
in	O
placentas	B-Anatomy
and	O
fetuses	B-Anatomy
.	O
At	O
all	O
times	O
studied	O
the	O
concentration	O
of	O
label	O
in	O
the	O
placenta	B-Anatomy
was	O
greater	O
than	O
in	O
the	O
fetus	B-Anatomy
.	O
The	O
highest	O
capacity	O
of	O
the	O
placenta	B-Anatomy
to	O
concentrate	O
label	O
was	O
found	O
on	O
day	O
15	O
decreasing	O
to	O
a	O
low	O
at	O
day	O
19	O
and	O
again	O
increasing	O
up	O
to	O
day	O
21	O
.	O
While	O
in	O
the	O
fetuses	B-Anatomy
,	O
the	O
concentration	O
of	O
label	O
per	O
gram	O
of	O
tissue	B-Anatomy
remained	O
remarkably	O
constant	O
throughout	O
the	O
study	O
.	O
The	O
quantity	O
of	O
labeled	O
compounds	O
transferred	O
into	O
the	O
fetus	B-Anatomy
per	O
gram	O
of	O
placental	B-Anatomy
tissue	I-Anatomy
increased	O
between	O
day	O
15	O
and	O
day	O
21	O
of	O
gestation	O
.	O
Possible	O
role	O
of	O
cyclooxygenase	O
II	O
in	O
the	O
acquisition	O
of	O
ovarian	B-Anatomy
luteal	I-Anatomy
function	O
in	O
rodents	O
.	O
The	O
development	O
of	O
the	O
corpus	B-Anatomy
luteum	I-Anatomy
(	O
CL	B-Anatomy
)	O
,	O
which	O
involves	O
angiogenesis	O
,	O
is	O
essential	O
for	O
the	O
establishment	O
of	O
early	O
pregnancy	O
.	O
We	O
investigated	O
the	O
roles	O
of	O
the	O
prostaglandin	O
synthases	O
cyclooxygenase	O
(	O
COX	O
)	O
I	O
and	O
COX	O
-	O
II	O
in	O
angiogenesis	O
and	O
progesterone	O
production	O
in	O
the	O
newly	O
formed	O
CL	B-Anatomy
,	O
using	O
inhibitors	O
of	O
the	O
COX	O
enzymes	O
and	O
the	O
gonadotropin	O
-	O
induced	O
pseudopregnant	O
rat	O
as	O
a	O
model	O
.	O
Injection	O
of	O
indomethacin	O
,	O
a	O
nonselective	O
COX	O
inhibitor	O
,	O
on	O
the	O
day	O
of	O
ovulation	O
and	O
the	O
following	O
day	O
decreased	O
serum	B-Anatomy
levels	O
of	O
progesterone	O
,	O
as	O
did	O
injection	O
of	O
the	O
selective	O
COX	O
-	O
II	O
inhibitor	O
NS	O
-	O
398	O
.	O
In	O
contrast	O
,	O
a	O
selective	O
COX	O
-	O
I	O
inhibitor	O
,	O
SC	O
-	O
560	O
,	O
had	O
no	O
effect	O
on	O
serum	B-Anatomy
progesterone	O
concentrations	O
.	O
None	O
of	O
the	O
inhibitors	O
had	O
any	O
effect	O
on	O
the	O
weight	O
of	O
the	O
superovulated	B-Anatomy
ovaries	I-Anatomy
or	O
on	O
the	O
synthesis	O
of	O
progesterone	O
by	O
cultured	B-Anatomy
luteal	I-Anatomy
cells	I-Anatomy
.	O
To	O
determine	O
whether	O
changes	O
in	O
angiogenesis	O
are	O
responsible	O
for	O
the	O
decrease	O
in	O
progesterone	O
synthesis	O
,	O
we	O
measured	O
hemoglobin	O
and	O
CD34	O
levels	O
in	O
luteinized	O
ovaries	B-Anatomy
following	O
injection	O
of	O
COX	O
inhibitors	O
and	O
measured	O
the	O
relative	O
frequency	O
of	O
cells	B-Anatomy
positive	O
for	O
platelet	O
-	O
endothelial	O
cell	O
adhesion	O
molecule	O
as	O
a	O
specific	O
marker	O
for	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
All	O
of	O
these	O
parameters	O
were	O
reduced	O
by	O
the	O
COX	O
-	O
II	O
inhibitors	O
,	O
suggesting	O
that	O
changes	O
in	O
the	O
vasculature	B-Anatomy
are	O
responsible	O
for	O
the	O
decrease	O
in	O
serum	B-Anatomy
progesterone	O
.	O
Histological	O
examination	O
of	O
ovarian	B-Anatomy
corrosion	O
casts	O
indicated	O
that	O
NS	O
-	O
398	O
inhibited	O
the	O
establishment	O
of	O
luteal	B-Anatomy
capillary	I-Anatomy
vessels	I-Anatomy
following	O
the	O
injection	O
of	O
hCG	O
.	O
The	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
activity	O
of	O
COX	O
-	O
II	O
is	O
associated	O
with	O
the	O
formation	O
of	O
functional	O
CL	B-Anatomy
via	O
its	O
stimulation	O
of	O
angiogenesis	O
.	O
Tumor	B-Anatomy
angiogenesis	O
modulates	O
leukocyte	B-Anatomy
-	O
vessel	B-Anatomy
wall	I-Anatomy
interactions	O
in	O
vivo	O
by	O
reducing	O
endothelial	O
adhesion	O
molecule	O
expression	O
.	O
The	O
expression	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
(	O
EC	B-Anatomy
)	O
adhesion	O
molecules	O
involved	O
in	O
leukocyte	B-Anatomy
-	O
vessel	B-Anatomy
wall	I-Anatomy
interactions	O
is	O
suppressed	O
in	O
malignancies	B-Anatomy
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
in	O
vivo	O
the	O
regulation	O
of	O
leukocyte	B-Anatomy
-	O
vessel	B-Anatomy
wall	I-Anatomy
interactions	O
by	O
the	O
presence	O
of	O
a	O
tumor	B-Anatomy
.	O
By	O
means	O
of	O
intravital	O
microscopy	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
-	O
stimulated	O
leukocyte	B-Anatomy
-	O
vessel	B-Anatomy
wall	I-Anatomy
interactions	O
were	O
studied	O
in	O
ear	B-Anatomy
skin	I-Anatomy
microvessels	I-Anatomy
of	O
nude	O
mice	O
bearing	O
small	O
human	O
LS174T	B-Anatomy
colon	I-Anatomy
carcinomas	I-Anatomy
and	O
in	O
C57Bl	O
/	O
6	O
mice	O
bearing	O
murine	O
B16F10	B-Anatomy
melanomas	I-Anatomy
.	O
Leukocyte	B-Anatomy
-	O
vessel	B-Anatomy
wall	I-Anatomy
interactions	O
were	O
studied	O
both	O
within	O
and	O
outside	O
small	O
tumors	B-Anatomy
growing	O
in	O
the	O
ear	B-Anatomy
,	O
and	O
in	O
ear	B-Anatomy
microvessels	I-Anatomy
of	O
mice	O
with	O
a	O
large	O
tumor	B-Anatomy
growing	O
on	O
their	O
flank	B-Anatomy
.	O
Tumor	B-Anatomy
-	O
free	O
mice	O
were	O
used	O
as	O
controls	O
.	O
Compared	O
with	O
values	O
measured	O
at	O
the	O
edge	O
of	O
the	O
ear	B-Anatomy
and	O
in	O
the	O
contralateral	O
ear	B-Anatomy
,	O
leukocyte	B-Anatomy
adhesion	O
was	O
found	O
to	O
be	O
diminished	O
significantly	O
in	O
vessels	B-Anatomy
inside	O
the	O
ear	B-Anatomy
tumor	I-Anatomy
in	O
both	O
mouse	O
models	O
.	O
This	O
reduction	O
disappeared	O
with	O
increasing	O
distance	O
from	O
the	O
tumor	B-Anatomy
.	O
Surprisingly	O
,	O
the	O
level	O
of	O
leukocyte	B-Anatomy
adhesion	O
in	O
ear	B-Anatomy
venules	I-Anatomy
of	O
mice	O
with	O
a	O
large	O
flank	B-Anatomy
tumor	I-Anatomy
was	O
also	O
reduced	O
significantly	O
.	O
Leukocyte	B-Anatomy
rolling	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
step	O
preceding	O
adhesion	O
,	O
was	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
a	O
tumor	B-Anatomy
in	O
nude	O
mice	O
,	O
but	O
was	O
down	O
-	O
regulated	O
in	O
immune	O
-	O
competent	O
C57Bl	O
/	O
6	O
mice	O
.	O
Treatment	O
of	O
mice	O
bearing	O
a	O
small	O
ear	B-Anatomy
tumor	I-Anatomy
with	O
a	O
humanized	O
antivascular	O
endothelial	O
growth	O
factor	O
antibody	O
prevented	O
the	O
down	O
-	O
regulation	O
of	O
leukocyte	B-Anatomy
-	O
vessel	B-Anatomy
wall	I-Anatomy
interactions	O
inside	O
the	O
tumor	B-Anatomy
vessels	I-Anatomy
compared	O
with	O
the	O
nontreated	O
group	O
.	O
Fluorescence	O
-	O
activated	O
cell	B-Anatomy
sorter	O
analysis	O
showed	O
that	O
isolated	O
tumor	B-Anatomy
ECs	I-Anatomy
have	O
suppressed	O
levels	O
of	O
intercellular	O
adhesion	O
molecule	O
1	O
as	O
compared	O
with	O
ECs	B-Anatomy
from	O
normal	O
mouse	O
tissues	B-Anatomy
.	O
In	O
cultured	O
b	B-Anatomy
.	I-Anatomy
END5	I-Anatomy
cells	I-Anatomy
the	O
tumor	O
necrosis	O
factor	O
alpha	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
intercellular	O
adhesion	O
molecule	O
1	O
and	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
was	O
reduced	O
in	O
ECs	B-Anatomy
that	O
were	O
preincubated	O
with	O
basic	O
fibroblast	O
growth	O
factor	O
or	O
vascular	O
endothelial	O
growth	O
factor	O
.	O
The	O
current	O
results	O
may	O
have	O
an	O
impact	O
on	O
the	O
effectiveness	O
of	O
clinical	O
immunotherapeutic	O
treatment	O
protocols	O
,	O
because	O
immune	B-Anatomy
effector	I-Anatomy
cells	I-Anatomy
may	O
not	O
be	O
able	O
to	O
enter	O
tumor	B-Anatomy
tissue	I-Anatomy
.	O
Impact	O
of	O
technology	O
on	O
the	O
utilisation	O
of	O
positron	O
emission	O
tomography	O
in	O
lymphoma	B-Anatomy
:	O
current	O
and	O
future	O
perspectives	O
.	O
Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
has	O
now	O
gained	O
a	O
place	O
in	O
the	O
management	O
of	O
patients	O
with	O
cancer	B-Anatomy
,	O
including	O
those	O
with	O
Hodgkin	O
'	O
s	O
disease	O
and	O
non	B-Anatomy
-	I-Anatomy
Hodgkin	I-Anatomy
'	I-Anatomy
s	I-Anatomy
lymphoma	I-Anatomy
.	O
Restaging	O
studies	O
and	O
those	O
addressing	O
the	O
monitoring	O
of	O
response	O
to	O
treatment	O
are	O
especially	O
in	O
focus	O
.	O
Most	O
of	O
the	O
knowledge	O
gained	O
has	O
been	O
achieved	O
with	O
dedicated	O
BGO	O
-	O
based	O
PET	O
technology	O
,	O
but	O
there	O
are	O
a	O
number	O
of	O
developments	O
that	O
will	O
impact	O
on	O
the	O
use	O
of	O
this	O
metabolic	O
imaging	O
technique	O
in	O
the	O
investigation	O
of	O
patients	O
with	O
lymphoma	B-Anatomy
.	O
The	O
challenges	O
ahead	O
are	O
determined	O
by	O
the	O
need	O
for	O
high	O
-	O
quality	O
whole	O
-	O
body	O
imaging	O
associated	O
with	O
increased	O
patient	O
throughput	O
and	O
the	O
need	O
to	O
investigate	O
the	O
role	O
of	O
new	O
labelled	O
ligands	O
.	O
The	O
latter	O
are	O
likely	O
to	O
yield	O
new	O
insights	O
into	O
tumour	B-Anatomy
cell	I-Anatomy
characterisation	O
,	O
tumour	B-Anatomy
behaviour	O
and	O
tumour	B-Anatomy
outcome	O
assessment	O
.	O
The	O
study	O
of	O
new	O
radiolabelled	O
ligands	O
will	O
impose	O
further	O
demands	O
for	O
rapid	O
dynamic	O
data	O
acquisition	O
and	O
accurate	O
tracer	O
quantification	O
.	O
Current	O
and	O
future	O
developments	O
in	O
PET	O
technology	O
range	O
from	O
the	O
use	O
of	O
new	O
detector	O
materials	O
to	O
different	O
detector	O
geometries	O
and	O
data	O
acquisition	O
modes	O
.	O
The	O
search	O
for	O
alternatives	O
to	O
BGO	O
scintillation	O
materials	O
for	O
PET	O
has	O
led	O
to	O
the	O
development	O
of	O
PET	O
instruments	O
utilising	O
new	O
crystals	O
such	O
as	O
LSO	O
and	O
GSO	O
.	O
The	O
use	O
of	O
these	O
new	O
detectors	O
and	O
the	O
increased	O
sensitivity	O
achieved	O
with	O
3D	O
data	O
acquisitions	O
represent	O
the	O
most	O
significant	O
current	O
developments	O
in	O
the	O
field	O
.	O
With	O
the	O
increasing	O
demands	O
imposed	O
on	O
the	O
clinical	O
utilisation	O
of	O
PET	O
,	O
issues	O
such	O
as	O
study	O
cost	O
and	O
patient	O
throughput	O
will	O
emerge	O
as	O
significant	O
future	O
factors	O
.	O
As	O
a	O
consequence	O
,	O
low	O
-	O
cost	O
units	O
are	O
being	O
offered	O
by	O
the	O
manufacturers	O
through	O
the	O
utilisation	O
of	O
gamma	O
camera	O
-	O
based	O
SPET	O
systems	O
for	O
PET	O
coincidence	O
imaging	O
.	O
Unfortunately	O
,	O
clinical	O
studies	O
in	O
lymphoma	B-Anatomy
and	O
other	O
cancers	B-Anatomy
have	O
already	O
demonstrated	O
the	O
limitations	O
of	O
this	O
technology	O
,	O
with	O
20	O
%	O
of	O
lesions	B-Anatomy
<	O
15	O
mm	O
in	O
size	O
escaping	O
detection	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
recent	O
development	O
of	O
combined	O
PET	O
/	O
CT	O
devices	O
attempts	O
to	O
address	O
the	O
lack	O
of	O
anatomical	O
information	O
inherent	O
with	O
PET	O
images	O
,	O
taking	O
advantage	O
of	O
further	O
improvement	O
in	O
patient	O
throughput	O
and	O
hence	O
cost	O
-	O
effectiveness	O
.	O
Preliminary	O
studies	O
using	O
this	O
multimodality	O
imaging	O
approach	O
have	O
already	O
demonstrated	O
the	O
potential	O
of	O
the	O
technique	O
.	O
Although	O
the	O
potential	O
exists	O
,	O
certain	O
technical	O
issues	O
with	O
PET	O
/	O
CT	O
require	O
refinement	O
of	O
the	O
methodology	O
.	O
Such	O
issues	O
include	O
organ	B-Anatomy
movement	O
(	O
such	O
as	O
respiratory	B-Anatomy
motion	O
)	O
,	O
which	O
strongly	O
influences	O
the	O
image	O
fusion	O
of	O
a	O
rapidly	O
acquired	O
CT	O
scan	O
with	O
the	O
slower	O
acquisition	O
of	O
a	O
PET	O
dataset	O
,	O
and	O
the	O
derivation	O
of	O
CT	O
-	O
based	O
attenuation	O
coefficients	O
in	O
the	O
presence	O
of	O
contrast	O
agents	O
or	O
metallic	O
implants	O
.	O
The	O
application	O
of	O
the	O
technology	O
for	O
radiotherapy	O
planning	O
also	O
poses	O
a	O
number	O
of	O
associated	O
challenges	O
.	O
Finally	O
,	O
the	O
development	O
of	O
dedicated	O
PET	O
systems	O
based	O
on	O
planar	O
detector	O
arrangements	O
with	O
new	O
detector	O
components	O
has	O
the	O
potential	O
to	O
improve	O
clinical	O
throughput	O
by	O
over	O
100	O
%	O
,	O
but	O
clinical	O
trials	O
using	O
such	O
systems	O
have	O
still	O
to	O
be	O
carried	O
out	O
in	O
order	O
to	O
establish	O
the	O
associated	O
whole	O
-	O
body	B-Anatomy
image	O
quality	O
.	O
[	O
Effects	O
of	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein	O
1	O
(	O
EBV	O
-	O
LMP1	O
)	O
on	O
related	O
factors	O
of	O
metastasis	O
of	O
nasopharyngeal	B-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
CNE1	I-Anatomy
]	O
.	O
BACKGROUND	O
&	O
#	O
38	O
;	O
OBJECTIVE	O
:	O
It	O
has	O
been	O
proved	O
that	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
latent	O
membrane	O
protein	O
1	O
(	O
EBV	O
-	O
LMP1	O
)	O
can	O
induce	O
the	O
expression	O
of	O
matrix	O
metalloproteinase	O
-	O
9	O
(	O
MMP	O
-	O
9	O
)	O
.	O
This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
EBV	O
-	O
LMP1	O
on	O
related	O
factors	O
of	O
metastasis	O
of	O
nasopharyngeal	B-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
CNE1	I-Anatomy
.	O
METHODS	O
:	O
Expression	O
of	O
MMP	O
-	O
9	O
was	O
studied	O
in	O
human	O
NPC	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
cultured	O
in	O
vitro	O
:	O
CNE1	B-Anatomy
(	O
well	O
differentiated	O
cell	B-Anatomy
line	I-Anatomy
of	O
NPC	B-Anatomy
)	O
and	O
CNE1	B-Anatomy
-	I-Anatomy
GL	I-Anatomy
(	O
CNE1	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
transfected	O
with	O
an	O
eukaryotic	O
LMP1	O
-	O
expression	O
plasmid	B-Anatomy
)	O
by	O
SP	O
immunohistochemistry	O
and	O
Western	O
blot	O
analysis	O
.	O
Cell	B-Anatomy
-	O
matrix	B-Anatomy
adhesion	O
assay	O
was	O
used	O
to	O
study	O
the	O
adhesive	O
ability	O
of	O
CNE1	B-Anatomy
-	I-Anatomy
GL	I-Anatomy
cells	I-Anatomy
.	O
The	O
effects	O
of	O
LMP1	O
on	O
the	O
invasion	O
and	O
migration	O
of	O
CNE1	B-Anatomy
cells	I-Anatomy
were	O
investigated	O
by	O
transwell	O
methods	O
.	O
RESULTS	O
:	O
MMP	O
-	O
9	O
was	O
expressed	O
in	O
both	O
cell	B-Anatomy
lines	I-Anatomy
but	O
the	O
intensity	O
of	O
the	O
staining	O
was	O
different	O
.	O
The	O
positive	O
rates	O
of	O
expression	O
of	O
MMP	O
-	O
9	O
in	O
CNE1	B-Anatomy
and	O
CNE1	B-Anatomy
-	I-Anatomy
GL	I-Anatomy
cells	I-Anatomy
were	O
30	O
.	O
2	O
%	O
and	O
98	O
.	O
2	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
The	O
increased	O
expression	O
of	O
MMP	O
-	O
9	O
was	O
also	O
shown	O
in	O
CNE1	B-Anatomy
-	I-Anatomy
GL	I-Anatomy
cells	I-Anatomy
by	O
Western	O
blot	O
analysis	O
.	O
Cell	B-Anatomy
-	O
matrix	B-Anatomy
adhesion	O
assay	O
showed	O
that	O
the	O
adhesive	O
ability	O
of	O
CNE1	B-Anatomy
-	I-Anatomy
GL	I-Anatomy
with	O
the	O
matrix	B-Anatomy
(	O
mean	O
A	O
value	O
:	O
1	O
.	O
2508	O
+	O
/	O
-	O
0	O
.	O
0711	O
)	O
was	O
higher	O
than	O
that	O
of	O
CNE1	B-Anatomy
cell	I-Anatomy
(	O
mean	O
A	O
value	O
:	O
0	O
.	O
9519	O
+	O
/	O
-	O
0	O
.	O
068	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
Invasion	O
assay	O
and	O
migration	O
assay	O
showed	O
that	O
the	O
invasion	O
and	O
migration	O
of	O
CNE1	B-Anatomy
-	I-Anatomy
GL	I-Anatomy
cell	I-Anatomy
were	O
higher	O
than	O
those	O
of	O
CNE1	B-Anatomy
cells	I-Anatomy
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
CONCLUSION	O
:	O
The	O
transfection	O
of	O
LMP1	O
can	O
increase	O
the	O
expression	O
of	O
MMP	O
-	O
9	O
in	O
CNE1	B-Anatomy
cells	I-Anatomy
.	O
Abilities	O
of	O
adhesion	O
,	O
migration	O
,	O
and	O
invasion	O
of	O
CNE1	B-Anatomy
cell	I-Anatomy
were	O
induced	O
by	O
LMP1	O
.	O
It	O
is	O
suggested	O
that	O
MMP	O
-	O
9	O
may	O
have	O
a	O
role	O
in	O
the	O
LMP1	O
-	O
induced	O
acceleration	O
of	O
invasion	O
and	O
metastasis	O
of	O
NPC	B-Anatomy
cells	I-Anatomy
.	O
Truncated	O
galectin	O
-	O
3	O
inhibits	O
tumor	B-Anatomy
growth	O
and	O
metastasis	O
in	O
orthotopic	O
nude	O
mouse	O
model	O
of	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
PURPOSE	O
:	O
The	O
goal	O
of	O
this	O
research	O
was	O
to	O
evaluate	O
a	O
potential	O
therapeutic	O
agent	O
for	O
breast	B-Anatomy
cancer	I-Anatomy
based	O
on	O
galectin	O
-	O
3	O
that	O
has	O
been	O
implicated	O
in	O
tumorigenicity	O
and	O
metastasis	O
of	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
The	O
hypothesis	O
was	O
that	O
therapy	O
with	O
NH	O
(	O
2	O
)	O
-	O
terminally	O
truncated	O
form	O
of	O
galectin	O
-	O
3	O
(	O
galectin	O
-	O
3C	O
)	O
will	O
be	O
efficacious	O
for	O
reduction	O
in	O
tumor	B-Anatomy
growth	O
and	O
for	O
inhibition	O
of	O
metastases	O
.	O
EXPERIMENTAL	O
DESIGN	O
:	O
Recombinant	O
human	O
galectin	O
-	O
3	O
was	O
produced	O
in	O
Escherichia	O
coli	O
from	O
which	O
galectin	O
-	O
3C	O
was	O
derived	O
by	O
collagenase	O
enzyme	O
digestion	O
.	O
Toxicity	O
,	O
pharmacokinetic	O
,	O
and	O
organ	B-Anatomy
biodistribution	O
studies	O
were	O
performed	O
in	O
nude	O
mice	O
.	O
For	O
efficacy	O
studies	O
,	O
nude	O
mice	O
bearing	O
orthotopically	O
implanted	O
tumors	B-Anatomy
derived	O
from	O
breast	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
MDA	I-Anatomy
-	I-Anatomy
MB	I-Anatomy
-	I-Anatomy
435	I-Anatomy
were	O
treated	O
with	O
galectin	O
-	O
3C	O
or	O
a	O
vehicle	O
control	O
i	O
.	O
m	O
.	O
twice	O
daily	O
for	O
90	O
days	O
.	O
RESULTS	O
:	O
The	O
maximum	O
tolerated	O
dose	O
of	O
galectin	O
-	O
3C	O
in	O
nude	O
mice	O
was	O
determined	O
to	O
be	O
>	O
125	O
mg	O
/	O
kg	O
without	O
overt	O
adverse	O
effects	O
.	O
The	O
elimination	O
half	O
-	O
life	O
when	O
administered	O
i	O
.	O
m	O
.	O
was	O
found	O
to	O
be	O
3	O
.	O
0	O
h	O
in	O
the	O
serum	B-Anatomy
and	O
4	O
.	O
3	O
h	O
in	O
the	O
cellular	B-Anatomy
fraction	O
of	O
the	O
blood	B-Anatomy
.	O
Organ	O
biodistribution	O
studies	O
revealed	O
that	O
galectin	O
-	O
3C	O
localized	O
in	O
the	O
liver	B-Anatomy
,	O
kidneys	B-Anatomy
,	O
and	O
spleen	B-Anatomy
but	O
not	O
in	O
the	O
heart	B-Anatomy
or	O
lungs	B-Anatomy
.	O
We	O
found	O
that	O
the	O
mean	O
tumor	B-Anatomy
volumes	O
and	O
weights	O
were	O
statistically	O
significantly	O
less	O
in	O
mice	O
treated	O
with	O
galectin	O
-	O
3C	O
compared	O
with	O
control	O
mice	O
,	O
and	O
that	O
fewer	O
numbers	O
of	O
mice	O
exhibited	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
in	O
the	O
treated	O
group	O
compared	O
with	O
the	O
control	O
group	O
.	O
CONCLUSIONS	O
:	O
Galectin	O
-	O
3C	O
is	O
not	O
overtly	O
toxic	O
,	O
and	O
is	O
efficacious	O
in	O
reducing	O
metastases	B-Anatomy
and	O
tumor	B-Anatomy
volumes	O
and	O
weights	O
in	O
primary	B-Anatomy
tumors	I-Anatomy
in	O
an	O
orthotopic	O
nude	O
mouse	O
model	O
of	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
[	O
Screening	O
and	O
identification	O
of	O
novel	O
genes	O
involved	O
in	O
biosynthesis	O
of	O
ginsenoside	O
in	O
Panax	O
ginseng	O
plant	O
]	O
.	O
The	O
root	B-Anatomy
of	O
Panax	O
ginseng	O
plant	O
undergoes	O
a	O
specific	O
developmental	O
process	O
to	O
become	O
a	O
biosynthesis	O
and	O
accumulation	O
organ	B-Anatomy
for	O
ginsenosides	O
.	O
To	O
identify	O
and	O
analyze	O
genes	O
involved	O
in	O
the	O
biosynthesis	O
of	O
ginsenoside	O
,	O
suppression	O
subtractive	O
hybridization	O
(	O
SSH	O
)	O
between	O
mRNAs	O
of	O
4	O
-	O
and	O
1	O
-	O
year	O
-	O
old	O
root	B-Anatomy
tissues	I-Anatomy
was	O
performed	O
,	O
and	O
a	O
subtracted	O
cDNA	O
library	O
specific	O
to	O
4	O
-	O
year	O
-	O
old	O
roots	B-Anatomy
was	O
constructed	O
.	O
Forty	O
cDNA	O
clones	O
selected	O
randomly	O
from	O
the	O
subtracted	O
cDNA	O
library	O
were	O
sequenced	O
.	O
Sequence	O
information	O
of	O
all	O
clones	O
was	O
evaluated	O
by	O
Nucleotide	O
Blast	O
analysis	O
in	O
GenBank	O
/	O
DDBJ	O
/	O
EMBL	O
.	O
The	O
results	O
showed	O
that	O
six	O
subtracted	O
cDNA	O
clones	O
represented	O
the	O
novel	O
genes	O
(	O
ESTs	O
)	O
,	O
because	O
no	O
sequence	O
homology	O
with	O
any	O
known	O
sequences	O
was	O
found	O
in	O
the	O
database	O
.	O
Expression	O
in	O
4	O
-	O
year	O
-	O
old	O
P	O
.	O
ginseng	O
root	B-Anatomy
tissues	I-Anatomy
was	O
verified	O
by	O
reverse	O
Northern	O
dot	O
hybridization	O
for	O
the	O
six	O
clones	O
.	O
These	O
six	O
novel	O
genes	O
were	O
named	O
GBR1	O
,	O
GBR2	O
,	O
GBR3	O
,	O
GBR4	O
,	O
GBR5	O
,	O
and	O
GBR6	O
,	O
and	O
their	O
Accession	O
numbers	O
of	O
GenBank	O
are	O
AF485334	O
,	O
AF485335	O
,	O
AF485336	O
,	O
AF485337	O
,	O
AF485332	O
,	O
and	O
AF485333	O
,	O
respectively	O
.	O
Finally	O
,	O
Northern	O
blot	O
analysis	O
and	O
semi	O
-	O
quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
confirmed	O
that	O
these	O
six	O
novel	O
genes	O
were	O
differentially	O
expressed	O
in	O
the	O
defined	O
development	O
stage	O
of	O
P	O
.	O
ginseng	O
plant	O
roots	B-Anatomy
.	O
It	O
is	O
possible	O
that	O
their	O
overexpression	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
ginsenoside	O
biosynthesis	O
.	O
In	O
addition	O
,	O
most	O
of	O
transcripts	O
of	O
all	O
genes	O
could	O
also	O
be	O
detected	O
in	O
other	O
P	O
.	O
ginseng	O
plant	O
tissues	B-Anatomy
such	O
as	O
stem	B-Anatomy
,	O
leaf	B-Anatomy
and	O
seed	B-Anatomy
.	O
Our	O
results	O
provided	O
a	O
basis	O
for	O
obtaining	O
the	O
full	O
-	O
length	O
cDNA	O
sequences	O
of	O
such	O
six	O
novel	O
genes	O
,	O
and	O
for	O
identifying	O
their	O
function	O
involved	O
in	O
the	O
biosynthesis	O
of	O
ginsenoside	O
.	O
Prognostic	O
value	O
of	O
p53	O
protein	O
expression	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
expression	O
in	O
resected	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
of	O
the	O
esophagus	B-Anatomy
.	O
The	O
most	O
common	O
genetic	O
alterations	O
found	O
in	O
a	O
wide	O
variety	O
of	O
cancers	B-Anatomy
are	O
p53	O
tumor	B-Anatomy
suppressor	O
gene	O
mutations	O
.	O
p53	O
appears	O
to	O
be	O
a	O
nuclear	B-Anatomy
transcription	O
factor	O
that	O
plays	O
a	O
role	O
in	O
the	O
control	O
of	O
cell	B-Anatomy
proliferation	O
,	O
apoptosis	O
,	O
and	O
the	O
maintenance	O
of	O
genetic	O
stability	O
.	O
Angiogenesis	O
is	O
a	O
critical	O
process	O
in	O
solid	B-Anatomy
tumor	I-Anatomy
growth	O
and	O
metastasis	O
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
a	O
recently	O
identified	O
growth	O
factor	O
with	O
significant	O
angiogenic	O
properties	O
,	O
may	O
be	O
a	O
major	O
tumor	B-Anatomy
angiogenesis	O
regulator	O
.	O
Few	O
studies	O
have	O
investigated	O
the	O
association	O
between	O
p53	O
and	O
VEGF	O
expressions	O
and	O
prognosis	O
in	O
esophageal	B-Anatomy
carcinoma	I-Anatomy
.	O
Forty	O
-	O
seven	O
specimens	B-Anatomy
resected	O
from	O
patients	O
with	O
stage	O
II	O
and	O
III	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	O
SCC	B-Anatomy
)	O
of	O
the	O
esophagus	B-Anatomy
were	O
studied	O
using	O
immunohistochemical	O
staining	O
.	O
VEGF	O
and	O
p53	O
expressions	O
were	O
observed	O
in	O
40	O
%	O
and	O
53	O
%	O
of	O
the	O
tumors	B-Anatomy
,	O
respectively	O
.	O
The	O
p53	O
and	O
VEGF	O
staining	O
statuses	O
were	O
coincident	O
in	O
only	O
21	O
%	O
of	O
the	O
tumors	B-Anatomy
,	O
and	O
no	O
significant	O
correlation	O
was	O
found	O
between	O
p53	O
and	O
VEGF	O
statuses	O
.	O
No	O
clinicopathologic	O
factors	O
were	O
significantly	O
correlated	O
with	O
p53	O
or	O
VEGF	O
expression	O
.	O
No	O
significant	O
association	O
between	O
p53	O
and	O
VEGF	O
expressions	O
and	O
poor	O
prognosis	O
was	O
found	O
.	O
In	O
conclusion	O
,	O
p53	O
and	O
VEGF	O
were	O
not	O
correlated	O
with	O
prognosis	O
in	O
patients	O
with	O
stage	O
II	O
and	O
III	O
SCC	B-Anatomy
of	O
the	O
esophagus	B-Anatomy
.	O
The	O
role	O
of	O
organ	B-Anatomy
vascularization	O
and	O
lipoplex	O
-	O
serum	B-Anatomy
initial	O
contact	O
in	O
intravenous	B-Anatomy
murine	O
lipofection	O
.	O
Following	O
intravenous	B-Anatomy
administration	O
of	O
cationic	O
lipid	O
-	O
DNA	O
complexes	O
(	O
lipoplexes	O
)	O
into	O
mice	O
,	O
transfection	O
(	O
lipofection	O
)	O
occurs	O
predominantly	O
in	O
the	O
lungs	B-Anatomy
.	O
This	O
was	O
attributed	O
to	O
high	O
entrapment	O
of	O
lipoplexes	O
in	O
the	O
extended	O
lung	B-Anatomy
vascular	I-Anatomy
tree	I-Anatomy
.	O
To	O
determine	O
whether	O
lipofection	O
in	O
other	O
organs	B-Anatomy
could	O
be	O
enhanced	O
by	O
increasing	O
the	O
degree	O
of	O
vascularization	O
,	O
we	O
used	O
a	O
transgenic	O
mouse	O
model	O
with	O
tissue	B-Anatomy
-	O
specific	O
angiogenesis	O
in	O
liver	B-Anatomy
.	O
Tail	B-Anatomy
vein	I-Anatomy
injection	O
of	O
N	O
-	O
(	O
1	O
-	O
(	O
2	O
,	O
3	O
-	O
dioleoyloxy	O
)	O
propyl	O
)	O
-	O
N	O
,	O
N	O
,	O
N	O
-	O
trimethylammonium	O
chloride	O
(	O
DOTAP	O
)	O
/	O
cholesterol	O
lipoplexes	O
resulted	O
in	O
increased	O
lipoplex	O
entrapment	O
in	O
hypervascularized	O
liver	B-Anatomy
but	O
did	O
not	O
boost	O
luciferase	O
expression	O
,	O
suggesting	O
that	O
lipoplex	O
delivery	O
is	O
not	O
a	O
sufficient	O
condition	O
for	O
efficient	O
organ	B-Anatomy
lipofection	O
.	O
Because	O
the	O
intravenously	B-Anatomy
injected	O
lipoplexes	O
migrated	O
within	O
seconds	O
to	O
lungs	B-Anatomy
,	O
we	O
checked	O
whether	O
the	O
effects	O
of	O
immediate	O
contact	O
with	O
serum	B-Anatomy
correlate	O
with	O
lung	B-Anatomy
lipofection	O
efficiency	O
of	O
different	O
DOTAP	O
-	O
based	O
formulations	O
.	O
Under	O
conditions	O
mimicking	O
the	O
injection	O
environment	O
,	O
the	O
lipoplex	O
-	O
serum	B-Anatomy
interaction	O
was	O
strongly	O
dependent	O
on	O
helper	O
lipid	O
and	O
ionic	O
strength	O
:	O
lipoplexes	O
prepared	O
in	O
150	O
mM	O
NaCl	O
or	O
lipoplexes	O
with	O
high	O
(	O
greater	O
than	O
33	O
mol	O
%	O
)	O
cholesterol	O
were	O
found	O
to	O
aggregate	O
immediately	O
.	O
This	O
aggregation	O
process	O
was	O
irreversible	O
and	O
was	O
inversely	O
correlated	O
with	O
the	O
percentage	O
of	O
lung	B-Anatomy
cells	I-Anatomy
that	O
took	O
up	O
lipoplexes	O
and	O
with	O
the	O
efficiency	O
of	O
lipofection	O
.	O
No	O
other	O
structural	O
changes	O
in	O
serum	B-Anatomy
were	O
observed	O
for	O
cholesterol	O
-	O
based	O
lipoplexes	O
.	O
Dioleoyl	O
phosphatidylethanolamine	O
-	O
based	O
lipoplexes	O
were	O
found	O
to	O
give	O
low	O
expression	O
,	O
apparently	O
because	O
of	O
an	O
immediate	O
loss	O
of	O
integrity	O
in	O
serum	B-Anatomy
,	O
without	O
lipid	O
-	O
DNA	O
dissociation	O
.	O
Our	O
study	O
suggests	O
that	O
efficient	O
in	O
vivo	O
lipofection	O
is	O
the	O
result	O
of	O
cross	O
-	O
talk	O
between	O
lipoplex	O
composition	O
,	O
interaction	O
with	O
serum	B-Anatomy
,	O
hemodynamics	O
,	O
and	O
target	O
tissue	B-Anatomy
""""	O
susceptibility	O
""""	O
to	O
transfection	O
.	O
Stereoselective	O
synthesis	O
of	O
1	O
-	O
aminoalkanephosphonic	O
acids	O
with	O
two	O
chiral	O
centers	O
and	O
their	O
activity	O
towards	O
leucine	O
aminopeptidase	O
.	O
The	O
stereoselective	O
synthesis	O
of	O
1	O
-	O
amino	O
-	O
2	O
-	O
alkylalkanephosphonic	O
acids	O
,	O
namely	O
,	O
compounds	O
bearing	O
two	O
chiral	O
centers	O
,	O
was	O
achieved	O
by	O
the	O
condensation	O
of	O
hypophosphorous	O
acid	O
salts	O
of	O
(	O
R	O
)	O
(	O
+	O
)	O
or	O
(	O
S	O
)	O
(	O
-	O
)	O
-	O
N	O
-	O
alpha	O
-	O
methylbenzylamine	O
with	O
the	O
appropriate	O
aldehydes	O
in	O
isopropanol	O
.	O
Simultaneous	O
deprotection	O
and	O
oxidation	O
by	O
the	O
action	O
of	O
bromine	O
water	O
provided	O
equimolar	O
mixtures	O
of	O
the	O
RS	O
:	O
RR	O
and	O
SR	O
:	O
SS	O
diastereomers	O
of	O
desired	O
acids	O
.	O
They	O
appeared	O
to	O
act	O
as	O
moderate	O
inhibitors	O
of	O
kidney	B-Anatomy
leucine	O
aminopeptidase	O
with	O
potency	O
dependent	O
on	O
the	O
absolute	O
configuration	O
of	O
both	O
centers	O
of	O
chirality	O
.	O
Proliferative	O
diabetic	O
retinopathy	O
is	O
associated	O
with	O
a	O
low	O
level	O
of	O
the	O
natural	O
ocular	B-Anatomy
anti	O
-	O
angiogenic	O
agent	O
pigment	O
epithelium	O
-	O
derived	O
factor	O
(	O
PEDF	O
)	O
in	O
aqueous	B-Anatomy
humor	I-Anatomy
.	O
a	O
pilot	O
study	O
.	O
Retinopathy	O
is	O
the	O
most	O
common	O
microvascular	B-Anatomy
diabetes	O
complication	O
and	O
represents	O
a	O
major	O
threat	O
to	O
the	O
eyesight	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
address	O
the	O
role	O
of	O
pro	O
-	O
and	O
anti	O
-	O
angiogenic	O
molecules	O
in	O
diabetic	O
retinopathy	O
in	O
the	O
aqueous	B-Anatomy
humor	I-Anatomy
of	O
the	O
eye	B-Anatomy
.	O
Aqueous	B-Anatomy
humor	I-Anatomy
was	O
collected	O
at	O
cataract	O
surgery	O
from	O
19	O
diabetic	O
patients	O
and	O
from	O
13	O
age	O
-	O
and	O
sex	O
-	O
matched	O
normoglycemic	O
controls	O
.	O
Levels	O
of	O
pro	O
-	O
angiogenic	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
angiogenic	O
inhibitor	O
pigment	O
epithelium	O
-	O
derived	O
factor	O
(	O
PEDF	O
)	O
were	O
determined	O
.	O
Angiogenic	O
activity	O
of	O
the	O
aqueous	B-Anatomy
humor	I-Anatomy
was	O
quantified	O
by	O
measuring	O
its	O
effect	O
on	O
the	O
migration	O
of	O
capillary	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
In	O
the	O
aqueous	B-Anatomy
fluid	I-Anatomy
,	O
VEGF	O
levels	O
were	O
increased	O
in	O
diabetics	O
(	O
mean	O
values	O
:	O
501	O
vs	O
.	O
367	O
pg	O
/	O
ml	O
;	O
p	O
=	O
0	O
.	O
05	O
)	O
,	O
compared	O
to	O
controls	O
.	O
PEDF	O
was	O
found	O
to	O
be	O
decreased	O
in	O
diabetics	O
(	O
mean	O
values	O
:	O
2080	O
vs	O
.	O
5780	O
ng	O
/	O
ml	O
;	O
p	O
=	O
0	O
.	O
04	O
)	O
compared	O
to	O
controls	O
.	O
In	O
seven	O
diabetic	O
patients	O
with	O
proliferative	O
retinopathy	O
,	O
the	O
most	O
profound	O
finding	O
was	O
a	O
significant	O
decrease	O
of	O
the	O
PEDF	O
level	O
(	O
mean	O
value	O
:	O
237	O
ng	O
/	O
ml	O
)	O
,	O
whereas	O
VEGF	O
levels	O
were	O
comparable	O
to	O
diabetic	O
patients	O
without	O
proliferation	O
(	O
mean	O
value	O
:	O
3153	O
;	O
p	O
=	O
0	O
.	O
003	O
)	O
.	O
Angiogenic	O
activity	O
in	O
samples	O
of	O
patients	O
from	O
the	O
control	O
group	O
was	O
generally	O
inhibitory	O
due	O
to	O
PEDF	O
,	O
and	O
inhibition	O
was	O
blocked	O
by	O
neutralizing	O
antibodies	O
to	O
PEDF	O
.	O
Likewise	O
,	O
in	O
diabetics	O
without	O
proliferation	O
,	O
angiogenic	O
activity	O
was	O
also	O
blocked	O
by	O
antibodies	O
to	O
PEDF	O
.	O
We	O
will	O
demonstrate	O
here	O
that	O
the	O
level	O
of	O
the	O
natural	O
ocular	B-Anatomy
anti	O
-	O
angiogenic	O
agent	O
PEDF	O
is	O
inversely	O
associated	O
with	O
proliferative	O
retinopathy	O
.	O
PEDF	O
is	O
an	O
important	O
negative	O
regulator	O
of	O
angiogenic	O
activity	O
of	O
aqueous	B-Anatomy
humor	I-Anatomy
.	O
Our	O
data	O
may	O
have	O
implications	O
for	O
the	O
development	O
of	O
novel	O
regimens	O
for	O
diabetic	O
retinopathy	O
.	O
Expression	O
of	O
osteoprotegerin	O
and	O
RANK	O
ligand	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
bone	B-Anatomy
metastasis	O
.	O
Bone	B-Anatomy
destruction	O
is	O
primarily	O
mediated	O
by	O
osteoclastic	B-Anatomy
bone	B-Anatomy
resorption	O
,	O
and	O
cancer	B-Anatomy
cells	I-Anatomy
stimulate	O
the	O
formation	O
and	O
activation	O
of	O
osteoclasts	B-Anatomy
next	O
to	O
metastatic	B-Anatomy
foci	I-Anatomy
.	O
Accumulating	O
evidences	O
indicate	O
that	O
receptor	O
activator	O
of	O
NF	O
-	O
kB	O
ligand	O
(	O
RANKL	O
)	O
is	O
the	O
ultimate	O
extracellular	B-Anatomy
mediator	O
that	O
stimulates	O
osteoclast	B-Anatomy
differentiation	O
into	O
mature	O
osteoclasts	B-Anatomy
.	O
In	O
contrast	O
,	O
osteoprotegerin	O
(	O
OPG	O
)	O
inhibits	O
osteoclast	B-Anatomy
development	O
.	O
In	O
order	O
to	O
elucidate	O
a	O
mechanism	O
for	O
cancer	B-Anatomy
-	O
induced	O
osteoclastogenesis	O
,	O
cells	B-Anatomy
from	O
a	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
line	I-Anatomy
,	O
MDA	B-Anatomy
-	I-Anatomy
MB	I-Anatomy
-	I-Anatomy
231	I-Anatomy
,	O
were	O
directly	O
co	O
-	O
cultured	O
with	O
ST2	B-Anatomy
,	O
MC3T3	B-Anatomy
-	I-Anatomy
E1	I-Anatomy
,	O
or	O
with	O
primary	O
mouse	O
calvarial	B-Anatomy
cells	I-Anatomy
.	O
Osteoclast	B-Anatomy
-	I-Anatomy
like	I-Anatomy
cells	I-Anatomy
and	O
tartarate	O
resistant	O
acid	O
phosphatase	O
(	O
TRAP	O
)	O
activities	O
were	O
then	O
quantitated	O
.	O
We	O
examined	O
these	O
cell	B-Anatomy
lines	I-Anatomy
and	O
samples	B-Anatomy
from	O
breast	B-Anatomy
cancer	I-Anatomy
by	O
RT	O
-	O
PCR	O
for	O
the	O
expressions	O
of	O
OPG	O
and	O
RANKL	O
mRNA	O
.	O
Compared	O
to	O
controls	O
,	O
co	O
-	O
culture	O
of	O
MDA	B-Anatomy
-	I-Anatomy
MB	I-Anatomy
-	I-Anatomy
231	I-Anatomy
cells	I-Anatomy
with	O
stromal	B-Anatomy
or	O
osteoblastic	B-Anatomy
cells	I-Anatomy
induced	O
an	O
increase	O
in	O
number	O
of	O
osteoclasts	B-Anatomy
and	O
TRAP	O
activities	O
.	O
MDA	B-Anatomy
-	I-Anatomy
MB	I-Anatomy
-	I-Anatomy
231	I-Anatomy
cells	I-Anatomy
alone	O
or	O
breast	B-Anatomy
cancer	I-Anatomy
samples	I-Anatomy
did	O
not	O
express	O
RANKL	O
mRNA	O
.	O
However	O
,	O
co	O
-	O
culture	O
of	O
these	O
cancer	B-Anatomy
cells	I-Anatomy
with	O
stromal	B-Anatomy
or	O
osteoblastic	B-Anatomy
cells	I-Anatomy
induced	O
RANKL	O
mRNA	O
expression	O
and	O
decreased	O
OPG	O
mRNA	O
expression	O
.	O
These	O
experiments	O
demonstrate	O
that	O
direct	O
interactions	O
between	O
breast	B-Anatomy
cancer	I-Anatomy
and	O
stromal	B-Anatomy
or	O
osteoblastic	B-Anatomy
cells	I-Anatomy
induce	O
osteoclastogenesis	O
in	O
vitro	O
through	O
modulating	O
RANKL	O
expression	O
.	O
[	O
Community	O
intervention	O
on	O
hypertension	O
and	O
stroke	O
]	O
.	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
community	O
-	O
based	O
intervention	O
on	O
reduction	O
of	O
hypertension	O
and	O
stroke	O
in	O
different	O
age	O
groups	O
and	O
subtypes	O
hypertension	O
.	O
METHODS	O
:	O
In	O
6	O
cities	O
,	O
2	O
geographically	O
separated	O
communities	O
with	O
a	O
registered	O
population	O
about	O
10	O
000	O
of	O
each	O
were	O
selected	O
as	O
either	O
intervention	O
or	O
control	O
communities	O
.	O
A	O
cohort	O
containing	O
2	O
700	O
subjects	O
,	O
35	O
years	O
or	O
older	O
,	O
and	O
free	O
of	O
stroke	O
were	O
sampled	O
from	O
each	O
community	O
.	O
The	O
baseline	O
survey	O
was	O
conducted	O
to	O
screen	O
the	O
subjects	O
for	O
intervention	O
.	O
In	O
each	O
city	O
,	O
a	O
program	O
for	O
control	O
of	O
hypertension	O
,	O
heart	B-Anatomy
diseases	O
and	O
diabetes	O
was	O
initiated	O
in	O
the	O
intervention	O
cohort	O
and	O
health	O
education	O
was	O
provided	O
to	O
the	O
whole	O
intervention	O
community	O
.	O
A	O
follow	O
-	O
up	O
survey	O
was	O
conducted	O
3	O
years	O
later	O
.	O
RESULTS	O
:	O
Within	O
3	O
years	O
,	O
the	O
prevalence	O
of	O
hypertension	O
increased	O
in	O
both	O
intervention	O
and	O
control	O
cohorts	O
,	O
as	O
well	O
as	O
in	O
the	O
middle	O
and	O
elderly	O
cohorts	O
,	O
especially	O
in	O
the	O
middle	O
aged	O
in	O
control	O
group	O
.	O
Among	O
hypertensives	O
in	O
the	O
intervention	O
cohort	O
,	O
the	O
rates	O
of	O
awareness	O
,	O
treatment	O
and	O
control	O
of	O
hypertension	O
got	O
improved	O
.	O
The	O
incidence	O
of	O
stroke	O
was	O
29	O
%	O
lower	O
(	O
HR	O
=	O
0	O
.	O
71	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
58	O
-	O
0	O
.	O
87	O
)	O
and	O
mortality	O
of	O
stroke	O
was	O
40	O
%	O
lower	O
(	O
HR	O
=	O
0	O
.	O
60	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
42	O
-	O
0	O
.	O
86	O
)	O
in	O
the	O
intervention	O
cohort	O
than	O
the	O
control	O
cohort	O
.	O
The	O
intervention	O
was	O
most	O
effective	O
in	O
reduction	O
of	O
stroke	O
for	O
those	O
with	O
isolated	O
systolic	O
hypertension	O
and	O
combined	O
systolic	O
and	O
diastolic	O
hypertension	O
(	O
All	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Meanwhile	O
,	O
all	O
-	O
cause	O
mortality	O
was	O
11	O
%	O
lower	O
(	O
HR	O
=	O
0	O
.	O
89	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
78	O
-	O
0	O
.	O
99	O
)	O
in	O
the	O
intervention	O
cohort	O
than	O
in	O
the	O
control	O
cohort	O
.	O
CONCLUSION	O
:	O
The	O
community	O
-	O
based	O
intervention	O
was	O
effective	O
in	O
controlling	O
the	O
development	O
of	O
hypertension	O
and	O
stroke	O
,	O
while	O
the	O
elderly	O
people	O
benefit	O
more	O
than	O
the	O
middle	O
aged	O
people	O
from	O
the	O
intervention	O
.	O
Angiogenesis	O
-	O
-	O
biomedical	O
technology	O
.	O
All	O
of	O
these	O
studies	O
show	O
that	O
angiogenesis	O
research	O
can	O
benefit	O
from	O
new	O
biomedical	O
technology	O
tools	O
currently	O
being	O
developed	O
,	O
as	O
well	O
as	O
contribute	O
by	O
providing	O
new	O
technologies	O
that	O
can	O
be	O
used	O
in	O
other	O
areas	O
of	O
medicine	O
.	O
It	O
is	O
hoped	O
that	O
the	O
chapters	O
in	O
this	O
book	O
in	O
this	O
area	O
will	O
provide	O
the	O
reader	O
with	O
an	O
up	O
-	O
to	O
-	O
date	O
appreciation	O
of	O
some	O
of	O
the	O
exciting	O
research	O
that	O
is	O
currently	O
being	O
pursued	O
.	O
Interleukin	O
-	O
1	O
receptor	O
antagonist	O
inhibits	O
ischaemic	O
and	O
excitotoxic	O
neuronal	B-Anatomy
damage	O
in	O
the	O
rat	O
.	O
Interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
synthesis	O
in	O
the	O
brain	B-Anatomy
is	O
stimulated	O
by	O
mechanical	O
injury	O
and	O
IL	O
-	O
1	O
mimics	O
some	O
effects	O
of	O
injury	O
,	O
such	O
as	O
gliosis	O
and	O
neovascularization	O
.	O
We	O
report	O
that	O
neuronal	B-Anatomy
death	O
resulting	O
from	O
focal	O
cerebral	B-Anatomy
ischaemia	O
(	O
middle	B-Anatomy
cerebral	I-Anatomy
artery	I-Anatomy
occlusion	O
,	O
24	O
h	O
)	O
is	O
significantly	O
inhibited	O
(	O
by	O
50	O
%	O
)	O
in	O
rats	O
injected	O
with	O
a	O
recombinant	O
IL	O
-	O
1	O
receptor	O
antagonist	O
(	O
IL	O
-	O
1ra	O
,	O
10	O
micrograms	O
,	O
icv	O
30	O
min	O
before	O
and	O
10	O
min	O
after	O
ischaemia	O
)	O
.	O
Excitotoxic	O
damage	O
due	O
to	O
striatal	B-Anatomy
infusion	O
of	O
an	O
NMDA	O
-	O
receptor	O
agonist	O
(	O
cis	O
-	O
2	O
,	O
4	O
-	O
methanoglutamate	O
)	O
was	O
also	O
markedly	O
inhibited	O
(	O
71	O
%	O
)	O
by	O
injection	O
of	O
the	O
IL	O
-	O
1ra	O
.	O
These	O
data	O
indicate	O
that	O
endogenous	O
IL	O
-	O
1	O
is	O
a	O
mediator	O
of	O
ischaemic	O
and	O
excitotoxic	O
brain	B-Anatomy
damage	O
,	O
and	O
that	O
inhibitors	O
of	O
IL	O
-	O
1	O
action	O
may	O
be	O
of	O
therapeutic	O
value	O
in	O
the	O
treatment	O
of	O
acute	O
or	O
chronic	O
neuronal	B-Anatomy
death	O
.	O
Transcriptional	O
and	O
post	O
-	O
translation	O
regulation	O
of	O
the	O
Tie1	O
receptor	O
by	O
fluid	O
shear	O
stress	O
changes	O
in	O
vascular	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
The	O
interaction	O
between	O
the	O
vascular	B-Anatomy
endothelium	I-Anatomy
and	O
hemodynamic	O
forces	O
(	O
and	O
more	O
specifically	O
,	O
fluid	O
shear	O
stress	O
)	O
,	O
induced	O
by	O
the	O
flow	O
of	O
blood	B-Anatomy
,	O
plays	O
a	O
major	O
role	O
in	O
vascular	B-Anatomy
remodeling	O
and	O
in	O
new	O
blood	B-Anatomy
vessels	I-Anatomy
formation	O
via	O
a	O
process	O
termed	O
arteriogenesis	O
.	O
Tie1	O
is	O
an	O
orphan	O
tyrosine	O
kinase	O
receptor	O
expressed	O
almost	O
exclusively	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
and	O
is	O
required	O
for	O
normal	O
vascular	B-Anatomy
development	O
and	O
maintenance	O
.	O
The	O
present	O
study	O
demonstrates	O
that	O
Tie1	O
expression	O
is	O
rapidly	O
down	O
-	O
regulated	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
exposed	O
to	O
shear	O
stress	O
,	O
and	O
more	O
so	O
to	O
shear	O
stress	O
changes	O
.	O
This	O
down	O
-	O
regulation	O
is	O
accompanied	O
by	O
a	O
rapid	O
cleavage	O
of	O
Tie1	O
and	O
binding	O
of	O
the	O
cleaved	O
Tie1	O
45	O
kDa	O
endodomain	O
to	O
Tie2	O
.	O
The	O
rapid	O
cleavage	O
of	O
Tie1	O
is	O
followed	O
by	O
a	O
transcriptional	O
down	O
-	O
regulation	O
in	O
response	O
to	O
shear	O
stress	O
.	O
The	O
activity	O
of	O
the	O
Tie1	O
promoter	O
is	O
suppressed	O
by	O
shear	O
stress	O
and	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
.	O
Shear	O
stress	O
-	O
induced	O
transcriptional	O
suppression	O
of	O
Tie1	O
is	O
mediated	O
by	O
a	O
negative	O
shear	O
stress	O
response	O
element	O
,	O
localized	O
in	O
a	O
region	O
of	O
250	O
bp	O
within	O
the	O
promoter	O
.	O
The	O
rapid	O
down	O
-	O
regulation	O
of	O
Tie1	O
by	O
shear	O
stress	O
changes	O
and	O
its	O
rapid	O
binding	O
to	O
Tie2	O
may	O
be	O
required	O
for	O
destabilization	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
in	O
order	O
to	O
initiate	O
the	O
process	O
of	O
vascular	B-Anatomy
restructuring	O
.	O
Therapeutic	O
angiogenesis	O
:	O
a	O
complex	O
problem	O
requiring	O
a	O
sophisticated	O
approach	O
.	O
Blood	B-Anatomy
and	O
vascular	B-Anatomy
disorders	O
underlie	O
a	O
plethora	O
of	O
pathologic	O
conditions	O
and	O
are	O
the	O
single	O
most	O
frequent	O
cause	O
of	O
human	O
disease	O
.	O
Ischemia	O
,	O
involving	O
restricted	O
blood	B-Anatomy
flow	O
to	O
tissues	B-Anatomy
is	O
the	O
most	O
common	O
consequence	O
of	O
vessel	B-Anatomy
dysfunction	O
resulting	O
in	O
the	O
disruption	O
of	O
oxygen	O
and	O
nutrient	O
delivery	O
and	O
the	O
accumulation	O
of	O
waste	O
metabolites	O
.	O
Cells	B-Anatomy
cannot	O
survive	O
extended	O
severe	O
ischemia	O
but	O
may	O
be	O
able	O
to	O
adapt	O
to	O
a	O
moderate	O
condition	O
where	O
diffusion	O
to	O
and	O
from	O
bordering	O
nonischemic	O
regions	O
sustains	O
vital	O
functions	O
.	O
Under	O
this	O
condition	O
,	O
the	O
secondary	O
functions	O
of	O
effected	O
cells	B-Anatomy
are	O
likely	O
to	O
be	O
impaired	O
,	O
and	O
a	O
new	O
metabolic	O
equilibrium	O
is	O
established	O
,	O
determined	O
by	O
the	O
level	O
of	O
cross	O
-	O
diffusion	O
and	O
degree	O
of	O
hypoxia	O
.	O
In	O
tissues	B-Anatomy
with	O
a	O
normally	O
high	O
metabolic	O
turnover	O
such	O
as	O
skeletal	B-Anatomy
and	O
cardiac	B-Anatomy
muscle	I-Anatomy
,	O
even	O
mild	O
ischemia	O
causes	O
hypoxia	O
,	O
acidosis	O
,	O
and	O
depressed	O
function	O
(	O
contractility	O
)	O
and	O
eventually	O
threatens	O
myocyte	B-Anatomy
viability	O
and	O
organ	B-Anatomy
function	O
.	O
Ischemic	O
cardiac	B-Anatomy
muscle	I-Anatomy
is	O
additionally	O
vulnerable	O
because	O
reperfusion	O
is	O
essential	O
for	O
survival	O
but	O
reperfusion	O
itself	O
poses	O
additional	O
stress	O
principally	O
from	O
increased	O
production	O
of	O
free	O
radicals	O
during	O
reoxygenation	O
.	O
The	O
latter	O
effect	O
is	O
called	O
reperfusion	O
injury	O
and	O
can	O
cause	O
as	O
much	O
damage	O
as	O
the	O
ischemia	O
.	O
The	O
treatment	O
possibilities	O
for	O
ischemia	O
-	O
related	O
vascular	B-Anatomy
disease	O
are	O
limited	O
.	O
Lipid	O
/	O
cholesterol	O
-	O
lowering	O
agents	O
,	O
diet	O
and	O
antiplatelet	B-Anatomy
adherence	O
(	O
aspirin	O
)	O
therapy	O
may	O
help	O
slow	O
the	O
progression	O
of	O
vessel	B-Anatomy
disease	O
in	O
some	O
instances	O
;	O
but	O
surgical	O
reconstruction	O
may	O
be	O
the	O
only	O
option	O
in	O
advanced	O
stages	O
,	O
and	O
even	O
this	O
is	O
not	O
always	O
an	O
option	O
.	O
An	O
alternative	O
and	O
rather	O
obvious	O
strategy	O
to	O
treat	O
ischemia	O
is	O
to	O
activate	O
endogenous	O
angiogenic	O
or	O
arteriogenic	O
pathways	O
to	O
stimulate	O
revascularization	O
of	O
the	O
tissue	B-Anatomy
.	O
The	O
feasibility	O
of	O
such	O
a	O
strategy	O
has	O
now	O
been	O
established	O
through	O
the	O
results	O
of	O
studies	O
over	O
the	O
past	O
decade	O
,	O
and	O
a	O
new	O
discipline	O
called	O
therapeutic	O
angiogenesis	O
has	O
emerged	O
.	O
This	O
review	O
focuses	O
on	O
the	O
application	O
of	O
therapeutic	O
angiogenesis	O
for	O
treating	O
ischemic	O
muscle	B-Anatomy
disease	O
and	O
includes	O
a	O
critical	O
evaluation	O
of	O
the	O
parameters	O
and	O
limitations	O
of	O
current	O
procedures	O
.	O
The	O
development	O
of	O
this	O
technology	O
has	O
benefited	O
from	O
its	O
application	O
to	O
both	O
peripheral	B-Anatomy
and	O
coronary	B-Anatomy
artery	I-Anatomy
disease	O
and	O
results	O
from	O
both	O
are	O
reviewed	O
here	O
.	O
Expression	O
,	O
regulation	O
,	O
and	O
function	O
of	O
IGF	O
-	O
1	O
,	O
IGF	O
-	O
1R	O
,	O
and	O
IGF	O
-	O
1	O
binding	O
proteins	O
in	O
blood	B-Anatomy
vessels	I-Anatomy
.	O
The	O
vascular	B-Anatomy
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
-	O
1	O
system	O
includes	O
the	O
IGFs	O
,	O
the	O
IGF	O
-	O
1	O
receptor	O
(	O
IGF	O
-	O
1R	O
)	O
,	O
and	O
multiple	O
binding	O
proteins	O
.	O
This	O
growth	O
factor	O
system	O
exerts	O
multiple	O
physiologic	O
effects	O
on	O
the	O
vasculature	B-Anatomy
through	O
both	O
endocrine	B-Anatomy
and	O
autocrine	B-Anatomy
/	I-Anatomy
paracrine	I-Anatomy
mechanisms	O
.	O
The	O
effects	O
of	O
IGF	O
-	O
1	O
are	O
mediated	O
principally	O
through	O
the	O
IGF	O
-	O
1R	O
but	O
are	O
modulated	O
by	O
complex	O
interactions	O
with	O
multiple	O
IGF	O
binding	O
proteins	O
that	O
themselves	O
are	O
regulated	O
by	O
phosphorylation	O
,	O
proteolysis	O
,	O
polymerization	O
,	O
and	O
cell	B-Anatomy
or	O
matrix	B-Anatomy
association	O
.	O
During	O
the	O
last	O
decade	O
,	O
a	O
significant	O
body	O
of	O
evidence	O
has	O
accumulated	O
,	O
indicating	O
that	O
expression	O
of	O
the	O
components	O
of	O
the	O
IGF	O
system	O
are	O
regulated	O
by	O
multiple	O
factors	O
,	O
including	O
growth	O
factors	O
,	O
cytokines	O
,	O
lipoproteins	O
,	O
reactive	O
oxygen	O
species	O
,	O
and	O
hemodynamic	O
forces	O
.	O
In	O
addition	O
,	O
cross	O
-	O
talk	O
between	O
the	O
IGF	O
system	O
and	O
other	O
growth	O
factors	O
and	O
integrin	O
receptors	O
has	O
been	O
demonstrated	O
.	O
There	O
is	O
accumulating	O
evidence	O
of	O
a	O
role	O
for	O
IGF	O
-	O
1	O
in	O
multiple	O
vascular	B-Anatomy
pathologies	O
,	O
including	O
atherosclerosis	O
,	O
hypertension	O
,	O
restenosis	O
,	O
angiogenesis	O
,	O
and	O
diabetic	O
vascular	B-Anatomy
disease	O
.	O
This	O
review	O
will	O
discuss	O
the	O
regulation	O
of	O
expression	O
of	O
IGF	O
-	O
1	O
,	O
IGF	O
-	O
1R	O
,	O
and	O
IGF	O
binding	O
proteins	O
in	O
the	O
vasculature	B-Anatomy
and	O
summarize	O
evidence	O
implicating	O
involvement	O
of	O
this	O
system	O
in	O
vascular	B-Anatomy
diseases	O
.	O
Microvascular	B-Anatomy
density	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
immunoreactivity	O
as	O
predictors	O
of	O
regional	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
from	O
betel	B-Anatomy
-	O
associated	O
oral	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
PURPOSE	O
:	O
Neovascularization	O
has	O
profound	O
effects	O
on	O
tumor	B-Anatomy
growth	O
and	O
metastasis	O
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
a	O
mitogen	O
that	O
acts	O
exclusively	O
on	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
The	O
roles	O
of	O
miscrovascularity	B-Anatomy
density	O
(	O
MVD	O
)	O
and	O
VEGF	O
expression	O
in	O
the	O
progression	O
of	O
oral	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	O
OSCC	B-Anatomy
)	O
have	O
been	O
controversial	O
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
measure	O
the	O
MVD	O
and	O
VEGF	O
expression	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
betel	B-Anatomy
-	O
associated	O
OSCC	B-Anatomy
and	O
to	O
evaluate	O
for	O
possible	O
clinicopathologic	O
correlations	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
The	O
paraffin	B-Anatomy
sections	I-Anatomy
from	O
49	O
subjects	O
with	O
OSCC	B-Anatomy
were	O
subjected	O
to	O
immunohistochemical	O
studies	O
to	O
measure	O
the	O
highest	O
MVD	O
(	O
h	O
-	O
MVD	O
)	O
and	O
cytoplasmic	B-Anatomy
immunoreactivity	O
of	O
VEGF	O
.	O
The	O
findings	O
in	O
the	O
tissue	B-Anatomy
samples	I-Anatomy
were	O
analyzed	O
with	O
regard	O
to	O
the	O
patients	O
'	O
risk	O
factors	O
and	O
clinical	O
course	O
.	O
RESULTS	O
:	O
The	O
OSCC	B-Anatomy
samples	I-Anatomy
had	O
an	O
average	O
h	O
-	O
MVD	O
score	O
of	O
27	O
.	O
7	O
/	O
mm	O
(	O
2	O
)	O
.	O
VEGF	O
immunoreactivity	O
was	O
positive	O
in	O
75	O
.	O
5	O
%	O
of	O
samples	B-Anatomy
.	O
Both	O
h	O
-	O
MVD	O
and	O
VEGF	O
immunoreactivity	O
were	O
statistically	O
associated	O
with	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
(	O
P	O
=	O
.	O
012	O
and	O
.	O
037	O
,	O
respectively	O
)	O
.	O
A	O
marginally	O
significant	O
association	O
was	O
also	O
noted	O
between	O
the	O
h	O
-	O
MVD	O
and	O
patient	O
survival	O
(	O
P	O
=	O
.	O
056	O
)	O
.	O
The	O
age	O
and	O
oral	B-Anatomy
habits	O
of	O
patients	O
,	O
as	O
well	O
as	O
the	O
tumor	B-Anatomy
site	I-Anatomy
and	O
size	O
,	O
did	O
not	O
appear	O
to	O
be	O
correlated	O
with	O
h	O
-	O
MVD	O
or	O
VEGF	O
immunoreactivity	O
.	O
CONCLUSION	O
:	O
The	O
data	O
suggest	O
that	O
both	O
h	O
-	O
MVD	O
and	O
VEGF	O
immunoreactivity	O
may	O
be	O
useful	O
predictors	O
for	O
the	O
progression	O
of	O
a	O
subset	O
of	O
OSCC	B-Anatomy
associated	O
mostly	O
with	O
betel	B-Anatomy
use	O
.	O
Antiangiogenesis	O
therapy	O
might	O
have	O
a	O
role	O
in	O
reducing	O
regional	O
metastasis	O
.	O
Promotion	O
of	O
tumorigenesis	O
by	O
heterozygous	O
disruption	O
of	O
the	O
beclin	O
1	O
autophagy	O
gene	O
.	O
Malignant	B-Anatomy
cells	I-Anatomy
often	O
display	O
defects	O
in	O
autophagy	O
,	O
an	O
evolutionarily	O
conserved	O
pathway	O
for	O
degrading	O
long	O
-	O
lived	O
proteins	O
and	O
cytoplasmic	B-Anatomy
organelles	I-Anatomy
.	O
However	O
,	O
as	O
yet	O
,	O
there	O
is	O
no	O
genetic	O
evidence	O
for	O
a	O
role	O
of	O
autophagy	O
genes	O
in	O
tumor	B-Anatomy
suppression	O
.	O
The	O
beclin	O
1	O
autophagy	O
gene	O
is	O
monoallelically	O
deleted	O
in	O
40	O
-	O
75	O
%	O
of	O
cases	O
of	O
human	O
sporadic	O
breast	B-Anatomy
,	O
ovarian	B-Anatomy
,	O
and	O
prostate	B-Anatomy
cancer	I-Anatomy
.	O
Therefore	O
,	O
we	O
used	O
a	O
targeted	O
mutant	O
mouse	O
model	O
to	O
test	O
the	O
hypothesis	O
that	O
monoallelic	O
deletion	O
of	O
beclin	O
1	O
promotes	O
tumorigenesis	O
.	O
Here	O
we	O
show	O
that	O
heterozygous	O
disruption	O
of	O
beclin	O
1	O
increases	O
the	O
frequency	O
of	O
spontaneous	O
malignancies	B-Anatomy
and	O
accelerates	O
the	O
development	O
of	O
hepatitis	O
B	O
virus	O
-	O
induced	O
premalignant	B-Anatomy
lesions	I-Anatomy
.	O
Molecular	O
analyses	O
of	O
tumors	B-Anatomy
in	O
beclin	O
1	O
heterozygous	O
mice	O
show	O
that	O
the	O
remaining	O
wild	O
-	O
type	O
allele	O
is	O
neither	O
mutated	O
nor	O
silenced	O
.	O
Furthermore	O
,	O
beclin	O
1	O
heterozygous	O
disruption	O
results	O
in	O
increased	O
cellular	B-Anatomy
proliferation	O
and	O
reduced	O
autophagy	O
in	O
vivo	O
.	O
These	O
findings	O
demonstrate	O
that	O
beclin	O
1	O
is	O
a	O
haplo	O
-	O
insufficient	O
tumor	B-Anatomy
-	O
suppressor	O
gene	O
and	O
provide	O
genetic	O
evidence	O
that	O
autophagy	O
is	O
a	O
novel	O
mechanism	O
of	O
cell	B-Anatomy
-	O
growth	O
control	O
and	O
tumor	B-Anatomy
suppression	O
.	O
Thus	O
,	O
mutation	O
of	O
beclin	O
1	O
or	O
other	O
autophagy	O
genes	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
human	O
cancers	B-Anatomy
.	O
Effects	O
of	O
dietary	O
folate	O
on	O
ulcerative	B-Anatomy
colitis	O
-	O
associated	O
colorectal	B-Anatomy
carcinogenesis	O
in	O
the	O
interleukin	O
2	O
-	O
and	O
beta	O
(	O
2	O
)	O
-	O
microglobulin	O
-	O
deficient	O
mice	O
.	O
Folate	O
supplementation	O
may	O
reduce	O
the	O
risk	O
of	O
colorectal	B-Anatomy
dysplasia	I-Anatomy
and	O
cancer	B-Anatomy
in	O
subjects	O
with	O
chronic	O
ulcerative	B-Anatomy
colitis	O
(	O
UC	O
)	O
.	O
The	O
interleukin	O
(	O
IL	O
)	O
2	O
-	O
and	O
beta	O
(	O
2	O
)	O
-	O
microglobulin	O
(	O
beta	O
(	O
2	O
)	O
m	O
)	O
-	O
deficient	O
(	O
IL	O
-	O
2	O
(	O
)	O
x	O
beta	O
(	O
2	O
)	O
m	O
(	O
)	O
)	O
mice	O
spontaneously	O
develop	O
colon	B-Anatomy
cancer	I-Anatomy
in	O
the	O
setting	O
of	O
chronic	O
UC	O
.	O
This	O
study	O
investigated	O
the	O
effects	O
of	O
dietary	O
folate	O
on	O
the	O
development	O
of	O
UC	O
-	O
associated	O
colon	B-Anatomy
cancer	I-Anatomy
in	O
the	O
IL	O
-	O
2	O
(	O
)	O
x	O
beta	O
(	O
2	O
)	O
m	O
(	O
)	O
mice	O
.	O
Weaning	O
IL	O
-	O
2	O
(	O
)	O
x	O
beta	O
(	O
2	O
)	O
m	O
(	O
)	O
mice	O
were	O
randomized	O
to	O
receive	O
0	O
(	O
deficient	O
;	O
n	O
=	O
40	O
)	O
,	O
2	O
(	O
basal	O
requirement	O
;	O
control	O
;	O
n	O
=	O
46	O
)	O
,	O
or	O
8	O
(	O
supplemented	O
;	O
n	O
=	O
36	O
)	O
mg	O
folate	O
/	O
kg	O
diet	O
for	O
32	O
weeks	O
.	O
At	O
necropsy	O
,	O
all	O
macroscopic	O
colonic	B-Anatomy
tumors	I-Anatomy
were	O
identified	O
and	O
histologically	O
classified	O
as	O
dysplasia	B-Anatomy
or	O
adenocarcinoma	B-Anatomy
.	O
The	O
incidence	O
of	O
high	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
lesions	I-Anatomy
(	O
high	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
dysplasia	I-Anatomy
/	O
carcinoma	B-Anatomy
in	I-Anatomy
situ	I-Anatomy
and	O
invasive	B-Anatomy
adenocarcinoma	I-Anatomy
)	O
in	O
the	O
folate	O
-	O
supplemented	O
group	O
was	O
46	O
%	O
lower	O
than	O
that	O
in	O
the	O
control	O
group	O
(	O
35	O
.	O
3	O
%	O
versus	O
65	O
.	O
1	O
%	O
,	O
P	O
=	O
0	O
.	O
009	O
)	O
.	O
The	O
incidence	O
of	O
high	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
lesions	I-Anatomy
in	O
the	O
folate	O
-	O
deficient	O
group	O
was	O
also	O
49	O
%	O
lower	O
than	O
that	O
in	O
the	O
control	O
group	O
(	O
33	O
.	O
3	O
%	O
versus	O
65	O
.	O
1	O
%	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O
The	O
higher	O
mortality	O
rate	O
in	O
the	O
folate	O
-	O
deficient	O
group	O
compared	O
with	O
the	O
other	O
two	O
groups	O
(	O
25	O
%	O
versus	O
6	O
.	O
5	O
%	O
and	O
5	O
.	O
6	O
%	O
,	O
P	O
<	O
0	O
.	O
02	O
)	O
partially	O
accounted	O
for	O
the	O
low	O
incidence	O
of	O
high	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
lesions	I-Anatomy
in	O
this	O
group	O
.	O
These	O
data	O
indicate	O
that	O
dietary	O
folate	O
supplementation	O
at	O
4x	O
the	O
basal	O
dietary	O
requirement	O
significantly	O
suppresses	O
UC	O
-	O
associated	O
colorectal	B-Anatomy
carcinogenesis	O
in	O
the	O
IL	O
-	O
2	O
(	O
)	O
x	O
beta	O
(	O
2	O
)	O
m	O
(	O
)	O
mice	O
.	O
These	O
data	O
also	O
suggest	O
that	O
folate	O
deficiency	O
may	O
inhibit	O
colorectal	B-Anatomy
carcinogenesis	O
in	O
chronic	O
UC	O
.	O
However	O
,	O
the	O
high	O
mortality	O
observed	O
in	O
the	O
folate	O
-	O
deficient	O
group	O
precludes	O
a	O
definitive	O
conclusion	O
concerning	O
the	O
effect	O
of	O
folate	O
deficiency	O
on	O
UC	O
-	O
associated	O
colorectal	B-Anatomy
carcinogenesis	O
in	O
this	O
model	O
.	O
[	O
Laboratory	O
diagnostics	O
of	O
Crimean	O
hemorrhagic	O
fever	O
by	O
polymerase	O
chain	O
reaction	O
]	O
.	O
Our	O
group	O
developed	O
,	O
within	O
the	O
present	O
case	O
study	O
,	O
two	O
techniques	O
'	O
variations	O
,	O
i	O
.	O
e	O
.	O
a	O
single	O
-	O
step	O
RT	O
-	O
PCR	O
and	O
nested	O
RT	O
-	O
PCR	O
assays	O
,	O
for	O
the	O
purpose	O
of	O
detecting	O
the	O
Crimean	O
-	O
Congo	O
hemorrhagic	O
fever	O
RNA	O
virus	O
in	O
human	O
samples	B-Anatomy
.	O
The	O
above	O
assays	O
as	O
well	O
as	O
those	O
previously	O
recommended	O
by	O
the	O
Ministry	O
of	O
Health	O
of	O
the	O
Russian	O
Federation	O
were	O
simultaneously	O
used	O
in	O
14	O
clinical	O
samples	B-Anatomy
obtained	O
from	O
patients	O
with	O
Crimean	O
hemorrhagic	O
fever	O
.	O
After	O
assessing	O
the	O
detection	O
accuracy	O
,	O
it	O
was	O
found	O
that	O
the	O
developed	O
-	O
by	O
-	O
us	O
test	O
system	O
displayed	O
the	O
same	O
or	O
even	O
better	O
diagnostic	O
values	O
versus	O
the	O
previously	O
recommended	O
nested	O
RT	O
-	O
PCR	O
and	O
a	O
1000	O
-	O
fold	O
advantage	O
over	O
the	O
previously	O
recommended	O
single	O
-	O
step	O
RT	O
-	O
PCA	O
.	O
The	O
single	O
-	O
step	O
RT	O
-	O
PCR	O
assay	O
variation	O
is	O
always	O
more	O
preferable	O
in	O
sense	O
of	O
technical	O
and	O
economic	O
motivations	O
.	O
Finally	O
,	O
the	O
test	O
system	O
developed	O
by	O
us	O
has	O
every	O
reason	O
to	O
become	O
the	O
method	O
of	O
choice	O
in	O
routine	O
PCR	O
diagnosis	O
of	O
Crimean	O
hemorrhagic	O
fever	O
after	O
all	O
official	O
trials	O
and	O
approvals	O
are	O
duly	O
complied	O
with	O
.	O
Prognostic	O
significance	O
and	O
correlation	O
with	O
survival	O
of	O
bcl	O
-	O
2	O
and	O
TGF	O
-	O
beta	O
RII	O
in	O
colon	B-Anatomy
cancer	I-Anatomy
.	O
Bcl	O
-	O
2	O
and	O
TGF	O
-	O
beta	O
receptors	O
type	O
II	O
(	O
RII	O
)	O
in	O
colon	B-Anatomy
carcinomas	I-Anatomy
were	O
studied	O
in	O
a	O
series	O
of	O
113	O
patients	O
,	O
to	O
determine	O
their	O
prognostic	O
significance	O
and	O
to	O
correlate	O
their	O
expression	O
with	O
other	O
prognostic	O
indicators	O
.	O
Bcl	O
-	O
2	O
expression	O
in	O
the	O
tumor	B-Anatomy
cells	I-Anatomy
showed	O
a	O
reverse	O
relation	O
with	O
tumor	B-Anatomy
size	O
(	O
P	O
=	O
0	O
.	O
018	O
)	O
,	O
histological	O
grade	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
,	O
and	O
stage	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O
Univariate	O
survival	O
analysis	O
using	O
the	O
log	O
rank	O
test	O
showed	O
that	O
the	O
survival	O
of	O
patients	O
with	O
bcl	B-Anatomy
-	I-Anatomy
2	I-Anatomy
-	I-Anatomy
positive	I-Anatomy
tumors	I-Anatomy
was	O
significantly	O
better	O
than	O
the	O
survival	O
of	O
patients	O
with	O
bcl	B-Anatomy
-	I-Anatomy
2	I-Anatomy
-	I-Anatomy
negative	I-Anatomy
tumors	I-Anatomy
(	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O
However	O
,	O
when	O
entered	O
into	O
a	O
multivariate	O
analysis	O
model	O
,	O
it	O
was	O
not	O
found	O
to	O
be	O
of	O
independent	O
prognostic	O
significance	O
.	O
TGF	O
-	O
beta	O
RII	O
expression	O
was	O
correlated	O
with	O
stage	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
,	O
while	O
no	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
TGF	O
-	O
beta	O
RII	O
expression	O
and	O
histological	O
grade	O
or	O
survival	O
.	O
In	O
conclusion	O
,	O
these	O
results	O
provide	O
additional	O
evidence	O
for	O
the	O
role	O
of	O
bcl	O
-	O
2	O
and	O
TGF	O
-	O
beta	O
RII	O
in	O
carcinogenesis	O
of	O
the	O
colon	B-Anatomy
,	O
while	O
they	O
do	O
not	O
support	O
the	O
use	O
of	O
these	O
factors	O
as	O
prognostic	O
markers	O
in	O
patients	O
with	O
colon	B-Anatomy
cancer	I-Anatomy
.	O
Antibiotic	O
-	O
induced	O
persistence	O
of	O
cytotoxic	O
Staphylococcus	O
aureus	O
in	O
non	B-Anatomy
-	I-Anatomy
phagocytic	I-Anatomy
cells	I-Anatomy
.	O
OBJECTIVES	O
:	O
After	O
infection	O
of	O
non	B-Anatomy
-	I-Anatomy
phagocytic	I-Anatomy
cells	I-Anatomy
,	O
some	O
Staphylococcus	O
aureus	O
strains	B-Anatomy
are	O
able	O
to	O
survive	O
and	O
kill	O
their	O
host	O
cells	B-Anatomy
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
action	O
of	O
various	O
antibiotics	O
on	O
the	O
survival	O
of	O
host	O
cells	B-Anatomy
and	O
/	O
or	O
intracellular	B-Anatomy
S	O
.	O
aureus	O
.	O
METHODS	O
:	O
Murine	O
keratinocyte	B-Anatomy
(	O
PAM212	B-Anatomy
)	O
and	O
fibroblast	B-Anatomy
(	I-Anatomy
mKSA	I-Anatomy
)	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
were	O
infected	O
with	O
cytotoxic	O
S	O
.	O
aureus	O
and	O
cultured	O
in	O
the	O
presence	O
of	O
various	O
antibiotics	O
at	O
graded	O
concentrations	O
.	O
The	O
viability	O
of	O
host	O
cells	B-Anatomy
was	O
measured	O
24	O
h	O
after	O
infection	O
.	O
To	O
determine	O
the	O
bacterial	O
viability	O
within	O
host	O
cells	B-Anatomy
,	O
cellular	B-Anatomy
lysates	I-Anatomy
were	O
prepared	O
and	O
colony	B-Anatomy
forming	O
units	O
were	O
quantified	O
using	O
a	O
spiral	O
plater	O
.	O
Host	O
cells	B-Anatomy
infected	O
with	O
fluorescein	O
isothiocyanate	O
(	O
FITC	O
)	O
-	O
labelled	O
S	O
.	O
aureus	O
were	O
analysed	O
by	O
flow	O
cytometry	O
and	O
microscopy	O
to	O
determine	O
the	O
subcellular	B-Anatomy
localization	O
S	O
.	O
aureus	O
.	O
RESULTS	O
:	O
Oxacillin	O
,	O
vancomycin	O
,	O
gentamicin	O
,	O
ciprofloxacin	O
and	O
trimethoprim	O
/	O
sulfamethoxazole	O
did	O
not	O
rescue	O
host	O
cells	B-Anatomy
from	O
cell	B-Anatomy
death	O
induced	O
by	O
intracellular	B-Anatomy
S	O
.	O
aureus	O
.	O
In	O
contrast	O
,	O
linezolid	O
,	O
rifampicin	O
,	O
azithromycin	O
,	O
clindamycin	O
,	O
erythromycin	O
and	O
quinupristin	O
/	O
dalfopristin	O
suppressed	O
the	O
cytotoxic	O
action	O
of	O
S	O
.	O
aureus	O
.	O
After	O
withdrawal	O
of	O
antibiotics	O
,	O
intracellular	B-Anatomy
S	O
.	O
aureus	O
regained	O
cytotoxic	O
activity	O
and	O
killed	O
their	O
host	O
cells	B-Anatomy
.	O
Only	O
rifampicin	O
was	O
able	O
to	O
eliminate	O
intracellular	B-Anatomy
S	O
.	O
aureus	O
completely	O
within	O
72	O
h	O
.	O
In	O
contrast	O
,	O
clindamycin	O
,	O
azithromycin	O
and	O
linezolid	O
induced	O
a	O
state	O
of	O
intracellular	B-Anatomy
persistence	O
of	O
viable	O
S	O
.	O
aureus	O
.	O
CONCLUSIONS	O
:	O
Antibiotics	O
commonly	O
used	O
for	O
the	O
management	O
of	O
S	O
.	O
aureus	O
infections	O
appear	O
to	O
create	O
a	O
niche	O
for	O
invasive	O
intracellular	B-Anatomy
S	O
.	O
aureus	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
for	O
persistence	O
and	O
recurrence	O
of	O
infection	O
.	O
Because	O
of	O
its	O
unique	O
ability	O
to	O
eliminate	O
intracellular	B-Anatomy
S	O
.	O
aureus	O
,	O
rifampicin	O
appears	O
to	O
be	O
valuable	O
for	O
the	O
treatment	O
of	O
invasive	O
S	O
.	O
aureus	O
infections	O
.	O
Full	O
sequencing	O
analysis	O
of	O
estrogen	O
receptor	O
-	O
alpha	O
gene	O
polymorphism	O
and	O
its	O
association	O
with	O
breast	B-Anatomy
cancer	I-Anatomy
risk	O
.	O
BACKGROUND	O
:	O
The	O
estrogen	O
receptor	O
plays	O
a	O
critical	O
role	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
development	O
and	O
progression	O
.	O
So	O
the	O
genetic	O
polymorphism	O
of	O
ER	O
-	O
alpha	O
gene	O
could	O
affect	O
cancer	B-Anatomy
risk	O
and	O
phenotype	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
We	O
fully	O
sequenced	O
the	O
ER	O
-	O
alpha	O
gene	O
to	O
investigate	O
its	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
100	O
breast	B-Anatomy
cancer	I-Anatomy
patients	O
and	O
100	O
controls	O
.	O
RESULTS	O
:	O
Six	O
novel	O
polymorphism	O
in	O
the	O
control	O
and	O
11	O
in	O
cancer	B-Anatomy
patients	O
were	O
found	O
.	O
The	O
G	O
/	O
G	O
genotype	O
at	O
C975	O
G	O
and	O
A	O
/	O
A	O
genotype	O
at	O
G1782	O
A	O
had	O
a	O
protective	O
effect	O
against	O
breast	B-Anatomy
cancer	I-Anatomy
when	O
compared	O
to	O
other	O
genotypes	O
(	O
OR	O
=	O
0	O
.	O
3	O
and	O
0	O
.	O
3	O
,	O
respectively	O
)	O
.	O
975G	O
allele	O
was	O
associated	O
inversely	O
with	O
the	O
p53	O
expression	O
and	O
positively	O
with	O
the	O
bcl	O
-	O
2	O
expression	O
in	O
cancer	B-Anatomy
with	O
borderline	O
significance	O
.	O
Combining	O
this	O
result	O
with	O
our	O
previous	O
study	O
,	O
these	O
associations	O
became	O
more	O
significant	O
(	O
p	O
=	O
0	O
.	O
005	O
and	O
0	O
.	O
019	O
,	O
respectively	O
)	O
.	O
CONCLUSION	O
:	O
Polymorphisms	O
in	O
ER	O
-	O
alpha	O
gene	O
can	O
affect	O
the	O
breast	B-Anatomy
cancer	I-Anatomy
susceptibility	O
and	O
may	O
be	O
related	O
to	O
other	O
protein	O
expression	O
,	O
such	O
as	O
p53	O
and	O
bcl	O
-	O
2	O
.	O
Effect	O
of	O
antitumor	B-Anatomy
agents	O
on	O
cytotoxicity	O
induction	O
by	O
sodium	O
fluoride	O
.	O
We	O
have	O
recently	O
found	O
that	O
sodium	O
fluoride	O
(	O
NaF	O
)	O
induced	O
apoptotic	O
cell	B-Anatomy
death	O
in	O
tumor	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
We	O
investigated	O
here	O
whether	O
6	O
popular	O
antitumor	B-Anatomy
compounds	O
modify	O
the	O
cytotoxic	O
activity	O
of	O
NaF	O
against	O
human	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	O
HSC	B-Anatomy
-	I-Anatomy
2	I-Anatomy
)	I-Anatomy
and	O
human	O
promyelocytic	B-Anatomy
leukemia	I-Anatomy
(	I-Anatomy
HL	I-Anatomy
-	I-Anatomy
60	I-Anatomy
)	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
Cytotoxic	O
concentrations	O
of	O
cisplatin	O
,	O
etoposide	O
,	O
doxorubicin	O
or	O
peplomycin	O
(	O
tentatively	O
termed	O
as	O
Group	O
I	O
compounds	O
)	O
,	O
but	O
not	O
methotrexate	O
and	O
5	O
-	O
FU	O
(	O
tentatively	O
termed	O
as	O
Group	O
II	O
compounds	O
)	O
,	O
enhanced	O
the	O
cytotoxic	O
activity	O
of	O
NaF	O
.	O
NaF	O
and	O
Group	O
I	O
compounds	O
induced	O
internucleosomal	O
DNA	O
fragmentation	O
in	O
HL	B-Anatomy
-	I-Anatomy
60	I-Anatomy
cells	I-Anatomy
,	O
whereas	O
Group	O
II	O
compounds	O
were	O
inactive	O
even	O
in	O
the	O
presence	O
of	O
NaF	O
.	O
Most	O
Group	O
I	O
compounds	O
except	O
doxorubicin	O
(	O
which	O
induced	O
DNA	O
fragmentation	O
less	O
effectively	O
than	O
others	O
)	O
activated	O
caspase	O
3	O
more	O
efficiently	O
than	O
Group	O
II	O
compounds	O
.	O
Caspase	O
8	O
(	O
involved	O
in	O
non	O
-	O
mitochondrial	B-Anatomy
extrinsic	O
pathway	O
)	O
and	O
caspase	O
9	O
(	O
involved	O
in	O
mitochondrial	B-Anatomy
intrinsic	O
pathway	O
)	O
were	O
also	O
activated	O
,	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
.	O
NaF	O
reduced	O
the	O
glucose	O
consumption	O
at	O
early	O
stage	O
,	O
possibly	O
by	O
inhibition	O
of	O
glycolysis	O
,	O
whereas	O
cisplatin	O
and	O
etoposide	O
reduced	O
the	O
glucose	O
consumption	O
at	O
later	O
stage	O
,	O
suggesting	O
that	O
early	O
decline	O
of	O
glucose	O
consumption	O
is	O
rather	O
specific	O
to	O
NaF	O
.	O
Covariance	O
structure	O
analysis	O
:	O
statistical	O
practice	O
,	O
theory	O
,	O
and	O
directions	O
.	O
Although	O
covariance	O
structure	O
analysis	O
is	O
used	O
increasingly	O
to	O
analyze	O
nonexperimental	O
data	O
,	O
important	O
statistical	O
requirements	O
for	O
its	O
proper	O
use	O
are	O
frequently	O
ignored	O
.	O
Valid	O
conclusions	O
about	O
the	O
adequacy	O
of	O
a	O
model	O
as	O
an	O
acceptable	O
representation	O
of	O
data	O
,	O
which	O
are	O
based	O
on	O
goodness	O
-	O
of	O
-	O
fit	O
test	O
statistics	O
and	O
standard	O
errors	O
of	O
parameter	O
estimates	O
,	O
rely	O
on	O
the	O
model	O
estimation	O
procedure	O
being	O
appropriate	O
for	O
the	O
data	O
.	O
Using	O
analogies	O
to	O
linear	O
regression	O
and	O
anova	O
,	O
this	O
review	O
examines	O
conditions	O
under	O
which	O
conclusions	O
drawn	O
from	O
various	O
estimation	O
methods	O
will	O
be	O
correct	O
and	O
the	O
consequences	O
of	O
ignoring	O
these	O
conditions	O
.	O
A	O
distinction	O
is	O
made	O
between	O
estimation	O
methods	O
that	O
are	O
either	O
correctly	O
or	O
incorrectly	O
specified	O
for	O
the	O
distribution	O
of	O
data	O
being	O
analyzed	O
,	O
and	O
it	O
is	O
shown	O
that	O
valid	O
conclusions	O
are	O
possible	O
even	O
under	O
misspecification	O
.	O
A	O
brief	O
example	O
illustrates	O
the	O
ideas	O
.	O
Internet	O
access	O
is	O
given	O
to	O
a	O
computer	O
code	O
for	O
several	O
methods	O
that	O
are	O
not	O
available	O
in	O
programs	O
such	O
as	O
EQS	O
or	O
LISREL	O
.	O
Morphogenesis	O
of	O
embryonic	B-Anatomy
CNS	I-Anatomy
vessels	I-Anatomy
.	O
This	O
chapter	O
focuses	O
on	O
the	O
morphology	O
of	O
blood	B-Anatomy
vessel	I-Anatomy
formation	O
in	O
and	O
around	O
the	O
early	O
central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
(	O
CNS	B-Anatomy
,	O
i	O
.	O
e	O
.	O
,	O
brain	B-Anatomy
and	O
spinal	B-Anatomy
cord	I-Anatomy
)	O
of	O
avian	O
embryos	B-Anatomy
.	O
We	O
discuss	O
cell	B-Anatomy
lineages	O
,	O
proliferation	O
and	O
interactions	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
pericytes	B-Anatomy
and	O
smooth	B-Anatomy
muscle	I-Anatomy
cells	I-Anatomy
,	O
and	O
macrophages	B-Anatomy
.	O
Due	O
to	O
space	O
limitations	O
,	O
we	O
can	O
not	O
review	O
the	O
molecular	O
control	O
of	O
CNS	B-Anatomy
angiogenesis	O
,	O
but	O
refer	O
the	O
reader	O
to	O
other	O
chapters	O
in	O
this	O
book	O
and	O
to	O
recent	O
publications	O
on	O
the	O
assembly	O
of	O
the	O
vasculature	B-Anatomy
(	O
1	O
,	O
2	O
)	O
.	O
The	O
candidate	O
tumour	B-Anatomy
suppressor	O
protein	O
ING4	O
regulates	O
brain	B-Anatomy
tumour	I-Anatomy
growth	O
and	O
angiogenesis	O
.	O
Gliomas	B-Anatomy
are	O
the	O
most	O
common	O
primary	B-Anatomy
tumours	I-Anatomy
of	O
the	O
central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
,	O
with	O
nearly	O
15	O
,	O
000	O
diagnosed	O
annually	O
in	O
the	O
United	O
States	O
and	O
a	O
lethality	O
approaching	O
80	O
%	O
within	O
the	O
first	O
year	O
of	O
glioblastoma	B-Anatomy
diagnosis	O
.	O
The	O
marked	O
induction	O
of	O
angiogenesis	O
in	O
glioblastomas	B-Anatomy
suggests	O
that	O
it	O
is	O
a	O
necessary	O
part	O
of	O
malignant	O
progression	O
;	O
however	O
,	O
the	O
precise	O
molecular	O
mechanisms	O
underlying	O
the	O
regulation	O
of	O
brain	B-Anatomy
tumour	I-Anatomy
growth	O
and	O
angiogenesis	O
remain	O
unresolved	O
.	O
Here	O
we	O
report	O
that	O
a	O
candidate	O
tumour	B-Anatomy
suppressor	O
gene	O
,	O
ING4	O
,	O
is	O
involved	O
in	O
regulating	O
brain	B-Anatomy
tumour	I-Anatomy
growth	O
and	O
angiogenesis	O
.	O
Expression	O
of	O
ING4	O
is	O
significantly	O
reduced	O
in	O
gliomas	B-Anatomy
as	O
compared	O
with	O
normal	O
human	O
brain	B-Anatomy
tissue	I-Anatomy
,	O
and	O
the	O
extent	O
of	O
reduction	O
correlates	O
with	O
the	O
progression	O
from	O
lower	O
to	O
higher	O
grades	O
of	O
tumours	B-Anatomy
.	O
In	O
mice	O
,	O
xenografts	B-Anatomy
of	O
human	O
glioblastoma	B-Anatomy
U87MG	I-Anatomy
,	O
which	O
has	O
decreased	O
expression	O
of	O
ING4	O
,	O
grow	O
significantly	O
faster	O
and	O
have	O
higher	O
vascular	B-Anatomy
volume	O
fractions	O
than	O
control	O
tumours	B-Anatomy
.	O
We	O
show	O
that	O
ING4	O
physically	O
interacts	O
with	O
p65	O
(	O
RelA	O
)	O
subunit	O
of	O
nuclear	O
factor	O
NF	O
-	O
kappaB	O
,	O
and	O
that	O
ING4	O
regulates	O
brain	B-Anatomy
tumour	I-Anatomy
angiogenesis	O
through	O
transcriptional	O
repression	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
.	O
These	O
results	O
indicate	O
that	O
ING4	O
has	O
an	O
important	O
role	O
in	O
brain	B-Anatomy
tumour	I-Anatomy
pathogenesis	O
.	O
TGFbeta1	O
,	O
back	O
to	O
the	O
future	O
:	O
revisiting	O
its	O
role	O
as	O
a	O
transforming	O
growth	O
factor	O
.	O
TGFbeta1	O
was	O
initially	O
identified	O
in	O
culture	O
media	O
from	O
transformed	O
cells	B-Anatomy
as	O
part	O
of	O
a	O
factor	O
that	O
could	O
produce	O
a	O
transformed	O
phenotype	O
in	O
a	O
nontransformed	O
cell	B-Anatomy
line	I-Anatomy
.	O
Subsequently	O
this	O
activity	O
was	O
separated	O
into	O
TGFbeta	O
and	O
TGFalpha	O
an	O
EGF	O
receptor	O
ligand	O
.	O
With	O
the	O
discovery	O
that	O
TGFbeta1	O
was	O
a	O
potent	O
growth	O
inhibitor	O
of	O
epithelial	B-Anatomy
cells	I-Anatomy
,	O
and	O
the	O
identification	O
of	O
inactivating	O
mutations	O
within	O
the	O
TGFbeta1	O
signaling	O
pathway	O
in	O
cancers	B-Anatomy
it	O
became	O
clear	O
that	O
TGFbeta1	O
signaling	O
is	O
a	O
tumor	B-Anatomy
suppressor	O
pathway	O
for	O
early	O
stages	O
of	O
cancer	B-Anatomy
.	O
However	O
many	O
human	O
carcinomas	B-Anatomy
overexpress	O
TGFbeta1	O
and	O
this	O
is	O
associated	O
with	O
poor	O
patient	O
prognosis	O
and	O
increased	O
frequency	O
of	O
metastasis	O
.	O
Similar	O
results	O
have	O
been	O
obtained	O
with	O
tumor	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
and	O
experimental	O
animal	O
models	O
.	O
Thus	O
stage	O
specific	O
duality	O
of	O
function	O
is	O
the	O
emerging	O
paradigm	O
for	O
the	O
role	O
of	O
TGFbeta1	O
in	O
cancer	B-Anatomy
.	O
This	O
review	O
will	O
focus	O
on	O
the	O
evidence	O
for	O
TGFbeta1	O
as	O
a	O
tumor	B-Anatomy
promoting	O
and	O
metastasis	O
factor	O
and	O
examine	O
the	O
biological	O
and	O
molecular	O
basis	O
for	O
these	O
effects	O
.	O
It	O
is	O
proposed	O
that	O
the	O
switch	O
from	O
tumor	B-Anatomy
suppressor	O
to	O
oncogene	O
reflects	O
genetic	O
or	O
epigenetic	O
alterations	O
in	O
signaling	O
pathways	O
in	O
tumor	B-Anatomy
cells	I-Anatomy
that	O
alter	O
the	O
readout	O
from	O
the	O
TGFbeta1	O
pathway	O
.	O
Role	O
of	O
thrombin	O
in	O
angiogenesis	O
and	O
tumor	B-Anatomy
progression	O
.	O
Clinical	O
,	O
laboratory	O
,	O
histopathological	O
,	O
and	O
pharmacological	O
evidence	O
support	O
the	O
notion	O
that	O
the	O
coagulation	O
system	O
,	O
which	O
is	O
activated	O
in	O
most	O
cancer	B-Anatomy
patients	O
,	O
plays	O
an	O
important	O
role	O
in	O
tumor	B-Anatomy
biology	O
.	O
Our	O
laboratory	O
has	O
provided	O
evidence	O
that	O
thrombin	O
activates	O
angiogenesis	O
,	O
a	O
process	O
which	O
is	O
essential	O
in	O
tumor	B-Anatomy
growth	O
and	O
metastasis	O
.	O
This	O
event	O
is	O
independent	O
of	O
fibrin	O
formation	O
.	O
At	O
the	O
cellular	B-Anatomy
level	O
many	O
actions	O
of	O
thrombin	O
can	O
contribute	O
to	O
activation	O
of	O
angiogenesis	O
:	O
(	O
1	O
)	O
.	O
Thrombin	O
decreases	O
the	O
ability	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
to	O
attach	O
to	O
basement	B-Anatomy
membrane	I-Anatomy
proteins	O
.	O
(	O
2	O
)	O
.	O
Thrombin	O
greatly	O
potentiates	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
(	O
VEGF	O
-	O
)	O
induced	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
.	O
This	O
potentiation	O
is	O
accompanied	O
by	O
up	O
-	O
regulation	O
of	O
the	O
expression	O
of	O
VEGF	O
receptors	O
(	O
kinase	O
insert	O
domain	O
-	O
containing	O
receptor	O
[	O
KDR	O
]	O
and	O
fms	O
-	O
like	O
tyrosine	O
kinase	O
[	O
Flt	O
-	O
1	O
]	O
)	O
.	O
(	O
3	O
)	O
.	O
Thrombin	O
increases	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
and	O
serves	O
as	O
a	O
ligand	O
to	O
this	O
receptor	O
.	O
Furthermore	O
,	O
thrombin	O
increases	O
the	O
secretion	O
of	O
VEGF	O
and	O
enhances	O
the	O
expression	O
and	O
protein	O
synthesis	O
of	O
matrix	O
metalloprotease	O
-	O
9	O
and	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
in	O
human	O
prostate	B-Anatomy
cancer	I-Anatomy
PC	I-Anatomy
-	I-Anatomy
3	I-Anatomy
cells	I-Anatomy
.	O
These	O
results	O
could	O
explain	O
the	O
angiogenic	O
and	O
tumor	B-Anatomy
-	O
promoting	O
effect	O
of	O
thrombin	O
and	O
provide	O
the	O
basis	O
for	O
development	O
of	O
thrombin	O
receptor	O
mimetics	O
or	O
antagonists	O
for	O
therapeutic	O
application	O
.	O
NIH3T3	B-Anatomy
transfectant	I-Anatomy
containing	O
human	O
K	O
-	O
ras	O
oncogene	O
shows	O
enhanced	O
metastatic	O
activity	O
after	O
in	O
vivo	O
tumor	B-Anatomy
growth	O
or	O
co	O
-	O
culture	O
with	O
fibroblasts	B-Anatomy
.	O
A	O
clone	B-Anatomy
of	O
NIH3T3	B-Anatomy
transformant	I-Anatomy
(	O
H	B-Anatomy
-	I-Anatomy
3	I-Anatomy
)	O
,	O
obtained	O
by	O
transfecting	O
genomic	O
DNA	O
of	O
a	O
human	O
colon	B-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
contains	O
human	O
K	O
-	O
ras	O
oncogene	O
and	O
yields	O
metastatic	B-Anatomy
pulmonary	I-Anatomy
nodules	I-Anatomy
after	O
intravenous	B-Anatomy
injection	O
of	O
the	O
cells	B-Anatomy
into	O
nude	O
mice	O
.	O
This	O
metastatic	O
ability	O
was	O
enhanced	O
remarkably	O
after	O
in	O
vivo	O
tumor	B-Anatomy
growth	O
(	O
subcutaneous	B-Anatomy
tumor	I-Anatomy
formation	O
in	O
nude	O
mice	O
)	O
accompanied	O
by	O
increased	O
mRNA	O
expression	O
and	O
gene	O
amplification	O
of	O
the	O
human	O
-	O
derived	O
K	O
-	O
ras	O
oncogene	O
,	O
while	O
it	O
declined	O
gradually	O
as	O
the	O
passage	O
number	O
increased	O
in	O
vitro	O
,	O
with	O
corresponding	O
decreases	O
of	O
gene	O
amplification	O
and	O
mRNA	O
expression	O
.	O
Six	O
subclones	B-Anatomy
were	O
randomly	O
selected	O
from	O
H	B-Anatomy
-	I-Anatomy
3	I-Anatomy
cells	I-Anatomy
which	O
had	O
been	O
subcultured	O
to	O
passage	O
22	O
.	O
All	O
of	O
the	O
clones	B-Anatomy
in	O
culture	O
showed	O
almost	O
the	O
same	O
low	O
level	O
of	O
metastatic	O
ability	O
and	O
exhibited	O
little	O
K	O
-	O
ras	O
oncogene	O
amplification	O
with	O
correspondingly	O
low	O
mRNA	O
expression	O
.	O
However	O
,	O
after	O
they	O
formed	O
tumors	B-Anatomy
in	O
nude	O
mice	O
,	O
every	O
clone	B-Anatomy
acquired	O
high	O
metastatic	O
ability	O
and	O
the	O
gene	O
amplification	O
increased	O
,	O
with	O
elevated	O
mRNA	O
expression	O
.	O
These	O
experimental	O
facts	O
indicated	O
that	O
acquisition	O
of	O
metastatic	O
ability	O
coupled	O
with	O
the	O
function	O
of	O
K	O
-	O
ras	O
oncogene	O
was	O
conditional	O
in	O
nature	O
,	O
being	O
strongly	O
affected	O
by	O
in	O
vivo	O
tumor	B-Anatomy
circumstances	O
.	O
The	O
low	O
metastatic	O
and	O
G	O
-	O
418	O
-	O
resistant	O
H	B-Anatomy
-	I-Anatomy
3	I-Anatomy
cells	I-Anatomy
were	O
co	O
-	O
cultured	O
with	O
BALB	B-Anatomy
/	I-Anatomy
c3T3	I-Anatomy
fibroblasts	I-Anatomy
for	O
2	O
-	O
4	O
weeks	O
.	O
After	O
removal	O
of	O
fibroblasts	B-Anatomy
by	O
exposure	O
to	O
G	O
-	O
418	O
,	O
the	O
tumor	B-Anatomy
cells	I-Anatomy
exhibited	O
increased	O
metastatic	O
ability	O
and	O
human	O
K	O
-	O
ras	O
oncogene	O
mRNA	O
,	O
suggesting	O
an	O
intimate	O
interaction	O
between	O
H	B-Anatomy
-	I-Anatomy
3	I-Anatomy
cells	I-Anatomy
and	O
fibroblasts	B-Anatomy
influencing	O
the	O
function	O
of	O
transfected	O
human	O
K	O
-	O
ras	O
oncogene	O
.	O
Fibroblasts	B-Anatomy
of	O
the	O
host	O
animal	O
may	O
thus	O
have	O
an	O
important	O
role	O
in	O
generating	O
enhanced	O
metastatic	O
activity	O
of	O
H	B-Anatomy
-	I-Anatomy
3	I-Anatomy
cells	I-Anatomy
.	O
Potent	O
antibacterial	O
activity	O
of	O
Y	O
-	O
754	O
,	O
a	O
novel	O
benzimidazole	O
compound	O
with	O
selective	O
action	O
against	O
Helicobacter	O
pylori	O
.	O
Y	O
-	O
754	O
,	O
a	O
novel	O
benzimidazole	O
compound	O
,	O
was	O
investigated	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
antibacterial	O
activity	O
.	O
Unlike	O
amoxicillin	O
,	O
clarithromycin	O
,	O
and	O
metronidazole	O
,	O
the	O
compound	O
had	O
no	O
activity	O
against	O
common	O
aerobic	O
and	O
anaerobic	O
bacteria	O
other	O
than	O
Helicobacter	O
pylori	O
.	O
The	O
minimum	O
inhibitory	O
concentration	O
of	O
Y	O
-	O
754	O
against	O
H	O
.	O
pylori	O
,	O
at	O
0	O
.	O
025	O
microg	O
/	O
ml	O
,	O
was	O
nearly	O
equal	O
to	O
that	O
of	O
amoxicillin	O
and	O
clarithromycin	O
.	O
The	O
respective	O
concentrations	O
of	O
Y	O
-	O
754	O
,	O
amoxicillin	O
,	O
clarithromycin	O
,	O
and	O
metronidazole	O
required	O
to	O
inhibit	O
90	O
%	O
of	O
39	O
isolates	O
of	O
H	O
.	O
pylori	O
were	O
0	O
.	O
05	O
,	O
0	O
.	O
39	O
,	O
6	O
.	O
25	O
,	O
and	O
25	O
microg	O
/	O
ml	O
,	O
indicating	O
the	O
potent	O
activity	O
of	O
Y	O
-	O
754	O
,	O
including	O
activity	O
against	O
clarithromycin	O
-	O
and	O
metronidazole	O
-	O
resistant	O
strains	B-Anatomy
.	O
The	O
anti	O
-	O
H	O
.	O
pylori	O
activity	O
of	O
Y	O
-	O
754	O
was	O
potent	O
even	O
at	O
pH	O
5	O
.	O
5	O
and	O
was	O
bactericidal	O
at	O
concentrations	O
of	O
0	O
.	O
1	O
microg	O
/	O
ml	O
and	O
above	O
.	O
Exposure	O
of	O
H	O
.	O
pylori	O
to	O
Y	O
-	O
754	O
did	O
not	O
result	O
in	O
the	O
induction	O
of	O
drug	O
-	O
resistant	O
mutation	O
.	O
Oral	B-Anatomy
administration	O
(	O
10	O
mg	O
/	O
kg	O
twice	O
a	O
day	O
for	O
7	O
days	O
)	O
to	O
Mongolian	O
gerbils	O
infected	O
with	O
strain	B-Anatomy
ATCC	O
43504	O
demonstrated	O
that	O
Y	O
-	O
754	O
was	O
effective	O
in	O
H	O
.	O
pylori	O
eradication	O
and	O
that	O
its	O
eradication	O
efficacy	O
increased	O
in	O
line	O
with	O
the	O
progress	O
of	O
damage	O
to	O
the	O
gastric	B-Anatomy
mucosa	I-Anatomy
caused	O
by	O
H	O
.	O
pylori	O
infection	O
.	O
Y	O
-	O
754	O
was	O
also	O
efficacious	O
in	O
the	O
treatment	O
of	O
infection	O
by	O
the	O
clarithromycin	O
-	O
resistant	O
strain	B-Anatomy
OIT	O
-	O
36	O
.	O
The	O
results	O
obtained	O
lead	O
to	O
the	O
expectation	O
that	O
the	O
new	O
benzimidazole	O
Y	O
-	O
754	O
will	O
,	O
in	O
the	O
near	O
future	O
,	O
be	O
used	O
for	O
H	O
.	O
pylori	O
eradication	O
therapy	O
in	O
peptic	B-Anatomy
ulcer	I-Anatomy
patients	O
.	O
Active	O
respiratory	O
syncytial	O
virus	O
purified	O
by	O
ion	O
-	O
exchange	O
chromatography	O
:	O
characterization	O
of	O
binding	O
and	O
elution	O
requirements	O
.	O
Two	O
viruses	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
were	O
used	O
to	O
evaluate	O
viral	O
purification	O
by	O
an	O
affinity	O
resin	O
column	O
(	O
Matrex	O
Cellufine	O
Sulfate	O
(	O
MCS	O
)	O
;	O
Amicon	O
Division	O
,	O
WR	O
Grace	O
&	O
Co	O
.	O
)	O
.	O
Viable	O
RSV	O
was	O
purified	O
significantly	O
from	O
crude	O
cell	B-Anatomy
lysate	I-Anatomy
by	O
a	O
single	O
pass	O
through	O
a	O
column	O
containing	O
the	O
anionic	O
MCS	O
resin	O
.	O
Most	O
cell	B-Anatomy
protein	O
and	O
albumin	O
eluted	O
from	O
the	O
MCS	O
resin	O
with	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
)	O
but	O
RSV	O
eluted	O
at	O
high	O
ionic	O
strength	O
,	O
i	O
.	O
e	O
.	O
,	O
greater	O
than	O
or	O
equal	O
to	O
0	O
.	O
6	O
M	O
NaCl	O
.	O
Further	O
purification	O
was	O
possible	O
by	O
sucrose	O
step	O
gradient	O
centrifugation	O
.	O
The	O
RSV	O
prepared	O
by	O
column	O
purification	O
or	O
by	O
column	O
plus	O
sucrose	O
gradient	O
separation	O
was	O
both	O
intact	O
and	O
infective	O
.	O
RSV	O
and	O
pure	O
samples	O
of	O
VSV	O
were	O
used	O
to	O
optimize	O
ionic	O
strength	O
and	O
salts	O
for	O
elution	O
from	O
the	O
MCS	O
column	O
:	O
0	O
.	O
8	O
M	O
NaCl	O
removed	O
most	O
of	O
the	O
viral	O
protein	O
.	O
The	O
capacity	O
of	O
the	O
MCS	O
gel	O
for	O
RSV	O
or	O
VSV	O
was	O
found	O
to	O
be	O
about	O
0	O
.	O
6	O
-	O
0	O
.	O
8	O
mg	O
viral	O
protein	O
per	O
ml	O
of	O
hydrated	O
resin	O
.	O
Detergent	O
-	O
solubilized	O
viral	O
membrane	B-Anatomy
proteins	O
bound	O
to	O
the	O
MCS	O
resin	O
in	O
0	O
.	O
145	O
M	O
NaCl	O
and	O
eluted	O
with	O
higher	O
salt	O
concentrations	O
.	O
Thus	O
,	O
this	O
resin	O
also	O
may	O
be	O
a	O
useful	O
aid	O
for	O
relatively	O
gentle	O
purification	O
of	O
these	O
proteins	O
.	O
Lactoferrin	O
enhances	O
Fas	O
expression	O
and	O
apoptosis	O
in	O
the	O
colon	B-Anatomy
mucosa	I-Anatomy
of	O
azoxymethane	O
-	O
treated	O
rats	O
.	O
Bovine	O
lactoferrin	O
,	O
a	O
multifunctional	O
glycoprotein	O
,	O
has	O
been	O
shown	O
to	O
strongly	O
inhibit	O
development	O
of	O
azoxymethane	O
(	O
AOM	O
)	O
-	O
induced	O
rat	O
colon	B-Anatomy
tumors	I-Anatomy
.	O
Little	O
,	O
however	O
,	O
is	O
known	O
about	O
the	O
inhibitory	O
mechanisms	O
.	O
We	O
have	O
demonstrated	O
recently	O
that	O
lactoferrin	O
enhances	O
the	O
expression	O
of	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
family	O
,	O
Fas	O
,	O
in	O
the	O
colon	B-Anatomy
mucosa	I-Anatomy
during	O
both	O
early	O
and	O
late	O
stages	O
of	O
carcinogenesis	O
.	O
Thus	O
,	O
Fas	O
could	O
be	O
involved	O
in	O
bovine	O
lactoferrin	O
-	O
mediated	O
inhibition	O
of	O
tumor	B-Anatomy
development	O
.	O
To	O
investigate	O
this	O
possibility	O
,	O
we	O
studied	O
the	O
influence	O
of	O
bovine	O
lactoferrin	O
on	O
Fas	O
-	O
mediated	O
apoptosis	O
with	O
regard	O
to	O
expression	O
of	O
Fas	O
,	O
activation	O
of	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
3	O
,	O
and	O
DNA	O
fragmentation	O
in	O
the	O
colon	B-Anatomy
mucosa	I-Anatomy
of	O
AOM	O
-	O
treated	O
rats	O
.	O
Western	O
blot	O
analysis	O
demonstrated	O
a	O
>	O
2	O
.	O
5	O
-	O
fold	O
increase	O
in	O
Fas	O
protein	O
expression	O
,	O
as	O
well	O
as	O
elevation	O
of	O
the	O
active	O
forms	O
of	O
both	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
3	O
.	O
Immunohistochemical	O
analysis	O
revealed	O
Fas	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
cells	I-Anatomy
and	O
apoptotic	O
cells	B-Anatomy
preferentially	O
within	O
the	O
proximal	O
colon	B-Anatomy
region	O
,	O
clearly	O
at	O
the	O
site	O
of	O
bovine	O
lactoferrin	O
-	O
mediated	O
tumor	B-Anatomy
inhibition	O
.	O
These	O
results	O
suggest	O
that	O
apoptosis	O
caused	O
by	O
elevated	O
expression	O
of	O
Fas	O
is	O
involved	O
in	O
chemoprevention	O
by	O
lactoferrin	O
of	O
colon	B-Anatomy
carcinogenesis	O
.	O
Dynein	O
light	O
chain	O
1	O
,	O
a	O
p21	O
-	O
activated	O
kinase	O
1	O
-	O
interacting	O
substrate	O
,	O
promotes	O
cancerous	B-Anatomy
phenotypes	O
.	O
We	O
identified	O
dynein	O
light	O
chain	O
1	O
(	O
DLC1	O
)	O
as	O
a	O
physiologic	O
substrate	O
of	O
p21	O
-	O
activated	O
kinase	O
1	O
(	O
Pak1	O
)	O
.	O
Pak1	O
-	O
DLC1	O
interaction	O
plays	O
an	O
essential	O
role	O
in	O
cell	B-Anatomy
survival	O
,	O
which	O
depends	O
on	O
Pak1	O
'	O
s	O
phosphorylation	O
of	O
DLC1	O
on	O
Ser88	O
.	O
Pak1	O
associates	O
with	O
the	O
complex	O
of	O
DLC1	O
and	O
BimL	O
,	O
a	O
proapoptotic	O
BH3	O
-	O
only	O
protein	O
,	O
and	O
phosphorylates	O
both	O
proteins	O
.	O
Phosphorylation	O
of	O
BimL	O
by	O
Pak1	O
prevents	O
it	O
from	O
interacting	O
with	O
and	O
inactivation	O
of	O
Bcl	O
-	O
2	O
,	O
an	O
antiapoptotic	O
protein	O
.	O
Overexpression	O
of	O
DLC1	O
but	O
not	O
DLC1	O
-	O
Ser88Ala	O
mutant	O
promotes	O
cancerous	B-Anatomy
properties	O
of	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
DLC1	O
protein	O
level	O
is	O
elevated	O
in	O
more	O
than	O
90	O
%	O
of	O
human	O
breast	B-Anatomy
tumors	I-Anatomy
.	O
The	O
regulation	O
of	O
cell	B-Anatomy
survival	O
functions	O
by	O
Pak1	O
-	O
DLC1	O
interaction	O
represents	O
a	O
novel	O
mechanism	O
by	O
which	O
a	O
signaling	O
kinase	O
might	O
regulate	O
the	O
cancerous	B-Anatomy
phenotypes	O
.	O
Novel	O
insights	O
into	O
the	O
pathogenesis	O
of	O
uric	O
acid	O
nephrolithiasis	O
.	O
PURPOSE	O
OF	O
REVIEW	O
:	O
The	O
factors	O
involved	O
in	O
the	O
pathogenesis	O
of	O
uric	O
acid	O
nephrolithiasis	O
are	O
well	O
known	O
.	O
A	O
low	O
urinary	B-Anatomy
pH	O
is	O
the	O
most	O
significant	O
element	O
in	O
the	O
generation	O
of	O
stones	B-Anatomy
,	O
with	O
hyperuricosuria	O
being	O
a	O
less	O
common	O
finding	O
.	O
The	O
underlying	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
these	O
disturbances	O
remain	O
poorly	O
characterized	O
.	O
This	O
review	O
summarizes	O
previous	O
knowledge	O
and	O
highlights	O
some	O
recent	O
developments	O
in	O
the	O
pathophysiology	O
of	O
low	O
urine	B-Anatomy
pH	O
and	O
hyperuricosuria	O
.	O
RECENT	O
FINDINGS	O
:	O
Epidemiological	O
and	O
metabolic	O
studies	O
have	O
indicated	O
an	O
association	O
between	O
uric	O
acid	O
nephrolithiasis	O
and	O
insulin	O
resistance	O
.	O
Some	O
potential	O
mechanisms	O
include	O
impaired	O
ammoniagenesis	O
caused	O
by	O
resistance	O
to	O
insulin	O
action	O
in	O
the	O
renal	B-Anatomy
proximal	I-Anatomy
tubule	I-Anatomy
,	O
or	O
substrate	O
competition	O
by	O
free	O
fatty	O
acids	O
.	O
The	O
evaluation	O
of	O
a	O
large	O
Sicilian	O
kindred	O
recently	O
revealed	O
a	O
putative	O
genetic	O
locus	O
linked	O
to	O
uric	B-Anatomy
acid	I-Anatomy
stone	I-Anatomy
disease	O
.	O
The	O
identification	O
of	O
novel	O
complementary	O
DNA	O
has	O
provided	O
an	O
interesting	O
insight	O
into	O
the	O
renal	B-Anatomy
handling	O
of	O
uric	O
acid	O
,	O
including	O
one	O
genetic	O
cause	O
of	O
renal	B-Anatomy
uric	O
acid	O
wasting	O
.	O
SUMMARY	O
:	O
The	O
recognition	O
of	O
metabolic	O
,	O
molecular	O
,	O
and	O
genetic	O
factors	O
that	O
influence	O
urinary	B-Anatomy
pH	O
,	O
and	O
uric	O
acid	O
metabolism	O
and	O
excretion	O
,	O
will	O
provide	O
novel	O
insights	O
into	O
the	O
pathogenesis	O
of	O
uric	B-Anatomy
acid	I-Anatomy
stones	I-Anatomy
,	O
and	O
open	O
the	O
way	O
for	O
new	O
therapeutic	O
strategies	O
.	O
Multicriteria	O
evaluation	O
of	O
simulated	O
logging	O
scenarios	O
in	O
a	O
tropical	O
rain	O
forest	O
.	O
Forest	O
growth	O
models	O
are	O
useful	O
tools	O
for	O
investigating	O
the	O
long	O
-	O
term	O
impacts	O
of	O
logging	O
.	O
In	O
this	O
paper	O
,	O
the	O
results	O
of	O
the	O
rain	O
forest	O
growth	O
model	O
FORMIND	O
were	O
assessed	O
by	O
a	O
multicriteria	O
decision	O
analysis	O
.	O
The	O
main	O
processes	O
covered	O
by	O
FORMIND	O
include	O
tree	O
growth	O
,	O
mortality	O
,	O
regeneration	O
and	O
competition	O
.	O
Tree	O
growth	O
is	O
calculated	O
based	O
on	O
a	O
carbon	O
balance	O
approach	O
.	O
Trees	O
compete	O
for	O
light	O
and	O
space	O
;	O
dying	O
large	O
trees	O
fall	O
down	O
and	O
create	O
gaps	O
in	O
the	O
forest	O
.	O
Sixty	O
-	O
four	O
different	O
logging	O
scenarios	O
for	O
an	O
initially	O
undisturbed	O
forest	O
stand	O
at	O
Deramakot	O
(	O
Malaysia	O
)	O
were	O
simulated	O
.	O
The	O
scenarios	O
differ	O
regarding	O
the	O
logging	O
cycle	O
,	O
logging	O
method	O
,	O
cutting	O
limit	O
and	O
logging	O
intensity	O
.	O
We	O
characterise	O
the	O
impacts	O
with	O
four	O
criteria	O
describing	O
the	O
yield	O
,	O
canopy	O
opening	O
and	O
changes	O
in	O
species	O
composition	O
.	O
Multicriteria	O
decision	O
analysis	O
was	O
used	O
for	O
the	O
first	O
time	O
to	O
evaluate	O
the	O
scenarios	O
and	O
identify	O
the	O
efficient	O
ones	O
.	O
Our	O
results	O
plainly	O
show	O
that	O
reduced	O
-	O
impact	O
logging	O
scenarios	O
are	O
more	O
'	O
efficient	O
'	O
than	O
the	O
others	O
,	O
since	O
in	O
these	O
scenarios	O
forest	O
damage	O
is	O
minimised	O
without	O
significantly	O
reducing	O
yield	O
.	O
Nevertheless	O
,	O
there	O
is	O
a	O
trade	O
-	O
off	O
between	O
yield	O
and	O
achieving	O
a	O
desired	O
ecological	O
state	O
of	O
logged	O
forest	O
;	O
the	O
ecological	O
state	O
of	O
the	O
logged	O
forests	O
can	O
only	O
be	O
improved	O
by	O
reducing	O
yields	O
and	O
enlarging	O
the	O
logging	O
cycles	O
.	O
Our	O
study	O
also	O
demonstrates	O
that	O
high	O
cutting	O
limits	O
or	O
low	O
logging	O
intensities	O
cannot	O
compensate	O
for	O
the	O
high	O
level	O
of	O
damage	O
caused	O
by	O
conventional	O
logging	O
techniques	O
.	O
Matrix	O
metalloproteinase	O
activity	O
and	O
immunohistochemical	O
profile	O
of	O
matrix	O
metalloproteinase	O
-	O
2	O
and	O
-	O
9	O
and	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
-	O
1	O
during	O
human	O
dermal	B-Anatomy
wound	I-Anatomy
healing	O
.	O
Proteolytic	O
activity	O
is	O
required	O
for	O
the	O
turnover	O
of	O
the	O
extracellular	B-Anatomy
matrix	I-Anatomy
during	O
wound	B-Anatomy
healing	O
.	O
Matrix	O
metalloproteinases	O
can	O
collectively	O
cleave	O
all	O
components	O
of	O
the	O
extracellular	B-Anatomy
matrix	I-Anatomy
,	O
with	O
the	O
endogenous	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
-	O
1	O
regulating	O
their	O
activity	O
.	O
Breast	B-Anatomy
tissue	I-Anatomy
taken	O
at	O
varying	O
postoperative	O
times	O
(	O
n	O
=	O
92	O
)	O
or	O
during	O
surgery	O
(	O
controls	O
,	O
n	O
=	O
17	O
)	O
,	O
was	O
used	O
to	O
investigate	O
the	O
temporal	O
and	O
spatial	O
activity	O
of	O
matrix	O
metalloproteinase	O
-	O
2	O
and	O
-	O
9	O
and	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
-	O
1	O
during	O
human	O
wound	B-Anatomy
healing	O
.	O
Matrix	O
metalloproteinase	O
activity	O
,	O
determined	O
using	O
a	O
quenched	O
fluorescence	O
substrate	O
assay	O
,	O
increased	O
during	O
early	O
healing	O
(	O
3	O
-	O
8	O
weeks	O
)	O
compared	O
to	O
controls	O
,	O
and	O
then	O
decreased	O
between	O
24	O
and	O
36	O
weeks	O
after	O
surgery	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
until	O
24	O
weeks	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
)	O
.	O
Immunohistochemistry	O
scores	O
for	O
matrix	O
metalloproteinase	O
-	O
9	O
expression	O
were	O
significantly	O
elevated	O
compared	O
to	O
controls	B-Anatomy
in	O
scar	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
and	O
fibroblasts	B-Anatomy
from	O
2	O
until	O
12	O
and	O
20	O
weeks	O
,	O
respectively	O
.	O
Matrix	O
metalloproteinase	O
-	O
2	O
staining	O
was	O
observed	O
exclusively	O
in	O
fibroblasts	B-Anatomy
,	O
reaching	O
maximum	O
levels	O
8	O
-	O
12	O
weeks	O
after	O
surgery	O
,	O
decreasing	O
by	O
1	O
.	O
5	O
years	O
but	O
remaining	O
significantly	O
increased	O
.	O
Tissue	O
inhibitor	O
of	O
metalloproteinase	O
-	O
1	O
staining	O
was	O
relatively	O
sparse	O
but	O
was	O
significantly	O
increased	O
until	O
8	O
weeks	O
after	O
surgery	O
.	O
These	O
results	O
show	O
that	O
matrix	O
metalloproteinases	O
are	O
present	O
at	O
elevated	O
levels	O
during	O
early	O
wound	B-Anatomy
healing	O
,	O
when	O
angiogenesis	O
occurs	O
,	O
and	O
suggest	O
that	O
matrix	O
metalloproteinase	O
-	O
9	O
may	O
play	O
a	O
significant	O
role	O
.	O
The	O
later	O
expression	O
of	O
matrix	O
metalloproteinase	O
-	O
2	O
and	O
-	O
9	O
in	O
fibroblasts	B-Anatomy
suggests	O
a	O
role	O
in	O
extracellular	B-Anatomy
matrix	I-Anatomy
remodeling	O
.	O
Convergence	O
of	O
p53	O
and	O
TGF	O
-	O
beta	O
signaling	O
networks	O
.	O
p53	O
is	O
a	O
protein	O
with	O
many	O
talents	O
.	O
One	O
of	O
the	O
most	O
fundamental	O
is	O
the	O
ability	O
to	O
act	O
as	O
essential	O
growth	O
checkpoint	O
that	O
protects	O
cells	B-Anatomy
against	O
cellular	B-Anatomy
transformation	O
.	O
p53	O
does	O
so	O
through	O
the	O
induction	O
of	O
genes	O
leading	O
to	O
growth	O
arrest	O
or	O
apoptosis	O
.	O
Most	O
of	O
the	O
studies	O
focusing	O
on	O
the	O
mechanisms	O
of	O
p53	O
activity	O
have	O
been	O
performed	O
in	O
cultured	O
cells	B-Anatomy
upon	O
treatment	O
with	O
well	O
-	O
established	O
p53	O
-	O
activating	O
inputs	O
,	O
such	O
as	O
high	O
doses	O
of	O
radiations	O
,	O
DNA	O
-	O
damaging	O
drugs	O
and	O
activated	O
oncogenes	O
.	O
However	O
,	O
how	O
the	O
tumor	B-Anatomy
suppressive	O
functions	O
of	O
p53	O
become	O
concerted	O
with	O
the	O
extracellular	B-Anatomy
cues	O
arriving	O
at	O
the	O
cell	B-Anatomy
surface	I-Anatomy
during	O
tissue	B-Anatomy
homeostasis	O
,	O
remains	O
largely	O
unknown	O
.	O
Intriguingly	O
,	O
two	O
recent	O
papers	O
have	O
shed	O
new	O
light	O
into	O
this	O
unexplored	O
field	O
,	O
indicating	O
that	O
p53	O
plays	O
a	O
key	O
role	O
in	O
TGF	O
-	O
beta	O
-	O
induced	O
growth	O
arrest	O
and	O
,	O
unexpectedly	O
,	O
in	O
the	O
developmental	O
effects	O
of	O
TGF	O
-	O
beta	O
in	O
early	O
embryos	B-Anatomy
.	O
Here	O
we	O
review	O
and	O
comment	O
on	O
these	O
findings	O
and	O
on	O
their	O
implications	O
for	O
cancer	B-Anatomy
biology	O
.	O
Enhanced	O
IGF	O
-	O
1	O
expression	O
improves	O
smooth	B-Anatomy
muscle	I-Anatomy
cell	I-Anatomy
engraftment	O
after	O
cell	B-Anatomy
transplantation	O
.	O
The	O
functional	O
benefit	O
of	O
cell	B-Anatomy
transplantation	O
after	O
a	O
myocardial	B-Anatomy
infarction	O
is	O
diminished	O
by	O
early	O
cell	B-Anatomy
losses	O
.	O
IGF	O
-	O
1	O
enhances	O
cell	B-Anatomy
proliferation	O
and	O
survival	O
.	O
We	O
hypothesized	O
that	O
IGF	O
-	O
1	O
-	O
transfected	O
smooth	B-Anatomy
muscle	I-Anatomy
cells	I-Anatomy
(	O
SMCs	B-Anatomy
)	O
would	O
enhance	O
cell	B-Anatomy
survival	O
and	O
improve	O
engraftment	O
after	O
cell	B-Anatomy
transplantation	O
.	O
The	O
IGF	O
-	O
1	O
gene	O
was	O
transfected	O
into	O
male	O
SMCs	B-Anatomy
and	O
compared	O
with	O
SMCs	B-Anatomy
transfected	O
with	O
a	O
plasmid	B-Anatomy
vector	O
(	O
vector	O
control	O
)	O
and	O
nontransfected	O
SMCs	B-Anatomy
(	O
cell	B-Anatomy
control	O
)	O
.	O
IGF	O
-	O
1	O
mRNA	O
(	O
n	O
=	O
10	O
/	O
group	O
)	O
and	O
protein	O
levels	O
(	O
n	O
=	O
6	O
/	O
group	O
)	O
were	O
higher	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
for	O
all	O
groups	O
)	O
at	O
3	O
,	O
7	O
,	O
and	O
14	O
days	O
compared	O
with	O
controls	O
.	O
VEGF	O
was	O
also	O
increased	O
in	O
parallel	O
to	O
enhanced	O
IGF	O
-	O
1	O
expression	O
.	O
IGF	O
-	O
1	O
-	O
transfected	O
cells	B-Anatomy
demonstrated	O
greater	O
cell	B-Anatomy
proliferation	O
,	O
stimulated	O
angiogenesis	O
,	O
and	O
decreased	O
caspase	O
-	O
3	O
activity	O
after	O
simulated	O
ischemia	O
and	O
reperfusion	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
for	O
all	O
groups	O
compared	O
with	O
vector	O
or	O
cell	B-Anatomy
controls	O
)	O
.	O
A	O
uniform	O
left	B-Anatomy
ventricular	I-Anatomy
injury	O
was	O
produced	O
in	O
female	O
rats	O
using	O
a	O
cryoprobe	O
.	O
Three	O
weeks	O
later	O
,	O
2	O
x	O
10	O
(	O
6	O
)	O
cells	B-Anatomy
from	O
three	O
groups	O
were	O
implanted	O
into	O
the	O
scar	B-Anatomy
.	O
One	O
week	O
later	O
,	O
IGF	O
-	O
1	O
-	O
transfected	O
SMCs	B-Anatomy
had	O
increased	O
myocardial	B-Anatomy
IGF	O
-	O
1	O
and	O
VEGF	O
levels	O
,	O
increased	O
Bcl2	O
expression	O
,	O
limited	O
cell	B-Anatomy
apoptosis	O
,	O
and	O
enhanced	O
vessel	B-Anatomy
formation	O
in	O
the	O
myocardial	B-Anatomy
scar	I-Anatomy
compared	O
with	O
the	O
two	O
control	O
groups	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
for	O
all	O
groups	O
)	O
.	O
The	O
proportion	O
of	O
SMCs	B-Anatomy
surviving	O
in	O
the	O
implanted	O
region	O
was	O
greater	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
the	O
IGF	O
-	O
1	O
-	O
transfected	O
group	O
than	O
in	O
the	O
vector	O
or	O
cell	B-Anatomy
controls	O
.	O
Gene	O
enhancement	O
with	O
IGF	O
-	O
1	O
improved	O
donor	B-Anatomy
cell	I-Anatomy
proliferation	O
,	O
survival	O
,	O
and	O
engraftment	O
after	O
cell	B-Anatomy
transplantation	O
,	O
perhaps	O
mediated	O
by	O
enhanced	O
angiogenesis	O
and	O
reduced	O
apoptosis	O
.	O
[	O
Altered	O
expression	O
of	O
PTEN	O
gene	O
and	O
LOH	O
of	O
its	O
epigenetic	O
microsatellite	O
in	O
gastric	B-Anatomy
carcinoma	I-Anatomy
]	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
the	O
expression	O
of	O
PTEN	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
of	O
its	O
epigenetic	O
microsatellite	O
in	O
gastric	B-Anatomy
carcinoma	I-Anatomy
and	O
explore	O
their	O
roles	O
in	O
progression	O
of	O
gastric	B-Anatomy
carcinoma	I-Anatomy
.	O
METHODS	O
:	O
LOH	O
of	O
epigenetic	O
microsatellites	O
of	O
PTEN	O
(	O
D10S541	O
,	O
D10S583	O
and	O
D10S1687	O
)	O
in	O
advanced	O
gastric	B-Anatomy
cancer	I-Anatomy
was	O
detected	O
by	O
PCR	O
-	O
SSCP	O
.	O
Expression	O
of	O
PTEN	O
mRNA	O
and	O
protein	O
in	O
normal	O
gastric	B-Anatomy
mucosa	I-Anatomy
and	O
gastric	B-Anatomy
cancer	I-Anatomy
was	O
evaluated	O
by	O
RT	O
-	O
PCR	O
and	O
SABC	O
immunohistochemistry	O
,	O
respectively	O
.	O
The	O
relationship	O
between	O
expression	O
of	O
PTEN	O
mRNA	O
and	O
protein	O
and	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
or	O
LOH	O
of	O
microsatellites	O
was	O
discussed	O
.	O
RESULTS	O
:	O
LOH	O
of	O
D10S541	O
,	O
D10S583	O
and	O
D10S1687	O
was	O
found	O
in	O
37	O
.	O
5	O
%	O
(	O
21	O
/	O
56	O
)	O
of	O
advanced	O
gastric	B-Anatomy
cancers	I-Anatomy
.	O
The	O
positive	O
rates	O
of	O
PTEN	O
mRNA	O
expression	O
were	O
80	O
.	O
4	O
%	O
(	O
45	O
/	O
56	O
)	O
,	O
45	O
.	O
5	O
%	O
(	O
5	O
/	O
11	O
)	O
and	O
32	O
.	O
1	O
%	O
(	O
18	O
/	O
56	O
)	O
in	O
normal	O
mucosa	B-Anatomy
,	O
early	O
and	O
advanced	O
gastric	B-Anatomy
carcinomas	I-Anatomy
,	O
respectively	O
,	O
while	O
78	O
.	O
6	O
%	O
(	O
44	O
/	O
56	O
)	O
,	O
44	O
.	O
5	O
%	O
(	O
5	O
/	O
11	O
)	O
and	O
28	O
.	O
6	O
%	O
(	O
16	O
/	O
56	O
)	O
at	O
the	O
protein	O
level	O
.	O
PTEN	O
mRNA	O
and	O
protein	O
were	O
less	O
frequently	O
expressed	O
in	O
early	O
and	O
advanced	O
gastric	B-Anatomy
carcinomas	I-Anatomy
than	O
that	O
in	O
normal	O
gastric	B-Anatomy
mucosa	I-Anatomy
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
There	O
was	O
positive	O
correlation	O
between	O
PTEN	O
mRNA	O
expression	O
and	O
LOH	O
of	O
microsatellites	O
in	O
advanced	O
gastric	B-Anatomy
carcinomas	I-Anatomy
.	O
PTEN	O
protein	O
expression	O
paralleled	O
with	O
its	O
mRNA	O
expression	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
The	O
expression	O
of	O
PTEN	O
mRNA	O
and	O
protein	O
was	O
negatively	O
correlated	O
with	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
of	O
advanced	O
gastric	B-Anatomy
carcinomas	I-Anatomy
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
CONCLUSION	O
:	O
Down	O
-	O
regulated	O
expression	O
of	O
PTEN	O
gene	O
is	O
found	O
in	O
different	O
stages	O
of	O
gastric	B-Anatomy
carcinoma	I-Anatomy
,	O
and	O
is	O
closely	O
correlated	O
with	O
LOH	O
of	O
its	O
epigenetic	O
microsatellites	O
,	O
which	O
probably	O
is	O
its	O
underlying	O
molecular	O
mechanisms	O
.	O
It	O
suggests	O
that	O
altered	O
PTEN	O
gene	O
contributes	O
to	O
tumorigenesis	O
and	O
progression	O
of	O
gastric	B-Anatomy
carcinomas	I-Anatomy
.	O
Flow	O
dynamics	O
of	O
the	O
internal	B-Anatomy
thoracic	I-Anatomy
and	O
radial	B-Anatomy
artery	I-Anatomy
T	O
-	O
graft	O
.	O
BACKGROUND	O
:	O
Complex	O
use	O
of	O
arterial	B-Anatomy
conduits	I-Anatomy
has	O
resurrected	O
concerns	O
about	O
the	O
adequacy	O
of	O
conduit	B-Anatomy
flow	O
.	O
The	O
T	O
-	O
graft	O
is	O
the	O
extreme	O
example	O
of	O
this	O
trend	O
.	O
Our	O
purpose	O
was	O
to	O
identify	O
the	O
limitation	O
of	O
single	O
source	O
inflow	O
and	O
to	O
compare	O
flow	O
capacity	O
with	O
completion	O
coronary	B-Anatomy
flow	O
.	O
METHODS	O
:	O
Between	O
February	O
1999	O
and	O
November	O
2001	O
,	O
372	O
patients	O
underwent	O
total	O
arterial	B-Anatomy
revascularization	O
with	O
the	O
T	O
-	O
graft	O
alone	O
.	O
Intraoperative	O
flows	O
were	O
recorded	O
for	O
each	O
limb	B-Anatomy
of	O
the	O
T	O
-	O
graft	O
before	O
and	O
after	O
distal	O
anastomoses	O
in	O
204	O
patients	O
.	O
Independent	O
predictors	O
of	O
T	O
-	O
graft	O
flow	O
were	O
identified	O
by	O
multivariate	O
analysis	O
.	O
RESULTS	O
:	O
Free	O
flow	O
for	O
the	O
radial	B-Anatomy
arterial	I-Anatomy
(	I-Anatomy
RA	I-Anatomy
)	I-Anatomy
limb	I-Anatomy
was	O
161	O
+	O
/	O
-	O
81	O
mL	O
/	O
min	O
,	O
the	O
internal	B-Anatomy
thoracic	I-Anatomy
artery	I-Anatomy
(	I-Anatomy
ITA	I-Anatomy
)	I-Anatomy
limb	I-Anatomy
137	O
+	O
/	O
-	O
57	O
mL	O
/	O
min	O
(	O
combined	O
298	O
+	O
/	O
-	O
101	O
mL	O
/	O
min	O
)	O
versus	O
simultaneous	O
limb	B-Anatomy
flow	O
of	O
226	O
+	O
/	O
-	O
84	O
mL	O
/	O
min	O
giving	O
a	O
flow	O
restriction	O
of	O
24	O
%	O
+	O
/	O
-	O
14	O
%	O
.	O
Completion	O
coronary	B-Anatomy
flow	O
was	O
88	O
+	O
/	O
-	O
49	O
mL	O
/	O
min	O
for	O
the	O
RA	B-Anatomy
,	O
60	O
+	O
/	O
-	O
45	O
mL	O
/	O
min	O
for	O
the	O
ITA	B-Anatomy
,	O
and	O
140	O
+	O
/	O
-	O
70	O
mL	O
/	O
min	O
for	O
both	O
limbs	B-Anatomy
simultaneously	O
to	O
give	O
a	O
flow	O
reserve	O
(	O
vs	O
simultaneous	O
free	O
flow	O
)	O
of	O
160	O
%	O
or	O
1	O
.	O
6	O
.	O
Independent	O
predictors	O
of	O
completion	O
RA	B-Anatomy
limb	I-Anatomy
flow	O
are	O
RA	B-Anatomy
proximal	O
diameter	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
number	O
of	O
anastomoses	O
(	O
p	O
=	O
0	O
.	O
018	O
)	O
,	O
and	O
target	O
stenosis	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O
CONCLUSIONS	O
:	O
A	O
flow	O
reserve	O
of	O
1	O
.	O
6	O
compares	O
favorably	O
with	O
an	O
ITA	B-Anatomy
flow	O
reserve	O
of	O
1	O
.	O
8	O
at	O
1	O
-	O
month	O
postoperatively	O
and	O
1	O
.	O
8	O
for	O
both	O
the	O
ITA	B-Anatomy
T	O
-	O
graft	O
and	O
the	O
ITA	B-Anatomy
/	I-Anatomy
RA	I-Anatomy
T	O
-	O
graft	O
at	O
1	O
-	O
week	O
postoperatively	O
as	O
reported	O
by	O
others	O
.	O
Proximal	O
RA	B-Anatomy
diameter	O
and	O
competitive	O
coronary	B-Anatomy
flow	O
influence	O
completion	O
T	O
-	O
graft	O
flow	O
.	O
These	O
data	O
quantitate	O
the	O
limitation	O
of	O
single	O
source	O
inflow	O
of	O
the	O
T	O
-	O
graft	O
configuration	O
and	O
support	O
its	O
continued	O
use	O
.	O
[	O
Glaucoma	B-Anatomy
and	O
ocular	B-Anatomy
ischemic	O
syndrome	O
-	O
-	O
case	O
report	O
]	O
PURPOSE	O
:	O
Ocular	B-Anatomy
ischemic	O
syndrome	O
(	O
OIS	O
)	O
is	O
often	O
poorly	O
diagnosed	O
and	O
treated	O
as	O
primary	B-Anatomy
open	I-Anatomy
angle	I-Anatomy
glaucoma	I-Anatomy
or	O
later	O
on	O
,	O
as	O
neovascular	B-Anatomy
glaucoma	I-Anatomy
.	O
We	O
present	O
a	O
54	O
year	O
old	O
male	O
,	O
treated	O
topical	O
since	O
23	O
years	O
for	O
glaucoma	B-Anatomy
and	O
sent	O
to	O
our	O
clinic	O
for	O
trabeculectomy	O
because	O
of	O
rapid	O
worsening	O
of	O
vision	O
on	O
right	B-Anatomy
eye	I-Anatomy
with	O
bilateral	O
total	O
excavation	O
of	O
optic	O
disc	O
.	O
MATERIAL	O
AND	O
METHODS	O
:	O
Observational	O
case	O
report	O
.	O
RESULTS	O
:	O
Because	O
of	O
typical	O
signs	O
of	O
IOS	O
(	O
iris	B-Anatomy
neovascularization	O
,	O
mid	O
-	O
peripheral	O
dot	O
and	O
blot	O
hemorrhages	O
in	O
both	O
eyes	B-Anatomy
,	O
narrowed	O
arterioles	B-Anatomy
in	O
right	B-Anatomy
eye	I-Anatomy
,	O
following	O
examinations	O
were	O
performed	O
:	O
Doppler	O
ultrasonography	O
of	O
carotid	B-Anatomy
arteries	I-Anatomy
,	O
digital	O
subtractional	O
angiography	O
of	O
the	O
carotid	B-Anatomy
vessels	I-Anatomy
and	O
magnetic	O
resonance	O
angiography	O
.	O
The	O
examinations	O
showed	O
occlusion	O
of	O
the	O
right	B-Anatomy
common	I-Anatomy
carotid	I-Anatomy
artery	I-Anatomy
and	O
with	O
80	O
%	O
stenosis	O
of	O
the	O
left	B-Anatomy
common	I-Anatomy
carotid	I-Anatomy
artery	I-Anatomy
,	O
occlusion	O
of	O
abdominal	B-Anatomy
aorta	I-Anatomy
.	O
After	O
phacoemulsification	O
with	O
implantation	O
of	O
intraocular	B-Anatomy
lens	I-Anatomy
because	O
of	O
rapid	O
intumescence	O
cataract	O
in	O
the	O
right	B-Anatomy
eye	I-Anatomy
,	O
and	O
endarterectomy	O
of	O
left	B-Anatomy
external	I-Anatomy
carotid	I-Anatomy
artery	I-Anatomy
,	O
the	O
neovascularization	O
of	O
the	O
iris	B-Anatomy
regressed	O
in	O
both	O
eyes	B-Anatomy
.	O
CONCLUSION	O
:	O
In	O
case	O
of	O
iris	B-Anatomy
neovascularization	O
or	O
mid	O
-	O
peripheral	O
hemorrhages	O
the	O
Doppler	O
sonography	O
of	O
carotid	B-Anatomy
arteries	I-Anatomy
should	O
be	O
performed	O
.	O
Quick	O
cooperation	O
between	O
ophthalmologist	O
,	O
radiologist	O
and	O
vascular	B-Anatomy
surgeon	O
following	O
endarterectomy	O
seems	O
to	O
stop	O
progressing	O
changes	O
of	O
ocular	B-Anatomy
ischemic	O
syndrome	O
.	O
Thiazole	O
orange	O
positive	O
platelets	B-Anatomy
in	O
a	O
dog	O
with	O
Evans	O
'	O
syndrome	O
.	O
We	O
examined	O
transition	O
for	O
the	O
percentage	O
of	O
reticulated	B-Anatomy
platelets	I-Anatomy
(	O
RP	B-Anatomy
%	O
)	O
and	O
platelet	B-Anatomy
count	O
in	O
a	O
canine	O
case	O
of	O
Evans	O
'	O
syndrome	O
.	O
The	O
result	O
demonstrated	O
that	O
measurement	O
of	O
the	O
RP	B-Anatomy
%	O
can	O
be	O
useful	O
in	O
evaluating	O
platelet	B-Anatomy
production	O
in	O
the	O
bone	B-Anatomy
marrow	I-Anatomy
and	O
response	O
to	O
treatment	O
.	O
Granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
and	O
interleukin	O
-	O
3	O
enhance	O
the	O
incorporation	O
of	O
cytosine	O
arabinoside	O
into	O
the	O
DNA	O
of	O
leukemic	B-Anatomy
blasts	I-Anatomy
and	O
the	O
cytotoxic	O
effect	O
on	O
clonogenic	B-Anatomy
cells	I-Anatomy
from	O
patients	O
with	O
acute	B-Anatomy
myeloid	I-Anatomy
leukemia	I-Anatomy
.	O
In	O
the	O
present	O
study	O
the	O
effects	O
of	O
the	O
48	O
-	O
hour	O
administration	O
of	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
(	O
100	O
U	O
/	O
mL	O
)	O
or	O
interleukin	O
-	O
3	O
(	O
IL	O
-	O
3	O
)	O
(	O
100	O
U	O
/	O
mL	O
)	O
on	O
the	O
proliferative	O
activity	O
of	O
leukemic	B-Anatomy
cells	I-Anatomy
and	O
on	O
the	O
intracellular	B-Anatomy
metabolism	O
and	O
cytotoxic	O
efficacy	O
of	O
a	O
subsequent	O
12	O
-	O
hour	O
application	O
of	O
cytosine	O
arabinoside	O
(	O
ara	O
-	O
C	O
)	O
at	O
doses	O
of	O
0	O
.	O
1	O
,	O
1	O
.	O
0	O
,	O
10	O
.	O
0	O
,	O
and	O
100	O
.	O
0	O
mumol	O
/	O
L	O
were	O
evaluated	O
on	O
bone	B-Anatomy
marrow	I-Anatomy
cells	I-Anatomy
from	O
17	O
patients	O
with	O
acute	B-Anatomy
myeloid	I-Anatomy
leukemia	I-Anatomy
.	O
After	O
GM	O
-	O
CSF	O
or	O
IL	O
-	O
3	O
,	O
a	O
1	O
.	O
2	O
-	O
to	O
2	O
.	O
4	O
-	O
fold	O
increase	O
in	O
S	O
-	O
phase	O
cells	B-Anatomy
was	O
observed	O
in	O
nine	O
of	O
14	O
GM	O
-	O
CSF	O
and	O
seven	O
of	O
11	O
IL	O
-	O
3	O
cases	O
.	O
3H	O
-	O
Cytosine	O
arabinoside	O
incorporation	O
into	O
the	O
DNA	O
was	O
enhanced	O
1	O
.	O
33	O
-	O
to	O
18	O
.	O
3	O
-	O
fold	O
over	O
respective	O
controls	O
in	O
14	O
of	O
17	O
patients	O
.	O
While	O
in	O
control	O
specimens	B-Anatomy
are	O
ara	O
-	O
C	O
dose	O
-	O
dependent	O
increase	O
in	O
3H	O
-	O
ara	O
-	O
C	O
uptake	O
was	O
accompanied	O
by	O
a	O
corresponding	O
rise	O
in	O
intracellular	B-Anatomy
ara	O
-	O
C	O
-	O
5	O
'	O
triphosphate	O
(	O
ara	O
-	O
CTP	O
)	O
levels	O
,	O
ara	O
-	O
CTP	O
concentrations	O
were	O
not	O
increased	O
after	O
GM	O
-	O
CSF	O
or	O
IL	O
-	O
3	O
exposure	O
,	O
resulting	O
in	O
a	O
higher	O
ara	O
-	O
C	O
to	O
ara	O
-	O
CTP	O
ratio	O
over	O
controls	O
.	O
This	O
finding	O
may	O
be	O
explained	O
by	O
a	O
stimulatory	O
effect	O
of	O
GM	O
-	O
CSF	O
and	O
IL	O
-	O
3	O
on	O
ara	O
-	O
C	O
phosphorylating	O
enzymes	O
and	O
a	O
more	O
rapid	O
incorporation	O
of	O
ara	O
-	O
CTP	O
into	O
the	O
DNA	O
of	O
leukemic	B-Anatomy
blasts	I-Anatomy
.	O
These	O
effects	O
translated	O
into	O
a	O
2	O
.	O
2	O
-	O
to	O
229	O
.	O
0	O
-	O
fold	O
increase	O
in	O
the	O
cytotoxic	O
activity	O
of	O
ara	O
-	O
C	O
against	O
clonogenic	B-Anatomy
leukemic	I-Anatomy
cells	I-Anatomy
after	O
GM	O
-	O
CSF	O
or	O
IL	O
-	O
3	O
pretreatment	O
.	O
Hence	O
,	O
GM	O
-	O
CSF	O
and	O
IL	O
-	O
3	O
enhance	O
the	O
intracellular	B-Anatomy
metabolism	O
of	O
ara	O
-	O
C	O
and	O
its	O
incorporation	O
into	O
the	O
DNA	O
of	O
leukemic	B-Anatomy
cells	I-Anatomy
leading	O
to	O
a	O
higher	O
antileukemic	O
activity	O
of	O
ara	O
-	O
C	O
on	O
clonogenic	B-Anatomy
leukemic	I-Anatomy
cells	I-Anatomy
(	O
CFU	B-Anatomy
-	I-Anatomy
L	I-Anatomy
)	O
.	O
Human	O
cytomegalovirus	O
5	O
-	O
kilobase	O
immediate	O
-	O
early	O
RNA	O
is	O
a	O
stable	O
intron	O
.	O
Immediate	O
-	O
early	O
viral	O
gene	O
products	O
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
are	O
derived	O
from	O
several	O
genomic	O
loci	O
and	O
largely	O
serve	O
to	O
establish	O
a	O
cellular	B-Anatomy
environment	O
conducive	O
to	O
viral	O
replication	O
.	O
We	O
have	O
further	O
examined	O
an	O
unusual	O
immediate	O
-	O
early	O
transcript	O
known	O
as	O
the	O
5	O
-	O
kb	O
RNA	O
,	O
concluding	O
that	O
it	O
is	O
a	O
stable	O
intron	O
encoded	O
by	O
HCMV	O
.	O
The	O
5	O
-	O
kb	O
RNA	O
is	O
highly	O
AT	O
rich	O
in	O
sequence	O
and	O
lacks	O
open	O
reading	O
frames	O
likely	O
to	O
be	O
translated	O
into	O
protein	O
.	O
We	O
confirmed	O
the	O
absence	O
of	O
polyadenylation	O
of	O
the	O
transcript	O
and	O
showed	O
that	O
it	O
is	O
primarily	O
nuclear	B-Anatomy
localized	O
during	O
viral	O
infection	O
.	O
We	O
mapped	O
the	O
5	O
'	O
end	O
of	O
the	O
5	O
-	O
kb	O
RNA	O
to	O
a	O
consensus	O
splice	O
donor	O
site	O
and	O
localized	O
the	O
3	O
'	O
end	O
in	O
the	O
vicinity	O
of	O
a	O
splice	O
acceptor	O
site	O
.	O
In	O
transfection	O
studies	O
,	O
we	O
showed	O
that	O
the	O
5	O
-	O
kb	O
RNA	O
can	O
be	O
spliced	O
from	O
a	O
heterologous	O
primary	O
transcript	O
.	O
Using	O
bacterial	O
artificial	O
chromosome	B-Anatomy
technology	O
,	O
we	O
constructed	O
a	O
viral	O
recombinant	O
containing	O
a	O
mutation	O
in	O
the	O
5	O
'	O
splice	O
donor	O
site	O
that	O
defines	O
the	O
5	O
'	O
end	O
of	O
the	O
RNA	O
and	O
found	O
that	O
this	O
mutation	O
eliminates	O
expression	O
of	O
the	O
5	O
-	O
kb	O
RNA	O
during	O
viral	O
infection	O
.	O
This	O
mutant	O
grows	O
in	O
human	O
fibroblasts	B-Anatomy
without	O
complementation	O
.	O
Taken	O
together	O
,	O
these	O
data	O
support	O
the	O
conclusion	O
that	O
the	O
5	O
-	O
kb	O
RNA	O
is	O
a	O
stable	O
intron	O
expressed	O
by	O
HCMV	O
.	O
Silencing	O
of	O
monocarboxylate	O
transporters	O
via	O
small	O
interfering	O
ribonucleic	O
acid	O
inhibits	O
glycolysis	O
and	O
induces	O
cell	B-Anatomy
death	O
in	O
malignant	B-Anatomy
glioma	I-Anatomy
:	O
an	O
in	O
vitro	O
study	O
.	O
OBJECTIVE	O
:	O
Dependence	O
on	O
glycolysis	O
is	O
a	O
hallmark	O
of	O
malignant	B-Anatomy
tumors	I-Anatomy
.	O
As	O
a	O
consequence	O
,	O
these	O
tumors	B-Anatomy
generate	O
more	O
lactate	O
,	O
which	O
is	O
effluxed	O
from	O
cells	B-Anatomy
by	O
monocarboxylate	O
transporters	O
(	O
MCTs	O
)	O
.	O
We	O
hypothesized	O
that	O
1	O
)	O
MCT	O
expression	O
in	O
malignant	B-Anatomy
tumors	I-Anatomy
may	O
differ	O
from	O
normal	O
tissue	B-Anatomy
in	O
quantity	O
,	O
isoform	O
,	O
or	O
both	O
;	O
and	O
2	O
)	O
silencing	O
MCT	O
expression	O
would	O
induce	O
intracellular	B-Anatomy
acidification	O
,	O
resulting	O
in	O
decreased	O
proliferation	O
and	O
/	O
or	O
increased	O
cell	B-Anatomy
death	O
.	O
METHODS	O
:	O
We	O
quantified	O
expression	O
of	O
MCT	O
isoforms	O
in	O
human	O
glioblastoma	B-Anatomy
multiforme	I-Anatomy
and	O
glioma	B-Anatomy
-	I-Anatomy
derived	I-Anatomy
cells	I-Anatomy
lines	I-Anatomy
by	O
Western	O
blot	O
analysis	O
.	O
MCTs	O
that	O
were	O
abundant	O
or	O
specific	O
to	O
glioma	B-Anatomy
then	O
were	O
targeted	O
in	O
the	O
model	O
U	B-Anatomy
-	I-Anatomy
87	I-Anatomy
MG	I-Anatomy
glioma	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
via	O
small	O
interfering	O
ribonucleic	O
acid	O
-	O
mediated	O
gene	O
silencing	O
and	O
tested	O
for	O
inhibition	O
of	O
lactate	O
efflux	O
,	O
intracellular	B-Anatomy
pH	O
changes	O
,	O
reduced	O
proliferation	O
,	O
and	O
/	O
or	O
induction	O
of	O
cell	B-Anatomy
death	O
.	O
RESULTS	O
:	O
MCT	O
1	O
and	O
2	O
were	O
the	O
primary	O
isoforms	O
expressed	O
in	O
human	O
glioblastoma	B-Anatomy
multiforme	I-Anatomy
and	O
glioma	B-Anatomy
-	I-Anatomy
derived	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
In	O
contrast	O
,	O
MCT	O
3	O
was	O
the	O
predominantly	O
expressed	O
isoform	O
in	O
normal	O
brain	B-Anatomy
.	O
Small	O
interfering	O
ribonucleic	O
acid	O
specific	O
for	O
MCT	O
1	O
and	O
2	O
reduced	O
expression	O
of	O
these	O
isoforms	O
in	O
U	B-Anatomy
-	I-Anatomy
87	I-Anatomy
MG	I-Anatomy
cells	I-Anatomy
to	O
barely	O
detectable	O
levels	O
and	O
reduced	O
lactate	O
efflux	O
by	O
30	O
%	O
individually	O
and	O
85	O
%	O
in	O
combination	O
,	O
with	O
a	O
concomitant	O
decrease	O
of	O
intracellular	B-Anatomy
pH	O
by	O
0	O
.	O
6	O
units	O
(	O
a	O
fourfold	O
increase	O
in	O
intracellular	B-Anatomy
H	O
(	O
+	O
)	O
)	O
.	O
Prolonged	O
silencing	O
of	O
both	O
MCTs	O
reduced	O
viability	O
by	O
75	O
%	O
individually	O
and	O
92	O
%	O
in	O
combination	O
,	O
as	O
measured	O
by	O
both	O
phenotypic	O
and	O
flow	O
cytometric	O
analyses	O
.	O
CONCLUSION	O
:	O
MCT	O
targeting	O
significantly	O
reduced	O
the	O
viability	O
of	O
U	B-Anatomy
-	I-Anatomy
87	I-Anatomy
MG	I-Anatomy
cells	I-Anatomy
mediated	O
by	O
both	O
apoptosis	O
and	O
necrosis	O
.	O
This	O
indicates	O
that	O
the	O
strategy	O
may	O
be	O
a	O
useful	O
therapeutic	O
avenue	O
for	O
treatment	O
of	O
patients	O
with	O
malignant	B-Anatomy
glioma	I-Anatomy
.	O
Hypoxia	O
-	O
responsive	O
element	O
-	O
mediated	O
soluble	O
Tie2	O
vector	O
exhibits	O
an	O
anti	O
-	O
angiogenic	O
activity	O
in	O
vitro	O
under	O
hypoxic	O
condition	O
.	O
Hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
(	O
HIF	O
-	O
1	O
)	O
is	O
one	O
of	O
the	O
key	O
mammalian	O
transcription	O
factors	O
and	O
shows	O
increased	O
levels	O
in	O
both	O
protein	O
stability	O
and	O
intrinsic	O
transcriptional	O
activity	O
during	O
low	O
oxygen	O
tension	O
.	O
Hypoxia	O
-	O
activated	O
functional	O
HIF	O
-	O
1	O
protein	O
binds	O
to	O
hypoxia	O
-	O
responsive	O
elements	O
(	O
HRE	O
)	O
in	O
the	O
enhancers	O
of	O
several	O
genes	O
including	O
VEGF	O
,	O
the	O
major	O
player	O
in	O
angiogenesis	O
,	O
and	O
initiates	O
their	O
mRNA	O
expression	O
.	O
The	O
molecular	O
mechanisms	O
regulating	O
the	O
gene	O
expression	O
under	O
hypoxic	O
conditions	O
could	O
increase	O
the	O
therapeutic	O
window	O
of	O
tumor	B-Anatomy
-	O
specific	O
delivery	O
systems	O
.	O
In	O
this	O
study	O
,	O
to	O
examine	O
hypoxia	O
-	O
specific	O
production	O
of	O
anti	O
-	O
angiogenic	O
therapeutic	O
gene	O
,	O
we	O
constructed	O
5	O
copies	O
of	O
HRE	O
(	O
5xHRE	O
)	O
of	O
human	O
VEGF	O
linked	O
to	O
soluble	O
Tie2	O
(	O
sTie2	O
)	O
driven	O
by	O
minimal	O
SV40	O
promoter	O
(	O
5xHRE	O
/	O
SV40	O
/	O
sTie2	O
)	O
.	O
Our	O
data	O
showed	O
that	O
under	O
hypoxia	O
the	O
secreted	O
sTie2	O
selectively	O
inhibited	O
tube	B-Anatomy
formation	O
and	O
migration	O
capacities	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
in	O
vitro	O
.	O
Hence	O
,	O
we	O
propose	O
that	O
the	O
vector	O
system	O
,	O
5xHRE	O
/	O
SV40	O
/	O
sTie2	O
,	O
might	O
be	O
a	O
useful	O
tool	O
for	O
down	O
-	O
regulating	O
tumor	B-Anatomy
angiogenesis	O
under	O
hypoxic	O
condition	O
.	O
Proteome	O
analysis	O
of	O
NIH3T3	B-Anatomy
cells	I-Anatomy
transformed	O
by	O
activated	O
Galpha12	O
:	O
regulation	O
of	O
leukemia	B-Anatomy
-	O
associated	O
protein	O
SET	O
.	O
Galpha	O
(	O
12	O
)	O
,	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
G12	O
family	O
of	O
heterotrimeric	O
G	O
proteins	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
cell	B-Anatomy
proliferation	O
and	O
neoplastic	B-Anatomy
transformation	O
.	O
GTPase	O
-	O
deficient	O
,	O
constitutively	O
activated	O
mutant	O
of	O
Galpha	O
(	O
12	O
)	O
(	O
Galpha	O
(	O
12	O
)	O
Q229L	O
or	O
Galpha	O
(	O
12	O
)	O
QL	O
)	O
has	O
been	O
previously	O
shown	O
to	O
induce	O
oncogenic	O
transformation	O
of	O
NIH3T3	B-Anatomy
cells	I-Anatomy
promoting	O
serum	B-Anatomy
-	O
and	O
anchorage	O
-	O
independent	O
growth	O
.	O
Reduced	O
growth	O
-	O
factor	O
dependent	O
,	O
autonomous	O
cell	B-Anatomy
growth	O
forms	O
a	O
critical	O
defining	O
point	O
at	O
which	O
a	O
normal	O
cell	B-Anatomy
turns	O
into	O
an	O
oncogenic	O
one	O
.	O
To	O
identify	O
the	O
underlying	O
mechanism	O
involved	O
in	O
such	O
growth	O
-	O
factor	O
/	O
serum	B-Anatomy
independent	O
growth	O
of	O
Galpha	O
(	O
12	O
)	O
QL	O
-	O
transformed	O
NIH3T3	B-Anatomy
,	O
we	O
carried	O
out	O
a	O
two	O
-	O
dimensional	O
differential	O
proteome	O
analysis	O
of	O
Galpha	O
(	O
12	O
)	O
QL	O
-	O
transformed	O
NIH3T3	B-Anatomy
cells	I-Anatomy
and	O
cells	B-Anatomy
expressing	O
vector	O
control	O
.	O
This	O
analysis	O
revealed	O
a	O
total	O
of	O
22	O
protein	O
-	O
spots	O
whose	O
expression	O
was	O
altered	O
by	O
more	O
than	O
3	O
-	O
folds	O
.	O
Two	O
of	O
these	O
spots	O
were	O
identified	O
by	O
MALDI	O
-	O
MS	O
analysis	O
as	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
)	O
and	O
myeloid	B-Anatomy
-	I-Anatomy
leukemia	I-Anatomy
-	O
associated	O
SET	O
protein	O
.	O
The	O
increased	O
expressions	O
of	O
these	O
proteins	O
in	O
Galpha	B-Anatomy
(	I-Anatomy
12	I-Anatomy
)	I-Anatomy
QL	I-Anatomy
cells	I-Anatomy
were	O
validated	O
by	O
immunoblot	O
analysis	O
.	O
Furthermore	O
,	O
transient	O
transfection	O
studies	O
with	O
NIH3T3	B-Anatomy
cells	I-Anatomy
indicated	O
that	O
the	O
expression	O
of	O
activated	O
Galpha	O
(	O
12	O
)	O
readily	O
increased	O
the	O
expression	O
of	O
SET	O
protein	O
by	O
24	O
h	O
.	O
As	O
SET	O
has	O
been	O
previously	O
reported	O
to	O
be	O
an	O
inhibitor	O
of	O
phosphatase	O
PP2A	O
,	O
the	O
nuclear	B-Anatomy
phosphatase	O
activity	O
was	O
monitored	O
in	O
cells	B-Anatomy
expressing	O
activated	O
Galpha	O
(	O
12	O
)	O
.	O
Our	O
results	O
indicate	O
that	O
the	O
nuclear	B-Anatomy
phosphatase	O
activity	O
is	O
inhibited	O
by	O
greater	O
than	O
50	O
%	O
in	O
Galpha	B-Anatomy
(	I-Anatomy
12	I-Anatomy
)	I-Anatomy
QL	I-Anatomy
cells	I-Anatomy
compared	O
to	O
vector	O
control	O
cells	B-Anatomy
.	O
Thus	O
,	O
our	O
results	O
from	O
differential	O
proteome	O
analysis	O
presented	O
here	O
report	O
for	O
the	O
first	O
time	O
a	O
role	O
for	O
SET	O
in	O
Galpha	O
(	O
12	O
)	O
-	O
mediated	O
signaling	O
pathways	O
and	O
a	O
role	O
for	O
Galpha	O
(	O
12	O
)	O
in	O
the	O
regulation	O
of	O
the	O
leukemia	B-Anatomy
-	O
associated	O
SET	O
-	O
protein	O
expression	O
.	O
Matrix	O
metalloproteinase	O
/	O
tissue	O
inhibitors	O
of	O
matrix	O
metalloproteinase	O
phenotype	O
identifies	O
poor	O
prognosis	O
colorectal	B-Anatomy
cancers	I-Anatomy
.	O
PURPOSE	O
:	O
The	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
are	O
a	O
family	O
of	O
proteolytic	O
enzymes	O
involved	O
in	O
tumor	B-Anatomy
invasion	O
;	O
several	O
individual	O
members	O
of	O
which	O
have	O
been	O
implicated	O
in	O
tumor	B-Anatomy
prognosis	O
.	O
These	O
enzymes	O
and	O
their	O
physiologic	O
inhibitors	O
,	O
the	O
tissue	B-Anatomy
inhibitors	O
of	O
matrix	O
metalloproteinases	O
(	O
TIMPs	O
)	O
,	O
act	O
in	O
a	O
coordinated	O
manner	O
to	O
form	O
an	O
integrated	O
system	O
.	O
Therefore	O
,	O
to	O
understand	O
their	O
role	O
in	O
tumor	B-Anatomy
invasion	O
,	O
it	O
is	O
necessary	O
to	O
evaluate	O
them	O
collectively	O
.	O
EXPERIMENTAL	O
DESIGN	O
:	O
In	O
this	O
study	O
all	O
of	O
the	O
major	O
members	O
of	O
the	O
matrix	O
metalloproteinase	O
(	O
MMP	O
-	O
1	O
,	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
3	O
,	O
MMP	O
-	O
7	O
,	O
MMP	O
-	O
9	O
,	O
MMP	O
-	O
13	O
,	O
MT1	O
-	O
MMP	O
and	O
MT2	O
-	O
MMP	O
)	O
/	O
tissue	O
inhibitor	O
of	O
matrix	O
metalloproteinase	O
(	O
TIMP	O
-	O
1	O
,	O
TIMP	O
-	O
2	O
,	O
and	O
TIMP	O
-	O
3	O
)	O
system	O
have	O
been	O
investigated	O
by	O
immunohistochemistry	O
in	O
a	O
series	O
(	O
n	O
=	O
90	O
)	O
of	O
stage	B-Anatomy
III	I-Anatomy
(	I-Anatomy
Dukes	I-Anatomy
'	I-Anatomy
C	I-Anatomy
)	I-Anatomy
colorectal	I-Anatomy
cancers	I-Anatomy
.	O
An	O
immunohistochemical	O
score	O
based	O
on	O
the	O
intensity	O
of	O
immunoreactivity	O
and	O
proportion	O
of	O
immunoreactive	O
cells	B-Anatomy
was	O
established	O
for	O
each	O
MMP	O
and	O
TIMP	O
.	O
RESULTS	O
:	O
The	O
MMP	O
/	O
TIMP	O
profile	O
defined	O
by	O
hierarchical	O
cluster	O
analysis	O
of	O
the	O
immunohistochemical	O
score	O
identifies	O
a	O
distinct	O
group	O
of	O
colorectal	B-Anatomy
cancers	I-Anatomy
with	O
poor	O
prognosis	O
(	O
log	O
-	O
rank	O
test	O
,	O
12	O
.	O
22	O
,	O
P	O
=	O
0	O
.	O
0005	O
)	O
.	O
The	O
median	O
survival	O
time	O
of	O
patients	O
in	O
this	O
survival	O
group	O
was	O
18	O
months	O
compared	O
with	O
a	O
median	O
survival	O
of	O
49	O
months	O
in	O
the	O
""""	O
good	O
""""	O
survival	O
group	O
.	O
Multivariate	O
analysis	O
showed	O
that	O
this	O
profile	O
was	O
independently	O
the	O
most	O
significant	O
prognostic	O
factor	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O
CONCLUSIONS	O
:	O
This	O
study	O
has	O
identified	O
that	O
the	O
MMP	O
/	O
TIMP	O
profile	O
is	O
an	O
independent	O
indicator	O
of	O
poor	O
prognosis	O
in	O
colorectal	B-Anatomy
cancer	I-Anatomy
.	O
2	O
-	O
methoxyestradiol	O
inhibits	O
hypoxia	O
-	O
inducible	O
factor	O
1alpha	O
,	O
tumor	B-Anatomy
growth	O
,	O
and	O
angiogenesis	O
and	O
augments	O
paclitaxel	O
efficacy	O
in	O
head	B-Anatomy
and	I-Anatomy
neck	I-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
PURPOSE	O
:	O
Head	B-Anatomy
and	I-Anatomy
neck	I-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinomas	I-Anatomy
have	O
been	O
reported	O
to	O
overexpress	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
-	O
1alpha	O
,	O
a	O
transcription	O
factor	O
that	O
promotes	O
expression	O
of	O
angiogenesis	O
factors	O
and	O
resistance	O
to	O
programmed	O
and	O
therapy	O
-	O
induced	O
cell	B-Anatomy
death	O
.	O
2	O
-	O
Methoxyestradiol	O
(	O
2ME2	O
)	O
is	O
a	O
natural	O
compound	O
with	O
HIF	O
-	O
1alpha	O
inhibitory	O
activity	O
that	O
is	O
currently	O
being	O
evaluated	O
in	O
phase	O
1	O
and	O
2	O
clinical	O
trials	O
for	O
advanced	O
solid	B-Anatomy
tumors	I-Anatomy
and	O
multiple	O
myeloma	B-Anatomy
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
evaluate	O
the	O
effects	O
of	O
2ME2	O
in	O
head	B-Anatomy
and	I-Anatomy
neck	I-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
EXPERIMENTAL	O
DESIGN	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
2ME2	O
alone	O
and	O
in	O
combination	O
with	O
paclitaxel	O
,	O
an	O
active	O
agent	O
in	O
recurrent	O
or	O
advanced	O
head	B-Anatomy
and	I-Anatomy
neck	I-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
RESULTS	O
:	O
2ME2	O
exhibited	O
antiproliferative	O
and	O
cytotoxic	O
effects	O
in	O
a	O
panel	O
of	O
five	O
head	B-Anatomy
and	I-Anatomy
neck	I-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
in	O
the	O
0	O
.	O
5	O
to	O
10	O
micromol	O
/	O
L	O
range	O
,	O
including	O
induction	O
of	O
G2	O
-	O
M	O
blockade	O
,	O
caspase	O
-	O
3	O
/	O
7	O
activation	O
,	O
and	O
apoptosis	O
at	O
48	O
hours	O
.	O
2ME2	O
resulted	O
in	O
decreased	O
nuclear	B-Anatomy
HIF	O
-	O
1alpha	O
-	O
binding	O
activity	O
and	O
affected	O
the	O
expression	O
of	O
downstream	O
genes	O
,	O
such	O
as	O
bid	O
,	O
a	O
proapoptotic	O
bcl	O
-	O
2	O
family	O
member	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
a	O
proangiogenic	O
cytokine	O
.	O
The	O
up	O
-	O
regulation	O
of	O
Bid	O
(	O
57	O
.	O
5	O
%	O
at	O
12	O
hours	O
,	O
P	O
less	O
than	O
0	O
.	O
0006	O
)	O
and	O
inhibition	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
secretion	O
(	O
57	O
.	O
7	O
%	O
at	O
24	O
hours	O
,	O
P	O
less	O
than	O
0	O
.	O
015	O
;	O
and	O
50	O
.	O
3	O
%	O
at	O
48	O
hours	O
,	O
P	O
less	O
than	O
0	O
.	O
0006	O
)	O
could	O
be	O
partially	O
attributed	O
to	O
the	O
effects	O
on	O
HIF	O
-	O
1alpha	O
,	O
because	O
HIF	O
-	O
1alpha	O
small	O
interfering	O
RNAs	O
produced	O
similar	O
effects	O
.	O
Finally	O
,	O
in	O
vivo	O
,	O
in	O
a	O
xenograft	B-Anatomy
model	O
of	O
head	B-Anatomy
and	I-Anatomy
neck	I-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
using	O
UM	B-Anatomy
-	I-Anatomy
SCC	I-Anatomy
-	I-Anatomy
11A	I-Anatomy
cells	I-Anatomy
,	O
2ME2	O
exhibited	O
antitumor	B-Anatomy
and	O
antiangiogenic	O
activity	O
,	O
as	O
measured	O
by	O
CD31	O
immunostaining	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
provide	O
support	O
for	O
the	O
use	O
of	O
2ME2	O
in	O
combination	O
with	O
paclitaxel	O
for	O
the	O
treatment	O
of	O
recurrent	O
or	O
advanced	O
head	B-Anatomy
and	I-Anatomy
neck	I-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
HIF	O
-	O
2alpha	O
expression	O
in	O
human	O
fetal	B-Anatomy
paraganglia	I-Anatomy
and	O
neuroblastoma	B-Anatomy
:	O
relation	O
to	O
sympathetic	O
differentiation	O
,	O
glucose	O
deficiency	O
,	O
and	O
hypoxia	O
.	O
Solid	B-Anatomy
tumors	I-Anatomy
are	O
frequently	O
necrotic	O
and	O
hypoxic	O
due	O
to	O
poor	O
vascularization	O
.	O
Tumor	B-Anatomy
cells	I-Anatomy
adapt	O
to	O
hypoxia	O
by	O
modulating	O
their	O
phenotype	O
.	O
Key	O
players	O
in	O
this	O
process	O
are	O
the	O
hypoxia	O
-	O
inducible	O
factors	O
(	O
HIF	O
-	O
1alpha	O
to	O
3alpha	O
)	O
.	O
HIFs	O
are	O
also	O
expressed	O
during	O
normal	O
development	O
;	O
for	O
example	O
,	O
HIF	O
-	O
2alpha	O
is	O
specifically	O
expressed	O
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
the	O
murine	O
sympathetic	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
(	O
SNS	B-Anatomy
)	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
HIF	O
-	O
2alpha	O
protein	O
is	O
selectively	O
present	O
in	O
human	O
fetal	B-Anatomy
week	O
8	O
.	O
5	O
SNS	B-Anatomy
paraganglia	I-Anatomy
.	O
Neuroblastoma	B-Anatomy
is	O
derived	O
from	O
SNS	B-Anatomy
precursors	I-Anatomy
.	O
In	O
a	O
subset	O
of	O
neuroblastomas	B-Anatomy
,	O
a	O
spontaneous	O
neuronal	B-Anatomy
to	O
neuroendocrine	B-Anatomy
differentiation	O
occurs	O
in	O
areas	O
adjacent	O
to	O
necrotic	B-Anatomy
zones	I-Anatomy
.	O
As	O
HIF	O
-	O
2alpha	O
activity	O
has	O
been	O
associated	O
not	O
only	O
with	O
hypoxic	O
but	O
also	O
with	O
hypoglycemic	O
conditions	O
,	O
we	O
have	O
investigated	O
putative	O
effects	O
of	O
hypoxia	O
,	O
glucose	O
depletion	O
,	O
and	O
HIF	O
-	O
2alpha	O
on	O
the	O
neuroblastoma	B-Anatomy
phenotype	O
.	O
HIF	O
-	O
2alpha	O
was	O
detected	O
in	O
hypoxic	O
and	O
in	O
well	O
-	O
oxygenized	O
neuroblastoma	B-Anatomy
cells	I-Anatomy
and	O
tissue	B-Anatomy
,	O
presumably	O
reflecting	O
their	O
embryonic	B-Anatomy
features	O
.	O
With	O
regard	O
to	O
differentiation	O
,	O
hypoxic	B-Anatomy
cells	I-Anatomy
lost	O
their	O
neuronal	B-Anatomy
/	O
neuroendocrine	B-Anatomy
features	O
and	O
gained	O
marker	O
gene	O
expression	O
associated	O
with	O
an	O
immature	O
,	O
neural	B-Anatomy
crest	I-Anatomy
-	O
like	O
phenotype	O
.	O
Low	O
glucose	O
potentiated	O
the	O
effect	O
of	O
hypoxia	O
.	O
These	O
findings	O
suggest	O
that	O
poorly	O
vascularized	O
neuroblastomas	B-Anatomy
become	O
immature	O
and	O
maintain	O
a	O
more	O
aggressive	O
phenotype	O
,	O
which	O
possibly	O
could	O
involve	O
a	O
sustained	O
stabilization	O
and	O
activation	O
of	O
HIF	O
-	O
2alpha	O
.	O
Reduced	O
prognostic	O
power	O
of	O
ventricular	B-Anatomy
late	O
potentials	O
in	O
post	O
-	O
infarction	O
patients	O
of	O
the	O
reperfusion	O
era	O
.	O
AIMS	O
:	O
To	O
test	O
the	O
prognostic	O
value	O
of	O
ventricular	B-Anatomy
late	O
potentials	O
(	O
LPs	O
)	O
in	O
a	O
large	O
cohort	O
of	O
post	O
-	O
infarction	O
patients	O
in	O
the	O
modern	O
reperfusion	O
era	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
1800	O
consecutive	O
survivors	O
of	O
acute	O
myocardial	B-Anatomy
infarction	O
in	O
sinus	O
rhythm	O
and	O
under	O
76	O
years	O
of	O
age	O
were	O
enrolled	O
.	O
Many	O
(	O
99	O
%	O
)	O
of	O
the	O
patients	O
received	O
reperfusion	O
/	O
revascularization	O
therapy	O
(	O
91	O
%	O
percutaneous	B-Anatomy
coronary	B-Anatomy
intervention	O
)	O
and	O
up	O
-	O
to	O
-	O
date	O
pharmacological	O
treatment	O
(	O
99	O
%	O
aspirin	O
,	O
93	O
%	O
beta	O
-	O
blockers	O
,	O
90	O
%	O
ACE	O
-	O
inhibitors	O
,	O
and	O
85	O
%	O
statins	O
)	O
.	O
LPs	O
were	O
calculated	O
in	O
968	O
patients	O
and	O
found	O
to	O
be	O
present	O
in	O
90	O
(	O
9	O
.	O
3	O
%	O
)	O
.	O
The	O
primary	O
endpoint	O
was	O
the	O
composite	O
of	O
cardiac	B-Anatomy
death	O
and	O
serious	O
arrhythmic	O
events	O
.	O
The	O
secondary	O
endpoint	O
was	O
the	O
composite	O
of	O
sudden	O
cardiac	B-Anatomy
death	O
and	O
serious	O
arrhythmic	O
events	O
.	O
During	O
follow	O
-	O
up	O
(	O
median	O
34	O
months	O
)	O
,	O
26	O
patients	O
reached	O
the	O
primary	O
endpoint	O
.	O
The	O
presence	O
of	O
LPs	O
was	O
not	O
significantly	O
associated	O
with	O
the	O
primary	O
endpoint	O
in	O
univariable	O
or	O
multivariable	O
analysis	O
.	O
In	O
contrast	O
,	O
low	O
(	O
<	O
or	O
=	O
30	O
%	O
)	O
left	B-Anatomy
ventricular	I-Anatomy
ejection	O
fraction	O
(	O
hazard	O
ratio	O
9	O
.	O
6	O
,	O
95	O
%	O
confidence	O
interval	O
4	O
.	O
1	O
-	O
22	O
.	O
4	O
)	O
,	O
heart	B-Anatomy
rate	O
turbulence	O
category	O
2	O
(	O
7	O
.	O
5	O
,	O
2	O
.	O
4	O
-	O
23	O
.	O
9	O
)	O
and	O
category	O
1	O
(	O
5	O
.	O
3	O
,	O
1	O
.	O
9	O
-	O
14	O
.	O
9	O
)	O
were	O
significant	O
predictors	O
in	O
both	O
univariable	O
and	O
multivariable	O
analysis	O
.	O
CONCLUSION	O
:	O
Ventricular	B-Anatomy
LPs	O
are	O
of	O
limited	O
use	O
for	O
risk	O
stratification	O
in	O
unselected	O
post	O
-	O
infarction	O
patients	O
in	O
the	O
modern	O
reperfusion	O
era	O
.	O
Expression	O
and	O
purification	O
of	O
the	O
catalytic	O
domain	O
of	O
human	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
for	O
inhibitor	O
screening	O
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
an	O
endothelial	B-Anatomy
cell	I-Anatomy
-	O
specific	O
mitogen	O
,	O
can	O
act	O
in	O
tumor	B-Anatomy
-	O
induced	O
angiogenesis	O
by	O
binding	O
to	O
specific	O
receptors	O
on	O
the	O
surface	B-Anatomy
of	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
One	O
such	O
receptor	O
,	O
VEGFR	O
-	O
2	O
/	O
KDR	O
,	O
plays	O
a	O
key	O
role	O
in	O
VEGF	O
-	O
induced	O
angiogenesis	O
.	O
Here	O
,	O
we	O
expressed	O
the	O
catalytic	O
domain	O
of	O
VEGFR	O
-	O
2	O
as	O
a	O
soluble	O
active	O
kinase	O
using	O
Bac	O
-	O
to	O
-	O
Bac	O
expression	O
system	O
,	O
and	O
investigated	O
correlations	O
between	O
VEGFR	O
-	O
2	O
activity	O
and	O
enzyme	O
concentration	O
,	O
ATP	O
concentration	O
,	O
substrate	O
concentration	O
and	O
divalent	O
cation	O
type	O
.	O
We	O
used	O
these	O
data	O
to	O
establish	O
a	O
convenient	O
,	O
effective	O
and	O
non	O
-	O
radioactive	O
ELISA	O
screening	O
technique	O
for	O
the	O
identification	O
and	O
evaluation	O
of	O
potential	O
inhibitors	O
for	O
VEGFR	O
-	O
2	O
kinase	O
.	O
We	O
screened	O
200	O
RTK	O
target	O
-	O
based	O
compounds	O
and	O
identified	O
one	O
(	O
TKI	O
-	O
31	O
)	O
that	O
potently	O
inhibited	O
VEGFR	O
-	O
2	O
kinase	O
activity	O
(	O
IC50	O
=	O
0	O
.	O
596	O
microM	O
)	O
.	O
Treatment	O
of	O
NIH3T3	B-Anatomy
/	I-Anatomy
KDR	I-Anatomy
cells	I-Anatomy
with	O
TKI	O
-	O
31	O
blocked	O
VEGF	O
-	O
induced	O
phosphorylation	O
of	O
KDR	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
Moreover	O
,	O
TKI	O
-	O
31	O
dose	O
-	O
dependently	O
suppressed	O
HUVEC	B-Anatomy
tube	I-Anatomy
formation	O
.	O
Thus	O
,	O
we	O
herein	O
report	O
a	O
novel	O
,	O
efficient	O
method	O
for	O
identifying	O
VEGFR	O
-	O
2	O
kinase	O
inhibitors	O
and	O
introduce	O
one	O
,	O
TKI	O
-	O
31	O
,	O
that	O
may	O
prove	O
to	O
be	O
a	O
useful	O
new	O
angiogenesis	O
inhibitor	O
.	O
Novel	O
biological	O
agents	O
for	O
the	O
treatment	O
of	O
hormone	B-Anatomy
-	I-Anatomy
refractory	I-Anatomy
prostate	I-Anatomy
cancer	I-Anatomy
(	O
HRPC	B-Anatomy
)	O
.	O
Hormone	B-Anatomy
-	I-Anatomy
refractory	I-Anatomy
prostate	I-Anatomy
cancer	I-Anatomy
(	O
HRPC	B-Anatomy
)	O
is	O
an	O
inevitable	O
evolution	O
of	O
prostate	B-Anatomy
carcinogenesis	O
,	O
through	O
which	O
the	O
normal	O
dependence	O
on	O
hormones	O
for	O
growth	O
and	O
survival	O
is	O
bypassed	O
.	O
Although	O
advances	O
in	O
terms	O
of	O
symptoms	O
palliation	O
and	O
quality	O
of	O
life	O
improvement	O
have	O
been	O
addressed	O
with	O
current	O
treatment	O
options	O
,	O
innovative	O
approaches	O
are	O
needed	O
to	O
improve	O
survival	O
rates	O
.	O
A	O
thorough	O
understanding	O
of	O
HRPC	B-Anatomy
-	O
associated	O
molecular	O
pathways	O
and	O
mechanisms	O
of	O
resistance	O
are	O
a	O
prerequisite	O
for	O
novel	O
potential	O
therapeutic	O
interventions	O
.	O
Preclinical	O
and	O
early	O
clinical	O
studies	O
are	O
ongoing	O
to	O
evaluate	O
new	O
therapies	O
that	O
target	O
specific	O
molecular	O
entities	O
.	O
Agents	O
under	O
development	O
include	O
growth	O
factor	O
receptor	O
inhibitors	O
,	O
small	O
molecules	O
targeting	O
signal	O
transduction	O
pathways	O
,	O
apoptosis	O
and	O
cell	B-Anatomy
-	O
cycle	O
regulators	O
,	O
angiogenesis	O
and	O
metastasis	O
inhibitors	O
,	O
differentiation	O
agents	O
,	O
telomerase	O
inactivators	O
,	O
and	O
epigenetic	O
therapeutics	O
.	O
Incorporation	O
of	O
these	O
agents	O
into	O
existing	O
treatment	O
regimens	O
will	O
guide	O
us	O
in	O
the	O
development	O
of	O
a	O
multidisciplinary	O
treatment	O
strategy	O
of	O
HRPC	B-Anatomy
.	O
This	O
article	O
critically	O
reviews	O
published	O
data	O
on	O
new	O
biological	O
agents	O
that	O
are	O
being	O
tested	O
in	O
HRPC	B-Anatomy
clinical	O
trials	O
,	O
highlights	O
ongoing	O
research	O
and	O
considers	O
the	O
future	O
perspectives	O
of	O
this	O
new	O
class	O
of	O
agents	O
.	O
Role	O
of	O
thrombogenic	O
factors	O
in	O
the	O
development	O
of	O
atherosclerosis	O
.	O
Hemostatic	O
factors	O
play	O
a	O
crucial	O
role	O
in	O
generating	O
thrombotic	B-Anatomy
plugs	I-Anatomy
at	O
sites	B-Anatomy
of	O
vascular	B-Anatomy
damage	O
(	O
atherothrombosis	O
)	O
.	O
However	O
,	O
whether	O
hemostatic	O
factors	O
contribute	O
directly	O
or	O
indirectly	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
remains	O
uncertain	O
.	O
Autopsy	O
studies	O
have	O
revealed	O
that	O
intimal	B-Anatomy
thickening	O
represents	O
the	O
first	O
stage	O
of	O
atherosclerosis	O
and	O
that	O
lipid	B-Anatomy
-	I-Anatomy
rich	I-Anatomy
plaque	I-Anatomy
arises	O
from	O
such	O
lesions	B-Anatomy
.	O
Several	O
factors	O
contribute	O
to	O
the	O
start	O
of	O
intimal	B-Anatomy
thickening	O
.	O
Platelets	B-Anatomy
release	O
several	O
growth	O
factors	O
and	O
bioactive	O
agents	O
that	O
play	O
a	O
central	O
role	O
in	O
development	O
of	O
not	O
only	O
thrombus	B-Anatomy
but	O
also	O
of	O
intimal	B-Anatomy
thickening	O
.	O
We	O
have	O
been	O
investigating	O
which	O
coagulation	O
factors	O
simultaneously	O
,	O
or	O
subsequently	O
with	O
platelet	B-Anatomy
aggregation	O
,	O
participate	O
in	O
thrombus	B-Anatomy
formation	O
.	O
Tissue	O
factor	O
(	O
TF	O
)	O
is	O
an	O
essential	O
initiator	O
of	O
blood	B-Anatomy
coagulation	O
that	O
is	O
expressed	O
in	O
various	O
stages	O
of	O
atherosclerotic	B-Anatomy
lesions	I-Anatomy
in	O
humans	O
and	O
other	O
animals	O
.	O
Factors	O
including	O
thrombin	O
and	O
fibrin	O
,	O
which	O
are	O
downstream	O
of	O
the	O
coagulation	O
cascade	O
activated	O
by	O
TF	O
,	O
also	O
contribute	O
to	O
atherosclerosis	O
.	O
TF	O
is	O
involved	O
in	O
cell	B-Anatomy
migration	O
,	O
embryogenesis	O
and	O
angiogenesis	O
.	O
Thus	O
TF	O
,	O
in	O
addition	O
to	O
factors	O
downstream	O
of	O
the	O
coagulation	O
cascade	O
and	O
the	O
protease	O
-	O
activated	O
receptor	O
2	O
activation	O
system	O
,	O
would	O
be	O
a	O
multifactorial	O
regulator	O
of	O
atherogenesis	O
.	O
Angiogenin	O
is	O
up	O
-	O
regulated	O
in	O
the	O
nucleus	B-Anatomy
and	O
cytoplasm	B-Anatomy
in	O
human	O
primary	B-Anatomy
breast	I-Anatomy
carcinoma	I-Anatomy
and	O
is	O
associated	O
with	O
markers	O
of	O
hypoxia	O
but	O
not	O
survival	O
.	O
Angiogenin	O
,	O
a	O
14	O
.	O
2	O
kD	O
polypeptide	O
that	O
was	O
originally	O
noted	O
for	O
its	O
angiogenic	O
activity	O
,	O
is	O
now	O
increasingly	O
recognized	O
to	O
have	O
a	O
multiplicity	O
of	O
biological	O
roles	O
in	O
both	O
physiological	O
and	O
pathological	O
conditions	O
.	O
In	O
breast	B-Anatomy
cancer	I-Anatomy
,	O
there	O
are	O
conflicting	O
studies	O
questioning	O
the	O
role	O
of	O
angiogenin	O
.	O
Here	O
,	O
the	O
pattern	O
of	O
expression	O
of	O
angiogenin	O
during	O
the	O
transition	O
from	O
normal	O
breast	B-Anatomy
tissue	I-Anatomy
to	O
ductal	B-Anatomy
carcinoma	I-Anatomy
in	I-Anatomy
situ	I-Anatomy
and	O
invasive	B-Anatomy
carcinoma	I-Anatomy
is	O
reported	O
together	O
with	O
the	O
correlates	O
between	O
the	O
level	O
of	O
angiogenin	O
in	O
239	O
invasive	B-Anatomy
carcinomas	I-Anatomy
and	O
standard	O
clinicopathological	O
parameters	O
,	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
-	O
1	O
alpha	O
and	O
the	O
HIF	O
-	O
1	O
alpha	O
target	O
gene	O
DEC	O
-	O
1	O
.	O
This	O
study	O
shows	O
that	O
angiogenin	O
expression	O
is	O
up	O
-	O
regulated	O
in	O
the	O
cytoplasmic	B-Anatomy
and	O
nuclear	B-Anatomy
compartments	I-Anatomy
in	O
in	B-Anatomy
situ	I-Anatomy
carcinoma	I-Anatomy
and	O
invasive	B-Anatomy
carcinoma	I-Anatomy
compared	O
with	O
normal	O
breast	B-Anatomy
tissue	I-Anatomy
and	O
that	O
angiogenin	O
expression	O
in	O
invasive	B-Anatomy
carcinomas	I-Anatomy
is	O
significantly	O
positively	O
associated	O
with	O
high	O
tumour	B-Anatomy
grade	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
positive	O
oestrogen	O
receptor	O
(	O
ER	O
)	O
status	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
HIF	O
-	O
1	O
alpha	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
DEC	O
1	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
but	O
not	O
with	O
patient	O
age	O
(	O
p	O
=	O
0	O
.	O
8	O
)	O
,	O
tumour	B-Anatomy
size	O
(	O
p	O
=	O
0	O
.	O
25	O
)	O
,	O
lymph	B-Anatomy
node	I-Anatomy
status	O
(	O
p	O
=	O
0	O
.	O
69	O
)	O
,	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
p	O
=	O
0	O
.	O
56	O
)	O
or	O
microvessel	B-Anatomy
density	O
(	O
p	O
=	O
0	O
.	O
32	O
)	O
.	O
No	O
difference	O
in	O
relapse	O
-	O
free	O
(	O
p	O
=	O
0	O
.	O
26	O
)	O
or	O
overall	O
(	O
p	O
=	O
0	O
.	O
63	O
)	O
survival	O
was	O
observed	O
in	O
patients	O
stratified	O
by	O
angiogenin	O
expression	O
.	O
This	O
study	O
suggests	O
that	O
angiogenin	O
may	O
be	O
important	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
progression	O
and	O
that	O
,	O
through	O
its	O
relationship	O
with	O
ER	O
,	O
it	O
may	O
be	O
a	O
target	O
for	O
tamoxifen	O
.	O
Hereditary	O
paraganglioma	B-Anatomy
/	O
pheochromocytoma	B-Anatomy
and	O
inherited	O
succinate	O
dehydrogenase	O
deficiency	O
.	O
Mitochondrial	B-Anatomy
complex	O
II	O
,	O
or	O
succinate	O
dehydrogenase	O
,	O
is	O
a	O
key	O
enzymatic	O
complex	O
involved	O
in	O
both	O
the	O
tricarboxylic	O
acid	O
(	O
TCA	O
)	O
cycle	O
and	O
oxidative	O
phosphorylation	O
as	O
part	O
of	O
the	O
mitochondrial	B-Anatomy
respiratory	O
chain	O
.	O
Germline	O
succinate	O
dehydrogenase	O
subunit	O
A	O
(	O
SDHA	O
)	O
mutations	O
have	O
been	O
reported	O
in	O
a	O
few	O
patients	O
with	O
a	O
classical	O
mitochondrial	B-Anatomy
neurodegenerative	O
disease	O
.	O
Mutations	O
in	O
the	O
genes	O
encoding	O
the	O
three	O
other	O
succinate	O
dehydrogenase	O
subunits	O
(	O
SDHB	O
,	O
SDHC	O
and	O
SDHD	O
)	O
have	O
been	O
identified	O
in	O
patients	O
affected	O
by	O
familial	O
or	O
'	O
apparently	O
sporadic	O
'	O
paraganglioma	B-Anatomy
and	O
/	O
or	O
pheochromocytoma	B-Anatomy
,	O
an	O
autosomal	O
inherited	O
cancer	B-Anatomy
-	O
susceptibility	O
syndrome	O
.	O
These	O
discoveries	O
have	O
dramatically	O
changed	O
the	O
work	O
-	O
up	O
and	O
genetic	O
counseling	O
of	O
patients	O
and	O
families	O
with	O
paragangliomas	B-Anatomy
and	O
/	O
or	O
pheochromocytomas	B-Anatomy
.	O
The	O
subsequent	O
identification	O
of	O
germline	O
mutations	O
in	O
the	O
gene	O
encoding	O
fumarase	O
-	O
-	O
another	O
TCA	O
cycle	O
enzyme	O
-	O
-	O
in	O
a	O
new	O
hereditary	O
form	O
of	O
susceptibility	O
to	O
renal	B-Anatomy
,	O
uterine	B-Anatomy
and	O
cutaneous	B-Anatomy
tumors	I-Anatomy
has	O
highlighted	O
the	O
potential	O
role	O
of	O
the	O
TCA	O
cycle	O
and	O
,	O
more	O
generally	O
,	O
of	O
the	O
mitochondria	B-Anatomy
in	O
cancer	B-Anatomy
.	O
[	O
Uncommon	O
etiology	O
of	O
gastrointestinal	B-Anatomy
bleeding	O
:	O
duodenal	B-Anatomy
metastases	I-Anatomy
from	O
renal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
]	O
.	O
Because	O
of	O
its	O
unpredictable	O
behavior	O
,	O
renal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
is	O
one	O
of	O
the	O
most	O
controversial	O
neoplasms	B-Anatomy
.	O
On	O
the	O
one	O
hand	O
,	O
patients	O
frequently	O
show	O
metastases	B-Anatomy
at	O
diagnosis	O
because	O
of	O
its	O
slight	O
manifestations	O
,	O
while	O
on	O
the	O
other	O
,	O
the	O
neoplasm	B-Anatomy
can	O
remain	O
stable	O
after	O
nephrectomy	O
and	O
can	O
then	O
metastasize	O
many	O
years	O
later	O
.	O
When	O
this	O
happens	O
,	O
the	O
metastases	B-Anatomy
usually	O
involve	O
more	O
than	O
2	O
organs	B-Anatomy
.	O
The	O
most	O
frequent	O
sites	B-Anatomy
of	O
metastases	B-Anatomy
are	O
the	O
lung	B-Anatomy
and	O
lymph	B-Anatomy
nodes	I-Anatomy
,	O
followed	O
by	O
the	O
bones	B-Anatomy
and	O
liver	B-Anatomy
,	O
while	O
duodenal	B-Anatomy
involvement	O
is	O
rare	O
.	O
Indeed	O
,	O
intestinal	B-Anatomy
metastases	I-Anatomy
are	O
found	O
in	O
only	O
2	O
%	O
of	O
autopsies	O
and	O
of	O
these	O
,	O
renal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
metastases	I-Anatomy
account	O
for	O
7	O
.	O
1	O
%	O
.	O
We	O
present	O
a	O
case	O
of	O
a	O
solitary	O
late	O
recurrence	O
presenting	O
as	O
upper	O
gastrointestinal	B-Anatomy
bleeding	O
19	O
years	O
after	O
nephrectomy	O
for	O
clear	B-Anatomy
cell	I-Anatomy
renal	I-Anatomy
carcinoma	I-Anatomy
.	O
Mouse	O
p10	O
,	O
an	O
alternative	O
spliced	O
form	O
of	O
p15INK4b	O
,	O
inhibits	O
cell	B-Anatomy
cycle	O
progression	O
and	O
malignant	O
transformation	O
.	O
The	O
INK4	O
family	O
of	O
proteins	O
negatively	O
regulates	O
cell	B-Anatomy
cycle	O
progression	O
at	O
the	O
G	O
(	O
1	O
)	O
-	O
S	O
transition	O
by	O
inhibiting	O
cyclin	O
-	O
dependent	O
kinases	O
.	O
Two	O
of	O
these	O
cell	B-Anatomy
cycle	O
inhibitors	O
,	O
p16	O
(	O
INK4A	O
)	O
and	O
p15	O
(	O
INK4B	O
)	O
,	O
have	O
tumor	B-Anatomy
suppressor	O
activities	O
and	O
are	O
inactivated	O
in	O
human	O
cancer	B-Anatomy
.	O
Interestingly	O
,	O
both	O
INK4	O
genes	O
express	O
alternative	O
splicing	O
variants	O
.	O
In	O
addition	O
to	O
p16	O
(	O
INK4A	O
)	O
,	O
the	O
INK4A	O
locus	O
encodes	O
a	O
splice	O
variant	O
,	O
termed	O
p12	O
-	O
-	O
specifically	O
expressed	O
in	O
human	O
pancreas	B-Anatomy
-	O
-	O
and	O
ARF	O
,	O
a	O
protein	O
encoded	O
by	O
an	O
alternative	O
reading	O
frame	O
that	O
acts	O
as	O
a	O
tumor	B-Anatomy
suppressor	O
through	O
the	O
p53	O
pathway	O
.	O
Similarly	O
,	O
the	O
human	O
INK4B	O
locus	O
encodes	O
the	O
p15	O
(	O
INK4B	O
)	O
tumor	B-Anatomy
suppressor	O
and	O
one	O
alternatively	O
spliced	O
form	O
,	O
termed	O
as	O
p10	O
.	O
We	O
show	O
here	O
that	O
p10	O
,	O
which	O
arises	O
from	O
the	O
use	O
of	O
an	O
alternative	O
splice	O
donor	O
site	O
within	O
intron	B-Anatomy
1	I-Anatomy
,	O
is	O
conserved	O
in	O
the	O
mouse	O
genome	O
and	O
is	O
widely	O
expressed	O
in	O
mouse	O
tissues	B-Anatomy
.	O
Similarly	O
to	O
mouse	O
p15	O
(	O
INK4B	O
)	O
,	O
p10	O
expression	O
is	O
also	O
induced	O
by	O
oncogenic	O
insults	O
and	O
transforming	O
growth	O
factor	O
-	O
beta	O
treatment	O
and	O
acts	O
as	O
a	O
cell	B-Anatomy
cycle	O
inhibitor	O
.	O
Importantly	O
,	O
we	O
show	O
that	O
mouse	O
p10	O
is	O
able	O
to	O
induce	O
cell	B-Anatomy
cycle	O
arrest	O
in	O
a	O
p53	O
-	O
dependent	O
manner	O
.	O
We	O
also	O
show	O
that	O
mouse	O
p10	O
is	O
able	O
to	O
inhibit	O
foci	B-Anatomy
formation	O
and	O
anchorage	O
-	O
independent	O
growth	O
in	O
wild	O
-	O
type	O
mouse	O
embryonic	B-Anatomy
fibroblasts	I-Anatomy
,	O
and	O
that	O
these	O
antitransforming	O
properties	O
of	O
mouse	O
p10	O
are	O
also	O
p53	O
-	O
dependent	O
.	O
These	O
results	O
indicate	O
that	O
the	O
INK4B	O
locus	O
,	O
similarly	O
to	O
INK4A	O
-	O
ARF	O
,	O
harbors	O
two	O
different	O
splicing	O
variants	O
that	O
can	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
both	O
the	O
p53	O
and	O
retinoblastoma	O
pathways	O
,	O
the	O
two	O
major	O
molecular	O
pathways	O
in	O
tumor	B-Anatomy
suppression	O
.	O
Rofecoxib	O
as	O
adjunctive	O
therapy	O
for	O
haemophilic	O
arthropathy	O
.	O
Joint	B-Anatomy
haemorrhage	O
and	O
subsequent	O
haemophilic	O
arthropathy	O
are	O
significant	O
complications	O
in	O
haemophilia	O
.	O
The	O
pathophysiology	O
involves	O
inflammation	O
and	O
angiogenesis	O
.	O
Cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
inhibitors	O
are	O
anti	O
-	O
inflammatory	O
agents	O
,	O
which	O
have	O
potent	O
anti	O
-	O
inflammatory	O
,	O
anti	O
-	O
angiogenic	O
and	O
analgesic	O
properties	O
yet	O
do	O
not	O
affect	O
platelet	B-Anatomy
function	O
in	O
the	O
manner	O
of	O
traditional	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
.	O
These	O
properties	O
make	O
such	O
agents	O
potentially	O
useful	O
as	O
adjunctive	O
therapy	O
in	O
haemophilia	O
.	O
There	O
is	O
only	O
one	O
prior	O
report	O
describing	O
rofecoxib	O
treatment	O
in	O
a	O
single	O
haemophilia	O
patient	O
.	O
Our	O
objectives	O
were	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
rofecoxib	O
in	O
treating	O
acute	O
haemarthrosis	O
,	O
chronic	O
synovitis	O
,	O
target	O
joints	B-Anatomy
and	O
pain	O
.	O
We	O
conducted	O
a	O
retrospective	O
medical	O
record	O
review	O
of	O
patients	O
treated	O
with	O
rofecoxib	O
for	O
acute	O
haemarthrosis	O
,	O
chronic	O
synovitis	O
,	O
target	O
joint	B-Anatomy
or	O
pain	O
.	O
The	O
safety	O
and	O
efficacy	O
of	O
rofecoxib	O
treatment	O
were	O
determined	O
based	O
on	O
subjective	O
patient	O
reports	O
and	O
physical	O
examinations	O
during	O
follow	O
-	O
up	O
clinic	O
visits	O
.	O
A	O
total	O
of	O
28	O
patients	O
between	O
3	O
and	O
37	O
years	O
of	O
age	O
were	O
treated	O
for	O
a	O
total	O
of	O
42	O
courses	O
of	O
rofecoxib	O
treatment	O
.	O
All	O
courses	O
were	O
evaluated	O
for	O
safety	O
and	O
31	O
for	O
efficacy	O
.	O
Rofecoxib	O
was	O
used	O
for	O
eight	O
acute	O
haemarthrosis	O
,	O
four	O
target	O
joints	B-Anatomy
,	O
seven	O
cases	O
of	O
synovitis	O
and	O
12	O
episodes	O
of	O
pain	O
.	O
Efficacy	O
was	O
demonstrated	O
particularly	O
for	O
chronic	O
synovitis	O
and	O
pain	O
and	O
no	O
serious	O
adverse	O
events	O
occurred	O
.	O
This	O
is	O
the	O
largest	O
study	O
to	O
date	O
evaluating	O
COX	O
-	O
2	O
inhibitors	O
as	O
adjunctive	O
therapy	O
in	O
haemophilia	O
and	O
suggests	O
that	O
these	O
agents	O
may	O
be	O
an	O
important	O
adjunctive	O
therapy	O
in	O
the	O
management	O
of	O
haemophilia	O
.	O
Bcl	O
-	O
2	O
decreases	O
cell	B-Anatomy
proliferation	O
and	O
promotes	O
accumulation	O
of	O
cells	B-Anatomy
in	O
S	O
phase	O
without	O
affecting	O
the	O
rate	O
of	O
apoptosis	O
in	O
human	O
ovarian	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
OBJECTIVES	O
:	O
The	O
Bcl	O
-	O
2	O
protein	O
is	O
an	O
important	O
regulator	O
of	O
the	O
apoptotic	O
cascade	O
and	O
promotes	O
cell	B-Anatomy
survival	O
.	O
Bcl	O
-	O
2	O
can	O
also	O
delay	O
entry	O
into	O
the	O
cell	B-Anatomy
cycle	O
from	O
quiescence	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
used	O
two	O
isogenic	O
human	O
ovarian	B-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
,	O
which	O
expressed	O
differential	O
levels	O
of	O
Bcl	O
-	O
2	O
proteins	O
,	O
to	O
demonstrate	O
that	O
Bcl	O
-	O
2	O
may	O
regulate	O
the	O
growth	O
rates	O
of	O
adenocarcinoma	B-Anatomy
cells	I-Anatomy
.	O
METHODS	O
:	O
The	O
growth	O
rates	O
of	O
two	O
isogenic	O
ovarian	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
were	O
determined	O
by	O
XTT	O
assays	O
and	O
flow	O
cytometry	O
combined	O
with	O
PI	O
staining	O
.	O
Bcl	B-Anatomy
-	I-Anatomy
2	I-Anatomy
-	I-Anatomy
overexpressing	I-Anatomy
SKOV3	I-Anatomy
cells	I-Anatomy
were	O
modified	O
to	O
express	O
a	O
doxycycline	O
-	O
inducible	O
anti	O
-	O
Bcl	O
-	O
2	O
single	O
-	O
chain	O
antibody	O
and	O
the	O
effects	O
of	O
Bcl	O
-	O
2	O
protein	O
inhibition	O
on	O
cell	B-Anatomy
proliferation	O
and	O
apoptosis	O
were	O
assessed	O
.	O
RESULTS	O
:	O
We	O
demonstrate	O
that	O
Bcl	O
-	O
2	O
promotes	O
the	O
accumulation	O
of	O
proliferating	O
carcinoma	B-Anatomy
cells	I-Anatomy
in	O
S	O
phase	O
.	O
The	O
Bcl	B-Anatomy
-	I-Anatomy
2	I-Anatomy
-	I-Anatomy
overexpressing	I-Anatomy
SKOV3	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
proliferates	O
markedly	O
faster	O
and	O
shows	O
delayed	O
progression	O
to	O
G2M	O
phase	O
compared	O
to	O
its	O
low	O
Bcl	B-Anatomy
-	I-Anatomy
2	I-Anatomy
-	I-Anatomy
expressing	I-Anatomy
counterpart	I-Anatomy
SKOV3	I-Anatomy
.	I-Anatomy
ip1	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
.	O
Single	O
-	O
chain	O
antibody	O
-	O
mediated	O
inhibition	O
of	O
Bcl	O
-	O
2	O
in	O
SKOV3	B-Anatomy
cells	I-Anatomy
was	O
associated	O
with	O
increased	O
growth	O
rates	O
and	O
more	O
rapid	O
cell	B-Anatomy
cycle	O
progression	O
.	O
Treatment	O
with	O
cisplatin	O
resulted	O
in	O
more	O
cells	B-Anatomy
accumulating	O
in	O
S	O
phase	O
in	O
Bcl	B-Anatomy
-	I-Anatomy
2	I-Anatomy
-	I-Anatomy
overexpressing	I-Anatomy
SKOV3	I-Anatomy
cells	I-Anatomy
,	O
while	O
the	O
inhibition	O
of	O
Bcl	O
-	O
2	O
abolished	O
delayed	O
entry	O
into	O
G2M	O
phase	O
without	O
affecting	O
cisplatin	O
-	O
induced	O
apoptosis	O
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
,	O
in	O
ovarian	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
,	O
Bcl	O
-	O
2	O
delays	O
cell	B-Anatomy
cycle	O
progression	O
by	O
promoting	O
accumulation	O
of	O
cells	B-Anatomy
in	O
S	O
phase	O
without	O
affecting	O
the	O
rate	O
of	O
apoptosis	O
.	O
Thus	O
,	O
in	O
addition	O
to	O
its	O
known	O
role	O
at	O
the	O
G0	O
/	O
G1	O
checkpoint	O
,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
Bcl	O
-	O
2	O
also	O
regulates	O
the	O
S	O
phase	O
.	O
Thalidomide	O
and	O
angiostatin	O
inhibit	O
tumor	B-Anatomy
growth	O
in	O
a	O
murine	O
xenograft	B-Anatomy
model	O
of	O
human	O
cervical	B-Anatomy
cancer	I-Anatomy
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
impact	O
of	O
thalidomide	O
and	O
angiostatin	O
on	O
tumor	B-Anatomy
growth	O
,	O
angiogenesis	O
,	O
and	O
apoptosis	O
in	O
a	O
xenograft	B-Anatomy
model	O
of	O
cervical	B-Anatomy
cancer	I-Anatomy
.	O
METHODS	O
:	O
Human	O
umbilical	O
endothelial	B-Anatomy
cells	I-Anatomy
were	O
treated	O
with	O
angiostatin	O
or	O
thalidomide	O
and	O
bFGF	O
-	O
induced	O
proliferation	O
was	O
assessed	O
with	O
the	O
MTT	O
assay	O
.	O
Human	O
cervical	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
(	O
CaSki	B-Anatomy
and	O
SiHa	B-Anatomy
)	O
were	O
injected	O
into	O
the	O
flanks	B-Anatomy
of	O
nude	O
mice	O
.	O
After	O
tumors	B-Anatomy
developed	O
,	O
mice	O
were	O
treated	O
with	O
angiostatin	O
20	O
mg	O
/	O
kg	O
/	O
day	O
or	O
thalidomide	O
200	O
mg	O
/	O
kg	O
/	O
day	O
for	O
30	O
days	O
.	O
Fractional	O
tumor	B-Anatomy
growth	O
was	O
determined	O
and	O
immunohistochemical	O
analysis	O
of	O
tumors	B-Anatomy
was	O
used	O
to	O
determine	O
degree	O
of	O
angiogenesis	O
.	O
TUNEL	O
assay	O
was	O
used	O
to	O
assess	O
apoptosis	O
.	O
RESULTS	O
:	O
Angiostatin	O
inhibited	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
by	O
50	O
-	O
60	O
%	O
.	O
Thalidomide	O
had	O
no	O
direct	O
effect	O
on	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
Angiostatin	O
and	O
thalidomide	O
both	O
inhibited	O
tumor	B-Anatomy
growth	O
by	O
about	O
55	O
%	O
.	O
We	O
found	O
no	O
additive	O
or	O
synergistic	O
effect	O
when	O
the	O
two	O
agents	O
were	O
combined	O
.	O
Both	O
agents	O
inhibited	O
angiogenesis	O
and	O
induced	O
apoptosis	O
when	O
compared	O
to	O
tumors	B-Anatomy
from	O
control	O
animals	O
.	O
CONCLUSIONS	O
:	O
Angiostatin	O
and	O
thalidomide	O
inhibit	O
tumor	B-Anatomy
growth	O
,	O
angiogenesis	O
,	O
and	O
induce	O
apoptosis	O
in	O
this	O
xenograft	B-Anatomy
model	O
of	O
cervical	B-Anatomy
cancer	I-Anatomy
.	O
Therapeutic	O
Electromagnetic	O
Field	O
(	O
TEMF	O
)	O
and	O
gamma	O
irradiation	O
on	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
xenograft	I-Anatomy
growth	O
,	O
angiogenesis	O
and	O
metastasis	O
.	O
BACKGROUND	O
:	O
The	O
effects	O
of	O
a	O
rectified	O
semi	O
-	O
sinewave	O
signal	O
(	O
15	O
mT	O
amplitude	O
,	O
120	O
pulses	O
per	O
second	O
,	O
EMF	O
Therapeutics	O
,	O
Inc	O
.	O
)	O
(	O
TEMF	O
)	O
alone	O
and	O
in	O
combination	O
with	O
gamma	O
irradiation	O
(	O
IR	O
)	O
therapy	O
in	O
nude	O
mice	O
bearing	O
a	O
human	O
MDA	B-Anatomy
MB231	I-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
xenograft	I-Anatomy
were	O
tested	O
.	O
Green	O
fluorescence	O
protein	O
transfected	O
cancer	B-Anatomy
cells	I-Anatomy
were	O
injected	O
into	O
the	O
mammary	B-Anatomy
fat	I-Anatomy
pad	I-Anatomy
of	O
young	O
female	O
mice	O
.	O
Six	O
weeks	O
later	O
,	O
mice	O
were	O
randomly	O
divided	O
into	O
four	O
treatment	O
groups	O
:	O
untreated	O
controls	O
;	O
10	O
minute	O
daily	O
TEMF	O
;	O
200	O
cGy	O
of	O
IR	O
every	O
other	O
day	O
(	O
total	O
800	O
cGy	O
)	O
;	O
IR	O
plus	O
daily	O
TEMF	O
.	O
Some	O
mice	O
in	O
each	O
group	O
were	O
euthanized	O
24	O
hours	O
after	O
the	O
end	O
of	O
IR	O
.	O
TEMF	O
treatment	O
continued	O
for	O
3	O
additional	O
weeks	O
.	O
Tumor	B-Anatomy
sections	I-Anatomy
were	O
stained	O
for	O
:	O
endothelial	B-Anatomy
cells	I-Anatomy
with	O
CD31	O
and	O
PAS	O
or	O
hypoxia	O
inducible	O
factor	O
1alpha	O
(	O
HIF	O
)	O
.	O
RESULTS	O
:	O
Most	O
tumors	B-Anatomy
less	O
than	O
35	O
mm3	O
were	O
white	O
but	O
tumors	B-Anatomy
greater	O
than	O
35	O
mm3	O
were	O
pink	O
and	O
had	O
a	O
vascularized	O
capsule	B-Anatomy
.	O
The	O
cortex	B-Anatomy
within	O
100	O
microns	O
of	O
the	O
capsule	B-Anatomy
had	O
little	O
vascularization	O
.	O
Blood	B-Anatomy
vessels	I-Anatomy
,	O
capillaries	B-Anatomy
,	O
and	O
endothelial	B-Anatomy
pseudopods	I-Anatomy
were	O
found	O
at	O
greater	O
than	O
100	O
microns	O
from	O
the	O
capsule	B-Anatomy
(	O
subcortex	B-Anatomy
)	O
.	O
Tumors	B-Anatomy
greater	O
than	O
35	O
mm3	O
treated	O
with	O
IR	O
24	O
hours	O
previously	O
or	O
with	O
TEMF	O
had	O
decreased	O
blood	B-Anatomy
vessels	I-Anatomy
in	O
the	O
subcortex	B-Anatomy
and	O
more	O
endothelial	B-Anatomy
pseudopods	I-Anatomy
projecting	O
into	O
hypoxic	O
,	O
HIF	O
positive	O
areas	O
than	O
tumors	B-Anatomy
from	O
the	O
control	O
group	O
.	O
Mice	O
that	O
received	O
either	O
IR	O
or	O
TEMF	O
had	O
significantly	O
fewer	O
lung	B-Anatomy
metastatic	I-Anatomy
sites	I-Anatomy
and	O
slower	O
tumor	B-Anatomy
growth	O
than	O
did	O
untreated	O
mice	O
.	O
No	O
harmful	O
side	O
effects	O
were	O
attributed	O
to	O
TEMF	O
.	O
CONCLUSION	O
:	O
TEMF	O
therapy	O
provided	O
a	O
safe	O
means	O
for	O
retarding	O
tumor	B-Anatomy
vascularization	O
,	O
growth	O
and	O
metastasis	O
.	O
A	O
novel	O
conotoxin	O
from	O
Conus	O
delessertii	O
with	O
posttranslationally	O
modified	O
lysine	O
residues	O
.	O
A	O
major	O
peptide	O
,	O
de13a	O
from	O
the	O
crude	O
venom	B-Anatomy
of	O
Conus	O
delessertii	O
collected	O
in	O
the	O
Yucatan	O
Channel	O
,	O
Mexico	O
,	O
was	O
purified	O
.	O
The	O
peptide	O
had	O
a	O
high	O
content	O
of	O
posttranslationally	O
modified	O
amino	O
acids	O
,	O
including	O
6	O
-	O
bromotryptophan	O
and	O
a	O
nonstandard	O
amino	O
acid	O
that	O
proved	O
to	O
be	O
5	O
-	O
hydroxylysine	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
5	O
-	O
hydroxylysine	O
residues	O
in	O
conotoxins	O
.	O
The	O
sequence	O
analysis	O
,	O
together	O
with	O
cDNA	O
cloning	O
and	O
a	O
mass	O
determination	O
(	O
monoisotopic	O
mass	O
of	O
3486	O
.	O
76	O
Da	O
)	O
,	O
established	O
that	O
the	O
mature	O
toxin	O
has	O
the	O
sequence	O
DCOTSCOTTCANGWECCKGYOCVNKACSGCTH	O
,	O
where	O
O	O
is	O
4	O
-	O
hydroxyproline	O
,	O
W	O
6	O
-	O
bromotryptophan	O
,	O
and	O
K	O
5	O
-	O
hydroxylysine	O
,	O
the	O
asterisk	O
represents	O
the	O
amidated	O
C	O
-	O
terminus	O
,	O
and	O
the	O
calculated	O
monoisotopic	O
mass	O
is	O
3487	O
.	O
09	O
Da	O
.	O
The	O
eight	O
Cys	O
residues	O
are	O
arranged	O
in	O
a	O
pattern	O
(	O
C	O
-	O
C	O
-	O
C	O
-	O
CC	O
-	O
C	O
-	O
C	O
-	O
C	O
)	O
not	O
described	O
previously	O
in	O
conotoxins	O
.	O
This	O
arrangement	O
,	O
for	O
which	O
we	O
propose	O
the	O
designation	O
of	O
framework	O
#	O
13	O
or	O
XIII	O
,	O
differs	O
from	O
the	O
ones	O
(	O
C	O
-	O
C	O
-	O
CC	O
-	O
CC	O
-	O
C	O
-	O
C	O
and	O
C	O
-	O
C	O
-	O
C	O
-	O
C	O
-	O
CC	O
-	O
C	O
-	O
C	O
)	O
present	O
in	O
other	O
conotoxins	O
which	O
also	O
contain	O
eight	O
Cys	O
residues	O
.	O
This	O
peptide	O
thus	O
defines	O
a	O
novel	O
class	O
of	O
conotoxins	O
,	O
with	O
a	O
new	O
posttranslational	O
modification	O
not	O
previously	O
found	O
in	O
other	O
Conus	O
peptide	O
families	O
.	O
Enhancement	O
of	O
skin	B-Anatomy
permeation	O
of	O
ketotifen	O
by	O
supersaturation	O
generated	O
by	O
amorphous	O
form	O
of	O
the	O
drug	O
.	O
Pressure	O
sensitive	O
adhesive	O
(	O
PSA	O
)	O
matrices	O
containing	O
amorphous	O
ketotifen	O
were	O
prepared	O
and	O
evaluated	O
for	O
enhanced	O
skin	B-Anatomy
permeability	O
of	O
the	O
drug	O
.	O
A	O
solvent	O
casting	O
method	O
using	O
silicone	O
-	O
typed	O
PSA	O
was	O
employed	O
,	O
and	O
n	O
-	O
hexane	O
,	O
an	O
original	O
solvent	O
for	O
the	O
PSA	O
and	O
one	O
more	O
solvent	O
,	O
dichloromethane	O
,	O
tetrahydrofuran	O
,	O
acetone	O
,	O
ethyl	O
acetate	O
or	O
toluene	O
,	O
were	O
used	O
for	O
complete	O
dissolution	O
of	O
ketotifen	O
and	O
high	O
dispersion	O
in	O
an	O
amorphous	O
state	O
of	O
the	O
drug	O
.	O
Presence	O
of	O
the	O
amorphous	O
form	O
was	O
judged	O
based	O
on	O
the	O
in	O
vitro	O
drug	O
release	O
rate	O
from	O
the	O
matrix	O
.	O
As	O
a	O
result	O
,	O
dichloromethane	O
and	O
tetrahudrofuran	O
were	O
selected	O
as	O
appropriate	O
dilution	O
solvents	O
.	O
In	O
vitro	O
permeation	O
experiments	O
through	O
excised	O
hairless	O
mouse	O
skin	B-Anatomy
revealed	O
that	O
the	O
steady	O
-	O
state	O
flux	O
from	O
the	O
amorphous	O
ketotifen	O
-	O
dispersed	O
matrices	O
was	O
about	O
five	O
times	O
greater	O
than	O
that	O
of	O
the	O
crystalline	O
ketotifen	O
-	O
dispersed	O
matrices	O
,	O
and	O
that	O
the	O
enhancement	O
ratio	O
was	O
in	O
good	O
agreement	O
with	O
the	O
solubility	O
ratio	O
of	O
the	O
amorphous	O
to	O
crystalline	O
form	O
of	O
the	O
drug	O
.	O
Comparison	O
of	O
the	O
skin	B-Anatomy
permeation	O
profiles	O
of	O
amorphous	O
ketotifen	O
-	O
dispersed	O
matrices	O
between	O
two	O
different	O
drug	O
contents	O
suggested	O
that	O
the	O
steady	O
-	O
state	O
flux	O
was	O
not	O
influenced	O
by	O
the	O
drug	O
content	O
.	O
In	O
addition	O
,	O
at	O
both	O
drug	O
contents	O
,	O
the	O
period	O
of	O
the	O
steady	O
-	O
state	O
permeation	O
coincided	O
with	O
the	O
time	O
until	O
the	O
amorphous	O
drug	O
was	O
depleted	O
from	O
the	O
matrix	O
.	O
These	O
results	O
suggest	O
that	O
the	O
increase	O
in	O
skin	B-Anatomy
permeation	O
of	O
ketotifen	O
from	O
PSA	O
matrix	O
was	O
due	O
to	O
the	O
supersaturation	O
generated	O
by	O
amorphous	O
form	O
,	O
and	O
that	O
the	O
amorphous	O
form	O
was	O
stable	O
during	O
the	O
application	O
period	O
.	O
Polybrominated	O
diphenyl	O
ethers	O
in	O
indoor	O
dust	O
in	O
Ottawa	O
,	O
Canada	O
:	O
implications	O
for	O
sources	O
and	O
exposure	O
.	O
Polybrominated	O
diphenyl	O
ethers	O
(	O
PBDEs	O
)	O
are	O
widely	O
used	O
as	O
additive	O
flame	O
retardants	O
in	O
plastics	O
,	O
soft	O
furnishings	O
,	O
electrical	O
and	O
electronic	O
equipment	O
,	O
and	O
insulation	O
in	O
the	O
indoor	O
environment	O
,	O
and	O
may	O
be	O
released	O
indoors	O
via	O
volatilization	O
or	O
as	O
dusts	O
.	O
The	O
penta	O
-	O
and	O
octa	O
-	O
brominated	O
mixes	O
are	O
now	O
banned	O
in	O
most	O
parts	O
of	O
Europe	O
,	O
and	O
phasing	O
out	O
of	O
their	O
use	O
has	O
recently	O
begun	O
in	O
North	O
America	O
.	O
This	O
study	O
follows	O
a	O
previous	O
investigation	O
into	O
indoor	O
air	O
levels	O
of	O
PBDEs	O
.	O
House	O
dust	O
was	O
analyzed	O
from	O
the	O
family	O
vacuum	O
cleaners	O
of	O
68	O
of	O
the	O
same	O
74	O
randomly	O
selected	O
homes	O
,	O
in	O
Ottawa	O
,	O
Canada	O
during	O
the	O
winter	O
of	O
2002	O
-	O
2003	O
.	O
PBDEs	O
,	O
comprising	O
on	O
average	O
42	O
%	O
BDE	O
-	O
209	O
,	O
were	O
found	O
in	O
all	O
samples	O
.	O
The	O
levels	O
were	O
log	O
-	O
normally	O
distributed	O
with	O
a	O
geometric	O
mean	O
sigmaPBDE	O
of	O
2000	O
ng	O
g	O
(	O
-	O
1	O
)	O
,	O
and	O
a	O
median	O
of	O
1800	O
ng	O
g	O
(	O
-	O
1	O
)	O
dust	O
.	O
The	O
levels	O
in	O
dust	O
did	O
not	O
correlate	O
with	O
questionnaire	O
information	O
on	O
house	O
characteristics	O
.	O
Correlations	O
were	O
found	O
between	O
pentamix	O
congener	O
levels	O
in	O
dust	O
and	O
in	O
air	O
from	O
the	O
same	O
homes	O
,	O
but	O
not	O
for	O
congeners	O
of	O
the	O
more	O
highly	O
brominated	O
mixes	O
.	O
Exposure	O
scenarios	O
are	O
presented	O
for	O
mean	O
and	O
high	O
dust	O
ingestion	O
rates	O
,	O
and	O
compared	O
against	O
exposures	O
from	O
other	O
pathways	O
,	O
for	O
both	O
adults	O
and	O
toddlers	O
(	O
6	O
months	O
-	O
2	O
years	O
)	O
.	O
Assuming	O
a	O
mean	O
dust	O
ingestion	O
rate	O
and	O
median	O
dust	O
and	O
air	O
concentrations	O
,	O
adults	O
would	O
be	O
exposed	O
to	O
ca	O
.	O
7	O
.	O
5	O
ng	O
sigmaPBDE	O
d	O
(	O
-	O
1	O
)	O
via	O
the	O
dust	O
ingestion	O
pathway	O
,	O
which	O
represents	O
approximately	O
14	O
%	O
of	O
total	O
daily	O
exposure	O
when	O
compared	O
to	O
diet	O
(	O
82	O
%	O
)	O
and	O
inhalation	O
(	O
4	O
%	O
)	O
.	O
However	O
,	O
for	O
toddlers	O
the	O
equivalent	O
intakes	O
would	O
be	O
99	O
ng	O
d	O
(	O
-	O
1	O
)	O
,	O
representing	O
80	O
%	O
of	O
their	O
daily	O
PBDE	O
exposure	O
.	O
At	O
high	O
dust	O
ingestion	O
rates	O
these	O
values	O
increase	O
to	O
180	O
ng	O
d	O
(	O
-	O
1	O
)	O
(	O
80	O
%	O
daily	O
intake	O
)	O
for	O
adults	O
and	O
360	O
ng	O
d	O
(	O
-	O
1	O
)	O
(	O
89	O
%	O
daily	O
intake	O
)	O
for	O
toddlers	O
.	O
The	O
data	O
give	O
a	O
clearer	O
picture	O
of	O
sources	O
of	O
PBDE	O
exposure	O
in	O
the	O
home	O
environment	O
and	O
suggest	O
that	O
dust	O
could	O
be	O
a	O
significant	O
exposure	O
pathway	O
for	O
some	O
individuals	O
,	O
particularly	O
children	O
.	O
The	O
threshold	O
level	O
of	O
adenomatous	O
polyposis	O
coli	O
protein	O
for	O
mouse	O
intestinal	B-Anatomy
tumorigenesis	O
.	O
The	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
,	O
whose	O
mutations	O
are	O
responsible	O
for	O
familial	O
adenomatous	O
polyposis	O
,	O
is	O
a	O
major	O
negative	O
controller	O
of	O
the	O
Wnt	O
/	O
beta	O
-	O
catenin	O
pathway	O
.	O
To	O
investigate	O
the	O
dose	O
-	O
dependent	O
effects	O
of	O
APC	O
protein	O
in	O
suppressing	O
intestinal	B-Anatomy
tumorigenesis	O
,	O
we	O
constructed	O
mutant	O
mice	O
carrying	O
hypomorphic	O
Apc	O
alleles	O
Apc	O
(	O
neoR	O
)	O
and	O
Apc	O
(	O
neoF	O
)	O
whose	O
expression	O
levels	O
were	O
reduced	O
to	O
20	O
%	O
and	O
10	O
%	O
of	O
the	O
wild	O
type	O
,	O
respectively	O
.	O
Although	O
both	O
hypomorphic	O
heterozygotes	O
developed	O
intestinal	B-Anatomy
polyps	I-Anatomy
,	O
tumor	B-Anatomy
multiplicities	O
were	O
much	O
lower	O
than	O
that	O
in	O
Apc	O
(	O
Delta716	O
)	O
mice	O
,	O
heterozygotes	O
of	O
an	O
Apc	O
allele	O
.	O
Like	O
in	O
Apc	O
(	O
Delta716	O
)	O
mice	O
,	O
loss	O
of	O
the	O
wild	O
-	O
type	O
Apc	O
allele	O
was	O
confirmed	O
for	O
all	O
polyps	B-Anatomy
examined	O
in	O
the	O
Apc	O
(	O
neoR	O
)	O
and	O
Apc	O
(	O
neoF	O
)	O
mice	O
.	O
In	O
the	O
embryonic	B-Anatomy
stem	I-Anatomy
cells	I-Anatomy
homozygous	O
for	O
these	O
hypomorphic	O
Apc	O
alleles	O
,	O
the	O
level	O
of	O
the	O
APC	O
protein	O
was	O
inversely	O
correlated	O
with	O
both	O
the	O
beta	O
-	O
catenin	O
accumulation	O
and	O
beta	O
-	O
catenin	O
/	O
T	O
-	O
cell	O
factor	O
transcriptional	O
activity	O
.	O
These	O
results	O
suggest	O
that	O
the	O
reduced	O
APC	O
protein	O
level	O
increases	O
intestinal	B-Anatomy
polyp	I-Anatomy
multiplicity	O
through	O
quantitative	O
stimulation	O
of	O
the	O
beta	O
-	O
catenin	O
/	O
T	O
-	O
cell	O
factor	O
transcription	O
.	O
We	O
further	O
estimated	O
the	O
threshold	O
of	O
APC	O
protein	O
level	O
that	O
forms	O
one	O
polyp	B-Anatomy
per	O
mouse	O
as	O
approximately	O
15	O
%	O
of	O
the	O
wild	O
type	O
.	O
These	O
results	O
also	O
suggest	O
therapeutic	O
implications	O
concerning	O
Wnt	O
signaling	O
inhibitors	O
.	O
Pathogenesis	O
of	O
thrombosis	O
in	O
essential	O
thrombocythemia	O
and	O
polycythemia	O
vera	O
:	O
the	O
role	O
of	O
neutrophils	B-Anatomy
.	O
Thrombotic	O
complications	O
are	O
frequently	O
observed	O
in	O
patients	O
with	O
polycythemia	O
vera	O
(	O
PV	O
)	O
and	O
essential	O
thrombocythemia	O
(	O
ET	O
)	O
.	O
Abnormalities	O
of	O
red	B-Anatomy
blood	I-Anatomy
cells	I-Anatomy
and	O
platelets	B-Anatomy
arising	O
from	O
the	O
clonal	O
rearrangement	O
of	O
hematopoietic	B-Anatomy
cells	I-Anatomy
have	O
been	O
considered	O
,	O
although	O
causal	O
relationships	O
between	O
any	O
of	O
these	O
specific	O
abnormalities	O
and	O
thrombosis	O
have	O
not	O
been	O
clearly	O
established	O
.	O
The	O
involvement	O
of	O
neutrophils	B-Anatomy
and	O
macrophages	B-Anatomy
,	O
which	O
participate	O
in	O
thrombosis	O
and	O
hemostasis	O
,	O
has	O
been	O
insufficiently	O
explored	O
in	O
PV	O
and	O
ET	O
.	O
Persistent	O
activation	O
of	O
circulating	O
neutrophils	B-Anatomy
was	O
recently	O
demonstrated	O
in	O
ET	O
and	O
PV	O
patients	O
,	O
in	O
parallel	O
with	O
an	O
increase	O
in	O
plasma	B-Anatomy
concentrations	O
of	O
endothelial	B-Anatomy
damage	O
-	O
derived	O
and	O
prothrombotic	O
substances	O
.	O
Other	O
studies	O
have	O
explored	O
whether	O
the	O
augmentation	O
of	O
adhesion	O
of	O
neutrophils	B-Anatomy
may	O
affect	O
neutrophil	B-Anatomy
/	O
platelet	B-Anatomy
interaction	O
since	O
a	O
significant	O
increase	O
in	O
circulating	O
neutrophil	B-Anatomy
/	O
platelet	B-Anatomy
aggregates	O
is	O
found	O
in	O
ET	O
and	O
PV	O
.	O
This	O
review	O
summarizes	O
the	O
current	O
knowledge	O
of	O
the	O
pathogenesis	O
of	O
thrombosis	O
in	O
PV	O
and	O
ET	O
,	O
with	O
emphasis	O
on	O
the	O
role	O
of	O
neutrophils	B-Anatomy
in	O
hemostasis	O
and	O
their	O
possible	O
involvement	O
in	O
the	O
mechanisms	O
of	O
the	O
acquired	O
thrombophilia	O
of	O
these	O
patients	O
.	O
Available	O
data	O
suggest	O
that	O
these	O
hemostatic	O
markers	O
deserve	O
to	O
be	O
included	O
in	O
prospective	O
clinical	O
studies	O
aimed	O
at	O
identifying	O
their	O
predictive	O
role	O
in	O
the	O
vascular	B-Anatomy
complications	O
of	O
patients	O
with	O
ET	O
and	O
PV	O
.	O
The	O
merits	O
of	O
vascular	B-Anatomy
targeting	O
for	O
gynecologic	O
malignancies	B-Anatomy
.	O
Neovascularization	O
is	O
an	O
early	O
and	O
critical	O
step	O
in	O
tumor	B-Anatomy
development	O
and	O
progression	O
.	O
Tumor	B-Anatomy
vessels	I-Anatomy
are	O
distinct	O
from	O
their	O
normal	O
counterparts	O
morphologically	O
as	O
well	O
as	O
at	O
a	O
molecular	O
level	O
.	O
Recent	O
studies	O
on	O
factors	O
involved	O
in	O
tumor	B-Anatomy
vascular	I-Anatomy
development	O
have	O
identified	O
new	O
therapeutic	O
targets	O
for	O
inhibiting	O
tumor	B-Anatomy
neovascularization	O
and	O
thus	O
tumor	B-Anatomy
progression	O
.	O
However	O
,	O
the	O
process	O
of	O
tumor	B-Anatomy
blood	I-Anatomy
vessel	I-Anatomy
formation	O
is	O
complex	O
,	O
and	O
each	O
tumor	B-Anatomy
exhibits	O
unique	O
features	O
in	O
its	O
vasculature	B-Anatomy
.	O
An	O
understanding	O
of	O
the	O
relative	O
contribution	O
of	O
various	O
pathways	O
in	O
the	O
development	O
of	O
tumor	B-Anatomy
vasculature	I-Anatomy
is	O
critical	O
for	O
developing	O
effective	O
and	O
selective	O
therapeutic	O
approaches	O
.	O
Several	O
such	O
agents	O
are	O
currently	O
in	O
clinical	O
trials	O
,	O
and	O
many	O
others	O
are	O
under	O
development	O
.	O
In	O
this	O
review	O
,	O
the	O
mechanisms	O
and	O
factors	O
involved	O
in	O
tumor	B-Anatomy
blood	I-Anatomy
vessel	I-Anatomy
formation	O
are	O
discussed	O
.	O
In	O
addition	O
,	O
selected	O
novel	O
classes	O
of	O
antivascular	B-Anatomy
therapies	O
,	O
including	O
those	O
targeting	O
tumor	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
and	O
other	O
components	O
of	O
the	O
tumor	B-Anatomy
vasculature	I-Anatomy
,	O
are	O
summarized	O
.	O
Normal	O
and	O
transforming	O
functions	O
of	O
RUNX1	O
:	O
a	O
perspective	O
.	O
Converging	O
studies	O
from	O
many	O
investigators	O
indicate	O
that	O
RUNX1	O
has	O
a	O
critical	O
role	O
in	O
the	O
correct	O
maintenance	O
of	O
essential	O
cellular	B-Anatomy
functions	O
during	O
embryonic	B-Anatomy
development	O
and	O
after	O
birth	O
.	O
The	O
discovery	O
that	O
this	O
gene	O
is	O
also	O
frequently	O
mutated	O
in	O
human	O
leukemia	B-Anatomy
has	O
increased	O
the	O
interest	O
in	O
the	O
role	O
that	O
RUNX1	O
plays	O
in	O
both	O
normal	O
and	O
transforming	O
pathways	O
.	O
Here	O
,	O
we	O
provide	O
an	O
overview	O
of	O
the	O
many	O
roles	O
of	O
RUNX1	O
in	O
hematopoietic	B-Anatomy
self	O
-	O
renewal	O
and	O
differentiation	O
and	O
summarize	O
the	O
information	O
that	O
is	O
currently	O
available	O
on	O
the	O
many	O
mechanisms	O
of	O
RUNX1	O
deregulation	O
in	O
human	O
leukemia	B-Anatomy
.	O
Sensitivity	O
variation	O
in	O
two	O
-	O
center	O
holographic	O
recording	O
.	O
An	O
experimental	O
study	O
of	O
variation	O
of	O
sensitivity	O
with	O
recording	O
and	O
sensitizing	O
intensities	O
in	O
two	O
-	O
center	O
recording	O
is	O
presented	O
.	O
The	O
experimental	O
results	O
are	O
in	O
good	O
agreement	O
with	O
the	O
theoretical	O
predictions	O
.	O
It	O
is	O
shown	O
experimentally	O
,	O
for	O
what	O
is	O
to	O
our	O
knowledge	O
the	O
first	O
time	O
,	O
that	O
the	O
sensitivity	O
is	O
a	O
function	O
of	O
the	O
ratio	O
of	O
recording	O
to	O
sensitizing	O
intensities	O
and	O
not	O
the	O
absolute	O
intensities	O
.	O
Also	O
,	O
the	O
ratio	O
of	O
recording	O
to	O
sensitizing	O
intensities	O
should	O
be	O
small	O
to	O
obtain	O
high	O
sensitivity	O
values	O
.	O
We	O
also	O
report	O
the	O
highest	O
sensitivity	O
(	O
S	O
=	O
0	O
.	O
15	O
cm	O
/	O
J	O
)	O
that	O
has	O
been	O
achieved	O
to	O
date	O
for	O
a	O
LiNbO3	O
:	O
Fe	O
:	O
Mn	O
crystal	O
.	O
Domain	O
5	O
of	O
cleaved	O
high	O
molecular	O
weight	O
kininogen	O
inhibits	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
through	O
Akt	O
.	O
Domain	O
5	O
(	O
D5	O
)	O
of	O
cleaved	O
high	O
molecular	O
weight	O
kininogen	O
(	O
HKa	O
)	O
inhibits	O
angiogenesis	O
in	O
vivo	O
and	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
in	O
vitro	O
,	O
but	O
the	O
cell	B-Anatomy
signaling	O
pathways	O
involved	O
in	O
HKa	O
and	O
D5	O
inhibition	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
are	O
incompletely	O
delineated	O
.	O
This	O
study	O
examines	O
the	O
mechanism	O
of	O
HKa	O
and	O
D5	O
inhibition	O
of	O
two	O
potent	O
stimulators	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
,	O
sphingosine	O
1	O
-	O
phosphate	O
(	O
S1P	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
that	O
act	O
through	O
the	O
P13	O
-	O
kinase	O
-	O
Akt	O
signaling	O
pathway	O
.	O
HKa	O
and	O
D5	O
inhibit	O
bovine	O
pulmonary	B-Anatomy
artery	I-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
(	O
BPAE	B-Anatomy
)	O
or	O
human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
chemotaxis	O
in	O
the	O
modified	O
-	O
Boyden	O
chamber	O
in	O
response	O
toVEGF	O
or	O
S1P	O
.	O
The	O
inhibition	O
of	O
migration	O
by	O
HKa	O
is	O
reversed	O
by	O
antibodies	O
to	O
urokinase	O
-	O
type	O
plasminogen	O
activator	O
receptor	O
.	O
Both	O
HKa	O
and	O
D5	O
decrease	O
the	O
speed	O
of	O
BPAE	B-Anatomy
cell	I-Anatomy
migration	O
and	O
alter	O
the	O
morphology	O
in	O
live	O
,	O
time	O
-	O
lapse	O
microscopy	O
after	O
stimulation	O
with	O
S1P	O
or	O
VEGF	O
.	O
HKa	O
and	O
D5	O
reduce	O
the	O
localization	O
of	O
paxillin	O
to	O
the	O
focal	B-Anatomy
adhesions	I-Anatomy
after	O
S1P	O
and	O
VEGF	O
stimulation	O
.	O
To	O
better	O
understand	O
the	O
intracellular	B-Anatomy
signaling	O
pathways	O
,	O
we	O
examined	O
the	O
effect	O
of	O
HKa	O
on	O
the	O
phosphorylation	O
of	O
Akt	O
and	O
its	O
downstream	O
effector	O
,	O
GSK	O
-	O
3alpha	O
HKa	O
and	O
D5	O
inhibit	O
phosphorylation	O
of	O
Akt	O
and	O
GSK	O
-	O
3alpha	O
after	O
stimulation	O
withVEGF	O
and	O
S1P	O
.	O
Inhibitors	O
of	O
Akt	O
and	O
P13	O
-	O
kinase	O
,	O
the	O
upstream	O
activator	O
of	O
Akt	O
,	O
block	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
and	O
disrupt	O
paxillin	O
localization	O
to	O
the	O
focal	B-Anatomy
adhesions	I-Anatomy
after	O
stimulation	O
with	O
VEGF	O
and	O
S1P	O
.	O
Therefore	O
we	O
suggest	O
that	O
HKa	O
through	O
its	O
D5	O
domain	O
alters	O
P13	O
-	O
kinase	O
-	O
Akt	O
signaling	O
to	O
inhibit	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
through	O
alterations	O
in	O
the	O
focal	B-Anatomy
adhesions	I-Anatomy
.	O
Effect	O
of	O
thalidomide	O
affecting	O
VEGF	O
secretion	O
,	O
cell	B-Anatomy
migration	O
,	O
adhesion	O
and	O
capillary	B-Anatomy
tube	I-Anatomy
formation	O
of	O
human	O
endothelial	B-Anatomy
EA	I-Anatomy
.	I-Anatomy
hy	I-Anatomy
926	I-Anatomy
cells	I-Anatomy
.	O
Angiogenesis	O
,	O
new	O
blood	B-Anatomy
vessel	I-Anatomy
formation	O
,	O
is	O
a	O
multistep	O
process	O
,	O
precisely	O
regulated	O
by	O
pro	O
-	O
angiogenic	O
cytokines	O
,	O
which	O
stimulate	O
endothelial	B-Anatomy
cells	I-Anatomy
to	O
migrate	O
,	O
proliferate	O
and	O
differentiate	O
to	O
form	O
new	O
capillary	B-Anatomy
microvessels	I-Anatomy
.	O
Excessive	O
vascular	B-Anatomy
development	O
and	O
blood	B-Anatomy
vessel	I-Anatomy
remodeling	O
appears	O
in	O
psoriasis	O
,	O
rheumatoid	O
arthritis	O
,	O
diabetic	O
retinopathy	O
and	O
solid	B-Anatomy
tumors	I-Anatomy
formation	O
.	O
Thalidomide	O
[	O
alpha	O
-	O
(	O
N	O
-	O
phthalimido	O
)	O
-	O
glutarimide	O
]	O
is	O
known	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
angiogenesis	O
,	O
but	O
the	O
mechanism	O
of	O
its	O
inhibitory	O
action	O
remains	O
unclear	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
potential	O
influence	O
of	O
thalidomide	O
on	O
the	O
several	O
steps	O
of	O
angiogenesis	O
,	O
using	O
in	O
vitro	O
models	O
.	O
We	O
have	O
evaluated	O
the	O
effect	O
of	O
thalidomide	O
on	O
VEGF	O
secretion	O
,	O
cell	B-Anatomy
migration	O
,	O
adhesion	O
as	O
well	O
as	O
in	O
capillary	B-Anatomy
formation	O
of	O
human	O
endothelial	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
EA	I-Anatomy
.	I-Anatomy
hy	I-Anatomy
926	I-Anatomy
.	O
Thalidomide	O
at	O
the	O
concentrations	O
of	O
0	O
.	O
01	O
microM	O
and	O
10	O
microM	O
inhibited	O
VEGF	O
secretion	O
into	O
supernatants	B-Anatomy
,	O
decreased	O
the	O
number	O
of	O
formed	O
capillary	B-Anatomy
tubes	I-Anatomy
and	O
increased	O
cell	B-Anatomy
adhesion	O
to	O
collagen	O
.	O
Administration	O
of	O
thalidomide	O
at	O
the	O
concentration	O
of	O
0	O
.	O
01	O
microM	O
increased	O
cell	B-Anatomy
migration	O
,	O
while	O
at	O
10	O
microM	O
,	O
it	O
decreased	O
cell	B-Anatomy
migration	O
.	O
Thalidomide	O
in	O
concentrations	O
from	O
0	O
.	O
1	O
microM	O
to	O
10	O
microM	O
did	O
not	O
change	O
cell	B-Anatomy
proliferation	O
of	O
72	O
-	O
h	O
cell	B-Anatomy
cultures	I-Anatomy
.	O
We	O
conclude	O
that	O
anti	O
-	O
angiogenic	O
action	O
of	O
thalidomide	O
is	O
due	O
to	O
direct	O
inhibitory	O
action	O
on	O
VEGF	O
secretion	O
and	O
capillary	B-Anatomy
microvessel	I-Anatomy
formation	O
as	O
well	O
as	O
immunomodulatory	O
influence	O
on	O
EA	B-Anatomy
.	I-Anatomy
hy	I-Anatomy
926	I-Anatomy
cells	I-Anatomy
migration	O
and	O
adhesion	O
.	O
Regulation	O
of	O
skin	B-Anatomy
microvasculature	I-Anatomy
angiogenesis	O
,	O
cell	B-Anatomy
migration	O
,	O
and	O
permeability	O
by	O
a	O
specific	O
inhibitor	O
of	O
PKCalpha	O
.	O
Activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
induces	O
phenotypic	O
changes	O
in	O
the	O
morphology	O
of	O
microvascular	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
that	O
affect	O
major	O
functions	O
of	O
the	O
microvasculature	B-Anatomy
.	O
These	O
functions	O
include	O
the	O
first	O
stages	O
of	O
sprouting	O
in	O
angiogenesis	O
,	O
cell	B-Anatomy
migration	O
following	O
wounding	O
,	O
and	O
vascular	B-Anatomy
permeability	O
.	O
The	O
specific	O
isoform	O
(	O
s	O
)	O
of	O
PKC	O
responsible	O
for	O
each	O
of	O
these	O
changes	O
has	O
not	O
been	O
previously	O
identified	O
.	O
In	O
this	O
study	O
,	O
we	O
used	O
two	O
inflammatory	O
agents	O
,	O
IL	O
-	O
1beta	O
and	O
phorbol	O
myristic	O
acetate	O
,	O
to	O
activate	O
PKC	O
isozymes	O
and	O
specific	O
inhibitors	O
of	O
PKCalpha	O
(	O
Go6976	O
)	O
and	O
PKCbeta	O
(	O
hispidin	O
)	O
to	O
distinguish	O
how	O
each	O
of	O
these	O
isoform	O
(	O
s	O
)	O
controls	O
angiogenesis	O
,	O
wound	B-Anatomy
healing	O
,	O
and	O
permeability	O
.	O
In	O
all	O
cases	O
,	O
only	O
inhibition	O
of	O
PKCalpha	O
inhibited	O
each	O
of	O
these	O
functions	O
when	O
compared	O
to	O
the	O
inhibition	O
of	O
PKCbeta	O
.	O
Additional	O
analysis	O
of	O
the	O
mechanism	O
of	O
action	O
of	O
Go6976	O
(	O
RT	O
-	O
PCR	O
,	O
Western	O
blots	O
,	O
and	O
immunohistochemistry	O
)	O
of	O
the	O
changes	O
in	O
the	O
phosphorylated	O
and	O
nonphosphorylated	O
forms	O
of	O
PKCalpha	O
in	O
the	O
cell	B-Anatomy
membrane	I-Anatomy
and	O
cytoplasm	B-Anatomy
confirmed	O
the	O
specificity	O
of	O
PKCalpha	O
inhibition	O
by	O
Go6976	O
.	O
These	O
studies	O
therefore	O
indicate	O
a	O
specific	O
and	O
a	O
regulatory	O
role	O
of	O
the	O
PKCalpha	O
isoform	O
in	O
three	O
major	O
endothelial	B-Anatomy
cell	I-Anatomy
functions	O
that	O
are	O
important	O
in	O
the	O
maintenance	O
of	O
microvascular	B-Anatomy
homeostasis	O
.	O
Recent	O
advances	O
in	O
minisatellite	O
biology	O
.	O
Highly	O
polymorphic	O
tandemly	O
repeated	O
'	O
minisatellite	O
'	O
loci	O
are	O
very	O
abundant	O
in	O
the	O
human	O
genome	O
,	O
and	O
of	O
considerable	O
utility	O
in	O
human	O
genetic	O
analysis	O
.	O
This	O
review	O
describes	O
the	O
use	O
of	O
an	O
ordered	O
-	O
array	O
Charomid	O
library	O
in	O
the	O
systematic	O
and	O
efficient	O
cloning	O
of	O
these	O
regions	O
,	O
and	O
in	O
the	O
analysis	O
of	O
the	O
relative	O
overlap	O
between	O
the	O
different	O
probes	O
used	O
to	O
screen	O
for	O
hypervariable	O
loci	O
.	O
Recent	O
work	O
on	O
the	O
process	O
of	O
mutation	O
leading	O
to	O
the	O
generation	O
of	O
new	O
-	O
length	O
alleles	O
is	O
also	O
discussed	O
,	O
including	O
the	O
observation	O
that	O
at	O
least	O
some	O
mutations	O
may	O
be	O
due	O
to	O
unequal	O
exchanges	O
.	O
The	O
differential	O
regulation	O
of	O
human	O
telomerase	O
reverse	O
transcriptase	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
may	O
contribute	O
to	O
the	O
clinically	O
more	O
aggressive	O
behavior	O
of	O
p63	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
breast	I-Anatomy
carcinomas	I-Anatomy
.	O
p63	O
,	O
a	O
p53	O
homologue	O
,	O
is	O
a	O
myoepithelial	B-Anatomy
cell	I-Anatomy
marker	O
in	O
the	O
normal	O
mammary	B-Anatomy
gland	I-Anatomy
but	O
p63	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
neoplastic	I-Anatomy
cells	I-Anatomy
may	O
be	O
found	O
in	O
up	O
to	O
11	O
%	O
of	O
invasive	B-Anatomy
breast	I-Anatomy
carcinomas	I-Anatomy
.	O
This	O
study	O
aims	O
to	O
verify	O
the	O
relationship	O
between	O
p63	O
expression	O
and	O
several	O
clinicopathological	O
features	O
and	O
tumor	B-Anatomy
markers	O
of	O
clinical	O
significance	O
in	O
breast	B-Anatomy
pathology	I-Anatomy
including	O
key	O
regulators	O
of	O
the	O
cell	B-Anatomy
cycle	O
,	O
oncogenes	O
,	O
apoptosis	O
-	O
related	O
proteins	O
,	O
metalloproteinases	O
and	O
their	O
inhibitors	O
.	O
Immunohistochemistry	O
with	O
27	O
primary	O
antibodies	O
was	O
performed	O
in	O
100	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
samples	B-Anatomy
of	O
invasive	B-Anatomy
ductal	I-Anatomy
carcinomas	I-Anatomy
.	O
p63	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
cells	I-Anatomy
were	O
found	O
in	O
16	O
%	O
of	O
carcinomas	B-Anatomy
.	O
p63	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
carcinomas	I-Anatomy
were	O
poorly	O
differentiated	O
,	O
hormone	O
receptor	O
-	O
negative	O
neoplasms	B-Anatomy
with	O
a	O
high	O
proliferation	O
rate	O
.	O
p63	O
also	O
correlated	O
with	O
advanced	O
pathological	O
stage	O
,	O
tumor	B-Anatomy
size	O
,	O
and	O
the	O
expression	O
of	O
human	O
telomerase	O
reverse	O
transcriptase	O
(	O
hTERT	O
)	O
,	O
tissue	O
inhibitor	O
of	O
matrix	O
metalloproteinase	O
1	O
(	O
TIMP1	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O
The	O
expression	O
of	O
TIMP1	O
suggests	O
that	O
the	O
anti	O
-	O
proteolytic	O
stimuli	O
may	O
be	O
preponderant	O
in	O
p63	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
carcinomas	I-Anatomy
.	O
hTERT	O
activity	O
is	O
associated	O
with	O
nodal	B-Anatomy
metastases	I-Anatomy
and	O
cellular	B-Anatomy
proliferation	O
.	O
VEGF	O
regulates	O
angiogenesis	O
,	O
which	O
is	O
also	O
a	O
fundamental	O
event	O
in	O
the	O
process	O
of	O
tumor	B-Anatomy
growth	O
and	O
metastatic	O
dissemination	O
.	O
Thus	O
,	O
the	O
differential	O
regulation	O
of	O
hTERT	O
and	O
VEGF	O
in	O
p63	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
breast	I-Anatomy
carcinomas	I-Anatomy
may	O
contribute	O
to	O
the	O
clinically	O
more	O
aggressive	O
behavior	O
of	O
these	O
neoplasms	B-Anatomy
.	O
Regulation	O
of	O
tumor	B-Anatomy
angiogenesis	O
by	O
thrombospondin	O
-	O
1	O
.	O
Angiogenesis	O
plays	O
a	O
critical	O
role	O
in	O
the	O
growth	O
and	O
metastasis	O
of	O
tumors	B-Anatomy
.	O
Thrombospondin	O
-	O
1	O
(	O
TSP	O
-	O
1	O
)	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
,	O
and	O
down	O
-	O
regulation	O
of	O
TSP	O
-	O
1	O
has	O
been	O
suggested	O
to	O
alter	O
tumor	B-Anatomy
growth	O
by	O
modulating	O
angiogenesis	O
in	O
a	O
variety	O
of	O
tumor	B-Anatomy
types	O
.	O
Expression	O
of	O
TSP	O
-	O
1	O
is	O
up	O
-	O
regulated	O
by	O
the	O
tumor	B-Anatomy
suppressor	O
gene	O
,	O
p53	O
,	O
and	O
down	O
-	O
regulated	O
by	O
oncogenes	O
such	O
as	O
Myc	O
and	O
Ras	O
.	O
TSP	O
-	O
1	O
inhibits	O
angiogenesis	O
by	O
inhibiting	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
and	O
proliferation	O
and	O
by	O
inducing	O
apoptosis	O
.	O
In	O
addition	O
,	O
activation	O
of	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
by	O
TSP	O
-	O
1	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
tumor	B-Anatomy
progression	O
.	O
An	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
TSP	O
-	O
1	O
-	O
mediated	O
inhibition	O
of	O
angiogenesis	O
and	O
tumor	B-Anatomy
progression	O
will	O
aid	O
in	O
the	O
development	O
of	O
novel	O
therapeutics	O
for	O
the	O
treatment	O
of	O
cancer	B-Anatomy
.	O
Regulation	O
of	O
the	O
composition	O
of	O
the	O
extracellular	B-Anatomy
matrix	I-Anatomy
by	O
low	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
-	O
1	O
:	O
activities	O
based	O
on	O
regulation	O
of	O
mRNA	O
expression	O
.	O
Low	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
-	O
1	O
(	O
LRP	O
-	O
1	O
)	O
is	O
a	O
catabolic	O
receptor	O
for	O
extracellular	B-Anatomy
matrix	I-Anatomy
(	O
ECM	B-Anatomy
)	O
structural	O
proteins	O
and	O
for	O
proteins	O
that	O
bind	O
to	O
ECM	B-Anatomy
.	O
LRP	O
-	O
1	O
also	O
is	O
implicated	O
in	O
integrin	O
maturation	O
.	O
In	O
this	O
study	O
,	O
we	O
applied	O
a	O
proteomics	O
strategy	O
to	O
identify	O
novel	O
proteins	O
involved	O
in	O
ECM	B-Anatomy
modeling	O
that	O
are	O
regulated	O
by	O
LRP	O
-	O
1	O
.	O
We	O
show	O
that	O
LRP	O
-	O
1	O
deficiency	O
in	O
murine	O
embryonic	B-Anatomy
fibroblasts	I-Anatomy
(	O
MEFs	B-Anatomy
)	O
is	O
associated	O
with	O
increased	O
levels	O
of	O
type	O
III	O
collagen	O
and	O
pigment	O
epithelium	O
-	O
derived	O
factor	O
,	O
which	O
accumulate	O
in	O
the	O
substratum	B-Anatomy
surrounding	O
cells	B-Anatomy
.	O
The	O
collagen	O
receptor	O
,	O
uPAR	O
-	O
AP	O
/	O
Endo	O
-	O
180	O
,	O
is	O
also	O
increased	O
in	O
LRP	O
-	O
1	O
-	O
deficient	O
MEFs	B-Anatomy
.	O
Human	O
LRP	O
-	O
1	O
reversed	O
the	O
changes	O
in	O
protein	O
expression	O
associated	O
with	O
LRP	O
-	O
1	O
deficiency	O
;	O
however	O
,	O
the	O
endocytic	O
activity	O
of	O
LRP	O
-	O
1	O
was	O
not	O
involved	O
.	O
Instead	O
,	O
regulation	O
occurred	O
at	O
the	O
mRNA	O
level	O
.	O
Inhibition	O
of	O
c	O
-	O
Jun	O
amino	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
blocked	O
type	O
III	O
collagen	O
expression	O
in	O
LRP	O
-	O
1	O
-	O
deficient	O
MEFs	B-Anatomy
,	O
suggesting	O
regulation	O
of	O
JNK	O
activity	O
as	O
a	O
mechanism	O
by	O
which	O
LRP	O
-	O
1	O
controls	O
mRNA	O
expression	O
.	O
The	O
ability	O
of	O
LRP	O
-	O
1	O
to	O
regulate	O
expression	O
of	O
the	O
factors	O
identified	O
here	O
suggests	O
a	O
role	O
for	O
LRP	O
-	O
1	O
in	O
determining	O
blood	B-Anatomy
vessel	I-Anatomy
structure	O
and	O
in	O
angiogenesis	O
.	O
L	O
-	O
Carnitine	O
ameliorates	O
methotrexate	O
-	O
induced	O
oxidative	O
organ	B-Anatomy
injury	O
and	O
inhibits	O
leukocyte	B-Anatomy
death	O
.	O
Methotrexate	O
(	O
MTX	O
)	O
,	O
a	O
folic	O
acid	O
antagonist	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
tumors	B-Anatomy
and	O
inflammatory	O
diseases	O
,	O
affects	O
normal	O
tissues	B-Anatomy
that	O
have	O
a	O
high	O
rate	O
of	O
proliferation	O
,	O
including	O
the	O
hematopoietic	B-Anatomy
cells	I-Anatomy
of	O
the	O
bone	B-Anatomy
marrow	I-Anatomy
and	O
the	O
gastrointestinal	B-Anatomy
mucosal	I-Anatomy
cells	I-Anatomy
.	O
To	O
elucidate	O
the	O
role	O
of	O
free	O
radicals	O
and	O
leukocytes	B-Anatomy
in	O
MTX	O
-	O
induced	O
oxidative	O
organ	B-Anatomy
damage	O
and	O
the	O
putative	O
protective	O
effect	O
of	O
L	O
-	O
carnitine	O
(	O
L	O
-	O
Car	O
)	O
,	O
Wistar	O
albino	O
rats	O
were	O
administered	O
a	O
single	O
dose	O
of	O
MTX	O
(	O
20	O
mg	O
/	O
kg	O
)	O
followed	O
by	O
either	O
saline	O
or	O
L	O
-	O
Car	O
(	O
500	O
mg	O
/	O
kg	O
)	O
for	O
5	O
days	O
.	O
After	O
decapitation	O
of	O
the	O
rats	O
,	O
trunk	B-Anatomy
blood	I-Anatomy
was	O
obtained	O
,	O
and	O
the	O
ileum	B-Anatomy
,	O
liver	B-Anatomy
,	O
and	O
kidney	B-Anatomy
were	O
removed	O
for	O
histological	O
examination	O
and	O
for	O
the	O
measurement	O
of	O
malondialdehyde	O
(	O
MDA	O
)	O
and	O
glutathione	O
(	O
GSH	O
)	O
levels	O
,	O
myeloperoxidase	O
(	O
MPO	O
)	O
activity	O
,	O
and	O
collagen	O
content	O
.	O
Our	O
results	O
showed	O
that	O
MTX	O
administration	O
increased	O
the	O
MDA	O
and	O
MPO	O
activities	O
and	O
collagen	O
content	O
and	O
decreased	O
GSH	O
levels	O
in	O
all	O
tissues	B-Anatomy
,	O
while	O
these	O
alterations	O
were	O
reversed	O
in	O
L	O
-	O
Car	O
-	O
treated	O
group	O
.	O
The	O
elevated	O
serum	B-Anatomy
TNF	O
-	O
alpha	O
level	O
observed	O
following	O
MTX	O
treatment	O
was	O
depressed	O
with	O
L	O
-	O
Car	O
.	O
The	O
oxidative	O
burst	O
of	O
neutrophils	B-Anatomy
stimulated	O
by	O
Annexin	O
V	O
was	O
reduced	O
in	O
the	O
saline	O
-	O
treated	O
MTX	O
group	O
,	O
while	O
L	O
-	O
Car	O
abolished	O
this	O
inhibition	O
.	O
Similarly	O
,	O
flow	O
cytometric	O
measurements	O
revealed	O
that	O
leukocyte	B-Anatomy
apoptosis	O
was	O
increased	O
in	O
MTX	O
-	O
treated	O
animals	O
,	O
while	O
L	O
-	O
Car	O
reversed	O
these	O
effects	O
.	O
Severe	O
degeneration	O
of	O
the	O
intestinal	B-Anatomy
mucosa	I-Anatomy
,	O
liver	B-Anatomy
parenchyma	I-Anatomy
,	O
and	O
glomerular	B-Anatomy
and	O
tubular	B-Anatomy
epithelium	I-Anatomy
observed	O
in	O
the	O
saline	O
-	O
treated	O
MTX	O
group	O
was	O
improved	O
by	O
L	O
-	O
Car	O
treatment	O
.	O
These	O
results	O
suggest	O
that	O
L	O
-	O
Car	O
,	O
possibly	O
via	O
its	O
free	O
radical	O
scavenging	O
and	O
antioxidant	O
properties	O
,	O
ameliorates	O
MTX	O
-	O
induced	O
oxidative	O
organ	B-Anatomy
injury	O
and	O
inhibits	O
leukocyte	B-Anatomy
apoptosis	O
.	O
Thus	O
,	O
supplementation	O
with	O
L	O
-	O
Carnitine	O
as	O
an	O
adjuvant	O
therapy	O
may	O
be	O
promising	O
in	O
alleviating	O
the	O
systemic	O
side	O
-	O
effects	O
of	O
chemotherapeutics	O
.	O
Pericytes	B-Anatomy
limit	O
tumor	B-Anatomy
cell	I-Anatomy
metastasis	O
.	O
Previously	O
we	O
observed	O
that	O
neural	O
cell	O
adhesion	O
molecule	O
(	O
NCAM	O
)	O
deficiency	O
in	O
beta	B-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
facilitates	O
metastasis	O
into	O
distant	O
organs	B-Anatomy
and	O
local	O
lymph	B-Anatomy
nodes	I-Anatomy
.	O
Here	O
,	O
we	O
show	O
that	O
NCAM	B-Anatomy
-	I-Anatomy
deficient	I-Anatomy
beta	I-Anatomy
cell	I-Anatomy
tumors	I-Anatomy
grew	O
leaky	O
blood	B-Anatomy
vessels	I-Anatomy
with	O
perturbed	O
pericyte	B-Anatomy
-	O
endothelial	B-Anatomy
cell	B-Anatomy
-	O
cell	B-Anatomy
interactions	O
and	O
deficient	O
perivascular	B-Anatomy
deposition	O
of	O
ECM	B-Anatomy
components	I-Anatomy
.	O
Conversely	O
,	O
tumor	B-Anatomy
cell	I-Anatomy
expression	O
of	O
NCAM	O
in	O
a	O
fibrosarcoma	B-Anatomy
model	O
(	O
T241	B-Anatomy
)	O
improved	O
pericyte	B-Anatomy
recruitment	O
and	O
increased	O
perivascular	B-Anatomy
deposition	O
of	O
ECM	B-Anatomy
molecules	I-Anatomy
.	O
Together	O
,	O
these	O
findings	O
suggest	O
that	O
NCAM	O
may	O
limit	O
tumor	B-Anatomy
cell	I-Anatomy
metastasis	O
by	O
stabilizing	O
the	O
microvessel	B-Anatomy
wall	I-Anatomy
.	O
To	O
directly	O
address	O
whether	O
pericyte	B-Anatomy
dysfunction	O
increases	O
the	O
metastatic	O
potential	O
of	O
solid	B-Anatomy
tumors	I-Anatomy
,	O
we	O
studied	O
beta	B-Anatomy
cell	I-Anatomy
tumorigenesis	O
in	O
primary	O
pericyte	B-Anatomy
-	O
deficient	O
Pdgfb	O
(	O
ret	O
/	O
ret	O
)	O
mice	O
.	O
This	O
resulted	O
in	O
beta	B-Anatomy
tumor	I-Anatomy
cell	I-Anatomy
metastases	I-Anatomy
in	O
distant	O
organs	B-Anatomy
and	O
local	O
lymph	B-Anatomy
nodes	I-Anatomy
,	O
demonstrating	O
a	O
role	O
for	O
pericytes	B-Anatomy
in	O
limiting	O
tumor	B-Anatomy
cell	I-Anatomy
metastasis	O
.	O
These	O
data	O
support	O
a	O
new	O
model	O
for	O
how	O
tumor	B-Anatomy
cells	I-Anatomy
trigger	O
metastasis	O
by	O
perturbing	O
pericyte	B-Anatomy
-	O
endothelial	B-Anatomy
cell	B-Anatomy
-	O
cell	B-Anatomy
interactions	O
.	O
NF	O
-	O
kappaB	O
and	O
IKK	O
as	O
therapeutic	O
targets	O
in	O
cancer	B-Anatomy
.	O
The	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
and	O
associated	O
regulatory	O
factors	O
(	O
including	O
IkappaB	O
kinase	O
subunits	O
and	O
the	O
IkappaB	O
family	O
member	O
Bcl	O
-	O
3	O
)	O
are	O
strongly	O
implicated	O
in	O
a	O
variety	O
of	O
hematologic	B-Anatomy
and	O
solid	B-Anatomy
tumor	I-Anatomy
malignancies	I-Anatomy
.	O
A	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
appears	O
to	O
involve	O
regulation	O
of	O
cell	B-Anatomy
proliferation	O
,	O
control	O
of	O
apoptosis	O
,	O
promotion	O
of	O
angiogenesis	O
,	O
and	O
stimulation	O
of	O
invasion	O
/	O
metastasis	O
.	O
Consistent	O
with	O
a	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
oncogenesis	O
are	O
observations	O
that	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
alone	O
or	O
in	O
combination	O
with	O
cancer	B-Anatomy
therapies	O
leads	O
to	O
tumor	B-Anatomy
cell	I-Anatomy
death	O
or	O
growth	O
inhibition	O
.	O
However	O
,	O
other	O
experimental	O
data	O
indicate	O
that	O
NF	O
-	O
kappaB	O
can	O
play	O
a	O
tumor	B-Anatomy
suppressor	O
role	O
in	O
certain	O
settings	O
and	O
that	O
it	O
can	O
be	O
important	O
in	O
promoting	O
an	O
apoptotic	O
signal	O
downstream	O
of	O
certain	O
cancer	B-Anatomy
therapy	O
regimens	O
.	O
In	O
order	O
to	O
appropriately	O
move	O
NF	O
-	O
kappaB	O
inhibitors	O
in	O
the	O
clinic	O
,	O
thorough	O
approaches	O
must	O
be	O
initiated	O
to	O
determine	O
the	O
molecular	O
mechanisms	O
that	O
dictate	O
the	O
complexity	O
of	O
oncologic	O
and	O
therapeutic	O
outcomes	O
that	O
are	O
controlled	O
by	O
NF	O
-	O
kappaB	O
.	O
Runx2	O
and	O
MYC	O
collaborate	O
in	O
lymphoma	B-Anatomy
development	O
by	O
suppressing	O
apoptotic	O
and	O
growth	O
arrest	O
pathways	O
in	O
vivo	O
.	O
Members	O
of	O
the	O
Runx	O
and	O
MYC	O
families	O
have	O
been	O
implicated	O
as	O
collaborating	O
oncogenes	O
.	O
The	O
mechanism	O
of	O
this	O
potent	O
collaboration	O
is	O
elucidated	O
in	O
this	O
study	O
of	O
Runx2	O
/	O
MYC	O
mice	O
.	O
As	O
shown	O
previously	O
,	O
ectopic	O
expression	O
of	O
Runx2	O
in	O
the	O
thymus	B-Anatomy
leads	O
to	O
a	O
preneoplastic	B-Anatomy
state	O
defined	O
by	O
an	O
accumulation	O
of	O
cells	B-Anatomy
with	O
an	O
immature	O
phenotype	O
and	O
a	O
low	O
proliferative	O
rate	O
.	O
We	O
now	O
show	O
that	O
c	O
-	O
MYC	O
overexpression	O
is	O
sufficient	O
to	O
rescue	O
proliferation	O
and	O
to	O
release	O
the	O
differentiation	O
block	O
imposed	O
by	O
Runx2	O
.	O
Analysis	O
of	O
Runx2	O
-	O
expressing	O
lymphomas	B-Anatomy
reveals	O
a	O
consistently	O
low	O
rate	O
of	O
apoptosis	O
,	O
in	O
contrast	O
to	O
lymphomas	B-Anatomy
of	O
MYC	O
mice	O
which	O
are	O
often	O
highly	O
apoptotic	O
.	O
The	O
low	O
apoptosis	O
phenotype	O
is	O
dominant	O
in	O
Runx2	B-Anatomy
/	I-Anatomy
MYC	I-Anatomy
tumors	I-Anatomy
,	O
indicating	O
that	O
Runx2	O
confers	O
a	O
potent	O
survival	O
advantage	O
to	O
MYC	O
-	O
expressing	O
tumor	B-Anatomy
cells	I-Anatomy
.	O
The	O
role	O
of	O
the	O
p53	O
pathway	O
in	O
Runx2	B-Anatomy
/	I-Anatomy
MYC	I-Anatomy
tumors	I-Anatomy
was	O
explored	O
on	O
a	O
p53	B-Anatomy
heterozygote	I-Anatomy
background	O
.	O
Surprisingly	O
,	O
functional	O
p53	O
was	O
retained	O
in	O
vivo	O
,	O
even	O
after	O
transplantation	O
,	O
whereas	O
explanted	O
tumor	B-Anatomy
cells	I-Anatomy
displayed	O
rapid	O
allele	O
loss	O
in	O
vitro	O
.	O
Our	O
results	O
show	O
that	O
Runx2	O
and	O
MYC	O
overcome	O
distinct	O
""""	O
fail	O
-	O
safe	O
""""	O
responses	O
and	O
that	O
their	O
selection	O
as	O
collaborating	O
genes	O
is	O
due	O
to	O
their	O
ability	O
to	O
neutralize	O
each	O
other	O
'	O
s	O
negative	O
growth	O
effect	O
.	O
Furthermore	O
,	O
the	O
Runx2	O
/	O
MYC	O
combination	O
overcomes	O
the	O
requirement	O
for	O
genetic	O
inactivation	O
of	O
the	O
p53	O
pathway	O
in	O
vivo	O
.	O
Inhibition	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
by	O
rapamycin	O
increases	O
chemosensitivity	O
of	O
CaSki	B-Anatomy
cells	I-Anatomy
to	O
paclitaxel	O
.	O
Paclitaxel	O
,	O
a	O
potent	O
anti	O
-	O
neoplastic	B-Anatomy
agent	O
,	O
has	O
been	O
found	O
to	O
be	O
effective	O
against	O
several	O
tumours	B-Anatomy
,	O
including	O
cervical	B-Anatomy
cancer	I-Anatomy
.	O
However	O
,	O
the	O
exact	O
mechanism	O
underlying	O
the	O
cytotoxic	O
effects	O
of	O
pacitaxel	O
,	O
especially	O
in	O
the	O
survival	O
-	O
signalling	O
pathway	O
,	O
is	O
poorly	O
understood	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
molecular	O
pathway	O
of	O
the	O
cytotoxic	O
effect	O
of	O
paclitaxel	O
in	O
human	O
cervical	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
Four	O
human	O
cervical	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
were	O
treated	O
for	O
24	O
h	O
with	O
various	O
concentration	O
of	O
paclitaxel	O
,	O
and	O
the	O
sensitivity	O
was	O
analysed	O
by	O
an	O
MTT	O
assay	O
.	O
The	O
cell	B-Anatomy
cycle	O
progression	O
and	O
sub	O
-	O
G1	O
population	O
were	O
analysed	O
by	O
flow	O
cytometry	O
.	O
Apoptosis	O
was	O
further	O
measured	O
by	O
DNA	O
fragmentation	O
and	O
microscope	O
examination	O
.	O
The	O
protein	O
expression	O
was	O
determined	O
by	O
Western	O
blot	O
analysis	O
.	O
Our	O
results	O
showed	O
that	O
HeLa	B-Anatomy
cells	I-Anatomy
demonstrated	O
the	O
highest	O
sensitivity	O
to	O
paclitaxel	O
,	O
whereas	O
CaSki	B-Anatomy
cells	I-Anatomy
showed	O
the	O
lowest	O
.	O
In	O
cervical	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
,	O
paclitaxel	O
induced	O
apoptosis	O
through	O
an	O
intrinsic	O
pathway	O
with	O
prior	O
G2	O
/	O
M	O
arrest	O
.	O
In	O
addition	O
,	O
we	O
showed	O
that	O
paclitaxel	O
downregulated	O
the	O
phosphorylation	O
of	O
Akt	O
in	O
both	O
HeLa	B-Anatomy
and	O
CaSki	B-Anatomy
cells	I-Anatomy
.	O
Interestingly	O
,	O
in	O
CaSki	B-Anatomy
cells	I-Anatomy
,	O
which	O
were	O
more	O
suggestive	O
of	O
a	O
resistant	O
phenotype	O
,	O
paclitaxel	O
induced	O
the	O
activation	O
of	O
mTOR	O
as	O
a	O
downstream	O
target	O
of	O
Akt	O
.	O
Pre	O
-	O
treatment	O
with	O
rapamycin	O
inhibited	O
activation	O
of	O
mTOR	O
signalling	O
and	O
significantly	O
enhanced	O
the	O
sensitivity	O
of	O
CaSki	B-Anatomy
cells	I-Anatomy
to	O
paclitaxel	O
by	O
increasing	O
apoptotic	O
cell	B-Anatomy
death	O
.	O
This	O
effect	O
was	O
mediated	O
,	O
at	O
least	O
partly	O
,	O
through	O
caspase	O
activation	O
.	O
Overall	O
,	O
paclitaxel	O
exerts	O
its	O
anti	O
-	O
tumour	B-Anatomy
effects	O
on	O
cervical	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
by	O
inducing	O
apoptosis	O
through	O
intrinsic	O
pathway	O
,	O
and	O
rapamycin	O
targeted	O
to	O
mTOR	O
can	O
sensitise	O
paclitaxel	O
-	O
resistant	O
cervical	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Circulating	O
endothelial	B-Anatomy
cells	I-Anatomy
in	O
malignant	B-Anatomy
disease	I-Anatomy
.	O
Cancer	B-Anatomy
is	O
a	O
disease	O
largely	O
dependent	O
on	O
neoangiogenesis	O
.	O
Cancer	B-Anatomy
neoangiogenesis	O
is	O
often	O
disordered	O
and	O
abnormal	O
,	O
with	O
evidence	O
of	O
coexisting	O
vascular	B-Anatomy
endothelial	I-Anatomy
dysfunction	O
.	O
A	O
novel	O
method	O
of	O
assessing	O
vascular	B-Anatomy
endothelial	I-Anatomy
function	O
in	O
cancer	B-Anatomy
is	O
via	O
the	O
quantification	O
of	O
circulating	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
(	O
CEC	B-Anatomy
)	O
.	O
Unusual	O
in	O
healthy	O
individuals	O
,	O
their	O
presence	O
in	O
elevated	O
numbers	O
often	O
indicates	O
substantial	O
vascular	B-Anatomy
endothelial	I-Anatomy
perturbation	O
.	O
Another	O
interesting	O
cell	B-Anatomy
type	O
is	O
the	O
endothelial	B-Anatomy
progenitor	I-Anatomy
cell	I-Anatomy
(	O
EPC	B-Anatomy
)	O
,	O
whose	O
numbers	O
increase	O
in	O
the	O
presence	O
of	O
vascular	B-Anatomy
damage	O
.	O
Recent	O
research	O
suggests	O
that	O
EPCs	B-Anatomy
have	O
an	O
important	O
role	O
in	O
tumor	B-Anatomy
vasculogenesis	O
.	O
Another	O
marker	O
being	O
investigated	O
in	O
the	O
context	O
of	O
vascular	B-Anatomy
dysfunction	O
and	O
coagulopathy	O
is	O
the	O
endothelial	B-Anatomy
microparticle	I-Anatomy
(	O
EMP	B-Anatomy
)	O
.	O
Thus	O
,	O
CECs	B-Anatomy
,	O
EPCs	B-Anatomy
and	O
EMPs	B-Anatomy
may	O
represent	O
potentially	O
novel	O
methods	O
for	O
evaluating	O
the	O
vascular	B-Anatomy
status	O
of	O
cancer	B-Anatomy
patients	O
.	O
This	O
review	O
will	O
summarize	O
the	O
current	O
position	O
of	O
CECs	B-Anatomy
,	O
EPCs	B-Anatomy
and	O
EMPs	B-Anatomy
in	O
cell	B-Anatomy
biology	O
terms	O
,	O
with	O
particular	O
emphasis	O
on	O
their	O
relationship	O
to	O
malignant	B-Anatomy
disease	I-Anatomy
.	O
The	O
ictal	O
bradycardia	O
syndrome	O
:	O
localization	O
and	O
lateralization	O
.	O
PURPOSE	O
:	O
Previous	O
studies	O
have	O
established	O
the	O
importance	O
of	O
the	O
insular	B-Anatomy
cortex	I-Anatomy
and	O
temporal	B-Anatomy
lobe	I-Anatomy
in	O
cardiovascular	B-Anatomy
autonomic	O
modulation	O
.	O
Some	O
investigators	O
,	O
based	O
on	O
the	O
results	O
of	O
cortical	B-Anatomy
stimulation	O
response	O
,	O
functional	O
imaging	O
,	O
EEG	O
recordings	O
of	O
seizures	O
,	O
and	O
lesional	O
studies	O
,	O
have	O
suggested	O
that	O
cardiac	B-Anatomy
sympathetic	O
and	O
parasympathetic	O
function	O
may	O
be	O
lateralized	O
,	O
with	O
sympathetic	O
representation	O
lateralized	O
to	O
the	O
right	B-Anatomy
insula	I-Anatomy
,	O
and	O
parasympathetic	O
,	O
to	O
the	O
left	B-Anatomy
.	O
These	O
studies	O
have	O
suggested	O
that	O
ictal	O
bradycardia	O
is	O
most	O
commonly	O
a	O
manifestation	O
of	O
activation	O
of	O
the	O
left	B-Anatomy
temporal	I-Anatomy
and	O
insular	B-Anatomy
cortex	I-Anatomy
.	O
However	O
,	O
the	O
evidence	O
for	O
this	O
is	O
inconsistent	O
.	O
We	O
sought	O
to	O
assess	O
critically	O
the	O
predictable	O
value	O
of	O
ictal	O
bradycardia	O
for	O
seizure	O
localization	O
and	O
lateralization	O
.	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
reviewed	O
the	O
localization	O
of	O
seizure	O
activity	O
in	O
13	O
consecutive	O
patients	O
with	O
ictal	O
bradycardia	O
diagnosed	O
during	O
prolonged	O
video	O
-	O
EEG	O
monitoring	O
at	O
Mayo	O
Clinic	O
Rochester	O
.	O
The	O
localization	O
of	O
electrographic	O
seizure	O
activity	O
at	O
seizure	O
onset	O
and	O
bradycardia	O
onset	O
was	O
identified	O
in	O
all	O
patients	O
.	O
In	O
addition	O
,	O
we	O
performed	O
a	O
comprehensive	O
review	O
of	O
the	O
ictal	O
bradycardia	O
literature	O
focusing	O
on	O
localization	O
of	O
seizure	O
activity	O
in	O
ictal	O
bradycardia	O
cases	O
.	O
RESULTS	O
:	O
All	O
occurrences	O
of	O
ictal	O
bradycardia	O
in	O
the	O
13	O
identified	O
patients	O
were	O
associated	O
with	O
temporal	O
lobe	O
-	O
onset	O
seizures	O
.	O
However	O
,	O
no	O
consistent	O
lateralization	O
of	O
seizure	O
activity	O
was	O
found	O
at	O
onset	O
of	O
seizure	O
activity	O
or	O
at	O
onset	O
of	O
bradycardia	O
in	O
this	O
population	O
.	O
Seizure	O
activity	O
was	O
bilateral	O
at	O
bradycardia	O
onset	O
in	O
nine	O
of	O
13	O
patients	O
.	O
The	O
results	O
from	O
the	O
literature	O
review	O
also	O
showed	O
that	O
a	O
predominance	O
of	O
patients	O
had	O
bilateral	O
activity	O
at	O
bradycardia	O
onset	O
;	O
however	O
,	O
more	O
of	O
the	O
ictal	O
bradycardia	O
cases	O
from	O
the	O
literature	O
had	O
left	B-Anatomy
hemispheric	I-Anatomy
localization	O
of	O
seizure	O
onset	O
.	O
CONCLUSIONS	O
:	O
Ictal	O
bradycardia	O
most	O
often	O
occurs	O
in	O
association	O
with	O
bilateral	O
hemispheric	O
seizure	O
activity	O
and	O
is	O
not	O
a	O
consistent	O
lateralizing	O
sign	O
in	O
localizing	O
seizure	O
onset	O
.	O
Our	O
data	O
do	O
not	O
support	O
the	O
existence	O
of	O
a	O
strictly	O
unilateral	O
parasympathetic	O
cardiomotor	O
representation	O
in	O
the	O
left	B-Anatomy
hemisphere	I-Anatomy
,	O
as	O
has	O
been	O
suggested	O
.	O
GDP	O
and	O
AGE	O
receptors	O
:	O
mechanisms	O
of	O
peritoneal	B-Anatomy
damage	O
.	O
Long	O
-	O
term	O
peritoneal	B-Anatomy
dialysis	O
(	O
PD	O
)	O
is	O
limited	O
by	O
morphological	O
changes	O
of	O
the	O
peritoneal	B-Anatomy
membrane	I-Anatomy
.	O
Structural	O
changes	O
were	O
promoted	O
by	O
toxicity	O
of	O
glucose	O
degradation	O
products	O
(	O
GDPs	O
)	O
which	O
are	O
generated	O
during	O
heat	O
sterilization	O
in	O
peritoneal	B-Anatomy
dialysis	O
fluids	O
(	O
PDFs	O
)	O
.	O
Besides	O
their	O
direct	O
toxicity	O
GDPs	O
promote	O
formation	O
of	O
advanced	O
glycation	O
endproducts	O
(	O
AGEs	O
)	O
.	O
RAGE	O
(	O
receptor	O
for	O
AGE	O
)	O
is	O
the	O
best	O
characterized	O
signal	O
transduction	O
receptor	O
for	O
AGEs	O
and	O
is	O
expressed	O
on	O
mesothelial	B-Anatomy
cells	I-Anatomy
.	O
The	O
effects	O
of	O
PDFs	O
with	O
different	O
amounts	O
of	O
GDPs	O
were	O
compared	O
on	O
morphological	O
changes	O
in	O
the	O
peritoneal	B-Anatomy
membrane	I-Anatomy
in	O
a	O
RAGE	O
-	O
/	O
-	O
mouse	O
model	O
.	O
It	O
could	O
be	O
demonstrated	O
that	O
RAGE	O
plays	O
a	O
pivotal	O
role	O
in	O
structural	O
damage	O
(	O
e	O
.	O
g	O
.	O
inflammation	O
,	O
neoangiogenesis	O
and	O
fibrosis	O
)	O
of	O
the	O
peritoneal	B-Anatomy
membrane	I-Anatomy
.	O
Further	O
investigations	O
of	O
this	O
pathway	O
with	O
regard	O
to	O
preventing	O
peritoneal	B-Anatomy
fibrosis	O
should	O
be	O
performed	O
to	O
maintain	O
the	O
integrity	O
of	O
the	O
peritoneal	B-Anatomy
membrane	I-Anatomy
in	O
peritoneal	B-Anatomy
dialysis	O
patients	O
.	O
Hyperfibrinogenemia	O
is	O
associated	O
with	O
lymphatic	B-Anatomy
as	O
well	O
as	O
hematogenous	O
metastasis	O
and	O
worse	O
clinical	O
outcome	O
in	O
T2	B-Anatomy
gastric	I-Anatomy
cancer	I-Anatomy
.	O
BACKGROUND	O
:	O
Abnormal	O
hemostasis	O
in	O
cancer	B-Anatomy
patients	O
has	O
previously	O
been	O
described	O
,	O
however	O
the	O
correlation	O
between	O
the	O
plasma	B-Anatomy
fibrinogen	O
level	O
and	O
cancer	B-Anatomy
metastasis	O
and	O
prognosis	O
has	O
not	O
been	O
reported	O
in	O
a	O
large	O
-	O
scale	O
clinical	O
study	O
.	O
METHODS	O
:	O
Preoperative	O
plasma	B-Anatomy
fibrinogen	O
levels	O
were	O
retrospectively	O
examined	O
in	O
405	O
patients	O
who	O
underwent	O
surgery	O
for	O
advanced	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
The	O
association	O
of	O
fibrinogen	O
levels	O
with	O
clinical	O
/	O
pathological	O
findings	O
and	O
clinical	O
outcome	O
was	O
evaluated	O
.	O
RESULTS	O
:	O
There	O
was	O
a	O
positive	O
correlation	O
between	O
plasma	B-Anatomy
fibrinogen	O
levels	O
and	O
the	O
depth	O
of	O
invasion	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Hyperfibrinogenemia	O
(	O
>	O
310	O
mg	O
/	O
dl	O
)	O
was	O
independently	O
associated	O
with	O
lymph	B-Anatomy
node	I-Anatomy
(	O
Odds	O
Ratio	O
;	O
2	O
.	O
342	O
,	O
P	O
=	O
0	O
.	O
0032	O
)	O
and	O
liver	B-Anatomy
(	O
Odds	O
Ratio	O
;	O
2	O
.	O
933	O
,	O
P	O
=	O
0	O
.	O
0147	O
)	O
metastasis	O
,	O
not	O
with	O
peritoneal	B-Anatomy
metastasis	O
in	O
this	O
series	O
.	O
Patients	O
with	O
hyperfibrinogenemia	O
showed	O
worse	O
clinical	O
outcome	O
in	O
T2	B-Anatomy
gastric	I-Anatomy
cancer	I-Anatomy
,	O
however	O
,	O
there	O
was	O
no	O
correlation	O
of	O
plasma	B-Anatomy
fibrinogen	O
level	O
with	O
prognosis	O
in	O
T3	B-Anatomy
/	I-Anatomy
T4	I-Anatomy
gastric	I-Anatomy
cancer	I-Anatomy
.	O
CONCLUSION	O
:	O
Our	O
results	O
might	O
support	O
the	O
idea	O
that	O
hyperfibrinogenemia	O
can	O
augment	O
lymphatic	B-Anatomy
and	O
hematogeneous	O
metastasis	O
of	O
advanced	O
gastric	B-Anatomy
cancer	I-Anatomy
,	O
which	O
is	O
major	O
determinant	O
of	O
the	O
prognosis	O
in	O
T2	B-Anatomy
gastric	I-Anatomy
cancer	I-Anatomy
.	O
Therefore	O
,	O
in	O
the	O
situation	O
without	O
peritoneal	B-Anatomy
involvement	O
,	O
hyperfibrinogenemia	O
is	O
a	O
useful	O
biomarker	O
to	O
predict	O
the	O
possible	O
metastasis	O
and	O
worse	O
clinical	O
outcome	O
in	O
T2	B-Anatomy
gastric	I-Anatomy
cancer	I-Anatomy
.	O
Dendrimer	O
-	O
templated	O
Fe	O
nanoparticles	O
for	O
the	O
growth	O
of	O
single	O
-	O
wall	O
carbon	O
nanotubes	O
by	O
plasma	O
-	O
enhanced	O
CVD	O
.	O
A	O
fourth	O
-	O
generation	O
(	O
G4	O
)	O
poly	O
(	O
amidoamine	O
)	O
(	O
PAMAM	O
)	O
dendrimer	O
(	O
G4	O
-	O
NH2	O
)	O
has	O
been	O
used	O
as	O
a	O
template	O
to	O
deliver	O
nearly	O
monodispersed	O
catalyst	O
nanoparticles	O
to	O
SiO2	O
/	O
Si	O
,	O
Ti	O
/	O
Si	O
,	O
sapphire	O
,	O
and	O
porous	O
anodic	O
alumina	O
(	O
PAA	O
)	O
substrates	O
.	O
Fe2O3	O
nanoparticles	O
obtained	O
after	O
calcination	O
of	O
the	O
immobilized	O
Fe3	O
+	O
/	O
G4	O
-	O
NH2	O
composite	O
served	O
as	O
catalytic	O
""""	O
seeds	O
""""	O
for	O
the	O
growth	O
of	O
single	O
-	O
wall	O
carbon	O
nanotubes	O
(	O
SWNTs	O
)	O
by	O
microwave	O
plasma	O
-	O
enhanced	O
CVD	O
(	O
PECVD	O
)	O
.	O
To	O
surmount	O
the	O
difficulty	O
associated	O
with	O
SWNT	O
growth	O
via	O
PECVD	O
,	O
reaction	O
conditions	O
that	O
promote	O
the	O
stabilization	O
of	O
Fe	O
nanoparticles	O
,	O
resulting	O
in	O
enhanced	O
SWNT	O
selectivity	O
and	O
quality	O
,	O
have	O
been	O
identified	O
.	O
In	O
particular	O
,	O
in	O
situ	O
annealing	O
of	O
Fe	O
catalyst	O
in	O
an	O
N2	O
atmosphere	O
was	O
found	O
to	O
improve	O
SWNT	O
selectivity	O
and	O
quality	O
.	O
H2	O
prereduction	O
at	O
900	O
degrees	O
C	O
for	O
5	O
min	O
was	O
also	O
found	O
to	O
enhance	O
SWNT	O
selectivity	O
and	O
quality	O
for	O
SiO2	O
/	O
Si	O
supported	O
catalyst	O
,	O
albeit	O
of	O
lower	O
quality	O
for	O
sapphire	O
supported	O
catalyst	O
.	O
The	O
application	O
of	O
positive	O
dc	O
bias	O
voltage	O
(	O
+	O
200	O
V	O
)	O
during	O
SWNT	O
growth	O
was	O
shown	O
to	O
be	O
very	O
effective	O
in	O
removing	O
amorphous	O
carbon	O
impurities	O
while	O
enhancing	O
graphitization	O
,	O
SWNT	O
selectivity	O
,	O
and	O
vertical	O
alignment	O
.	O
The	O
results	O
of	O
this	O
study	O
should	O
promote	O
the	O
use	O
of	O
exposed	O
Fe	O
nanoparticles	O
supported	O
on	O
different	O
substrates	O
for	O
the	O
growth	O
of	O
high	O
-	O
quality	O
SWNTs	O
by	O
PECVD	O
.	O
Fluoro	O
-	O
Jade	O
B	O
staining	O
following	O
zymosan	O
microinjection	O
into	O
the	O
spinal	B-Anatomy
cord	I-Anatomy
white	I-Anatomy
matter	I-Anatomy
.	O
1	O
.	O
The	O
fluorescein	O
derivate	O
Fluoro	O
-	O
Jade	O
B	O
(	O
FJB	O
)	O
,	O
which	O
primarily	O
labels	O
dead	O
or	O
dying	O
neurons	B-Anatomy
,	O
was	O
used	O
to	O
study	O
the	O
acute	O
focal	O
inflammation	O
in	O
the	O
spinal	B-Anatomy
cord	I-Anatomy
white	I-Anatomy
matter	I-Anatomy
.	O
Inflammation	O
was	O
induced	O
by	O
microinjection	O
of	O
the	O
yeast	O
particulate	O
zymosan	O
to	O
evaluate	O
the	O
biological	O
effects	O
of	O
intraspinal	B-Anatomy
macrophages	I-Anatomy
activation	O
without	O
the	O
confounding	O
effects	O
of	O
physical	O
trauma	O
.	O
2	O
.	O
A	O
single	O
bolus	O
of	O
zymosan	O
(	O
Sigma	O
,	O
75	O
nL	O
)	O
was	O
stereotaxically	O
injected	O
at	O
the	O
thoracic	B-Anatomy
level	O
into	O
the	O
lateral	B-Anatomy
white	I-Anatomy
matter	I-Anatomy
of	O
rat	O
spinal	B-Anatomy
cord	I-Anatomy
.	O
A	O
standard	O
Fluoro	O
-	O
Jade	O
B	O
staining	O
protocol	O
was	O
applied	O
to	O
spinal	B-Anatomy
cord	I-Anatomy
sections	I-Anatomy
at	O
6	O
,	O
12	O
,	O
24	O
h	O
and	O
2	O
,	O
4	O
days	O
postinjection	O
.	O
Neutral	O
Red	O
,	O
NADPH	O
-	O
diaphorase	O
,	O
Iba1	O
-	O
IR	O
,	O
and	O
DAPI	O
staining	O
protocols	O
accomplished	O
examination	O
of	O
the	O
cells	B-Anatomy
participating	O
in	O
the	O
acute	O
inflammatory	O
response	O
.	O
3	O
.	O
Zymosan	O
caused	O
formation	O
of	O
clearly	O
delineated	O
inflammation	O
lesions	B-Anatomy
localized	O
in	O
the	O
lateral	B-Anatomy
white	I-Anatomy
matter	I-Anatomy
of	O
the	O
spinal	B-Anatomy
cord	I-Anatomy
.	O
Fluoro	O
-	O
Jade	O
B	O
stained	O
cells	B-Anatomy
in	O
the	O
area	B-Anatomy
of	O
inflammation	O
were	O
not	O
observed	O
at	O
12	O
h	O
postinjection	O
while	O
mild	O
FJB	O
staining	O
appeared	O
at	O
24	O
h	O
and	O
intense	O
staining	O
was	O
observed	O
at	O
2	O
and	O
4	O
days	O
postinjection	O
.	O
4	O
.	O
This	O
study	O
shows	O
that	O
the	O
acute	O
response	O
to	O
zymosan	O
-	O
induced	O
inflammation	O
in	O
the	O
rat	O
spinal	B-Anatomy
cord	I-Anatomy
white	I-Anatomy
matter	I-Anatomy
causes	O
a	O
gradual	O
appearance	O
of	O
phagocytic	B-Anatomy
microglia	I-Anatomy
/	O
macrophages	B-Anatomy
and	O
delayed	O
FJB	O
staining	O
of	O
the	O
inflammatory	B-Anatomy
cells	I-Anatomy
.	O
5	O
.	O
FJB	O
,	O
a	O
reliable	O
marker	O
of	O
dying	O
neurons	B-Anatomy
,	O
is	O
a	O
more	O
universal	O
agent	O
than	O
formerly	O
believed	O
.	O
One	O
possible	O
explanation	O
for	O
the	O
gradual	O
appearance	O
of	O
FJB	O
-	O
stained	O
cells	B-Anatomy
in	O
the	O
area	B-Anatomy
of	O
inflammation	O
is	O
that	O
specific	O
time	O
is	O
required	O
for	O
sufficient	O
levels	O
of	O
proteins	O
and	O
/	O
or	O
myelin	O
debris	O
of	O
axonal	O
origin	O
to	O
appear	O
in	O
the	O
cytoplasm	B-Anatomy
of	O
phagocytic	B-Anatomy
microglia	I-Anatomy
/	O
macrophages	B-Anatomy
.	O
Defective	O
expression	O
of	O
HRK	O
is	O
associated	O
with	O
promoter	O
methylation	O
in	O
primary	B-Anatomy
central	I-Anatomy
nervous	I-Anatomy
system	I-Anatomy
lymphomas	I-Anatomy
.	O
OBJECTIVES	O
:	O
Recently	O
,	O
it	O
has	O
been	O
reported	O
that	O
expression	O
of	O
the	O
HRK	O
gene	O
was	O
significantly	O
reduced	O
by	O
hypermethylation	O
in	O
astrocytic	B-Anatomy
tumors	I-Anatomy
.	O
Our	O
aim	O
is	O
to	O
verify	O
the	O
alterations	O
in	O
the	O
HRK	O
gene	O
in	O
primary	B-Anatomy
central	I-Anatomy
nervous	I-Anatomy
system	I-Anatomy
lymphomas	I-Anatomy
(	O
PCNSLs	B-Anatomy
)	O
.	O
METHODS	O
:	O
We	O
analyzed	O
the	O
hypermethylation	O
status	O
and	O
expression	O
of	O
the	O
gene	O
and	O
12q13	O
.	O
1	O
loss	O
of	O
heterozygosity	O
in	O
31	O
PCNSLs	B-Anatomy
.	O
RESULTS	O
:	O
A	O
total	O
of	O
13	O
PCNSLs	B-Anatomy
(	O
31	O
%	O
)	O
demonstrated	O
hypermethylation	O
in	O
either	O
the	O
promoter	O
or	O
exon	O
1	O
;	O
loss	O
of	O
HRK	O
expression	O
was	O
immunohistochemically	O
observed	O
in	O
9	O
tumors	B-Anatomy
and	O
was	O
significantly	O
associated	O
with	O
promoter	O
methylation	O
.	O
In	O
addition	O
,	O
higher	O
apoptotic	O
counts	O
were	O
associated	O
with	O
HRK	O
positivity	O
.	O
PCNSLs	B-Anatomy
with	O
HRK	O
methylation	O
also	O
showed	O
methylation	O
of	O
multiple	O
genes	O
,	O
such	O
as	O
p14ARF	O
,	O
p16INK4a	O
,	O
RB1	O
,	O
p27Kip1	O
and	O
O6	O
-	O
MGMT	O
.	O
Patients	O
with	O
tumors	B-Anatomy
demonstrating	O
concurrent	O
methylation	O
of	O
more	O
than	O
half	O
of	O
their	O
genes	O
demonstrated	O
significantly	O
poorer	O
survival	O
and	O
earlier	O
recurrence	O
.	O
Hypermethylation	O
of	O
the	O
HRK	O
promoter	O
alone	O
was	O
not	O
associated	O
with	O
overall	O
outcome	O
,	O
but	O
relapse	O
-	O
free	O
survival	O
was	O
significantly	O
shorter	O
.	O
CONCLUSIONS	O
:	O
Our	O
findings	O
suggest	O
that	O
transcriptional	O
repression	O
of	O
HRK	O
is	O
caused	O
by	O
promoter	O
hypermethylation	O
in	O
PCNSL	B-Anatomy
,	O
and	O
that	O
the	O
loss	O
of	O
HRK	O
associated	O
with	O
the	O
methylation	O
profile	O
of	O
other	O
genes	O
is	O
a	O
potential	O
step	O
in	O
the	O
modulation	O
of	O
cellular	B-Anatomy
death	O
by	O
apoptosis	O
during	O
PCNSL	B-Anatomy
tumorigenesis	O
.	O
Changes	O
of	O
lymphocyte	B-Anatomy
subsets	O
in	O
leukemia	B-Anatomy
patients	O
who	O
received	O
allogenic	O
bone	B-Anatomy
marrow	I-Anatomy
transplantation	O
.	O
Proportional	O
changes	O
of	O
lymphocyte	B-Anatomy
subsets	O
in	O
the	O
peripheral	B-Anatomy
blood	I-Anatomy
were	O
monitored	O
by	O
two	O
-	O
color	O
flow	O
-	O
cytometry	O
in	O
seven	O
leukemia	B-Anatomy
patients	O
who	O
had	O
received	O
allogenic	O
bone	B-Anatomy
marrow	I-Anatomy
transplantation	O
(	O
BMT	O
)	O
.	O
Lymphocyte	B-Anatomy
counts	O
,	O
and	O
proportions	O
of	O
T	B-Anatomy
and	O
B	B-Anatomy
-	I-Anatomy
cells	I-Anatomy
returned	O
to	O
normal	O
ranges	O
between	O
the	O
2nd	O
and	O
12th	O
months	O
after	O
BMT	O
.	O
Activated	O
T	B-Anatomy
-	I-Anatomy
cells	I-Anatomy
prominently	O
increased	O
after	O
BMT	O
,	O
and	O
the	O
values	O
gradually	O
returned	O
toward	O
normal	O
.	O
As	O
to	O
lymphocyte	B-Anatomy
subsets	O
,	O
the	O
proportions	O
of	O
CD	B-Anatomy
4	I-Anatomy
+	I-Anatomy
cells	I-Anatomy
had	O
remained	O
low	O
,	O
while	O
those	O
of	O
CD	B-Anatomy
8	I-Anatomy
+	I-Anatomy
cells	I-Anatomy
high	O
for	O
a	O
whole	O
observation	O
period	O
after	O
BMT	O
.	O
The	O
changes	O
of	O
CD	B-Anatomy
4	I-Anatomy
+	I-Anatomy
cells	I-Anatomy
were	O
caused	O
by	O
the	O
decrease	O
of	O
suppressor	B-Anatomy
-	I-Anatomy
inducer	I-Anatomy
T	I-Anatomy
-	I-Anatomy
cells	I-Anatomy
(	O
CD	O
4	O
+	O
Leu	O
8	O
+	O
)	O
.	O
High	O
proportion	O
of	O
CD	B-Anatomy
8	I-Anatomy
+	I-Anatomy
cells	I-Anatomy
was	O
mainly	O
associated	O
with	O
increased	O
suppressor	B-Anatomy
T	I-Anatomy
-	I-Anatomy
cells	I-Anatomy
(	O
CD	O
8	O
+	O
CD	O
11	O
+	O
)	O
.	O
Among	O
natural	B-Anatomy
killer	I-Anatomy
(	I-Anatomy
NK	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
,	O
highly	O
active	O
NK	B-Anatomy
cells	I-Anatomy
(	O
CD	O
16	O
+	O
CD	O
57	O
-	O
)	O
markedly	O
increased	O
shortly	O
after	O
BMT	O
,	O
and	O
gradually	O
returned	O
to	O
normal	O
.	O
CD	B-Anatomy
16	I-Anatomy
-	I-Anatomy
CD	I-Anatomy
57	I-Anatomy
+	I-Anatomy
NK	I-Anatomy
cells	I-Anatomy
increased	O
beyond	O
normal	O
ranges	O
after	O
the	O
2nd	O
month	O
.	O
The	O
incidence	O
or	O
degree	O
of	O
acute	O
and	O
chronic	O
graft	B-Anatomy
-	O
versus	O
-	O
host	O
diseases	O
(	O
GVHD	O
)	O
did	O
not	O
correlate	O
with	O
the	O
changes	O
of	O
any	O
lymphocyte	B-Anatomy
subsets	O
.	O
The	O
present	O
results	O
suggest	O
that	O
the	O
increase	O
of	O
activated	O
T	B-Anatomy
-	I-Anatomy
cells	I-Anatomy
shortly	O
after	O
BMT	O
reflects	O
lymphocyte	B-Anatomy
reconstitution	O
.	O
The	O
prolonged	O
immune	O
deficiency	O
after	O
BMT	O
might	O
be	O
related	O
to	O
either	O
deficient	O
expression	O
of	O
homing	O
receptor	O
(	O
Leu	O
8	O
antigen	O
)	O
on	O
CD	B-Anatomy
4	I-Anatomy
+	I-Anatomy
cells	I-Anatomy
or	O
increased	O
suppressor	B-Anatomy
T	I-Anatomy
-	I-Anatomy
cells	I-Anatomy
(	O
CD	O
8	O
+	O
CD	O
11	O
+	O
)	O
.	O
In	O
addition	O
,	O
the	O
early	O
increase	O
of	O
NK	B-Anatomy
cells	I-Anatomy
after	O
BMT	O
may	O
compensate	O
for	O
the	O
immune	O
deficiency	O
in	O
BMT	O
patients	O
.	O
Fluoroscopically	O
guided	O
cervical	B-Anatomy
prolotherapy	O
for	O
instability	O
with	O
blinded	O
pre	O
and	O
post	O
radiographic	O
reading	O
.	O
BACKGROUND	O
:	O
Several	O
authors	O
have	O
postulated	O
that	O
cervical	B-Anatomy
instability	O
is	O
a	O
major	O
cause	O
of	O
traumatic	O
spinal	B-Anatomy
pain	O
.	O
OBJECTIVE	O
:	O
The	O
purpose	O
of	O
this	O
prospective	O
case	O
series	O
study	O
(	O
n	O
=	O
6	O
)	O
was	O
to	O
determine	O
if	O
proliferant	O
injections	O
have	O
an	O
effect	O
on	O
cervical	B-Anatomy
translation	O
as	O
measured	O
by	O
a	O
blinded	O
reader	O
.	O
DESIGN	O
:	O
This	O
study	O
was	O
a	O
prospective	O
case	O
series	O
.	O
Study	O
participants	O
were	O
selected	O
from	O
patients	O
seen	O
for	O
the	O
primary	O
complaint	O
of	O
Motor	O
Vehicle	O
Collision	O
related	O
neck	B-Anatomy
pain	O
in	O
a	O
private	O
sub	O
-	O
specialty	O
pain	O
clinic	O
.	O
METHODS	O
:	O
Flexion	O
and	O
extension	O
views	O
were	O
obtained	O
by	O
standard	O
radiographs	O
taken	O
with	O
a	O
C	O
-	O
Arm	O
fluoroscope	O
under	O
Valium	O
sedation	O
.	O
Patients	O
with	O
more	O
than	O
2	O
.	O
7	O
mm	O
of	O
absolute	O
cervical	B-Anatomy
translation	O
and	O
at	O
least	O
50	O
%	O
reduction	O
of	O
cervical	B-Anatomy
and	O
referred	O
pain	O
with	O
a	O
two	O
day	O
rigid	O
cervical	B-Anatomy
immobilization	O
test	O
were	O
admitted	O
into	O
the	O
study	O
.	O
Participants	O
underwent	O
3	O
prolotherapy	O
injections	O
at	O
all	O
sites	O
that	O
demonstrated	O
translation	O
.	O
The	O
difference	O
in	O
means	O
between	O
pre	O
-	O
test	O
and	O
post	O
-	O
test	O
measurements	O
(	O
flexion	O
translation	O
,	O
extension	O
translation	O
,	O
and	O
pain	O
VAS	O
scores	O
)	O
were	O
assessed	O
by	O
a	O
Wilcoxon	O
signed	O
ranks	O
test	O
(	O
alpha	O
=	O
0	O
.	O
05	O
)	O
.	O
RESULTS	O
:	O
The	O
mean	O
post	O
-	O
test	O
VAS	O
score	O
(	O
M	O
=	O
3	O
.	O
83	O
,	O
SD	O
=	O
2	O
.	O
3	O
,	O
t	O
=	O
2	O
.	O
889	O
)	O
was	O
significantly	O
less	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
than	O
the	O
mean	O
pre	O
-	O
test	O
VAS	O
score	O
(	O
M	O
=	O
5	O
.	O
75	O
,	O
SD	O
=	O
1	O
.	O
94	O
)	O
.	O
The	O
correlation	O
between	O
difference	O
in	O
mean	O
extension	O
at	O
C2	O
-	O
3	O
and	O
C5	O
-	O
6	O
and	O
difference	O
in	O
mean	O
extension	O
was	O
significant	O
(	O
rho	O
=	O
0	O
.	O
89	O
,	O
p	O
=	O
0	O
.	O
02	O
and	O
rho	O
=	O
0	O
.	O
85	O
,	O
p	O
=	O
0	O
.	O
03	O
respectively	O
)	O
.	O
Difference	O
in	O
mean	O
flexion	O
at	O
C3	O
-	O
4	O
and	O
C4	O
-	O
5	O
was	O
significantly	O
correlated	O
with	O
difference	O
in	O
mean	O
flexion	O
(	O
rho	O
=	O
0	O
.	O
88	O
,	O
p	O
=	O
0	O
.	O
02	O
and	O
rho	O
=	O
0	O
.	O
941	O
,	O
p	O
<	O
0	O
.	O
01	O
respectively	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
of	O
this	O
study	O
demonstrate	O
statistically	O
significant	O
correlations	O
between	O
proliferant	O
injections	O
,	O
a	O
reduction	O
of	O
both	O
cervical	B-Anatomy
flexion	O
and	O
extension	O
translation	O
,	O
as	O
well	O
as	O
a	O
reduction	O
in	O
pain	O
VAS	O
score	O
.	O
Since	O
patients	O
with	O
traumatic	O
cervical	B-Anatomy
instability	O
have	O
few	O
viable	O
treatment	O
options	O
other	O
than	O
surgical	O
fusion	O
,	O
cervical	B-Anatomy
proliferant	O
injections	O
under	O
C	O
-	O
Arm	O
fluoroscope	O
may	O
be	O
a	O
viable	O
treatment	O
option	O
.	O
Differential	O
mechanisms	O
of	O
radiosensitization	O
by	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
in	O
the	O
monolayers	B-Anatomy
and	O
multicellular	B-Anatomy
spheroids	I-Anatomy
of	O
a	O
human	O
glioma	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
.	O
In	O
vitro	O
studies	O
using	O
monolayer	B-Anatomy
cultures	I-Anatomy
of	O
human	O
tumor	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
have	O
shown	O
that	O
2	O
-	O
DG	O
selectively	O
inhibits	O
energy	O
-	O
dependent	O
DNA	O
repair	O
and	O
cellular	B-Anatomy
recovery	O
processes	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
However	O
,	O
monolayer	B-Anatomy
cultures	I-Anatomy
differ	O
greatly	O
from	O
the	O
complex	O
environmental	O
conditions	O
generated	O
in	O
solid	B-Anatomy
tumors	I-Anatomy
that	O
develop	O
inhomogeneous	B-Anatomy
hypoxic	I-Anatomy
and	O
necrotic	B-Anatomy
regions	I-Anatomy
.	O
In	O
contrast	O
,	O
multicellular	B-Anatomy
spheroids	I-Anatomy
mimic	O
heterogeneous	O
cellular	B-Anatomy
behavior	O
and	O
the	O
consequent	O
functional	O
characteristics	O
of	O
in	O
vivo	O
solid	B-Anatomy
tumors	I-Anatomy
,	O
and	O
serve	O
as	O
important	O
in	O
vitro	O
model	O
to	O
investigate	O
tumor	B-Anatomy
biology	O
and	O
responses	O
to	O
potential	O
therapeutic	O
agents	O
.	O
The	O
present	O
study	O
compares	O
the	O
radiomodification	O
by	O
2	O
-	O
DG	O
in	O
monolayer	B-Anatomy
cultures	I-Anatomy
and	O
spheroids	B-Anatomy
of	O
a	O
human	O
glioma	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
(	O
BMG	B-Anatomy
-	I-Anatomy
1	I-Anatomy
)	O
to	O
gain	O
insight	O
into	O
the	O
effects	O
in	O
solid	B-Anatomy
tumors	I-Anatomy
.	O
In	O
spheroids	B-Anatomy
,	O
the	O
glucose	O
consumption	O
(	O
2	O
.	O
1	O
p	O
mole	O
/	O
cell	O
/	O
h	O
)	O
and	O
lactate	O
production	O
(	O
3	O
.	O
67	O
p	O
mole	O
/	O
cell	O
/	O
h	O
)	O
was	O
nearly	O
2	O
-	O
3	O
fold	O
higher	O
than	O
in	O
monolayer	B-Anatomy
cells	I-Anatomy
(	O
0	O
.	O
83	O
and	O
1	O
.	O
43	O
p	O
mole	O
/	O
cell	O
/	O
h	O
respectively	O
)	O
.	O
Presence	O
of	O
2	O
-	O
DG	O
(	O
5	O
mM	O
)	O
for	O
2	O
-	O
4	O
h	O
inhibited	O
the	O
glucose	O
usage	O
and	O
lactate	O
production	O
by	O
70	O
%	O
in	O
spheroids	B-Anatomy
,	O
while	O
a	O
35	O
%	O
reduction	O
was	O
observed	O
in	O
monolayer	B-Anatomy
cells	I-Anatomy
.	O
Under	O
these	O
conditions	O
,	O
2	O
-	O
DG	O
drastically	O
enhanced	O
the	O
radiation	O
-	O
induced	O
cell	B-Anatomy
death	O
of	O
spheroids	B-Anatomy
(	O
by	O
2	O
-	O
3	O
folds	O
)	O
;	O
while	O
a	O
40	O
%	O
increase	O
was	O
observed	O
in	O
monolayer	B-Anatomy
cells	I-Anatomy
.	O
Radiosensitization	O
by	O
2	O
-	O
DG	O
in	O
monolayer	B-Anatomy
cells	I-Anatomy
was	O
primarily	O
due	O
to	O
an	O
increase	O
in	O
mitotic	O
death	O
(	O
23	O
%	O
)	O
linked	O
to	O
cytogenetic	O
damage	O
(	O
micronuclei	B-Anatomy
)	O
,	O
whereas	O
a	O
profound	O
induction	O
of	O
apoptosis	O
(	O
40	O
%	O
)	O
accounted	O
for	O
the	O
sensitization	O
in	O
spheroids	B-Anatomy
.	O
Although	O
the	O
Bcl	O
-	O
2	O
and	O
Bax	O
levels	O
were	O
significantly	O
higher	O
in	O
spheroids	B-Anatomy
,	O
Bcl	O
-	O
2	O
/	O
Bax	O
ratio	O
was	O
similar	O
in	O
monolayers	B-Anatomy
and	O
spheroids	B-Anatomy
.	O
Comet	O
assay	O
revealed	O
a	O
late	O
onset	O
of	O
DNA	O
breaks	O
in	O
the	O
presence	O
of	O
2	O
-	O
DG	O
following	O
irradiation	O
only	O
in	O
spheroids	B-Anatomy
,	O
which	O
corroborated	O
well	O
with	O
the	O
late	O
onset	O
of	O
oxidative	O
stress	O
.	O
2	O
-	O
DG	O
did	O
not	O
induce	O
a	O
significant	O
cell	B-Anatomy
cycle	O
delay	O
in	O
monolayers	B-Anatomy
,	O
while	O
a	O
transient	O
G	O
(	O
2	O
)	O
delay	O
was	O
apparent	O
in	O
spheroids	B-Anatomy
.	O
[	O
Autologous	O
bone	B-Anatomy
marrow	I-Anatomy
stem	I-Anatomy
cell	I-Anatomy
or	O
peripheral	B-Anatomy
blood	I-Anatomy
endothelial	I-Anatomy
progenitor	I-Anatomy
cell	I-Anatomy
therapy	O
in	O
patients	O
with	O
peripheral	O
limb	B-Anatomy
ischaemia	O
]	O
No	O
effective	O
medical	O
therapies	O
have	O
been	O
developed	O
sofar	O
to	O
enhance	O
blood	B-Anatomy
flow	O
in	O
the	O
legs	B-Anatomy
of	O
patients	O
with	O
peripheral	B-Anatomy
arterial	I-Anatomy
disease	O
(	O
PAD	O
)	O
.	O
For	O
patients	O
with	O
limb	B-Anatomy
threatening	O
ischaemia	O
the	O
only	O
option	O
for	O
relief	O
of	O
rest	O
pain	O
or	O
gangraena	O
is	O
amputation	O
.	O
There	O
is	O
evidence	O
in	O
experimental	O
and	O
clinical	O
studies	O
that	O
adult	O
bone	B-Anatomy
marrow	I-Anatomy
-	I-Anatomy
derived	I-Anatomy
stem	I-Anatomy
cells	I-Anatomy
and	O
endothelial	B-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
participate	O
in	O
the	O
development	O
of	O
new	O
blood	B-Anatomy
vessels	I-Anatomy
,	O
called	O
neoangiogenesis	O
or	O
neovascularization	O
.	O
Clinical	O
results	O
induced	O
by	O
autologous	O
bone	B-Anatomy
marrow	I-Anatomy
stem	I-Anatomy
cells	I-Anatomy
or	O
angiogenic	O
growth	O
/	O
differentiation	O
factors	O
in	O
end	O
-	O
stage	O
patients	O
with	O
PAD	O
are	O
summarized	O
.	O
Considering	O
the	O
relatively	O
few	O
number	O
of	O
patients	O
treated	O
by	O
angiogenic	O
therapy	O
,	O
the	O
interpretation	O
of	O
clinical	O
results	O
needs	O
cautiousness	O
.	O
Formation	O
of	O
new	O
bone	B-Anatomy
during	O
vertical	O
distraction	O
osteogenesis	O
of	O
the	O
human	O
mandible	B-Anatomy
is	O
related	O
to	O
the	O
presence	O
of	O
blood	B-Anatomy
vessels	I-Anatomy
.	O
We	O
examined	O
the	O
effect	O
of	O
distraction	O
rate	O
on	O
blood	B-Anatomy
vessel	I-Anatomy
growth	O
in	O
intramembraneous	O
ossification	O
after	O
vertical	O
distraction	O
osteogenesis	O
in	O
the	O
human	O
mandible	B-Anatomy
.	O
Six	O
edentulous	O
patients	O
(	O
aged	O
60	O
+	O
/	O
-	O
9	O
years	O
)	O
with	O
a	O
severely	O
atrophic	O
mandible	B-Anatomy
underwent	O
bone	B-Anatomy
augmentation	O
with	O
distraction	O
osteogenesis	O
.	O
Two	O
distraction	O
rates	O
(	O
0	O
.	O
5	O
and	O
1	O
mm	O
/	O
day	O
)	O
were	O
compared	O
and	O
for	O
each	O
group	O
three	O
patients	O
were	O
analyzed	O
.	O
Vascular	B-Anatomy
histomorphometry	O
was	O
carried	O
out	O
in	O
two	O
different	O
areas	B-Anatomy
in	O
the	O
distraction	O
gap	O
:	O
(	O
1	O
)	O
in	O
the	O
first	O
and	O
(	O
2	O
)	O
in	O
the	O
second	O
1	O
mm	O
area	B-Anatomy
from	O
the	O
osteotomy	O
line	O
,	O
representing	O
the	O
oldest	O
and	O
younger	O
new	B-Anatomy
-	I-Anatomy
bone	I-Anatomy
area	I-Anatomy
,	O
respectively	O
.	O
Correlation	O
analysis	O
was	O
performed	O
between	O
blood	B-Anatomy
vessel	I-Anatomy
parameters	O
and	O
the	O
amount	O
of	O
new	O
bone	B-Anatomy
formed	O
during	O
distraction	O
.	O
Histological	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
blood	B-Anatomy
vessels	I-Anatomy
throughout	O
the	O
soft	B-Anatomy
connective	I-Anatomy
tissue	I-Anatomy
in	O
the	O
distraction	O
gap	O
.	O
The	O
volume	O
density	O
of	O
blood	B-Anatomy
vessels	I-Anatomy
between	O
the	O
two	O
investigated	O
areas	O
was	O
significantly	O
lower	O
in	O
the	O
1	O
mm	O
/	O
day	O
groups	O
,	O
suggesting	O
a	O
delay	O
in	O
angiogenesis	O
in	O
this	O
group	O
of	O
patients	O
.	O
A	O
positive	O
correlation	O
between	O
blood	B-Anatomy
vessel	I-Anatomy
volume	O
and	O
bone	B-Anatomy
volume	O
density	O
was	O
found	O
in	O
the	O
younger	O
new	B-Anatomy
-	I-Anatomy
bone	I-Anatomy
area	I-Anatomy
but	O
not	O
in	O
the	O
oldest	O
new	B-Anatomy
-	I-Anatomy
bone	I-Anatomy
area	I-Anatomy
.	O
This	O
correlation	O
was	O
due	O
to	O
a	O
higher	O
number	O
of	O
blood	B-Anatomy
vessels	I-Anatomy
rather	O
than	O
to	O
a	O
larger	O
size	O
of	O
the	O
blood	B-Anatomy
vessels	I-Anatomy
.	O
Our	O
data	O
suggest	O
that	O
the	O
lower	O
blood	B-Anatomy
vessel	I-Anatomy
density	O
found	O
in	O
the	O
patients	O
with	O
1	O
mm	O
/	O
day	O
distraction	O
rate	O
may	O
be	O
related	O
to	O
disruption	O
of	O
angiogenesis	O
in	O
the	O
soft	B-Anatomy
connective	I-Anatomy
tissue	I-Anatomy
of	O
the	O
gap	O
or	O
to	O
a	O
less	O
optimal	O
mechanical	O
stimulation	O
of	O
cells	B-Anatomy
involved	O
in	O
angiogenesis	O
.	O
This	O
probably	O
results	O
in	O
the	O
slower	O
rate	O
of	O
osteogenesis	O
seen	O
at	O
the	O
1	O
mm	O
/	O
day	O
distraction	O
rate	O
compared	O
with	O
the	O
0	O
.	O
5	O
mm	O
/	O
day	O
distraction	O
rate	O
.	O
The	O
data	O
support	O
the	O
concept	O
that	O
a	O
positive	O
relationship	O
exists	O
between	O
the	O
density	O
of	O
blood	B-Anatomy
vessels	I-Anatomy
and	O
the	O
formation	O
of	O
bone	B-Anatomy
.	O
For	O
distraction	O
of	O
the	O
human	O
mandible	B-Anatomy
in	O
elderly	O
patients	O
,	O
a	O
distraction	O
rate	O
of	O
0	O
.	O
5	O
mm	O
/	O
day	O
seems	O
beneficial	O
.	O
[	O
The	O
prevalence	O
of	O
ADHD	O
and	O
attention	O
problems	O
in	O
preschool	O
-	O
aged	O
children	O
.	O
A	O
comparison	O
of	O
two	O
diagnostic	O
instruments	O
]	O
.	O
OBJECTIVES	O
:	O
In	O
order	O
to	O
analyse	O
the	O
prevalence	O
of	O
ADHD	O
and	O
attention	O
problems	O
in	O
preschool	O
-	O
aged	O
children	O
,	O
mothers	O
were	O
asked	O
to	O
rate	O
their	O
children	O
using	O
two	O
measuring	O
instruments	O
.	O
METHODS	O
:	O
The	O
analysis	O
is	O
part	O
of	O
a	O
prospective	O
,	O
randomised	O
control	O
study	O
of	O
N	O
=	O
280	O
children	O
aged	O
three	O
to	O
six	O
years	O
,	O
whose	O
mothers	O
rated	O
them	O
using	O
the	O
Child	O
Behaviour	O
Checklist	O
/	O
CBCL	O
1	O
1	O
/	O
2	O
-	O
5	O
and	O
the	O
Parent	O
Rating	O
Scale	O
for	O
Attention	O
-	O
Deficit	O
Hyperactivity	O
Disorder	O
(	O
ADHD	O
)	O
.	O
RESULTS	O
:	O
The	O
prevalence	O
rates	O
ranged	O
from	O
2	O
.	O
7	O
%	O
to	O
9	O
.	O
9	O
%	O
.	O
There	O
was	O
no	O
significant	O
gender	O
effect	O
in	O
this	O
age	O
group	O
.	O
CONCLUSIONS	O
:	O
The	O
study	O
delivers	O
initial	O
findings	O
and	O
provides	O
support	O
for	O
decisions	O
to	O
implement	O
in	O
Germany	O
new	O
assessment	O
methods	O
for	O
preschool	O
-	O
aged	O
children	O
with	O
ADHD	O
or	O
hyperkinetic	O
syndrome	O
.	O
Finally	O
,	O
the	O
different	O
rates	O
of	O
prevalence	O
and	O
the	O
implications	O
of	O
the	O
findings	O
for	O
epidemiology	O
and	O
the	O
prevention	O
of	O
ADHD	O
and	O
attention	O
problems	O
among	O
preschool	O
-	O
aged	O
children	O
are	O
discussed	O
.	O
Medical	O
adherence	O
and	O
childhood	O
chronic	O
illness	O
:	O
family	O
daily	O
management	O
skills	O
and	O
emotional	O
climate	O
as	O
emerging	O
contributors	O
.	O
PURPOSE	O
OF	O
REVIEW	O
:	O
To	O
describe	O
recent	O
research	O
that	O
examines	O
family	O
factors	O
that	O
promote	O
or	O
derail	O
adherence	O
to	O
medical	O
regimens	O
for	O
children	O
with	O
chronic	O
health	O
conditions	O
,	O
primarily	O
asthma	O
,	O
diabetes	O
,	O
and	O
cystic	O
fibrosis	O
.	O
From	O
the	O
past	O
2	O
years	O
,	O
eight	O
correlational	O
studies	O
were	O
identified	O
which	O
specifically	O
examined	O
the	O
links	O
between	O
family	O
management	O
strategies	O
,	O
family	O
climate	O
and	O
medical	O
adherence	O
.	O
RECENT	O
FINDINGS	O
:	O
Findings	O
from	O
the	O
studies	O
suggest	O
that	O
team	O
-	O
based	O
management	O
strategies	O
and	O
cohesive	O
family	O
climate	O
promote	O
adherence	O
to	O
medical	O
treatments	O
over	O
time	O
.	O
Family	O
interactions	O
that	O
are	O
characterized	O
by	O
conflict	O
and	O
disengagement	O
tend	O
to	O
disrupt	O
adherence	O
and	O
inevitably	O
cause	O
a	O
decline	O
in	O
child	O
health	O
.	O
Moreover	O
,	O
these	O
findings	O
seem	O
to	O
be	O
moderated	O
by	O
child	O
age	O
in	O
that	O
poorer	O
adherence	O
often	O
occurs	O
when	O
a	O
child	O
reaches	O
adolescence	O
and	O
is	O
searching	O
for	O
greater	O
autonomy	O
.	O
SUMMARY	O
:	O
Future	O
research	O
should	O
consider	O
the	O
challenges	O
in	O
measuring	O
medical	O
adherence	O
in	O
the	O
family	O
context	O
as	O
well	O
as	O
incorporating	O
more	O
naturalistic	O
studies	O
of	O
family	O
interactions	O
.	O
Randomized	O
controlled	O
trials	O
using	O
family	O
-	O
based	O
interventions	O
may	O
consider	O
focusing	O
on	O
medical	O
adherence	O
as	O
an	O
important	O
mediator	O
between	O
family	O
process	O
and	O
child	O
health	O
outcomes	O
.	O
Neoplastic	B-Anatomy
transformation	O
of	O
ciliary	B-Anatomy
body	I-Anatomy
epithelium	I-Anatomy
is	O
associated	O
with	O
loss	O
of	O
opticin	O
expression	O
.	O
BACKGROUND	O
:	O
Opticin	O
is	O
a	O
recently	O
discovered	O
glycoprotein	O
present	O
predominantly	O
in	O
the	O
vitreous	B-Anatomy
humour	I-Anatomy
.	O
It	O
is	O
synthesised	O
and	O
secreted	O
by	O
the	O
ciliary	B-Anatomy
body	I-Anatomy
epithelium	I-Anatomy
(	O
CBE	B-Anatomy
)	O
from	O
the	O
initiation	O
of	O
CBE	B-Anatomy
development	O
in	O
the	O
embryo	B-Anatomy
,	O
and	O
production	O
continues	O
throughout	O
life	O
.	O
AIM	O
:	O
To	O
determine	O
whether	O
a	O
variety	O
of	O
ciliary	B-Anatomy
body	I-Anatomy
tumours	I-Anatomy
synthesise	O
opticin	O
to	O
characterise	O
further	O
its	O
role	O
in	O
ciliary	B-Anatomy
body	I-Anatomy
health	O
and	O
disease	O
.	O
METHODS	O
:	O
Immunohistochemistry	O
was	O
used	O
to	O
determine	O
the	O
distribution	O
of	O
opticin	O
in	O
normal	O
human	O
CBE	B-Anatomy
,	O
and	O
in	O
hyperplastic	B-Anatomy
and	O
neoplastic	B-Anatomy
CBE	I-Anatomy
lesions	I-Anatomy
.	O
RESULTS	O
:	O
Opticin	O
was	O
immunolocalised	O
to	O
the	O
basal	B-Anatomy
cell	I-Anatomy
surface	I-Anatomy
and	O
basement	B-Anatomy
membrane	I-Anatomy
material	I-Anatomy
of	O
the	O
non	B-Anatomy
-	I-Anatomy
pigmented	I-Anatomy
CBE	I-Anatomy
in	O
nine	O
donor	O
eyes	B-Anatomy
as	O
well	O
as	O
four	O
hyperplastic	B-Anatomy
lesions	I-Anatomy
of	O
the	O
CBE	B-Anatomy
(	O
Fuchs	B-Anatomy
'	I-Anatomy
s	I-Anatomy
adenoma	I-Anatomy
)	O
.	O
By	O
contrast	O
,	O
none	O
of	O
eight	O
neoplastic	B-Anatomy
lesions	I-Anatomy
(	O
two	O
adenoma	B-Anatomy
and	O
six	O
adenocarcinoma	B-Anatomy
)	O
of	O
CBE	B-Anatomy
stained	O
for	O
opticin	O
.	O
CONCLUSION	O
:	O
The	O
present	O
series	O
supports	O
the	O
theory	O
that	O
opticin	O
is	O
produced	O
by	O
the	O
non	B-Anatomy
-	I-Anatomy
pigmented	I-Anatomy
CBE	I-Anatomy
throughout	O
adult	O
life	O
.	O
Loss	O
of	O
opticin	O
expression	O
by	O
this	O
tissue	B-Anatomy
is	O
associated	O
with	O
and	O
could	O
contribute	O
towards	O
neoplastic	B-Anatomy
transformation	O
.	O
Imaging	O
tumor	B-Anatomy
angiogenesis	O
.	O
Since	O
the	O
discovery	O
of	O
vascular	B-Anatomy
-	O
specific	O
growth	O
factors	O
with	O
angiogenic	O
activity	O
,	O
there	O
has	O
been	O
a	O
significant	O
effort	O
to	O
develop	O
cancer	B-Anatomy
drugs	O
that	O
restrict	O
tumorigenesis	O
by	O
targeting	O
the	O
blood	B-Anatomy
supply	O
.	O
In	O
this	O
issue	O
of	O
the	O
JCI	O
,	O
Mancuso	O
et	O
al	O
.	O
use	O
mouse	O
models	O
to	O
better	O
understand	O
the	O
plasticity	O
of	O
the	O
tumor	B-Anatomy
vasculature	I-Anatomy
in	O
the	O
face	O
of	O
antiangiogenic	O
therapy	O
(	O
see	O
the	O
related	O
article	O
beginning	O
on	O
page	O
2610	O
)	O
.	O
They	O
describe	O
a	O
rapid	O
regrowth	O
of	O
the	O
tumor	B-Anatomy
vasculature	I-Anatomy
following	O
withdrawal	O
of	O
VEGFR	O
inhibitors	O
,	O
emphasizing	O
the	O
importance	O
of	O
fully	O
understanding	O
the	O
function	O
of	O
these	O
and	O
similar	O
treatments	O
used	O
in	O
the	O
clinic	O
at	O
the	O
cellular	B-Anatomy
and	O
molecular	O
level	O
.	O
Collagen	O
-	O
poly	O
glycolic	O
acid	O
hybrid	O
matrix	O
with	O
basic	O
fibroblast	O
growth	O
factor	O
accelerated	O
angiogenesis	O
and	O
granulation	B-Anatomy
tissue	I-Anatomy
formation	O
in	O
diabetic	O
mice	O
.	O
Because	O
poor	O
skin	B-Anatomy
wound	I-Anatomy
healing	O
associated	O
with	O
diabetes	O
is	O
thought	O
to	O
be	O
partly	O
a	O
result	O
from	O
impaired	O
angiogenesis	O
,	O
treatments	O
that	O
improve	O
angiogenesis	O
could	O
have	O
important	O
clinical	O
applications	O
.	O
We	O
herein	O
report	O
the	O
effects	O
of	O
novel	O
developed	O
material	O
,	O
collagen	O
-	O
poly	O
glycolic	O
acid	O
fiber	O
hybrid	O
matrix	O
,	O
being	O
used	O
together	O
with	O
basic	O
fibroblast	O
growth	O
factor	O
to	O
promote	O
wound	B-Anatomy
healing	O
of	O
full	O
-	O
thickness	O
skin	B-Anatomy
defects	O
on	O
the	O
back	O
of	O
type	O
2	O
diabetic	O
Lepr	O
(	O
db	O
)	O
mice	O
.	O
Our	O
data	O
indicates	O
that	O
this	O
therapeutic	O
approach	O
markedly	O
promotes	O
angiogenesis	O
and	O
granulation	B-Anatomy
tissue	I-Anatomy
formation	O
in	O
comparison	O
with	O
other	O
conditions	O
14	O
days	O
after	O
wounding	O
.	O
p18Ink4c	O
,	O
but	O
not	O
p27Kip1	O
,	O
collaborates	O
with	O
Men1	O
to	O
suppress	O
neuroendocrine	B-Anatomy
organ	I-Anatomy
tumors	I-Anatomy
.	O
Mutant	O
mice	O
lacking	O
both	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
CDK	O
)	O
inhibitors	O
p18	O
(	O
Ink4c	O
)	O
and	O
p27	O
(	O
Kip1	O
)	O
develop	O
a	O
tumor	B-Anatomy
spectrum	O
reminiscent	O
of	O
human	O
multiple	B-Anatomy
endocrine	I-Anatomy
neoplasia	I-Anatomy
(	O
MEN	B-Anatomy
)	O
syndromes	O
.	O
To	O
determine	O
how	O
p18	O
and	O
p27	O
genetically	O
interact	O
with	O
Men1	O
,	O
the	O
tumor	B-Anatomy
suppressor	O
gene	O
mutated	O
in	O
familial	O
MEN1	B-Anatomy
,	O
we	O
characterized	O
p18	O
-	O
Men1	O
and	O
p27	O
-	O
Men1	O
double	O
mutant	O
mice	O
.	O
Compared	O
with	O
their	O
corresponding	O
single	O
mutant	O
littermates	O
,	O
the	O
p18	O
(	O
-	O
/	O
-	O
)	O
;	O
Men1	O
(	O
+	O
/	O
-	O
)	O
mice	O
develop	O
tumors	B-Anatomy
at	O
an	O
accelerated	O
rate	O
and	O
with	O
an	O
increased	O
incidence	O
in	O
the	O
pituitary	B-Anatomy
,	O
thyroid	B-Anatomy
,	O
parathyroid	B-Anatomy
,	O
and	O
pancreas	B-Anatomy
.	O
In	O
the	O
pituitary	B-Anatomy
and	O
pancreatic	B-Anatomy
islets	I-Anatomy
,	O
phosphorylation	O
of	O
the	O
retinoblastoma	O
(	O
Rb	O
)	O
protein	O
at	O
both	O
CDK2	O
and	O
CDK4	O
/	O
6	O
sites	O
was	O
increased	O
in	O
p18	B-Anatomy
(	I-Anatomy
-	I-Anatomy
/	I-Anatomy
-	I-Anatomy
)	I-Anatomy
and	I-Anatomy
Men1	I-Anatomy
(	I-Anatomy
+	I-Anatomy
/	I-Anatomy
-	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
and	O
was	O
further	O
increased	O
in	O
p18	B-Anatomy
(	I-Anatomy
-	I-Anatomy
/	I-Anatomy
-	I-Anatomy
)	I-Anatomy
;	I-Anatomy
Men1	I-Anatomy
(	I-Anatomy
+	I-Anatomy
/	I-Anatomy
-	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
.	O
The	O
remaining	O
wild	O
-	O
type	O
Men1	O
allele	O
was	O
lost	O
in	O
most	O
tumors	B-Anatomy
from	O
Men1	O
(	O
+	O
/	O
-	O
)	O
mice	O
but	O
was	O
retained	O
in	O
most	O
tumors	B-Anatomy
from	O
p18	O
(	O
-	O
/	O
-	O
)	O
;	O
Men1	O
(	O
+	O
/	O
-	O
)	O
mice	O
.	O
Combined	O
mutations	O
of	O
p27	O
(	O
-	O
/	O
-	O
)	O
and	O
Men1	O
(	O
+	O
/	O
-	O
)	O
,	O
in	O
contrast	O
,	O
did	O
not	O
exhibit	O
noticeable	O
synergistic	O
stimulation	O
of	O
Rb	O
kinase	O
activity	O
,	O
cell	B-Anatomy
proliferation	O
,	O
and	O
tumor	B-Anatomy
growth	O
.	O
These	O
results	O
demonstrate	O
that	O
functional	O
collaboration	O
exists	O
between	O
p18	O
and	O
Men1	O
and	O
suggest	O
that	O
Men1	O
may	O
regulate	O
additional	O
factor	O
(	O
s	O
)	O
that	O
interact	O
with	O
p18	O
and	O
p27	O
differently	O
.	O
Punica	O
granatum	O
(	O
pomegranate	O
)	O
and	O
its	O
potential	O
for	O
prevention	O
and	O
treatment	O
of	O
inflammation	O
and	O
cancer	B-Anatomy
.	O
The	O
last	O
7	O
years	O
have	O
seen	O
over	O
seven	O
times	O
as	O
many	O
publications	O
indexed	O
by	O
Medline	O
dealing	O
with	O
pomegranate	O
and	O
Punica	O
granatum	O
than	O
in	O
all	O
the	O
years	O
preceding	O
them	O
.	O
Because	O
of	O
this	O
,	O
and	O
the	O
virtual	O
explosion	O
of	O
interest	O
in	O
pomegranate	O
as	O
a	O
medicinal	O
and	O
nutritional	O
product	O
that	O
has	O
followed	O
,	O
this	O
review	O
is	O
accordingly	O
launched	O
.	O
The	O
pomegranate	O
tree	O
,	O
Punica	O
granatum	O
,	O
especially	O
its	O
fruit	O
,	O
possesses	O
a	O
vast	O
ethnomedical	O
history	O
and	O
represents	O
a	O
phytochemical	O
reservoir	O
of	O
heuristic	O
medicinal	O
value	O
.	O
The	O
tree	O
/	O
fruit	B-Anatomy
can	O
be	O
divided	O
into	O
several	O
anatomical	O
compartments	B-Anatomy
:	O
(	O
1	O
)	O
seed	B-Anatomy
,	O
(	O
2	O
)	O
juice	B-Anatomy
,	O
(	O
3	O
)	O
peel	B-Anatomy
,	O
(	O
4	O
)	O
leaf	B-Anatomy
,	O
(	O
5	O
)	O
flower	B-Anatomy
,	O
(	O
6	O
)	O
bark	B-Anatomy
,	O
and	O
(	O
7	O
)	O
roots	B-Anatomy
,	O
each	O
of	O
which	O
has	O
interesting	O
pharmacologic	O
activity	O
.	O
Juice	B-Anatomy
and	O
peels	B-Anatomy
,	O
for	O
example	O
,	O
possess	O
potent	O
antioxidant	O
properties	O
,	O
while	O
juice	B-Anatomy
,	O
peel	B-Anatomy
and	O
oil	B-Anatomy
are	O
all	O
weakly	O
estrogenic	O
and	O
heuristically	O
of	O
interest	O
for	O
the	O
treatment	O
of	O
menopausal	O
symptoms	O
and	O
sequellae	O
.	O
The	O
use	O
of	O
juice	B-Anatomy
,	O
peel	B-Anatomy
and	O
oil	B-Anatomy
have	O
also	O
been	O
shown	O
to	O
possess	O
anticancer	B-Anatomy
activities	O
,	O
including	O
interference	O
with	O
tumor	B-Anatomy
cell	I-Anatomy
proliferation	O
,	O
cell	B-Anatomy
cycle	O
,	O
invasion	O
and	O
angiogenesis	O
.	O
These	O
may	O
be	O
associated	O
with	O
plant	O
based	O
anti	O
-	O
inflammatory	O
effects	O
,	O
The	O
phytochemistry	O
and	O
pharmacological	O
actions	O
of	O
all	O
Punica	O
granatum	O
components	O
suggest	O
a	O
wide	O
range	O
of	O
clinical	O
applications	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
cancer	B-Anatomy
,	O
as	O
well	O
as	O
other	O
diseases	O
where	O
chronic	O
inflammation	O
is	O
believed	O
to	O
play	O
an	O
essential	O
etiologic	O
role	O
.	O
Activation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
through	O
reactive	O
oxygen	O
species	O
mediates	O
20	O
-	O
hydroxyeicosatetraenoic	O
acid	O
-	O
induced	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
.	O
20	O
-	O
Hydroxyeicosatetraenoic	O
acid	O
(	O
20	O
-	O
HETE	O
)	O
is	O
formed	O
by	O
the	O
omega	O
-	O
hydroxylation	O
of	O
arachidonic	O
acid	O
by	O
cytochrome	O
P450	O
4A	O
and	O
4F	O
enzymes	O
,	O
and	O
it	O
induces	O
angiogenic	O
responses	O
in	O
vivo	O
.	O
To	O
test	O
the	O
hypothesis	O
that	O
20	O
-	O
HETE	O
increases	O
endothelial	B-Anatomy
cell	I-Anatomy
(	O
EC	B-Anatomy
)	O
proliferation	O
via	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
we	O
studied	O
the	O
effects	O
of	O
WIT003	O
[	O
20	O
-	O
hydroxyeicosa	O
-	O
5	O
(	O
Z	O
)	O
,	O
14	O
(	O
Z	O
)	O
-	O
dienoic	O
acid	O
]	O
,	O
a	O
20	O
-	O
HETE	O
analog	O
on	O
human	O
macrovascular	B-Anatomy
or	O
microvascular	B-Anatomy
EC	I-Anatomy
.	O
WIT003	O
,	O
as	O
well	O
as	O
pure	O
20	O
-	O
HETE	O
,	O
stimulated	O
EC	B-Anatomy
proliferation	O
by	O
approximately	O
40	O
%	O
.	O
These	O
proliferative	O
effects	O
were	O
accompanied	O
by	O
increased	O
VEGF	O
expression	O
and	O
release	O
that	O
were	O
observed	O
as	O
early	O
as	O
4	O
h	O
after	O
20	O
-	O
HETE	O
agonist	O
addition	O
.	O
This	O
was	O
accompanied	O
by	O
increased	O
phosphorylation	O
of	O
the	O
VEGF	O
receptor	O
2	O
.	O
The	O
proliferative	O
effects	O
of	O
20	O
-	O
HETE	O
were	O
markedly	O
inhibited	O
by	O
a	O
VEGF	O
-	O
neutralizing	O
antibody	O
.	O
Polyethylene	O
glycol	O
-	O
superoxide	O
dismutase	O
(	O
PEG	O
-	O
SOD	O
)	O
markedly	O
inhibited	O
both	O
the	O
increases	O
in	O
VEGF	O
expression	O
and	O
the	O
proliferative	O
effects	O
of	O
20	O
-	O
HETE	O
.	O
In	O
contrast	O
,	O
administration	O
of	O
the	O
NAD	O
(	O
P	O
)	O
H	O
oxidase	O
inhibitor	O
apocynin	O
had	O
no	O
effect	O
to	O
the	O
proliferative	O
response	O
to	O
20	O
-	O
HETE	O
.	O
The	O
20	O
-	O
HETE	O
agonist	O
markedly	O
increased	O
superoxide	O
formation	O
as	O
reflected	O
by	O
an	O
increase	O
in	O
dihydroethidium	O
staining	O
of	O
EC	B-Anatomy
,	O
and	O
this	O
increase	O
was	O
inhibited	O
by	O
PEG	O
-	O
SOD	O
but	O
not	O
by	O
apocynin	O
.	O
20	O
-	O
HETE	O
also	O
increased	O
the	O
phosphorylation	O
of	O
p42	O
/	O
p44	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
in	O
EC	B-Anatomy
,	O
whereas	O
an	O
inhibitor	O
of	O
MAPK	O
[	O
U0126	O
,	O
1	O
,	O
4	O
-	O
diamino	O
-	O
2	O
,	O
3	O
-	O
dicyano	O
-	O
1	O
,	O
4	O
-	O
bis	O
(	O
2	O
-	O
aminophenylthio	O
)	O
butadiene	O
]	O
suppressed	O
the	O
proliferative	O
and	O
the	O
VEGF	O
changes	O
but	O
not	O
the	O
pro	O
-	O
oxidant	O
effects	O
of	O
20	O
-	O
HETE	O
.	O
These	O
data	O
suggest	O
that	O
20	O
-	O
HETE	O
stimulates	O
superoxide	O
formation	O
by	O
pathways	O
other	O
than	O
apocynin	O
-	O
sensitive	O
NAD	O
(	O
P	O
)	O
H	O
oxidase	O
,	O
thereby	O
activating	O
MAPK	O
and	O
then	O
enhancing	O
VEGF	O
synthesis	O
that	O
drives	O
EC	B-Anatomy
proliferation	O
.	O
Thus	O
,	O
20	O
-	O
HETE	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
EC	B-Anatomy
functions	O
,	O
such	O
as	O
angiogenesis	O
.	O
Relationship	O
of	O
cellular	B-Anatomy
immunity	O
,	O
cytokines	O
and	O
CRP	O
with	O
clinical	O
course	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
patients	O
with	O
endocrine	B-Anatomy
-	O
dependent	O
distant	O
metastases	B-Anatomy
treated	O
with	O
immunotherapy	O
.	O
We	O
have	O
reported	O
important	O
benefits	O
and	O
survival	O
with	O
an	O
immunotherapy	O
schedule	O
in	O
patients	O
with	O
endocrine	B-Anatomy
-	O
dependent	O
breast	B-Anatomy
cancer	I-Anatomy
and	O
distant	O
metastases	B-Anatomy
.	O
Here	O
clinical	O
outcome	O
is	O
updated	O
and	O
its	O
correlation	O
with	O
new	O
immunological	O
data	O
is	O
shown	O
.	O
In	O
32	O
evaluated	O
breast	B-Anatomy
cancer	I-Anatomy
patients	O
with	O
endocrine	B-Anatomy
-	O
dependent	O
distant	O
metastases	B-Anatomy
treated	O
with	O
a	O
new	O
immunotherapy	O
schedule	O
(	O
cyclic	O
administration	O
of	O
beta	O
-	O
interferon	O
and	O
interleukin	O
-	O
2	O
)	O
,	O
cellular	B-Anatomy
immunity	O
,	O
cytokines	O
and	O
CRP	O
were	O
related	O
to	O
the	O
clinical	O
course	O
.	O
Estimated	O
and	O
true	O
5	O
-	O
10	O
year	O
overall	O
survival	O
rates	O
from	O
first	O
line	O
antiestrogen	O
and	O
distant	O
metastases	B-Anatomy
were	O
higher	O
than	O
previously	O
reported	O
in	O
a	O
similar	O
population	O
.	O
Interleukin	O
-	O
2	O
administration	O
was	O
followed	O
by	O
a	O
significant	O
increase	O
in	O
total	O
lymphocytes	B-Anatomy
,	O
CD4	B-Anatomy
+	I-Anatomy
,	I-Anatomy
CD8	I-Anatomy
+	I-Anatomy
,	I-Anatomy
CD16	I-Anatomy
+	I-Anatomy
56	I-Anatomy
+	I-Anatomy
(	I-Anatomy
NK	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
12	O
,	O
and	O
CRP	O
(	O
from	O
P	O
<	O
0	O
.	O
04	O
to	O
P	O
<	O
0	O
.	O
000	O
)	O
but	O
no	O
change	O
in	O
IL	O
-	O
10	O
and	O
TGFbeta1	O
during	O
clinical	O
benefit	O
.	O
During	O
progressive	O
disease	O
no	O
change	O
was	O
observed	O
in	O
the	O
former	O
parameters	O
,	O
concomitant	O
with	O
a	O
significant	O
increase	O
in	O
IL	O
-	O
10	O
(	O
P	O
=	O
0	O
.	O
020	O
)	O
and	O
a	O
significant	O
decrease	O
in	O
TGFbeta1	O
(	O
P	O
=	O
0	O
.	O
023	O
)	O
.	O
These	O
findings	O
confirm	O
that	O
cellular	B-Anatomy
immunity	O
is	O
significantly	O
stimulated	O
by	O
IL	O
-	O
2	O
only	O
during	O
clinical	O
benefit	O
.	O
Furthermore	O
,	O
these	O
results	O
demonstrate	O
that	O
different	O
changes	O
of	O
proinflammatory	O
cytokines	O
,	O
CRP	O
and	O
inhibiting	O
factors	O
are	O
consistent	O
with	O
associated	O
clinical	O
benefit	O
or	O
with	O
disease	O
progression	O
,	O
respectively	O
.	O
Trib1	O
and	O
Evi1	O
cooperate	O
with	O
Hoxa	O
and	O
Meis1	O
in	O
myeloid	B-Anatomy
leukemogenesis	O
.	O
Cooperative	O
activation	O
of	O
Meis1	O
and	O
Hoxa9	O
perturbs	O
myeloid	B-Anatomy
differentiation	O
and	O
eventually	O
leads	O
myeloid	B-Anatomy
progenitors	I-Anatomy
to	O
leukemia	B-Anatomy
,	O
yet	O
it	O
remains	O
to	O
be	O
clarified	O
what	O
kinds	O
of	O
subsequent	O
molecular	O
processes	O
are	O
required	O
for	O
development	O
of	O
overt	B-Anatomy
leukemia	I-Anatomy
.	O
To	O
understand	O
the	O
molecular	O
pathway	O
in	O
Hoxa9	O
/	O
Meis1	O
-	O
induced	O
leukemogenesis	O
,	O
retroviral	O
insertional	O
mutagenesis	O
was	O
applied	O
using	O
retrovirus	O
-	O
mediated	O
gene	O
transfer	O
.	O
The	O
mice	O
that	O
received	O
Hoxa9	O
/	O
Meis1	O
-	O
transduced	O
bone	B-Anatomy
marrow	I-Anatomy
cells	I-Anatomy
developed	O
acute	B-Anatomy
myeloid	I-Anatomy
leukemia	I-Anatomy
(	O
AML	B-Anatomy
)	O
,	O
and	O
Trib1	O
,	O
Evi1	O
,	O
Ahi1	O
,	O
Raralpha	O
,	O
Pitpnb	O
,	O
and	O
AK039950	O
were	O
identified	O
as	O
candidate	O
cooperative	O
genes	O
located	O
near	O
common	O
retroviral	O
integration	O
sites	O
.	O
Trib1	O
and	O
Evi1	O
were	O
up	O
-	O
regulated	O
due	O
to	O
retroviral	O
insertions	O
,	O
and	O
coexpression	O
of	O
these	O
genes	O
significantly	O
accelerated	O
the	O
onset	O
of	O
Hoxa9	O
/	O
Meis1	O
-	O
induced	O
AML	B-Anatomy
,	O
suggesting	O
that	O
Trib1	O
and	O
Evi1	O
are	O
the	O
key	O
collaborators	O
.	O
Furthermore	O
,	O
Trib1	O
by	O
itself	O
is	O
a	O
novel	O
myeloid	B-Anatomy
oncogene	O
,	O
enhancing	O
phosphorylation	O
of	O
ERK	O
,	O
resulting	O
in	O
inhibition	O
of	O
apoptosis	O
.	O
These	O
results	O
demonstrate	O
the	O
importance	O
of	O
specific	O
oncogene	O
interaction	O
in	O
myeloid	B-Anatomy
leukemogenesis	O
.	O
Pro	O
/	O
antioxidant	O
status	O
and	O
AP	O
-	O
1	O
transcription	O
factor	O
in	O
murine	O
skin	B-Anatomy
following	O
topical	O
exposure	O
to	O
cumene	O
hydroperoxide	O
.	O
Organic	O
peroxides	O
,	O
widely	O
used	O
in	O
the	O
chemical	O
and	O
pharmaceutical	O
industries	O
,	O
can	O
act	O
as	O
skin	B-Anatomy
tumor	I-Anatomy
promoters	O
and	O
cause	O
epidermal	B-Anatomy
hyperplasia	I-Anatomy
.	O
They	O
are	O
also	O
known	O
to	O
trigger	O
free	O
radical	O
generation	O
.	O
The	O
present	O
study	O
evaluated	O
the	O
effect	O
of	O
cumene	O
hydroperoxide	O
(	O
Cum	O
-	O
OOH	O
)	O
on	O
the	O
induction	O
of	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
,	O
which	O
is	O
linked	O
to	O
the	O
expression	O
of	O
genes	O
regulating	O
cell	B-Anatomy
proliferation	O
,	O
growth	O
and	O
transformation	O
.	O
Previously	O
,	O
we	O
reported	O
that	O
topical	O
exposure	O
to	O
Cum	O
-	O
OOH	O
caused	O
formation	O
of	O
free	O
radicals	O
and	O
oxidative	O
stress	O
in	O
the	O
skin	B-Anatomy
of	O
vitamin	O
E	O
-	O
deficient	O
mice	O
.	O
The	O
present	O
study	O
used	O
JB6	B-Anatomy
P	I-Anatomy
+	I-Anatomy
mouse	I-Anatomy
epidermal	I-Anatomy
cells	I-Anatomy
and	O
AP	O
-	O
1	O
-	O
luciferase	O
reporter	O
transgenic	O
mice	O
to	O
identify	O
whether	O
exposure	O
to	O
Cum	O
-	O
OOH	O
caused	O
activation	O
of	O
AP	O
-	O
1	O
,	O
oxidative	O
stress	O
,	O
depletion	O
of	O
antioxidants	O
and	O
tumor	B-Anatomy
formation	O
during	O
two	O
-	O
stage	O
carcinogenesis	O
.	O
In	O
vitro	O
studies	O
found	O
that	O
exposure	O
to	O
Cum	O
-	O
OOH	O
reduced	O
the	O
level	O
of	O
glutathione	O
(	O
GSH	O
)	O
in	O
mouse	O
epidermal	B-Anatomy
cells	I-Anatomy
(	O
JB6	B-Anatomy
P	I-Anatomy
+	I-Anatomy
)	O
and	O
caused	O
the	O
induction	O
of	O
AP	O
-	O
1	O
.	O
Mice	O
primed	O
with	O
dimethyl	O
-	O
benz	O
[	O
a	O
]	O
anthracene	O
(	O
DMBA	O
)	O
were	O
topically	O
exposed	O
to	O
Cum	O
-	O
OOH	O
(	O
82	O
.	O
6	O
micromol	O
)	O
or	O
the	O
positive	O
control	O
,	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
,	O
17	O
nmol	O
)	O
,	O
twice	O
weekly	O
for	O
29	O
weeks	O
.	O
Activation	O
of	O
AP	O
-	O
1	O
in	O
skin	B-Anatomy
was	O
detected	O
as	O
early	O
as	O
2	O
weeks	O
following	O
Cum	O
-	O
OOH	O
or	O
TPA	O
exposure	O
.	O
No	O
AP	O
-	O
1	O
expression	O
was	O
found	O
19	O
weeks	O
after	O
initiation	O
.	O
Papilloma	B-Anatomy
formation	O
was	O
observed	O
in	O
both	O
the	O
DMBA	O
-	O
TPA	O
-	O
and	O
DMBA	O
-	O
Cum	O
-	O
OOH	O
-	O
exposed	O
animals	O
,	O
whereas	O
skin	B-Anatomy
carcinomas	I-Anatomy
were	O
found	O
only	O
in	O
the	O
DMBA	O
-	O
Cum	O
-	O
OOH	O
-	O
treated	O
mice	O
.	O
A	O
greater	O
accumulation	O
of	O
peroxidative	O
products	O
(	O
thiobarbituric	O
acid	O
-	O
reactive	O
substances	O
)	O
,	O
inflammation	O
and	O
decreased	O
levels	O
of	O
GSH	O
and	O
total	O
antioxidant	O
reserves	O
were	O
also	O
observed	O
in	O
the	O
skin	B-Anatomy
of	O
DMBA	O
-	O
Cum	O
-	O
OOH	O
-	O
exposed	O
mice	O
.	O
These	O
results	O
suggest	O
that	O
Cum	O
-	O
OOH	O
-	O
induced	O
carcinogenesis	O
is	O
accompanied	O
by	O
increased	O
AP	O
-	O
1	O
activation	O
and	O
changes	O
in	O
antioxidant	O
status	O
.	O
Hyperforin	O
blocks	O
neutrophil	B-Anatomy
activation	O
of	O
matrix	O
metalloproteinase	O
-	O
9	O
,	O
motility	O
and	O
recruitment	O
,	O
and	O
restrains	O
inflammation	O
-	O
triggered	O
angiogenesis	O
and	O
lung	B-Anatomy
fibrosis	O
.	O
Hyperforin	O
(	O
Hyp	O
)	O
,	O
a	O
polyphenol	O
-	O
derivative	O
of	O
St	O
.	O
John	O
'	O
s	O
wort	O
(	O
Hypericum	O
perforatum	O
)	O
,	O
has	O
emerged	O
as	O
key	O
player	O
not	O
only	O
in	O
the	O
antidepressant	O
activity	O
of	O
the	O
plant	O
but	O
also	O
as	O
an	O
inhibitor	O
of	O
bacteria	O
lymphocyte	B-Anatomy
and	O
tumor	B-Anatomy
cell	I-Anatomy
proliferation	O
,	O
and	O
matrix	O
proteinases	O
.	O
We	O
tested	O
whether	O
as	O
well	O
as	O
inhibiting	O
leukocyte	O
elastase	O
(	O
LE	O
)	O
activity	O
,	O
Hyp	O
might	O
be	O
effective	O
in	O
containing	O
both	O
polymorphonuclear	B-Anatomy
neutrophil	I-Anatomy
(	I-Anatomy
PMN	I-Anatomy
)	I-Anatomy
leukocyte	I-Anatomy
recruitment	O
and	O
unfavorable	O
eventual	O
tissue	B-Anatomy
responses	O
.	O
The	O
results	O
show	O
that	O
,	O
without	O
affecting	O
in	O
vitro	O
human	O
PMN	B-Anatomy
viability	O
and	O
chemokine	O
-	O
receptor	O
expression	O
,	O
Hyp	O
(	O
as	O
stable	O
dicyclohexylammonium	O
salt	O
)	O
was	O
able	O
to	O
inhibit	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
their	O
chemotaxis	O
and	O
chemoinvasion	O
(	O
IC50	O
=	O
1	O
microM	O
for	O
both	O
)	O
;	O
this	O
effect	O
was	O
associated	O
with	O
a	O
reduced	O
expression	O
of	O
the	O
adhesion	O
molecule	O
CD11b	O
by	O
formyl	O
-	O
Met	O
-	O
Leu	O
-	O
Phe	O
-	O
stimulated	O
neutrophils	B-Anatomy
and	O
block	O
of	O
LE	O
-	O
triggered	O
activation	O
of	O
the	O
gelatinase	O
matrix	O
metalloproteinase	O
-	O
9	O
.	O
PMN	B-Anatomy
-	O
triggered	O
angiogenesis	O
is	O
also	O
blocked	O
by	O
both	O
local	O
injection	O
and	O
daily	O
i	O
.	O
p	O
.	O
administration	O
of	O
the	O
Hyp	O
salt	O
in	O
an	O
interleukin	O
-	O
8	O
-	O
induced	O
murine	O
model	O
.	O
Furthermore	O
,	O
i	O
.	O
p	O
.	O
treatment	O
with	O
Hyp	O
reduces	O
acute	O
PMN	B-Anatomy
recruitment	O
and	O
enhances	O
resolution	O
in	O
a	O
pulmonary	B-Anatomy
bleomycin	O
-	O
induced	O
inflammation	O
model	O
,	O
significantly	O
reducing	O
consequent	O
fibrosis	O
.	O
These	O
results	O
indicate	O
that	O
Hyp	O
is	O
a	O
powerful	O
anti	O
-	O
inflammatory	O
compound	O
with	O
therapeutic	O
potential	O
,	O
and	O
they	O
elucidate	O
mechanistic	O
keys	O
.	O
New	O
vectors	O
and	O
strategies	O
for	O
cardiovascular	B-Anatomy
gene	O
therapy	O
.	O
Cardiovascular	B-Anatomy
diseases	O
are	O
the	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
both	O
men	O
and	O
women	O
in	O
industrially	O
developed	O
countries	O
.	O
These	O
disorders	O
may	O
result	O
from	O
impaired	O
angiogenesis	O
,	O
particularly	O
in	O
response	O
to	O
hypoxia	O
.	O
Despite	O
many	O
limitations	O
,	O
gene	O
therapy	O
is	O
still	O
emerging	O
as	O
a	O
potential	O
alternative	O
for	O
patients	O
who	O
are	O
not	O
candidates	O
for	O
traditional	O
revascularization	O
procedures	O
,	O
like	O
angioplasty	O
or	O
vein	B-Anatomy
grafts	I-Anatomy
.	O
This	O
review	O
focuses	O
on	O
recent	O
approaches	O
in	O
the	O
development	O
of	O
new	O
gene	O
delivery	O
vectors	O
,	O
with	O
great	O
respect	O
to	O
newly	O
discovered	O
AAV	O
serotypes	O
and	O
their	O
modified	O
forms	O
.	O
Moreover	O
,	O
some	O
new	O
cardiovascular	B-Anatomy
gene	O
therapy	O
strategies	O
have	O
been	O
highlighted	O
,	O
such	O
as	O
combination	O
of	O
different	O
angiogenic	O
growth	O
factors	O
or	O
simultaneous	O
application	O
of	O
genes	O
and	O
progenitor	B-Anatomy
cells	I-Anatomy
in	O
order	O
to	O
obtain	O
stable	O
and	O
functional	O
blood	B-Anatomy
vessels	I-Anatomy
in	O
ischemic	O
tissue	B-Anatomy
.	O
Impaired	O
apoptosis	O
of	O
pulmonary	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
is	O
associated	O
with	O
intimal	B-Anatomy
proliferation	O
and	O
irreversibility	O
of	O
pulmonary	B-Anatomy
hypertension	O
in	O
congenital	O
heart	B-Anatomy
disease	O
.	O
OBJECTIVES	O
:	O
This	O
study	O
sought	O
to	O
assess	O
the	O
cellular	B-Anatomy
and	O
histologic	O
basis	O
of	O
irreversible	O
pulmonary	B-Anatomy
hypertension	O
(	O
PHT	O
)	O
in	O
the	O
clinical	O
setting	O
of	O
congenital	O
heart	B-Anatomy
disease	O
(	O
CHD	O
)	O
.	O
BACKGROUND	O
:	O
Although	O
many	O
children	O
with	O
CHD	O
develop	O
pulmonary	B-Anatomy
vascular	I-Anatomy
disease	O
,	O
it	O
is	O
unclear	O
why	O
this	O
complication	O
is	O
reversible	O
after	O
complete	O
repair	O
in	O
some	O
cases	O
but	O
irreversible	O
in	O
others	O
.	O
Because	O
failure	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
apoptosis	O
might	O
lead	O
to	O
intimal	B-Anatomy
proliferation	O
and	O
lack	O
of	O
reversibility	O
of	O
PHT	O
,	O
we	O
investigated	O
this	O
and	O
other	O
key	O
markers	O
of	O
vasoactivity	O
and	O
angiogenesis	O
in	O
subjects	O
with	O
PHT	O
and	O
CHD	O
.	O
METHODS	O
:	O
We	O
assessed	O
antiapoptotic	O
and	O
proapoptotic	O
markers	O
in	O
vascular	B-Anatomy
and	O
perivascular	B-Anatomy
cells	I-Anatomy
in	O
lung	B-Anatomy
biopsy	I-Anatomy
samples	I-Anatomy
from	O
18	O
patients	O
with	O
CHD	O
,	O
7	O
with	O
reversible	O
and	O
11	O
with	O
irreversible	O
PHT	O
,	O
and	O
6	O
control	O
patients	O
.	O
Immunostaining	O
for	O
endothelial	O
nitric	O
oxide	O
synthase	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
and	O
CD34	O
(	O
markers	O
of	O
vasoactivity	O
and	O
neoangiogenesis	O
)	O
was	O
also	O
performed	O
.	O
RESULTS	O
:	O
The	O
antiapoptotic	O
protein	O
Bcl	O
-	O
2	O
was	O
highly	O
expressed	O
by	O
pulmonary	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
in	O
all	O
cases	O
of	O
irreversible	O
PHT	O
but	O
in	O
no	O
cases	O
of	O
reversible	O
PHT	O
,	O
nor	O
in	O
control	O
patients	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
Intimal	B-Anatomy
proliferation	O
was	O
present	O
in	O
10	O
of	O
11	O
irreversible	O
PHT	O
cases	O
,	O
but	O
never	O
observed	O
in	O
reversible	O
PHT	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
Similarly	O
,	O
perivascular	B-Anatomy
inflammatory	I-Anatomy
T	I-Anatomy
-	I-Anatomy
cells	I-Anatomy
expressed	O
more	O
antiapoptotic	O
proteins	O
in	O
irreversible	O
PHT	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
Irreversible	O
PHT	O
cases	O
were	O
also	O
more	O
likely	O
to	O
show	O
compensatory	O
upregulation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
new	O
small	O
vessel	B-Anatomy
formation	O
at	O
the	O
sites	B-Anatomy
of	O
native	O
vessel	B-Anatomy
stenosis	O
or	O
occlusion	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
CONCLUSIONS	O
:	O
Irreversible	O
PHT	O
is	O
strongly	O
associated	O
with	O
impaired	O
endothelial	B-Anatomy
cell	I-Anatomy
apoptosis	O
and	O
antiapoptotic	O
signaling	O
from	O
perivascular	B-Anatomy
inflammatory	I-Anatomy
cells	I-Anatomy
.	O
These	O
changes	O
are	O
associated	O
with	O
intimal	B-Anatomy
proliferation	O
and	O
vessel	B-Anatomy
narrowing	O
,	O
and	O
thereby	O
may	O
contribute	O
to	O
clinical	O
outcomes	O
associated	O
with	O
pulmonary	B-Anatomy
hypertension	O
.	O
Inhibition	O
of	O
Dll4	O
-	O
mediated	O
signaling	O
induces	O
proliferation	O
of	O
immature	O
vessels	B-Anatomy
and	O
results	O
in	O
poor	O
tissue	B-Anatomy
perfusion	O
.	O
Vascular	B-Anatomy
development	O
is	O
dependent	O
on	O
various	O
growth	O
factors	O
and	O
certain	O
modifiers	O
critical	O
for	O
providing	O
arterial	B-Anatomy
or	O
venous	B-Anatomy
identity	O
,	O
interaction	O
with	O
the	O
surrounding	O
stroma	B-Anatomy
and	O
tissues	B-Anatomy
,	O
hierarchic	B-Anatomy
network	I-Anatomy
formation	O
,	O
and	O
recruitment	O
of	O
pericytes	B-Anatomy
.	O
Notch	O
receptors	O
and	O
ligands	O
(	O
Jagged	O
and	O
Delta	O
-	O
like	O
)	O
play	O
a	O
critical	O
role	O
in	O
this	O
process	O
in	O
addition	O
to	O
VEGF	O
.	O
Dll4	O
is	O
one	O
of	O
the	O
Notch	O
ligands	O
that	O
regulates	O
arterial	B-Anatomy
specification	O
and	O
maturation	O
events	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
have	O
shown	O
that	O
loss	O
of	O
function	O
by	O
either	O
targeted	O
allele	O
deletion	O
or	O
use	O
of	O
a	O
soluble	O
form	O
of	O
Dll4	O
extracellular	B-Anatomy
domain	O
leads	O
to	O
inhibition	O
of	O
Notch	O
signaling	O
,	O
resulting	O
in	O
increased	O
vascular	B-Anatomy
proliferation	O
but	O
defective	O
maturation	O
.	O
Newly	O
forming	O
vessels	B-Anatomy
have	O
thin	O
caliber	B-Anatomy
,	O
a	O
markedly	O
reduced	O
vessel	B-Anatomy
lumen	I-Anatomy
,	O
markedly	O
reduced	O
pericyte	B-Anatomy
recruitment	O
,	O
and	O
deficient	O
vascular	B-Anatomy
perfusion	O
.	O
sDll4	O
similarly	O
induced	O
defective	O
vascular	B-Anatomy
response	O
in	O
tumor	B-Anatomy
implants	O
leading	O
to	O
reduced	O
tumor	B-Anatomy
growth	O
.	O
Interference	O
with	O
Dll4	O
-	O
Notch	O
signaling	O
may	O
be	O
particularly	O
desirable	O
in	O
tumors	B-Anatomy
that	O
have	O
highly	O
induced	O
Dll4	O
-	O
Notch	O
pathway	O
.	O
SWAP	O
-	O
70	O
is	O
required	O
for	O
oncogenic	O
transformation	O
by	O
v	O
-	O
Src	O
in	O
mouse	O
embryo	B-Anatomy
fibroblasts	I-Anatomy
.	O
SWAP	O
-	O
70	O
is	O
a	O
phosphatidylinositol	O
trisphosphate	O
(	O
PtdIns	O
(	O
3	O
,	O
4	O
,	O
5	O
)	O
P	O
(	O
3	O
)	O
)	O
binding	O
protein	O
,	O
which	O
acts	O
in	O
F	O
-	O
actin	O
rearrangement	O
.	O
The	O
role	O
of	O
SWAP	O
-	O
70	O
in	O
oncogenic	O
transformation	O
of	O
mouse	O
embryo	B-Anatomy
fibroblasts	I-Anatomy
(	O
MEFs	B-Anatomy
)	O
by	O
v	O
-	O
Src	O
was	O
examined	O
by	O
use	O
of	O
MEFs	B-Anatomy
defective	O
in	O
SWAP	O
-	O
70	O
.	O
v	O
-	O
Src	O
morphologically	O
transformed	O
MEFs	B-Anatomy
lacking	O
SWAP	O
-	O
70	O
,	O
but	O
growth	O
of	O
the	O
transformed	O
cells	B-Anatomy
in	O
culture	O
was	O
slower	O
than	O
that	O
of	O
cells	B-Anatomy
supplemented	O
with	O
exogenous	O
SWAP	O
-	O
70	O
.	O
The	O
v	O
-	O
Src	O
-	O
transformed	O
MEFs	B-Anatomy
deficient	O
in	O
SWAP	O
-	O
70	O
were	O
unable	O
to	O
grow	O
in	O
soft	O
agar	O
while	O
those	O
expressing	O
SWAP70	O
readily	O
formed	O
colonies	B-Anatomy
,	O
suggesting	O
that	O
SWAP	O
-	O
70	O
is	O
required	O
for	O
anchorage	O
independent	O
growth	O
of	O
v	O
-	O
Src	O
transformed	O
MEFs	B-Anatomy
.	O
When	O
transplanted	O
in	O
nude	O
mice	O
,	O
tumors	B-Anatomy
formed	O
by	O
the	O
v	O
-	O
Src	O
transformed	O
SWAP	B-Anatomy
-	I-Anatomy
70	I-Anatomy
(	I-Anatomy
-	I-Anatomy
/	I-Anatomy
-	I-Anatomy
)	I-Anatomy
MEFs	I-Anatomy
were	O
smaller	O
than	O
those	O
formed	O
by	O
cells	B-Anatomy
expressing	O
exogenous	O
SWAP	O
-	O
70	O
.	O
These	O
results	O
suggest	O
that	O
SWAP	O
-	O
70	O
may	O
be	O
required	O
for	O
oncogenic	O
transformation	O
and	O
contributes	O
to	O
cell	B-Anatomy
growth	O
in	O
MEFs	B-Anatomy
transformed	O
by	O
v	O
-	O
Src	O
.	O
Tsg101	O
is	O
upregulated	O
in	O
a	O
subset	O
of	O
invasive	B-Anatomy
human	I-Anatomy
breast	I-Anatomy
cancers	I-Anatomy
and	O
its	O
targeted	O
overexpression	O
in	O
transgenic	O
mice	O
reveals	O
weak	O
oncogenic	O
properties	O
for	O
mammary	B-Anatomy
cancer	I-Anatomy
initiation	O
.	O
Previous	O
studies	O
reported	O
that	O
the	O
Tumor	O
Susceptibility	O
Gene	O
101	O
(	O
TSG101	O
)	O
is	O
upregulated	O
in	O
selected	O
human	O
malignancies	B-Anatomy
,	O
and	O
the	O
expression	O
of	O
exogenous	O
Tsg101	O
was	O
suggested	O
to	O
transform	O
immortalized	O
fibroblasts	B-Anatomy
in	O
culture	O
.	O
To	O
date	O
,	O
the	O
potential	O
oncogenic	O
properties	O
of	O
Tsg101	O
have	O
not	O
been	O
examined	O
in	O
vivo	O
owing	O
to	O
the	O
lack	O
of	O
appropriate	O
model	O
systems	O
.	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
Tsg101	O
is	O
highly	O
expressed	O
in	O
a	O
subset	O
of	O
invasive	B-Anatomy
human	I-Anatomy
breast	I-Anatomy
cancers	I-Anatomy
.	O
Based	O
on	O
this	O
observation	O
,	O
we	O
generated	O
the	O
first	O
transgenic	O
mouse	O
model	O
with	O
a	O
targeted	O
overexpression	O
of	O
Tsg101	O
in	O
the	O
developing	O
mammary	B-Anatomy
gland	I-Anatomy
to	O
test	O
whether	O
exogenous	O
Tsg101	O
is	O
capable	O
of	O
initiating	O
tumorigenesis	O
.	O
Normal	O
functionality	O
of	O
exogenous	O
Tsg101	O
was	O
tested	O
by	O
rescuing	O
the	O
survival	O
of	O
Tsg101	O
-	O
deficient	O
mammary	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
in	O
conditional	O
knockout	O
mice	O
.	O
The	O
overexpression	O
of	O
Tsg101	O
resulted	O
in	O
increased	O
phosphorylation	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
and	O
downstream	O
activation	O
of	O
MAP	O
kinases	O
.	O
Despite	O
an	O
increase	O
in	O
the	O
activation	O
of	O
these	O
signal	O
transducers	O
,	O
the	O
mammary	B-Anatomy
gland	I-Anatomy
of	O
females	O
expressing	O
exogenous	O
Tsg101	O
developed	O
normally	O
throughout	O
the	O
reproductive	O
cycle	O
.	O
In	O
aging	O
females	O
,	O
the	O
overexpression	O
of	O
Tsg101	O
seemed	O
to	O
increase	O
the	O
susceptibility	O
of	O
mammary	B-Anatomy
epithelia	I-Anatomy
toward	O
malignant	O
transformation	O
.	O
However	O
,	O
owing	O
to	O
the	O
long	O
latency	O
of	O
tumor	B-Anatomy
formation	O
and	O
the	O
sporadic	O
occurrence	O
of	O
bona	O
fide	O
mammary	B-Anatomy
cancers	I-Anatomy
,	O
we	O
conclude	O
that	O
the	O
Tsg101	O
protein	O
has	O
only	O
weak	O
oncogenic	O
properties	O
.	O
Instead	O
of	O
cancer	B-Anatomy
initiation	O
,	O
it	O
is	O
therefore	O
likely	O
that	O
Tsg101	O
plays	O
a	O
more	O
predominant	O
role	O
in	O
the	O
progression	O
of	O
a	O
subset	O
of	O
spontaneously	O
arising	O
breast	B-Anatomy
cancers	I-Anatomy
.	O
Expression	O
of	O
Bcl	O
-	O
xL	O
,	O
Bax	O
,	O
and	O
p53	O
in	O
primary	B-Anatomy
tumors	I-Anatomy
and	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
in	O
oral	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
Disturbances	O
in	O
expression	O
of	O
apoptosis	O
-	O
associated	O
proteins	O
take	O
part	O
in	O
the	O
development	O
and	O
progression	O
of	O
many	O
human	O
malignancies	B-Anatomy
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
the	O
assessment	O
of	O
correlations	O
among	O
proteins	O
involved	O
in	O
apoptosis	O
-	O
Bcl	O
-	O
xL	O
,	O
Bax	O
,	O
and	O
p53	O
-	O
as	O
well	O
as	O
relationships	O
of	O
these	O
proteins	O
with	O
selected	O
clinicopathological	O
features	O
in	O
oral	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
Consequently	O
,	O
we	O
examined	O
by	O
immunohistochemistry	O
,	O
using	O
the	O
avidin	O
-	O
biotin	O
-	O
peroxidase	O
method	O
,	O
Bcl	O
-	O
xL	O
,	O
Bax	O
,	O
and	O
p53	O
expression	O
in	O
56	O
samples	B-Anatomy
of	O
primary	B-Anatomy
oral	I-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
and	O
in	O
22	O
matched	O
pairs	O
of	O
primary	B-Anatomy
and	O
metastatic	B-Anatomy
tumors	I-Anatomy
.	O
The	O
evaluation	O
of	O
immunostaining	O
of	O
Bcl	O
-	O
xL	O
,	O
Bax	O
,	O
and	O
p53	O
was	O
analyzed	O
in	O
10	O
different	O
tumor	B-Anatomy
fields	O
,	O
and	O
the	O
mean	O
percentage	O
of	O
tumor	B-Anatomy
cells	I-Anatomy
with	O
positive	O
staining	O
was	O
evaluated	O
.	O
The	O
significance	O
of	O
the	O
associations	O
was	O
determined	O
using	O
Spearman	O
correlation	O
analysis	O
and	O
the	O
chi	O
-	O
square	O
test	O
.	O
We	O
found	O
positive	O
Bcl	O
-	O
xL	O
,	O
Bax	O
,	O
and	O
p53	O
immunostaining	O
in	O
44	O
.	O
6	O
%	O
,	O
28	O
.	O
6	O
%	O
,	O
and	O
58	O
.	O
9	O
%	O
of	O
the	O
studied	O
primary	B-Anatomy
tumors	I-Anatomy
and	O
in	O
63	O
.	O
6	O
%	O
,	O
45	O
.	O
5	O
%	O
,	O
and	O
72	O
.	O
7	O
%	O
of	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
,	O
respectively	O
.	O
Analysis	O
of	O
associations	O
among	O
studied	O
proteins	O
revealed	O
positive	O
correlation	O
between	O
Bcl	O
-	O
xL	O
and	O
Bax	O
in	O
primary	B-Anatomy
tumors	I-Anatomy
(	O
P	O
<	O
0	O
.	O
03	O
,	O
r	O
=	O
0	O
.	O
307	O
)	O
.	O
Statistically	O
significant	O
relationship	O
between	O
p53	O
expression	O
in	O
primary	B-Anatomy
oral	I-Anatomy
cancers	I-Anatomy
and	O
its	O
expression	O
in	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
(	O
P	O
<	O
0	O
.	O
02	O
)	O
as	O
well	O
as	O
increased	O
expression	O
of	O
Bcl	O
-	O
xL	O
,	O
Bax	O
,	O
and	O
p53	O
in	O
metastatic	B-Anatomy
sites	I-Anatomy
compared	O
with	O
primary	B-Anatomy
tumors	I-Anatomy
could	O
indicate	O
an	O
association	O
of	O
these	O
proteins	O
with	O
oral	B-Anatomy
cancer	I-Anatomy
progression	O
and	O
development	O
of	O
metastases	B-Anatomy
.	O
Moreover	O
,	O
we	O
suppose	O
that	O
knowledge	O
about	O
heterogeneity	O
between	O
primary	B-Anatomy
and	O
metastatic	B-Anatomy
tumor	I-Anatomy
might	O
help	O
to	O
understand	O
mechanisms	O
of	O
oral	B-Anatomy
cancer	I-Anatomy
progression	O
.	O
The	O
relationship	O
between	O
brain	B-Anatomy
activity	O
and	O
peak	O
grip	O
force	O
is	O
modulated	O
by	O
corticospinal	B-Anatomy
system	I-Anatomy
integrity	O
after	O
subcortical	B-Anatomy
stroke	O
.	O
In	O
healthy	O
human	O
subjects	O
,	O
the	O
relative	O
contribution	O
of	O
cortical	B-Anatomy
regions	I-Anatomy
to	O
motor	O
performance	O
varies	O
with	O
the	O
task	O
parameters	O
.	O
Additionally	O
,	O
after	O
stroke	O
,	O
recruitment	O
of	O
cortical	B-Anatomy
areas	I-Anatomy
during	O
a	O
simple	O
motor	O
task	O
varies	O
with	O
corticospinal	B-Anatomy
system	I-Anatomy
integrity	O
.	O
We	O
investigated	O
whether	O
the	O
pattern	O
of	O
motor	O
system	O
recruitment	O
in	O
a	O
task	O
involving	O
increasingly	O
forceful	O
hand	B-Anatomy
grips	O
is	O
influenced	O
by	O
the	O
degree	O
of	O
corticospinal	B-Anatomy
system	I-Anatomy
damage	O
.	O
Nine	O
chronic	O
subcortical	B-Anatomy
stroke	O
patients	O
and	O
nine	O
age	O
-	O
matched	O
controls	O
underwent	O
functional	O
magnetic	O
brain	B-Anatomy
imaging	O
whilst	O
performing	O
repetitive	O
isometric	O
hand	B-Anatomy
grips	O
.	O
Target	O
grip	O
forces	O
were	O
varied	O
between	O
15	O
%	O
and	O
45	O
%	O
of	O
individual	O
maximum	O
grip	O
force	O
.	O
Corticospinal	O
system	O
functional	O
integrity	O
was	O
assessed	O
with	O
transcranial	O
magnetic	O
stimulation	O
.	O
Averaged	O
across	O
all	O
forces	O
,	O
there	O
was	O
more	O
task	O
-	O
related	O
activation	O
compared	O
with	O
rest	O
in	O
the	O
secondary	O
motor	O
areas	O
of	O
patients	O
with	O
greater	O
corticospinal	B-Anatomy
system	I-Anatomy
damage	O
,	O
confirming	O
previous	O
reports	O
.	O
However	O
,	O
here	O
we	O
were	O
primarily	O
interested	O
in	O
regional	O
brain	B-Anatomy
activation	O
,	O
which	O
covaried	O
with	O
the	O
amount	O
of	O
force	O
generated	O
,	O
implying	O
a	O
prominent	O
executive	O
role	O
in	O
force	O
production	O
.	O
We	O
found	O
that	O
in	O
control	O
subjects	O
and	O
patients	O
with	O
lesser	O
corticospinal	B-Anatomy
system	I-Anatomy
damage	O
,	O
signal	O
change	O
increased	O
linearly	O
with	O
increasing	O
force	O
output	O
in	O
contralateral	B-Anatomy
primary	I-Anatomy
motor	I-Anatomy
cortex	I-Anatomy
,	O
supplementary	B-Anatomy
motor	I-Anatomy
area	I-Anatomy
and	O
ipsilateral	B-Anatomy
cerebellum	I-Anatomy
.	O
In	O
contrast	O
,	O
in	O
patients	O
with	O
greater	O
corticospinal	B-Anatomy
system	I-Anatomy
damage	O
,	O
force	O
-	O
related	O
signal	O
changes	O
were	O
seen	O
mainly	O
in	O
contralesional	B-Anatomy
dorsolateral	I-Anatomy
premotor	I-Anatomy
cortex	I-Anatomy
,	O
bilateral	B-Anatomy
ventrolateral	I-Anatomy
premotor	I-Anatomy
cortices	I-Anatomy
and	O
contralesional	B-Anatomy
cerebellum	I-Anatomy
,	O
but	O
not	O
ipsilesional	B-Anatomy
primary	I-Anatomy
motor	I-Anatomy
cortex	I-Anatomy
.	O
These	O
findings	O
suggest	O
that	O
the	O
premotor	B-Anatomy
cortices	I-Anatomy
might	O
play	O
a	O
new	O
and	O
functionally	O
relevant	O
role	O
in	O
controlling	O
force	O
production	O
in	O
patients	O
with	O
more	O
severe	O
corticospinal	B-Anatomy
system	I-Anatomy
disruption	O
.	O
An	O
antibody	O
directed	O
against	O
PDGF	O
receptor	O
beta	O
enhances	O
the	O
antitumor	B-Anatomy
and	O
the	O
anti	O
-	O
angiogenic	O
activities	O
of	O
an	O
anti	O
-	O
VEGF	O
receptor	O
2	O
antibody	O
.	O
Platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
and	O
its	O
receptors	O
(	O
PDGFR	O
)	O
play	O
important	O
roles	O
in	O
tumorigenesis	O
through	O
stimulating	O
tumor	B-Anatomy
growth	O
and	O
promoting	O
angiogenesis	O
via	O
enhancing	O
pericyte	B-Anatomy
recruitment	O
and	O
vessel	B-Anatomy
maturation	O
.	O
Here	O
we	O
produced	O
a	O
neutralizing	O
antibody	O
,	O
1B3	O
,	O
directed	O
against	O
mouse	O
PDGFRbeta	O
.	O
1B3	O
binds	O
to	O
PDGFRbeta	O
with	O
high	O
affinity	O
(	O
9x10	O
(	O
-	O
11	O
)	O
M	O
)	O
and	O
blocks	O
PDGF	O
-	O
BB	O
from	O
binding	O
to	O
the	O
receptor	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
approximately	O
1	O
.	O
2	O
nM	O
.	O
The	O
antibody	O
also	O
blocks	O
ligand	O
-	O
stimulated	O
activation	O
of	O
PDGFRbeta	O
and	O
downstream	O
signaling	O
molecules	O
,	O
including	O
Akt	O
and	O
MAPK	O
p42	O
/	O
44	O
,	O
in	O
tumor	B-Anatomy
cells	I-Anatomy
.	O
In	O
animal	O
studies	O
,	O
1B3	O
significantly	O
enhanced	O
the	O
antitumor	B-Anatomy
and	O
the	O
anti	O
-	O
angiogenic	O
activities	O
of	O
DC101	O
,	O
an	O
antibody	O
directed	O
against	O
mouse	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
,	O
in	O
a	O
pancreatic	B-Anatomy
(	O
BxPC	B-Anatomy
-	I-Anatomy
3	I-Anatomy
)	O
and	O
a	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
(	I-Anatomy
NCI	I-Anatomy
-	I-Anatomy
H460	I-Anatomy
)	I-Anatomy
tumor	I-Anatomy
xenograft	I-Anatomy
models	O
.	O
Treatment	O
with	O
the	O
combination	O
of	O
1B3	O
and	O
DC101	O
in	O
BxPC	B-Anatomy
-	I-Anatomy
3	I-Anatomy
xenograft	I-Anatomy
-	O
bearing	O
mice	O
resulted	O
in	O
tumor	B-Anatomy
regression	O
in	O
58	O
%	O
of	O
mice	O
compared	O
to	O
that	O
in	O
18	O
%	O
of	O
mice	O
treated	O
with	O
DC101	O
alone	O
.	O
Taken	O
together	O
,	O
these	O
results	O
lend	O
great	O
support	O
to	O
use	O
PDGFRbeta	O
antagonists	O
in	O
combinations	O
with	O
other	O
antitumor	B-Anatomy
and	O
/	O
or	O
anti	O
-	O
angiogenic	O
agents	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
cancers	B-Anatomy
.	O
In	O
vivo	O
p53	O
response	O
and	O
immune	O
reaction	O
underlie	O
highly	O
effective	O
low	O
-	O
dose	O
radiotherapy	O
in	O
follicular	B-Anatomy
lymphoma	I-Anatomy
.	O
Very	O
low	O
-	O
dose	O
irradiation	O
(	O
2	O
x	O
2	O
Gy	O
)	O
is	O
a	O
new	O
,	O
effective	O
,	O
and	O
safe	O
local	O
treatment	O
for	O
follicular	B-Anatomy
lymphoma	I-Anatomy
.	O
To	O
understand	O
the	O
biologic	O
mechanisms	O
of	O
this	O
extremely	O
effective	O
response	O
,	O
we	O
compared	O
by	O
microarray	O
the	O
gene	O
-	O
expression	O
profile	O
of	O
patients	O
'	O
biopsies	B-Anatomy
taken	O
before	O
and	O
after	O
radiation	O
.	O
In	O
all	O
patients	O
,	O
a	O
major	O
and	O
consistent	O
induction	O
of	O
p53	O
target	O
genes	O
was	O
seen	O
.	O
p53	O
targets	O
involved	O
in	O
cell	B-Anatomy
-	O
cycle	O
arrest	O
and	O
apoptosis	O
showed	O
the	O
same	O
mode	O
of	O
regulation	O
,	O
indicating	O
that	O
,	O
in	O
vivo	O
,	O
both	O
are	O
activated	O
simultaneously	O
.	O
p53	O
up	O
-	O
regulation	O
and	O
p53	O
-	O
mediated	O
proliferation	O
arrest	O
and	O
apoptosis	O
were	O
substantiated	O
using	O
immunohistochemistry	O
,	O
with	O
activation	O
of	O
both	O
the	O
intrinsic	O
and	O
the	O
extrinsic	O
apoptotic	O
pathways	O
.	O
The	O
other	O
induced	O
genes	O
revealed	O
a	O
whole	O
set	O
of	O
biologically	O
meaningful	O
genes	O
related	O
to	O
macrophage	B-Anatomy
activation	O
and	O
TH1	O
immune	O
response	O
.	O
Immunohistochemical	O
analysis	O
suggested	O
a	O
specific	O
activation	O
or	O
differentiation	O
of	O
resident	O
macrophages	B-Anatomy
by	O
apoptotic	O
cells	B-Anatomy
.	O
These	O
biologic	O
insights	O
are	O
important	O
arguments	O
to	O
advocate	O
the	O
use	O
of	O
low	O
-	O
dose	O
radiotherapy	O
as	O
an	O
effective	O
palliative	O
treatment	O
for	O
follicular	B-Anatomy
lymphoma	I-Anatomy
.	O
Moreover	O
,	O
this	O
study	O
is	O
the	O
first	O
in	O
vivo	O
report	O
of	O
the	O
radiation	O
-	O
induced	O
p53	O
apoptotic	O
response	O
in	O
patients	O
and	O
suggests	O
that	O
this	O
apoptotic	O
response	O
is	O
not	O
immunologically	O
silent	O
.	O
Caffeine	O
inhibits	O
adenosine	O
-	O
induced	O
accumulation	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
and	O
interleukin	O
-	O
8	O
expression	O
in	O
hypoxic	O
human	O
colon	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Frequent	O
coffee	O
consumption	O
has	O
been	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
colorectal	B-Anatomy
cancer	I-Anatomy
in	O
a	O
number	O
of	O
case	O
-	O
control	O
studies	O
.	O
Coffee	O
is	O
a	O
leading	O
source	O
of	O
methylxanthines	O
,	O
such	O
as	O
caffeine	O
.	O
The	O
induction	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
is	O
an	O
essential	O
feature	O
of	O
tumor	B-Anatomy
angiogenesis	O
,	O
and	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
(	O
HIF	O
-	O
1	O
)	O
transcription	O
factor	O
is	O
known	O
to	O
be	O
a	O
key	O
regulator	O
of	O
this	O
process	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
caffeine	O
on	O
HIF	O
-	O
1	O
protein	O
accumulation	O
and	O
on	O
VEGF	O
and	O
IL	O
-	O
8	O
expression	O
in	O
the	O
human	O
colon	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
HT29	I-Anatomy
under	O
hypoxic	O
conditions	O
.	O
Our	O
results	O
show	O
that	O
caffeine	O
significantly	O
inhibits	O
adenosine	O
-	O
induced	O
HIF	O
-	O
1alpha	O
protein	O
accumulation	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
We	O
show	O
that	O
HIF	O
-	O
1alpha	O
and	O
VEGF	O
are	O
increased	O
through	O
A3	O
adenosine	O
receptor	O
stimulation	O
,	O
whereas	O
the	O
effects	O
on	O
IL	O
-	O
8	O
are	O
mediated	O
via	O
the	O
A2B	O
subtype	O
.	O
Pretreatment	O
of	O
cells	B-Anatomy
with	O
caffeine	O
significantly	O
reduces	O
adenosine	O
-	O
induced	O
VEGF	O
promoter	O
activity	O
and	O
VEGF	O
and	O
IL	O
-	O
8	O
expression	O
.	O
The	O
mechanism	O
of	O
caffeine	O
seems	O
to	O
involve	O
the	O
inhibition	O
of	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
,	O
p38	O
,	O
and	O
Akt	O
,	O
leading	O
to	O
a	O
marked	O
decrease	O
in	O
adenosine	O
-	O
induced	O
HIF	O
-	O
1alpha	O
accumulation	O
,	O
VEGF	O
transcriptional	O
activation	O
,	O
and	O
VEGF	O
and	O
IL	O
-	O
8	O
protein	O
accumulation	O
.	O
From	O
a	O
functional	O
perspective	O
,	O
we	O
observe	O
that	O
caffeine	O
also	O
significantly	O
inhibits	O
the	O
A3	O
receptor	O
-	O
stimulated	O
cell	B-Anatomy
migration	O
of	O
colon	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Conditioned	O
media	O
prepared	O
from	O
colon	B-Anatomy
cells	I-Anatomy
treated	O
with	O
an	O
adenosine	O
analog	O
increased	O
human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
migration	O
.	O
These	O
data	O
provide	O
evidence	O
that	O
adenosine	O
could	O
modulate	O
the	O
migration	O
of	O
colon	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
by	O
an	O
HIF	O
-	O
1alpha	O
/	O
VEGF	O
/	O
IL	O
-	O
8	O
-	O
dependent	O
mechanism	O
and	O
that	O
caffeine	O
has	O
the	O
potential	O
to	O
inhibit	O
colon	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
growth	O
.	O
Stress	O
and	O
psychological	O
distress	O
among	O
SARS	O
survivors	O
1	O
year	O
after	O
the	O
outbreak	O
.	O
OBJECTIVE	O
:	O
Our	O
study	O
examined	O
the	O
stress	O
level	O
and	O
psychological	O
distress	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
survivors	O
1	O
year	O
after	O
the	O
outbreak	O
.	O
METHOD	O
:	O
During	O
the	O
SARS	O
outbreak	O
in	O
2003	O
,	O
we	O
used	O
the	O
10	O
-	O
item	O
Perceived	O
Stress	O
Scale	O
(	O
PSS	O
-	O
10	O
)	O
to	O
assess	O
SARS	O
survivors	O
treated	O
in	O
2	O
major	O
hospitals	O
(	O
non	O
-	O
health	O
care	O
workers	O
,	O
n	O
=	O
49	O
;	O
health	O
care	O
workers	O
,	O
n	O
=	O
30	O
)	O
.	O
We	O
invited	O
SARS	O
survivors	O
from	O
the	O
same	O
hospitals	O
(	O
non	O
-	O
health	O
care	O
workers	O
,	O
n	O
=	O
63	O
;	O
health	O
care	O
workers	O
,	O
n	O
=	O
33	O
)	O
to	O
complete	O
the	O
PSS	O
-	O
10	O
again	O
in	O
2004	O
.	O
At	O
that	O
time	O
,	O
they	O
were	O
also	O
asked	O
to	O
complete	O
the	O
General	O
Health	O
Questionnaire	O
(	O
GHQ	O
-	O
12	O
)	O
and	O
measures	O
of	O
depression	O
,	O
anxiety	O
,	O
and	O
posttraumatic	O
symptoms	O
.	O
PSS	O
-	O
10	O
scores	O
were	O
also	O
obtained	O
from	O
matched	O
community	O
control	O
subjects	O
during	O
the	O
outbreak	O
(	O
n	O
=	O
145	O
)	O
and	O
again	O
in	O
2004	O
(	O
n	O
=	O
112	O
)	O
.	O
RESULTS	O
:	O
SARS	O
survivors	O
had	O
higher	O
stress	O
levels	O
during	O
the	O
outbreak	O
,	O
compared	O
with	O
control	O
subjects	O
(	O
PSS	O
-	O
10	O
scores	O
=	O
19	O
.	O
8	O
and	O
17	O
.	O
9	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
this	O
persisted	O
1	O
year	O
later	O
(	O
PSS	O
-	O
10	O
scores	O
=	O
19	O
.	O
9	O
and	O
17	O
.	O
3	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
without	O
signs	O
of	O
decrease	O
.	O
In	O
2004	O
,	O
SARS	O
survivors	O
also	O
showed	O
worrying	O
levels	O
of	O
depression	O
,	O
anxiety	O
,	O
and	O
posttraumatic	O
symptoms	O
.	O
An	O
alarming	O
proportion	O
(	O
64	O
%	O
)	O
scored	O
above	O
the	O
GHQ	O
-	O
12	O
cut	O
-	O
off	O
that	O
suggests	O
psychiatric	O
morbidity	O
.	O
During	O
the	O
outbreak	O
,	O
health	O
care	O
worker	O
SARS	O
survivors	O
had	O
stress	O
levels	O
similar	O
to	O
those	O
of	O
non	O
-	O
health	O
care	O
workers	O
,	O
but	O
health	O
care	O
workers	O
showed	O
significantly	O
higher	O
stress	O
levels	O
in	O
2004	O
(	O
PSS	O
-	O
10	O
score	O
=	O
22	O
.	O
8	O
,	O
compared	O
with	O
PSS	O
-	O
10	O
score	O
=	O
18	O
.	O
4	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
had	O
higher	O
depression	O
,	O
anxiety	O
,	O
posttraumatic	O
symptoms	O
,	O
and	O
GHQ	O
-	O
12	O
scores	O
.	O
CONCLUSIONS	O
:	O
One	O
year	O
after	O
the	O
outbreak	O
,	O
SARS	O
survivors	O
still	O
had	O
elevated	O
stress	O
levels	O
and	O
worrying	O
levels	O
of	O
psychological	O
distress	O
.	O
The	O
situation	O
of	O
health	O
care	O
worker	O
SARS	O
survivors	O
is	O
particularly	O
worrying	O
.	O
The	O
long	O
-	O
term	O
psychological	O
implications	O
of	O
infectious	O
diseases	O
should	O
not	O
be	O
ignored	O
.	O
Mental	O
health	O
services	O
could	O
play	O
an	O
important	O
role	O
in	O
rehabilitation	O
.	O
Characterization	O
of	O
transferrin	O
glycoforms	O
in	O
human	O
serum	B-Anatomy
by	O
CE	O
-	O
UV	O
and	O
CE	O
-	O
ESI	O
-	O
MS	O
.	O
Human	O
transferrin	O
(	O
Tf	O
)	O
is	O
a	O
model	O
glycoprotein	O
for	O
congenital	O
disorders	O
of	O
glycosylation	O
(	O
CDG	O
)	O
diagnosis	O
.	O
In	O
the	O
last	O
few	O
years	O
,	O
new	O
CE	O
-	O
UV	O
methods	O
for	O
intact	O
Tf	O
glycoforms	O
analysis	O
have	O
been	O
developed	O
using	O
nonvolatile	O
BGEs	O
and	O
organic	O
modifiers	O
.	O
However	O
,	O
the	O
use	O
of	O
these	O
BGEs	O
does	O
not	O
allow	O
the	O
coupling	O
of	O
these	O
procedures	O
with	O
electrospray	O
MS	O
(	O
ESI	O
-	O
MS	O
)	O
.	O
In	O
this	O
study	O
,	O
a	O
new	O
CE	O
-	O
UV	O
separation	O
method	O
of	O
Tf	O
glycoforms	O
is	O
developed	O
,	O
using	O
a	O
double	O
-	O
layer	O
stable	O
coating	O
and	O
a	O
volatile	O
BGE	O
based	O
on	O
ammonium	O
acetate	O
.	O
The	O
separation	O
method	O
is	O
optimized	O
using	O
standard	O
Tf	O
and	O
their	O
potential	O
is	O
demonstrated	O
applying	O
the	O
method	O
to	O
the	O
analysis	O
of	O
sera	B-Anatomy
Tf	O
from	O
healthy	O
individuals	O
and	O
CDG	O
patients	O
.	O
The	O
CE	O
-	O
UV	O
separation	O
method	O
has	O
been	O
coupled	O
to	O
ESI	O
-	O
MS	O
detection	O
.	O
Main	O
parameters	O
such	O
as	O
sheath	O
liquid	O
composition	O
are	O
optimized	O
in	O
order	O
to	O
obtain	O
a	O
good	O
sensitivity	O
.	O
The	O
CE	O
-	O
ESI	O
-	O
MS	O
method	O
has	O
also	O
been	O
used	O
in	O
serum	B-Anatomy
samples	I-Anatomy
obtaining	O
the	O
separation	O
of	O
the	O
different	O
proteins	O
present	O
in	O
serum	B-Anatomy
and	O
partial	O
separation	O
of	O
Tf	O
glycoforms	O
.	O
Different	O
mass	O
spectra	O
and	O
deconvoluted	O
molecular	O
masses	O
were	O
obtained	O
for	O
each	O
sialoform	O
,	O
allowing	O
unequivocal	O
glycoform	O
identification	O
.	O
Medical	O
therapy	O
for	O
intermittent	O
claudication	O
.	O
Medical	O
therapy	O
to	O
improve	O
symptoms	O
,	O
stabilise	O
the	O
underlying	O
vascular	B-Anatomy
disease	O
and	O
improve	O
lower	B-Anatomy
limb	I-Anatomy
outcomes	O
is	O
an	O
important	O
and	O
effective	O
adjunct	O
to	O
lifestyle	O
modification	O
and	O
surgical	O
or	O
endovascular	B-Anatomy
interventions	O
in	O
patients	O
with	O
IC	O
.	O
Randomised	O
placebo	O
controlled	O
trials	O
have	O
shown	O
that	O
the	O
phosphodiesterase	O
III	O
inhibitor	O
cilostazol	O
100mg	O
bid	O
improves	O
pain	O
-	O
free	O
and	O
maximum	O
walking	O
distance	O
,	O
as	O
well	O
as	O
quality	O
of	O
life	O
,	O
in	O
a	O
range	O
of	O
patients	O
with	O
intermittent	O
claudication	O
in	O
whom	O
there	O
is	O
no	O
evidence	O
of	O
tissue	B-Anatomy
necrosis	O
or	O
rest	O
pain	O
.	O
This	O
review	O
summarises	O
the	O
evidence	O
from	O
8	O
pivotal	O
trials	O
of	O
cilostazol	O
involving	O
over	O
2000	O
patients	O
with	O
intermittent	O
claudication	O
treated	O
for	O
up	O
to	O
6	O
months	O
.	O
There	O
is	O
comparatively	O
less	O
evidence	O
to	O
support	O
the	O
use	O
of	O
other	O
treatment	O
modalities	O
for	O
relief	O
of	O
symptoms	O
in	O
intermittent	O
claudication	O
,	O
but	O
there	O
is	O
considerable	O
interest	O
in	O
therapeutic	O
angiogenesis	O
to	O
promote	O
new	O
vessel	B-Anatomy
formation	O
and	O
enhance	O
collateralisation	O
of	O
the	O
lower	B-Anatomy
limb	I-Anatomy
using	O
recombinant	O
growth	O
factor	O
proteins	O
or	O
gene	O
transfer	O
strategies	O
.	O
The	O
rationale	O
for	O
therapeutic	O
angiogenesis	O
is	O
discussed	O
,	O
together	O
with	O
the	O
most	O
recent	O
results	O
from	O
randomised	O
trials	O
in	O
patients	O
with	O
peripheral	B-Anatomy
arterial	I-Anatomy
disease	O
.	O
Modulating	O
metastasis	O
by	O
a	O
lymphangiogenic	O
switch	O
in	O
prostate	B-Anatomy
cancer	I-Anatomy
.	O
Prostate	B-Anatomy
cancer	I-Anatomy
dissemination	O
is	O
difficult	O
to	O
detect	O
in	O
the	O
clinic	O
,	O
and	O
few	O
treatment	O
options	O
exist	O
for	O
patients	O
with	O
advanced	O
-	O
stage	O
disease	O
.	O
Our	O
aim	O
was	O
to	O
investigate	O
the	O
role	O
of	O
tumor	B-Anatomy
lymphangiogenesis	O
during	O
metastasis	O
.	O
Further	O
,	O
we	O
implemented	O
a	O
noninvasive	O
molecular	O
imaging	O
technique	O
to	O
facilitate	O
the	O
assessment	O
of	O
the	O
metastatic	O
process	O
.	O
The	O
metastatic	O
potentials	O
of	O
several	O
human	O
prostate	B-Anatomy
cancer	I-Anatomy
xenograft	I-Anatomy
models	O
,	O
LAPC	B-Anatomy
-	I-Anatomy
4	I-Anatomy
,	O
LAPC	B-Anatomy
-	I-Anatomy
9	I-Anatomy
,	O
PC3	B-Anatomy
and	O
CWR22Rv	B-Anatomy
-	I-Anatomy
1	I-Anatomy
were	O
compared	O
.	O
The	O
cells	B-Anatomy
were	O
labeled	O
with	O
luciferase	O
,	O
a	O
bioluminescence	O
imaging	O
reporter	O
gene	O
,	O
to	O
enable	O
optical	O
imaging	O
.	O
After	O
tumor	B-Anatomy
implantation	O
the	O
animals	O
were	O
examined	O
weekly	O
during	O
several	O
months	O
for	O
the	O
appearance	O
of	O
metastases	B-Anatomy
.	O
Metastatic	B-Anatomy
lesions	I-Anatomy
were	O
confirmed	O
by	O
immunohistochemistry	O
.	O
Additionally	O
,	O
the	O
angiogenic	O
and	O
lymphangiogenic	O
profiles	O
of	O
the	O
tumors	B-Anatomy
were	O
characterized	O
.	O
To	O
confirm	O
the	O
role	O
of	O
lymphangiogenesis	O
in	O
mediating	O
metastasis	O
,	O
the	O
low	B-Anatomy
-	I-Anatomy
metastatic	I-Anatomy
LAPC	I-Anatomy
-	I-Anatomy
9	I-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
were	O
engineered	O
to	O
overexpress	O
VEGF	O
-	O
C	O
,	O
and	O
the	O
development	O
of	O
metastases	B-Anatomy
was	O
evaluated	O
.	O
Our	O
results	O
show	O
CWR22Rv	B-Anatomy
-	I-Anatomy
1	I-Anatomy
and	O
PC3	B-Anatomy
tumor	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
to	O
be	O
more	O
metastatic	O
than	O
LAPC	B-Anatomy
-	I-Anatomy
4	I-Anatomy
,	O
which	O
in	O
turn	O
disseminates	O
more	O
readily	O
than	O
LAPC	B-Anatomy
-	I-Anatomy
9	I-Anatomy
.	O
The	O
difference	O
in	O
metastatic	O
potential	O
correlated	O
with	O
the	O
endogenous	O
production	O
levels	O
of	O
lymphangiogenic	O
growth	O
factor	O
VEGF	O
-	O
C	O
and	O
the	O
presence	O
of	O
tumor	B-Anatomy
lymphatics	I-Anatomy
.	O
In	O
agreement	O
,	O
induced	O
overexpression	O
of	O
VEGF	O
-	O
C	O
in	O
LAPC	B-Anatomy
-	I-Anatomy
9	I-Anatomy
enhanced	O
tumor	B-Anatomy
lymphangiogenesis	O
leading	O
to	O
the	O
development	O
of	O
metastatic	B-Anatomy
lesions	I-Anatomy
.	O
Taken	O
together	O
,	O
our	O
studies	O
,	O
based	O
on	O
a	O
molecular	O
imaging	O
approach	O
for	O
semiquantitative	O
detection	O
of	O
micrometastases	O
,	O
point	O
to	O
an	O
important	O
role	O
of	O
tumor	B-Anatomy
lymphatics	I-Anatomy
in	O
the	O
metastatic	O
process	O
of	O
human	O
prostate	B-Anatomy
cancer	I-Anatomy
.	O
In	O
particular	O
,	O
VEGF	O
-	O
C	O
seems	O
to	O
play	O
a	O
key	O
role	O
in	O
prostate	B-Anatomy
cancer	I-Anatomy
metastasis	O
.	O
Selective	O
activation	O
of	O
mast	B-Anatomy
cells	I-Anatomy
in	O
rheumatoid	B-Anatomy
synovial	I-Anatomy
tissue	I-Anatomy
results	O
in	O
production	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
1Ra	O
.	O
OBJECTIVES	O
AND	O
DESIGN	O
:	O
To	O
study	O
the	O
consequences	O
of	O
mast	B-Anatomy
cell	I-Anatomy
activation	O
in	O
human	O
synovial	B-Anatomy
tissue	I-Anatomy
.	O
METHODS	O
:	O
Synovial	B-Anatomy
tissue	I-Anatomy
was	O
obtained	O
from	O
18	O
RA	O
patients	O
and	O
mast	B-Anatomy
cells	I-Anatomy
was	O
selectively	O
activated	O
in	O
synovial	B-Anatomy
tissue	I-Anatomy
explant	O
cultures	O
.	O
Expression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
1Ra	O
were	O
determined	O
and	O
tissue	B-Anatomy
distribution	O
of	O
IL	O
-	O
1beta	O
was	O
studied	O
.	O
RESULTS	O
:	O
Compared	O
to	O
untreated	O
synovia	B-Anatomy
,	O
selective	O
activation	O
of	O
synovial	B-Anatomy
mast	I-Anatomy
cells	I-Anatomy
increased	O
significantly	O
the	O
production	O
of	O
TNF	O
-	O
alpha	O
(	O
0	O
.	O
49	O
+	O
/	O
-	O
0	O
.	O
88	O
vs	O
.	O
4	O
.	O
56	O
+	O
/	O
-	O
3	O
.	O
18	O
pg	O
/	O
mg	O
wet	B-Anatomy
tissue	I-Anatomy
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
IL	O
-	O
1beta	O
(	O
0	O
.	O
058	O
+	O
/	O
-	O
0	O
.	O
032	O
vs	O
.	O
2	O
.	O
55	O
+	O
/	O
-	O
1	O
.	O
98	O
pg	O
/	O
mg	O
wet	B-Anatomy
tissue	I-Anatomy
,	O
p	O
=	O
0	O
.	O
013	O
)	O
.	O
The	O
expression	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1beta	O
mRNA	O
increased	O
significantly	O
(	O
19	O
-	O
fold	O
(	O
p	O
=	O
0	O
.	O
009	O
)	O
and	O
13	O
-	O
fold	O
(	O
p	O
=	O
0	O
.	O
031	O
)	O
,	O
respectively	O
)	O
.	O
Mast	B-Anatomy
cell	I-Anatomy
activation	O
induced	O
IL	O
-	O
1beta	O
expression	O
in	O
particular	O
in	O
nearby	O
CD68	B-Anatomy
positive	I-Anatomy
synovial	I-Anatomy
macrophages	I-Anatomy
.	O
Secretion	O
of	O
IL	O
-	O
1Ra	O
was	O
also	O
increased	O
but	O
to	O
a	O
lesser	O
degree	O
than	O
that	O
of	O
IL	O
-	O
1beta	O
.	O
CONCLUSIONS	O
:	O
Synovial	B-Anatomy
mast	I-Anatomy
cells	I-Anatomy
produce	O
proinflammmatory	O
cytokines	O
and	O
may	O
thus	O
contribute	O
to	O
the	O
inflammation	O
in	O
RA	O
.	O
An	O
assay	O
to	O
measure	O
angiogenesis	O
in	O
human	O
fat	B-Anatomy
tissue	I-Anatomy
.	O
BACKGROUND	O
:	O
Inhibition	O
of	O
angiogenesis	O
reverses	O
rodent	O
obesity	O
.	O
A	O
validated	O
assay	O
in	O
human	O
fat	B-Anatomy
tissue	I-Anatomy
is	O
needed	O
to	O
study	O
the	O
role	O
of	O
angiogenesis	O
in	O
human	O
obesity	O
.	O
METHODS	O
:	O
Human	O
fat	B-Anatomy
tissue	I-Anatomy
fragments	I-Anatomy
from	O
surgery	O
were	O
placed	O
in	O
96	O
-	O
well	O
plates	O
,	O
embedded	O
in	O
fibrin	O
thrombin	O
clot	B-Anatomy
and	O
overlaid	O
with	O
cell	B-Anatomy
culture	O
media	O
containing	O
20	O
%	O
fetal	B-Anatomy
bovine	I-Anatomy
serum	I-Anatomy
.	O
After	O
15	O
days	O
,	O
the	O
clots	B-Anatomy
were	O
examined	O
by	O
histology	O
and	O
electron	O
microscopy	O
.	O
The	O
effect	O
of	O
taxol	O
,	O
cobalt	O
chloride	O
and	O
a	O
heparin	O
-	O
steroid	O
combination	O
was	O
tested	O
in	O
the	O
fat	B-Anatomy
tissue	I-Anatomy
assay	O
and	O
compared	O
to	O
the	O
validated	O
human	O
placental	B-Anatomy
vein	I-Anatomy
angiogenesis	O
model	O
(	O
HPVAM	O
)	O
.	O
RESULTS	O
:	O
Blood	B-Anatomy
vessels	I-Anatomy
initiated	O
growth	O
and	O
elongated	O
from	O
the	O
fat	B-Anatomy
tissue	I-Anatomy
fragments	I-Anatomy
over	O
15	O
days	O
.	O
Presence	O
of	O
blood	B-Anatomy
vessels	I-Anatomy
was	O
confirmed	O
with	O
histology	O
and	O
electron	O
microscopy	O
.	O
Taxol	O
at	O
10	O
(	O
-	O
6	O
)	O
and	O
10	O
(	O
-	O
7	O
)	O
M	O
completely	O
inhibited	O
angiogenesis	O
,	O
while	O
Taxol	O
10	O
(	O
-	O
8	O
)	O
and	O
10	O
(	O
-	O
9	O
)	O
M	O
and	O
the	O
heparin	O
-	O
steroid	O
partially	O
inhibited	O
angiogenesis	O
.	O
The	O
response	O
to	O
taxol	O
and	O
heparin	O
-	O
steroid	O
was	O
similar	O
to	O
that	O
of	O
the	O
HPVAM	O
,	O
a	O
validated	O
angiogenesis	O
assay	O
.	O
Cobalt	O
chloride	O
,	O
a	O
stimulator	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
stimulated	O
angiogenesis	O
initiation	O
at	O
10	O
(	O
-	O
9	O
)	O
M	O
in	O
fat	B-Anatomy
tissue	I-Anatomy
and	O
the	O
HPVAM	O
,	O
but	O
at	O
10	O
(	O
-	O
10	O
)	O
M	O
blood	B-Anatomy
vessel	I-Anatomy
growth	O
was	O
stimulated	O
only	O
in	O
the	O
fat	B-Anatomy
assay	O
.	O
CONCLUSION	O
:	O
This	O
angiogenesis	O
assay	O
based	O
on	O
human	O
fat	B-Anatomy
tissue	I-Anatomy
uses	O
three	O
-	O
dimensionally	O
intact	O
human	O
tissue	B-Anatomy
.	O
The	O
vessels	B-Anatomy
are	O
derived	O
from	O
quiescient	B-Anatomy
vessels	I-Anatomy
within	O
the	O
fat	B-Anatomy
.	O
These	O
properties	O
allow	O
the	O
angiogenic	O
switch	O
to	O
be	O
evaluated	O
in	O
an	O
in	O
vitro	O
setting	O
.	O
The	O
angiogenic	O
response	O
of	O
fat	B-Anatomy
tissue	I-Anatomy
is	O
not	O
identical	O
to	O
placental	B-Anatomy
tissue	I-Anatomy
.	O
This	O
assay	O
allows	O
exploration	O
of	O
angiogenesis	O
in	O
fat	B-Anatomy
tissue	I-Anatomy
.	O
Rapid	O
mixing	O
between	O
old	O
and	O
new	O
C	O
pools	O
in	O
the	O
canopy	O
of	O
mature	O
forest	O
trees	O
.	O
Stable	O
C	O
isotope	O
signals	O
in	O
plant	O
tissues	B-Anatomy
became	O
a	O
key	O
tool	O
in	O
explaining	O
growth	O
responses	O
to	O
the	O
environment	O
.	O
The	O
technique	O
is	O
based	O
on	O
the	O
fundamental	O
assumption	O
that	O
the	O
isotopic	O
composition	O
of	O
a	O
given	O
unit	O
of	O
tissue	B-Anatomy
(	O
e	O
.	O
g	O
.	O
a	O
tree	B-Anatomy
ring	I-Anatomy
)	O
reflects	O
the	O
specific	O
C	O
uptake	O
conditions	O
in	O
the	O
leaf	B-Anatomy
at	O
a	O
given	O
time	O
.	O
Beyond	O
the	O
methodological	O
implications	O
of	O
any	O
deviation	O
from	O
this	O
assumption	O
,	O
it	O
is	O
of	O
physiological	O
interest	O
whether	O
new	O
C	O
is	O
transferred	O
directly	O
from	O
sources	O
(	O
a	O
photosynthesizing	O
leaf	B-Anatomy
)	O
to	O
structural	O
sinks	O
(	O
e	O
.	O
g	O
.	O
adjacent	O
stem	B-Anatomy
tissue	I-Anatomy
)	O
,	O
or	O
inherently	O
passes	O
through	O
existing	O
(	O
mobile	O
)	O
C	O
pools	O
,	O
which	O
may	O
be	O
of	O
variable	O
(	O
older	O
)	O
age	O
.	O
Here	O
,	O
we	O
explore	O
the	O
fate	O
of	O
(	O
13	O
)	O
C	O
-	O
labelled	O
photosynthates	O
in	O
the	O
crowns	B-Anatomy
of	O
a	O
30	O
-	O
35	O
m	O
tall	O
,	O
mixed	O
forest	O
using	O
a	O
canopy	O
crane	O
.	O
In	O
all	O
nine	O
study	O
species	O
labelled	O
C	O
reached	O
woody	B-Anatomy
tissue	I-Anatomy
within	O
2	O
-	O
9	O
h	O
after	O
labelling	O
.	O
Four	O
months	O
later	O
,	O
very	O
small	O
signals	O
were	O
left	O
in	O
branch	B-Anatomy
wood	I-Anatomy
of	O
Tilia	O
suggesting	O
that	O
low	O
mixing	O
of	O
new	O
,	O
labelled	O
C	O
with	O
old	O
C	O
had	O
taken	O
place	O
.	O
In	O
contrast	O
,	O
signals	O
in	O
Fagus	O
and	O
Quercus	O
had	O
increased	O
,	O
indicating	O
more	O
intense	O
mixing	O
.	O
This	O
species	O
-	O
specific	O
mixing	O
of	O
new	O
with	O
old	O
C	O
pools	O
is	O
likely	O
to	O
mask	O
year	O
-	O
or	O
season	O
-	O
specific	O
linkages	O
between	O
tree	B-Anatomy
ring	I-Anatomy
formation	O
and	O
climate	O
and	O
has	O
considerable	O
implications	O
for	O
climate	O
reconstruction	O
using	O
stable	O
isotopes	O
as	O
proxies	O
for	O
past	O
climatic	O
conditions	O
.	O
Subcellular	B-Anatomy
localisation	O
of	O
BAG	O
-	O
1	O
and	O
its	O
regulation	O
of	O
vitamin	O
D	O
receptor	O
-	O
mediated	O
transactivation	O
and	O
involucrin	O
expression	O
in	O
oral	B-Anatomy
keratinocytes	I-Anatomy
:	O
implications	O
for	O
oral	B-Anatomy
carcinogenesis	O
.	O
In	O
oral	B-Anatomy
cancers	I-Anatomy
,	O
cytoplasmic	B-Anatomy
BAG	O
-	O
1	O
overexpression	O
is	O
a	O
marker	O
of	O
poor	O
prognosis	O
.	O
BAG	O
-	O
1	O
regulates	O
cellular	B-Anatomy
growth	O
,	O
differentiation	O
and	O
survival	O
through	O
interactions	O
with	O
diverse	O
proteins	O
,	O
including	O
the	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
,	O
a	O
key	O
regulator	O
of	O
keratinocyte	B-Anatomy
growth	O
and	O
differentiation	O
.	O
BAG	O
-	O
1	O
is	O
expressed	O
ubiquitously	O
in	O
human	O
cells	B-Anatomy
as	O
three	O
major	O
isoforms	O
of	O
50	O
kDa	O
(	O
BAG	O
-	O
1L	O
)	O
,	O
46	O
kDa	O
(	O
BAG	O
-	O
1M	O
)	O
and	O
36	O
kDa	O
(	O
BAG	O
-	O
1S	O
)	O
from	O
a	O
single	O
mRNA	O
.	O
In	O
oral	B-Anatomy
keratinocytes	I-Anatomy
BAG	O
-	O
1L	O
,	O
but	O
not	O
BAG	O
-	O
1M	O
and	O
BAG	O
-	O
1S	O
,	O
enhanced	O
VDR	O
transactivation	O
in	O
response	O
to	O
1alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
.	O
BAG	O
-	O
1L	O
was	O
nucleoplasmic	B-Anatomy
and	O
nucleolar	B-Anatomy
,	O
whereas	O
BAG	O
-	O
1S	O
and	O
BAG	O
-	O
1M	O
were	O
cytoplasmic	B-Anatomy
and	O
nucleoplasmic	B-Anatomy
in	O
localisation	O
.	O
Having	O
identified	O
the	O
nucleolar	B-Anatomy
localisation	O
sequence	O
in	O
BAG	O
-	O
1L	O
,	O
we	O
showed	O
that	O
mutation	O
of	O
this	O
sequence	O
did	O
not	O
prevent	O
BAG	O
-	O
1L	O
from	O
potentiating	O
VDR	O
activity	O
.	O
BAG	O
-	O
1L	O
also	O
potentiated	O
transactivation	O
of	O
known	O
vitamin	O
-	O
D	O
-	O
responsive	O
gene	O
promoters	O
,	O
osteocalcin	O
and	O
24	O
-	O
hydroxylase	O
,	O
and	O
enhanced	O
VDR	O
-	O
dependent	O
transcription	O
and	O
protein	O
expression	O
of	O
the	O
keratinocyte	B-Anatomy
differentiation	O
marker	O
,	O
involucrin	O
.	O
These	O
results	O
demonstrate	O
endogenous	O
gene	O
regulation	O
by	O
BAG	O
-	O
1L	O
by	O
potentiating	O
nuclear	O
hormone	O
receptor	O
function	O
and	O
suggest	O
a	O
role	O
for	O
BAG	O
-	O
1L	O
in	O
24	O
-	O
hydroxylase	O
regulation	O
of	O
vitamin	O
D	O
metabolism	O
and	O
the	O
cellular	B-Anatomy
response	O
of	O
oral	B-Anatomy
keratinocytes	I-Anatomy
to	O
1alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
.	O
By	O
contrast	O
to	O
the	O
cytoplasmic	B-Anatomy
BAG	O
-	O
1	O
isoforms	O
,	O
BAG	O
-	O
1L	O
may	O
act	O
to	O
suppress	O
tumorigenesis	O
.	O
Transporters	O
,	O
enzymes	O
,	O
and	O
enalapril	O
removal	O
in	O
a	O
rat	O
(	O
CC531	B-Anatomy
-	O
induced	O
)	O
liver	B-Anatomy
metastatic	O
model	O
.	O
Temporal	O
changes	O
in	O
physiological	O
spaces	O
,	O
protein	O
expression	O
of	O
transporters	O
and	O
enzymes	O
,	O
and	O
enalapril	O
removal	O
were	O
appraised	O
in	O
the	O
metastatic	B-Anatomy
liver	I-Anatomy
tumor	I-Anatomy
model	O
developed	O
from	O
male	O
Wag	O
/	O
Rij	O
rats	O
after	O
the	O
intraportal	O
injection	O
of	O
CC531	B-Anatomy
colon	I-Anatomy
adenocarcinoma	I-Anatomy
cells	I-Anatomy
;	O
sham	O
-	O
operated	O
preparations	O
received	O
PBS	O
.	O
Liver	B-Anatomy
tissue	I-Anatomy
spaces	O
,	O
investigated	O
with	O
multiple	O
indicator	O
dilution	O
technique	O
in	O
liver	B-Anatomy
perfusion	O
studies	O
,	O
were	O
unchanged	O
at	O
week	O
3	O
after	O
tumor	B-Anatomy
induction	O
.	O
At	O
week	O
4	O
,	O
however	O
,	O
the	O
sinusoidal	B-Anatomy
blood	I-Anatomy
volume	O
and	O
albumin	O
Disse	O
space	O
in	O
tumor	B-Anatomy
-	O
bearing	O
livers	B-Anatomy
were	O
slightly	O
lower	O
compared	O
with	O
those	O
of	O
shams	O
.	O
Increased	O
levels	O
of	O
the	O
canalicular	B-Anatomy
ATP	O
transporters	O
,	O
P	O
-	O
glycoprotein	O
,	O
multidrug	O
resistance	O
-	O
associated	O
protein	O
2	O
(	O
Mrp2	O
)	O
,	O
and	O
bile	O
salt	O
export	O
pump	O
(	O
Bsep	O
)	O
at	O
week	O
2	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
unchanged	O
levels	O
of	O
Ntcp	O
,	O
Oatp1a1	O
,	O
Oatp1a4	O
,	O
and	O
Mct2	O
,	O
but	O
decreased	O
levels	O
of	O
cytochrome	O
P450	O
3a2	O
(	O
Cyp3a2	O
)	O
and	O
glutathione	O
S	O
-	O
transferase	O
(	O
Gst4	O
-	O
4	O
)	O
at	O
week	O
4	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
observed	O
in	O
peritumor	B-Anatomy
vs	O
.	O
sham	O
-	O
operated	O
liver	B-Anatomy
tissues	I-Anatomy
with	O
Western	O
blotting	O
.	O
The	O
steady	O
-	O
state	O
extraction	O
ratio	O
of	O
enalapril	O
,	O
a	O
substrate	O
that	O
enters	O
the	O
liver	B-Anatomy
rapidly	O
via	O
Oatp1a1	O
and	O
primarily	O
undergoes	O
metabolism	O
by	O
the	O
carboxylesterases	O
,	O
was	O
unaffected	O
by	O
liver	B-Anatomy
metastasis	O
at	O
week	O
4	O
regardless	O
of	O
its	O
delivery	O
via	O
the	O
portal	B-Anatomy
vein	I-Anatomy
or	O
hepatic	B-Anatomy
artery	I-Anatomy
into	O
the	O
perfused	O
liver	B-Anatomy
preparations	O
.	O
Wnt	O
signaling	O
,	O
stem	B-Anatomy
cells	I-Anatomy
,	O
and	O
the	O
cellular	B-Anatomy
origin	O
of	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
The	O
breast	B-Anatomy
epithelium	I-Anatomy
comprises	O
cells	B-Anatomy
at	O
different	O
stages	O
of	O
differentiation	O
,	O
including	O
stem	B-Anatomy
cells	I-Anatomy
,	O
progenitor	B-Anatomy
cells	I-Anatomy
,	O
and	O
more	O
differentiated	O
epithelial	B-Anatomy
and	O
myoepithelial	B-Anatomy
cells	I-Anatomy
.	O
Wnt	O
signaling	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
stem	B-Anatomy
/	I-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
in	O
the	O
mammary	B-Anatomy
gland	I-Anatomy
as	O
well	O
as	O
other	O
tissue	B-Anatomy
compartments	I-Anatomy
.	O
Furthermore	O
,	O
there	O
is	O
strong	O
evidence	O
suggesting	O
that	O
aberrant	O
activation	O
of	O
Wnt	O
signaling	O
induces	O
mammary	B-Anatomy
tumors	I-Anatomy
from	O
stem	B-Anatomy
/	I-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
,	O
and	O
that	O
Wnt	O
exerts	O
its	O
oncogenic	O
effects	O
through	O
LRP5	O
/	O
6	O
-	O
mediated	O
activation	O
of	O
beta	O
-	O
catenin	O
and	O
mTOR	O
pathways	O
.	O
Recent	O
studies	O
using	O
avian	O
retrovirus	O
-	O
mediated	O
introduction	O
of	O
oncogenes	O
into	O
a	O
small	O
subset	O
of	O
somatic	B-Anatomy
mammary	I-Anatomy
cells	I-Anatomy
suggest	O
that	O
polyoma	O
middle	O
T	O
antigen	O
(	O
PyMT	O
)	O
may	O
also	O
preferentially	O
transform	O
stem	B-Anatomy
/	I-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
.	O
These	O
observations	O
suggest	O
that	O
stem	B-Anatomy
/	I-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
in	O
the	O
mammary	B-Anatomy
gland	I-Anatomy
may	O
be	O
especially	O
susceptible	O
to	O
oncogenic	O
transformation	O
.	O
Whether	O
more	O
differentiated	O
cells	B-Anatomy
may	O
also	O
be	O
transformed	O
by	O
particular	O
oncogenes	O
is	O
actively	O
debated	O
;	O
it	O
is	O
presently	O
unclear	O
whether	O
stem	B-Anatomy
cells	I-Anatomy
or	O
differentiated	O
mammary	B-Anatomy
cells	I-Anatomy
are	O
more	O
susceptible	O
to	O
transformation	O
by	O
individual	O
oncogenes	O
.	O
Better	O
stem	B-Anatomy
cell	I-Anatomy
and	O
progenitor	B-Anatomy
cell	I-Anatomy
markers	O
as	O
well	O
as	O
the	O
ability	O
to	O
specifically	O
target	O
oncogenes	O
into	O
different	O
mammary	B-Anatomy
cell	I-Anatomy
types	O
will	O
be	O
needed	O
to	O
determine	O
the	O
spectrum	O
of	O
oncogene	O
transformation	O
for	O
stem	B-Anatomy
cells	I-Anatomy
versus	O
more	O
differentiated	O
cells	B-Anatomy
.	O
Ovarian	B-Anatomy
cancers	I-Anatomy
overexpress	O
the	O
antimicrobial	O
protein	O
hCAP	O
-	O
18	O
and	O
its	O
derivative	O
LL	O
-	O
37	O
increases	O
ovarian	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
proliferation	O
and	O
invasion	O
.	O
The	O
role	O
of	O
the	O
pro	O
-	O
inflammatory	O
peptide	O
,	O
LL	O
-	O
37	O
,	O
and	O
its	O
pro	O
-	O
form	O
,	O
human	O
cationic	O
antimicrobial	O
protein	O
18	O
(	O
hCAP	O
-	O
18	O
)	O
,	O
in	O
cancer	B-Anatomy
development	O
and	O
progression	O
is	O
poorly	O
understood	O
.	O
In	O
damaged	O
and	O
inflamed	O
tissue	B-Anatomy
,	O
LL	O
-	O
37	O
functions	O
as	O
a	O
chemoattractant	O
,	O
mitogen	O
and	O
pro	O
-	O
angiogenic	O
factor	O
suggesting	O
that	O
the	O
peptide	O
may	O
potentiate	O
tumor	B-Anatomy
progression	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
distribution	O
of	O
hCAP	O
-	O
18	O
/	O
LL	O
-	O
37	O
in	O
normal	O
and	O
cancerous	B-Anatomy
ovarian	I-Anatomy
tissue	I-Anatomy
and	O
to	O
examine	O
the	O
effects	O
of	O
LL	O
-	O
37	O
on	O
ovarian	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Expression	O
of	O
hCAP	O
-	O
18	O
/	O
LL	O
-	O
37	O
was	O
localized	O
to	O
immune	B-Anatomy
and	O
granulosa	B-Anatomy
cells	I-Anatomy
of	O
normal	O
ovarian	B-Anatomy
tissue	I-Anatomy
.	O
By	O
contrast	O
,	O
ovarian	B-Anatomy
tumors	I-Anatomy
displayed	O
significantly	O
higher	O
levels	O
of	O
hCAP	O
-	O
18	O
/	O
LL	O
-	O
37	O
where	O
expression	O
was	O
observed	O
in	O
tumor	B-Anatomy
and	O
stromal	B-Anatomy
cells	I-Anatomy
.	O
Protein	O
expression	O
was	O
statistically	O
compared	O
to	O
the	O
degree	O
of	O
immune	B-Anatomy
cell	I-Anatomy
infiltration	O
and	O
microvessel	B-Anatomy
density	O
in	O
epithelial	B-Anatomy
-	I-Anatomy
derived	I-Anatomy
ovarian	I-Anatomy
tumors	I-Anatomy
and	O
a	O
significant	O
correlation	O
was	O
observed	O
for	O
both	O
.	O
It	O
was	O
demonstrated	O
that	O
ovarian	B-Anatomy
tumor	I-Anatomy
tissue	I-Anatomy
lysates	I-Anatomy
and	O
ovarian	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
express	O
hCAP	O
-	O
18	O
/	O
LL	O
-	O
37	O
.	O
Treatment	O
of	O
ovarian	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
with	O
recombinant	O
LL	O
-	O
37	O
stimulated	O
proliferation	O
,	O
chemotaxis	O
,	O
invasion	O
and	O
matrix	O
metalloproteinase	O
expression	O
.	O
These	O
data	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
hCAP	O
-	O
18	O
/	O
LL	O
-	O
37	O
is	O
significantly	O
overexpressed	O
in	O
ovarian	B-Anatomy
tumors	I-Anatomy
and	O
suggest	O
LL	O
-	O
37	O
may	O
contribute	O
to	O
ovarian	B-Anatomy
tumorigenesis	O
through	O
direct	O
stimulation	O
of	O
tumor	B-Anatomy
cells	I-Anatomy
,	O
initiation	O
of	O
angiogenesis	O
and	O
recruitment	O
of	O
immune	B-Anatomy
cells	I-Anatomy
.	O
These	O
data	O
provide	O
further	O
evidence	O
of	O
the	O
existing	O
relationship	O
between	O
pro	O
-	O
inflammatory	O
molecules	O
and	O
ovarian	B-Anatomy
cancer	I-Anatomy
progression	O
.	O
Role	O
of	O
telomeres	B-Anatomy
in	O
vascular	B-Anatomy
senescence	O
.	O
Telomeres	B-Anatomy
are	O
DNA	O
regions	O
composed	O
of	O
TTAGGG	O
repeats	O
that	O
are	O
located	O
at	O
the	O
ends	O
of	O
chromosomes	B-Anatomy
.	O
Specific	O
proteins	O
associate	O
with	O
the	O
telomeres	B-Anatomy
and	O
form	O
non	O
-	O
nucleosomal	O
DNA	O
-	O
protein	O
complexes	O
that	O
serve	O
as	O
protective	O
caps	O
for	O
the	O
chromosome	B-Anatomy
ends	O
.	O
There	O
is	O
accumulating	O
evidence	O
that	O
progressive	O
telomere	B-Anatomy
shortening	O
is	O
closely	O
related	O
to	O
cardiovascular	B-Anatomy
disease	O
.	O
For	O
example	O
,	O
vascular	B-Anatomy
cell	I-Anatomy
senescence	O
has	O
been	O
reported	O
to	O
occur	O
in	O
human	O
atherosclerotic	B-Anatomy
lesions	I-Anatomy
and	O
this	O
change	O
is	O
associated	O
with	O
telomere	B-Anatomy
shortening	O
.	O
Impairment	O
of	O
telomere	B-Anatomy
integrity	O
causes	O
vascular	B-Anatomy
dysfunction	O
,	O
which	O
is	O
prevented	O
by	O
the	O
activation	O
of	O
telomerase	O
.	O
Mice	O
with	O
short	O
telomeres	B-Anatomy
develop	O
hypertension	O
and	O
exhibit	O
impaired	O
neovascularization	O
.	O
Short	O
telomeres	B-Anatomy
have	O
also	O
been	O
reported	O
in	O
the	O
leukocytes	B-Anatomy
of	O
patients	O
with	O
cardiovascular	B-Anatomy
disease	O
or	O
various	O
cardiovascular	B-Anatomy
risk	O
factors	O
.	O
Although	O
it	O
remains	O
unclear	O
whether	O
short	O
telomeres	B-Anatomy
directly	O
cause	O
cardiovascular	B-Anatomy
disease	O
,	O
manipulation	O
of	O
telomere	B-Anatomy
function	O
is	O
potentially	O
an	O
attractive	O
strategy	O
for	O
the	O
treatment	O
of	O
vascular	B-Anatomy
senescence	O
.	O
M	O
.	O
leprae	O
-	O
and	O
BCG	O
-	O
induced	O
chemiluminescence	O
response	O
of	O
monocytes	B-Anatomy
from	O
leprosy	O
patients	O
and	O
healthy	O
subjects	O
:	O
effects	O
of	O
gamma	O
-	O
interferon	O
and	O
GM	O
-	O
CSF	O
.	O
Mycobacterium	O
leprae	O
,	O
in	O
contrast	O
to	O
BCG	O
,	O
failed	O
to	O
trigger	O
any	O
chemiluminescence	O
(	O
CL	O
)	O
response	O
in	O
mononuclear	B-Anatomy
cells	I-Anatomy
from	O
either	O
leprosy	O
patients	O
or	O
healthy	O
subjects	O
,	O
a	O
deficit	O
not	O
reversed	O
by	O
either	O
interferon	O
-	O
gamma	O
or	O
GM	O
-	O
CSF	O
.	O
Chemiluminescence	O
responses	O
induced	O
without	O
mycobacteria	O
or	O
with	O
BCG	O
were	O
found	O
to	O
be	O
lower	O
in	O
leprosy	O
patients	O
than	O
in	O
controls	O
.	O
M	O
.	O
leprae	O
were	O
also	O
less	O
well	O
phagocytosed	O
than	O
BCG	O
.	O
However	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
phagocytosis	O
between	O
healthy	O
and	O
tuberculoid	O
leprosy	O
subjects	O
.	O
Phagocytosis	O
was	O
not	O
altered	O
by	O
the	O
addition	O
of	O
either	O
lymphokine	O
,	O
and	O
no	O
major	O
differences	O
between	O
healthy	O
subjects	O
and	O
patients	O
were	O
observed	O
.	O
Preincubating	O
mononuclear	B-Anatomy
cells	I-Anatomy
with	O
anti	O
-	O
mycobacteria	O
antibodies	O
(	O
lepromatous	O
patients	O
'	O
sera	B-Anatomy
)	O
did	O
not	O
increase	O
the	O
CL	O
response	O
nor	O
the	O
phagocytosis	O
of	O
M	O
.	O
leprae	O
or	O
BCG	O
.	O
Tumor	B-Anatomy
microenvironment	O
,	O
a	O
dangerous	O
society	O
leading	O
to	O
cancer	B-Anatomy
metastasis	O
.	O
From	O
mechanisms	O
to	O
therapy	O
and	O
prevention	O
.	O
Cancer	B-Anatomy
is	O
no	O
longer	O
considered	O
by	O
scientists	O
just	O
a	O
jumble	O
of	O
mutated	O
cells	B-Anatomy
.	O
To	O
grow	O
,	O
invade	O
and	O
metastasize	O
,	O
a	O
treacherous	O
society	O
between	O
cancer	B-Anatomy
and	O
host	O
cells	B-Anatomy
must	O
be	O
formed	O
,	O
and	O
this	O
association	O
provides	O
novel	O
and	O
effective	O
clinical	O
targets	O
for	O
cancer	B-Anatomy
control	O
and	O
prevention	O
.	O
This	O
collection	O
of	O
reviews	O
at	O
the	O
front	O
-	O
edge	O
of	O
scientific	O
knowledge	O
focuses	O
on	O
host	O
-	O
tumor	B-Anatomy
cell	I-Anatomy
interactions	O
,	O
the	O
disastrous	O
consequences	O
they	O
can	O
produce	O
and	O
approaches	O
the	O
ways	O
to	O
break	O
up	O
these	O
cellular	B-Anatomy
conspiracies	O
,	O
to	O
leave	O
the	O
tumor	B-Anatomy
cells	I-Anatomy
unattended	O
and	O
vulnerable	O
.	O
[	O
Photodynamic	O
therapy	O
in	O
severe	O
chronic	O
central	O
serous	B-Anatomy
chorioretinopaty	O
]	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
efficacy	O
of	O
Photodynamic	O
Therapy	O
(	O
PDT	O
)	O
in	O
chronic	O
Central	O
Serous	B-Anatomy
Chorioretinopathy	O
(	O
CSC	O
)	O
.	O
METHODS	O
:	O
Patients	O
diagnosed	O
with	O
chronic	O
CSC	O
,	O
with	O
clinical	O
evidence	O
of	O
activity	O
and	O
treated	O
with	O
Photodynamic	O
Therapy	O
,	O
are	O
included	O
in	O
this	O
report	O
.	O
All	O
were	O
assessed	O
by	O
a	O
complete	O
ophthalmological	O
examination	O
,	O
including	O
assessment	O
of	O
the	O
best	O
corrected	O
visual	O
acuity	O
(	O
BCVA	O
)	O
using	O
an	O
ETDRS	O
chart	O
,	O
fluorescein	O
and	O
indocyanine	O
angiography	O
and	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
.	O
The	O
main	O
objective	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
mean	O
visual	O
acuity	O
change	O
.	O
RESULTS	O
:	O
11	O
eyes	B-Anatomy
of	O
11	O
patients	O
were	O
included	O
in	O
the	O
study	O
,	O
which	O
had	O
a	O
mean	O
follow	O
-	O
up	O
period	O
of	O
11	O
months	O
.	O
The	O
mean	O
BCVA	O
increased	O
from	O
20	O
/	O
76	O
to	O
20	O
/	O
64	O
.	O
35	O
%	O
of	O
eyes	B-Anatomy
improved	O
their	O
BCVA	O
by	O
2	O
lines	O
or	O
more	O
,	O
45	O
%	O
remained	O
stable	O
and	O
18	O
%	O
lost	O
2	O
lines	O
or	O
more	O
.	O
Choroidal	B-Anatomy
hyperpermeability	O
was	O
reduced	O
in	O
every	O
case	O
.	O
Neurosensorial	O
retinal	B-Anatomy
detachment	O
decreased	O
in	O
80	O
%	O
of	O
cases	O
.	O
Only	O
one	O
eye	B-Anatomy
received	O
a	O
second	O
PDT	O
treatment	O
due	O
to	O
choroidal	B-Anatomy
neovascularization	O
.	O
An	O
increase	O
of	O
atrophy	O
over	O
the	O
Retinal	B-Anatomy
Pigment	I-Anatomy
Epithelium	I-Anatomy
(	O
RPE	B-Anatomy
)	O
was	O
observed	O
in	O
another	O
patient	O
.	O
CONCLUSIONS	O
:	O
PDT	O
can	O
reduce	O
the	O
clinical	O
signs	O
of	O
activity	O
,	O
such	O
as	O
choroidal	B-Anatomy
hyperpermeability	O
or	O
neurosensorial	O
retinal	B-Anatomy
detachment	O
,	O
in	O
patients	O
affected	O
by	O
chronic	O
CSC	O
.	O
However	O
,	O
the	O
increase	O
in	O
visual	O
acuity	O
is	O
variable	O
,	O
probably	O
due	O
to	O
the	O
extent	O
of	O
RPE	B-Anatomy
damage	O
.	O
Angiopoietin	O
-	O
1	O
prevents	O
VEGF	O
-	O
induced	O
endothelial	B-Anatomy
permeability	O
by	O
sequestering	O
Src	O
through	O
mDia	O
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
Angiopoietin	O
1	O
(	O
Ang1	O
)	O
are	O
both	O
potent	O
proangiogenic	O
factors	O
,	O
but	O
,	O
whereas	O
VEGF	O
causes	O
vascular	B-Anatomy
permeability	O
,	O
Ang1	O
stabilizes	O
blood	B-Anatomy
vessels	I-Anatomy
and	O
protects	O
them	O
from	O
VEGF	O
-	O
induced	O
plasma	B-Anatomy
leakage	O
.	O
The	O
antivascular	B-Anatomy
permeability	O
mechanisms	O
deployed	O
by	O
Ang1	O
are	O
still	O
undefined	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
Ang1	O
halts	O
the	O
ability	O
of	O
VEGF	O
to	O
induce	O
the	O
phosphorylation	O
-	O
dependent	O
redistribution	O
of	O
the	O
adhesion	O
molecule	O
VE	O
-	O
cadherin	O
,	O
thereby	O
rescuing	O
the	O
endothelial	B-Anatomy
barrier	I-Anatomy
function	O
.	O
Ang1	O
inhibits	O
the	O
activation	O
of	O
Src	O
by	O
VEGF	O
,	O
the	O
most	O
upstream	O
component	O
of	O
the	O
pathway	O
linking	O
VEGF	O
receptors	O
to	O
VE	O
-	O
cadherin	O
internalization	O
.	O
Indeed	O
,	O
Ang1	O
promotes	O
the	O
activation	O
of	O
mDia	O
through	O
RhoA	O
,	O
resulting	O
in	O
the	O
association	O
of	O
mDia	O
with	O
Src	O
.	O
This	O
ultimately	O
deprives	O
VEGF	O
receptors	O
of	O
an	O
essential	O
molecule	O
required	O
for	O
promoting	O
the	O
disruption	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
-	I-Anatomy
cell	I-Anatomy
contacts	I-Anatomy
and	O
paracellular	B-Anatomy
permeability	O
.	O
RUNX1	O
DNA	O
-	O
binding	O
mutations	O
and	O
RUNX1	O
-	O
PRDM16	O
cryptic	O
fusions	O
in	O
BCR	B-Anatomy
-	I-Anatomy
ABL	I-Anatomy
+	I-Anatomy
leukemias	I-Anatomy
are	O
frequently	O
associated	O
with	O
secondary	O
trisomy	O
21	B-Anatomy
and	O
may	O
contribute	O
to	O
clonal	B-Anatomy
evolution	O
and	O
imatinib	O
resistance	O
.	O
Acquired	O
molecular	O
abnormalities	O
(	O
mutations	O
or	O
chromosomal	B-Anatomy
translocations	O
)	O
of	O
the	O
RUNX1	O
transcription	O
factor	O
gene	O
are	O
frequent	O
in	O
acute	B-Anatomy
myeloblastic	I-Anatomy
leukemias	I-Anatomy
(	O
AMLs	B-Anatomy
)	O
and	O
in	O
therapy	O
-	O
related	O
myelodysplastic	O
syndromes	O
,	O
but	O
rarely	O
in	O
acute	B-Anatomy
lymphoblastic	I-Anatomy
leukemias	I-Anatomy
(	O
ALLs	B-Anatomy
)	O
and	O
chronic	B-Anatomy
myelogenous	I-Anatomy
leukemias	I-Anatomy
(	O
CMLs	B-Anatomy
)	O
.	O
Among	O
18	O
BCR	B-Anatomy
-	I-Anatomy
ABL	I-Anatomy
+	I-Anatomy
leukemias	I-Anatomy
presenting	O
acquired	O
trisomy	O
of	O
chromosome	B-Anatomy
21	I-Anatomy
,	O
we	O
report	O
a	O
high	O
frequency	O
(	O
33	O
%	O
)	O
of	O
recurrent	O
point	O
mutations	O
(	O
4	O
in	O
myeloid	B-Anatomy
blast	I-Anatomy
crisis	I-Anatomy
[	I-Anatomy
BC	I-Anatomy
]	I-Anatomy
CML	I-Anatomy
and	O
one	O
in	O
chronic	B-Anatomy
phase	I-Anatomy
CML	I-Anatomy
)	O
within	O
the	O
DNA	O
-	O
binding	O
region	O
of	O
RUNX1	O
.	O
We	O
did	O
not	O
found	O
any	O
mutation	O
in	O
de	O
novo	O
BCR	B-Anatomy
-	I-Anatomy
ABL	I-Anatomy
+	I-Anatomy
ALLs	I-Anatomy
or	O
lymphoid	B-Anatomy
BC	I-Anatomy
CML	I-Anatomy
.	O
Emergence	O
of	O
the	O
RUNX1	O
mutations	O
was	O
detected	O
at	O
diagnosis	O
or	O
before	O
the	O
acquisition	O
of	O
trisomy	O
21	B-Anatomy
during	O
disease	O
progression	O
.	O
In	O
addition	O
,	O
we	O
also	O
report	O
a	O
high	O
frequency	O
of	O
cryptic	O
chromosomal	B-Anatomy
RUNX1	O
translocation	O
to	O
a	O
novel	O
recently	O
described	O
gene	O
partner	O
,	O
PRDM16	O
on	O
chromosome	B-Anatomy
1p36	I-Anatomy
,	O
for	O
3	O
(	O
21	O
.	O
4	O
%	O
)	O
of	O
14	O
investigated	O
patients	O
:	O
2	O
myeloid	B-Anatomy
BC	I-Anatomy
CMLs	I-Anatomy
and	O
,	O
for	O
the	O
first	O
time	O
,	O
1	O
therapy	O
-	O
related	O
BCR	B-Anatomy
-	I-Anatomy
ABL	I-Anatomy
+	I-Anatomy
ALL	I-Anatomy
.	O
Two	O
patients	O
presented	O
both	O
RUNX1	O
mutations	O
and	O
RUNX1	O
-	O
PRDM16	O
fusion	O
.	O
These	O
events	O
are	O
associated	O
with	O
a	O
short	O
survival	O
and	O
support	O
the	O
concept	O
of	O
a	O
cooperative	O
effect	O
of	O
BCR	O
-	O
ABL	O
with	O
molecular	O
RUNX1	O
abnormalities	O
on	O
the	O
differentiation	O
arrest	O
phenotype	O
observed	O
during	O
progression	O
of	O
CML	B-Anatomy
and	O
in	O
BCR	B-Anatomy
-	I-Anatomy
ABL	I-Anatomy
+	I-Anatomy
ALL	I-Anatomy
.	O
Suppression	O
of	O
lung	B-Anatomy
tumor	I-Anatomy
growth	O
and	O
metastasis	O
in	O
mice	O
by	O
adeno	O
-	O
associated	O
virus	O
-	O
mediated	O
expression	O
of	O
vasostatin	O
.	O
PURPOSE	O
:	O
Angiogenesis	O
inhibitors	O
have	O
strong	O
therapeutic	O
potential	O
as	O
antitumor	B-Anatomy
agents	O
in	O
suppressing	O
tumor	B-Anatomy
growth	O
and	O
metastatic	O
progression	O
.	O
Vasostatin	O
,	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
calreticulin	O
,	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O
In	O
this	O
study	O
,	O
we	O
determined	O
the	O
effectiveness	O
of	O
vasostatin	O
delivered	O
by	O
recombinant	O
pseudotype	O
adeno	O
-	O
associated	O
virus	O
2	O
/	O
5	O
(	O
rAAV2	O
/	O
5	O
-	O
VAS	O
)	O
as	O
a	O
gene	O
therapy	O
approach	O
for	O
lung	B-Anatomy
cancer	I-Anatomy
treatment	O
.	O
EXPERIMENTAL	O
DESIGN	O
:	O
We	O
used	O
rAAV2	O
/	O
5	O
to	O
deliver	O
vasostatin	O
intratumorally	B-Anatomy
or	O
systemically	O
in	O
different	O
mouse	O
lung	B-Anatomy
tumor	I-Anatomy
models	O
-	O
-	O
subcutaneous	B-Anatomy
,	I-Anatomy
orthotopic	I-Anatomy
xenograft	I-Anatomy
,	O
and	O
spontaneous	O
metastasis	O
lung	B-Anatomy
tumor	I-Anatomy
models	O
.	O
The	O
therapeutic	O
efficacy	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
was	O
determined	O
by	O
monitoring	O
tumor	B-Anatomy
volume	O
,	O
survival	O
rate	O
,	O
and	O
degree	O
of	O
neovascularization	O
after	O
treatment	O
in	O
these	O
models	O
.	O
RESULTS	O
:	O
Mice	O
bearing	O
subcutaneous	B-Anatomy
tumor	I-Anatomy
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
pretreated	O
Lewis	B-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
showed	O
>	O
50	O
%	O
reduction	O
in	O
primary	B-Anatomy
tumor	I-Anatomy
volume	O
and	O
reduced	O
spontaneous	O
pulmonary	B-Anatomy
metastases	I-Anatomy
.	O
The	O
tumor	B-Anatomy
-	O
suppressive	O
action	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
in	O
subcutaneous	B-Anatomy
human	I-Anatomy
lung	I-Anatomy
tumor	I-Anatomy
A549	I-Anatomy
xenograft	I-Anatomy
correlated	O
with	O
a	O
reduced	O
number	O
of	O
capillary	B-Anatomy
vessels	I-Anatomy
in	O
tumors	B-Anatomy
.	O
In	O
the	O
orthotopic	O
xenograft	B-Anatomy
model	O
,	O
rAAV2	O
/	O
5	O
-	O
VAS	O
suppressed	O
metastasis	O
of	O
A549	B-Anatomy
tumors	I-Anatomy
to	O
mediastinal	O
lymph	B-Anatomy
nodes	I-Anatomy
and	O
contralateral	O
lung	B-Anatomy
.	O
Furthermore	O
,	O
treatment	O
of	O
immunocompetent	O
mice	O
in	O
the	O
spontaneous	O
lung	B-Anatomy
metastases	I-Anatomy
model	O
with	O
rAAV2	O
/	O
5	O
-	O
VAS	O
after	O
primary	B-Anatomy
tumor	I-Anatomy
excision	O
prolonged	O
their	O
median	O
survival	O
from	O
21	O
to	O
51	O
.	O
5	O
days	O
.	O
CONCLUSION	O
:	O
Our	O
results	O
show	O
the	O
effectiveness	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
as	O
an	O
angiogenesis	O
inhibitor	O
in	O
suppressing	O
tumor	B-Anatomy
growth	O
during	O
different	O
stages	O
of	O
tumor	B-Anatomy
progression	O
,	O
validating	O
the	O
application	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
gene	O
therapy	O
in	O
treatment	O
against	O
lung	B-Anatomy
cancer	I-Anatomy
.	O
Radiation	O
retinopathy	O
is	O
treatable	O
with	O
anti	O
-	O
vascular	O
endothelial	O
growth	O
factor	O
bevacizumab	O
(	O
Avastin	O
)	O
.	O
PURPOSE	O
:	O
To	O
report	O
on	O
bevacizumab	O
treatment	O
for	O
radiation	O
retinopathy	O
affecting	O
the	O
macula	B-Anatomy
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Twenty	O
-	O
one	O
patients	O
with	O
radiation	O
retinopathy	O
(	O
edema	B-Anatomy
,	O
hemorrhages	O
,	O
capillary	B-Anatomy
dropout	O
,	O
and	O
neovascularization	O
)	O
and	O
a	O
subjective	O
or	O
objective	O
loss	O
of	O
vision	O
were	O
treated	O
.	O
Treatment	O
involved	O
intravitreal	O
injection	O
of	O
bevacizumab	O
(	O
1	O
.	O
25	O
mg	O
in	O
0	O
.	O
05	O
mL	O
)	O
every	O
6	O
-	O
12	O
weeks	O
.	O
Treatment	O
was	O
discontinued	O
at	O
patient	O
request	O
or	O
if	O
there	O
was	O
no	O
measurable	O
response	O
to	O
therapy	O
.	O
Main	O
outcome	O
measures	O
included	O
best	O
corrected	O
visual	O
acuity	O
,	O
ophthalmic	O
examination	O
,	O
retinal	B-Anatomy
photography	O
,	O
and	O
angiography	O
.	O
RESULTS	O
:	O
Bevacizumab	O
treatment	O
was	O
followed	O
by	O
reductions	O
in	O
retinal	B-Anatomy
hemorrhage	O
,	O
exudation	O
,	O
and	O
edema	B-Anatomy
.	O
Visual	O
acuities	O
were	O
stable	O
or	O
improved	O
in	O
86	O
%	O
(	O
n	O
=	O
18	O
)	O
.	O
Three	O
patients	O
discontinued	O
therapy	O
.	O
Each	O
was	O
legally	O
blind	O
before	O
treatment	O
(	O
n	O
=	O
1	O
)	O
,	O
experienced	O
little	O
to	O
no	O
subjective	O
improvement	O
(	O
n	O
=	O
2	O
)	O
,	O
or	O
was	O
poorly	O
compliant	O
(	O
n	O
=	O
2	O
)	O
.	O
Three	O
patients	O
(	O
14	O
%	O
)	O
regained	O
2	O
or	O
more	O
lines	O
of	O
visual	O
acuity	O
.	O
No	O
ocular	B-Anatomy
or	O
systemic	O
bevacizumab	O
-	O
related	O
side	O
effects	O
were	O
observed	O
.	O
CONCLUSIONS	O
:	O
Intravitreal	O
bevacizumab	O
can	O
be	O
used	O
to	O
treat	O
radiation	O
retinopathy	O
.	O
In	O
most	O
cases	O
treatment	O
was	O
associated	O
with	O
decreased	O
vascular	B-Anatomy
leakage	O
,	O
stabilization	O
,	O
or	O
improved	O
vision	O
.	O
An	O
anti	O
-	O
vascular	O
endothelial	O
growth	O
factor	O
strategy	O
may	O
reduce	O
tissue	B-Anatomy
damage	O
associated	O
with	O
radiation	O
vasculopathy	O
and	O
neuropathy	O
.	O
Mitogen	O
-	O
activated	O
protein	O
kinase	O
kinase	O
signaling	O
promotes	O
growth	O
and	O
vascularization	O
of	O
fibrosarcoma	B-Anatomy
.	O
We	O
hypothesized	O
that	O
signaling	O
through	O
multiple	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
kinase	O
(	O
MKK	O
)	O
pathways	O
is	O
essential	O
for	O
the	O
growth	O
and	O
vascularization	O
of	O
soft	B-Anatomy
-	I-Anatomy
tissue	I-Anatomy
sarcomas	I-Anatomy
,	O
which	O
are	O
malignant	B-Anatomy
tumors	I-Anatomy
derived	O
from	O
mesenchymal	B-Anatomy
tissues	I-Anatomy
.	O
We	O
tested	O
this	O
using	O
HT	B-Anatomy
-	I-Anatomy
1080	I-Anatomy
,	O
NCI	B-Anatomy
,	O
and	O
Shac	B-Anatomy
fibrosarcoma	I-Anatomy
-	I-Anatomy
derived	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
and	O
anthrax	O
lethal	O
toxin	O
(	O
LeTx	O
)	O
,	O
a	O
bacterial	O
toxin	O
that	O
inactivates	O
MKKs	O
.	O
Western	O
blots	O
confirmed	O
that	O
LeTx	O
treatment	O
reduced	O
the	O
levels	O
of	O
phosphorylated	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
and	O
p38	O
MAPK	O
in	O
vitro	O
.	O
Although	O
short	O
treatments	O
with	O
LeTx	O
only	O
modestly	O
affected	O
cell	B-Anatomy
proliferation	O
,	O
sustained	O
treatment	O
markedly	O
reduced	O
cell	B-Anatomy
numbers	O
.	O
LeTx	O
also	O
substantially	O
inhibited	O
the	O
extracellular	B-Anatomy
release	O
of	O
angioproliferative	O
factors	O
including	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
interleukin	O
-	O
8	O
,	O
and	O
basic	O
fibroblast	O
growth	O
factor	O
.	O
Similar	O
results	O
were	O
obtained	O
with	O
cell	B-Anatomy
lines	I-Anatomy
derived	O
from	O
malignant	B-Anatomy
fibrous	I-Anatomy
histiocytomas	I-Anatomy
,	O
leiomyosarcomas	B-Anatomy
,	O
and	O
liposarcomas	B-Anatomy
.	O
In	O
vivo	O
,	O
LeTx	O
decreased	O
MAPK	O
activity	O
and	O
blocked	O
fibrosarcoma	B-Anatomy
growth	O
.	O
Growth	O
inhibition	O
correlated	O
with	O
decreased	O
cellular	B-Anatomy
proliferation	O
and	O
extensive	O
necrosis	O
,	O
and	O
it	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
tumor	B-Anatomy
mean	O
vessel	B-Anatomy
density	O
as	O
well	O
as	O
a	O
reduction	O
in	O
serum	B-Anatomy
expression	O
of	O
angioproliferative	O
cytokines	O
.	O
Vital	O
imaging	O
using	O
high	O
-	O
resolution	O
ultrasound	O
enhanced	O
with	O
contrast	O
microbubbles	O
revealed	O
that	O
the	O
effects	O
of	O
LeTx	O
on	O
tumor	B-Anatomy
perfusion	O
were	O
remarkably	O
rapid	O
(	O
less	O
than	O
24	O
h	O
)	O
and	O
resulted	O
in	O
a	O
marked	O
reduction	O
of	O
perfusion	O
within	O
the	O
tumor	B-Anatomy
but	O
not	O
in	O
nontumor	B-Anatomy
tissues	I-Anatomy
.	O
These	O
results	O
are	O
consistent	O
with	O
our	O
initial	O
hypothesis	O
and	O
lead	O
us	O
to	O
propose	O
that	O
MKK	O
inhibition	O
by	O
LeTx	O
is	O
a	O
broadly	O
effective	O
strategy	O
for	O
targeting	O
neovascularization	O
in	O
fibrosarcomas	B-Anatomy
and	O
other	O
similar	O
proliferative	B-Anatomy
lesions	I-Anatomy
.	O
A	O
novel	O
putative	O
tyrosine	O
kinase	O
receptor	O
with	O
oncogenic	O
potential	O
.	O
We	O
have	O
detected	O
transforming	O
activity	O
by	O
a	O
tumorigenicity	O
assay	O
using	O
NIH3T3	B-Anatomy
cells	I-Anatomy
transfected	O
with	O
DNA	O
from	O
a	O
chronic	O
myeloproliferative	O
disorder	O
patient	O
.	O
Here	O
,	O
we	O
report	O
the	O
cDNA	O
cloning	O
of	O
the	O
corresponding	O
oncogene	O
,	O
designated	O
UFO	O
,	O
in	O
allusion	O
to	O
the	O
as	O
yet	O
unidentified	O
function	O
of	O
its	O
protein	O
.	O
Nucleotide	O
sequence	O
analysis	O
of	O
a	O
3116bp	O
cDNA	O
clone	O
revealed	O
a	O
2682	O
-	O
bp	O
-	O
long	O
open	O
reading	O
frame	O
capable	O
of	O
directing	O
the	O
synthesis	O
of	O
a	O
894	O
amino	O
acid	O
polypeptide	O
.	O
The	O
predicted	O
UFO	O
protein	O
exhibits	O
characteristic	O
features	O
of	O
a	O
transmembrane	B-Anatomy
receptor	O
with	O
associated	O
tyrosine	O
kinase	O
activity	O
.	O
The	O
UFO	O
proto	O
-	O
oncogene	O
maps	O
to	O
human	O
chromosome	B-Anatomy
19q13	I-Anatomy
.	I-Anatomy
1	I-Anatomy
and	O
is	O
transcribed	O
into	O
two	O
5	O
.	O
0	O
kb	O
and	O
3	O
.	O
2	O
kb	O
mRNAs	O
in	O
human	O
bone	B-Anatomy
marrow	I-Anatomy
and	O
human	O
tumor	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
The	O
UFO	O
locus	O
is	O
evolutionarily	O
conserved	O
between	O
vertebrate	O
species	O
.	O
A	O
4	O
.	O
0	O
kb	O
mRNA	O
of	O
the	O
murine	O
UFO	O
homolog	O
is	O
expressed	O
in	O
a	O
variety	O
of	O
different	O
mouse	O
tissues	B-Anatomy
.	O
We	O
thus	O
have	O
identified	O
a	O
novel	O
element	O
of	O
the	O
complex	O
signaling	O
network	O
involved	O
in	O
the	O
control	O
of	O
cell	B-Anatomy
proliferation	O
and	O
differentiation	O
.	O
Proteomic	O
comparison	O
of	O
nasopharyngeal	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
C666	I-Anatomy
-	I-Anatomy
1	I-Anatomy
and	O
NP69	B-Anatomy
identifies	O
down	O
-	O
regulation	O
of	O
annexin	O
II	O
and	O
beta2	O
-	O
tubulin	O
for	O
nasopharyngeal	B-Anatomy
carcinoma	I-Anatomy
.	O
CONTEXT	O
:	O
Nasopharyngeal	B-Anatomy
carcinoma	I-Anatomy
(	O
NPC	B-Anatomy
)	O
,	O
common	O
in	O
southern	O
China	O
and	O
North	O
Africa	O
,	O
has	O
a	O
complex	O
etiology	O
involving	O
interplay	O
between	O
viral	O
,	O
environmental	O
,	O
and	O
hereditary	O
factors	O
and	O
is	O
almost	O
constantly	O
associated	O
with	O
the	O
Epstein	O
-	O
Barr	O
virus	O
.	O
Since	O
the	O
prognosis	O
of	O
locally	O
advanced	O
and	O
metastatic	B-Anatomy
diseases	I-Anatomy
is	O
poor	O
,	O
increased	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
NPC	B-Anatomy
would	O
be	O
important	O
for	O
discovering	O
novel	O
markers	O
for	O
patients	O
'	O
management	O
.	O
OBJECTIVES	O
:	O
To	O
compare	O
the	O
proteomic	O
expression	O
profile	O
between	O
an	O
Epstein	O
-	O
Barr	O
virus	O
-	O
associated	O
NPC	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
(	O
C666	B-Anatomy
-	I-Anatomy
1	I-Anatomy
)	O
and	O
a	O
normal	O
NP	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
(	O
NP69	B-Anatomy
)	O
.	O
The	O
proteins	O
with	O
differential	O
expression	O
were	O
analyzed	O
in	O
40	O
undifferentiated	O
NPC	B-Anatomy
paraffin	O
-	O
embedded	O
specimens	B-Anatomy
.	O
DESIGN	O
:	O
Differentially	O
expressed	O
proteins	O
discovered	O
between	O
the	O
two	O
cell	B-Anatomy
lines	I-Anatomy
were	O
identified	O
by	O
mass	O
spectrometry	O
.	O
After	O
confirmation	O
by	O
immunocytochemical	O
staining	O
,	O
their	O
expression	O
in	O
patient	O
samples	B-Anatomy
was	O
measured	O
using	O
40	O
pairs	O
of	O
undifferentiated	O
NPCs	B-Anatomy
together	O
with	O
their	O
adjacent	O
normal	O
epithelia	B-Anatomy
.	O
RESULTS	O
:	O
Proteomic	O
findings	O
indicated	O
that	O
adenosine	O
triphosphate	O
synthase	O
alpha	O
chain	O
was	O
up	O
-	O
regulated	O
,	O
whereas	O
annexin	O
II	O
,	O
annexin	O
V	O
,	O
beta	O
(	O
2	O
)	O
-	O
tubulin	O
,	O
and	O
profilin	O
1	O
were	O
down	O
-	O
regulated	O
.	O
After	O
confirming	O
the	O
results	O
in	O
agar	O
-	O
processed	O
cell	B-Anatomy
lines	I-Anatomy
,	O
annexin	O
II	O
and	O
beta	O
(	O
2	O
)	O
-	O
tubulin	O
expression	O
were	O
found	O
to	O
be	O
lower	O
in	O
tumor	B-Anatomy
cells	I-Anatomy
than	O
in	O
adjacent	O
normal	O
epithelial	B-Anatomy
cells	I-Anatomy
in	O
100	O
%	O
and	O
90	O
%	O
of	O
the	O
patients	O
'	O
specimens	B-Anatomy
,	O
respectively	O
.	O
Finally	O
,	O
annexin	O
II	O
down	O
-	O
regulation	O
was	O
positively	O
associated	O
with	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
,	O
suggesting	O
that	O
it	O
may	O
be	O
a	O
prognostic	O
factor	O
in	O
NPC	B-Anatomy
.	O
CONCLUSIONS	O
:	O
The	O
results	O
suggest	O
that	O
annexin	O
II	O
and	O
beta	O
(	O
2	O
)	O
-	O
tubulin	O
down	O
-	O
regulation	O
is	O
important	O
in	O
NPC	B-Anatomy
formation	O
and	O
may	O
represent	O
potential	O
targets	O
for	O
further	O
investigations	O
.	O
A	O
practical	O
interface	O
for	O
microfluidics	O
and	O
nanoelectrospray	O
mass	O
spectrometry	O
.	O
We	O
report	O
a	O
new	O
method	O
for	O
fabricating	O
nanospray	O
ionization	O
tips	O
for	O
MS	O
,	O
formed	O
from	O
glass	O
substrates	O
and	O
the	O
inert	O
polymer	O
,	O
parylene	O
-	O
C	O
.	O
Using	O
a	O
single	O
photolithography	O
step	O
,	O
the	O
emitters	O
are	O
formed	O
contiguously	O
with	O
microchannels	O
,	O
such	O
that	O
no	O
dead	O
volumes	O
are	O
observed	O
.	O
In	O
addition	O
,	O
because	O
the	O
devices	O
are	O
very	O
thin	O
(	O
approximately	O
0	O
.	O
3	O
mm	O
)	O
and	O
the	O
tips	O
are	O
formed	O
at	O
rectangular	O
corners	O
,	O
the	O
Taylor	O
cone	O
volumes	O
are	O
small	O
,	O
which	O
makes	O
the	O
method	O
attractive	O
for	O
future	O
integration	O
with	O
microfluidic	O
separations	O
.	O
Device	O
performance	O
was	O
demonstrated	O
by	O
evaluating	O
diverse	O
analytes	O
,	O
ranging	O
from	O
synthetic	O
polymers	O
,	O
to	O
peptides	O
,	O
to	O
nucleic	O
acids	O
.	O
For	O
all	O
analytes	O
,	O
performance	O
was	O
similar	O
to	O
that	O
of	O
conventional	O
emitters	O
(	O
pulled	O
-	O
glass	O
capillaries	O
and	O
the	O
Agilent	O
HPLC	O
Chip	O
)	O
with	O
the	O
advantage	O
of	O
rapid	O
,	O
batch	O
fabrication	O
of	O
identical	O
devices	O
.	O
MMTV	O
-	O
cre	O
-	O
mediated	O
fur	O
inactivation	O
concomitant	O
with	O
PLAG1	O
proto	O
-	O
oncogene	O
activation	O
delays	O
salivary	B-Anatomy
gland	I-Anatomy
tumorigenesis	O
in	O
mice	O
.	O
Proprotein	O
convertases	O
are	O
serine	O
endoproteases	O
implicated	O
in	O
the	O
proteolytic	O
processing	O
of	O
a	O
large	O
variety	O
of	O
regulatory	O
proteins	O
.	O
An	O
important	O
role	O
of	O
proprotein	O
convertases	O
in	O
tumorigenic	O
processes	O
has	O
been	O
suggested	O
by	O
various	O
studies	O
.	O
In	O
this	O
study	O
,	O
the	O
role	O
of	O
the	O
proprotein	O
convertase	O
furin	O
in	O
PLAG1	O
proto	O
-	O
oncogene	O
-	O
induced	O
salivary	B-Anatomy
gland	I-Anatomy
tumorigenesis	O
was	O
investigated	O
.	O
PLAG1	O
overexpression	O
in	O
salivary	B-Anatomy
glands	I-Anatomy
has	O
previously	O
been	O
shown	O
to	O
result	O
in	O
salivary	B-Anatomy
gland	I-Anatomy
tumors	I-Anatomy
in	O
100	O
%	O
of	O
mice	O
within	O
5	O
weeks	O
after	O
birth	O
.	O
MMTV	O
-	O
cre	O
-	O
mediated	O
inactivation	O
of	O
fur	O
without	O
over	O
-	O
expression	O
of	O
PLAG1	O
caused	O
smaller	O
but	O
histologically	O
normal	O
salivary	B-Anatomy
glands	I-Anatomy
.	O
Moreover	O
,	O
the	O
lymph	B-Anatomy
nodes	I-Anatomy
close	O
to	O
the	O
salivary	B-Anatomy
glands	I-Anatomy
were	O
enlarged	O
,	O
and	O
histology	O
showed	O
that	O
they	O
had	O
activated	O
follicles	B-Anatomy
.	O
When	O
genetic	O
ablation	O
of	O
1	O
or	O
2	O
alleles	O
of	O
fur	O
and	O
overexpression	O
of	O
the	O
PLAG1	O
transgene	O
were	O
simultaneously	O
achieved	O
,	O
a	O
significant	O
delay	O
in	O
tumorigenesis	O
was	O
observed	O
.	O
Collectively	O
,	O
these	O
results	O
suggest	O
an	O
important	O
role	O
for	O
furin	O
in	O
PLAG1	O
-	O
induced	O
salivary	B-Anatomy
gland	I-Anatomy
tumorigenesis	O
in	O
mice	O
.	O
Isotype	O
-	O
specific	O
inhibitors	O
of	O
the	O
glycolytic	O
key	O
regulator	O
pyruvate	O
kinase	O
subtype	O
M2	O
moderately	O
decelerate	O
tumor	B-Anatomy
cell	I-Anatomy
proliferation	O
.	O
Tumor	B-Anatomy
cells	I-Anatomy
express	O
the	O
glycolytic	O
regulator	O
pyruvate	O
kinase	O
subtype	O
M2	O
(	O
M2	O
-	O
PK	O
)	O
,	O
which	O
can	O
occur	O
in	O
a	O
tetrameric	O
form	O
with	O
high	O
affinity	O
to	O
its	O
substrate	O
phosphoenolpyruvate	O
(	O
PEP	O
)	O
and	O
a	O
dimeric	O
form	O
with	O
a	O
low	O
PEP	O
affinity	O
.	O
The	O
transition	O
between	O
both	O
conformations	O
contributes	O
to	O
the	O
control	O
of	O
glycolysis	O
and	O
is	O
important	O
for	O
tumor	B-Anatomy
cell	I-Anatomy
proliferation	O
and	O
survival	O
.	O
Here	O
we	O
targeted	O
M2	O
-	O
PK	O
by	O
synthetic	O
peptide	O
aptamers	O
,	O
which	O
specifically	O
bind	O
to	O
M2	O
-	O
PK	O
and	O
shift	O
the	O
isoenzyme	O
into	O
its	O
low	O
affinity	O
dimeric	O
conformation	O
.	O
The	O
aptamer	O
-	O
induced	O
dimerization	O
and	O
inactivation	O
of	O
M2	O
-	O
PK	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
the	O
PK	O
mass	O
-	O
action	O
ratio	O
as	O
well	O
as	O
ATP	O
:	O
ADP	O
ratio	O
in	O
the	O
target	O
cells	B-Anatomy
.	O
Furthermore	O
,	O
the	O
expression	O
of	O
M2	O
-	O
PK	O
-	O
binding	O
peptide	O
aptamers	O
moderately	O
reduced	O
the	O
growth	O
of	O
immortalized	O
NIH3T3	B-Anatomy
cell	I-Anatomy
populations	I-Anatomy
by	O
decelerating	O
cell	B-Anatomy
proliferation	O
,	O
but	O
without	O
affecting	O
apoptotic	O
cell	B-Anatomy
death	O
.	O
Moreover	O
,	O
the	O
M2	O
-	O
PK	O
-	O
binding	O
peptide	O
aptamers	O
also	O
reduced	O
the	O
proliferation	O
rate	O
of	O
human	O
U	B-Anatomy
-	I-Anatomy
2	I-Anatomy
OS	I-Anatomy
osteosarcoma	I-Anatomy
cells	I-Anatomy
.	O
In	O
the	O
present	O
study	O
,	O
we	O
developed	O
the	O
first	O
specific	O
inhibitors	O
of	O
the	O
pyruvate	O
kinase	O
isoenzyme	O
type	O
M2	O
and	O
present	O
evidence	O
that	O
these	O
inhibitors	O
moderately	O
decelerate	O
tumor	B-Anatomy
cell	I-Anatomy
proliferation	O
.	O
Hematogenous	O
metastasis	O
in	O
gastric	B-Anatomy
cancer	I-Anatomy
requires	O
isolated	B-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
and	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
1	O
.	O
PURPOSE	O
:	O
Recent	O
studies	O
of	O
cancer	B-Anatomy
metastasis	O
have	O
focused	O
on	O
the	O
role	O
of	O
premetastatic	O
gene	O
expression	O
and	O
circulating	O
tumor	B-Anatomy
cells	I-Anatomy
.	O
We	O
did	O
a	O
blind	O
prospective	O
study	O
in	O
gastric	B-Anatomy
cancer	I-Anatomy
to	O
assess	O
the	O
significance	O
of	O
isolated	B-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
(	O
ITC	B-Anatomy
)	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
1	O
(	O
VEGFR	O
-	O
1	O
)	O
is	O
expressed	O
within	O
the	O
bone	B-Anatomy
marrow	I-Anatomy
at	O
tumor	B-Anatomy
-	O
specific	O
,	O
premetastatic	B-Anatomy
sites	I-Anatomy
.	O
EXPERIMENTAL	O
DESIGN	O
:	O
Both	O
bone	B-Anatomy
marrow	I-Anatomy
and	O
peripheral	B-Anatomy
blood	I-Anatomy
samples	I-Anatomy
from	O
810	O
gastric	B-Anatomy
cancer	I-Anatomy
patients	O
were	O
collected	O
at	O
the	O
Central	O
Hospital	O
,	O
National	O
Cancer	O
Center	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O
The	O
samples	B-Anatomy
were	O
transferred	O
to	O
Kyushu	O
University	O
Hospital	O
(	O
Beppu	O
,	O
Japan	O
)	O
where	O
they	O
were	O
analyzed	O
by	O
quantitative	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
for	O
three	O
epithelial	B-Anatomy
cell	I-Anatomy
markers	O
,	O
carcinoembryonic	O
antigen	O
,	O
cytokeratin	O
-	O
19	O
,	O
and	O
cytokeratin	O
-	O
7	O
,	O
as	O
well	O
as	O
VEGFR	O
-	O
1	O
.	O
RESULTS	O
:	O
ITCs	B-Anatomy
were	O
observed	O
in	O
peripheral	B-Anatomy
blood	I-Anatomy
and	O
bone	B-Anatomy
marrow	I-Anatomy
even	O
in	O
early	O
stages	O
of	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
The	O
frequency	O
of	O
ITC	B-Anatomy
in	O
bone	B-Anatomy
marrow	I-Anatomy
was	O
significantly	O
associated	O
with	O
the	O
stage	O
of	O
disease	O
by	O
ANOVA	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
Gastric	B-Anatomy
cancer	I-Anatomy
metastasized	O
when	O
ITCs	B-Anatomy
were	O
observed	O
in	O
the	O
presence	O
of	O
VEGFR	O
-	O
1	O
.	O
In	O
the	O
380	O
patients	O
who	O
were	O
ITC	B-Anatomy
negative	O
and	O
showed	O
low	O
VEGFR	O
-	O
1	O
expression	O
,	O
synchronous	O
(	O
at	O
the	O
time	O
of	O
surgery	O
)	O
and	O
heterochronous	O
(	O
recurrent	O
)	O
metastases	B-Anatomy
were	O
not	O
observed	O
.	O
CONCLUSIONS	O
:	O
ITCs	B-Anatomy
circulate	O
even	O
in	O
early	O
stages	O
of	O
disease	O
.	O
Furthermore	O
,	O
elevated	O
expression	O
of	O
VEGFR	O
-	O
1	O
facilitates	O
the	O
establishment	O
of	O
hematogenous	B-Anatomy
metastases	I-Anatomy
in	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
This	O
study	O
indicates	O
that	O
the	O
simultaneous	O
presence	O
of	O
ITC	B-Anatomy
and	O
VEGFR	O
-	O
1	O
expression	O
at	O
premetastatic	B-Anatomy
sites	I-Anatomy
is	O
clinically	O
significant	O
for	O
disease	O
progression	O
.	O
Acute	O
ethanol	O
exposure	O
disrupts	O
VEGF	O
receptor	O
cell	B-Anatomy
signaling	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
Physiological	O
angiogenesis	O
is	O
regulated	O
by	O
various	O
factors	O
,	O
including	O
signaling	O
through	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
receptors	O
.	O
We	O
previously	O
reported	O
that	O
a	O
single	O
dose	O
of	O
ethanol	O
(	O
1	O
.	O
4	O
g	O
/	O
kg	O
)	O
,	O
yielding	O
a	O
blood	B-Anatomy
alcohol	O
concentration	O
of	O
100	O
mg	O
/	O
dl	O
,	O
significantly	O
impairs	O
angiogenesis	O
in	O
murine	O
wounds	B-Anatomy
,	O
despite	O
adequate	O
levels	O
of	O
VEGF	O
,	O
suggesting	O
direct	O
effects	O
of	O
ethanol	O
on	O
endothelial	B-Anatomy
cell	I-Anatomy
signaling	O
(	O
40	O
)	O
.	O
To	O
examine	O
the	O
mechanism	O
by	O
which	O
ethanol	O
influences	O
angiogenesis	O
in	O
wounds	B-Anatomy
,	O
we	O
employed	O
two	O
different	O
in	O
vitro	O
angiogenesis	O
assays	O
to	O
determine	O
whether	O
acute	O
ethanol	O
exposure	O
(	O
100	O
mg	O
/	O
dl	O
)	O
would	O
have	O
long	O
-	O
lasting	O
effects	O
on	O
VEGF	O
-	O
induced	O
capillary	B-Anatomy
network	I-Anatomy
formation	O
.	O
Ethanol	O
exposure	O
resulted	O
in	O
reduced	O
VEGF	O
-	O
induced	O
cord	B-Anatomy
formation	O
on	O
collagen	O
and	O
reduced	O
capillary	B-Anatomy
network	I-Anatomy
structure	O
on	O
Matrigel	O
in	O
vitro	O
.	O
In	O
addition	O
,	O
ethanol	O
exposure	O
decreased	O
expression	O
of	O
endothelial	B-Anatomy
VEGF	O
receptor	O
-	O
2	O
,	O
as	O
well	O
as	O
VEGF	O
receptor	O
-	O
2	O
phosphorylation	O
in	O
vitro	O
.	O
Inhibition	O
of	O
ethanol	O
metabolism	O
by	O
4	O
-	O
methylpyrazole	O
partially	O
abrogated	O
the	O
effect	O
of	O
ethanol	O
on	O
endothelial	B-Anatomy
cell	I-Anatomy
cord	I-Anatomy
formation	O
.	O
However	O
,	O
mice	O
treated	O
with	O
t	O
-	O
butanol	O
,	O
an	O
alcohol	O
not	O
metabolized	O
by	O
alcohol	O
dehydrogenase	O
,	O
exhibited	O
no	O
change	O
in	O
wound	B-Anatomy
vascularity	O
.	O
These	O
results	O
suggest	O
that	O
products	O
of	O
ethanol	O
metabolism	O
are	O
important	O
factors	O
in	O
the	O
development	O
of	O
ethanol	O
-	O
induced	O
changes	O
in	O
endothelial	B-Anatomy
cell	I-Anatomy
responsiveness	O
to	O
VEGF	O
.	O
In	O
vivo	O
,	O
ethanol	O
exposure	O
caused	O
both	O
decreased	O
angiogenesis	O
and	O
increased	O
hypoxia	O
in	O
wounds	B-Anatomy
.	O
Moreover	O
,	O
in	O
vitro	O
experiments	O
demonstrated	O
a	O
direct	O
effect	O
of	O
ethanol	O
on	O
the	O
response	O
to	O
hypoxia	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
as	O
ethanol	O
diminished	O
nuclear	B-Anatomy
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
protein	O
levels	O
.	O
Together	O
,	O
the	O
data	O
establish	O
that	O
acute	O
ethanol	O
exposure	O
significantly	O
impairs	O
angiogenesis	O
and	O
suggest	O
that	O
this	O
effect	O
is	O
mediated	O
by	O
changes	O
in	O
endothelial	B-Anatomy
cell	I-Anatomy
responsiveness	O
to	O
both	O
VEGF	O
and	O
hypoxia	O
.	O
Adenomatoid	B-Anatomy
tumour	I-Anatomy
of	O
the	O
liver	B-Anatomy
.	O
An	O
unusual	O
primary	B-Anatomy
adenomatoid	I-Anatomy
tumour	I-Anatomy
arising	O
in	O
the	O
normal	O
liver	B-Anatomy
is	O
described	O
.	O
Hepatectomy	O
was	O
performed	O
,	O
and	O
the	O
patient	O
is	O
alive	O
and	O
free	O
of	O
disease	O
1	O
year	O
postsurgery	O
.	O
Grossly	O
,	O
the	O
tumour	B-Anatomy
showed	O
a	O
haemorrhagic	O
cut	O
surface	B-Anatomy
with	O
numerous	O
microcystic	B-Anatomy
structures	I-Anatomy
.	O
Histological	O
examination	O
revealed	O
cystic	B-Anatomy
or	O
angiomatoid	O
spaces	O
of	O
various	O
sizes	O
lined	O
by	O
cuboidal	O
,	O
low	O
-	O
columnar	O
,	O
or	O
flattened	O
epithelioid	B-Anatomy
cells	I-Anatomy
with	O
vacuolated	B-Anatomy
cytoplasm	I-Anatomy
and	O
round	O
to	O
oval	O
nuclei	B-Anatomy
.	O
The	O
epithelioid	B-Anatomy
cells	I-Anatomy
were	O
entirely	O
supported	O
by	O
proliferated	O
capillaries	B-Anatomy
and	O
arteries	B-Anatomy
together	O
with	O
collagenous	B-Anatomy
stroma	I-Anatomy
.	O
Immunohistochemical	O
studies	O
showed	O
that	O
the	O
epithelioid	B-Anatomy
cells	I-Anatomy
were	O
strongly	O
positive	O
for	O
a	O
broad	O
spectrum	O
of	O
cytokeratins	O
(	O
AE1	O
/	O
AE3	O
,	O
CAM5	O
.	O
2	O
,	O
epithelial	O
membrane	O
antigen	O
and	O
cytokeratin	O
7	O
)	O
and	O
mesothelial	B-Anatomy
markers	O
(	O
calretinin	O
,	O
Wilms	O
'	O
tumour	O
1	O
and	O
D2	O
-	O
40	O
)	O
.	O
These	O
cells	B-Anatomy
were	O
negative	O
for	O
Hep	O
par	O
-	O
1	O
,	O
carcinoembryonic	O
antigen	O
,	O
neural	O
cell	O
adhesion	O
molecule	O
,	O
CD34	O
,	O
CD31	O
and	O
HMB45	O
.	O
Atypically	O
,	O
abundant	O
capillaries	B-Anatomy
were	O
observed	O
;	O
however	O
,	O
the	O
cystic	B-Anatomy
proliferation	O
of	O
epithelioid	B-Anatomy
cells	I-Anatomy
with	O
vacuoles	B-Anatomy
and	O
immunohistochemical	O
profile	O
of	O
the	O
epithelioid	B-Anatomy
element	I-Anatomy
were	O
consistent	O
with	O
hepatic	B-Anatomy
adenomatoid	I-Anatomy
tumour	I-Anatomy
.	O
Research	O
advances	O
of	O
endostatin	O
and	O
its	O
short	O
internal	O
fragments	O
.	O
Endostatin	O
,	O
the	O
C	O
-	O
terminal	O
fragment	O
of	O
collagen	O
XVIII	O
,	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O
At	O
present	O
,	O
there	O
are	O
a	O
large	O
number	O
of	O
research	O
papers	O
on	O
endostatin	O
.	O
However	O
,	O
the	O
action	O
mechanism	O
of	O
endostatin	O
is	O
still	O
a	O
matter	O
of	O
ongoing	O
discussion	O
.	O
The	O
objective	O
of	O
this	O
review	O
is	O
to	O
elucidate	O
its	O
origin	O
and	O
elementary	O
structure	O
,	O
and	O
to	O
discuss	O
its	O
structure	O
basis	O
of	O
activity	O
and	O
action	O
mechanisms	O
based	O
on	O
the	O
latest	O
research	O
.	O
Furthermore	O
,	O
some	O
published	O
studies	O
reporting	O
the	O
antiangiogenic	O
effects	O
of	O
endostatin	O
-	O
derived	O
peptides	O
were	O
also	O
reviewed	O
.	O
It	O
is	O
proposed	O
that	O
the	O
amino	O
acid	O
sequence	O
of	O
endostatin	O
contains	O
both	O
angiosuppressive	O
and	O
angiostimulatory	O
domains	O
.	O
Short	O
endostatin	O
fragments	O
may	O
be	O
exploited	O
as	O
a	O
new	O
angiogenesis	O
inhibitor	O
for	O
therapeutic	O
applications	O
,	O
in	O
substitution	O
of	O
the	O
full	O
length	O
endostatin	O
.	O
These	O
studies	O
on	O
endostatin	O
fragments	O
also	O
shed	O
light	O
on	O
our	O
understanding	O
of	O
the	O
molecular	O
action	O
mechanisms	O
of	O
endostatin	O
.	O
Contemporary	O
perspectives	O
on	O
vital	O
pulp	B-Anatomy
therapy	O
:	O
views	O
from	O
the	O
endodontists	O
and	O
pediatric	O
dentists	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
level	O
of	O
agreement	O
between	O
pediatric	O
dentists	O
and	O
endodontists	O
at	O
a	O
pulp	B-Anatomy
therapy	O
symposium	O
conjointly	O
sponsored	O
by	O
the	O
American	O
Association	O
of	O
Endodontists	O
(	O
AAE	O
)	O
and	O
the	O
American	O
Academy	O
of	O
Pediatric	O
Dentistry	O
(	O
AAPD	O
)	O
on	O
November	O
2	O
-	O
3	O
,	O
2007	O
.	O
Presymposium	O
and	O
postsymposium	O
tests	O
were	O
administered	O
,	O
and	O
respondent	O
answers	O
were	O
compared	O
between	O
pediatric	O
dentists	O
and	O
endodontists	O
.	O
Opinions	O
on	O
3	O
areas	O
were	O
sought	O
:	O
pulp	B-Anatomy
therapy	O
for	O
cariously	B-Anatomy
involved	O
primary	O
teeth	B-Anatomy
;	O
indirect	O
pulp	B-Anatomy
treatment	O
(	O
IPT	O
)	O
for	O
cariously	B-Anatomy
involved	O
immature	O
permanent	O
teeth	B-Anatomy
;	O
and	O
innovative	O
treatment	O
options	O
including	O
pulpal	B-Anatomy
revascularization	O
and	O
regeneration	O
.	O
Results	O
were	O
analyzed	O
with	O
chi2	O
tests	O
.	O
Comparisons	O
of	O
presymposium	O
and	O
postsymposium	O
responses	O
and	O
between	O
the	O
2	O
groups	O
of	O
attendees	O
indicated	O
that	O
the	O
pediatric	O
dentistry	O
and	O
endodontic	O
communities	O
agree	O
that	O
formocresol	O
will	O
be	O
replaced	O
as	O
a	O
primary	O
tooth	B-Anatomy
pulpotomy	O
agent	O
,	O
that	O
mineral	O
trioxide	O
is	O
the	O
first	O
choice	O
to	O
take	O
its	O
place	O
,	O
that	O
IPT	O
in	O
primary	O
teeth	B-Anatomy
holds	O
hope	O
as	O
a	O
replacement	O
for	O
pulpotomy	O
,	O
and	O
that	O
IPT	O
is	O
an	O
acceptable	O
pulp	B-Anatomy
therapy	O
technique	O
for	O
cariously	B-Anatomy
involved	O
young	O
permanent	O
teeth	B-Anatomy
.	O
Both	O
groups	O
believe	O
that	O
pulp	B-Anatomy
revascularization	O
and	O
regeneration	O
will	O
be	O
viable	O
treatment	O
modalities	O
in	O
the	O
future	O
.	O
The	O
AAE	O
and	O
the	O
AAPD	O
are	O
positioned	O
to	O
begin	O
preparation	O
of	O
best	O
practice	O
guidelines	O
that	O
share	O
common	O
language	O
and	O
treatment	O
recommendations	O
for	O
pulp	B-Anatomy
therapies	O
performed	O
by	O
both	O
specialties	O
.	O
Intraoperative	O
handling	O
and	O
wound	B-Anatomy
healing	O
of	O
arthroscopic	O
portal	O
wounds	B-Anatomy
:	O
a	O
clinical	O
study	O
comparing	O
nylon	O
suture	O
with	O
wound	B-Anatomy
closure	O
strips	O
.	O
This	O
prospective	O
,	O
single	O
-	O
centre	O
study	O
compared	O
wound	B-Anatomy
closure	O
methods	O
in	O
patients	O
undergoing	O
arthroscopy	O
.	O
Closure	O
of	O
arthroscopic	O
portal	O
wounds	B-Anatomy
with	O
sterile	O
adhesive	O
strips	O
is	O
effective	O
and	O
convenient	O
for	O
wound	B-Anatomy
management	O
.	O
The	O
method	O
was	O
associated	O
with	O
a	O
reduced	O
potential	O
for	O
infection	O
,	O
faster	O
renewal	O
of	O
tensile	O
strength	O
,	O
greater	O
cost	O
effectiveness	O
,	O
and	O
better	O
cosmetic	O
effects	O
comparing	O
with	O
suture	O
closure	O
.	O
This	O
method	O
of	O
wound	B-Anatomy
closure	O
may	O
also	O
reduce	O
the	O
incidence	O
of	O
needle	O
stick	O
injury	O
in	O
the	O
theatre	O
environment	O
.	O
Thereby	O
the	O
incidence	O
of	O
percutaneous	B-Anatomy
exposure	O
following	O
a	O
surgical	O
procedure	O
may	O
not	O
facilitate	O
transmission	O
of	O
blood	B-Anatomy
borne	O
pathogens	O
such	O
as	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
hepatitis	O
C	O
virus	O
and	O
hepatitis	O
B	O
virus	O
.	O
As	O
a	O
result	O
it	O
may	O
reduce	O
litigation	O
in	O
today	O
'	O
s	O
changing	O
healthcare	O
climate	O
.	O
The	O
role	O
of	O
platelet	O
-	O
derived	O
endothelial	O
cell	O
growth	O
factor	O
/	O
thymidine	O
phosphorylase	O
in	O
tumor	B-Anatomy
behavior	O
.	O
Platelet	O
-	O
derived	O
endothelial	O
cell	O
growth	O
-	O
factor	O
(	O
PD	O
-	O
ECGF	O
)	O
is	O
similar	O
to	O
the	O
pyrimidine	O
enzyme	O
thymidine	O
phosphorylase	O
(	O
TP	O
)	O
.	O
A	O
high	O
TP	O
expression	O
at	O
tumor	B-Anatomy
sites	I-Anatomy
is	O
correlated	O
with	O
tumor	B-Anatomy
growth	O
,	O
induction	O
of	O
angiogenesis	O
,	O
and	O
metastasis	O
.	O
Therefore	O
,	O
high	O
TP	O
is	O
most	O
likely	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O
TP	O
is	O
not	O
only	O
expressed	O
in	O
tumor	B-Anatomy
cells	I-Anatomy
but	O
also	O
in	O
tumor	B-Anatomy
surrounding	I-Anatomy
tissues	I-Anatomy
,	O
such	O
as	O
tumor	B-Anatomy
infiltrating	I-Anatomy
macrophages	I-Anatomy
.	O
TP	O
catalyzes	O
the	O
conversion	O
of	O
thymidine	O
to	O
thymine	O
and	O
doxyribose	O
-	O
1	O
-	O
phosphate	O
(	O
dR	O
-	O
1	O
-	O
P	O
)	O
.	O
The	O
latter	O
in	O
its	O
parent	O
form	O
or	O
in	O
its	O
sugar	O
form	O
,	O
deoxyribose	O
(	O
dR	O
)	O
may	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
angiogenesis	O
.	O
It	O
may	O
modulate	O
cellular	B-Anatomy
energy	O
metabolism	O
or	O
be	O
a	O
substrate	O
in	O
a	O
chemical	O
reaction	O
generating	O
reactive	O
oxygen	O
species	O
.	O
L	O
-	O
deoxyribose	O
(	O
L	O
-	O
dR	O
)	O
and	O
thymidine	O
phosphorylase	O
inhibitor	O
(	O
TPI	O
)	O
can	O
reverse	O
these	O
effects	O
.	O
The	O
mechanism	O
of	O
TP	O
induction	O
is	O
not	O
yet	O
completely	O
clear	O
,	O
but	O
TNF	O
,	O
IL10	O
and	O
other	O
cytokines	O
have	O
been	O
clearly	O
shown	O
to	O
induce	O
its	O
expression	O
.	O
The	O
various	O
complex	O
interactions	O
of	O
TP	O
give	O
it	O
an	O
essential	O
role	O
in	O
cellular	B-Anatomy
functioning	O
and	O
,	O
hence	O
,	O
it	O
is	O
an	O
ideal	O
target	O
in	O
cancer	B-Anatomy
therapy	O
.	O
Investigation	O
of	O
the	O
effect	O
of	O
kaolin	O
and	O
tissue	O
-	O
factor	O
-	O
activated	O
citrated	O
whole	B-Anatomy
blood	I-Anatomy
,	O
on	O
clot	B-Anatomy
-	O
forming	O
variables	O
,	O
as	O
evaluated	O
by	O
thromboelastography	O
.	O
BACKGROUND	O
:	O
The	O
Thrombelastograph	O
(	O
TEG	O
;	O
Haemoscope	O
Corp	O
.	O
)	O
analyzes	O
clot	B-Anatomy
formation	O
in	O
whole	B-Anatomy
blood	I-Anatomy
(	O
WB	B-Anatomy
)	O
and	O
treatment	O
based	O
on	O
this	O
analysis	O
has	O
been	O
shown	O
to	O
reduce	O
transfusion	O
requirements	O
in	O
liver	B-Anatomy
and	O
cardiac	B-Anatomy
surgery	O
when	O
compared	O
to	O
conventional	O
coagulation	O
analysis	O
.	O
Implementing	O
TEG	O
as	O
a	O
routine	O
laboratory	O
-	O
based	O
analysis	O
,	O
however	O
,	O
requires	O
validation	O
of	O
the	O
activators	O
employed	O
and	O
the	O
effect	O
of	O
storage	O
of	O
the	O
WB	B-Anatomy
sample	I-Anatomy
in	O
citrate	O
before	O
analysis	O
.	O
STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
The	O
effect	O
of	O
kaolin	O
,	O
tissue	O
factor	O
(	O
TF	O
)	O
1	O
:	O
17	O
,	O
000	O
,	O
or	O
TF	O
1	O
:	O
42	O
,	O
500	O
on	O
TEG	O
clotting	O
time	O
(	O
R	O
)	O
,	O
Angle	O
(	O
velocity	O
of	O
clot	B-Anatomy
formation	O
)	O
,	O
and	O
maximum	O
clot	B-Anatomy
strength	O
(	O
amplitude	O
[	O
MA	O
]	O
)	O
were	O
evaluated	O
,	O
together	O
with	O
day	O
-	O
to	O
-	O
day	O
variation	O
,	O
the	O
coefficient	O
of	O
variance	O
(	O
CV	O
%	O
)	O
,	O
and	O
the	O
effect	O
of	O
citrate	O
storage	O
time	O
.	O
RESULTS	O
:	O
Clot	B-Anatomy
formation	O
variables	O
were	O
equally	O
affected	O
by	O
TF	O
1	O
:	O
17	O
,	O
000	O
and	O
kaolin	O
activation	O
,	O
whereas	O
R	O
was	O
significantly	O
longer	O
when	O
TF	O
1	O
:	O
42	O
,	O
500	O
was	O
used	O
.	O
The	O
CV	O
for	O
the	O
different	O
variables	O
varied	O
from	O
3	O
to	O
13	O
percent	O
with	O
no	O
significant	O
differences	O
between	O
assays	O
.	O
Storage	O
of	O
citrated	O
WB	B-Anatomy
significantly	O
affected	O
the	O
TEG	O
variables	O
in	O
a	O
hypercoagulable	O
direction	O
.	O
Only	O
the	O
R	O
,	O
however	O
,	O
was	O
significantly	O
affected	O
(	O
12	O
%	O
)	O
when	O
samples	B-Anatomy
rested	O
for	O
0	O
and	O
30	O
minutes	O
were	O
evaluated	O
with	O
kaolin	O
as	O
the	O
activator	O
.	O
CONCLUSION	O
:	O
The	O
TEG	O
assays	O
evaluated	O
were	O
reproducible	O
and	O
present	O
with	O
an	O
acceptable	O
CV	O
%	O
for	O
routine	O
clinical	O
practice	O
.	O
Kaolin	O
and	O
TF	O
1	O
:	O
17	O
,	O
000	O
equally	O
affected	O
the	O
clot	B-Anatomy
formation	O
variables	O
.	O
Storage	O
of	O
WB	B-Anatomy
for	O
up	O
to	O
30	O
minutes	O
in	O
citrate	O
did	O
not	O
,	O
except	O
for	O
R	O
,	O
affect	O
clot	B-Anatomy
formation	O
variables	O
when	O
kaolin	O
was	O
used	O
as	O
activator	O
allowing	O
for	O
immediate	O
analysis	O
when	O
the	O
sample	B-Anatomy
arrives	O
in	O
the	O
laboratory	O
.	O
Reversal	O
of	O
the	O
malignant	O
phenotype	O
of	O
ovarian	B-Anatomy
cancer	I-Anatomy
A2780	I-Anatomy
cells	I-Anatomy
through	O
transfection	O
with	O
wild	O
-	O
type	O
PTEN	O
gene	O
.	O
OBJECTIVE	O
:	O
PTEN	O
(	O
phosphatase	O
and	O
tensin	O
homologue	O
deleted	O
on	O
chromosome	O
10	O
)	O
is	O
a	O
tumor	B-Anatomy
suppressor	O
gene	O
identified	O
on	O
human	O
chromosome	B-Anatomy
10q23	I-Anatomy
.	O
Substantial	O
studies	O
have	O
demonstrated	O
that	O
PTEN	O
can	O
inhibit	O
cell	B-Anatomy
proliferation	O
,	O
migration	O
and	O
invasion	O
of	O
many	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
upregulation	O
of	O
PTEN	O
gene	O
by	O
transfection	O
wild	O
-	O
type	O
PTEN	O
gene	O
to	O
ovarian	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
can	O
inhibit	O
growth	O
and	O
migration	O
and	O
to	O
explore	O
the	O
potential	O
for	O
PTEN	O
gene	O
therapy	O
of	O
ovarian	B-Anatomy
cancers	I-Anatomy
.	O
METHOD	O
:	O
Wild	O
-	O
type	O
and	O
phosphatase	O
-	O
inactive	O
(	O
C124A	O
)	O
PTEN	O
plasmids	B-Anatomy
were	O
transfected	O
into	O
ovarian	B-Anatomy
epithelial	I-Anatomy
cancer	I-Anatomy
A2780	I-Anatomy
cells	I-Anatomy
,	O
and	O
their	O
effects	O
on	O
cell	B-Anatomy
apoptosis	O
,	O
cell	B-Anatomy
proliferation	O
,	O
cell	B-Anatomy
migration	O
and	O
cell	B-Anatomy
invasion	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
analysis	O
,	O
TUNEL	O
assay	O
,	O
MTT	O
assay	O
,	O
wound	B-Anatomy
-	O
healing	O
assay	O
and	O
transwell	O
assay	O
.	O
RESULTS	O
:	O
Both	O
wild	O
-	O
type	O
and	O
mutant	O
PTEN	O
can	O
upregulate	O
the	O
expression	O
of	O
PTEN	O
gene	O
dramatically	O
;	O
however	O
,	O
it	O
is	O
wild	O
-	O
type	O
PTEN	O
not	O
phosphatase	O
-	O
inactive	O
PTEN	O
that	O
can	O
induce	O
apoptosis	O
and	O
decrease	O
cell	B-Anatomy
migration	O
,	O
invasion	O
and	O
proliferation	O
in	O
ovarian	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
CONCLUSION	O
:	O
These	O
results	O
demonstrated	O
that	O
PTEN	O
had	O
played	O
an	O
important	O
role	O
in	O
the	O
cell	B-Anatomy
proliferation	O
,	O
cell	B-Anatomy
migration	O
and	O
invasion	O
dependent	O
on	O
its	O
phosphatase	O
activity	O
.	O
Enhanced	O
expression	O
of	O
PTEN	O
by	O
gene	O
transfer	O
is	O
sufficient	O
to	O
reverse	O
the	O
malignant	O
phenotype	O
of	O
ovarian	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
and	O
transfection	O
of	O
ovarian	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
with	O
wild	O
-	O
type	O
PTEN	O
gene	O
might	O
be	O
another	O
novel	O
approach	O
for	O
therapeutic	O
intervention	O
in	O
ovarian	B-Anatomy
cancer	I-Anatomy
.	O
Allogeneic	O
injection	O
of	O
fetal	B-Anatomy
membrane	I-Anatomy
-	I-Anatomy
derived	I-Anatomy
mesenchymal	I-Anatomy
stem	I-Anatomy
cells	I-Anatomy
induces	O
therapeutic	O
angiogenesis	O
in	O
a	O
rat	O
model	O
of	O
hind	B-Anatomy
limb	I-Anatomy
ischemia	O
.	O
Bone	B-Anatomy
marrow	I-Anatomy
-	I-Anatomy
derived	I-Anatomy
mesenchymal	I-Anatomy
stem	I-Anatomy
cells	I-Anatomy
(	O
BM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
)	O
have	O
been	O
demonstrated	O
to	O
be	O
an	O
attractive	O
therapeutic	O
cell	B-Anatomy
source	O
for	O
tissue	B-Anatomy
regeneration	O
and	O
repair	O
.	O
However	O
,	O
it	O
remains	O
unknown	O
whether	O
or	O
not	O
allogeneic	O
transplantation	O
of	O
mesenchymal	B-Anatomy
stem	I-Anatomy
cells	I-Anatomy
(	O
MSC	B-Anatomy
)	O
derived	O
from	O
fetal	B-Anatomy
membranes	I-Anatomy
(	O
FM	B-Anatomy
)	O
,	O
which	O
are	O
generally	O
discarded	O
as	O
medical	O
waste	O
after	O
delivery	O
,	O
has	O
therapeutic	O
potential	O
.	O
FM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
were	O
obtained	O
from	O
Lewis	O
rats	O
and	O
had	O
surface	B-Anatomy
antigen	O
expression	O
and	O
multipotent	O
potential	O
partly	O
similar	O
to	O
those	O
of	O
BM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
.	O
Compared	O
with	O
BM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
,	O
FM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
secreted	O
a	O
comparable	O
amount	O
of	O
hepatocyte	O
growth	O
factor	O
despite	O
a	O
small	O
amount	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
.	O
FM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
and	O
BM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
both	O
expressed	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
but	O
not	O
MHC	O
class	O
II	O
antigens	O
and	O
did	O
not	O
elicit	O
allogeneic	O
lymphocyte	B-Anatomy
proliferation	O
in	O
mixed	O
lymphocyte	B-Anatomy
culture	I-Anatomy
.	O
FM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
or	O
BM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
obtained	O
from	O
Lewis	O
rats	O
were	O
injected	O
into	O
a	O
MHC	O
-	O
mismatched	O
August	O
-	O
Copenhagen	O
-	O
Irish	O
rat	O
model	O
of	O
hind	B-Anatomy
limb	I-Anatomy
ischemia	O
.	O
Three	O
weeks	O
after	O
injection	O
,	O
blood	B-Anatomy
perfusion	O
and	O
capillary	B-Anatomy
density	O
were	O
significantly	O
higher	O
in	O
the	O
FM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
and	O
BM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
groups	O
than	O
in	O
the	O
phosphate	O
-	O
buffered	O
saline	O
group	O
,	O
and	O
allogeneic	O
FM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
and	O
BM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
were	O
still	O
observed	O
.	O
In	O
nonischemic	O
hind	B-Anatomy
limb	I-Anatomy
tissues	I-Anatomy
,	O
allogeneic	O
FM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
and	O
BM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
injection	O
were	O
associated	O
with	O
a	O
comparatively	O
small	O
amount	O
of	O
T	B-Anatomy
lymphocyte	I-Anatomy
infiltration	O
,	O
compared	O
with	O
the	O
injection	O
of	O
allogeneic	O
splenic	B-Anatomy
lymphocytes	I-Anatomy
.	O
In	O
conclusion	O
,	O
allogeneic	O
FM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
injection	O
did	O
not	O
elicit	O
a	O
lymphocyte	B-Anatomy
proliferative	O
response	O
and	O
provided	O
significant	O
improvement	O
in	O
a	O
rat	O
model	O
of	O
hind	B-Anatomy
limb	I-Anatomy
ischemia	O
,	O
comparable	O
to	O
the	O
response	O
to	O
BM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
.	O
Thus	O
,	O
allogeneic	O
injection	O
of	O
FM	B-Anatomy
-	I-Anatomy
MSC	I-Anatomy
may	O
be	O
a	O
new	O
therapeutic	O
strategy	O
for	O
the	O
treatment	O
of	O
severe	O
peripheral	B-Anatomy
vascular	I-Anatomy
disease	O
.	O
Disclosure	O
of	O
potential	O
conflicts	O
of	O
interest	O
is	O
found	O
at	O
the	O
end	O
of	O
this	O
article	O
.	O
Regulation	O
of	O
the	O
Warburg	O
effect	O
in	O
early	B-Anatomy
-	I-Anatomy
passage	I-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Malignancy	O
in	O
cancer	B-Anatomy
is	O
associated	O
with	O
aerobic	O
glycolysis	O
(	O
Warburg	O
effect	O
)	O
evidenced	O
by	O
increased	O
trapping	O
of	O
[	O
(	O
18	O
)	O
F	O
]	O
deoxyglucose	O
(	O
FdG	O
)	O
in	O
patients	O
imaged	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O
[	O
(	O
18	O
)	O
F	O
]	O
deoxyglucose	O
uptake	O
correlates	O
with	O
glucose	O
transporter	O
(	O
GLUT	O
-	O
1	O
)	O
expression	O
,	O
which	O
can	O
be	O
regulated	O
by	O
hypoxia	O
-	O
inducible	O
factor	O
1	O
alpha	O
(	O
HIF	O
-	O
1alpha	O
)	O
.	O
We	O
have	O
previously	O
reported	O
in	O
established	O
breast	B-Anatomy
lines	I-Anatomy
that	O
HIF	O
-	O
1alpha	O
levels	O
in	O
the	O
presence	O
of	O
oxygen	O
leads	O
to	O
the	O
Warburg	O
effect	O
.	O
However	O
,	O
glycolysis	O
and	O
GLUT	O
-	O
1	O
can	O
also	O
be	O
induced	O
independent	O
of	O
HIF	O
-	O
1alpha	O
by	O
other	O
factors	O
,	O
such	O
as	O
c	O
-	O
Myc	O
and	O
phosphorylated	O
Akt	O
(	O
pAkt	O
)	O
.	O
This	O
study	O
investigates	O
HIF	O
-	O
1alpha	O
,	O
c	O
-	O
Myc	O
,	O
pAkt	O
,	O
and	O
aerobic	O
glycolysis	O
in	O
low	O
-	O
passage	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
under	O
the	O
assumption	O
that	O
these	O
represent	O
the	O
in	O
vivo	O
condition	O
better	O
than	O
established	O
lines	B-Anatomy
.	O
Similar	O
to	O
in	O
vivo	O
FdG	O
-	O
PET	O
or	O
primary	B-Anatomy
breast	I-Anatomy
cancers	I-Anatomy
,	O
rates	O
of	O
glycolysis	O
were	O
diverse	O
,	O
being	O
higher	O
in	O
cells	B-Anatomy
expressing	O
both	O
c	O
-	O
Myc	O
and	O
HIF	O
-	O
1alpha	O
and	O
lower	O
in	O
cell	B-Anatomy
lines	I-Anatomy
low	O
or	O
negative	O
in	O
both	O
transcription	O
factors	O
.	O
No	O
correlations	O
were	O
observed	O
between	O
glycolytic	O
rates	O
and	O
pAkt	O
levels	O
.	O
Two	O
of	O
12	O
cell	B-Anatomy
lines	I-Anatomy
formed	O
xenografts	B-Anatomy
in	O
mice	O
.	O
Both	O
were	O
positive	O
for	O
HIF	O
-	O
1alpha	O
and	O
phosphorylated	O
c	O
-	O
Myc	O
,	O
and	O
only	O
one	O
was	O
positive	O
for	O
pAkt	O
.	O
Glycolysis	O
was	O
affected	O
by	O
pharmacological	O
regulation	O
of	O
c	O
-	O
Myc	O
and	O
HIF	O
-	O
1alpha	O
.	O
These	O
findings	O
suggest	O
that	O
c	O
-	O
Myc	O
and	O
/	O
or	O
HIF	O
-	O
1alpha	O
activities	O
are	O
both	O
involved	O
in	O
the	O
regulation	O
of	O
glycolysis	O
in	O
breast	B-Anatomy
cancers	I-Anatomy
.	O
Intracerebral	O
grafting	O
of	O
cultured	O
autologous	O
skin	B-Anatomy
fibroblasts	I-Anatomy
into	O
the	O
rat	O
striatum	B-Anatomy
:	O
an	O
assessment	O
of	O
graft	B-Anatomy
size	O
and	O
ultrastructure	O
.	O
To	O
identify	O
a	O
suitable	O
donor	B-Anatomy
cell	I-Anatomy
population	I-Anatomy
for	O
gene	O
therapy	O
applications	O
to	O
the	O
central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
,	O
primary	O
fibroblasts	B-Anatomy
isolated	O
from	O
skin	B-Anatomy
biopsies	I-Anatomy
and	O
maintained	O
in	O
culture	O
are	O
employed	O
as	O
autologous	O
cells	B-Anatomy
for	O
intracerebral	B-Anatomy
grafting	O
within	O
the	O
adult	O
rat	O
striatum	B-Anatomy
.	O
Results	O
from	O
the	O
present	O
investigation	O
reveal	O
that	O
cultured	O
primary	O
skin	B-Anatomy
fibroblasts	I-Anatomy
cease	O
to	O
proliferate	O
once	O
they	O
reach	O
confluence	O
;	O
these	O
cells	B-Anatomy
are	O
thus	O
contact	O
inhibited	O
in	O
vitro	O
.	O
Following	O
implantation	O
within	O
the	O
striatum	B-Anatomy
,	O
the	O
volume	O
of	O
the	O
primary	O
fibroblast	B-Anatomy
grafts	I-Anatomy
,	O
stained	O
immunohistochemically	O
for	O
fibronectin	O
,	O
does	O
not	O
differ	O
significantly	O
at	O
3	O
and	O
8	O
weeks	O
.	O
The	O
graft	B-Anatomy
size	O
is	O
dependent	O
on	O
the	O
density	O
of	O
the	O
cell	B-Anatomy
suspension	O
,	O
but	O
not	O
dependent	O
on	O
either	O
the	O
number	O
of	O
passages	O
the	O
cells	B-Anatomy
are	O
taken	O
through	O
in	O
culture	O
prior	O
to	O
grafting	O
or	O
on	O
the	O
postoperative	O
survival	O
period	O
.	O
Ultrastructural	O
evidence	O
reveals	O
that	O
at	O
8	O
weeks	O
the	O
grafts	B-Anatomy
are	O
composed	O
primarily	O
of	O
collagen	O
and	O
fibroblasts	B-Anatomy
with	O
rough	O
endoplasmic	B-Anatomy
reticulum	I-Anatomy
and	O
vesicles	B-Anatomy
.	O
Reactive	O
astrocytic	B-Anatomy
processes	I-Anatomy
and	O
phagocytic	B-Anatomy
cells	I-Anatomy
are	O
also	O
present	O
in	O
the	O
grafts	B-Anatomy
.	O
The	O
grafts	B-Anatomy
are	O
extensively	O
vascularized	O
with	O
capillaries	B-Anatomy
composed	O
of	O
nonfenestrated	O
endothelium	B-Anatomy
;	O
intercellular	B-Anatomy
junctions	I-Anatomy
are	O
evident	O
at	O
sites	B-Anatomy
of	O
apposition	O
between	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
It	O
is	O
concluded	O
that	O
primary	O
skin	B-Anatomy
fibroblasts	I-Anatomy
are	O
able	O
to	O
survive	O
for	O
at	O
least	O
8	O
weeks	O
following	O
intracerebral	B-Anatomy
implantation	O
and	O
continue	O
to	O
synthesize	O
collagen	O
and	O
fibronectin	O
in	O
vivo	O
.	O
Also	O
,	O
the	O
grafts	B-Anatomy
maintain	O
a	O
constant	O
volume	O
between	O
3	O
and	O
8	O
weeks	O
,	O
thereby	O
indicating	O
that	O
primary	O
skin	B-Anatomy
fibroblasts	I-Anatomy
do	O
not	O
produce	O
tumors	B-Anatomy
.	O
Finally	O
,	O
dynamic	O
host	O
-	O
to	O
-	O
graft	B-Anatomy
interactions	O
-	O
-	O
including	O
phagocytic	O
migration	O
,	O
astrocytic	O
hypertrophy	O
and	O
infiltration	O
within	O
the	O
grafts	B-Anatomy
,	O
and	O
angiogenesis	O
-	O
-	O
are	O
features	O
that	O
constitute	O
the	O
structural	O
integration	O
of	O
primary	O
skin	B-Anatomy
fibroblasts	I-Anatomy
grafted	O
within	O
the	O
adult	O
rat	O
central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
.	O
[	O
TESE	O
and	O
mTESE	O
.	O
Therapeutic	O
options	O
in	O
male	O
infertility	O
due	O
to	O
testicular	B-Anatomy
azoospermia	O
]	O
.	O
Modern	O
techniques	O
of	O
testicular	B-Anatomy
sperm	I-Anatomy
extraction	O
(	O
TESE	O
)	O
make	O
it	O
possible	O
for	O
an	O
infertile	O
man	O
to	O
father	O
a	O
child	O
.	O
The	O
operations	O
are	O
standardized	O
to	O
a	O
large	O
extent	O
and	O
the	O
underlying	O
morphological	O
alterations	O
of	O
spermatogenesis	O
also	O
appear	O
to	O
be	O
sufficiently	O
known	O
.	O
Current	O
research	O
is	O
focused	O
on	O
prognostic	O
factors	O
for	O
the	O
testicular	B-Anatomy
material	O
that	O
determine	O
the	O
sperm	B-Anatomy
retrieval	O
rate	O
and	O
success	O
rates	O
after	O
in	O
vitro	O
fertilization	O
/	O
intracytoplasmic	O
sperm	B-Anatomy
injection	O
(	O
IVF	O
-	O
ICSI	O
)	O
.	O
TESE	O
and	O
microTESE	O
are	O
accepted	O
standard	O
operations	O
for	O
testicular	B-Anatomy
sperm	I-Anatomy
retrieval	O
for	O
IVF	O
/	O
ICSI	O
.	O
Predictions	O
for	O
effective	O
sperm	B-Anatomy
recovery	O
are	O
addressed	O
.	O
Quantitative	O
retention	O
-	O
biological	O
activity	O
relationship	O
study	O
by	O
micellar	O
liquid	O
chromatography	O
.	O
In	O
a	O
previous	O
paper	O
,	O
the	O
usefulness	O
of	O
micellar	O
liquid	O
chromatography	O
(	O
MLC	O
)	O
in	O
predicting	O
octanol	O
-	O
water	O
partition	O
coefficients	O
of	O
organic	O
compounds	O
was	O
reported	O
.	O
This	O
paper	O
is	O
the	O
first	O
successful	O
report	O
of	O
a	O
quantitative	O
retention	O
-	O
activity	O
relationship	O
study	O
using	O
the	O
retention	O
factor	O
in	O
MLC	O
for	O
predicting	O
the	O
biological	O
activity	O
of	O
a	O
group	O
of	O
phenolic	O
compounds	O
.	O
Excellent	O
correlation	O
was	O
obtained	O
between	O
the	O
capacity	O
factor	O
in	O
MLC	O
and	O
the	O
bioactivity	O
(	O
measured	O
as	O
log	O
1	O
/	O
C	O
,	O
where	O
C	O
is	O
the	O
50	O
%	O
inhibitory	O
growth	O
concentration	O
)	O
of	O
26	O
para	O
-	O
substituted	O
phenols	O
.	O
A	O
single	O
MLC	O
retention	O
parameter	O
is	O
capable	O
of	O
describing	O
the	O
bioactivity	O
of	O
phenols	O
,	O
while	O
three	O
conventional	O
molecular	O
descriptors	O
(	O
log	O
P	O
(	O
ow	O
)	O
,	O
pKa	O
,	O
and	O
R	O
)	O
are	O
needed	O
to	O
achieve	O
a	O
similar	O
correlation	O
.	O
This	O
indicates	O
that	O
both	O
hydrophobic	O
and	O
electronic	O
interactions	O
are	O
incorporated	O
in	O
a	O
single	O
MLC	O
retention	O
parameter	O
,	O
which	O
is	O
due	O
to	O
the	O
amphiphilic	O
nature	O
of	O
surfactants	O
in	O
the	O
system	O
.	O
In	O
situations	O
like	O
this	O
,	O
QRAR	O
is	O
a	O
suitable	O
alternative	O
to	O
QSAR	O
since	O
measuring	O
MLC	O
retention	O
is	O
much	O
easier	O
than	O
measuring	O
different	O
molecular	O
descriptors	O
needed	O
to	O
build	O
the	O
QSAR	O
model	O
.	O
Addition	O
of	O
10	O
%	O
2	O
-	O
propanol	O
to	O
a	O
micellar	O
system	O
(	O
hybrid	O
system	O
)	O
proved	O
to	O
be	O
the	O
best	O
chromatographic	O
system	O
for	O
the	O
best	O
estimation	O
of	O
the	O
phenols	O
bioactivity	O
.	O
Other	O
chromatographic	O
factors	O
such	O
as	O
pH	O
and	O
stationary	O
phase	O
also	O
showed	O
significant	O
effect	O
on	O
the	O
correlation	O
between	O
capacity	O
factor	O
k	O
'	O
and	O
log	O
1	O
/	O
C	O
.	O
Thermostability	O
and	O
molecular	O
encapsulation	O
within	O
an	O
engineered	O
caged	O
protein	O
scaffold	O
.	O
Self	O
-	O
assembling	O
biological	O
complexes	O
such	O
as	O
viral	O
capsids	O
have	O
been	O
manipulated	O
to	O
function	O
in	O
innovative	O
nanotechnology	O
applications	O
.	O
The	O
E2	O
component	O
of	O
pyruvate	O
dehydrogenase	O
from	O
Bacillus	O
stearothermophilus	O
forms	O
a	O
dodecahedral	O
complex	O
and	O
potentially	O
provides	O
another	O
platform	O
for	O
these	O
purposes	O
.	O
In	O
this	O
investigation	O
,	O
we	O
show	O
that	O
this	O
protein	O
assembly	O
exhibits	O
unusual	O
stability	O
and	O
can	O
be	O
modified	O
to	O
encapsulate	O
model	O
drug	O
molecules	O
.	O
To	O
distill	O
the	O
E2	O
protein	O
down	O
to	O
its	O
structural	O
scaffold	O
core	O
,	O
we	O
synthesized	O
a	O
truncated	O
gene	O
optimized	O
for	O
expression	O
in	O
Escherichia	O
coli	O
.	O
The	O
correct	O
assembly	O
and	O
dodecahedral	O
structure	O
of	O
the	O
resulting	O
scaffold	O
was	O
confirmed	O
with	O
dynamic	O
light	O
scattering	O
and	O
transmission	O
electron	O
microscopy	O
.	O
Using	O
circular	O
dichroism	O
and	O
differential	O
scanning	O
calorimetry	O
,	O
we	O
found	O
the	O
thermostability	O
of	O
the	O
complex	O
to	O
be	O
unusually	O
high	O
,	O
with	O
an	O
onset	O
temperature	O
of	O
unfolding	O
at	O
81	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
9	O
degrees	O
C	O
and	O
an	O
apparent	O
midpoint	O
unfolding	O
temperature	O
of	O
91	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
4	O
degrees	O
C	O
.	O
To	O
evaluate	O
the	O
potential	O
of	O
this	O
scaffold	O
for	O
encapsulation	O
of	O
guest	O
molecules	O
,	O
we	O
made	O
variants	O
at	O
residues	O
381	O
and	O
239	O
which	O
altered	O
the	O
physicochemical	O
properties	O
of	O
the	O
hollow	O
internal	O
cavity	O
.	O
These	O
mutants	O
,	O
yielding	O
60	O
and	O
120	O
mutations	O
within	O
this	O
cavity	O
,	O
assembled	O
into	O
the	O
correct	O
architecture	O
and	O
exhibited	O
high	O
thermostability	O
that	O
was	O
comparable	O
to	O
the	O
wild	O
-	O
type	O
scaffold	O
.	O
To	O
show	O
the	O
applicability	O
of	O
this	O
scaffold	O
,	O
two	O
different	O
fluorescent	O
dye	O
molecules	O
were	O
covalently	O
coupled	O
to	O
the	O
cysteine	O
mutant	O
at	O
site	O
381	O
.	O
We	O
demonstrate	O
that	O
these	O
mutations	O
can	O
introduce	O
non	O
-	O
native	O
functionality	O
and	O
enable	O
molecular	O
encapsulation	O
within	O
the	O
cavity	O
while	O
still	O
retaining	O
the	O
dodecahedral	O
structure	O
.	O
The	O
unusually	O
robust	O
nature	O
of	O
this	O
scaffold	O
and	O
its	O
amenability	O
to	O
internal	O
changes	O
reveal	O
its	O
potential	O
for	O
nanoscale	O
applications	O
.	O
Angiogenesis	O
associated	O
with	O
visceral	B-Anatomy
and	O
subcutaneous	B-Anatomy
adipose	I-Anatomy
tissue	I-Anatomy
in	O
severe	O
human	O
obesity	O
.	O
OBJECTIVE	O
:	O
The	O
expansion	O
of	O
adipose	B-Anatomy
tissue	I-Anatomy
is	O
linked	O
to	O
the	O
development	O
of	O
its	O
vasculature	B-Anatomy
.	O
However	O
,	O
the	O
regulation	O
of	O
adipose	B-Anatomy
tissue	I-Anatomy
angiogenesis	O
in	O
humans	O
has	O
not	O
been	O
extensively	O
studied	O
.	O
Our	O
aim	O
was	O
to	O
compare	O
the	O
angiogenesis	O
associated	O
with	O
subcutaneous	B-Anatomy
adipose	I-Anatomy
tissue	I-Anatomy
(	O
SAT	B-Anatomy
)	O
and	O
visceral	B-Anatomy
adipose	I-Anatomy
tissue	I-Anatomy
(	O
VAT	B-Anatomy
)	O
from	O
the	O
same	O
obese	O
patients	O
in	O
an	O
in	O
vivo	O
model	O
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
Adipose	B-Anatomy
tissue	I-Anatomy
samples	I-Anatomy
from	O
visceral	B-Anatomy
(	O
VAT	B-Anatomy
)	O
and	O
subcutaneous	B-Anatomy
(	I-Anatomy
SAT	I-Anatomy
)	I-Anatomy
sites	I-Anatomy
,	O
obtained	O
from	O
36	O
obese	O
patients	O
(	O
mean	O
BMI	O
46	O
.	O
5	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
during	O
bariatric	O
surgery	O
,	O
were	O
layered	O
on	O
chick	O
chorioallantoic	B-Anatomy
membrane	I-Anatomy
(	O
CAM	B-Anatomy
)	O
.	O
RESULTS	O
:	O
Both	O
SAT	B-Anatomy
and	O
VAT	B-Anatomy
expressed	O
angiogenic	O
factors	O
without	O
significant	O
difference	O
for	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
.	O
Adipose	B-Anatomy
tissue	I-Anatomy
layered	O
on	O
CAM	B-Anatomy
stimulated	O
angiogenesis	O
.	O
Angiogenic	O
stimulation	O
was	O
macroscopically	O
detectable	O
,	O
with	O
engulfment	O
of	O
the	O
samples	B-Anatomy
,	O
in	O
39	O
%	O
and	O
was	O
evidenced	O
by	O
angiography	O
in	O
59	O
%	O
of	O
the	O
samples	B-Anatomy
.	O
A	O
connection	O
between	O
CAM	B-Anatomy
and	O
adipose	B-Anatomy
tissue	I-Anatomy
vessels	I-Anatomy
was	O
evidenced	O
by	O
immunohistochemistry	O
,	O
with	O
recruitment	O
of	O
both	O
avian	O
and	O
human	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
The	O
angiogenic	O
potency	O
of	O
adipose	B-Anatomy
tissue	I-Anatomy
was	O
not	O
related	O
to	O
its	O
localization	O
(	O
with	O
an	O
angiogenic	O
stimulation	O
in	O
60	O
%	O
of	O
SAT	B-Anatomy
samples	I-Anatomy
and	O
61	O
%	O
of	O
VAT	B-Anatomy
samples	I-Anatomy
)	O
or	O
to	O
adipocyte	B-Anatomy
size	O
or	O
inflammatory	O
infiltrate	O
assessed	O
in	O
adipose	B-Anatomy
samples	I-Anatomy
before	O
the	O
graft	B-Anatomy
on	O
CAM	B-Anatomy
.	O
Stimulation	O
of	O
angiogenesis	O
by	O
adipose	B-Anatomy
tissue	I-Anatomy
was	O
nearly	O
abolished	O
by	O
bevacizumab	O
,	O
which	O
specifically	O
targets	O
human	O
VEGF	O
.	O
CONCLUSIONS	O
:	O
We	O
have	O
established	O
a	O
model	O
to	O
study	O
the	O
regulation	O
of	O
angiogenesis	O
by	O
human	O
adipose	B-Anatomy
tissue	I-Anatomy
.	O
This	O
model	O
highlighted	O
the	O
role	O
of	O
VEGF	O
in	O
angiogenesis	O
in	O
both	O
SAT	B-Anatomy
and	O
VAT	B-Anatomy
.	O
M	O
-	O
CSF	O
signals	O
through	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
via	O
Sp1	O
to	O
induce	O
VEGF	O
production	O
and	O
induces	O
angiogenesis	O
in	O
vivo	O
.	O
BACKGROUND	O
:	O
M	O
-	O
CSF	O
recruits	O
mononuclear	B-Anatomy
phagocytes	I-Anatomy
which	O
regulate	O
processes	O
such	O
as	O
angiogenesis	O
and	O
metastases	B-Anatomy
in	O
tumors	B-Anatomy
.	O
VEGF	O
is	O
a	O
potent	O
activator	O
of	O
angiogenesis	O
as	O
it	O
promotes	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
and	O
new	O
blood	B-Anatomy
vessel	I-Anatomy
formation	O
.	O
Previously	O
,	O
we	O
reported	O
that	O
in	O
vitro	O
M	O
-	O
CSF	O
induces	O
the	O
expression	O
of	O
biologically	O
-	O
active	O
VEGF	O
from	O
human	O
monocytes	B-Anatomy
.	O
METHODOLOGY	O
AND	O
RESULTS	O
:	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
molecular	O
mechanism	O
of	O
M	O
-	O
CSF	O
-	O
induced	O
VEGF	O
production	O
.	O
Using	O
a	O
construct	O
containing	O
the	O
VEGF	O
promoter	O
linked	O
to	O
a	O
luciferase	O
reporter	O
,	O
we	O
found	O
that	O
a	O
mutation	O
reducing	O
HIF	O
binding	O
to	O
the	O
VEGF	O
promoter	O
had	O
no	O
significant	O
effect	O
on	O
luciferase	O
production	O
induced	O
by	O
M	O
-	O
CSF	O
stimulation	O
.	O
Further	O
analysis	O
revealed	O
that	O
M	O
-	O
CSF	O
induced	O
VEGF	O
through	O
the	O
MAPK	O
/	O
ERK	O
signaling	O
pathway	O
via	O
the	O
transcription	O
factor	O
,	O
Sp1	O
.	O
Thus	O
,	O
inhibition	O
of	O
either	O
ERK	O
or	O
Sp1	O
suppressed	O
M	O
-	O
CSF	O
-	O
induced	O
VEGF	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
.	O
M	O
-	O
CSF	O
also	O
induced	O
the	O
nuclear	B-Anatomy
localization	O
of	O
Sp1	O
,	O
which	O
was	O
blocked	O
by	O
ERK	O
inhibition	O
.	O
Finally	O
,	O
mutating	O
the	O
Sp1	O
binding	O
sites	O
within	O
the	O
VEGF	O
promoter	O
or	O
inhibiting	O
ERK	O
decreased	O
VEGF	O
promoter	O
activity	O
in	O
M	O
-	O
CSF	O
-	O
treated	O
human	O
monocytes	B-Anatomy
.	O
To	O
evaluate	O
the	O
biological	O
significance	O
of	O
M	O
-	O
CSF	O
induced	O
VEGF	O
production	O
,	O
we	O
used	O
an	O
in	O
vivo	O
angiogenesis	O
model	O
to	O
illustrate	O
the	O
ability	O
of	O
M	O
-	O
CSF	O
to	O
recruit	O
mononuclear	B-Anatomy
phagocytes	I-Anatomy
,	O
increase	O
VEGF	O
levels	O
,	O
and	O
enhance	O
angiogenesis	O
.	O
Importantly	O
,	O
the	O
addition	O
of	O
a	O
neutralizing	O
VEGF	O
antibody	O
abolished	O
M	O
-	O
CSF	O
-	O
induced	O
blood	B-Anatomy
vessel	I-Anatomy
formation	O
.	O
CONCLUSION	O
:	O
These	O
data	O
delineate	O
an	O
ERK	O
-	O
and	O
Sp1	O
-	O
dependent	O
mechanism	O
of	O
M	O
-	O
CSF	O
induced	O
VEGF	O
production	O
and	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
ability	O
of	O
M	O
-	O
CSF	O
to	O
induce	O
angiogenesis	O
via	O
VEGF	O
in	O
vivo	O
.	O
PI3K	O
/	O
Akt	O
-	O
dependent	O
transcriptional	O
regulation	O
and	O
activation	O
of	O
BMP	O
-	O
2	O
-	O
Smad	O
signaling	O
by	O
NF	O
-	O
kappaB	O
in	O
metastatic	B-Anatomy
prostate	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
BACKGROUND	O
:	O
Bone	B-Anatomy
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
exert	O
osteoinductive	O
effects	O
in	O
prostate	B-Anatomy
cancer	I-Anatomy
(	O
PC	B-Anatomy
)	O
via	O
uncharacterized	O
mechanisms	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
the	O
nuclear	B-Anatomy
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
implicated	O
in	O
PC	B-Anatomy
metastasis	O
,	O
is	O
involved	O
in	O
transcriptional	O
regulation	O
and	O
activation	O
of	O
BMP	O
-	O
2	O
or	O
BMP	O
-	O
4	O
/	O
Smad	O
signaling	O
in	O
PC	B-Anatomy
cells	I-Anatomy
.	O
METHODS	O
:	O
NF	O
-	O
kappaB	O
inhibition	O
was	O
achieved	O
by	O
IkappaBalpha	O
super	O
-	O
repressor	O
adenoviral	O
vector	O
and	O
activation	O
was	O
monitored	O
by	O
EMSA	O
and	O
reporter	O
assays	O
.	O
BMP	O
expression	O
and	O
activation	O
was	O
measured	O
by	O
PCR	O
and	O
reporter	O
assays	O
.	O
Promoter	O
binding	O
assay	O
was	O
performed	O
by	O
chromatin	B-Anatomy
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
.	O
Smad1	O
/	O
5	O
/	O
8	O
phosphorylation	O
was	O
measured	O
by	O
Western	O
blot	O
analysis	O
.	O
RESULTS	O
:	O
PCR	O
and	O
chimeric	O
BMP	O
-	O
2	O
and	O
BMP	O
-	O
4	O
luciferase	O
assays	O
demonstrate	O
that	O
NF	O
-	O
kappaB	O
confers	O
robust	O
and	O
selective	O
activation	O
of	O
BMP	O
-	O
2	O
in	O
p65	O
overexpressing	O
or	O
rhTNF	O
-	O
alpha	O
-	O
stimulated	O
PC	B-Anatomy
cells	I-Anatomy
.	O
Inhibition	O
of	O
NF	O
-	O
kappaB	O
significantly	O
reduced	O
transcript	O
levels	O
and	O
autocrine	O
production	O
of	O
BMP	O
-	O
2	O
by	O
rhTNF	O
-	O
alpha	O
stimulated	O
C4	B-Anatomy
-	I-Anatomy
2B	I-Anatomy
cells	I-Anatomy
and	O
to	O
a	O
lesser	O
extent	O
by	O
the	O
parental	O
LNCaP	B-Anatomy
cells	I-Anatomy
.	O
Selective	O
inhibition	O
of	O
PI3K	O
/	O
Akt	O
suppressed	O
the	O
NF	O
-	O
kappaB	O
-	O
induced	O
BMP	O
-	O
2	O
promoter	O
activity	O
.	O
Furthermore	O
,	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
decreased	O
the	O
transcript	O
levels	O
and	O
BMP	O
-	O
2	O
-	O
induced	O
phosphorylation	O
of	O
Smad1	O
/	O
5	O
/	O
8	O
,	O
critical	O
downstream	O
targets	O
of	O
BMP	O
-	O
2	O
signaling	O
in	O
PC	B-Anatomy
cells	I-Anatomy
.	O
Notably	O
,	O
the	O
activation	O
of	O
BMPRII	O
by	O
BMP	O
-	O
2	O
is	O
required	O
for	O
modulation	O
of	O
Smad	O
activation	O
by	O
NF	O
-	O
kappaB	O
in	O
PC	B-Anatomy
cells	I-Anatomy
.	O
Based	O
on	O
ChIP	O
analysis	O
,	O
the	O
transcriptional	O
regulation	O
of	O
BMP	O
-	O
2	O
gene	O
by	O
NF	O
-	O
kappaB	O
may	O
be	O
partially	O
attributed	O
to	O
binding	O
to	O
kappab	O
site	O
on	O
the	O
BMP	O
-	O
2	O
promoter	O
.	O
CONCLUSIONS	O
:	O
The	O
data	O
suggest	O
that	O
PI3K	O
/	O
Akt	O
-	O
NF	O
-	O
kappaB	O
axis	O
may	O
promote	O
PC	B-Anatomy
bone	I-Anatomy
metastasis	O
in	O
part	O
by	O
regulating	O
transcription	O
and	O
activation	O
of	O
the	O
BMP	O
-	O
2	O
-	O
Smad	O
signaling	O
cascade	O
in	O
osteotropic	B-Anatomy
PC	I-Anatomy
cells	I-Anatomy
.	O
Atypical	O
mycobacteriosis	O
of	O
the	O
larynx	B-Anatomy
:	O
an	O
unusual	O
clinical	O
presentation	O
secondary	O
to	O
steroids	O
inhalation	O
.	O
Vocal	B-Anatomy
cords	I-Anatomy
stiffness	O
can	O
be	O
associated	O
with	O
a	O
variety	O
of	O
etiologic	O
agents	O
,	O
but	O
it	O
is	O
rarely	O
seen	O
with	O
atypical	O
mycobacteria	O
,	O
for	O
example	O
,	O
Mycobacterium	O
avium	O
complex	O
.	O
We	O
report	O
a	O
case	O
of	O
a	O
35	O
-	O
year	O
-	O
old	O
white	O
woman	O
who	O
is	O
and	O
was	O
maintained	O
on	O
inhaled	O
steroids	O
.	O
She	O
presented	O
with	O
hoarseness	O
and	O
low	O
-	O
grade	O
fever	O
,	O
but	O
her	O
medical	O
history	O
was	O
otherwise	O
unremarkable	O
.	O
Laryngoscopy	O
revealed	O
bilateral	O
scarring	O
of	O
the	O
vocal	B-Anatomy
cords	I-Anatomy
.	O
Vocal	B-Anatomy
cord	I-Anatomy
biopsies	O
were	O
performed	O
.	O
Histologic	O
examination	O
revealed	O
unremarkable	O
laryngeal	B-Anatomy
mucosa	I-Anatomy
,	O
except	O
for	O
abundant	O
subepithelial	B-Anatomy
non	I-Anatomy
-	I-Anatomy
necrotizing	I-Anatomy
granulomata	I-Anatomy
.	O
The	O
differential	O
diagnosis	O
included	O
sarcoid	B-Anatomy
,	O
Klebsiella	B-Anatomy
scleroma	I-Anatomy
,	O
and	O
tuberculosis	O
.	O
Special	O
stains	O
reviewed	O
abundant	O
acid	O
-	O
fast	O
bacilli	O
,	O
later	O
confirmed	O
by	O
a	O
DNA	O
assay	O
on	O
induced	O
deep	O
sputum	B-Anatomy
,	O
consistent	O
with	O
M	O
avium	O
complex	O
.	O
Subsequently	O
,	O
steroids	O
were	O
withdrawn	O
,	O
and	O
the	O
patient	O
was	O
treated	O
with	O
a	O
multiple	O
-	O
drug	O
antituberculous	O
regimen	O
and	O
had	O
a	O
full	O
recovery	O
.	O
This	O
unusual	O
clinical	O
presentation	O
of	O
the	O
atypical	O
mycobacteriosis	O
may	O
be	O
encountered	O
by	O
otolaryngologists	O
and	O
pathologists	O
,	O
and	O
it	O
is	O
critical	O
to	O
recognize	O
it	O
in	O
patients	O
immunocompromised	O
because	O
of	O
steroids	O
.	O
A	O
novel	O
integrin	O
alpha5beta1	O
antagonistic	O
peptide	O
,	O
A5	O
-	O
1	O
,	O
screened	O
by	O
Protein	O
Chip	O
system	O
as	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O
Integrin	O
alpha5beta1	O
immobilized	O
on	O
a	O
ProteoChip	O
was	O
used	O
to	O
screen	O
new	O
antagonistic	O
peptides	O
from	O
multiple	O
hexapeptide	O
sub	O
-	O
libraries	O
of	O
the	O
positional	O
scanning	O
synthetic	O
peptide	O
combinatorial	O
library	O
(	O
PS	O
-	O
SPCL	O
)	O
.	O
The	O
integrin	O
alpha5beta1	O
-	O
Fibronectin	O
interaction	O
was	O
demonstrated	O
on	O
the	O
chip	O
.	O
A	O
novel	O
peptide	O
ligand	O
,	O
A5	O
-	O
1	O
(	O
VILVLF	O
)	O
,	O
with	O
high	O
affinity	O
to	O
integrin	O
alpha5beta1	O
was	O
identified	O
from	O
the	O
hexapeptide	O
libraries	O
with	O
this	O
chip	O
-	O
based	O
screening	O
method	O
on	O
the	O
basis	O
of	O
a	O
competitive	O
inhibition	O
assay	O
.	O
A5	O
-	O
1	O
inhibits	O
the	O
integrin	O
-	O
fibronectin	O
interaction	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC	O
(	O
50	O
)	O
;	O
1	O
.	O
56	O
+	O
/	O
-	O
0	O
.	O
28	O
microM	O
.	O
In	O
addition	O
,	O
it	O
inhibits	O
human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
proliferation	O
,	O
migration	O
,	O
adhesion	O
,	O
tubular	B-Anatomy
network	I-Anatomy
formation	O
,	O
and	O
bFGF	O
-	O
induced	O
neovascularization	O
in	O
a	O
chick	O
chorioallantoic	B-Anatomy
membrane	I-Anatomy
.	O
These	O
results	O
suggest	O
that	O
A5	O
-	O
1	O
will	O
be	O
a	O
potent	O
inhibitor	O
of	O
neovascularization	O
.	O
Are	O
former	O
female	O
elite	O
athletes	O
more	O
likely	O
to	O
experience	O
urinary	B-Anatomy
incontinence	O
later	O
in	O
life	O
than	O
non	O
-	O
athletes	O
?	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
former	O
female	O
elite	O
athletes	O
are	O
more	O
likely	O
to	O
experience	O
urinary	B-Anatomy
incontinence	O
(	O
UI	O
)	O
later	O
in	O
life	O
than	O
non	O
-	O
athletes	O
and	O
to	O
assess	O
possible	O
risk	O
factors	O
for	O
UI	O
in	O
athletes	O
.	O
Three	O
hundred	O
and	O
thirty	O
-	O
one	O
former	O
elite	O
athletes	O
(	O
response	O
rate	O
81	O
%	O
)	O
and	O
640	O
controls	O
replied	O
to	O
a	O
postal	O
questionnaire	O
including	O
validated	O
questions	O
on	O
UI	O
.	O
While	O
competing	O
in	O
sport	O
,	O
10	O
.	O
9	O
%	O
and	O
2	O
.	O
7	O
%	O
of	O
the	O
former	O
elite	O
athletes	O
reported	O
stress	O
urinary	B-Anatomy
incontinence	O
(	O
SUI	O
)	O
and	O
urge	O
incontinence	O
,	O
respectively	O
.	O
Presently	O
,	O
36	O
.	O
5	O
%	O
of	O
the	O
former	O
elite	O
athletes	O
and	O
36	O
.	O
9	O
%	O
of	O
the	O
controls	O
reported	O
SUI	O
.	O
9	O
.	O
1	O
%	O
and	O
9	O
.	O
4	O
%	O
reported	O
urge	O
incontinence	O
.	O
Among	O
former	O
elite	O
athletes	O
,	O
those	O
with	O
two	O
or	O
three	O
children	O
were	O
more	O
likely	O
than	O
nulliparous	O
women	O
to	O
have	O
UI	O
now	O
.	O
Also	O
,	O
among	O
former	O
athletes	O
,	O
UI	O
was	O
more	O
common	O
in	O
women	O
with	O
vs	O
those	O
without	O
UI	O
while	O
competing	O
(	O
odds	O
ratio	O
8	O
.	O
57	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
3	O
.	O
55	O
-	O
20	O
.	O
71	O
)	O
.	O
Age	O
,	O
menopause	O
and	O
being	O
regularly	O
physically	O
active	O
now	O
were	O
not	O
associated	O
with	O
UI	O
in	O
either	O
group	O
.	O
Based	O
on	O
this	O
study	O
,	O
the	O
prevalence	O
of	O
UI	O
does	O
not	O
seem	O
to	O
be	O
higher	O
in	O
former	O
athletes	O
than	O
in	O
controls	O
.	O
However	O
,	O
the	O
results	O
indicate	O
that	O
UI	O
early	O
in	O
life	O
,	O
as	O
reported	O
during	O
elite	O
sport	O
,	O
is	O
a	O
strong	O
predictor	O
of	O
UI	O
later	O
in	O
life	O
.	O
Evaluation	O
of	O
electrical	O
stimulation	O
for	O
ischemic	O
wound	B-Anatomy
therapy	O
:	O
a	O
feasibility	O
study	O
using	O
the	O
lapine	O
wound	B-Anatomy
model	O
.	O
Chronic	O
wounds	B-Anatomy
are	O
a	O
major	O
secondary	O
complication	O
for	O
many	O
people	O
with	O
impaired	O
mobility	O
.	O
Electrical	O
stimulation	O
(	O
ES	O
)	O
has	O
been	O
recommended	O
as	O
a	O
adjunctive	O
therapy	O
,	O
however	O
optimal	O
treatment	O
paradigms	O
have	O
not	O
been	O
established	O
.	O
Our	O
group	O
seeks	O
to	O
determine	O
the	O
basic	O
mechanisms	O
underlying	O
ES	O
wound	B-Anatomy
therapy	O
,	O
an	O
area	O
where	O
understanding	O
is	O
currently	O
limited	O
.	O
A	O
feasibility	O
study	O
was	O
carried	O
out	O
to	O
develop	O
the	O
Ahn	O
/	O
Mustoe	O
lapine	O
wound	B-Anatomy
model	O
for	O
systematic	O
investigation	O
of	O
the	O
effects	O
of	O
electrical	O
stimulation	O
on	O
ischemic	O
wound	B-Anatomy
therapy	O
.	O
A	O
standardized	O
surgical	O
procedure	O
incorporated	O
a	O
hybrid	O
stimulation	O
system	O
comprising	O
an	O
implantable	O
mini	O
-	O
stimulator	O
and	O
surface	O
electrodes	O
,	O
with	O
creation	O
of	O
repeatable	O
ischemic	O
wounds	B-Anatomy
.	O
Twenty	O
mature	O
male	O
New	O
Zealand	O
white	O
rabbits	O
(	O
3	O
kg	O
weight	O
)	O
were	O
employed	O
to	O
evaluate	O
the	O
effects	O
of	O
two	O
empirically	O
selected	O
stimulation	O
paradigms	O
applied	O
continuously	O
for	O
7	O
-	O
21	O
days	O
,	O
using	O
each	O
animal	O
as	O
its	O
own	O
control	O
.	O
Outcomes	O
measures	O
included	O
transcutaneous	B-Anatomy
blood	B-Anatomy
gas	O
levels	O
,	O
histology	O
,	O
total	O
RNA	O
content	O
and	O
analysis	O
of	O
alpha2	O
(	O
I	O
)	O
collagen	O
(	O
COL	O
-	O
I	O
)	O
,	O
type	O
IV	O
collagen	O
(	O
COL	O
-	O
IV	O
)	O
,	O
alpha1	O
(	O
V	O
)	O
collagen	O
(	O
COL	O
-	O
V	O
)	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
using	O
real	O
-	O
time	O
quantitative	O
PCR	O
.	O
All	O
markers	O
for	O
stimulated	O
wounds	B-Anatomy
showed	O
increased	O
activity	O
relative	O
to	O
non	O
-	O
stimulated	O
control	O
wounds	B-Anatomy
between	O
7	O
and	O
14	O
days	O
following	O
injury	O
,	O
with	O
peak	O
activity	O
at	O
14	O
days	O
.	O
By	O
21	O
days	O
post	O
-	O
injury	O
,	O
all	O
activity	O
had	O
returned	O
to	O
near	O
baseline	O
level	O
.	O
VEGF	O
and	O
COL	O
-	O
IV	O
levels	O
were	O
found	O
to	O
be	O
significantly	O
higher	O
for	O
pattern	O
A	O
(	O
110	O
mus	O
pulse	O
width	O
)	O
compared	O
to	O
pattern	O
B	O
(	O
5	O
mus	O
pulse	O
width	O
)	O
at	O
14	O
days	O
,	O
implying	O
that	O
pattern	O
A	O
may	O
be	O
more	O
effective	O
at	O
promoting	O
angiogenesis	O
.	O
All	O
wounds	B-Anatomy
were	O
fully	O
re	O
-	O
epithelialized	O
by	O
10	O
days	O
post	O
-	O
injury	O
.	O
Both	O
COL	O
-	O
I	O
and	O
COL	O
-	O
V	O
showed	O
statistically	O
significant	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
increased	O
activity	O
between	O
day	O
7	O
and	O
day	O
14	O
for	O
pattern	O
A	O
,	O
potentially	O
indicating	O
a	O
continued	O
effect	O
on	O
matrix	B-Anatomy
remodeling	O
.	O
The	O
early	O
closure	O
of	O
all	O
wounds	B-Anatomy
implies	O
that	O
the	O
rabbit	O
ear	B-Anatomy
model	O
may	O
not	O
be	O
valid	O
for	O
chronic	O
wound	B-Anatomy
studies	O
.	O
VEGF	O
,	O
angiopoietin	O
-	O
1	O
and	O
-	O
2	O
in	O
bronchial	O
asthma	O
:	O
new	O
molecular	O
targets	O
in	O
airway	B-Anatomy
angiogenesis	O
and	O
microvascular	B-Anatomy
remodeling	O
.	O
Airway	B-Anatomy
angiogenesis	O
and	O
microvascular	B-Anatomy
remodeling	O
are	O
known	O
features	O
of	O
bronchial	O
asthma	O
,	O
but	O
the	O
mechanisms	O
of	O
these	O
structural	O
alterations	O
are	O
just	O
beginning	O
to	O
be	O
elucidated	O
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
angiogenic	O
factors	O
,	O
stimulates	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
and	O
induces	O
the	O
angiogenesis	O
.	O
Recently	O
,	O
considerable	O
attentions	O
have	O
been	O
devoted	O
to	O
the	O
physiological	O
roles	O
of	O
angiopoietin	O
(	O
Ang	O
)	O
-	O
1	O
and	O
-	O
2	O
as	O
regulatory	O
factors	O
of	O
VEGF	O
.	O
Ang	O
-	O
1	O
has	O
been	O
shown	O
to	O
induce	O
the	O
migration	O
and	O
sprouting	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
and	O
coexpression	O
of	O
Ang	O
-	O
1	O
and	O
VEGF	O
enhanced	O
angiogenesis	O
.	O
In	O
the	O
presence	O
of	O
high	O
levels	O
of	O
VEGF	O
,	O
Ang	O
-	O
2	O
also	O
promotes	O
rapid	O
increase	O
in	O
capillary	B-Anatomy
diameter	O
,	O
remodeling	O
of	O
the	O
basal	B-Anatomy
lamina	I-Anatomy
,	O
proliferation	O
and	O
migration	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
and	O
stimulates	O
sprouting	O
of	O
new	O
blood	B-Anatomy
vessels	I-Anatomy
.	O
Thus	O
,	O
VEGF	O
,	O
Ang	O
-	O
1	O
and	O
-	O
2	O
may	O
play	O
complementary	O
and	O
coordinated	O
roles	O
in	O
airway	B-Anatomy
angiogenesis	O
and	O
microvascular	B-Anatomy
remodeling	O
,	O
and	O
these	O
structural	O
changes	O
are	O
potentially	O
reversible	O
by	O
therapeutic	O
intervention	O
.	O
The	O
scope	O
of	O
the	O
present	O
review	O
is	O
to	O
discuss	O
from	O
a	O
clinical	O
point	O
of	O
view	O
the	O
potential	O
interactions	O
between	O
VEGF	O
and	O
angiopoietins	O
in	O
the	O
asthmatic	O
airways	B-Anatomy
,	O
and	O
focus	O
on	O
the	O
therapeutic	O
implications	O
targeting	O
for	O
these	O
angiogenic	O
factors	O
.	O
Recently	O
,	O
there	O
is	O
an	O
increasing	O
number	O
of	O
patents	O
which	O
have	O
been	O
focused	O
on	O
the	O
inhibitors	O
of	O
VEGF	O
action	O
.	O
These	O
inhibitors	O
are	O
directed	O
towards	O
the	O
receptors	O
of	O
VEGF	O
or	O
intracellular	B-Anatomy
substrates	O
for	O
the	O
receptors	O
.	O
We	O
will	O
also	O
discuss	O
several	O
patents	O
regarding	O
inhibitors	O
of	O
VEGF	O
action	O
in	O
the	O
present	O
review	O
.	O
Effect	O
of	O
transplanted	O
mesenchymal	B-Anatomy
stem	I-Anatomy
cells	I-Anatomy
from	O
rats	O
of	O
different	O
ages	O
on	O
the	O
improvement	O
of	O
heart	B-Anatomy
function	O
after	O
acute	O
myocardial	B-Anatomy
infarction	O
.	O
BACKGROUND	O
:	O
Mesenchymal	B-Anatomy
stem	I-Anatomy
cells	I-Anatomy
(	O
MSCs	B-Anatomy
)	O
transplantation	O
is	O
of	O
therapeutic	O
potential	O
after	O
ischemic	O
injury	O
in	O
both	O
experimental	O
and	O
clinical	O
studies	O
.	O
Clinically	O
,	O
elderly	O
patients	O
are	O
more	O
vulnerable	O
to	O
acute	O
myocardial	B-Anatomy
infarction	O
(	O
AMI	O
)	O
.	O
But	O
little	O
is	O
known	O
about	O
the	O
characteristics	O
of	O
young	O
donor	O
-	O
derived	O
MSCs	B-Anatomy
transplanted	O
to	O
old	O
patients	O
with	O
AMI	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
transplanted	O
MSCs	B-Anatomy
from	O
rats	O
of	O
different	O
ages	O
on	O
the	O
improvement	O
of	O
heart	B-Anatomy
function	O
after	O
AMI	O
.	O
METHODS	O
:	O
MSCs	B-Anatomy
from	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
were	O
isolated	O
and	O
cultured	O
in	O
vitro	O
.	O
The	O
apoptosis	O
characteristics	O
of	O
MSCs	B-Anatomy
were	O
observed	O
under	O
conditions	O
of	O
ischemia	O
and	O
anoxia	O
.	O
SD	O
rats	O
underwent	O
MI	O
received	O
intramyocardial	B-Anatomy
injection	O
of	O
MSCs	B-Anatomy
from	O
young	O
donor	O
rats	O
(	O
n	O
=	O
8	O
)	O
,	O
old	O
donor	O
rats	O
(	O
n	O
=	O
8	O
)	O
,	O
respectively	O
.	O
AMI	O
control	O
group	O
received	O
equal	O
volume	O
physiological	O
saline	O
.	O
Immunofluorescence	O
was	O
used	O
to	O
observe	O
the	O
differentiation	O
of	O
the	O
grafted	O
cells	B-Anatomy
into	O
cardiomyocytes	B-Anatomy
.	O
Four	O
weeks	O
after	O
cell	B-Anatomy
transplantation	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
immunohistochemistry	O
for	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
VIII	O
-	O
factor	O
immunohistochemistry	O
for	O
vessel	B-Anatomy
density	O
,	O
TUNEL	O
,	O
caspase	O
-	O
3	O
for	O
cardiomyocyte	B-Anatomy
apoptosis	O
,	O
echocardiography	O
and	O
hemodynamic	O
detection	O
for	O
heart	B-Anatomy
function	O
were	O
performed	O
.	O
RESULTS	O
:	O
The	O
apoptosis	O
rate	O
of	O
the	O
old	O
donor	O
-	O
derived	O
MSCs	B-Anatomy
group	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
young	O
donor	O
-	O
derived	O
MSCs	B-Anatomy
group	O
under	O
conditions	O
of	O
ischemia	O
and	O
anoxia	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
Engrafted	O
MSCs	B-Anatomy
survived	O
,	O
proliferated	O
and	O
differentiated	O
into	O
myocardium	B-Anatomy
-	I-Anatomy
like	I-Anatomy
cells	I-Anatomy
.	O
VEGF	O
gene	O
expression	O
and	O
capillary	B-Anatomy
density	O
in	O
the	O
old	O
donor	O
-	O
derived	O
group	O
were	O
lower	O
than	O
those	O
in	O
the	O
young	O
donor	O
-	O
derived	O
group	O
but	O
higher	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
The	O
transplantation	O
of	O
old	O
donor	O
-	O
derived	O
MSCs	B-Anatomy
attenuated	O
apoptosis	O
of	O
cardiomyocytes	B-Anatomy
in	O
the	O
peri	O
-	O
infarct	O
region	O
compared	O
with	O
the	O
control	O
group	O
and	O
the	O
effect	O
was	O
elevated	O
in	O
young	O
donor	O
-	O
derived	O
MSCs	B-Anatomy
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
The	O
heart	B-Anatomy
functions	O
(	O
left	B-Anatomy
ventricle	I-Anatomy
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
left	B-Anatomy
ventricle	I-Anatomy
fractional	O
shortening	O
(	O
LVFS	O
)	O
)	O
were	O
improved	O
more	O
significantly	O
in	O
the	O
old	O
donor	O
-	O
derived	O
MSCs	B-Anatomy
group	O
than	O
in	O
the	O
control	O
group	O
and	O
the	O
heart	B-Anatomy
function	O
in	O
the	O
young	O
donor	O
-	O
derived	O
MSCs	B-Anatomy
group	O
further	O
improved	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
CONCLUSIONS	O
:	O
Young	O
donor	O
-	O
derived	O
MSCs	B-Anatomy
can	O
improve	O
heart	B-Anatomy
function	O
significantly	O
through	O
angiogenesis	O
and	O
decreasing	O
cardiomyocyte	B-Anatomy
apoptosis	O
when	O
transplanted	O
to	O
the	O
infarcted	O
area	B-Anatomy
.	O
Clinical	O
significance	O
of	O
chicken	O
ovalbumin	O
upstream	O
promoter	O
-	O
transcription	O
factor	O
II	O
expression	O
in	O
human	O
colorectal	B-Anatomy
cancer	I-Anatomy
.	O
Chicken	O
ovalbumin	O
upstream	O
promoter	O
-	O
transcription	O
factor	O
II	O
(	O
COUP	O
-	O
TFII	O
)	O
plays	O
an	O
essential	O
role	O
in	O
angiogenesis	O
and	O
development	O
.	O
A	O
previous	O
study	O
showed	O
that	O
the	O
expression	O
of	O
COUP	O
-	O
TFII	O
enhanced	O
invasiveness	O
of	O
human	O
lung	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
However	O
,	O
no	O
published	O
data	O
are	O
available	O
concerning	O
the	O
biological	O
and	O
clinical	O
significance	O
of	O
COUP	O
-	O
TFII	O
expression	O
in	O
colorectal	B-Anatomy
cancer	I-Anatomy
.	O
Thus	O
,	O
our	O
objective	O
was	O
to	O
explore	O
the	O
expression	O
of	O
COUP	O
-	O
TFII	O
in	O
colorectal	B-Anatomy
cancer	I-Anatomy
as	O
well	O
as	O
its	O
association	O
with	O
clinicopathological	O
features	O
,	O
and	O
to	O
evaluate	O
the	O
role	O
of	O
COUP	O
-	O
TFII	O
as	O
a	O
prognostic	O
indicator	O
in	O
colorectal	B-Anatomy
cancer	I-Anatomy
.	O
We	O
investigated	O
the	O
presence	O
of	O
COUP	O
-	O
TFII	O
in	O
human	O
colorectal	B-Anatomy
cancer	I-Anatomy
tissues	I-Anatomy
and	O
adjacent	O
normal	O
tissues	B-Anatomy
from	O
95	O
primary	B-Anatomy
colorectal	I-Anatomy
cancer	I-Anatomy
patients	O
by	O
immunohistochemistry	O
.	O
The	O
correlation	O
between	O
the	O
expression	O
of	O
COUP	O
-	O
TFII	O
and	O
clinicopathologic	O
features	O
was	O
investigated	O
.	O
The	O
3	O
-	O
year	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
patients	O
with	O
tumors	B-Anatomy
expressing	O
different	O
levels	O
of	O
COUP	O
-	O
TFII	O
were	O
evaluated	O
by	O
the	O
Kaplan	O
-	O
Meier	O
method	O
.	O
No	O
significant	O
correlation	O
was	O
found	O
between	O
COUP	O
-	O
TFII	O
expression	O
and	O
age	O
at	O
surgery	O
,	O
gender	O
,	O
histopathologic	O
differentiation	O
,	O
vessel	B-Anatomy
invasion	O
,	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
,	O
or	O
nodal	B-Anatomy
involvement	O
.	O
However	O
,	O
survival	O
analysis	O
showed	O
that	O
the	O
COUP	O
-	O
TFII	O
-	O
positive	O
group	O
had	O
a	O
significantly	O
better	O
OS	O
compared	O
to	O
COUP	O
-	O
TFII	O
-	O
negative	O
group	O
(	O
80	O
.	O
4	O
%	O
vs	O
.	O
57	O
.	O
7	O
%	O
,	O
P	O
=	O
0	O
.	O
0491	O
)	O
.	O
Based	O
on	O
our	O
results	O
,	O
COUP	O
-	O
TFII	O
may	O
represent	O
a	O
biomarker	O
for	O
good	O
prognosis	O
in	O
colorectal	B-Anatomy
cancer	I-Anatomy
.	O
Homeostatic	O
functions	O
of	O
the	O
p53	O
tumor	B-Anatomy
suppressor	O
:	O
regulation	O
of	O
energy	O
metabolism	O
and	O
antioxidant	O
defense	O
.	O
The	O
p53	O
tumor	B-Anatomy
suppressor	O
plays	O
pivotal	O
role	O
in	O
the	O
organism	O
by	O
supervising	O
strict	O
compliance	O
of	O
individual	O
cells	B-Anatomy
to	O
needs	O
of	O
the	O
whole	O
organisms	O
.	O
It	O
has	O
been	O
widely	O
accepted	O
that	O
p53	O
acts	O
in	O
response	O
to	O
stresses	O
and	O
abnormalities	O
in	O
cell	B-Anatomy
physiology	O
by	O
mobilizing	O
the	O
repair	O
processes	O
or	O
by	O
removing	O
the	O
diseased	O
cells	B-Anatomy
through	O
initiating	O
the	O
cell	B-Anatomy
death	O
programs	O
.	O
Recent	O
studies	O
,	O
however	O
,	O
indicate	O
that	O
even	O
under	O
normal	O
physiological	O
conditions	O
certain	O
activities	O
of	O
p53	O
participate	O
in	O
homeostatic	O
regulation	O
of	O
metabolic	O
processes	O
and	O
that	O
these	O
activities	O
are	O
important	O
for	O
prevention	O
of	O
cancer	B-Anatomy
.	O
These	O
novel	O
functions	O
of	O
p53	O
help	O
to	O
align	O
metabolic	O
processes	O
with	O
the	O
proliferation	O
and	O
energy	O
status	O
,	O
to	O
maintain	O
optimal	O
mode	O
of	O
glucose	O
metabolism	O
and	O
to	O
boost	O
the	O
energy	O
efficient	O
mitochondrial	B-Anatomy
respiration	O
in	O
response	O
to	O
ATP	O
deficiency	O
.	O
Additional	O
activities	O
of	O
p53	O
in	O
non	O
-	O
stressed	O
cells	B-Anatomy
tune	O
up	O
the	O
antioxidant	O
defense	O
mechanisms	O
reducing	O
the	O
probability	O
of	O
mutations	O
caused	O
by	O
DNA	O
oxidation	O
under	O
conditions	O
of	O
daily	O
stresses	O
.	O
The	O
deficiency	O
in	O
the	O
p53	O
-	O
mediated	O
regulation	O
of	O
glycolysis	O
and	O
mitochondrial	B-Anatomy
respiration	O
greatly	O
accounts	O
for	O
the	O
deficient	O
respiration	O
of	O
the	O
predominance	O
of	O
aerobic	O
glycolysis	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
(	O
the	O
Warburg	O
effect	O
)	O
,	O
while	O
the	O
deficiency	O
in	O
the	O
p53	O
-	O
modulated	O
antioxidant	O
defense	O
mechanisms	O
contributes	O
to	O
mutagenesis	O
and	O
additionally	O
boosts	O
the	O
carcinogenesis	O
process	O
.	O
Involvement	O
of	O
PTEN	O
promoter	O
methylation	O
in	O
cerebral	B-Anatomy
cavernous	I-Anatomy
malformations	I-Anatomy
.	O
BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	B-Anatomy
cavernous	I-Anatomy
malformations	I-Anatomy
(	O
CCMs	B-Anatomy
)	O
are	O
prevalent	O
cerebral	B-Anatomy
vascular	I-Anatomy
lesions	I-Anatomy
involving	O
aberrant	O
angiogenesis	O
.	O
However	O
,	O
the	O
underlying	O
mechanism	O
is	O
poorly	O
understood	O
.	O
Phosphatase	O
and	O
tension	O
homolog	O
deleted	O
on	O
chromosome	O
10	O
(	O
PTEN	O
)	O
,	O
a	O
tumor	B-Anatomy
suppressor	O
,	O
is	O
frequently	O
deficient	O
in	O
various	O
pathologies	O
due	O
to	O
mutation	O
or	O
epigenetic	O
alterations	O
.	O
PTEN	O
promoter	O
hypermethylation	O
is	O
a	O
major	O
epigenetic	O
silencing	O
mechanism	O
leading	O
to	O
activation	O
of	O
angiogenesis	O
in	O
tumors	B-Anatomy
.	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
whether	O
PTEN	O
promoter	O
methylation	O
was	O
involved	O
in	O
CCMs	B-Anatomy
.	O
METHODS	O
:	O
PTEN	O
promoter	O
methylation	O
was	O
detected	O
in	O
surgical	B-Anatomy
specimens	I-Anatomy
of	O
CCMs	B-Anatomy
(	O
n	O
=	O
69	O
)	O
by	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O
The	O
methylation	O
status	O
was	O
correlated	O
to	O
the	O
clinical	O
manifestations	O
and	O
to	O
PTEN	O
expression	O
,	O
which	O
was	O
analyzed	O
by	O
both	O
Western	O
blot	O
and	O
immunohistochemistry	O
.	O
To	O
investigate	O
the	O
endothelial	B-Anatomy
proliferation	O
and	O
the	O
potential	O
signaling	O
pathways	O
affected	O
by	O
PTEN	O
methylation	O
,	O
proliferating	O
cell	O
nuclear	O
antigen	O
as	O
well	O
as	O
phosphor	O
-	O
Akt	O
and	O
phosphor	O
-	O
Erk1	O
,	O
2	O
were	O
detected	O
by	O
immunofluorescence	O
and	O
Western	O
blot	O
,	O
respectively	O
,	O
in	O
CCM	B-Anatomy
specimens	I-Anatomy
.	O
RESULTS	O
:	O
Methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
revealed	O
PTEN	O
promoter	O
methylation	O
in	O
15	O
.	O
9	O
%	O
CCMs	B-Anatomy
.	O
Strikingly	O
,	O
5	O
of	O
6	O
familial	O
CCMs	B-Anatomy
showed	O
PTEN	O
promoter	O
methylation	O
(	O
83	O
.	O
3	O
%	O
)	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
in	O
sporadic	O
cases	O
(	O
9	O
.	O
4	O
%	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
In	O
addition	O
,	O
PTEN	O
promoter	O
methylation	O
appeared	O
more	O
frequently	O
in	O
multiple	O
CCMs	B-Anatomy
,	O
including	O
familial	O
cases	O
(	O
46	O
.	O
7	O
%	O
)	O
,	O
than	O
that	O
in	O
single	O
-	O
lesioned	O
CCMs	B-Anatomy
(	O
11	O
.	O
8	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Immunostaining	O
and	O
Western	O
blot	O
revealed	O
a	O
more	O
significant	O
PTEN	O
downregulation	O
in	O
PTEN	O
-	O
methylated	O
CCMs	B-Anatomy
in	O
comparison	O
to	O
PTEN	O
-	O
unmethylated	O
CCMs	B-Anatomy
.	O
Reduced	O
PTEN	O
expression	O
was	O
inversely	O
correlated	O
to	O
the	O
expression	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
and	O
to	O
the	O
activation	O
of	O
Erk1	O
,	O
2	O
,	O
but	O
not	O
of	O
Akt	O
.	O
CONCLUSIONS	O
:	O
We	O
reported	O
here	O
for	O
the	O
first	O
time	O
the	O
involvement	O
of	O
PTEN	O
promoter	O
methylation	O
in	O
CCMs	B-Anatomy
,	O
particularly	O
in	O
familial	O
CCMs	B-Anatomy
,	O
suggesting	O
this	O
epigenetic	O
alteration	O
as	O
a	O
potential	O
pathomechanism	O
of	O
CCMs	B-Anatomy
.	O
The	O
identification	O
of	O
Erk1	O
,	O
2	O
as	O
triggered	O
signaling	O
in	O
the	O
lesions	B-Anatomy
may	O
be	O
valuable	O
for	O
the	O
development	O
of	O
effective	O
therapy	O
for	O
this	O
disease	O
.	O
Aflibercept	O
(	O
AVE0005	O
)	O
:	O
an	O
alternative	O
strategy	O
for	O
inhibiting	O
tumour	B-Anatomy
angiogenesis	O
by	O
vascular	O
endothelial	O
growth	O
factors	O
.	O
BACKGROUND	O
:	O
Aberrant	O
angiogenesis	O
is	O
a	O
landmark	O
feature	O
in	O
cancer	B-Anatomy
,	O
which	O
is	O
important	O
for	O
proliferation	O
,	O
growth	O
and	O
metastasis	O
,	O
and	O
is	O
mediated	O
by	O
various	O
pro	O
-	O
angiogenic	O
factors	O
.	O
The	O
VEGF	O
pathway	O
is	O
one	O
of	O
the	O
most	O
important	O
and	O
best	O
-	O
studied	O
angiogenic	O
pathways	O
.	O
Inhibition	O
of	O
this	O
pathway	O
may	O
provide	O
clinical	O
benefits	O
to	O
cancer	B-Anatomy
patients	O
.	O
OBJECTIVES	O
:	O
Strategies	O
to	O
inhibit	O
the	O
VEGF	O
pathway	O
,	O
including	O
antibodies	O
to	O
VEGF	O
,	O
antibodies	O
to	O
the	O
extracellular	B-Anatomy
domain	O
of	O
VEGFR	O
-	O
1	O
or	O
VEGFR	O
-	O
2	O
,	O
decoy	O
receptors	O
for	O
VEGF	O
and	O
tyrosine	O
kinase	O
inhibitors	O
of	O
VEGFRs	O
,	O
are	O
summarized	O
.	O
METHODS	O
:	O
This	O
review	O
outlines	O
and	O
compares	O
the	O
latest	O
development	O
of	O
these	O
strategies	O
,	O
with	O
emphasis	O
on	O
aflibercept	O
,	O
a	O
novel	O
decoy	O
fusion	O
protein	O
of	O
domain	O
2	O
of	O
VEGFR	O
-	O
1	O
and	O
domain	O
3	O
of	O
VEGFR	O
-	O
2	O
with	O
the	O
Fc	O
fragment	O
of	O
IgG1	O
.	O
RESULTS	O
:	O
Aflibercept	O
was	O
shown	O
to	O
have	O
early	O
clinical	O
activity	O
.	O
Multiple	O
studies	O
are	O
ongoing	O
to	O
determine	O
the	O
clinical	O
benefits	O
of	O
aflibercept	O
in	O
cancer	B-Anatomy
patients	O
.	O
Handling	O
within	O
run	O
retention	O
time	O
shifts	O
in	O
two	O
-	O
dimensional	O
chromatography	O
data	O
using	O
shift	O
correction	O
and	O
modeling	O
.	O
The	O
use	O
of	O
PARAFAC	O
for	O
modeling	O
GC	O
x	O
GC	O
-	O
TOFMS	O
peaks	O
is	O
well	O
documented	O
.	O
This	O
success	O
is	O
due	O
to	O
the	O
trilinear	O
structure	O
of	O
these	O
data	O
under	O
ideal	O
,	O
or	O
sufficiently	O
close	O
to	O
ideal	O
,	O
chromatographic	O
conditions	O
.	O
However	O
,	O
using	O
temperature	O
programming	O
to	O
cope	O
with	O
the	O
general	O
elution	O
problem	O
,	O
deviations	O
from	O
trilinearity	O
within	O
a	O
run	O
are	O
more	O
likely	O
to	O
be	O
seen	O
for	O
the	O
following	O
three	O
cases	O
:	O
(	O
1	O
)	O
compounds	O
(	O
i	O
.	O
e	O
.	O
,	O
analytes	O
)	O
severely	O
broadened	O
on	O
the	O
first	O
column	O
hence	O
defined	O
by	O
many	O
modulation	O
periods	O
,	O
(	O
2	O
)	O
analytes	O
with	O
a	O
very	O
high	O
retention	O
factor	O
on	O
the	O
second	O
column	O
and	O
likely	O
wrapped	O
around	O
in	O
that	O
dimension	O
,	O
or	O
(	O
3	O
)	O
with	O
fast	O
temperature	O
program	O
rates	O
.	O
This	O
deviation	O
from	O
trilinearity	O
is	O
seen	O
as	O
retention	O
time	O
-	O
shifted	O
peak	O
profiles	O
in	O
subsequent	O
modulation	O
periods	O
(	O
first	O
column	O
fractions	O
)	O
.	O
In	O
this	O
report	O
,	O
a	O
relaxed	O
yet	O
powerful	O
version	O
of	O
PARAFAC	O
,	O
known	O
as	O
PARAFAC2	O
has	O
been	O
applied	O
to	O
handle	O
this	O
shift	O
within	O
the	O
model	O
step	O
by	O
allowing	O
generation	O
of	O
individual	O
peak	O
profiles	O
in	O
subsequent	O
first	O
column	O
fractions	O
.	O
An	O
alternative	O
approach	O
was	O
also	O
studied	O
,	O
utilizing	O
a	O
standard	O
retention	O
time	O
shift	O
correction	O
to	O
restore	O
the	O
data	O
trilinearity	O
structure	O
followed	O
by	O
PARAFAC	O
.	O
These	O
two	O
approaches	O
are	O
compared	O
when	O
identifying	O
and	O
quantifying	O
a	O
known	O
analyte	O
over	O
a	O
large	O
concentration	O
series	O
where	O
a	O
certain	O
shift	O
is	O
simulated	O
in	O
the	O
successive	O
first	O
column	O
fractions	O
.	O
Finally	O
,	O
the	O
methods	O
are	O
applied	O
to	O
real	O
chromatographic	O
data	O
showing	O
severely	O
shifted	O
peak	O
profiles	O
.	O
The	O
pros	O
and	O
cons	O
of	O
the	O
presented	O
approaches	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
model	O
parameters	O
,	O
the	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
and	O
the	O
degree	O
of	O
shift	O
.	O
The	O
effect	O
of	O
perfluorocarbon	O
-	O
based	O
artificial	O
oxygen	O
carriers	O
on	O
tissue	B-Anatomy
-	I-Anatomy
engineered	I-Anatomy
trachea	I-Anatomy
.	O
The	O
biological	O
effect	O
of	O
the	O
perfluorocarbon	O
-	O
based	O
artificial	O
oxygen	O
carrier	O
(	O
Oxygent	O
)	O
was	O
investigated	O
in	O
tissue	B-Anatomy
-	I-Anatomy
engineered	I-Anatomy
trachea	I-Anatomy
(	O
TET	B-Anatomy
)	O
construction	O
.	O
Media	O
supplemented	O
with	O
and	O
without	O
10	O
%	O
Oxygent	O
were	O
compared	O
in	O
all	O
assessments	O
.	O
Partial	O
tissue	B-Anatomy
oxygen	O
tension	O
(	O
PtO	O
(	O
2	O
)	O
)	O
was	O
measured	O
with	O
polarographic	O
microprobes	O
;	O
epithelial	B-Anatomy
metabolism	O
was	O
monitored	O
by	O
microdialysis	O
inside	O
the	O
TET	B-Anatomy
epithelium	I-Anatomy
perfused	O
with	O
the	O
medium	O
underneath	O
.	O
Chondrocyte	B-Anatomy
-	O
DegraPol	O
constructs	O
were	O
cultured	O
for	O
1	O
month	O
with	O
the	O
medium	O
before	O
glycosaminoglycan	O
assessment	O
and	O
histology	O
.	O
Tissue	B-Anatomy
reaction	O
of	O
TET	B-Anatomy
epithelial	I-Anatomy
scaffolds	I-Anatomy
immersed	O
with	O
the	O
medium	O
was	O
evaluated	O
on	O
the	O
chick	O
embryo	B-Anatomy
chorioallantoic	I-Anatomy
membrane	I-Anatomy
.	O
Oxygent	O
perfusion	O
medium	O
increased	O
the	O
TET	B-Anatomy
epithelial	I-Anatomy
PtO	O
(	O
2	O
)	O
(	O
51	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
3	O
mm	O
Hg	O
vs	O
.	O
33	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
3	O
mm	O
Hg	O
at	O
200	O
microm	O
thickness	O
;	O
12	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
1	O
mm	O
Hg	O
vs	O
.	O
3	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
mm	O
Hg	O
at	O
400	O
microm	O
thickness	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
decreased	O
the	O
lactate	O
concentration	O
(	O
0	O
.	O
63	O
+	O
/	O
-	O
0	O
.	O
08	O
vs	O
.	O
0	O
.	O
80	O
+	O
/	O
-	O
0	O
.	O
06	O
mmol	O
/	O
L	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
lactate	O
/	O
pyruvate	O
(	O
1	O
.	O
87	O
+	O
/	O
-	O
0	O
.	O
26	O
vs	O
.	O
3	O
.	O
36	O
+	O
/	O
-	O
10	O
.	O
13	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
and	O
lactate	O
/	O
glucose	O
ratios	O
(	O
0	O
.	O
10	O
+	O
/	O
-	O
0	O
.	O
00	O
vs	O
.	O
0	O
.	O
29	O
+	O
/	O
-	O
0	O
.	O
14	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
Chondrocyte	B-Anatomy
-	O
DegraPol	O
in	O
Oxygent	O
group	O
presented	O
lower	O
glycosaminoglycan	O
value	O
(	O
0	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
00	O
vs	O
.	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
00	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
;	O
histology	O
slides	O
showed	O
poor	O
acid	O
mucopolysaccharides	O
formation	O
.	O
Orthogonal	O
polarization	O
spectral	O
imaging	O
showed	O
no	O
difference	O
in	O
functional	O
capillary	B-Anatomy
density	O
between	O
the	O
scaffolds	O
cultured	O
on	O
chorioallantoic	B-Anatomy
membranes	I-Anatomy
.	O
The	O
foreign	O
body	B-Anatomy
reaction	O
was	O
similar	O
in	O
both	O
groups	O
.	O
We	O
conclude	O
that	O
Oxygent	O
increases	O
TET	B-Anatomy
epithelial	I-Anatomy
PtO	O
(	O
2	O
)	O
,	O
improves	O
epithelial	B-Anatomy
metabolism	O
,	O
does	O
not	O
impair	O
angiogenesis	O
,	O
and	O
tends	O
to	O
slow	O
cartilage	B-Anatomy
tissue	I-Anatomy
formation	O
.	O
The	O
semaphorin	O
7A	O
receptor	O
Plexin	O
C1	O
is	O
lost	O
during	O
melanoma	B-Anatomy
metastasis	O
.	O
The	O
transformation	O
of	O
normal	O
melanocytes	B-Anatomy
,	O
or	O
melanocyte	B-Anatomy
stem	I-Anatomy
cells	I-Anatomy
,	O
to	O
melanoma	B-Anatomy
,	O
is	O
a	O
complex	O
process	O
involving	O
multiple	O
mechanisms	O
.	O
Loss	O
of	O
tumor	B-Anatomy
suppressor	O
proteins	O
,	O
which	O
function	O
as	O
brakes	O
on	O
cell	B-Anatomy
growth	O
,	O
migration	O
,	O
or	O
cell	B-Anatomy
survival	O
,	O
was	O
recognized	O
early	O
on	O
as	O
an	O
important	O
mechanism	O
for	O
initiation	O
and	O
progression	O
of	O
melanoma	B-Anatomy
.	O
Semaphorins	O
and	O
their	O
cognate	O
receptors	O
,	O
Plexins	O
and	O
neuropilins	O
,	O
are	O
involved	O
in	O
neuronal	B-Anatomy
pathfinding	O
,	O
immune	O
function	O
,	O
and	O
tumor	B-Anatomy
progression	O
through	O
effects	O
on	O
blood	B-Anatomy
vessel	I-Anatomy
growth	O
and	O
cell	B-Anatomy
migration	O
.	O
Semaphorin	O
7A	O
(	O
Sema7A	O
)	O
is	O
a	O
membrane	B-Anatomy
-	O
linked	O
semaphorin	O
that	O
is	O
expressed	O
by	O
human	O
keratinocytes	B-Anatomy
,	O
and	O
we	O
have	O
shown	O
that	O
Sema7A	O
binds	O
to	O
human	O
melanocytes	B-Anatomy
through	O
beta1	O
-	O
integrins	O
and	O
the	O
Plexin	O
C1	O
receptor	O
.	O
Functional	O
studies	O
showed	O
that	O
Sema7A	O
stimulates	O
cytoskeletal	B-Anatomy
reorganization	O
in	O
human	O
melanocytes	B-Anatomy
,	O
resulting	O
in	O
adhesion	O
and	O
dendrite	B-Anatomy
formation	O
.	O
Downstream	O
targets	O
of	O
Plexin	O
C1	O
signaling	O
in	O
human	O
melanocytes	B-Anatomy
include	O
cofilin	O
and	O
LIM	O
kinase	O
II	O
,	O
both	O
of	O
which	O
are	O
critical	O
mediators	O
of	O
cell	B-Anatomy
adhesion	O
and	O
migration	O
.	O
In	O
this	O
report	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
Plexin	O
C1	O
using	O
immunohistochemistry	O
on	O
sections	B-Anatomy
of	O
primary	B-Anatomy
and	O
matched	O
metastatic	B-Anatomy
lesions	I-Anatomy
from	O
19	O
subjects	O
and	O
in	O
a	O
large	O
melanoma	B-Anatomy
tumor	I-Anatomy
microarray	O
.	O
Our	O
data	O
show	O
a	O
significant	O
loss	O
of	O
Plexin	O
C1	O
in	O
metastatic	B-Anatomy
melanoma	I-Anatomy
compared	O
with	O
primary	B-Anatomy
melanoma	I-Anatomy
,	O
suggesting	O
the	O
possibility	O
that	O
the	O
Plexin	O
C1	O
receptor	O
is	O
a	O
tumor	B-Anatomy
suppressor	O
protein	O
for	O
melanoma	B-Anatomy
.	O
Coagulation	O
function	O
in	O
patients	O
with	O
pancreatic	B-Anatomy
carcinoma	I-Anatomy
.	O
BACKGROUND	O
:	O
The	O
coagulation	O
function	O
in	O
patients	O
with	O
pancreatic	B-Anatomy
carcinoma	I-Anatomy
is	O
abnormal	O
and	O
the	O
reason	O
is	O
not	O
very	O
clear	O
.	O
In	O
this	O
study	O
,	O
we	O
retrospectively	O
analyzed	O
the	O
coagulation	O
function	O
in	O
patients	O
with	O
pancreatic	B-Anatomy
carcinoma	I-Anatomy
.	O
METHODS	O
:	O
From	O
June	O
2004	O
to	O
December	O
2007	O
,	O
132	O
patients	O
received	O
diagnosis	O
and	O
treatment	O
in	O
our	O
hospital	O
.	O
The	O
coagulative	O
parameters	O
including	O
the	O
prothrombin	O
time	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
,	O
and	O
fibrinogen	O
levels	O
were	O
collected	O
and	O
studied	O
retrospectively	O
.	O
RESULTS	O
:	O
The	O
average	O
fibrinogen	O
levels	O
in	O
patients	O
with	O
pancreatic	B-Anatomy
carcinoma	I-Anatomy
,	O
(	O
476	O
.	O
21	O
+	O
/	O
-	O
142	O
.	O
05	O
)	O
mg	O
/	O
dl	O
,	O
were	O
significantly	O
higher	O
than	O
in	O
patients	O
with	O
cholangiolithiasis	O
,	O
(	O
403	O
.	O
28	O
+	O
/	O
-	O
126	O
.	O
41	O
)	O
mg	O
/	O
dl	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
In	O
patients	O
with	O
pancreatic	B-Anatomy
carcinoma	I-Anatomy
,	O
the	O
levels	O
of	O
fibrinogen	O
in	O
the	O
group	O
with	O
jaundice	O
were	O
significantly	O
higher	O
than	O
in	O
patients	O
without	O
jaundice	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
In	O
patients	O
who	O
received	O
Pancreaticoduodenectomy	O
,	O
Whipple	O
'	O
s	O
operation	O
,	O
the	O
level	O
of	O
fibrinogen	O
in	O
the	O
group	O
with	O
local	O
invasiveness	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
group	O
without	O
invasiveness	O
.	O
The	O
group	O
with	O
lymphatic	B-Anatomy
metastasis	O
had	O
higher	O
levels	O
than	O
the	O
group	O
without	O
lymphatic	B-Anatomy
metastasis	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
There	O
was	O
no	O
significant	O
difference	O
of	O
intraoperative	O
blood	B-Anatomy
loss	O
between	O
patients	O
with	O
vitamin	O
K	O
,	O
(	O
748	O
.	O
27	O
+	O
/	O
-	O
448	O
.	O
51	O
)	O
ml	O
,	O
and	O
those	O
without	O
vitamin	O
K	O
,	O
(	O
767	O
.	O
31	O
+	O
/	O
-	O
547	O
.	O
89	O
)	O
ml	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
level	O
of	O
fibrinogen	O
in	O
patients	O
with	O
pancreatic	B-Anatomy
carcinoma	I-Anatomy
was	O
elevated	O
.	O
The	O
elevated	O
fibrinogen	O
level	O
may	O
be	O
associated	O
with	O
invasiveness	O
and	O
lymphatic	B-Anatomy
metastasis	O
.	O
Using	O
vitamin	O
K	O
in	O
perioperation	O
management	O
did	O
not	O
reduce	O
intraoperative	O
blood	B-Anatomy
loss	O
.	O
Molecular	O
analysis	O
of	O
genetic	O
instability	O
caused	O
by	O
chronic	O
inflammation	O
.	O
Genetic	O
instability	O
is	O
a	O
hallmark	O
of	O
human	O
cancers	B-Anatomy
.	O
It	O
is	O
the	O
driving	O
force	O
for	O
tumor	B-Anatomy
development	O
as	O
it	O
facilitates	O
the	O
accumulation	O
of	O
mutations	O
in	O
genes	O
that	O
regulate	O
cell	B-Anatomy
death	O
and	O
proliferation	O
and	O
therefore	O
promotes	O
malignant	O
transformation	O
.	O
Chronic	O
inflammation	O
is	O
a	O
common	O
underlying	O
condition	O
for	O
human	O
tumor	B-Anatomy
development	O
,	O
accounting	O
for	O
approximately	O
20	O
%	O
of	O
human	O
cancers	B-Anatomy
.	O
TNFalpha	O
is	O
an	O
important	O
inflammation	O
cytokine	O
and	O
is	O
crucial	O
to	O
the	O
development	O
of	O
inflammation	O
-	O
associated	O
cancers	B-Anatomy
.	O
We	O
have	O
shown	O
that	O
TNFalpha	O
can	O
cause	O
DNA	O
damages	O
through	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O
TNFalpha	O
treatment	O
in	O
cultured	O
cells	B-Anatomy
resulted	O
in	O
increased	O
gene	O
mutations	O
,	O
gene	O
amplification	O
,	O
micronuclei	B-Anatomy
formation	O
and	O
chromosomal	B-Anatomy
instability	O
.	O
Antioxidants	O
significantly	O
reduced	O
TNFalpha	O
-	O
induced	O
genetic	O
damage	O
.	O
In	O
addition	O
,	O
TNFalpha	O
treatment	O
alone	O
led	O
to	O
increased	O
malignant	O
transformation	O
of	O
mouse	O
embryo	B-Anatomy
fibroblasts	I-Anatomy
,	O
which	O
could	O
be	O
partially	O
suppressed	O
by	O
antioxidants	O
.	O
Therefore	O
,	O
genetic	O
instability	O
plays	O
an	O
important	O
role	O
in	O
inflammation	O
-	O
associated	O
cancers	B-Anatomy
.	O
PTTG	O
overexpression	O
promotes	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
in	O
human	O
esophageal	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
Human	O
pituitary	O
tumor	O
transforming	O
gene	O
(	O
PTTG	O
)	O
overexpression	O
correlates	O
with	O
metastasis	O
in	O
multiple	O
tumors	B-Anatomy
,	O
and	O
yet	O
its	O
molecular	O
mechanisms	O
of	O
action	O
remain	O
elusive	O
.	O
We	O
detected	O
PTTG	O
overexpression	O
in	O
66	O
%	O
(	O
111	O
of	O
169	O
)	O
of	O
primary	B-Anatomy
esophageal	I-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	I-Anatomy
ESCC	I-Anatomy
)	I-Anatomy
tumor	I-Anatomy
tissues	I-Anatomy
by	O
in	O
situ	O
hybridization	O
.	O
PTTG	O
overexpression	O
correlated	O
with	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Ectopic	O
PTTG	O
overexpression	O
in	O
a	O
representative	O
ESCC	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
EC9706	B-Anatomy
,	O
increased	O
in	O
vitro	O
cell	B-Anatomy
migration	O
and	O
invasion	O
and	O
promoted	O
in	O
vivo	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
.	O
Suppressing	O
PTTG	O
expression	O
by	O
siRNA	O
decreased	O
cell	B-Anatomy
motility	O
in	O
both	O
PTTG	B-Anatomy
-	I-Anatomy
HA	I-Anatomy
/	I-Anatomy
EC9706	I-Anatomy
and	O
KYSE150	B-Anatomy
cells	I-Anatomy
.	O
By	O
using	O
mass	O
spectrometric	O
analysis	O
,	O
we	O
identified	O
that	O
PTTG	O
up	O
-	O
regulated	O
S100A4	O
and	O
galectin	O
-	O
1	O
secretion	O
and	O
down	O
-	O
regulated	O
tissue	B-Anatomy
inhibitor	O
of	O
metalloproteinase	O
-	O
2	O
secretion	O
to	O
the	O
culture	O
media	O
.	O
PTTG	O
induced	O
S100A4	O
and	O
galectin	O
-	O
1	O
mRNA	O
and	O
protein	O
expression	O
as	O
assessed	O
by	O
Western	O
blot	O
and	O
reverse	O
transcription	O
-	O
PCR	O
.	O
Attenuating	O
galectin	O
-	O
1	O
expression	O
by	O
siRNA	O
constrained	O
PTTG	B-Anatomy
-	I-Anatomy
HA	I-Anatomy
/	I-Anatomy
EC9706	I-Anatomy
cell	I-Anatomy
motility	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
PTTG	O
activated	O
E	O
-	O
box	O
transcription	O
and	O
induced	O
c	O
-	O
Myc	O
protein	O
expression	O
in	O
EC9706	B-Anatomy
cells	I-Anatomy
,	O
which	O
in	O
turn	O
may	O
act	O
on	O
an	O
E	O
-	O
box	O
motif	O
within	O
the	O
galectin	O
-	O
1	O
promoter	O
.	O
Chromatin	B-Anatomy
immunoprecipitation	O
assays	O
further	O
confirmed	O
specific	O
c	O
-	O
Myc	O
binding	O
to	O
galectin	O
-	O
1	O
promoter	O
.	O
PTTG	O
-	O
induced	O
galectin	O
-	O
1	O
transactivation	O
and	O
expression	O
were	O
mediated	O
by	O
c	O
-	O
Myc	O
,	O
and	O
both	O
inductions	O
were	O
suppressed	O
by	O
c	O
-	O
Myc	O
RNAi	O
cotranfection	O
.	O
These	O
findings	O
elucidate	O
the	O
molecular	O
mechanisms	O
of	O
PTTG	O
overexpression	O
in	O
promoting	O
tumor	B-Anatomy
metastasis	O
,	O
whereby	O
up	O
-	O
regulated	O
PTTG	O
modulates	O
expression	O
and	O
secretion	O
of	O
metastasis	O
-	O
related	O
factors	O
to	O
facilitate	O
cell	B-Anatomy
motility	O
.	O
Characterization	O
of	O
the	O
metabolic	O
changes	O
underlying	O
growth	O
factor	O
angiogenic	O
activation	O
:	O
identification	O
of	O
new	O
potential	O
therapeutic	O
targets	O
.	O
Angiogenesis	O
is	O
a	O
fundamental	O
process	O
to	O
normal	O
and	O
abnormal	O
tissue	B-Anatomy
growth	O
and	O
repair	O
,	O
which	O
consists	O
of	O
recruiting	O
endothelial	B-Anatomy
cells	I-Anatomy
toward	O
an	O
angiogenic	O
stimulus	O
.	O
The	O
cells	B-Anatomy
subsequently	O
proliferate	O
and	O
differentiate	O
to	O
form	O
endothelial	B-Anatomy
tubes	I-Anatomy
and	O
capillary	B-Anatomy
-	I-Anatomy
like	I-Anatomy
structures	I-Anatomy
.	O
Little	O
is	O
known	O
about	O
the	O
metabolic	O
adaptation	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
through	O
such	O
a	O
transformation	O
.	O
We	O
studied	O
the	O
metabolic	O
changes	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
activation	O
by	O
growth	O
factors	O
using	O
human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
(	O
HUVECs	B-Anatomy
)	O
,	O
[	O
1	O
,	O
2	O
-	O
(	O
13	O
)	O
C	O
(	O
2	O
)	O
]	O
-	O
glucose	O
and	O
mass	O
isotopomer	O
distribution	O
analysis	O
.	O
The	O
metabolism	O
of	O
[	O
1	O
,	O
2	O
-	O
(	O
13	O
)	O
C	O
(	O
2	O
)	O
]	O
-	O
glucose	O
by	O
HUVEC	B-Anatomy
allows	O
us	O
to	O
trace	O
many	O
of	O
the	O
main	O
glucose	O
metabolic	O
pathways	O
,	O
including	O
glycogen	O
synthesis	O
,	O
the	O
pentose	O
cycle	O
and	O
the	O
glycolytic	O
pathways	O
.	O
So	O
we	O
established	O
that	O
these	O
pathways	O
were	O
crucial	O
to	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
under	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
stimulation	O
.	O
A	O
specific	O
VEGF	O
receptor	O
-	O
2	O
inhibitor	O
demonstrated	O
the	O
importance	O
of	O
glycogen	O
metabolism	O
and	O
pentose	O
cycle	O
pathway	O
.	O
Furthermore	O
,	O
we	O
showed	O
that	O
glycogen	O
was	O
depleted	O
in	O
a	O
low	O
glucose	O
medium	O
,	O
but	O
conserved	O
under	O
hypoxic	O
conditions	O
.	O
Finally	O
,	O
we	O
demonstrated	O
that	O
direct	O
inhibition	O
of	O
key	O
enzymes	O
to	O
glycogen	O
metabolism	O
and	O
pentose	O
phosphate	O
pathways	O
reduced	O
HUVEC	B-Anatomy
viability	O
and	O
migration	O
.	O
In	O
this	O
regard	O
,	O
inhibitors	O
of	O
these	O
pathways	O
have	O
been	O
shown	O
to	O
be	O
effective	O
antitumoral	B-Anatomy
agents	O
.	O
To	O
sum	O
up	O
,	O
our	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
metabolic	O
pathways	O
offers	O
a	O
novel	O
and	O
powerful	O
therapeutic	O
approach	O
,	O
which	O
simultaneously	O
inhibits	O
tumor	B-Anatomy
cell	I-Anatomy
proliferation	O
and	O
tumor	B-Anatomy
-	O
induced	O
angiogenesis	O
.	O
Rab	O
GTPase	O
regulation	O
of	O
VEGFR2	O
trafficking	O
and	O
signaling	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
OBJECTIVE	O
:	O
Vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
(	O
VEGFR2	O
)	O
is	O
a	O
receptor	O
tyrosine	O
kinase	O
that	O
regulates	O
vascular	B-Anatomy
physiology	O
.	O
However	O
,	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
VEGFR2	O
signaling	O
and	O
trafficking	O
is	O
coordinated	O
are	O
not	O
clear	O
.	O
Here	O
,	O
we	O
have	O
tested	O
endocytic	O
Rab	O
GTPases	O
for	O
regulation	O
of	O
VEGFR2	O
trafficking	O
and	O
signaling	O
linked	O
to	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
Quiescent	O
VEGFR2	O
displays	O
endosomal	B-Anatomy
localization	O
and	O
colocalization	O
with	O
the	O
Rab5a	O
GTPase	O
,	O
an	O
early	B-Anatomy
endosome	I-Anatomy
fusion	O
regulator	O
.	O
Expression	O
of	O
GTP	O
or	O
GDP	O
-	O
bound	O
Rab5a	O
mutants	O
block	O
activated	O
VEGFR2	O
trafficking	O
and	O
degradation	O
.	O
Manipulation	O
of	O
Rab7a	O
GTPase	O
activity	O
associated	O
with	O
late	B-Anatomy
endosomes	I-Anatomy
using	O
overexpression	O
of	O
wild	O
-	O
type	O
or	O
mutant	O
proteins	O
blocks	O
activated	O
VEGFR2	O
trafficking	O
and	O
degradation	O
.	O
Depletion	O
of	O
Rab7a	O
decreased	O
VEGFR2	O
Y1175	O
phosphorylation	O
but	O
increased	O
p42	O
/	O
44	O
(	O
pERK1	O
/	O
2	O
)	O
MAPK	O
phosphorylation	O
.	O
Endothelial	B-Anatomy
cell	I-Anatomy
migration	O
was	O
increased	O
by	O
Rab5a	O
depletion	O
but	O
decreased	O
by	O
Rab7a	O
depletion	O
.	O
CONCLUSIONS	O
:	O
Rab5a	O
and	O
Rab7a	O
regulate	O
VEGFR2	O
trafficking	O
toward	O
early	B-Anatomy
and	O
late	B-Anatomy
endosomes	I-Anatomy
.	O
Our	O
data	O
suggest	O
that	O
VEGFR2	O
-	O
mediated	O
regulation	O
of	O
endothelial	B-Anatomy
function	O
is	O
dependent	O
on	O
different	O
but	O
specific	O
Rab	O
-	O
mediated	O
GTP	O
hydrolysis	O
activity	O
required	O
for	O
endosomal	B-Anatomy
trafficking	O
.	O
FOXO3a	O
elicits	O
a	O
pro	O
-	O
apoptotic	O
transcription	O
program	O
and	O
cellular	B-Anatomy
response	O
to	O
human	O
lung	B-Anatomy
carcinogen	O
nicotine	O
-	O
derived	O
nitrosaminoketone	O
(	O
NNK	O
)	O
.	O
Long	O
-	O
term	O
carcinogen	O
exposure	O
exerts	O
continuous	O
pressure	O
on	O
key	O
mechanisms	O
that	O
repair	O
or	O
eliminate	O
carcinogen	O
-	O
damaged	O
cells	B-Anatomy
giving	O
rise	O
to	O
selective	O
failures	O
that	O
contribute	O
to	O
lung	B-Anatomy
cancer	I-Anatomy
.	O
FOXO3a	O
is	O
a	O
transcription	O
factor	O
that	O
elicits	O
a	O
protective	O
response	O
to	O
diverse	O
cellular	B-Anatomy
stresses	O
.	O
Although	O
implicated	O
as	O
a	O
tumor	B-Anatomy
suppressor	O
,	O
its	O
role	O
in	O
sporadic	B-Anatomy
cancer	I-Anatomy
is	O
uncertain	O
.	O
We	O
recently	O
observed	O
that	O
FOXO3a	O
gene	O
inactivation	O
occurs	O
frequently	O
in	O
carcinogen	O
-	O
induced	O
lung	B-Anatomy
adenocarcinoma	I-Anatomy
(	O
LAC	B-Anatomy
)	O
.	O
This	O
suggests	O
that	O
FOXO3a	O
may	O
play	O
a	O
role	O
in	O
LAC	B-Anatomy
suppression	O
by	O
eliciting	O
a	O
protective	O
response	O
to	O
carcinogenic	O
stress	O
.	O
Here	O
we	O
investigated	O
this	O
possibility	O
by	O
examining	O
the	O
role	O
of	O
FOXO3a	O
in	O
the	O
cellular	B-Anatomy
response	O
to	O
nicotine	O
-	O
derived	O
nitrosaminoketone	O
(	O
NNK	O
)	O
,	O
a	O
lung	B-Anatomy
carcinogen	O
implicated	O
as	O
a	O
cause	O
of	O
human	O
LAC	B-Anatomy
.	O
We	O
show	O
that	O
restoration	O
of	O
FOXO3a	O
in	O
FOXO3a	O
-	O
deficient	O
LAC	B-Anatomy
cells	I-Anatomy
increases	O
sensitivity	O
to	O
apoptosis	O
caused	O
by	O
a	O
DNA	O
-	O
damaging	O
intermediate	O
of	O
NNK	O
.	O
Prior	O
to	O
this	O
cellular	B-Anatomy
outcome	O
,	O
FOXO3a	O
is	O
functionally	O
activated	O
and	O
mediates	O
a	O
large	O
-	O
scale	O
transcription	O
program	O
in	O
response	O
to	O
this	O
damage	O
involving	O
a	O
significant	O
modulation	O
of	O
440	O
genes	O
.	O
Genes	O
most	O
significantly	O
represented	O
in	O
this	O
program	O
are	O
those	O
with	O
roles	O
in	O
cell	B-Anatomy
growth	O
and	O
proliferation	O
>	O
protein	O
synthesis	O
>	O
gene	O
expression	O
>	O
cell	B-Anatomy
death	O
>	O
cell	B-Anatomy
cycle	O
.	O
The	O
results	O
of	O
this	O
study	O
show	O
that	O
FOXO3a	O
directs	O
an	O
anti	O
-	O
carcinogenic	O
transcription	O
program	O
that	O
culminates	O
in	O
the	O
elimination	O
of	O
carcinogen	O
-	O
damaged	O
cells	B-Anatomy
.	O
This	O
suggests	O
that	O
FOXO3a	O
is	O
a	O
potential	O
suppressor	O
of	O
carcinogenic	O
damage	O
in	O
LAC	B-Anatomy
.	O
Bmi	O
-	O
1	O
over	O
-	O
expression	O
in	O
neural	B-Anatomy
stem	I-Anatomy
/	I-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
increases	O
proliferation	O
and	O
neurogenesis	O
in	O
culture	O
but	O
has	O
little	O
effect	O
on	O
these	O
functions	O
in	O
vivo	O
.	O
The	O
polycomb	O
gene	O
Bmi	O
-	O
1	O
is	O
required	O
for	O
the	O
self	O
-	O
renewal	O
of	O
stem	B-Anatomy
cells	I-Anatomy
from	O
diverse	O
tissues	B-Anatomy
,	O
including	O
the	O
central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
(	O
CNS	B-Anatomy
)	O
.	O
Bmi	O
-	O
1	O
expression	O
is	O
elevated	O
in	O
most	O
human	O
gliomas	B-Anatomy
,	O
irrespective	O
of	O
grade	O
,	O
raising	O
the	O
question	O
of	O
whether	O
Bmi	O
-	O
1	O
over	O
-	O
expression	O
is	O
sufficient	O
to	O
promote	O
self	O
-	O
renewal	O
or	O
tumorigenesis	O
by	O
CNS	B-Anatomy
stem	I-Anatomy
/	I-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
.	O
To	O
test	O
this	O
we	O
generated	O
Nestin	O
-	O
Bmi	O
-	O
1	O
-	O
GFP	O
transgenic	O
mice	O
.	O
Analysis	O
of	O
two	O
independent	O
lines	O
with	O
expression	O
in	O
the	O
fetal	B-Anatomy
and	O
adult	B-Anatomy
CNS	I-Anatomy
demonstrated	O
that	O
transgenic	O
neural	B-Anatomy
stem	I-Anatomy
cells	I-Anatomy
formed	O
larger	O
colonies	B-Anatomy
,	O
more	O
self	O
-	O
renewing	O
divisions	O
,	O
and	O
more	O
neurons	B-Anatomy
in	O
culture	O
.	O
However	O
,	O
in	O
vivo	O
,	O
Bmi	O
-	O
1	O
over	O
-	O
expression	O
had	O
little	O
effect	O
on	O
CNS	B-Anatomy
stem	I-Anatomy
cell	I-Anatomy
frequency	O
,	O
subventricular	B-Anatomy
zone	I-Anatomy
proliferation	O
,	O
olfactory	B-Anatomy
bulb	I-Anatomy
neurogenesis	O
,	O
or	O
neurogenesis	O
/	O
gliogenesis	O
during	O
development	O
.	O
Bmi	O
-	O
1	O
transgenic	O
mice	O
were	O
born	O
with	O
enlarged	O
lateral	B-Anatomy
ventricles	I-Anatomy
and	O
a	O
minority	O
developed	O
idiopathic	O
hydrocephalus	O
as	O
adults	O
,	O
but	O
none	O
of	O
the	O
transgenic	O
mice	O
formed	O
detectable	O
CNS	B-Anatomy
tumors	I-Anatomy
,	O
even	O
when	O
aged	O
.	O
The	O
more	O
pronounced	O
effects	O
of	O
Bmi	O
-	O
1	O
over	O
-	O
expression	O
in	O
culture	O
were	O
largely	O
attributable	O
to	O
the	O
attenuated	O
induction	O
of	O
p16	O
(	O
Ink4a	O
)	O
and	O
p19	O
(	O
Arf	O
)	O
in	O
culture	O
,	O
proteins	O
that	O
are	O
generally	O
not	O
expressed	O
by	O
neural	B-Anatomy
stem	I-Anatomy
/	I-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
in	O
young	O
mice	O
in	O
vivo	O
.	O
Bmi	O
-	O
1	O
over	O
-	O
expression	O
therefore	O
has	O
more	O
pronounced	O
effects	O
in	O
culture	O
and	O
does	O
not	O
appear	O
to	O
be	O
sufficient	O
to	O
induce	O
tumorigenesis	O
in	O
vivo	O
.	O
Erbb2	O
suppresses	O
DNA	O
damage	O
-	O
induced	O
checkpoint	O
activation	O
and	O
UV	O
-	O
induced	O
mouse	O
skin	B-Anatomy
tumorigenesis	O
.	O
The	O
Erbb2	O
receptor	O
is	O
activated	O
by	O
UV	O
irradiation	O
,	O
the	O
primary	O
cause	O
of	O
non	B-Anatomy
-	I-Anatomy
melanoma	I-Anatomy
skin	I-Anatomy
cancer	I-Anatomy
.	O
We	O
hypothesized	O
that	O
Erbb2	O
activation	O
contributes	O
to	O
UV	O
-	O
induced	O
skin	B-Anatomy
tumorigenesis	O
by	O
suppressing	O
cell	B-Anatomy
cycle	O
arrest	O
.	O
Consistent	O
with	O
this	O
hypothesis	O
,	O
inhibition	O
of	O
Erbb2	O
in	O
v	O
-	O
ras	O
(	O
Ha	O
)	O
transgenic	O
mice	O
before	O
UV	O
exposure	O
resulted	O
in	O
both	O
56	O
%	O
fewer	O
skin	B-Anatomy
tumors	I-Anatomy
and	O
tumors	B-Anatomy
that	O
were	O
70	O
%	O
smaller	O
.	O
Inhibition	O
of	O
the	O
UV	O
-	O
induced	O
activation	O
of	O
Erbb2	O
also	O
resulted	O
in	O
milder	O
epidermal	B-Anatomy
hyperplasia	I-Anatomy
,	O
S	O
-	O
phase	O
accumulation	O
,	O
and	O
decreased	O
levels	O
of	O
the	O
cell	B-Anatomy
cycle	O
regulator	O
Cdc25a	O
,	O
suggesting	O
altered	O
cell	B-Anatomy
cycle	O
regulation	O
on	O
inhibition	O
of	O
Erbb2	O
.	O
Further	O
investigation	O
using	O
inhibition	O
or	O
genetic	O
deletion	O
of	O
Erbb2	O
in	O
vitro	O
revealed	O
reduced	O
Cdc25a	O
levels	O
and	O
increased	O
S	O
-	O
phase	O
arrest	O
in	O
UV	O
-	O
irradiated	O
cells	B-Anatomy
lacking	O
Erbb2	O
activity	O
.	O
Ectopic	O
expression	O
of	O
Cdc25a	O
prevented	O
UV	O
-	O
induced	O
S	O
-	O
phase	O
arrest	O
in	O
keratinocytes	B-Anatomy
lacking	O
Erbb2	O
activity	O
,	O
demonstrating	O
that	O
maintenance	O
of	O
Cdc25a	O
by	O
Erbb2	O
suppresses	O
cell	B-Anatomy
cycle	O
arrest	O
.	O
Examination	O
of	O
checkpoint	O
pathway	O
activation	O
upstream	O
of	O
Cdc25a	O
revealed	O
Erbb2	O
activation	O
did	O
not	O
alter	O
Ataxia	O
Telangiectasia	O
and	O
Rad3	O
-	O
related	O
/	O
Ataxia	O
Telangiectasia	O
Mutated	O
activity	O
but	O
increased	O
inhibitory	O
phosphorylation	O
of	O
Chk1	O
-	O
Ser	O
(	O
280	O
)	O
.	O
Since	O
Akt	O
phosphorylates	O
Chk1	O
-	O
Ser	O
(	O
280	O
)	O
,	O
the	O
effect	O
of	O
Erbb2	O
on	O
phosphatidyl	O
inositol	O
-	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
/	O
Akt	O
signaling	O
during	O
UV	O
-	O
induced	O
cell	B-Anatomy
cycle	O
arrest	O
was	O
determined	O
.	O
Erbb2	O
ablation	O
reduced	O
the	O
UV	O
-	O
induced	O
activation	O
of	O
PI3K	O
while	O
inhibition	O
of	O
PI3K	O
/	O
Akt	O
increased	O
UV	O
-	O
induced	O
S	O
-	O
phase	O
arrest	O
.	O
Thus	O
,	O
UV	O
-	O
induced	O
Erbb2	O
activation	O
increases	O
skin	B-Anatomy
tumorigenesis	O
through	O
inhibitory	O
phosphorylation	O
of	O
Chk1	O
,	O
Cdc25a	O
maintenance	O
,	O
and	O
suppression	O
of	O
S	O
-	O
phase	O
arrest	O
via	O
a	O
PI3K	O
/	O
Akt	O
-	O
dependent	O
mechanism	O
.	O
The	O
EGFR	O
-	O
GEP100	O
-	O
Arf6	O
-	O
AMAP1	O
signaling	O
pathway	O
specific	O
to	O
breast	B-Anatomy
cancer	I-Anatomy
invasion	O
and	O
metastasis	O
.	O
Tumors	B-Anatomy
are	O
tissue	B-Anatomy
-	O
specific	O
diseases	O
,	O
and	O
their	O
mechanisms	O
of	O
invasion	O
and	O
metastasis	O
are	O
highly	O
diverse	O
.	O
In	O
breast	B-Anatomy
cancer	I-Anatomy
,	O
biomarkers	O
that	O
specifically	O
correlate	O
with	O
the	O
invasive	O
phenotypes	O
have	O
not	O
been	O
clearly	O
identified	O
.	O
A	O
small	O
GTPase	O
Arf6	O
primarily	O
regulates	O
recycling	O
of	O
plasma	B-Anatomy
membrane	I-Anatomy
components	I-Anatomy
.	O
We	O
have	O
shown	O
that	O
Arf6	O
and	O
its	O
effector	O
AMAP1	O
(	O
DDEF1	O
,	O
DEF1	O
,	O
ASAP1	O
and	O
centaurin	O
beta4	O
)	O
are	O
abnormally	O
overexpressed	O
in	O
some	O
breast	B-Anatomy
cancers	I-Anatomy
and	O
used	O
for	O
their	O
invasion	O
and	O
metastasis	O
.	O
Overexpression	O
of	O
these	O
proteins	O
is	O
independent	O
of	O
the	O
transcriptional	O
upregulation	O
of	O
their	O
genes	O
,	O
and	O
occurs	O
only	O
in	O
highly	O
malignant	B-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
We	O
recently	O
identified	O
GEP100	O
(	O
BRAG2	O
)	O
to	O
be	O
responsible	O
for	O
the	O
Arf6	O
activation	O
to	O
induce	O
invasion	O
and	O
metastasis	O
,	O
by	O
directly	O
binding	O
to	O
ligand	O
-	O
activated	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
.	O
A	O
series	O
of	O
our	O
studies	O
revealed	O
that	O
for	O
activation	O
of	O
the	O
invasion	O
pathway	O
of	O
EGFR	O
,	O
it	O
is	O
prerequisite	O
that	O
Arf6	O
and	O
AMAP1	O
both	O
are	O
highly	O
overexpressed	O
,	O
and	O
that	O
EGFR	O
is	O
activated	O
by	O
ligands	O
.	O
Pathological	O
analyses	O
indicate	O
that	O
a	O
significant	O
large	O
population	O
of	O
human	O
ductal	B-Anatomy
cancers	I-Anatomy
may	O
utilize	O
the	O
EGFR	O
-	O
GEP100	O
-	O
Arf6	O
-	O
AMAP1	O
pathway	O
for	O
their	O
malignancy	O
.	O
Microenvironments	O
have	O
been	O
highly	O
implicated	O
in	O
the	O
malignancy	O
of	O
mammary	B-Anatomy
tumors	I-Anatomy
.	O
Our	O
results	O
reveal	O
an	O
aspect	O
of	O
the	O
precise	O
molecular	O
mechanisms	O
of	O
some	O
breast	B-Anatomy
cancers	I-Anatomy
,	O
in	O
which	O
full	O
invasiveness	O
is	O
not	O
acquired	O
just	O
by	O
intracellular	B-Anatomy
alterations	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
,	O
but	O
extracellular	B-Anatomy
factors	O
from	O
microenvironments	O
may	O
also	O
be	O
necessary	O
.	O
Possible	O
translation	O
of	O
our	O
knowledge	O
to	O
cancer	B-Anatomy
therapeutics	O
will	O
also	O
be	O
discussed	O
.	O
Met	O
amplification	O
and	O
tumor	B-Anatomy
progression	O
in	O
Cdkn2a	B-Anatomy
-	I-Anatomy
deficient	I-Anatomy
melanocytes	I-Anatomy
.	O
While	O
many	O
genetic	O
alterations	O
have	O
been	O
identified	O
in	O
melanoma	B-Anatomy
,	O
the	O
relevant	O
molecular	O
events	O
that	O
contribute	O
to	O
disease	O
progression	O
are	O
poorly	O
understood	O
.	O
Most	O
primary	B-Anatomy
human	I-Anatomy
melanomas	I-Anatomy
exhibit	O
loss	O
of	O
expression	O
of	O
the	O
CDKN2A	O
locus	O
in	O
addition	O
to	O
activation	O
of	O
the	O
canonical	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signaling	O
pathway	O
.	O
In	O
this	O
study	O
,	O
we	O
used	O
a	O
Cdkn2a	O
-	O
deficient	O
mouse	O
melanocyte	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
to	O
screen	O
for	O
secondary	O
genetic	O
events	O
in	O
melanoma	B-Anatomy
tumor	I-Anatomy
progression	O
.	O
Upon	O
investigation	O
,	O
intrachromosomal	B-Anatomy
gene	O
amplification	O
of	O
Met	O
,	O
a	O
receptor	O
tyrosine	O
kinase	O
implicated	O
in	O
melanoma	B-Anatomy
progression	O
,	O
was	O
identified	O
in	O
Cdkn2a	B-Anatomy
-	I-Anatomy
deficient	I-Anatomy
tumors	I-Anatomy
.	O
RNA	O
interference	O
targeting	O
Met	O
in	O
these	O
tumor	B-Anatomy
cells	I-Anatomy
resulted	O
in	O
a	O
significant	O
delay	O
in	O
tumor	B-Anatomy
growth	O
in	O
vivo	O
compared	O
with	O
the	O
control	O
cells	B-Anatomy
.	O
MET	O
expression	O
is	O
rarely	O
detected	O
in	O
primary	B-Anatomy
human	I-Anatomy
melanoma	I-Anatomy
but	O
is	O
frequently	O
observed	O
in	O
metastatic	B-Anatomy
disease	I-Anatomy
.	O
This	O
study	O
validates	O
a	O
role	O
for	O
Met	O
activation	O
in	O
melanoma	B-Anatomy
tumor	I-Anatomy
progression	O
in	O
the	O
context	O
of	O
Cdkn2a	O
deficiency	O
.	O
Activated	O
platelets	B-Anatomy
enhance	O
ovarian	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
invasion	O
in	O
a	O
cellular	B-Anatomy
model	O
of	O
metastasis	O
.	O
Increased	O
platelet	B-Anatomy
counts	O
and	O
systemic	O
coagulation	O
activation	O
are	O
associated	O
with	O
ovarian	B-Anatomy
cancer	I-Anatomy
progression	O
.	O
Platelet	B-Anatomy
activation	O
occurs	O
in	O
the	O
tumor	B-Anatomy
microenvironment	O
and	O
may	O
influence	O
local	O
invasion	O
and	O
metastasis	O
.	O
We	O
used	O
a	O
cellular	B-Anatomy
model	O
of	O
tumor	B-Anatomy
invasion	O
to	O
investigate	O
the	O
effect	O
of	O
activated	O
platelets	B-Anatomy
on	O
the	O
human	O
ovarian	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
SKOV3	B-Anatomy
.	O
SKOV3	B-Anatomy
cells	I-Anatomy
were	O
exposed	O
to	O
washed	O
,	O
thrombin	O
receptor	O
activating	O
peptide	O
(	O
TRAP	O
)	O
-	O
activated	O
or	O
TRAP	O
-	O
naive	O
platelets	B-Anatomy
under	O
various	O
experimental	O
conditions	O
,	O
and	O
tumor	B-Anatomy
cell	I-Anatomy
invasion	O
was	O
assayed	O
in	O
Matrigel	O
chambers	O
.	O
The	O
effect	O
of	O
platelets	B-Anatomy
on	O
the	O
content	O
of	O
urokinase	O
plasminogen	O
activator	O
(	O
uPA	O
)	O
and	O
VEGF	O
in	O
SKOV3	B-Anatomy
cell	I-Anatomy
conditioned	O
medium	O
was	O
measured	O
using	O
an	O
ELISA	O
assay	O
.	O
TRAP	O
-	O
activated	O
platelets	B-Anatomy
stimulated	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
SKOV3	B-Anatomy
cell	I-Anatomy
invasion	O
.	O
Exposure	O
to	O
activated	O
platelet	B-Anatomy
membranes	I-Anatomy
and	O
to	O
soluble	O
proteins	O
contained	O
in	O
activated	O
platelet	B-Anatomy
releasate	O
both	O
contributed	O
to	O
the	O
observed	O
increase	O
in	O
invasion	O
.	O
The	O
inhibition	O
of	O
platelet	B-Anatomy
activation	O
with	O
prostaglandin	O
E1	O
(	O
PGE	O
(	O
1	O
)	O
)	O
attenuated	O
the	O
invasive	O
capacity	O
of	O
SKOV3	B-Anatomy
cells	I-Anatomy
.	O
Exposure	O
to	O
platelets	B-Anatomy
resulted	O
in	O
significantly	O
increased	O
uPA	O
and	O
VEGF	O
content	O
of	O
SKOV3	B-Anatomy
cell	I-Anatomy
conditioned	O
medium	O
.	O
Activated	O
platelets	B-Anatomy
enhance	O
SKOV3	B-Anatomy
human	O
ovarian	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
invasion	O
through	O
Matrigel	O
and	O
increase	O
the	O
amount	O
of	O
uPA	O
and	O
VEGF	O
secreted	O
into	O
SKOV3	B-Anatomy
cell	I-Anatomy
conditioned	O
medium	O
.	O
If	O
generalizable	O
to	O
additional	O
cell	B-Anatomy
lines	I-Anatomy
and	O
human	O
disease	O
,	O
this	O
observation	O
may	O
partially	O
explain	O
the	O
adverse	O
prognosis	O
associated	O
with	O
thrombocytosis	O
in	O
ovarian	B-Anatomy
cancer	I-Anatomy
.	O
Platelets	B-Anatomy
,	O
therefore	O
,	O
may	O
represent	O
a	O
potential	O
target	O
for	O
therapeutic	O
intervention	O
in	O
human	O
ovarian	B-Anatomy
cancer	I-Anatomy
.	O
AngiomiRs	O
-	O
-	O
key	O
regulators	O
of	O
angiogenesis	O
.	O
The	O
formation	O
of	O
new	O
blood	B-Anatomy
vessels	I-Anatomy
through	O
the	O
process	O
of	O
angiogenesis	O
is	O
critical	O
in	O
vascular	B-Anatomy
development	O
and	O
homeostasis	O
.	O
Aberrant	O
angiogenesis	O
leads	O
to	O
a	O
variety	O
of	O
diseases	O
,	O
such	O
as	O
ischemia	O
and	O
cancer	B-Anatomy
.	O
Recent	O
studies	O
have	O
revealed	O
important	O
roles	O
for	O
miRNAs	O
in	O
regulating	O
endothelial	B-Anatomy
cell	I-Anatomy
(	O
EC	B-Anatomy
)	O
function	O
,	O
especially	O
angiogenesis	O
.	O
Mice	O
with	O
EC	B-Anatomy
-	O
specific	O
deletion	O
of	O
Dicer	O
,	O
a	O
key	O
enzyme	O
for	O
generating	O
miRNAs	O
,	O
display	O
defective	O
postnatal	O
angiogenesis	O
.	O
Specific	O
miRNAs	O
(	O
angiomiRs	O
)	O
have	O
recently	O
been	O
shown	O
to	O
regulate	O
angiogenesis	O
in	O
vivo	O
.	O
miRNA	O
-	O
126	O
,	O
an	O
EC	B-Anatomy
-	O
restricted	O
miRNA	O
,	O
regulates	O
vascular	B-Anatomy
integrity	O
and	O
developmental	O
angiogenesis	O
.	O
miR	O
-	O
378	O
,	O
miR	O
-	O
296	O
,	O
and	O
the	O
miR	O
-	O
17	O
-	O
92	O
cluster	O
contribute	O
to	O
tumor	B-Anatomy
angiogenesis	O
.	O
Manipulating	O
angiomiRs	O
in	O
the	O
settings	O
of	O
pathological	O
vascularization	O
represents	O
a	O
new	O
therapeutic	O
approach	O
.	O
[	O
Incidence	O
of	O
fungal	O
infection	O
in	O
surgical	O
diseases	O
of	O
the	O
pancreas	B-Anatomy
]	O
.	O
Recently	O
the	O
number	O
of	O
mycotic	O
infections	O
has	O
increased	O
significantly	O
.	O
Authors	O
have	O
observed	O
13	O
mycotic	O
infections	O
on	O
operated	O
patients	O
suffering	O
pancreatic	B-Anatomy
diseases	O
between	O
1984	O
and	O
1990	O
.	O
9	O
of	O
13	O
patients	O
had	O
pancreatic	B-Anatomy
abscesses	I-Anatomy
as	O
well	O
.	O
The	O
risk	O
factors	O
of	O
fungal	O
infections	O
are	O
analysed	O
.	O
It	O
is	O
important	O
to	O
take	O
differentiation	O
between	O
fungal	O
colonisation	O
and	O
septicaemia	O
caused	O
by	O
yeasts	O
.	O
Repeated	O
microbiological	O
examinations	O
can	O
promote	O
recognising	O
of	O
the	O
fungal	O
invasion	O
.	O
The	O
base	O
of	O
the	O
therapy	O
is	O
to	O
avoid	O
risk	O
factors	O
of	O
infections	O
and	O
to	O
use	O
antifungal	O
medication	O
in	O
time	O
.	O
Promoting	O
angiogenesis	O
via	O
manipulation	O
of	O
VEGF	O
responsiveness	O
with	O
notch	O
signaling	O
.	O
Promoting	O
angiogenesis	O
via	O
delivery	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
other	O
angiogenic	O
factors	O
is	O
both	O
a	O
potential	O
therapy	O
for	O
cardiovascular	B-Anatomy
diseases	O
and	O
a	O
critical	O
aspect	O
for	O
tissue	B-Anatomy
regeneration	O
.	O
The	O
recent	O
demonstration	O
that	O
VEGF	O
signaling	O
is	O
modulated	O
by	O
the	O
Notch	O
signaling	O
pathway	O
,	O
however	O
,	O
suggests	O
that	O
inhibiting	O
Notch	O
signaling	O
may	O
enhance	O
regional	O
neovascularization	O
,	O
by	O
altering	O
the	O
responsiveness	O
of	O
local	O
endothelial	B-Anatomy
cells	I-Anatomy
to	O
angiogenic	O
stimuli	O
.	O
We	O
tested	O
this	O
possibility	O
with	O
in	O
vitro	O
assays	O
using	O
human	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
as	O
well	O
as	O
in	O
a	O
rodent	O
hindlimb	B-Anatomy
ischemia	O
model	O
.	O
Treatment	O
of	O
cultured	O
human	O
endothelial	B-Anatomy
cells	I-Anatomy
with	O
DAPT	O
,	O
a	O
gamma	O
secretase	O
inhibitor	O
,	O
increased	O
cell	B-Anatomy
migration	O
and	O
sprout	B-Anatomy
formation	O
in	O
response	O
to	O
VEGF	O
stimulation	O
with	O
a	O
biphasic	O
dependence	O
on	O
DAPT	O
concentration	O
.	O
Further	O
,	O
delivery	O
of	O
an	O
appropriate	O
combination	O
of	O
DAPT	O
and	O
VEGF	O
from	O
an	O
injectable	O
alginate	O
hydrogel	O
system	O
into	O
ischemic	O
hindlimbs	B-Anatomy
led	O
to	O
a	O
faster	O
recovery	O
of	O
blood	B-Anatomy
flow	O
than	O
VEGF	O
or	O
DAPT	O
alone	O
;	O
perfusion	O
levels	O
reached	O
80	O
%	O
of	O
the	O
normal	O
level	O
by	O
week	O
4	O
with	O
combined	O
DAPT	O
and	O
VEGF	O
delivery	O
.	O
Direct	O
intramuscular	B-Anatomy
or	O
intraperitoneal	B-Anatomy
injection	O
of	O
DAPT	O
did	O
not	O
result	O
in	O
the	O
same	O
level	O
of	O
improvement	O
,	O
suggesting	O
that	O
appropriate	O
presentation	O
of	O
DAPT	O
(	O
gel	O
delivery	O
)	O
is	O
important	O
for	O
its	O
activity	O
.	O
DAPT	O
delivery	O
from	O
the	O
hydrogels	O
also	O
did	O
not	O
lead	O
to	O
any	O
adverse	O
side	O
effects	O
,	O
in	O
contrast	O
to	O
systemic	O
introduction	O
of	O
DAPT	O
.	O
Altogether	O
,	O
these	O
results	O
suggest	O
a	O
new	O
approach	O
to	O
promote	O
angiogenesis	O
by	O
controlling	O
Notch	O
signaling	O
,	O
and	O
may	O
provide	O
new	O
options	O
to	O
treat	O
patients	O
with	O
diseases	O
that	O
diminish	O
angiogenic	O
responsiveness	O
.	O
[	O
Activation	O
of	O
sterol	O
regulatory	O
element	O
binding	O
protein	O
and	O
its	O
involvement	O
in	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
]	O
OBJECTIVE	O
:	O
To	O
study	O
the	O
activation	O
of	O
sterol	O
regulatory	O
element	O
binding	O
protein	O
(	O
SREBP	O
)	O
and	O
its	O
critical	O
role	O
in	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
.	O
METHODS	O
:	O
Bovine	O
aortic	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
(	O
ECs	B-Anatomy
)	O
were	O
cultured	O
.	O
The	O
expression	O
of	O
SREBP	O
and	O
Cdc42	O
were	O
determined	O
by	O
Western	O
blot	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O
Moreover	O
,	O
outward	O
growth	O
migration	O
model	O
and	O
transwell	O
chamber	O
assay	O
were	O
used	O
to	O
detect	O
ECs	B-Anatomy
migration	O
.	O
RESULTS	O
:	O
(	O
1	O
)	O
SREBP	O
was	O
activated	O
during	O
ECs	B-Anatomy
migration	O
.	O
Western	O
blot	O
analysis	O
demonstrated	O
increased	O
active	O
form	O
SREBP	O
in	O
migrating	O
as	O
compared	O
to	O
non	O
-	O
migrating	O
ECs	B-Anatomy
population	O
.	O
SREBP	O
activation	O
decreased	O
as	O
ECs	B-Anatomy
migration	O
slowed	O
;	O
(	O
2	O
)	O
Coincidental	O
with	O
SREBP	O
activation	O
,	O
mRNA	O
expression	O
of	O
its	O
target	O
genes	O
such	O
as	O
low	O
density	O
lipoprotein	O
receptor	O
,	O
HMG	O
-	O
CoA	O
reductase	O
,	O
and	O
fatty	O
acid	O
synthase	O
also	O
increased	O
in	O
migrating	O
ECs	B-Anatomy
population	O
as	O
detected	O
by	O
real	O
-	O
time	O
PCR	O
;	O
(	O
3	O
)	O
Migration	O
induced	O
SREBP	O
activation	O
in	O
ECs	B-Anatomy
was	O
inhibited	O
by	O
SREBP	O
-	O
acting	O
protein	O
RNAi	O
and	O
pharmacologically	O
by	O
25	O
-	O
hydroxycholesterol	O
;	O
(	O
4	O
)	O
Inhibition	O
of	O
SREBP	O
led	O
to	O
decreased	O
ECs	B-Anatomy
migration	O
in	O
various	O
models	O
;	O
(	O
5	O
)	O
Cells	B-Anatomy
genetically	O
deficient	O
in	O
SREBP	O
-	O
acting	O
protein	O
,	O
S1P	O
,	O
or	O
S2P	O
,	O
phenotypically	O
exhibited	O
impaired	O
migration	O
;	O
(	O
6	O
)	O
SREBP	O
inhibition	O
in	O
ECs	B-Anatomy
suppressed	O
the	O
activity	O
of	O
small	O
GTPase	O
Cdc42	O
,	O
a	O
key	O
molecule	O
for	O
ECs	B-Anatomy
motility	O
.	O
CONCLUSIONS	O
:	O
SREBP	O
is	O
activated	O
during	O
and	O
plays	O
a	O
critical	O
role	O
in	O
ECs	B-Anatomy
migration	O
.	O
Targeting	O
SREBP	O
could	O
become	O
a	O
novel	O
approach	O
in	O
fighting	O
diseases	O
involving	O
abnormal	O
ECs	B-Anatomy
migration	O
.	O
Fibroblast	B-Anatomy
growth	I-Anatomy
factor	I-Anatomy
receptor	I-Anatomy
2	I-Anatomy
-	I-Anatomy
positive	I-Anatomy
fibroblasts	I-Anatomy
provide	O
a	O
suitable	O
microenvironment	O
for	O
tumor	B-Anatomy
development	O
and	O
progression	O
in	O
esophageal	B-Anatomy
carcinoma	I-Anatomy
.	O
PURPOSE	O
:	O
Tumor	B-Anatomy
fibroblasts	I-Anatomy
(	O
TF	B-Anatomy
)	O
have	O
been	O
suggested	O
to	O
play	O
an	O
essential	O
role	O
in	O
the	O
complex	O
process	O
of	O
tumor	B-Anatomy
-	O
stroma	B-Anatomy
interactions	O
and	O
tumorigenesis	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
specific	O
role	O
of	O
TF	B-Anatomy
in	O
the	O
esophageal	B-Anatomy
cancer	I-Anatomy
microenvironment	O
.	O
EXPERIMENTAL	O
DESIGN	O
:	O
An	O
Affymetrix	O
expression	O
microarray	O
was	O
used	O
to	O
compare	O
gene	O
expression	O
profiles	O
between	O
six	O
pairs	O
of	O
TFs	B-Anatomy
and	O
normal	O
fibroblasts	B-Anatomy
from	O
esophageal	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	O
ESCC	B-Anatomy
)	O
.	O
Differentially	O
expressed	O
genes	O
were	O
identified	O
,	O
and	O
a	O
subset	O
was	O
evaluated	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
and	O
immunohistochemistry	O
.	O
RESULTS	O
:	O
About	O
43	O
%	O
(	O
126	O
of	O
292	O
)	O
of	O
known	O
deregulated	O
genes	O
in	O
TFs	B-Anatomy
were	O
associated	O
with	O
cell	B-Anatomy
proliferation	O
,	O
extracellular	B-Anatomy
matrix	I-Anatomy
remodeling	O
,	O
and	O
immune	O
response	O
.	O
Up	O
-	O
regulation	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
2	O
(	O
FGFR2	O
)	O
,	O
which	O
showed	O
the	O
most	O
significant	O
change	O
,	O
was	O
detected	O
in	O
all	O
six	O
tested	O
TFs	B-Anatomy
compared	O
with	O
their	O
paired	O
normal	O
fibroblasts	B-Anatomy
.	O
A	O
further	O
study	O
found	O
that	O
FGFR2	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
fibroblasts	I-Anatomy
were	O
only	O
observed	O
inside	O
the	O
tumor	B-Anatomy
tissues	I-Anatomy
and	O
not	O
in	O
tumor	B-Anatomy
-	I-Anatomy
surrounding	I-Anatomy
stromal	I-Anatomy
tissues	I-Anatomy
,	O
suggesting	O
that	O
FGFR2	O
could	O
be	O
used	O
as	O
a	O
TF	B-Anatomy
-	O
specific	O
marker	O
in	O
ESCC	B-Anatomy
.	O
Moreover	O
,	O
the	O
conditioned	O
medium	O
from	O
TFs	B-Anatomy
was	O
found	O
to	O
be	O
able	O
to	O
promote	O
ESCC	B-Anatomy
tumor	I-Anatomy
cell	I-Anatomy
growth	O
,	O
migration	O
,	O
and	O
invasion	O
in	O
vitro	O
.	O
CONCLUSIONS	O
:	O
Our	O
study	O
provides	O
new	O
candidate	O
genes	O
for	O
the	O
esophageal	B-Anatomy
cancer	I-Anatomy
microenvironment	O
.	O
Based	O
on	O
our	O
results	O
,	O
we	O
hypothesize	O
that	O
FGFR2	B-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
-	I-Anatomy
TFs	I-Anatomy
might	O
provide	O
cancer	B-Anatomy
cells	I-Anatomy
with	O
a	O
suitable	O
microenvironment	O
via	O
secretion	O
of	O
proteins	O
that	O
could	O
promote	O
cancer	B-Anatomy
development	O
and	O
progression	O
through	O
stimulation	O
of	O
cancer	B-Anatomy
cell	I-Anatomy
proliferation	O
,	O
induction	O
of	O
angiogenesis	O
,	O
inhibition	O
of	O
cell	B-Anatomy
adhesion	O
,	O
enhancement	O
of	O
cell	B-Anatomy
mobility	O
,	O
and	O
promotion	O
of	O
the	O
epithelial	B-Anatomy
-	O
mesenchymal	B-Anatomy
transition	O
.	O
[	O
Role	O
of	O
the	O
tumor	B-Anatomy
suppressor	O
ARF	O
in	O
oncogenesis	O
]	O
The	O
paper	O
reviews	O
the	O
data	O
available	O
in	O
the	O
literature	O
on	O
a	O
role	O
of	O
the	O
tumor	B-Anatomy
suppressor	O
ARF	O
in	O
oncogenesis	O
and	O
considers	O
the	O
structure	O
of	O
a	O
gene	O
encoding	O
ARF	O
protein	O
.	O
The	O
p53	O
-	O
dependent	O
and	O
p	O
-	O
53	O
-	O
independent	O
functions	O
of	O
this	O
protein	O
are	O
under	O
many	O
studies	O
.	O
There	O
is	O
evidence	O
for	O
the	O
implication	O
of	O
ARF	O
in	O
angiogenesis	O
.	O
There	O
is	O
more	O
and	O
more	O
information	O
on	O
the	O
role	O
of	O
ARF	O
in	O
the	O
regulation	O
of	O
a	O
cell	B-Anatomy
cycle	O
,	O
apoptosis	O
,	O
and	O
autophagy	O
.	O
The	O
importance	O
of	O
this	O
tumor	B-Anatomy
suppressor	O
in	O
the	O
mechanisms	O
of	O
carcinogenesis	O
is	O
beyond	O
question	O
as	O
the	O
inactivation	O
of	O
ARF	O
suppressor	O
activity	O
leads	O
to	O
the	O
rapid	O
growth	O
of	O
neoplasia	B-Anatomy
.	O
However	O
,	O
the	O
exact	O
mechanisms	O
of	O
ARF	O
action	O
yet	O
remain	O
unclear	O
and	O
require	O
further	O
studies	O
by	O
different	O
specialists	O
at	O
both	O
the	O
molecular	O
genetic	O
and	O
other	O
levels	O
of	O
investigation	O
.	O
Mechanical	O
regulation	O
of	O
the	O
proangiogenic	O
factor	O
CCN1	O
/	O
CYR61	O
gene	O
requires	O
the	O
combined	O
activities	O
of	O
MRTF	O
-	O
A	O
and	O
CREB	O
-	O
binding	O
protein	O
histone	O
acetyltransferase	O
.	O
Smooth	B-Anatomy
muscle	I-Anatomy
-	I-Anatomy
rich	I-Anatomy
tissues	I-Anatomy
respond	O
to	O
mechanical	O
overload	O
by	O
an	O
adaptive	O
hypertrophic	O
growth	O
combined	O
with	O
activation	O
of	O
angiogenesis	O
,	O
which	O
potentiates	O
their	O
mechanical	O
overload	O
-	O
bearing	O
capabilities	O
.	O
Neovascularization	O
is	O
associated	O
with	O
mechanical	O
strain	O
-	O
dependent	O
induction	O
of	O
angiogenic	O
factors	O
such	O
as	O
CCN1	O
,	O
an	O
immediate	O
-	O
early	O
gene	O
-	O
encoded	O
matricellular	O
molecule	O
critical	O
for	O
vascular	B-Anatomy
development	O
and	O
repair	O
.	O
Here	O
we	O
have	O
demonstrated	O
that	O
mechanical	O
strain	O
-	O
dependent	O
induction	O
of	O
the	O
CCN1	O
gene	O
involves	O
signaling	O
cascades	O
through	O
RhoA	O
-	O
mediated	O
actin	B-Anatomy
remodeling	O
and	O
the	O
p38	O
stress	O
-	O
activated	O
protein	O
kinase	O
(	O
SAPK	O
)	O
.	O
Actin	O
signaling	O
controls	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
activity	O
via	O
SRF	O
interaction	O
with	O
the	O
myocardin	O
-	O
related	O
transcriptional	O
activator	O
(	O
MRTF	O
)	O
-	O
A	O
and	O
tethering	O
to	O
a	O
single	O
CArG	O
box	O
sequence	O
within	O
the	O
CCN1	O
promoter	O
.	O
Such	O
activity	O
was	O
abolished	O
in	O
mechanically	O
stimulated	O
mouse	O
MRTF	B-Anatomy
-	I-Anatomy
A	I-Anatomy
(	I-Anatomy
-	I-Anatomy
/	I-Anatomy
-	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
or	O
upon	O
inhibition	O
of	O
CREB	O
-	O
binding	O
protein	O
(	O
CBP	O
)	O
histone	O
acetyltransferase	O
(	O
HAT	O
)	O
either	O
pharmacologically	O
or	O
by	O
siRNAs	O
.	O
Mechanical	O
strain	O
induced	O
CBP	O
-	O
mediated	O
acetylation	O
of	O
histones	O
3	O
and	O
4	O
at	O
the	O
SRF	O
-	O
binding	O
site	O
and	O
within	O
the	O
CCN1	O
gene	O
coding	O
region	O
.	O
Inhibition	O
of	O
p38	O
SAPK	O
reduced	O
CBP	O
HAT	O
activity	O
and	O
its	O
recruitment	O
to	O
the	O
SRF	O
.	O
MRTF	O
-	O
A	O
complex	O
,	O
whereas	O
enforced	O
induction	O
of	O
p38	O
by	O
upstream	O
activators	O
(	O
e	O
.	O
g	O
.	O
MKK3	O
and	O
MKK6	O
)	O
enhanced	O
both	O
CBP	O
HAT	O
and	O
CCN1	O
promoter	O
activities	O
.	O
Similarly	O
,	O
mechanical	O
overload	O
-	O
induced	O
CCN1	O
gene	O
expression	O
in	O
vivo	O
was	O
associated	O
with	O
nuclear	B-Anatomy
localization	O
of	O
MRTF	O
-	O
A	O
and	O
enrichment	O
of	O
the	O
CCN1	O
promoter	O
with	O
both	O
MRTF	O
-	O
A	O
and	O
acetylated	O
histone	O
H3	O
.	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
signal	O
-	O
controlled	O
activation	O
of	O
SRF	O
,	O
MRTF	O
-	O
A	O
,	O
and	O
CBP	O
provides	O
a	O
novel	O
connection	O
between	O
mechanical	O
stimuli	O
and	O
angiogenic	O
gene	O
expression	O
.	O
Angiogenesis	O
in	O
platelet	O
endothelial	O
cell	O
adhesion	O
molecule	O
-	O
1	O
-	O
mice	O
.	O
Platelet	O
endothelial	O
cell	O
adhesion	O
molecule	O
(	O
PECAM	O
)	O
-	O
1	O
has	O
been	O
previously	O
implicated	O
in	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
;	O
additionally	O
,	O
anti	O
-	O
PECAM	O
-	O
1	O
antibodies	O
have	O
been	O
shown	O
to	O
inhibit	O
in	O
vivo	O
angiogenesis	O
.	O
Studies	O
were	O
therefore	O
performed	O
with	O
PECAM	O
-	O
1	O
-	O
mice	O
to	O
further	O
define	O
the	O
involvement	O
of	O
PECAM	O
-	O
1	O
in	O
blood	B-Anatomy
vessel	I-Anatomy
formation	O
.	O
Vascularization	O
of	O
subcutaneous	B-Anatomy
Matrigel	O
implants	O
as	O
well	O
as	O
tumor	B-Anatomy
angiogenesis	O
were	O
both	O
inhibited	O
in	O
PECAM	O
-	O
1	O
-	O
mice	O
.	O
Reciprocal	O
bone	B-Anatomy
marrow	I-Anatomy
transplants	O
that	O
involved	O
both	O
wild	O
-	O
type	O
and	O
PECAM	O
-	O
1	O
-	O
deficient	O
mice	O
revealed	O
that	O
the	O
impaired	O
angiogenic	O
response	O
resulted	O
from	O
a	O
loss	O
of	O
endothelial	B-Anatomy
,	O
but	O
not	O
leukocyte	B-Anatomy
,	O
PECAM	O
-	O
1	O
.	O
In	O
vitro	O
wound	B-Anatomy
migration	O
and	O
single	O
-	O
cell	B-Anatomy
motility	O
by	O
PECAM	B-Anatomy
-	I-Anatomy
1	I-Anatomy
-	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
were	O
also	O
compromised	O
.	O
In	O
addition	O
,	O
filopodia	B-Anatomy
formation	O
,	O
a	O
feature	O
of	O
motile	O
cells	B-Anatomy
,	O
was	O
inhibited	O
in	O
PECAM	B-Anatomy
-	I-Anatomy
1	I-Anatomy
-	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
as	O
well	O
as	O
in	O
human	O
endothelial	B-Anatomy
cells	I-Anatomy
treated	O
with	O
either	O
anti	O
-	O
PECAM	O
-	O
1	O
antibody	O
or	O
PECAM	O
-	O
1	O
siRNA	O
.	O
Furthermore	O
,	O
the	O
expression	O
of	O
PECAM	O
-	O
1	O
promoted	O
filopodia	B-Anatomy
formation	O
and	O
increased	O
the	O
protein	O
expression	O
levels	O
of	O
Cdc42	O
,	O
a	O
Rho	O
GTPase	O
that	O
is	O
known	O
to	O
promote	O
the	O
formation	O
of	O
filopodia	B-Anatomy
.	O
In	O
the	O
developing	O
retinal	B-Anatomy
vasculature	I-Anatomy
,	O
numerous	O
,	O
long	B-Anatomy
filamentous	I-Anatomy
filopodia	I-Anatomy
,	O
emanating	O
from	O
endothelial	B-Anatomy
cells	I-Anatomy
at	O
the	O
tips	O
of	O
angiogenic	O
sprouts	B-Anatomy
,	O
were	O
observed	O
in	O
wild	O
-	O
type	O
animals	O
,	O
but	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
PECAM	O
-	O
1	O
-	O
mice	O
.	O
Together	O
,	O
these	O
data	O
further	O
establish	O
the	O
involvement	O
of	O
endothelial	B-Anatomy
PECAM	O
-	O
1	O
in	O
angiogenesis	O
and	O
suggest	O
that	O
,	O
in	O
vivo	O
,	O
PECAM	O
-	O
1	O
may	O
stimulate	O
endothelial	B-Anatomy
cell	I-Anatomy
motility	O
by	O
promoting	O
the	O
formation	O
of	O
filopodia	B-Anatomy
.	O
Desipramine	O
inhibits	O
the	O
growth	O
of	O
a	O
mouse	O
skin	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
and	O
affects	O
glucocorticoid	O
receptor	O
-	O
mediated	O
transcription	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effect	O
of	O
tricyclic	O
antidepressant	O
desipramine	O
(	O
DMI	O
)	O
on	O
the	O
growth	O
inhibition	O
and	O
translocation	O
of	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
from	O
the	O
cytoplasm	B-Anatomy
to	O
the	O
nucleus	B-Anatomy
in	O
cancerous	B-Anatomy
and	O
noncancerous	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
and	O
the	O
effect	O
of	O
DMI	O
on	O
GR	O
-	O
mediated	O
transcription	O
.	O
Nontumorigenic	O
,	O
immortalized	O
keratinocytes	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
(	O
3PC	B-Anatomy
)	O
,	O
papilloma	B-Anatomy
(	O
MT1	B-Anatomy
/	I-Anatomy
2	I-Anatomy
)	O
,	O
and	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	I-Anatomy
Ca3	I-Anatomy
/	I-Anatomy
7	I-Anatomy
)	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
were	O
initially	O
used	O
to	O
study	O
the	O
cell	B-Anatomy
growth	O
inhibition	O
by	O
DMI	O
.	O
Although	O
,	O
the	O
growth	O
of	O
all	O
three	O
cell	B-Anatomy
lines	I-Anatomy
was	O
suppressed	O
by	O
DMI	O
,	O
it	O
was	O
more	O
effective	O
in	O
Ca3	B-Anatomy
/	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
.	O
Therefore	O
,	O
we	O
next	O
examined	O
the	O
effect	O
of	O
DMI	O
on	O
Ca3	B-Anatomy
/	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
,	O
resistant	O
to	O
growth	O
inhibition	O
by	O
the	O
synthetic	O
glucocorticoid	O
fluocinolone	O
acetonide	O
(	O
FA	O
)	O
.	O
DMI	O
inhibited	O
cell	B-Anatomy
proliferation	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O
The	O
translocation	O
of	O
GR	O
was	O
induced	O
by	O
FA	O
alone	O
,	O
DMI	O
alone	O
,	O
and	O
combination	O
of	O
both	O
agents	O
.	O
FA	O
induced	O
GR	O
-	O
mediated	O
transcription	O
in	O
Ca3	B-Anatomy
/	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
transfected	O
with	O
a	O
luciferase	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
glucocorticoid	O
response	O
element	O
(	O
GRE	O
)	O
,	O
but	O
DMI	O
alone	O
did	O
not	O
affect	O
GR	O
-	O
mediated	O
transcription	O
.	O
However	O
,	O
DMI	O
inhibited	O
FA	O
-	O
induced	O
,	O
GR	O
-	O
mediated	O
transcription	O
when	O
both	O
agents	O
were	O
given	O
together	O
.	O
Pretreatment	O
with	O
DMI	O
followed	O
by	O
combination	O
of	O
DMI	O
and	O
FA	O
decreased	O
GR	O
-	O
mediated	O
transcription	O
more	O
than	O
pretreatment	O
with	O
FA	O
.	O
The	O
expression	O
of	O
metallothionein	O
-	O
1	O
(	O
Mt	O
-	O
1	O
)	O
gene	O
,	O
which	O
is	O
regulated	O
by	O
GR	O
,	O
was	O
induced	O
significantly	O
by	O
the	O
combination	O
of	O
DMI	O
and	O
FA	O
,	O
and	O
enhanced	O
significantly	O
by	O
pretreatment	O
with	O
FA	O
but	O
not	O
DMI	O
.	O
DMI	O
is	O
suggested	O
to	O
inhibit	O
the	O
growth	O
of	O
Ca3	B-Anatomy
/	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
and	O
to	O
affect	O
GR	O
-	O
mediated	O
transcription	O
.	O
[	O
Quantitative	O
analysis	O
of	O
regional	O
cerebral	B-Anatomy
blood	B-Anatomy
flow	O
in	O
elderly	O
with	O
white	B-Anatomy
matter	I-Anatomy
lesions	I-Anatomy
]	O
.	O
OBJECTIVE	O
:	O
To	O
observe	O
whether	O
the	O
severity	O
of	O
white	B-Anatomy
matter	I-Anatomy
lesions	I-Anatomy
(	O
WML	B-Anatomy
)	O
is	O
related	O
to	O
ischemia	O
in	O
elderly	O
.	O
METHODS	O
:	O
WML	B-Anatomy
were	O
divided	O
into	O
2	O
categories	O
(	O
centrum	B-Anatomy
semiovale	I-Anatomy
and	O
periventricular	B-Anatomy
regions	I-Anatomy
)	O
and	O
four	O
grades	O
(	O
grade	O
0	O
,	O
grade	O
1	O
,	O
grade	O
2	O
and	O
grade	O
3	O
)	O
according	O
to	O
the	O
severity	O
of	O
WML	B-Anatomy
showing	O
on	O
the	O
FLAIR	O
sequence	O
of	O
MRI	O
using	O
modified	O
Fazekas	O
scale	O
.	O
The	O
values	O
of	O
regional	O
cerebral	B-Anatomy
blood	B-Anatomy
flow	O
(	O
rCBF	O
)	O
within	O
WML	B-Anatomy
and	O
other	O
brain	B-Anatomy
regions	O
were	O
measured	O
using	O
Xenon	O
contrast	O
CT	O
.	O
RESULTS	O
:	O
Mean	O
rCBF	O
(	O
ml	O
x	O
100	O
g	O
(	O
-	O
1	O
)	O
x	O
min	O
(	O
-	O
1	O
)	O
)	O
within	O
lesions	B-Anatomy
around	O
periventricular	B-Anatomy
areas	I-Anatomy
,	O
in	O
right	B-Anatomy
and	O
left	B-Anatomy
centrum	I-Anatomy
semiovale	I-Anatomy
were	O
20	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
8	O
,	O
22	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
and	O
22	O
.	O
2	O
+	O
/	O
-	O
2	O
.	O
1	O
in	O
grade	O
0	O
;	O
20	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
,	O
21	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
0	O
and	O
21	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
8	O
in	O
grade1	O
;	O
16	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
0	O
,	O
15	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
7	O
and	O
15	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
9	O
in	O
grade	O
2	O
;	O
14	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
6	O
,	O
14	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
2	O
and	O
14	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
9	O
in	O
grade	O
3	O
respectively	O
.	O
The	O
severity	O
of	O
WML	B-Anatomy
is	O
associated	O
significantly	O
with	O
reduction	O
of	O
rCBF	O
within	O
lesions	B-Anatomy
both	O
in	O
centrum	B-Anatomy
semiovale	I-Anatomy
and	O
periventricular	B-Anatomy
regions	I-Anatomy
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
rCBF	O
values	O
between	O
grade	O
0	O
and	O
1	O
,	O
but	O
significant	O
differences	O
existed	O
between	O
grade	O
0	O
and	O
grades	O
2	O
and	O
3	O
,	O
between	O
grade	O
1	O
and	O
grades	O
2	O
and	O
3	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Statistical	O
significance	O
also	O
existed	O
between	O
the	O
severity	O
of	O
white	B-Anatomy
matter	I-Anatomy
lesions	I-Anatomy
and	O
rCBF	O
in	O
bilateral	O
temporal	B-Anatomy
lobes	I-Anatomy
and	O
lentiform	O
nucleases	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
severity	O
of	O
WML	B-Anatomy
both	O
in	O
centrum	B-Anatomy
semiovale	I-Anatomy
and	O
periventricular	B-Anatomy
regions	I-Anatomy
is	O
associated	O
significantly	O
with	O
reduction	O
of	O
rCBF	O
within	O
lesions	B-Anatomy
.	O
MEK5	O
/	O
ERK5	O
signaling	O
modulates	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
and	O
focal	B-Anatomy
contact	I-Anatomy
turnover	O
.	O
The	O
formation	O
of	O
new	O
blood	B-Anatomy
vessels	I-Anatomy
from	O
pre	O
-	O
existing	O
ones	O
requires	O
highly	O
coordinated	O
restructuring	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
(	O
EC	B-Anatomy
)	O
and	O
the	O
surrounding	O
extracellular	B-Anatomy
matrix	I-Anatomy
.	O
Directed	O
EC	B-Anatomy
migration	O
is	O
a	O
central	O
step	O
in	O
this	O
process	O
and	O
depends	O
on	O
cellular	B-Anatomy
signaling	O
cascades	O
that	O
initiate	O
and	O
control	O
the	O
structural	O
rearrangements	O
.	O
On	O
the	O
basis	O
of	O
earlier	O
findings	O
that	O
ERK5	O
deficiency	O
in	O
mouse	O
EC	B-Anatomy
results	O
in	O
massive	O
defects	O
in	O
vessel	B-Anatomy
architecture	I-Anatomy
,	O
we	O
focused	O
on	O
the	O
impact	O
of	O
the	O
MEK5	O
/	O
ERK5	O
signaling	O
pathway	O
on	O
EC	B-Anatomy
migration	O
.	O
Using	O
a	O
retroviral	O
gene	O
transfer	O
approach	O
,	O
we	O
found	O
that	O
constitutive	O
activation	O
of	O
MEK5	O
/	O
ERK5	O
signaling	O
strongly	O
inhibits	O
EC	B-Anatomy
migration	O
and	O
results	O
in	O
massive	O
morphological	O
changes	O
.	O
The	O
area	O
covered	O
by	O
spread	O
EC	B-Anatomy
was	O
dramatically	O
enlarged	O
,	O
accompanied	O
by	O
an	O
increase	O
in	O
focal	B-Anatomy
contacts	I-Anatomy
and	O
altered	O
organization	O
of	O
actin	O
filaments	B-Anatomy
.	O
Consequently	O
,	O
cells	B-Anatomy
were	O
more	O
rigid	O
and	O
show	O
reduced	O
motility	O
.	O
This	O
phenotype	O
was	O
most	O
likely	O
based	O
on	O
decreased	O
focal	B-Anatomy
contact	I-Anatomy
turnover	O
caused	O
by	O
reduced	O
expression	O
of	O
p130Cas	O
,	O
a	O
key	O
player	O
in	O
directed	O
cell	B-Anatomy
migration	O
.	O
We	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
ERK5	O
signaling	O
not	O
only	O
is	O
involved	O
in	O
EC	B-Anatomy
survival	O
and	O
stress	O
response	O
but	O
also	O
controls	O
migration	O
and	O
morphology	O
of	O
EC	B-Anatomy
.	O
[	O
The	O
prediction	O
of	O
the	O
level	O
of	O
depression	O
by	O
cognitive	O
,	O
behavioral	O
,	O
and	O
temperamental	O
variables	O
in	O
a	O
six	O
-	O
month	O
time	O
interval	O
]	O
.	O
Several	O
models	O
have	O
been	O
proposed	O
to	O
explain	O
the	O
depressive	O
phenomenon	O
,	O
such	O
as	O
the	O
theory	O
of	O
dysfunctional	O
attitudes	O
,	O
the	O
hopelessness	O
theory	O
,	O
the	O
behavioral	O
model	O
of	O
activity	O
level	O
,	O
or	O
temperamental	O
models	O
.	O
This	O
article	O
presents	O
data	O
about	O
the	O
role	O
of	O
those	O
models	O
in	O
the	O
prediction	O
of	O
the	O
level	O
of	O
depression	O
in	O
a	O
sample	O
of	O
414	O
college	O
students	O
,	O
assessed	O
over	O
a	O
temporal	O
interval	O
of	O
six	O
months	O
.	O
Dysfunctional	O
attitudes	O
,	O
attributional	O
styles	O
,	O
the	O
level	O
of	O
activity	O
,	O
and	O
the	O
five	O
-	O
factors	O
of	O
personality	O
were	O
assessed	O
.	O
The	O
BDI	O
-	O
II	O
was	O
the	O
depression	O
level	O
measure	O
.	O
The	O
results	O
showed	O
that	O
these	O
variables	O
predict	O
depression	O
levels	O
,	O
but	O
with	O
low	O
coefficients	O
.	O
The	O
dimensions	O
of	O
Need	O
of	O
Achievement	O
(	O
a	O
dysfunctional	O
attitude	O
)	O
and	O
Neuroticism	O
had	O
particularly	O
greater	O
weight	O
in	O
the	O
prediction	O
,	O
but	O
only	O
Neuroticism	O
seems	O
to	O
behave	O
like	O
a	O
vulnerability	O
element	O
.	O
Attributional	O
styles	O
did	O
not	O
contribute	O
significantly	O
to	O
the	O
prediction	O
of	O
depression	O
.	O
Activity	O
level	O
lost	O
its	O
predictive	O
role	O
during	O
the	O
6	O
-	O
month	O
interval	O
.	O
These	O
results	O
are	O
discussed	O
according	O
to	O
the	O
role	O
of	O
the	O
proposed	O
models	O
and	O
the	O
need	O
for	O
a	O
deeper	O
explanation	O
of	O
the	O
variance	O
of	O
depression	O
scores	O
.	O
EPOX	O
inhibits	O
angiogenesis	O
by	O
degradation	O
of	O
Mcl	O
-	O
1	O
through	O
ERK	O
inactivation	O
.	O
PURPOSE	O
:	O
Antiangiogenic	O
therapy	O
is	O
considered	O
as	O
an	O
effective	O
strategy	O
for	O
controlling	O
the	O
growth	O
and	O
metastasis	O
of	O
tumors	B-Anatomy
.	O
Among	O
a	O
myriad	O
of	O
biological	O
activities	O
described	O
for	O
xanthone	O
derivatives	O
,	O
the	O
anticancer	B-Anatomy
activity	O
is	O
quite	O
remarkable	O
,	O
but	O
the	O
molecular	O
mechanism	O
is	O
not	O
clearly	O
resolved	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
antiangiogenic	O
mechanism	O
of	O
3	O
,	O
6	O
-	O
di	O
(	O
2	O
,	O
3	O
-	O
epoxypropoxy	O
)	O
xanthone	O
(	O
EPOX	O
)	O
,	O
a	O
novel	O
Mcl	O
-	O
1	O
targeting	O
drug	O
.	O
EXPERIMENTAL	O
DESIGN	O
:	O
To	O
evaluate	O
the	O
antiangiogenic	O
activity	O
of	O
EPOX	O
,	O
we	O
did	O
cell	B-Anatomy
viability	O
,	O
cell	B-Anatomy
cycle	O
,	O
tube	B-Anatomy
formation	O
assay	O
in	O
vitro	O
,	O
and	O
Matrigel	O
plug	O
assay	O
in	O
vivo	O
.	O
To	O
evaluate	O
the	O
effect	O
of	O
EPOX	O
on	O
the	O
endothelial	B-Anatomy
signaling	O
pathway	O
,	O
we	O
did	O
immunoblotting	O
,	O
immunoprecipitation	O
,	O
and	O
immunofluorescence	O
analysis	O
.	O
Intracellular	B-Anatomy
glutathione	O
levels	O
were	O
determined	O
with	O
the	O
use	O
of	O
monochlorobimane	O
,	O
a	O
glutathione	O
-	O
specific	O
probe	O
.	O
RESULTS	O
:	O
EPOX	O
induced	O
endothelial	B-Anatomy
cell	I-Anatomy
apoptosis	O
in	O
association	O
with	O
proteasome	O
-	O
dependent	O
Mcl	O
-	O
1	O
degradation	O
.	O
Down	O
-	O
regulation	O
of	O
Mcl	O
-	O
1	O
resulted	O
in	O
an	O
increase	O
in	O
Mcl	O
-	O
1	O
-	O
free	O
Bim	O
,	O
activation	O
of	O
Bax	O
,	O
and	O
then	O
signaling	O
of	O
mitochondria	B-Anatomy
-	O
mediated	O
apoptosis	O
.	O
Additionally	O
,	O
glutathione	O
depletion	O
and	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
inactivation	O
was	O
observed	O
in	O
EPOX	O
-	O
treated	O
cells	B-Anatomy
.	O
Glutathione	O
supplementation	O
reversed	O
the	O
inhibitory	O
effects	O
of	O
EPOX	O
on	O
ERK	O
,	O
which	O
increases	O
the	O
phosphorylation	O
of	O
Mcl	O
-	O
1	O
at	O
T	O
(	O
163	O
.	O
)	O
Overexpression	O
of	O
mitogen	O
-	O
activated	O
protein	O
/	O
ERK	O
kinase	O
(	O
MEK	O
)	O
partially	O
reversed	O
the	O
effect	O
of	O
EPOX	O
on	O
Mcl	O
-	O
1	O
dephosphorylation	O
,	O
ubiquitination	O
,	O
and	O
degradation	O
,	O
further	O
implicating	O
ERK	O
in	O
the	O
regulation	O
of	O
Mcl	O
-	O
1	O
stability	O
.	O
CONCLUSIONS	O
:	O
This	O
study	O
provides	O
evidence	O
that	O
EPOX	O
induces	O
glutathione	O
depletion	O
,	O
ERK	O
inactivation	O
,	O
and	O
Mcl	O
-	O
1	O
degradation	O
on	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
which	O
leads	O
to	O
inhibition	O
of	O
angiogenesis	O
.	O
Our	O
results	O
suggest	O
that	O
EPOX	O
is	O
a	O
novel	O
antiangiogenic	O
agent	O
,	O
making	O
it	O
a	O
promising	O
lead	O
compound	O
for	O
further	O
development	O
in	O
the	O
treatment	O
of	O
angiogenesis	O
-	O
related	O
pathologies	O
.	O
Targeting	O
angiogenesis	O
:	O
progress	O
with	O
anti	O
-	O
VEGF	O
treatment	O
with	O
large	O
molecules	O
.	O
Angiogenesis	O
-	O
-	O
one	O
of	O
the	O
hallmarks	O
of	O
cancer	B-Anatomy
-	O
-	O
has	O
emerged	O
as	O
a	O
valid	O
therapeutic	O
target	O
in	O
oncology	O
.	O
The	O
VEGF	O
system	O
represents	O
a	O
key	O
mediator	O
of	O
tumor	B-Anatomy
-	O
initiated	O
angiogenesis	O
and	O
the	O
first	O
target	O
of	O
antiangiogenesis	O
agents	O
introduced	O
in	O
clinical	O
practice	O
.	O
Although	O
anti	O
-	O
VEGF	O
therapies	O
have	O
clearly	O
demonstrated	O
antitumor	B-Anatomy
efficacy	O
in	O
various	O
malignancies	B-Anatomy
,	O
especially	O
when	O
combined	O
with	O
conventional	O
cytotoxic	O
chemotherapy	O
,	O
their	O
mechanism	O
of	O
action	O
is	O
not	O
fully	O
understood	O
.	O
This	O
Review	O
will	O
discuss	O
the	O
rationale	O
for	O
using	O
antiangiogenic	O
compounds	O
and	O
will	O
focus	O
on	O
large	O
molecules	O
,	O
such	O
as	O
antibodies	O
,	O
that	O
target	O
the	O
VEGF	O
system	O
.	O
Clinical	O
data	O
on	O
bevacizumab	O
is	O
discussed	O
in	O
detail	O
.	O
Predictive	O
markers	O
for	O
anti	O
-	O
VEGF	O
agents	O
have	O
not	O
yet	O
been	O
identified	O
and	O
questions	O
regarding	O
the	O
usefulness	O
of	O
bevacizumab	O
in	O
the	O
adjuvant	O
setting	O
as	O
well	O
as	O
its	O
continued	O
use	O
beyond	O
progression	O
remain	O
unanswered	O
,	O
in	O
spite	O
of	O
negative	O
data	O
on	O
bevacizumab	O
in	O
treating	O
patients	O
with	O
adjuvant	O
colon	B-Anatomy
cancer	I-Anatomy
.	O
Nonetheless	O
,	O
anti	O
-	O
VEGF	O
therapy	O
has	O
enhanced	O
the	O
arsenal	O
of	O
anticancer	B-Anatomy
therapies	O
and	O
has	O
provided	O
new	O
insights	O
into	O
the	O
biology	O
of	O
malignancy	B-Anatomy
.	O
[	O
Ambiguity	O
role	O
of	O
neutrophils	B-Anatomy
in	O
oncogenesis	O
]	O
The	O
review	O
is	O
focused	O
on	O
the	O
participation	O
of	O
polymorphonuclear	B-Anatomy
granulocytes	I-Anatomy
(	O
neutrophils	B-Anatomy
)	O
in	O
development	O
and	O
spreading	O
of	O
a	O
tumor	B-Anatomy
.	O
We	O
consider	O
both	O
the	O
well	O
known	O
functions	O
of	O
neutrophils	B-Anatomy
(	O
degranulation	O
,	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
)	O
and	O
the	O
recently	O
shown	O
one	O
(	O
presentation	O
of	O
an	O
antigene	O
)	O
.	O
The	O
special	O
attention	O
is	O
focused	O
on	O
the	O
ambiguity	O
of	O
the	O
neutrophil	B-Anatomy
role	O
in	O
oncogenesis	O
.	O
The	O
dominant	O
view	O
is	O
that	O
neutrophils	B-Anatomy
display	O
exclusively	O
antitumor	B-Anatomy
properties	O
.	O
The	O
update	O
information	O
testifies	O
about	O
protumoral	B-Anatomy
activity	O
of	O
neutrophils	B-Anatomy
:	O
they	O
migrate	O
to	O
a	O
tumor	B-Anatomy
and	O
promote	O
angiogenesis	O
and	O
metastasis	O
at	O
late	O
stages	O
of	O
the	O
tumor	B-Anatomy
.	O
It	O
is	O
interesting	O
that	O
certain	O
components	O
of	O
neutrophil	B-Anatomy
cytotoxic	O
arsenal	O
(	O
ROS	O
,	O
cytokines	O
,	O
specific	O
enzymes	O
)	O
participate	O
both	O
in	O
antitumoral	B-Anatomy
defenses	O
of	O
an	O
organism	O
and	O
protumoral	B-Anatomy
activity	O
.	O
Endothelial	B-Anatomy
cell	I-Anatomy
migration	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
expression	O
are	O
the	O
result	O
of	O
loss	O
of	O
breast	B-Anatomy
tissue	I-Anatomy
polarity	O
.	O
Recruiting	O
a	O
new	O
blood	B-Anatomy
supply	O
is	O
a	O
rate	O
-	O
limiting	O
step	O
in	O
tumor	B-Anatomy
progression	O
.	O
In	O
a	O
three	O
-	O
dimensional	O
model	O
of	O
breast	B-Anatomy
carcinogenesis	O
,	O
disorganized	O
,	O
proliferative	O
transformed	O
breast	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
express	O
significantly	O
higher	O
expression	O
of	O
angiogenic	O
genes	O
compared	O
with	O
their	O
polarized	O
,	O
growth	O
-	O
arrested	O
nonmalignant	B-Anatomy
counterparts	I-Anatomy
.	O
Elevated	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
secretion	O
by	O
malignant	B-Anatomy
cells	I-Anatomy
enhanced	O
recruitment	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
(	O
EC	B-Anatomy
)	O
in	O
heterotypic	O
cocultures	O
.	O
Significantly	O
,	O
phenotypic	O
reversion	O
of	O
malignant	B-Anatomy
cells	I-Anatomy
via	O
reexpression	O
of	O
HoxD10	O
,	O
which	O
is	O
lost	O
in	O
malignant	O
progression	O
,	O
significantly	O
attenuated	O
VEGF	O
expression	O
in	O
a	O
hypoxia	O
-	O
inducible	O
factor	O
1alpha	O
-	O
independent	O
fashion	O
and	O
reduced	O
EC	B-Anatomy
migration	O
.	O
This	O
was	O
due	O
primarily	O
to	O
restoring	O
polarity	O
:	O
forced	O
proliferation	O
of	O
polarized	O
,	O
nonmalignant	B-Anatomy
cells	I-Anatomy
did	O
not	O
induce	O
VEGF	O
expression	O
and	O
EC	B-Anatomy
recruitment	O
,	O
whereas	O
disrupting	O
the	O
architecture	O
of	O
growth	O
-	O
arrested	O
,	O
reverted	O
cells	B-Anatomy
did	O
.	O
These	O
data	O
show	O
that	O
disrupting	O
cytostructure	B-Anatomy
activates	O
the	O
angiogenic	O
switch	O
even	O
in	O
the	O
absence	O
of	O
proliferation	O
and	O
/	O
or	O
hypoxia	O
and	O
restoring	O
organization	O
of	O
malignant	B-Anatomy
clusters	I-Anatomy
reduces	O
VEGF	O
expression	O
and	O
EC	B-Anatomy
activation	O
to	O
levels	O
found	O
in	O
quiescent	O
nonmalignant	B-Anatomy
epithelium	I-Anatomy
.	O
These	O
data	O
confirm	O
the	O
importance	O
of	O
tissue	B-Anatomy
architecture	O
and	O
polarity	O
in	O
malignant	O
progression	O
.	O
Aging	O
affects	O
the	O
cardiovascular	B-Anatomy
responses	O
to	O
cold	O
stress	O
in	O
humans	O
.	O
Cardiovascular	B-Anatomy
-	O
related	O
mortality	O
peaks	O
during	O
cold	O
winter	O
months	O
,	O
particularly	O
in	O
older	O
adults	O
.	O
Acute	O
physiological	O
responses	O
,	O
such	O
as	O
increases	O
in	O
blood	B-Anatomy
pressure	O
,	O
in	O
response	O
to	O
cold	O
exposure	O
may	O
contribute	O
to	O
these	O
associations	O
.	O
To	O
determine	O
whether	O
the	O
blood	B-Anatomy
pressure	O
-	O
raising	O
effect	O
(	O
pressor	O
response	O
)	O
of	O
non	O
-	O
internal	O
body	B-Anatomy
temperature	O
-	O
reducing	O
cold	O
stress	O
is	O
greater	O
with	O
age	O
,	O
we	O
measured	O
physiological	O
responses	O
to	O
20	O
min	O
of	O
superficial	O
skin	B-Anatomy
cooling	O
,	O
via	O
water	O
-	O
perfused	O
suit	O
,	O
in	O
12	O
younger	O
[	O
25	O
+	O
/	O
-	O
1	O
(	O
SE	O
)	O
yr	O
old	O
]	O
and	O
12	O
older	O
(	O
65	O
+	O
/	O
-	O
2	O
yr	O
old	O
)	O
adults	O
.	O
We	O
found	O
that	O
superficial	O
skin	B-Anatomy
cooling	O
elicited	O
an	O
increase	O
in	O
blood	B-Anatomy
pressure	O
from	O
resting	O
levels	O
(	O
pressor	O
response	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
younger	O
and	O
older	O
adults	O
.	O
However	O
,	O
the	O
magnitude	O
of	O
this	O
pressor	O
response	O
(	O
systolic	O
and	O
mean	O
blood	B-Anatomy
pressure	O
)	O
was	O
more	O
than	O
twofold	O
higher	O
in	O
older	O
adults	O
(	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
younger	O
adults	O
)	O
.	O
The	O
magnitude	O
of	O
the	O
pressor	O
response	O
was	O
similar	O
at	O
peripheral	O
(	O
brachial	B-Anatomy
)	O
and	O
central	O
(	O
estimated	O
in	O
the	O
aorta	B-Anatomy
)	O
measurement	O
sites	B-Anatomy
.	O
Regression	O
analysis	O
revealed	O
that	O
aortic	B-Anatomy
pulse	O
wave	O
velocity	O
,	O
a	O
measure	O
of	O
central	O
arterial	B-Anatomy
stiffness	O
obtained	O
before	O
cooling	O
,	O
was	O
the	O
best	O
predictor	O
of	O
the	O
increased	O
pressor	O
response	O
to	O
superficial	O
skin	B-Anatomy
cooling	O
in	O
older	O
adults	O
,	O
explaining	O
approximately	O
63	O
%	O
of	O
its	O
variability	O
.	O
These	O
results	O
indicate	O
that	O
there	O
is	O
a	O
greater	O
pressor	O
response	O
to	O
non	O
-	O
internal	O
body	B-Anatomy
temperature	O
-	O
reducing	O
cold	O
stress	O
with	O
age	O
in	O
humans	O
that	O
may	O
be	O
mediated	O
by	O
increased	O
levels	O
of	O
central	O
arterial	B-Anatomy
stiffness	O
.	O
Metronomic	O
5	O
-	O
fluorouracil	O
,	O
oxaliplatin	O
and	O
irinotecan	O
in	O
colorectal	B-Anatomy
cancer	I-Anatomy
.	O
Metronomic	O
chemotherapy	O
(	O
the	O
frequent	O
,	O
long	O
term	O
,	O
low	O
dose	O
administration	O
of	O
chemotherapeutic	O
drugs	O
)	O
is	O
a	O
promising	O
therapy	O
because	O
it	O
enhances	O
the	O
anti	O
-	O
endothelial	B-Anatomy
activity	O
of	O
conventional	O
chemotherapeutics	O
,	O
but	O
with	O
lower	O
or	O
no	O
toxic	O
effects	O
compared	O
to	O
maximum	O
tolerated	O
dose	O
administration	O
.	O
The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
compare	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
the	O
antiangiogenic	O
and	O
antitumor	B-Anatomy
activities	O
of	O
metronomic	O
irinotecan	O
(	O
CPT	O
-	O
11	O
)	O
,	O
oxaliplatin	O
(	O
L	O
-	O
OHP	O
)	O
and	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
in	O
colorectal	B-Anatomy
cancer	I-Anatomy
and	O
to	O
investigate	O
the	O
metronomic	O
combination	O
of	O
these	O
drugs	O
.	O
In	O
vitro	O
cell	B-Anatomy
proliferation	O
,	O
combination	O
studies	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
secretion	O
analyses	O
were	O
performed	O
on	O
endothelial	B-Anatomy
(	I-Anatomy
HMVEC	I-Anatomy
-	I-Anatomy
d	I-Anatomy
)	I-Anatomy
and	O
colorectal	B-Anatomy
cancer	I-Anatomy
(	I-Anatomy
HT	I-Anatomy
-	I-Anatomy
29	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
exposed	O
for	O
144	O
h	O
to	O
metronomic	O
concentrations	O
of	O
SN	O
-	O
38	O
,	O
the	O
active	O
metabolite	O
of	O
CPT	O
-	O
11	O
,	O
L	O
-	O
OHP	O
and	O
5	O
-	O
FU	O
.	O
HT	B-Anatomy
-	I-Anatomy
29	I-Anatomy
human	O
colorectal	B-Anatomy
cancer	I-Anatomy
xenograft	I-Anatomy
model	O
was	O
used	O
and	O
tumour	B-Anatomy
growth	O
,	O
microvessel	B-Anatomy
density	O
and	O
VEGF	O
quantification	O
were	O
performed	O
in	O
tumours	B-Anatomy
after	O
the	O
administration	O
of	O
metronomic	O
CPT	O
-	O
11	O
,	O
L	O
-	O
OHP	O
,	O
5	O
-	O
FU	O
and	O
their	O
simultaneous	O
combination	O
.	O
Low	O
concentrations	O
of	O
SN	O
-	O
38	O
,	O
but	O
not	O
5	O
-	O
FU	O
and	O
L	O
-	O
OHP	O
,	O
preferentially	O
inhibited	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
.	O
Simultaneous	O
and	O
continuous	O
exposure	O
of	O
HT	B-Anatomy
-	I-Anatomy
29	I-Anatomy
and	O
HMVEC	B-Anatomy
-	I-Anatomy
d	I-Anatomy
cells	I-Anatomy
to	O
low	O
concentrations	O
SN	O
-	O
38	O
+	O
L	O
-	O
OHP	O
+	O
5	O
-	O
FU	O
for	O
144	O
h	O
showed	O
a	O
strong	O
antagonism	O
and	O
an	O
unfavorable	O
dose	O
-	O
reduction	O
index	O
.	O
Moreover	O
,	O
the	O
ternary	O
combination	O
resulted	O
in	O
a	O
significant	O
increase	O
of	O
VEGF	O
secretion	O
in	O
HT	B-Anatomy
-	I-Anatomy
29	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
In	O
a	O
xenograft	B-Anatomy
model	O
metronomic	O
CPT	O
-	O
11	O
,	O
but	O
not	O
5	O
-	O
FU	O
and	O
L	O
-	O
OHP	O
,	O
significantly	O
inhibits	O
HT	B-Anatomy
-	I-Anatomy
29	I-Anatomy
tumor	I-Anatomy
growth	O
and	O
microvessel	B-Anatomy
density	O
in	O
the	O
absence	O
of	O
toxicity	O
.	O
On	O
the	O
contrary	O
,	O
metronomic	O
5	O
-	O
FU	O
+	O
L	O
-	O
OHP	O
+	O
CPT	O
-	O
11	O
therapy	O
did	O
not	O
affect	O
the	O
microvascular	B-Anatomy
count	O
.	O
The	O
metronomic	O
concept	O
might	O
not	O
universally	O
apply	O
to	O
every	O
cytotoxic	O
drug	O
in	O
colorectal	B-Anatomy
cancer	I-Anatomy
and	O
metronomic	O
combination	O
regimens	O
should	O
be	O
used	O
with	O
caution	O
.	O
A	O
key	O
role	O
for	O
the	O
integrin	O
alpha2beta1	O
in	O
experimental	O
and	O
developmental	O
angiogenesis	O
.	O
The	O
alpha2beta1	O
integrin	O
receptor	O
plays	O
a	O
key	O
role	O
in	O
angiogenesis	O
.	O
Here	O
we	O
investigated	O
the	O
effects	O
of	O
small	O
molecule	O
inhibitors	O
(	O
SMIs	O
)	O
designed	O
to	O
disrupt	O
integrin	O
alpha2	O
I	O
or	O
beta1	O
I	O
-	O
like	O
domain	O
function	O
on	O
angiogenesis	O
.	O
In	O
unchallenged	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
fibrillar	B-Anatomy
collagen	O
induced	O
robust	O
capillary	B-Anatomy
morphogenesis	O
.	O
In	O
contrast	O
,	O
tube	B-Anatomy
formation	O
was	O
significantly	O
reduced	O
by	O
SMI496	O
,	O
a	O
beta1	O
I	O
-	O
like	O
domain	O
inhibitor	O
and	O
by	O
function	O
-	O
blocking	O
anti	O
-	O
alpha2beta1	O
but	O
not	O
-	O
alpha1beta1	O
antibodies	O
.	O
Endothelial	B-Anatomy
cells	I-Anatomy
bound	O
fluorescein	O
-	O
labeled	O
collagen	O
I	O
fibrils	B-Anatomy
,	O
an	O
interaction	O
specifically	O
inhibited	O
by	O
SMI496	O
.	O
Moreover	O
,	O
SMI496	O
caused	O
cell	B-Anatomy
retraction	O
and	O
cytoskeletal	B-Anatomy
collapse	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
as	O
well	O
as	O
delayed	O
endothelial	B-Anatomy
cell	I-Anatomy
wound	B-Anatomy
healing	O
.	O
SMI	O
activities	O
were	O
examined	O
in	O
vivo	O
by	O
supplementing	O
the	O
growth	O
medium	O
of	O
zebrafish	O
embryos	B-Anatomy
expressing	O
green	O
fluorescent	O
protein	O
under	O
the	O
control	O
of	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
2	O
promoter	O
.	O
SMI496	O
,	O
but	O
not	O
a	O
control	O
compound	O
,	O
interfered	O
with	O
angiogenesis	O
in	O
vivo	O
by	O
reversibly	O
inhibiting	O
sprouting	O
from	O
the	O
axial	B-Anatomy
vessels	I-Anatomy
.	O
We	O
further	O
characterized	O
zebrafish	O
alpha2	O
integrin	O
and	O
discovered	O
that	O
this	O
integrin	O
is	O
highly	O
conserved	O
,	O
especially	O
the	O
I	O
domain	O
.	O
Notably	O
,	O
a	O
similar	O
vascular	B-Anatomy
phenotype	O
was	O
induced	O
by	O
morpholino	O
-	O
mediated	O
knockdown	O
of	O
the	O
integrin	O
alpha2	O
subunit	O
.	O
By	O
live	O
videomicroscopy	O
,	O
we	O
confirmed	O
that	O
the	O
vessels	B-Anatomy
were	O
largely	O
nonfunctional	O
in	O
the	O
absence	O
of	O
alpha2beta1	O
integrin	O
.	O
Collectively	O
,	O
our	O
results	O
provide	O
strong	O
biochemical	O
and	O
genetic	O
evidence	O
of	O
a	O
central	O
role	O
for	O
alpha2beta1	O
integrin	O
in	O
experimental	O
and	O
developmental	O
angiogenesis	O
.	O
[	O
The	O
value	O
of	O
intermittent	O
ultrasound	O
treatment	O
in	O
subacromial	O
impingement	O
syndrome	O
]	O
.	O
OBJECTIVES	O
:	O
The	O
role	O
of	O
intermittent	O
ultrasound	O
in	O
the	O
conservative	O
treatment	O
of	O
subacromial	O
impingement	O
syndrome	O
(	O
SIS	O
)	O
has	O
not	O
been	O
clarified	O
.	O
We	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
of	O
ultrasound	O
treatment	O
in	O
SIS	O
.	O
METHODS	O
:	O
Thirty	O
-	O
six	O
patients	O
(	O
29	O
females	O
,	O
7	O
males	O
;	O
mean	O
age	O
51	O
years	O
;	O
range	O
40	O
to	O
69	O
years	O
)	O
with	O
type	O
II	O
SIS	O
were	O
randomized	O
to	O
two	O
groups	O
to	O
receive	O
intermittent	O
ultrasound	O
(	O
group	O
1	O
,	O
n	O
=	O
20	O
)	O
and	O
placebo	O
ultrasound	O
(	O
group	O
2	O
,	O
n	O
=	O
16	O
)	O
for	O
three	O
weeks	O
(	O
15	O
sessions	O
)	O
.	O
All	O
the	O
patients	O
received	O
the	O
same	O
standard	O
physical	O
therapy	O
and	O
rehabilitation	O
modalities	O
besides	O
ultrasound	O
treatment	O
.	O
Evaluations	O
were	O
made	O
before	O
and	O
three	O
and	O
six	O
weeks	O
after	O
treatment	O
.	O
Functional	O
results	O
were	O
assessed	O
by	O
the	O
Constant	O
score	O
,	O
pain	O
was	O
assessed	O
by	O
a	O
visual	O
analog	O
scale	O
,	O
and	O
range	O
of	O
motion	O
was	O
measured	O
.	O
RESULTS	O
:	O
Within	O
-	O
group	O
comparisons	O
showed	O
significant	O
improvements	O
in	O
both	O
groups	O
three	O
and	O
six	O
weeks	O
after	O
treatment	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Comparison	O
between	O
pretreatment	O
and	O
6	O
-	O
week	O
values	O
were	O
as	O
follows	O
:	O
the	O
mean	O
flexion	O
increased	O
from	O
148	O
.	O
8	O
+	O
/	O
-	O
20	O
.	O
4	O
degrees	O
to	O
175	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
0	O
degrees	O
in	O
group	O
1	O
,	O
and	O
from	O
165	O
.	O
9	O
+	O
/	O
-	O
14	O
.	O
1	O
degrees	O
to	O
177	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
4	O
degrees	O
in	O
group	O
2	O
;	O
internal	O
and	O
external	O
rotation	O
increased	O
from	O
66	O
.	O
8	O
+	O
/	O
-	O
20	O
.	O
7	O
degrees	O
and	O
61	O
.	O
9	O
+	O
/	O
-	O
22	O
.	O
9	O
degrees	O
to	O
83	O
.	O
2	O
+	O
/	O
-	O
10	O
.	O
9	O
degrees	O
and	O
84	O
.	O
4	O
+	O
/	O
-	O
9	O
.	O
6	O
degrees	O
in	O
group	O
1	O
,	O
and	O
from	O
75	O
.	O
0	O
+	O
/	O
-	O
17	O
.	O
3	O
degrees	O
and	O
70	O
.	O
0	O
+	O
/	O
-	O
19	O
.	O
8	O
degrees	O
to	O
87	O
.	O
1	O
+	O
/	O
-	O
6	O
.	O
8	O
degrees	O
and	O
84	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
4	O
degrees	O
in	O
group	O
2	O
,	O
respectively	O
.	O
There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
with	O
respect	O
to	O
the	O
range	O
of	O
motion	O
at	O
the	O
end	O
of	O
six	O
weeks	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O
The	O
Constant	O
score	O
improved	O
from	O
43	O
.	O
7	O
+	O
/	O
-	O
12	O
.	O
9	O
to	O
65	O
.	O
7	O
+	O
/	O
-	O
7	O
.	O
7	O
in	O
group	O
1	O
,	O
and	O
from	O
43	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
4	O
to	O
65	O
.	O
3	O
+	O
/	O
-	O
7	O
.	O
6	O
in	O
group	O
2	O
.	O
Pain	O
scores	O
decreased	O
from	O
5	O
.	O
5	O
to	O
2	O
and	O
from	O
5	O
to	O
1	O
in	O
group	O
1	O
and	O
2	O
,	O
respectively	O
.	O
Improvements	O
in	O
Constant	O
scores	O
and	O
pain	O
scores	O
were	O
similar	O
in	O
both	O
groups	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O
CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
intermittent	O
ultrasound	O
added	O
to	O
conservative	O
treatment	O
of	O
SIS	O
do	O
not	O
provide	O
an	O
additional	O
benefit	O
to	O
the	O
patients	O
.	O
Islet	B-Anatomy
endothelial	I-Anatomy
activation	O
and	O
oxidative	O
stress	O
gene	O
expression	O
is	O
reduced	O
by	O
IL	O
-	O
1Ra	O
treatment	O
in	O
the	O
type	O
2	O
diabetic	O
GK	O
rat	O
.	O
BACKGROUND	O
:	O
Inflammation	O
followed	O
by	O
fibrosis	O
is	O
a	O
component	O
of	O
islet	B-Anatomy
dysfunction	O
in	O
both	O
rodent	O
and	O
human	O
type	O
2	O
diabetes	O
.	O
Because	O
islet	B-Anatomy
inflammation	O
may	O
originate	O
from	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
we	O
assessed	O
the	O
expression	O
of	O
selected	O
genes	O
involved	O
in	O
endothelial	B-Anatomy
cell	I-Anatomy
activation	O
in	O
islets	B-Anatomy
from	O
a	O
spontaneous	O
model	O
of	O
type	O
2	O
diabetes	O
,	O
the	O
Goto	O
-	O
Kakizaki	O
(	O
GK	O
)	O
rat	O
.	O
We	O
also	O
examined	O
islet	B-Anatomy
endotheliuml	I-Anatomy
/	O
oxidative	O
stress	O
(	O
OS	O
)	O
/	O
inflammation	O
-	O
related	O
gene	O
expression	O
,	O
islet	B-Anatomy
vascularization	O
and	O
fibrosis	O
after	O
treatment	O
with	O
the	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
receptor	O
antagonist	O
(	O
IL	O
-	O
1Ra	O
)	O
.	O
METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Gene	O
expression	O
was	O
analyzed	O
by	O
quantitative	O
RT	O
-	O
PCR	O
on	O
islets	B-Anatomy
isolated	O
from	O
10	O
-	O
week	O
-	O
old	O
diabetic	O
GK	O
and	O
control	O
Wistar	O
rats	O
.	O
Furthermore	O
,	O
GK	O
rats	O
were	O
treated	O
s	O
.	O
c	O
twice	O
daily	O
with	O
IL	O
-	O
1Ra	O
(	O
Kineret	O
,	O
Amgen	O
,	O
100	O
mg	O
/	O
kg	O
/	O
day	O
)	O
or	O
saline	O
,	O
from	O
4	O
weeks	O
of	O
age	O
onwards	O
(	O
onset	O
of	O
diabetes	O
)	O
.	O
Four	O
weeks	O
later	O
,	O
islet	B-Anatomy
gene	O
analysis	O
and	O
pancreas	B-Anatomy
immunochemistry	O
were	O
performed	O
.	O
Thirty	O
-	O
two	O
genes	O
were	O
selected	O
encoding	O
molecules	O
involved	O
in	O
endothelial	B-Anatomy
cell	I-Anatomy
activation	O
,	O
particularly	O
fibrinolysis	O
,	O
vascular	B-Anatomy
tone	O
,	O
OS	O
,	O
angiogenesis	O
and	O
also	O
inflammation	O
.	O
All	O
genes	O
except	O
those	O
encoding	O
angiotensinogen	O
and	O
epoxide	O
hydrolase	O
(	O
that	O
were	O
decreased	O
)	O
,	O
and	O
12	O
-	O
lipoxygenase	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
that	O
showed	O
no	O
change	O
)	O
,	O
were	O
significantly	O
up	O
-	O
regulated	O
in	O
GK	O
islets	B-Anatomy
.	O
After	O
IL	O
-	O
1Ra	O
treatment	O
of	O
GK	O
rats	O
in	O
vivo	O
,	O
most	O
selected	O
genes	O
implied	O
in	O
endothelium	B-Anatomy
/	O
OS	O
/	O
immune	B-Anatomy
cells	I-Anatomy
/	O
fibrosis	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O
IL	O
-	O
1Ra	O
also	O
improved	O
islet	B-Anatomy
vascularization	O
,	O
reduced	O
fibrosis	O
and	O
ameliorated	O
glycemia	O
.	O
CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
GK	O
rat	O
islets	B-Anatomy
have	O
increased	O
mRNA	O
expression	O
of	O
markers	O
of	O
early	O
islet	B-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
activation	O
,	O
possibly	O
triggered	O
by	O
several	O
metabolic	O
factors	O
,	O
and	O
also	O
some	O
defense	O
mechanisms	O
.	O
The	O
beneficial	O
effect	O
of	O
IL	O
-	O
1Ra	O
on	O
most	O
islet	B-Anatomy
endothelial	I-Anatomy
/	O
OS	O
/	O
immune	B-Anatomy
cells	I-Anatomy
/	O
fibrosis	O
parameters	O
analyzed	O
highlights	O
a	O
major	O
endothelial	B-Anatomy
-	O
related	O
role	O
for	O
IL	O
-	O
1	O
in	O
GK	O
islet	B-Anatomy
alterations	O
.	O
Thus	O
,	O
metabolically	O
-	O
altered	O
islet	B-Anatomy
endothelium	I-Anatomy
might	O
affect	O
the	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
microenvironment	O
and	O
contribute	O
to	O
progressive	O
type	O
2	O
diabetic	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
dysfunction	O
in	O
GK	O
rats	O
.	O
Counteracting	O
islet	B-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
inflammation	O
might	O
be	O
one	O
way	O
to	O
ameliorate	O
/	O
prevent	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
dysfunction	O
in	O
type	O
2	O
diabetes	O
.	O
Magnesium	O
for	O
treatment	O
of	O
asthma	O
in	O
children	O
.	O
QUESTION	O
:	O
Magnesium	O
is	O
considered	O
adjuvant	O
therapy	O
for	O
moderate	O
to	O
severe	O
asthma	O
exacerbations	O
in	O
adults	O
,	O
but	O
can	O
it	O
be	O
used	O
to	O
treat	O
children	O
?	O
ANSWER	O
:	O
Magnesium	O
seems	O
to	O
be	O
beneficial	O
in	O
the	O
treatment	O
of	O
moderate	O
to	O
severe	O
asthma	O
in	O
children	O
.	O
It	O
is	O
a	O
safe	O
drug	O
to	O
administer	O
,	O
but	O
there	O
have	O
been	O
minor	O
side	O
effects	O
reported	O
,	O
such	O
as	O
epigastric	B-Anatomy
or	O
facial	B-Anatomy
warmth	O
,	O
flushing	O
,	O
pain	O
and	O
numbness	O
at	O
the	O
infusion	O
site	B-Anatomy
,	O
dry	O
mouth	B-Anatomy
,	O
malaise	O
,	O
and	O
hypotension	O
.	O
Owing	O
to	O
its	O
bronchodilating	O
and	O
anti	O
-	O
inflammatory	O
effects	O
,	O
magnesium	O
is	O
an	O
encouraging	O
adjuvant	O
therapy	O
for	O
pediatric	O
patients	O
who	O
do	O
not	O
respond	O
to	O
conventional	O
treatment	O
in	O
acute	O
severe	O
exacerbations	O
.	O
Future	O
studies	O
should	O
focus	O
on	O
establishing	O
the	O
optimal	O
dosage	O
for	O
maximal	O
benefits	O
and	O
the	O
best	O
route	O
of	O
administration	O
.	O
Magnesium	O
should	O
also	O
be	O
considered	O
as	O
a	O
prophylactic	O
treatment	O
.	O
AVE8062	O
:	O
a	O
new	O
combretastatin	O
derivative	O
vascular	B-Anatomy
disrupting	O
agent	O
.	O
Angiogenesis	O
has	O
an	O
essential	O
role	O
in	O
promoting	O
and	O
supporting	O
tumor	B-Anatomy
growth	O
and	O
it	O
is	O
an	O
important	O
therapeutic	O
target	O
.	O
The	O
tumor	B-Anatomy
vascular	I-Anatomy
network	I-Anatomy
is	O
the	O
result	O
of	O
pro	O
-	O
angiogenic	O
and	O
inhibitory	O
factors	O
as	O
well	O
as	O
of	O
the	O
interaction	O
between	O
endothelial	B-Anatomy
cells	I-Anatomy
and	O
extracellular	B-Anatomy
matrix	I-Anatomy
.	O
Different	O
antiangiogenic	O
therapeutics	O
have	O
been	O
developed	O
to	O
improve	O
tumor	B-Anatomy
control	O
through	O
vascular	B-Anatomy
-	O
targeting	O
agents	O
(	O
VTA	O
)	O
.	O
VTAs	O
can	O
be	O
divided	O
into	O
two	O
groups	O
:	O
antiangiogenic	O
agents	O
and	O
vascular	B-Anatomy
-	O
disrupting	O
agents	O
(	O
VDAs	O
)	O
.	O
VTAs	O
inhibit	O
specific	O
factors	O
required	O
to	O
induce	O
and	O
direct	O
the	O
angiogenic	O
process	O
,	O
with	O
major	O
activity	O
against	O
small	O
tumor	B-Anatomy
masses	I-Anatomy
and	O
at	O
the	O
tumor	B-Anatomy
periphery	I-Anatomy
,	O
encompassing	O
monoclonal	O
antibodies	O
and	O
small	O
molecules	O
inhibitors	O
of	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
VEGF	O
receptor	O
.	O
VDAs	O
specifically	O
target	O
and	O
destroy	O
well	O
-	O
established	O
tumor	B-Anatomy
vessels	I-Anatomy
with	O
ischemia	O
and	O
destruction	O
of	O
large	O
masses	B-Anatomy
with	O
central	O
hemorrhagic	O
necrosis	O
and	O
survival	O
of	O
a	O
thin	O
peripheral	B-Anatomy
tumor	I-Anatomy
layer	I-Anatomy
.	O
VDAs	O
can	O
be	O
divided	O
into	O
biologics	O
,	O
such	O
as	O
ligand	O
-	O
based	O
,	O
and	O
small	O
-	O
molecule	O
agents	O
;	O
this	O
second	O
group	O
includes	O
small	O
-	O
molecule	O
VDAs	O
like	O
flavonoids	O
,	O
such	O
as	O
5	O
,	O
6	O
-	O
dimethylxanthenone	O
-	O
4	O
-	O
acetic	O
acid	O
(	O
DMXAA	O
)	O
,	O
and	O
microtubule	B-Anatomy
-	O
destabilizing	O
agents	O
.	O
In	O
this	O
review	O
we	O
will	O
discuss	O
the	O
mechanism	O
of	O
action	O
,	O
as	O
well	O
as	O
the	O
preclinical	O
and	O
clinical	O
results	O
,	O
of	O
one	O
of	O
the	O
most	O
promising	O
antitubulin	O
agents	O
:	O
the	O
combretastatin	O
A4	O
-	O
phosphate	O
derivative	O
,	O
AVE8062A	O
.	O
Targeting	O
TNF	O
for	O
Treatment	O
of	O
Cancer	B-Anatomy
and	O
Autoimmunity	O
.	O
Tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
was	O
first	O
isolated	O
two	O
decades	O
ago	O
as	O
a	O
macrophageproduced	O
protein	O
that	O
can	O
effectively	O
kill	O
tumor	B-Anatomy
cells	I-Anatomy
.	O
TNF	O
-	O
alpha	O
is	O
also	O
an	O
essential	O
component	O
of	O
the	O
immune	B-Anatomy
system	I-Anatomy
and	O
is	O
required	O
for	O
hematopoiesis	O
,	O
for	O
protection	O
from	O
bacterial	O
infection	O
and	O
for	O
immune	B-Anatomy
cell	I-Anatomy
-	O
mediated	O
cytotoxicity	O
.	O
Extensive	O
research	O
,	O
however	O
,	O
has	O
revealed	O
that	O
TNF	O
-	O
alpha	O
is	O
one	O
of	O
the	O
major	O
players	O
in	O
tumor	B-Anatomy
initiation	O
,	O
proliferation	O
,	O
invasion	O
,	O
angiogenesis	O
and	O
metastasis	O
.	O
The	O
proinflammatory	O
activities	O
link	O
TNF	O
-	O
alpha	O
with	O
a	O
wide	O
variety	O
of	O
autoimmune	O
diseases	O
,	O
including	O
psoriasis	O
,	O
inflammatory	O
bowel	B-Anatomy
disease	O
,	O
rheumatoid	O
arthritis	O
,	O
systemic	O
sclerosis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
multiple	O
sclerosis	O
,	O
diabetes	O
and	O
ankylosing	O
spondylitis	O
.	O
Systemic	O
inhibitors	O
of	O
TNF	O
such	O
as	O
etanercept	O
(	O
Enbrel	O
)	O
(	O
a	O
soluble	O
TNF	O
receptor	O
)	O
and	O
infliximab	O
(	O
Remicade	O
)	O
and	O
adalimumab	O
(	O
Humira	O
)	O
(	O
anti	O
-	O
TNF	O
antibodies	O
)	O
have	O
been	O
approved	O
for	O
the	O
treatment	O
inflammatory	O
bowel	B-Anatomy
disease	O
,	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
.	O
These	O
drugs	O
,	O
however	O
,	O
exhibit	O
severe	O
side	O
effects	O
and	O
are	O
expensive	O
.	O
Hence	O
orally	B-Anatomy
active	O
blockers	O
of	O
TNF	O
-	O
alpha	O
that	O
are	O
safe	O
,	O
efficacious	O
and	O
inexpensive	O
are	O
urgently	O
needed	O
.	O
Numerous	O
products	O
from	O
fruits	B-Anatomy
,	O
vegetable	B-Anatomy
and	O
traditional	O
medicinal	O
plants	O
have	O
been	O
described	O
which	O
can	O
suppress	O
TNF	O
expression	O
and	O
TNF	O
signaling	O
but	O
their	O
clinical	O
potential	O
is	O
yet	O
uncertain	O
.	O
[	O
Effect	O
of	O
osteopontin	O
silencing	O
by	O
lentivirus	O
-	O
mediated	O
delivery	O
of	O
siRNA	O
on	O
glioma	B-Anatomy
cell	I-Anatomy
invasion	O
and	O
apoptosis	O
]	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
osteopontin	O
silencing	O
on	O
the	O
invasion	O
and	O
apoptosis	O
of	O
U251	B-Anatomy
cells	I-Anatomy
.	O
METHODS	O
:	O
The	O
invasion	O
,	O
apoptosis	O
and	O
levels	O
of	O
uPA	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
were	O
determined	O
by	O
invasion	O
assay	O
,	O
flow	O
cytometry	O
,	O
Western	O
blot	O
and	O
real	O
-	O
time	O
fluorescence	O
quantitative	O
PCR	O
respectively	O
.	O
RESULTS	O
:	O
Osteopontin	O
small	O
interference	O
RNA	O
(	O
siRNA	O
)	O
inhibited	O
osteopontin	O
expression	O
and	O
cell	B-Anatomy
invasion	O
,	O
promoted	O
apoptosis	O
in	O
U251	B-Anatomy
cells	I-Anatomy
.	O
In	O
addition	O
,	O
the	O
expression	O
of	O
Bcl	O
-	O
2	O
,	O
uPA	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
was	O
decreased	O
,	O
while	O
Bax	O
level	O
was	O
elevated	O
.	O
CONCLUSION	O
:	O
Osteopontin	O
siRNA	O
can	O
inhibit	O
U251	B-Anatomy
cells	I-Anatomy
invasion	O
via	O
the	O
down	O
-	O
regulation	O
of	O
uPA	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
levels	O
,	O
and	O
promote	O
apoptosis	O
through	O
induction	O
of	O
Bax	O
expression	O
and	O
inhibition	O
of	O
Bcl	O
2	O
level	O
.	O
It	O
suggests	O
that	O
osteopontin	O
plays	O
an	O
important	O
role	O
in	O
human	O
glioma	B-Anatomy
progression	O
.	O
Magnitude	O
of	O
malate	O
-	O
aspartate	O
reduced	O
nicotinamide	O
adenine	O
dinucleotide	O
shuttle	O
activity	O
in	O
intact	O
respiring	O
tumor	B-Anatomy
cells	I-Anatomy
.	O
Measurements	O
of	O
respiration	O
,	O
CO2	O
and	O
lactate	O
production	O
,	O
and	O
changes	O
in	O
the	O
levels	O
of	O
various	O
key	O
metabolites	O
of	O
the	O
glycolytic	O
sequence	O
and	O
tricarboxylic	O
acid	O
cycle	O
were	O
made	O
on	O
five	O
lines	O
of	O
rodent	O
ascites	B-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
(	O
two	O
strains	B-Anatomy
of	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
,	O
Krebs	B-Anatomy
II	I-Anatomy
carcinoma	I-Anatomy
,	O
AS	B-Anatomy
-	I-Anatomy
30D	I-Anatomy
carcinoma	I-Anatomy
,	O
and	O
L1210	B-Anatomy
cells	I-Anatomy
)	O
incubated	O
aerobically	O
in	O
the	O
presence	O
of	O
uniformly	O
labeled	O
D	O
-	O
[	O
14C	O
]	O
glucose	O
.	O
From	O
these	O
data	O
,	O
as	O
well	O
as	O
earlier	O
evidence	O
demonstrating	O
that	O
the	O
reduced	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NADH	O
)	O
shuttle	O
in	O
these	O
cells	B-Anatomy
requires	O
a	O
transaminase	O
step	O
and	O
is	O
thus	O
identified	O
as	O
the	O
malate	O
-	O
aspartate	O
shuttle	O
(	O
W	O
.	O
V	O
.	O
V	O
.	O
Greenhouse	O
and	O
A	O
.	O
L	O
.	O
Lehninger	O
,	O
Cancer	O
Res	O
.	O
,	O
36	O
:	O
1392	O
-	O
1396	O
,	O
1976	O
)	O
,	O
metabolic	O
flux	O
diagrams	O
were	O
constructed	O
for	O
the	O
five	O
cell	B-Anatomy
lines	I-Anatomy
.	O
These	O
diagrams	O
show	O
the	O
relative	O
rates	O
of	O
glycolysis	O
,	O
the	O
tricarboxylic	O
acid	O
cycle	O
,	O
electron	O
transport	O
,	O
and	O
the	O
malate	O
-	O
aspartate	O
shuttle	O
in	O
these	O
tumors	B-Anatomy
.	O
Large	O
amounts	O
of	O
cytosolic	B-Anatomy
NADH	O
were	O
oxidized	O
by	O
the	O
mitochondrial	B-Anatomy
respiratory	O
chain	O
via	O
the	O
NADH	O
shuttle	O
,	O
comprising	O
anywhere	O
from	O
about	O
20	O
to	O
80	O
%	O
of	O
the	O
total	O
flow	O
of	O
reducing	O
equivalents	O
to	O
oxygen	O
in	O
these	O
tumors	B-Anatomy
.	O
Calculations	O
of	O
the	O
sources	O
of	O
energy	O
for	O
adenosine	O
triphosphate	O
synthesis	O
indicated	O
that	O
on	O
the	O
average	O
about	O
one	O
-	O
third	O
of	O
the	O
respiratory	O
adenosine	O
triphosphate	O
is	O
generated	O
by	O
electron	O
flow	O
originating	O
from	O
cytosolic	B-Anatomy
NADH	O
via	O
the	O
malate	O
-	O
aspartate	O
shuttle	O
.	O
AKT2	O
is	O
a	O
downstream	O
target	O
of	O
metabotropic	O
glutamate	O
receptor	O
1	O
(	O
Grm1	O
)	O
.	O
We	O
reported	O
earlier	O
on	O
the	O
oncogenic	O
properties	O
of	O
Grm1	O
by	O
demonstrating	O
that	O
stable	O
Grm1	O
-	O
mouse	O
-	O
melanocytic	B-Anatomy
clones	I-Anatomy
proliferate	O
in	O
the	O
absence	O
of	O
growth	O
supplement	O
and	O
anchorage	O
in	O
vitro	O
.	O
In	O
addition	O
,	O
these	O
clones	B-Anatomy
also	O
exhibit	O
aggressive	O
tumorigenic	O
phenotypes	O
in	O
vivo	O
with	O
short	O
latency	O
in	O
tumor	B-Anatomy
formation	O
in	O
both	O
immunodeficient	O
and	O
syngeneic	O
mice	O
.	O
We	O
also	O
detected	O
strong	O
activation	O
of	O
AKT	O
in	O
allograft	B-Anatomy
tumors	I-Anatomy
specifically	O
AKT2	O
as	O
the	O
predominant	O
isoform	O
involved	O
.	O
In	O
parallel	O
,	O
we	O
assessed	O
several	O
human	O
melanoma	B-Anatomy
biopsy	I-Anatomy
samples	I-Anatomy
and	O
found	O
again	O
that	O
AKT2	O
was	O
the	O
predominantly	O
activated	O
AKT	O
in	O
these	O
human	O
melanoma	B-Anatomy
biopsies	I-Anatomy
.	O
In	O
cultured	O
stable	O
Grm1	O
-	O
mouse	O
-	O
melanocytic	B-Anatomy
clones	I-Anatomy
,	O
as	O
well	O
as	O
an	O
metabotropic	O
glutamate	O
receptor	O
1	O
(	O
Grm1	O
)	O
expressing	O
human	O
melanoma	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	I-Anatomy
C8161	I-Anatomy
,	O
stimulation	O
of	O
Grm1	O
by	O
its	O
agonist	O
led	O
to	O
the	O
activation	O
of	O
AKT	O
,	O
while	O
preincubation	O
with	O
Grm1	O
-	O
antagonist	O
abolished	O
Grm1	O
-	O
agonist	O
-	O
induced	O
AKT	O
activation	O
.	O
In	O
addition	O
,	O
a	O
reduction	O
in	O
tumor	B-Anatomy
volume	O
of	O
Grm1	O
-	O
mouse	O
-	O
melanocytic	B-Anatomy
-	I-Anatomy
allografts	I-Anatomy
was	O
detected	O
in	O
the	O
presence	O
of	O
small	O
interfering	O
AKT2	O
RNA	O
(	O
siAKT2	O
)	O
.	O
Taken	O
together	O
,	O
these	O
results	O
showed	O
that	O
,	O
in	O
addition	O
to	O
the	O
MAPK	O
pathway	O
previously	O
reported	O
being	O
a	O
downstream	O
target	O
of	O
stimulated	O
Grm1	O
,	O
AKT2	O
is	O
another	O
downstream	O
target	O
in	O
Grm1	O
mediated	O
melanocyte	B-Anatomy
transformation	O
.	O
Effectiveness	O
of	O
different	O
approaches	O
for	O
establishing	O
cisplatin	O
-	O
induced	O
cochlear	B-Anatomy
lesions	I-Anatomy
in	O
mice	O
.	O
CONCLUSIONS	O
:	O
Mouse	O
cochleae	B-Anatomy
are	O
highly	O
resistant	O
to	O
systemically	O
administered	O
cisplatin	O
.	O
However	O
,	O
cochlear	B-Anatomy
lesions	I-Anatomy
can	O
be	O
produced	O
effectively	O
in	O
mice	O
when	O
cisplatin	O
is	O
applied	O
locally	O
through	O
the	O
round	B-Anatomy
window	I-Anatomy
niche	I-Anatomy
or	O
tympanum	B-Anatomy
.	O
OBJECTIVE	O
:	O
To	O
explore	O
the	O
optimal	O
approach	O
for	O
creating	O
cisplatin	O
-	O
induced	O
cochlear	B-Anatomy
lesions	I-Anatomy
in	O
mice	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Cisplatin	O
was	O
administered	O
to	O
adult	O
C57BL	O
/	O
6J	O
mice	O
via	O
four	O
approaches	O
:	O
(	O
1	O
)	O
transtympanic	B-Anatomy
injection	O
,	O
(	O
2	O
)	O
round	B-Anatomy
window	I-Anatomy
niche	I-Anatomy
injection	O
,	O
(	O
3	O
)	O
intraperitoneal	B-Anatomy
injection	O
(	O
i	O
.	O
p	O
.	O
)	O
at	O
4	O
mg	O
/	O
kg	O
/	O
day	O
for	O
4	O
consecutive	O
days	O
,	O
and	O
(	O
4	O
)	O
one	O
15	O
mg	O
/	O
kg	O
dose	O
i	O
.	O
p	O
.	O
The	O
hearing	O
was	O
monitored	O
using	O
frequency	O
-	O
specific	O
auditory	O
brainstem	B-Anatomy
responses	O
(	O
ABRs	O
)	O
and	O
distortion	O
-	O
product	O
otoacoustic	O
emissions	O
(	O
DPOAEs	O
)	O
.	O
Cochlear	B-Anatomy
pathology	O
was	O
observed	O
in	O
cochleograms	O
with	O
Harris	O
'	O
hematoxylin	O
staining	O
.	O
RESULTS	O
:	O
Cisplatin	O
applied	O
systemically	O
did	O
not	O
cause	O
any	O
significant	O
ABR	O
threshold	O
elevation	O
across	O
the	O
frequencies	O
tested	O
(	O
2	O
-	O
32	O
kHz	O
)	O
,	O
whereas	O
local	O
application	O
of	O
cisplatin	O
through	O
the	O
round	B-Anatomy
window	I-Anatomy
niche	I-Anatomy
or	O
tympanum	B-Anatomy
resulted	O
in	O
significant	O
ABR	O
threshold	O
elevations	O
from	O
high	O
to	O
medium	O
frequencies	O
.	O
The	O
functional	O
changes	O
were	O
consistent	O
with	O
the	O
cochlear	B-Anatomy
pathology	O
across	O
groups	O
.	O
[	O
Reconstruction	O
of	O
hepatic	B-Anatomy
artery	I-Anatomy
in	O
adult	O
to	O
adult	O
living	O
donor	O
liver	B-Anatomy
transplantation	O
in	O
104	O
patients	O
]	O
.	O
OBJECTIVE	O
:	O
To	O
report	O
the	O
experience	O
of	O
hepatic	B-Anatomy
artery	I-Anatomy
reconstruction	O
with	O
adult	O
-	O
to	O
-	O
adult	O
living	O
donor	O
liver	B-Anatomy
transplantation	O
(	O
ALDLT	O
)	O
using	O
right	B-Anatomy
lobe	I-Anatomy
liver	I-Anatomy
grafts	I-Anatomy
.	O
METHODS	O
:	O
From	O
January	O
2002	O
to	O
August	O
2007	O
,	O
104	O
patients	O
underwent	O
ALDLT	O
using	O
right	B-Anatomy
lobe	I-Anatomy
grafts	I-Anatomy
.	O
Hepatic	B-Anatomy
arteries	I-Anatomy
of	O
donors	O
and	O
recipients	O
were	O
assessed	O
carefully	O
with	O
spiral	O
CT	O
angiography	O
and	O
DSA	O
before	O
ALDLT	O
.	O
All	O
patients	O
underwent	O
reconstruction	O
of	O
hepatic	B-Anatomy
artery	I-Anatomy
between	O
right	B-Anatomy
lobe	I-Anatomy
liver	I-Anatomy
grafts	I-Anatomy
of	O
donor	O
and	O
recipient	O
which	O
included	O
the	O
anastomosis	O
between	O
right	B-Anatomy
hepatic	I-Anatomy
artery	I-Anatomy
of	O
donors	O
and	O
recipients	O
;	O
the	O
reconstruction	O
of	O
right	B-Anatomy
hepatic	I-Anatomy
artery	I-Anatomy
between	O
donor	O
grafts	B-Anatomy
and	O
left	B-Anatomy
hepatic	I-Anatomy
artery	I-Anatomy
of	O
recipients	O
;	O
interpositional	O
bypass	O
using	O
autogenous	O
saphenous	B-Anatomy
vein	I-Anatomy
and	O
cryopreserved	O
iliac	B-Anatomy
artery	I-Anatomy
between	O
right	B-Anatomy
hepatic	I-Anatomy
artery	I-Anatomy
of	O
donors	O
and	O
hepatic	B-Anatomy
artery	I-Anatomy
,	O
common	O
hepatic	B-Anatomy
artery	I-Anatomy
and	O
abdominal	B-Anatomy
aorta	I-Anatomy
of	O
recipients	O
.	O
The	O
microsurgical	O
technique	O
was	O
employed	O
under	O
the	O
magnification	O
of	O
3	O
.	O
5	O
times	O
and	O
operative	O
microscope	O
of	O
5	O
-	O
10	O
times	O
.	O
RESULTS	O
:	O
In	O
these	O
series	O
,	O
HAT	O
occurred	O
in	O
2	O
recipients	O
at	O
Days	O
1	O
and	O
7	O
post	O
-	O
ALDLT	O
(	O
1	O
.	O
9	O
%	O
)	O
.	O
Both	O
were	O
revascularized	O
with	O
autogenous	O
saphenous	B-Anatomy
vein	I-Anatomy
between	O
right	B-Anatomy
hepatic	I-Anatomy
artery	I-Anatomy
of	O
donor	O
and	O
abdominal	B-Anatomy
aorta	I-Anatomy
of	O
recipient	O
.	O
HAT	O
occurred	O
in	O
1	O
recipient	O
at	O
Days	O
90	O
post	O
-	O
ALDLT	O
,	O
but	O
no	O
symptom	O
was	O
presented	O
.	O
There	O
was	O
no	O
severe	O
complication	O
and	O
mortality	O
related	O
to	O
hepatic	B-Anatomy
artery	I-Anatomy
reconstruction	O
in	O
recipients	O
.	O
No	O
HAT	O
,	O
hepatic	B-Anatomy
artery	I-Anatomy
stenosis	O
and	O
aneurysm	B-Anatomy
occurred	O
during	O
the	O
follow	O
-	O
up	O
period	O
of	O
2	O
-	O
60	O
months	O
.	O
The	O
1	O
,	O
2	O
and	O
3	O
-	O
year	O
survival	O
rates	O
were	O
89	O
.	O
3	O
%	O
,	O
76	O
.	O
0	O
%	O
and	O
69	O
.	O
3	O
%	O
respectively	O
.	O
CONCLUSION	O
:	O
Careful	O
evaluation	O
of	O
hepatic	B-Anatomy
artery	I-Anatomy
condition	O
and	O
using	O
microsurgical	O
techniques	O
are	O
important	O
for	O
safer	O
arterial	B-Anatomy
reconstruction	O
and	O
a	O
long	O
-	O
term	O
patency	O
of	O
hepatic	B-Anatomy
artery	I-Anatomy
in	O
living	O
donor	O
liver	B-Anatomy
transplantation	O
in	O
adults	O
using	O
right	B-Anatomy
lobe	I-Anatomy
liver	I-Anatomy
grafts	I-Anatomy
.	O
Hormonal	O
regulation	O
and	O
distinct	O
functions	O
of	O
semaphorin	O
-	O
3B	O
and	O
semaphorin	O
-	O
3F	O
in	O
ovarian	B-Anatomy
cancer	I-Anatomy
.	O
Semaphorins	O
comprise	O
a	O
family	O
of	O
molecules	O
that	O
influence	O
neuronal	B-Anatomy
growth	O
and	O
guidance	O
.	O
Class	O
-	O
3	O
semaphorins	O
,	O
semaphorin	O
-	O
3B	O
(	O
SEMA3B	O
)	O
and	O
semaphorin	O
-	O
3F	O
(	O
SEMA3F	O
)	O
,	O
illustrate	O
their	O
effects	O
by	O
forming	O
a	O
complex	O
with	O
neuropilins	O
(	O
NP	O
-	O
1	O
or	O
NP	O
-	O
2	O
)	O
and	O
plexins	O
.	O
We	O
examined	O
the	O
status	O
and	O
regulation	O
of	O
semaphorins	O
and	O
their	O
receptors	O
in	O
human	O
ovarian	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
A	O
significantly	O
reduced	O
expression	O
of	O
SEMA3B	O
(	O
83	O
kDa	O
)	O
,	O
SEMA3F	O
(	O
90	O
kDa	O
)	O
,	O
and	O
plexin	O
-	O
A3	O
was	O
observed	O
in	O
ovarian	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
when	O
compared	O
with	O
normal	O
human	O
ovarian	B-Anatomy
surface	I-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
.	O
The	O
expression	O
of	O
NP	O
-	O
1	O
,	O
NP	O
-	O
2	O
,	O
and	O
plexin	O
-	O
A1	O
was	O
not	O
altered	O
in	O
human	O
ovarian	B-Anatomy
surface	I-Anatomy
epithelial	I-Anatomy
and	O
ovarian	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
The	O
decreased	O
expression	O
of	O
SEMA3B	O
,	O
SEMA3F	O
,	O
and	O
plexin	O
-	O
A3	O
was	O
confirmed	O
in	O
stage	O
3	O
ovarian	B-Anatomy
tumors	I-Anatomy
.	O
The	O
treatment	O
of	O
ovarian	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
with	O
luteinizing	O
hormone	O
,	O
follicle	O
-	O
stimulating	O
hormone	O
,	O
and	O
estrogen	O
induced	O
a	O
significant	O
upregulation	O
of	O
SEMA3B	O
,	O
whereas	O
SEMA3F	O
was	O
upregulated	O
only	O
by	O
estrogen	O
.	O
Cotreatment	O
of	O
cell	B-Anatomy
lines	I-Anatomy
with	O
a	O
hormone	O
and	O
its	O
specific	O
antagonist	O
blocked	O
the	O
effect	O
of	O
the	O
hormone	O
.	O
Ectopic	O
expression	O
of	O
SEMA3B	O
or	O
SEMA3F	O
reduced	O
soft	O
-	O
agar	O
colony	B-Anatomy
formation	O
,	O
adhesion	O
,	O
and	O
cell	B-Anatomy
invasion	O
of	O
ovarian	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
cultures	I-Anatomy
.	O
Forced	O
expression	O
of	O
SEMA3B	O
,	O
but	O
not	O
SEMA3F	O
,	O
inhibited	O
viability	O
of	O
ovarian	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Overexpression	O
of	O
SEMA3B	O
and	O
SEMA3F	O
reduced	O
focal	O
adhesion	O
kinase	O
phosphorylation	O
and	O
matrix	O
metalloproteinase	O
-	O
2	O
and	O
matrix	O
metalloproteinase	O
-	O
9	O
expression	O
in	O
ovarian	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Forced	O
expression	O
of	O
SEMA3F	O
,	O
but	O
not	O
SEMA3B	O
in	O
ovarian	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
,	O
significantly	O
inhibited	O
endothelial	B-Anatomy
cell	I-Anatomy
tube	I-Anatomy
formation	O
.	O
Collectively	O
,	O
our	O
results	O
suggest	O
that	O
the	O
loss	O
of	O
SEMA3	O
expression	O
could	O
be	O
a	O
hallmark	O
of	O
cancer	B-Anatomy
progression	O
.	O
Furthermore	O
,	O
gonadotropin	O
-	O
and	O
/	O
or	O
estrogen	O
-	O
mediated	O
maintenance	O
of	O
SEMA3	O
expression	O
could	O
control	O
ovarian	B-Anatomy
cancer	I-Anatomy
angiogenesis	O
and	O
metastasis	O
.	O
Tobacco	O
smoke	O
promotes	O
lung	B-Anatomy
tumorigenesis	O
by	O
triggering	O
IKKbeta	O
-	O
and	O
JNK1	O
-	O
dependent	O
inflammation	O
.	O
Chronic	O
exposure	O
to	O
tobacco	O
smoke	O
,	O
which	O
contains	O
over	O
60	O
tumor	B-Anatomy
-	O
initiating	O
carcinogens	O
,	O
is	O
the	O
major	O
risk	O
factor	O
for	O
development	O
of	O
lung	B-Anatomy
cancer	I-Anatomy
,	O
accounting	O
for	O
a	O
large	O
portion	O
of	O
cancer	B-Anatomy
-	O
related	O
deaths	O
worldwide	O
.	O
It	O
is	O
well	O
established	O
that	O
tobacco	O
smoke	O
is	O
a	O
tumor	B-Anatomy
initiator	O
,	O
but	O
we	O
asked	O
whether	O
it	O
also	O
acts	O
as	O
a	O
tumor	B-Anatomy
promoter	O
once	O
malignant	O
initiation	O
,	O
such	O
as	O
caused	O
by	O
K	O
-	O
ras	O
activation	O
,	O
has	O
taken	O
place	O
.	O
Here	O
we	O
demonstrate	O
that	O
repetitive	O
exposure	O
to	O
tobacco	O
smoke	O
promotes	O
tumor	B-Anatomy
development	O
both	O
in	O
carcinogen	O
-	O
treated	O
mice	O
and	O
in	O
transgenic	O
mice	O
undergoing	O
sporadic	O
K	O
-	O
ras	O
activation	O
in	O
lung	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
.	O
Tumor	B-Anatomy
promotion	O
is	O
due	O
to	O
induction	O
of	O
inflammation	O
that	O
results	O
in	O
enhanced	O
pneumocyte	B-Anatomy
proliferation	O
and	O
is	O
abrogated	O
by	O
IKKbeta	O
ablation	O
in	O
myeloid	B-Anatomy
cells	I-Anatomy
or	O
inactivation	O
of	O
JNK1	O
.	O
Further	O
Characterization	O
of	O
Activin	O
A	O
-	O
induced	O
IgA	O
Response	O
in	O
Murine	O
B	B-Anatomy
Lymphocytes	I-Anatomy
.	O
We	O
have	O
recently	O
shown	O
that	O
activin	O
A	O
,	O
a	O
member	O
of	O
TGF	O
-	O
beta	O
superfamily	O
,	O
stimulates	O
mouse	O
B	B-Anatomy
cells	I-Anatomy
to	O
express	O
IgA	O
isotype	O
but	O
other	O
isotypes	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
further	O
characterized	O
effects	O
of	O
activin	O
A	O
on	O
B	B-Anatomy
cell	I-Anatomy
growth	O
and	O
IgA	O
expression	O
.	O
We	O
found	O
that	O
activin	O
A	O
did	O
not	O
have	O
effect	O
on	O
LPS	O
-	O
stimulated	O
cell	B-Anatomy
viability	O
.	O
In	O
parallel	O
,	O
CFSE	O
staining	O
analysis	O
revealed	O
that	O
activin	O
A	O
did	O
not	O
alter	O
cell	B-Anatomy
division	O
.	O
An	O
increase	O
of	O
IgA	O
secretion	O
by	O
activin	O
A	O
was	O
completely	O
abrogated	O
by	O
anti	O
-	O
activin	O
A	O
Ab	O
but	O
not	O
by	O
anti	O
-	O
TGFbeta1	O
Ab	O
.	O
In	O
the	O
same	O
conditions	O
,	O
no	O
other	O
isotypes	O
are	O
significantly	O
affected	O
by	O
each	O
antibody	O
treatment	O
.	O
Finally	O
,	O
activin	O
A	O
,	O
as	O
similar	O
to	O
TGF	O
-	O
beta1	O
,	O
increased	O
IgA	O
secretion	O
by	O
mesenteric	O
lymph	B-Anatomy
node	I-Anatomy
cells	I-Anatomy
.	O
These	O
results	O
suggest	O
that	O
activin	O
A	O
can	O
specifically	O
stimulate	O
IgA	O
response	O
,	O
independent	O
of	O
TGF	O
-	O
beta	O
in	O
the	O
gut	B-Anatomy
.	O
Posterior	O
stabilization	O
of	O
the	O
cervical	B-Anatomy
spine	I-Anatomy
with	O
hook	O
plates	O
.	O
Hook	O
-	O
plate	O
fixation	O
is	O
designed	O
for	O
posterior	O
cervical	B-Anatomy
stabilization	O
from	O
C2	O
to	O
C7	O
.	O
Indications	O
remain	O
the	O
same	O
as	O
for	O
standard	O
posterior	O
fixations	O
.	O
The	O
prime	O
indications	O
are	O
discoligamentous	O
injuries	O
.	O
The	O
plates	O
are	O
hooked	O
under	O
the	O
lower	B-Anatomy
laminas	I-Anatomy
and	O
attached	O
to	O
the	O
articular	B-Anatomy
masses	I-Anatomy
of	O
the	O
upper	O
vertebra	B-Anatomy
by	O
oblique	O
screws	O
.	O
An	O
H	O
-	O
graft	O
is	O
placed	O
between	O
the	O
spinous	O
processes	O
.	O
The	O
vertebrae	B-Anatomy
are	O
compressed	O
together	O
by	O
the	O
plates	O
at	O
three	O
points	O
,	O
the	O
facet	O
joints	O
,	O
and	O
graft	O
.	O
The	O
resulting	O
pre	O
-	O
stressed	O
system	O
is	O
stable	O
in	O
all	O
directions	O
.	O
A	O
protocol	O
for	O
safe	O
reduction	O
of	O
cervical	B-Anatomy
dislocations	O
is	O
observed	O
.	O
Of	O
70	O
patients	O
treated	O
from	O
1979	O
to	O
1986	O
,	O
51	O
were	O
examined	O
12	O
-	O
54	O
months	O
after	O
surgery	O
.	O
All	O
fusions	O
consolidated	O
.	O
Two	O
neurologic	B-Anatomy
complications	O
not	O
attributable	O
to	O
the	O
fixation	O
occurred	O
.	O
Other	O
major	O
complications	O
were	O
not	O
seen	O
.	O
Dose	O
-	O
and	O
time	O
-	O
dependent	O
effects	O
of	O
doxorubicin	O
on	O
cytotoxicity	O
,	O
cell	B-Anatomy
cycle	O
and	O
apoptotic	O
cell	B-Anatomy
death	O
in	O
human	O
colon	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
The	O
cytostatic	O
drug	O
doxorubicin	O
is	O
a	O
well	O
-	O
known	O
chemotherapeutic	O
agent	O
which	O
is	O
used	O
in	O
treatment	O
of	O
a	O
wide	O
variety	O
of	O
cancers	B-Anatomy
.	O
A	O
key	O
factor	O
in	O
the	O
response	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
to	O
chemotherapeutic	O
drugs	O
is	O
the	O
activation	O
of	O
the	O
apoptotic	O
pathway	O
,	O
a	O
pathway	O
that	O
is	O
often	O
impaired	O
in	O
chemoresistant	O
colon	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
doxorubicin	O
in	O
Hct	B-Anatomy
-	I-Anatomy
116	I-Anatomy
human	I-Anatomy
colon	I-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
in	O
order	O
to	O
clarify	O
if	O
a	O
time	O
/	O
concentration	O
range	O
for	O
optimal	O
doxorubicin	O
-	O
induced	O
apoptosis	O
exists	O
.	O
We	O
compared	O
a	O
treatment	O
schedule	O
were	O
cells	B-Anatomy
were	O
bolus	O
incubated	O
for	O
3h	O
with	O
doxorubicin	O
followed	O
by	O
24h	O
in	O
drug	O
-	O
free	O
medium	O
,	O
with	O
a	O
continuous	O
doxorubicin	O
treatment	O
schedule	O
for	O
24h	O
.	O
Bolus	O
incubation	O
was	O
carried	O
out	O
to	O
determine	O
effects	O
of	O
doxorubicin	O
accumulated	O
during	O
the	O
first	O
3h	O
,	O
whereas	O
continuous	O
incubation	O
allowed	O
further	O
(	O
continuous	O
)	O
exposure	O
to	O
doxorubicin	O
.	O
We	O
found	O
that	O
bolus	O
(	O
3h	O
)	O
treatment	O
with	O
doxorubicin	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
decrease	O
of	O
viable	O
cells	B-Anatomy
and	O
concomitant	O
increase	O
of	O
apoptosis	O
.	O
Additionally	O
,	O
bolus	O
(	O
3h	O
)	O
doxorubicin	O
incubation	O
led	O
to	O
phosphorylation	O
of	O
p53	O
at	O
serine	O
392	O
,	O
induction	O
of	O
p21	O
,	O
G2	O
arrest	O
and	O
increase	O
of	O
proapoptotic	O
protein	O
Bax	O
.	O
In	O
contrast	O
,	O
continuous	O
(	O
24h	O
)	O
treatment	O
with	O
doxorubicin	O
reduced	O
the	O
number	O
of	O
living	O
cells	B-Anatomy
with	O
no	O
parallel	O
raise	O
in	O
the	O
amount	O
of	O
dead	O
cells	B-Anatomy
.	O
Continuous	O
(	O
24h	O
)	O
treatment	O
with	O
5	O
microM	O
doxorubicin	O
resulted	O
in	O
cell	B-Anatomy
cycle	O
arrest	O
in	O
G0	O
/	O
G1	O
phase	O
that	O
was	O
neither	O
accompanied	O
by	O
phosphorylation	O
and	O
activation	O
of	O
p53	O
nor	O
enhanced	O
expression	O
of	O
p21	O
.	O
These	O
results	O
suggest	O
that	O
doxorubicin	O
is	O
able	O
to	O
induce	O
cell	B-Anatomy
death	O
by	O
apoptosis	O
only	O
at	O
particular	O
dose	O
and	O
treatment	O
conditions	O
and	O
imply	O
a	O
completely	O
different	O
cellular	B-Anatomy
response	O
following	O
bolus	O
or	O
continuous	O
exposure	O
to	O
doxorubicin	O
.	O
Lactate	O
-	O
dehydrogenase	O
5	O
is	O
overexpressed	O
in	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
and	O
correlates	O
with	O
the	O
expression	O
of	O
the	O
transketolase	O
-	O
like	O
protein	O
1	O
.	O
AIMS	O
:	O
As	O
one	O
of	O
the	O
five	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
isoenzymes	O
,	O
LDH5	O
has	O
the	O
highest	O
efficiency	O
to	O
catalyze	O
pyruvate	O
transformation	O
to	O
lactate	O
.	O
LDH5	O
overexpression	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
induces	O
an	O
upregulated	O
glycolytic	O
metabolism	O
and	O
reduced	O
dependence	O
on	O
the	O
presence	O
of	O
oxygen	O
.	O
Here	O
we	O
analyzed	O
LDH5	O
protein	O
expression	O
in	O
a	O
well	O
characterized	O
large	O
cohort	O
of	O
primary	B-Anatomy
lung	I-Anatomy
cancers	I-Anatomy
in	O
correlation	O
to	O
clinico	O
-	O
pathological	O
data	O
and	O
its	O
possible	O
impact	O
on	O
patient	O
survival	O
.	O
METHODS	O
:	O
Primary	B-Anatomy
lung	I-Anatomy
cancers	I-Anatomy
(	O
n	O
=	O
269	O
)	O
and	O
non	B-Anatomy
neoplastic	I-Anatomy
lung	I-Anatomy
tissue	I-Anatomy
(	O
n	O
=	O
35	O
)	O
were	O
tested	O
for	O
LDH5	O
expression	O
by	O
immunohistochemistry	O
using	O
a	O
polyclonal	O
LDH5	O
antibody	O
(	O
ab53010	O
)	O
.	O
The	O
results	O
of	O
LDH5	O
expression	O
were	O
correlated	O
to	O
clinico	O
-	O
pathological	O
data	O
as	O
well	O
as	O
to	O
patient	O
'	O
s	O
survival	O
.	O
In	O
addition	O
,	O
the	O
results	O
of	O
the	O
previously	O
tested	O
transketolase	O
like	O
1	O
protein	O
(	O
TKTL1	O
)	O
expression	O
were	O
correlated	O
to	O
LDH5	O
expression	O
.	O
RESULTS	O
:	O
89	O
.	O
5	O
%	O
(	O
n	O
=	O
238	O
)	O
of	O
NSCLC	B-Anatomy
revealed	O
LDH5	O
expression	O
whereas	O
LDH5	O
expression	O
was	O
not	O
detected	O
in	O
non	B-Anatomy
neoplastic	I-Anatomy
lung	I-Anatomy
tissues	I-Anatomy
(	O
n	O
=	O
34	O
)	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O
LDH5	O
overexpression	O
was	O
associated	O
with	O
histological	O
type	O
(	O
adenocarcinoma	B-Anatomy
=	O
57	O
%	O
,	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
=	O
45	O
%	O
,	O
large	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
=	O
46	O
%	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O
No	O
significant	O
correlation	O
could	O
be	O
detected	O
with	O
regard	O
to	O
TNM	O
-	O
stage	O
,	O
grading	O
or	O
survival	O
.	O
A	O
two	O
sided	O
correlation	O
between	O
the	O
expression	O
of	O
TKTL1	O
and	O
LDH5	O
could	O
be	O
shown	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
within	O
the	O
overall	O
cohort	O
as	O
well	O
as	O
for	O
each	O
grading	O
and	O
pN	O
group	O
.	O
A	O
significant	O
correlation	O
between	O
LDH5	O
and	O
TKTL1	O
within	O
each	O
histologic	O
tumortype	B-Anatomy
could	O
not	O
be	O
revealed	O
.	O
CONCLUSIONS	O
:	O
LDH5	O
is	O
overexpressed	O
in	O
NSCLC	B-Anatomy
and	O
could	O
hence	O
serve	O
as	O
an	O
additional	O
marker	O
for	O
malignancy	O
.	O
Furthermore	O
,	O
LDH5	O
correlates	O
positively	O
with	O
the	O
prognostic	O
marker	O
TKTL1	O
.	O
Our	O
results	O
confirm	O
a	O
close	O
link	O
between	O
the	O
two	O
metabolic	O
enzymes	O
and	O
indicate	O
an	O
alteration	O
in	O
the	O
glucose	O
metabolism	O
in	O
the	O
process	O
of	O
malignant	O
transformation	O
.	O
Is	O
the	O
elimination	O
of	O
HIV	O
infection	O
within	O
reach	O
in	O
the	O
United	O
States	O
?	O
Lessons	O
from	O
an	O
epidemiologic	O
transmission	O
model	O
.	O
Recent	O
estimates	O
show	O
that	O
the	O
transmission	O
rate	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
in	O
the	O
U	O
.	O
S	O
.	O
has	O
substantially	O
decreased	O
.	O
This	O
raises	O
the	O
question	O
,	O
is	O
elimination	O
of	O
HIV	O
infection	O
in	O
the	O
nation	O
feasible	O
in	O
the	O
foreseeable	O
future	O
?	O
We	O
demonstrate	O
that	O
if	O
the	O
HIV	O
transmission	O
rate	O
were	O
reduced	O
by	O
50	O
%	O
,	O
then	O
the	O
reproductive	O
rate	O
of	O
HIV	O
infection	O
would	O
drop	O
below	O
unity	O
and	O
lead	O
to	O
eventual	O
elimination	O
of	O
infection	O
.	O
In	O
recent	O
congressional	O
testimony	O
,	O
the	O
director	O
of	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
and	O
others	O
asserted	O
that	O
the	O
HIV	O
transmission	O
rate	O
can	O
be	O
halved	O
by	O
2020	O
,	O
if	O
not	O
earlier	O
,	O
provided	O
sufficient	O
investment	O
is	O
made	O
toward	O
achieving	O
this	O
goal	O
.	O
We	O
assert	O
that	O
if	O
adequate	O
investment	O
is	O
made	O
and	O
the	O
transmission	O
rate	O
is	O
in	O
fact	O
lowered	O
by	O
50	O
%	O
,	O
then	O
the	O
HIV	O
reproductive	O
rate	O
would	O
fall	O
below	O
unity	O
,	O
setting	O
the	O
stage	O
for	O
eventual	O
elimination	O
of	O
HIV	O
infection	O
in	O
the	O
U	O
.	O
S	O
.	O
Pain	O
assessment	O
by	O
continuous	O
EEG	O
:	O
association	O
between	O
subjective	O
perception	O
of	O
tonic	O
pain	O
and	O
peak	O
frequency	O
of	O
alpha	O
oscillations	O
during	O
stimulation	O
and	O
at	O
rest	O
.	O
Recordings	O
of	O
neurophysiological	O
brain	B-Anatomy
responses	O
to	O
noxious	O
stimuli	O
have	O
been	O
traditionally	O
based	O
on	O
short	O
stimuli	O
,	O
in	O
the	O
order	O
of	O
milliseconds	O
,	O
which	O
induce	O
distinct	O
event	O
-	O
related	O
potentials	O
(	O
ERPs	O
)	O
.	O
However	O
,	O
using	O
such	O
stimuli	O
in	O
the	O
experimental	O
setting	O
is	O
disadvantageous	O
as	O
they	O
are	O
too	O
brief	O
to	O
faithfully	O
simulate	O
clinical	O
pain	O
.	O
We	O
aimed	O
at	O
utilizing	O
continuous	O
EEG	O
to	O
investigate	O
the	O
properties	O
of	O
peak	O
alpha	O
frequency	O
(	O
PAF	O
)	O
as	O
an	O
objective	O
cortical	B-Anatomy
measure	O
associated	O
with	O
subjective	O
perception	O
of	O
tonic	O
pain	O
.	O
Five	O
minute	O
long	O
continuous	O
EEG	O
was	O
recorded	O
in	O
18	O
healthy	O
volunteers	O
under	O
:	O
(	O
i	O
)	O
resting	O
-	O
state	O
;	O
(	O
ii	O
)	O
innocuous	O
temperature	O
;	O
and	O
(	O
iii	O
)	O
psychophysically	O
-	O
anchored	O
noxious	O
temperature	O
.	O
Numerical	O
pain	O
scores	O
(	O
NPSs	O
)	O
collected	O
during	O
the	O
application	O
of	O
tonic	O
noxious	O
stimuli	O
were	O
tested	O
for	O
correlation	O
with	O
peak	O
frequencies	O
of	O
alpha	O
power	O
-	O
curves	O
derived	O
from	O
central	O
,	O
temporal	O
and	O
frontal	O
electrodes	O
.	O
NPSs	O
and	O
PAFs	O
remained	O
stable	O
throughout	O
the	O
recording	O
conditions	O
(	O
RM	O
-	O
ANOVAs	O
;	O
Ps	O
>	O
0	O
.	O
51	O
)	O
.	O
In	O
the	O
noxious	O
condition	O
,	O
PAFs	O
obtained	O
at	O
the	O
bilateral	O
temporal	B-Anatomy
scalp	I-Anatomy
were	O
correlated	O
with	O
NPSs	O
(	O
Ps	O
<	O
0	O
.	O
001	O
)	O
.	O
Moreover	O
,	O
resting	O
-	O
state	O
PAFs	O
recorded	O
at	O
the	O
bilateral	O
temporal	B-Anatomy
scalp	I-Anatomy
were	O
correlated	O
with	O
NPSs	O
reported	O
during	O
the	O
noxious	O
condition	O
(	O
Ps	O
<	O
0	O
.	O
01	O
)	O
.	O
These	O
psychophysical	O
-	O
neurophysiological	O
relations	O
attest	O
to	O
the	O
properties	O
of	O
PAF	O
as	O
a	O
novel	O
cortical	B-Anatomy
objective	O
measure	O
of	O
subjective	O
perception	O
of	O
tonic	O
pain	O
.	O
Moreover	O
,	O
resting	O
-	O
state	O
PAFs	O
might	O
hold	O
inherent	O
pain	O
modulation	O
attributes	O
,	O
possibly	O
enabling	O
the	O
prediction	O
of	O
individual	O
responsiveness	O
to	O
prolonged	O
pain	O
.	O
The	O
relevance	O
of	O
PAF	O
to	O
the	O
neural	B-Anatomy
processing	O
of	O
tonic	O
pain	O
may	O
indicate	O
its	O
potential	O
to	O
advance	O
pain	O
research	O
as	O
well	O
as	O
clinical	O
pain	O
characterization	O
.	O
Acoustic	O
trauma	O
evokes	O
hyperactivity	O
and	O
changes	O
in	O
gene	O
expression	O
in	O
guinea	O
-	O
pig	O
auditory	O
brainstem	B-Anatomy
.	O
Hearing	O
loss	O
from	O
acoustic	O
trauma	O
is	O
a	O
risk	O
factor	O
for	O
tinnitus	O
.	O
Animal	O
models	O
using	O
acoustic	O
trauma	O
have	O
demonstrated	O
hyperactivity	O
in	O
central	O
auditory	O
pathways	O
,	O
which	O
has	O
been	O
suggested	O
as	O
a	O
substrate	O
for	O
tinnitus	O
.	O
We	O
used	O
a	O
guinea	O
-	O
pig	O
model	O
of	O
unilateral	O
acoustic	O
trauma	O
.	O
Within	O
the	O
same	O
animals	O
,	O
measurements	O
of	O
peripheral	O
hearing	O
loss	O
,	O
spontaneous	O
activity	O
of	O
single	O
neurons	B-Anatomy
in	O
the	O
inferior	B-Anatomy
colliculus	I-Anatomy
and	O
gene	O
expression	O
in	O
cochlear	B-Anatomy
nucleus	I-Anatomy
and	O
inferior	B-Anatomy
colliculus	I-Anatomy
were	O
combined	O
,	O
acutely	O
and	O
after	O
recovery	O
from	O
acoustic	O
trauma	O
.	O
Genes	O
investigated	O
related	O
to	O
inhibitory	O
(	O
GABA	O
-	O
A	O
receptor	O
subunit	O
alpha	O
1	O
;	O
glycine	O
receptor	O
subunit	O
alpha	O
1	O
)	O
and	O
excitatory	O
neurotransmission	O
(	O
glutamate	O
decarboxylase	O
1	O
;	O
glutamate	O
receptor	O
AMPA	O
subunit	O
alpha	O
2	O
;	O
glutamate	O
receptor	O
NMDA	O
subunit	O
1	O
)	O
,	O
regulation	O
of	O
transmitter	O
release	O
(	O
member	O
of	O
RAB	O
family	O
of	O
small	O
GTPase	O
;	O
RAB3	O
GTPase	O
activating	O
protein	O
subunit	O
1	O
)	O
and	O
neuronal	B-Anatomy
excitability	O
(	O
potassium	O
channel	O
subfamily	O
K	O
member	O
15	O
)	O
.	O
Acoustic	O
trauma	O
resulted	O
in	O
unilateral	O
hearing	O
loss	O
and	O
hyperactivity	O
bilaterally	O
in	O
inferior	B-Anatomy
colliculus	I-Anatomy
.	O
Changes	O
in	O
expression	O
of	O
different	O
mRNAs	O
were	O
observed	O
in	O
ipsilateral	O
cochlear	B-Anatomy
nucleus	I-Anatomy
and	O
in	O
ipsi	O
-	O
and	O
contralateral	O
inferior	B-Anatomy
colliculus	I-Anatomy
,	O
immediately	O
after	O
acoustic	O
trauma	O
,	O
and	O
after	O
2	O
and	O
4	O
weeks	O
'	O
recovery	O
.	O
Gene	O
expression	O
was	O
generally	O
reduced	O
immediately	O
after	O
trauma	O
,	O
followed	O
by	O
a	O
return	O
to	O
near	O
normal	O
levels	O
or	O
over	O
-	O
expression	O
as	O
recovery	O
time	O
increased	O
.	O
Different	O
mechanisms	O
appear	O
to	O
underlie	O
the	O
spontaneous	O
hyperactivity	O
observed	O
.	O
There	O
is	O
evidence	O
of	O
down	O
-	O
regulation	O
of	O
genes	O
associated	O
with	O
neuronal	B-Anatomy
inhibition	O
in	O
the	O
contralateral	O
inferior	B-Anatomy
colliculus	I-Anatomy
,	O
whereas	O
in	O
ipsilateral	O
cochlear	B-Anatomy
nucleus	I-Anatomy
,	O
competing	O
actions	O
of	O
inhibitory	O
and	O
excitatory	O
systems	O
seem	O
to	O
play	O
a	O
major	O
role	O
in	O
determining	O
overall	O
excitability	O
.	O
Telomere	B-Anatomy
/	O
telomerase	O
interplay	O
in	O
virus	O
-	O
driven	O
and	O
virus	O
-	O
independent	O
lymphomagenesis	O
:	O
pathogenic	O
and	O
clinical	O
implications	O
.	O
Telomerase	O
is	O
a	O
ribonucleoprotein	O
complex	O
critically	O
involved	O
in	O
extending	O
and	O
maintaining	O
telomeres	B-Anatomy
.	O
Unlike	O
the	O
majority	O
of	O
somatic	B-Anatomy
cells	I-Anatomy
,	O
in	O
which	O
hTERT	O
and	O
telomerase	O
activity	O
are	O
generally	O
silent	O
,	O
normal	O
lymphocytes	B-Anatomy
show	O
transient	O
physiological	O
hTERT	O
expression	O
and	O
telomerase	O
activity	O
according	O
to	O
their	O
differentiation	O
/	O
activation	O
status	O
.	O
During	O
lymphomagenesis	O
,	O
induction	O
of	O
persistent	O
telomerase	O
expression	O
and	O
activity	O
may	O
occur	O
before	O
or	O
after	O
telomere	B-Anatomy
shortening	O
,	O
as	O
a	O
consequence	O
of	O
the	O
different	O
mechanisms	O
through	O
which	O
transforming	O
factors	O
/	O
agents	O
may	O
activate	O
telomerase	O
.	O
Available	O
data	O
indicate	O
that	O
the	O
timing	O
of	O
telomerase	O
activation	O
may	O
allow	O
the	O
distinction	O
of	O
two	O
different	O
lymphomagenetic	O
models	O
:	O
(	O
i	O
)	O
an	O
early	O
activation	O
of	O
telomerase	O
via	O
exogenous	O
regulators	O
of	O
hTERT	O
,	O
along	O
with	O
an	O
increased	O
lymphocyte	B-Anatomy
growth	O
and	O
a	O
subsequent	O
selection	O
of	O
cells	B-Anatomy
with	O
increased	O
transforming	O
potential	O
may	O
characterize	O
several	O
virus	O
-	O
related	O
lymphoid	B-Anatomy
malignancies	I-Anatomy
;	O
(	O
ii	O
)	O
a	O
progressive	O
shortening	O
of	O
telomeres	B-Anatomy
,	O
leading	O
to	O
genetic	O
instability	O
which	O
favors	O
a	O
subsequent	O
activation	O
of	O
telomerase	O
via	O
endogenous	O
regulators	O
may	O
occur	O
in	O
most	O
virus	O
-	O
unrelated	O
lymphoid	B-Anatomy
tumors	I-Anatomy
.	O
These	O
models	O
may	O
have	O
clinically	O
relevant	O
implications	O
,	O
particularly	O
for	O
the	O
tailoring	O
of	O
therapeutic	O
strategies	O
targeting	O
telomerase	O
.	O
Yellow	O
-	O
green	O
52	O
.	O
3W	O
laser	O
at	O
556nm	O
based	O
on	O
frequency	O
doubling	O
of	O
a	O
diode	O
side	O
-	O
pumped	O
Q	O
-	O
switched	O
Nd	O
:	O
YAG	O
laser	O
.	O
We	O
demonstrate	O
a	O
high	O
-	O
power	O
556nm	O
yellow	O
-	O
green	O
laser	O
generated	O
by	O
intracavity	O
frequency	O
doubling	O
of	O
a	O
diode	O
side	O
-	O
pumped	O
Nd	O
:	O
YAG	O
laser	O
at	O
1112nm	O
.	O
A	O
symmetrical	O
L	O
-	O
shaped	O
flat	O
-	O
flat	O
cavity	O
was	O
employed	O
to	O
implement	O
efficient	O
operation	O
of	O
the	O
low	O
-	O
gain	O
1112nm	O
transition	O
and	O
to	O
achieve	O
good	O
power	O
scalability	O
.	O
The	O
coatings	O
of	O
the	O
cavity	O
mirrors	O
were	O
carefully	O
designed	O
to	O
optimize	O
the	O
performance	O
of	O
the	O
laser	O
,	O
and	O
a	O
92W	O
continuous	O
wave	O
laser	O
output	O
at	O
1112nm	O
was	O
achieved	O
when	O
the	O
pumping	O
power	O
of	O
the	O
laser	O
diodes	O
reached	O
960W	O
.	O
By	O
intracavity	O
frequency	O
doubling	O
of	O
the	O
fundamental	O
laser	O
in	O
a	O
lithium	O
triborate	O
crystal	O
,	O
the	O
maximum	O
power	O
of	O
the	O
frequency	O
-	O
doubled	O
output	O
at	O
556nm	O
was	O
found	O
to	O
be	O
as	O
high	O
as	O
52	O
.	O
3W	O
with	O
a	O
pulse	O
repetition	O
frequency	O
of	O
10kHz	O
.	O
This	O
corresponds	O
to	O
an	O
optical	O
-	O
to	O
-	O
optical	O
conversion	O
efficiency	O
of	O
about	O
5	O
.	O
4	O
%	O
.	O
Betulin	O
induces	O
mitochondrial	B-Anatomy
cytochrome	O
c	O
release	O
associated	O
apoptosis	O
in	O
human	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
We	O
examined	O
whether	O
betulin	O
,	O
a	O
naturally	O
abundant	O
compound	O
,	O
has	O
anticancer	B-Anatomy
functions	O
in	O
human	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
The	O
results	O
showed	O
that	O
betulin	O
significantly	O
inhibited	O
cell	B-Anatomy
viability	O
in	O
cervix	B-Anatomy
carcinoma	I-Anatomy
HeLa	I-Anatomy
cells	I-Anatomy
,	O
hepatoma	B-Anatomy
HepG2	I-Anatomy
cells	I-Anatomy
,	O
lung	B-Anatomy
adenocarcinoma	I-Anatomy
A549	I-Anatomy
cells	I-Anatomy
,	O
and	O
breast	B-Anatomy
cancer	I-Anatomy
MCF	I-Anatomy
-	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
10	O
to	O
15	O
microg	O
/	O
mL	O
.	O
While	O
betulin	O
exhibited	O
only	O
moderate	O
anticancer	B-Anatomy
activity	O
in	O
other	O
human	O
cancer	B-Anatomy
cells	I-Anatomy
such	O
as	O
hepatoma	B-Anatomy
SK	I-Anatomy
-	I-Anatomy
HEP	I-Anatomy
-	I-Anatomy
1	I-Anatomy
cells	I-Anatomy
,	O
prostate	B-Anatomy
carcinoma	I-Anatomy
PC	I-Anatomy
-	I-Anatomy
3	I-Anatomy
,	O
and	O
lung	B-Anatomy
carcinoma	I-Anatomy
NCI	I-Anatomy
-	I-Anatomy
H460	I-Anatomy
,	O
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
20	O
to	O
60	O
microg	O
/	O
mL	O
,	O
it	O
showed	O
minor	O
growth	O
inhibition	O
in	O
human	O
erythroleukemia	B-Anatomy
K562	I-Anatomy
cells	I-Anatomy
(	O
IC	O
(	O
50	O
)	O
>	O
100	O
microg	O
/	O
mL	O
)	O
.	O
We	O
further	O
investigated	O
the	O
mechanism	O
of	O
anticancer	B-Anatomy
activity	O
by	O
betulin	O
,	O
using	O
HeLa	B-Anatomy
cells	I-Anatomy
as	O
an	O
experimental	O
model	O
.	O
Betulin	O
(	O
10	O
microg	O
/	O
mL	O
)	O
induces	O
apoptotic	O
cell	B-Anatomy
death	O
,	O
as	O
evidenced	O
by	O
morphological	O
characteristics	O
such	O
as	O
membrane	B-Anatomy
phosphatidylserine	O
translocation	O
,	O
nuclear	B-Anatomy
condensation	O
/	O
fragmentation	O
,	O
and	O
apoptotic	B-Anatomy
body	I-Anatomy
formation	O
.	O
A	O
kinetics	O
analysis	O
showed	O
that	O
the	O
depolarization	O
of	O
mitochondrial	B-Anatomy
membrane	I-Anatomy
potential	O
and	O
the	O
release	O
of	O
mitochondrial	B-Anatomy
cytochrome	O
c	O
occurred	O
as	O
early	O
as	O
30	O
min	O
after	O
treatment	O
with	O
betulin	O
.	O
Betulin	O
,	O
unlike	O
its	O
chemical	O
derivative	O
betulinic	O
acid	O
,	O
did	O
not	O
directly	O
trigger	O
mitochondrial	B-Anatomy
cytochrome	O
c	O
release	O
in	O
isolated	O
mitochondria	B-Anatomy
.	O
Importantly	O
,	O
Bax	O
and	O
Bak	O
were	O
rapidly	O
translocated	O
to	O
the	O
mitochondria	B-Anatomy
30	O
min	O
after	O
betulin	O
treatment	O
.	O
The	O
sequential	O
activation	O
of	O
caspase	O
-	O
9	O
and	O
caspase	O
-	O
3	O
/	O
-	O
7	O
and	O
the	O
cleavage	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
were	O
observed	O
behind	O
those	O
mitochondrial	B-Anatomy
events	O
.	O
Furthermore	O
,	O
specific	O
downregulation	O
of	O
either	O
caspase	O
-	O
9	O
,	O
Bax	O
,	O
or	O
Bak	O
by	O
siRNA	O
effectively	O
reduced	O
PARP	O
cleavage	O
and	O
caspase	O
-	O
3	O
activation	O
.	O
Taken	O
together	O
,	O
the	O
lines	O
of	O
evidence	O
demonstrate	O
that	O
betulin	O
triggers	O
apoptosis	O
of	O
human	O
cancer	B-Anatomy
cells	I-Anatomy
through	O
the	O
intrinsic	O
apoptotic	O
pathway	O
.	O
Structure	O
of	O
human	O
hemoglobin	O
messenger	O
RNA	O
and	O
its	O
relation	O
to	O
hemoglobinopathies	O
.	O
1	O
.	O
One	O
-	O
fifth	O
to	O
1	O
/	O
4	O
of	O
globin	O
mRNA	O
is	O
untranslated	O
sequence	O
other	O
than	O
polyadenylic	O
acid	O
.	O
2	O
.	O
The	O
untranslated	O
sequences	O
of	O
mRNA	O
vary	O
markedly	O
in	O
their	O
sequence	O
and	O
in	O
their	O
length	O
.	O
3	O
.	O
Globin	O
mRNAs	O
demonstrate	O
a	O
marked	O
bias	O
in	O
codon	O
selection	O
.	O
4	O
.	O
Viral	O
mRNA	O
shows	O
a	O
quite	O
different	O
pattern	O
of	O
codon	O
selection	O
;	O
therefore	O
,	O
the	O
selection	O
of	O
codons	O
is	O
not	O
uniform	O
for	O
all	O
mRNAs	O
functioning	O
in	O
animal	O
cells	B-Anatomy
.	O
5	O
.	O
Elongated	O
hemoglobin	O
chains	O
can	O
be	O
accounted	O
for	O
by	O
frame	O
-	O
shift	O
mutations	O
,	O
or	O
point	O
mutations	O
within	O
the	O
normal	O
termination	O
codon	O
.	O
The	O
additional	O
amino	O
acids	O
are	O
then	O
coded	O
for	O
by	O
sequences	O
that	O
are	O
normally	O
untranslated	O
.	O
6	O
.	O
Certain	O
hemoglobin	O
deletion	O
mutants	O
occur	O
at	O
sites	O
where	O
there	O
are	O
partially	O
reiterated	O
sequences	O
within	O
the	O
heomoglobin	O
messenger	O
RNA	O
.	O
Ventral	B-Anatomy
and	O
dorsal	B-Anatomy
striatal	I-Anatomy
dopamine	O
efflux	O
and	O
behavior	O
in	O
rats	O
with	O
simple	O
vs	O
.	O
co	O
-	O
morbid	O
histories	O
of	O
cocaine	O
sensitization	O
and	O
neonatal	B-Anatomy
ventral	I-Anatomy
hippocampal	I-Anatomy
lesions	I-Anatomy
.	O
UNLABELLED	O
:	O
RATIONAL	O
:	O
Exposing	O
animal	O
models	O
of	O
mental	O
illness	O
to	O
addictive	O
drugs	O
provides	O
an	O
approach	O
to	O
understanding	O
the	O
neural	B-Anatomy
etiology	O
of	O
dual	O
diagnosis	O
disorders	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
neonatal	B-Anatomy
ventral	I-Anatomy
hippocampal	I-Anatomy
lesions	I-Anatomy
(	O
NVHL	B-Anatomy
)	O
in	O
rats	O
produce	O
features	O
of	O
both	O
schizophrenia	O
and	O
addiction	O
vulnerability	O
.	O
OBJECTIVE	O
:	O
This	O
study	O
investigated	O
ventral	B-Anatomy
and	O
dorsal	B-Anatomy
striatal	I-Anatomy
dopamine	O
(	O
DA	O
)	O
efflux	O
in	O
NVHL	B-Anatomy
rats	O
combined	O
with	O
behavioral	O
sensitization	O
to	O
cocaine	O
.	O
METHODS	O
:	O
Adult	O
NVHL	B-Anatomy
vs	O
.	O
SHAM	O
-	O
operated	O
rats	O
underwent	O
a	O
5	O
-	O
day	O
injection	O
series	O
of	O
cocaine	O
(	O
15	O
mg	O
/	O
kg	O
/	O
day	O
)	O
vs	O
.	O
saline	O
.	O
One	O
week	O
later	O
,	O
rats	O
were	O
cannulated	O
in	O
nucleus	B-Anatomy
accumbens	I-Anatomy
SHELL	O
,	O
CORE	O
,	O
or	O
caudate	B-Anatomy
-	I-Anatomy
putamen	I-Anatomy
.	O
Another	O
week	O
later	O
,	O
in	O
vivo	O
microdialysis	O
sampled	O
DA	O
during	O
locomotor	O
testing	O
in	O
which	O
a	O
single	O
cocaine	O
injection	O
(	O
15	O
mg	O
/	O
kg	O
)	O
was	O
delivered	O
.	O
RESULTS	O
:	O
NVHLs	B-Anatomy
and	O
cocaine	O
history	O
significantly	O
increased	O
behavioral	O
activation	O
approximately	O
2	O
-	O
fold	O
over	O
SHAM	O
-	O
saline	O
history	O
rats	O
.	O
DA	O
efflux	O
curves	O
corresponded	O
time	O
dependently	O
with	O
the	O
cocaine	O
injection	O
and	O
locomotor	O
curves	O
and	O
varied	O
significantly	O
by	O
striatal	B-Anatomy
region	I-Anatomy
:	O
Baseline	O
DA	O
levels	O
increased	O
5	O
-	O
fold	O
while	O
cocaine	O
-	O
stimulated	O
DA	O
efflux	O
decreased	O
by	O
half	O
across	O
a	O
ventral	B-Anatomy
to	O
dorsal	B-Anatomy
striatal	I-Anatomy
gradient	O
.	O
However	O
,	O
NVHLs	B-Anatomy
,	O
prior	O
cocaine	O
history	O
,	O
and	O
individual	O
differences	O
in	O
behavior	O
were	O
not	O
underpinned	O
by	O
differential	O
DA	O
efflux	O
overall	O
or	O
within	O
any	O
striatal	B-Anatomy
region	I-Anatomy
.	O
CONCLUSION	O
:	O
Differences	O
in	O
ventral	B-Anatomy
/	O
dorsal	B-Anatomy
striatal	I-Anatomy
DA	O
efflux	O
are	O
not	O
present	O
in	O
and	O
are	O
not	O
required	O
for	O
producing	O
differential	O
levels	O
of	O
acute	O
cocaine	O
-	O
induced	O
behavioral	O
activation	O
in	O
NVHLs	B-Anatomy
with	O
and	O
without	O
a	O
behaviorally	O
sensitizing	O
cocaine	O
history	O
.	O
These	O
findings	O
suggest	O
other	O
neurotransmitter	O
systems	O
,	O
and	O
alterations	O
in	O
striatal	B-Anatomy
network	I-Anatomy
function	O
post	O
-	O
synaptic	O
to	O
DA	O
transmission	O
are	O
more	O
important	O
to	O
understanding	O
the	O
interactive	O
effects	O
of	O
addictive	O
drugs	O
and	O
mental	O
illness	O
.	O
Adenovirus	O
5	O
E1A	O
enhances	O
histone	O
deacetylase	O
inhibitors	O
-	O
induced	O
apoptosis	O
through	O
Egr	O
-	O
1	O
-	O
mediated	O
Bim	O
upregulation	O
.	O
Histone	O
deacetylase	O
inhibitors	O
(	O
HDACi	O
)	O
are	O
potent	O
anti	O
-	O
cancer	B-Anatomy
agents	O
for	O
variety	O
of	O
cancer	B-Anatomy
types	O
.	O
Suberoylanilide	O
hydroxamic	O
acid	O
(	O
SAHA	O
)	O
has	O
been	O
approved	O
as	O
a	O
drug	O
to	O
treat	O
cutaneous	B-Anatomy
T	I-Anatomy
cell	I-Anatomy
lymphoma	I-Anatomy
,	O
and	O
the	O
combination	O
of	O
HDACi	O
and	O
other	O
agents	O
have	O
been	O
actively	O
tested	O
in	O
many	O
clinical	O
trials	O
.	O
Adenovirus	O
5	O
early	O
region	O
1A	O
(	O
E1A	O
)	O
has	O
been	O
shown	O
to	O
exhibit	O
high	O
tumor	B-Anatomy
suppressor	O
activity	O
,	O
and	O
gene	O
therapy	O
using	O
E1A	O
has	O
been	O
tested	O
in	O
clinical	O
trials	O
.	O
Here	O
,	O
we	O
showed	O
that	O
proapoptotic	O
activity	O
of	O
HDACi	O
was	O
robustly	O
enhanced	O
by	O
E1A	O
in	O
multiple	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
,	O
but	O
not	O
in	O
normal	O
cells	B-Anatomy
.	O
Moreover	O
,	O
we	O
showed	O
that	O
combination	O
of	O
E1A	O
gene	O
therapy	O
and	O
SAHA	O
showed	O
high	O
therapeutic	O
efficacy	O
with	O
low	O
toxicity	O
in	O
vivo	O
ovarian	B-Anatomy
and	O
breast	B-Anatomy
xenograft	I-Anatomy
models	O
.	O
SAHA	O
downregulated	O
Bcl	O
-	O
XL	O
and	O
upregulated	O
proapoptotic	O
BH3	O
-	O
only	O
protein	O
Bim	O
,	O
whose	O
expression	O
was	O
further	O
enhanced	O
by	O
E1A	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
These	O
alterations	O
of	O
Bcl	O
-	O
2	O
family	O
proteins	O
were	O
critical	O
for	O
apoptosis	O
induced	O
by	O
the	O
combination	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
SAHA	O
enhanced	O
acetylation	O
of	O
histone	O
H3	O
in	O
Bim	O
promoter	O
region	O
,	O
while	O
E1A	O
upregulated	O
Egr	O
-	O
1	O
,	O
which	O
was	O
directly	O
involved	O
in	O
Bim	O
transactivation	O
.	O
Together	O
,	O
our	O
results	O
provide	O
not	O
only	O
a	O
novel	O
insight	O
into	O
the	O
mechanisms	O
underlying	O
anti	O
-	O
tumor	B-Anatomy
activity	O
of	O
E1A	O
,	O
but	O
also	O
a	O
rationale	O
for	O
the	O
combined	O
HDACi	O
and	O
E1A	O
gene	O
therapy	O
in	O
future	O
clinical	O
trials	O
.	O
Using	O
a	O
web	O
-	O
based	O
orthopaedic	O
clinic	O
in	O
the	O
curricular	O
teaching	O
of	O
a	O
German	O
university	O
hospital	O
:	O
analysis	O
of	O
learning	O
effect	O
,	O
student	O
usage	O
and	O
reception	O
.	O
PURPOSE	O
:	O
Modern	O
teaching	O
concepts	O
for	O
undergraduate	O
medical	O
students	O
in	O
Germany	O
include	O
problem	O
based	O
learning	O
as	O
a	O
major	O
component	O
of	O
the	O
new	O
licensing	O
regulations	O
for	O
physicians	O
.	O
Here	O
we	O
describe	O
the	O
usage	O
of	O
a	O
web	O
-	O
based	O
virtual	O
outpatient	O
clinic	O
in	O
the	O
teaching	O
curriculum	O
of	O
undergraduate	O
medical	O
students	O
,	O
its	O
effect	O
on	O
learning	O
success	O
,	O
and	O
student	O
reception	O
.	O
METHODS	O
:	O
Fifth	O
year	O
medial	O
students	O
were	O
requested	O
to	O
examine	O
7	O
virtual	O
orthopaedic	O
patients	O
which	O
had	O
been	O
created	O
by	O
the	O
authors	O
using	O
the	O
Inmedea	O
-	O
Simulator	O
.	O
They	O
also	O
had	O
to	O
take	O
a	O
multiple	O
-	O
choice	O
examination	O
on	O
two	O
different	O
occasions	O
and	O
their	O
utilisation	O
of	O
the	O
simulator	O
was	O
analysed	O
subjectively	O
and	O
objectively	O
.	O
RESULTS	O
:	O
One	O
hundred	O
and	O
sixty	O
students	O
took	O
part	O
in	O
the	O
study	O
.	O
The	O
average	O
age	O
was	O
24	O
.	O
9	O
years	O
,	O
60	O
%	O
were	O
female	O
.	O
Most	O
of	O
the	O
participants	O
studied	O
on	O
their	O
own	O
using	O
their	O
private	O
computer	O
with	O
a	O
fast	O
internet	O
-	O
connection	O
at	O
home	O
.	O
The	O
average	O
usage	O
time	O
was	O
263	O
min	O
,	O
most	O
of	O
the	O
students	O
worked	O
with	O
the	O
system	O
in	O
the	O
afternoon	O
,	O
although	O
a	O
considerable	O
number	O
used	O
it	O
late	O
in	O
the	O
night	O
.	O
Regarding	O
learning	O
success	O
,	O
we	O
found	O
that	O
the	O
examination	O
results	O
were	O
significantly	O
better	O
after	O
using	O
the	O
system	O
(	O
7	O
.	O
66	O
versus	O
8	O
.	O
37	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O
Eighty	O
percent	O
of	O
the	O
students	O
enjoyed	O
dealing	O
with	O
the	O
virtual	O
patients	O
emphasizing	O
the	O
completeness	O
of	O
patient	O
cases	O
,	O
the	O
artistic	O
graphic	O
design	O
and	O
the	O
expert	O
comments	O
available	O
,	O
as	O
well	O
as	O
the	O
good	O
applicability	O
to	O
real	O
cases	O
.	O
Eighty	O
-	O
seven	O
percent	O
of	O
the	O
students	O
graded	O
the	O
virtual	O
orthopaedic	O
clinic	O
as	O
appropriate	O
to	O
teach	O
orthopaedic	O
content	O
.	O
CONCLUSION	O
:	O
Using	O
the	O
Inmedea	O
-	O
Simulator	O
is	O
an	O
effective	O
method	O
to	O
enhance	O
students	O
'	O
learning	O
efficacy	O
.	O
The	O
way	O
the	O
system	O
was	O
used	O
by	O
the	O
students	O
emphasises	O
the	O
advantages	O
of	O
the	O
internet	O
-	O
like	O
free	O
time	O
management	O
and	O
the	O
implementation	O
of	O
multimedia	O
-	O
based	O
content	O
.	O
Constitutively	O
nuclear	B-Anatomy
FOXO3a	O
localization	O
predicts	O
poor	O
survival	O
and	O
promotes	O
Akt	O
phosphorylation	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
BACKGROUND	O
:	O
The	O
PI3K	O
-	O
Akt	O
signal	O
pathway	O
plays	O
a	O
key	O
role	O
in	O
tumorigenesis	O
and	O
the	O
development	O
of	O
drug	O
-	O
resistance	O
.	O
Cytotoxic	O
chemotherapy	O
resistance	O
is	O
linked	O
to	O
limited	O
therapeutic	O
options	O
and	O
poor	O
prognosis	O
.	O
METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Examination	O
of	O
FOXO3a	O
and	O
phosphorylated	O
-	O
Akt	O
(	O
P	O
-	O
Akt	O
)	O
expression	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
tissue	I-Anatomy
microarrays	O
showed	O
nuclear	B-Anatomy
FOXO3a	O
was	O
associated	O
with	O
lymph	B-Anatomy
node	I-Anatomy
positivity	O
(	O
p	O
=	O
0	O
.	O
052	O
)	O
,	O
poor	O
prognosis	O
(	O
p	O
=	O
0	O
.	O
014	O
)	O
,	O
and	O
P	O
-	O
Akt	O
expression	O
in	O
invasive	B-Anatomy
ductal	I-Anatomy
carcinoma	I-Anatomy
.	O
Using	O
tamoxifen	O
and	O
doxorubicin	O
-	O
sensitive	O
and	O
-	O
resistant	O
breast	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
as	O
models	O
,	O
we	O
found	O
that	O
doxorubicin	O
-	O
but	O
not	O
tamoxifen	O
-	O
resistance	O
is	O
associated	O
with	O
nuclear	B-Anatomy
accumulation	O
of	O
FOXO3a	O
,	O
consistent	O
with	O
the	O
finding	O
that	O
sustained	O
nuclear	B-Anatomy
FOXO3a	O
is	O
associated	O
with	O
poor	O
prognosis	O
.	O
We	O
also	O
established	O
that	O
doxorubicin	O
treatment	O
induces	O
proliferation	O
arrest	O
and	O
FOXO3a	O
nuclear	B-Anatomy
relocation	O
in	O
sensitive	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Induction	O
of	O
FOXO3a	O
activity	O
in	O
doxorubicin	O
-	O
sensitive	O
MCF	B-Anatomy
-	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
was	O
sufficient	O
to	O
promote	O
Akt	O
phosphorylation	O
and	O
arrest	O
cell	B-Anatomy
proliferation	O
.	O
Conversely	O
,	O
knockdown	O
of	O
endogenous	O
FOXO3a	O
expression	O
reduced	O
PI3K	O
/	O
Akt	O
activity	O
.	O
Using	O
MDA	B-Anatomy
-	I-Anatomy
MB	I-Anatomy
-	I-Anatomy
231	I-Anatomy
cells	I-Anatomy
,	O
in	O
which	O
FOXO3a	O
activity	O
can	O
be	O
induced	O
by	O
4	O
-	O
hydroxytamoxifen	O
,	O
we	O
showed	O
that	O
FOXO3a	O
induction	O
up	O
-	O
regulates	O
PI3K	O
-	O
Akt	O
activity	O
and	O
enhanced	O
doxorubicin	O
resistance	O
.	O
However	O
FOXO3a	O
induction	O
has	O
little	O
effect	O
on	O
cell	B-Anatomy
proliferation	O
,	O
indicating	O
that	O
FOXO3a	O
or	O
its	O
downstream	O
activity	O
is	O
deregulated	O
in	O
the	O
cytotoxic	O
drug	O
resistant	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Thus	O
,	O
our	O
results	O
suggest	O
that	O
sustained	O
FOXO3a	O
activation	O
can	O
enhance	O
hyperactivation	O
of	O
the	O
PI3K	O
/	O
Akt	O
pathway	O
.	O
CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
Together	O
these	O
data	O
suggest	O
that	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
and	O
poor	O
survival	O
in	O
invasive	B-Anatomy
ductal	I-Anatomy
breast	I-Anatomy
carcinoma	I-Anatomy
are	O
linked	O
to	O
an	O
uncoupling	O
of	O
the	O
Akt	O
-	O
FOXO3a	O
signaling	O
axis	O
.	O
In	O
these	O
breast	B-Anatomy
cancers	I-Anatomy
activated	O
Akt	O
fails	O
to	O
inactivate	O
and	O
re	O
-	O
localize	O
FOXO3a	O
to	O
the	O
cytoplasm	B-Anatomy
,	O
and	O
nuclear	B-Anatomy
-	O
targeted	O
FOXO3a	O
does	O
not	O
induce	O
cell	B-Anatomy
death	O
or	O
cell	B-Anatomy
cycle	O
arrest	O
.	O
As	O
such	O
,	O
sustained	O
nuclear	B-Anatomy
FOXO3a	O
expression	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
may	O
culminate	O
in	O
cancer	B-Anatomy
progression	O
and	O
the	O
development	O
of	O
an	O
aggressive	O
phenotype	O
similar	O
to	O
that	O
observed	O
in	O
cytotoxic	O
chemotherapy	O
resistant	O
breast	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
models	O
.	O
Skin	B-Anatomy
deep	O
and	O
deeper	O
:	O
multiple	O
pathways	O
in	O
basal	B-Anatomy
cell	I-Anatomy
carcinogenesis	O
.	O
This	O
perspective	O
places	O
the	O
report	O
by	O
Villani	O
et	O
al	O
.	O
that	O
appears	O
in	O
this	O
issue	O
of	O
the	O
journal	O
(	O
beginning	O
on	O
page	O
1222	O
)	O
in	O
the	O
context	O
of	O
recent	O
work	O
showing	O
an	O
intersection	O
between	O
two	O
important	O
developmental	O
pathways	O
implicated	O
in	O
oncogenesis	O
:	O
the	O
hedgehog	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
pathways	O
.	O
Villani	O
et	O
al	O
.	O
define	O
a	O
key	O
role	O
for	O
the	O
IGF	O
regulatory	O
protein	O
Igfbp2	O
in	O
a	O
genetic	O
model	O
of	O
basal	B-Anatomy
cell	I-Anatomy
carcinogenesis	O
driven	O
by	O
targeted	O
constitutive	O
activation	O
of	O
hedgehog	O
signaling	O
.	O
Placed	O
in	O
the	O
framework	O
of	O
other	O
recently	O
published	O
work	O
,	O
the	O
observations	O
of	O
Villani	O
et	O
al	O
.	O
both	O
raise	O
questions	O
about	O
the	O
cell	B-Anatomy
of	O
origin	O
for	O
basal	B-Anatomy
cell	I-Anatomy
cancers	I-Anatomy
and	O
define	O
additional	O
putative	O
therapeutic	O
and	O
preventive	O
targets	O
for	O
this	O
disease	O
.	O
Brick1	O
is	O
an	O
essential	O
regulator	O
of	O
actin	O
cytoskeleton	B-Anatomy
required	O
for	O
embryonic	B-Anatomy
development	O
and	O
cell	B-Anatomy
transformation	O
.	O
Brick1	O
(	O
Brk1	O
)	O
is	O
the	O
less	O
-	O
studied	O
component	O
of	O
the	O
Wave	O
/	O
Scar	O
pathway	O
involved	O
in	O
the	O
branched	O
nucleation	O
of	O
actin	O
fibers	B-Anatomy
.	O
The	O
clinical	O
relevance	O
of	O
Brk1	O
is	O
emphasized	O
by	O
correlative	O
data	O
showing	O
that	O
Von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
patients	O
that	O
also	O
lose	O
the	O
BRK1	O
gene	O
are	O
protected	O
against	O
the	O
development	O
of	O
tumors	B-Anatomy
.	O
This	O
contrasts	O
with	O
recent	O
evidence	O
suggesting	O
that	O
the	O
Wave	O
complex	O
may	O
function	O
as	O
an	O
invasion	O
suppressor	O
in	O
epithelial	B-Anatomy
cancers	I-Anatomy
.	O
Here	O
,	O
we	O
show	O
that	O
the	O
downregulation	O
of	O
Brk1	O
results	O
in	O
abnormal	O
actin	O
stress	B-Anatomy
fiber	I-Anatomy
formation	O
and	O
vinculin	O
distribution	O
and	O
loss	O
of	O
Arp2	O
/	O
3	O
and	O
Wave	O
proteins	O
at	O
the	O
cellular	B-Anatomy
protrusions	O
.	O
Brk1	O
is	O
required	O
for	O
cell	B-Anatomy
proliferation	O
and	O
cell	B-Anatomy
transformation	O
by	O
oncogenes	O
.	O
In	O
addition	O
,	O
Brk1	O
downregulation	O
results	O
in	O
defective	O
directional	O
migration	O
and	O
invasive	O
growth	O
in	O
renal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
as	O
well	O
as	O
in	O
other	O
tumor	B-Anatomy
cell	I-Anatomy
types	O
.	O
Finally	O
,	O
genetic	O
ablation	O
of	O
Brk1	O
results	O
in	O
dramatic	O
defects	O
in	O
embryo	B-Anatomy
compaction	O
and	O
development	O
,	O
suggesting	O
an	O
essential	O
role	O
for	O
this	O
protein	O
in	O
actin	O
dynamics	O
.	O
Thus	O
,	O
genetic	O
loss	O
or	O
inhibition	O
of	O
BRK1	O
is	O
likely	O
to	O
be	O
protective	O
against	O
tumor	B-Anatomy
development	O
due	O
to	O
proliferation	O
and	O
motility	O
defects	O
in	O
affected	O
cells	B-Anatomy
.	O
Ras	O
-	O
association	O
domain	O
family	O
1C	O
protein	O
promotes	O
breast	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
migration	O
and	O
attenuates	O
apoptosis	O
.	O
BACKGROUND	O
:	O
The	O
Ras	O
association	O
domain	O
family	O
1	O
(	O
RASSF1	O
)	O
gene	O
is	O
a	O
Ras	O
effector	O
encoding	O
two	O
major	O
mRNA	O
forms	O
,	O
RASSF1A	O
and	O
RASSF1C	O
,	O
derived	O
by	O
alternative	O
promoter	O
selection	O
and	O
alternative	O
mRNA	O
splicing	O
.	O
RASSF1A	O
is	O
a	O
tumor	B-Anatomy
suppressor	O
gene	O
.	O
However	O
,	O
very	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
RASSF1C	O
both	O
in	O
normal	O
and	O
transformed	O
cells	B-Anatomy
.	O
METHODS	O
:	O
Gene	O
silencing	O
and	O
over	O
-	O
expression	O
techniques	O
were	O
used	O
to	O
modulate	O
RASSF1C	O
expression	O
in	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Affymetrix	O
-	O
microarray	O
analysis	O
was	O
performed	O
using	O
T47D	B-Anatomy
cells	I-Anatomy
over	O
-	O
expressing	O
RASSF1C	O
to	O
identify	O
RASSF1C	O
target	O
genes	O
.	O
RT	O
-	O
PCR	O
and	O
western	O
blot	O
techniques	O
were	O
used	O
to	O
validate	O
target	O
gene	O
expression	O
.	O
Cell	B-Anatomy
invasion	O
and	O
apoptosis	O
assays	O
were	O
also	O
performed	O
.	O
RESULTS	O
:	O
In	O
this	O
article	O
,	O
we	O
report	O
the	O
effects	O
of	O
altering	O
RASSF1C	O
expression	O
in	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
We	O
found	O
that	O
silencing	O
RASSF1C	O
mRNA	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
(	O
MDA	B-Anatomy
-	I-Anatomy
MB231	I-Anatomy
and	O
T47D	B-Anatomy
)	O
caused	O
a	O
small	O
but	O
significant	O
decrease	O
in	O
cell	B-Anatomy
proliferation	O
.	O
Conversely	O
,	O
inducible	O
over	O
-	O
expression	O
of	O
RASSF1C	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
(	O
MDA	B-Anatomy
-	I-Anatomy
MB231	I-Anatomy
and	O
T47D	B-Anatomy
)	O
resulted	O
in	O
a	O
small	O
increase	O
in	O
cell	B-Anatomy
proliferation	O
.	O
We	O
also	O
report	O
on	O
the	O
identification	O
of	O
novel	O
RASSF1C	O
target	O
genes	O
.	O
RASSF1C	O
down	O
-	O
regulates	O
several	O
pro	O
-	O
apoptotic	O
and	O
tumor	B-Anatomy
suppressor	O
genes	O
and	O
up	O
-	O
regulates	O
several	O
growth	O
promoting	O
genes	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
We	O
further	O
show	O
that	O
down	O
-	O
regulation	O
of	O
caspase	O
3	O
via	O
overexpression	O
of	O
RASSF1C	O
reduces	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
'	O
sensitivity	O
to	O
the	O
apoptosis	O
inducing	O
agent	O
,	O
etoposide	O
.	O
Furthermore	O
,	O
we	O
found	O
that	O
RASSF1C	O
over	O
-	O
expression	O
enhances	O
T47D	B-Anatomy
cell	I-Anatomy
invasion	O
/	O
migration	O
in	O
vitro	O
.	O
CONCLUSION	O
:	O
Together	O
,	O
our	O
findings	O
suggest	O
that	O
RASSF1C	O
,	O
unlike	O
RASSF1A	O
,	O
is	O
not	O
a	O
tumor	B-Anatomy
suppressor	O
,	O
but	O
instead	O
may	O
play	O
a	O
role	O
in	O
stimulating	O
metastasis	O
and	O
survival	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Role	O
of	O
stromal	B-Anatomy
myofibroblasts	I-Anatomy
in	O
invasive	B-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
:	O
stromal	B-Anatomy
expression	O
of	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
correlates	O
with	O
worse	O
clinical	O
outcome	O
.	O
BACKGROUND	O
:	O
Recently	O
,	O
the	O
desmoplastic	O
reaction	O
has	O
been	O
implicated	O
as	O
having	O
an	O
important	O
function	O
in	O
epithelial	B-Anatomy
solid	I-Anatomy
tumor	I-Anatomy
biology	O
.	O
There	O
have	O
been	O
no	O
reports	O
showing	O
the	O
relativity	O
of	O
invasive	B-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
and	O
the	O
desmoplastic	O
reaction	O
by	O
a	O
quantitative	O
analysis	O
of	O
the	O
myofibroblasts	B-Anatomy
that	O
were	O
an	O
important	O
player	O
in	O
the	O
desmoplastic	O
reaction	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
immunohistochemically	O
investigate	O
the	O
correlation	O
between	O
the	O
desmoplastic	O
reaction	O
and	O
the	O
clinicopathology	O
of	O
invasive	B-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
.	O
METHODS	O
:	O
The	O
study	O
included	O
60	O
patients	O
with	O
a	O
known	O
prognosis	O
of	O
invasive	B-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
.	O
We	O
quantified	O
the	O
expression	O
of	O
alpha	O
-	O
SMA	O
as	O
a	O
marker	O
of	O
myofibroblasts	B-Anatomy
in	O
the	O
invasive	B-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
.	O
After	O
staining	O
samples	B-Anatomy
for	O
alpha	O
-	O
SMA	O
,	O
their	O
expression	O
was	O
extracted	O
and	O
quantified	O
as	O
a	O
relative	O
percentage	O
by	O
computer	O
-	O
assisted	O
image	O
analysis	O
.	O
RESULTS	O
:	O
There	O
was	O
relatively	O
wide	O
variation	O
in	O
the	O
expression	O
of	O
alpha	O
-	O
SMA	O
with	O
the	O
percentage	O
of	O
the	O
area	O
from	O
0	O
.	O
68	O
to	O
28	O
.	O
15	O
%	O
(	O
mean	O
8	O
.	O
48	O
+	O
/	O
-	O
5	O
.	O
40	O
%	O
)	O
.	O
The	O
metastasis	O
group	O
showed	O
significantly	O
higher	O
alpha	O
-	O
SMA	O
expression	O
compared	O
with	O
the	O
no	O
metastasis	O
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
When	O
the	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
according	O
to	O
their	O
alpha	O
-	O
SMA	O
expression	O
using	O
a	O
cutoff	O
point	O
at	O
the	O
mean	O
value	O
of	O
8	O
.	O
48	O
%	O
,	O
the	O
high	O
alpha	O
-	O
SMA	O
group	O
had	O
a	O
significantly	O
poorer	O
overall	O
survival	O
rate	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
Multivariate	O
analysis	O
demonstrated	O
that	O
alpha	O
-	O
SMA	O
and	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
were	O
identified	O
as	O
independent	O
predictive	O
factors	O
of	O
metastasis	O
.	O
CONCLUSION	O
:	O
Myofibroblasts	B-Anatomy
represent	O
an	O
important	O
prognostic	O
factor	O
for	O
invasive	O
growth	O
that	O
is	O
translated	O
into	O
a	O
poor	O
clinical	O
prognosis	O
for	O
patients	O
with	O
invasive	B-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
.	O
The	O
disintegrin	O
-	O
like	O
and	O
cysteine	O
-	O
rich	O
domains	O
of	O
ADAM	O
-	O
9	O
mediate	O
interactions	O
between	O
melanoma	B-Anatomy
cells	I-Anatomy
and	O
fibroblasts	B-Anatomy
.	O
A	O
characteristic	O
of	O
malignant	B-Anatomy
cells	I-Anatomy
is	O
their	O
capacity	O
to	O
invade	O
their	O
surrounding	O
and	O
to	O
metastasize	O
to	O
distant	O
organs	B-Anatomy
.	O
During	O
these	O
processes	O
,	O
proteolytic	O
activities	O
of	O
tumor	B-Anatomy
and	O
stromal	B-Anatomy
cells	I-Anatomy
modify	O
the	O
extracellular	B-Anatomy
matrix	I-Anatomy
to	O
produce	O
a	O
microenvironment	O
suitable	O
for	O
their	O
growth	O
and	O
migration	O
.	O
In	O
recent	O
years	O
the	O
family	O
of	O
ADAM	O
proteases	O
has	O
been	O
ascribed	O
important	O
roles	O
in	O
these	O
processes	O
.	O
ADAM	O
-	O
9	O
is	O
expressed	O
in	O
human	O
melanoma	B-Anatomy
at	O
the	O
tumor	B-Anatomy
-	I-Anatomy
stroma	I-Anatomy
border	I-Anatomy
where	O
direct	O
or	O
indirect	O
interactions	O
between	O
tumor	B-Anatomy
cells	I-Anatomy
and	O
fibroblasts	B-Anatomy
occur	O
.	O
To	O
analyze	O
the	O
role	O
of	O
ADAM	O
-	O
9	O
for	O
the	O
interaction	O
between	O
melanoma	B-Anatomy
cells	I-Anatomy
and	O
stromal	B-Anatomy
fibroblasts	I-Anatomy
,	O
we	O
produced	O
the	O
recombinant	O
disintegrin	O
-	O
like	O
and	O
cysteine	O
-	O
rich	O
domain	O
of	O
ADAM	O
-	O
9	O
(	O
DC	O
-	O
9	O
)	O
.	O
Melanoma	B-Anatomy
cells	I-Anatomy
and	O
human	O
fibroblasts	B-Anatomy
adhered	O
to	O
immobilized	O
DC	O
-	O
9	O
in	O
a	O
Mn	O
(	O
2	O
+	O
)	O
-	O
dependent	O
fashion	O
suggesting	O
an	O
integrin	O
-	O
mediated	O
process	O
.	O
Inhibition	O
studies	O
showed	O
that	O
adhesion	O
of	O
fibroblasts	B-Anatomy
was	O
mediated	O
by	O
several	O
beta1	O
integrin	O
receptors	O
independent	O
of	O
the	O
RGD	O
and	O
ECD	O
recognition	O
motif	O
.	O
Furthermore	O
,	O
interaction	O
of	O
fibroblasts	B-Anatomy
and	O
high	B-Anatomy
invasive	I-Anatomy
melanoma	I-Anatomy
cells	I-Anatomy
with	O
soluble	O
recombinant	O
DC	O
-	O
9	O
resulted	O
in	O
enhanced	O
expression	O
of	O
MMP	O
-	O
1	O
and	O
MMP	O
-	O
2	O
.	O
Silencing	O
of	O
ADAM	O
-	O
9	O
in	O
melanoma	B-Anatomy
cells	I-Anatomy
significantly	O
reduced	O
cell	B-Anatomy
adhesion	O
to	O
fibroblasts	B-Anatomy
.	O
Ablation	O
of	O
ADAM	O
-	O
9	O
in	O
fibroblasts	B-Anatomy
almost	O
completely	O
abolished	O
these	O
cellular	B-Anatomy
interactions	O
and	O
melanoma	B-Anatomy
cell	I-Anatomy
invasion	O
in	O
vitro	O
.	O
In	O
summary	O
,	O
these	O
results	O
suggest	O
that	O
ADAM	O
-	O
9	O
expression	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
cell	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
contacts	I-Anatomy
between	O
fibroblasts	B-Anatomy
and	O
melanoma	B-Anatomy
cells	I-Anatomy
and	O
that	O
these	O
interactions	O
contribute	O
to	O
proteolytic	O
activities	O
required	O
during	O
invasion	O
of	O
melanoma	B-Anatomy
cells	I-Anatomy
.	O
Emerging	O
metabolic	O
targets	O
in	O
cancer	B-Anatomy
therapy	O
.	O
Cancer	B-Anatomy
cells	I-Anatomy
are	O
different	O
from	O
normal	O
cells	B-Anatomy
in	O
their	O
metabolic	O
properties	O
.	O
Normal	O
cells	B-Anatomy
mostly	O
rely	O
on	O
mitochondrial	B-Anatomy
oxidative	O
phosphorylation	O
to	O
produce	O
energy	O
.	O
In	O
contrast	O
,	O
cancer	B-Anatomy
cells	I-Anatomy
depend	O
mostly	O
on	O
glycolysis	O
,	O
the	O
aerobic	O
breakdown	O
of	O
glucose	O
into	O
ATP	O
.	O
This	O
altered	O
energy	O
dependency	O
is	O
known	O
as	O
the	O
""""	O
Warburg	O
effect	O
""""	O
and	O
is	O
a	O
hallmark	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
In	O
recent	O
years	O
,	O
investigating	O
the	O
metabolic	O
changes	O
within	O
cancer	B-Anatomy
cells	I-Anatomy
has	O
been	O
a	O
rapidly	O
growing	O
area	O
.	O
Emerging	O
evidence	O
shows	O
that	O
oncogenes	O
that	O
drive	O
the	O
cancer	B-Anatomy
-	O
promoting	O
signals	O
also	O
drive	O
the	O
altered	O
metabolism	O
.	O
Although	O
the	O
exact	O
mechanisms	O
underlying	O
the	O
Warburg	O
effect	O
are	O
unclear	O
,	O
the	O
existing	O
evidence	O
suggests	O
that	O
increased	O
glycolysis	O
plays	O
an	O
important	O
role	O
in	O
support	O
malignant	O
behavior	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
A	O
thorough	O
understanding	O
of	O
the	O
unique	O
metabolism	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
will	O
help	O
to	O
design	O
of	O
more	O
effective	O
drugs	O
targeting	O
metabolic	O
pathways	O
,	O
which	O
will	O
greatly	O
impact	O
the	O
capacity	O
to	O
effectively	O
treat	O
cancer	B-Anatomy
patients	O
.	O
Here	O
we	O
provide	O
an	O
overview	O
of	O
the	O
current	O
understanding	O
of	O
the	O
Warburg	O
effect	O
upon	O
tumor	B-Anatomy
cell	I-Anatomy
growth	O
and	O
survival	O
,	O
and	O
discussion	O
on	O
the	O
potential	O
metabolic	O
targets	O
for	O
cancer	B-Anatomy
therapy	O
.	O
MTSS1	O
:	O
a	O
multifunctional	O
protein	O
and	O
its	O
role	O
in	O
cancer	B-Anatomy
invasion	O
and	O
metastasis	O
.	O
MTSS1	O
(	O
metastasis	O
suppressor	O
-	O
1	O
)	O
was	O
first	O
identified	O
as	O
a	O
metastasis	O
suppressor	O
missing	O
in	O
metastatic	B-Anatomy
bladder	I-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
The	O
down	O
-	O
regulation	O
of	O
MTSS1	O
that	O
may	O
be	O
caused	O
by	O
DNA	O
methylation	O
was	O
also	O
observed	O
in	O
many	O
other	O
types	O
of	O
cancer	B-Anatomy
.	O
While	O
accumlating	O
evidence	O
for	O
the	O
function	O
of	O
MTSS1	O
support	O
the	O
concept	O
that	O
it	O
is	O
unlikely	O
to	O
be	O
a	O
metastasis	O
suppressor	O
,	O
but	O
actually	O
acts	O
as	O
a	O
scaffold	O
protein	O
that	O
interacts	O
with	O
multiple	O
partners	O
to	O
regulate	O
actin	O
dynamics	O
.	O
It	O
has	O
also	O
been	O
demonstrated	O
that	O
MTSS1	O
is	O
involved	O
in	O
the	O
Shh	O
signaling	O
pathway	O
in	O
the	O
developing	O
hair	B-Anatomy
follicle	I-Anatomy
and	O
in	O
basal	B-Anatomy
cell	I-Anatomy
carcinomas	I-Anatomy
of	O
the	O
skin	B-Anatomy
.	O
Such	O
evidence	O
indicates	O
that	O
MTSS1	O
as	O
a	O
multiple	O
functional	O
molecular	O
player	O
and	O
has	O
an	O
important	O
role	O
in	O
development	O
,	O
carcinogenesis	O
and	O
metastasis	O
.	O
However	O
,	O
the	O
biochemical	O
mechanisms	O
by	O
which	O
MTSS1	O
functions	O
in	O
cells	B-Anatomy
and	O
the	O
physiological	O
role	O
of	O
this	O
protein	O
in	O
animals	O
remain	O
largely	O
unknown	O
.	O
In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
the	O
current	O
knowledge	O
of	O
MTSS1	O
'	O
s	O
role	O
in	O
cancer	B-Anatomy
metastasis	O
,	O
carcinogenesis	O
,	O
and	O
development	O
.	O
The	O
clinical	O
significance	O
of	O
MTSS1	O
will	O
also	O
be	O
discussed	O
.	O
Ras	O
p21	O
onco	O
-	O
protein	O
in	O
the	O
sera	B-Anatomy
of	O
mice	O
carrying	O
an	O
experimentally	O
induced	O
tumor	B-Anatomy
and	O
in	O
human	O
cancer	B-Anatomy
patients	O
.	O
We	O
have	O
established	O
a	O
model	O
system	O
to	O
detect	O
the	O
presence	O
of	O
ras	O
p21	O
in	O
the	O
sera	B-Anatomy
of	O
Balb	O
/	O
c	O
mice	O
carrying	O
tumors	B-Anatomy
induced	O
by	O
a	O
mouse	O
cell	B-Anatomy
line	I-Anatomy
transformed	O
with	O
the	O
Harvey	O
murine	O
sarcoma	O
virus	O
in	O
the	O
presence	O
of	O
a	O
helper	O
Friend	O
murine	O
leukemia	O
virus	O
.	O
As	O
determined	O
by	O
ELISA	O
and	O
immunoblot	O
assays	O
,	O
ras	O
p21	O
in	O
the	O
serum	B-Anatomy
increased	O
with	O
increased	O
tumor	B-Anatomy
growth	O
.	O
Since	O
ras	O
genes	O
have	O
been	O
found	O
to	O
be	O
frequently	O
activated	O
in	O
human	O
tumours	B-Anatomy
,	O
we	O
examined	O
the	O
levels	O
of	O
ras	O
p21	O
in	O
the	O
sera	B-Anatomy
of	O
a	O
variety	O
of	O
human	O
cancer	B-Anatomy
patients	O
.	O
In	O
only	O
3	O
out	O
of	O
13	O
cases	O
,	O
representing	O
patients	O
with	O
adenocarcinomas	B-Anatomy
of	O
the	O
stomach	B-Anatomy
receiving	O
chemotherapy	O
,	O
was	O
ras	O
p21	O
detected	O
at	O
elevated	O
levels	O
,	O
whereas	O
in	O
patients	O
with	O
the	O
following	O
types	O
of	O
cancer	B-Anatomy
no	O
substantial	O
change	O
in	O
serum	B-Anatomy
ras	O
p21	O
was	O
observed	O
;	O
nine	O
with	O
breast	B-Anatomy
,	O
5	O
colon	B-Anatomy
,	O
5	O
lung	B-Anatomy
,	O
5	O
ovarian	B-Anatomy
and	O
5	O
hepatocellular	B-Anatomy
carcinomas	I-Anatomy
.	O
Serum	B-Anatomy
soluble	O
vascular	O
adhesion	O
protein	O
-	O
1	O
is	O
a	O
valuable	O
prognostic	O
marker	O
in	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
BACKGROUND	O
:	O
Vascular	O
adhesion	O
protein	O
-	O
1	O
(	O
VAP	O
-	O
1	O
)	O
regulates	O
leukocyte	B-Anatomy
tissue	I-Anatomy
infiltration	O
.	O
Elevated	O
serum	B-Anatomy
soluble	O
VAP	O
-	O
1	O
(	O
sVAP	O
-	O
1	O
)	O
levels	O
occur	O
in	O
certain	O
diseases	O
having	O
an	O
inflammatory	O
component	O
.	O
We	O
previously	O
showed	O
in	O
colorectal	B-Anatomy
cancer	I-Anatomy
that	O
sVAP	O
-	O
1	O
expression	O
is	O
significantly	O
higher	O
relative	O
to	O
controls	O
,	O
and	O
this	O
decreased	O
expression	O
is	O
associated	O
with	O
poor	O
prognosis	O
and	O
lymph	B-Anatomy
node	I-Anatomy
and	O
liver	B-Anatomy
metastasis	O
.	O
However	O
,	O
sVAP	O
-	O
1	O
expression	O
has	O
not	O
been	O
described	O
for	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
This	O
study	O
determines	O
the	O
relationship	O
between	O
preoperative	O
serum	B-Anatomy
sVAP	O
-	O
1	O
levels	O
and	O
clinicopathological	O
features	O
and	O
prognosis	O
in	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
METHODS	O
:	O
Preoperative	O
serum	B-Anatomy
was	O
collected	O
from	O
107	O
gastric	B-Anatomy
cancer	I-Anatomy
patients	O
and	O
33	O
normal	O
controls	O
.	O
sVAP	O
-	O
1	O
levels	O
were	O
assayed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O
RESULTS	O
:	O
The	O
mean	O
sVAP	O
-	O
1	O
level	O
for	O
cancer	B-Anatomy
patients	O
was	O
significantly	O
higher	O
relative	O
to	O
controls	O
,	O
and	O
decreased	O
with	O
disease	O
progression	O
.	O
Tumor	B-Anatomy
size	O
,	O
serosal	B-Anatomy
invasion	O
,	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
,	O
peritoneal	B-Anatomy
dissemination	O
,	O
and	O
TNM	O
classification	O
was	O
significantly	O
correlated	O
with	O
sVAP	O
-	O
1	O
level	O
.	O
sVAP	O
-	O
1	O
is	O
also	O
an	O
independent	O
predictive	O
marker	O
for	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
.	O
Patients	O
having	O
low	O
sVAP	O
-	O
1	O
levels	O
had	O
significantly	O
poorer	O
prognosis	O
relative	O
to	O
patients	O
having	O
elevated	O
sVAP	O
-	O
1	O
in	O
all	O
or	O
stages	O
I	O
-	O
III	O
gastric	B-Anatomy
cancer	I-Anatomy
patients	O
,	O
respectively	O
.	O
CONCLUSIONS	O
:	O
Low	O
sVAP	O
-	O
1	O
levels	O
are	O
associated	O
with	O
poor	O
prognosis	O
in	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
Determining	O
sVAP	O
-	O
1	O
levels	O
may	O
be	O
valuable	O
for	O
predicting	O
prognosis	O
and	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
.	O
Metabolic	O
regulation	O
by	O
p53	O
.	O
We	O
are	O
increasingly	O
aware	O
that	O
cellular	B-Anatomy
metabolism	O
plays	O
a	O
vital	O
role	O
in	O
diseases	O
such	O
as	O
cancer	B-Anatomy
,	O
and	O
that	O
p53	O
is	O
an	O
important	O
regulator	O
of	O
metabolic	O
pathways	O
.	O
By	O
transcriptional	O
activation	O
and	O
other	O
means	O
,	O
p53	O
is	O
able	O
to	O
contribute	O
to	O
the	O
regulation	O
of	O
glycolysis	O
,	O
oxidative	O
phosphorylation	O
,	O
glutaminolysis	O
,	O
insulin	O
sensitivity	O
,	O
nucleotide	O
biosynthesis	O
,	O
mitochondrial	B-Anatomy
integrity	O
,	O
fatty	O
acid	O
oxidation	O
,	O
antioxidant	O
response	O
,	O
autophagy	O
and	O
mTOR	O
signalling	O
.	O
The	O
ability	O
to	O
positively	O
and	O
negatively	O
regulate	O
many	O
of	O
these	O
pathways	O
,	O
combined	O
with	O
feedback	O
signalling	O
from	O
these	O
pathways	O
to	O
p53	O
,	O
demonstrates	O
the	O
reciprocal	O
and	O
flexible	O
nature	O
of	O
the	O
regulation	O
,	O
facilitating	O
a	O
diverse	O
range	O
of	O
responses	O
to	O
metabolic	O
stress	O
.	O
Intriguingly	O
,	O
metabolic	O
stress	O
triggers	O
primarily	O
an	O
adaptive	O
(	O
rather	O
than	O
pro	O
-	O
apoptotic	O
)	O
p53	O
response	O
,	O
and	O
p53	O
is	O
emerging	O
as	O
an	O
important	O
regulator	O
of	O
metabolic	O
homeostasis	O
.	O
A	O
better	O
understanding	O
of	O
how	O
p53	O
coordinates	O
metabolic	O
adaptation	O
will	O
facilitate	O
the	O
identification	O
of	O
novel	O
therapeutic	O
targets	O
and	O
will	O
also	O
illuminate	O
the	O
wider	O
role	O
of	O
p53	O
in	O
human	O
biology	O
.	O
Use	O
of	O
DNA	O
microarray	O
and	O
small	O
animal	O
positron	O
emission	O
tomography	O
in	O
preclinical	O
drug	O
evaluation	O
of	O
RAF265	O
,	O
a	O
novel	O
B	O
-	O
Raf	O
/	O
VEGFR	O
-	O
2	O
inhibitor	O
.	O
Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
imaging	O
has	O
become	O
a	O
useful	O
tool	O
for	O
assessing	O
early	O
biologic	O
response	O
to	O
cancer	B-Anatomy
therapy	O
and	O
may	O
be	O
particularly	O
useful	O
in	O
the	O
development	O
of	O
new	O
cancer	B-Anatomy
therapeutics	O
.	O
RAF265	O
,	O
a	O
novel	O
B	O
-	O
Raf	O
/	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
2	O
inhibitor	O
,	O
was	O
evaluated	O
in	O
the	O
preclinical	O
setting	O
for	O
its	O
ability	O
to	O
inhibit	O
the	O
uptake	O
of	O
PET	O
tracers	O
in	O
the	O
A375M	B-Anatomy
(	I-Anatomy
B	I-Anatomy
-	I-Anatomy
Raf	I-Anatomy
(	I-Anatomy
V600E	I-Anatomy
)	I-Anatomy
)	I-Anatomy
human	I-Anatomy
melanoma	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
.	O
RAF265	O
inhibited	O
2	O
-	O
deoxy	O
-	O
2	O
-	O
[	O
(	O
18	O
)	O
F	O
]	O
fluoro	O
-	O
d	O
-	O
glucose	O
(	O
FDG	O
)	O
accumulation	O
in	O
cell	B-Anatomy
culture	I-Anatomy
at	O
28	O
hours	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
RAF265	O
also	O
inhibited	O
FDG	O
accumulation	O
in	O
tumor	B-Anatomy
xenografts	I-Anatomy
after	O
1	O
day	O
of	O
drug	O
treatment	O
.	O
This	O
decrease	O
persisted	O
for	O
the	O
remaining	O
2	O
weeks	O
of	O
treatment	O
.	O
DNA	O
microarray	O
analysis	O
of	O
treated	O
tumor	B-Anatomy
xenografts	I-Anatomy
revealed	O
significantly	O
decreased	O
expression	O
of	O
genes	O
regulating	O
glucose	O
and	O
thymidine	O
metabolism	O
and	O
revealed	O
changes	O
in	O
apoptotic	O
genes	O
,	O
suggesting	O
that	O
the	O
imaging	O
tracers	O
FDG	O
,	O
3	O
-	O
deoxy	O
-	O
3	O
-	O
[	O
(	O
18	O
)	O
F	O
]	O
fluorothymidine	O
,	O
and	O
annexin	O
V	O
could	O
serve	O
as	O
potential	O
imaging	O
biomarkers	O
for	O
RAF265	O
therapy	O
monitoring	O
.	O
We	O
concluded	O
that	O
RAF265	O
is	O
highly	O
efficacious	O
in	O
this	O
xenograft	B-Anatomy
model	O
of	O
human	O
melanoma	B-Anatomy
and	O
decreases	O
glucose	O
metabolism	O
as	O
measured	O
by	O
DNA	O
microarray	O
analysis	O
,	O
cell	B-Anatomy
culture	I-Anatomy
assays	O
,	O
and	O
small	O
animal	O
FDG	O
PET	O
scans	O
as	O
early	O
as	O
1	O
day	O
after	O
treatment	O
.	O
Our	O
results	O
support	O
the	O
use	O
of	O
FDG	O
PET	O
in	O
clinical	O
trials	O
with	O
RAF265	O
to	O
assess	O
early	O
tumor	B-Anatomy
response	O
.	O
DNA	O
microarray	O
analysis	O
and	O
small	O
animal	O
PET	O
studies	O
may	O
be	O
used	O
as	O
complementary	O
technologies	O
in	O
drug	O
development	O
.	O
DNA	O
microarray	O
analysis	O
allows	O
for	O
analysis	O
of	O
drug	O
effects	O
on	O
multiple	O
pathways	O
linked	O
to	O
cancer	B-Anatomy
and	O
can	O
suggest	O
corresponding	O
imaging	O
tracers	O
for	O
further	O
analysis	O
as	O
biomarkers	O
of	O
tumor	B-Anatomy
response	O
.	O
Predictive	O
value	O
of	O
serum	B-Anatomy
carbohydrate	O
antigen	O
19	O
-	O
9	O
in	O
malignant	B-Anatomy
intraductal	I-Anatomy
papillary	I-Anatomy
mucinous	I-Anatomy
neoplasms	I-Anatomy
.	O
BACKGROUND	O
:	O
The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
predictive	O
value	O
of	O
serum	B-Anatomy
carbohydrate	O
antigen	O
19	O
-	O
9	O
(	O
CA	O
19	O
-	O
9	O
)	O
in	O
the	O
diagnosis	O
of	O
malignant	B-Anatomy
intraductal	I-Anatomy
papillary	I-Anatomy
mucinous	I-Anatomy
neoplasms	I-Anatomy
of	O
pancreas	B-Anatomy
(	O
IPMNs	B-Anatomy
)	O
.	O
METHODS	O
:	O
Eighty	O
-	O
six	O
patients	O
with	O
pathological	O
diagnosis	O
of	O
IPMNs	B-Anatomy
in	O
Zhongshan	O
Hospital	O
between	O
March	O
1999	O
and	O
November	O
2008	O
were	O
retrospectively	O
reviewed	O
.	O
Data	O
reflecting	O
clinical	O
characteristics	O
,	O
tumor	B-Anatomy
marker	O
level	O
,	O
and	O
prognosis	O
were	O
collected	O
.	O
The	O
potential	O
predictive	O
value	O
of	O
CA	O
19	O
-	O
9	O
was	O
analyzed	O
by	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
.	O
RESULTS	O
:	O
Eighty	O
-	O
six	O
consecutive	O
patients	O
with	O
IPMNs	B-Anatomy
all	O
underwent	O
surgical	O
intervention	O
.	O
A	O
high	O
level	O
of	O
CA	O
19	O
-	O
9	O
or	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
was	O
associated	O
with	O
more	O
advanced	O
stage	O
of	O
malignant	B-Anatomy
IPMNs	I-Anatomy
.	O
Carbohydrate	O
antigen	O
19	O
-	O
9	O
was	O
significant	O
for	O
judging	O
malignant	B-Anatomy
IPMNs	I-Anatomy
in	O
the	O
binary	O
logistic	O
regression	O
model	O
(	O
p	O
=	O
0	O
.	O
047	O
)	O
.	O
The	O
hazard	O
ratio	O
was	O
1	O
.	O
014	O
,	O
whose	O
95	O
.	O
0	O
%	O
confidence	O
interval	O
was	O
0	O
.	O
91	O
-	O
1	O
.	O
028	O
.	O
Receiver	O
operating	O
characteristic	O
analysis	O
showed	O
that	O
the	O
serum	B-Anatomy
CA	O
19	O
-	O
9	O
level	O
had	O
good	O
predictive	O
value	O
for	O
malignant	B-Anatomy
or	O
invasive	B-Anatomy
IPMNs	I-Anatomy
,	O
postoperative	O
survival	O
,	O
and	O
disease	O
-	O
specific	O
recurrence	O
.	O
The	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
was	O
0	O
.	O
856	O
,	O
0	O
.	O
893	O
,	O
0	O
.	O
815	O
,	O
and	O
0	O
.	O
857	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
respectively	O
.	O
According	O
to	O
the	O
follow	O
-	O
up	O
,	O
mean	O
survival	O
time	O
for	O
groups	O
with	O
CA	O
19	O
-	O
9	O
>	O
63	O
.	O
60	O
U	O
/	O
ml	O
was	O
dramatically	O
shorter	O
than	O
that	O
for	O
groups	O
with	O
CA	O
19	O
-	O
9	O
<	O
=	O
63	O
.	O
60	O
U	O
/	O
ml	O
(	O
57	O
.	O
38	O
+	O
/	O
-	O
2	O
.	O
85	O
versus	O
29	O
.	O
24	O
+	O
/	O
-	O
5	O
.	O
82	O
[	O
months	O
]	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
CONCLUSIONS	O
:	O
Serum	B-Anatomy
CA	O
19	O
-	O
9	O
level	O
has	O
good	O
predictive	O
value	O
for	O
malignant	B-Anatomy
or	O
invasive	B-Anatomy
IPMNs	I-Anatomy
.	O
Patients	O
with	O
CA	O
19	O
-	O
9	O
>	O
63	O
.	O
60	O
U	O
/	O
ml	O
had	O
poor	O
postoperative	O
prognosis	O
in	O
IPMNs	B-Anatomy
.	O
Preoperative	O
abnormal	O
serum	B-Anatomy
CA	O
19	O
-	O
9	O
might	O
be	O
predictive	O
for	O
an	O
aggressive	O
surgical	O
intervention	O
in	O
IPMNs	B-Anatomy
.	O
Saliva	O
proteins	O
of	O
vector	O
Culicoides	O
modify	O
structure	O
and	O
infectivity	O
of	O
bluetongue	O
virus	O
particles	O
.	O
Bluetongue	O
virus	O
(	O
BTV	O
)	O
and	O
epizootic	O
haemorrhagic	O
disease	O
virus	O
(	O
EHDV	O
)	O
are	O
related	O
orbiviruses	O
,	O
transmitted	O
between	O
their	O
ruminant	O
hosts	O
primarily	O
by	O
certain	O
haematophagous	O
midge	O
vectors	O
(	O
Culicoides	O
spp	O
.	O
)	O
.	O
The	O
larger	O
of	O
the	O
BTV	O
outer	O
-	O
capsid	O
proteins	O
,	O
'	O
VP2	O
'	O
,	O
can	O
be	O
cleaved	O
by	O
proteases	O
(	O
including	O
trypsin	O
or	O
chymotrypsin	O
)	O
,	O
forming	O
infectious	O
subviral	O
particles	O
(	O
ISVP	O
)	O
which	O
have	O
enhanced	O
infectivity	O
for	O
adult	O
Culicoides	O
,	O
or	O
KC	B-Anatomy
cells	I-Anatomy
(	O
a	O
cell	B-Anatomy
-	I-Anatomy
line	I-Anatomy
derived	O
from	O
C	O
.	O
sonorensis	O
)	O
.	O
We	O
demonstrate	O
that	O
VP2	O
present	O
on	O
purified	O
virus	O
particles	O
from	O
3	O
different	O
BTV	O
strains	O
can	O
also	O
be	O
cleaved	O
by	O
treatment	O
with	O
saliva	O
from	O
adult	O
Culicoides	O
.	O
The	O
saliva	O
proteins	O
from	O
C	O
.	O
sonorensis	O
(	O
a	O
competent	O
BTV	O
vector	O
)	O
,	O
cleaved	O
BTV	O
-	O
VP2	O
more	O
efficiently	O
than	O
those	O
from	O
C	O
.	O
nubeculosus	O
(	O
a	O
less	O
competent	O
/	O
non	O
-	O
vector	O
species	O
)	O
.	O
Electrophoresis	O
and	O
mass	O
spectrometry	O
identified	O
a	O
trypsin	O
-	O
like	O
protease	O
in	O
C	O
.	O
sonorensis	O
saliva	O
,	O
which	O
was	O
significantly	O
reduced	O
or	O
absent	O
from	O
C	O
.	O
nubeculosus	O
saliva	O
.	O
Incubating	O
purified	O
BTV	O
-	O
1	O
with	O
C	O
.	O
sonorensis	O
saliva	O
proteins	O
also	O
increased	O
their	O
infectivity	O
for	O
KC	B-Anatomy
cells	I-Anatomy
~	O
10	O
fold	O
,	O
while	O
infectivity	O
for	O
BHK	B-Anatomy
cells	I-Anatomy
was	O
reduced	O
by	O
2	O
-	O
6	O
fold	O
.	O
Treatment	O
of	O
an	O
'	O
eastern	O
'	O
strain	O
of	O
EHDV	O
-	O
2	O
with	O
saliva	O
proteins	O
of	O
either	O
C	O
.	O
sonorensis	O
or	O
C	O
.	O
nubeculosus	O
cleaved	O
VP2	O
,	O
but	O
a	O
'	O
western	O
'	O
strain	O
of	O
EHDV	O
-	O
2	O
remained	O
unmodified	O
.	O
These	O
results	O
indicate	O
that	O
temperature	O
,	O
strain	O
of	O
virus	O
and	O
protein	O
composition	O
of	O
Culicoides	O
saliva	O
(	O
particularly	O
its	O
protease	O
content	O
which	O
is	O
dependent	O
upon	O
vector	O
species	O
)	O
,	O
can	O
all	O
play	O
a	O
significant	O
role	O
in	O
the	O
efficiency	O
of	O
VP2	O
cleavage	O
,	O
influencing	O
virus	O
infectivity	O
.	O
Saliva	O
of	O
several	O
other	O
arthropod	O
species	O
has	O
previously	O
been	O
shown	O
to	O
increase	O
transmission	O
,	O
infectivity	O
and	O
virulence	O
of	O
certain	O
arboviruses	O
,	O
by	O
modulating	O
and	O
/	O
or	O
suppressing	O
the	O
mammalian	O
immune	O
response	O
.	O
The	O
findings	O
presented	O
here	O
,	O
however	O
,	O
demonstrate	O
a	O
novel	O
mechanism	O
by	O
which	O
proteases	O
in	O
Culicoides	O
saliva	O
can	O
also	O
directly	O
modify	O
the	O
orbivirus	O
particle	O
structure	O
,	O
leading	O
to	O
increased	O
infectivity	O
specifically	O
for	O
Culicoides	O
cells	B-Anatomy
and	O
,	O
in	O
turn	O
,	O
efficiency	O
of	O
transmission	O
to	O
the	O
insect	O
vector	O
.	O
Systematic	O
proteomic	O
analysis	O
of	O
human	O
hepotacellular	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
reveals	O
molecular	O
pathways	O
and	O
networks	O
involved	O
in	O
metastasis	O
.	O
Systematic	O
proteomic	O
studying	O
of	O
the	O
mechanism	O
of	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
(	O
HCC	B-Anatomy
)	O
metastasis	O
remains	O
challenging	O
.	O
We	O
performed	O
comparative	O
proteomic	O
and	O
pathway	O
analysis	O
of	O
four	O
human	O
metastatic	B-Anatomy
HCC	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
to	O
identify	O
metastasis	O
-	O
associated	O
proteins	O
.	O
These	O
HCC	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
had	O
a	O
similar	O
genetic	O
background	O
but	O
with	O
an	O
increasing	O
potential	O
of	O
metastasis	O
.	O
Using	O
a	O
combination	O
of	O
two	O
dimensional	O
electrophoresis	O
(	O
2	O
-	O
DE	O
)	O
and	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
,	O
a	O
total	O
of	O
125	O
proteins	O
and	O
their	O
post	O
-	O
translational	O
modification	O
forms	O
or	O
isoforms	O
were	O
found	O
to	O
be	O
differentially	O
expressed	O
in	O
the	O
cell	B-Anatomy
lines	I-Anatomy
.	O
Among	O
them	O
,	O
29	O
were	O
gradually	O
up	O
-	O
regulated	O
whereas	O
17	O
were	O
down	O
-	O
regulated	O
with	O
increasing	O
metastatic	O
potential	O
.	O
Instead	O
of	O
a	O
traditional	O
single	O
-	O
gene	O
readout	O
,	O
global	O
bioinformatics	O
analysis	O
was	O
carried	O
out	O
,	O
which	O
revealed	O
that	O
the	O
glycolysis	O
pathway	O
was	O
the	O
most	O
significantly	O
enriched	O
pathway	O
.	O
The	O
heat	O
shock	O
proteins	O
(	O
HSPs	O
)	O
centered	O
and	O
NF	O
-	O
kappaB	O
centered	O
networks	O
were	O
also	O
enriched	O
in	O
the	O
result	O
,	O
which	O
may	O
imply	O
the	O
key	O
function	O
of	O
inflaming	O
on	O
metastasis	O
.	O
Meanwhile	O
,	O
knockdown	O
of	O
HDGF	O
,	O
an	O
up	O
-	O
regulated	O
protein	O
and	O
a	O
target	O
of	O
NF	O
-	O
kappaB	O
,	O
induced	O
cell	B-Anatomy
apoptosis	O
in	O
the	O
metastatic	B-Anatomy
HCC	I-Anatomy
cells	I-Anatomy
.	O
This	O
work	O
provides	O
a	O
demonstration	O
that	O
a	O
combination	O
of	O
bioinformatics	O
and	O
comparative	O
proteomics	O
can	O
help	O
in	O
finding	O
out	O
potential	O
biomarkers	O
associated	O
with	O
HCC	B-Anatomy
metastasis	O
on	O
the	O
level	O
of	O
pathways	O
.	O
Induction	O
of	O
Id	O
-	O
1	O
by	O
FGF	O
-	O
2	O
involves	O
activity	O
of	O
EGR	O
-	O
1	O
and	O
sensitizes	O
neuroblastoma	B-Anatomy
cells	I-Anatomy
to	O
cell	B-Anatomy
death	O
.	O
Inhibitor	O
of	O
differentiation	O
-	O
1	O
(	O
Id	O
-	O
1	O
)	O
is	O
a	O
member	O
of	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
HLH	O
)	O
family	O
of	O
proteins	O
that	O
regulate	O
gene	O
transcription	O
through	O
their	O
inhibitory	O
binding	O
to	O
basic	O
-	O
HLH	O
transcription	O
factors	O
.	O
Similarly	O
to	O
other	O
members	O
of	O
this	O
family	O
,	O
Id	O
-	O
1	O
is	O
involved	O
in	O
the	O
repression	O
of	O
cell	B-Anatomy
differentiation	O
and	O
activation	O
of	O
cell	B-Anatomy
growth	O
.	O
The	O
dual	O
function	O
of	O
Id	O
-	O
1	O
,	O
inhibition	O
of	O
differentiation	O
,	O
and	O
stimulation	O
of	O
cell	B-Anatomy
proliferation	O
,	O
might	O
be	O
interdependent	O
,	O
as	O
cell	B-Anatomy
differentiation	O
is	O
generally	O
coupled	O
with	O
the	O
exit	O
from	O
the	O
cell	B-Anatomy
cycle	O
.	O
Fibroblast	O
growth	O
factor	O
-	O
2	O
(	O
FGF	O
-	O
2	O
)	O
has	O
been	O
reported	O
to	O
play	O
multiple	O
roles	O
in	O
different	O
biological	O
processes	O
during	O
development	O
of	O
the	O
central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
(	O
CNS	B-Anatomy
)	O
.	O
In	O
addition	O
,	O
FGF	O
-	O
2	O
has	O
been	O
described	O
to	O
induce	O
""""	O
neuronal	B-Anatomy
-	O
like	O
""""	O
differentiation	O
and	O
trigger	O
apoptosis	O
in	O
neuroblastoma	B-Anatomy
SK	I-Anatomy
-	I-Anatomy
N	I-Anatomy
-	I-Anatomy
MC	I-Anatomy
cells	I-Anatomy
.	O
Although	O
regulation	O
of	O
Id	O
-	O
1	O
protein	O
by	O
several	O
mitogenic	O
factors	O
is	O
well	O
-	O
established	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
FGF	O
-	O
2	O
in	O
the	O
regulation	O
of	O
Id	O
-	O
1	O
.	O
Using	O
human	O
neuroblastoma	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
SK	B-Anatomy
-	I-Anatomy
N	I-Anatomy
-	I-Anatomy
MC	I-Anatomy
,	O
we	O
found	O
that	O
treatment	O
of	O
these	O
cells	B-Anatomy
with	O
FGF	O
-	O
2	O
resulted	O
in	O
early	O
induction	O
of	O
both	O
Id	O
-	O
1	O
mRNA	O
and	O
protein	O
.	O
The	O
induction	O
occurs	O
within	O
1	O
h	O
from	O
FGF	O
-	O
2	O
treatment	O
and	O
is	O
mediated	O
by	O
ERK1	O
/	O
2	O
pathway	O
,	O
which	O
in	O
turn	O
stimulates	O
expression	O
of	O
the	O
early	O
growth	O
response	O
-	O
1	O
(	O
Egr	O
-	O
1	O
)	O
transcription	O
factor	O
.	O
We	O
also	O
demonstrate	O
direct	O
interaction	O
of	O
Egr	O
-	O
1	O
with	O
Id	O
-	O
1	O
promoter	O
in	O
vitro	O
and	O
in	O
cell	B-Anatomy
culture	I-Anatomy
.	O
Finally	O
,	O
inhibition	O
of	O
Id	O
-	O
1	O
expression	O
results	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
accumulation	O
of	O
FGF	O
-	O
2	O
-	O
treated	O
cells	B-Anatomy
and	O
delayed	O
cell	B-Anatomy
death	O
.	O
Vimentin	O
is	O
preferentially	O
expressed	O
in	O
human	O
breast	B-Anatomy
carcinomas	I-Anatomy
with	O
low	O
estrogen	O
receptor	O
and	O
high	O
Ki	O
-	O
67	O
growth	O
fraction	O
.	O
Vimentin	O
expression	O
,	O
growth	O
fractions	O
(	O
GF	O
)	O
,	O
and	O
estrogen	O
receptor	O
(	O
ER	O
)	O
levels	O
were	O
determined	O
for	O
90	O
untreated	O
primary	B-Anatomy
breast	I-Anatomy
carcinomas	I-Anatomy
.	O
Coexpression	O
of	O
keratin	O
and	O
vimentin	O
was	O
found	O
in	O
approximately	O
20	O
%	O
of	O
the	O
tumors	B-Anatomy
regardless	O
of	O
menopausal	O
status	O
.	O
Vimentin	O
was	O
expressed	O
preferentially	O
in	O
tumor	B-Anatomy
cells	I-Anatomy
of	O
high	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
ductal	I-Anatomy
breast	I-Anatomy
carcinomas	I-Anatomy
(	O
15	O
of	O
28	O
histologic	O
grade	O
3	O
vs	O
.	O
0	O
of	O
40	O
grades	O
1	O
and	O
2	O
)	O
.	O
Vimentin	O
expression	O
was	O
found	O
preferentially	O
in	O
tumors	B-Anatomy
with	O
high	O
GF	O
(	O
greater	O
than	O
15	O
%	O
Ki	O
-	O
67	O
positive	O
by	O
immunoperoxidase	O
staining	O
)	O
and	O
low	O
ER	O
levels	O
(	O
less	O
than	O
60	O
fmols	O
/	O
mg	O
protein	O
by	O
a	O
monoclonal	O
enzyme	O
immunoassay	O
)	O
.	O
Sixty	O
-	O
eight	O
percent	O
of	O
tumors	B-Anatomy
in	O
this	O
group	O
were	O
vimentin	O
positive	O
and	O
88	O
%	O
of	O
all	O
vimentin	O
-	O
positive	O
tumors	B-Anatomy
fell	O
into	O
this	O
category	O
.	O
More	O
than	O
50	O
%	O
of	O
the	O
tumor	B-Anatomy
cells	I-Anatomy
coexpressed	O
vimentin	O
and	O
keratin	O
.	O
Thus	O
,	O
vimentin	O
expression	O
may	O
be	O
helpful	O
in	O
identifying	O
a	O
substantial	O
subset	O
of	O
ER	O
-	O
independent	O
breast	B-Anatomy
carcinomas	I-Anatomy
with	O
poor	O
prognostic	O
indicators	O
.	O
mirAct	O
:	O
a	O
web	O
tool	O
for	O
evaluating	O
microRNA	O
activity	O
based	O
on	O
gene	O
expression	O
data	O
.	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
critical	O
regulators	O
in	O
the	O
complex	O
cellular	B-Anatomy
networks	I-Anatomy
.	O
The	O
mirAct	O
web	O
server	O
(	O
http	O
:	O
/	O
/	O
sysbio	O
.	O
ustc	O
.	O
edu	O
.	O
cn	O
/	O
software	O
/	O
mirAct	O
)	O
is	O
a	O
tool	O
designed	O
to	O
investigate	O
miRNA	O
activity	O
based	O
on	O
gene	O
-	O
expression	O
data	O
by	O
using	O
the	O
negative	O
regulation	O
relationship	O
between	O
miRNAs	O
and	O
their	O
target	O
genes	O
.	O
mirAct	O
supports	O
multiple	O
-	O
class	O
data	O
and	O
enables	O
clustering	O
analysis	O
based	O
on	O
computationally	O
determined	O
miRNA	O
activity	O
.	O
Here	O
,	O
we	O
describe	O
the	O
framework	O
of	O
mirAct	O
,	O
demonstrate	O
its	O
performance	O
by	O
comparing	O
with	O
other	O
similar	O
programs	O
and	O
exemplify	O
its	O
applications	O
using	O
case	O
studies	O
.	O
Non	O
-	O
heart	B-Anatomy
-	O
beating	O
organ	B-Anatomy
donation	O
in	O
Italy	O
.	O
In	O
2007	O
the	O
non	O
-	O
heart	B-Anatomy
-	O
beating	O
organ	B-Anatomy
donation	O
(	O
NHBD	O
)	O
""""	O
Programma	O
Alba	O
""""	O
(	O
Sunrise	O
Programme	O
)	O
started	O
in	O
Pavia	O
,	O
Italy	O
.	O
The	O
initial	O
plan	O
was	O
to	O
cut	O
down	O
waiting	O
list	O
for	O
kidney	B-Anatomy
transplantation	O
,	O
while	O
its	O
final	O
aim	O
is	O
to	O
shorten	O
organ	B-Anatomy
transplantation	O
waiting	O
lists	O
.	O
When	O
compared	O
to	O
European	O
countries	O
and	O
the	O
USA	O
,	O
the	O
Italian	O
NHBD	O
program	O
has	O
taken	O
longer	O
to	O
get	O
established	O
.	O
Initially	O
Italian	O
physicians	O
were	O
not	O
entirely	O
aware	O
of	O
the	O
NHBD	O
organ	B-Anatomy
viability	O
for	O
transplantation	O
,	O
furthermore	O
ethical	O
issues	O
and	O
the	O
need	O
to	O
regulate	O
medical	O
requirements	O
to	O
Italian	O
law	O
slowed	O
down	O
the	O
NHBD	O
program	O
.	O
In	O
particular	O
,	O
Italian	O
legislation	O
provides	O
for	O
death	O
ascertainment	O
after	O
irreversible	O
cardiac	B-Anatomy
arrest	O
,	O
20	O
-	O
minute	O
flat	O
electrocardiogram	O
.	O
This	O
no	O
-	O
touch	O
period	O
is	O
longer	O
when	O
compared	O
to	O
worldwide	O
legislation	O
,	O
and	O
organ	B-Anatomy
viability	O
has	O
been	O
a	O
main	O
concern	O
for	O
Italian	O
transplant	O
doctors	O
over	O
the	O
years	O
.	O
However	O
,	O
recent	O
data	O
let	O
up	O
to	O
40	O
-	O
minute	O
warm	O
ischemia	O
time	O
to	O
preserve	O
organ	B-Anatomy
viability	O
;	O
this	O
has	O
encouraged	O
Pavia	O
'	O
s	O
group	O
to	O
establish	O
the	O
NHBD	O
""""	O
Programma	O
Alba	O
""""	O
.	O
It	O
was	O
designed	O
according	O
to	O
Italian	O
legislation	O
from	O
death	O
diagnosis	O
to	O
graft	B-Anatomy
placement	O
,	O
from	O
this	O
perspective	O
must	O
the	O
significant	O
role	O
of	O
the	O
Transplant	O
coordinator	O
be	O
recognized	O
.	O
Since	O
2007	O
seven	O
kidneys	B-Anatomy
have	O
been	O
gathered	O
from	O
seven	O
NHBD	O
.	O
Of	O
these	O
,	O
six	O
NHBD	O
kidneys	B-Anatomy
have	O
been	O
transplanted	O
.	O
Currently	O
,	O
four	O
patients	O
are	O
out	O
of	O
dialysis	O
.	O
This	O
report	O
is	O
a	O
detailed	O
description	O
of	O
NHBD	O
""""	O
Programma	O
Alba	O
""""	O
and	O
its	O
preliminary	O
results	O
.	O
[	O
Expression	O
of	O
Merlin	O
protein	O
in	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
and	O
the	O
clinical	O
significance	O
]	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
expression	O
and	O
clinical	O
significance	O
of	O
Merlin	O
protein	O
in	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
(	O
NSCLC	B-Anatomy
)	O
.	O
METHODS	O
:	O
The	O
expression	O
of	O
Merlin	O
protein	O
in	O
45	O
cases	O
of	O
NSCLC	B-Anatomy
and	O
adjacent	O
tissue	B-Anatomy
of	O
NSCLC	B-Anatomy
and	O
normal	O
lung	B-Anatomy
tissue	I-Anatomy
was	O
checked	O
by	O
immunohistochemistry	O
.	O
The	O
relation	O
between	O
the	O
expression	O
of	O
Merlin	O
protein	O
and	O
the	O
multiple	O
factors	O
of	O
pathological	O
type	O
,	O
gender	O
,	O
P	O
-	O
TNM	O
stage	O
,	O
differentiation	O
and	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
was	O
analyzed	O
.	O
RESULTS	O
:	O
The	O
expression	O
rates	O
of	O
Merlin	O
protein	O
in	O
NSCLC	B-Anatomy
and	O
normal	O
lung	B-Anatomy
tissue	I-Anatomy
sections	I-Anatomy
were	O
73	O
.	O
33	O
%	O
and	O
15	O
.	O
56	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
The	O
expression	O
of	O
Merlin	O
protein	O
was	O
not	O
associated	O
with	O
the	O
pathological	O
type	O
,	O
gender	O
,	O
P	O
-	O
TNM	O
stage	O
,	O
differentiation	O
and	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
CONCLUSION	O
:	O
Merlin	O
protein	O
might	O
contribute	O
to	O
the	O
initiation	O
of	O
metastasis	O
of	O
NSCLC	B-Anatomy
.	O
The	O
members	O
of	O
an	O
Epstein	O
-	O
Barr	O
virus	O
microRNA	O
cluster	O
cooperate	O
to	O
transform	O
B	B-Anatomy
lymphocytes	I-Anatomy
.	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
transforms	O
B	B-Anatomy
lymphocytes	I-Anatomy
through	O
the	O
expression	O
of	O
the	O
latent	O
viral	O
proteins	O
EBNA	O
and	O
latent	O
membrane	O
protein	O
(	O
LMP	O
)	O
.	O
Recently	O
,	O
it	O
has	O
become	O
apparent	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
also	O
contribute	O
to	O
EBV	O
'	O
s	O
oncogenic	O
properties	O
;	O
recombinant	O
EBVs	O
that	O
lack	O
the	O
BHRF1	O
miRNA	O
cluster	O
display	O
a	O
reduced	O
ability	O
to	O
transform	O
B	B-Anatomy
lymphocytes	I-Anatomy
in	O
vitro	O
.	O
Furthermore	O
,	O
infected	O
cells	B-Anatomy
evince	O
a	O
marked	O
upregulation	O
of	O
the	O
EBNA	O
genes	O
.	O
Using	O
recombinant	O
viruses	O
that	O
lack	O
only	O
one	O
member	O
of	O
the	O
cluster	O
,	O
we	O
now	O
show	O
that	O
all	O
three	O
BHRF1	O
miRNAs	O
contribute	O
to	O
B	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
transformation	O
.	O
Recombinants	O
that	O
lacked	O
miR	O
-	O
BHRF1	O
-	O
2	O
or	O
miR	O
-	O
BHRF1	O
-	O
3	O
displayed	O
enhanced	O
EBNA	O
expression	O
initiated	O
at	O
the	O
Cp	O
and	O
Wp	O
promoters	O
.	O
Interestingly	O
,	O
we	O
find	O
that	O
the	O
deletion	O
of	O
miR	O
-	O
BHRF1	O
-	O
2	O
reduced	O
the	O
expression	O
level	O
of	O
miR	O
-	O
BHRF1	O
-	O
3	O
and	O
possibly	O
that	O
of	O
miR	O
-	O
BHRF1	O
-	O
1	O
,	O
demonstrating	O
that	O
the	O
expression	O
of	O
one	O
miRNA	O
can	O
potentiate	O
the	O
expression	O
of	O
other	O
miRNAs	O
located	O
in	O
the	O
same	O
cluster	O
.	O
Therefore	O
,	O
the	O
phenotypic	O
traits	O
of	O
the	O
miR	O
-	O
BHRF1	O
-	O
2	O
mutant	O
could	O
result	O
partly	O
from	O
reduced	O
miR	O
-	O
BHRF1	O
-	O
1	O
and	O
miR	O
-	O
BHRF1	O
-	O
3	O
expression	O
levels	O
.	O
Nevertheless	O
,	O
using	O
an	O
miR	O
-	O
BHRF1	O
-	O
1	O
and	O
miR	O
-	O
BHRF1	O
-	O
3	O
double	O
mutant	O
,	O
we	O
could	O
directly	O
assess	O
and	O
confirm	O
the	O
contribution	O
of	O
miR	O
-	O
BHRF1	O
-	O
2	O
to	O
B	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
transformation	O
.	O
Furthermore	O
,	O
we	O
found	O
that	O
the	O
potentiating	O
effect	O
of	O
miR	O
-	O
BHRF1	O
-	O
2	O
on	O
miR	O
-	O
BHRF1	O
-	O
3	O
synthesis	O
can	O
be	O
reproduced	O
with	O
simple	O
expression	O
plasmids	B-Anatomy
,	O
provided	O
that	O
both	O
miRNAs	O
are	O
processed	O
from	O
the	O
same	O
transcript	O
.	O
Therefore	O
,	O
this	O
enhancing	O
effect	O
does	O
not	O
result	O
from	O
an	O
idiosyncrasy	O
of	O
the	O
EBV	O
genome	O
but	O
rather	O
reflects	O
a	O
general	O
property	O
of	O
these	O
miRNAs	O
.	O
This	O
study	O
highlights	O
the	O
advantages	O
of	O
arranging	O
the	O
BHRF1	O
miRNAs	O
in	O
clusters	O
:	O
it	O
allows	O
the	O
synchronous	O
and	O
synergistic	O
expression	O
of	O
genetic	O
elements	O
that	O
cooperate	O
to	O
transform	O
their	O
target	O
cells	B-Anatomy
.	O
Massive	O
osteolysis	O
in	O
a	O
dog	O
resembling	O
Gorham	O
'	O
s	O
disease	O
in	O
humans	O
.	O
An	O
eight	O
-	O
month	O
-	O
old	O
mixed	O
-	O
breed	O
dog	O
was	O
presented	O
with	O
a	O
history	O
of	O
sudden	O
onset	O
pelvic	B-Anatomy
limb	I-Anatomy
lameness	O
.	O
Radiographic	O
and	O
computed	O
tomographic	O
examinations	O
demonstrated	O
an	O
osteolytic	O
process	O
involving	O
the	O
lumbar	B-Anatomy
spine	I-Anatomy
and	O
pelvis	B-Anatomy
.	O
A	O
comprehensive	O
work	O
-	O
up	O
including	O
serial	O
radiographic	O
skeletal	B-Anatomy
survey	O
,	O
biopsy	O
,	O
routine	O
laboratory	O
investigation	O
and	O
evaluation	O
of	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
and	O
25	O
-	O
hydroxy	O
-	O
vitamin	O
D	O
levels	O
failed	O
to	O
reveal	O
any	O
underlying	O
cause	O
for	O
the	O
osteolysis	O
.	O
Conservative	O
treatment	O
using	O
the	O
bisphosphonate	O
drug	O
alendronate	O
and	O
oral	B-Anatomy
analgesic	O
medications	O
resulted	O
in	O
a	O
return	O
to	O
nearly	O
normal	O
long	O
-	O
term	O
function	O
,	O
despite	O
massive	O
lumbar	O
and	O
pelvic	O
osteolysis	O
.	O
The	O
clinical	O
,	O
radiological	O
and	O
histopathological	O
features	O
in	O
this	O
dog	O
are	O
reported	O
,	O
and	O
similarities	O
with	O
the	O
human	O
condition	O
known	O
as	O
Gorham	O
'	O
s	O
disease	O
are	O
discussed	O
.	O
Sunitinib	O
induces	O
apoptosis	O
in	O
pheochromocytoma	B-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
by	O
inhibiting	O
VEGFR2	O
/	O
Akt	O
/	O
mTOR	O
/	O
S6K1	O
pathways	O
through	O
modulation	O
of	O
Bcl	O
-	O
2	O
and	O
BAD	O
.	O
Sunitinib	O
is	O
an	O
oral	B-Anatomy
multitargeted	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
with	O
antiangiogenic	O
and	O
antitumor	B-Anatomy
activity	O
that	O
mainly	O
targets	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
(	O
VEGFRs	O
)	O
.	O
Very	O
recently	O
,	O
sunitinib	O
has	O
been	O
shown	O
to	O
be	O
an	O
active	O
agent	O
for	O
the	O
treatment	O
of	O
malignant	B-Anatomy
pheochromocytomas	I-Anatomy
.	O
However	O
,	O
it	O
is	O
unclear	O
whether	O
sunitinib	O
acts	O
only	O
through	O
an	O
antiangiogenic	O
mechanism	O
or	O
whether	O
it	O
may	O
also	O
directly	O
target	O
tumor	B-Anatomy
cells	I-Anatomy
.	O
Sunitinib	O
markedly	O
induced	O
apoptosis	O
of	O
PC12	B-Anatomy
cells	I-Anatomy
in	O
a	O
dose	O
-	O
dependent	O
and	O
time	O
-	O
dependent	O
manner	O
.	O
Furthermore	O
,	O
in	O
support	O
of	O
these	O
findings	O
,	O
we	O
found	O
that	O
sunitinib	O
induced	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
the	O
antiapoptotic	O
molecule	O
Bcl	O
-	O
2	O
as	O
well	O
as	O
dephosphorylation	O
of	O
the	O
proapoptotic	O
molecule	O
BAD	O
,	O
which	O
results	O
in	O
the	O
activation	O
of	O
BAD	O
in	O
these	O
cells	B-Anatomy
.	O
Consistent	O
with	O
these	O
apoptotic	O
effects	O
,	O
our	O
results	O
showed	O
that	O
sunitinib	O
inhibited	O
phosphorylation	O
of	O
Akt	O
and	O
mTOR	O
and	O
was	O
followed	O
by	O
a	O
reduction	O
of	O
S6K1	O
,	O
which	O
is	O
a	O
well	O
-	O
known	O
target	O
of	O
mTOR	O
.	O
Knockdown	O
of	O
VEGFR	O
-	O
2	O
attenuated	O
the	O
sunitinib	O
-	O
induced	O
effects	O
,	O
including	O
apoptosis	O
and	O
inhibition	O
of	O
signaling	O
pathways	O
such	O
as	O
the	O
phosphorylation	O
of	O
Akt	O
as	O
well	O
as	O
mTOR	O
,	O
and	O
Bcl	O
-	O
2	O
,	O
which	O
confirmed	O
that	O
these	O
effects	O
could	O
be	O
mediated	O
by	O
VEGFR	O
-	O
2	O
.	O
In	O
addition	O
,	O
silencing	O
of	O
S6K1	O
induced	O
apoptosis	O
accompanied	O
by	O
a	O
decrease	O
in	O
the	O
phosphorylation	O
of	O
BAD	O
and	O
Bcl	O
-	O
2	O
,	O
similar	O
to	O
that	O
observed	O
with	O
sunitinib	O
treatment	O
.	O
Thus	O
,	O
these	O
results	O
together	O
suggest	O
that	O
sunitinib	O
initially	O
exerts	O
its	O
apoptotic	O
effect	O
through	O
the	O
inhibition	O
of	O
VEGFR	O
-	O
2	O
,	O
which	O
,	O
when	O
followed	O
by	O
reduction	O
of	O
its	O
downstream	O
effectors	O
,	O
including	O
Akt	O
/	O
mTOR	O
/	O
S6K1	O
,	O
may	O
lead	O
to	O
inhibition	O
of	O
the	O
antiapoptotic	O
molecule	O
Bcl	O
-	O
2	O
and	O
activation	O
of	O
the	O
proapoptotic	O
molecule	O
BAD	O
in	O
PC12	B-Anatomy
cells	I-Anatomy
.	O
However	O
,	O
PC12	B-Anatomy
cells	I-Anatomy
do	O
not	O
precisely	O
reflect	O
the	O
pathogenesis	O
of	O
malignant	B-Anatomy
cells	I-Anatomy
.	O
Therefore	O
,	O
we	O
confirmed	O
the	O
key	O
findings	O
by	O
replicating	O
these	O
experiments	O
in	O
human	O
neuroblastoma	B-Anatomy
SK	I-Anatomy
-	I-Anatomy
N	I-Anatomy
-	I-Anatomy
SH	I-Anatomy
cells	I-Anatomy
.	O
Development	O
of	O
a	O
mouse	O
model	O
for	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
with	O
endometrial	B-Anatomy
cancer	I-Anatomy
.	O
Controlling	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
is	O
currently	O
a	O
key	O
issue	O
in	O
cancer	B-Anatomy
therapy	O
.	O
Lymph	B-Anatomy
node	I-Anatomy
metastasis	O
is	O
one	O
of	O
the	O
most	O
important	O
prognostic	O
factors	O
in	O
various	O
types	O
of	O
cancers	B-Anatomy
,	O
including	O
endometrial	B-Anatomy
cancer	I-Anatomy
.	O
Vascular	O
endothelial	O
growth	O
factor	O
-	O
C	O
(	O
VEGF	O
-	O
C	O
)	O
plays	O
a	O
crucial	O
role	O
in	O
lymphangiogenesis	O
,	O
and	O
is	O
implicated	O
to	O
play	O
an	O
important	O
role	O
in	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
.	O
To	O
evaluate	O
the	O
role	O
of	O
VEGF	O
-	O
C	O
in	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
,	O
we	O
developed	O
an	O
animal	O
model	O
by	O
using	O
an	O
endometrial	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
HEC1A	B-Anatomy
.	O
This	O
cell	B-Anatomy
line	I-Anatomy
is	O
not	O
invasive	O
by	O
nature	O
and	O
secretes	O
moderate	O
amounts	O
of	O
VEGF	O
-	O
C	O
;	O
intrauterine	B-Anatomy
injection	O
of	O
HEC1A	B-Anatomy
cells	I-Anatomy
into	O
Balb	O
/	O
c	O
nude	O
mice	O
resulted	O
in	O
uterine	B-Anatomy
cancer	I-Anatomy
with	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
after	O
8	O
weeks	O
.	O
To	O
analyze	O
the	O
contribution	O
of	O
VEGF	O
-	O
C	O
to	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
,	O
its	O
corresponding	O
gene	O
was	O
stably	O
introduced	O
into	O
HEC1A	B-Anatomy
cells	I-Anatomy
(	O
HEC1A	B-Anatomy
/	O
VEGF	O
-	O
C	O
)	O
,	O
which	O
then	O
produced	O
more	O
than	O
10	O
times	O
the	O
amount	O
of	O
VEGF	O
-	O
C	O
.	O
The	O
number	O
of	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
was	O
significantly	O
higher	O
in	O
HEC1A	B-Anatomy
/	I-Anatomy
VEGF	I-Anatomy
-	I-Anatomy
C	I-Anatomy
cells	I-Anatomy
than	O
in	O
HEC1A	B-Anatomy
cells	I-Anatomy
(	O
3	O
.	O
2	O
vs	O
1	O
.	O
1	O
nodes	B-Anatomy
/	O
animal	O
,	O
respectively	O
)	O
.	O
Augmented	O
lymphangiogenesis	O
was	O
observed	O
within	O
tumors	B-Anatomy
when	O
HEC1A	B-Anatomy
/	I-Anatomy
VEGF	I-Anatomy
-	I-Anatomy
C	I-Anatomy
cells	I-Anatomy
were	O
inoculated	O
.	O
These	O
results	O
indicate	O
that	O
VEGF	O
-	O
C	O
plays	O
a	O
critical	O
role	O
in	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
,	O
in	O
addition	O
to	O
serving	O
as	O
a	O
platform	O
to	O
test	O
the	O
efficacy	O
of	O
various	O
therapeutic	O
modalities	O
against	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
.	O
[	O
Rubella	O
in	O
Poland	O
in	O
2009	O
]	O
.	O
In	O
Poland	O
,	O
7	O
,	O
587	O
cases	O
of	O
rubella	O
were	O
registered	O
in	O
2009	O
(	O
incidence	O
19	O
.	O
9	O
per	O
100	O
,	O
000	O
population	O
)	O
.	O
According	O
to	O
a	O
new	O
rubella	O
case	O
definition	O
,	O
introduced	O
in	O
2009	O
,	O
7	O
(	O
0	O
.	O
1	O
%	O
)	O
cases	O
were	O
classified	O
as	O
confirmed	O
cases	O
,	O
30	O
(	O
0	O
.	O
4	O
%	O
)	O
as	O
probable	O
.	O
One	O
case	O
of	O
congenital	O
rubella	O
syndrome	O
was	O
reported	O
.	O
The	O
incidence	O
in	O
men	O
(	O
26	O
.	O
6	O
)	O
was	O
1	O
.	O
9	O
-	O
times	O
higher	O
than	O
in	O
women	O
(	O
13	O
.	O
6	O
)	O
.	O
The	O
highest	O
incidence	O
was	O
observed	O
in	O
children	O
aged	O
7	O
and	O
8	O
years	O
(	O
180	O
.	O
3	O
and	O
175	O
.	O
6	O
,	O
respectively	O
)	O
.	O
No	O
rubella	O
deaths	O
were	O
registered	O
.	O
An	O
improvement	O
of	O
laboratory	O
diagnosis	O
of	O
reported	O
cases	O
is	O
necessary	O
to	O
assess	O
the	O
impact	O
of	O
2	O
-	O
dose	O
immunization	O
implemented	O
in	O
2003	O
on	O
rubella	O
epidemiology	O
in	O
Poland	O
.	O
Burns	O
from	O
hot	O
wheat	O
bags	O
:	O
a	O
public	O
safety	O
issue	O
.	O
Introduction	O
:	O
Wheat	O
bags	O
are	O
therapeutic	O
devices	O
that	O
are	O
heated	O
in	O
microwaves	O
and	O
commonly	O
used	O
to	O
provide	O
relief	O
from	O
muscle	B-Anatomy
and	O
joint	B-Anatomy
pain	O
.	O
The	O
Royal	O
Adelaide	O
Hospital	O
Burns	O
Unit	O
has	O
observed	O
a	O
number	O
of	O
patients	O
with	O
significant	O
burn	O
injuries	O
resulting	O
from	O
their	O
use	O
.	O
Despite	O
their	O
dangers	O
,	O
the	O
products	O
come	O
with	O
limited	O
safety	O
information	O
.	O
Methods	O
:	O
Data	O
were	O
collected	O
from	O
the	O
Burns	O
Unit	O
database	O
for	O
all	O
patients	O
admitted	O
with	O
burns	O
due	O
to	O
hot	O
wheat	O
bags	O
from	O
2004	O
to	O
2009	O
.	O
This	O
was	O
analyzed	O
to	O
determine	O
the	O
severity	O
of	O
the	O
burn	O
injury	O
and	O
identify	O
any	O
predisposing	O
factors	O
.	O
An	O
experimental	O
study	O
was	O
performed	O
to	O
measure	O
the	O
temperature	O
of	O
wheat	O
bags	O
when	O
heated	O
to	O
determine	O
their	O
potential	O
for	O
causing	O
thermal	O
injury	O
.	O
Results	O
:	O
11	O
patients	O
were	O
admitted	O
with	O
burns	O
due	O
to	O
hot	O
wheat	O
bags	O
.	O
The	O
median	O
age	O
was	O
52	O
years	O
and	O
the	O
mean	O
total	O
body	B-Anatomy
surface	I-Anatomy
area	I-Anatomy
was	O
1	O
.	O
1	O
%	O
.	O
All	O
burns	O
were	O
either	O
deep	O
dermal	B-Anatomy
(	O
45	O
.	O
5	O
%	O
)	O
or	O
full	O
thickness	O
(	O
54	O
.	O
5	O
%	O
)	O
.	O
Ten	O
patients	O
required	O
operative	O
management	O
.	O
Predisposing	O
factors	O
(	O
eg	O
,	O
neuropathy	O
)	O
to	O
thermal	O
injury	O
were	O
identified	O
in	O
7	O
patients	O
.	O
The	O
experimental	O
study	O
showed	O
that	O
hot	O
wheat	O
bags	O
reached	O
temperatures	O
of	O
57	O
.	O
3degreesC	O
(	O
135	O
.	O
1degreesF	O
)	O
when	O
heated	O
according	O
to	O
instructions	O
,	O
63	O
.	O
3degreesC	O
(	O
145	O
.	O
9degreesF	O
)	O
in	O
a	O
1000	O
W	O
microwave	O
and	O
69	O
.	O
6degreesC	O
(	O
157	O
.	O
3degreesF	O
)	O
on	O
reheating	O
.	O
Conclusions	O
:	O
Hot	O
wheat	O
bags	O
cause	O
serious	O
burn	O
injury	O
.	O
When	O
heated	O
improperly	O
,	O
they	O
can	O
reach	O
temperatures	O
high	O
enough	O
to	O
cause	O
epidermal	B-Anatomy
necrosis	O
in	O
a	O
short	O
period	O
of	O
time	O
.	O
Patients	O
with	O
impaired	O
temperature	O
sensation	O
are	O
particularly	O
at	O
risk	O
.	O
There	O
should	O
be	O
greater	O
public	O
awareness	O
of	O
the	O
dangers	O
of	O
wheat	O
bag	O
use	O
and	O
more	O
specific	O
safety	O
warnings	O
on	O
the	O
products	O
.	O
IL	O
-	O
17F	O
deficiency	O
inhibits	O
small	B-Anatomy
intestinal	I-Anatomy
tumorigenesis	O
in	O
ApcMin	O
/	O
+	O
mice	O
.	O
IL	O
-	O
17	O
plays	O
an	O
important	O
role	O
in	O
gut	B-Anatomy
homeostasis	O
.	O
However	O
,	O
the	O
role	O
of	O
IL	O
-	O
17F	O
in	O
intestinal	B-Anatomy
tumorigenesis	O
has	O
not	O
been	O
addressed	O
.	O
Here	O
we	O
demonstrate	O
that	O
ablation	O
of	O
IL	O
-	O
17F	O
significantly	O
inhibits	O
spontaneous	O
intestinal	B-Anatomy
tumorigenesis	O
in	O
the	O
small	B-Anatomy
intestine	I-Anatomy
of	O
Apc	O
(	O
Min	O
/	O
+	O
)	O
mice	O
.	O
IL	O
-	O
17F	O
ablation	O
decreased	O
IL	O
-	O
1beta	O
and	O
Cox	O
-	O
2	O
expression	O
as	O
well	O
as	O
IL	O
-	O
17	O
receptor	O
C	O
(	O
IL	O
-	O
17RC	O
)	O
expression	O
,	O
which	O
were	O
increased	O
in	O
tumors	B-Anatomy
from	O
Apc	O
(	O
Min	O
/	O
+	O
)	O
mice	O
.	O
Lack	O
of	O
IL	O
-	O
17F	O
did	O
not	O
reverse	O
the	O
splenomegaly	B-Anatomy
but	O
partially	O
restored	O
thymic	B-Anatomy
atrophy	O
,	O
suggesting	O
a	O
local	O
effect	O
of	O
IL	O
-	O
17F	O
in	O
the	O
intestine	B-Anatomy
.	O
IL	O
-	O
17F	O
deficient	O
Apc	O
(	O
Min	O
/	O
+	O
)	O
mice	O
showed	O
a	O
significant	O
decrease	O
in	O
immune	B-Anatomy
cell	I-Anatomy
infiltration	O
in	O
the	O
lamina	B-Anatomy
propria	I-Anatomy
.	O
Interestingly	O
,	O
the	O
expression	O
of	O
IL	O
-	O
17A	O
from	O
CD4	B-Anatomy
T	I-Anatomy
cells	I-Anatomy
in	O
the	O
lamina	B-Anatomy
propria	I-Anatomy
remains	O
unchanged	O
in	O
the	O
absence	O
of	O
IL	O
-	O
17F	O
.	O
Collectively	O
,	O
our	O
results	O
suggest	O
the	O
proinflammatory	O
and	O
essential	O
role	O
of	O
IL	O
-	O
17F	O
to	O
develop	O
spontaneous	O
intestinal	B-Anatomy
tumorigenesis	O
in	O
Apc	O
(	O
Min	O
/	O
+	O
)	O
mice	O
in	O
the	O
presence	O
of	O
IL	O
-	O
17A	O
.	O
Curcumin	O
inhibits	O
metastatic	O
progression	O
of	O
breast	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
through	O
suppression	O
of	O
urokinase	O
-	O
type	O
plasminogen	O
activator	O
by	O
NF	O
-	O
kappa	O
B	O
signaling	O
pathways	O
.	O
Curcumin	O
(	O
1	O
,	O
7	O
-	O
bis	O
(	O
4	O
-	O
hydroxy	O
-	O
3	O
-	O
methoxyphenyl	O
)	O
-	O
1	O
,	O
6	O
-	O
heptadiene	O
-	O
3	O
,	O
5	O
-	O
dione	O
)	O
,	O
is	O
extracted	O
from	O
the	O
plant	O
Curcuma	O
longa	O
.	O
It	O
was	O
recently	O
reported	O
for	O
its	O
anticancer	B-Anatomy
effect	O
on	O
several	O
types	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
in	O
vitro	O
however	O
,	O
the	O
molecular	O
mechanisms	O
of	O
this	O
anticancer	B-Anatomy
effect	O
are	O
not	O
fully	O
understood	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
curcumin	O
on	O
human	O
mammary	B-Anatomy
epithelial	I-Anatomy
carcinoma	I-Anatomy
MCF	I-Anatomy
-	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
.	O
Cells	B-Anatomy
were	O
treated	O
with	O
curcumin	O
and	O
examined	O
for	O
cell	B-Anatomy
viability	O
by	O
MTT	O
assay	O
.	O
The	O
cells	B-Anatomy
invasion	O
was	O
demonstrated	O
by	O
transwell	O
assay	O
.	O
The	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
to	O
DNA	O
was	O
examined	O
in	O
nuclear	B-Anatomy
extracts	I-Anatomy
using	O
Trans	O
-	O
AM	O
NF	O
-	O
kappaB	O
ELISA	O
kit	O
.	O
Western	O
blot	O
was	O
performed	O
to	O
detect	O
the	O
effect	O
of	O
curcumin	O
on	O
the	O
expression	O
of	O
uPA	O
.	O
Our	O
results	O
showed	O
that	O
curcumin	O
dose	O
-	O
dependently	O
inhibited	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
proliferation	O
of	O
MCF	B-Anatomy
-	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
.	O
Meanwhile	O
,	O
the	O
adhesion	O
and	O
invasion	O
ability	O
of	O
MCF	B-Anatomy
-	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
were	O
sharply	O
inhibited	O
when	O
treated	O
with	O
different	O
concentrations	O
of	O
curcumin	O
.	O
Curcumin	O
also	O
significantly	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
expression	O
of	O
uPA	O
and	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
,	O
respectively	O
.	O
It	O
is	O
concluded	O
that	O
curcumin	O
inhibits	O
the	O
adhesion	O
and	O
invasion	O
of	O
MCF	B-Anatomy
-	I-Anatomy
7	I-Anatomy
cells	I-Anatomy
through	O
down	O
-	O
regulating	O
the	O
protein	O
expression	O
of	O
uPA	O
via	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O
Accordingly	O
,	O
the	O
therapeutic	O
potential	O
of	O
curcumin	O
for	O
breast	B-Anatomy
cancer	I-Anatomy
deserves	O
further	O
study	O
.	O
c	O
-	O
MYC	O
functions	O
as	O
a	O
molecular	O
switch	O
to	O
alter	O
the	O
response	O
of	O
human	O
mammary	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
to	O
oncostatin	O
M	O
.	O
Cytokines	O
play	O
an	O
important	O
role	O
in	O
creating	O
an	O
inflammatory	O
microenvironment	O
,	O
which	O
is	O
now	O
considered	O
a	O
hallmark	O
of	O
cancer	B-Anatomy
.	O
Although	O
tumor	B-Anatomy
cells	I-Anatomy
can	O
exploit	O
cytokine	O
signaling	O
to	O
promote	O
growth	O
,	O
invasion	O
,	O
and	O
metastasis	O
,	O
the	O
response	O
of	O
normal	O
and	O
premalignant	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
to	O
cytokines	O
present	O
in	O
a	O
developing	O
tumor	B-Anatomy
microenvironment	O
remains	O
unclear	O
.	O
Oncostatin	O
M	O
(	O
OSM	O
)	O
,	O
an	O
IL	O
-	O
6	O
family	O
cytokine	O
responsible	O
for	O
STAT3	O
activation	O
,	O
has	O
been	O
implicated	O
in	O
cancer	B-Anatomy
development	O
,	O
progression	O
,	O
invasion	O
,	O
and	O
metastasis	O
.	O
Paradoxically	O
,	O
OSM	O
can	O
also	O
suppress	O
the	O
growth	O
of	O
normal	O
cells	B-Anatomy
and	O
certain	B-Anatomy
tumor	I-Anatomy
-	I-Anatomy
derived	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
Using	O
isogenic	O
human	O
mammary	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
(	O
HMEC	B-Anatomy
)	O
at	O
different	O
stages	O
of	O
neoplastic	B-Anatomy
transformation	O
,	O
we	O
found	O
that	O
OSM	O
signaling	O
suppressed	O
c	O
-	O
MYC	O
expression	O
and	O
engaged	O
a	O
p16	O
-	O
and	O
p53	O
-	O
independent	O
growth	O
arrest	O
that	O
required	O
STAT3	O
activity	O
.	O
Inhibition	O
of	O
STAT3	O
activation	O
by	O
expressing	O
a	O
dominant	O
-	O
negative	O
STAT3	O
protein	O
or	O
a	O
STAT3	O
-	O
shRNA	O
prevented	O
the	O
OSM	O
-	O
mediated	O
arrest	O
.	O
In	O
addition	O
,	O
expression	O
of	O
c	O
-	O
MYC	O
from	O
a	O
constitutive	O
promoter	O
also	O
abrogated	O
the	O
STAT3	O
-	O
mediated	O
arrest	O
,	O
and	O
strikingly	O
,	O
cooperated	O
with	O
OSM	O
to	O
promote	O
anchorage	O
-	O
independent	O
growth	O
(	O
AIG	O
)	O
,	O
a	O
property	O
associated	O
with	O
malignant	O
transformation	O
.	O
Cooperative	O
transformation	O
by	O
c	O
-	O
MYC	O
and	O
OSM	O
required	O
PI3K	O
and	O
AKT	O
signaling	O
,	O
showing	O
the	O
importance	O
of	O
multiple	O
signaling	O
pathways	O
downstream	O
of	O
the	O
OSM	O
receptor	O
in	O
defining	O
the	O
cellular	B-Anatomy
response	O
to	O
cytokines	O
.	O
These	O
findings	O
identify	O
c	O
-	O
MYC	O
as	O
an	O
important	O
molecular	O
switch	O
that	O
alters	O
the	O
cellular	B-Anatomy
response	O
to	O
OSM	O
-	O
mediated	O
signaling	O
from	O
tumor	B-Anatomy
suppressive	O
to	O
tumor	B-Anatomy
promoting	O
.	O
PTHrP	O
drives	O
breast	B-Anatomy
tumor	I-Anatomy
initiation	O
,	O
progression	O
,	O
and	O
metastasis	O
in	O
mice	O
and	O
is	O
a	O
potential	O
therapy	O
target	O
.	O
Parathyroid	O
hormone	O
-	O
related	O
protein	O
(	O
PTHrP	O
)	O
is	O
a	O
secreted	O
factor	O
expressed	O
in	O
almost	O
all	O
normal	O
fetal	B-Anatomy
and	O
adult	B-Anatomy
tissues	I-Anatomy
.	O
It	O
is	O
involved	O
in	O
a	O
wide	O
range	O
of	O
developmental	O
and	O
physiological	O
processes	O
,	O
including	O
serum	B-Anatomy
calcium	O
regulation	O
.	O
PTHrP	O
is	O
also	O
associated	O
with	O
the	O
progression	O
of	O
skeletal	B-Anatomy
metastases	I-Anatomy
,	O
and	O
its	O
dysregulated	O
expression	O
in	O
advanced	O
cancers	B-Anatomy
causes	O
malignancy	O
-	O
associated	O
hypercalcemia	O
.	O
Although	O
PTHrP	O
is	O
frequently	O
expressed	O
by	O
breast	B-Anatomy
tumors	I-Anatomy
and	O
other	O
solid	B-Anatomy
cancers	I-Anatomy
,	O
its	O
effects	O
on	O
tumor	B-Anatomy
progression	O
are	O
unclear	O
.	O
Here	O
,	O
we	O
demonstrate	O
in	O
mice	O
pleiotropic	O
involvement	O
of	O
PTHrP	O
in	O
key	O
steps	O
of	O
breast	B-Anatomy
cancer	I-Anatomy
-	O
it	O
influences	O
the	O
initiation	O
and	O
progression	O
of	O
primary	B-Anatomy
tumors	I-Anatomy
and	O
metastases	B-Anatomy
.	O
Pthrp	O
ablation	O
in	O
the	O
mammary	B-Anatomy
epithelium	I-Anatomy
of	O
the	O
PyMT	O
-	O
MMTV	O
breast	B-Anatomy
cancer	I-Anatomy
mouse	O
model	O
caused	O
a	O
delay	O
in	O
primary	B-Anatomy
tumor	I-Anatomy
initiation	O
,	O
inhibited	O
tumor	B-Anatomy
progression	O
,	O
and	O
reduced	O
metastasis	O
to	O
distal	B-Anatomy
sites	I-Anatomy
.	O
Mechanistically	O
,	O
it	O
reduced	O
expression	O
of	O
molecular	O
markers	O
of	O
cell	B-Anatomy
proliferation	O
(	O
Ki67	O
)	O
and	O
angiogenesis	O
(	O
factor	O
VIII	O
)	O
,	O
antiapoptotic	O
factor	O
Bcl	O
-	O
2	O
,	O
cell	B-Anatomy
-	O
cycle	O
progression	O
regulator	O
cyclin	O
D1	O
,	O
and	O
survival	O
factor	O
AKT1	O
.	O
PTHrP	O
also	O
influenced	O
expression	O
of	O
the	O
adhesion	O
factor	O
CXCR4	O
,	O
and	O
coexpression	O
of	O
PTHrP	O
and	O
CXCR4	O
was	O
crucial	O
for	O
metastatic	O
spread	O
.	O
Importantly	O
,	O
PTHrP	O
-	O
specific	O
neutralizing	O
antibodies	O
slowed	O
the	O
progression	O
and	O
metastasis	O
of	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
xenografts	I-Anatomy
.	O
Our	O
data	O
identify	O
what	O
we	O
believe	O
to	O
be	O
new	O
functions	O
for	O
PTHrP	O
in	O
several	O
key	O
steps	O
of	O
breast	B-Anatomy
cancer	I-Anatomy
and	O
suggest	O
that	O
PTHrP	O
may	O
constitute	O
a	O
novel	O
target	O
for	O
therapeutic	O
intervention	O
.	O
Aquaporins	O
in	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
:	O
identification	O
and	O
involvement	O
in	O
carcinogenesis	O
of	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Aquaporins	O
(	O
AQPs	O
)	O
play	O
important	O
roles	O
in	O
water	O
and	O
glycerol	O
transport	O
.	O
Recently	O
,	O
the	O
role	O
of	O
AQPs	O
in	O
human	O
carcinogenesis	O
has	O
become	O
an	O
area	O
of	O
great	O
interest	O
.	O
However	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
AQPs	O
in	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
expression	O
profile	O
of	O
AQPs	O
in	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
and	O
its	O
significance	O
.	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
screened	O
the	O
expression	O
profile	O
of	O
AQP0	O
-	O
12	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
tissues	I-Anatomy
and	O
corresponding	O
normal	O
tissues	B-Anatomy
by	O
RT	O
-	O
PCR	O
,	O
Western	O
blotting	O
and	O
immunohistochemistry	O
.	O
RESULTS	O
:	O
AQP1	O
,	O
3	O
-	O
5	O
,	O
and	O
10	O
-	O
12	O
were	O
expressed	O
in	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
and	O
/	O
or	O
normal	O
breast	B-Anatomy
tissues	I-Anatomy
,	O
and	O
AQP1	O
and	O
3	O
-	O
5	O
exhibited	O
differential	O
expression	O
.	O
AQP1	O
was	O
expressed	O
in	O
cell	B-Anatomy
membranes	I-Anatomy
and	O
its	O
expression	O
was	O
higher	O
in	O
cancer	B-Anatomy
than	O
that	O
in	O
normal	O
tissues	B-Anatomy
.	O
AQP4	O
was	O
expressed	O
in	O
the	O
cell	B-Anatomy
membrane	I-Anatomy
and	O
cytoplasm	B-Anatomy
and	O
was	O
detected	O
markedly	O
stronger	O
in	O
normal	O
than	O
in	O
cancer	B-Anatomy
tissues	I-Anatomy
.	O
AQP5	O
was	O
expressed	O
mainly	O
in	O
cell	B-Anatomy
membranes	I-Anatomy
in	O
carcinoma	B-Anatomy
tissues	I-Anatomy
,	O
but	O
was	O
almost	O
absent	O
in	O
normal	O
breast	B-Anatomy
tissues	I-Anatomy
.	O
Expression	O
of	O
AQP5	O
was	O
associated	O
with	O
cellular	B-Anatomy
differentiation	O
,	O
lymph	B-Anatomy
node	I-Anatomy
invasion	O
,	O
and	O
clinicopathological	O
staging	O
.	O
CONCLUSIONS	O
:	O
These	O
observations	O
suggested	O
that	O
several	O
subtypes	O
of	O
the	O
AQP	O
family	O
play	O
a	O
role	O
in	O
human	O
breast	B-Anatomy
carcinogenesis	O
.	O
Research	O
and	O
discovery	O
of	O
the	O
first	O
human	O
cancer	B-Anatomy
virus	O
,	O
HTLV	O
-	O
1	O
.	O
Human	O
T	O
-	O
cell	O
lymphoma	O
virus	O
(	O
HTLV	O
)	O
-	O
1	O
was	O
the	O
first	O
human	O
retrovirus	O
to	O
be	O
discovered	O
.	O
It	O
has	O
been	O
recognized	O
as	O
the	O
cause	O
of	O
adult	B-Anatomy
T	I-Anatomy
-	I-Anatomy
cell	I-Anatomy
leukemia	I-Anatomy
(	O
ATL	B-Anatomy
)	O
.	O
In	O
addition	O
to	O
giving	O
a	O
historical	O
perspective	O
on	O
HTLV	O
-	O
1	O
and	O
other	O
retrovirus	O
research	O
,	O
this	O
paper	O
discusses	O
the	O
origin	O
of	O
HTLV	O
-	O
1	O
;	O
the	O
modes	O
of	O
transmission	O
and	O
global	O
epidemiology	O
of	O
HTLV	O
-	O
1	O
infection	O
;	O
the	O
genome	O
of	O
HTLV	O
-	O
1	O
and	O
the	O
mechanism	O
of	O
HTLV	O
-	O
1	O
-	O
induced	O
leukemogenesis	O
;	O
the	O
role	O
of	O
HTLV	O
-	O
1	O
in	O
other	O
diseases	O
,	O
and	O
recent	O
breakthroughs	O
in	O
ATL	B-Anatomy
therapy	O
.	O
Selective	O
inhibition	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
by	O
nuclear	O
factor	O
-	O
kappaB	O
essential	O
modulator	O
-	O
binding	O
domain	O
peptide	O
suppresses	O
the	O
metastasis	O
of	O
highly	O
metastatic	B-Anatomy
oral	I-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
Nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activation	O
contributes	O
to	O
the	O
development	O
of	O
metastasis	O
,	O
thus	O
leading	O
to	O
a	O
poor	O
prognosis	O
in	O
many	O
cancers	B-Anatomy
,	O
including	O
OSCC	B-Anatomy
.	O
However	O
,	O
little	O
in	O
vivo	O
experimental	O
data	O
are	O
available	O
about	O
the	O
effects	O
of	O
NF	O
-	O
kappaB	O
inhibition	O
on	O
OSCC	B-Anatomy
metastasis	O
.	O
OSCC	B-Anatomy
sublines	I-Anatomy
were	O
established	O
from	O
a	O
GFP	O
-	O
expressing	O
parental	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
GSAS	B-Anatomy
,	O
and	O
designated	O
GSAS	B-Anatomy
/	I-Anatomy
N3	I-Anatomy
and	O
N5	B-Anatomy
according	O
to	O
the	O
in	O
vivo	O
passage	O
number	O
after	O
cervical	B-Anatomy
lymph	I-Anatomy
node	I-Anatomy
metastasis	O
by	O
a	O
serial	O
orthotopic	O
transplantation	O
model	O
.	O
In	O
vitro	O
migration	O
and	O
invasion	O
were	O
assessed	O
in	O
these	O
cells	B-Anatomy
,	O
and	O
the	O
NF	O
-	O
kappaB	O
activities	O
and	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
metastasis	O
-	O
related	O
molecules	O
were	O
also	O
examined	O
.	O
In	O
in	O
vivo	O
experiments	O
,	O
the	O
metastasis	O
and	O
survival	O
of	O
tumor	B-Anatomy
-	O
engrafted	O
mice	O
were	O
monitored	O
.	O
Furthermore	O
,	O
the	O
effects	O
of	O
a	O
selective	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
NEMO	O
-	O
binding	O
domain	O
(	O
NBD	O
)	O
peptide	O
,	O
on	O
metastasis	O
in	O
GSAS	B-Anatomy
/	I-Anatomy
N5	I-Anatomy
-	O
engrafted	O
mice	O
were	O
assessed	O
,	O
and	O
engrafted	O
tongue	B-Anatomy
tumors	I-Anatomy
were	O
immunohistochemically	O
examined	O
.	O
Highly	O
metastatic	B-Anatomy
GSAS	I-Anatomy
/	I-Anatomy
N3	I-Anatomy
and	O
N5	B-Anatomy
cells	I-Anatomy
showed	O
an	O
enhanced	O
NF	O
-	O
kappaB	O
activity	O
,	O
thus	O
contributing	O
to	O
increased	O
migration	O
,	O
invasion	O
,	O
and	O
a	O
poor	O
prognosis	O
compared	O
with	O
the	O
parent	O
cells	B-Anatomy
.	O
Furthermore	O
,	O
the	O
expression	O
levels	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
metastasis	O
-	O
related	O
molecules	O
,	O
such	O
as	O
fibronectin	O
,	O
beta1	O
integrin	O
,	O
MMP	O
-	O
1	O
,	O
-	O
2	O
,	O
-	O
9	O
,	O
and	O
-	O
14	O
,	O
and	O
VEGF	O
-	O
C	O
,	O
were	O
upregulated	O
in	O
the	O
highly	O
metastatic	B-Anatomy
cells	I-Anatomy
.	O
The	O
NBD	O
peptide	O
suppressed	O
metastasis	O
and	O
tongue	B-Anatomy
tumor	I-Anatomy
growth	O
in	O
GSAS	B-Anatomy
/	I-Anatomy
N5	I-Anatomy
-	O
inoculated	O
mice	O
,	O
and	O
was	O
accompanied	O
by	O
the	O
downregulation	O
of	O
the	O
NF	O
-	O
kappaB	O
-	O
regulated	O
metastasis	O
-	O
related	O
molecules	O
in	O
engrafted	O
tongue	B-Anatomy
tumors	I-Anatomy
.	O
Our	O
results	O
suggest	O
that	O
the	O
selective	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
NBD	O
peptide	O
may	O
provide	O
an	O
effective	O
approach	O
for	O
the	O
treatment	O
of	O
highly	O
metastatic	B-Anatomy
OSCC	I-Anatomy
.	O
beta	O
-	O
catenin	O
signaling	O
controls	O
metastasis	O
in	O
Braf	O
-	O
activated	O
Pten	O
-	O
deficient	O
melanomas	B-Anatomy
.	O
Malignant	B-Anatomy
melanoma	I-Anatomy
is	O
characterized	O
by	O
frequent	O
metastasis	O
,	O
however	O
,	O
specific	O
changes	O
that	O
regulate	O
this	O
process	O
have	O
not	O
been	O
clearly	O
delineated	O
.	O
Although	O
it	O
is	O
well	O
known	O
that	O
Wnt	O
signaling	O
is	O
frequently	O
dysregulated	O
in	O
melanoma	B-Anatomy
,	O
the	O
functional	O
implications	O
of	O
this	O
observation	O
are	O
unclear	O
.	O
By	O
modulating	O
beta	O
-	O
catenin	O
levels	O
in	O
a	O
mouse	O
model	O
of	O
melanoma	B-Anatomy
that	O
is	O
based	O
on	O
melanocyte	B-Anatomy
-	O
specific	O
Pten	O
loss	O
and	O
Braf	O
(	O
V600E	O
)	O
mutation	O
,	O
we	O
demonstrate	O
that	O
beta	O
-	O
catenin	O
is	O
a	O
central	O
mediator	O
of	O
melanoma	B-Anatomy
metastasis	O
to	O
the	O
lymph	B-Anatomy
nodes	I-Anatomy
and	O
lungs	B-Anatomy
.	O
In	O
addition	O
to	O
altering	O
metastasis	O
,	O
beta	O
-	O
catenin	O
levels	O
control	O
tumor	B-Anatomy
differentiation	O
and	O
regulate	O
both	O
MAPK	O
/	O
Erk	O
and	O
PI3K	O
/	O
Akt	O
signaling	O
.	O
Highly	O
metastatic	B-Anatomy
tumors	I-Anatomy
with	O
beta	O
-	O
catenin	O
stabilization	O
are	O
very	O
similar	O
to	O
a	O
subset	O
of	O
human	O
melanomas	B-Anatomy
.	O
Together	O
these	O
findings	O
establish	O
Wnt	O
signaling	O
as	O
a	O
metastasis	O
regulator	O
in	O
melanoma	B-Anatomy
.	O
Mitochondrial	B-Anatomy
apoptosis	O
and	O
FAK	O
signaling	O
disruption	O
by	O
a	O
novel	O
histone	O
deacetylase	O
inhibitor	O
,	O
HTPB	O
,	O
in	O
antitumor	B-Anatomy
and	O
antimetastatic	O
mouse	O
models	O
.	O
BACKGROUND	O
:	O
Compound	O
targeting	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
represents	O
a	O
new	O
era	O
in	O
molecular	O
cancer	B-Anatomy
therapeutics	O
.	O
However	O
,	O
effective	O
HDAC	O
inhibitors	O
for	O
the	O
treatment	O
of	O
solid	B-Anatomy
tumors	I-Anatomy
remain	O
to	O
be	O
developed	O
.	O
METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Here	O
,	O
we	O
propose	O
a	O
novel	O
HDAC	O
inhibitor	O
,	O
N	O
-	O
Hydroxy	O
-	O
4	O
-	O
(	O
4	O
-	O
phenylbutyryl	O
-	O
amino	O
)	O
benzamide	O
(	O
HTPB	O
)	O
,	O
as	O
a	O
potential	O
chemotherapeutic	O
drug	O
for	O
solid	B-Anatomy
tumors	I-Anatomy
.	O
The	O
HDAC	O
inhibition	O
of	O
HTPB	O
was	O
confirmed	O
using	O
HDAC	O
activity	O
assay	O
.	O
The	O
antiproliferative	O
and	O
anti	O
-	O
migratory	O
mechanisms	O
of	O
HTPB	O
were	O
investigated	O
by	O
cell	B-Anatomy
proliferation	O
,	O
flow	O
cytometry	O
,	O
DNA	O
ladder	O
,	O
caspase	O
activity	O
,	O
Rho	O
activity	O
,	O
F	O
-	O
actin	O
polymerization	O
,	O
and	O
gelatin	O
-	O
zymography	O
for	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
.	O
Mice	O
with	O
tumor	B-Anatomy
xenograft	I-Anatomy
and	O
experimental	O
metastasis	O
model	O
were	O
used	O
to	O
evaluate	O
effects	O
on	O
tumor	B-Anatomy
growth	O
and	O
metastasis	O
.	O
Our	O
results	O
indicated	O
that	O
HTPB	O
was	O
a	O
pan	O
-	O
HDAC	O
inhibitor	O
in	O
suppressing	O
cell	B-Anatomy
viability	O
specifically	O
of	O
lung	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
but	O
not	O
of	O
the	O
normal	O
lung	B-Anatomy
cells	I-Anatomy
.	O
Upon	O
HTPB	O
treatment	O
,	O
cell	B-Anatomy
cycle	O
arrest	O
was	O
induced	O
and	O
subsequently	O
led	O
to	O
mitochondria	B-Anatomy
-	O
mediated	O
apoptosis	O
.	O
HTPB	O
disrupted	O
F	O
-	O
actin	O
dynamics	O
via	O
downregulating	O
RhoA	O
activity	O
.	O
Moreover	O
,	O
HTPB	O
inhibited	O
activity	O
of	O
MMP2	O
and	O
MMP9	O
,	O
reduced	O
integrin	O
-	O
beta1	O
/	O
focal	O
adhesion	O
complex	O
formation	O
and	O
decreased	O
pericellular	B-Anatomy
poly	O
-	O
fibronectin	O
assemblies	O
.	O
Finally	O
,	O
intraperitoneal	B-Anatomy
injection	O
or	O
oral	B-Anatomy
administration	O
of	O
HTPB	O
efficiently	O
inhibited	O
A549	B-Anatomy
xenograft	I-Anatomy
tumor	I-Anatomy
growth	O
in	O
vivo	O
without	O
side	O
effects	O
.	O
HTPB	O
delayed	O
lung	B-Anatomy
metastasis	O
of	O
4T1	B-Anatomy
mouse	I-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Acetylation	O
of	O
histone	O
and	O
non	O
-	O
histone	O
proteins	O
,	O
induction	O
of	O
apoptotic	O
-	O
related	O
proteins	O
and	O
de	O
-	O
phosphorylation	O
of	O
focal	O
adhesion	O
kinase	O
were	O
confirmed	O
in	O
treated	O
mice	O
.	O
CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
These	O
results	O
suggested	O
that	O
intrinsic	O
apoptotic	O
pathway	O
may	O
involve	O
in	O
anti	O
-	O
tumor	B-Anatomy
growth	O
effects	O
of	O
HTPB	O
in	O
lung	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
HTPB	O
significantly	O
suppresses	O
tumor	B-Anatomy
metastasis	O
partly	O
through	O
inhibition	O
of	O
integrin	O
-	O
beta1	O
/	O
FAK	O
/	O
MMP	O
/	O
RhoA	O
/	O
F	O
-	O
actin	O
pathways	O
.	O
We	O
have	O
provided	O
convincing	O
preclinical	O
evidence	O
that	O
HTPB	O
is	O
a	O
potent	O
HDAC	O
targeted	O
inhibitor	O
and	O
is	O
thus	O
a	O
promising	O
candidate	O
for	O
lung	B-Anatomy
cancer	I-Anatomy
chemotherapy	O
.	O
Expression	O
of	O
HER2	O
and	O
bradykinin	O
B1	O
receptors	O
in	O
precursor	B-Anatomy
lesions	I-Anatomy
of	O
gallbladder	B-Anatomy
carcinoma	I-Anatomy
.	O
AIM	O
:	O
To	O
determine	O
the	O
expression	O
of	O
HER2	O
and	O
bradykinin	O
B	O
(	O
1	O
)	O
receptors	O
(	O
B	O
(	O
1	O
)	O
R	O
)	O
in	O
the	O
two	O
pathogenic	O
models	O
of	O
gallbladder	B-Anatomy
cancer	I-Anatomy
:	O
the	O
metaplasia	B-Anatomy
-	I-Anatomy
dysplasia	I-Anatomy
-	I-Anatomy
carcinoma	I-Anatomy
and	O
the	O
adenoma	B-Anatomy
-	I-Anatomy
carcinoma	I-Anatomy
pathways	O
.	O
METHODS	O
:	O
Receptor	O
proteins	O
were	O
visualized	O
by	O
immunohistochemistry	O
on	O
5	O
-	O
mum	O
sections	B-Anatomy
of	O
paraffin	O
-	O
embedded	O
tissue	B-Anatomy
.	O
Expression	O
of	O
both	O
receptors	O
was	O
studied	O
in	O
biopsy	B-Anatomy
samples	I-Anatomy
from	O
92	O
patients	O
(	O
6	O
males	O
and	O
86	O
females	O
;	O
age	O
ranging	O
from	O
28	O
to	O
86	O
years	O
,	O
mean	O
56	O
years	O
)	O
.	O
High	O
HER2	O
expression	O
in	O
specimens	B-Anatomy
was	O
additionally	O
investigated	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O
Cell	B-Anatomy
proliferation	O
in	O
each	O
sample	B-Anatomy
was	O
assessed	O
by	O
using	O
the	O
Ki	O
-	O
67	O
proliferation	O
marker	O
.	O
RESULTS	O
:	O
HER2	O
receptor	O
protein	O
was	O
absent	O
in	O
adenomas	B-Anatomy
and	O
in	O
normal	O
gallbladder	B-Anatomy
epithelium	I-Anatomy
.	O
On	O
the	O
contrary	O
,	O
there	O
was	O
intense	O
staining	O
for	O
HER2	O
on	O
the	O
basolateral	B-Anatomy
membrane	I-Anatomy
of	O
epithelial	B-Anatomy
cells	I-Anatomy
of	O
intestinal	B-Anatomy
metaplasia	I-Anatomy
(	O
22	O
/	O
24	O
;	O
91	O
.	O
7	O
%	O
)	O
and	O
carcinoma	B-Anatomy
in	I-Anatomy
situ	I-Anatomy
(	O
9	O
/	O
10	O
;	O
90	O
%	O
)	O
,	O
the	O
lesions	B-Anatomy
that	O
displayed	O
a	O
significantly	O
high	O
proliferation	O
index	O
.	O
Protein	O
up	O
-	O
regulation	O
of	O
HER2	O
in	O
the	O
epithelium	B-Anatomy
with	O
metaplasia	B-Anatomy
or	O
carcinoma	B-Anatomy
in	I-Anatomy
situ	I-Anatomy
was	O
not	O
accompanied	O
by	O
HER2	O
gene	O
amplification	O
.	O
A	O
similar	O
result	O
was	O
observed	O
in	O
invasive	B-Anatomy
carcinomas	I-Anatomy
(	O
0	O
/	O
12	O
)	O
.	O
The	O
B	O
(	O
1	O
)	O
R	O
distribution	O
pattern	O
mirrored	O
that	O
of	O
HER2	O
except	O
that	O
B	O
(	O
1	O
)	O
R	O
was	O
additionally	O
observed	O
in	O
the	O
adenomas	B-Anatomy
.	O
The	O
B	O
(	O
1	O
)	O
R	O
appeared	O
either	O
as	O
cytoplasmic	B-Anatomy
dots	O
or	O
labeling	O
on	O
the	O
apical	B-Anatomy
cell	I-Anatomy
membrane	I-Anatomy
of	O
the	O
cells	B-Anatomy
composing	O
the	O
epithelia	B-Anatomy
with	O
intestinal	B-Anatomy
metaplasia	I-Anatomy
(	O
24	O
/	O
24	O
;	O
100	O
%	O
)	O
and	O
carcinoma	B-Anatomy
in	I-Anatomy
situ	I-Anatomy
(	O
10	O
/	O
10	O
;	O
100	O
%	O
)	O
and	O
in	O
the	O
epithelial	B-Anatomy
cells	I-Anatomy
of	O
adenomas	B-Anatomy
.	O
In	O
contrast	O
,	O
both	O
HER2	O
(	O
4	O
/	O
12	O
;	O
33	O
%	O
)	O
and	O
B	O
(	O
1	O
)	O
R	O
(	O
1	O
/	O
12	O
;	O
8	O
.	O
3	O
%	O
)	O
showed	O
a	O
low	O
expression	O
in	O
invasive	B-Anatomy
gallbladder	I-Anatomy
carcinomas	I-Anatomy
.	O
CONCLUSION	O
:	O
The	O
up	O
-	O
regulation	O
of	O
HER2	O
and	O
B	O
(	O
1	O
)	O
R	O
in	O
precursor	B-Anatomy
lesions	I-Anatomy
of	O
gallbladder	B-Anatomy
carcinoma	I-Anatomy
suggests	O
cross	O
-	O
talk	O
between	O
these	O
two	O
receptors	O
that	O
may	O
be	O
of	O
importance	O
in	O
the	O
modulation	O
of	O
cell	B-Anatomy
proliferation	O
in	O
gallbladder	B-Anatomy
carcinogenesis	O
.	O
Expression	O
of	O
basic	O
fibroblast	O
growth	O
factor	O
in	O
normal	O
human	O
tissues	B-Anatomy
.	O
The	O
distribution	O
of	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
was	O
studied	O
immunohistochemically	O
in	O
fresh	O
frozen	O
sections	B-Anatomy
of	O
normal	O
human	O
tissues	B-Anatomy
.	O
Immunodetection	O
was	O
performed	O
with	O
a	O
specific	O
anti	O
-	O
bFGF	O
mouse	O
monoclonal	O
antibody	O
that	O
was	O
found	O
to	O
react	O
with	O
recombinant	O
human	O
bFGF	O
in	O
Western	O
blot	O
analysis	O
,	O
and	O
to	O
specifically	O
neutralize	O
the	O
mitogenic	O
activity	O
of	O
bFGF	O
on	O
bovine	O
vascular	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
Expression	O
of	O
bFGF	O
on	O
normal	O
human	O
tissues	B-Anatomy
was	O
ubiquitously	O
detected	O
in	O
the	O
basement	B-Anatomy
membranes	I-Anatomy
of	O
all	O
size	O
blood	B-Anatomy
vessels	I-Anatomy
,	O
but	O
was	O
not	O
found	O
in	O
epidermal	B-Anatomy
or	O
epithelial	B-Anatomy
basement	I-Anatomy
membranes	I-Anatomy
of	O
a	O
variety	O
of	O
tissues	B-Anatomy
tested	O
.	O
Intensity	O
and	O
patterns	O
of	O
localization	O
in	O
blood	B-Anatomy
vessels	I-Anatomy
was	O
consistent	O
in	O
various	O
tissues	B-Anatomy
,	O
but	O
varied	O
among	O
different	O
regions	O
of	O
the	O
vascular	B-Anatomy
bed	I-Anatomy
.	O
Whereas	O
homogeneous	O
and	O
intense	O
immunoreactivity	O
were	O
observed	O
in	O
large	O
and	O
intermediate	O
size	O
blood	B-Anatomy
vessels	I-Anatomy
,	O
heterogeneity	O
of	O
expression	O
was	O
found	O
in	O
capillaries	B-Anatomy
.	O
The	O
most	O
intense	O
immunoreactivity	O
was	O
observed	O
in	O
branching	O
capillaries	B-Anatomy
.	O
Endothelial	B-Anatomy
cell	I-Anatomy
staining	O
was	O
heterogeneous	O
and	O
varied	O
in	O
different	O
regions	O
.	O
Strong	O
staining	O
for	O
bFGF	O
was	O
also	O
found	O
in	O
cardiac	B-Anatomy
muscle	I-Anatomy
fibers	I-Anatomy
,	O
smooth	B-Anatomy
muscle	I-Anatomy
cells	I-Anatomy
of	O
mid	O
-	O
size	O
blood	B-Anatomy
vessels	I-Anatomy
,	O
the	O
gut	B-Anatomy
and	O
the	O
myometrium	B-Anatomy
,	O
in	O
central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
neurons	I-Anatomy
and	O
cerebellar	B-Anatomy
Purkinje	I-Anatomy
cells	I-Anatomy
,	O
and	O
on	O
epithelial	B-Anatomy
cells	I-Anatomy
of	O
the	O
bronchi	B-Anatomy
,	O
colon	B-Anatomy
,	O
endometrium	B-Anatomy
,	O
and	O
sweat	B-Anatomy
gland	I-Anatomy
ducts	I-Anatomy
of	O
the	O
skin	B-Anatomy
.	O
The	O
presence	O
of	O
bFGF	O
in	O
the	O
extracellular	B-Anatomy
compartment	I-Anatomy
of	O
a	O
diverse	O
variety	O
of	O
organs	B-Anatomy
may	O
play	O
a	O
role	O
in	O
angiogenesis	O
.	O
However	O
,	O
the	O
function	O
of	O
bFGF	O
in	O
parenchymal	B-Anatomy
cells	I-Anatomy
remains	O
to	O
be	O
determined	O
.	O
Overexpression	O
confers	O
an	O
oncogenic	O
potential	O
upon	O
the	O
eph	O
gene	O
.	O
The	O
eph	O
gene	O
encodes	O
a	O
putative	O
receptor	O
tyrosine	O
kinase	O
for	O
an	O
as	O
yet	O
unknown	O
ligand	O
.	O
Some	O
human	O
cancer	B-Anatomy
cells	I-Anatomy
have	O
been	O
found	O
to	O
overexpress	O
eph	O
mRNAs	O
without	O
gene	O
amplification	O
.	O
We	O
show	O
here	O
that	O
NIH3T3	B-Anatomy
cells	I-Anatomy
acquire	O
tumorigenic	O
ability	O
in	O
nude	O
mice	O
and	O
make	O
colonies	B-Anatomy
in	O
soft	O
agar	O
with	O
a	O
viral	O
LTR	B-Anatomy
(	O
Long	B-Anatomy
Terminal	I-Anatomy
Repeat	I-Anatomy
)	O
-	O
driven	O
artificial	O
expression	O
of	O
the	O
eph	O
gene	O
to	O
a	O
high	O
level	O
.	O
This	O
result	O
supports	O
the	O
alleged	O
contribution	O
of	O
overexpressed	O
receptor	O
tyrosine	O
kinases	O
to	O
cell	B-Anatomy
transformation	O
.	O
The	O
enlarging	O
clinical	O
spectrum	O
of	O
Lyme	O
disease	O
:	O
Lyme	O
cerebral	B-Anatomy
vasculitis	O
,	O
a	O
new	O
disease	O
entity	O
.	O
The	O
case	O
of	O
a	O
patient	O
with	O
cerebral	B-Anatomy
vasculitis	O
with	O
a	O
right	B-Anatomy
thalamic	I-Anatomy
infarct	O
associated	O
with	O
cerebral	B-Anatomy
spinal	I-Anatomy
fluid	I-Anatomy
Lyme	O
disease	O
is	O
presented	O
.	O
This	O
entity	O
has	O
not	O
been	O
described	O
in	O
the	O
United	O
States	O
,	O
and	O
only	O
one	O
similar	O
case	O
in	O
the	O
world	O
literature	O
could	O
be	O
found	O
.	O
The	O
patient	O
presented	O
with	O
a	O
progressive	O
headache	O
and	O
subsequent	O
development	O
of	O
grand	O
mal	O
seizure	O
activity	O
.	O
Lyme	O
disease	O
has	O
been	O
associated	O
with	O
cranial	B-Anatomy
nerve	I-Anatomy
palsies	O
,	O
peripheral	O
and	O
cranial	B-Anatomy
radiculopathies	O
,	O
aseptic	O
meningitis	O
,	O
encephalitic	O
symptoms	O
,	O
chorea	O
,	O
and	O
demyelinating	O
polyneuropathy	O
presenting	O
like	O
Guillain	O
-	O
Barre	O
syndrome	O
.	O
These	O
syndromes	O
can	O
occur	O
separately	O
or	O
in	O
combination	O
.	O
Stroke	O
and	O
strokelike	O
syndromes	O
have	O
been	O
attributed	O
to	O
Lyme	O
disease	O
.	O
The	O
literature	O
concerning	O
the	O
neurologic	B-Anatomy
manifestations	O
of	O
Lyme	O
disease	O
is	O
reviewed	O
.	O
Retinal	B-Anatomy
revascularisation	O
in	O
diabetic	O
retinopathy	O
.	O
The	O
case	O
history	O
of	O
a	O
33	O
-	O
year	O
-	O
old	O
diabetic	O
patient	O
who	O
has	O
had	O
diabetes	O
for	O
24	O
years	O
is	O
presented	O
.	O
When	O
first	O
seen	O
in	O
1975	O
he	O
had	O
bilateral	O
proliferative	O
retinopathy	O
with	O
new	O
vessels	B-Anatomy
in	O
the	O
retinal	B-Anatomy
periphery	I-Anatomy
.	O
He	O
had	O
large	O
areas	O
of	O
capillary	B-Anatomy
non	O
-	O
perfusion	O
lateral	O
to	O
the	O
macula	B-Anatomy
in	O
the	O
right	B-Anatomy
eye	I-Anatomy
associated	O
with	O
the	O
new	O
vessels	B-Anatomy
.	O
Nine	O
years	O
later	O
,	O
after	O
extensive	O
repeated	O
photocoagulation	O
,	O
revascularisation	O
of	O
large	O
areas	O
previously	O
not	O
perfused	O
were	O
seen	O
.	O
The	O
vessels	B-Anatomy
are	O
in	O
the	O
plane	O
of	O
the	O
retina	B-Anatomy
and	O
do	O
not	O
have	O
the	O
appearance	O
of	O
new	O
vessels	B-Anatomy
.	O
Gastric	B-Anatomy
microcirculatory	O
change	O
and	O
development	O
of	O
acute	O
gastric	B-Anatomy
mucosal	I-Anatomy
lesions	I-Anatomy
(	O
stress	B-Anatomy
ulcer	I-Anatomy
)	O
.	O
Concerning	O
the	O
pathogenesis	O
of	O
acute	O
gastric	B-Anatomy
mucosal	I-Anatomy
lesions	I-Anatomy
,	O
gastric	B-Anatomy
microcirculatory	O
change	O
has	O
drawn	O
attention	O
as	O
an	O
important	O
factor	O
.	O
In	O
view	O
of	O
this	O
fact	O
,	O
gastric	B-Anatomy
mucosal	I-Anatomy
blood	B-Anatomy
flow	O
and	O
microvascular	B-Anatomy
structure	O
were	O
investigated	O
in	O
normal	O
and	O
in	O
burn	O
stressed	O
rats	O
.	O
Moreover	O
,	O
alterations	O
in	O
acid	O
and	O
pepsin	O
activities	O
in	O
by	O
morphological	O
and	O
biochemical	O
procedures	O
in	O
order	O
to	O
evaluate	O
the	O
relationship	O
between	O
defensive	O
and	O
aggressive	O
factors	O
of	O
the	O
gastric	B-Anatomy
mucosa	I-Anatomy
.	O
Gastric	B-Anatomy
mucosal	I-Anatomy
blood	B-Anatomy
flow	O
decreased	O
significantly	O
in	O
early	O
period	O
after	O
induction	O
of	O
stress	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
The	O
incidence	O
of	O
ulceration	O
showed	O
a	O
correlative	O
relation	O
with	O
the	O
decrease	O
of	O
mucosal	B-Anatomy
blood	B-Anatomy
flow	O
.	O
Reduction	O
of	O
blood	B-Anatomy
flow	O
in	O
burn	O
was	O
due	O
to	O
opening	O
of	O
arteriovenular	B-Anatomy
shunt	O
and	O
it	O
appeared	O
that	O
this	O
was	O
responsible	O
for	O
mucosal	B-Anatomy
ischemia	O
and	O
congestion	O
.	O
Following	O
the	O
decrease	O
of	O
blood	B-Anatomy
flow	O
,	O
acid	O
output	O
was	O
lower	O
in	O
stress	O
than	O
that	O
in	O
control	O
.	O
Finally	O
,	O
the	O
results	O
of	O
these	O
studies	O
demonstrated	O
the	O
importance	O
of	O
defensive	O
factors	O
.	O
The	O
reduction	O
of	O
mucosal	B-Anatomy
blood	B-Anatomy
flow	O
resulted	O
in	O
the	O
sequence	O
of	O
events	O
that	O
led	O
to	O
formation	O
of	O
acute	O
gastric	B-Anatomy
mucosal	I-Anatomy
lesion	I-Anatomy
.	O
Type	O
-	O
A	O
cholecystokinin	O
receptors	O
in	O
CHP212	B-Anatomy
neuroblastoma	I-Anatomy
cells	I-Anatomy
:	O
evidence	O
for	O
association	O
with	O
G	O
protein	O
and	O
activation	O
of	O
phosphoinositide	O
hydrolysis	O
.	O
125I	O
-	O
Bolton	O
Hunter	O
-	O
cholecystokinin	O
octapeptide	O
(	O
BH	O
-	O
CCK8	O
)	O
and	O
(	O
-	O
)	O
-	O
[	O
3H	O
]	O
L	O
-	O
364718	O
membrane	B-Anatomy
binding	O
assays	O
were	O
used	O
to	O
identify	O
and	O
characterize	O
cholecystokinin	O
(	O
CCK	O
)	O
receptors	O
in	O
CHP212	B-Anatomy
human	O
neuroblastoma	B-Anatomy
cells	I-Anatomy
.	O
The	O
ligand	O
binding	O
properties	O
of	O
CCK	O
receptors	O
in	O
these	O
cells	B-Anatomy
are	O
similar	O
to	O
those	O
found	O
in	O
pancreas	B-Anatomy
(	O
CCK	O
-	O
A	O
sites	O
)	O
and	O
differ	O
from	O
the	O
predominant	O
type	O
of	O
CCK	O
binding	O
site	O
found	O
in	O
brain	B-Anatomy
(	O
CCK	O
-	O
B	O
sites	O
)	O
.	O
The	O
specific	O
binding	O
of	O
125I	O
-	O
BH	O
-	O
CCK8	O
but	O
not	O
(	O
-	O
)	O
-	O
[	O
3H	O
]	O
L	O
-	O
364718	O
was	O
reduced	O
by	O
the	O
metabolically	O
stable	O
GTP	O
analog	O
guanosine	O
5	O
'	O
-	O
(	O
beta	O
-	O
delta	O
-	O
imido	O
)	O
trisphosphate	O
.	O
A	O
substantial	O
difference	O
in	O
the	O
Bmax	O
for	O
the	O
radiolabeled	O
agonist	O
(	O
125I	O
-	O
BH	O
-	O
CCK8	O
)	O
and	O
antagonist	O
[	O
(	O
-	O
)	O
-	O
[	O
3H	O
]	O
L	O
-	O
364718	O
]	O
was	O
noted	O
.	O
These	O
observations	O
are	O
consistent	O
with	O
CCK	O
receptors	O
existing	O
in	O
guanine	O
nucleotide	O
-	O
binding	O
protein	O
-	O
coupled	O
and	O
-	O
uncoupled	O
states	O
.	O
Similar	O
to	O
its	O
action	O
in	O
pancreatic	B-Anatomy
acinar	I-Anatomy
cells	I-Anatomy
,	O
CCK8	O
(	O
S	O
)	O
stimulated	O
the	O
accumulation	O
of	O
[	O
3H	O
]	O
inositol	O
phosphates	O
in	O
cells	B-Anatomy
prelabeled	O
with	O
[	O
3H	O
]	O
myo	O
-	O
inositol	O
(	O
EC50	O
=	O
3	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
4	O
nM	O
;	O
maximum	O
response	O
=	O
4	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
4	O
x	O
basal	O
)	O
.	O
The	O
intrinsic	O
activity	O
of	O
CCK	O
analogues	O
in	O
stimulating	O
phosphoinositide	O
hydrolysis	O
was	O
substantially	O
less	O
than	O
their	O
reported	O
intrinsic	O
activity	O
in	O
stimulating	O
phosphoinositide	O
hydrolysis	O
in	O
pancreatic	B-Anatomy
acinar	I-Anatomy
cells	I-Anatomy
.	O
The	O
CHP212	B-Anatomy
neuroblastoma	I-Anatomy
cell	I-Anatomy
may	O
serve	O
as	O
a	O
useful	O
model	O
for	O
the	O
recently	O
reported	O
CCK	O
-	O
A	O
binding	O
site	O
found	O
in	O
the	O
central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
.	O
Energy	O
supply	O
of	O
the	O
mitotic	O
cell	B-Anatomy
cycle	O
and	O
the	O
Na	O
+	O
/	O
H	O
+	O
-	O
antiport	O
in	O
ascites	B-Anatomy
tumors	I-Anatomy
.	O
The	O
activation	O
of	O
Na	O
+	O
transport	O
is	O
due	O
to	O
the	O
exchange	O
of	O
protons	O
formed	O
via	O
glucose	O
conversion	O
into	O
lactate	O
for	O
Na	O
+	O
,	O
i	O
.	O
e	O
.	O
,	O
to	O
the	O
stimulation	O
of	O
the	O
Na	O
+	O
/	O
H	O
+	O
-	O
antiport	O
.	O
Experimental	O
results	O
and	O
theoretical	O
calculations	O
suggest	O
that	O
in	O
glucose	O
-	O
containing	O
medium	O
the	O
Na	O
+	O
transport	O
increases	O
from	O
0	O
.	O
75	O
to	O
1	O
.	O
78	O
pmol	O
/	O
hour	O
per	O
cell	B-Anatomy
.	O
The	O
permeability	O
of	O
plasma	B-Anatomy
membranes	I-Anatomy
for	O
K	O
+	O
increases	O
2	O
.	O
75	O
fold	O
,	O
while	O
the	O
passive	O
flux	O
of	O
Na	O
+	O
diminishes	O
.	O
The	O
intensity	O
of	O
O2	O
adsorption	O
by	O
ascites	B-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
does	O
not	O
practically	O
depend	O
on	O
the	O
monovalent	O
cation	O
concentration	O
gradient	O
between	O
the	O
cells	B-Anatomy
and	O
the	O
culture	O
medium	O
,	O
whereas	O
the	O
rate	O
of	O
glycolysis	O
decreases	O
simultaneously	O
with	O
the	O
diminution	O
of	O
the	O
concentration	O
gradient	O
.	O
In	O
synchronized	O
cultures	B-Anatomy
at	O
the	O
beginning	O
of	O
the	O
mitotic	O
cycle	O
,	O
the	O
bulk	O
of	O
ATP	O
resynthesized	O
via	O
glycolysis	O
is	O
utilized	O
for	O
the	O
synthesis	O
of	O
biopolymers	O
,	O
whereas	O
that	O
at	O
the	O
end	O
of	O
the	O
S	O
-	O
phase	O
and	O
in	O
the	O
G2	O
-	O
phase	O
is	O
utilized	O
for	O
cation	O
transport	O
across	O
plasma	B-Anatomy
membranes	I-Anatomy
.	O
From	O
35	O
to	O
100	O
%	O
of	O
the	O
whole	O
amount	O
of	O
ATP	O
resynthesized	O
via	O
glycolysis	O
is	O
utilized	O
for	O
transport	O
purposes	O
.	O
It	O
is	O
concluded	O
that	O
the	O
observed	O
increase	O
in	O
the	O
Na	O
+	O
/	O
K	O
+	O
ratio	O
in	O
ascites	B-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
is	O
connected	O
with	O
their	O
enhanced	O
ability	O
to	O
synthesize	O
lactic	O
acid	O
.	O
Presumably	O
,	O
glycolysis	O
is	O
one	O
of	O
the	O
regulatory	O
mechanisms	O
of	O
intracellular	B-Anatomy
ratios	O
of	O
monovalent	O
cations	O
.	O
Screening	O
method	O
for	O
insecticidal	O
activity	O
using	O
first	O
instars	O
of	O
black	O
blow	O
fly	O
(	O
Diptera	O
:	O
Calliphoridae	O
)	O
.	O
A	O
bioassay	O
method	O
suitable	O
for	O
rapid	O
mass	O
screening	O
of	O
fermentation	O
and	O
synthetic	O
organic	O
compounds	O
for	O
insecticidal	O
activity	O
is	O
described	O
.	O
The	O
test	O
,	O
which	O
uses	O
first	O
instars	O
of	O
susceptible	O
black	O
blow	O
fly	O
,	O
Phormia	O
regina	O
(	O
Meigen	O
)	O
,	O
in	O
a	O
bovine	O
serum	B-Anatomy
medium	O
,	O
detects	O
insecticidal	O
activity	O
with	O
reproducible	O
results	O
.	O
It	O
is	O
capable	O
of	O
selecting	O
the	O
most	O
active	O
compound	O
in	O
structure	O
-	O
activity	O
relationships	O
by	O
minimum	O
effective	O
dose	O
concentration	O
studies	O
.	O
The	O
bioassay	O
system	O
is	O
easy	O
to	O
operate	O
and	O
requires	O
only	O
a	O
minute	O
quantity	O
of	O
chemical	O
compound	O
.	O
Early	O
post	O
-	O
mortem	O
metabolism	O
and	O
muscle	B-Anatomy
shortening	O
in	O
the	O
Pectoralis	O
major	O
muscle	B-Anatomy
of	O
broiler	O
chickens	O
.	O
Three	O
experiments	O
were	O
conducted	O
to	O
examine	O
the	O
effects	O
of	O
sodium	O
pentobarbital	O
(	O
SP	O
)	O
,	O
iodoacetate	O
(	O
IO	O
)	O
,	O
tubocurarine	O
(	O
TC	O
)	O
,	O
and	O
surgical	O
denervation	O
(	O
DN	O
)	O
on	O
early	O
rigor	O
development	O
in	O
broiler	O
breast	B-Anatomy
muscle	I-Anatomy
.	O
In	O
Experiment	O
1	O
,	O
birds	O
were	O
either	O
anesthetized	O
or	O
not	O
with	O
SP	O
before	O
receiving	O
an	O
injection	O
of	O
IO	O
or	O
TC	O
or	O
maintained	O
as	O
noninjected	O
controls	O
.	O
Experiment	O
2	O
was	O
identical	O
except	O
that	O
a	O
treatment	O
of	O
denervation	O
of	O
the	O
breast	B-Anatomy
muscle	I-Anatomy
was	O
added	O
.	O
Experiment	O
3	O
was	O
conducted	O
to	O
contrast	O
birds	O
at	O
1	O
day	O
(	O
DN1	O
)	O
and	O
3	O
days	O
(	O
DN3	O
)	O
denervation	O
prior	O
to	O
slaughter	O
to	O
nonoperated	O
controls	O
.	O
Measurements	O
of	O
muscle	B-Anatomy
lactate	O
,	O
ATP	O
,	O
R	O
value	O
(	O
ratio	O
of	O
inosine	O
to	O
adenine	O
nucleotides	O
)	O
,	O
pH	O
,	O
sarcomere	B-Anatomy
lengths	O
,	O
and	O
shear	O
were	O
used	O
to	O
evaluate	O
treatment	O
effects	O
.	O
Results	O
for	O
Experiment	O
1	O
showed	O
no	O
significant	O
differences	O
among	O
treatment	O
and	O
control	O
groups	O
for	O
ATP	O
and	O
lactate	O
contents	O
,	O
R	O
values	O
,	O
or	O
sarcomere	B-Anatomy
lengths	O
;	O
however	O
,	O
significantly	O
lower	O
pH	O
and	O
higher	O
shear	O
values	O
were	O
observed	O
for	O
control	O
birds	O
.	O
In	O
Experiment	O
2	O
,	O
no	O
significant	O
differences	O
were	O
observed	O
among	O
the	O
treatment	O
groups	O
for	O
ATP	O
,	O
R	O
values	O
,	O
or	O
sarcomere	B-Anatomy
lengths	O
.	O
However	O
,	O
lactate	O
and	O
shear	O
values	O
were	O
significantly	O
lower	O
,	O
and	O
pH	O
higher	O
,	O
for	O
the	O
DN	O
and	O
SP	O
treated	O
birds	O
.	O
Experiment	O
3	O
resulted	O
in	O
lower	O
lactate	O
and	O
higher	O
pH	O
values	O
for	O
the	O
DN3	O
treatment	O
in	O
comparison	O
with	O
both	O
DN1	O
and	O
control	O
groups	O
.	O
Results	O
of	O
these	O
studies	O
indicate	O
that	O
the	O
use	O
of	O
SP	O
and	O
DN	O
can	O
be	O
used	O
to	O
alter	O
the	O
early	O
profiles	O
of	O
rigor	O
development	O
.	O
[	O
Tumor	B-Anatomy
metastasis	O
and	O
the	O
fibrinolytic	O
system	O
]	O
.	O
Metastatic	O
spread	O
of	O
malignant	B-Anatomy
tumor	I-Anatomy
appears	O
to	O
correlate	O
with	O
activation	O
of	O
the	O
fibrolytic	O
system	O
.	O
The	O
role	O
of	O
fibrinolysis	O
in	O
growth	O
and	O
metastasis	O
was	O
examined	O
in	O
Lewis	B-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
of	O
mice	O
.	O
The	O
inhibition	O
of	O
fibrinolysis	O
or	O
proteases	O
decreased	O
the	O
primary	B-Anatomy
tumor	I-Anatomy
growth	O
and	O
pulmonary	B-Anatomy
metastasis	O
,	O
whereas	O
the	O
activation	O
of	O
fibrinolysis	O
or	O
proteases	O
increased	O
the	O
number	O
of	O
metastatic	B-Anatomy
foci	I-Anatomy
in	O
the	O
lung	B-Anatomy
.	O
Electronmicroscopically	O
,	O
thrombus	B-Anatomy
formation	O
in	O
the	O
primary	O
site	B-Anatomy
prevented	O
tumor	B-Anatomy
invasion	O
and	O
metastasis	O
formation	O
.	O
Plasminogen	O
activator	O
(	O
PA	O
)	O
content	O
of	O
excised	O
tumors	B-Anatomy
was	O
determined	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
major	O
PA	O
was	O
found	O
to	O
be	O
urokinase	O
(	O
UK	O
)	O
type	O
.	O
Immunohistochemical	O
study	O
with	O
specific	O
antisera	O
was	O
done	O
.	O
When	O
tumor	B-Anatomy
cells	I-Anatomy
possessed	O
a	O
high	O
level	O
of	O
UK	O
,	O
laminin	O
and	O
type	O
IV	O
collagen	O
,	O
components	O
of	O
the	O
basement	B-Anatomy
membrane	I-Anatomy
,	O
disappeared	O
from	O
tumor	B-Anatomy
tissues	I-Anatomy
.	O
These	O
findings	O
suggest	O
that	O
PA	O
through	O
protease	O
cascade	O
plays	O
a	O
role	O
in	O
tumor	B-Anatomy
invasion	O
and	O
metastasis	O
.	O
Clinically	O
,	O
patients	O
with	O
advanced	O
cancer	B-Anatomy
are	O
usually	O
in	O
a	O
hypercoagulable	O
state	O
with	O
elevated	O
fibrinogen	O
,	O
and	O
fibrin	O
deposition	O
around	O
tumor	B-Anatomy
mass	I-Anatomy
is	O
a	O
serious	O
problem	O
in	O
cancer	B-Anatomy
chemotherapy	O
.	O
UK	O
infusion	O
prior	O
to	O
5	O
-	O
fluorouracil	O
increased	O
tissue	B-Anatomy
concentration	O
of	O
antitumor	B-Anatomy
agent	O
.	O
However	O
,	O
development	O
of	O
consumption	O
coagulopathy	O
characterized	O
by	O
progression	O
from	O
hypercoagulable	O
state	O
to	O
disseminated	O
intravascular	B-Anatomy
coagulation	O
has	O
also	O
been	O
found	O
in	O
several	O
cases	O
.	O
Invagination	O
of	O
the	O
otic	B-Anatomy
placode	I-Anatomy
:	O
normal	O
development	O
and	O
experimental	O
manipulation	O
.	O
The	O
inner	B-Anatomy
ear	I-Anatomy
forms	O
from	O
paired	O
ectodermal	B-Anatomy
primordia	I-Anatomy
that	O
lie	O
to	O
either	O
side	O
of	O
the	O
developing	O
hindbrain	B-Anatomy
.	O
Initially	O
each	O
primordium	B-Anatomy
forms	O
a	O
shallow	O
depression	B-Anatomy
in	O
the	O
ectodermal	B-Anatomy
surface	I-Anatomy
.	O
Invagination	O
to	O
form	O
an	O
otic	B-Anatomy
pit	I-Anatomy
coincides	O
with	O
the	O
formation	O
of	O
several	O
deep	O
folds	B-Anatomy
in	O
the	O
epithelial	B-Anatomy
surface	I-Anatomy
.	O
An	O
initial	O
fold	B-Anatomy
appears	O
parallel	O
to	O
the	O
embryonic	B-Anatomy
axis	I-Anatomy
and	O
at	O
the	O
junction	O
of	O
the	O
rhombencephalon	B-Anatomy
with	O
somitomeric	B-Anatomy
mesoderm	I-Anatomy
.	O
This	O
is	O
followed	O
by	O
formation	O
of	O
cranial	B-Anatomy
and	O
caudal	B-Anatomy
folds	I-Anatomy
perpendicular	O
to	O
the	O
axis	B-Anatomy
and	O
minor	O
folds	B-Anatomy
that	O
are	O
within	O
the	O
pit	B-Anatomy
formed	O
by	O
earlier	O
folding	O
.	O
The	O
central	O
region	O
of	O
the	O
otic	B-Anatomy
primordium	I-Anatomy
remains	O
in	O
close	O
apposition	O
to	O
the	O
lateral	B-Anatomy
surface	I-Anatomy
of	O
the	O
neural	B-Anatomy
tube	I-Anatomy
during	O
the	O
process	O
of	O
fold	B-Anatomy
formation	O
,	O
until	O
the	O
otic	B-Anatomy
pit	I-Anatomy
becomes	O
quite	O
deep	O
.	O
At	O
that	O
time	O
,	O
mesenchymal	B-Anatomy
cells	I-Anatomy
penetrate	O
between	O
the	O
two	O
layers	O
.	O
Experimental	O
analysis	O
of	O
invagination	O
supports	O
the	O
conclusion	O
that	O
otic	B-Anatomy
invagination	O
is	O
controlled	O
differently	O
from	O
that	O
of	O
similar	O
organ	B-Anatomy
primordia	I-Anatomy
,	O
such	O
as	O
the	O
eye	B-Anatomy
and	O
thyroid	B-Anatomy
.	O
Whereas	O
these	O
other	O
primordia	B-Anatomy
can	O
be	O
stimulated	O
to	O
undergo	O
normal	O
morphogenetic	O
shape	O
changes	O
precociously	O
by	O
treatments	O
that	O
presumably	O
activate	O
motile	O
processes	O
in	O
the	O
cytoskeleton	B-Anatomy
,	O
the	O
same	O
conditions	O
have	O
little	O
effect	O
on	O
the	O
otic	B-Anatomy
placode	I-Anatomy
.	O
Similarly	O
,	O
neither	O
inhibitors	O
of	O
calcium	O
transport	O
nor	O
inactivators	O
of	O
calmodulin	O
activity	O
prevent	O
otic	B-Anatomy
pit	I-Anatomy
formation	O
,	O
while	O
these	O
drugs	O
block	O
invagination	O
of	O
other	O
primordia	B-Anatomy
.	O
These	O
results	O
suggest	O
that	O
otic	B-Anatomy
invagination	O
may	O
be	O
caused	O
by	O
changes	O
in	O
the	O
surrounding	O
tissues	B-Anatomy
rather	O
than	O
by	O
an	O
activation	O
of	O
motility	O
within	O
the	O
primordium	B-Anatomy
.	O
Anaplastic	B-Anatomy
and	I-Anatomy
sarcomatoid	I-Anatomy
carcinoma	I-Anatomy
of	O
the	O
small	B-Anatomy
intestine	I-Anatomy
:	O
a	O
clinicopathologic	O
study	O
.	O
Carcinomas	B-Anatomy
involving	O
the	O
jejunum	B-Anatomy
and	O
ileum	B-Anatomy
are	O
rare	O
tumors	B-Anatomy
.	O
During	O
a	O
review	O
of	O
small	B-Anatomy
intestinal	I-Anatomy
neoplasms	I-Anatomy
,	O
six	O
primary	B-Anatomy
carcinomas	I-Anatomy
of	O
jejunum	B-Anatomy
or	O
ileum	B-Anatomy
with	O
an	O
anaplastic	O
and	O
sarcomatoid	B-Anatomy
histology	O
were	O
identified	O
.	O
At	O
presentation	O
,	O
three	O
of	O
the	O
patients	O
had	O
symptoms	O
related	O
to	O
metastatic	B-Anatomy
disease	I-Anatomy
and	O
three	O
had	O
symptoms	O
referable	O
to	O
the	O
local	O
tumor	B-Anatomy
.	O
The	O
tumors	B-Anatomy
were	O
large	O
(	O
greater	O
than	O
4	O
.	O
5	O
cm	O
in	O
diameter	O
)	O
,	O
usually	O
endophytic	O
masses	B-Anatomy
composed	O
of	O
large	O
cells	B-Anatomy
with	O
eosinophilic	B-Anatomy
cytoplasm	I-Anatomy
,	O
anaplastic	O
nuclei	B-Anatomy
,	O
and	O
prominent	O
nucleoli	B-Anatomy
.	O
In	O
many	O
areas	O
,	O
the	O
cells	B-Anatomy
had	O
a	O
spindled	O
configuration	O
.	O
Mucin	O
positivity	O
was	O
identified	O
in	O
all	O
six	O
cases	O
.	O
Electron	O
microscopic	O
findings	O
in	O
two	O
cases	O
were	O
indicative	O
of	O
epithelial	B-Anatomy
differentiation	O
.	O
The	O
tumors	B-Anatomy
behaved	O
aggressively	O
;	O
all	O
five	O
patients	O
for	O
whom	O
there	O
was	O
clinical	O
follow	O
-	O
up	O
died	O
of	O
metastases	B-Anatomy
within	O
40	O
months	O
.	O
The	O
six	O
anaplastic	B-Anatomy
and	I-Anatomy
sarcomatoid	I-Anatomy
carcinomas	I-Anatomy
were	O
compared	O
with	O
29	O
typical	O
adenocarcinomas	B-Anatomy
arising	O
in	O
the	O
jejunum	B-Anatomy
or	O
ileum	B-Anatomy
.	O
Only	O
two	O
of	O
the	O
latter	O
group	O
had	O
symptoms	O
referable	O
to	O
distant	O
metastases	B-Anatomy
at	O
presentation	O
.	O
These	O
tumors	B-Anatomy
also	O
tended	O
to	O
be	O
smaller	O
at	O
presentation	O
(	O
11	O
tumors	B-Anatomy
were	O
less	O
than	O
4	O
cm	O
in	O
greatest	O
dimension	O
)	O
.	O
Of	O
25	O
patients	O
with	O
typical	O
adenocarcinomas	B-Anatomy
who	O
had	O
acceptable	O
follow	O
-	O
up	O
,	O
18	O
(	O
72	O
%	O
)	O
died	O
of	O
disease	O
and	O
five	O
(	O
20	O
%	O
)	O
were	O
alive	O
with	O
no	O
evidence	O
of	O
disease	O
after	O
5	O
years	O
.	O
We	O
conclude	O
that	O
anaplastic	B-Anatomy
and	I-Anatomy
sarcomatoid	I-Anatomy
carcinoma	I-Anatomy
is	O
a	O
rare	O
variant	O
of	O
small	B-Anatomy
intestinal	I-Anatomy
carcinoma	I-Anatomy
with	O
an	O
aggressive	O
clinical	O
course	O
.	O
Time	O
course	O
of	O
transmitter	O
action	O
at	O
the	O
sympathetic	B-Anatomy
neuroeffector	I-Anatomy
junction	I-Anatomy
in	O
rodent	O
vascular	B-Anatomy
and	O
non	B-Anatomy
-	I-Anatomy
vascular	I-Anatomy
smooth	I-Anatomy
muscle	I-Anatomy
.	O
1	O
.	O
Transmitter	O
release	O
from	O
sympathetic	B-Anatomy
postganglionic	I-Anatomy
nerve	I-Anatomy
terminals	I-Anatomy
innervating	O
the	O
guinea	O
-	O
pig	O
and	O
mouse	O
vas	B-Anatomy
deferens	I-Anatomy
and	O
the	O
rat	O
tail	B-Anatomy
artery	I-Anatomy
has	O
been	O
studied	O
in	O
vitro	O
by	O
focal	O
extracellular	B-Anatomy
recording	O
with	O
particular	O
emphasis	O
on	O
the	O
time	O
course	O
of	O
transmitter	O
action	O
underlying	O
the	O
intracellular	B-Anatomy
potential	O
changes	O
.	O
2	O
.	O
In	O
the	O
absence	O
of	O
stimulation	O
,	O
spontaneous	O
excitatory	B-Anatomy
junction	I-Anatomy
currents	O
(	O
SEJCs	O
)	O
were	O
recorded	O
with	O
amplitudes	O
up	O
to	O
500	O
microV	O
and	O
durations	O
between	O
40	O
and	O
100	O
ms	O
.	O
SEJCs	O
were	O
unaffected	O
by	O
the	O
competitive	O
alpha	O
-	O
adrenoceptor	O
antagonist	O
prazosin	O
but	O
blocked	O
by	O
alpha	O
,	O
beta	O
-	O
methylene	O
ATP	O
which	O
desensitizes	O
P2	O
-	O
purinoceptors	O
.	O
3	O
.	O
During	O
trains	O
of	O
supramaximal	O
stimuli	O
at	O
0	O
.	O
1	O
-	O
4	O
Hz	O
stimulus	O
locked	O
excitatory	B-Anatomy
junction	I-Anatomy
currents	O
(	O
EJCs	O
)	O
were	O
evoked	O
intermittently	O
from	O
the	O
population	O
of	O
varicosities	O
located	O
under	O
the	O
suction	O
electrode	O
.	O
4	O
.	O
SEJCs	O
were	O
similar	O
in	O
amplitude	O
and	O
time	O
course	O
to	O
EJCs	O
evoked	O
by	O
low	O
-	O
frequency	O
stimulation	O
in	O
the	O
same	O
attachment	O
in	O
all	O
three	O
tissues	B-Anatomy
.	O
5	O
.	O
SEJCs	O
recorded	O
using	O
either	O
a	O
conventional	O
AC	O
amplifier	O
or	O
a	O
patch	O
clamp	O
amplifier	O
had	O
the	O
same	O
time	O
course	O
.	O
6	O
.	O
These	O
studies	O
show	O
that	O
the	O
time	O
course	O
of	O
the	O
current	O
underlying	O
the	O
excitatory	B-Anatomy
junction	I-Anatomy
potential	O
is	O
brief	O
and	O
essentially	O
the	O
same	O
in	O
three	O
different	O
tissues	B-Anatomy
.	O
The	O
prolonged	O
time	O
course	O
of	O
the	O
excitatory	B-Anatomy
junction	I-Anatomy
potential	O
in	O
different	O
tissues	B-Anatomy
can	O
be	O
accounted	O
for	O
by	O
the	O
passive	O
membrane	B-Anatomy
properties	O
.	O
On	O
the	O
mechanism	O
of	O
glycolysis	O
stimulation	O
by	O
neutral	O
detergents	O
in	O
3T3	B-Anatomy
and	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
.	O
Glycolysis	O
of	O
3T3	B-Anatomy
and	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
was	O
greatly	O
enhanced	O
by	O
Nonidet	O
P	O
-	O
40	O
or	O
Triton	O
X	O
-	O
100	O
at	O
about	O
100	O
micrograms	O
/	O
mg	O
cell	B-Anatomy
protein	O
.	O
This	O
enhanced	O
glycolysis	O
was	O
partly	O
sensitive	O
to	O
rutamycin	O
and	O
partly	O
sensitive	O
to	O
ouabain	O
,	O
suggesting	O
that	O
the	O
detergent	O
released	O
the	O
control	O
of	O
the	O
ATPase	O
of	O
the	O
mitochondria	B-Anatomy
and	O
of	O
the	O
plasma	B-Anatomy
membrane	I-Anatomy
Na	O
+	O
K	O
+	O
-	O
ATPase	O
.	O
Nonidet	O
P	O
-	O
40	O
had	O
no	O
effect	O
on	O
glycolysis	O
in	O
cell	B-Anatomy
-	O
free	O
extracts	B-Anatomy
from	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
to	O
which	O
soluble	O
mitochondrial	B-Anatomy
ATPase	O
was	O
added	O
.	O
Measuring	O
ouabain	O
-	O
sensitive	O
22Na	O
efflux	O
and	O
using	O
ouabain	O
-	O
sensitive	O
lactate	O
production	O
as	O
a	O
measure	O
of	O
ATP	O
hydrolysis	O
by	O
the	O
Na	O
+	O
K	O
+	O
pump	O
,	O
it	O
was	O
shown	O
that	O
Nonidet	O
P	O
-	O
40	O
greatly	O
decreased	O
the	O
efficiency	O
of	O
the	O
Na	O
+	O
K	O
+	O
pump	O
.	O
Quercetin	O
increased	O
the	O
efficiency	O
of	O
pumping	O
in	O
EAT	B-Anatomy
cells	I-Anatomy
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
the	O
detergent	O
.	O
Elevated	O
levels	O
of	O
diacylglycerol	O
and	O
decreased	O
phorbol	O
ester	O
sensitivity	O
in	O
ras	O
-	O
transformed	O
fibroblasts	B-Anatomy
.	O
Diacylglycerol	O
(	O
DG	O
)	O
plays	O
a	O
central	O
role	O
in	O
phospholipid	O
metabolism	O
and	O
is	O
an	O
endogenous	O
activator	O
of	O
protein	O
kinase	O
C	O
.	O
We	O
have	O
suggested	O
that	O
constitutive	O
activation	O
of	O
this	O
kinase	O
is	O
one	O
mechanism	O
by	O
which	O
oncogenes	O
transform	O
cells	B-Anatomy
.	O
The	O
ras	O
-	O
encoded	O
proteins	O
are	O
similar	O
to	O
regulatory	O
G	O
-	O
proteins	O
and	O
are	O
candidates	O
for	O
the	O
unknown	O
G	O
-	O
protein	O
that	O
modulates	O
phosphatidylinositol	O
(	O
PI	O
)	O
turnover	O
.	O
Differences	O
in	O
polyphosphoinositide	O
metabolism	O
have	O
been	O
reported	O
for	O
ras	O
-	O
transformed	O
cells	B-Anatomy
.	O
But	O
because	O
these	O
experiments	O
were	O
performed	O
on	O
confluent	O
cultures	B-Anatomy
of	O
established	O
cell	B-Anatomy
lines	I-Anatomy
,	O
the	O
differences	O
are	O
difficult	O
to	O
attribute	O
to	O
ras	O
transformation	O
.	O
Here	O
we	O
show	O
that	O
exponentially	O
growing	O
NIH	B-Anatomy
3T3	I-Anatomy
fibroblasts	I-Anatomy
recently	O
transformed	O
by	O
Ha	O
-	O
ras	O
or	O
Ki	O
-	O
ras	O
possess	O
elevated	O
DG	O
concentrations	O
without	O
significant	O
alterations	O
in	O
the	O
levels	O
of	O
other	O
polyphosphoinositide	O
metabolites	O
.	O
The	O
basal	O
phosphorylation	O
of	O
protein	O
kinase	O
C	O
substrate	O
of	O
relative	O
molecular	O
mass	O
(	O
Mr	O
)	O
80	O
,	O
000	O
(	O
80K	O
)	O
is	O
significantly	O
increased	O
in	O
all	O
the	O
ras	O
-	O
transformed	O
cell	B-Anatomy
lines	I-Anatomy
.	O
Surprisingly	O
,	O
however	O
,	O
further	O
phosphorylation	O
of	O
this	O
protein	O
on	O
addition	O
of	O
phorbol	O
ester	O
was	O
greatly	O
reduced	O
.	O
Ha	B-Anatomy
-	I-Anatomy
ras	I-Anatomy
cells	I-Anatomy
also	O
show	O
less	O
binding	O
of	O
phorbol	O
ester	O
than	O
control	O
cells	B-Anatomy
,	O
suggesting	O
that	O
elevation	O
of	O
DG	O
causes	O
partial	O
down	O
-	O
regulation	O
in	O
addition	O
to	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O
Epidermal	O
growth	O
factor	O
and	O
its	O
receptor	O
.	O
Epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
binds	O
with	O
high	O
affinity	O
and	O
specificity	O
to	O
a	O
single	O
site	O
on	O
the	O
external	O
domain	O
of	O
its	O
transmembrane	B-Anatomy
receptor	O
to	O
activate	O
the	O
tyrosine	O
protein	O
kinase	O
activity	O
of	O
its	O
cytoplasmic	B-Anatomy
portion	O
.	O
The	O
EGF	O
receptor	O
gene	O
is	O
amplified	O
and	O
over	O
-	O
expressed	O
in	O
several	O
human	O
tumors	B-Anatomy
,	O
suggesting	O
that	O
increased	O
concentrations	O
of	O
the	O
proto	O
-	O
oncogene	O
leads	O
to	O
constitutive	O
activity	O
similar	O
to	O
that	O
seen	O
with	O
oncogene	O
erb	O
B	O
.	O
Synthesis	O
and	O
degradation	O
of	O
the	O
EGF	O
receptor	O
are	O
regulated	O
,	O
in	O
addition	O
,	O
covalent	O
modification	O
by	O
phosphorylation	O
regulates	O
activity	O
of	O
the	O
receptor	O
protein	O
.	O
Intramolecular	O
self	O
-	O
phosphorylation	O
of	O
Tyr1173	O
removes	O
a	O
competitive	O
inhibitory	O
constraint	O
to	O
enhance	O
phosphorylation	O
of	O
substrates	O
.	O
Phosphorylation	O
of	O
Thr654	O
by	O
protein	O
kinase	O
C	O
decreases	O
high	O
affinity	O
EGF	O
binding	O
and	O
EGF	O
-	O
stimulated	O
tyrosine	O
protein	O
kinase	O
activity	O
,	O
providing	O
a	O
mechanism	O
for	O
heterologous	O
regulation	O
of	O
the	O
EGF	O
receptor	O
by	O
tumor	B-Anatomy
promoters	O
and	O
other	O
ligand	O
X	O
receptor	O
complexes	O
.	O
Extensive	O
regulation	O
contributes	O
to	O
normal	O
growth	O
control	O
,	O
abrogation	O
of	O
regulatory	O
controls	O
contributes	O
to	O
uncontrolled	O
growth	O
as	O
seen	O
with	O
erb	O
B	O
transformation	O
and	O
EGF	O
receptor	O
gene	O
amplification	O
in	O
human	O
tumors	B-Anatomy
.	O
Differential	O
secretion	O
of	O
proteins	O
and	O
glycoproteins	O
by	O
livers	B-Anatomy
of	O
immature	O
and	O
adult	O
rats	O
.	O
Effect	O
of	O
antimicrotubule	B-Anatomy
drugs	O
.	O
This	O
study	O
was	O
initiated	O
to	O
re	O
-	O
examine	O
reported	O
differences	O
in	O
the	O
action	O
of	O
antimicrotubule	B-Anatomy
agents	O
on	O
plasma	B-Anatomy
protein	O
secretion	O
from	O
livers	B-Anatomy
of	O
immature	O
versus	O
adult	O
rats	O
.	O
The	O
aim	O
was	O
(	O
1	O
)	O
to	O
determine	O
the	O
composition	O
and	O
to	O
monitor	O
the	O
secretion	O
of	O
various	O
plasma	B-Anatomy
proteins	O
and	O
glycoproteins	O
from	O
liver	B-Anatomy
slices	I-Anatomy
labeled	O
in	O
vitro	O
with	O
specific	O
amino	O
acids	O
and	O
sugar	O
residues	O
,	O
and	O
(	O
2	O
)	O
to	O
correlate	O
observed	O
differences	O
in	O
secretion	O
of	O
these	O
proteins	O
with	O
structural	O
changes	O
in	O
the	O
hepatocytes	B-Anatomy
of	O
the	O
different	O
aged	O
animals	O
.	O
For	O
the	O
most	O
part	O
,	O
slices	B-Anatomy
of	O
liver	B-Anatomy
from	O
fetal	B-Anatomy
(	O
term	O
)	O
,	O
neonatal	O
(	O
4	O
-	O
to	O
5	O
days	O
old	O
)	O
,	O
and	O
adult	O
rats	O
(	O
70	O
days	O
old	O
)	O
were	O
incubated	O
with	O
radioactive	O
amino	O
acids	O
or	O
various	O
tritiated	O
sugars	O
specific	O
for	O
N	O
-	O
linked	O
core	O
oligosaccharide	O
and	O
/	O
or	O
N	O
-	O
linked	O
terminal	O
oligosaccharide	O
chains	O
.	O
Our	O
findings	O
indicate	O
that	O
liver	B-Anatomy
slices	I-Anatomy
of	O
fetal	B-Anatomy
and	O
neonatal	O
rats	O
are	O
efficient	O
in	O
synthesizing	O
plasma	B-Anatomy
proteins	O
including	O
fully	O
glycosylated	O
glycoproteins	O
.	O
The	O
secretion	O
of	O
glycosylated	O
and	O
nonglycosylated	O
proteins	O
believed	O
to	O
be	O
processed	O
through	O
Golgi	B-Anatomy
complexes	I-Anatomy
was	O
inhibited	O
to	O
the	O
same	O
extent	O
(	O
approximately	O
70	O
-	O
80	O
%	O
)	O
by	O
antimicrotubule	B-Anatomy
agents	O
,	O
regardless	O
of	O
the	O
age	O
of	O
the	O
host	O
animal	O
.	O
However	O
,	O
other	O
proteins	O
and	O
glycoproteins	O
secreted	O
by	O
livers	B-Anatomy
of	O
immature	O
rats	O
were	O
found	O
to	O
be	O
relatively	O
insensitive	O
(	O
i	O
.	O
e	O
.	O
inhibited	O
to	O
only	O
30	O
-	O
40	O
%	O
)	O
to	O
the	O
action	O
of	O
various	O
antimicrotubule	B-Anatomy
drugs	O
.	O
The	O
glycoproteins	O
were	O
found	O
to	O
lack	O
N	O
-	O
linked	O
terminal	O
sugars	O
(	O
although	O
the	O
glycoproteins	O
did	O
contain	O
N	O
-	O
linked	O
core	O
sugars	O
)	O
,	O
and	O
it	O
is	O
likely	O
that	O
the	O
drug	O
-	O
insensitive	O
proteins	O
bypassed	O
critical	O
glycosylating	O
sites	O
in	O
the	O
Golgi	B-Anatomy
compartment	I-Anatomy
prior	O
to	O
release	O
.	O
Overall	O
,	O
these	O
findings	O
support	O
earlier	O
data	O
showing	O
that	O
antimicrotubule	B-Anatomy
drugs	O
have	O
a	O
special	O
impact	O
on	O
Golgi	B-Anatomy
-	O
associated	O
events	O
in	O
liver	B-Anatomy
cells	I-Anatomy
.	O
To	O
what	O
extent	O
these	O
findings	O
are	O
related	O
to	O
the	O
action	O
of	O
microtubules	B-Anatomy
remains	O
to	O
be	O
seen	O
.	O
The	O
posterior	O
tether	O
in	O
scoliosis	O
.	O
The	O
hypothesis	O
that	O
a	O
localized	O
lordosis	O
,	O
or	O
tethering	O
of	O
the	O
posterior	O
elements	O
of	O
the	O
spine	B-Anatomy
,	O
is	O
the	O
primary	O
cause	O
of	O
the	O
vertebral	B-Anatomy
rotation	O
in	O
idiopathic	O
scoliosis	O
was	O
investigated	O
in	O
anatomic	B-Anatomy
specimens	I-Anatomy
of	O
human	O
and	O
calf	O
spinal	B-Anatomy
columns	I-Anatomy
.	O
The	O
specimens	B-Anatomy
were	O
axially	O
loaded	O
with	O
and	O
without	O
a	O
posterior	O
tether	O
created	O
using	O
Zielke	O
instrumentation	O
.	O
Lateral	O
deflection	O
and	O
axial	O
rotation	O
were	O
monitored	O
roentgenographically	O
.	O
The	O
vertebrae	B-Anatomy
of	O
tethered	O
spines	B-Anatomy
showed	O
increased	O
rotation	O
in	O
the	O
direction	O
associated	O
with	O
idiopathic	O
scoliosis	O
.	O
The	O
spinous	O
processes	O
moved	O
toward	O
the	O
concavity	O
at	O
the	O
apex	O
of	O
the	O
induced	O
lateral	O
curve	O
.	O
Conversely	O
,	O
untethered	O
spines	B-Anatomy
either	O
exhibited	O
little	O
rotation	O
or	O
rotated	O
in	O
the	O
opposite	O
direction	O
;	O
the	O
spinous	O
processes	O
moved	O
toward	O
the	O
convexity	O
of	O
the	O
curve	O
.	O
Rotations	O
toward	O
the	O
convexity	O
occur	O
in	O
rotational	O
kyphosis	O
.	O
Thus	O
the	O
hypothesis	O
that	O
idiopathic	O
scoliosis	O
is	O
a	O
rotational	O
lordosis	O
is	O
substantiated	O
;	O
the	O
characteristic	O
rotation	O
can	O
be	O
explained	O
with	O
the	O
aid	O
of	O
a	O
geometric	O
model	O
.	O
Glutamine	O
and	O
glucose	O
as	O
energy	O
substrates	O
for	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumour	I-Anatomy
cells	I-Anatomy
.	O
Energy	O
metabolism	O
of	O
freshly	O
harvested	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumour	I-Anatomy
cells	I-Anatomy
in	O
the	O
presence	O
of	O
5	O
mM	O
glucose	O
and	O
/	O
or	O
0	O
.	O
5	O
mM	O
glutamine	O
was	O
studied	O
.	O
The	O
rate	O
of	O
oxygen	O
utilization	O
was	O
not	O
altered	O
by	O
the	O
addition	O
of	O
0	O
.	O
5	O
mM	O
glutamine	O
;	O
5	O
mM	O
glucose	O
induced	O
an	O
inhibition	O
of	O
respiration	O
.	O
In	O
the	O
presence	O
of	O
both	O
glucose	O
and	O
glutamine	O
,	O
the	O
Crabtree	O
effect	O
decreased	O
.	O
In	O
these	O
conditions	O
,	O
the	O
rates	O
of	O
oxygen	O
uptake	O
,	O
the	O
CO2	O
evolution	O
and	O
the	O
changes	O
in	O
the	O
redox	O
states	O
of	O
cytochromes	O
indicate	O
that	O
glucose	O
is	O
preferred	O
by	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumour	I-Anatomy
cells	I-Anatomy
as	O
energy	O
substrate	O
.	O
Glucose	O
decreased	O
the	O
rate	O
of	O
glutamine	O
utilization	O
by	O
34	O
%	O
.	O
On	O
the	O
other	O
hand	O
,	O
glutaminolysis	O
did	O
not	O
inhibit	O
glycolysis	O
.	O
Growth	O
state	O
-	O
dependent	O
regulation	O
of	O
protein	O
kinase	O
C	O
in	O
normal	O
and	O
transformed	O
murine	O
cells	B-Anatomy
.	O
We	O
determined	O
whether	O
growth	O
state	O
can	O
influence	O
the	O
action	O
of	O
protein	O
kinase	O
C	O
by	O
measuring	O
protein	O
kinase	O
C	O
activity	O
in	O
growing	O
and	O
stationary	O
cultures	B-Anatomy
of	O
normal	O
and	O
transformed	O
cells	B-Anatomy
.	O
Two	O
approaches	O
were	O
used	O
to	O
measure	O
protein	O
kinase	O
C	O
:	O
assay	O
of	O
intact	O
cells	B-Anatomy
for	O
inhibition	O
of	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
binding	O
in	O
response	O
to	O
phorbol	O
dibutyrate	O
(	O
PDBu	O
)	O
;	O
and	O
assay	O
of	O
detergent	O
extracts	B-Anatomy
for	O
total	O
calcium	O
,	O
phospholipid	O
-	O
dependent	O
kinase	O
activity	O
.	O
In	O
extracts	B-Anatomy
of	O
growing	O
and	O
stationary	O
Swiss	B-Anatomy
3T3	I-Anatomy
cells	I-Anatomy
,	O
the	O
total	O
amount	O
of	O
protein	O
kinase	O
C	O
activity	O
was	O
similar	O
,	O
indicating	O
that	O
growth	O
state	O
does	O
not	O
alter	O
the	O
level	O
of	O
enzyme	O
in	O
the	O
cell	B-Anatomy
.	O
The	O
short	O
-	O
term	O
response	O
of	O
Swiss	B-Anatomy
3T3	I-Anatomy
cells	I-Anatomy
to	O
an	O
activator	O
of	O
protein	O
kinase	O
C	O
also	O
appeared	O
to	O
be	O
independent	O
of	O
growth	O
state	O
,	O
since	O
the	O
50	O
%	O
effective	O
dose	O
for	O
PDBu	O
inhibition	O
of	O
EGF	O
binding	O
to	O
its	O
receptor	O
was	O
approximately	O
7	O
nM	O
for	O
both	O
growth	O
conditions	O
.	O
In	O
contrast	O
,	O
the	O
response	O
of	O
cells	B-Anatomy
to	O
long	O
-	O
term	O
treatment	O
with	O
PDBu	O
was	O
significantly	O
different	O
depending	O
upon	O
the	O
initial	O
growth	O
state	O
of	O
the	O
cells	B-Anatomy
.	O
In	O
both	O
growth	O
states	O
,	O
PDBu	O
caused	O
loss	O
of	O
protein	O
kinase	O
C	O
activity	O
,	O
which	O
reflected	O
a	O
loss	O
in	O
protein	O
mass	O
as	O
determined	O
by	O
immunoblotting	O
with	O
antiserum	B-Anatomy
to	O
protein	O
kinase	O
C	O
.	O
However	O
,	O
the	O
maximum	O
decrease	O
approached	O
100	O
%	O
in	O
stationary	O
cultures	B-Anatomy
versus	O
approximately	O
75	O
%	O
in	O
growing	O
cells	B-Anatomy
.	O
Protein	O
kinase	O
C	O
levels	O
in	O
several	O
transformed	O
cell	B-Anatomy
lines	I-Anatomy
were	O
subject	O
to	O
down	O
modulation	O
in	O
a	O
similar	O
growth	O
state	O
-	O
dependent	O
manner	O
.	O
Further	O
,	O
the	O
inhibition	O
of	O
EGF	O
binding	O
by	O
tumor	B-Anatomy
promoters	O
following	O
long	O
-	O
term	O
treatment	O
of	O
Swiss	B-Anatomy
3T3	I-Anatomy
cells	I-Anatomy
with	O
PDBu	O
also	O
varied	O
with	O
growth	O
state	O
.	O
In	O
down	O
modulated	O
growing	O
cells	B-Anatomy
,	O
PDBu	O
caused	O
almost	O
complete	O
inhibition	O
of	O
EGF	O
binding	O
,	O
whereas	O
in	O
down	O
modulated	O
stationary	O
cells	B-Anatomy
,	O
minimal	O
inhibition	O
of	O
EGF	O
binding	O
by	O
PDBu	O
was	O
observed	O
.	O
These	O
results	O
suggest	O
that	O
prolonged	O
treatment	O
with	O
tumor	B-Anatomy
promoters	O
alters	O
the	O
sensitivity	O
of	O
cells	B-Anatomy
to	O
activators	O
of	O
protein	O
kinase	O
C	O
in	O
a	O
growth	O
state	O
-	O
dependent	O
manner	O
.	O
Suppression	O
and	O
re	O
-	O
expression	O
of	O
transformed	O
phenotype	O
in	O
hybrids	B-Anatomy
of	O
HA	O
-	O
ras	O
-	O
1	O
-	O
transformed	O
rat	B-Anatomy
-	I-Anatomy
1	I-Anatomy
cells	I-Anatomy
and	O
early	O
-	O
passage	O
rat	O
embryonic	B-Anatomy
fibroblasts	I-Anatomy
.	O
Rat	B-Anatomy
-	I-Anatomy
1	I-Anatomy
cells	I-Anatomy
which	O
had	O
been	O
transformed	O
with	O
the	O
activated	O
Ha	O
-	O
ras	O
-	O
1	O
gene	O
from	O
human	O
EJ	B-Anatomy
bladder	I-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
were	O
fused	O
with	O
diploid	O
embryonic	B-Anatomy
rat	I-Anatomy
fibroblasts	I-Anatomy
.	O
Four	O
selected	O
cell	B-Anatomy
hybrids	I-Anatomy
expressed	O
the	O
human	O
transforming	O
gene	O
product	O
p21	O
at	O
levels	O
of	O
10	O
to	O
30	O
%	O
compared	O
to	O
100	O
%	O
in	O
the	O
transformed	O
parental	O
cells	B-Anatomy
.	O
The	O
hybrid	B-Anatomy
cells	I-Anatomy
,	O
however	O
,	O
exhibited	O
normal	O
morphology	O
,	O
anchorage	O
requirement	O
for	O
proliferation	O
,	O
and	O
largely	O
extended	O
latency	O
periods	O
of	O
tumorigenicity	O
in	O
newborn	O
rats	O
.	O
Tumorigenic	O
hybrid	B-Anatomy
derivatives	I-Anatomy
contained	O
lower	O
numbers	O
of	O
chromosomes	B-Anatomy
than	O
the	O
tetraploid	O
parental	B-Anatomy
hybrids	I-Anatomy
.	O
DNA	O
of	O
the	O
non	O
-	O
tumorigenic	O
cell	B-Anatomy
hybrids	I-Anatomy
transformed	O
Rat	B-Anatomy
-	I-Anatomy
1	I-Anatomy
cells	I-Anatomy
to	O
anchorage	O
-	O
independent	O
proliferation	O
as	O
expected	O
for	O
the	O
transforming	O
human	O
Ha	O
-	O
ras	O
gene	O
present	O
in	O
the	O
donor	O
DNA	O
.	O
We	O
conclude	O
that	O
the	O
transforming	O
properties	O
of	O
the	O
activated	O
Ha	O
-	O
ras	O
gene	O
in	O
Rat	B-Anatomy
-	I-Anatomy
1	I-Anatomy
cells	I-Anatomy
can	O
be	O
suppressed	O
at	O
the	O
post	O
-	O
translational	O
level	O
by	O
the	O
presence	O
of	O
the	O
genome	O
from	O
diploid	O
embryonic	B-Anatomy
rat	I-Anatomy
fibroblasts	I-Anatomy
but	O
additional	O
controls	O
of	O
expression	O
of	O
the	O
transforming	O
gene	O
are	O
likely	O
to	O
exist	O
.	O
Normal	O
cells	B-Anatomy
contain	O
suppressor	O
gene	O
(	O
s	O
)	O
which	O
safeguard	O
these	O
cells	B-Anatomy
against	O
transformation	O
by	O
the	O
product	O
of	O
the	O
transforming	O
Ha	O
-	O
ras	O
-	O
1	O
oncogene	O
.	O
Torsade	O
de	O
pointes	O
during	O
loading	O
with	O
amiodarone	O
.	O
Torsade	O
de	O
pointes	O
represents	O
a	O
potential	O
complication	O
of	O
chronic	O
amiodarone	O
therapy	O
.	O
Several	O
reports	O
have	O
emphasized	O
the	O
need	O
for	O
a	O
loading	O
dose	O
in	O
order	O
to	O
achieve	O
therapeutic	O
blood	B-Anatomy
levels	O
rapidly	O
.	O
We	O
report	O
a	O
case	O
of	O
torsade	O
de	O
pointes	O
following	O
a	O
single	O
oral	B-Anatomy
dose	O
of	O
amiodarone	O
(	O
1400	O
mg	O
or	O
30	O
mg	O
kg	O
-	O
1	O
)	O
administered	O
after	O
short	O
intravenous	B-Anatomy
loading	O
for	O
prevention	O
of	O
paroxysmal	O
atrial	B-Anatomy
flutter	O
.	O
Torsades	O
de	O
pointes	O
were	O
preceded	O
and	O
associated	O
with	O
marked	O
QT	O
prolongation	O
and	O
bradycardia	O
.	O
This	O
report	O
suggests	O
that	O
careful	O
monitoring	O
of	O
patients	O
undergoing	O
oral	B-Anatomy
amiodarone	O
loading	O
is	O
necessary	O
.	O
Unsatisfactory	O
forehead	B-Anatomy
scar	I-Anatomy
following	O
face	B-Anatomy
lift	O
.	O
The	O
W	O
-	O
plasty	O
scar	B-Anatomy
revision	O
technique	O
has	O
been	O
found	O
to	O
be	O
effective	O
in	O
the	O
repair	O
of	O
the	O
difficult	O
and	O
cosmetically	O
unsatisfactory	O
hairline	B-Anatomy
scar	I-Anatomy
following	O
the	O
ill	O
-	O
advised	O
face	B-Anatomy
lift	O
technique	O
that	O
excises	O
forehead	B-Anatomy
skin	I-Anatomy
.	O
Clinical	O
evaluation	O
of	O
radiotherapy	O
for	O
Graves	O
'	O
ophthalmopathy	O
.	O
Seventeen	O
patients	O
with	O
moderately	O
severe	O
ophthalmopathy	O
due	O
to	O
Graves	O
'	O
disease	O
were	O
treated	O
by	O
cobalt	O
or	O
supervoltage	O
radiotherapy	O
.	O
All	O
patients	O
complained	O
of	O
diplopia	O
.	O
The	O
mean	O
proptosis	O
value	O
was	O
21	O
.	O
4	O
mm	O
.	O
Three	O
patients	O
(	O
18	O
%	O
)	O
showed	O
good	O
response	O
,	O
7	O
(	O
41	O
%	O
)	O
moderate	O
and	O
7	O
minimal	O
or	O
no	O
response	O
.	O
Improvement	O
was	O
noted	O
mainly	O
in	O
soft	B-Anatomy
tissue	I-Anatomy
changes	O
and	O
diplopia	O
,	O
while	O
proptosis	O
decreased	O
in	O
only	O
5	O
patients	O
.	O
All	O
except	O
one	O
patient	O
who	O
had	O
marked	O
extraocular	B-Anatomy
muscle	I-Anatomy
involvement	O
revealed	O
by	O
computed	O
tomography	O
responded	O
to	O
treatment	O
.	O
These	O
data	O
indicate	O
that	O
radiotherapy	O
may	O
be	O
indicated	O
in	O
patients	O
with	O
progressive	O
ophthalmopathy	O
,	O
especially	O
in	O
those	O
who	O
are	O
associated	O
with	O
extraocular	B-Anatomy
muscle	I-Anatomy
enlargement	O
.	O
The	O
effect	O
of	O
aflatoxin	O
B1	O
on	O
the	O
utilization	O
of	O
serum	B-Anatomy
calcium	O
.	O
The	O
mathematical	O
analysis	O
for	O
plasma	B-Anatomy
disappearance	O
curve	O
of	O
aflatoxicosed	O
animals	O
,	O
subsequently	O
injected	O
with	O
45Ca	O
was	O
determined	O
.	O
The	O
analysis	O
showed	O
that	O
the	O
three	O
main	O
compartments	O
of	O
the	O
calcium	O
pool	O
(	O
plasma	B-Anatomy
,	O
bone	B-Anatomy
and	O
the	O
labile	O
calcium	O
pool	O
on	O
the	O
surface	B-Anatomy
of	O
bone	B-Anatomy
and	O
soft	B-Anatomy
tissues	I-Anatomy
)	O
had	O
been	O
affected	O
.	O
Specifically	O
,	O
the	O
fractional	O
rate	O
constant	O
for	O
migration	O
of	O
45Ca	O
from	O
plasma	B-Anatomy
pool	O
to	O
the	O
labile	O
pool	O
had	O
been	O
diminished	O
to	O
its	O
third	O
value	O
.	O
This	O
led	O
to	O
a	O
corresponding	O
reduction	O
in	O
the	O
calcium	O
content	O
of	O
the	O
bone	B-Anatomy
ash	I-Anatomy
.	O
The	O
probable	O
mechanism	O
by	O
which	O
aflatoxin	O
B1	O
affects	O
calcium	O
dynamics	O
may	O
be	O
interpreted	O
by	O
the	O
inhibitory	O
effect	O
of	O
aflatoxin	O
in	O
the	O
hydroxylation	O
mechanism	O
of	O
vitamin	O
D3	O
into	O
an	O
active	O
intermediate	O
.	O
During	O
aflatoxicosis	O
(	O
induction	O
of	O
15	O
days	O
)	O
the	O
animals	O
entered	O
a	O
state	O
of	O
calcium	O
deficiency	O
,	O
secondary	O
to	O
intestinal	B-Anatomy
absorption	O
inhibition	O
.	O
This	O
was	O
followed	O
by	O
bone	B-Anatomy
resorption	O
and	O
disturbance	O
of	O
the	O
fractional	O
removal	O
rate	O
constant	O
among	O
different	O
calcium	O
compartments	O
.	O
Mast	B-Anatomy
cells	I-Anatomy
and	O
tumors	B-Anatomy
.	O
The	O
specific	O
enhancement	O
of	O
tumor	B-Anatomy
proliferation	O
in	O
vitro	O
.	O
Mast	B-Anatomy
cells	I-Anatomy
were	O
found	O
to	O
be	O
unique	O
among	O
the	O
peritoneal	B-Anatomy
leukocytes	I-Anatomy
by	O
virtue	O
of	O
their	O
capacity	O
to	O
enhance	O
profoundly	O
the	O
proliferation	O
of	O
a	O
variety	O
of	O
tumors	B-Anatomy
in	O
vitro	O
.	O
This	O
phenomenon	O
occurs	O
at	O
mast	B-Anatomy
cell	I-Anatomy
/	O
tumor	B-Anatomy
ratios	O
which	O
reflect	O
the	O
stoichiometry	O
of	O
host	O
cell	B-Anatomy
/	O
tumor	B-Anatomy
relationships	O
in	O
vivo	O
.	O
The	O
growth	O
factor	O
was	O
found	O
to	O
reside	O
in	O
mast	B-Anatomy
cell	I-Anatomy
granules	B-Anatomy
and	O
was	O
identified	O
as	O
heparin	O
by	O
sequential	O
purification	O
and	O
enzymatic	O
degradation	O
.	O
This	O
cellular	B-Anatomy
interaction	O
was	O
tumor	B-Anatomy
-	O
specific	O
,	O
although	O
isolated	O
granules	B-Anatomy
could	O
enhance	O
fibroblast	B-Anatomy
proliferation	O
.	O
The	O
findings	O
are	O
discussed	O
in	O
relation	O
to	O
previous	O
morphologic	O
studies	O
,	O
reports	O
of	O
in	O
vitro	O
mast	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
-	O
mediated	O
tumor	B-Anatomy
cytotoxicity	O
,	O
and	O
the	O
role	O
of	O
mast	B-Anatomy
cells	I-Anatomy
in	O
angiogenesis	O
and	O
connective	B-Anatomy
tissue	I-Anatomy
proliferation	O
.	O
Management	O
of	O
the	O
tortuous	B-Anatomy
internal	I-Anatomy
carotid	I-Anatomy
artery	I-Anatomy
.	O
The	O
tortuous	B-Anatomy
internal	I-Anatomy
carotid	I-Anatomy
artery	I-Anatomy
as	O
the	O
basis	O
of	O
cerebral	B-Anatomy
vascular	I-Anatomy
insufficiency	O
is	O
a	O
controversial	O
entity	O
,	O
as	O
such	O
lesions	B-Anatomy
frequently	O
occur	O
without	O
neurologic	B-Anatomy
symptoms	O
.	O
However	O
,	O
some	O
tortuous	B-Anatomy
vessels	I-Anatomy
are	O
associated	O
with	O
significant	O
carotid	B-Anatomy
atherosclerotic	O
disease	O
requiring	O
a	O
specific	O
surgical	O
approach	O
.	O
This	O
formed	O
the	O
basis	O
of	O
our	O
report	O
.	O
Symptoms	O
of	O
cerebrovascular	B-Anatomy
insufficiency	O
in	O
association	O
with	O
a	O
tortuous	B-Anatomy
internal	I-Anatomy
carotid	I-Anatomy
artery	I-Anatomy
was	O
encountered	O
in	O
27	O
of	O
853	O
carotid	B-Anatomy
endarterectomies	O
over	O
a	O
22	O
year	O
period	O
.	O
Stenosis	O
of	O
hemodynamic	O
significance	O
was	O
noted	O
in	O
nine	O
patients	O
and	O
irregularities	O
or	O
ulceration	O
were	O
noted	O
in	O
the	O
rest	O
.	O
With	O
the	O
standard	O
technique	O
of	O
carotid	B-Anatomy
endarterectomy	O
,	O
removal	O
of	O
plaque	B-Anatomy
from	O
a	O
tortuous	B-Anatomy
vessel	I-Anatomy
leads	O
to	O
loss	O
of	O
the	O
stenting	O
effect	O
provided	O
by	O
the	O
plaque	B-Anatomy
such	O
that	O
angulation	O
occlusion	O
is	O
likely	O
to	O
occur	O
.	O
The	O
optimal	O
reconstruction	O
in	O
our	O
experience	O
is	O
eversion	O
endarterectomy	O
by	O
transection	O
and	O
lower	O
reimplantation	O
of	O
the	O
internal	B-Anatomy
carotid	I-Anatomy
artery	I-Anatomy
on	O
the	O
common	B-Anatomy
carotid	I-Anatomy
artery	I-Anatomy
.	O
Our	O
experience	O
with	O
17	O
such	O
procedures	O
in	O
15	O
patients	O
has	O
been	O
presented	O
.	O
Rapid	O
enzyme	O
analysis	O
of	O
amniotic	B-Anatomy
fluid	I-Anatomy
phospholipids	O
containing	O
choline	O
:	O
a	O
comparison	O
with	O
the	O
lecithin	O
to	O
sphingomyelin	O
ratio	O
in	O
prenatal	O
assessment	O
of	O
fetal	B-Anatomy
lung	I-Anatomy
maturity	O
.	O
The	O
relation	O
between	O
the	O
choline	O
containing	O
surfactant	O
phospholipids	O
lecithin	O
and	O
sphingomyelin	O
in	O
amniotic	B-Anatomy
fluid	I-Anatomy
and	O
fetal	B-Anatomy
lung	I-Anatomy
maturity	O
is	O
well	O
established	O
.	O
An	O
enzymatic	O
method	O
that	O
had	O
been	O
automated	O
and	O
optimised	O
for	O
use	O
on	O
a	O
centrifugal	O
analyser	O
was	O
used	O
to	O
measure	O
the	O
total	O
choline	O
containing	O
phospholipids	O
in	O
amniotic	B-Anatomy
fluid	I-Anatomy
.	O
The	O
total	O
time	O
taken	O
for	O
this	O
assay	O
was	O
10	O
minutes	O
.	O
The	O
results	O
obtained	O
from	O
100	O
patient	O
samples	B-Anatomy
,	O
using	O
this	O
procedure	O
,	O
compared	O
favourably	O
with	O
the	O
results	O
obtained	O
by	O
the	O
thin	O
layer	O
chromatography	O
procedure	O
used	O
to	O
determine	O
the	O
lecithin	O
to	O
sphingomyelin	O
ratio	O
(	O
r	O
=	O
0	O
.	O
93	O
)	O
.	O
A	O
clinical	O
study	O
of	O
60	O
patients	O
showed	O
that	O
this	O
assay	O
predicted	O
prenatal	O
respiratory	B-Anatomy
distress	O
syndrome	O
as	O
well	O
as	O
the	O
lecithin	O
to	O
sphingomyelin	O
ratios	O
.	O
The	O
advantage	O
of	O
this	O
assay	O
over	O
existing	O
procedures	O
is	O
that	O
it	O
requires	O
minimum	O
preparation	O
of	O
the	O
specimen	B-Anatomy
and	O
no	O
extraction	O
,	O
is	O
quick	O
,	O
and	O
shows	O
a	O
high	O
degree	O
of	O
precision	O
.	O
Differences	O
between	O
the	O
arterial	B-Anatomy
and	O
the	O
venous	B-Anatomy
pathomorphology	O
in	O
Buerger	O
'	O
s	O
disease	O
.	O
Morphological	O
lesions	B-Anatomy
were	O
found	O
to	O
be	O
different	O
in	O
arteries	B-Anatomy
and	O
in	O
veins	B-Anatomy
,	O
in	O
9	O
cases	O
of	O
Buerger	O
'	O
s	O
disease	O
.	O
The	O
arterial	B-Anatomy
lesions	I-Anatomy
were	O
not	O
characteristic	O
and	O
consisted	O
of	O
non	O
-	O
specific	O
inflammation	O
,	O
thrombosis	O
and	O
obliteration	O
which	O
also	O
occur	O
in	O
many	O
other	O
disease	O
.	O
In	O
contrast	O
,	O
in	O
addition	O
to	O
wall	B-Anatomy
infiltration	O
and	O
thrombosis	O
,	O
the	O
veins	B-Anatomy
showed	O
microabscesses	B-Anatomy
and	O
giant	B-Anatomy
cell	I-Anatomy
granulomas	I-Anatomy
,	O
which	O
we	O
believe	O
to	O
be	O
absent	O
in	O
all	O
other	O
known	O
diseases	O
.	O
The	O
affected	O
venous	B-Anatomy
segment	O
exhibited	O
a	O
variety	O
of	O
lesions	B-Anatomy
.	O
In	O
the	O
earliest	O
period	O
,	O
the	O
morphological	O
aspect	O
of	O
inflammation	O
in	O
arteries	B-Anatomy
and	O
veins	B-Anatomy
was	O
fairly	O
similar	O
.	O
In	O
a	O
late	O
periods	O
,	O
that	O
is	O
those	O
of	O
vascular	B-Anatomy
obliteration	O
,	O
the	O
arteries	B-Anatomy
and	O
veins	B-Anatomy
did	O
not	O
show	O
any	O
distinguishing	O
morphological	O
differences	O
.	O
Identification	O
of	O
the	O
putative	O
transforming	O
protein	O
of	O
the	O
human	O
T	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
leukemia	I-Anatomy
viruses	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
.	O
The	O
human	O
T	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
leukemia	I-Anatomy
viruses	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
are	O
unique	O
among	O
the	O
transforming	O
retroviruses	O
of	O
vertebrates	O
in	O
their	O
ability	O
to	O
transform	O
human	O
T	B-Anatomy
cells	I-Anatomy
in	O
vitro	O
and	O
in	O
their	O
close	O
association	O
with	O
human	O
malignancies	B-Anatomy
(	O
T	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lymphomas	I-Anatomy
and	O
leukemia	B-Anatomy
)	O
.	O
Their	O
genomes	O
are	O
relatively	O
simple	O
,	O
containing	O
the	O
genes	O
gag	O
,	O
pol	O
,	O
env	O
,	O
and	O
a	O
3	B-Anatomy
'	I-Anatomy
region	I-Anatomy
termed	O
""""	O
X	B-Anatomy
.	O
""""	O
This	O
3	B-Anatomy
'	I-Anatomy
region	I-Anatomy
may	O
be	O
responsible	O
for	O
the	O
transforming	O
potential	O
of	O
the	O
viruses	O
.	O
The	O
existence	O
of	O
proteins	O
encoded	O
by	O
the	O
3	B-Anatomy
'	I-Anatomy
region	I-Anatomy
has	O
been	O
postulated	O
on	O
the	O
basis	O
of	O
multiple	O
open	O
reading	O
frames	O
.	O
In	O
the	O
present	O
study	O
this	O
region	O
is	O
shown	O
to	O
contain	O
a	O
gene	O
encoding	O
a	O
protein	O
of	O
40	O
kilodaltons	O
in	O
HTLV	O
-	O
I	O
and	O
37	O
kilodaltons	O
in	O
HTLV	O
-	O
II	O
.	O
It	O
is	O
proposed	O
that	O
these	O
proteins	O
be	O
called	O
,	O
respectively	O
,	O
p40xI	O
and	O
p37xII	O
.	O
Phosphorylation	O
-	O
induced	O
mobility	O
shift	O
in	O
phospholamban	O
in	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gels	O
.	O
Evidence	O
for	O
a	O
protein	O
structure	O
consisting	O
of	O
multiple	O
identical	O
phosphorylatable	O
subunits	O
.	O
Phosphorylation	O
of	O
purified	O
phospholamban	O
isolated	O
from	O
canine	O
cardiac	B-Anatomy
sarcoplasmic	I-Anatomy
reticulum	I-Anatomy
vesicles	I-Anatomy
decreased	O
the	O
electrophoretic	O
mobility	O
of	O
the	O
protein	O
in	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
-	O
polyacrylamide	O
gels	O
.	O
Different	O
mobility	O
forms	O
of	O
phospholamban	O
in	O
SDS	O
gels	O
were	O
visualized	O
both	O
by	O
direct	O
protein	O
staining	O
and	O
by	O
autoradiography	O
.	O
Unphosphorylated	O
phospholamban	O
migrated	O
with	O
an	O
apparent	O
Mr	O
=	O
25	O
,	O
000	O
in	O
SDS	O
gels	O
;	O
maximal	O
phosphorylation	O
of	O
phospholamban	O
by	O
cAMP	O
-	O
or	O
Ca2	O
+	O
-	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
increased	O
the	O
apparent	O
Mr	O
to	O
27	O
,	O
000	O
.	O
Partial	O
phosphorylation	O
of	O
phospholamban	O
by	O
either	O
protein	O
kinase	O
gave	O
intermediate	O
mobility	O
forms	O
of	O
molecular	O
weights	O
between	O
25	O
,	O
000	O
and	O
27	O
,	O
000	O
,	O
suggesting	O
that	O
more	O
than	O
one	O
phosphorylation	O
site	O
was	O
present	O
on	O
the	O
holoprotein	O
for	O
each	O
activity	O
.	O
Boiling	O
of	O
phospholamban	O
in	O
SDS	O
dissociated	O
the	O
holoprotein	O
into	O
an	O
apparently	O
homogeneous	O
class	O
of	O
low	O
molecular	O
weight	O
""""	O
monomers	O
.	O
""""	O
Only	O
two	O
mobility	O
forms	O
of	O
monomeric	O
phospholamban	O
were	O
observed	O
in	O
SDS	O
gels	O
after	O
phosphorylation	O
by	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
,	O
corresponding	O
to	O
9	O
-	O
kDa	O
dephospho	O
-	O
and	O
11	O
-	O
kDa	O
phosphoproteins	O
.	O
All	O
of	O
the	O
9	O
-	O
kDa	O
protein	O
could	O
be	O
phosphorylated	O
and	O
converted	O
into	O
the	O
11	O
-	O
kDa	O
mobility	O
form	O
,	O
suggesting	O
the	O
presence	O
of	O
only	O
one	O
site	O
of	O
phosphorylation	O
on	O
a	O
single	O
type	O
of	O
monomer	O
for	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
.	O
Simultaneous	O
phosphorylation	O
of	O
monomeric	O
phospholamban	O
by	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
and	O
Ca2	O
+	O
-	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
gave	O
an	O
additional	O
mobility	O
form	O
of	O
the	O
protein	O
,	O
suggesting	O
that	O
different	O
sites	O
of	O
phosphorylation	O
were	O
present	O
for	O
each	O
activity	O
on	O
each	O
monomer	O
.	O
Incomplete	O
dissociation	O
of	O
the	O
holoprotein	O
by	O
boiling	O
it	O
in	O
a	O
relatively	O
low	O
concentration	O
of	O
SDS	O
facilitated	O
the	O
detection	O
of	O
five	O
major	O
mobility	O
forms	O
of	O
the	O
protein	O
in	O
SDS	O
gels	O
,	O
and	O
the	O
mobilities	O
of	O
all	O
of	O
these	O
forms	O
were	O
decreased	O
by	O
phosphorylation	O
.	O
We	O
propose	O
that	O
the	O
high	O
molecular	O
weight	O
form	O
of	O
phospholamban	O
is	O
a	O
multimer	O
of	O
electrophoretically	O
indistinguishable	O
monomers	O
,	O
each	O
of	O
which	O
contains	O
a	O
different	O
phosphorylation	O
site	O
for	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
activity	O
and	O
Ca2	O
+	O
-	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
activity	O
.	O
Phosphorylation	O
of	O
phospholamban	O
at	O
multiple	O
sites	O
is	O
responsible	O
for	O
the	O
various	O
mobility	O
forms	O
of	O
the	O
holoprotein	O
detected	O
in	O
SDS	O
-	O
polyacrylamide	O
gels	O
.	O
Cells	B-Anatomy
transformed	O
by	O
Rous	O
sarcoma	O
virus	O
release	O
transforming	O
growth	O
factors	O
.	O
Chicken	O
embryo	B-Anatomy
fibroblasts	I-Anatomy
and	O
hamster	B-Anatomy
BHK	I-Anatomy
cells	I-Anatomy
transformed	O
by	O
Rous	O
sarcoma	O
virus	O
(	O
RSV	O
)	O
release	O
in	O
their	O
culture	O
media	O
growth	O
factors	O
which	O
enhance	O
markedly	O
anchorage	O
-	O
independent	O
colony	B-Anatomy
formation	O
in	O
gelified	O
medium	O
,	O
at	O
the	O
restrictive	O
temperature	O
(	O
41	O
degrees	O
5	O
C	O
)	O
,	O
of	O
chicken	O
embryo	B-Anatomy
fibroblasts	I-Anatomy
(	O
CEF	B-Anatomy
)	O
infected	O
by	O
RSV	O
mutants	O
with	O
a	O
ts	O
mutation	O
of	O
the	O
src	O
gene	O
.	O
This	O
action	O
is	O
not	O
observed	O
with	O
uninfected	O
CEF	B-Anatomy
,	O
and	O
,	O
therefore	O
,	O
appears	O
to	O
require	O
some	O
expression	O
of	O
the	O
viral	O
src	O
gene	O
in	O
the	O
target	O
cells	B-Anatomy
.	O
The	O
enhancing	O
factors	O
are	O
proteins	O
related	O
to	O
the	O
family	O
of	O
the	O
transforming	O
growth	O
factors	O
(	O
TGFs	O
)	O
by	O
their	O
molecular	O
weight	O
(	O
about	O
20	O
kd	O
)	O
,	O
their	O
heat	O
and	O
acid	O
resistance	O
,	O
and	O
their	O
sensitivity	O
to	O
dithiothreitol	O
.	O
They	O
do	O
not	O
compete	O
with	O
125I	O
EGF	O
for	O
binding	O
on	O
the	O
EGF	O
receptors	O
of	O
the	O
membrane	B-Anatomy
of	O
A431	B-Anatomy
cells	I-Anatomy
.	O
As	O
chicken	O
embryo	B-Anatomy
fibroblasts	I-Anatomy
are	O
devoid	O
of	O
EGF	O
receptors	O
,	O
their	O
activity	O
is	O
not	O
potentiated	O
by	O
EGF	O
.	O
The	O
genetics	O
of	O
transformation	O
by	O
SV	O
40	O
.	O
Experiments	O
using	O
the	O
tsA	O
58	O
allele	O
of	O
the	O
SV	O
40	O
-	O
A	O
gene	O
have	O
demonstrated	O
that	O
the	O
SV	O
40	O
large	O
T	O
-	O
antigen	O
is	O
strictly	O
required	O
both	O
for	O
immortalization	O
and	O
induction	O
anchorage	O
independence	O
of	O
cells	B-Anatomy
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
immortalized	O
phenotype	O
is	O
mediated	O
by	O
an	O
extra	B-Anatomy
cellular	I-Anatomy
factor	O
.	O
The	O
synthesis	O
and	O
/	O
or	O
the	O
excretion	O
of	O
this	O
factor	O
in	O
a	O
medium	O
is	O
controlled	O
by	O
the	O
A	O
gene	O
.	O
Molecular	O
events	O
leading	O
to	O
enhanced	O
glucose	O
transport	O
in	O
Rous	O
sarcoma	O
virus	O
-	O
transformed	O
cells	B-Anatomy
.	O
Transformation	O
by	O
Rous	O
sarcoma	O
virus	O
results	O
in	O
a	O
dramatic	O
increase	O
in	O
the	O
rate	O
at	O
which	O
the	O
transformed	O
cells	B-Anatomy
transport	O
glucose	O
across	O
the	O
cell	B-Anatomy
membrane	I-Anatomy
.	O
The	O
increased	O
transport	O
rate	O
is	O
a	O
consequence	O
of	O
an	O
increased	O
number	O
of	O
transporters	O
in	O
the	O
transformed	O
cells	B-Anatomy
.	O
Utilizing	O
antibody	O
raised	O
against	O
the	O
purified	O
human	O
erythrocyte	B-Anatomy
glucose	O
transporter	O
,	O
we	O
have	O
identified	O
the	O
glucose	O
transporter	O
as	O
a	O
membrane	B-Anatomy
glycoprotein	O
with	O
a	O
monomer	O
Mr	O
of	O
approximately	O
41	O
,	O
000	O
.	O
The	O
increased	O
rate	O
of	O
glucose	O
transport	O
is	O
dependent	O
on	O
the	O
activity	O
of	O
pp60src	O
,	O
the	O
transforming	O
protein	O
of	O
Rous	O
sarcoma	O
virus	O
.	O
This	O
protein	O
has	O
been	O
shown	O
to	O
be	O
a	O
protein	O
kinase	O
that	O
phosphorylates	O
on	O
tyrosine	O
residues	O
.	O
We	O
have	O
examined	O
the	O
tyrosine	O
phosphorylation	O
of	O
a	O
major	O
cellular	B-Anatomy
protein	O
of	O
Mr	O
36	O
,	O
000	O
in	O
cells	B-Anatomy
infected	O
with	O
a	O
panel	O
of	O
partially	O
transforming	O
mutants	O
of	O
Rous	O
sarcoma	O
virus	O
.	O
One	O
of	O
these	O
mutants	O
(	O
CU2	O
)	O
increases	O
the	O
rate	O
of	O
glucose	O
transport	O
only	O
slightly	O
and	O
does	O
not	O
render	O
the	O
infected	O
cells	B-Anatomy
fully	O
anchorage	O
independent	O
or	O
tumorigenic	O
(	O
although	O
other	O
transformation	O
parameters	O
are	O
fully	O
induced	O
)	O
.	O
Cells	B-Anatomy
infected	O
with	O
this	O
mutant	O
display	O
a	O
36	O
,	O
000	O
-	O
dalton	O
protein	O
that	O
is	O
phosphorylated	O
to	O
a	O
considerably	O
lesser	O
extent	O
than	O
cells	B-Anatomy
infected	O
with	O
wild	O
-	O
type	O
virus	O
.	O
Analyses	O
of	O
this	O
sort	O
may	O
help	O
to	O
identify	O
the	O
cellular	B-Anatomy
targets	O
of	O
pp60src	O
whose	O
phosphorylation	O
is	O
necessary	O
for	O
the	O
increased	O
glucose	O
transport	O
rate	O
.	O
Preliminary	O
evidence	O
for	O
a	O
pyridine	O
nucleotide	O
cycle	O
in	O
Bordetella	O
pertussis	O
.	O
Preliminary	O
evidence	O
that	O
Bordetella	O
pertussis	O
has	O
a	O
functional	O
pyridine	O
nucleotide	O
cycle	O
was	O
the	O
observation	O
that	O
[	O
14C	O
]	O
-	O
nicotinic	O
acid	O
was	O
rapidly	O
metabolized	O
during	O
its	O
uptake	O
by	O
the	O
bacteria	O
to	O
pyridine	O
nucleotides	O
and	O
nicotinamide	O
.	O
Nicotinamide	O
deamidase	O
activity	O
,	O
necessary	O
for	O
the	O
completion	O
of	O
the	O
cycle	O
by	O
conversion	O
of	O
nicotinamide	O
to	O
nicotinic	O
acid	O
,	O
was	O
found	O
in	O
a	O
soluble	O
extract	B-Anatomy
(	O
20	O
000	O
X	O
g	O
supernatant	B-Anatomy
)	O
of	O
B	O
.	O
pertussis	O
cell	B-Anatomy
lysates	I-Anatomy
.	O
Use	O
of	O
monoclonal	O
antibodies	O
to	O
investigate	O
a	O
possible	O
role	O
of	O
thyroglobulin	O
in	O
the	O
pathogenesis	O
of	O
Graves	O
'	O
ophthalmopathy	O
.	O
One	O
possible	O
mechanism	O
for	O
Graves	O
'	O
ophthalmopathy	O
is	O
that	O
the	O
progressive	O
orbital	B-Anatomy
inflammation	O
is	O
initiated	O
by	O
formation	O
of	O
thyroglobulin	O
(	O
Tg	O
)	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
at	O
sites	O
of	O
Tg	O
binding	O
to	O
extraocular	B-Anatomy
muscle	I-Anatomy
membranes	I-Anatomy
.	O
In	O
this	O
study	O
monoclonal	O
antibodies	O
(	O
MCAB	O
)	O
against	O
human	O
Tg	O
were	O
used	O
as	O
probes	O
(	O
1	O
)	O
to	O
identify	O
Tg	O
in	O
eye	B-Anatomy
muscle	I-Anatomy
membranes	I-Anatomy
prepared	O
from	O
normal	O
subjects	O
and	O
(	O
2	O
)	O
to	O
measure	O
binding	O
of	O
human	O
Tg	O
and	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
to	O
eye	B-Anatomy
muscle	I-Anatomy
membranes	I-Anatomy
.	O
Reactivity	O
of	O
anti	O
-	O
Tg	O
MCAB	O
with	O
Tg	O
,	O
thyroid	B-Anatomy
,	O
and	O
eye	B-Anatomy
muscle	I-Anatomy
membranes	I-Anatomy
was	O
determined	O
by	O
binding	O
of	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
monoclonal	O
antibody	O
,	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
and	O
the	O
indirect	O
immunofluorescence	O
technique	O
.	O
Seven	O
membrane	B-Anatomy
fractions	I-Anatomy
,	O
prepared	O
by	O
differential	O
sucrose	O
gradient	O
centrifugation	O
,	O
were	O
used	O
.	O
Whereas	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
MCAB	O
bound	O
to	O
all	O
thyroid	B-Anatomy
membrane	I-Anatomy
fractions	I-Anatomy
tested	O
,	O
no	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
bound	O
to	O
eye	B-Anatomy
muscle	I-Anatomy
membranes	I-Anatomy
.	O
Similarly	O
,	O
reactivity	O
of	O
anti	O
-	O
Tg	O
MCAB	O
with	O
eye	B-Anatomy
muscle	I-Anatomy
membranes	I-Anatomy
was	O
not	O
demonstrated	O
in	O
ELISA	O
or	O
immunofluorescence	O
tests	O
.	O
Although	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
bound	O
to	O
thyroid	B-Anatomy
membranes	I-Anatomy
,	O
such	O
complexes	O
did	O
not	O
bind	O
to	O
eye	B-Anatomy
muscle	I-Anatomy
membranes	I-Anatomy
.	O
Significant	O
binding	O
of	O
[	O
125I	O
]	O
human	O
Tg	O
to	O
eye	B-Anatomy
muscle	I-Anatomy
or	O
thyroid	B-Anatomy
membranes	I-Anatomy
was	O
not	O
demonstrated	O
for	O
any	O
membrane	B-Anatomy
preparation	I-Anatomy
.	O
On	O
the	O
other	O
hand	O
moderate	O
,	O
but	O
significant	O
,	O
binding	O
to	O
skeletal	B-Anatomy
muscle	I-Anatomy
was	O
shown	O
.	O
Similar	O
results	O
were	O
found	O
using	O
an	O
ELISA	O
.	O
Binding	O
of	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
-	O
Tg	O
complexes	O
of	O
[	O
125I	O
]	O
Tg	O
to	O
thyroid	B-Anatomy
and	O
eye	B-Anatomy
muscle	I-Anatomy
membranes	I-Anatomy
was	O
not	O
affected	O
by	O
the	O
presence	O
of	O
normal	O
human	O
serum	B-Anatomy
,	O
phosphate	O
ions	O
,	O
pH	O
,	O
or	O
incubation	O
temperature	O
,	O
conditions	O
claimed	O
by	O
others	O
to	O
be	O
critical	O
for	O
Tg	O
and	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complex	O
binding	O
.	O
Since	O
Tg	O
is	O
not	O
present	O
in	O
normal	O
human	O
eye	B-Anatomy
muscle	I-Anatomy
a	O
major	O
role	O
of	O
Tg	O
,	O
or	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
,	O
in	O
the	O
pathogenesis	O
of	O
Graves	O
'	O
ophthalmopathy	O
appears	O
to	O
have	O
been	O
excluded	O
by	O
these	O
findings	O
.	O
DNA	O
methylation	O
and	O
expression	O
of	O
HLA	O
-	O
DR	O
alpha	O
.	O
B	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
established	O
from	O
two	O
individuals	O
with	O
T	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
acute	I-Anatomy
lymphocytic	I-Anatomy
leukemia	I-Anatomy
(	O
T	B-Anatomy
-	I-Anatomy
ALL	I-Anatomy
)	O
express	O
HLA	O
-	O
DR	O
antigens	O
,	O
whereas	O
the	O
isogenic	O
T	B-Anatomy
-	I-Anatomy
cells	I-Anatomy
do	O
not	O
.	O
The	O
lack	O
of	O
expression	O
correlates	O
with	O
a	O
lack	O
of	O
detectable	O
HLA	O
-	O
DR	O
mRNA	O
.	O
All	O
of	O
the	O
DR	O
alpha	O
DNA	O
sequences	O
detected	O
by	O
a	O
cloned	O
DR	O
alpha	O
cDNA	O
probe	O
are	O
contained	O
in	O
a	O
BglII	O
fragment	O
which	O
varies	O
slightly	O
in	O
size	O
(	O
4	O
.	O
0	O
to	O
4	O
.	O
8	O
kilobases	O
)	O
from	O
one	O
individual	O
to	O
another	O
.	O
In	O
DNA	O
from	O
the	O
T	B-Anatomy
-	I-Anatomy
cells	I-Anatomy
not	O
expressing	O
DR	O
alpha	O
mRNA	O
,	O
all	O
of	O
the	O
potential	O
HpaII	O
sites	O
within	O
the	O
BglII	O
fragment	O
appeared	O
to	O
be	O
methylated	O
.	O
In	O
contrast	O
,	O
at	O
least	O
some	O
of	O
these	O
sites	O
were	O
not	O
methylated	O
in	O
DNA	O
from	O
the	O
B	B-Anatomy
-	I-Anatomy
cells	I-Anatomy
expressing	O
high	O
levels	O
of	O
DR	O
alpha	O
mRNA	O
.	O
Treatment	O
of	O
these	O
T	B-Anatomy
-	I-Anatomy
cells	I-Anatomy
with	O
5	O
-	O
azacytidine	O
resulted	O
in	O
the	O
induction	O
of	O
DR	O
surface	B-Anatomy
antigen	O
expression	O
,	O
the	O
appearance	O
of	O
DR	O
alpha	O
mRNA	O
,	O
and	O
the	O
partial	O
demethylation	O
of	O
the	O
DR	O
alpha	O
DNA	O
sequences	O
.	O
T	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
established	O
from	O
human	O
T	O
-	O
cell	O
leukemia	O
-	O
lymphoma	O
virus	O
associated	O
T	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
neoplasias	I-Anatomy
,	O
in	O
contrast	O
to	O
the	O
T	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
acute	I-Anatomy
lymphocytic	I-Anatomy
leukemia	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
,	O
expressed	O
both	O
DR	O
antigens	O
and	O
DR	O
alpha	O
mRNA	O
;	O
the	O
HpaII	O
sites	O
within	O
the	O
BglII	O
fragment	O
of	O
DR	O
alpha	O
DNA	O
of	O
these	O
human	O
T	O
-	O
cell	O
leukemia	O
-	O
lymphoma	O
virus	O
-	O
positive	O
T	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
were	O
in	O
all	O
cases	O
at	O
least	O
partially	O
unmethylated	O
.	O
Uncultured	O
peripheral	B-Anatomy
blood	I-Anatomy
T	I-Anatomy
-	I-Anatomy
cells	I-Anatomy
from	O
human	O
T	O
-	O
cell	O
leukemia	O
-	O
lymphoma	O
virus	O
-	O
infected	O
individuals	O
expressed	O
DR	O
antigens	O
at	O
a	O
low	O
level	O
,	O
and	O
the	O
DR	O
alpha	O
locus	O
was	O
partially	O
unmethylated	O
.	O
After	O
48	O
h	O
in	O
culture	O
,	O
DR	O
antigen	O
expression	O
was	O
substantially	O
increased	O
,	O
but	O
no	O
significant	O
changes	O
were	O
observed	O
in	O
methylation	O
of	O
the	O
DR	O
alpha	O
locus	O
or	O
in	O
the	O
amount	O
of	O
DR	O
mRNA	O
which	O
was	O
present	O
.	O
This	O
suggests	O
that	O
expression	O
of	O
DR	O
antigens	O
also	O
can	O
be	O
modulated	O
post	O
-	O
transcriptionally	O
.	O
Rapid	O
micromeasurement	O
of	O
lactate	O
in	O
whole	B-Anatomy
blood	I-Anatomy
.	O
A	O
new	O
lactate	O
sensor	O
makes	O
it	O
possible	O
to	O
measure	O
the	O
lactate	O
content	O
of	O
whole	B-Anatomy
blood	I-Anatomy
directly	O
in	O
less	O
than	O
1	O
min	O
,	O
using	O
only	O
a	O
10	O
-	O
microL	O
blood	B-Anatomy
sample	I-Anatomy
.	O
The	O
procedure	O
works	O
equally	O
well	O
with	O
plasma	B-Anatomy
,	O
serum	B-Anatomy
,	O
spinal	B-Anatomy
fluid	I-Anatomy
,	O
other	O
body	B-Anatomy
fluids	I-Anatomy
,	O
or	O
tissue	B-Anatomy
homogenates	I-Anatomy
.	O
The	O
instrument	O
is	O
calibrated	O
with	O
lactate	O
standards	O
between	O
0	O
and	O
15	O
mMol	O
/	O
L	O
.	O
The	O
sensor	O
,	O
a	O
polarographic	O
enzyme	O
electrode	O
,	O
gives	O
a	O
current	O
which	O
is	O
a	O
linear	O
function	O
of	O
the	O
lactate	O
concentration	O
.	O
There	O
is	O
no	O
interference	O
from	O
glucose	O
,	O
pyruvate	O
,	O
alcohol	O
,	O
ascorbate	O
,	O
anticoagulants	O
,	O
lidocaine	O
,	O
acetaminophen	O
,	O
or	O
other	O
drugs	O
and	O
metabolites	O
commonly	O
encountered	O
in	O
critically	O
ill	O
patients	O
.	O
The	O
lactate	O
sensor	O
is	O
composed	O
of	O
a	O
peroxide	O
sensor	O
and	O
an	O
enzyme	O
transducer	O
membrane	O
.	O
The	O
lactate	O
is	O
stoichiometrically	O
converted	O
to	O
pyruvate	O
and	O
hydrogen	O
peroxide	O
by	O
lactate	O
oxygen	O
oxidoreductase	O
derived	O
from	O
Pediococcus	O
species	O
.	O
The	O
oxygen	O
required	O
for	O
the	O
enzymatic	O
oxidation	O
is	O
supplied	O
via	O
an	O
air	O
-	O
permeable	O
silicone	O
elastomeric	O
membrane	O
used	O
for	O
stirring	O
.	O
Comparison	O
of	O
our	O
new	O
electroenzymatic	O
method	O
with	O
the	O
Boehringer	O
-	O
Mannheim	O
photoenzymatic	O
method	O
gives	O
correlations	O
of	O
0	O
.	O
997	O
for	O
both	O
whole	B-Anatomy
blood	I-Anatomy
and	O
plasma	B-Anatomy
.	O
Hemostasis	O
and	O
mechanism	O
of	O
action	O
of	O
selective	O
antimetastatic	O
drugs	O
in	O
mice	O
bearing	O
Lewis	B-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
.	O
The	O
selective	O
antimetastatic	O
agents	O
p	O
-	O
(	O
3	O
,	O
3	O
-	O
dimethyl	O
-	O
1	O
-	O
triazeno	O
)	O
benzoic	O
acid	O
potassium	O
salt	O
(	O
DM	O
-	O
COOK	O
)	O
,	O
5	O
-	O
(	O
3	O
,	O
3	O
-	O
dimethyl	O
-	O
1	O
-	O
triazeno	O
)	O
imidazole	O
-	O
4	O
-	O
carboxamide	O
(	O
DTIC	O
)	O
and	O
(	O
+	O
/	O
-	O
)	O
1	O
,	O
2	O
-	O
di	O
(	O
3	O
,	O
5	O
-	O
dioxopiperazin	O
-	O
1	O
-	O
yl	O
)	O
propane	O
(	O
ICRF	O
-	O
159	O
)	O
have	O
been	O
shown	O
to	O
markedly	O
depress	O
the	O
formation	O
of	O
spontaneous	O
hematogenous	O
metastases	B-Anatomy
in	O
mice	O
bearing	O
s	O
.	O
c	O
.	O
Lewis	B-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
,	O
with	O
a	O
mechanism	O
unrelated	O
to	O
cytotoxicity	O
for	O
tumor	B-Anatomy
cells	I-Anatomy
.	O
The	O
effects	O
on	O
hemostasis	O
of	O
DM	O
-	O
COOK	O
,	O
DTIC	O
and	O
ICRF	O
-	O
159	O
have	O
thus	O
been	O
examined	O
in	O
comparison	O
with	O
those	O
of	O
a	O
purely	O
cytotoxic	O
agent	O
,	O
cyclophosphamide	O
,	O
in	O
mice	O
bearing	O
i	O
.	O
m	O
.	O
Lewis	B-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
.	O
The	O
parameters	O
considered	O
are	O
the	O
number	O
of	O
platelets	B-Anatomy
and	O
their	O
aggregability	O
,	O
prothrombin	O
and	O
partial	O
thromboplastin	O
times	O
,	O
plasma	B-Anatomy
fibrinogen	O
concentration	O
and	O
tumor	B-Anatomy
cell	I-Anatomy
procoagulant	O
activity	O
.	O
Slight	O
variations	O
are	O
caused	O
by	O
drug	O
treatment	O
in	O
tumor	B-Anatomy
-	O
bearing	O
mice	O
as	O
compared	O
with	O
untreated	O
tumor	B-Anatomy
-	O
bearing	O
controls	O
;	O
the	O
pattern	O
of	O
effects	O
of	O
the	O
selective	O
antimetastatic	O
agents	O
does	O
not	O
differ	O
from	O
that	O
of	O
the	O
reference	O
cytotoxic	O
compound	O
used	O
,	O
cyclophosphamide	O
.	O
These	O
data	O
thus	O
indicate	O
that	O
the	O
effects	O
on	O
hemostasis	O
of	O
the	O
drugs	O
examined	O
can	O
contribute	O
only	O
marginally	O
to	O
their	O
antimetastatic	O
action	O
,	O
since	O
more	O
pronounced	O
effects	O
on	O
hemostasis	O
have	O
been	O
shown	O
to	O
be	O
required	O
to	O
significantly	O
affect	O
metastasis	O
formation	O
.	O
Purification	O
and	O
characterization	O
of	O
various	O
esterases	O
from	O
rat	O
liver	B-Anatomy
.	O
The	O
major	O
rat	O
liver	B-Anatomy
microsomal	I-Anatomy
esterases	O
acting	O
on	O
o	O
-	O
nitrophenylacetate	O
with	O
isoelectric	O
points	O
5	O
.	O
0	O
,	O
5	O
.	O
5	O
,	O
6	O
.	O
1	O
and	O
6	O
.	O
4	O
were	O
resolved	O
by	O
isoelectric	O
focusing	O
.	O
Molecular	O
weights	O
were	O
determined	O
by	O
sedimentation	O
analysis	O
in	O
isokinetic	O
gradients	O
of	O
sucrose	O
and	O
,	O
after	O
purification	O
,	O
in	O
sodium	O
dodecyl	O
sulphate	O
/	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O
Their	O
subunit	O
molecular	O
weights	O
were	O
between	O
57	O
000	O
and	O
60	O
000	O
.	O
They	O
behaved	O
as	O
monomers	O
except	O
the	O
pI	O
-	O
6	O
.	O
1	O
enzyme	O
which	O
behaved	O
as	O
a	O
trimer	O
.	O
Esterases	O
of	O
pI	O
5	O
.	O
0	O
,	O
pI	O
6	O
.	O
1	O
and	O
pI	O
6	O
.	O
4	O
behaved	O
like	O
glycoproteins	O
of	O
the	O
polymannose	O
type	O
in	O
the	O
presence	O
of	O
125I	O
-	O
labelled	O
concanavalin	O
A	O
.	O
Preparations	O
of	O
the	O
pI	O
-	O
5	O
.	O
0	O
enzyme	O
contained	O
two	O
esterases	O
of	O
highly	O
homologous	O
structure	O
.	O
Antibodies	O
directed	O
against	O
this	O
preparation	O
did	O
not	O
inhibit	O
but	O
precipitated	O
pI	O
-	O
5	O
.	O
0	O
esterase	O
activity	O
quantitatively	O
.	O
They	O
did	O
not	O
react	O
with	O
the	O
pI	O
-	O
6	O
.	O
1	O
and	O
pI	O
-	O
6	O
.	O
4	O
esterases	O
but	O
precipitated	O
several	O
nonimmunologically	O
related	O
esterases	O
.	O
Two	O
of	O
these	O
enzymes	O
were	O
inducible	O
by	O
phenobarbital	O
.	O
Total	O
activity	O
was	O
very	O
low	O
in	O
3	O
-	O
day	O
-	O
old	O
animals	O
.	O
Individual	O
esterase	O
activities	O
rose	O
at	O
different	O
rates	O
during	O
development	O
;	O
the	O
enzyme	O
focusing	O
near	O
pI	O
5	O
.	O
0	O
was	O
about	O
three	O
times	O
more	O
active	O
in	O
adult	O
females	O
than	O
in	O
males	O
.	O
All	O
microsomal	O
esterases	O
are	O
located	O
on	O
the	O
luminal	B-Anatomy
side	O
of	O
the	O
endoplasmic	B-Anatomy
reticulum	I-Anatomy
.	O
Hippocampal	B-Anatomy
afterdischarge	O
interferes	O
with	O
storage	O
of	O
spatial	O
information	O
in	O
a	O
working	O
memory	O
test	O
.	O
In	O
an	O
attempt	O
to	O
impair	O
spatial	O
working	O
memory	O
by	O
reversible	O
functional	O
blockade	O
rather	O
than	O
by	O
irreversible	O
lesion	B-Anatomy
of	O
the	O
hippocampus	B-Anatomy
,	O
eight	O
male	O
hooded	O
rats	O
were	O
trained	O
to	O
asymptotic	O
performance	O
of	O
1	O
.	O
2	O
to	O
1	O
.	O
4	O
errors	O
per	O
trial	O
in	O
the	O
spatial	O
12	O
-	O
choice	O
apparatus	O
(	O
Bure	O
s	O
et	O
al	O
.	O
1982	O
)	O
,	O
formally	O
similar	O
to	O
the	O
radial	O
maze	O
.	O
The	O
rats	O
were	O
implanted	O
with	O
hippocampal	B-Anatomy
stimulating	O
and	O
recording	O
electrodes	O
,	O
which	O
were	O
used	O
for	O
eliciting	O
and	O
monitoring	O
hippocampal	B-Anatomy
afterdischarge	O
(	O
HAD	O
)	O
lasting	O
for	O
at	O
least	O
20	O
s	O
.	O
In	O
Experiment	O
1	O
,	O
HAD	O
elicited	O
1	O
or	O
10	O
min	O
before	O
testing	O
increased	O
the	O
incidence	O
of	O
errors	O
to	O
2	O
.	O
75	O
or	O
2	O
.	O
50	O
per	O
trial	O
,	O
respectively	O
,	O
but	O
the	O
performance	O
still	O
remained	O
above	O
chance	O
level	O
(	O
4	O
.	O
18	O
)	O
.	O
In	O
Experiment	O
2	O
,	O
interruption	O
of	O
the	O
trial	O
by	O
1	O
,	O
10	O
,	O
20	O
and	O
30	O
min	O
intervals	O
inserted	O
between	O
choices	O
6	O
and	O
7	O
increased	O
the	O
incidence	O
of	O
errors	O
in	O
choices	O
7	O
to	O
12	O
to	O
1	O
.	O
0	O
,	O
1	O
.	O
5	O
,	O
2	O
.	O
1	O
and	O
2	O
.	O
5	O
,	O
respectively	O
.	O
HAD	O
elicited	O
immediately	O
after	O
choice	O
6	O
increased	O
error	O
incidence	O
in	O
the	O
subsequent	O
6	O
choices	O
performed	O
after	O
1	O
-	O
min	O
or	O
10	O
-	O
min	O
intervals	O
to	O
3	O
.	O
1	O
or	O
2	O
.	O
75	O
,	O
respectively	O
,	O
i	O
.	O
e	O
.	O
to	O
the	O
chance	O
level	O
of	O
3	O
errors	O
in	O
6	O
choices	O
.	O
It	O
is	O
concluded	O
that	O
HAD	O
elicits	O
transient	O
shortening	O
of	O
the	O
memory	O
span	O
for	O
newly	O
acquired	O
spatial	O
information	O
(	O
anterograde	O
effect	O
)	O
and	O
erases	O
the	O
current	O
spatial	O
working	O
memory	O
record	O
(	O
retrograde	O
effect	O
)	O
.	O
[	O
In	O
vitro	O
studies	O
of	O
the	O
thyroid	B-Anatomy
gland	I-Anatomy
regulation	O
principles	O
and	O
their	O
evaluation	O
]	O
.	O
The	O
free	O
fractions	O
of	O
the	O
thyroid	O
hormone	O
further	O
the	O
metabolism	O
of	O
the	O
body	B-Anatomy
cells	I-Anatomy
and	O
regulate	O
the	O
synthesis	O
of	O
the	O
thyroid	O
hormone	O
.	O
Once	O
the	O
level	O
of	O
FT3	O
and	O
FT4	O
decreases	O
.	O
With	O
the	O
help	O
of	O
a	O
liberation	O
of	O
the	O
hormone	O
stimulating	O
the	O
thyroid	B-Anatomy
gland	I-Anatomy
from	O
the	O
anterior	B-Anatomy
lobe	I-Anatomy
of	O
the	O
pituitary	B-Anatomy
gland	I-Anatomy
the	O
lack	O
of	O
thyroid	O
hormone	O
is	O
corrected	O
.	O
The	O
synthesis	O
and	O
secretion	O
of	O
the	O
thyroid	B-Anatomy
gland	I-Anatomy
stimulating	O
hormone	O
is	O
induced	O
by	O
the	O
thyreotropin	O
releasing	O
hormone	O
which	O
is	O
given	O
by	O
the	O
hypothalamus	B-Anatomy
.	O
Moreover	O
,	O
the	O
organism	O
is	O
able	O
as	O
needed	O
to	O
carry	O
out	O
the	O
monodiodation	O
of	O
LT4	O
to	O
biologically	O
active	O
LT3	O
or	O
biologically	O
inactive	O
so	O
-	O
called	O
revers	O
T3	O
(	O
RT3	O
)	O
.	O
The	O
estimation	O
of	O
thyroid	B-Anatomy
gland	I-Anatomy
stimulating	O
hormone	O
before	O
and	O
30	O
minutes	O
after	O
intravenous	B-Anatomy
application	O
of	O
thyreotropin	O
releasing	O
hormone	O
has	O
its	O
main	O
importance	O
for	O
the	O
early	O
recognition	O
of	O
a	O
disturbance	O
of	O
the	O
regulating	O
circle	O
hypophysis	O
-	O
thyroid	B-Anatomy
gland	I-Anatomy
,	O
above	O
all	O
in	O
the	O
diagnosis	O
of	O
clinically	O
not	O
yet	O
manifest	O
clinical	O
pictures	O
,	O
such	O
as	O
the	O
latent	O
hypothyreosis	O
and	O
the	O
latent	O
hyperthyreosis	O
,	O
respectively	O
(	O
Basedow	O
hyperthyreosis	O
and	O
thyroidal	O
autonomy	O
)	O
.	O
According	O
to	O
the	O
questioning	O
the	O
estimations	O
of	O
the	O
levels	O
of	O
the	O
thyroid	O
hormones	O
and	O
of	O
the	O
thyroid	B-Anatomy
gland	I-Anatomy
stimulating	O
hormone	O
should	O
be	O
used	O
stepwise	O
.	O
Relationship	O
of	O
self	O
-	O
concept	O
during	O
late	O
pregnancy	O
to	O
neonatal	O
perception	O
and	O
parenting	O
profile	O
.	O
Thirty	O
-	O
one	O
gravidas	O
were	O
studied	O
to	O
examine	O
the	O
relationship	O
between	O
a	O
woman	O
'	O
s	O
feelings	O
about	O
herself	O
during	O
late	O
pregnancy	O
,	O
her	O
perception	O
of	O
her	O
newborn	O
,	O
and	O
her	O
profile	O
of	O
parenting	O
.	O
The	O
Tennessee	O
Self	O
-	O
Concept	O
Scale	O
was	O
completed	O
during	O
the	O
third	O
trimester	O
of	O
pregnancy	O
,	O
the	O
Neonatal	O
Perception	O
Inventory	O
I	O
at	O
one	O
-	O
to	O
-	O
two	O
days	O
postpartum	O
,	O
and	O
the	O
Neonatal	O
Perception	O
Inventory	O
II	O
and	O
the	O
Michigan	O
Screening	O
Profile	O
of	O
Parenting	O
at	O
four	O
-	O
to	O
-	O
six	O
weeks	O
postpartum	O
.	O
When	O
considered	O
separately	O
,	O
no	O
positive	O
significant	O
relationships	O
were	O
found	O
between	O
scores	O
on	O
these	O
variables	O
.	O
However	O
,	O
all	O
subjects	O
with	O
negative	O
scores	O
on	O
both	O
self	O
-	O
concept	O
and	O
neonatal	O
perception	O
had	O
negative	O
scores	O
on	O
at	O
least	O
two	O
subscales	O
of	O
the	O
parenting	O
profile	O
.	O
Subretinal	B-Anatomy
neovascularization	O
following	O
rubella	O
retinopathy	O
.	O
A	O
17	O
-	O
year	O
-	O
old	O
girl	O
and	O
an	O
11	O
-	O
year	O
-	O
old	O
girl	O
with	O
rubella	O
retinopathy	O
had	O
decreased	O
vision	O
in	O
one	O
eye	B-Anatomy
secondary	O
to	O
subretinal	B-Anatomy
neovascularization	O
and	O
hemorrhage	O
.	O
In	O
both	O
cases	O
a	O
disciform	O
scar	B-Anatomy
with	O
permanent	O
decrease	O
in	O
central	O
vision	O
resulted	O
.	O
Verrucous	B-Anatomy
carcinoma	I-Anatomy
of	O
the	O
endometrium	B-Anatomy
-	O
-	O
a	O
unique	O
neoplasm	B-Anatomy
with	O
long	O
survival	O
.	O
A	O
case	O
of	O
verrucous	B-Anatomy
carcinoma	I-Anatomy
of	O
the	O
endometrium	B-Anatomy
with	O
long	O
survival	O
is	O
described	O
.	O
It	O
represents	O
the	O
first	O
of	O
its	O
type	O
to	O
be	O
recorded	O
in	O
this	O
site	B-Anatomy
.	O
The	O
literature	O
on	O
verrucous	B-Anatomy
carcinoma	I-Anatomy
and	O
on	O
other	O
cases	O
of	O
squamous	B-Anatomy
carcinoma	I-Anatomy
of	O
the	O
endometrium	B-Anatomy
is	O
briefly	O
reviewed	O
.	O
Metabolic	O
alterations	O
in	O
a	O
noncachectic	O
animal	O
tumor	B-Anatomy
system	O
.	O
The	O
increased	O
energy	O
expended	O
by	O
the	O
host	O
to	O
synthesize	O
substrate	O
,	O
which	O
is	O
utilized	O
by	O
the	O
tumor	B-Anatomy
,	O
is	O
a	O
potential	O
cause	O
of	O
cancer	B-Anatomy
cachexia	I-Anatomy
.	O
In	O
vivo	O
glucose	O
and	O
alanine	O
kinetics	O
were	O
examined	O
by	O
tracer	O
methodology	O
in	O
a	O
sarcoma	B-Anatomy
-	O
bearing	O
rat	O
model	O
.	O
The	O
effects	O
of	O
3	O
-	O
mercaptopicolinic	O
acid	O
,	O
a	O
potent	O
inhibitor	O
of	O
gluconeogenesis	O
,	O
was	O
also	O
examined	O
on	O
this	O
model	O
.	O
Both	O
tumor	B-Anatomy
-	O
bearing	O
(	O
TB	O
)	O
and	O
nontumor	B-Anatomy
bearing	O
(	O
NTB	O
)	O
animals	O
were	O
gaining	O
weight	O
prior	O
to	O
study	O
and	O
the	O
tumors	B-Anatomy
were	O
relatively	O
small	O
.	O
The	O
TB	O
animals	O
had	O
significantly	O
lower	O
plasma	B-Anatomy
glucose	O
and	O
higher	O
blood	B-Anatomy
lactic	O
acid	O
levels	O
compared	O
with	O
NTB	O
animals	O
.	O
After	O
inhibition	O
of	O
gluconeogenesis	O
,	O
the	O
plasma	B-Anatomy
glucose	O
decreased	O
and	O
the	O
blood	B-Anatomy
lactate	O
increased	O
significantly	O
more	O
in	O
TB	O
than	O
NTB	O
animals	O
.	O
The	O
glucose	O
turnover	O
rate	O
was	O
significantly	O
greater	O
in	O
TB	O
compared	O
with	O
NTB	O
animals	O
,	O
as	O
was	O
the	O
rate	O
of	O
glucose	O
recycling	O
and	O
the	O
rate	O
of	O
gluconeogenesis	O
(	O
alanine	O
leads	O
to	O
glucose	O
)	O
,	O
both	O
energy	O
demanding	O
processes	O
.	O
These	O
results	O
suggest	O
that	O
the	O
tumor	B-Anatomy
-	O
bearing	O
animal	O
,	O
even	O
prior	O
to	O
significant	O
cachexia	B-Anatomy
,	O
has	O
an	O
excess	O
demand	O
for	O
energy	O
,	O
the	O
provision	O
of	O
which	O
may	O
be	O
a	O
significant	O
factor	O
in	O
malignant	B-Anatomy
cachexia	I-Anatomy
.	O
[	O
Organization	O
of	O
pectoral	B-Anatomy
muscle	I-Anatomy
motor	I-Anatomy
neurons	I-Anatomy
in	O
the	O
rat	O
.	O
Contribution	O
to	O
the	O
study	O
of	O
the	O
axillary	B-Anatomy
arch	I-Anatomy
(	O
Achselbogen	O
)	O
]	O
.	O
In	O
spite	O
of	O
their	O
role	O
of	O
the	O
forelimb	B-Anatomy
activity	O
,	O
the	O
organization	O
of	O
the	O
mammalian	O
pectoral	B-Anatomy
muscles	I-Anatomy
remains	O
unclear	O
.	O
In	O
order	O
to	O
get	O
more	O
information	O
,	O
we	O
have	O
studied	O
,	O
qualitatively	O
and	O
quantitatively	O
,	O
the	O
motor	O
pools	O
of	O
the	O
various	O
pectoral	B-Anatomy
muscles	I-Anatomy
in	O
the	O
rat	O
(	O
musculus	B-Anatomy
pectoralis	I-Anatomy
major	I-Anatomy
,	O
musculus	B-Anatomy
pectoralis	I-Anatomy
minor	I-Anatomy
and	O
musculus	B-Anatomy
panniculus	I-Anatomy
carnosus	I-Anatomy
)	O
.	O
The	O
method	O
applied	O
was	O
the	O
retrograde	O
transport	O
of	O
horseradish	O
peroxidase	O
by	O
the	O
peripheral	B-Anatomy
nerves	I-Anatomy
supplying	O
the	O
various	O
muscles	B-Anatomy
.	O
The	O
results	O
provided	O
the	O
precise	O
localization	O
within	O
the	O
ventral	B-Anatomy
horn	I-Anatomy
of	O
the	O
motor	B-Anatomy
neurons	I-Anatomy
from	O
the	O
pectoral	B-Anatomy
muscles	I-Anatomy
which	O
were	O
all	O
in	O
the	O
most	O
ventral	B-Anatomy
part	I-Anatomy
of	O
the	O
gray	B-Anatomy
matter	I-Anatomy
.	O
Three	O
distinct	O
motor	O
pools	O
were	O
observed	O
,	O
which	O
confirms	O
the	O
functional	O
identity	O
of	O
each	O
muscle	B-Anatomy
.	O
The	O
motor	B-Anatomy
neurons	I-Anatomy
of	O
m	B-Anatomy
.	I-Anatomy
panniculus	I-Anatomy
carnosus	I-Anatomy
exhibited	O
some	O
particularities	O
.	O
They	O
were	O
4	O
times	O
more	O
numerous	O
than	O
those	O
from	O
m	B-Anatomy
.	I-Anatomy
pectoralis	I-Anatomy
major	I-Anatomy
,	O
they	O
occupied	O
the	O
whole	O
ventral	B-Anatomy
edge	I-Anatomy
of	O
the	O
ventral	B-Anatomy
horn	I-Anatomy
,	O
from	O
its	O
medial	B-Anatomy
part	I-Anatomy
to	O
its	O
lateral	B-Anatomy
tip	I-Anatomy
.	O
The	O
cell	B-Anatomy
size	O
was	O
different	O
from	O
that	O
of	O
the	O
other	O
muscles	B-Anatomy
.	O
These	O
results	O
were	O
discussed	O
,	O
according	O
to	O
the	O
role	O
of	O
this	O
muscle	B-Anatomy
,	O
which	O
links	O
the	O
forelimb	B-Anatomy
to	O
the	O
whole	O
trunk	B-Anatomy
.	O
In	O
mammals	O
,	O
m	B-Anatomy
.	I-Anatomy
panniculus	I-Anatomy
carnosus	I-Anatomy
constitutes	O
,	O
with	O
musculus	B-Anatomy
latissimus	I-Anatomy
dorsi	I-Anatomy
,	O
the	O
axillary	B-Anatomy
arch	I-Anatomy
(	O
Achselbogen	O
)	O
.	O
A	O
small	O
area	O
of	O
overlapping	O
between	O
the	O
motor	O
pools	O
of	O
these	O
two	O
muscles	B-Anatomy
was	O
observed	O
.	O
It	O
was	O
suggested	O
that	O
the	O
muscular	B-Anatomy
fibers	I-Anatomy
from	O
the	O
axillary	B-Anatomy
arch	I-Anatomy
were	O
innervated	O
by	O
the	O
same	O
,	O
well	O
-	O
defined	O
spinal	B-Anatomy
area	I-Anatomy
,	O
independent	O
of	O
the	O
muscle	B-Anatomy
from	O
which	O
they	O
originate	O
.	O
The	O
inhibition	O
of	O
cultured	O
myoblast	B-Anatomy
differentiation	O
by	O
the	O
simian	O
virus	O
40	O
large	O
T	O
antigen	O
occurs	O
after	O
myogenin	O
expression	O
and	O
Rb	O
up	O
-	O
regulation	O
and	O
is	O
not	O
exerted	O
by	O
transformation	O
-	O
competent	O
cytoplasmic	B-Anatomy
mutants	O
.	O
We	O
have	O
investigated	O
the	O
mechanism	O
by	O
which	O
the	O
simian	O
virus	O
40	O
large	O
T	O
antigen	O
(	O
SVLT	O
)	O
interferes	O
with	O
the	O
differentiation	O
of	O
C2	B-Anatomy
myoblasts	I-Anatomy
.	O
SVLT	O
mutants	O
,	O
defective	O
either	O
in	O
the	O
Rb	O
binding	O
site	O
,	O
near	O
the	O
N	O
-	O
terminal	O
end	O
,	O
in	O
a	O
region	O
that	O
affects	O
binding	O
to	O
p53	O
,	O
or	O
in	O
the	O
nuclear	B-Anatomy
transport	O
signal	O
,	O
were	O
also	O
employed	O
to	O
determine	O
whether	O
the	O
interference	O
was	O
especially	O
dependent	O
on	O
these	O
functional	O
domains	O
.	O
It	O
was	O
found	O
that	O
wild	O
-	O
type	O
(	O
wt	O
)	O
SVLT	O
strongly	O
inhibited	O
the	O
terminal	O
differentiation	O
of	O
mouse	O
C2	B-Anatomy
myoblasts	I-Anatomy
,	O
but	O
this	O
arrest	O
occurred	O
only	O
after	O
the	O
synthesis	O
of	O
myogenin	O
,	O
an	O
initial	O
step	O
in	O
biochemical	O
differentiation	O
.	O
Neither	O
the	O
synthesis	O
nor	O
some	O
basic	O
activities	O
of	O
MyoD	O
appeared	O
to	O
be	O
affected	O
by	O
wt	O
SVLT	O
.	O
In	O
these	O
transformants	B-Anatomy
,	O
mitogen	O
depletion	O
elicited	O
an	O
increase	O
in	O
the	O
Rb	O
level	O
comparable	O
to	O
that	O
in	O
normal	O
C2	B-Anatomy
cells	I-Anatomy
;	O
wt	O
SVLT	O
,	O
however	O
,	O
promoted	O
the	O
phosphorylation	O
of	O
a	O
large	O
part	O
of	O
the	O
induced	O
Rb	O
.	O
Mutations	O
affecting	O
nuclear	B-Anatomy
transport	O
were	O
far	O
more	O
critical	O
for	O
the	O
ability	O
to	O
interfere	O
with	O
myogenic	O
differentiation	O
than	O
were	O
those	O
affecting	O
the	O
transforming	O
potential	O
;	O
cytoplasmic	B-Anatomy
SVLT	O
expression	O
was	O
fully	O
compatible	O
with	O
the	O
terminal	O
differentiation	O
of	O
C2	B-Anatomy
cells	I-Anatomy
,	O
despite	O
enabling	O
them	O
to	O
grow	O
in	O
semisolid	O
medium	O
,	O
thus	O
showing	O
that	O
the	O
myogenesis	O
-	O
inhibiting	O
property	O
can	O
be	O
dissociated	O
from	O
transforming	O
competence	O
.	O
The	O
remaining	O
SVLT	O
mutants	O
presented	O
different	O
degrees	O
of	O
ability	O
to	O
inhibit	O
differentiation	O
(	O
as	O
shown	O
by	O
the	O
expression	O
of	O
tissue	B-Anatomy
-	O
specific	O
markers	O
in	O
transformants	B-Anatomy
)	O
.	O
The	O
inhibiting	O
mutants	O
,	O
including	O
the	O
Rb	O
binding	O
site	O
mutant	O
,	O
were	O
able	O
to	O
promote	O
a	O
higher	O
state	O
of	O
Rb	O
phosphorylation	O
than	O
that	O
observed	O
in	O
either	O
normal	O
cells	B-Anatomy
or	O
cytoplasmic	B-Anatomy
-	O
SVLT	O
transformants	B-Anatomy
.	O
A	O
transcript	O
from	O
the	O
long	B-Anatomy
terminal	I-Anatomy
repeats	I-Anatomy
of	O
a	O
murine	O
retrovirus	O
associated	O
with	O
trans	O
activation	O
of	O
cellular	B-Anatomy
genes	O
.	O
Infection	O
of	O
human	O
or	O
murine	O
cells	B-Anatomy
with	O
murine	O
leukemia	O
viruses	O
rapidly	O
increases	O
the	O
expression	O
of	O
a	O
number	O
of	O
genes	O
that	O
belong	O
to	O
the	O
immunoglobulin	O
superfamily	O
and	O
are	O
involved	O
in	O
T	B-Anatomy
-	I-Anatomy
lymphocyte	I-Anatomy
activation	O
,	O
including	O
the	O
class	O
I	O
major	O
histocompatibility	O
complex	O
antigens	O
.	O
We	O
have	O
reported	O
recently	O
that	O
the	O
long	B-Anatomy
terminal	I-Anatomy
repeat	I-Anatomy
(	O
LTR	B-Anatomy
)	O
of	O
Moloney	O
murine	O
leukemia	O
virus	O
encodes	O
a	O
trans	O
activator	O
which	O
induces	O
transcription	O
and	O
expression	O
of	O
class	O
I	O
major	O
histocompatibility	O
complex	O
genes	O
and	O
certain	O
cytokine	O
genes	O
.	O
The	O
portion	O
of	O
the	O
LTR	B-Anatomy
responsible	O
for	O
trans	O
activation	O
was	O
mapped	O
by	O
deletions	O
to	O
lie	O
within	O
the	O
U3	O
region	O
.	O
We	O
demonstrate	O
here	O
that	O
a	O
transcript	O
is	O
initiated	O
within	O
the	O
U3	O
region	O
and	O
that	O
its	O
presence	O
correlates	O
with	O
the	O
trans	O
-	O
activating	O
activity	O
.	O
Analysis	O
of	O
the	O
LTR	B-Anatomy
region	O
reveals	O
a	O
potential	O
internal	O
promoter	O
element	O
for	O
RNA	O
polymerase	O
III	O
transcription	O
within	O
the	O
U3	O
region	O
.	O
Studies	O
with	O
polymerase	O
inhibitors	O
suggest	O
that	O
this	O
LTR	B-Anatomy
transcript	O
,	O
designated	O
let	O
(	O
LTR	O
-	O
encoded	O
trans	O
activator	O
)	O
,	O
is	O
a	O
product	O
of	O
RNA	O
polymerase	O
III	O
.	O
The	O
mechanisms	O
whereby	O
RNA	O
leukemia	O
viruses	O
cause	O
lymphoid	B-Anatomy
neoplasia	I-Anatomy
after	O
a	O
long	O
latent	O
period	O
have	O
been	O
extensively	O
studied	O
but	O
are	O
only	O
partially	O
understood	O
.	O
The	O
region	O
of	O
the	O
LTR	B-Anatomy
identified	O
here	O
as	O
being	O
important	O
in	O
trans	O
activation	O
has	O
recently	O
been	O
shown	O
to	O
be	O
a	O
critical	O
determinant	O
of	O
the	O
leukemogenicity	O
and	O
latency	O
of	O
Moloney	O
murine	O
leukemia	O
virus	O
.	O
These	O
findings	O
suggest	O
a	O
novel	O
mechanism	O
of	O
retrovirus	O
-	O
induced	O
activation	O
of	O
cellular	B-Anatomy
gene	O
expression	O
,	O
potentially	O
contributing	O
to	O
leukemogenesis	O
.	O
Anti	O
-	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
antibodies	O
inhibit	O
breast	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
tumorigenicity	O
and	O
increase	O
mouse	O
spleen	B-Anatomy
natural	I-Anatomy
killer	I-Anatomy
cell	I-Anatomy
activity	O
.	O
Implications	O
for	O
a	O
possible	O
role	O
of	O
tumor	B-Anatomy
cell	I-Anatomy
/	O
host	O
TGF	O
-	O
beta	O
interactions	O
in	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
progression	O
.	O
TGF	O
-	O
beta	O
effects	O
on	O
angiogenesis	O
,	O
stroma	B-Anatomy
formation	O
,	O
and	O
immune	O
function	O
suggest	O
its	O
possible	O
involvement	O
in	O
tumor	B-Anatomy
progression	O
.	O
This	O
hypothesis	O
was	O
tested	O
using	O
the	O
2G7	O
IgG2b	O
,	O
which	O
neutralizes	O
TGF	O
-	O
beta	O
1	O
,	O
-	O
beta	O
2	O
,	O
and	O
-	O
beta	O
3	O
,	O
and	O
the	O
MDA	B-Anatomy
-	I-Anatomy
231	I-Anatomy
human	O
breast	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
.	O
Inoculation	O
of	O
these	O
cells	B-Anatomy
in	O
athymic	O
mice	O
decreases	O
mouse	O
spleen	B-Anatomy
natural	I-Anatomy
killer	I-Anatomy
(	I-Anatomy
NK	I-Anatomy
)	I-Anatomy
cell	I-Anatomy
activity	O
.	O
Intraperitoneal	B-Anatomy
injections	O
of	O
2G7	O
starting	O
1	O
d	O
after	O
intraperitoneal	B-Anatomy
inoculation	O
of	O
tumor	B-Anatomy
cells	I-Anatomy
suppressed	O
intraabdominal	B-Anatomy
tumor	I-Anatomy
and	O
lung	B-Anatomy
metastases	I-Anatomy
,	O
whereas	O
the	O
nonneutralizing	O
anti	O
-	O
TGF	O
-	O
beta	O
12H5	O
IgG2a	O
had	O
no	O
effect	O
.	O
2G7	O
transiently	O
inhibited	O
growth	O
of	O
established	O
MDA	B-Anatomy
-	I-Anatomy
231	I-Anatomy
subcutaneous	I-Anatomy
tumors	I-Anatomy
.	O
Histologically	O
,	O
both	O
2G7	O
-	O
treated	O
and	O
control	O
tumors	B-Anatomy
were	O
identical	O
.	O
Intraperitoneal	B-Anatomy
administration	O
of	O
2G7	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
mouse	O
spleen	B-Anatomy
NK	I-Anatomy
cell	I-Anatomy
activity	O
.	O
2G7	O
did	O
not	O
inhibit	O
MDA	B-Anatomy
-	I-Anatomy
231	I-Anatomy
primary	I-Anatomy
tumor	I-Anatomy
or	O
metastases	B-Anatomy
formation	O
,	O
nor	O
did	O
it	O
stimulate	O
NK	B-Anatomy
cell	I-Anatomy
-	O
mediated	O
cytotoxicity	O
in	O
beige	O
NK	O
-	O
deficient	O
nude	O
mice	O
.	O
Finally	O
,	O
serum	B-Anatomy
-	O
free	O
conditioned	O
medium	O
from	O
MDA	B-Anatomy
-	I-Anatomy
231	I-Anatomy
cells	I-Anatomy
inhibited	O
the	O
NK	B-Anatomy
cell	I-Anatomy
activity	O
of	O
human	O
blood	B-Anatomy
lymphocytes	I-Anatomy
.	O
This	O
inhibition	O
was	O
blocked	O
by	O
the	O
neutralizing	O
anti	O
-	O
TGF	O
-	O
beta	O
2G7	O
antibody	O
but	O
not	O
by	O
a	O
nonspecific	O
IgG2	O
.	O
These	O
data	O
support	O
a	O
possible	O
role	O
for	O
tumor	B-Anatomy
cell	I-Anatomy
TGF	O
-	O
beta	O
in	O
the	O
progression	O
of	O
mammary	B-Anatomy
carcinomas	I-Anatomy
by	O
suppressing	O
host	O
immune	O
surveillance	O
.	O
Additional	O
tests	O
of	O
interest	O
to	O
the	O
dermatologist	O
.	O
The	O
carcinoid	O
syndrome	O
and	O
its	O
clinical	O
manifestations	O
have	O
been	O
discussed	O
.	O
The	O
standard	O
laboratory	O
test	O
for	O
making	O
that	O
diagnosis	O
is	O
urinary	B-Anatomy
5	O
-	O
HIAA	O
levels	O
but	O
newer	O
,	O
more	O
sensitive	O
tests	O
may	O
also	O
be	O
available	O
.	O
Enhanced	O
DNA	O
-	O
binding	O
activity	O
of	O
a	O
Stat3	O
-	O
related	O
protein	O
in	O
cells	B-Anatomy
transformed	O
by	O
the	O
Src	O
oncoprotein	O
.	O
Cytokines	O
and	O
growth	O
factors	O
induce	O
tyrosine	O
phosphorylation	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	O
)	O
that	O
directly	O
activate	O
gene	O
expression	O
.	O
Cells	B-Anatomy
stably	O
transformed	O
by	O
the	O
Src	O
oncogene	O
tyrosine	O
kinase	O
were	O
examined	O
for	O
STAT	O
protein	O
activation	O
.	O
Assays	O
of	O
electrophoretic	O
mobility	O
,	O
DNA	O
-	O
binding	O
specificity	O
,	O
and	O
antigenicity	O
indicated	O
that	O
Stat3	O
or	O
a	O
closely	O
related	O
STAT	O
family	O
member	O
was	O
constitutively	O
activated	O
by	O
the	O
Src	O
oncoprotein	O
.	O
Induction	O
of	O
this	O
DNA	O
-	O
binding	O
activity	O
was	O
accompanied	O
by	O
tyrosine	O
phosphorylation	O
of	O
Stat3	O
and	O
correlated	O
with	O
Src	O
transformation	O
.	O
These	O
findings	O
demonstrate	O
that	O
Src	O
can	O
activate	O
STAT	O
signaling	O
pathways	O
and	O
raise	O
the	O
possibility	O
that	O
Stat3	O
contributes	O
to	O
oncogenesis	O
by	O
Src	O
.	O
Bicistronic	O
retroviral	O
vector	O
reveals	O
capacity	O
of	O
v	O
-	O
erbA	O
to	O
induce	O
erythroleukemia	B-Anatomy
and	O
to	O
co	O
-	O
operate	O
with	O
v	O
-	O
myb	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
v	O
-	O
erbA	O
and	O
v	O
-	O
myb	O
can	O
induce	O
the	O
proliferation	O
of	O
avian	O
erythroid	B-Anatomy
cells	I-Anatomy
in	O
culture	O
.	O
To	O
study	O
the	O
combined	O
effects	O
of	O
v	O
-	O
erbA	O
and	O
v	O
-	O
myb	O
,	O
the	O
two	O
oncogenes	O
were	O
engineered	O
into	O
a	O
retrovirus	O
bicistronic	O
vector	O
with	O
an	O
internal	O
ribosomal	B-Anatomy
entry	O
site	O
(	O
IRES	O
)	O
or	O
into	O
a	O
vector	O
with	O
a	O
splice	O
acceptor	O
(	O
SPL	O
)	O
.	O
This	O
allowed	O
coexpression	O
of	O
the	O
two	O
proteins	O
and	O
a	O
comparison	O
with	O
the	O
same	O
vector	O
containing	O
either	O
v	O
-	O
erbA	O
or	O
v	O
-	O
myb	O
only	O
.	O
Both	O
the	O
erbA	O
IRES	O
and	O
the	O
erbA	O
/	O
myb	O
IRES	O
virus	O
constructs	O
transformed	O
erythroid	B-Anatomy
cells	I-Anatomy
after	O
infection	O
of	O
bone	B-Anatomy
marrow	I-Anatomy
or	O
blastoderm	B-Anatomy
cultures	I-Anatomy
.	O
The	O
erbA	O
/	O
myb	O
IRES	O
virus	O
exhibited	O
a	O
5	O
-	O
10	O
-	O
fold	O
higher	O
transformed	O
colony	B-Anatomy
forming	O
efficiency	O
than	O
the	O
erbA	O
IRES	O
virus	O
in	O
the	O
blastoderm	B-Anatomy
assay	O
.	O
Surprisingly	O
,	O
when	O
injected	O
into	O
chicken	O
embryos	B-Anatomy
in	O
the	O
presence	O
of	O
helper	O
virus	O
,	O
both	O
viruses	O
induced	O
an	O
erythroleukemia	B-Anatomy
in	O
about	O
half	O
of	O
the	O
animals	O
.	O
In	O
contrast	O
,	O
no	O
leukemia	B-Anatomy
was	O
observed	O
with	O
a	O
myb	O
IRES	O
virus	O
,	O
with	O
spliced	O
vectors	O
containing	O
v	O
-	O
erbA	O
alone	O
or	O
v	O
-	O
erbA	O
in	O
combination	O
with	O
v	O
-	O
myb	O
,	O
nor	O
with	O
erbA	O
IRES	O
and	O
erbA	O
/	O
myb	O
IRES	O
viruses	O
produced	O
in	O
the	O
absence	O
of	O
helper	O
virus	O
.	O
The	O
average	O
latency	O
of	O
leukemia	B-Anatomy
induction	O
was	O
shorter	O
for	O
the	O
erbA	O
/	O
myb	O
IRES	O
virus	O
(	O
3	O
.	O
5	O
weeks	O
)	O
than	O
for	O
the	O
erbA	O
IRES	O
virus	O
(	O
5	O
weeks	O
)	O
.	O
Nevertheless	O
,	O
for	O
both	O
viruses	O
the	O
leukemic	B-Anatomy
blasts	I-Anatomy
retained	O
full	O
factor	O
dependence	O
for	O
growth	O
.	O
These	O
results	O
show	O
that	O
v	O
-	O
erbA	O
is	O
capable	O
of	O
inducing	O
an	O
erythroleukemia	B-Anatomy
when	O
expressed	O
by	O
a	O
high	O
titer	O
bicistronic	O
retrovirus	O
under	O
conditions	O
of	O
virus	O
spreading	O
and	O
that	O
its	O
in	O
vitro	O
and	O
in	O
vivo	O
transforming	O
potential	O
can	O
be	O
enhanced	O
by	O
v	O
-	O
myb	O
.	O
VEGF165	O
expressed	O
by	O
a	O
replication	O
-	O
deficient	O
recombinant	O
adenovirus	O
vector	O
induces	O
angiogenesis	O
in	O
vivo	O
.	O
To	O
evaluate	O
the	O
concept	O
that	O
localized	O
delivery	O
of	O
angiogenic	O
factors	O
via	O
virus	O
-	O
mediated	O
gene	O
transfer	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
ischemic	O
disorders	O
,	O
the	O
replication	O
-	O
deficient	O
adenovirus	O
(	O
Ad	O
)	O
vector	O
AdCMV	O
.	O
VEGF165	O
(	O
where	O
CMV	O
is	O
cytomegalovirus	O
and	O
VEGF	O
is	O
vascular	O
endothelial	O
growth	O
factor	O
)	O
containing	O
the	O
cDNA	O
for	O
human	O
VEGF165	O
,	O
a	O
secreted	O
endothelial	B-Anatomy
cell	I-Anatomy
-	O
specific	O
angiogenic	O
growth	O
factor	O
,	O
was	O
constructed	O
.	O
Human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
(	O
HUVECs	B-Anatomy
)	O
and	O
rat	B-Anatomy
aorta	I-Anatomy
smooth	I-Anatomy
muscle	I-Anatomy
cells	I-Anatomy
(	O
RASMCs	B-Anatomy
)	O
infected	O
with	O
AdCMV	O
.	O
VEGF165	O
(	O
5	O
and	O
20	O
plaque	O
-	O
forming	O
units	O
[	O
pfu	O
]	O
per	O
cell	B-Anatomy
)	O
demonstrated	O
VEGF	O
mRNA	O
expression	O
and	O
protein	O
secretion	O
into	O
the	O
supernatant	B-Anatomy
.	O
Furthermore	O
,	O
the	O
conditioned	O
medium	O
from	O
these	O
cells	B-Anatomy
enhanced	O
vascular	B-Anatomy
permeability	O
in	O
vivo	O
.	O
In	O
contrast	O
,	O
neither	O
VEGF	O
mRNA	O
nor	O
secreted	O
protein	O
was	O
found	O
in	O
uninfected	O
HUVECs	B-Anatomy
or	O
RASMCs	B-Anatomy
or	O
in	O
cells	B-Anatomy
infected	O
with	O
the	O
control	O
vector	O
AdCMV	O
.	O
beta	O
gal	O
(	O
where	O
beta	O
gal	O
is	O
beta	O
-	O
galactosidase	O
)	O
.	O
Assessment	O
of	O
starved	O
HUVECs	B-Anatomy
at	O
14	O
days	O
demonstrated	O
sixfold	O
more	O
cells	B-Anatomy
for	O
AdCMV	O
.	O
VEGF165	O
-	O
infected	O
HUVECs	B-Anatomy
(	O
20	O
pfu	O
per	O
cell	B-Anatomy
)	O
than	O
for	O
either	O
infected	O
or	O
uninfected	O
control	O
cells	B-Anatomy
.	O
RASMC	B-Anatomy
proliferation	O
was	O
unaffected	O
by	O
infection	O
with	O
AdCMV	O
.	O
VEGF165	O
.	O
When	O
plated	O
in	O
2	O
%	O
serum	B-Anatomy
on	O
dishes	O
precoated	O
with	O
reconstituted	O
basement	B-Anatomy
membrane	I-Anatomy
(	O
Matrigel	O
)	O
,	O
HUVECs	B-Anatomy
infected	O
with	O
AdCMV	O
.	O
VEGF165	O
(	O
20	O
pfu	O
per	O
cell	B-Anatomy
)	O
differentiated	O
into	O
capillary	B-Anatomy
-	I-Anatomy
like	I-Anatomy
structures	I-Anatomy
.	O
Under	O
similar	O
conditions	O
,	O
both	O
uninfected	O
HUVECs	B-Anatomy
and	O
HUVECs	B-Anatomy
infected	O
with	O
AdCMV	O
.	O
beta	O
gal	O
did	O
not	O
differentiate	O
.	O
To	O
evaluate	O
the	O
ability	O
of	O
AdCMV	O
.	O
VEGF165	O
to	O
function	O
in	O
vivo	O
,	O
either	O
AdCMV	O
.	O
VEGF165	O
or	O
AdCMV	O
.	O
beta	O
gal	O
(	O
2	O
x	O
10	O
(	O
10	O
)	O
pfu	O
)	O
was	O
resuspended	O
in	O
0	O
.	O
5	O
mL	O
Matrigel	O
and	O
injected	O
subcutaneously	B-Anatomy
into	O
mice	O
.	O
Immunohistochemical	O
staining	O
demonstrated	O
VEGF	O
in	O
the	O
tissues	B-Anatomy
surrounding	O
the	O
Matrigel	O
plugs	O
containing	O
AdCMV	O
.	O
VEGF165	O
up	O
to	O
3	O
weeks	O
after	O
injection	O
,	O
whereas	O
no	O
VEGF	O
was	O
found	O
in	O
the	O
control	O
plugs	O
with	O
AdCMV	O
.	O
beta	O
gal	O
.	O
Two	O
weeks	O
after	O
injection	O
,	O
there	O
was	O
histological	O
evidence	O
of	O
neovascularization	O
in	O
the	O
tissues	B-Anatomy
surrounding	O
the	O
Matrigel	O
containing	O
AdCMV	O
.	O
VEGF165	O
,	O
whereas	O
no	O
significant	O
angiogenesis	O
was	O
observed	O
in	O
response	O
to	O
AdCMV	O
.	O
beta	O
gal	O
.	O
Furthermore	O
,	O
the	O
Matrigel	O
plugs	O
with	O
AdCMV	O
.	O
VEGF165	O
demonstrated	O
hemoglobin	O
content	O
fourfold	O
higher	O
than	O
the	O
plugs	O
with	O
AdCMV	O
.	O
beta	O
gal	O
.	O
Together	O
,	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
are	O
consistent	O
with	O
the	O
concept	O
that	O
Ad	O
vectors	O
may	O
provide	O
a	O
useful	O
strategy	O
for	O
efficient	O
local	O
delivery	O
of	O
VEGF165	O
in	O
the	O
treatment	O
of	O
ischemic	O
diseases	O
.	O
Central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
infection	O
with	O
Eikenella	O
corrodens	O
:	O
report	O
of	O
two	O
cases	O
.	O
Two	O
cases	O
of	O
central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
infections	O
from	O
which	O
E	O
.	O
corrodens	O
has	O
been	O
isolated	O
are	O
reported	O
.	O
The	O
portals	O
of	O
entry	O
,	O
clinical	O
course	O
,	O
and	O
antimicrobial	O
responses	O
conform	O
to	O
other	O
reports	O
in	O
the	O
literature	O
.	O
The	O
importance	O
of	O
obtaining	O
careful	O
anaerobic	O
cultures	O
is	O
emphasized	O
.	O
Comparative	O
immunohistochemical	O
study	O
of	O
primary	B-Anatomy
and	O
metastatic	B-Anatomy
carcinomas	I-Anatomy
of	O
the	O
liver	B-Anatomy
.	O
Distinguishing	O
primary	B-Anatomy
hepatocellular	I-Anatomy
carcinoma	I-Anatomy
(	O
HCC	B-Anatomy
)	O
from	O
metastatic	B-Anatomy
carcinomas	I-Anatomy
to	O
the	O
liver	B-Anatomy
is	O
often	O
difficult	O
,	O
if	O
not	O
impossible	O
,	O
particularly	O
in	O
needle	O
biopsy	B-Anatomy
and	O
fine	O
-	O
needle	O
aspiration	O
specimens	B-Anatomy
.	O
In	O
an	O
attempt	O
to	O
identify	O
a	O
specific	O
immunohistochemical	O
profile	O
that	O
would	O
distinguish	O
HCC	B-Anatomy
from	O
metastatic	B-Anatomy
carcinomas	I-Anatomy
,	O
we	O
studied	O
56	O
HCCs	B-Anatomy
,	O
8	O
cholangiocarcinomas	B-Anatomy
,	O
and	O
24	O
metastatic	B-Anatomy
adenocarcinomas	I-Anatomy
with	O
monoclonal	O
antibodies	O
to	O
alpha	O
-	O
fetoprotein	O
(	O
AFP	O
)	O
,	O
keratin	O
(	O
AE1	O
,	O
AE3	O
,	O
and	O
CAM5	O
.	O
2	O
)	O
,	O
Leu	O
-	O
M1	O
,	O
human	O
milk	O
fat	O
globule	O
(	O
HMFG	O
-	O
2	O
)	O
,	O
tumor	B-Anatomy
-	O
associated	O
glycoprotein	O
-	O
72	O
(	O
B72	O
.	O
3	O
)	O
,	O
epithelial	B-Anatomy
specific	O
membrane	B-Anatomy
antigen	O
(	O
Ber	O
-	O
EP4	O
)	O
,	O
and	O
BCA	O
-	O
225	O
(	O
CU	O
-	O
18	O
)	O
.	O
Both	O
monoclonal	O
and	O
polyclonal	O
(	O
mCEA	O
and	O
pCEA	O
)	O
antibodies	O
to	O
carcinoembryonic	O
antigen	O
also	O
were	O
used	O
.	O
Metastatic	B-Anatomy
adenocarcinomas	I-Anatomy
were	O
often	O
positive	O
for	O
CU	O
-	O
18	O
(	O
71	O
%	O
)	O
,	O
Leu	O
-	O
M1	O
(	O
75	O
%	O
)	O
,	O
B72	O
.	O
3	O
(	O
50	O
%	O
)	O
,	O
HMFG	O
-	O
2	O
(	O
67	O
%	O
)	O
,	O
Ber	O
-	O
EP4	O
(	O
83	O
%	O
)	O
and	O
mCEA	O
(	O
71	O
%	O
)	O
.	O
Using	O
these	O
antibodies	O
,	O
the	O
frequency	O
of	O
positivity	O
for	O
HCC	B-Anatomy
was	O
9	O
%	O
,	O
16	O
%	O
,	O
11	O
%	O
,	O
20	O
%	O
,	O
36	O
%	O
,	O
and	O
11	O
%	O
,	O
respectively	O
.	O
CU	O
-	O
18	O
was	O
the	O
only	O
monoclonal	O
antibody	O
in	O
which	O
there	O
was	O
a	O
significant	O
difference	O
in	O
positive	O
rates	O
between	O
HCC	B-Anatomy
and	O
metastatic	B-Anatomy
adenocarcinomas	I-Anatomy
.	O
Most	O
HCCs	B-Anatomy
(	O
71	O
%	O
)	O
revealed	O
a	O
bile	B-Anatomy
canalicular	I-Anatomy
staining	O
pattern	O
with	O
pCEA	O
.	O
Because	O
this	O
staining	O
pattern	O
was	O
absent	O
in	O
metastatic	B-Anatomy
carcinomas	I-Anatomy
,	O
pCEA	O
appears	O
to	O
be	O
useful	O
in	O
confirming	O
a	O
diagnosis	O
of	O
HCC	B-Anatomy
.	O
AE1	O
,	O
AE3	O
and	O
CAM5	O
.	O
2	O
antibodies	O
were	O
not	O
useful	O
in	O
distinguishing	O
HCC	B-Anatomy
from	O
metastatic	B-Anatomy
carcinomas	I-Anatomy
.	O
Each	O
cholangiocarcinoma	B-Anatomy
shared	O
a	O
staining	O
profile	O
similar	O
to	O
that	O
of	O
metastatic	B-Anatomy
carcinomas	I-Anatomy
.	O
Differential	O
effects	O
of	O
carbachol	O
on	O
calcium	O
entry	O
and	O
release	O
in	O
CHO	B-Anatomy
cells	I-Anatomy
expressing	O
the	O
m3	O
muscarinic	O
receptor	O
.	O
Calcium	O
signalling	O
was	O
examined	O
in	O
CHO	B-Anatomy
-	I-Anatomy
k1	I-Anatomy
cells	I-Anatomy
that	O
stably	O
express	O
the	O
m3	O
subtype	O
of	O
the	O
muscarinic	O
receptor	O
.	O
The	O
calcium	O
indicator	O
Fura	O
-	O
2	O
was	O
retained	O
in	O
these	O
cells	B-Anatomy
only	O
in	O
the	O
presence	O
of	O
probenecid	O
(	O
1	O
mM	O
)	O
,	O
suggesting	O
that	O
Fura	O
-	O
2	O
efflux	O
was	O
mediated	O
by	O
an	O
organic	O
anion	O
transporter	O
.	O
The	O
addition	O
of	O
carbachol	O
(	O
CCh	O
)	O
to	O
Fura	O
-	O
2	O
loaded	O
cells	B-Anatomy
in	O
suspension	O
caused	O
a	O
rapid	O
transient	O
increase	O
in	O
intracellular	B-Anatomy
calcium	O
[	O
Ca	O
]	O
i	O
followed	O
by	O
a	O
smaller	O
sustained	O
plateau	O
phase	O
.	O
The	O
transient	O
rise	O
in	O
[	O
Ca	O
]	O
i	O
was	O
dose	O
-	O
dependent	O
with	O
a	O
threshold	O
response	O
of	O
89	O
+	O
/	O
-	O
18	O
nM	O
above	O
baseline	O
with	O
10	O
nM	O
CCh	O
and	O
a	O
maximum	O
stimulation	O
of	O
734	O
+	O
/	O
-	O
46	O
nM	O
with	O
10	O
microM	O
CCh	O
.	O
This	O
phase	O
was	O
accompanied	O
by	O
a	O
similar	O
dose	O
-	O
dependent	O
stimulation	O
of	O
total	O
inositol	O
phosphate	O
production	O
and	O
was	O
assumed	O
to	O
be	O
generated	O
by	O
release	O
from	O
intracellular	B-Anatomy
stores	O
of	O
the	O
endoplasmic	B-Anatomy
reticulum	I-Anatomy
(	O
ER	B-Anatomy
)	O
.	O
The	O
sustained	O
increase	O
in	O
[	O
Ca	O
]	O
i	O
was	O
generated	O
by	O
entry	O
from	O
the	O
extracellular	B-Anatomy
bath	O
since	O
it	O
was	O
blocked	O
by	O
pretreatment	O
with	O
La3	O
+	O
(	O
1	O
microM	O
)	O
and	O
was	O
absent	O
when	O
bath	O
calcium	O
was	O
chelated	O
with	O
EGTA	O
.	O
This	O
phase	O
was	O
not	O
dependent	O
on	O
CCh	O
dose	O
,	O
and	O
a	O
stimulation	O
of	O
[	O
Ca	O
]	O
i	O
of	O
approximately	O
90	O
nM	O
above	O
baseline	O
was	O
observed	O
with	O
CCh	O
concentrations	O
between	O
50	O
nM	O
and	O
10	O
microM	O
.	O
With	O
this	O
dose	O
range	O
,	O
the	O
rate	O
of	O
Mn2	O
+	O
quenching	O
of	O
Fura	O
-	O
2	O
at	O
the	O
Ca	O
-	O
insensitive	O
excitation	O
wavelength	O
of	O
360	O
nm	O
was	O
likewise	O
maximally	O
stimulated	O
.	O
At	O
lower	O
CCh	O
concentrations	O
(	O
10	O
-	O
50	O
nM	O
)	O
,	O
it	O
was	O
clear	O
that	O
the	O
activation	O
of	O
Ca	O
entry	O
could	O
not	O
be	O
dissociated	O
from	O
a	O
threshold	O
release	O
of	O
Ca	O
from	O
intracellular	B-Anatomy
stores	O
.	O
The	O
phorbol	O
ester	O
PMA	O
,	O
which	O
uncouples	O
the	O
muscarinic	O
receptor	O
from	O
phospholipase	O
C	O
,	O
reduced	O
the	O
transient	O
rise	O
in	O
[	O
Ca	O
]	O
i	O
by	O
approximately	O
50	O
%	O
with	O
little	O
or	O
no	O
effect	O
on	O
Ca	O
entry	O
at	O
higher	O
CCh	O
levels	O
(	O
>	O
or	O
=	O
1	O
microM	O
)	O
.	O
At	O
lower	O
CCh	O
concentrations	O
(	O
<	O
or	O
=	O
100	O
nM	O
)	O
however	O
,	O
pretreatment	O
with	O
PMA	O
completely	O
blocked	O
all	O
Ca	O
mobilization	O
and	O
supports	O
the	O
contention	O
that	O
Ca	O
entry	O
is	O
coupled	O
to	O
Ca	O
release	O
from	O
stores	O
or	O
to	O
store	O
depletion	O
.	O
The	O
emptying	O
of	O
inositol	O
trisphosphate	O
-	O
sensitive	O
stores	O
with	O
thapsigargin	O
(	O
10	O
nM	O
)	O
stimulated	O
Ca	O
entry	O
and	O
also	O
the	O
rate	O
of	O
Mn2	O
+	O
quenching	O
.	O
Store	O
depletion	O
by	O
incubation	O
in	O
Ca	O
-	O
free	O
media	O
likewise	O
stimulated	O
Mn2	O
+	O
uptake	O
without	O
a	O
rise	O
in	O
[	O
Ca	O
]	O
i	O
.	O
Our	O
data	O
are	O
therefore	O
consistent	O
with	O
a	O
'	O
capacitative	O
'	O
coupling	O
model	O
,	O
whereby	O
the	O
activation	O
of	O
the	O
plasma	B-Anatomy
membrane	I-Anatomy
receptor	O
leads	O
to	O
an	O
InsP3	O
-	O
induced	O
change	O
in	O
the	O
degree	O
of	O
filling	O
of	O
the	O
ER	B-Anatomy
Ca	O
pool	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Modulation	O
of	O
apoptosis	O
in	O
human	O
myeloid	B-Anatomy
leukemic	I-Anatomy
cells	I-Anatomy
by	O
GM	O
-	O
CSF	O
.	O
Apoptosis	O
(	O
programmed	O
cell	B-Anatomy
death	O
)	O
regulates	O
cell	B-Anatomy
population	O
size	O
.	O
To	O
determine	O
the	O
mechanisms	O
whereby	O
hematopoietic	O
growth	O
factors	O
(	O
HGFs	O
)	O
modulate	O
apoptosis	O
in	O
human	O
myeloid	B-Anatomy
leukemic	I-Anatomy
cells	I-Anatomy
,	O
we	O
evaluated	O
the	O
roles	O
of	O
protein	O
and	O
mRNA	O
synthesis	O
for	O
altering	O
apoptosis	O
in	O
growth	O
factor	O
-	O
stimulated	O
vs	O
.	O
quiescent	O
leukemic	B-Anatomy
TF1	I-Anatomy
cells	I-Anatomy
.	O
Lysates	B-Anatomy
of	O
cells	B-Anatomy
from	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
-	O
dependent	O
myeloid	B-Anatomy
leukemic	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
TF1	I-Anatomy
were	O
separated	O
into	O
high	O
molecular	O
weight	O
(	O
HMW	O
)	O
pellets	O
of	O
intact	O
DNA	O
and	O
supernatants	B-Anatomy
of	O
fragmented	O
low	O
MW	O
(	O
LMW	O
)	O
DNA	O
,	O
and	O
the	O
DNA	O
purified	O
from	O
these	O
fractions	O
was	O
quantified	O
.	O
In	O
the	O
absence	O
of	O
both	O
GM	O
-	O
CSF	O
and	O
fetal	B-Anatomy
bovine	I-Anatomy
serum	I-Anatomy
(	O
FBS	B-Anatomy
)	O
,	O
70	O
%	O
of	O
the	O
DNA	O
was	O
fragmented	O
after	O
3	O
days	O
in	O
culture	O
,	O
with	O
a	O
characteristic	O
apoptotic	O
ladder	O
-	O
like	O
pattern	O
on	O
agarose	O
gel	O
electrophoresis	O
,	O
whereas	O
this	O
proportion	O
had	O
initially	O
been	O
<	O
5	O
%	O
.	O
In	O
contrast	O
,	O
less	O
than	O
5	O
%	O
of	O
the	O
DNA	O
was	O
fragmented	O
in	O
cells	B-Anatomy
incubated	O
with	O
GM	O
-	O
CSF	O
plus	O
FBS	B-Anatomy
or	O
GM	O
-	O
CSF	O
alone	O
.	O
Delayed	O
addition	O
of	O
GM	O
-	O
CSF	O
,	O
but	O
not	O
FBS	B-Anatomy
,	O
permitted	O
partial	O
rescue	O
of	O
the	O
cells	B-Anatomy
,	O
inhibiting	O
increasing	O
rates	O
of	O
accumulation	O
of	O
fragmented	O
DNA	O
.	O
When	O
the	O
macro	O
-	O
molecular	O
synthesis	O
inhibitor	O
cycloheximide	O
(	O
CHX	O
)	O
or	O
actinomycin	O
D	O
(	O
Act	O
D	O
)	O
was	O
present	O
for	O
26	O
hours	O
in	O
the	O
absence	O
of	O
GM	O
-	O
CSF	O
and	O
FBS	B-Anatomy
,	O
apoptosis	O
was	O
inhibited	O
.	O
In	O
contrast	O
,	O
in	O
the	O
presence	O
of	O
GM	O
-	O
CSF	O
or	O
FBS	B-Anatomy
,	O
apoptosis	O
was	O
enhanced	O
upon	O
addition	O
of	O
CHX	O
or	O
Act	O
D	O
.	O
The	O
latter	O
effect	O
persisted	O
even	O
with	O
the	O
late	O
addition	O
of	O
CHX	O
.	O
These	O
findings	O
indicate	O
that	O
disparate	O
mechanisms	O
of	O
enhancing	O
or	O
inhibiting	O
apoptosis	O
exist	O
in	O
myeloid	B-Anatomy
leukemic	I-Anatomy
cells	I-Anatomy
related	O
to	O
environmental	O
conditions	O
,	O
including	O
HGF	O
-	O
regulated	O
cellular	B-Anatomy
synthesis	O
of	O
distinct	O
proteins	O
and	O
mRNA	O
.	O
Effects	O
of	O
doxycycline	O
on	O
in	O
vitro	O
growth	O
,	O
migration	O
,	O
and	O
gelatinase	O
activity	O
of	O
breast	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
Metastatic	O
disease	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
death	O
from	O
cancer	B-Anatomy
in	O
human	O
beings	O
.	O
Several	O
enzyme	O
systems	O
have	O
been	O
implicated	O
in	O
the	O
metastatic	O
process	O
,	O
but	O
the	O
metalloproteinases	O
(	O
MPs	O
)	O
appear	O
to	O
be	O
the	O
major	O
group	O
involved	O
in	O
most	O
instances	O
of	O
neoplastic	B-Anatomy
invasion	O
.	O
Increased	O
MP	O
activity	O
has	O
been	O
correlated	O
with	O
the	O
metastatic	O
potential	O
of	O
many	O
cancers	B-Anatomy
,	O
including	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
MPs	O
also	O
play	O
a	O
role	O
in	O
tumor	B-Anatomy
angiogenesis	O
.	O
Tetracyclines	O
are	O
antimicrobial	O
agents	O
that	O
can	O
suppress	O
MP	O
activity	O
in	O
a	O
variety	O
of	O
tissues	B-Anatomy
,	O
including	O
gingiva	B-Anatomy
,	O
bone	B-Anatomy
,	O
and	O
cartilage	B-Anatomy
.	O
Several	O
reports	O
have	O
indicated	O
that	O
tetracyclines	O
can	O
suppress	O
tumor	B-Anatomy
MPs	O
as	O
well	O
.	O
A	O
synthetic	O
tetracycline	O
,	O
doxycycline	O
,	O
inhibits	O
migration	O
of	O
human	O
MDA	B-Anatomy
-	I-Anatomy
MB	I-Anatomy
-	I-Anatomy
435	I-Anatomy
breast	I-Anatomy
adenocarcinoma	I-Anatomy
cells	I-Anatomy
through	O
a	O
reconstituted	O
basement	B-Anatomy
membrane	I-Anatomy
(	O
Matrigel	O
)	O
,	O
an	O
assay	O
used	O
as	O
an	O
in	O
vitro	O
surrogate	O
for	O
the	O
in	O
vivo	O
process	O
of	O
tumor	B-Anatomy
invasion	O
through	O
basement	B-Anatomy
membranes	I-Anatomy
.	O
Additionally	O
,	O
doxycycline	O
diminishes	O
the	O
proliferation	O
of	O
this	O
breast	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
and	O
also	O
decreases	O
its	O
gelatinolytic	O
activity	O
,	O
as	O
determined	O
by	O
gel	O
zymography	O
.	O
Transforming	O
growth	O
factor	O
beta	O
1	O
promotes	O
spontaneous	O
transformation	O
of	O
cultured	O
rat	O
liver	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
.	O
The	O
neoplastic	B-Anatomy
transformation	O
of	O
cultured	O
rat	O
liver	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
by	O
various	O
means	O
has	O
consistently	O
been	O
associated	O
with	O
the	O
development	O
of	O
resistance	O
to	O
the	O
mito	O
-	O
inhibitory	O
effect	O
of	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
,	O
suggesting	O
that	O
such	O
phenotype	O
plays	O
a	O
mechanistic	O
role	O
during	O
the	O
transformation	O
of	O
these	O
cells	B-Anatomy
.	O
We	O
have	O
studied	O
the	O
induction	O
of	O
the	O
""""	O
TGF	O
-	O
beta	O
-	O
resistant	O
""""	O
phenotype	O
in	O
a	O
clonal	B-Anatomy
strain	I-Anatomy
of	O
early	O
passage	O
WB	B-Anatomy
-	I-Anatomy
F344	I-Anatomy
normal	O
cultured	O
rat	O
liver	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
,	O
the	O
proliferation	O
of	O
which	O
was	O
markedly	O
inhibited	O
by	O
TGF	O
-	O
beta	O
.	O
The	O
control	O
WB	B-Anatomy
cells	I-Anatomy
in	O
continuous	O
culture	O
slowly	O
developed	O
TGF	O
-	O
beta	O
resistance	O
.	O
However	O
,	O
when	O
the	O
same	O
cells	B-Anatomy
were	O
exposed	O
to	O
step	O
-	O
wise	O
increases	O
of	O
TGF	O
-	O
beta	O
concentration	O
in	O
their	O
culture	O
medium	O
,	O
the	O
development	O
of	O
TGF	O
-	O
beta	O
resistance	O
was	O
accelerated	O
.	O
Cells	B-Anatomy
which	O
had	O
been	O
grown	O
in	O
medium	O
containing	O
1	O
ng	O
/	O
ml	O
TGF	O
-	O
beta	O
developed	O
colony	B-Anatomy
-	O
forming	O
capacity	O
in	O
soft	O
agar	O
containing	O
epidermal	O
growth	O
factor	O
.	O
Cells	B-Anatomy
which	O
were	O
grown	O
in	O
media	O
containing	O
5	O
and	O
10	O
ng	O
/	O
ml	O
TGF	O
-	O
beta	O
demonstrated	O
a	O
low	O
level	O
of	O
colony	B-Anatomy
-	O
forming	O
efficiency	O
in	O
soft	O
agar	O
medium	O
without	O
added	O
epidermal	O
growth	O
factor	O
and	O
tumorigenicity	O
in	O
isogeneic	O
rats	O
.	O
These	O
TGF	O
-	O
beta	O
-	O
resistant	O
cells	B-Anatomy
also	O
exhibited	O
progressively	O
increasing	O
levels	O
of	O
expression	O
of	O
the	O
c	O
-	O
fos	O
and	O
and	O
myc	O
mRNA	O
,	O
and	O
increased	O
resistance	O
to	O
the	O
cytotoxicity	O
of	O
Adriamycin	O
and	O
melphalan	O
.	O
The	O
latter	O
phenomenon	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
mdr	O
-	O
1	O
mRNA	O
expression	O
,	O
cellular	B-Anatomy
glutathione	O
level	O
,	O
and	O
glutathione	O
S	O
-	O
transferase	O
activity	O
.	O
The	O
results	O
suggest	O
that	O
chronic	O
exposure	O
to	O
high	O
concentration	O
of	O
TGF	O
-	O
beta	O
promotes	O
the	O
spontaneous	O
neoplastic	B-Anatomy
transformation	O
of	O
cultured	O
rat	O
liver	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
,	O
and	O
that	O
this	O
process	O
may	O
represent	O
one	O
of	O
the	O
mechanisms	O
of	O
cellular	B-Anatomy
adaptation	O
for	O
induction	O
of	O
the	O
multidrug	O
-	O
resistant	O
phenotype	O
during	O
the	O
carcinogenesis	O
of	O
epithelial	B-Anatomy
cells	I-Anatomy
.	O
Appetite	O
regulation	O
by	O
serotoninergic	O
mechanisms	O
and	O
effects	O
of	O
d	O
-	O
fenfluramine	O
.	O
In	O
this	O
literature	O
review	O
,	O
evidence	O
is	O
presented	O
for	O
the	O
theory	O
that	O
the	O
neurotransmitter	O
,	O
serotonin	O
(	O
5	O
-	O
hydroxytryptamine	O
,	O
5HT	O
)	O
,	O
in	O
medial	B-Anatomy
hypothalamic	I-Anatomy
centres	I-Anatomy
is	O
an	O
important	O
regulator	O
for	O
appetite	O
and	O
for	O
the	O
selection	O
of	O
major	O
food	O
constituents	O
.	O
High	O
local	O
levels	O
of	O
5HT	O
cause	O
a	O
reduction	O
of	O
appetite	O
and	O
a	O
preference	O
for	O
protein	O
,	O
low	O
levels	O
the	O
opposite	O
.	O
The	O
main	O
antagonistic	O
system	O
is	O
noradrenergic	O
.	O
The	O
drug	O
d	O
-	O
fenfluramine	O
mimics	O
the	O
effects	O
of	O
5HT	O
by	O
releasing	O
5HT	O
from	O
serotoninergic	O
nerve	B-Anatomy
endings	I-Anatomy
and	O
inhibiting	O
its	O
neuronal	B-Anatomy
re	O
-	O
uptake	O
.	O
Further	O
experimental	O
data	O
prove	O
that	O
a	O
high	O
-	O
carbohydrate	O
,	O
low	O
-	O
protein	O
diet	O
promotes	O
uptake	O
of	O
serum	B-Anatomy
tryptophan	O
in	O
the	O
brain	B-Anatomy
and	O
its	O
conversion	O
into	O
5HT	O
.	O
Hence	O
,	O
this	O
serotoninergic	O
system	O
may	O
function	O
as	O
a	O
self	O
-	O
regulatory	O
mechanism	O
.	O
In	O
patients	O
with	O
decreased	O
peripheral	O
insulin	O
sensitivity	O
,	O
the	O
system	O
may	O
be	O
disturbed	O
,	O
causing	O
overconsumption	O
of	O
carbohydrates	O
.	O
This	O
is	O
sometimes	O
compulsive	O
(	O
""""	O
carbohydrate	O
craving	O
""""	O
)	O
.	O
It	O
may	O
be	O
presumed	O
that	O
in	O
the	O
treatment	O
of	O
obesity	O
,	O
in	O
addition	O
to	O
the	O
use	O
of	O
serotoninergic	O
drugs	O
,	O
successes	O
with	O
reducing	O
diets	O
may	O
be	O
enhanced	O
by	O
including	O
periods	O
of	O
high	O
-	O
carbohydrate	O
,	O
low	O
-	O
protein	O
intake	O
.	O
It	O
would	O
be	O
worthwhile	O
to	O
explore	O
whether	O
similar	O
alimentary	O
self	O
-	O
regulatory	O
mechanisms	O
of	O
neurotransmitter	O
function	O
exist	O
in	O
other	O
regulatory	O
systems	O
.	O
[	O
Preliminary	O
results	O
of	O
observing	O
18	O
cases	O
of	O
retinoblastoma	B-Anatomy
carried	O
within	O
the	O
international	O
research	O
program	O
RICS	O
]	O
.	O
In	O
the	O
years	O
1988	O
-	O
1989	O
,	O
the	O
Ophthalmological	O
Clinic	O
in	O
Cracow	O
took	O
part	O
in	O
the	O
International	O
Research	O
Programme	O
on	O
Retinoblastoma	B-Anatomy
as	O
one	O
of	O
28	O
clinical	O
centres	O
in	O
14	O
countries	O
.	O
The	O
study	O
included	O
18	O
children	O
with	O
retinoblastoma	B-Anatomy
,	O
in	O
most	O
cases	O
in	O
the	O
advanced	O
stadium	O
of	O
the	O
disease	O
.	O
As	O
a	O
rule	O
,	O
the	O
eyes	B-Anatomy
filled	O
with	O
tumours	B-Anatomy
were	O
enucleated	O
,	O
and	O
the	O
less	O
advanced	O
cases	O
were	O
treated	O
with	O
combined	O
methods	O
applying	O
radiation	O
with	O
60Co	O
plaques	O
with	O
xenon	O
arc	O
photocoagulation	O
,	O
cryopexy	O
,	O
and	O
chemotherapy	O
.	O
In	O
18	O
treated	O
children	O
23	O
eyes	B-Anatomy
were	O
enucleated	O
(	O
in	O
5	O
children	O
both	O
eyes	B-Anatomy
,	O
in	O
6	O
children	O
with	O
bilateral	O
retinoblastoma	B-Anatomy
1	O
eye	B-Anatomy
,	O
and	O
7	O
eyes	B-Anatomy
in	O
all	O
unilateral	O
cases	O
)	O
.	O
Six	O
eyes	B-Anatomy
with	O
less	O
advanced	O
lesions	B-Anatomy
were	O
treated	O
with	O
combined	O
methods	O
.	O
One	O
child	O
died	O
because	O
of	O
metastases	B-Anatomy
to	O
the	O
brain	B-Anatomy
.	O
The	O
obtained	O
data	O
reveal	O
that	O
retinoblastoma	B-Anatomy
is	O
diagnosed	O
too	O
late	O
,	O
which	O
decreases	O
the	O
chance	O
of	O
cure	O
and	O
causes	O
great	O
danger	O
for	O
the	O
life	O
of	O
the	O
child	O
.	O
Identification	O
of	O
latency	O
-	O
associated	O
transcripts	O
that	O
map	O
antisense	O
to	O
the	O
ICP4	O
homolog	O
gene	O
of	O
Marek	O
'	O
s	O
disease	O
virus	O
.	O
Two	O
small	O
RNAs	O
(	O
0	O
.	O
9	O
and	O
0	O
.	O
75	O
kb	O
)	O
,	O
named	O
Marek	O
'	O
s	O
disease	O
virus	O
(	O
MDV	O
)	O
small	O
RNAs	O
(	O
MSRs	O
)	O
and	O
a	O
10	O
-	O
kb	O
RNA	O
,	O
all	O
of	O
which	O
map	O
antisense	O
to	O
the	O
MDV	O
ICP4	O
homolog	O
gene	O
,	O
have	O
been	O
readily	O
detected	O
in	O
MDCC	B-Anatomy
-	I-Anatomy
MSB1	I-Anatomy
MDV	O
-	O
transformed	O
T	B-Anatomy
-	I-Anatomy
lymphoblastoid	I-Anatomy
cells	I-Anatomy
.	O
These	O
RNAs	O
were	O
not	O
detectable	O
in	O
reticuloendotheliosis	O
virus	O
-	O
transformed	O
T	B-Anatomy
cells	I-Anatomy
.	O
When	O
MDV	O
was	O
reactivated	O
by	O
treatment	O
of	O
lymphoblastoid	B-Anatomy
cells	I-Anatomy
with	O
25	O
micrograms	O
of	O
iododeoxyuridine	O
per	O
ml	O
,	O
the	O
relative	O
levels	O
of	O
the	O
transcripts	O
decreased	O
.	O
These	O
RNAs	O
were	O
not	O
detected	O
by	O
Northern	O
(	O
RNA	O
)	O
hybridization	O
in	O
productively	O
infected	O
chicken	O
embryo	B-Anatomy
fibroblasts	I-Anatomy
48	O
h	O
postinfection	O
;	O
however	O
,	O
they	O
were	O
apparent	O
140	O
h	O
postinfection	O
.	O
By	O
using	O
Northern	O
hybridization	O
,	O
RNase	O
protection	O
assays	O
,	O
and	O
primer	O
extension	O
analysis	O
,	O
the	O
MSRs	O
were	O
determined	O
to	O
map	O
antisense	O
to	O
the	O
predicted	O
translational	O
start	O
site	O
of	O
the	O
ICP4	O
homolog	O
gene	O
.	O
The	O
conclusion	O
most	O
consistent	O
with	O
the	O
data	O
is	O
that	O
the	O
two	O
MSRs	O
are	O
overlapping	O
,	O
spliced	O
RNAs	O
.	O
Both	O
small	O
RNAs	O
contain	O
a	O
latency	O
promoter	O
binding	O
factor	O
consensus	O
recognition	O
sequence	O
located	O
toward	O
their	O
5	O
'	O
ends	O
as	O
well	O
as	O
two	O
potential	O
ICP4	O
recognition	O
consensus	O
sequences	O
,	O
one	O
in	O
each	O
orientation	O
.	O
The	O
region	O
contains	O
a	O
number	O
of	O
small	O
open	O
reading	O
frames	O
on	O
each	O
side	O
and	O
within	O
the	O
MSRs	O
.	O
Although	O
the	O
exact	O
endpoints	O
are	O
unknown	O
,	O
the	O
large	O
10	O
-	O
kb	O
species	O
spans	O
the	O
entire	O
ICP4	O
homolog	O
region	O
.	O
We	O
believe	O
that	O
this	O
group	O
of	O
RNAs	O
,	O
which	O
map	O
antisense	O
to	O
the	O
ICP4	O
homolog	O
gene	O
,	O
are	O
latency	O
-	O
associated	O
transcripts	O
of	O
MDV	O
.	O
Increased	O
expression	O
of	O
specific	O
protein	O
tyrosine	O
phosphatases	O
in	O
human	O
breast	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
neoplastically	O
transformed	O
by	O
the	O
neu	O
oncogene	O
.	O
Protein	O
tyrosine	O
phosphorylation	O
/	O
dephosphorylation	O
is	O
a	O
fundamental	O
mechanism	O
in	O
the	O
regulation	O
of	O
cell	B-Anatomy
proliferation	O
and	O
neoplastic	B-Anatomy
transformation	O
;	O
this	O
metabolic	O
process	O
is	O
modulated	O
by	O
the	O
opposing	O
activities	O
of	O
protein	O
tyrosine	O
kinases	O
and	O
protein	O
tyrosine	O
phosphatases	O
(	O
PTPases	O
)	O
.	O
While	O
the	O
role	O
of	O
protein	O
tyrosine	O
kinases	O
has	O
been	O
examined	O
extensively	O
in	O
human	O
breast	B-Anatomy
tumorigenesis	O
,	O
the	O
role	O
of	O
PTPases	O
in	O
this	O
process	O
is	O
virtually	O
unknown	O
.	O
To	O
address	O
this	O
issue	O
,	O
an	O
activated	O
neu	O
oncogene	O
was	O
introduced	O
into	O
an	O
immortalized	O
nontumorigenic	O
human	O
breast	B-Anatomy
epithelial	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
(	O
184B5	B-Anatomy
)	O
.	O
This	O
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
P185neu	O
expression	O
,	O
which	O
led	O
to	O
the	O
formation	O
of	O
progressively	O
growing	O
carcinomas	B-Anatomy
after	O
such	O
cells	B-Anatomy
were	O
inoculated	O
into	O
athymic	O
nude	O
mice	O
.	O
Importantly	O
,	O
a	O
striking	O
increase	O
in	O
the	O
expression	O
of	O
specific	O
PTPases	O
,	O
LAR	O
and	O
PTP1B	O
,	O
was	O
observed	O
in	O
3	O
independently	O
neu	O
transformed	O
cell	B-Anatomy
lines	I-Anatomy
and	O
their	O
derived	O
tumors	B-Anatomy
.	O
This	O
elevation	O
was	O
verified	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O
TC	O
-	O
PTP	O
PTPase	O
expression	O
was	O
only	O
slightly	O
increased	O
in	O
these	O
neu	O
transformed	O
cells	B-Anatomy
,	O
and	O
no	O
expression	O
of	O
CD45	O
PTPase	O
was	O
observed	O
.	O
The	O
level	O
of	O
neu	O
expression	O
,	O
as	O
well	O
as	O
the	O
differential	O
expression	O
between	O
P185neu	O
and	O
LAR	O
/	O
PTP1B	O
,	O
directly	O
correlated	O
with	O
tumorigenicity	O
.	O
Furthermore	O
,	O
rat	O
mammary	B-Anatomy
carcinomas	I-Anatomy
with	O
elevated	O
neu	O
expression	O
(	O
neu	O
-	O
induced	O
)	O
also	O
had	O
sharply	O
elevated	O
LAR	O
-	O
PTPase	O
expression	O
when	O
compared	O
to	O
rat	O
mammary	B-Anatomy
carcinomas	I-Anatomy
with	O
little	O
or	O
no	O
neu	O
expression	O
(	O
7	O
,	O
12	O
-	O
dimethylbenzanthracene	O
induced	O
)	O
;	O
the	O
level	O
of	O
expression	O
of	O
LAR	O
PTPase	O
was	O
directly	O
correlated	O
with	O
the	O
level	O
of	O
neu	O
expression	O
.	O
Thus	O
,	O
our	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
,	O
in	O
human	O
breast	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
and	O
in	O
rat	O
mammary	B-Anatomy
carcinomas	I-Anatomy
that	O
have	O
an	O
induced	O
increase	O
in	O
neu	O
expression	O
,	O
a	O
consistent	O
and	O
substantial	O
increase	O
in	O
the	O
expression	O
of	O
specific	O
PTPases	O
occurs	O
.	O
The	O
relationship	O
between	O
P185neu	O
-	O
protein	O
tyrosine	O
kinase	O
expression	O
and	O
specific	O
PTPase	O
expression	O
may	O
play	O
a	O
critical	O
role	O
in	O
human	O
breast	B-Anatomy
tumorigenesis	O
.	O
Epilepsy	O
in	O
Down	O
syndrome	O
:	O
clinical	O
aspects	O
and	O
possible	O
mechanisms	O
.	O
Although	O
epilepsy	O
is	O
more	O
common	O
in	O
persons	O
with	O
trisomy	O
21	O
(	O
Down	O
syndrome	O
)	O
than	O
in	O
the	O
general	O
population	O
,	O
the	O
mechanisms	O
by	O
which	O
seizures	O
are	O
generated	O
in	O
this	O
population	O
have	O
received	O
little	O
attention	O
.	O
It	O
is	O
likely	O
that	O
this	O
increased	O
seizure	O
susceptibility	O
is	O
due	O
to	O
a	O
combination	O
of	O
medical	O
risk	O
factors	O
and	O
inherent	O
neurologic	B-Anatomy
abnormalities	O
characteristic	O
of	O
Down	O
syndrome	O
.	O
In	O
this	O
review	O
clinical	O
aspects	O
of	O
seizures	O
among	O
individuals	O
with	O
Down	O
syndrome	O
were	O
described	O
and	O
possible	O
mechanisms	O
by	O
which	O
the	O
trisomy	O
21	O
brain	B-Anatomy
may	O
generate	O
seizures	O
were	O
explored	O
.	O
In	O
vivo	O
effects	O
of	O
insulin	O
on	O
tumor	B-Anatomy
and	O
skeletal	B-Anatomy
muscle	I-Anatomy
glucose	O
metabolism	O
in	O
patients	O
with	O
lymphoma	B-Anatomy
.	O
BACKGROUND	O
:	O
The	O
anabolic	O
properties	O
of	O
insulin	O
have	O
been	O
suggested	O
for	O
use	O
to	O
reverse	O
malnutrition	O
associated	O
with	O
cancer	B-Anatomy
.	O
The	O
host	O
and	O
tumor	B-Anatomy
sensitivities	O
to	O
insulin	O
are	O
critical	O
for	O
such	O
treatments	O
,	O
which	O
aim	O
to	O
improve	O
patient	O
nutrition	O
.	O
The	O
authors	O
studied	O
insulin	O
effects	O
on	O
tumor	B-Anatomy
and	O
skeletal	B-Anatomy
muscle	I-Anatomy
metabolism	O
with	O
2	O
-	O
[	O
18F	O
]	O
-	O
fluoro	O
-	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
(	O
[	O
18F	O
]	O
FDG	O
)	O
and	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O
METHODS	O
:	O
Six	O
patients	O
with	O
lymphoma	B-Anatomy
twice	O
underwent	O
[	O
18F	O
]	O
FDG	O
-	O
PET	O
imaging	O
:	O
once	O
after	O
fasting	O
overnight	O
and	O
once	O
during	O
euglycemic	O
hyperinsulinemic	O
clamp	O
.	O
The	O
dynamic	O
uptake	O
of	O
the	O
glucose	O
analogue	O
[	O
18F	O
]	O
FDG	O
was	O
measured	O
in	O
diseased	B-Anatomy
nodes	I-Anatomy
and	O
upper	B-Anatomy
arm	I-Anatomy
skeletal	I-Anatomy
muscle	I-Anatomy
in	O
both	O
metabolic	O
states	O
.	O
The	O
[	O
18F	O
]	O
FDG	O
uptake	O
in	O
muscle	B-Anatomy
and	O
the	O
whole	O
body	B-Anatomy
glucose	O
use	O
during	O
euglycemic	O
hyperinsulinemic	O
clamp	O
were	O
compared	O
with	O
those	O
of	O
weight	O
-	O
matched	O
healthy	O
subjects	O
studied	O
under	O
similar	O
circumstances	O
.	O
RESULTS	O
:	O
In	O
lymphomatous	B-Anatomy
tissue	I-Anatomy
,	O
[	O
18F	O
]	O
FDG	O
uptake	O
rates	O
were	O
similar	O
in	O
overnight	O
fasting	O
and	O
euglycemic	O
hyperinsulinemic	O
clamp	O
(	O
38	O
+	O
/	O
-	O
10	O
versus	O
41	O
+	O
/	O
-	O
9	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
not	O
significant	O
)	O
,	O
whereas	O
glucose	O
uptake	O
in	O
skeletal	B-Anatomy
muscle	I-Anatomy
was	O
increased	O
by	O
insulin	O
(	O
1	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
2	O
versus	O
3	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
012	O
)	O
.	O
Both	O
basal	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
2	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
061	O
)	O
and	O
insulin	O
-	O
stimulated	O
(	O
8	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
9	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
055	O
)	O
skeletal	B-Anatomy
arm	I-Anatomy
muscle	I-Anatomy
glucose	O
uptake	O
rates	O
were	O
higher	O
in	O
control	O
subjects	O
than	O
in	O
patients	O
.	O
Whole	O
body	B-Anatomy
glucose	O
use	O
was	O
55	O
%	O
lower	O
in	O
patients	O
than	O
in	O
control	O
subjects	O
(	O
17	O
+	O
/	O
-	O
3	O
mumol	O
/	O
kg	O
/	O
minute	O
versus	O
38	O
+	O
/	O
-	O
3	O
mumol	O
/	O
kg	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
,	O
consistent	O
with	O
insulin	O
resistance	O
in	O
cancer	B-Anatomy
.	O
CONCLUSIONS	O
:	O
We	O
found	O
that	O
insulin	O
does	O
not	O
induce	O
major	O
changes	O
in	O
glucose	O
uptake	O
of	O
lymphomatous	B-Anatomy
tissue	I-Anatomy
.	O
Although	O
insulin	O
sensitivity	O
of	O
skeletal	B-Anatomy
muscle	I-Anatomy
was	O
also	O
reduced	O
in	O
patients	O
with	O
lymphoma	B-Anatomy
,	O
the	O
net	O
insulin	O
effect	O
may	O
counteract	O
imbalance	O
between	O
glucose	O
uptake	O
of	O
tumor	B-Anatomy
and	O
muscle	B-Anatomy
,	O
offering	O
a	O
potential	O
means	O
to	O
circumvent	O
at	O
least	O
some	O
metabolic	O
abnormalities	O
found	O
in	O
cancer	B-Anatomy
.	O
Kinins	O
contribute	O
to	O
the	O
improvement	O
of	O
insulin	O
sensitivity	O
during	O
treatment	O
with	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
.	O
Although	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
and	O
alpha	O
1	O
-	O
blockers	O
have	O
been	O
reported	O
to	O
improve	O
insulin	O
sensitivity	O
,	O
their	O
mechanisms	O
of	O
action	O
have	O
not	O
been	O
elucidated	O
.	O
To	O
investigate	O
the	O
role	O
of	O
kinins	O
in	O
insulin	O
sensitivity	O
,	O
we	O
treated	O
4	O
-	O
week	O
-	O
old	O
spontaneously	O
hypertensive	O
rats	O
with	O
either	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
(	O
enalapril	O
)	O
,	O
an	O
alpha	O
1	O
-	O
blocker	O
(	O
doxazosin	O
)	O
,	O
or	O
an	O
angiotensin	O
II	O
antagonist	O
(	O
losartan	O
)	O
for	O
3	O
weeks	O
.	O
A	O
control	O
group	O
received	O
no	O
drugs	O
.	O
In	O
addition	O
,	O
18	O
rats	O
treated	O
with	O
enalapril	O
or	O
doxazosin	O
received	O
a	O
simultaneous	O
administration	O
of	O
a	O
kinin	O
antagonist	O
(	O
Hoe	O
140	O
)	O
.	O
Glucose	O
clamp	O
testing	O
was	O
performed	O
in	O
each	O
group	O
.	O
Enalapril	O
(	O
128	O
+	O
/	O
-	O
1	O
mmHg	O
)	O
and	O
doxazosin	O
(	O
132	O
+	O
/	O
-	O
2	O
mmHg	O
)	O
decreased	O
mean	O
blood	B-Anatomy
pressure	O
compared	O
with	O
control	O
levels	O
(	O
148	O
+	O
/	O
-	O
1	O
mmHg	O
)	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O
The	O
glucose	O
requirement	O
for	O
the	O
clamp	O
test	O
during	O
the	O
administration	O
of	O
enalapril	O
(	O
25	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
or	O
doxazosin	O
(	O
28	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
was	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
19	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O
Although	O
Hoe	O
140	O
did	O
not	O
alter	O
the	O
glucose	O
requirement	O
of	O
doxazosin	O
(	O
27	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
,	O
it	O
decreased	O
that	O
of	O
enalapril	O
(	O
22	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
9	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
(	O
P	O
<	O
.	O
05	O
)	O
without	O
affecting	O
the	O
changes	O
in	O
mean	O
blood	B-Anatomy
pressure	O
induced	O
by	O
enalapril	O
.	O
In	O
addition	O
,	O
losartan	O
decreased	O
mean	O
blood	B-Anatomy
pressure	O
but	O
did	O
not	O
affect	O
the	O
glucose	O
requirement	O
.	O
Thus	O
,	O
the	O
improvement	O
in	O
insulin	O
sensitivity	O
produced	O
by	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
is	O
mostly	O
dependent	O
on	O
kinins	O
but	O
not	O
on	O
angiotensin	O
II	O
antagonism	O
,	O
and	O
an	O
alpha	O
1	O
-	O
blocker	O
improves	O
insulin	O
sensitivity	O
irrespective	O
of	O
kinins	O
.	O
Distribution	O
and	O
predictors	O
of	O
depressive	O
symptoms	O
in	O
osteoarthritis	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
prevalence	O
and	O
correlates	O
of	O
depressive	O
symptoms	O
in	O
a	O
sample	O
of	O
elderly	O
persons	O
with	O
osteoarthritis	O
(	O
OA	O
)	O
.	O
METHODS	O
:	O
Secondary	O
analysis	O
of	O
cross	O
sectional	O
interview	O
data	O
from	O
108	O
community	O
living	O
persons	O
age	O
50	O
or	O
over	O
who	O
met	O
American	O
College	O
of	O
Rheumatology	O
clinical	O
criteria	O
for	O
OA	O
of	O
the	O
hip	B-Anatomy
and	O
/	O
or	O
knee	B-Anatomy
.	O
RESULTS	O
:	O
The	O
prevalence	O
of	O
substantial	O
depressive	O
symptomatology	O
appeared	O
to	O
be	O
no	O
greater	O
than	O
would	O
be	O
expected	O
in	O
the	O
general	O
population	O
for	O
this	O
age	O
group	O
.	O
However	O
,	O
persons	O
currently	O
under	O
a	O
physician	O
'	O
s	O
care	O
for	O
OA	O
were	O
significantly	O
more	O
depressed	O
than	O
those	O
not	O
under	O
care	O
,	O
and	O
,	O
with	O
the	O
exception	O
of	O
those	O
who	O
had	O
post	O
-	O
high	O
school	O
education	O
,	O
depression	O
was	O
a	O
better	O
predictor	O
of	O
being	O
under	O
care	O
than	O
OA	O
symptoms	O
.	O
The	O
direct	O
and	O
interactive	O
effects	O
of	O
3	O
variables	O
-	O
-	O
education	O
,	O
age	O
and	O
self	O
-	O
perceived	O
impact	O
of	O
the	O
OA	O
problem	O
-	O
-	O
were	O
found	O
to	O
explain	O
40	O
%	O
of	O
variance	O
in	O
depression	O
scores	O
in	O
the	O
total	O
sample	O
and	O
50	O
%	O
among	O
those	O
currently	O
receiving	O
care	O
.	O
Younger	O
and	O
less	O
educated	O
subjects	O
had	O
relatively	O
more	O
depressive	O
symptoms	O
and	O
,	O
furthermore	O
,	O
in	O
this	O
subgroup	O
the	O
correlation	O
between	O
OA	O
impact	O
and	O
depression	O
was	O
high	O
.	O
CONCLUSIONS	O
:	O
The	O
importance	O
of	O
assessing	O
depression	O
in	O
persons	O
who	O
seek	O
care	O
for	O
OA	O
is	O
supported	O
.	O
Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
observed	O
relationship	O
between	O
education	O
and	O
arthritis	O
outcomes	O
could	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
depression	O
.	O
Effect	O
of	O
1	O
-	O
alkylpyrrolidine	O
N	O
-	O
oxides	O
on	O
energy	O
metabolism	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
The	O
main	O
purpose	O
of	O
the	O
present	O
investigation	O
was	O
to	O
study	O
the	O
effect	O
of	O
a	O
homologous	O
series	O
of	O
1	O
-	O
alkylpyrrolidine	O
N	O
-	O
oxides	O
on	O
ATP	O
-	O
producing	O
processes	O
in	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
and	O
L1210	B-Anatomy
murine	I-Anatomy
leukemia	I-Anatomy
cells	I-Anatomy
.	O
The	O
effect	O
on	O
aerobic	O
glucose	O
consumption	O
,	O
lactic	O
acid	O
formation	O
,	O
content	O
of	O
total	O
(	O
T	O
-	O
SH	O
)	O
and	O
non	O
-	O
protein	O
thiol	O
groups	O
(	O
NP	O
-	O
SH	O
)	O
,	O
endogenous	O
respiration	O
and	O
the	O
level	O
of	O
ATP	O
in	O
tumor	B-Anatomy
cells	I-Anatomy
incubated	O
in	O
vitro	O
was	O
investigated	O
.	O
1	O
-	O
Tetradecylpyrrolidine	O
N	O
-	O
oxide	O
(	O
TPNO	O
)	O
,	O
one	O
of	O
the	O
most	O
active	O
compounds	O
,	O
immediately	O
after	O
addition	O
to	O
the	O
suspension	O
of	O
Ehrlich	B-Anatomy
cells	I-Anatomy
in	O
an	O
ice	O
bath	O
,	O
decreased	O
the	O
level	O
of	O
ATP	O
to	O
the	O
same	O
extent	O
over	O
the	O
whole	O
concentration	O
range	O
.	O
After	O
2	O
h	O
incubation	O
at	O
37	O
degrees	O
C	O
the	O
drop	O
in	O
the	O
ATP	O
level	O
was	O
lower	O
.	O
The	O
decrease	O
in	O
ATP	O
level	O
might	O
be	O
explained	O
through	O
the	O
interaction	O
of	O
the	O
amine	O
oxide	O
with	O
the	O
cell	B-Anatomy
membrane	I-Anatomy
integrity	O
.	O
Chelation	O
treatment	O
of	O
neurological	B-Anatomy
Wilson	O
'	O
s	O
disease	O
.	O
The	O
results	O
of	O
chelation	O
treatment	O
of	O
137	O
patients	O
presenting	O
with	O
neurological	B-Anatomy
Wilson	O
'	O
s	O
disease	O
are	O
described	O
,	O
together	O
with	O
the	O
more	O
commonly	O
observed	O
toxic	O
reactions	O
to	O
the	O
various	O
drugs	O
employed	O
.	O
Fifty	O
-	O
seven	O
patients	O
made	O
an	O
excellent	O
response	O
to	O
treatment	O
and	O
became	O
symptom	O
free	O
.	O
Thirty	O
-	O
six	O
patients	O
made	O
a	O
good	O
recovery	O
,	O
but	O
were	O
left	O
with	O
some	O
minor	O
neurological	B-Anatomy
deficit	O
.	O
Twenty	O
-	O
four	O
patients	O
had	O
a	O
poor	O
response	O
:	O
although	O
the	O
disease	O
process	O
was	O
arrested	O
they	O
were	O
left	O
more	O
or	O
less	O
disabled	O
.	O
Twenty	O
patients	O
died	O
:	O
nine	O
had	O
little	O
or	O
no	O
treatment	O
,	O
but	O
11	O
died	O
despite	O
apparently	O
adequate	O
chelation	O
therapy	O
.	O
There	O
was	O
no	O
obvious	O
reason	O
for	O
this	O
failure	O
.	O
The	O
liver	B-Anatomy
copper	O
level	O
was	O
estimated	O
in	O
six	O
of	O
these	O
patients	O
:	O
it	O
was	O
still	O
significantly	O
elevated	O
in	O
only	O
one	O
,	O
but	O
in	O
all	O
four	O
in	O
whom	O
it	O
was	O
possible	O
to	O
make	O
the	O
determination	O
,	O
the	O
concentration	O
of	O
copper	O
in	O
the	O
basal	B-Anatomy
ganglia	I-Anatomy
was	O
in	O
excess	O
of	O
45	O
micrograms	O
/	O
g	O
wet	O
weight	O
.	O
It	O
was	O
not	O
apparent	O
why	O
adequate	O
therapy	O
failed	O
to	O
remove	O
copper	O
from	O
the	O
brains	B-Anatomy
of	O
these	O
patients	O
.	O
There	O
was	O
no	O
obvious	O
clinical	O
,	O
histological	O
or	O
biochemical	O
indicator	O
of	O
failure	O
to	O
respond	O
to	O
treatment	O
.	O
Initial	O
deterioration	O
before	O
improvement	O
was	O
seen	O
in	O
30	O
patients	O
:	O
the	O
prognosis	O
for	O
a	O
useful	O
recovery	O
was	O
not	O
necessarily	O
worse	O
than	O
that	O
in	O
patients	O
who	O
did	O
not	O
show	O
this	O
phenomenon	O
.	O
Transformation	O
-	O
associated	O
cytokine	O
9E3	O
/	O
CEF4	O
is	O
chemotactic	O
for	O
chicken	O
peripheral	B-Anatomy
blood	I-Anatomy
mononuclear	I-Anatomy
cells	I-Anatomy
.	O
9E3	O
/	O
CEF4	O
,	O
which	O
is	O
released	O
from	O
transformed	O
chicken	O
embryo	B-Anatomy
fibroblasts	I-Anatomy
(	O
CEF	B-Anatomy
)	O
,	O
is	O
a	O
member	O
of	O
the	O
platelet	O
factor	O
4	O
family	O
of	O
inflammatory	O
proteins	O
and	O
may	O
be	O
the	O
avian	O
homolog	O
of	O
interleukin	O
-	O
8	O
.	O
Since	O
the	O
function	O
of	O
9E3	O
/	O
CEF4	O
is	O
unknown	O
,	O
we	O
examined	O
the	O
effect	O
of	O
the	O
protein	O
on	O
mitogenicity	O
and	O
chemotaxis	O
,	O
as	O
well	O
as	O
its	O
expression	O
,	O
in	O
fibroblasts	B-Anatomy
and	O
peripheral	B-Anatomy
blood	I-Anatomy
cells	I-Anatomy
.	O
9E3	O
/	O
CEF4	O
mRNA	O
was	O
expressed	O
in	O
chicken	O
peripheral	B-Anatomy
blood	I-Anatomy
monocytes	I-Anatomy
,	O
and	O
its	O
expression	O
was	O
stimulated	O
by	O
incubation	O
of	O
the	O
monocytes	B-Anatomy
with	O
lipopolysaccharide	O
or	O
phorbol	O
myristic	O
acetate	O
.	O
Boyden	O
double	O
-	O
membrane	O
analysis	O
of	O
chemotaxis	O
showed	O
that	O
9E3	O
/	O
CEF4	O
was	O
chemotactic	O
for	O
chicken	O
peripheral	B-Anatomy
blood	I-Anatomy
mononuclear	I-Anatomy
cells	I-Anatomy
,	O
as	O
well	O
as	O
for	O
heterophils	B-Anatomy
.	O
Untransformed	O
CEF	B-Anatomy
and	O
CEF	B-Anatomy
transformed	O
with	O
Rous	O
sarcoma	O
virus	O
also	O
migrated	O
to	O
9E3	O
/	O
CEF4	O
protein	O
,	O
as	O
measured	O
by	O
Boyden	O
single	O
-	O
membrane	O
analysis	O
.	O
9E3	O
/	O
CEF4	O
was	O
slightly	O
mitogenic	O
for	O
CEF	B-Anatomy
,	O
causing	O
a	O
doubling	O
of	O
[	O
3H	O
]	O
thymidine	O
uptake	O
when	O
added	O
to	O
serum	B-Anatomy
-	O
starved	O
CEF	B-Anatomy
.	O
9E3	O
/	O
CEF4	O
was	O
found	O
associated	O
not	O
only	O
with	O
the	O
cell	B-Anatomy
and	O
in	O
the	O
culture	O
medium	O
of	O
Rous	O
sarcoma	O
virus	O
-	O
transformed	O
CEF	B-Anatomy
but	O
also	O
with	O
the	O
extracellular	B-Anatomy
matrix	I-Anatomy
.	O
The	O
in	O
vivo	O
role	O
of	O
9E3	O
/	O
CEF4	O
may	O
be	O
involved	O
with	O
chemotaxis	O
and	O
metastasis	O
,	O
rather	O
than	O
with	O
direct	O
stimulation	O
of	O
mitogenicity	O
.	O
Vitamins	O
regulate	O
gene	O
expression	O
and	O
induce	O
differentiation	O
and	O
growth	O
inhibition	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
Their	O
relevance	O
in	O
cancer	B-Anatomy
prevention	O
.	O
Although	O
several	O
hypotheses	O
for	O
human	O
carcinogenesis	O
have	O
been	O
proposed	O
,	O
the	O
specific	O
genetic	O
changes	O
that	O
cause	O
normal	O
cells	B-Anatomy
to	O
become	O
cancer	B-Anatomy
cells	I-Anatomy
have	O
not	O
been	O
identified	O
.	O
In	O
spite	O
of	O
uncertainties	O
regarding	O
the	O
mechanisms	O
of	O
carcinogenesis	O
,	O
several	O
vitamins	O
such	O
as	O
beta	O
-	O
carotene	O
and	O
vitamins	O
A	O
,	O
C	O
,	O
and	O
E	O
,	O
which	O
can	O
reduce	O
the	O
risk	O
of	O
cancer	B-Anatomy
,	O
have	O
been	O
identified	O
,	O
using	O
animal	O
and	O
in	O
vitro	O
models	O
of	O
carcinogenesis	O
.	O
These	O
studies	O
have	O
led	O
to	O
a	O
hypothesis	O
that	O
the	O
supplemental	O
intake	O
of	O
these	O
vitamins	O
may	O
reduce	O
the	O
risk	O
of	O
cancer	B-Anatomy
.	O
This	O
hypothesis	O
in	O
humans	O
can	O
be	O
tested	O
only	O
by	O
intervention	O
trials	O
that	O
are	O
in	O
progress	O
.	O
Prospective	O
and	O
retrospective	O
case	O
-	O
controlled	O
experimental	O
designs	O
are	O
not	O
suitable	O
for	O
testing	O
the	O
above	O
hypothesis	O
.	O
The	O
fact	O
that	O
some	O
vitamins	O
induce	O
cell	B-Anatomy
differentiation	O
and	O
/	O
or	O
growth	O
inhibition	O
in	O
tumor	B-Anatomy
cells	I-Anatomy
in	O
culture	O
suggests	O
that	O
the	O
use	O
of	O
these	O
vitamins	O
in	O
cancer	B-Anatomy
prevention	O
has	O
a	O
cellular	B-Anatomy
basis	O
.	O
In	O
addition	O
to	O
having	O
a	O
direct	O
effect	O
on	O
tumor	B-Anatomy
cells	I-Anatomy
,	O
vitamins	O
such	O
as	O
alpha	O
-	O
tocopheryl	O
succinate	O
and	O
beta	O
-	O
carotene	O
enhance	O
the	O
effect	O
of	O
other	O
agents	O
that	O
induce	O
differentiation	O
in	O
tumor	B-Anatomy
cells	I-Anatomy
.	O
Some	O
vitamins	O
like	O
beta	O
-	O
carotene	O
,	O
retinoic	O
acid	O
,	O
alpha	O
-	O
tocopheryl	O
succinate	O
,	O
and	O
vitamin	O
D	O
also	O
regulate	O
the	O
expressions	O
of	O
certain	O
oncogenes	O
and	O
cellular	B-Anatomy
genes	O
.	O
These	O
are	O
exciting	O
new	O
functions	O
of	O
vitamins	O
that	O
nobody	O
could	O
have	O
predicted	O
only	O
a	O
few	O
years	O
ago	O
.	O
Increased	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
messenger	O
RNA	O
expression	O
and	O
absence	O
of	O
mutations	O
in	O
colon	B-Anatomy
carcinomas	I-Anatomy
of	O
low	O
and	O
high	O
metastatic	O
potential	O
.	O
BACKGROUND	O
:	O
The	O
murine	O
nm23	O
gene	O
suppresses	O
the	O
metastatic	O
behavior	O
of	O
malignant	B-Anatomy
rodent	I-Anatomy
tumor	I-Anatomy
lines	I-Anatomy
,	O
and	O
reduced	O
nm23	O
expression	O
correlates	O
with	O
increased	O
likelihood	O
of	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
in	O
human	O
breast	B-Anatomy
cancers	I-Anatomy
.	O
More	O
recent	O
data	O
have	O
demonstrated	O
the	O
existence	O
of	O
two	O
human	O
nm23	O
gene	O
homologues	O
,	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
,	O
and	O
have	O
shown	O
that	O
deletion	O
of	O
nm23	O
-	O
H1	O
alleles	O
occurs	O
in	O
some	O
colon	B-Anatomy
carcinomas	I-Anatomy
associated	O
with	O
poor	O
prognosis	O
.	O
These	O
findings	O
suggest	O
that	O
nm23	O
-	O
H1	O
encodes	O
for	O
suppression	O
of	O
colon	B-Anatomy
carcinoma	I-Anatomy
metastasis	O
.	O
In	O
contrast	O
,	O
we	O
have	O
previously	O
reported	O
that	O
total	O
nm23	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
is	O
increased	O
to	O
similar	O
levels	O
in	O
colon	B-Anatomy
tumors	I-Anatomy
of	O
both	O
high	O
and	O
low	O
metastatic	O
potential	O
.	O
PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
reconcile	O
our	O
previous	O
findings	O
with	O
the	O
recent	O
report	O
of	O
nm23	O
-	O
H1	O
allelic	O
deletion	O
in	O
human	O
colon	B-Anatomy
cancers	I-Anatomy
associated	O
with	O
poor	O
prognosis	O
.	O
Our	O
purpose	O
was	O
to	O
examine	O
human	O
colon	B-Anatomy
cancers	I-Anatomy
for	O
inactivation	O
of	O
two	O
candidate	O
metastasis	O
suppressor	O
genes	O
,	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
,	O
either	O
by	O
mutation	O
or	O
by	O
loss	O
of	O
gene	O
transcription	O
.	O
METHODS	O
:	O
We	O
used	O
ribonuclease	O
protection	O
assays	O
to	O
analyze	O
human	O
colon	B-Anatomy
tumors	I-Anatomy
for	O
the	O
level	O
of	O
nm23	O
-	O
H1	O
(	O
43	O
samples	B-Anatomy
)	O
and	O
nm23	O
-	O
H2	O
(	O
41	O
samples	B-Anatomy
)	O
transcript	O
(	O
mRNA	O
)	O
expression	O
and	O
the	O
presence	O
of	O
mutations	O
that	O
could	O
inactivate	O
potential	O
suppressor	O
function	O
.	O
RESULTS	O
:	O
We	O
detected	O
only	O
wild	O
-	O
type	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
mRNA	O
.	O
Expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
increased	O
in	O
33	O
of	O
41	O
colon	B-Anatomy
tumors	I-Anatomy
,	O
and	O
expression	O
of	O
nm23	O
-	O
H2	O
mRNA	O
was	O
elevated	O
in	O
28	O
of	O
41	O
colon	B-Anatomy
tumors	I-Anatomy
relative	O
to	O
that	O
in	O
matched	O
normal	O
mucosa	B-Anatomy
.	O
Increases	O
in	O
these	O
mRNA	O
levels	O
were	O
similar	O
in	O
tumors	B-Anatomy
of	O
both	O
low	O
and	O
high	O
metastatic	O
potential	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
,	O
despite	O
correlation	O
of	O
nm23	O
-	O
H1	O
allelic	O
deletions	O
with	O
colon	B-Anatomy
cancers	I-Anatomy
associated	O
with	O
poor	O
prognosis	O
,	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
alleles	O
do	O
not	O
directly	O
mediate	O
metastasis	O
suppression	O
in	O
colon	B-Anatomy
carcinoma	I-Anatomy
.	O
Our	O
results	O
leave	O
unexplained	O
the	O
observation	O
that	O
nm23	O
-	O
H1	O
allelic	O
deletion	O
correlates	O
with	O
metastatic	O
potential	O
of	O
colon	B-Anatomy
carcinomas	I-Anatomy
.	O
IMPLICATIONS	O
:	O
These	O
findings	O
also	O
contrast	O
with	O
the	O
demonstration	O
of	O
nm23	O
metastasis	O
suppressor	O
activity	O
in	O
murine	O
melanoma	B-Anatomy
and	O
with	O
the	O
correlation	O
of	O
loss	O
of	O
nm23	O
expression	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
with	O
poor	O
prognosis	O
.	O
It	O
may	O
be	O
that	O
metastasis	O
suppression	O
by	O
the	O
nm23	O
gene	O
is	O
a	O
tissue	B-Anatomy
-	O
specific	O
phenomenon	O
.	O
E	O
mu	O
-	O
bcl	O
-	O
2	O
transgene	O
facilitates	O
spontaneous	O
transformation	O
of	O
early	O
pre	B-Anatomy
-	I-Anatomy
B	I-Anatomy
and	O
immunoglobulin	O
-	O
secreting	O
cells	B-Anatomy
but	O
not	O
T	B-Anatomy
cells	I-Anatomy
.	O
To	O
assess	O
the	O
lymphoid	B-Anatomy
tumorigenic	O
potential	O
of	O
bcl	O
-	O
2	O
,	O
mice	O
of	O
five	O
independent	O
strains	O
expressing	O
a	O
bcl	O
-	O
2	O
transgene	O
in	O
B	B-Anatomy
and	O
/	O
or	O
T	B-Anatomy
cells	I-Anatomy
were	O
monitored	O
for	O
disease	O
up	O
to	O
12	O
months	O
of	O
age	O
.	O
Lymphoma	B-Anatomy
prevalence	O
was	O
minimal	O
in	O
the	O
T	B-Anatomy
lineage	I-Anatomy
but	O
significant	O
,	O
although	O
low	O
(	O
3	O
-	O
15	O
%	O
)	O
,	O
in	O
the	O
B	B-Anatomy
lineage	I-Anatomy
.	O
The	O
principal	O
types	O
of	O
tumors	B-Anatomy
were	O
plasmacytomas	B-Anatomy
secreting	O
immunoglobulin	O
and	O
novel	O
lymphomas	B-Anatomy
that	O
expressed	O
markers	O
such	O
as	O
Sca	O
-	O
1	O
,	O
CD4	O
,	O
Thy	O
-	O
1	O
,	O
CD34	O
and	O
CD45	O
(	O
B220	O
)	O
,	O
consistent	O
with	O
an	O
origin	O
very	O
early	O
in	O
B	B-Anatomy
-	I-Anatomy
lymphoid	I-Anatomy
development	O
.	O
Rearrangement	O
of	O
the	O
c	O
-	O
myc	O
gene	O
was	O
common	O
in	O
the	O
plasmacytomas	B-Anatomy
,	O
implying	O
a	O
synergistic	O
role	O
for	O
myc	O
and	O
bcl	O
-	O
2	O
in	O
their	O
etiology	O
,	O
but	O
was	O
not	O
detected	O
in	O
the	O
lymphomas	B-Anatomy
.	O
[	O
Prehospital	O
service	O
in	O
Denmark	O
]	O
.	O
In	O
Denmark	O
,	O
emergency	O
ambulances	O
are	O
dispatched	O
by	O
41	O
centres	O
manned	O
either	O
by	O
trained	O
firemen	O
(	O
in	O
Copenhagen	O
)	O
or	O
policemen	O
(	O
outside	O
Copenhagen	O
)	O
.	O
In	O
1990	O
,	O
emergency	O
ambulance	O
calls	O
totalled	O
284	O
,	O
000	O
.	O
Utilisation	O
of	O
emergency	O
ambulance	O
services	O
increases	O
with	O
urbanisation	O
.	O
A	O
doctor	O
-	O
manned	O
ambulance	O
is	O
in	O
operation	O
in	O
Copenhagen	O
,	O
and	O
in	O
some	O
other	O
large	O
towns	O
anaesthesiology	O
and	O
intensive	O
care	O
teams	O
can	O
be	O
dispatched	O
from	O
hospital	O
to	O
give	O
on	O
-	O
the	O
-	O
spot	O
care	O
.	O
In	O
less	O
populated	O
areas	O
,	O
some	O
general	O
practitioners	O
give	O
advanced	O
life	O
-	O
support	O
.	O
Although	O
many	O
areas	O
are	O
serviced	O
by	O
ambulances	O
equipped	O
with	O
defibrillators	O
,	O
the	O
majority	O
of	O
patients	O
receive	O
only	O
basic	O
life	O
-	O
support	O
from	O
ambulance	O
personnel	O
.	O
New	O
initiatives	O
resulting	O
from	O
a	O
recent	O
report	O
by	O
a	O
commission	O
appointed	O
by	O
central	O
authorities	O
,	O
and	O
focused	O
on	O
prehospital	O
treatment	O
,	O
are	O
expected	O
to	O
improve	O
the	O
service	O
by	O
raising	O
the	O
level	O
of	O
training	O
given	O
to	O
ambulance	O
personnel	O
.	O
Tumorigenic	O
activity	O
of	O
rho	O
genes	O
from	O
Aplysia	O
californica	O
.	O
rho	O
genes	O
have	O
been	O
found	O
in	O
both	O
lower	O
and	O
higher	O
eucaryotes	O
.	O
They	O
code	O
for	O
proteins	O
of	O
21	O
kDa	O
,	O
highly	O
conserved	O
in	O
evolution	O
,	O
which	O
belong	O
to	O
the	O
superfamily	O
of	O
ras	O
GTPases	O
.	O
Among	O
the	O
members	O
of	O
this	O
superfamily	O
there	O
are	O
proteins	O
with	O
a	O
regulatory	O
function	O
,	O
such	O
as	O
ras	O
,	O
and	O
proteins	O
involved	O
in	O
vesicular	B-Anatomy
trafficking	O
,	O
such	O
as	O
the	O
family	O
of	O
rab	O
proteins	O
.	O
We	O
have	O
investigated	O
the	O
putative	O
role	O
of	O
rho	O
proteins	O
from	O
Aplysia	O
californica	O
as	O
transforming	O
GTPases	O
utilizing	O
the	O
wild	O
-	O
type	O
and	O
a	O
Val	O
-	O
14	O
mutant	O
,	O
equivalent	O
to	O
the	O
oncogenic	O
Val	O
-	O
12	O
mutation	O
of	O
ras	O
genes	O
found	O
in	O
animal	O
and	O
human	O
tumors	B-Anatomy
.	O
Over	O
-	O
expression	O
of	O
either	O
rho	O
gene	O
was	O
sufficient	O
to	O
confer	O
anchorage	O
-	O
and	O
serum	B-Anatomy
-	O
independent	O
growth	O
.	O
Moreover	O
,	O
when	O
introduced	O
into	O
nude	O
mice	O
,	O
selected	O
clones	O
generated	O
from	O
either	O
gene	O
were	O
able	O
to	O
induce	O
tumors	B-Anatomy
,	O
although	O
those	O
carrying	O
the	O
mutated	O
version	O
were	O
more	O
efficient	O
.	O
Pathological	O
analysis	O
indicated	O
that	O
generated	O
tumors	B-Anatomy
corresponded	O
to	O
well	O
-	O
differentiated	O
fibrosarcomas	B-Anatomy
with	O
distinct	O
and	O
intersecting	O
bundles	B-Anatomy
and	O
spindle	B-Anatomy
cells	I-Anatomy
.	O
By	O
contrast	O
,	O
ras	O
-	O
induced	O
tumors	B-Anatomy
were	O
poorly	O
differentiated	O
fibrosarcomas	B-Anatomy
.	O
Thus	O
,	O
our	O
results	O
indicate	O
that	O
under	O
appropriate	O
conditions	O
rho	O
genes	O
function	O
as	O
oncogenes	O
and	O
may	O
have	O
a	O
role	O
in	O
the	O
regulation	O
of	O
proliferation	O
in	O
fibroblast	B-Anatomy
cells	I-Anatomy
.	O
Pancreatic	B-Anatomy
somatostatin	O
-	O
secreting	O
gangliocytic	B-Anatomy
paraganglioma	I-Anatomy
with	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
.	O
Gangliocytic	B-Anatomy
paraganglioma	I-Anatomy
(	O
GPG	B-Anatomy
)	O
with	O
local	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
was	O
found	O
in	O
the	O
pancreas	B-Anatomy
of	O
a	O
74	O
-	O
yr	O
-	O
old	O
female	O
who	O
presented	O
with	O
diarrhea	O
,	O
steatorrhea	O
,	O
vomiting	O
,	O
nausea	O
,	O
and	O
abdominal	B-Anatomy
pain	O
.	O
A	O
Whipple	O
procedure	O
led	O
to	O
a	O
complete	O
resolution	O
of	O
these	O
symptoms	O
and	O
a	O
return	O
of	O
an	O
elevated	O
stomatostatin	O
level	O
to	O
normal	O
.	O
This	O
is	O
the	O
first	O
description	O
of	O
GPG	B-Anatomy
in	O
this	O
location	O
and	O
the	O
first	O
endocrinologically	O
active	O
GPG	B-Anatomy
.	O
Cell	B-Anatomy
surface	I-Anatomy
binding	O
characteristics	O
correlate	O
with	O
consensus	O
type	O
I	O
interferon	O
enhanced	O
activity	O
.	O
The	O
binding	O
characteristics	O
of	O
a	O
genetically	O
engineered	O
consensus	O
interferon	O
with	O
unusually	O
high	O
biologic	O
activity	O
were	O
compared	O
to	O
the	O
characteristics	O
of	O
recombinant	O
interferon	O
-	O
alpha	O
2	O
.	O
Both	O
interferon	O
-	O
alpha	O
2	O
and	O
the	O
consensus	O
interferon	O
produced	O
typical	O
biphasic	O
Scatchard	O
plots	O
,	O
indicating	O
multiple	O
independent	O
binding	O
sites	O
.	O
The	O
consensus	O
interferon	O
,	O
which	O
exhibited	O
a	O
biologic	O
potency	O
more	O
than	O
10	O
-	O
fold	O
greater	O
than	O
all	O
other	O
type	O
I	O
interferons	O
,	O
also	O
exhibited	O
binding	O
site	O
affinities	O
greater	O
than	O
those	O
for	O
IFN	O
-	O
alpha	O
2b	O
.	O
In	O
addition	O
,	O
a	O
larger	O
number	O
of	O
high	O
,	O
and	O
low	O
-	O
affinity	O
cell	B-Anatomy
surface	I-Anatomy
sites	O
were	O
recognized	O
by	O
the	O
consensus	O
interferon	O
,	O
resulting	O
in	O
equivalent	O
numbers	O
of	O
sites	O
at	O
reduced	O
molar	O
concentrations	O
compared	O
to	O
IFN	O
-	O
a2b	O
.	O
Thus	O
,	O
at	O
any	O
given	O
biologic	O
activity	O
,	O
similar	O
numbers	O
of	O
sites	O
were	O
bound	O
by	O
the	O
consensus	O
interferon	O
and	O
IFN	O
-	O
alpha	O
2	O
,	O
despite	O
differences	O
in	O
their	O
molar	O
concentrations	O
.	O
No	O
differences	O
in	O
internalization	O
kinetics	O
were	O
identified	O
between	O
the	O
two	O
interferons	O
,	O
indicating	O
that	O
the	O
differences	O
in	O
cell	B-Anatomy
surface	I-Anatomy
binding	O
may	O
be	O
sufficient	O
to	O
produce	O
the	O
differences	O
in	O
biologic	O
activity	O
.	O
Human	O
immunodeficiency	O
virus	O
type	O
1	O
viral	O
background	O
plays	O
a	O
major	O
role	O
in	O
development	O
of	O
resistance	O
to	O
protease	O
inhibitors	O
.	O
The	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
benefit	O
of	O
combination	O
treatment	O
with	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
agents	O
prompted	O
us	O
to	O
examine	O
the	O
potential	O
of	O
resistance	O
development	O
when	O
two	O
protease	O
inhibitors	O
are	O
used	O
concurrently	O
.	O
Recombinant	O
HIV	O
-	O
1	O
(	O
NL4	O
-	O
3	O
)	O
proteases	O
containing	O
combined	O
resistance	O
mutations	O
associated	O
with	O
BMS	O
-	O
186318	O
and	O
A	O
-	O
77003	O
(	O
or	O
saquinavir	O
)	O
were	O
either	O
inactive	O
or	O
had	O
impaired	O
enzyme	O
activity	O
.	O
Subsequent	O
construction	O
of	O
HIV	O
-	O
1	O
(	O
NL4	O
-	O
3	O
)	O
proviral	O
clones	O
containing	O
the	O
same	O
mutations	O
yielded	O
viruses	O
that	O
were	O
severely	O
impaired	O
in	O
growth	O
or	O
nonviable	O
,	O
confirming	O
that	O
combination	O
therapy	O
may	O
be	O
advantageous	O
.	O
However	O
,	O
passage	O
of	O
BMS	O
-	O
186318	O
-	O
resistant	O
HIV	O
-	O
1	O
(	O
RF	O
)	O
in	O
the	O
presence	O
of	O
either	O
saquinavir	O
or	O
SC52151	O
,	O
which	O
represented	O
sequential	O
drug	O
treatment	O
,	O
produced	O
viable	O
viruses	O
resistant	O
to	O
both	O
BMS	O
-	O
186318	O
and	O
the	O
second	O
compound	O
.	O
The	O
predominant	O
breakthrough	O
virus	O
contained	O
the	O
G48V	O
/	O
A71T	O
/	O
V82A	O
protease	O
mutations	O
.	O
The	O
clone	O
-	O
purified	O
RF	O
(	O
G48V	O
/	O
A71T	O
/	O
V82A	O
)	O
virus	O
,	O
unlike	O
the	O
corresponding	O
defective	O
NL4	O
-	O
3	O
triple	O
mutant	O
,	O
grew	O
well	O
and	O
displayed	O
cross	O
-	O
resistance	O
to	O
four	O
distinct	O
protease	O
inhibitors	O
.	O
Chimeric	O
virus	O
and	O
in	O
vitro	O
mutagenesis	O
studies	O
indicated	O
that	O
the	O
RF	O
-	O
specific	O
protease	O
sequence	O
,	O
specifically	O
the	O
Ile	O
at	O
residue	O
10	O
,	O
enabled	O
the	O
NL4	O
-	O
3	O
strain	O
with	O
the	O
triple	O
mutant	O
to	O
grow	O
.	O
Our	O
results	O
clearly	O
indicate	O
that	O
viral	O
genetic	O
background	O
will	O
play	O
a	O
key	O
role	O
in	O
determining	O
whether	O
cross	O
-	O
resistance	O
variants	O
will	O
arise	O
.	O
Stimulation	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
by	O
vascular	O
permeability	O
factor	O
/	O
vascular	O
endothelial	O
growth	O
factor	O
through	O
cooperative	O
mechanisms	O
involving	O
the	O
alphavbeta3	O
integrin	O
,	O
osteopontin	O
,	O
and	O
thrombin	O
.	O
We	O
have	O
identified	O
several	O
mechanisms	O
by	O
which	O
the	O
angiogenic	O
cytokine	O
vascular	O
permeability	O
factor	O
/	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VPF	O
/	O
VEGF	O
)	O
likely	O
regulates	O
endothelial	B-Anatomy
cells	I-Anatomy
(	O
EC	B-Anatomy
)	O
migration	O
.	O
VPF	O
/	O
VEGF	O
induced	O
dermal	B-Anatomy
microvascular	I-Anatomy
EC	I-Anatomy
expression	O
of	O
mRNAs	O
encoding	O
the	O
alphav	O
and	O
beta3	O
integrin	O
subunits	O
resulting	O
in	O
increased	O
levels	O
of	O
the	O
alphavbeta3	O
heterodimer	O
at	O
the	O
cell	B-Anatomy
surface	I-Anatomy
,	O
and	O
VPF	O
/	O
VEGF	O
also	O
induced	O
mRNA	O
encoding	O
osteopontin	O
(	O
OPN	O
)	O
,	O
an	O
alphavbeta3	O
ligand	O
.	O
OPN	O
promoted	O
EC	B-Anatomy
migration	O
in	O
vitro	O
;	O
and	O
VPF	O
/	O
VEGF	O
induction	O
of	O
alphavbeta3	O
was	O
accompanied	O
by	O
increased	O
EC	B-Anatomy
migration	O
toward	O
OPN	O
.	O
Because	O
thrombin	O
cleavage	O
of	O
OPN	O
results	O
in	O
substantial	O
enhancement	O
of	O
OPN	O
'	O
s	O
adhesive	O
properties	O
,	O
and	O
because	O
VPF	O
/	O
VEGF	O
promotes	O
increased	O
microvascular	B-Anatomy
permeability	O
leading	O
to	O
activation	O
of	O
the	O
extrinsic	O
coagulation	O
pathway	O
,	O
we	O
also	O
investigated	O
whether	O
VPF	O
/	O
VEGF	O
facilitates	O
thrombin	O
cleavage	O
of	O
OPN	O
in	O
vivo	O
.	O
Consistent	O
with	O
this	O
hypothesis	O
,	O
co	O
-	O
injection	O
of	O
VPF	O
/	O
VEGF	O
together	O
with	O
OPN	O
resulted	O
in	O
rapid	O
cleavage	O
of	O
OPN	O
by	O
endogenous	O
thrombin	O
.	O
Furthermore	O
,	O
in	O
comparison	O
with	O
native	O
OPN	O
,	O
thrombin	O
-	O
cleaved	O
OPN	O
stimulated	O
a	O
greater	O
rate	O
of	O
EC	B-Anatomy
migration	O
in	O
vitro	O
,	O
which	O
was	O
additive	O
to	O
the	O
increased	O
migration	O
associated	O
with	O
induction	O
of	O
alpha	O
v	O
beta	O
3	O
.	O
Thus	O
,	O
these	O
data	O
demonstrate	O
cooperative	O
mechanisms	O
for	O
VPF	O
/	O
VEGF	O
regulation	O
of	O
EC	B-Anatomy
migration	O
involving	O
the	O
alphavbeta3	O
integrin	O
,	O
the	O
alphavbeta3	O
ligand	O
OPN	O
,	O
and	O
thrombin	O
cleavage	O
of	O
OPN	O
.	O
These	O
findings	O
also	O
illustrate	O
an	O
operational	O
link	O
between	O
VPF	O
/	O
VEGF	O
induction	O
of	O
EC	B-Anatomy
gene	O
expression	O
and	O
VPF	O
/	O
VEGF	O
enhancement	O
of	O
microvascular	B-Anatomy
permeability	O
,	O
suggesting	O
that	O
these	O
distinct	O
biological	O
activities	O
may	O
act	O
accordingly	O
to	O
stimulate	O
EC	B-Anatomy
migration	O
during	O
angiogenesis	O
.	O
Referral	O
bias	O
among	O
health	O
workers	O
in	O
studies	O
using	O
hospitalization	O
as	O
a	O
proxy	O
measure	O
of	O
the	O
underlying	O
incidence	O
rate	O
.	O
Contacts	O
with	O
health	O
services	O
like	O
hospitals	O
or	O
general	O
practitioners	O
are	O
usually	O
the	O
only	O
available	O
proxy	O
measure	O
of	O
incidence	O
of	O
disease	O
in	O
studies	O
based	O
on	O
secondary	O
data	O
and	O
differential	O
referrals	O
or	O
care	O
-	O
seeking	O
behavior	O
often	O
bias	O
such	O
proxy	O
measures	O
.	O
In	O
former	O
analyses	O
based	O
on	O
the	O
Occupational	O
Hospitalization	O
Register	O
in	O
Denmark	O
assisting	O
nurses	O
had	O
high	O
Standardized	O
Hospitalization	O
Ratios	O
for	O
many	O
diseases	O
.	O
It	O
was	O
,	O
however	O
,	O
suspected	O
that	O
it	O
fully	O
or	O
partly	O
was	O
due	O
to	O
a	O
referral	O
bias	O
or	O
self	O
-	O
selection	O
to	O
hospital	O
treatment	O
rather	O
than	O
exposures	O
to	O
occupational	O
hazards	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
the	O
referral	O
bias	O
hypothesis	O
by	O
comparing	O
hospitalization	O
and	O
mortality	O
data	O
for	O
health	O
workers	O
for	O
a	O
disease	O
category	O
with	O
a	O
high	O
mortality	O
.	O
Cohorts	O
of	O
all	O
gainfully	O
employed	O
20	O
-	O
to	O
59	O
-	O
year	O
-	O
old	O
Danes	O
were	O
formed	O
in	O
order	O
to	O
compare	O
Standardized	O
Mortality	O
Ratios	O
and	O
Standardized	O
Hospitalization	O
Ratios	O
of	O
ischemic	O
heart	B-Anatomy
disease	O
(	O
IHD	O
)	O
in	O
occupational	O
groups	O
.	O
The	O
follow	O
-	O
up	O
period	O
was	O
10	O
years	O
.	O
For	O
most	O
of	O
the	O
investigated	O
occupational	O
groups	O
a	O
similar	O
disease	O
pattern	O
was	O
found	O
whether	O
hospitalization	O
or	O
death	O
was	O
used	O
as	O
the	O
outcome	O
measure	O
.	O
In	O
""""	O
nurse	O
assistants	O
""""	O
a	O
statistically	O
significant	O
higher	O
risk	O
was	O
,	O
however	O
,	O
found	O
using	O
hospitalization	O
due	O
to	O
IHD	O
as	O
the	O
end	O
point	O
rather	O
than	O
mortality	O
.	O
Additional	O
analysis	O
did	O
not	O
support	O
the	O
hypothesis	O
that	O
the	O
finding	O
could	O
be	O
explained	O
by	O
differentiated	O
hospitalization	O
due	O
to	O
social	O
factors	O
.	O
The	O
true	O
incidence	O
rates	O
of	O
the	O
disease	O
need	O
not	O
be	O
equally	O
well	O
described	O
by	O
proxy	O
measures	O
such	O
as	O
hospitalization	O
diagnosis	O
or	O
death	O
diagnosis	O
in	O
all	O
occupational	O
groups	O
.	O
Differential	O
access	O
to	O
medical	O
treatment	O
in	O
some	O
groups	O
may	O
lead	O
to	O
bias	O
when	O
hospital	O
data	O
are	O
used	O
as	O
proxy	O
measures	O
for	O
the	O
underlying	O
incidence	O
rates	O
.	O
The	O
impact	O
of	O
multiskilling	O
on	O
quality	O
of	O
care	O
.	O
Hospital	O
finances	O
in	O
the	O
USA	O
are	O
in	O
a	O
crisis	O
.	O
While	O
profits	O
earned	O
from	O
the	O
healthcare	O
industry	O
appear	O
to	O
be	O
at	O
an	O
all	O
-	O
time	O
high	O
,	O
individual	O
hospitals	O
are	O
going	O
bankrupt	O
.	O
Hospitals	O
are	O
not	O
generating	O
sufficient	O
income	O
to	O
pay	O
their	O
expenses	O
given	O
how	O
they	O
have	O
traditionally	O
operated	O
.	O
Hence	O
,	O
we	O
are	O
witnessing	O
the	O
merger	O
and	O
consolidation	O
of	O
competitors	O
,	O
resulting	O
in	O
significantly	O
fewer	O
hospital	O
beds	O
in	O
certain	O
geographical	O
areas	O
.	O
In	O
addition	O
to	O
the	O
strategy	O
of	O
closing	O
hospital	O
beds	O
,	O
severe	O
budget	O
restrictions	O
are	O
impacting	O
upon	O
all	O
remaining	O
services	O
within	O
the	O
hospitals	O
.	O
Acetaminophen	O
and	O
hepatic	B-Anatomy
dysfunction	O
in	O
infectious	O
mononucleosis	O
.	O
Two	O
family	O
members	O
developed	O
severe	O
hepatitic	O
dysfunction	O
in	O
association	O
with	O
infectious	O
mononucleosis	O
and	O
acetaminophen	O
administration	O
.	O
Since	O
severe	O
hepatitis	O
is	O
an	O
extremely	O
rare	O
complication	O
of	O
infectious	O
mononucleosis	O
,	O
we	O
postulate	O
that	O
the	O
hepatic	B-Anatomy
dysfunction	O
was	O
induced	O
by	O
acetaminophen	O
.	O
c	O
-	O
erb	O
B2	O
overexpression	O
decreases	O
the	O
benefit	O
of	O
adjuvant	O
tamoxifen	O
in	O
early	B-Anatomy
-	I-Anatomy
stage	I-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
without	O
axillary	B-Anatomy
lymph	I-Anatomy
node	I-Anatomy
metastases	I-Anatomy
.	O
PURPOSE	O
:	O
We	O
studied	O
retrospectively	O
the	O
interaction	O
between	O
c	O
-	O
erbB2	O
overexpression	O
and	O
adjuvant	O
tomoxifen	O
in	O
node	B-Anatomy
-	O
negative	O
breast	B-Anatomy
cancer	I-Anatomy
patients	O
enrolled	O
in	O
the	O
Gruppo	O
Universitario	O
Napoletano	O
1	O
(	O
GUN	O
-	O
1	O
)	O
trial	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
c	O
-	O
erbB2	O
,	O
evaluated	O
by	O
immunohistochemistry	O
in	O
145	O
of	O
173	O
patients	O
randomly	O
assigned	O
to	O
2	O
-	O
year	O
adjuvant	O
tamoxifen	O
or	O
no	O
further	O
therapy	O
,	O
was	O
considered	O
overexpressed	O
if	O
greater	O
than	O
10	O
%	O
of	O
the	O
cells	B-Anatomy
showed	O
specific	O
membrane	B-Anatomy
staining	O
.	O
The	O
role	O
of	O
each	O
prognostic	O
variable	O
and	O
their	O
independent	O
effect	O
were	O
studied	O
using	O
the	O
Cox	O
model	O
.	O
Disease	O
-	O
free	O
(	O
DFS	O
)	O
and	O
overall	O
(	O
OAS	O
)	O
survival	O
curves	O
were	O
estimated	O
by	O
the	O
Kaplan	O
-	O
Meier	O
method	O
.	O
RESULTS	O
:	O
As	O
of	O
November	O
30	O
,	O
1994	O
,	O
the	O
median	O
follow	O
-	O
up	O
period	O
was	O
12	O
years	O
.	O
c	O
-	O
erbB2	O
was	O
overexpressed	O
in	O
43	O
of	O
145	O
patients	O
(	O
29	O
.	O
7	O
%	O
)	O
,	O
which	O
directly	O
correlated	O
with	O
tumor	B-Anatomy
size	O
and	O
inversely	O
with	O
estrogen	O
receptor	O
(	O
ER	O
)	O
level	O
.	O
At	O
univariate	O
analysis	O
,	O
overexpression	O
of	O
c	O
-	O
erbB2	O
did	O
not	O
affect	O
either	O
DFS	O
or	O
OAS	O
;	O
tamoxifen	O
had	O
a	O
greater	O
effect	O
on	O
reducing	O
the	O
risk	O
of	O
recurrence	O
than	O
of	O
death	O
.	O
Addition	O
of	O
c	O
-	O
erbB2	O
to	O
a	O
multivariate	O
Cox	O
model	O
that	O
contained	O
menopausal	O
status	O
,	O
tumor	B-Anatomy
size	O
,	O
nuclear	B-Anatomy
grade	O
,	O
and	O
treatment	O
as	O
covariates	O
did	O
not	O
affect	O
the	O
significance	O
of	O
the	O
model	O
for	O
DSF	O
or	O
OAS	O
,	O
whereas	O
addition	O
of	O
the	O
first	O
-	O
order	O
interaction	O
between	O
c	O
-	O
erbB2	O
and	O
tamoxifen	O
was	O
statistically	O
significant	O
both	O
for	O
DFS	O
and	O
OAS	O
.	O
The	O
same	O
result	O
was	O
obtained	O
when	O
the	O
model	O
contained	O
ER	O
status	O
and	O
ER	O
-	O
tamoxifen	O
interaction	O
.	O
Indeed	O
,	O
adjuvant	O
tamoxifen	O
significantly	O
prolonged	O
DFS	O
and	O
OAS	O
in	O
c	O
-	O
erbB2	O
-	O
negative	O
cases	O
,	O
whereas	O
it	O
had	O
no	O
effect	O
on	O
DFS	O
and	O
OAS	O
in	O
c	O
-	O
erbB2	O
-	O
positive	O
patients	O
.	O
CONCLUSION	O
:	O
In	O
early	B-Anatomy
-	I-Anatomy
stage	I-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
patients	O
,	O
overexpression	O
of	O
c	O
-	O
erbB2	O
is	O
a	O
marker	O
of	O
lack	O
of	O
efficacy	O
of	O
adjuvant	O
tamoxifen	O
.	O
Gene	O
transfer	O
of	O
naked	O
DNA	O
encoding	O
for	O
three	O
isoforms	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
stimulates	O
collateral	B-Anatomy
development	O
in	O
vivo	O
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
a	O
naturally	O
secreted	O
endothelial	B-Anatomy
cell	I-Anatomy
-	O
specific	O
mitogen	O
.	O
We	O
investigated	O
the	O
hypothesis	O
that	O
naked	O
DNA	O
encoding	O
for	O
VEGF	O
could	O
be	O
used	O
in	O
a	O
strategy	O
of	O
arterial	B-Anatomy
gene	O
therapy	O
to	O
stimulate	O
collateral	B-Anatomy
artery	I-Anatomy
development	O
.	O
Plasmid	B-Anatomy
DNA	O
encoding	O
each	O
of	O
the	O
three	O
principal	O
human	O
VEGF	O
isoforms	O
(	O
phVEGF121	O
,	O
phVEGF165	O
,	O
or	O
phVEGF189	O
)	O
was	O
applied	O
to	O
the	O
hydrogel	O
polymer	O
coating	O
of	O
an	O
angioplasty	O
balloon	O
and	O
delivered	O
percutaneously	B-Anatomy
to	O
one	O
iliac	B-Anatomy
artery	I-Anatomy
of	O
rabbits	O
with	O
operatively	O
induced	O
hindlimb	B-Anatomy
ischemia	O
.	O
Compared	O
with	O
control	O
animals	O
transfected	O
with	O
LacZ	O
,	O
site	O
-	O
specific	O
transfection	O
of	O
phVEGF	O
resulted	O
in	O
augmented	O
collateral	B-Anatomy
vessel	I-Anatomy
development	O
documented	O
by	O
serial	O
angiography	O
,	O
and	O
improvement	O
in	O
calf	B-Anatomy
blood	I-Anatomy
pressure	O
ratio	O
(	O
ischemic	O
to	O
normal	O
limb	B-Anatomy
)	O
,	O
resting	O
and	O
maximum	O
blood	B-Anatomy
flow	O
,	O
and	O
capillary	B-Anatomy
to	O
myocyte	B-Anatomy
ratio	O
.	O
Similar	O
results	O
were	O
obtained	O
with	O
phVEGF121	O
,	O
phVEGF165	O
,	O
and	O
phVEGF189	O
,	O
which	O
suggests	O
that	O
these	O
isoforms	O
are	O
biologically	O
equivalent	O
with	O
respect	O
to	O
in	O
vivo	O
angiogenesis	O
.	O
The	O
fact	O
that	O
viral	O
or	O
other	O
adjunctive	O
vectors	O
were	O
not	O
required	O
further	O
suggests	O
that	O
secreted	O
gene	O
products	O
may	O
have	O
potential	O
therapeutic	O
utility	O
even	O
when	O
the	O
number	O
of	O
successfully	O
transfected	O
cells	B-Anatomy
remains	O
low	O
.	O
Arterial	B-Anatomy
gene	O
transfer	O
of	O
naked	O
DNA	O
encoding	O
for	O
a	O
secreted	O
angiogenic	O
cytokine	O
,	O
thus	O
,	O
represents	O
a	O
potential	O
alternative	O
to	O
recombinant	O
protein	O
administration	O
for	O
stimulating	O
collateral	B-Anatomy
vessel	I-Anatomy
development	O
.	O
Induction	O
of	O
p18INK4c	O
and	O
its	O
predominant	O
association	O
with	O
CDK4	O
and	O
CDK6	O
during	O
myogenic	O
differentiation	O
.	O
Terminal	O
cell	B-Anatomy
differentiation	O
involves	O
permanent	O
withdrawal	O
from	O
the	O
cell	B-Anatomy
division	O
cycle	O
.	O
The	O
inhibitors	O
of	O
cyclin	O
-	O
dependent	O
kinases	O
(	O
CDKs	O
)	O
are	O
potential	O
molecules	O
functioning	O
to	O
couple	O
cell	B-Anatomy
cycle	O
arrest	O
and	O
cell	B-Anatomy
differentiation	O
.	O
In	O
murine	O
C2C12	B-Anatomy
myoblast	I-Anatomy
cells	I-Anatomy
,	O
G1	O
CDK	O
enzymes	O
(	O
CDK2	O
,	O
CDK4	O
,	O
and	O
CDK6	O
)	O
associate	O
with	O
four	O
CDK	O
inhibitors	O
:	O
p18INK4c	O
,	O
p19INK4d	O
,	O
p21	O
,	O
and	O
p27Kip1	O
.	O
During	O
induced	O
myogenesis	O
,	O
p21	O
and	O
its	O
associated	O
CDK	O
proteins	O
underwent	O
an	O
initial	O
increase	O
followed	O
by	O
a	O
decrease	O
as	O
cells	B-Anatomy
became	O
terminally	O
differentiated	O
.	O
The	O
level	O
of	O
p27	O
protein	O
gradually	O
increased	O
,	O
but	O
the	O
amount	O
of	O
total	O
associated	O
CDK	O
proteins	O
remained	O
unchanged	O
.	O
p19	O
protein	O
decreased	O
gradually	O
during	O
differentiation	O
,	O
as	O
did	O
its	O
associated	O
CDK4	O
protein	O
.	O
In	O
contrast	O
,	O
p18	O
protein	O
increased	O
50	O
-	O
fold	O
,	O
from	O
negligible	O
levels	O
in	O
proliferating	O
myoblasts	B-Anatomy
to	O
clearly	O
detectable	O
levels	O
within	O
8	O
-	O
12	O
h	O
of	O
myogenic	O
induction	O
.	O
This	O
initial	O
rise	O
was	O
followed	O
by	O
a	O
precipitous	O
increase	O
between	O
12	O
and	O
24	O
h	O
postinduction	O
,	O
with	O
p18	O
protein	O
finally	O
accumulating	O
to	O
its	O
highest	O
level	O
in	O
terminally	O
differentiated	O
cells	B-Anatomy
.	O
Induction	O
of	O
p18	O
correlated	O
with	O
increased	O
and	O
sequential	O
complex	O
formation	O
-	O
-	O
first	O
increasing	O
association	O
with	O
CDK6	O
and	O
then	O
with	O
CDK4	O
over	O
the	O
course	O
of	O
myogenic	O
differentiation	O
.	O
All	O
of	O
the	O
CDK6	O
and	O
half	O
of	O
the	O
CDK4	O
were	O
complexed	O
with	O
p18	O
in	O
terminally	O
differentiated	O
C2C12	B-Anatomy
cells	I-Anatomy
as	O
well	O
as	O
in	O
adult	O
mouse	O
muscle	B-Anatomy
tissue	I-Anatomy
.	O
Finally	O
,	O
kinase	O
activity	O
of	O
CDK2	O
and	O
CDK4	O
decreases	O
as	O
C2C12	B-Anatomy
cells	I-Anatomy
differentiate	O
,	O
whereas	O
the	O
CDK6	O
kinase	O
activity	O
is	O
low	O
in	O
both	O
proliferating	O
myoblasts	B-Anatomy
and	O
differentiated	O
myotubes	B-Anatomy
.	O
Our	O
results	O
indicate	O
that	O
p18	O
may	O
play	O
a	O
critical	O
role	O
in	O
causing	O
and	O
/	O
or	O
maintaining	O
permanent	O
cell	B-Anatomy
cycle	O
arrest	O
associated	O
with	O
mature	O
muscle	B-Anatomy
formation	O
.	O
Functional	O
model	O
of	O
benign	O
paroxysmal	O
positional	O
vertigo	O
using	O
an	O
isolated	O
frog	O
semicircular	B-Anatomy
canal	I-Anatomy
.	O
Bull	O
frogs	O
posterior	B-Anatomy
semicircular	I-Anatomy
canals	I-Anatomy
(	O
psc	B-Anatomy
)	O
wee	O
used	O
to	O
simulate	O
the	O
condition	O
of	O
benign	O
paroxysmal	O
positional	O
vertigo	O
(	O
BPPV	O
)	O
.	O
The	O
psc	B-Anatomy
was	O
isolated	O
in	O
frog	O
Ringer	O
'	O
s	O
solution	O
,	O
and	O
the	O
saccular	B-Anatomy
otoconia	I-Anatomy
were	O
used	O
as	O
a	O
responsible	O
material	O
to	O
stimulate	O
the	O
cupula	B-Anatomy
.	O
When	O
the	O
otoconia	B-Anatomy
were	O
placed	O
on	O
the	O
cupular	B-Anatomy
surface	I-Anatomy
to	O
mimic	O
the	O
condition	O
of	O
cupulolithiasis	O
,	O
the	O
psc	B-Anatomy
ampullary	I-Anatomy
nerve	I-Anatomy
action	O
potentials	O
instantaneously	O
changed	O
according	O
to	O
the	O
direction	O
of	O
the	O
gravity	O
produced	O
by	O
otoconia	B-Anatomy
.	O
When	O
the	O
otoconia	B-Anatomy
were	O
dropped	O
into	O
the	O
canal	B-Anatomy
to	O
mimic	O
the	O
condition	O
of	O
moving	O
otoconia	B-Anatomy
in	O
the	O
canal	B-Anatomy
,	O
the	O
action	O
potentials	O
changed	O
together	O
with	O
the	O
otoconial	B-Anatomy
flow	O
after	O
a	O
latent	O
period	O
.	O
Both	O
cupulolithiasis	O
and	O
moving	O
otoconia	B-Anatomy
are	O
possibly	O
valid	O
mechanisms	O
of	O
BPPV	O
,	O
since	O
they	O
effectively	O
stimulate	O
the	O
cupula	B-Anatomy
.	O
However	O
,	O
moving	O
otoconia	B-Anatomy
with	O
a	O
latent	O
period	O
would	O
better	O
explain	O
clinical	O
features	O
of	O
BPPV	O
.	O
[	O
Considerations	O
regarding	O
two	O
cases	O
of	O
macromastia	O
(	O
author	O
'	O
s	O
transl	O
)	O
]	O
.	O
Two	O
cases	O
of	O
macromastia	O
have	O
been	O
shown	O
;	O
one	O
which	O
appeared	O
during	O
puberty	O
,	O
the	O
other	O
during	O
menopause	O
.	O
Histopathological	O
examination	O
has	O
demonstrated	O
for	O
the	O
both	O
cases	O
a	O
cystic	B-Anatomy
degeneracy	O
of	O
the	O
glandular	B-Anatomy
tissue	I-Anatomy
with	O
a	O
hyperplazia	O
and	O
hypertrophy	O
of	O
the	O
conjunctive	B-Anatomy
tissue	I-Anatomy
.	O
The	O
pathogeny	O
of	O
macromastia	O
is	O
being	O
discussed	O
and	O
it	O
is	O
demonstrated	O
both	O
the	O
role	O
of	O
hypophysis	O
hormones	O
(	O
prolactine	O
and	O
growth	O
hormone	O
)	O
and	O
of	O
ovarian	B-Anatomy
hormones	O
(	O
estrogens	O
)	O
.	O
The	O
treatment	O
was	O
surgical	O
for	O
the	O
both	O
cases	O
.	O
Comparison	O
of	O
transformation	O
by	O
manganese	O
sulfate	O
and	O
5	O
-	O
azacytidine	O
in	O
Rat	B-Anatomy
6	I-Anatomy
cells	I-Anatomy
overexpressing	O
the	O
c	O
-	O
myc	O
oncogene	O
.	O
Rat	B-Anatomy
6	I-Anatomy
cells	I-Anatomy
are	O
not	O
transformed	O
by	O
treatment	O
with	O
the	O
well	O
-	O
known	O
carcinogens	O
benzo	O
[	O
a	O
]	O
pyrene	O
(	O
BP	O
)	O
or	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitro	O
-	O
N	O
'	O
-	O
nitrosoguanidine	O
(	O
MNNG	O
)	O
.	O
Upon	O
retroviral	O
transduction	O
of	O
the	O
mouse	O
c	O
-	O
myc	O
gene	O
,	O
Rat	B-Anatomy
6	I-Anatomy
cells	I-Anatomy
showed	O
mildly	O
altered	O
morphology	O
and	O
formed	O
microcolonies	B-Anatomy
in	O
soft	O
agar	O
;	O
furthermore	O
,	O
they	O
could	O
be	O
transformed	O
by	O
BP	O
and	O
MNNG	O
to	O
form	O
large	O
colonies	B-Anatomy
in	O
agar	O
(	O
Hsiao	O
et	O
al	O
.	O
(	O
1992	O
)	O
Mol	O
.	O
Carcinogenesis	O
,	O
5	O
,	O
140	O
-	O
154	O
)	O
.	O
In	O
the	O
current	O
report	O
,	O
we	O
tested	O
the	O
sensitivity	O
of	O
the	O
c	B-Anatomy
-	I-Anatomy
myc	I-Anatomy
-	I-Anatomy
overexpressing	I-Anatomy
cells	I-Anatomy
(	O
Rat	B-Anatomy
6	I-Anatomy
/	I-Anatomy
c	I-Anatomy
-	I-Anatomy
myc	I-Anatomy
)	O
to	O
two	O
additional	O
chemicals	O
:	O
5	O
-	O
azacytidine	O
and	O
MnSO4	O
.	O
These	O
chemicals	O
differ	O
from	O
the	O
direct	O
-	O
acting	O
mutagens	O
tested	O
previously	O
.	O
5	O
-	O
Azacytidine	O
,	O
a	O
potent	O
DNA	O
methylation	O
inhibitor	O
,	O
induced	O
growth	O
of	O
large	O
colonies	B-Anatomy
in	O
soft	O
agar	O
cultures	B-Anatomy
of	O
Rat	B-Anatomy
6	I-Anatomy
or	O
Rat	B-Anatomy
6	I-Anatomy
/	I-Anatomy
c	I-Anatomy
-	I-Anatomy
myc	I-Anatomy
cells	I-Anatomy
.	O
On	O
the	O
other	O
hand	O
,	O
MnSO4	O
only	O
induced	O
transformation	O
in	O
Rat	B-Anatomy
6	I-Anatomy
/	I-Anatomy
c	I-Anatomy
-	I-Anatomy
myc	I-Anatomy
cells	I-Anatomy
,	O
but	O
not	O
the	O
parental	O
Rat	B-Anatomy
6	I-Anatomy
cells	I-Anatomy
.	O
Transformants	B-Anatomy
induced	O
by	O
5	O
-	O
azacytidine	O
lost	O
c	O
-	O
myc	O
-	O
induced	O
apoptotic	O
cell	B-Anatomy
death	O
,	O
whereas	O
MnSO4	O
-	O
induced	O
transformants	B-Anatomy
showed	O
a	O
higher	O
degree	O
of	O
apoptosis	O
than	O
the	O
parental	O
Rat	B-Anatomy
6	I-Anatomy
/	I-Anatomy
c	I-Anatomy
-	I-Anatomy
myc	I-Anatomy
cells	I-Anatomy
.	O
These	O
results	O
suggest	O
that	O
MnSO4	O
co	O
-	O
operates	O
with	O
overexpressed	O
c	O
-	O
myc	O
in	O
inducing	O
transformation	O
,	O
while	O
5	O
-	O
azacytidine	O
transformation	O
is	O
independent	O
of	O
c	O
-	O
myc	O
overexpression	O
and	O
may	O
involve	O
alterations	O
in	O
the	O
regulation	O
of	O
apoptosis	O
.	O
Procedural	O
memory	O
stimulation	O
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
impact	O
of	O
a	O
training	O
programme	O
.	O
The	O
study	O
evaluates	O
the	O
efficacy	O
of	O
a	O
procedural	O
memory	O
stimulation	O
programme	O
in	O
mild	O
and	O
mild	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O
Twenty	O
basic	O
and	O
instrumental	O
activities	O
of	O
daily	O
living	O
have	O
been	O
selected	O
,	O
and	O
divided	O
into	O
two	O
groups	O
,	O
comparable	O
for	O
difficulty	O
.	O
Ten	O
normal	O
elderly	O
subjects	O
(	O
age	O
68	O
.	O
0	O
+	O
/	O
-	O
4	O
.	O
8	O
years	O
;	O
MMSE	O
score	O
:	O
28	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
9	O
;	O
education	O
:	O
7	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
5	O
years	O
)	O
were	O
asked	O
to	O
perform	O
the	O
two	O
groups	O
of	O
daily	O
activities	O
and	O
the	O
time	O
required	O
to	O
perform	O
the	O
tasks	O
of	O
each	O
group	O
was	O
recorded	O
and	O
used	O
as	O
a	O
reference	O
.	O
Ten	O
mild	O
and	O
mild	O
-	O
moderate	O
AD	O
patients	O
(	O
age	O
77	O
.	O
2	O
+	O
/	O
-	O
5	O
.	O
3	O
years	O
;	O
MMSE	O
score	O
:	O
19	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
5	O
;	O
education	O
:	O
7	O
.	O
3	O
+	O
/	O
-	O
4	O
.	O
7	O
years	O
)	O
without	O
major	O
behavioural	O
disturbances	O
constituted	O
the	O
experimental	O
group	O
.	O
Patients	O
were	O
evaluated	O
in	O
all	O
20	O
daily	O
activities	O
and	O
the	O
time	O
employed	O
was	O
recorded	O
at	O
baseline	O
and	O
after	O
a	O
3	O
-	O
week	O
training	O
(	O
1	O
h	O
/	O
d	O
,	O
5	O
d	O
/	O
week	O
)	O
period	O
.	O
Five	O
patients	O
were	O
trained	O
during	O
the	O
3	O
weeks	O
on	O
half	O
of	O
the	O
20	O
daily	O
activities	O
and	O
the	O
other	O
five	O
patients	O
were	O
trained	O
on	O
the	O
remainder	O
.	O
This	O
procedure	O
was	O
adopted	O
in	O
order	O
to	O
detect	O
separately	O
the	O
improvement	O
in	O
""""	O
trained	O
""""	O
and	O
""""	O
not	O
trained	O
""""	O
activities	O
,	O
allowing	O
to	O
control	O
better	O
the	O
effects	O
of	O
the	O
intervention	O
.	O
The	O
assessment	O
of	O
the	O
functional	O
impact	O
of	O
the	O
training	O
was	O
directly	O
measured	O
,	O
through	O
the	O
variation	O
of	O
time	O
employed	O
to	O
perform	O
tasks	O
before	O
and	O
after	O
training	O
.	O
After	O
3	O
weeks	O
of	O
training	O
a	O
significant	O
improvement	O
was	O
observed	O
for	O
the	O
trained	O
activities	O
,	O
from	O
3	O
.	O
6	O
to	O
1	O
.	O
9	O
standard	O
deviations	O
below	O
the	O
performance	O
of	O
the	O
normal	O
elderly	O
controls	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
AD	O
patients	O
improved	O
also	O
in	O
not	O
-	O
trained	O
activities	O
from	O
3	O
.	O
5	O
to	O
2	O
.	O
7	O
standard	O
deviations	O
below	O
the	O
controls	O
'	O
performance	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
The	O
rehabilitation	O
of	O
activities	O
of	O
daily	O
living	O
through	O
developing	O
procedural	O
memory	O
strategies	O
may	O
be	O
effective	O
in	O
mild	O
and	O
mild	O
-	O
moderate	O
AD	O
patients	O
.	O
Regulation	O
of	O
p53	O
-	O
dependent	O
apoptosis	O
,	O
transcriptional	O
repression	O
,	O
and	O
cell	B-Anatomy
transformation	O
by	O
phosphorylation	O
of	O
the	O
55	O
-	O
kilodalton	O
E1B	O
protein	O
of	O
human	O
adenovirus	O
type	O
5	O
.	O
The	O
adenovirus	O
type	O
5	O
55	O
-	O
kDa	O
E1B	O
protein	O
(	O
E1B	O
-	O
55kDa	O
)	O
cooperates	O
with	O
E1A	O
gene	O
products	O
to	O
induce	O
cell	B-Anatomy
transformation	O
.	O
E1A	O
proteins	O
stimulate	O
DNA	O
synthesis	O
and	O
cell	B-Anatomy
proliferation	O
;	O
however	O
,	O
they	O
also	O
cause	O
rapid	O
cell	B-Anatomy
death	O
by	O
p53	O
-	O
dependent	O
and	O
p53	O
-	O
independent	O
apoptosis	O
.	O
It	O
is	O
believed	O
that	O
the	O
role	O
of	O
the	O
E1B	O
-	O
55kDa	O
protein	O
in	O
transformation	O
is	O
to	O
protect	O
against	O
p53	O
-	O
dependent	O
apoptosis	O
by	O
binding	O
to	O
and	O
inactivating	O
p53	O
.	O
It	O
has	O
been	O
shown	O
previously	O
that	O
the	O
55	O
-	O
kDa	O
polypeptide	O
abrogates	O
p53	O
-	O
mediated	O
transactivation	O
and	O
that	O
mutants	O
defective	O
in	O
p53	O
binding	O
are	O
unable	O
to	O
cooperate	O
with	O
E1A	O
in	O
transformation	O
.	O
We	O
have	O
previously	O
mapped	O
phosphorylation	O
sites	O
near	O
the	O
carboxy	O
terminus	O
of	O
the	O
E1B	O
-	O
55kDa	O
protein	O
at	O
Ser	O
-	O
490	O
and	O
Ser	O
-	O
491	O
,	O
which	O
lie	O
within	O
casein	O
kinase	O
II	O
consensus	O
sequences	O
.	O
Conversion	O
of	O
these	O
sites	O
to	O
alanine	O
residues	O
greatly	O
reduced	O
transforming	O
activity	O
,	O
and	O
although	O
the	O
mutant	O
55	O
-	O
kDa	O
protein	O
was	O
found	O
to	O
interact	O
with	O
p53	O
at	O
normal	O
levels	O
,	O
it	O
was	O
somewhat	O
defective	O
for	O
suppression	O
of	O
p53	O
transactivation	O
activity	O
.	O
We	O
now	O
report	O
that	O
a	O
nearby	O
residue	O
,	O
Thr	O
-	O
495	O
,	O
also	O
appears	O
to	O
be	O
phosphorylated	O
.	O
We	O
demonstrate	O
directly	O
that	O
the	O
wild	O
-	O
type	O
55	O
-	O
kDa	O
protein	O
is	O
able	O
to	O
block	O
E1A	O
-	O
induced	O
p53	O
-	O
dependent	O
apoptosis	O
,	O
whereas	O
cells	B-Anatomy
infected	O
by	O
mutant	O
pm490	O
/	O
1	O
/	O
5A	O
,	O
which	O
contains	O
alanine	O
residues	O
at	O
all	O
three	O
phosphorylation	O
sites	O
,	O
exhibited	O
extensive	O
DNA	O
fragmentation	O
and	O
classic	O
apoptotic	O
cell	B-Anatomy
death	O
.	O
The	O
E1B	O
-	O
55kDa	O
product	O
has	O
been	O
shown	O
to	O
exhibit	O
intrinsic	O
transcriptional	O
repression	O
activity	O
when	O
localized	O
to	O
promoters	O
,	O
such	O
as	O
by	O
fusion	O
with	O
the	O
GAL4	O
DNA	O
-	O
binding	O
domain	O
,	O
even	O
in	O
the	O
absence	O
of	O
p53	O
.	O
Such	O
repression	O
activity	O
was	O
totally	O
absent	O
with	O
mutant	O
pm490	O
/	O
1	O
/	O
5A	O
.	O
These	O
data	O
suggested	O
that	O
inhibition	O
of	O
p53	O
-	O
dependent	O
apoptosis	O
may	O
depend	O
on	O
the	O
transcriptional	O
repression	O
function	O
of	O
the	O
55	O
-	O
kDa	O
protein	O
,	O
which	O
appears	O
to	O
be	O
regulated	O
be	O
phosphorylation	O
at	O
the	O
carboxy	O
terminus	O
.	O
Non	O
-	O
invasive	O
grading	O
of	O
primary	B-Anatomy
brain	I-Anatomy
tumours	I-Anatomy
:	O
results	O
of	O
a	O
comparative	O
study	O
between	O
SPET	O
with	O
123I	O
-	O
alpha	O
-	O
methyl	O
tyrosine	O
and	O
PET	O
with	O
18F	O
-	O
deoxyglucose	O
.	O
Use	O
of	O
iodine	O
-	O
123	O
-	O
alpha	O
-	O
methyl	O
tyrosine	O
(	O
123I	O
-	O
IMT	O
)	O
allows	O
investigation	O
of	O
the	O
amino	O
acid	O
transport	O
rate	O
in	O
gliomas	B-Anatomy
.	O
It	O
was	O
the	O
aim	O
of	O
this	O
study	O
to	O
compare	O
the	O
value	O
of	O
measurement	O
of	O
glucose	O
metabolism	O
with	O
that	O
of	O
measurement	O
of	O
123I	O
-	O
IMT	O
uptake	O
for	O
the	O
non	O
-	O
invasive	O
grading	O
of	O
brain	B-Anatomy
tumours	I-Anatomy
.	O
The	O
study	O
population	O
comprised	O
23	O
patients	O
with	O
histopathologically	O
proven	O
primary	B-Anatomy
brain	I-Anatomy
tumours	I-Anatomy
;	O
14	O
had	O
high	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
gliomas	I-Anatomy
,	O
and	O
nine	O
low	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
brain	I-Anatomy
neoplasms	I-Anatomy
.	O
Glucose	O
metabolism	O
was	O
studied	O
using	O
an	O
ECAT	O
EXACT	O
47	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
camera	O
and	O
fluorine	O
-	O
18	O
fluorodeoxyglucose	O
(	O
18F	O
-	O
FDG	O
)	O
;	O
123I	O
-	O
IMT	O
uptake	O
was	O
measured	O
with	O
the	O
triple	O
-	O
headed	O
single	O
-	O
photon	O
emission	O
tomography	O
(	O
SPET	O
)	O
camera	O
,	O
MULTISPECT	O
3	O
.	O
18F	O
-	O
FDG	O
and	O
123I	O
-	O
IMT	O
uptake	O
was	O
quantified	O
as	O
ratios	O
between	O
the	O
uptake	O
by	O
the	O
tumour	B-Anatomy
and	O
contralateral	O
regions	O
of	O
reference	O
.	O
Glucose	O
metabolism	O
and	O
amino	O
acid	O
uptake	O
of	O
the	O
brain	B-Anatomy
tumours	I-Anatomy
correlated	O
significantly	O
(	O
r	O
=	O
0	O
.	O
71	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
Assuming	O
discrimination	O
thresholds	O
between	O
high	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
and	O
low	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
tumours	I-Anatomy
of	O
0	O
.	O
8	O
for	O
18F	O
-	O
FDG	O
uptake	O
and	O
1	O
.	O
8	O
for	O
123I	O
-	O
IMT	O
uptake	O
,	O
the	O
accuracy	O
values	O
of	O
18F	O
-	O
FDG	O
PET	O
and	O
123I	O
-	O
IMT	O
SPET	O
for	O
differentiating	O
between	O
high	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
and	O
low	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
tumours	I-Anatomy
were	O
21	O
/	O
23	O
(	O
91	O
%	O
)	O
and	O
19	O
/	O
23	O
(	O
83	O
%	O
)	O
,	O
respectively	O
.	O
The	O
difference	O
in	O
diagnostic	O
performance	O
was	O
not	O
significant	O
on	O
receiver	O
operating	O
characteristic	O
analysis	O
(	O
P	O
>	O
0	O
.	O
4	O
)	O
.	O
It	O
is	O
concluded	O
that	O
there	O
is	O
no	O
major	O
difference	O
between	O
the	O
PET	O
investigation	O
of	O
glucose	O
metabolism	O
and	O
the	O
less	O
expensive	O
SPET	O
measurement	O
of	O
amino	O
acid	O
uptake	O
in	O
terms	O
of	O
their	O
accuracy	O
in	O
evaluating	O
the	O
malignancy	O
grade	O
of	O
primary	B-Anatomy
brain	I-Anatomy
tumours	I-Anatomy
.	O
This	O
encourages	O
the	O
performance	O
of	O
further	O
studies	O
to	O
analyse	O
the	O
potential	O
impact	O
of	O
123I	O
-	O
IMT	O
SPET	O
on	O
the	O
therapeutic	O
management	O
of	O
patients	O
with	O
brain	B-Anatomy
tumours	I-Anatomy
.	O
Some	O
findings	O
concerning	O
beliefs	O
about	O
alcoholism	O
.	O
The	O
beliefs	O
that	O
alcoholics	O
hold	O
about	O
alcoholism	O
and	O
themselves	O
,	O
and	O
the	O
beliefs	O
that	O
hospital	O
staff	O
and	O
other	O
personnel	O
hold	O
about	O
alcoholism	O
,	O
were	O
investigated	O
using	O
methods	O
derived	O
from	O
the	O
repertory	O
grid	O
,	O
with	O
anonymous	O
facial	B-Anatomy
photographs	O
as	O
elements	O
.	O
Data	O
are	O
presented	O
as	O
to	O
the	O
degree	O
of	O
association	O
of	O
various	O
characteristics	O
with	O
alcoholism	O
for	O
the	O
various	O
groups	O
.	O
Differences	O
between	O
groups	O
,	O
and	O
overall	O
changes	O
during	O
group	O
psychotherapy	O
for	O
patients	O
were	O
small	O
.	O
The	O
relative	O
contribution	O
of	O
personal	O
and	O
shared	O
aspects	O
of	O
belief	O
was	O
measured	O
.	O
It	O
was	O
found	O
that	O
the	O
agreement	O
between	O
groups	O
was	O
high	O
and	O
closely	O
similar	O
to	O
that	O
predictable	O
from	O
consistencies	O
within	O
groups	O
.	O
It	O
is	O
concluded	O
that	O
there	O
may	O
be	O
a	O
very	O
general	O
stereotype	O
of	O
alcoholism	O
,	O
consistent	O
with	O
a	O
personality	O
disorder	O
concept	O
which	O
is	O
implicitly	O
held	O
even	O
in	O
the	O
face	O
of	O
nominal	O
acceptance	O
of	O
other	O
concepts	O
.	O
The	O
self	O
constructs	O
of	O
alcoholics	O
were	O
found	O
to	O
be	O
complex	O
.	O
In	O
a	O
small	O
follow	O
-	O
up	O
study	O
of	O
patients	O
,	O
there	O
was	O
found	O
to	O
be	O
a	O
relationship	O
of	O
poor	O
outcome	O
with	O
tightness	O
of	O
construing	O
for	O
key	O
constructs	O
after	O
psychotherapy	O
.	O
The	O
implications	O
of	O
the	O
findings	O
are	O
discussed	O
briefly	O
.	O
The	O
Wilms	B-Anatomy
tumor	I-Anatomy
suppressor	O
gene	O
WT1	O
induces	O
G1	O
arrest	O
and	O
apoptosis	O
in	O
myeloblastic	B-Anatomy
leukemia	I-Anatomy
M1	I-Anatomy
cells	I-Anatomy
.	O
WT1	O
was	O
isolated	O
as	O
a	O
tumor	B-Anatomy
suppressor	O
gene	O
of	O
Wilms	B-Anatomy
tumor	I-Anatomy
.	O
However	O
,	O
high	O
expression	O
of	O
WT1	O
correlates	O
with	O
poor	O
prognosis	O
in	O
acute	B-Anatomy
leukemia	I-Anatomy
.	O
In	O
addition	O
suppression	O
of	O
WT1	O
expression	O
by	O
WT1	O
anti	O
-	O
sense	O
oligonucleotide	O
inhibits	O
proliferation	O
of	O
leukemia	B-Anatomy
cells	I-Anatomy
,	O
suggesting	O
that	O
WT1	O
is	O
important	O
for	O
their	O
proliferation	O
.	O
To	O
further	O
elucidate	O
the	O
biological	O
significance	O
of	O
WT1	O
in	O
leukemic	O
cell	B-Anatomy
growth	O
,	O
we	O
overexpressed	O
exogenous	O
WT1	O
in	O
murine	O
M1	B-Anatomy
myeloblastic	I-Anatomy
leukemia	I-Anatomy
cells	I-Anatomy
using	O
the	O
isopropyl	O
-	O
beta	O
-	O
D	O
-	O
thiogalactoside	O
(	O
IPTG	O
)	O
-	O
controlled	O
expression	O
system	O
.	O
We	O
found	O
that	O
induction	O
of	O
one	O
splicing	O
variant	O
of	O
WT1	O
[	O
WT1	O
-	O
17AA	O
(	O
+	O
)	O
-	O
KTS	O
(	O
-	O
)	O
]	O
in	O
M1	B-Anatomy
cells	I-Anatomy
induces	O
cell	B-Anatomy
cycle	O
arrest	O
and	O
apoptotic	O
cell	B-Anatomy
death	O
.	O
These	O
results	O
suggest	O
that	O
the	O
role	O
of	O
WT1	O
is	O
different	O
depending	O
on	O
the	O
type	O
of	O
leukemia	B-Anatomy
cell	I-Anatomy
in	O
which	O
it	O
is	O
expressed	O
.	O
[	O
Expression	O
of	O
metastasis	O
suppressor	O
gene	O
nm23	O
in	O
human	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
]	O
.	O
For	O
the	O
purpose	O
of	O
investigating	O
the	O
relationship	O
between	O
the	O
metastatic	O
potential	O
of	O
the	O
tumor	B-Anatomy
as	O
well	O
as	O
the	O
expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
,	O
and	O
for	O
determing	O
the	O
location	O
of	O
the	O
positive	O
sites	O
in	O
the	O
cells	B-Anatomy
,	O
tumor	B-Anatomy
metastasis	O
suppressor	O
gene	O
nm23	O
-	O
H1	O
in	O
human	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
(	O
and	O
the	O
nonneoplastic	B-Anatomy
area	I-Anatomy
surrounding	O
the	O
tumor	B-Anatomy
)	O
was	O
detected	O
by	O
in	O
situ	O
hybridization	O
using	O
digoxiginin	O
-	O
labeled	O
nm23	O
-	O
H1	O
antisense	O
complementary	O
RNA	O
probe	O
.	O
The	O
primary	O
results	O
indicated	O
(	O
i	O
)	O
positive	O
results	O
of	O
in	O
situ	O
hybridization	O
are	O
presence	O
of	O
granules	B-Anatomy
or	O
masses	B-Anatomy
in	O
the	O
cytoplasm	B-Anatomy
;	O
(	O
ii	O
)	O
the	O
less	O
expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
,	O
the	O
higher	O
metastatic	O
rate	O
of	O
the	O
human	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
(	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
(	O
iii	O
)	O
expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
dose	O
not	O
correlate	O
with	O
some	O
other	O
factors	O
such	O
as	O
tumor	B-Anatomy
size	O
and	O
the	O
background	O
of	O
other	O
liver	B-Anatomy
diseases	O
.	O
Monitoring	O
the	O
efficiency	O
of	O
interferon	O
-	O
alpha	O
therapy	O
in	O
chronic	B-Anatomy
myelogenous	I-Anatomy
leukemia	I-Anatomy
(	O
CML	B-Anatomy
)	O
patients	O
by	O
competitive	O
polymerase	O
chain	O
reaction	O
.	O
Interferon	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
induces	O
cytogenetic	O
responses	O
of	O
variable	O
degree	O
in	O
patients	O
with	O
CML	B-Anatomy
.	O
We	O
sought	O
to	O
establish	O
the	O
relationship	O
between	O
BCR	O
-	O
ABL	O
transcript	O
numbers	O
measured	O
by	O
competitive	O
two	O
-	O
step	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
cytogenetic	O
status	O
in	O
CML	B-Anatomy
patients	O
treated	O
with	O
IFN	O
-	O
alpha	O
.	O
All	O
398	O
samples	B-Anatomy
from	O
163	O
patients	O
investigated	O
by	O
RT	O
-	O
PCR	O
were	O
positive	O
for	O
BCR	O
-	O
ABL	O
transcripts	O
.	O
In	O
order	O
to	O
standardize	O
results	O
for	O
variability	O
in	O
RNA	O
and	O
cDNA	O
quality	O
,	O
we	O
quantified	O
total	O
ABL	O
transcripts	O
in	O
each	O
sample	B-Anatomy
as	O
internal	O
control	O
.	O
The	O
BCR	O
-	O
ABL	O
/	O
ABL	O
ratios	O
correlated	O
with	O
the	O
cytogenetic	O
results	O
.	O
Quantitative	O
nested	O
PCR	O
allowed	O
the	O
detection	O
of	O
residual	O
BCR	O
-	O
ABL	O
transcripts	O
in	O
all	O
complete	O
cytogenetic	O
responders	O
on	O
IFN	O
-	O
alpha	O
.	O
We	O
conclude	O
that	O
competitive	O
PCR	O
with	O
internal	O
controls	O
is	O
a	O
reliable	O
method	O
for	O
monitoring	O
patients	O
on	O
IFN	O
-	O
alpha	O
and	O
reduces	O
the	O
need	O
for	O
repeated	O
marrow	B-Anatomy
investigations	O
.	O
[	O
Treatment	O
of	O
acute	O
liver	B-Anatomy
failure	O
in	O
children	O
]	O
.	O
Among	O
the	O
main	O
causes	O
of	O
acute	O
liver	B-Anatomy
failure	O
(	O
ALF	O
)	O
in	O
children	O
,	O
metabolic	O
diseases	O
(	O
especially	O
in	O
infants	O
)	O
,	O
viral	O
and	O
toxin	O
or	O
drug	O
induced	O
hepatitis	O
are	O
the	O
most	O
frequent	O
.	O
The	O
cause	O
remains	O
,	O
however	O
,	O
undetermined	O
in	O
about	O
30	O
%	O
of	O
the	O
cases	O
.	O
Management	O
must	O
be	O
conducted	O
in	O
a	O
pediatric	O
hepatology	O
unit	O
or	O
intensive	O
care	O
unit	O
in	O
relation	O
with	O
a	O
pediatric	O
transplant	O
team	O
in	O
order	O
:	O
1	O
)	O
to	O
perform	O
urgent	O
etiological	O
diagnosis	O
;	O
2	O
)	O
to	O
initiate	O
specific	O
therapy	O
and	O
symptomatic	O
treatment	O
;	O
3	O
)	O
to	O
evaluate	O
the	O
severity	O
and	O
prognosis	O
of	O
liver	B-Anatomy
disease	O
for	O
selection	O
of	O
children	O
for	O
emergency	O
liver	B-Anatomy
transplantation	O
;	O
4	O
)	O
to	O
evaluate	O
contraindications	O
to	O
liver	B-Anatomy
transplantation	O
.	O
The	O
overall	O
survival	O
of	O
post	O
-	O
emergency	O
liver	B-Anatomy
transplantation	O
for	O
ALF	O
in	O
children	O
averages	O
65	O
%	O
.	O
Blind	O
separation	O
of	O
auditory	O
event	O
-	O
related	O
brain	B-Anatomy
responses	O
into	O
independent	O
components	O
.	O
Averaged	O
event	O
-	O
related	O
potential	O
(	O
ERP	O
)	O
data	O
recorded	O
from	O
the	O
human	O
scalp	B-Anatomy
reveal	O
electroencephalographic	O
(	O
EEG	O
)	O
activity	O
that	O
is	O
reliably	O
time	O
-	O
locked	O
and	O
phase	O
-	O
locked	O
to	O
experimental	O
events	O
.	O
We	O
report	O
here	O
the	O
application	O
of	O
a	O
method	O
based	O
on	O
information	O
theory	O
that	O
decomposes	O
one	O
or	O
more	O
ERPs	O
recorded	O
at	O
multiple	O
scalp	B-Anatomy
sensors	O
into	O
a	O
sum	O
of	O
components	O
with	O
fixed	O
scalp	B-Anatomy
distributions	O
and	O
sparsely	O
activated	O
,	O
maximally	O
independent	O
time	O
courses	O
.	O
Independent	O
component	O
analysis	O
(	O
ICA	O
)	O
decomposes	O
ERP	O
data	O
into	O
a	O
number	O
of	O
components	O
equal	O
to	O
the	O
number	O
of	O
sensors	O
.	O
The	O
derived	O
components	O
have	O
distinct	O
but	O
not	O
necessarily	O
orthogonal	O
scalp	B-Anatomy
projections	O
.	O
Unlike	O
dipole	O
-	O
fitting	O
methods	O
,	O
the	O
algorithm	O
does	O
not	O
model	O
the	O
locations	O
of	O
their	O
generators	O
in	O
the	O
head	B-Anatomy
.	O
Unlike	O
methods	O
that	O
remove	O
second	O
-	O
order	O
correlations	O
,	O
such	O
as	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
,	O
ICA	O
also	O
minimizes	O
higher	O
-	O
order	O
dependencies	O
.	O
Applied	O
to	O
detected	O
-	O
and	O
undetected	O
-	O
target	O
ERPs	O
from	O
an	O
auditory	O
vigilance	O
experiment	O
,	O
the	O
algorithm	O
derived	O
ten	O
components	O
that	O
decomposed	O
each	O
of	O
the	O
major	O
response	O
peaks	O
into	O
one	O
or	O
more	O
ICA	O
components	O
with	O
relatively	O
simple	O
scalp	B-Anatomy
distributions	O
.	O
Three	O
of	O
these	O
components	O
were	O
active	O
only	O
when	O
the	O
subject	O
detected	O
the	O
targets	O
,	O
three	O
other	O
components	O
only	O
when	O
the	O
target	O
went	O
undetected	O
,	O
and	O
one	O
in	O
both	O
cases	O
.	O
Three	O
additional	O
components	O
accounted	O
for	O
the	O
steady	O
-	O
state	O
brain	B-Anatomy
response	O
to	O
a	O
39	O
-	O
Hz	O
background	O
click	O
train	O
.	O
Major	O
features	O
of	O
the	O
decomposition	O
proved	O
robust	O
across	O
sessions	O
and	O
changes	O
in	O
sensor	O
number	O
and	O
placement	O
.	O
This	O
method	O
of	O
ERP	O
analysis	O
can	O
be	O
used	O
to	O
compare	O
responses	O
from	O
multiple	O
stimuli	O
,	O
task	O
conditions	O
,	O
and	O
subject	O
states	O
.	O
CD56	O
+	O
putative	O
natural	B-Anatomy
killer	I-Anatomy
cell	I-Anatomy
lymphomas	I-Anatomy
:	O
production	O
of	O
cytolytic	O
effectors	O
and	O
related	O
proteins	O
mediating	O
tumor	B-Anatomy
cell	I-Anatomy
apoptosis	O
?	O
Apoptosis	O
is	O
a	O
regulated	O
form	O
of	O
cell	B-Anatomy
death	O
that	O
may	O
be	O
triggered	O
by	O
natural	B-Anatomy
killer	I-Anatomy
(	O
NK	B-Anatomy
)	O
or	O
cytotoxic	B-Anatomy
T	I-Anatomy
cells	I-Anatomy
,	O
which	O
effect	O
target	O
cell	B-Anatomy
lysis	O
by	O
cytolytic	O
effector	O
and	O
related	O
proteins	O
through	O
complex	O
intracellular	B-Anatomy
signals	O
.	O
This	O
study	O
was	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
selective	O
expression	O
of	O
these	O
cytolytic	O
markers	O
in	O
the	O
putative	O
NK	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lymphomas	I-Anatomy
and	O
whether	O
there	O
is	O
correlation	O
with	O
zonal	O
tumor	B-Anatomy
cell	I-Anatomy
death	O
in	O
these	O
tumors	B-Anatomy
.	O
Expression	O
of	O
the	O
cytolytic	O
effectors	O
perforin	O
,	O
granzyme	O
B9	O
,	O
and	O
the	O
granule	B-Anatomy
membrane	I-Anatomy
protein	O
TIA1	O
were	O
examined	O
in	O
24	O
putative	O
NK	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lymphomas	I-Anatomy
,	O
18	O
postthymic	B-Anatomy
T	I-Anatomy
-	I-Anatomy
cell	I-Anatomy
lymphomas	I-Anatomy
(	O
one	O
case	O
CD8	B-Anatomy
+	I-Anatomy
CD56	I-Anatomy
+	I-Anatomy
and	O
three	O
anaplastic	B-Anatomy
large	I-Anatomy
cell	I-Anatomy
lymphomas	I-Anatomy
(	O
ALCL	B-Anatomy
)	O
,	O
three	O
T	B-Anatomy
-	I-Anatomy
lymphoblastic	I-Anatomy
lymphomas	I-Anatomy
,	O
and	O
20	O
B	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lymphomas	I-Anatomy
.	O
Nineteen	O
(	O
79	O
%	O
)	O
putative	O
NK	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lymphomas	I-Anatomy
expressed	O
perforin	O
,	O
and	O
all	O
24	O
cases	O
expressed	O
granzyme	O
B9	O
and	O
TIA1	O
.	O
The	O
only	O
CD8	B-Anatomy
+	I-Anatomy
CD56	I-Anatomy
+	I-Anatomy
postthymic	I-Anatomy
T	I-Anatomy
-	I-Anatomy
cell	I-Anatomy
lymphoma	I-Anatomy
also	O
expressed	O
all	O
three	O
cytolytic	O
markers	O
,	O
two	O
CD8	B-Anatomy
-	I-Anatomy
ALCL	I-Anatomy
expressed	O
TIA1	O
;	O
other	O
postthymic	B-Anatomy
T	I-Anatomy
-	I-Anatomy
cell	I-Anatomy
,	O
T	B-Anatomy
-	I-Anatomy
lymphoblastic	I-Anatomy
,	O
and	O
B	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lymphomas	I-Anatomy
were	O
consistently	O
negative	O
.	O
There	O
was	O
strong	O
correlation	O
between	O
percentage	O
perforin	O
-	O
positive	O
cells	B-Anatomy
and	O
zonal	O
tumor	B-Anatomy
cell	I-Anatomy
death	O
.	O
Angioinvasion	O
,	O
in	O
contrast	O
,	O
was	O
present	O
only	O
in	O
a	O
proportion	O
(	O
37	O
%	O
)	O
of	O
these	O
lymphomas	B-Anatomy
despite	O
the	O
frequent	O
presence	O
of	O
zonal	O
tumor	B-Anatomy
cell	I-Anatomy
death	O
(	O
71	O
%	O
)	O
.	O
We	O
propose	O
that	O
cytolytic	O
effector	O
and	O
related	O
proteins	O
produced	O
by	O
putative	O
NK	B-Anatomy
and	O
some	O
CD8	B-Anatomy
+	I-Anatomy
CD56	I-Anatomy
+	I-Anatomy
postthymic	I-Anatomy
T	I-Anatomy
-	I-Anatomy
cell	I-Anatomy
lymphomas	I-Anatomy
,	O
probably	O
in	O
conjunction	O
with	O
other	O
mechanisms	O
,	O
may	O
effect	O
massive	O
tumor	B-Anatomy
cell	I-Anatomy
apoptosis	O
.	O
The	O
frequent	O
expression	O
of	O
cytolytic	O
effector	O
markers	O
in	O
the	O
CD2	B-Anatomy
+	I-Anatomy
surface	I-Anatomy
CD3	I-Anatomy
-	I-Anatomy
CD56	I-Anatomy
+	I-Anatomy
putative	I-Anatomy
NK	I-Anatomy
-	I-Anatomy
cell	I-Anatomy
lymphomas	I-Anatomy
lends	O
further	O
support	O
to	O
their	O
probable	O
NK	B-Anatomy
cell	I-Anatomy
origin	O
.	O
[	O
Extra	O
-	O
anatomic	O
bypass	O
from	O
the	O
ascending	B-Anatomy
aorta	I-Anatomy
to	O
the	O
supraceliac	O
abdominal	B-Anatomy
aorta	I-Anatomy
-	O
-	O
surgical	O
option	O
applied	O
to	O
reoperation	O
for	O
aortic	B-Anatomy
coarctation	O
or	O
interruption	O
]	O
.	O
The	O
optimal	O
approach	O
for	O
reoperation	O
following	O
repair	O
of	O
aortic	B-Anatomy
coarctation	O
(	O
CoA	O
)	O
or	O
interruption	O
(	O
IAA	O
)	O
remains	O
controversial	O
.	O
Four	O
patients	O
underwent	O
extra	O
-	O
anatomic	O
bypass	O
for	O
restenosis	O
after	O
repair	O
of	O
CoA	O
or	O
IAA	O
.	O
The	O
age	O
ranged	O
from	O
4	O
to	O
12	O
years	O
.	O
The	O
initial	O
repairs	O
for	O
two	O
CoA	O
,	O
one	O
type	O
A	O
-	O
IAA	O
,	O
and	O
one	O
type	O
B	O
-	O
IAA	O
consisted	O
of	O
two	O
grafting	O
,	O
one	O
subclavian	O
arterial	B-Anatomy
turning	O
-	O
down	O
aortoplasty	O
,	O
and	O
one	O
subclavian	O
flap	B-Anatomy
aortoplasty	O
.	O
All	O
of	O
them	O
underwent	O
during	O
infancy	O
.	O
Preoperative	O
right	B-Anatomy
arm	I-Anatomy
systolic	O
pressure	O
ranged	O
from	O
140	O
to	O
190	O
mmHg	O
ar	O
rest	O
.	O
Through	O
a	O
midline	O
sternotomy	O
and	O
an	O
upper	O
laparotmy	O
incision	O
,	O
an	O
extra	O
-	O
anatomic	O
bypass	O
from	O
the	O
ascending	B-Anatomy
aorta	I-Anatomy
to	O
the	O
supraceliac	O
abdominal	B-Anatomy
aorta	I-Anatomy
was	O
employed	O
using	O
a	O
12	O
to	O
18	O
mm	O
tube	O
graft	O
.	O
All	O
patients	O
survived	O
surgeries	O
,	O
and	O
their	O
hypertension	O
markedly	O
improved	O
.	O
Our	O
experience	O
confirms	O
safety	O
and	O
effectiveness	O
of	O
this	O
option	O
in	O
selected	O
young	O
patients	O
with	O
re	O
-	O
stenosis	O
of	O
following	O
repair	O
of	O
CoA	O
or	O
IAA	O
.	O
Effect	O
of	O
a	O
mutation	O
in	O
the	O
anticodon	O
of	O
human	O
mitochondrial	B-Anatomy
tRNAPro	O
on	O
its	O
post	O
-	O
transcriptional	O
modification	O
pattern	O
.	O
Although	O
the	O
gene	O
sequences	O
of	O
all	O
22	O
tRNAs	O
encoded	O
in	O
the	O
human	O
mitochondrial	B-Anatomy
genome	I-Anatomy
are	O
known	O
,	O
little	O
information	O
exists	O
about	O
their	O
sequences	O
at	O
the	O
RNA	O
level	O
.	O
This	O
becomes	O
a	O
crucial	O
limitation	O
when	O
searching	O
for	O
a	O
molecular	O
understanding	O
of	O
the	O
growing	O
number	O
of	O
maternally	O
inherited	O
human	O
diseases	O
correlated	O
with	O
point	O
mutations	O
in	O
tRNA	O
genes	O
.	O
Here	O
we	O
describe	O
the	O
sequence	O
of	O
human	O
mt	O
-	O
tRNAPropurified	O
from	O
placenta	B-Anatomy
.	O
It	O
shows	O
absence	O
of	O
editing	O
events	O
in	O
this	O
tRNA	O
and	O
highlights	O
the	O
presence	O
of	O
eight	O
post	O
-	O
transcriptional	O
modifications	O
.	O
These	O
include	O
T54	O
,	O
never	O
found	O
so	O
far	O
in	O
an	O
animal	O
mt	O
-	O
tRNA	O
,	O
and	O
m1G37	O
,	O
a	O
modification	O
known	O
to	O
have	O
fundamental	O
functional	O
properties	O
in	O
a	O
number	O
of	O
canonical	O
tRNAs	O
.	O
Occurrence	O
of	O
m1G37	O
was	O
further	O
investigated	O
in	O
an	O
analysis	O
of	O
the	O
substrate	O
properties	O
of	O
in	O
vitro	O
transcripts	O
of	O
human	O
mt	O
-	O
tRNAProtowards	O
pure	O
Escherichia	O
coli	O
methylguanosine	O
transferase	O
.	O
This	O
enzyme	O
properly	O
methylates	O
G37	O
in	O
mt	O
-	O
tRNA	O
and	O
is	O
sensitive	O
to	O
the	O
presence	O
of	O
a	O
second	O
G	O
at	O
position	O
36	O
,	O
neighboring	O
the	O
target	O
nucleotide	O
for	O
methylation	O
.	O
Since	O
mutation	O
of	O
nt	O
36	O
was	O
shown	O
to	O
be	O
correlated	O
with	O
myopathy	O
,	O
the	O
potential	O
consequences	O
of	O
non	O
-	O
modification	O
or	O
under	O
-	O
modification	O
of	O
mt	O
-	O
tRNA	O
nucleotides	O
in	O
expression	O
of	O
the	O
particular	O
myopathy	O
and	O
of	O
mitochondrial	B-Anatomy
diseases	O
in	O
general	O
are	O
discussed	O
.	O
Clozapine	O
-	O
induced	O
agranulocytosis	O
and	O
thrombopenia	O
in	O
a	O
patient	O
with	O
dopaminergic	O
psychosis	O
.	O
In	O
patients	O
with	O
Parkinson	O
'	O
disease	O
and	O
dopaminergic	O
psychosis	O
,	O
clozapine	O
treatment	O
is	O
recommended	O
as	O
the	O
drug	O
is	O
free	O
from	O
extrapyramidal	O
side	O
effects	O
and	O
does	O
not	O
worsen	O
motor	O
symptoms	O
of	O
the	O
underlying	O
disease	O
.	O
The	O
use	O
of	O
clozapine	O
,	O
however	O
,	O
is	O
limited	O
due	O
to	O
its	O
hematotoxic	O
side	O
effects	O
.	O
For	O
treatment	O
of	O
clozapine	O
-	O
induced	O
agranulocytosis	O
,	O
granulocyte	O
colony	O
-	O
stimulating	O
factors	O
(	O
G	O
-	O
CSF	O
)	O
are	O
recommended	O
.	O
We	O
report	O
the	O
case	O
of	O
a	O
72	O
-	O
years	O
-	O
old	O
male	O
patient	O
with	O
clozapine	O
-	O
induced	O
agranulocytosis	O
and	O
thrombopenia	O
.	O
Neutropenia	O
was	O
successfully	O
treated	O
with	O
G	O
-	O
CSF	O
,	O
but	O
thrombopenia	O
persisted	O
and	O
resolved	O
spontaneously	O
after	O
14	O
days	O
.	O
Bone	B-Anatomy
marrow	I-Anatomy
toxicity	O
of	O
clozapine	O
is	O
not	O
restricted	O
to	O
white	B-Anatomy
cell	I-Anatomy
maturation	O
,	O
but	O
may	O
also	O
impair	O
thrombocytopoesis	O
.	O
Prophylactic	O
thyroidectomy	O
in	O
MEN	B-Anatomy
IIA	I-Anatomy
:	O
does	O
the	O
calcitonin	O
level	O
correlate	O
with	O
tumor	B-Anatomy
spread	O
?	O
BACKGROUND	O
:	O
The	O
fate	O
of	O
patients	O
with	O
multiple	B-Anatomy
endocrine	I-Anatomy
neoplasia	I-Anatomy
of	I-Anatomy
type	I-Anatomy
II	I-Anatomy
A	I-Anatomy
(	O
MEN	B-Anatomy
II	I-Anatomy
A	I-Anatomy
)	O
is	O
determined	O
by	O
medullary	B-Anatomy
thyroid	I-Anatomy
carcinoma	I-Anatomy
,	O
which	O
occurs	O
in	O
all	O
cases	O
.	O
This	O
has	O
led	O
to	O
the	O
therapeutic	O
concept	O
of	O
prophylactic	O
thyroidectomy	O
in	O
affected	O
family	O
members	O
with	O
the	O
goal	O
of	O
removing	O
the	O
thyroid	B-Anatomy
before	O
the	O
manifestation	O
of	O
carcinoma	B-Anatomy
.	O
We	O
investigated	O
a	O
prophylactically	O
thyroidectomized	O
MEN	B-Anatomy
II	I-Anatomy
A	I-Anatomy
population	O
to	O
determine	O
whether	O
the	O
highly	O
specific	O
and	O
sensitive	O
tumor	B-Anatomy
marker	O
calcitonin	O
correlates	O
with	O
tumor	B-Anatomy
spread	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Fifteen	O
patients	O
with	O
MEN	B-Anatomy
II	I-Anatomy
A	I-Anatomy
(	O
aged	O
4	O
-	O
24	O
years	O
)	O
who	O
had	O
undergone	O
prophylactic	O
thyroidectomy	O
since	O
1990	O
were	O
included	O
in	O
the	O
study	O
.	O
Baseline	O
and	O
pentagastrin	O
-	O
stimulated	O
calcitonin	O
levels	O
were	O
preoperatively	O
determined	O
in	O
all	O
cases	O
.	O
The	O
indication	O
for	O
surgery	O
was	O
established	O
on	O
the	O
basis	O
of	O
pathologic	O
calcitonin	O
levels	O
in	O
the	O
first	O
seven	O
patients	O
and	O
on	O
the	O
basis	O
of	O
detected	O
RET	O
proto	O
-	O
oncogene	O
mutation	O
in	O
the	O
other	O
eight	O
patients	O
.	O
Bilateral	O
central	O
lymphadenectomy	O
was	O
performed	O
in	O
all	O
patients	O
in	O
addition	O
to	O
thyroidectomy	O
.	O
RESULTS	O
:	O
Histology	O
demonstrated	O
C	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
hyperplasia	O
in	O
five	O
patients	O
(	O
aged	O
4	O
-	O
13	O
years	O
)	O
,	O
unilateral	O
medullary	B-Anatomy
microcarcinoma	I-Anatomy
in	O
six	O
(	O
aged	O
9	O
-	O
17	O
years	O
)	O
and	O
a	O
bilateral	O
medullary	B-Anatomy
microcarcinoma	I-Anatomy
in	O
three	O
cases	O
(	O
aged	O
17	O
-	O
24	O
years	O
)	O
.	O
One	O
9	O
-	O
year	O
-	O
old	O
boy	O
with	O
bilateral	O
microcarcinoma	B-Anatomy
already	O
had	O
a	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
.	O
The	O
mean	O
baseline	O
calcitonin	O
level	O
correlated	O
with	O
the	O
histologic	O
findings	O
(	O
r	O
=	O
0	O
.	O
71	O
,	O
P	O
=	O
0	O
.	O
003	O
)	O
but	O
there	O
was	O
no	O
correlation	O
between	O
pentagastrin	O
-	O
stimulated	O
calcitonin	O
levels	O
and	O
histology	O
(	O
r	O
=	O
0	O
.	O
21	O
,	O
P	O
=	O
0	O
.	O
47	O
)	O
.	O
CONCLUSION	O
:	O
In	O
MEN	B-Anatomy
II	I-Anatomy
A	I-Anatomy
patients	O
undergoing	O
prophylactic	O
thyroidectomy	O
,	O
baseline	O
but	O
not	O
stimulated	O
calcitonin	O
levels	O
already	O
correlate	O
with	O
the	O
histologic	O
tumor	B-Anatomy
stage	O
at	O
the	O
stage	O
of	O
clinically	O
occult	O
C	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
hyperplasia	O
or	O
medullary	B-Anatomy
microcarcinoma	I-Anatomy
.	O
However	O
,	O
biochemical	O
screening	O
cannot	O
reliably	O
discriminate	O
the	O
transition	O
from	O
C	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
hyperplasia	O
to	O
invasive	B-Anatomy
microcarcinoma	I-Anatomy
.	O
Individuals	O
with	O
MEN	B-Anatomy
IIA	I-Anatomy
should	O
therefore	O
undergo	O
early	O
prophylactic	O
thyroidectomy	O
once	O
the	O
diagnosis	O
is	O
confirmed	O
by	O
molecular	O
genetic	O
testing	O
.	O
Induction	O
of	O
Ets	O
-	O
1	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
during	O
reendothelialization	O
after	O
denuding	O
injury	O
.	O
Ets	O
-	O
1	O
,	O
a	O
transcription	O
factor	O
,	O
is	O
induced	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
(	O
ECs	B-Anatomy
)	O
during	O
angiogenesis	O
.	O
Here	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
Ets	O
-	O
1	O
during	O
reendothelialization	O
.	O
When	O
a	O
confluent	O
monolayer	B-Anatomy
of	O
human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
ECV304	B-Anatomy
,	O
was	O
denuded	O
,	O
ECV304	B-Anatomy
at	O
the	O
wound	B-Anatomy
edge	I-Anatomy
expressed	O
Ets	O
-	O
1	O
.	O
An	O
immunohistochemical	O
analysis	O
revealed	O
that	O
Ets	O
-	O
1	O
accumulated	O
in	O
migrating	B-Anatomy
cells	I-Anatomy
at	O
the	O
wound	B-Anatomy
edge	I-Anatomy
and	O
returned	O
to	O
basal	O
level	O
when	O
reendothelialization	O
was	O
accomplished	O
.	O
This	O
induction	O
of	O
Ets	O
-	O
1	O
could	O
be	O
reproduced	O
in	O
in	O
vivo	O
denudation	O
of	O
rat	O
aortic	B-Anatomy
endothelium	I-Anatomy
by	O
a	O
balloon	O
catheter	O
.	O
The	O
induction	O
of	O
Ets	O
-	O
1	O
in	O
ECs	B-Anatomy
after	O
denudation	O
was	O
regulated	O
transcriptionally	O
,	O
and	O
humeral	O
factors	O
released	O
from	O
injured	O
ECs	B-Anatomy
might	O
not	O
be	O
responsible	O
.	O
Mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
activities	O
were	O
investigated	O
to	O
explore	O
the	O
mechanism	O
of	O
this	O
induction	O
.	O
Although	O
extracellular	O
signal	O
-	O
regulated	O
protein	O
kinase	O
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
,	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
1	O
(	O
JNK1	O
)	O
,	O
and	O
p38	O
were	O
activated	O
after	O
denudation	O
,	O
the	O
activation	O
of	O
ERK1	O
and	O
p38	O
was	O
more	O
rapid	O
and	O
prominent	O
.	O
PD98059	O
,	O
a	O
specific	O
MAPK	O
/	O
ERK	O
kinase	O
(	O
MEK	O
)	O
1	O
inhibitor	O
,	O
did	O
not	O
affect	O
the	O
induction	O
of	O
ets	O
-	O
1	O
mRNA	O
,	O
whereas	O
SB203580	O
,	O
a	O
specific	O
p38	O
inhibitor	O
,	O
almost	O
completely	O
abrogated	O
its	O
induction	O
.	O
These	O
results	O
indicate	O
that	O
Ets	O
-	O
1	O
is	O
induced	O
in	O
ECs	B-Anatomy
after	O
denudation	O
through	O
activation	O
of	O
p38	O
.	O
This	O
induction	O
of	O
Ets	O
-	O
1	O
may	O
be	O
relevant	O
for	O
reendothelialization	O
by	O
regulating	O
the	O
expression	O
of	O
certain	O
genes	O
.	O
SV40	O
Tag	O
transformation	O
of	O
the	O
normal	O
invasive	O
trophoblast	B-Anatomy
results	O
in	O
a	O
premalignant	O
phenotype	O
.	O
I	O
.	O
Mechanisms	O
responsible	O
for	O
hyperinvasiveness	O
and	O
resistance	O
to	O
anti	O
-	O
invasive	O
action	O
of	O
TGFbeta	O
.	O
Invasion	O
of	O
the	O
uterus	B-Anatomy
by	O
first	O
trimester	O
human	O
placental	B-Anatomy
extravillous	I-Anatomy
trophoblast	I-Anatomy
(	I-Anatomy
EVT	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
depends	O
on	O
mechanisms	O
shared	O
by	O
malignant	B-Anatomy
cells	I-Anatomy
.	O
However	O
,	O
unlike	O
tumor	B-Anatomy
invasion	O
,	O
trophoblast	B-Anatomy
invasion	O
of	O
the	O
uterus	B-Anatomy
is	O
stringently	O
controlled	O
in	O
situ	O
by	O
local	O
molecules	O
such	O
as	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
beta	O
.	O
Since	O
EVT	B-Anatomy
cells	I-Anatomy
possess	O
active	O
invasion	O
-	O
associated	O
genes	O
but	O
are	O
nontumorigenic	O
,	O
our	O
objective	O
was	O
to	O
induce	O
premalignant	O
and	O
then	O
malignant	O
phenotype	O
into	O
a	O
normal	O
EVT	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
in	O
order	O
to	O
identify	O
the	O
molecular	O
basis	O
of	O
tumor	B-Anatomy
progression	O
.	O
Simian	O
virus	O
40	O
large	O
T	O
antigen	O
(	O
SV40	O
Tag	O
)	O
was	O
introduced	O
into	O
a	O
normal	O
human	O
first	O
trimester	O
invasive	O
EVT	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
HTR8	B-Anatomy
,	O
established	O
in	O
our	O
laboratory	O
.	O
Since	O
the	O
HTR8	B-Anatomy
line	I-Anatomy
has	O
a	O
limited	O
in	O
vitro	O
lifespan	O
of	O
12	O
-	O
15	O
passages	O
,	O
SV40	O
Tag	O
-	O
transformed	O
cells	B-Anatomy
were	O
selected	O
on	O
the	O
basis	O
of	O
extended	O
lifespan	O
.	O
A	O
long	O
-	O
lived	O
line	B-Anatomy
,	O
RSVT	B-Anatomy
-	I-Anatomy
2	I-Anatomy
,	O
was	O
produced	O
and	O
an	O
immortalized	O
subclone	B-Anatomy
,	O
RSVT2	B-Anatomy
/	I-Anatomy
C	I-Anatomy
,	O
was	O
further	O
derived	O
under	O
a	O
forced	O
crisis	O
regimen	O
.	O
We	O
examined	O
transformation	O
-	O
induced	O
alterations	O
in	O
proliferative	O
and	O
invasive	O
abilities	O
,	O
responses	O
to	O
the	O
invasion	O
and	O
proliferation	O
-	O
regulating	O
growth	O
factor	O
TGFbeta	O
and	O
changes	O
in	O
gene	O
expression	O
for	O
invasion	O
-	O
associated	O
enzymes	O
or	O
enzyme	O
inhibitors	O
.	O
RSVT	B-Anatomy
-	I-Anatomy
2	I-Anatomy
and	O
RSVT2	B-Anatomy
/	I-Anatomy
C	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
were	O
hyperproliferative	O
and	O
hyperinvasive	O
when	O
compared	O
with	O
the	O
parental	O
HTR8	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
.	O
They	O
were	O
also	O
variably	O
resistant	O
to	O
the	O
anti	O
-	O
proliferative	O
and	O
anti	O
-	O
invasive	O
signals	O
from	O
TGFbeta	O
.	O
Since	O
both	O
cell	B-Anatomy
lines	I-Anatomy
remained	O
non	O
-	O
tumorigenic	O
in	O
nude	O
mice	O
,	O
these	O
properties	O
indicate	O
that	O
they	O
attained	O
a	O
premalignant	O
phenotype	O
.	O
Both	O
cell	B-Anatomy
lines	I-Anatomy
showed	O
reduced	O
expression	O
of	O
tissue	O
inhibitor	O
of	O
metalloproteases	O
(	O
TIMP	O
)	O
-	O
1	O
,	O
while	O
TIMP	O
-	O
2	O
and	O
plasminogen	O
activator	O
inhibitor	O
(	O
PAI	O
)	O
-	O
I	O
expression	O
was	O
was	O
also	O
reduced	O
in	O
RSVT2	B-Anatomy
/	I-Anatomy
C	I-Anatomy
cells	I-Anatomy
,	O
thus	O
contributing	O
to	O
their	O
hyperinvasiveness	O
.	O
Their	O
resistance	O
to	O
the	O
anti	O
-	O
invasive	O
action	O
of	O
TGFbeta	O
was	O
explained	O
by	O
the	O
failure	O
of	O
TGFbeta	O
to	O
upregulate	O
TIMPs	O
and	O
PAI	O
-	O
I	O
,	O
in	O
contrast	O
to	O
the	O
TGFbeta	O
-	O
induced	O
upregulation	O
noted	O
in	O
parental	O
HTR8	B-Anatomy
cells	I-Anatomy
.	O
Acylase	O
I	O
-	O
catalyzed	O
deacetylation	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
and	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
.	O
The	O
aminoacylase	O
that	O
catalyzes	O
the	O
hydrolysis	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
was	O
identified	O
as	O
acylase	O
I	O
after	O
purification	O
by	O
column	O
chromatography	O
and	O
electrophoretic	O
analysis	O
.	O
Rat	O
kidney	B-Anatomy
cytosol	I-Anatomy
was	O
fractionated	O
by	O
ammonium	O
sulfate	O
precipitation	O
,	O
and	O
the	O
proteins	O
were	O
separated	O
by	O
ion	O
-	O
exchange	O
column	O
chromatography	O
,	O
gel	O
-	O
filtration	O
column	O
chromatography	O
,	O
and	O
hydrophobic	O
interaction	O
column	O
chromatography	O
.	O
Acylase	O
activity	O
with	O
NAC	O
and	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
methionine	O
(	O
NAM	O
)	O
,	O
a	O
known	O
substrate	O
for	O
acylase	O
I	O
,	O
as	O
substrates	O
coeluted	O
during	O
all	O
chromatographic	O
steps	O
.	O
Sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
showed	O
that	O
the	O
protein	O
was	O
purified	O
to	O
near	O
homogeneity	O
and	O
had	O
a	O
subunit	O
Mr	O
of	O
43	O
000	O
,	O
which	O
is	O
identical	O
with	O
the	O
Mr	O
of	O
acylase	O
I	O
from	O
porcine	O
kidney	B-Anatomy
and	O
bovine	O
liver	B-Anatomy
.	O
n	O
-	O
Butylmalonic	O
acid	O
was	O
a	O
slow	O
-	O
binding	O
inhibitor	O
of	O
acylase	O
I	O
and	O
inhibited	O
the	O
deacetylation	O
of	O
NAC	O
with	O
a	O
Ki	O
of	O
192	O
+	O
/	O
-	O
27	O
microM	O
.	O
These	O
results	O
show	O
that	O
acylase	O
I	O
catalyzes	O
the	O
deacetylation	O
of	O
NAC	O
.	O
The	O
acylase	O
I	O
-	O
catalyzed	O
deacetylation	O
of	O
a	O
range	O
of	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
,	O
their	O
carbon	O
and	O
oxygen	O
analogues	O
,	O
and	O
the	O
selenium	O
analogue	O
of	O
NAM	O
was	O
also	O
studied	O
with	O
porcine	O
kidney	B-Anatomy
acylase	O
I	O
.	O
The	O
specific	O
activity	O
of	O
the	O
acylase	O
I	O
-	O
catalyzed	O
deacetylation	O
of	O
these	O
substrates	O
was	O
related	O
to	O
their	O
calculated	O
molar	O
volumes	O
and	O
log	O
P	O
values	O
.	O
The	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
with	O
short	O
(	O
C0	O
-	O
C3	O
)	O
and	O
unbranched	O
S	O
-	O
alkyl	O
substituents	O
were	O
good	O
acylase	O
I	O
substrates	O
,	O
whereas	O
the	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
with	O
long	O
(	O
>	O
C3	O
)	O
and	O
branched	O
S	O
-	O
alkyl	O
substituents	O
were	O
poLr	O
acylase	O
I	O
substrates	O
.	O
The	O
carbon	O
and	O
oxygen	O
analogues	O
of	O
S	O
-	O
methyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
and	O
the	O
carbon	O
analogue	O
of	O
S	O
-	O
ethyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
were	O
poor	O
acylase	O
I	O
substrates	O
,	O
whereas	O
the	O
selenium	O
analogue	O
of	O
NAM	O
was	O
a	O
good	O
acylase	O
I	O
substrate	O
.	O
Expression	O
of	O
two	O
type	O
II	O
-	O
like	O
tumor	O
hexokinase	O
RNA	O
transcripts	O
in	O
cancer	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
To	O
maintain	O
an	O
elevated	O
glycolytic	O
rate	O
,	O
cancerous	B-Anatomy
or	O
proliferating	O
cells	B-Anatomy
alter	O
the	O
expression	O
pattern	O
of	O
rate	O
limiting	O
glycolytic	O
enzymes	O
.	O
Since	O
glucose	O
phosphorylation	O
is	O
the	O
first	O
step	O
in	O
glycolysis	O
,	O
hexokinase	O
(	O
HK	O
)	O
,	O
the	O
first	O
rate	O
limiting	O
glycolytic	O
enzyme	O
,	O
can	O
play	O
a	O
key	O
regulatory	O
role	O
in	O
this	O
process	O
.	O
A	O
low	O
-	O
Km	O
,	O
mitochondrial	B-Anatomy
type	O
II	O
-	O
like	O
tumor	O
HK	O
is	O
described	O
as	O
the	O
predominant	O
form	O
in	O
hepatomas	B-Anatomy
.	O
However	O
,	O
recent	O
identification	O
of	O
a	O
high	O
-	O
Km	O
glucose	O
phosphorylating	O
activity	O
in	O
a	O
range	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
prompted	O
us	O
to	O
characterize	O
glucose	O
phosphorylating	O
enzymes	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
at	O
the	O
molecular	O
level	O
.	O
Highly	O
sensitive	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
identifies	O
an	O
induction	O
and	O
overexpression	O
of	O
a	O
type	O
II	O
-	O
like	O
tumor	O
HK	O
RNA	O
in	O
a	O
range	O
of	O
cancer	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
irrespective	O
of	O
tissue	B-Anatomy
origin	O
.	O
In	O
addition	O
,	O
we	O
report	O
here	O
the	O
identification	O
of	O
two	O
RNA	O
transcripts	O
of	O
type	O
II	O
-	O
like	O
tumor	O
HK	O
of	O
approximately	O
5	O
.	O
5	O
and	O
approximately	O
4	O
.	O
0	O
kb	O
in	O
these	O
cancer	B-Anatomy
cells	I-Anatomy
lines	I-Anatomy
,	O
including	O
muscle	B-Anatomy
-	O
derived	O
L6	B-Anatomy
myoblast	I-Anatomy
cells	I-Anatomy
.	O
Interestingly	O
,	O
under	O
normal	O
conditions	O
muscle	B-Anatomy
cells	I-Anatomy
express	O
only	O
a	O
approximately	O
5	O
.	O
5	O
-	O
kb	O
type	O
II	O
HK	O
RNA	O
transcript	O
.	O
A	O
significant	O
amount	O
of	O
type	O
I	O
HK	O
RNA	O
was	O
also	O
found	O
expressed	O
in	O
cancer	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
RNA	O
encoding	O
glucokinase	O
(	O
GK	O
)	O
,	O
the	O
high	O
-	O
Km	O
HK	O
isozyme	O
,	O
was	O
found	O
only	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
originating	O
from	O
liver	B-Anatomy
and	O
pancreas	B-Anatomy
,	O
which	O
express	O
GK	O
under	O
normal	O
conditions	O
.	O
Homeobox	O
genes	O
in	O
hematopoiesis	O
and	O
leukemogenesis	O
.	O
Homeobox	O
genes	O
have	O
a	O
strikingly	O
conserved	O
61	O
-	O
amino	O
acid	O
sequence	O
,	O
encoding	O
DNA	O
-	O
binding	O
domain	O
.	O
Some	O
homeobox	O
genes	O
,	O
located	O
in	O
four	O
clusters	O
are	O
designated	O
HOX	O
A	O
through	O
D	O
,	O
while	O
others	O
are	O
known	O
as	O
divergent	O
homeobox	O
genes	O
.	O
Many	O
researchers	O
have	O
demonstrated	O
that	O
hematopoietic	B-Anatomy
cells	I-Anatomy
express	O
many	O
homeobox	O
genes	O
.	O
Induced	O
over	O
-	O
and	O
under	O
-	O
expression	O
of	O
these	O
genes	O
has	O
been	O
used	O
to	O
demonstrate	O
their	O
affect	O
on	O
some	O
aspects	O
of	O
hematopoiesis	O
and	O
leukemogenesis	O
.	O
Recently	O
,	O
knock	O
-	O
out	O
mice	O
of	O
homeobox	O
genes	O
by	O
targeted	O
disruption	O
have	O
also	O
been	O
used	O
to	O
examine	O
their	O
hematological	O
effect	O
.	O
There	O
are	O
examples	O
of	O
the	O
aberrant	O
expression	O
of	O
a	O
homeobox	O
gene	O
causing	O
leukemias	B-Anatomy
in	O
humans	O
.	O
In	O
pre	B-Anatomy
-	I-Anatomy
B	I-Anatomy
acute	I-Anatomy
lymphoblastic	I-Anatomy
leukemia	I-Anatomy
(	O
ALL	B-Anatomy
)	O
with	O
t	O
(	O
1	O
;	O
19	O
)	O
translocation	O
,	O
a	O
fusion	O
protein	O
is	O
created	O
between	O
E2A	O
and	O
a	O
homeobox	O
gene	O
PBX	O
.	O
In	O
T	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
ALL	I-Anatomy
with	O
t	O
(	O
10	O
;	O
14	O
)	O
translocation	O
,	O
the	O
HOX	O
11	O
gene	O
is	O
deregulated	O
.	O
In	O
acute	B-Anatomy
myeloid	I-Anatomy
leukemia	I-Anatomy
(	O
AML	B-Anatomy
)	O
with	O
t	O
(	O
7	O
;	O
11	O
)	O
translocation	O
,	O
the	O
HOX	O
A9	O
gene	O
is	O
rearranged	O
.	O
In	O
this	O
review	O
article	O
,	O
many	O
functions	O
of	O
homeobox	O
genes	O
both	O
at	O
the	O
early	O
stem	B-Anatomy
cell	I-Anatomy
level	O
as	O
well	O
as	O
at	O
the	O
later	O
stages	O
of	O
hematopoietic	B-Anatomy
differentiation	O
,	O
and	O
the	O
leukemogenic	O
effect	O
of	O
altered	O
homeobox	O
genes	O
are	O
discussed	O
.	O
Store	O
-	O
operated	O
calcium	O
entry	O
promotes	O
shape	O
change	O
in	O
pulmonary	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
expressing	O
Trp1	O
.	O
Activation	O
of	O
Ca2	O
+	O
entry	O
is	O
known	O
to	O
produce	O
endothelial	B-Anatomy
cell	I-Anatomy
shape	O
change	O
,	O
leading	O
to	O
increased	O
permeability	O
,	O
leukocyte	B-Anatomy
migration	O
,	O
and	O
initiation	O
of	O
angiogenesis	O
in	O
conduit	B-Anatomy
-	I-Anatomy
vessel	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
The	O
mode	O
of	O
Ca2	O
+	O
entry	O
regulating	O
cell	B-Anatomy
shape	O
is	O
unknown	O
.	O
We	O
hypothesized	O
that	O
activation	O
of	O
store	O
-	O
operated	O
Ca2	O
+	O
channels	O
(	O
SOCs	O
)	O
is	O
sufficient	O
to	O
promote	O
cell	B-Anatomy
shape	O
change	O
necessary	O
for	O
these	O
processes	O
.	O
SOC	O
activation	O
in	O
rat	O
pulmonary	B-Anatomy
arterial	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
increased	O
free	O
cytosolic	B-Anatomy
Ca2	O
+	O
that	O
was	O
dependent	O
on	O
a	O
membrane	B-Anatomy
current	O
having	O
a	O
net	O
inward	O
component	O
of	O
5	O
.	O
45	O
+	O
/	O
-	O
0	O
.	O
90	O
pA	O
/	O
pF	O
at	O
-	O
80	O
mV	O
.	O
Changes	O
in	O
endothelial	B-Anatomy
cell	I-Anatomy
shape	O
accompanied	O
SOC	O
activation	O
and	O
were	O
dependent	O
on	O
Ca2	O
+	O
entry	O
-	O
induced	O
reconfiguration	O
of	O
peripheral	O
(	O
cortical	B-Anatomy
)	O
filamentous	B-Anatomy
actin	O
(	O
F	O
-	O
actin	O
)	O
.	O
Because	O
the	O
identity	O
of	O
pulmonary	B-Anatomy
endothelial	I-Anatomy
SOCs	O
is	O
unknown	O
,	O
but	O
mammalian	O
homologues	O
of	O
the	O
Drosophila	O
melanogaster	O
transient	O
receptor	O
potential	O
(	O
trp	O
)	O
gene	O
have	O
been	O
proposed	O
to	O
form	O
Ca2	O
+	O
entry	O
channels	O
in	O
nonexcitable	O
cells	B-Anatomy
,	O
we	O
performed	O
RT	O
-	O
PCR	O
using	O
Trp	O
oligonucleotide	O
primers	O
in	O
both	O
rat	O
and	O
human	O
pulmonary	B-Anatomy
arterial	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
Both	O
cell	B-Anatomy
types	O
were	O
found	O
to	O
express	O
Trp1	O
,	O
but	O
neither	O
expressed	O
Trp3	O
nor	O
Trp6	O
.	O
Our	O
study	O
indicates	O
that	O
1	O
)	O
Ca2	O
+	O
entry	O
in	O
pulmonary	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
through	O
SOCs	O
produces	O
cell	B-Anatomy
shape	O
change	O
that	O
is	O
dependent	O
on	O
site	O
-	O
specific	O
rearrangement	O
of	O
the	O
microfilamentous	B-Anatomy
cytoskeleton	I-Anatomy
and	O
2	O
)	O
Trp1	O
may	O
be	O
a	O
component	O
of	O
pulmonary	B-Anatomy
endothelial	I-Anatomy
SOCs	O
.	O
Hemispheric	O
control	O
of	O
motor	O
function	O
:	O
a	O
whole	O
brain	B-Anatomy
echo	O
planar	O
fMRI	O
study	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
whether	O
recruitment	O
of	O
the	O
ipsilateral	B-Anatomy
motor	I-Anatomy
cortex	I-Anatomy
during	O
non	O
-	O
dominant	O
motor	O
movement	O
reflects	O
left	B-Anatomy
hemispheric	I-Anatomy
control	O
of	O
motor	O
function	O
or	O
simply	O
the	O
greater	O
complexity	O
or	O
unfamiliarity	O
of	O
the	O
motor	O
task	O
.	O
BOLD	O
fMRI	O
was	O
performed	O
in	O
normal	O
right	O
-	O
handers	O
during	O
two	O
motor	O
tasks	O
:	O
(	O
1	O
)	O
sequential	O
finger	B-Anatomy
movements	O
(	O
SM	O
task	O
)	O
with	O
the	O
right	B-Anatomy
or	O
left	B-Anatomy
hand	I-Anatomy
;	O
and	O
(	O
2	O
)	O
random	O
finger	B-Anatomy
movements	O
(	O
RM	O
task	O
)	O
with	O
the	O
right	B-Anatomy
hand	I-Anatomy
.	O
In	O
all	O
subjects	O
,	O
activation	O
was	O
predominantly	O
in	O
the	O
contralateral	B-Anatomy
motor	I-Anatomy
areas	I-Anatomy
(	O
primary	B-Anatomy
sensorimotor	I-Anatomy
,	O
lateral	B-Anatomy
premotor	I-Anatomy
,	O
parietal	B-Anatomy
and	O
supplementary	B-Anatomy
motor	I-Anatomy
regions	I-Anatomy
)	O
and	O
ipsilateral	B-Anatomy
cerebellum	I-Anatomy
.	O
While	O
the	O
ipsilateral	B-Anatomy
motor	I-Anatomy
areas	I-Anatomy
were	O
also	O
activated	O
,	O
single	O
subject	O
analysis	O
revealed	O
these	O
areas	O
to	O
be	O
more	O
extensive	O
and	O
to	O
be	O
seen	O
in	O
more	O
subjects	O
during	O
the	O
non	O
-	O
dominant	O
hand	B-Anatomy
SM	O
task	O
and	O
dominant	O
hand	B-Anatomy
RM	O
task	O
than	O
during	O
the	O
more	O
familiar	O
dominant	O
hand	B-Anatomy
SM	O
task	O
.	O
Similarly	O
,	O
group	O
analysis	O
also	O
revealed	O
ipsilateral	O
activation	O
in	O
the	O
primary	B-Anatomy
sensorimotor	I-Anatomy
and	O
lateral	B-Anatomy
premotor	I-Anatomy
areas	I-Anatomy
,	O
but	O
only	O
during	O
the	O
non	O
-	O
dominant	O
SM	O
task	O
and	O
the	O
dominant	O
hand	B-Anatomy
RM	O
task	O
.	O
Non	O
-	O
dominant	O
hand	B-Anatomy
movements	O
,	O
perhaps	O
because	O
they	O
are	O
less	O
'	O
automatic	O
'	O
,	O
appear	O
to	O
require	O
more	O
cortical	B-Anatomy
activity	O
similar	O
to	O
complex	O
tasks	O
with	O
the	O
dominant	O
hand	B-Anatomy
,	O
and	O
result	O
in	O
greater	O
recruitment	O
of	O
ipsilateral	B-Anatomy
cortical	I-Anatomy
motor	I-Anatomy
areas	I-Anatomy
and	O
striatum	B-Anatomy
.	O
The	O
study	O
also	O
illustrates	O
how	O
potentially	O
meaningful	O
subtleties	O
seen	O
on	O
individual	O
maps	O
may	O
be	O
obscured	O
with	O
group	O
averaging	O
approaches	O
.	O
Glucose	O
and	O
lactate	O
metabolism	O
in	O
C6	B-Anatomy
glioma	I-Anatomy
cells	I-Anatomy
:	O
evidence	O
for	O
the	O
preferential	O
utilization	O
of	O
lactate	O
for	O
cell	B-Anatomy
oxidative	O
metabolism	O
.	O
13C	O
and	O
1H	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
(	O
NMR	O
)	O
was	O
used	O
to	O
investigate	O
the	O
metabolism	O
of	O
L	O
-	O
lactate	O
and	O
D	O
-	O
glucose	O
in	O
C6	B-Anatomy
glioma	I-Anatomy
cells	I-Anatomy
.	O
The	O
13C	O
enrichment	O
of	O
cell	B-Anatomy
metabolites	O
was	O
examined	O
after	O
a	O
4	O
-	O
h	O
incubation	O
in	O
media	O
containing	O
5	O
.	O
5	O
mM	O
glucose	O
and	O
11	O
mM	O
lactate	O
,	O
each	O
metabolite	O
being	O
alternatively	O
labelled	O
with	O
either	O
[	O
1	O
-	O
13C	O
]	O
D	O
-	O
glucose	O
or	O
[	O
3	O
-	O
13C	O
]	O
L	O
-	O
lactate	O
.	O
The	O
results	O
indicated	O
that	O
exogenous	O
lactate	O
was	O
the	O
major	O
substrate	O
for	O
oxidative	O
metabolism	O
.	O
They	O
were	O
consistent	O
with	O
the	O
concept	O
of	O
the	O
existence	O
of	O
2	O
pools	O
of	O
both	O
lactate	O
and	O
pyruvate	O
,	O
of	O
which	O
1	O
pool	O
was	O
closely	O
connected	O
with	O
exogenous	O
lactate	O
and	O
oxidative	O
metabolism	O
,	O
and	O
the	O
other	O
pool	O
was	O
closely	O
related	O
to	O
glycolysis	O
and	O
disconnected	O
from	O
oxidative	O
metabolism	O
.	O
The	O
molecular	O
basis	O
of	O
this	O
behaviour	O
could	O
be	O
related	O
to	O
different	O
locations	O
for	O
the	O
lactate	O
dehydrogenase	O
isoenzymes	O
,	O
as	O
suggested	O
by	O
their	O
immunohistochemical	O
labelling	O
.	O
Tumors	B-Anatomy
of	O
the	O
retinal	B-Anatomy
pigment	I-Anatomy
epithelium	I-Anatomy
metastasize	O
to	O
inguinal	B-Anatomy
lymph	I-Anatomy
nodes	I-Anatomy
and	O
spleen	B-Anatomy
in	O
tyrosinase	O
-	O
related	O
protein	O
1	O
/	O
SV40	O
T	O
antigen	O
transgenic	O
mice	O
.	O
The	O
pigment	B-Anatomy
epithelium	I-Anatomy
of	O
the	O
retina	B-Anatomy
(	O
RPE	B-Anatomy
)	O
is	O
derived	O
from	O
the	O
optic	B-Anatomy
cup	I-Anatomy
and	O
is	O
essential	O
for	O
function	O
and	O
development	O
of	O
the	O
eye	B-Anatomy
.	O
We	O
produced	O
a	O
transgenic	O
mouse	O
line	O
that	O
expresses	O
simian	O
virus	O
(	O
SV40	O
)	O
transforming	O
sequences	O
under	O
control	O
of	O
the	O
1	O
.	O
4	O
kb	O
tyrosinase	O
-	O
related	O
protein	O
1	O
(	O
TRP	O
-	O
1	O
)	O
promoter	O
,	O
targeting	O
expression	O
of	O
T	O
antigen	O
(	O
Tag	O
)	O
to	O
the	O
RPE	B-Anatomy
.	O
In	O
transgenic	O
embryos	B-Anatomy
,	O
RPE	B-Anatomy
cells	I-Anatomy
proliferated	O
in	O
the	O
anterior	B-Anatomy
part	I-Anatomy
of	O
the	O
eye	B-Anatomy
and	O
near	O
the	O
optic	B-Anatomy
nerve	I-Anatomy
.	O
This	O
resulted	O
in	O
formation	O
of	O
tumors	B-Anatomy
,	O
which	O
were	O
pigmented	O
and	O
of	O
epithelial	B-Anatomy
origin	O
.	O
In	O
3	O
months	O
-	O
old	O
mice	O
,	O
pigmented	B-Anatomy
cells	I-Anatomy
were	O
detected	O
in	O
spleen	B-Anatomy
and	O
inguinal	B-Anatomy
lymph	I-Anatomy
nodes	I-Anatomy
.	O
In	O
spleen	B-Anatomy
,	O
tyrosinase	O
,	O
TRP	O
-	O
1	O
and	O
SV40	O
Tag	O
were	O
expressed	O
and	O
tyrosinase	O
was	O
enzymatically	O
active	O
.	O
Pigmented	O
regions	O
were	O
positive	O
for	O
an	O
epithelial	B-Anatomy
marker	O
,	O
cytokeratin	O
.	O
Cell	B-Anatomy
lines	I-Anatomy
were	O
established	O
from	O
tumor	B-Anatomy
and	O
metastases	B-Anatomy
and	O
kept	O
in	O
culture	O
for	O
more	O
than	O
2	O
months	O
.	O
These	O
were	O
pigmented	O
,	O
and	O
maintained	O
expression	O
of	O
tyrosinase	O
,	O
TRP	O
-	O
1	O
,	O
cytokeratin	O
and	O
SV40	O
Tag	O
.	O
This	O
demonstrates	O
that	O
RPE	B-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
metastasize	O
to	O
lymph	B-Anatomy
node	I-Anatomy
and	O
spleen	B-Anatomy
.	O
In	O
conclusion	O
,	O
the	O
metastasis	O
from	O
TRP	B-Anatomy
-	I-Anatomy
1	I-Anatomy
/	I-Anatomy
Tag	I-Anatomy
RPE	I-Anatomy
tumors	I-Anatomy
towards	O
spleen	B-Anatomy
and	O
lymph	B-Anatomy
nodes	I-Anatomy
serves	O
as	O
potential	O
tool	O
to	O
investigate	O
biology	O
and	O
metastasis	O
of	O
tumors	B-Anatomy
derived	O
from	O
the	O
pigment	B-Anatomy
epithelium	I-Anatomy
.	O
Glucagon	O
induces	O
suppression	O
of	O
ATP	O
-	O
sensitive	O
K	O
+	O
channel	O
activity	O
through	O
a	O
Ca2	O
+	O
/	O
calmodulin	O
-	O
dependent	O
pathway	O
in	O
mouse	O
pancreatic	B-Anatomy
beta	I-Anatomy
-	I-Anatomy
cells	I-Anatomy
.	O
Glucagon	O
is	O
known	O
to	O
increase	O
intracellular	B-Anatomy
cAMP	O
levels	O
and	O
enhance	O
glucose	O
-	O
induced	O
electrical	O
activity	O
and	O
insulin	O
secretion	O
in	O
pancreatic	B-Anatomy
beta	I-Anatomy
-	I-Anatomy
cell	I-Anatomy
perfused	O
with	O
Krebs	O
-	O
Ringer	O
bicarbonate	O
solution	O
.	O
The	O
present	O
experiments	O
were	O
aimed	O
at	O
evaluation	O
of	O
the	O
hypothesis	O
that	O
changes	O
in	O
beta	B-Anatomy
-	I-Anatomy
cells	I-Anatomy
ATP	O
-	O
sensitive	O
K	O
+	O
(	O
K	O
(	O
ATP	O
)	O
)	O
channel	O
activity	O
are	O
involved	O
in	O
the	O
glucagon	O
-	O
induced	O
enhancement	O
of	O
electrical	O
activity	O
.	O
Channel	O
activity	O
was	O
recorded	O
using	O
the	O
cell	B-Anatomy
-	O
attached	O
configuration	O
of	O
the	O
patch	O
-	O
clamp	O
technique	O
.	O
Addition	O
of	O
glucagon	O
(	O
2	O
.	O
9	O
x	O
10	O
(	O
-	O
7	O
)	O
m	O
)	O
in	O
the	O
presence	O
of	O
11	O
.	O
1	O
mm	O
glucose	O
caused	O
closure	O
of	O
K	O
(	O
ATP	O
)	O
channels	O
followed	O
by	O
an	O
increase	O
in	O
the	O
frequency	O
of	O
biphasic	O
current	O
transients	O
(	O
action	O
currents	O
)	O
due	O
to	O
action	O
potential	O
generation	O
in	O
the	O
cell	B-Anatomy
.	O
Three	O
calmodulin	O
-	O
antagonists	O
(	O
W	O
-	O
7	O
,	O
chlorpromazine	O
,	O
and	O
trifluoperazine	O
)	O
restored	O
with	O
similar	O
efficacy	O
K	O
(	O
ATP	O
)	O
channel	O
activity	O
in	O
cells	B-Anatomy
being	O
exposed	O
to	O
glucagon	O
.	O
At	O
2	O
.	O
8	O
mm	O
glucose	O
,	O
glucagon	O
did	O
not	O
affect	O
K	O
(	O
ATP	O
)	O
channel	O
activity	O
until	O
Ca2	O
+	O
was	O
released	O
from	O
Nitr	O
-	O
5	O
by	O
flash	O
photolysis	O
,	O
at	O
which	O
point	O
channel	O
activity	O
was	O
transiently	O
suppressed	O
.	O
Similar	O
effects	O
were	O
seen	O
when	O
db	O
-	O
cAMP	O
was	O
used	O
instead	O
of	O
glucagon	O
.	O
These	O
results	O
support	O
the	O
view	O
that	O
glucagon	O
and	O
other	O
cAMP	O
-	O
generating	O
agonists	O
enhance	O
glucose	O
-	O
induced	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
electrical	O
activity	O
through	O
a	O
Ca2	O
+	O
/	O
calmodulin	O
dependent	O
-	O
closure	O
of	O
K	O
(	O
ATP	O
)	O
channels	O
.	O
Effect	O
of	O
U	O
-	O
995	O
,	O
a	O
potent	O
shark	O
cartilage	B-Anatomy
-	O
derived	O
angiogenesis	O
inhibitor	O
,	O
on	O
anti	O
-	O
angiogenesis	O
and	O
anti	O
-	O
tumor	B-Anatomy
activities	O
.	O
BACKGROUND	O
:	O
A	O
potent	O
angiogenesis	O
inhibitor	O
,	O
U	O
-	O
995	O
,	O
has	O
been	O
purified	O
from	O
the	O
cartilage	B-Anatomy
of	O
the	O
blue	O
shark	O
(	O
Prionace	O
glauca	O
)	O
.	O
U	O
-	O
995	O
is	O
composed	O
of	O
two	O
single	O
peptides	O
with	O
molecular	O
mass	O
of	O
10	O
and	O
14	O
kDa	O
,	O
respectively	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
U	O
-	O
995	O
was	O
designed	O
to	O
study	O
human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
(	O
HUVEC	B-Anatomy
)	O
migration	O
and	O
proliferation	O
in	O
vitro	O
and	O
angiogenesis	O
induced	O
by	O
TNF	O
alpha	O
in	O
chicken	O
chorioallantoic	B-Anatomy
membrane	I-Anatomy
(	O
CAM	B-Anatomy
)	O
.	O
Furthermore	O
,	O
we	O
determined	O
the	O
ability	O
of	O
U	O
-	O
995	O
to	O
inhibiting	O
tumor	B-Anatomy
cell	I-Anatomy
growth	O
and	O
metastasis	O
.	O
RESULTS	O
:	O
U	O
-	O
995	O
(	O
15	O
and	O
30	O
micrograms	O
/	O
ml	O
)	O
markedly	O
inhibited	O
HUVEC	B-Anatomy
migration	O
and	O
,	O
at	O
15	O
-	O
50	O
micrograms	O
/	O
ml	O
produced	O
a	O
dose	O
-	O
dependent	O
decline	O
in	O
[	O
3H	O
]	O
-	O
thymidine	O
incorporation	O
.	O
30	O
and	O
50	O
micrograms	O
/	O
ml	O
of	O
U	O
-	O
995	O
,	O
when	O
added	O
to	O
TNF	O
alpha	O
-	O
induced	O
angiogenesis	O
caused	O
discontinuous	O
and	O
disrupted	O
blood	B-Anatomy
vessels	I-Anatomy
.	O
Moreover	O
,	O
U	O
-	O
995	O
(	O
30	O
micrograms	O
/	O
ml	O
)	O
markedly	O
prevented	O
collagenase	O
-	O
induced	O
collagenolysis	O
.	O
In	O
addition	O
,	O
when	O
200	O
micrograms	O
U	O
-	O
995	O
was	O
injected	O
i	O
.	O
p	O
.	O
into	O
mice	O
it	O
suppressed	O
sarcoma	B-Anatomy
-	I-Anatomy
180	I-Anatomy
cell	I-Anatomy
growth	O
and	O
B16	B-Anatomy
-	I-Anatomy
F10	I-Anatomy
mouse	I-Anatomy
melanoma	I-Anatomy
cell	I-Anatomy
metastasis	O
in	O
vivo	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
the	O
anti	O
-	O
angiogenic	O
effects	O
of	O
U	O
-	O
995	O
may	O
be	O
be	O
due	O
to	O
interference	O
with	O
the	O
proliferation	O
and	O
migration	O
of	O
HUVECs	B-Anatomy
as	O
well	O
as	O
inhibition	O
of	O
collagenolysis	O
,	O
thereby	O
leading	O
to	O
inhibition	O
of	O
both	O
angiogenesis	O
and	O
tumor	B-Anatomy
cell	I-Anatomy
growth	O
.	O
Selective	O
inhibition	O
of	O
the	O
renal	B-Anatomy
dopamine	O
subtype	O
D1A	O
receptor	O
induces	O
antinatriuresis	O
in	O
conscious	O
rats	O
.	O
Both	O
dopamine	O
D1	O
-	O
like	O
(	O
D1A	O
and	O
D1B	O
)	O
and	O
D2	O
-	O
like	O
(	O
D2	O
,	O
D3	O
,	O
and	O
D4	O
)	O
receptor	O
subfamilies	O
are	O
present	O
in	O
the	O
kidney	B-Anatomy
.	O
Blockade	O
of	O
the	O
intrarenal	O
D1	O
-	O
like	O
receptor	O
family	O
is	O
associated	O
with	O
natriuresis	O
and	O
diuresis	O
.	O
Because	O
the	O
D1A	O
and	O
D1B	O
receptor	O
subtypes	O
are	O
not	O
distinguishable	O
by	O
currently	O
available	O
dopaminergic	O
agents	O
,	O
their	O
functional	O
role	O
remains	O
undefined	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
selective	O
inhibition	O
of	O
the	O
renal	B-Anatomy
D1A	O
receptor	O
with	O
phosphorothioated	O
antisense	O
oligodeoxynucleotide	O
(	O
AS	O
-	O
ODN	O
)	O
was	O
investigated	O
in	O
conscious	O
uninephrectomized	O
rats	O
.	O
After	O
renal	B-Anatomy
interstitial	I-Anatomy
administration	O
of	O
Texas	O
red	O
-	O
labeled	O
D1A	O
receptor	O
AS	O
-	O
ODN	O
,	O
intense	O
fluorescent	O
signal	O
was	O
localized	O
in	O
the	O
renal	B-Anatomy
tubular	I-Anatomy
epithelium	I-Anatomy
and	O
vasculature	B-Anatomy
.	O
In	O
rats	O
on	O
normal	O
salt	O
intake	O
,	O
AS	O
-	O
ODN	O
injected	O
interstitially	O
into	O
the	O
kidney	B-Anatomy
reduced	O
daily	O
urinary	B-Anatomy
sodium	O
excretion	O
(	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
04	O
versus	O
0	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
2	O
mEq	O
/	O
d	O
,	O
n	O
=	O
5	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
urine	B-Anatomy
output	O
(	O
16	O
.	O
9	O
+	O
/	O
-	O
3	O
.	O
8	O
versus	O
12	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
6	O
mL	O
/	O
d	O
,	O
n	O
=	O
5	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
In	O
rats	O
on	O
high	O
sodium	O
intake	O
,	O
continuous	O
renal	B-Anatomy
interstitial	I-Anatomy
administration	O
of	O
D1A	O
receptor	O
AS	O
-	O
ODN	O
transiently	O
decreased	O
daily	O
urinary	B-Anatomy
sodium	O
excretion	O
(	O
5	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
5	O
versus	O
4	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
3	O
mEq	O
/	O
d	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
urine	B-Anatomy
output	O
(	O
27	O
.	O
6	O
+	O
/	O
-	O
4	O
.	O
5	O
versus	O
18	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
8	O
mL	O
/	O
d	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
Neither	O
vehicle	O
nor	O
sense	O
oligodeoxynucleotide	O
had	O
significant	O
effects	O
.	O
Systolic	O
blood	B-Anatomy
pressure	O
remained	O
unchanged	O
.	O
The	O
renal	B-Anatomy
D1A	O
receptor	O
protein	O
was	O
significantly	O
decreased	O
by	O
35	O
%	O
and	O
46	O
%	O
at	O
the	O
end	O
of	O
the	O
study	O
in	O
AS	O
-	O
ODN	O
-	O
treated	O
rats	O
on	O
normal	O
and	O
high	O
salt	O
intake	O
,	O
respectively	O
,	O
whereas	O
the	O
D1B	O
receptor	O
and	O
beta	O
-	O
actin	O
were	O
not	O
affected	O
.	O
These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
the	O
renal	B-Anatomy
D1A	O
receptor	O
subtype	O
plays	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
sodium	O
excretion	O
.	O
Selegiline	B-Chemical
-	O
induced	O
postural	B-Disease
hypotension	I-Disease
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
:	O
a	O
longitudinal	O
study	O
on	O
the	O
effects	O
of	O
drug	O
withdrawal	O
.	O
OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	B-Chemical
per	O
day	O
and	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
compared	O
with	O
those	O
taking	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
alone	O
.	O
Recently	O
,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	B-Chemical
and	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
was	O
associated	O
with	O
selective	O
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	O
was	O
abolished	O
by	O
withdrawal	O
of	O
selegiline	B-Chemical
.	O
This	O
unwanted	O
effect	O
on	O
postural	O
blood	O
pressure	O
was	O
not	O
the	O
result	O
of	O
underlying	O
autonomic	O
failure	O
.	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
confirm	O
our	O
previous	O
findings	O
in	O
a	O
separate	O
cohort	O
of	O
patients	O
and	O
to	O
determine	O
the	O
time	O
course	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
stopping	O
selegiline	B-Chemical
in	O
the	O
expectation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanisms	O
by	O
which	O
the	O
drug	O
causes	O
orthostatic	B-Disease
hypotension	I-Disease
.	O
METHODS	O
:	O
The	O
cardiovascular	O
responses	O
to	O
standing	O
and	O
head	O
-	O
up	O
tilt	O
were	O
studied	O
repeatedly	O
in	O
PD	B-Disease
patients	O
receiving	O
selegiline	B-Chemical
and	O
as	O
the	O
drug	O
was	O
withdrawn	O
.	O
RESULTS	O
:	O
Head	O
-	O
up	O
tilt	O
caused	O
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	B-Disease
patients	O
on	O
selegiline	B-Chemical
,	O
one	O
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures	O
.	O
A	O
lesser	O
degree	O
of	O
orthostatic	B-Disease
hypotension	I-Disease
occurred	O
with	O
standing	O
.	O
Orthostatic	B-Disease
hypotension	I-Disease
was	O
ameliorated	O
4	O
days	O
after	O
withdrawal	O
of	O
selegiline	B-Chemical
and	O
totally	O
abolished	O
7	O
days	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O
Stopping	O
selegiline	B-Chemical
also	O
significantly	O
reduced	B-Disease
the	I-Disease
supine	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
blood	I-Disease
pressures	I-Disease
consistent	O
with	O
a	O
previously	O
undescribed	O
supine	O
pressor	O
action	O
.	O
CONCLUSION	O
:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	O
that	O
selegiline	B-Chemical
in	O
combination	O
with	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
is	O
associated	O
with	O
selective	O
orthostatic	B-Disease
hypotension	I-Disease
.	O
The	O
possibilities	O
that	O
these	O
cardiovascular	O
findings	O
might	O
be	O
the	O
result	O
of	O
non	O
-	O
selective	O
inhibition	O
of	O
monoamine	O
oxidase	O
or	O
of	O
amphetamine	B-Chemical
and	O
metamphetamine	B-Chemical
are	O
discussed	O
.	O
Further	O
studies	O
on	O
effects	O
of	O
irrigation	O
solutions	O
on	O
rat	O
bladders	O
.	O
Further	O
studies	O
on	O
the	O
effects	O
of	O
certain	O
irrigating	O
fluids	O
on	O
the	O
rat	O
bladder	O
for	O
18	O
hours	O
are	O
reported	O
.	O
The	O
results	O
have	O
shown	O
that	O
the	O
degradation	O
product	O
p	B-Chemical
-	I-Chemical
choloroaniline	I-Chemical
is	O
not	O
a	O
significant	O
factor	O
in	O
chlorhexidine	B-Chemical
-	I-Chemical
digluconate	I-Chemical
associated	O
erosive	O
cystitis	B-Disease
.	O
A	O
high	O
percentage	O
of	O
kanamycin	B-Chemical
-	O
colistin	B-Chemical
and	O
povidone	B-Chemical
-	I-Chemical
iodine	I-Chemical
irrigations	O
were	O
associated	O
with	O
erosive	O
cystitis	B-Disease
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O
Picloxydine	B-Chemical
irrigations	O
appeared	O
to	O
have	O
a	O
lower	O
incidence	O
of	O
erosive	O
cystitis	B-Disease
but	O
further	O
studies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recommended	O
for	O
use	O
in	O
urological	O
procedures	O
.	O
Effects	O
of	O
tetrandrine	B-Chemical
and	O
fangchinoline	B-Chemical
on	O
experimental	O
thrombosis	B-Disease
in	O
mice	O
and	O
human	O
platelet	B-Disease
aggregation	I-Disease
.	O
Tetrandrine	B-Chemical
(	O
TET	B-Chemical
)	O
and	O
fangchinoline	B-Chemical
(	O
FAN	B-Chemical
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	O
a	O
bisbenzylisoquinoline	B-Chemical
structure	O
.	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
on	O
the	O
experimental	O
thrombosis	B-Disease
induced	O
by	O
collagen	O
plus	O
epinephrine	B-Chemical
(	O
EP	B-Chemical
)	O
in	O
mice	O
,	O
and	O
platelet	B-Disease
aggregation	I-Disease
and	O
blood	B-Disease
coagulation	I-Disease
in	O
vitro	O
.	O
In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
in	O
mice	O
showed	O
the	O
inhibition	O
of	O
thrombosis	B-Disease
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	B-Chemical
acid	I-Chemical
(	O
ASA	B-Chemical
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
30	O
%	O
inhibition	O
.	O
In	O
the	O
vitro	O
human	O
platelet	B-Disease
aggregations	I-Disease
induced	O
by	O
the	O
agonists	O
used	O
in	O
tests	O
,	O
TET	B-Chemical
and	O
FAN	B-Chemical
showed	O
the	O
inhibitions	O
dose	O
dependently	O
.	O
In	O
addition	O
,	O
neither	O
TET	B-Chemical
nor	O
FAN	B-Chemical
showed	O
any	O
anticoagulation	O
activities	O
in	O
the	O
measurement	O
of	O
the	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
thrombin	O
time	O
(	O
TT	O
)	O
using	O
human	O
-	O
citrated	O
plasma	O
.	O
These	O
results	O
suggest	O
that	O
antithrombosis	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
in	O
mice	O
may	O
be	O
mainly	O
related	O
to	O
the	O
antiplatelet	O
aggregation	O
activities	O
.	O
Angioedema	B-Disease
due	O
to	O
ACE	B-Chemical
inhibitors	I-Chemical
:	O
common	O
and	O
inadequately	O
diagnosed	O
.	O
The	O
estimated	O
incidence	O
of	O
angioedema	B-Disease
during	O
angiotensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzyme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhibitor	I-Chemical
treatment	O
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patients	O
.	O
This	O
potentially	O
serious	O
adverse	O
effect	O
is	O
often	O
preceded	O
by	O
minor	O
manifestations	O
that	O
may	O
serve	O
as	O
a	O
warning	O
.	O
Cocaine	B-Chemical
-	O
induced	O
mood	B-Disease
disorder	I-Disease
:	O
prevalence	O
rates	O
and	O
psychiatric	B-Disease
symptoms	O
in	O
an	O
outpatient	O
cocaine	B-Chemical
-	O
dependent	O
sample	O
.	O
This	O
paper	O
attempts	O
to	O
examine	O
and	O
compare	O
prevalence	O
rates	O
and	O
symptom	O
patterns	O
of	O
DSM	O
substance	O
-	O
induced	O
and	O
other	O
mood	B-Disease
disorders	I-Disease
.	O
243	O
cocaine	B-Chemical
-	O
dependent	O
outpatients	O
with	O
cocaine	B-Chemical
-	O
induced	O
mood	B-Disease
disorder	I-Disease
(	O
CIMD	B-Disease
)	O
,	O
other	O
mood	B-Disease
disorders	I-Disease
,	O
or	O
no	O
mood	B-Disease
disorder	I-Disease
were	O
compared	O
on	O
measures	O
of	O
psychiatric	B-Disease
symptoms	O
.	O
The	O
prevalence	O
rate	O
for	O
CIMD	B-Disease
was	O
12	O
%	O
at	O
baseline	O
.	O
Introduction	O
of	O
the	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
CIMD	B-Disease
did	O
not	O
substantially	O
affect	O
rates	O
of	O
the	O
other	O
depressive	B-Disease
disorders	I-Disease
.	O
Patients	O
with	O
CIMD	B-Disease
had	O
symptom	O
severity	O
levels	O
between	O
those	O
of	O
patients	O
with	O
and	O
without	O
a	O
mood	B-Disease
disorder	I-Disease
.	O
These	O
findings	O
suggest	O
some	O
validity	O
for	O
the	O
new	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
CIMD	B-Disease
,	O
but	O
also	O
suggest	O
that	O
it	O
requires	O
further	O
specification	O
and	O
replication	O
.	O
Effect	O
of	O
fucoidan	B-Chemical
treatment	O
on	O
collagenase	O
-	O
induced	O
intracerebral	B-Disease
hemorrhage	I-Disease
in	O
rats	O
.	O
Inflammatory	O
cells	O
are	O
postulated	O
to	O
mediate	O
some	O
of	O
the	O
brain	B-Disease
damage	I-Disease
following	O
ischemic	B-Disease
stroke	I-Disease
.	O
Intracerebral	B-Disease
hemorrhage	I-Disease
is	O
associated	O
with	O
more	O
inflammation	B-Disease
than	O
ischemic	B-Disease
stroke	I-Disease
.	O
We	O
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	B-Chemical
,	O
which	O
has	O
been	O
reported	O
to	O
reduce	O
inflammatory	O
brain	B-Disease
damage	I-Disease
,	O
in	O
a	O
rat	O
model	O
of	O
intracerebral	B-Disease
hemorrhage	I-Disease
induced	O
by	O
injection	O
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus	O
.	O
Rats	O
were	O
treated	O
with	O
seven	O
day	O
intravenous	O
infusion	O
of	O
fucoidan	B-Chemical
(	O
30	O
micrograms	O
h	O
-	O
1	O
)	O
or	O
vehicle	O
.	O
The	O
hematoma	B-Disease
was	O
assessed	O
in	O
vivo	O
by	O
magnetic	O
resonance	O
imaging	O
.	O
Motor	O
behavior	O
,	O
passive	O
avoidance	O
,	O
and	O
skilled	O
forelimb	O
function	O
were	O
tested	O
repeatedly	O
for	O
six	O
weeks	O
.	O
Fucoidan	B-Chemical
-	O
treated	O
rats	O
exhibited	O
evidence	O
of	O
impaired	B-Disease
blood	I-Disease
clotting	I-Disease
and	O
hemodilution	B-Disease
,	O
had	O
larger	O
hematomas	B-Disease
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	B-Disease
in	O
the	O
vicinity	O
of	O
the	O
hematoma	B-Disease
after	O
three	O
days	O
.	O
They	O
showed	O
significantly	O
more	O
rapid	O
improvement	O
of	O
motor	O
function	O
in	O
the	O
first	O
week	O
following	O
hemorrhage	B-Disease
and	O
better	O
memory	O
retention	O
in	O
the	O
passive	O
avoidance	O
test	O
.	O
Acute	O
white	B-Disease
matter	I-Disease
edema	I-Disease
and	O
eventual	O
neuronal	B-Disease
loss	I-Disease
in	O
the	O
striatum	O
adjacent	O
to	O
the	O
hematoma	B-Disease
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O
Investigation	O
of	O
more	O
specific	O
anti	O
-	O
inflammatory	O
agents	O
and	O
hemodiluting	O
agents	O
are	O
warranted	O
in	O
intracerebral	B-Disease
hemorrhage	I-Disease
.	O
Recurarization	O
in	O
the	O
recovery	O
room	O
.	O
A	O
case	O
of	O
recurarization	O
in	O
the	O
recovery	O
room	O
is	O
reported	O
.	O
Accumulation	O
of	O
atracurium	B-Chemical
in	O
the	O
intravenous	O
line	O
led	O
to	O
recurarization	O
after	O
flushing	O
the	O
line	O
in	O
the	O
recovery	O
room	O
.	O
A	O
respiratory	B-Disease
arrest	I-Disease
with	O
severe	O
desaturation	B-Disease
and	O
bradycardia	B-Disease
occurred	O
.	O
Circumstances	O
leading	O
to	O
this	O
event	O
and	O
the	O
mechanisms	O
enabling	O
a	O
neuromuscular	B-Disease
blockade	I-Disease
to	O
occur	O
,	O
following	O
the	O
administration	O
of	O
a	O
small	O
dose	O
of	O
relaxant	O
,	O
are	O
discussed	O
.	O
The	O
haemodynamic	O
effects	O
of	O
propofol	B-Chemical
in	O
combination	O
with	O
ephedrine	B-Chemical
in	O
elderly	O
patients	O
(	O
ASA	O
groups	O
3	O
and	O
4	O
)	O
.	O
The	O
marked	O
vasodilator	O
and	O
negative	O
inotropic	O
effects	O
of	O
propofol	B-Chemical
are	O
disadvantages	O
in	O
frail	O
elderly	O
patients	O
.	O
We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
adding	O
different	O
doses	O
of	O
ephedrine	B-Chemical
to	O
propofol	B-Chemical
in	O
order	O
to	O
obtund	O
the	O
hypotensive	B-Disease
response	O
.	O
The	O
haemodynamic	O
effects	O
of	O
adding	O
15	O
,	O
20	O
or	O
25	O
mg	O
of	O
ephedrine	B-Chemical
to	O
200	O
mg	O
of	O
propofol	B-Chemical
were	O
compared	O
to	O
control	O
in	O
40	O
ASA	O
3	O
/	O
4	O
patients	O
over	O
60	O
years	O
presenting	O
for	O
genito	O
-	O
urinary	O
surgery	O
.	O
The	O
addition	O
of	O
ephedrine	B-Chemical
to	O
propofol	B-Chemical
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	B-Disease
response	O
to	O
propofol	B-Chemical
at	O
all	O
doses	O
used	O
in	O
this	O
study	O
.	O
However	O
,	O
marked	O
tachycardia	B-Disease
associated	O
with	O
the	O
use	O
of	O
ephedrine	B-Chemical
in	O
combination	O
with	O
propofol	B-Chemical
occurred	O
in	O
the	O
majority	O
of	O
patients	O
,	O
occasionally	O
reaching	O
high	O
levels	O
in	O
individual	O
patients	O
.	O
Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	B-Disease
inducing	O
myocardial	B-Disease
ischemia	I-Disease
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	B-Chemical
/	O
propofol	B-Chemical
/	O
mixtures	O
studied	O
.	O
Gemcitabine	B-Chemical
plus	O
vinorelbine	B-Chemical
in	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
patients	O
age	O
70	O
years	O
or	O
older	O
or	O
patients	O
who	O
cannot	O
receive	O
cisplatin	B-Chemical
.	O
Oncopaz	O
Cooperative	O
Group	O
.	O
BACKGROUND	O
:	O
Although	O
the	O
prevalence	O
of	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
(	O
NSCLC	B-Disease
)	O
is	O
high	O
among	O
elderly	O
patients	O
,	O
few	O
data	O
are	O
available	O
regarding	O
the	O
efficacy	O
and	O
toxicity	B-Disease
of	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients	O
.	O
Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	O
with	O
vinorelbine	B-Chemical
(	O
VNB	B-Chemical
)	O
or	O
gemcitabine	B-Chemical
(	O
GEM	B-Chemical
)	O
may	O
obtain	O
a	O
response	O
rate	O
of	O
20	O
-	O
30	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	B-Disease
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O
In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	B-Disease
of	O
the	O
combination	O
of	O
GEM	B-Chemical
and	O
VNB	B-Chemical
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	B-Disease
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	B-Chemical
were	O
assessed	O
.	O
METHODS	O
:	O
Forty	O
-	O
nine	O
patients	O
with	O
advanced	O
NSCLC	B-Disease
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
age	O
>	O
/	O
=	O
70	O
years	O
and	O
11	O
were	O
age	O
<	O
70	O
years	O
but	O
who	O
had	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	B-Chemical
.	O
All	O
patients	O
were	O
evaluable	O
for	O
response	O
and	O
toxicity	B-Disease
.	O
Treatment	O
was	O
comprised	O
of	O
VNB	B-Chemical
,	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
plus	O
GEM	B-Chemical
,	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
both	O
on	O
Days	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
days	O
.	O
Patients	O
received	O
a	O
minimum	O
of	O
three	O
courses	O
unless	O
progressive	O
disease	O
was	O
detected	O
.	O
RESULTS	O
:	O
One	O
hundred	O
sixty	O
-	O
five	O
courses	O
were	O
administered	O
,	O
with	O
a	O
median	O
of	O
3	O
.	O
6	O
courses	O
per	O
patient	O
.	O
The	O
overall	O
response	O
rate	O
was	O
26	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
15	O
-	O
41	O
%	O
)	O
.	O
Two	O
patients	O
attained	O
a	O
complete	O
response	O
(	O
4	O
%	O
)	O
and	O
11	O
patients	O
(	O
22	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
.	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
improved	O
in	O
35	O
%	O
of	O
those	O
patients	O
with	O
an	O
initial	O
value	O
>	O
0	O
,	O
whereas	O
relief	O
of	O
at	O
least	O
1	O
symptom	O
without	O
worsening	O
of	O
other	O
symptoms	O
was	O
noted	O
in	O
27	O
patients	O
(	O
55	O
%	O
)	O
.	O
The	O
median	O
time	O
to	O
progression	O
was	O
16	O
weeks	O
and	O
the	O
1	O
-	O
year	O
survival	O
rate	O
was	O
33	O
%	O
.	O
Toxicity	B-Disease
was	O
mild	O
.	O
Six	O
patients	O
(	O
12	O
%	O
)	O
had	O
World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	B-Disease
,	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
-	O
4	O
thrombocytopenia	B-Disease
,	O
and	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
neurotoxicity	B-Disease
.	O
Three	O
patients	O
with	O
severe	O
neutropenia	B-Disease
(	O
6	O
%	O
)	O
died	O
of	O
sepsis	B-Disease
.	O
The	O
median	O
age	O
of	O
those	O
patients	O
developing	O
Grade	O
3	O
-	O
4	O
neutropenia	B-Disease
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
remaining	O
patients	O
(	O
75	O
years	O
vs	O
.	O
72	O
years	O
;	O
P	O
=	O
0	O
.	O
047	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
combination	O
of	O
GEM	B-Chemical
and	O
VNB	B-Chemical
is	O
moderately	O
active	O
and	O
well	O
tolerated	O
except	O
in	O
patients	O
age	O
>	O
/	O
=	O
75	O
years	O
.	O
This	O
age	O
group	O
had	O
an	O
increased	O
risk	O
of	O
myelosuppression	B-Disease
.	O
Therefore	O
the	O
prophylactic	O
use	O
of	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
should	O
be	O
considered	O
with	O
this	O
treatment	O
.	O
New	O
chemotherapy	O
combinations	O
with	O
higher	O
activity	O
and	O
lower	O
toxicity	B-Disease
are	O
needed	O
for	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	B-Disease
.	O
A	O
selective	O
dopamine	B-Chemical
D4	O
receptor	O
antagonist	O
,	O
NRA0160	B-Chemical
:	O
a	O
preclinical	O
neuropharmacological	O
profile	O
.	O
NRA0160	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluorobenzylidene	I-Chemical
)	I-Chemical
piperidin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
fluorophenyl	I-Chemical
)	I-Chemical
thiazole	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
carboxamide	I-Chemical
,	O
has	O
a	O
high	O
affinity	O
for	O
human	O
cloned	O
dopamine	B-Chemical
D4	O
.	O
2	O
,	O
D4	O
.	O
4	O
and	O
D4	O
.	O
7	O
receptors	O
,	O
with	O
Ki	O
values	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
9	O
and	O
2	O
.	O
7	O
nM	O
,	O
respectively	O
.	O
NRA0160	B-Chemical
is	O
over	O
20	O
,	O
000fold	O
more	O
potent	O
at	O
the	O
dopamine	B-Chemical
D4	O
.	O
2	O
receptor	O
compared	O
with	O
the	O
human	O
cloned	O
dopamine	B-Chemical
D2L	O
receptor	O
.	O
NRA0160	B-Chemical
has	O
negligible	O
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	B-Chemical
D3	O
receptor	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotonin	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
2A	O
receptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O
NRA0160	B-Chemical
and	O
clozapine	B-Chemical
antagonized	O
locomotor	O
hyperactivity	B-Disease
induced	O
by	O
methamphetamine	B-Chemical
(	O
MAP	B-Chemical
)	O
in	O
mice	O
.	O
NRA0160	B-Chemical
and	O
clozapine	B-Chemical
antagonized	O
MAP	B-Chemical
-	O
induced	O
stereotyped	O
behavior	O
in	O
mice	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
inhibition	O
,	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O
NRA0160	B-Chemical
and	O
clozapine	B-Chemical
significantly	O
induced	O
catalepsy	B-Disease
in	O
rats	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
induction	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O
NRA0160	B-Chemical
and	O
clozapine	B-Chemical
significantly	O
reversed	O
the	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
rats	O
produced	O
by	O
apomorphine	B-Chemical
.	O
NRA0160	B-Chemical
and	O
clozapine	B-Chemical
significantly	O
shortened	O
the	O
phencyclidine	B-Chemical
(	O
PCP	B-Chemical
)	O
-	O
induced	O
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O
These	O
findings	O
suggest	O
that	O
NRA0160	B-Chemical
may	O
have	O
unique	O
antipsychotic	O
activities	O
without	O
the	O
liability	O
of	O
motor	O
side	O
effects	O
typical	O
of	O
classical	O
antipsychotics	O
.	O
Warfarin	B-Chemical
-	O
induced	O
artery	B-Disease
calcification	I-Disease
is	O
accelerated	O
by	O
growth	O
and	O
vitamin	B-Chemical
D	I-Chemical
.	O
The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	B-Chemical
D	I-Chemical
treatment	O
enhance	O
the	O
extent	O
of	O
artery	B-Disease
calcification	I-Disease
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	B-Chemical
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	B-Disease
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O
The	O
first	O
series	O
of	O
experiments	O
examined	O
the	O
influence	O
of	O
age	O
and	O
growth	O
status	O
on	O
artery	B-Disease
calcification	I-Disease
in	O
Warfarin	B-Chemical
-	O
treated	O
rats	O
.	O
Treatment	O
for	O
2	O
weeks	O
with	O
Warfarin	B-Chemical
caused	O
massive	O
focal	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
20	O
-	O
day	O
-	O
old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	B-Disease
in	O
42	O
-	O
day	O
-	O
old	O
rats	O
.	O
In	O
contrast	O
,	O
no	O
artery	B-Disease
calcification	I-Disease
could	O
be	O
detected	O
in	O
10	O
-	O
month	O
-	O
old	O
adult	O
rats	O
even	O
after	O
4	O
weeks	O
of	O
Warfarin	B-Chemical
treatment	O
.	O
To	O
directly	O
examine	O
the	O
importance	O
of	O
growth	O
to	O
Warfarin	B-Chemical
-	O
induced	O
artery	B-Disease
calcification	I-Disease
in	O
animals	O
of	O
the	O
same	O
age	O
,	O
20	O
-	O
day	O
-	O
old	O
rats	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
libitum	O
diet	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
diet	O
that	O
maintains	O
weight	O
but	O
prevents	O
growth	O
.	O
Concurrent	O
treatment	O
of	O
both	O
dietary	O
groups	O
with	O
Warfarin	B-Chemical
produced	O
massive	O
focal	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
the	O
ad	O
libitum	O
-	O
fed	O
rats	O
but	O
no	O
detectable	O
artery	B-Disease
calcification	I-Disease
in	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
group	O
.	O
Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	B-Disease
calcification	I-Disease
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	B-Chemical
and	O
susceptibility	O
to	O
artery	B-Disease
calcification	I-Disease
,	O
with	O
30	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	B-Chemical
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	B-Chemical
-	O
induced	O
artery	B-Disease
calcification	I-Disease
,	O
ie	O
,	O
the	O
10	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O
This	O
observation	O
suggests	O
that	O
increased	O
susceptibility	O
to	O
Warfarin	B-Chemical
-	O
induced	O
artery	B-Disease
calcification	I-Disease
could	O
be	O
related	O
to	O
higher	O
serum	O
phosphate	B-Chemical
levels	O
.	O
The	O
second	O
set	O
of	O
experiments	O
examined	O
the	O
possible	O
synergy	O
between	O
vitamin	B-Chemical
D	I-Chemical
and	O
Warfarin	B-Chemical
in	O
artery	B-Disease
calcification	I-Disease
.	O
High	O
doses	O
of	O
vitamin	B-Chemical
D	I-Chemical
are	O
known	O
to	O
cause	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days	O
.	O
High	O
doses	O
of	O
the	O
vitamin	B-Chemical
K	I-Chemical
antagonist	O
Warfarin	B-Chemical
are	O
also	O
known	O
to	O
cause	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	O
Warfarin	B-Chemical
administration	O
dramatically	O
increased	O
the	O
extent	O
of	O
calcification	B-Disease
in	O
the	O
media	O
of	O
vitamin	B-Chemical
D	I-Chemical
-	O
treated	O
rats	O
at	O
3	O
and	O
4	O
days	O
.	O
There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	B-Chemical
D	I-Chemical
dose	O
on	O
artery	B-Disease
calcification	I-Disease
and	O
the	O
effect	O
of	O
vitamin	B-Chemical
D	I-Chemical
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	B-Chemical
,	O
which	O
suggests	O
that	O
vitamin	B-Chemical
D	I-Chemical
may	O
induce	O
artery	B-Disease
calcification	I-Disease
through	O
its	O
effect	O
on	O
serum	O
calcium	B-Chemical
.	O
Because	O
Warfarin	B-Chemical
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	B-Chemical
produced	O
by	O
vitamin	B-Chemical
D	I-Chemical
,	O
the	O
synergy	O
between	O
Warfarin	B-Chemical
and	O
vitamin	B-Chemical
D	I-Chemical
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	B-Chemical
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	B-Disease
inhibitor	O
.	O
High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	B-Disease
calcification	I-Disease
in	O
rats	O
treated	O
with	O
vitamin	B-Chemical
D	I-Chemical
plus	O
Warfarin	B-Chemical
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	B-Chemical
-	I-Chemical
carboxylated	I-Chemical
.	O
These	O
observations	O
indicate	O
that	O
although	O
the	O
gamma	B-Chemical
-	I-Chemical
carboxyglutamate	I-Chemical
residues	O
of	O
matrix	O
Gla	O
protein	O
are	O
apparently	O
required	O
for	O
its	O
function	O
as	O
a	O
calcification	B-Disease
inhibitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	O
at	O
calcification	B-Disease
sites	O
.	O
Test	O
conditions	O
influence	O
the	O
response	O
to	O
a	O
drug	O
challenge	O
in	O
rodents	O
.	O
These	O
studies	O
were	O
conducted	O
to	O
examine	O
the	O
differential	O
response	O
to	O
a	O
drug	O
challenge	O
under	O
varied	O
experimental	O
test	O
conditions	O
routinely	O
employed	O
to	O
study	O
drug	O
-	O
induced	O
behavioral	O
and	O
neurophysiological	O
responses	O
in	O
rodents	O
.	O
Apomorphine	B-Chemical
,	O
a	O
nonselective	O
dopamine	B-Chemical
agonist	I-Chemical
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	B-Disease
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	B-Chemical
turnover	O
in	O
the	O
rodent	O
brain	O
.	O
From	O
such	O
experiments	O
there	O
is	O
evidence	O
that	O
characterization	O
and	O
detection	O
of	O
apomorphine	B-Chemical
-	O
induced	O
activity	O
in	O
rodents	O
critically	O
depends	O
upon	O
the	O
test	O
conditions	O
employed	O
.	O
In	O
rats	O
,	O
detection	O
of	O
apomorphine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
was	O
facilitated	O
by	O
a	O
period	O
of	O
acclimatization	O
to	O
the	O
test	O
conditions	O
.	O
Moreover	O
,	O
test	O
conditions	O
can	O
impact	O
upon	O
other	O
physiological	O
responses	O
to	O
apomorphine	B-Chemical
such	O
as	O
drug	O
-	O
induced	O
hypothermia	B-Disease
.	O
In	O
mice	O
,	O
apomorphine	B-Chemical
produced	O
qualitatively	O
different	O
responses	O
under	O
novel	O
conditions	O
when	O
compared	O
to	O
those	O
behaviors	O
elicited	O
in	O
the	O
home	O
test	O
cage	O
.	O
Drug	O
-	O
induced	O
gross	O
activity	O
counts	O
were	O
increased	O
in	O
the	O
novel	O
exploratory	O
box	O
only	O
,	O
while	O
measures	O
of	O
stereotypic	O
behavior	O
were	O
similar	O
in	O
both	O
.	O
By	O
contrast	O
,	O
apomorphine	B-Chemical
-	O
induced	O
locomotion	O
was	O
more	O
prominent	O
in	O
the	O
novel	O
exploratory	O
box	O
.	O
Dopamine	B-Chemical
turnover	O
ratios	O
(	O
DOPAC	B-Chemical
:	O
DA	B-Chemical
and	O
HVA	B-Chemical
:	O
DA	B-Chemical
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O
However	O
,	O
apomorphine	B-Chemical
-	O
induced	O
reductions	O
in	O
striatal	O
dopamine	B-Chemical
turnover	O
were	O
detected	O
in	O
both	O
novel	O
and	O
home	O
cage	O
environments	O
.	O
The	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
with	O
particular	O
emphasis	O
upon	O
conducting	O
psychopharmacological	O
challenge	O
tests	O
in	O
rodents	O
.	O
Hemolysis	B-Disease
of	O
human	O
erythrocytes	O
induced	O
by	O
tamoxifen	B-Chemical
is	O
related	O
to	O
disruption	O
of	O
membrane	O
structure	O
.	O
Tamoxifen	B-Chemical
(	O
TAM	B-Chemical
)	O
,	O
the	O
antiestrogenic	O
drug	O
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	B-Disease
anemia	I-Disease
.	O
This	O
work	O
evaluates	O
the	O
effects	O
of	O
TAM	B-Chemical
on	O
isolated	O
human	O
erythrocytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechanisms	O
on	O
TAM	B-Chemical
-	O
induced	O
hemolytic	B-Disease
anemia	I-Disease
and	O
the	O
involvement	O
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms	O
.	O
TAM	B-Chemical
induces	O
hemolysis	B-Disease
of	O
erythrocytes	O
as	O
a	O
function	O
of	O
concentration	O
.	O
The	O
extension	O
of	O
hemolysis	B-Disease
is	O
variable	O
with	O
erythrocyte	O
samples	O
,	O
but	O
12	O
.	O
5	O
microM	O
TAM	B-Chemical
induces	O
total	O
hemolysis	B-Disease
of	O
all	O
tested	O
suspensions	O
.	O
Despite	O
inducing	O
extensive	O
erythrocyte	O
lysis	O
,	O
TAM	B-Chemical
does	O
not	O
shift	O
the	O
osmotic	O
fragility	O
curves	O
of	O
erythrocytes	O
.	O
The	O
hemolytic	B-Disease
effect	O
of	O
TAM	B-Chemical
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
(	O
alpha	B-Chemical
-	I-Chemical
T	I-Chemical
)	O
and	O
alpha	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
acetate	I-Chemical
(	O
alpha	B-Chemical
-	I-Chemical
TAc	I-Chemical
)	O
(	O
inactivated	O
functional	O
hydroxyl	B-Chemical
)	O
indicating	O
that	O
TAM	B-Chemical
-	O
induced	O
hemolysis	B-Disease
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O
This	O
was	O
further	O
evidenced	O
by	O
absence	O
of	O
oxygen	B-Chemical
consumption	O
and	O
hemoglobin	O
oxidation	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	B-Chemical
-	O
induced	O
hemolysis	B-Disease
.	O
Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	B-Chemical
inhibits	O
the	O
peroxidation	O
of	O
human	O
erythrocytes	O
induced	O
by	O
AAPH	B-Chemical
,	O
thus	O
ruling	O
out	O
TAM	B-Chemical
-	O
induced	O
cell	O
oxidative	O
stress	O
.	O
Hemolysis	B-Disease
caused	O
by	O
TAM	B-Chemical
was	O
not	O
preceded	O
by	O
the	O
leakage	O
of	O
K	B-Chemical
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	B-Disease
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O
.	O
However	O
,	O
TAM	B-Chemical
induces	O
release	O
of	O
peripheral	O
proteins	O
of	O
membrane	O
-	O
cytoskeleton	O
and	O
cytosol	O
proteins	O
essentially	O
bound	O
to	O
band	O
3	O
.	O
Either	O
alpha	B-Chemical
-	I-Chemical
T	I-Chemical
or	O
alpha	B-Chemical
-	I-Chemical
TAc	I-Chemical
increases	O
membrane	O
packing	O
and	O
prevents	O
TAM	B-Chemical
partition	O
into	O
model	O
membranes	O
.	O
These	O
effects	O
suggest	O
that	O
the	O
protection	O
from	O
hemolysis	B-Disease
by	O
tocopherols	B-Chemical
is	O
related	O
to	O
a	O
decreased	O
TAM	B-Chemical
incorporation	O
in	O
condensed	O
membranes	O
and	O
the	O
structural	O
damage	O
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided	O
.	O
Therefore	O
,	O
TAM	B-Chemical
-	O
induced	O
hemolysis	B-Disease
results	O
from	O
a	O
structural	O
perturbation	O
of	O
red	O
cell	O
membrane	O
,	O
leading	O
to	O
changes	O
in	O
the	O
framework	O
of	O
the	O
erythrocyte	O
membrane	O
and	O
its	O
cytoskeleton	O
caused	O
by	O
its	O
high	O
partition	O
in	O
the	O
membrane	O
.	O
These	O
defects	O
explain	O
the	O
abnormal	O
erythrocyte	O
shape	O
and	O
decreased	O
mechanical	O
stability	O
promoted	O
by	O
TAM	B-Chemical
,	O
resulting	O
in	O
hemolytic	B-Disease
anemia	I-Disease
.	O
Additionally	O
,	O
since	O
membrane	O
leakage	O
is	O
a	O
final	O
stage	O
of	O
cytotoxicity	O
,	O
the	O
disruption	O
of	O
the	O
structural	O
characteristics	O
of	O
biomembranes	O
by	O
TAM	B-Chemical
may	O
contribute	O
to	O
the	O
multiple	O
mechanisms	O
of	O
its	O
anticancer	O
action	O
.	O
Changes	O
of	O
sodium	B-Chemical
and	O
ATP	B-Chemical
affinities	O
of	O
the	O
cardiac	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	B-Chemical
oxide	I-Chemical
deficient	O
hypertension	B-Disease
.	O
In	O
the	O
cardiovascular	O
system	O
,	O
NO	B-Chemical
is	O
involved	O
in	O
the	O
regulation	O
of	O
a	O
variety	O
of	O
functions	O
.	O
Inhibition	O
of	O
NO	B-Chemical
synthesis	O
induces	O
sustained	O
hypertension	B-Disease
.	O
In	O
several	O
models	O
of	O
hypertension	B-Disease
,	O
elevation	O
of	O
intracellular	O
sodium	B-Chemical
level	O
was	O
documented	O
in	O
cardiac	O
tissue	O
.	O
To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	B-Chemical
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
to	O
NO	B-Chemical
-	O
deficient	O
hypertension	B-Disease
induced	O
in	O
rats	O
by	O
NO	B-Chemical
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	B-Chemical
(	I-Chemical
G	I-Chemical
)	I-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
methyl	I-Chemical
ester	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
)	O
for	O
4	O
four	O
weeks	O
.	O
After	O
4	O
-	O
week	O
administration	O
of	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
,	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
increased	O
by	O
36	O
%	O
.	O
Two	O
weeks	O
after	O
terminating	O
the	O
treatment	O
,	O
the	O
SBP	O
recovered	O
to	O
control	O
value	O
.	O
When	O
activating	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	B-Chemical
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	B-Chemical
-	O
deficient	O
rats	O
.	O
During	O
activation	O
with	O
Na	B-Chemical
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	B-Chemical
(	O
Na	B-Chemical
)	O
increased	O
by	O
50	O
%	O
,	O
indicating	O
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na	B-Chemical
+	O
-	O
binding	O
site	O
in	O
NO	B-Chemical
-	O
deficient	O
rats	O
.	O
After	O
recovery	O
from	O
hypertension	B-Disease
,	O
the	O
activity	O
of	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	B-Chemical
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	B-Chemical
.	O
The	O
K	B-Chemical
(	O
Na	B-Chemical
)	O
value	O
for	O
Na	B-Chemical
+	O
returned	O
to	O
control	O
value	O
.	O
Inhibition	O
of	O
NO	B-Chemical
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	B-Disease
accompanied	O
by	O
depressed	B-Disease
Na	B-Chemical
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	B-Chemical
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
.	O
After	O
recovery	O
of	O
blood	O
pressure	O
to	O
control	O
values	O
,	O
the	O
extrusion	O
of	O
Na	B-Chemical
+	O
from	O
cardiac	O
cells	O
was	O
normalized	O
,	O
as	O
revealed	O
by	O
restoration	O
of	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
activity	O
.	O
Effects	O
of	O
long	O
-	O
term	O
pretreatment	O
with	O
isoproterenol	B-Chemical
on	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	B-Disease
in	O
conscious	O
rats	O
.	O
It	O
has	O
been	O
shown	O
that	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	B-Disease
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	B-Chemical
D2	O
receptor	O
activation	O
and	O
(	O
ii	O
)	O
reduced	O
by	O
5	O
-	O
day	O
isoproterenol	B-Chemical
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O
This	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonged	O
pretreatment	O
with	O
isoproterenol	B-Chemical
could	O
abolish	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	B-Disease
in	O
conscious	O
rats	O
.	O
Isoproterenol	B-Chemical
pretreatment	O
for	O
15	O
days	O
caused	O
cardiac	B-Disease
hypertrophy	I-Disease
without	O
affecting	O
baseline	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O
In	O
control	O
rats	O
,	O
intravenous	O
bromocriptine	B-Chemical
(	O
150	O
microg	O
/	O
kg	O
)	O
induced	O
significant	O
hypotension	B-Disease
and	O
tachycardia	B-Disease
.	O
Bromocriptine	B-Chemical
-	O
induced	O
hypotension	B-Disease
was	O
unaffected	O
by	O
isoproterenol	B-Chemical
pretreatment	O
,	O
while	O
tachycardia	B-Disease
was	O
reversed	O
to	O
significant	O
bradycardia	B-Disease
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O
Neither	O
cardiac	O
vagal	O
nor	O
sympathetic	O
tone	O
was	O
altered	O
by	O
isoproterenol	B-Chemical
pretreatment	O
.	O
In	O
isolated	O
perfused	O
heart	O
preparations	O
from	O
isoproterenol	B-Chemical
-	O
pretreated	O
rats	O
,	O
the	O
isoproterenol	B-Chemical
-	O
induced	O
maximal	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced	O
,	O
compared	O
with	O
saline	O
-	O
pretreated	O
rats	O
(	O
the	O
EC50	O
of	O
the	O
isoproterenol	B-Chemical
-	O
induced	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22	O
-	O
fold	O
)	O
.	O
These	O
results	O
show	O
that	O
15	O
-	O
day	O
isoproterenol	B-Chemical
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	B-Disease
to	O
bradycardia	B-Disease
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O
They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	B-Disease
of	O
bromocriptine	B-Chemical
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	B-Disease
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	B-Chemical
D2	O
receptors	O
.	O
A	O
developmental	O
analysis	O
of	O
clonidine	B-Chemical
'	O
s	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
in	O
infant	O
rats	O
.	O
Under	O
controlled	O
conditions	O
,	O
infant	O
rats	O
emit	O
ultrasonic	O
vocalizations	O
during	O
extreme	O
cold	O
exposure	O
and	O
after	O
administration	O
of	O
the	O
alpha	O
(	O
2	O
)	O
adrenoceptor	O
agonist	O
,	O
clonidine	B-Chemical
.	O
Previous	O
investigations	O
have	O
determined	O
that	O
,	O
in	O
response	O
to	O
clonidine	B-Chemical
,	O
ultrasound	O
production	O
increases	O
through	O
the	O
2nd	O
-	O
week	O
postpartum	O
and	O
decreases	O
thereafter	O
.	O
Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	O
that	O
clonidine	B-Chemical
induces	O
sympathetic	O
withdrawal	O
and	O
bradycardia	B-Disease
,	O
we	O
hypothesized	O
that	O
clonidine	B-Chemical
'	O
s	O
developmental	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other	O
.	O
Therefore	O
,	O
in	O
the	O
present	O
experiment	O
,	O
the	O
effects	O
of	O
clonidine	B-Chemical
administration	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
were	O
examined	O
in	O
2	O
-	O
,	O
8	O
-	O
,	O
15	O
-	O
,	O
and	O
20	O
-	O
day	O
-	O
old	O
rats	O
.	O
Age	O
-	O
related	O
changes	O
in	O
ultrasound	O
production	O
corresponded	O
with	O
changes	O
in	O
cardiovascular	O
variables	O
,	O
including	O
baseline	O
cardiac	O
rate	O
and	O
clonidine	B-Chemical
-	O
induced	O
bradycardia	B-Disease
.	O
This	O
experiment	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
hypothesis	O
that	O
ultrasound	O
production	O
is	O
the	O
acoustic	O
by	O
-	O
product	O
of	O
a	O
physiological	O
maneuver	O
that	O
compensates	O
for	O
clonidine	B-Chemical
'	O
s	O
detrimental	O
effects	O
on	O
cardiovascular	O
function	O
.	O
Recurrent	O
use	O
of	O
newer	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
.	O
The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	B-Disease
)	O
associated	O
with	O
newer	O
oral	B-Chemical
contraceptives	I-Chemical
(	O
OC	B-Chemical
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	B-Chemical
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O
Data	O
from	O
a	O
Transnational	O
case	O
-	O
control	O
study	O
were	O
used	O
to	O
assess	O
the	O
risk	O
of	O
VTE	B-Disease
for	O
the	O
latter	O
patterns	O
of	O
use	O
,	O
while	O
accounting	O
for	O
duration	O
of	O
use	O
.	O
Over	O
the	O
period	O
1993	O
-	O
1996	O
,	O
551	O
cases	O
of	O
VTE	B-Disease
were	O
identified	O
in	O
Germany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
controls	O
.	O
Totals	O
of	O
128	O
cases	O
and	O
650	O
controls	O
were	O
analysed	O
for	O
repeat	O
use	O
and	O
135	O
cases	O
and	O
622	O
controls	O
for	O
switching	O
patterns	O
.	O
The	O
adjusted	O
rate	O
ratio	O
of	O
VTE	B-Disease
for	O
repeat	O
users	O
of	O
third	O
generation	O
OC	B-Chemical
was	O
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
3	O
-	O
1	O
.	O
2	O
)	O
relative	O
to	O
repeat	O
users	O
of	O
second	O
generation	O
pills	O
,	O
whereas	O
it	O
was	O
1	O
.	O
3	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
-	O
2	O
.	O
4	O
)	O
for	O
switchers	O
from	O
second	O
to	O
third	O
generation	O
pills	O
relative	O
to	O
switchers	O
from	O
third	O
to	O
second	O
generation	O
pills	O
.	O
We	O
conclude	O
that	O
second	O
and	O
third	O
generation	O
agents	O
are	O
associated	O
with	O
equivalent	O
risks	O
of	O
VTE	B-Disease
when	O
the	O
same	O
agent	O
is	O
used	O
repeatedly	O
after	O
interruption	O
periods	O
or	O
when	O
users	O
are	O
switched	O
between	O
the	O
two	O
generations	O
of	O
pills	O
.	O
These	O
analyses	O
suggest	O
that	O
the	O
higher	O
risk	O
observed	O
for	O
the	O
newer	O
OC	B-Chemical
in	O
other	O
studies	O
may	O
be	O
the	O
result	O
of	O
inadequate	O
comparisons	O
of	O
pill	O
users	O
with	O
different	O
patterns	O
of	O
pill	O
use	O
.	O
Differential	O
effects	O
of	O
systemically	O
administered	O
ketamine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
dynamic	O
and	O
static	O
hyperalgesia	B-Disease
induced	O
by	O
intradermal	O
capsaicin	B-Chemical
in	O
humans	O
.	O
We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	B-Disease
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	B-Disease
induced	O
by	O
capsaicin	B-Chemical
.	O
In	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
,	O
we	O
studied	O
12	O
volunteers	O
in	O
three	O
experiments	O
.	O
Capsaicin	B-Chemical
100	O
micrograms	O
was	O
injected	O
intradermally	O
on	O
the	O
volar	O
forearm	O
followed	O
by	O
an	O
i	O
.	O
v	O
.	O
infusion	O
of	O
ketamine	B-Chemical
(	O
bolus	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
infusion	O
of	O
7	O
micrograms	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
lidocaine	B-Chemical
5	O
mg	O
kg	O
-	O
1	O
or	O
saline	O
for	O
50	O
min	O
.	O
Infusion	O
started	O
15	O
min	O
after	O
injection	O
of	O
capsaicin	B-Chemical
.	O
The	O
following	O
were	O
measured	O
:	O
spontaneous	O
pain	B-Disease
,	O
pain	B-Disease
evoked	O
by	O
punctate	O
and	O
brush	O
stimuli	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	B-Disease
.	O
Ketamine	B-Chemical
reduced	O
both	O
the	O
area	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	B-Disease
significantly	O
and	O
it	O
tended	O
to	O
reduce	O
brush	O
-	O
evoked	O
pain	B-Disease
.	O
Lidocaine	B-Chemical
reduced	O
the	O
area	O
of	O
punctate	O
-	O
evoked	O
hyperalgesia	B-Disease
significantly	O
.	O
It	O
tended	O
to	O
reduce	O
VAS	O
scores	O
of	O
spontaneous	O
pain	B-Disease
but	O
had	O
no	O
effect	O
on	O
evoked	O
pain	B-Disease
.	O
The	O
differential	O
effects	O
of	O
ketamine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
static	O
and	O
dynamic	O
hyperalgesia	B-Disease
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	B-Disease
are	O
mediated	O
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O
Development	O
of	O
apomorphine	B-Chemical
-	O
induced	O
aggressive	B-Disease
behavior	I-Disease
:	O
comparison	O
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
.	O
The	O
development	O
of	O
apomorphine	B-Chemical
-	O
induced	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
once	O
daily	O
)	O
aggressive	B-Disease
behavior	I-Disease
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
obtained	O
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	O
sets	O
.	O
In	O
male	O
animals	O
,	O
repeated	O
apomorphine	B-Chemical
treatment	O
induced	O
a	O
gradual	O
development	O
of	O
aggressive	B-Disease
behavior	I-Disease
as	O
evidenced	O
by	O
the	O
increased	O
intensity	O
of	O
aggressiveness	B-Disease
and	O
shortened	O
latency	O
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent	O
.	O
In	O
female	O
rats	O
,	O
only	O
a	O
weak	O
tendency	O
toward	O
aggressiveness	B-Disease
was	O
found	O
.	O
In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
gender	O
differences	O
in	O
the	O
development	O
of	O
the	O
apomorphine	B-Chemical
-	O
induced	O
aggressive	B-Disease
behavior	I-Disease
and	O
indicates	O
that	O
the	O
female	O
rats	O
do	O
not	O
fill	O
the	O
validation	O
criteria	O
for	O
use	O
in	O
this	O
method	O
.	O
Intracranial	B-Disease
aneurysms	I-Disease
and	O
cocaine	B-Disease
abuse	I-Disease
:	O
analysis	O
of	O
prognostic	O
indicators	O
.	O
OBJECTIVE	O
:	O
The	O
outcome	O
of	O
subarachnoid	B-Disease
hemorrhage	I-Disease
associated	O
with	O
cocaine	B-Disease
abuse	I-Disease
is	O
reportedly	O
poor	O
.	O
However	O
,	O
no	O
study	O
in	O
the	O
literature	O
has	O
reported	O
the	O
use	O
of	O
a	O
statistical	O
model	O
to	O
analyze	O
the	O
variables	O
that	O
influence	O
outcome	O
.	O
METHODS	O
:	O
A	O
review	O
of	O
admissions	O
during	O
a	O
6	O
-	O
year	O
period	O
revealed	O
14	O
patients	O
with	O
cocaine	B-Chemical
-	O
related	O
aneurysms	B-Disease
.	O
This	O
group	O
was	O
compared	O
with	O
a	O
control	O
group	O
of	O
135	O
patients	O
with	O
ruptured	B-Disease
aneurysms	I-Disease
and	O
no	O
history	O
of	O
cocaine	B-Disease
abuse	I-Disease
.	O
Age	O
at	O
presentation	O
,	O
time	O
of	O
ictus	O
after	O
intoxication	O
,	O
Hunt	O
and	O
Hess	O
grade	O
of	O
subarachnoid	B-Disease
hemorrhage	I-Disease
,	O
size	O
of	O
the	O
aneurysm	B-Disease
,	O
location	O
of	O
the	O
aneurysm	B-Disease
,	O
and	O
the	O
Glasgow	O
Outcome	O
Scale	O
score	O
were	O
assessed	O
and	O
compared	O
.	O
RESULTS	O
:	O
The	O
patients	O
in	O
the	O
study	O
group	O
were	O
significantly	O
younger	O
than	O
the	O
patients	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O
In	O
patients	O
in	O
the	O
study	O
group	O
,	O
all	O
aneurysms	B-Disease
were	O
located	O
in	O
the	O
anterior	O
circulation	O
.	O
The	O
majority	O
of	O
these	O
aneurysms	B-Disease
were	O
smaller	O
than	O
those	O
of	O
the	O
control	O
group	O
(	O
8	O
+	O
/	O
-	O
6	O
.	O
08	O
mm	O
versus	O
11	O
+	O
/	O
-	O
5	O
.	O
4	O
mm	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O
The	O
differences	O
in	O
mortality	O
and	O
morbidity	O
between	O
the	O
two	O
groups	O
were	O
not	O
significant	O
.	O
Hunt	O
and	O
Hess	O
grade	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
age	O
(	O
P	O
<	O
0	O
.	O
007	O
)	O
were	O
significant	O
predictors	O
of	O
outcome	O
for	O
the	O
patients	O
with	O
cocaine	B-Chemical
-	O
related	O
aneurysms	B-Disease
.	O
CONCLUSION	O
:	O
Cocaine	B-Chemical
use	O
predisposed	O
aneurysmal	B-Disease
rupture	I-Disease
at	O
a	O
significantly	O
earlier	O
age	O
and	O
in	O
much	O
smaller	O
aneurysms	B-Disease
.	O
Contrary	O
to	O
the	O
published	O
literature	O
,	O
this	O
group	O
did	O
reasonably	O
well	O
with	O
aggressive	O
management	O
.	O
Effect	O
of	O
intravenous	O
nimodipine	B-Chemical
on	O
blood	O
pressure	O
and	O
outcome	O
after	O
acute	B-Disease
stroke	I-Disease
.	O
BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	B-Chemical
West	O
European	O
Stroke	B-Disease
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	B-Chemical
-	O
induced	O
reduction	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	B-Disease
stroke	I-Disease
.	O
We	O
sought	O
to	O
confirm	O
this	O
correlation	O
with	O
and	O
without	O
adjustment	O
for	O
prognostic	O
variables	O
and	O
to	O
investigate	O
outcome	O
in	O
subgroups	O
with	O
increasing	O
levels	O
of	O
BP	B-Disease
reduction	I-Disease
.	O
METHODS	O
:	O
Patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
ischemic	B-Disease
stroke	I-Disease
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
placebo	O
(	O
n	O
=	O
100	O
)	O
,	O
1	O
mg	O
/	O
h	O
(	O
low	O
-	O
dose	O
)	O
nimodipine	B-Chemical
(	O
n	O
=	O
101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
dose	O
)	O
nimodipine	B-Chemical
(	O
n	O
=	O
94	O
)	O
.	O
The	O
correlation	O
between	O
average	O
BP	O
change	O
during	O
the	O
first	O
2	O
days	O
and	O
the	O
outcome	O
at	O
day	O
21	O
was	O
analyzed	O
.	O
RESULTS	O
:	O
Two	O
hundred	O
sixty	O
-	O
five	O
patients	O
were	O
included	O
in	O
this	O
analysis	O
(	O
n	O
=	O
92	O
,	O
93	O
,	O
and	O
80	O
for	O
placebo	O
,	O
low	O
dose	O
,	O
and	O
high	O
dose	O
,	O
respectively	O
)	O
.	O
Nimodipine	B-Chemical
treatment	O
resulted	O
in	O
a	O
statistically	O
significant	O
reduction	B-Disease
in	I-Disease
systolic	I-Disease
BP	I-Disease
(	O
SBP	O
)	O
and	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
compared	O
with	O
placebo	O
during	O
the	O
first	O
few	O
days	O
.	O
In	O
multivariate	O
analysis	O
,	O
a	O
significant	O
correlation	O
between	O
DBP	B-Disease
reduction	I-Disease
and	O
worsening	O
of	O
the	O
neurological	O
score	O
was	O
found	O
for	O
the	O
high	O
-	O
dose	O
group	O
(	O
beta	O
=	O
0	O
.	O
49	O
,	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O
Patients	O
with	O
a	O
DBP	B-Disease
reduction	I-Disease
of	O
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	O
-	O
dose	O
group	O
had	O
a	O
significantly	O
increased	O
adjusted	O
OR	O
for	O
the	O
compound	O
outcome	O
variable	O
death	B-Disease
or	O
dependency	O
(	O
Barthel	O
Index	O
<	O
60	O
)	O
(	O
n	O
/	O
N	O
=	O
25	O
/	O
26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
to	O
101	O
.	O
74	O
)	O
and	O
death	B-Disease
alone	O
(	O
n	O
/	O
N	O
=	O
9	O
/	O
26	O
,	O
OR	O
4	O
.	O
336	O
,	O
95	O
%	O
CI	O
1	O
.	O
131	O
16	O
.	O
619	O
)	O
compared	O
with	O
all	O
placebo	O
patients	O
(	O
n	O
/	O
N	O
=	O
62	O
/	O
92	O
and	O
14	O
/	O
92	O
,	O
respectively	O
)	O
.	O
There	O
was	O
no	O
correlation	O
between	O
SBP	O
change	O
and	O
outcome	O
.	O
CONCLUSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
reduction	O
was	O
associated	O
with	O
neurological	O
worsening	O
after	O
the	O
intravenous	O
administration	O
of	O
high	O
-	O
dose	O
nimodipine	B-Chemical
after	O
acute	B-Disease
stroke	I-Disease
.	O
For	O
low	O
-	O
dose	O
nimodipine	B-Chemical
,	O
the	O
results	O
were	O
not	O
conclusive	O
.	O
These	O
results	O
do	O
not	O
confirm	O
or	O
exclude	O
a	O
neuroprotective	O
property	O
of	O
nimodipine	B-Chemical
.	O
Neonatal	O
pyridoxine	B-Chemical
responsive	O
convulsions	B-Disease
due	O
to	O
isoniazid	B-Chemical
therapy	O
.	O
A	O
17	O
-	O
day	O
-	O
old	O
infant	O
on	O
isoniazid	B-Chemical
therapy	O
13	O
mg	O
/	O
kg	O
daily	O
from	O
birth	O
because	O
of	O
maternal	O
tuberculosis	B-Disease
was	O
admitted	O
after	O
4	O
days	O
of	O
clonic	B-Disease
fits	I-Disease
.	O
No	O
underlying	O
infective	O
or	O
biochemical	O
cause	O
could	O
be	O
found	O
.	O
The	O
fits	B-Disease
ceased	O
within	O
4	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	B-Chemical
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	B-Chemical
deficiency	O
secondary	O
to	O
isoniazid	B-Chemical
medication	O
.	O
Ketamine	B-Chemical
sedation	O
for	O
the	O
reduction	O
of	O
children	O
'	O
s	O
fractures	B-Disease
in	O
the	O
emergency	O
department	O
.	O
BACKGROUND	O
:	O
There	O
recently	O
has	O
been	O
a	O
resurgence	O
in	O
the	O
utilization	O
of	O
ketamine	B-Chemical
,	O
a	O
unique	O
anesthetic	O
,	O
for	O
emergency	O
-	O
department	O
procedures	O
requiring	O
sedation	O
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
safety	O
and	O
efficacy	O
of	O
ketamine	B-Chemical
for	O
sedation	O
in	O
the	O
treatment	O
of	O
children	O
'	O
s	O
fractures	B-Disease
in	O
the	O
emergency	O
department	O
.	O
METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5	O
.	O
3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	B-Disease
or	O
dislocation	B-Disease
in	O
the	O
emergency	O
department	O
at	O
a	O
level	O
-	O
I	O
trauma	B-Disease
center	O
were	O
prospectively	O
evaluated	O
.	O
Ketamine	B-Chemical
hydrochloride	I-Chemical
was	O
administered	O
intravenously	O
(	O
at	O
a	O
dose	O
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
ninety	O
-	O
nine	O
of	O
the	O
patients	O
and	O
intramuscularly	O
(	O
at	O
a	O
dose	O
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
the	O
other	O
fifteen	O
.	O
A	O
board	O
-	O
certified	O
emergency	O
physician	O
skilled	O
in	O
airway	O
management	O
supervised	O
administration	O
of	O
the	O
anesthetic	O
,	O
and	O
the	O
patients	O
were	O
monitored	O
by	O
a	O
registered	O
nurse	O
.	O
Any	O
pain	B-Disease
during	O
the	O
reduction	O
was	O
rated	O
by	O
the	O
orthopaedic	O
surgeon	O
treating	O
the	O
patient	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	B-Disease
Scale	O
(	O
CHEOPS	O
)	O
.	O
RESULTS	O
:	O
The	O
average	O
time	O
from	O
intravenous	O
administration	O
of	O
ketamine	B-Chemical
to	O
manipulation	O
of	O
the	O
fracture	B-Disease
or	O
dislocation	B-Disease
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
minutes	O
)	O
,	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	O
was	O
four	O
minutes	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes	O
)	O
.	O
The	O
average	O
score	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	B-Disease
Scale	O
was	O
6	O
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
minimal	O
or	O
no	O
pain	B-Disease
during	O
fracture	B-Disease
reduction	O
.	O
Adequate	O
fracture	B-Disease
reduction	O
was	O
obtained	O
in	O
111	O
of	O
the	O
children	O
.	O
Ninety	O
-	O
nine	O
percent	O
(	O
sixty	O
-	O
eight	O
)	O
of	O
the	O
sixty	O
-	O
nine	O
parents	O
present	O
during	O
the	O
reduction	O
were	O
pleased	O
with	O
the	O
sedation	O
and	O
would	O
allow	O
it	O
to	O
be	O
used	O
again	O
in	O
a	O
similar	O
situation	O
.	O
Patency	O
of	O
the	O
airway	O
and	O
independent	O
respiration	O
were	O
maintained	O
in	O
all	O
of	O
the	O
patients	O
.	O
Blood	O
pressure	O
and	O
heart	O
rate	O
remained	O
stable	O
.	O
Minor	O
side	O
effects	O
included	O
nausea	B-Disease
(	O
thirteen	O
patients	O
)	O
,	O
emesis	B-Disease
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	B-Disease
)	O
,	O
clumsiness	B-Disease
(	O
evident	O
as	O
ataxic	B-Disease
movements	I-Disease
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	B-Disease
reaction	I-Disease
(	O
one	O
patient	O
)	O
.	O
No	O
long	O
-	O
term	O
sequelae	O
were	O
noted	O
,	O
and	O
no	O
patients	O
had	O
hallucinations	B-Disease
or	O
nightmares	O
.	O
CONCLUSIONS	O
:	O
Ketamine	B-Chemical
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	O
adequate	O
sedation	O
to	O
effectively	O
facilitate	O
the	O
reduction	O
of	O
children	O
'	O
s	O
fractures	B-Disease
in	O
the	O
emergency	O
department	O
at	O
our	O
institution	O
.	O
Ketamine	B-Chemical
should	O
only	O
be	O
used	O
in	O
an	O
environment	O
such	O
as	O
the	O
emergency	O
department	O
,	O
where	O
proper	O
one	O
-	O
on	O
-	O
one	O
monitoring	O
is	O
used	O
and	O
board	O
-	O
certified	O
physicians	O
skilled	O
in	O
airway	O
management	O
are	O
directly	O
involved	O
in	O
the	O
care	O
of	O
the	O
patient	O
.	O
Cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
-	O
associated	O
thrombotic	B-Disease
microangiopathy	I-Disease
.	O
The	O
development	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
(	O
TMA	B-Disease
)	O
associated	O
with	O
the	O
use	O
of	O
cyclosporine	B-Chemical
has	O
been	O
well	O
documented	O
.	O
Treatments	O
have	O
included	O
discontinuation	O
or	O
reduction	O
of	O
cyclosporine	B-Chemical
dose	O
with	O
or	O
without	O
concurrent	O
plasma	O
exchange	O
,	O
plasma	O
infusion	O
,	O
anticoagulation	O
,	O
and	O
intravenous	O
immunoglobulin	O
G	O
infusion	O
.	O
However	O
,	O
for	O
recipients	O
of	O
organ	O
transplantation	O
,	O
removing	O
the	O
inciting	O
agent	O
is	O
not	O
without	O
the	O
attendant	O
risk	O
of	O
precipitating	O
acute	O
rejection	O
and	O
graft	O
loss	O
.	O
The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
tacrolimus	B-Chemical
as	O
a	O
potent	O
immunosuppressive	O
agent	O
with	O
mechanisms	O
of	O
action	O
virtually	O
identical	O
to	O
those	O
of	O
cyclosporine	B-Chemical
.	O
As	O
a	O
result	O
,	O
switching	O
to	O
tacrolimus	B-Chemical
has	O
been	O
reported	O
to	O
be	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	O
setting	O
of	O
cyclosporine	B-Chemical
-	O
induced	O
TMA	B-Disease
.	O
With	O
the	O
more	O
widespread	O
application	O
of	O
tacrolimus	B-Chemical
in	O
organ	O
transplantation	O
,	O
tacrolimus	B-Chemical
-	O
associated	O
TMA	B-Disease
has	O
also	O
been	O
recognized	O
.	O
However	O
,	O
literature	O
regarding	O
the	O
incidence	O
of	O
the	O
recurrence	O
of	O
TMA	B-Disease
in	O
patients	O
exposed	O
sequentially	O
to	O
cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
is	O
limited	O
.	O
We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	O
who	O
developed	O
cyclosporine	B-Chemical
-	O
induced	O
TMA	B-Disease
that	O
responded	O
to	O
the	O
withdrawal	O
of	O
cyclosporine	B-Chemical
in	O
conjunction	O
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy	O
.	O
Introduction	O
of	O
tacrolimus	B-Chemical
as	O
an	O
alternative	O
immunosuppressive	O
agent	O
resulted	O
in	O
the	O
recurrence	O
of	O
TMA	B-Disease
and	O
the	O
subsequent	O
loss	O
of	O
the	O
renal	O
allograft	O
.	O
Patients	O
who	O
are	O
switched	O
from	O
cyclosporine	B-Chemical
to	O
tacrolimus	B-Chemical
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
recurrent	O
TMA	B-Disease
.	O
Analgesic	O
effect	O
of	O
intravenous	O
ketamine	B-Chemical
in	O
cancer	B-Disease
patients	O
on	O
morphine	B-Chemical
therapy	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O
Pain	B-Disease
not	O
responsive	O
to	O
morphine	B-Chemical
is	O
often	O
problematic	O
.	O
Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
antagonists	O
,	O
such	O
as	O
ketamine	B-Chemical
,	O
may	O
be	O
effective	O
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	B-Disease
syndromes	O
,	O
such	O
as	O
neuropathic	B-Disease
pain	I-Disease
.	O
A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	B-Chemical
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancer	B-Disease
patients	O
whose	O
pain	B-Disease
was	O
unrelieved	O
by	O
morphine	B-Chemical
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O
Pain	B-Disease
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	O
;	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
drowsiness	O
,	O
confusion	B-Disease
,	O
and	O
dry	B-Disease
mouth	I-Disease
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O
Ketamine	B-Chemical
,	O
but	O
not	O
saline	O
solution	O
,	O
significantly	O
reduced	O
the	O
pain	B-Disease
intensity	O
in	O
almost	O
all	O
the	O
patients	O
at	O
both	O
doses	O
.	O
This	O
effect	O
was	O
more	O
relevant	O
in	O
patients	O
treated	O
with	O
higher	O
doses	O
.	O
Hallucinations	B-Disease
occurred	O
in	O
4	O
patients	O
,	O
and	O
an	O
unpleasant	O
sensation	O
(	O
""""	O
empty	O
head	O
""""	O
)	O
was	O
also	O
reported	O
by	O
2	O
patients	O
.	O
These	O
episodes	O
reversed	O
after	O
the	O
administration	O
of	O
diazepam	B-Chemical
1	O
mg	O
intravenously	O
.	O
Significant	O
increases	O
in	O
drowsiness	O
were	O
reported	O
in	O
patients	O
treated	O
with	O
ketamine	B-Chemical
in	O
both	O
groups	O
and	O
were	O
more	O
marked	O
with	O
ketamine	B-Chemical
0	O
.	O
50	O
mg	O
/	O
kg	O
.	O
A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patients	O
who	O
received	O
0	O
.	O
50	O
mg	O
/	O
kg	O
of	O
ketamine	B-Chemical
.	O
Ketamine	B-Chemical
can	O
improve	O
morphine	B-Chemical
analgesia	O
in	O
difficult	O
pain	B-Disease
syndromes	O
,	O
such	O
as	O
neuropathic	B-Disease
pain	I-Disease
.	O
However	O
,	O
the	O
occurrence	O
of	O
central	O
adverse	O
effects	O
should	O
be	O
taken	O
into	O
account	O
,	O
especially	O
when	O
using	O
higher	O
doses	O
.	O
This	O
observation	O
should	O
be	O
tested	O
in	O
studies	O
of	O
prolonged	O
ketamine	B-Chemical
administration	O
.	O
Paclitaxel	B-Chemical
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	B-Chemical
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	O
in	O
metastatic	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
.	O
BACKGROUND	O
:	O
Cisplatin	B-Chemical
-	O
based	O
chemotherapy	O
combinations	O
improve	O
quality	O
of	O
life	O
and	O
survival	O
in	O
advanced	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
(	O
NSCLC	B-Disease
)	O
.	O
The	O
emergence	O
of	O
new	O
active	O
drugs	O
might	O
translate	O
into	O
more	O
effective	O
regimens	O
for	O
the	O
treatment	O
of	O
this	O
disease	O
.	O
METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	B-Disease
of	O
a	O
paclitaxel	B-Chemical
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	B-Chemical
combination	O
to	O
treat	O
metastatic	O
NSCLC	B-Disease
.	O
Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	B-Disease
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	O
with	O
a	O
combination	O
of	O
paclitaxel	B-Chemical
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	B-Chemical
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	B-Chemical
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O
Although	O
responding	O
patients	O
were	O
scheduled	O
to	O
receive	O
consolidation	O
radiotherapy	O
and	O
24	O
patients	O
received	O
preplanned	O
second	O
-	O
line	O
chemotherapy	O
after	O
disease	O
progression	O
,	O
the	O
response	O
and	O
toxicity	B-Disease
rates	O
reported	O
refer	O
only	O
to	O
the	O
chemotherapy	O
regimen	O
given	O
.	O
RESULTS	O
:	O
All	O
the	O
patients	O
were	O
examined	O
for	O
toxicity	B-Disease
;	O
34	O
were	O
examinable	O
for	O
response	O
.	O
An	O
objective	O
response	O
was	O
observed	O
in	O
73	O
.	O
5	O
%	O
of	O
the	O
patients	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
55	O
.	O
6	O
-	O
87	O
.	O
1	O
%	O
)	O
,	O
including	O
4	O
complete	O
responses	O
(	O
11	O
.	O
7	O
%	O
)	O
.	O
According	O
to	O
intention	O
-	O
to	O
-	O
treat	O
,	O
the	O
overall	O
response	O
rate	O
was	O
71	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
,	O
53	O
.	O
7	O
-	O
85	O
.	O
4	O
%	O
)	O
.	O
After	O
154	O
courses	O
of	O
therapy	O
,	O
the	O
median	O
dose	O
intensity	O
was	O
131	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
paclitaxel	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
117	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
cisplatin	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gemcitabine	B-Chemical
(	O
86	O
.	O
2	O
%	O
)	O
.	O
World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	B-Disease
and	O
thrombocytopenia	B-Disease
occurred	O
in	O
39	O
.	O
9	O
%	O
and	O
11	O
.	O
4	O
%	O
of	O
patients	O
,	O
respectively	O
.	O
There	O
was	O
one	O
treatment	O
-	O
related	O
death	B-Disease
.	O
Nonhematologic	O
toxicities	B-Disease
were	O
mild	O
.	O
After	O
a	O
median	O
follow	O
-	O
up	O
of	O
22	O
months	O
,	O
the	O
median	O
progression	O
free	O
survival	O
rate	O
was	O
7	O
months	O
,	O
and	O
the	O
median	O
survival	O
time	O
was	O
16	O
months	O
.	O
CONCLUSIONS	O
:	O
The	O
combination	O
of	O
paclitaxel	B-Chemical
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	B-Chemical
is	O
well	O
tolerated	O
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	B-Disease
.	O
This	O
treatment	O
merits	O
further	O
comparison	O
with	O
other	O
cisplatin	B-Chemical
-	O
based	O
regimens	O
.	O
Serotonergic	B-Chemical
antidepressants	I-Chemical
and	O
urinary	B-Disease
incontinence	I-Disease
.	O
Many	O
new	O
serotonergic	B-Chemical
antidepressants	I-Chemical
have	O
been	O
introduced	O
over	O
the	O
past	O
decade	O
.	O
Although	O
urinary	B-Disease
incontinence	I-Disease
is	O
listed	O
as	O
one	O
side	O
effect	O
of	O
these	O
drugs	O
in	O
their	O
package	O
inserts	O
there	O
is	O
only	O
one	O
report	O
in	O
the	O
literature	O
.	O
This	O
concerns	O
2	O
male	O
patients	O
who	O
experienced	O
incontinence	B-Disease
while	O
taking	O
venlafaxine	B-Chemical
.	O
In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	B-Disease
secondary	O
to	O
the	O
selective	O
serotonin	B-Chemical
reuptake	O
inhibitors	O
paroxetine	B-Chemical
and	O
sertraline	B-Chemical
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	B-Chemical
.	O
In	O
2	O
of	O
the	O
3	O
cases	O
the	O
patients	O
were	O
also	O
taking	O
lithium	B-Chemical
carbonate	I-Chemical
and	O
beta	O
-	O
blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
incontinence	B-Disease
.	O
Animal	O
studies	O
suggest	O
that	O
incontinence	B-Disease
secondary	O
to	O
serotonergic	B-Chemical
antidepressants	I-Chemical
could	O
be	O
mediated	O
by	O
the	O
5HT4	O
receptors	O
found	O
on	O
the	O
bladder	O
.	O
Further	O
research	O
is	O
needed	O
to	O
delineate	O
the	O
frequency	O
of	O
this	O
troubling	O
side	O
effect	O
and	O
how	O
best	O
to	O
treat	O
it	O
.	O
Acute	O
cocaine	B-Chemical
-	O
induced	O
seizures	B-Disease
:	O
differential	O
sensitivity	O
of	O
six	O
inbred	O
mouse	O
strains	O
.	O
Mature	O
male	O
and	O
female	O
mice	O
from	O
six	O
inbred	O
stains	O
were	O
tested	O
for	O
susceptibility	O
to	O
behavioral	O
seizures	B-Disease
induced	O
by	O
a	O
single	O
injection	O
of	O
cocaine	B-Chemical
.	O
Cocaine	B-Chemical
was	O
injected	O
ip	O
over	O
a	O
range	O
of	O
doses	O
(	O
50	O
-	O
100	O
mg	O
/	O
kg	O
)	O
and	O
behavior	O
was	O
monitored	O
for	O
20	O
minutes	O
.	O
Seizure	B-Disease
end	O
points	O
included	O
latency	O
to	O
forelimb	O
or	O
hindlimb	O
clonus	O
,	O
latency	O
to	O
clonic	O
running	O
seizure	B-Disease
and	O
latency	O
to	O
jumping	O
bouncing	O
seizure	B-Disease
.	O
A	O
range	O
of	O
strain	O
specific	O
sensitivities	O
was	O
documented	O
with	O
A	O
/	O
J	O
and	O
SJL	O
mice	O
being	O
most	O
sensitive	O
and	O
C57BL	O
/	O
6J	O
most	O
resistant	O
.	O
DBA	O
/	O
2J	O
,	O
BALB	O
/	O
cByJ	O
and	O
NZW	O
/	O
LacJ	O
strains	O
exhibited	O
intermediate	O
sensitivity	O
.	O
EEG	O
recordings	O
were	O
made	O
in	O
SJL	O
,	O
A	O
/	O
J	O
and	O
C57BL	O
/	O
6J	O
mice	O
revealing	O
a	O
close	O
correspondence	O
between	O
electrical	O
activity	O
and	O
behavior	O
.	O
Additionally	O
,	O
levels	O
of	O
cocaine	B-Chemical
determined	O
in	O
hippocampus	O
and	O
cortex	O
were	O
not	O
different	O
between	O
sensitive	O
and	O
resistant	O
strains	O
.	O
Additional	O
studies	O
of	O
these	O
murine	O
strains	O
may	O
be	O
useful	O
for	O
investigating	O
genetic	O
influences	O
on	O
cocaine	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O
Hypotension	B-Disease
following	O
the	O
initiation	O
of	O
tizanidine	B-Chemical
in	O
a	O
patient	O
treated	O
with	O
an	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	B-Disease
.	O
Centrally	O
acting	O
alpha	O
-	O
2	O
adrenergic	O
agonists	O
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
spasticity	B-Disease
related	O
to	O
disorders	B-Disease
of	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
.	O
In	O
addition	O
to	O
their	O
effects	O
on	O
spasticity	B-Disease
,	O
certain	O
adverse	O
cardiorespiratory	O
effects	O
have	O
been	O
reported	O
.	O
Adults	O
chronically	O
treated	O
with	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitors	O
may	O
have	O
a	O
limited	O
ability	O
to	O
respond	O
to	O
hypotension	B-Disease
when	O
the	O
sympathetic	O
response	O
is	O
simultaneously	O
blocked	O
.	O
The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	B-Chemical
,	O
an	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	B-Disease
who	O
developed	O
hypotension	B-Disease
following	O
the	O
addition	O
of	O
tizanidine	B-Chemical
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	B-Disease
.	O
The	O
possible	O
interaction	O
of	O
tizanidine	B-Chemical
and	O
other	O
antihypertensive	O
agents	O
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribing	O
therapy	O
to	O
treat	O
either	O
hypertension	B-Disease
or	O
spasticity	B-Disease
in	O
such	O
patients	O
.	O
Two	O
mouse	O
lines	O
selected	O
for	O
differential	O
sensitivities	O
to	O
beta	B-Chemical
-	I-Chemical
carboline	I-Chemical
-	O
induced	O
seizures	B-Disease
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	O
of	O
other	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
ligands	O
.	O
Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	B-Disease
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	B-Chemical
beta	I-Chemical
-	I-Chemical
carboline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
beta	B-Chemical
-	I-Chemical
CCM	I-Chemical
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
benzodiazepine	B-Chemical
site	O
.	O
Our	O
aim	O
was	O
to	O
characterize	O
both	O
lines	O
'	O
sensitivities	O
to	O
various	O
physiological	O
effects	O
of	O
other	O
ligands	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
.	O
We	O
measured	O
diazepam	B-Chemical
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	B-Chemical
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	B-Chemical
-	O
and	O
pentylenetetrazol	B-Chemical
-	O
induced	O
seizures	B-Disease
after	O
i	O
.	O
p	O
.	O
injections	O
.	O
Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	B-Chemical
-	I-Chemical
CCM	I-Chemical
can	O
be	O
extended	O
to	O
diazepam	B-Chemical
,	O
picrotoxin	B-Chemical
,	O
and	O
pentylenetetrazol	B-Chemical
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
.	O
Propylthiouracil	B-Chemical
-	O
induced	O
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibody	O
-	O
positive	O
vasculitis	B-Disease
in	O
conjunction	O
with	O
pericarditis	B-Disease
.	O
OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
propylthiouracil	B-Chemical
-	O
induced	O
vasculitis	B-Disease
manifesting	O
with	O
pericarditis	B-Disease
.	O
METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	B-Disease
treated	O
with	O
propylthiouracil	B-Chemical
in	O
whom	O
a	O
syndrome	O
of	O
pericarditis	B-Disease
,	O
fever	B-Disease
,	O
and	O
glomerulonephritis	B-Disease
developed	O
.	O
Serologic	O
testing	O
and	O
immunologic	O
studies	O
were	O
done	O
,	O
and	O
a	O
pericardial	O
biopsy	O
was	O
performed	O
.	O
RESULTS	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
had	O
a	O
febrile	B-Disease
illness	I-Disease
and	O
evidence	O
of	O
pericarditis	B-Disease
,	O
which	O
was	O
confirmed	O
by	O
biopsy	O
.	O
Serologic	O
evaluation	O
revealed	O
the	O
presence	O
of	O
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
(	O
pANCA	O
)	O
against	O
myeloperoxidase	O
(	O
MPO	O
)	O
.	O
Propylthiouracil	B-Chemical
therapy	O
was	O
withdrawn	O
,	O
and	O
she	O
was	O
treated	O
with	O
a	O
1	O
-	O
month	O
course	O
of	O
prednisone	B-Chemical
,	O
which	O
alleviated	O
her	O
symptoms	O
.	O
A	O
literature	O
review	O
revealed	O
no	O
prior	O
reports	O
of	O
pericarditis	B-Disease
in	O
anti	O
-	O
MPO	O
pANCA	O
-	O
positive	O
vasculitis	B-Disease
associated	O
with	O
propylthio	B-Chemical
-	I-Chemical
uracil	I-Chemical
therapy	O
.	O
CONCLUSION	O
:	O
Pericarditis	B-Disease
may	O
be	O
the	O
initial	O
manifestation	O
of	O
drug	O
-	O
induced	O
vasculitis	B-Disease
attributable	O
to	O
propylthio	B-Chemical
-	I-Chemical
uracil	I-Chemical
therapy	O
.	O
Repeated	O
transient	O
anuria	B-Disease
following	O
losartan	B-Chemical
administration	O
in	O
a	O
patient	O
with	O
a	O
solitary	O
kidney	O
.	O
We	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
hypertensive	B-Disease
man	O
with	O
a	O
solitary	O
kidney	O
and	O
chronic	B-Disease
renal	I-Disease
insufficiency	I-Disease
who	O
developed	O
two	O
episodes	O
of	O
transient	O
anuria	B-Disease
after	O
losartan	B-Chemical
administration	O
.	O
He	O
was	O
hospitalized	O
for	O
a	O
myocardial	B-Disease
infarction	I-Disease
with	O
pulmonary	B-Disease
edema	I-Disease
,	O
treated	O
with	O
high	O
-	O
dose	O
diuretics	O
.	O
Due	O
to	O
severe	O
systolic	B-Disease
dysfunction	I-Disease
losartan	B-Chemical
was	O
prescribed	O
.	O
Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
50	O
mg	O
of	O
losartan	B-Chemical
resulted	O
in	O
a	O
sudden	O
anuria	B-Disease
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dose	O
furosemide	B-Chemical
and	O
amine	B-Chemical
infusion	O
.	O
One	O
week	O
later	O
,	O
by	O
mistake	O
,	O
losartan	B-Chemical
was	O
prescribed	O
again	O
and	O
after	O
the	O
second	O
dose	O
of	O
50	O
mg	O
,	O
the	O
patient	O
developed	O
a	O
second	O
episode	O
of	O
transient	O
anuria	B-Disease
lasting	O
10	O
hours	O
.	O
During	O
these	O
two	O
episodes	O
,	O
his	O
blood	O
pressure	O
diminished	O
but	O
no	O
severe	O
hypotension	B-Disease
was	O
noted	O
.	O
Ultimately	O
,	O
an	O
arteriography	O
showed	O
a	O
70	O
-	O
80	O
%	O
renal	B-Disease
artery	I-Disease
stenosis	I-Disease
.	O
In	O
this	O
patient	O
,	O
renal	B-Disease
artery	I-Disease
stenosis	I-Disease
combined	O
with	O
heart	B-Disease
failure	I-Disease
and	O
diuretic	O
therapy	O
certainly	O
resulted	O
in	O
a	O
strong	O
activation	O
of	O
the	O
renin	O
-	O
angiotensin	B-Chemical
system	O
(	O
RAS	O
)	O
.	O
Under	O
such	O
conditions	O
,	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
blockade	O
by	O
losartan	B-Chemical
probably	O
induced	O
a	O
critical	O
fall	O
in	O
glomerular	O
filtration	O
pressure	O
.	O
This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
antagonist	O
losartan	B-Chemical
can	O
cause	O
serious	O
unexpected	O
complications	O
in	O
patients	O
with	O
renovascular	B-Disease
disease	I-Disease
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O
Calcineurin	O
-	O
inhibitor	O
induced	O
pain	B-Disease
syndrome	O
(	O
CIPS	B-Disease
)	O
:	O
a	O
severe	O
disabling	O
complication	O
after	O
organ	O
transplantation	O
.	O
Bone	O
pain	B-Disease
after	O
transplantation	O
is	O
a	O
frequent	O
complication	O
that	O
can	O
be	O
caused	O
by	O
several	O
diseases	O
.	O
Treatment	O
strategies	O
depend	O
on	O
the	O
correct	O
diagnosis	O
of	O
the	O
pain	B-Disease
.	O
Nine	O
patients	O
with	O
severe	O
pain	B-Disease
in	O
their	O
feet	O
,	O
which	O
was	O
registered	O
after	O
transplantation	O
,	O
were	O
investigated	O
.	O
Bone	O
scans	O
showed	O
an	O
increased	O
tracer	O
uptake	O
of	O
the	O
foot	O
bones	O
.	O
Magnetic	O
resonance	O
imaging	O
demonstrated	O
bone	B-Disease
marrow	I-Disease
oedema	I-Disease
in	O
the	O
painful	O
bones	O
.	O
Pain	B-Disease
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	O
foot	O
pain	B-Disease
,	O
like	O
reflex	B-Disease
sympathetic	I-Disease
dystrophy	I-Disease
,	O
polyneuropathy	B-Disease
,	O
Morton	B-Disease
'	I-Disease
s	I-Disease
neuralgia	I-Disease
,	O
gout	B-Disease
,	O
osteoporosis	B-Disease
,	O
avascular	B-Disease
necrosis	I-Disease
,	O
intermittent	B-Disease
claudication	I-Disease
,	O
orthopaedic	O
foot	B-Disease
deformities	I-Disease
,	O
stress	B-Disease
fractures	I-Disease
,	O
and	O
hyperparathyroidism	B-Disease
.	O
The	O
reduction	O
of	O
cyclosporine	B-Chemical
-	O
or	O
tacrolimus	B-Chemical
trough	O
levels	O
and	O
the	O
administration	O
of	O
calcium	B-Chemical
channel	O
blockers	O
led	O
to	O
relief	O
of	O
pain	B-Disease
.	O
The	O
Calcineurin	O
-	O
inhibitor	O
Induced	O
Pain	B-Disease
Syndrome	O
(	O
CIPS	B-Disease
)	O
is	O
a	O
rare	O
but	O
severe	O
side	O
effect	O
of	O
cyclosporine	B-Chemical
or	O
tacrolimus	B-Chemical
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O
Incorrect	O
diagnosis	O
of	O
the	O
syndrome	O
will	O
lead	O
to	O
a	O
significant	O
reduction	O
of	O
life	O
quality	O
in	O
patients	O
suffering	O
from	O
CIPS	B-Disease
.	O
Brain	O
natriuretic	O
peptide	O
is	O
a	O
predictor	O
of	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
Anthracyclines	B-Chemical
are	O
effective	O
antineoplastic	O
drugs	O
,	O
but	O
they	O
frequently	O
cause	O
dose	O
-	O
related	O
cardiotoxicity	B-Disease
.	O
The	O
cardiotoxicity	B-Disease
of	O
conventional	O
anthracycline	B-Chemical
therapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methods	O
that	O
are	O
highly	O
sensitive	O
and	O
capable	O
of	O
predicting	O
cardiac	B-Disease
dysfunction	I-Disease
.	O
We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
in	O
patients	O
with	O
acute	B-Disease
leukemia	I-Disease
treated	O
with	O
a	O
daunorubicin	B-Chemical
(	O
DNR	B-Chemical
)	O
-	O
containing	O
regimen	O
.	O
Thirteen	O
patients	O
with	O
acute	B-Disease
leukemia	I-Disease
were	O
treated	O
with	O
a	O
DNR	B-Chemical
-	O
containing	O
regimen	O
.	O
Cardiac	O
functions	O
were	O
evaluated	O
with	O
radionuclide	O
angiography	O
before	O
chemotherapies	O
.	O
The	O
plasma	O
levels	O
of	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
and	O
BNP	O
were	O
measured	O
at	O
the	O
time	O
of	O
radionuclide	O
angiography	O
.	O
Three	O
patients	O
developed	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O
Five	O
patients	O
were	O
diagnosed	O
as	O
having	O
subclinical	O
heart	B-Disease
failure	I-Disease
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O
The	O
plasma	O
levels	O
of	O
BNP	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	B-Disease
failure	I-Disease
increased	O
above	O
the	O
normal	O
limit	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	O
the	O
detection	O
of	O
clinical	O
or	O
subclinical	O
heart	B-Disease
failure	I-Disease
by	O
radionuclide	O
angiography	O
.	O
On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
increase	O
in	O
the	O
patients	O
without	O
heart	B-Disease
failure	I-Disease
given	O
DNR	B-Chemical
,	O
even	O
at	O
more	O
than	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
The	O
plasma	O
level	O
of	O
ANP	O
did	O
not	O
always	O
increase	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	B-Disease
failure	I-Disease
.	O
These	O
preliminary	O
results	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
early	O
and	O
sensitive	O
indicator	O
of	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
Nephrotoxicity	B-Disease
of	O
combined	O
cephalothin	B-Chemical
-	O
gentamicin	B-Chemical
regimen	O
.	O
Two	O
patients	O
developed	O
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	B-Disease
renal	I-Disease
failure	I-Disease
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	O
of	O
cephalothin	B-Chemical
sodium	I-Chemical
and	O
gentamicin	B-Chemical
sulfate	I-Chemical
therapy	O
.	O
Patients	O
who	O
are	O
given	O
this	O
drug	O
regimen	O
should	O
be	O
observed	O
very	O
carefully	O
for	O
early	O
signs	O
of	O
nephrotoxicity	B-Disease
.	O
High	O
doses	O
of	O
this	O
antibiotic	O
combination	O
should	O
be	O
avoided	O
especially	O
in	O
elderly	O
patients	O
.	O
Patients	O
with	O
renal	B-Disease
insufficiency	I-Disease
should	O
not	O
be	O
given	O
this	O
regimen	O
.	O
In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	B-Disease
cell	O
deaths	O
during	O
acetaminophen	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
,	O
amiodarone	B-Chemical
-	O
induced	O
lung	B-Disease
toxicity	I-Disease
and	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
by	O
a	O
novel	O
IH636	B-Chemical
grape	I-Chemical
seed	I-Chemical
proanthocyanidin	I-Chemical
extract	I-Chemical
.	O
Grape	B-Chemical
seed	I-Chemical
extract	I-Chemical
,	O
primarily	O
a	O
mixture	O
of	O
proanthocyanidins	B-Chemical
,	O
has	O
been	O
shown	O
to	O
modulate	O
a	O
wide	O
-	O
range	O
of	O
biological	O
,	O
pharmacological	O
and	O
toxicological	O
effects	O
which	O
are	O
mainly	O
cytoprotective	O
.	O
This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	B-Chemical
grape	I-Chemical
seed	I-Chemical
proanthocyanidin	I-Chemical
extract	I-Chemical
(	O
GSPE	B-Chemical
)	O
to	O
prevent	O
acetaminophen	B-Chemical
(	O
AAP	B-Chemical
)	O
-	O
induced	O
nephrotoxicity	B-Disease
,	O
amiodarone	B-Chemical
(	O
AMI	B-Chemical
)	O
-	O
induced	O
lung	B-Disease
toxicity	I-Disease
,	O
and	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
induced	O
cardiotoxicity	B-Disease
in	O
mice	O
.	O
Experimental	O
design	O
consisted	O
of	O
four	O
groups	O
:	O
control	O
(	O
vehicle	O
alone	O
)	O
,	O
GSPE	B-Chemical
alone	O
,	O
drug	O
alone	O
and	O
GSPE	B-Chemical
+	O
drug	O
.	O
For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
100	O
mg	O
/	O
Kg	O
GSPE	B-Chemical
for	O
7	O
-	O
10	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	B-Chemical
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	B-Chemical
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	B-Chemical
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O
Parameters	O
of	O
study	O
included	O
analysis	O
of	O
serum	O
chemistry	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
orderly	O
fragmentation	O
of	O
genomic	O
DNA	O
(	O
both	O
endonuclease	O
-	O
dependent	O
and	O
independent	O
)	O
in	O
addition	O
to	O
microscopic	O
evaluation	O
of	O
damage	O
and	O
/	O
or	O
protection	O
in	O
corresponding	O
PAS	O
stained	O
tissues	O
.	O
Results	O
indicate	O
that	O
GSPE	B-Chemical
preexposure	O
prior	O
to	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O
Histopathological	O
examination	O
of	O
kidney	O
,	O
heart	O
and	O
lung	O
sections	O
revealed	O
moderate	O
to	O
massive	O
tissue	B-Disease
damage	I-Disease
with	O
a	O
variety	O
of	O
morphological	O
aberrations	O
by	O
all	O
the	O
three	O
drugs	O
in	O
the	O
absence	O
of	O
GSPE	B-Chemical
preexposure	O
than	O
in	O
its	O
presence	O
.	O
GSPE	B-Chemical
+	O
drug	O
exposed	O
tissues	O
exhibited	O
minor	O
residual	O
damage	O
or	O
near	O
total	O
recovery	O
.	O
Additionally	O
,	O
histopathological	O
alterations	O
mirrored	O
both	O
serum	O
chemistry	O
changes	O
and	O
the	O
pattern	O
of	O
DNA	O
fragmentation	O
.	O
Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
induced	O
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	B-Disease
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	B-Chemical
.	O
Since	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	B-Chemical
may	O
be	O
linked	O
to	O
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O
In	O
addition	O
,	O
its	O
'	O
presumed	O
contribution	O
to	O
DNA	O
repair	O
may	O
be	O
another	O
important	O
attribute	O
,	O
which	O
played	O
a	O
role	O
in	O
the	O
chemoprevention	O
process	O
.	O
Additionally	O
,	O
this	O
may	O
have	O
been	O
the	O
first	O
report	O
on	O
AMI	B-Chemical
-	O
induced	O
apoptotic	O
death	O
in	O
the	O
lung	O
tissue	O
.	O
Taken	O
together	O
,	O
these	O
events	O
undoubtedly	O
establish	O
GSPE	B-Chemical
'	O
s	O
abundant	O
bioavailability	O
,	O
and	O
the	O
power	O
to	O
defend	O
multiple	O
target	O
organs	O
from	O
toxic	O
assaults	O
induced	O
by	O
structurally	O
diverse	O
and	O
functionally	O
different	O
entities	O
in	O
vivo	O
.	O
Antidepressant	B-Chemical
-	O
induced	O
mania	B-Disease
in	O
bipolar	B-Disease
patients	O
:	O
identification	O
of	O
risk	O
factors	O
.	O
BACKGROUND	O
:	O
Concerns	O
about	O
possible	O
risks	O
of	O
switching	O
to	O
mania	B-Disease
associated	O
with	O
antidepressants	B-Chemical
continue	O
to	O
interfere	O
with	O
the	O
establishment	O
of	O
an	O
optimal	O
treatment	O
paradigm	O
for	O
bipolar	B-Disease
depression	I-Disease
.	O
METHOD	O
:	O
The	O
response	O
of	O
44	O
patients	O
meeting	O
DSM	O
-	O
IV	O
criteria	O
for	O
bipolar	B-Disease
disorder	I-Disease
to	O
naturalistic	O
treatment	O
was	O
assessed	O
for	O
at	O
least	O
6	O
weeks	O
using	O
the	O
Montgomery	O
-	O
Asberg	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Bech	O
-	O
Rafaelson	O
Mania	O
Rating	O
Scale	O
.	O
Patients	O
who	O
experienced	O
a	O
manic	B-Disease
or	O
hypomanic	B-Disease
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	B-Disease
-	I-Disease
IV	I-Disease
bipolar	I-Disease
I	I-Disease
vs	O
.	O
bipolar	B-Disease
II	I-Disease
)	O
,	O
number	O
of	O
previous	O
manic	B-Disease
episodes	O
,	O
type	O
of	O
antidepressant	B-Chemical
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	B-Chemical
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	B-Chemical
reuptake	I-Chemical
inhibitors	I-Chemical
[	O
SSRIs	B-Chemical
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	B-Chemical
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O
RESULTS	O
:	O
Switches	O
to	O
hypomania	B-Disease
or	O
mania	B-Disease
occurred	O
in	O
27	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	B-Chemical
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
manic	B-Disease
episodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomanic	B-Disease
episodes	O
.	O
Sex	O
,	O
age	O
,	O
diagnosis	O
(	O
bipolar	B-Disease
I	I-Disease
vs	O
.	O
bipolar	B-Disease
II	I-Disease
)	O
,	O
and	O
additional	O
treatment	O
did	O
not	O
affect	O
the	O
risk	O
of	O
switching	O
.	O
The	O
incidence	O
of	O
mood	O
switches	O
seemed	O
not	O
to	O
differ	O
between	O
patients	O
receiving	O
an	O
anticonvulsant	O
and	O
those	O
receiving	O
no	O
mood	O
stabilizer	O
.	O
In	O
contrast	O
,	O
mood	O
switches	O
were	O
less	O
frequent	O
in	O
patients	O
receiving	O
lithium	B-Chemical
(	O
15	O
%	O
,	O
4	O
/	O
26	O
)	O
than	O
in	O
patients	O
not	O
treated	O
with	O
lithium	B-Chemical
(	O
44	O
%	O
,	O
8	O
/	O
18	O
;	O
p	O
=	O
.	O
04	O
)	O
.	O
The	O
number	O
of	O
previous	O
manic	B-Disease
episodes	O
did	O
not	O
affect	O
the	O
probability	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
score	O
on	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semistructured	O
Affective	O
Temperament	O
Interview	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
switching	O
(	O
p	O
=	O
.	O
008	O
)	O
.	O
CONCLUSION	O
:	O
The	O
frequency	O
of	O
mood	O
switching	O
associated	O
with	O
acute	O
antidepressant	B-Chemical
therapy	O
may	O
be	O
reduced	O
by	O
lithium	B-Chemical
treatment	O
.	O
Particular	O
attention	O
should	O
be	O
paid	O
to	O
patients	O
with	O
a	O
hyperthymic	O
temperament	O
,	O
who	O
have	O
a	O
greater	O
risk	O
of	O
mood	O
switches	O
.	O
Peritubular	O
capillary	O
basement	O
membrane	O
reduplication	O
in	O
allografts	O
and	O
native	O
kidney	B-Disease
disease	I-Disease
:	O
a	O
clinicopathologic	O
study	O
of	O
278	O
consecutive	O
renal	O
specimens	O
.	O
BACKGROUND	O
:	O
An	O
association	O
has	O
been	O
found	O
between	O
transplant	B-Disease
glomerulopathy	I-Disease
(	O
TG	B-Disease
)	O
and	O
reduplication	O
of	O
peritubular	O
capillary	O
basement	O
membranes	O
(	O
PTCR	O
)	O
.	O
Although	O
such	O
an	O
association	O
is	O
of	O
practical	O
and	O
theoretical	O
importance	O
,	O
only	O
one	O
prospective	O
study	O
has	O
tried	O
to	O
confirm	O
it	O
.	O
METHODS	O
:	O
We	O
examined	O
278	O
consecutive	O
renal	O
specimens	O
(	O
from	O
135	O
transplants	O
and	O
143	O
native	O
kidneys	O
)	O
for	O
ultrastructural	O
evidence	O
of	O
PTCR	O
.	O
In	O
addition	O
to	O
renal	O
allografts	O
with	O
TG	B-Disease
,	O
we	O
also	O
examined	O
grafts	O
with	O
acute	O
rejection	O
,	O
recurrent	O
glomerulonephritis	B-Disease
,	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
and	O
stable	O
grafts	O
(	O
""""	O
protocol	O
biopsies	O
""""	O
)	O
.	O
Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	B-Disease
as	O
well	O
as	O
cases	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
,	O
malignant	B-Disease
hypertension	I-Disease
,	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
,	O
and	O
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
.	O
RESULTS	O
:	O
We	O
found	O
PTCR	O
in	O
14	O
of	O
15	O
cases	O
of	O
TG	B-Disease
,	O
in	O
7	O
transplant	O
biopsy	O
specimens	O
without	O
TG	B-Disease
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	O
biopsy	O
specimens	O
.	O
These	O
13	O
included	O
cases	O
of	O
malignant	B-Disease
hypertension	I-Disease
,	O
thrombotic	B-Disease
microangiopathy	I-Disease
,	O
lupus	B-Disease
nephritis	I-Disease
,	O
Henoch	B-Disease
-	I-Disease
Schonlein	I-Disease
nephritis	I-Disease
,	O
crescentic	O
glomerulonephritis	B-Disease
,	O
and	O
cocaine	B-Chemical
-	O
related	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O
Mild	O
PTCR	O
in	O
allografts	O
without	O
TG	B-Disease
did	O
not	O
predict	O
renal	B-Disease
failure	I-Disease
or	O
significant	O
proteinuria	B-Disease
after	O
follow	O
-	O
up	O
periods	O
of	O
between	O
3	O
months	O
and	O
1	O
year	O
.	O
CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplants	O
,	O
there	O
is	O
a	O
strong	O
association	O
between	O
well	O
-	O
developed	O
PTCR	O
and	O
TG	B-Disease
,	O
while	O
the	O
significance	O
of	O
mild	O
PTCR	O
and	O
its	O
predictive	O
value	O
in	O
the	O
absence	O
of	O
TG	B-Disease
is	O
unclear	O
.	O
PTCR	O
also	O
occurs	O
in	O
certain	O
native	O
kidney	B-Disease
diseases	I-Disease
,	O
though	O
the	O
association	O
is	O
not	O
as	O
strong	O
as	O
that	O
for	O
TG	B-Disease
.	O
We	O
suggest	O
that	O
repeated	O
endothelial	B-Disease
injury	I-Disease
,	O
including	O
immunologic	B-Disease
injury	I-Disease
,	O
may	O
be	O
the	O
cause	O
of	O
this	O
lesion	O
both	O
in	O
allografts	O
and	O
native	O
kidneys	O
.	O
Caffeine	B-Chemical
-	O
induced	O
cardiac	B-Disease
arrhythmia	I-Disease
:	O
an	O
unrecognised	O
danger	O
of	O
healthfood	O
products	O
.	O
We	O
describe	O
a	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
pre	O
-	O
existing	O
mitral	B-Disease
valve	I-Disease
prolapse	I-Disease
who	O
developed	O
intractable	O
ventricular	B-Disease
fibrillation	I-Disease
after	O
consuming	O
a	O
""""	O
natural	O
energy	O
""""	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	O
of	O
caffeine	B-Chemical
.	O
This	O
case	O
highlights	O
the	O
need	O
for	O
adequate	O
labelling	O
and	O
regulation	O
of	O
such	O
products	O
.	O
Conformationally	O
restricted	O
analogs	O
of	O
BD1008	B-Chemical
and	O
an	O
antisense	O
oligodeoxynucleotide	B-Chemical
targeting	O
sigma1	O
receptors	O
produce	O
anti	O
-	O
cocaine	B-Chemical
effects	O
in	O
mice	O
.	O
Cocaine	B-Chemical
'	O
s	O
ability	O
to	O
interact	O
with	O
sigma	O
receptors	O
suggests	O
that	O
these	O
proteins	O
mediate	O
some	O
of	O
its	O
behavioral	O
effects	O
.	O
Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	B-Chemical
(	O
3S	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diazabicyclo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
nonane	I-Chemical
)	O
,	O
BD1063	B-Chemical
(	O
1	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methylpiperazine	I-Chemical
)	O
,	O
and	O
LR132	B-Chemical
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O
Competition	O
binding	O
assays	O
demonstrated	O
that	O
all	O
three	O
compounds	O
have	O
high	O
affinities	O
for	O
sigma1	O
receptors	O
.	O
The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	O
negligible	O
affinities	O
for	O
dopamine	B-Chemical
,	O
opioid	O
,	O
GABA	B-Chemical
(	O
A	O
)	O
and	O
NMDA	B-Chemical
receptors	O
.	O
In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD1018	B-Chemical
,	O
BD1063	B-Chemical
,	O
or	O
LR132	B-Chemical
significantly	O
attenuated	O
cocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
and	O
lethality	O
.	O
Moreover	O
,	O
post	O
-	O
treatment	O
with	O
LR132	B-Chemical
prevented	O
cocaine	B-Chemical
-	O
induced	O
lethality	O
in	O
a	O
significant	O
proportion	O
of	O
animals	O
.	O
In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	B-Chemical
-	I-Chemical
o	I-Chemical
-	I-Chemical
tolylguanidine	I-Chemical
(	O
DTG	B-Chemical
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	B-Chemical
(	O
3R	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diazabicyclo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
nonane	I-Chemical
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	B-Disease
of	O
cocaine	B-Chemical
.	O
At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	O
on	O
locomotion	O
,	O
BD1018	B-Chemical
,	O
BD1063	B-Chemical
and	O
LR132	B-Chemical
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	B-Chemical
.	O
To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti	O
-	O
cocaine	B-Chemical
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	B-Chemical
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	O
the	O
convulsive	B-Disease
and	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	B-Chemical
.	O
Together	O
,	O
the	O
data	O
suggests	O
that	O
functional	O
antagonism	O
of	O
sigma	O
receptors	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
cocaine	B-Chemical
-	O
induced	O
behaviors	O
.	O
Ranitidine	B-Chemical
-	O
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	O
a	O
cadaveric	O
renal	O
allograft	O
.	O
Ranitidine	B-Chemical
frequently	O
is	O
used	O
for	O
preventing	O
peptic	O
ulceration	O
after	O
renal	O
transplantation	O
.	O
This	O
drug	O
occasionally	O
has	O
been	O
associated	O
with	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	O
native	O
kidneys	O
.	O
There	O
are	O
no	O
similar	O
reports	O
with	O
renal	O
transplantation	O
.	O
We	O
report	O
a	O
case	O
of	O
ranitidine	B-Chemical
-	O
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	O
a	O
recipient	O
of	O
a	O
cadaveric	O
renal	O
allograft	O
presenting	O
with	O
acute	O
allograft	O
dysfunction	O
within	O
48	O
hours	O
of	O
exposure	O
to	O
the	O
drug	O
.	O
The	O
biopsy	O
specimen	O
showed	O
pathognomonic	O
features	O
,	O
including	O
eosinophilic	O
infiltration	O
of	O
the	O
interstitial	O
compartment	O
.	O
Allograft	O
function	O
improved	O
rapidly	O
and	O
returned	O
to	O
baseline	O
after	O
stopping	O
the	O
drug	O
.	O
Liver	B-Disease
disease	I-Disease
caused	O
by	O
propylthiouracil	B-Chemical
.	O
This	O
report	O
presents	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
light	O
and	O
electron	O
microscopic	O
observations	O
on	O
a	O
patient	O
with	O
chronic	B-Disease
active	I-Disease
(	I-Disease
aggressive	I-Disease
)	I-Disease
hepatitis	I-Disease
caused	O
by	O
the	O
administration	O
of	O
propylthiouracil	B-Chemical
.	O
This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
drugs	O
that	O
must	O
be	O
considered	O
in	O
the	O
evaluation	O
of	O
chronic	O
liver	B-Disease
disease	I-Disease
.	O
Withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
rabbit	I-Disease
syndrome	I-Disease
during	O
dose	O
reduction	O
of	O
risperidone	B-Chemical
.	O
Rabbit	B-Disease
syndrome	I-Disease
(	O
RS	B-Disease
)	O
is	O
a	O
rare	O
extrapyramidal	O
side	O
effect	O
caused	O
by	O
prolonged	O
neuroleptic	O
medication	O
.	O
Here	O
we	O
present	O
a	O
case	O
of	O
withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
RS	I-Disease
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported	O
.	O
The	O
patient	O
developed	O
RS	B-Disease
during	O
dose	O
reduction	O
of	O
risperidone	B-Chemical
.	O
The	O
symptom	O
was	O
treated	O
successfully	O
with	O
trihexyphenidyl	B-Chemical
anticholinergic	O
therapy	O
.	O
The	O
underlying	O
mechanism	O
of	O
withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
RS	I-Disease
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	B-Chemical
,	O
a	O
serotonin	B-Chemical
-	O
dopamine	B-Chemical
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	B-Chemical
system	O
in	O
the	O
development	O
of	O
RS	B-Disease
.	O
Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	O
of	O
the	O
effects	O
of	O
E4031	B-Chemical
,	O
cisapride	B-Chemical
,	O
terfenadine	B-Chemical
and	O
terodiline	B-Chemical
on	O
monophasic	O
action	O
potential	O
duration	O
in	O
dog	O
.	O
1	O
.	O
Torsades	B-Disease
de	I-Disease
pointes	I-Disease
(	O
TDP	B-Disease
)	O
is	O
a	O
potentially	O
fatal	O
ventricular	B-Disease
tachycardia	I-Disease
associated	O
with	O
increases	O
in	O
QT	O
interval	O
and	O
monophasic	O
action	O
potential	O
duration	O
(	O
MAPD	O
)	O
.	O
TDP	B-Disease
is	O
a	O
side	O
-	O
effect	O
that	O
has	O
led	O
to	O
withdrawal	O
of	O
several	O
drugs	O
from	O
the	O
market	O
(	O
e	O
.	O
g	O
.	O
terfenadine	B-Chemical
and	O
terodiline	B-Chemical
)	O
.	O
2	O
.	O
The	O
potential	O
of	O
compounds	O
to	O
cause	O
TDP	B-Disease
was	O
evaluated	O
by	O
monitoring	O
their	O
effects	O
on	O
MAPD	O
in	O
dog	O
.	O
Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	B-Disease
were	O
investigated	O
:	O
terfenadine	B-Chemical
,	O
terodiline	B-Chemical
,	O
cisapride	B-Chemical
and	O
E4031	B-Chemical
.	O
On	O
the	O
basis	O
that	O
only	O
free	O
drug	O
in	O
the	O
systemic	O
circulation	O
will	O
elicit	O
a	O
pharmacological	O
response	O
target	O
,	O
free	O
concentrations	O
in	O
plasma	O
were	O
selected	O
to	O
mimic	O
the	O
free	O
drug	O
exposures	O
in	O
man	O
.	O
Infusion	O
regimens	O
were	O
designed	O
that	O
rapidly	O
achieved	O
and	O
maintained	O
target	O
-	O
free	O
concentrations	O
of	O
these	O
drugs	O
in	O
plasma	O
and	O
data	O
on	O
the	O
relationship	O
between	O
free	O
concentration	O
and	O
changes	O
in	O
MAPD	O
were	O
obtained	O
for	O
these	O
compounds	O
.	O
3	O
.	O
These	O
data	O
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasma	O
for	O
terfenadine	B-Chemical
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terodiline	B-Chemical
(	O
76	O
nM	O
)	O
,	O
cisapride	B-Chemical
(	O
11	O
nM	O
)	O
and	O
E4031	B-Chemical
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O
For	O
compounds	O
that	O
have	O
shown	O
TDP	B-Disease
in	O
the	O
clinic	O
(	O
terfenadine	B-Chemical
,	O
terodiline	B-Chemical
,	O
cisapride	B-Chemical
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O
These	O
data	O
underline	O
the	O
need	O
to	O
maximize	O
the	O
therapeutic	O
ratio	O
with	O
respect	O
to	O
TDP	B-Disease
in	O
potential	O
development	O
candidates	O
and	O
the	O
importance	O
of	O
using	O
free	O
drug	O
concentrations	O
in	O
pharmacokinetic	O
/	O
pharmacodynamic	O
studies	O
.	O
Bladder	O
retention	B-Disease
of	I-Disease
urine	I-Disease
as	O
a	O
result	O
of	O
continuous	O
intravenous	O
infusion	O
of	O
fentanyl	B-Chemical
:	O
2	O
case	O
reports	O
.	O
Sedation	O
has	O
been	O
commonly	O
used	O
in	O
the	O
neonate	O
to	O
decrease	O
the	O
stress	O
and	O
pain	B-Disease
from	O
the	O
noxious	O
stimuli	O
and	O
invasive	O
procedures	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
synchrony	O
between	O
ventilator	O
and	O
spontaneous	O
breaths	O
.	O
Fentanyl	B-Chemical
,	O
an	O
opioid	O
analgesic	O
,	O
is	O
frequently	O
used	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
setting	O
for	O
these	O
very	O
purposes	O
.	O
Various	O
reported	O
side	O
effects	O
of	O
fentanyl	B-Chemical
administration	O
include	O
chest	B-Disease
wall	I-Disease
rigidity	I-Disease
,	O
hypotension	B-Disease
,	O
respiratory	B-Disease
depression	I-Disease
,	O
and	O
bradycardia	B-Disease
.	O
Here	O
,	O
2	O
cases	O
of	O
urinary	B-Disease
bladder	I-Disease
retention	I-Disease
leading	O
to	O
renal	O
pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	B-Disease
as	O
a	O
result	O
of	O
continuous	O
infusion	O
of	O
fentanyl	B-Chemical
are	O
reported	O
.	O
Fatal	O
myeloencephalopathy	B-Disease
due	O
to	O
accidental	O
intrathecal	O
vincristin	B-Chemical
administration	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O
We	O
report	O
on	O
two	O
fatal	O
cases	O
of	O
accidental	O
intrathecal	O
vincristine	B-Chemical
instillation	O
in	O
a	O
5	O
-	O
year	O
old	O
girl	O
with	O
recurrent	O
acute	B-Disease
lymphoblastic	I-Disease
leucemia	I-Disease
and	O
a	O
57	O
-	O
year	O
old	O
man	O
with	O
lymphoblastic	B-Disease
lymphoma	I-Disease
.	O
The	O
girl	O
died	O
seven	O
days	O
,	O
the	O
man	O
four	O
weeks	O
after	O
intrathecal	O
injection	O
of	O
vincristine	B-Chemical
.	O
Clinically	O
,	O
the	O
onset	O
was	O
characterized	O
by	O
the	O
signs	O
of	O
opistothonus	B-Disease
,	I-Disease
sensory	I-Disease
and	I-Disease
motor	I-Disease
dysfunction	I-Disease
and	O
ascending	O
paralysis	B-Disease
.	O
Histological	O
and	O
immunohistochemical	O
investigations	O
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neurofilament	O
)	O
revealed	O
degeneration	B-Disease
of	I-Disease
myelin	I-Disease
and	I-Disease
axons	I-Disease
as	O
well	O
as	O
pseudocystic	B-Disease
transformation	I-Disease
in	O
areas	O
exposed	O
to	O
vincristine	B-Chemical
,	O
accompanied	O
by	O
secondary	O
changes	O
with	O
numerous	O
prominent	O
macrophages	O
.	O
The	O
clinical	O
course	O
and	O
histopathological	O
results	O
of	O
the	O
two	O
cases	O
are	O
presented	O
.	O
A	O
review	O
of	O
all	O
reported	O
cases	O
in	O
the	O
literature	O
is	O
given	O
.	O
A	O
better	O
controlled	O
regimen	O
for	O
administering	O
vincristine	B-Chemical
and	O
intrathecal	O
chemotherapy	O
is	O
recommended	O
.	O
Palpebral	B-Disease
twitching	I-Disease
in	O
a	O
depressed	B-Disease
adolescent	O
on	O
citalopram	B-Chemical
.	O
Current	O
estimates	O
suggest	O
that	O
between	O
0	O
.	O
4	O
%	O
and	O
8	O
.	O
3	O
%	O
of	O
children	O
and	O
adolescents	O
are	O
affected	O
by	O
major	B-Disease
depression	I-Disease
.	O
We	O
report	O
a	O
favorable	O
response	O
to	O
treatment	O
with	O
citalopram	B-Chemical
by	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
major	B-Disease
depression	I-Disease
who	O
exhibited	O
palpebral	B-Disease
twitching	I-Disease
during	O
his	O
first	O
2	O
weeks	O
of	O
treatment	O
.	O
This	O
may	O
have	O
been	O
a	O
side	O
effect	O
of	O
citalopram	B-Chemical
as	O
it	O
remitted	O
with	O
redistribution	O
of	O
doses	O
.	O
The	O
3	O
-	O
week	O
sulphasalazine	B-Chemical
syndrome	O
strikes	O
again	O
.	O
A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	B-Disease
,	O
fever	B-Disease
,	O
lymphadenopathy	B-Disease
and	O
hepatitis	B-Disease
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-Chemical
for	O
sero	O
-	O
negative	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O
Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	B-Disease
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	B-Disease
drug	I-Disease
reaction	I-Disease
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	B-Disease
-	I-Disease
induced	I-Disease
hepatitis	I-Disease
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	B-Disease
)	O
,	O
and	O
accompanied	O
by	O
multi	B-Disease
-	I-Disease
organ	I-Disease
failure	I-Disease
and	O
sepsis	B-Disease
,	O
supervened	O
.	O
She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	O
Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	B-Disease
hepatocellular	I-Disease
necrosis	I-Disease
,	O
acute	O
hypersensitivity	O
myocarditis	B-Disease
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	O
nephritis	B-Disease
and	O
extensive	O
bone	B-Disease
marrow	I-Disease
necrosis	I-Disease
,	O
with	O
no	O
evidence	O
of	O
malignancy	B-Disease
.	O
It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
""""	O
3	O
-	O
week	O
sulphasalazine	B-Chemical
syndrome	O
""""	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	B-Chemical
.	O
Intravenous	O
administration	O
of	O
prochlorperazine	B-Chemical
by	O
15	O
-	O
minute	O
infusion	O
versus	O
2	O
-	O
minute	O
bolus	O
does	O
not	O
affect	O
the	O
incidence	O
of	O
akathisia	B-Disease
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O
STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
compare	O
the	O
rate	O
of	O
akathisia	B-Disease
after	O
administration	O
of	O
intravenous	O
prochlorperazine	B-Chemical
as	O
a	O
2	O
-	O
minute	O
bolus	O
or	O
15	O
-	O
minute	O
infusion	O
.	O
METHODS	O
:	O
We	O
conducted	O
a	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
in	O
the	O
emergency	O
department	O
of	O
a	O
central	O
-	O
city	O
teaching	O
hospital	O
.	O
Patients	O
aged	O
18	O
years	O
or	O
older	O
treated	O
with	O
prochlorperazine	B-Chemical
for	O
headache	B-Disease
,	O
nausea	B-Disease
,	O
or	O
vomiting	B-Disease
were	O
eligible	O
for	O
inclusion	O
.	O
Study	O
participants	O
were	O
randomized	O
to	O
receive	O
10	O
mg	O
of	O
prochlorperazine	B-Chemical
administered	O
intravenously	O
by	O
means	O
of	O
2	O
-	O
minute	O
push	O
(	O
bolus	O
group	O
)	O
or	O
10	O
mg	O
diluted	O
in	O
50	O
mL	O
of	O
normal	O
saline	O
solution	O
administered	O
by	O
means	O
of	O
intravenous	O
infusion	O
during	O
a	O
15	O
-	O
minute	O
period	O
(	O
infusion	O
group	O
)	O
.	O
The	O
main	O
outcome	O
was	O
the	O
number	O
of	O
study	O
participants	O
experiencing	O
akathisia	B-Disease
within	O
60	O
minutes	O
of	O
administration	O
.	O
Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	O
of	O
restlessness	O
or	O
agitation	B-Disease
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient	O
-	O
reported	O
akathisia	B-Disease
rating	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator	O
-	O
observed	O
akathisia	B-Disease
rating	O
scale	O
.	O
The	O
intensity	O
of	O
headache	B-Disease
and	O
nausea	B-Disease
was	O
measured	O
with	O
a	O
100	O
-	O
mm	O
visual	O
analog	O
scale	O
.	O
RESULTS	O
:	O
One	O
hundred	O
patients	O
were	O
enrolled	O
.	O
One	O
study	O
participant	O
was	O
excluded	O
after	O
protocol	O
violation	O
.	O
Seventy	O
-	O
three	O
percent	O
(	O
73	O
/	O
99	O
)	O
of	O
the	O
study	O
participants	O
were	O
treated	O
for	O
headache	B-Disease
and	O
70	O
%	O
(	O
70	O
/	O
99	O
)	O
for	O
nausea	B-Disease
.	O
In	O
the	O
bolus	O
group	O
,	O
26	O
.	O
0	O
%	O
(	O
13	O
/	O
50	O
)	O
had	O
akathisia	B-Disease
compared	O
with	O
32	O
.	O
7	O
%	O
(	O
16	O
/	O
49	O
)	O
in	O
the	O
infusion	O
group	O
(	O
Delta	O
=	O
-	O
6	O
.	O
7	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
-	O
24	O
.	O
6	O
%	O
to	O
11	O
.	O
2	O
%	O
)	O
.	O
The	O
difference	O
between	O
the	O
bolus	O
and	O
infusion	O
groups	O
in	O
the	O
percentage	O
of	O
participants	O
who	O
saw	O
a	O
50	O
%	O
reduction	O
in	O
their	O
headache	B-Disease
intensity	O
within	O
30	O
minutes	O
was	O
11	O
.	O
8	O
%	O
(	O
95	O
%	O
CI	O
-	O
9	O
.	O
6	O
%	O
to	O
33	O
.	O
3	O
%	O
)	O
.	O
The	O
difference	O
in	O
the	O
percentage	O
of	O
patients	O
with	O
a	O
50	O
%	O
reduction	O
in	O
their	O
nausea	B-Disease
was	O
12	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
-	O
4	O
.	O
6	O
%	O
to	O
29	O
.	O
8	O
%	O
)	O
.	O
CONCLUSION	O
:	O
A	O
50	O
%	O
reduction	O
in	O
the	O
incidence	O
of	O
akathisia	B-Disease
when	O
prochlorperazine	B-Chemical
was	O
administered	O
by	O
means	O
of	O
15	O
-	O
minute	O
intravenous	O
infusion	O
versus	O
a	O
2	O
-	O
minute	O
intravenous	O
push	O
was	O
not	O
detected	O
.	O
The	O
efficacy	O
of	O
prochlorperazine	B-Chemical
in	O
the	O
treatment	O
of	O
headache	B-Disease
and	O
nausea	B-Disease
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
rate	O
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	O
comparisons	O
were	O
made	O
.	O
Combined	O
antiretroviral	O
therapy	O
causes	O
cardiomyopathy	B-Disease
and	O
elevates	O
plasma	O
lactate	B-Chemical
in	O
transgenic	O
AIDS	B-Disease
mice	O
.	O
Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	B-Disease
(	O
CM	B-Disease
)	O
and	O
in	O
elevated	O
plasma	O
lactate	B-Chemical
(	O
LA	B-Chemical
)	O
in	O
AIDS	B-Disease
through	O
mechanisms	O
of	O
mitochondrial	B-Disease
dysfunction	I-Disease
.	O
To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemizygous	O
transgenic	O
AIDS	B-Disease
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O
n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	O
combination	O
of	O
zidovudine	B-Chemical
,	O
lamivudine	B-Chemical
,	O
and	O
indinavir	B-Chemical
or	O
vehicle	O
control	O
for	O
10	O
days	O
or	O
35	O
days	O
.	O
At	O
termination	O
of	O
the	O
experiments	O
,	O
mice	O
underwent	O
echocardiography	O
,	O
quantitation	O
of	O
abundance	O
of	O
molecular	O
markers	O
of	O
CM	B-Disease
(	O
ventricular	O
mRNA	O
encoding	O
atrial	O
natriuretic	O
factor	O
[	O
ANF	O
]	O
and	O
sarcoplasmic	O
calcium	B-Chemical
ATPase	O
[	O
SERCA2	O
]	O
)	O
,	O
and	O
determination	O
of	O
plasma	O
LA	B-Chemical
.	O
Myocardial	O
histologic	O
features	O
were	O
analyzed	O
semiquantitatively	O
and	O
results	O
were	O
confirmed	O
by	O
transmission	O
electron	O
microscopy	O
.	O
After	O
35	O
days	O
in	O
the	O
TG	O
+	O
HAART	O
cohort	O
,	O
left	O
ventricular	O
mass	O
increased	O
160	O
%	O
by	O
echocardiography	O
.	O
Molecularly	O
,	O
ANF	O
mRNA	O
increased	O
250	O
%	O
and	O
SERCA2	O
mRNA	O
decreased	O
57	O
%	O
.	O
Biochemically	O
,	O
LA	B-Chemical
was	O
elevated	O
(	O
8	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
0	O
mM	O
)	O
.	O
Pathologically	O
,	O
granular	O
cytoplasmic	O
changes	O
were	O
found	O
in	O
cardiac	O
myocytes	O
,	O
indicating	O
enlarged	O
,	O
damaged	O
mitochondria	O
.	O
Findings	O
were	O
confirmed	O
ultrastructurally	O
.	O
No	O
changes	O
were	O
found	O
in	O
other	O
cohorts	O
.	O
After	O
10	O
days	O
,	O
only	O
ANF	O
was	O
elevated	O
,	O
and	O
only	O
in	O
the	O
TG	O
+	O
HAART	O
cohort	O
.	O
Results	O
show	O
that	O
cumulative	O
HAART	O
caused	O
mitochondrial	O
CM	B-Disease
with	O
elevated	O
LA	B-Chemical
in	O
AIDS	B-Disease
transgenic	O
mice	O
.	O
A	O
Phase	O
II	O
trial	O
of	O
cisplatin	B-Chemical
plus	O
WR	B-Chemical
-	I-Chemical
2721	I-Chemical
(	O
amifostine	B-Chemical
)	O
for	O
metastatic	O
breast	B-Disease
carcinoma	I-Disease
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	O
)	O
.	O
BACKGROUND	O
:	O
Cisplatin	B-Chemical
has	O
minimal	O
antitumor	O
activity	O
when	O
used	O
as	O
second	O
-	O
or	O
third	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	B-Disease
carcinoma	I-Disease
.	O
Older	O
reports	O
suggest	O
an	O
objective	O
response	O
rate	O
of	O
8	O
%	O
when	O
60	O
-	O
120	O
mg	O
/	O
m2	O
of	O
cisplatin	B-Chemical
is	O
administered	O
every	O
3	O
-	O
4	O
weeks	O
.	O
Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	B-Chemical
,	O
the	O
dose	O
-	O
limiting	O
toxicities	B-Disease
associated	O
with	O
cisplatin	B-Chemical
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	B-Disease
,	O
ototoxicity	B-Disease
,	O
and	O
neurotoxicity	B-Disease
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	B-Disease
carcinoma	I-Disease
.	O
WR	B-Chemical
-	I-Chemical
2721	I-Chemical
or	O
amifostine	B-Chemical
initially	O
was	O
developed	O
to	O
protect	O
military	O
personnel	O
in	O
the	O
event	O
of	O
nuclear	O
war	O
.	O
Amifostine	B-Chemical
subsequently	O
was	O
shown	O
to	O
protect	O
normal	O
tissues	O
from	O
the	O
toxic	O
effects	O
of	O
alkylating	B-Chemical
agents	I-Chemical
and	O
cisplatin	B-Chemical
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy	O
.	O
Early	O
trials	O
of	O
cisplatin	B-Chemical
and	O
amifostine	B-Chemical
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
,	O
ototoxicity	B-Disease
,	O
and	O
neuropathy	B-Disease
were	O
reduced	O
.	O
METHODS	O
:	O
A	O
Phase	O
II	O
study	O
of	O
the	O
combination	O
of	O
cisplatin	B-Chemical
plus	O
amifostine	B-Chemical
was	O
conducted	O
in	O
patients	O
with	O
progressive	O
metastatic	O
breast	B-Disease
carcinoma	I-Disease
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	O
.	O
Patients	O
received	O
amifostine	B-Chemical
,	O
910	O
mg	O
/	O
m2	O
intravenously	O
over	O
15	O
minutes	O
.	O
After	O
completion	O
of	O
the	O
amifostine	B-Chemical
infusion	O
,	O
cisplatin	B-Chemical
120	O
mg	O
/	O
m2	O
was	O
administered	O
over	O
30	O
minutes	O
.	O
Intravenous	O
hydration	O
and	O
mannitol	B-Chemical
was	O
administered	O
before	O
and	O
after	O
cisplatin	B-Chemical
.	O
Treatment	O
was	O
administered	O
every	O
3	O
weeks	O
until	O
disease	O
progression	O
.	O
RESULTS	O
:	O
Forty	O
-	O
four	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
of	O
which	O
7	O
(	O
16	O
%	O
)	O
were	O
ineligible	O
.	O
A	O
median	O
of	O
2	O
cycles	O
of	O
therapy	O
was	O
administered	O
to	O
the	O
37	O
eligible	O
patients	O
.	O
Six	O
partial	O
responses	O
were	O
observed	O
for	O
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O
Most	O
patients	O
(	O
57	O
%	O
)	O
stopped	O
treatment	O
because	O
of	O
disease	O
progression	O
.	O
Neurologic	B-Disease
toxicity	I-Disease
was	O
reported	O
in	O
52	O
%	O
of	O
patients	O
.	O
Seven	O
different	O
life	O
-	O
threatening	O
toxicities	B-Disease
were	O
observed	O
in	O
patients	O
while	O
receiving	O
treatment	O
.	O
CONCLUSIONS	O
:	O
The	O
combination	O
of	O
cisplatin	B-Chemical
and	O
amifostine	B-Chemical
in	O
this	O
study	O
resulted	O
in	O
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O
Neither	O
a	O
tumor	B-Disease
-	O
protective	O
effect	O
nor	O
reduced	O
toxicity	B-Disease
to	O
normal	O
tissues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amifostine	B-Chemical
to	O
cisplatin	B-Chemical
in	O
this	O
trial	O
.	O
Oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
.	O
BACKGROUND	O
:	O
An	O
association	O
between	O
the	O
use	O
of	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studies	O
.	O
We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	B-Chemical
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	B-Chemical
or	O
gestodene	B-Chemical
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	B-Chemical
)	O
oral	B-Chemical
contraceptives	I-Chemical
,	O
the	O
dose	O
of	O
estrogen	B-Chemical
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	B-Disease
infarction	I-Disease
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	B-Disease
infarction	I-Disease
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O
Subjects	O
supplied	O
information	O
on	O
oral	B-Chemical
-	I-Chemical
contraceptive	I-Chemical
use	O
and	O
major	O
cardiovascular	O
risk	O
factors	O
.	O
An	O
analysis	O
for	O
factor	O
V	O
Leiden	O
and	O
the	O
G20210A	O
mutation	O
in	O
the	O
prothrombin	O
gene	O
was	O
conducted	O
in	O
217	O
patients	O
and	O
763	O
controls	O
RESULTS	O
:	O
The	O
odds	O
ratio	O
for	O
myocardial	B-Disease
infarction	I-Disease
among	O
women	O
who	O
used	O
any	O
type	O
of	O
combined	O
oral	B-Chemical
contraceptive	I-Chemical
,	O
as	O
compared	O
with	O
nonusers	O
,	O
was	O
2	O
.	O
0	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
2	O
.	O
8	O
)	O
.	O
The	O
adjusted	O
odds	O
ratio	O
was	O
2	O
.	O
5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
4	O
.	O
1	O
)	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
1	O
.	O
3	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O
Among	O
women	O
who	O
used	O
oral	B-Chemical
contraceptives	I-Chemical
,	O
the	O
odds	O
ratio	O
was	O
2	O
.	O
1	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS	O
:	O
The	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
was	O
increased	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O
The	O
results	O
with	O
respect	O
to	O
the	O
use	O
of	O
third	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
were	O
inconclusive	O
but	O
suggested	O
that	O
the	O
risk	O
was	O
lower	O
than	O
the	O
risk	O
associated	O
with	O
second	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O
The	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
was	O
similar	O
among	O
women	O
who	O
used	O
oral	B-Chemical
contraceptives	I-Chemical
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombotic	O
mutation	O
.	O
End	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
using	O
calcineurin	O
-	O
based	O
immunotherapy	O
:	O
risk	O
of	O
development	O
and	O
treatment	O
.	O
BACKGROUND	O
:	O
The	O
calcineurin	O
inhibitors	O
cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
are	O
both	O
known	O
to	O
be	O
nephrotoxic	B-Disease
.	O
Their	O
use	O
in	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
has	O
dramatically	O
improved	O
success	O
rates	O
.	O
Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	O
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
.	O
This	O
retrospective	O
study	O
examines	O
the	O
incidence	O
and	O
treatment	O
of	O
ESRD	B-Disease
and	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
(	O
CRF	B-Disease
)	O
in	O
OLTX	O
patients	O
.	O
METHODS	O
:	O
Patients	O
receiving	O
an	O
OLTX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
months	O
postoperatively	O
were	O
studied	O
(	O
n	O
=	O
834	O
)	O
.	O
Our	O
prospectively	O
collected	O
database	O
was	O
the	O
source	O
of	O
information	O
.	O
Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	B-Disease
or	O
ESRD	B-Disease
,	O
n	O
=	O
748	O
;	O
CRF	B-Disease
,	O
sustained	O
serum	O
creatinine	B-Chemical
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	B-Disease
,	O
n	O
=	O
45	O
.	O
Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	O
of	O
ESRD	B-Disease
therapy	O
,	O
and	O
survival	O
from	O
onset	O
of	O
ESRD	B-Disease
.	O
RESULTS	O
:	O
At	O
13	O
years	O
after	O
OLTX	O
,	O
the	O
incidence	O
of	O
severe	O
renal	B-Disease
dysfunction	I-Disease
was	O
18	O
.	O
1	O
%	O
(	O
CRF	B-Disease
8	O
.	O
6	O
%	O
and	O
ESRD	B-Disease
9	O
.	O
5	O
%	O
)	O
.	O
Compared	O
with	O
control	O
patients	O
,	O
CRF	B-Disease
and	O
ESRD	B-Disease
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	B-Chemical
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	B-Disease
syndrome	I-Disease
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	B-Chemical
.	O
Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	B-Chemical
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O
Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups	O
,	O
but	O
by	O
year	O
13	O
,	O
the	O
survival	O
of	O
the	O
patients	O
who	O
had	O
ESRD	B-Disease
was	O
only	O
28	O
.	O
2	O
%	O
compared	O
with	O
54	O
.	O
6	O
%	O
in	O
the	O
control	O
group	O
.	O
Patients	O
developing	O
ESRD	B-Disease
had	O
a	O
6	O
-	O
year	O
survival	O
after	O
onset	O
of	O
ESRD	B-Disease
of	O
27	O
%	O
for	O
the	O
patients	O
receiving	O
hemodialysis	O
versus	O
71	O
.	O
4	O
%	O
for	O
the	O
patients	O
developing	O
ESRD	B-Disease
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O
CONCLUSIONS	O
:	O
Patients	O
who	O
are	O
more	O
than	O
10	O
years	O
post	O
-	O
OLTX	O
have	O
CRF	B-Disease
and	O
ESRD	B-Disease
at	O
a	O
high	O
rate	O
.	O
The	O
development	O
of	O
ESRD	B-Disease
decreases	O
survival	O
,	O
particularly	O
in	O
those	O
patients	O
treated	O
with	O
dialysis	O
only	O
.	O
Patients	O
who	O
develop	O
ESRD	B-Disease
have	O
a	O
higher	O
preoperative	O
and	O
1	O
-	O
year	O
serum	O
creatinine	B-Chemical
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	B-Disease
syndrome	I-Disease
.	O
However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	B-Chemical
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
.	O
New	O
strategies	O
for	O
long	O
-	O
term	O
immunosuppression	O
may	O
be	O
needed	O
to	O
decrease	O
this	O
complication	O
.	O
Epileptic	B-Disease
seizures	I-Disease
following	O
cortical	O
application	O
of	O
fibrin	O
sealants	O
containing	O
tranexamic	B-Chemical
acid	I-Chemical
in	O
rats	O
.	O
BACKGROUND	O
:	O
Fibrin	O
sealants	O
(	O
FS	O
)	O
derived	O
from	O
human	O
plasma	O
are	O
frequently	O
used	O
in	O
neurosurgery	O
.	O
In	O
order	O
to	O
increase	O
clot	O
stability	O
,	O
FS	O
typically	O
contain	O
aprotinin	O
,	O
a	O
natural	O
fibrinolysis	O
inhibitor	O
.	O
Recently	O
,	O
synthetic	O
fibrinolysis	O
inhibitors	O
such	O
as	O
tranexamic	B-Chemical
acid	I-Chemical
(	O
tAMCA	B-Chemical
)	O
have	O
been	O
considered	O
as	O
substitutes	O
for	O
aprotinin	O
.	O
However	O
,	O
tAMCA	B-Chemical
has	O
been	O
shown	O
to	O
cause	O
epileptic	B-Disease
seizures	I-Disease
.	O
We	O
wanted	O
to	O
study	O
whether	O
tAMCA	B-Chemical
retains	O
its	O
convulsive	B-Disease
action	O
if	O
incorporated	O
into	O
a	O
FS	O
.	O
METHOD	O
:	O
FS	O
containing	O
aprotinin	O
or	O
different	O
concentrations	O
of	O
tAMCA	B-Chemical
(	O
0	O
.	O
5	O
-	O
47	O
.	O
5	O
mg	O
/	O
ml	O
)	O
were	O
applied	O
to	O
the	O
pial	O
surface	O
of	O
the	O
cortex	O
of	O
anaesthetized	O
rats	O
.	O
The	O
response	O
of	O
the	O
animals	O
was	O
evaluated	O
using	O
electroencephalography	O
and	O
by	O
monitoring	O
the	O
clinical	O
behaviour	O
during	O
and	O
after	O
recovery	O
from	O
anaesthesia	O
.	O
FINDINGS	O
:	O
FS	O
containing	O
tAMCA	B-Chemical
caused	O
paroxysmal	O
brain	O
activity	O
which	O
was	O
associated	O
with	O
distinct	O
convulsive	B-Disease
behaviours	O
.	O
The	O
degree	O
of	O
these	O
seizures	B-Disease
increased	O
with	O
increasing	O
concentration	O
of	O
tAMCA	B-Chemical
.	O
Thus	O
,	O
FS	O
containing	O
47	O
.	O
5	O
mg	O
/	O
ml	O
tAMCA	B-Chemical
evoked	O
generalized	B-Disease
seizures	I-Disease
in	O
all	O
tested	O
rats	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	O
convulsive	B-Disease
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O
In	O
contrast	O
,	O
FS	O
containing	O
aprotinin	O
did	O
not	O
evoke	O
any	O
paroxysmal	O
activity	O
.	O
INTERPRETATION	O
:	O
Tranexamic	B-Chemical
acid	I-Chemical
retains	O
its	O
convulsive	B-Disease
action	O
within	O
FS	O
.	O
Thus	O
,	O
use	O
of	O
FS	O
containing	O
tAMCA	B-Chemical
for	O
surgery	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
risk	O
to	O
the	O
patient	O
.	O
Sequential	O
observations	O
of	O
exencephaly	B-Disease
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	O
:	O
analysis	O
of	O
the	O
mechanism	O
of	O
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	B-Disease
.	O
Anencephaly	B-Disease
has	O
been	O
suggested	O
to	O
develop	O
from	O
exencephaly	B-Disease
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
experimental	O
evidence	O
to	O
support	O
this	O
,	O
and	O
the	O
mechanism	O
of	O
transformation	O
remains	O
unclear	O
.	O
We	O
examined	O
this	O
theory	O
using	O
the	O
exo	O
utero	O
development	O
system	O
that	O
allows	O
direct	O
and	O
sequential	O
observations	O
of	O
mid	O
-	O
to	O
late	O
-	O
gestation	O
mouse	O
embryos	O
.	O
We	O
observed	O
the	O
exencephaly	B-Disease
induced	O
by	O
5	B-Chemical
-	I-Chemical
azacytidine	I-Chemical
at	O
embryonic	O
day	O
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
,	O
let	O
the	O
embryos	O
develop	O
exo	O
utero	O
until	O
E18	O
.	O
5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embryos	O
at	O
E18	O
.	O
5	O
.	O
We	O
confirmed	O
several	O
cases	O
of	O
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	B-Disease
.	O
However	O
,	O
in	O
many	O
cases	O
,	O
the	O
exencephalic	B-Disease
brain	O
tissue	O
was	O
preserved	O
with	O
more	O
or	O
less	O
reduction	O
during	O
this	O
period	O
.	O
To	O
analyze	O
the	O
transformation	O
patterns	O
,	O
we	O
classified	O
the	O
exencephaly	B-Disease
by	O
size	O
and	O
shape	O
of	O
the	O
exencephalic	B-Disease
tissue	O
into	O
several	O
types	O
at	O
E13	O
.	O
5	O
and	O
E18	O
.	O
5	O
.	O
It	O
was	O
found	O
that	O
the	O
transformation	O
of	O
exencephalic	B-Disease
tissue	O
was	O
not	O
simply	O
size	O
-	O
dependent	O
,	O
and	O
all	O
cases	O
of	O
anencephaly	B-Disease
at	O
E18	O
.	O
5	O
resulted	O
from	O
embryos	O
with	O
a	O
large	O
amount	O
of	O
exencephalic	B-Disease
tissue	O
at	O
E13	O
.	O
5	O
.	O
Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	B-Disease
at	O
E13	O
.	O
5	O
,	O
frequent	O
hemorrhaging	B-Disease
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	B-Disease
head	O
at	O
E15	O
.	O
5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	B-Disease
tissue	O
at	O
E18	O
.	O
5	O
.	O
From	O
observations	O
of	O
the	O
vasculature	O
,	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
were	O
identified	O
in	O
the	O
exencephalic	B-Disease
head	O
.	O
These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	B-Disease
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	B-Disease
failure	I-Disease
and	O
/	O
or	O
hemorrhaging	B-Disease
in	O
various	O
parts	O
of	O
the	O
exencephalic	B-Disease
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	B-Disease
.	O
99mTc	B-Chemical
-	I-Chemical
glucarate	I-Chemical
for	O
detection	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
Infarct	B-Disease
-	O
avid	O
radiopharmaceuticals	O
are	O
necessary	O
for	O
rapid	O
and	O
timely	O
diagnosis	O
of	O
acute	O
myocardial	B-Disease
infarction	I-Disease
.	O
The	O
animal	O
model	O
used	O
to	O
produce	O
infarction	B-Disease
implies	O
artery	O
ligation	O
but	O
chemical	O
induction	O
can	O
be	O
easily	O
obtained	O
with	O
isoproterenol	B-Chemical
.	O
A	O
new	O
infarct	B-Disease
-	O
avid	O
radiopharmaceutical	O
based	O
on	O
glucaric	B-Chemical
acid	I-Chemical
was	O
prepared	O
in	O
the	O
hospital	O
radiopharmacy	O
of	O
the	O
INCMNSZ	O
.	O
99mTc	B-Chemical
-	I-Chemical
glucarate	I-Chemical
was	O
easy	O
to	O
prepare	O
,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	O
its	O
biodistribution	O
in	O
rats	O
with	O
isoproterenol	B-Chemical
-	O
induced	O
acute	O
myocardial	B-Disease
infarction	I-Disease
.	O
Histological	O
studies	O
demonstrated	O
that	O
the	O
rats	O
developed	O
an	O
infarct	B-Disease
18	O
h	O
after	O
isoproterenol	B-Chemical
administration	O
.	O
The	O
rat	O
biodistribution	O
studies	O
showed	O
a	O
rapid	O
blood	O
clearance	O
via	O
the	O
kidneys	O
.	O
Thirty	O
minutes	O
after	O
99mTc	B-Chemical
-	I-Chemical
glucarate	I-Chemical
administration	O
the	O
standardised	O
heart	O
uptake	O
value	O
S	O
(	O
h	O
)	O
UV	O
was	O
4	O
.	O
7	O
in	O
infarcted	O
rat	O
heart	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
normal	O
rats	O
.	O
ROIs	O
drawn	O
over	O
the	O
gamma	O
camera	O
images	O
showed	O
a	O
ratio	O
of	O
4	O
.	O
4	O
.	O
The	O
high	O
image	O
quality	O
suggests	O
that	O
high	O
contrast	O
images	O
can	O
be	O
obtained	O
in	O
humans	O
and	O
the	O
96	O
h	O
stability	O
makes	O
it	O
an	O
ideal	O
agent	O
to	O
detect	O
,	O
in	O
patients	O
,	O
early	O
cardiac	B-Disease
infarction	I-Disease
.	O
Bupropion	B-Chemical
(	O
Zyban	B-Chemical
)	O
toxicity	B-Disease
.	O
Bupropion	B-Chemical
is	O
a	O
monocyclic	O
antidepressant	B-Chemical
structurally	O
related	O
to	O
amphetamine	B-Chemical
.	O
Zyban	B-Chemical
,	O
a	O
sustained	O
-	O
release	O
formulation	O
of	O
bupropion	B-Chemical
hydrochloride	I-Chemical
,	O
was	O
recently	O
released	O
in	O
Ireland	O
,	O
as	O
a	O
smoking	O
cessation	O
aid	O
.	O
In	O
the	O
initial	O
6	O
months	O
since	O
it	O
'	O
s	O
introduction	O
,	O
12	O
overdose	B-Disease
cases	O
have	O
been	O
reported	O
to	O
The	O
National	O
Poisons	O
Information	O
Centre	O
.	O
8	O
patients	O
developed	O
symptoms	O
of	O
toxicity	B-Disease
.	O
Common	O
features	O
included	O
tachycardia	B-Disease
,	O
drowsiness	O
,	O
hallucinations	B-Disease
and	O
convulsions	B-Disease
.	O
Two	O
patients	O
developed	O
severe	O
cardiac	B-Disease
arrhythmias	I-Disease
,	O
including	O
one	O
patient	O
who	O
was	O
resuscitated	O
following	O
a	O
cardiac	B-Disease
arrest	I-Disease
.	O
All	O
patients	O
recovered	O
without	O
sequelae	O
.	O
We	O
report	O
a	O
case	O
of	O
a	O
31	O
year	O
old	O
female	O
who	O
required	O
admission	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
ventilation	O
and	O
full	O
supportive	O
therapy	O
,	O
following	O
ingestion	O
of	O
13	O
.	O
5g	O
bupropion	B-Chemical
.	O
Recurrent	O
seizures	B-Disease
were	O
treated	O
with	O
diazepam	B-Chemical
and	O
broad	O
complex	O
tachycardia	B-Disease
was	O
successfully	O
treated	O
with	O
adenosine	B-Chemical
.	O
Zyban	B-Chemical
caused	O
significant	O
neurological	B-Disease
and	I-Disease
cardiovascular	I-Disease
toxicity	I-Disease
in	O
overdose	B-Disease
.	O
The	O
potential	O
toxic	O
effects	O
should	O
be	O
considered	O
when	O
prescribing	O
it	O
as	O
a	O
smoking	O
cessation	O
aid	O
.	O
GLEPP1	O
receptor	O
tyrosine	B-Chemical
phosphatase	O
(	O
Ptpro	O
)	O
in	O
rat	O
PAN	B-Chemical
nephrosis	B-Disease
.	O
A	O
marker	O
of	O
acute	O
podocyte	O
injury	O
.	O
Glomerular	O
epithelial	O
protein	O
1	O
(	O
GLEPP1	O
)	O
is	O
a	O
podocyte	O
receptor	O
membrane	O
protein	O
tyrosine	B-Chemical
phosphatase	O
located	O
on	O
the	O
apical	O
cell	O
membrane	O
of	O
visceral	O
glomerular	O
epithelial	O
cell	O
and	O
foot	O
processes	O
.	O
This	O
receptor	O
plays	O
a	O
role	O
in	O
regulating	O
the	O
structure	O
and	O
function	O
of	O
podocyte	O
foot	O
process	O
.	O
To	O
better	O
understand	O
the	O
utility	O
of	O
GLEPP1	O
as	O
a	O
marker	O
of	O
glomerular	B-Disease
injury	I-Disease
,	O
the	O
amount	O
and	O
distribution	O
of	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemistry	O
,	O
Western	O
blot	O
and	O
RNase	O
protection	O
assay	O
in	O
a	O
model	O
of	O
podocyte	O
injury	O
in	O
the	O
rat	O
.	O
Puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
,	O
20	O
mg	O
/	O
100g	O
BW	O
)	O
.	O
Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	B-Chemical
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	O
of	O
proteinuria	B-Disease
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	O
the	O
chronic	O
phase	O
of	O
proteinuria	B-Disease
associated	O
with	O
glomerulosclerosis	B-Disease
(	O
days	O
45	O
-	O
126	O
)	O
.	O
At	O
day	O
5	O
,	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
reduced	O
from	O
the	O
normal	O
range	O
(	O
265	O
.	O
2	O
+	O
/	O
-	O
79	O
.	O
6	O
x	O
10	O
(	O
6	O
)	O
moles	O
/	O
glomerulus	O
and	O
100	O
%	O
)	O
to	O
15	O
%	O
of	O
normal	O
(	O
41	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
8	O
x	O
10	O
(	O
6	O
)	O
moles	O
/	O
glomerulus	O
,	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O
This	O
occurred	O
in	O
association	O
with	O
an	O
increase	O
in	O
urinary	O
protein	O
content	O
from	O
1	O
.	O
8	O
+	O
/	O
-	O
1	O
to	O
99	O
.	O
0	O
+	O
/	O
-	O
61	O
mg	O
/	O
day	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
In	O
contrast	O
,	O
podocalyxin	O
did	O
not	O
change	O
significantly	O
at	O
this	O
time	O
.	O
By	O
day	O
11	O
,	O
GLEPP1	O
protein	O
and	O
mRNA	O
had	O
begun	O
to	O
return	O
towards	O
baseline	O
.	O
By	O
day	O
45	O
-	O
126	O
,	O
at	O
a	O
time	O
when	O
glomerular	O
scarring	O
was	O
present	O
,	O
GLEPP1	O
was	O
absent	O
from	O
glomerulosclerotic	O
areas	O
although	O
the	O
total	O
glomerular	O
content	O
of	O
GLEPP1	O
was	O
not	O
different	O
from	O
normal	O
.	O
We	O
conclude	O
that	O
GLEPP1	O
expression	O
,	O
unlike	O
podocalyxin	O
,	O
reflects	O
podocyte	O
injury	O
induced	O
by	O
PAN	B-Chemical
.	O
GLEPP1	O
expression	O
may	O
be	O
a	O
useful	O
marker	O
of	O
podocyte	O
injury	O
.	O
Antithymocyte	B-Chemical
globulin	I-Chemical
in	O
the	O
treatment	O
of	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
.	O
A	O
patient	O
who	O
received	O
antithymocyte	B-Chemical
globulin	I-Chemical
therapy	O
for	O
aplastic	B-Disease
anemia	I-Disease
due	O
to	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
therapy	O
is	O
described	O
.	O
Bone	O
marrow	O
recovery	O
and	O
peripheral	O
blood	O
recovery	O
were	O
complete	O
1	O
month	O
and	O
3	O
months	O
,	O
respectively	O
,	O
after	O
treatment	O
,	O
and	O
blood	O
transfusion	O
or	O
other	O
therapies	O
were	O
not	O
necessary	O
in	O
a	O
follow	O
-	O
up	O
period	O
of	O
more	O
than	O
2	O
years	O
.	O
Use	O
of	O
antithymocyte	B-Chemical
globulin	I-Chemical
may	O
be	O
the	O
optimal	O
treatment	O
of	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
.	O
Metamizol	B-Chemical
potentiates	O
morphine	B-Chemical
antinociception	O
but	O
not	O
constipation	B-Disease
after	O
chronic	O
treatment	O
.	O
This	O
work	O
evaluates	O
the	O
antinociceptive	O
and	O
constipating	B-Disease
effects	O
of	O
the	O
combination	O
of	O
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
morphine	B-Chemical
with	O
177	O
.	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
metamizol	B-Chemical
in	O
acutely	O
and	O
chronically	O
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	O
)	O
rats	O
.	O
On	O
the	O
13th	O
day	O
,	O
antinociceptive	O
effects	O
were	O
assessed	O
using	O
a	O
model	O
of	O
inflammatory	O
nociception	O
,	O
pain	B-Disease
-	O
induced	O
functional	O
impairment	O
model	O
,	O
and	O
the	O
charcoal	B-Chemical
meal	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
intestinal	O
transit	O
.	O
Simultaneous	O
administration	O
of	O
morphine	B-Chemical
with	O
metamizol	B-Chemical
resulted	O
in	O
a	O
markedly	O
antinociceptive	O
potentiation	O
and	O
an	O
increasing	O
of	O
the	O
duration	O
of	O
action	O
after	O
a	O
single	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
139	O
+	O
/	O
-	O
36	O
units	O
area	O
(	O
ua	O
)	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
repeated	O
administration	O
(	O
280	O
+	O
/	O
-	O
17	O
vs	O
.	O
131	O
+	O
/	O
-	O
22	O
ua	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
Antinociceptive	O
effect	O
of	O
morphine	B-Chemical
was	O
reduced	O
in	O
chronically	O
treated	O
rats	O
(	O
39	O
+	O
/	O
-	O
10	O
vs	O
.	O
18	O
+	O
/	O
-	O
5	O
au	O
)	O
while	O
the	O
combination	O
-	O
induced	O
antinociception	O
was	O
remained	O
similar	O
as	O
an	O
acute	O
treatment	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
280	O
+	O
/	O
-	O
17	O
au	O
)	O
.	O
Acute	O
antinociceptive	O
effects	O
of	O
the	O
combination	O
were	O
partially	O
prevented	O
by	O
3	O
.	O
2	O
mg	O
/	O
kg	O
naloxone	B-Chemical
s	O
.	O
c	O
.	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
suggesting	O
the	O
partial	O
involvement	O
of	O
the	O
opioidergic	O
system	O
in	O
the	O
synergism	O
observed	O
.	O
In	O
independent	O
groups	O
,	O
morphine	B-Chemical
inhibited	O
the	O
intestinal	O
transit	O
in	O
48	O
+	O
/	O
-	O
4	O
%	O
and	O
38	O
+	O
/	O
-	O
4	O
%	O
after	O
acute	O
and	O
chronic	O
treatment	O
,	O
respectively	O
,	O
suggesting	O
that	O
tolerance	O
did	O
not	O
develop	O
to	O
the	O
constipating	B-Disease
effects	O
.	O
The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	B-Chemical
regardless	O
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	O
that	O
metamizol	B-Chemical
did	O
not	O
potentiate	O
morphine	B-Chemical
-	O
induced	O
constipation	B-Disease
.	O
These	O
findings	O
show	O
a	O
significant	O
interaction	O
between	O
morphine	B-Chemical
and	O
metamizol	B-Chemical
in	O
chronically	O
treated	O
rats	O
,	O
suggesting	O
that	O
this	O
combination	O
could	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	B-Disease
pain	I-Disease
.	O
Ifosfamide	B-Chemical
encephalopathy	B-Disease
presenting	O
with	O
asterixis	B-Disease
.	O
CNS	O
toxic	O
effects	O
of	O
the	O
antineoplastic	O
agent	O
ifosfamide	B-Chemical
(	O
IFX	B-Chemical
)	O
are	O
frequent	O
and	O
include	O
a	O
variety	O
of	O
neurological	O
symptoms	O
that	O
can	O
limit	O
drug	O
use	O
.	O
We	O
report	O
a	O
case	O
of	O
a	O
51	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
severe	O
,	O
disabling	O
negative	O
myoclonus	B-Disease
of	O
the	O
upper	O
and	O
lower	O
extremities	O
after	O
the	O
infusion	O
of	O
ifosfamide	B-Chemical
for	O
plasmacytoma	B-Disease
.	O
He	O
was	O
awake	O
,	O
revealed	O
no	O
changes	O
of	O
mental	O
status	O
and	O
at	O
rest	O
there	O
were	O
no	O
further	O
motor	O
symptoms	O
.	O
Cranial	O
magnetic	O
resonance	O
imaging	O
and	O
extensive	O
laboratory	O
studies	O
failed	O
to	O
reveal	O
structural	B-Disease
lesions	I-Disease
of	I-Disease
the	I-Disease
brain	I-Disease
and	O
metabolic	B-Disease
abnormalities	I-Disease
.	O
An	O
electroencephalogram	O
showed	O
continuous	O
,	O
generalized	O
irregular	O
slowing	O
with	O
admixed	O
periodic	O
triphasic	O
waves	O
indicating	O
symptomatic	O
encephalopathy	B-Disease
.	O
The	O
administration	O
of	O
ifosfamide	B-Chemical
was	O
discontinued	O
and	O
within	O
12	O
h	O
the	O
asterixis	B-Disease
resolved	O
completely	O
.	O
In	O
the	O
patient	O
described	O
,	O
the	O
presence	O
of	O
asterixis	B-Disease
during	O
infusion	O
of	O
ifosfamide	B-Chemical
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	O
that	O
negative	O
myoclonus	B-Disease
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	B-Chemical
.	O
Antagonism	O
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	O
mice	O
with	O
azidothymidine	B-Chemical
-	O
induced	O
anemia	B-Disease
and	O
in	O
bone	O
marrow	O
endothelial	O
cells	O
.	O
Azidothymidine	B-Chemical
(	O
AZT	B-Chemical
)	O
-	O
induced	O
anemia	B-Disease
in	O
mice	O
can	O
be	O
reversed	O
by	O
the	O
administration	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fusion	O
protein	O
of	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukin	O
3	O
)	O
.	O
Although	O
interleukin	O
3	O
(	O
IL	O
-	O
3	O
)	O
and	O
erythropoietin	O
(	O
EPO	O
)	O
are	O
known	O
to	O
act	O
synergistically	O
on	O
hematopoietic	O
cell	O
proliferation	O
in	O
vitro	O
,	O
injection	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
in	O
AZT	B-Chemical
-	O
treated	O
mice	O
resulted	O
in	O
a	O
reduction	O
of	O
red	O
cells	O
and	O
an	O
increase	O
of	O
plasma	O
EPO	O
levels	O
as	O
compared	O
to	O
animals	O
treated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
or	O
EPO	O
alone	O
.	O
We	O
tested	O
the	O
hypothesis	O
that	O
the	O
antagonistic	O
effect	O
of	O
IL	O
-	O
3	O
and	O
EPO	O
on	O
erythroid	O
cells	O
may	O
be	O
mediated	O
by	O
endothelial	O
cells	O
.	O
Bovine	O
liver	O
erythroid	O
cells	O
were	O
cultured	O
on	O
monolayers	O
of	O
human	O
bone	O
marrow	O
endothelial	O
cells	O
previously	O
treated	O
with	O
EPO	O
and	O
IGF	O
-	O
IL	O
-	O
3	O
.	O
There	O
was	O
a	O
significant	O
reduction	O
of	O
thymidine	B-Chemical
incorporation	O
into	O
both	O
erythroid	O
and	O
endothelial	O
cells	O
in	O
cultures	O
pre	O
-	O
treated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
.	O
Endothelial	O
cell	O
culture	O
supernatants	O
separated	O
by	O
ultrafiltration	O
and	O
ultracentrifugation	O
from	O
cells	O
treated	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
significantly	O
reduced	O
thymidine	B-Chemical
incorporation	O
into	O
erythroid	O
cells	O
as	O
compared	O
to	O
identical	O
fractions	O
obtained	O
from	O
the	O
media	O
of	O
cells	O
cultured	O
with	O
EPO	O
alone	O
.	O
These	O
results	O
suggest	O
that	O
endothelial	O
cells	O
treated	O
simultaneously	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
have	O
a	O
negative	O
effect	O
on	O
erythroid	O
cell	O
production	O
.	O
The	O
relationship	O
between	O
hippocampal	O
acetylcholine	B-Chemical
release	O
and	O
cholinergic	O
convulsant	O
sensitivity	O
in	O
withdrawal	O
seizure	B-Disease
-	O
prone	O
and	O
withdrawal	O
seizure	B-Disease
-	O
resistant	O
selected	O
mouse	O
lines	O
.	O
BACKGROUND	O
:	O
The	O
septo	O
-	O
hippocampal	O
cholinergic	O
pathway	O
has	O
been	O
implicated	O
in	O
epileptogenesis	O
,	O
and	O
genetic	O
factors	O
influence	O
the	O
response	O
to	O
cholinergic	O
agents	O
,	O
but	O
limited	O
data	O
are	O
available	O
on	O
cholinergic	O
involvement	O
in	O
alcohol	B-Chemical
withdrawal	O
severity	O
.	O
Thus	O
,	O
the	O
relationship	O
between	O
cholinergic	O
activity	O
and	O
responsiveness	O
and	O
alcohol	B-Chemical
withdrawal	O
was	O
investigated	O
in	O
a	O
genetic	O
animal	O
model	O
of	O
ethanol	B-Chemical
withdrawal	O
severity	O
.	O
METHODS	O
:	O
Cholinergic	O
convulsant	O
sensitivity	O
was	O
examined	O
in	O
alcohol	B-Chemical
-	O
na	O
ve	O
Withdrawal	O
Seizure	B-Disease
-	O
Prone	O
(	O
WSP	O
)	O
and	O
-	O
Resistant	O
(	O
WSR	O
)	O
mice	O
.	O
Animals	O
were	O
administered	O
nicotine	B-Chemical
,	O
carbachol	B-Chemical
,	O
or	O
neostigmine	B-Chemical
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	B-Disease
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O
We	O
also	O
used	O
microdialysis	O
to	O
measure	O
basal	O
and	O
potassium	B-Chemical
-	O
stimulated	O
acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
release	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O
Potassium	B-Chemical
was	O
applied	O
by	O
reverse	O
dialysis	O
twice	O
,	O
separated	O
by	O
75	O
min	O
.	O
Hippocampal	O
ACh	B-Chemical
also	O
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	B-Disease
.	O
RESULTS	O
:	O
Sensitivity	O
to	O
several	O
convulsion	B-Disease
endpoints	O
induced	O
by	O
nicotine	B-Chemical
,	O
carbachol	B-Chemical
,	O
and	O
neostigmine	B-Chemical
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O
In	O
microdialysis	O
experiments	O
,	O
the	O
lines	O
did	O
not	O
differ	O
in	O
basal	O
release	O
of	O
ACh	B-Chemical
,	O
and	O
50	O
mM	O
KCl	B-Chemical
increased	O
ACh	B-Chemical
output	O
in	O
both	O
lines	O
of	O
mice	O
.	O
However	O
,	O
the	O
increase	O
in	O
release	O
of	O
ACh	B-Chemical
produced	O
by	O
the	O
first	O
application	O
of	O
KCl	B-Chemical
was	O
2	O
-	O
fold	O
higher	O
in	O
WSP	O
versus	O
WSR	O
mice	O
.	O
When	O
hippocampal	O
ACh	B-Chemical
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	B-Disease
,	O
extracellular	O
ACh	B-Chemical
was	O
significantly	O
elevated	O
(	O
192	O
%	O
)	O
in	O
WSP	O
mice	O
,	O
but	O
was	O
nonsignificantly	O
elevated	O
(	O
59	O
%	O
)	O
in	O
WSR	O
mice	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	O
and	O
postsynaptic	O
sensitivity	O
to	O
cholinergic	O
convulsants	B-Disease
may	O
be	O
associated	O
with	O
ethanol	B-Chemical
withdrawal	O
severity	O
and	O
implicate	O
cholinergic	O
mechanisms	O
in	O
alcohol	B-Chemical
withdrawal	O
.	O
Specifically	O
,	O
WSP	O
mice	O
may	O
have	O
lower	O
sensitivity	O
to	O
cholinergic	O
convulsants	B-Disease
compared	O
with	O
WSR	O
because	O
of	O
postsynaptic	O
receptor	O
desensitization	O
brought	O
on	O
by	O
higher	O
activity	O
of	O
cholinergic	O
neurons	O
.	O
Capsaicin	B-Chemical
-	O
induced	O
muscle	B-Disease
pain	I-Disease
alters	O
the	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
.	O
The	O
pathophysiology	O
of	O
painful	O
temporomandibular	B-Disease
disorders	I-Disease
is	O
not	O
fully	O
understood	O
,	O
but	O
evidence	O
suggests	O
that	O
muscle	B-Disease
pain	I-Disease
modulates	O
motor	O
function	O
in	O
characteristic	O
ways	O
.	O
This	O
study	O
tested	O
the	O
hypothesis	O
that	O
activation	O
of	O
nociceptive	B-Disease
muscle	I-Disease
afferent	O
fibers	O
would	O
be	O
linked	O
to	O
an	O
increased	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
and	O
whether	O
this	O
process	O
would	O
be	O
sensitive	O
to	O
length	O
and	O
velocity	O
of	O
the	O
stretch	O
.	O
Capsaicin	B-Chemical
(	O
10	O
micro	O
g	O
)	O
was	O
injected	O
into	O
the	O
masseter	O
muscle	O
to	O
induce	O
pain	B-Disease
in	O
11	O
healthy	O
volunteers	O
.	O
Short	O
-	O
latency	O
reflex	O
responses	O
were	O
evoked	O
in	O
the	O
masseter	O
and	O
temporalis	O
muscles	O
by	O
a	O
stretch	O
device	O
with	O
different	O
velocities	O
and	O
displacements	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
pain	B-Disease
.	O
The	O
normalized	O
reflex	O
amplitude	O
increased	O
with	O
an	O
increase	O
in	O
velocity	O
at	O
a	O
given	O
displacement	O
,	O
but	O
remained	O
constant	O
with	O
different	O
displacements	O
at	O
a	O
given	O
velocity	O
.	O
The	O
normalized	O
reflex	O
amplitude	O
was	O
significantly	O
higher	O
during	O
pain	B-Disease
,	O
but	O
only	O
at	O
faster	O
stretches	O
in	O
the	O
painful	B-Disease
muscle	I-Disease
.	O
Increased	O
sensitivity	O
of	O
the	O
fusimotor	O
system	O
during	O
acute	O
muscle	B-Disease
pain	I-Disease
could	O
be	O
one	O
likely	O
mechanism	O
to	O
explain	O
the	O
findings	O
.	O
Effects	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbal	O
shell	O
or	O
core	O
on	O
the	O
cocaine	B-Chemical
-	O
induced	O
locomotor	B-Disease
hyperactivity	I-Disease
in	O
rats	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
subregions	O
of	O
the	O
nucleus	O
accumbens	O
(	O
the	O
shell	O
and	O
the	O
core	O
)	O
on	O
the	O
locomotor	B-Disease
hyperactivity	I-Disease
induced	O
by	O
cocaine	B-Chemical
in	O
rats	O
.	O
Male	O
Wistar	O
rats	O
were	O
implanted	O
bilaterally	O
with	O
cannulae	O
into	O
the	O
accumbens	O
shell	O
or	O
core	O
,	O
and	O
then	O
were	O
locally	O
injected	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
an	O
antagonist	O
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
an	O
agonist	O
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
.	O
Given	O
alone	O
to	O
any	O
accumbal	O
subregion	O
,	O
GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
did	O
not	O
change	O
basal	O
locomotor	O
activity	O
.	O
Systemic	O
cocaine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
locomotor	O
activity	O
of	O
rats	O
.	O
GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
,	O
administered	O
intra	O
-	O
accumbens	O
shell	O
prior	O
to	O
cocaine	B-Chemical
,	O
dose	O
-	O
dependently	O
attenuated	O
the	O
psychostimulant	O
-	O
induced	O
locomotor	B-Disease
hyperactivity	I-Disease
.	O
Such	O
attenuation	O
was	O
not	O
found	O
in	O
animals	O
which	O
had	O
been	O
injected	O
with	O
GR	B-Chemical
55562	I-Chemical
into	O
the	O
accumbens	O
core	O
.	O
When	O
injected	O
into	O
the	O
accumbens	O
shell	O
(	O
but	O
not	O
the	O
core	O
)	O
before	O
cocaine	B-Chemical
,	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
enhanced	O
the	O
locomotor	O
response	O
to	O
cocaine	B-Chemical
;	O
the	O
maximum	O
effect	O
being	O
observed	O
after	O
10	O
microg	O
/	O
side	O
of	O
the	O
agonist	O
.	O
The	O
later	O
enhancement	O
was	O
attenuated	O
after	O
intra	O
-	O
accumbens	O
shell	O
treatment	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
1	O
microg	O
/	O
side	O
)	O
.	O
Our	O
findings	O
indicate	O
that	O
cocaine	B-Chemical
induced	O
hyperlocomotion	B-Disease
is	O
modified	O
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5	O
-	O
HT1B	O
receptor	O
antagonist	O
(	O
GR	B-Chemical
55562	I-Chemical
)	O
and	O
agonist	O
(	O
CP	B-Chemical
93129	I-Chemical
)	O
,	O
respectively	O
.	O
In	O
other	O
words	O
,	O
the	O
present	O
results	O
suggest	O
that	O
the	O
accumbal	O
shell	O
5	O
-	O
HT1B	O
receptors	O
play	O
a	O
permissive	O
role	O
in	O
the	O
behavioural	O
response	O
to	O
the	O
psychostimulant	O
.	O
Cocaine	B-Chemical
related	O
chest	B-Disease
pain	I-Disease
:	O
are	O
we	O
seeing	O
the	O
tip	O
of	O
an	O
iceberg	O
?	O
The	O
recreational	O
use	O
of	O
cocaine	B-Chemical
is	O
on	O
the	O
increase	O
.	O
The	O
emergency	O
nurse	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
cocaine	B-Chemical
use	O
.	O
In	O
particular	O
,	O
the	O
tendency	O
of	O
cocaine	B-Chemical
to	O
produce	O
chest	B-Disease
pain	I-Disease
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	O
with	O
a	O
young	O
victim	O
of	O
chest	B-Disease
pain	I-Disease
who	O
is	O
otherwise	O
at	O
low	O
risk	O
.	O
The	O
mechanism	O
of	O
chest	B-Disease
pain	I-Disease
related	O
to	O
cocaine	B-Chemical
use	O
is	O
discussed	O
and	O
treatment	O
dilemmas	O
are	O
discussed	O
.	O
Finally	O
,	O
moral	O
issues	O
relating	O
to	O
the	O
testing	O
of	O
potential	O
cocaine	B-Chemical
users	O
will	O
be	O
addressed	O
.	O
Crossover	O
comparison	O
of	O
efficacy	O
and	O
preference	O
for	O
rizatriptan	B-Chemical
10	O
mg	O
versus	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
in	O
migraine	B-Disease
.	O
Rizatriptan	B-Chemical
is	O
a	O
selective	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
1B	O
/	O
1D	O
)	O
receptor	O
agonist	O
with	O
rapid	O
oral	O
absorption	O
and	O
early	O
onset	O
of	O
action	O
in	O
the	O
acute	O
treatment	O
of	O
migraine	B-Disease
.	O
This	O
randomized	O
double	O
-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	O
for	O
1	O
rizatriptan	B-Chemical
10	O
mg	O
tablet	O
to	O
2	O
ergotamine	B-Chemical
1	O
mg	O
/	O
caffeine	B-Chemical
100	O
mg	O
tablets	O
in	O
439	O
patients	O
treating	O
a	O
single	O
migraine	B-Disease
attack	O
with	O
each	O
therapy	O
.	O
Of	O
patients	O
expressing	O
a	O
preference	O
(	O
89	O
.	O
1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatriptan	B-Chemical
to	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
69	O
.	O
9	O
vs	O
.	O
30	O
.	O
1	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O
Faster	O
relief	O
of	O
headache	B-Disease
was	O
the	O
most	O
important	O
reason	O
for	O
preference	O
,	O
cited	O
by	O
67	O
.	O
3	O
%	O
of	O
patients	O
preferring	O
rizatriptan	B-Chemical
and	O
54	O
.	O
2	O
%	O
of	O
patients	O
who	O
preferred	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
.	O
The	O
co	O
-	O
primary	O
endpoint	O
of	O
being	O
pain	B-Disease
free	O
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatriptan	B-Chemical
.	O
Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	B-Disease
free	O
2	O
h	O
after	O
rizatriptan	B-Chemical
,	O
compared	O
with	O
24	O
.	O
3	O
%	O
treated	O
with	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rizatriptan	B-Chemical
being	O
superior	O
within	O
1	O
h	O
of	O
treatment	O
.	O
Headache	B-Disease
relief	O
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizatriptan	B-Chemical
and	O
47	O
.	O
3	O
%	O
for	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatriptan	B-Chemical
being	O
superior	O
to	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
within	O
30	O
min	O
of	O
dosing	O
.	O
Almost	O
36	O
%	O
of	O
patients	O
taking	O
rizatriptan	B-Chemical
were	O
pain	B-Disease
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	O
or	O
need	O
for	O
additional	O
medication	O
within	O
24	O
h	O
,	O
compared	O
to	O
20	O
%	O
of	O
patients	O
on	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O
Rizatriptan	B-Chemical
was	O
also	O
superior	O
to	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	B-Disease
,	O
vomiting	B-Disease
,	O
phonophobia	B-Disease
or	O
photophobia	B-Disease
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O
More	O
patients	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfied	O
2	O
h	O
after	O
treatment	O
with	O
rizatriptan	B-Chemical
(	O
69	O
.	O
8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatment	O
with	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
38	O
.	O
6	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O
Recurrence	O
rates	O
were	O
31	O
.	O
4	O
%	O
with	O
rizatriptan	B-Chemical
and	O
15	O
.	O
3	O
%	O
with	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
.	O
Both	O
active	O
treatments	O
were	O
well	O
tolerated	O
.	O
The	O
most	O
common	O
adverse	O
events	O
(	O
incidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	B-Chemical
and	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
,	O
respectively	O
,	O
were	O
dizziness	B-Disease
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
nausea	B-Disease
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
somnolence	B-Disease
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O
Severe	O
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
after	O
intracarotid	O
injection	O
of	O
carboplatin	B-Chemical
for	O
recurrent	O
glioblastomas	B-Disease
.	O
BACKGROUND	O
:	O
Glioblastoma	B-Disease
is	O
a	O
malignant	B-Disease
tumor	I-Disease
that	O
occurs	O
in	O
the	O
cerebrum	O
during	O
adulthood	O
.	O
With	O
current	O
treatment	O
regimens	O
including	O
combined	O
surgery	O
,	O
radiation	O
and	O
chemotherapy	O
,	O
the	O
average	O
life	O
expectancy	O
of	O
the	O
patients	O
is	O
limited	O
to	O
approximately	O
1	O
year	O
.	O
Therefore	O
,	O
patients	O
with	O
glioblastoma	B-Disease
sometimes	O
have	O
intracarotid	O
injection	O
of	O
carcinostatics	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O
Generally	O
,	O
carboplatin	B-Chemical
is	O
said	O
to	O
have	O
milder	O
side	O
effects	O
than	O
cisplatin	B-Chemical
,	O
whose	O
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
are	O
well	O
known	O
.	O
However	O
,	O
we	O
experienced	O
a	O
case	O
of	O
severe	O
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
after	O
intracarotid	O
injection	O
of	O
carboplatin	B-Chemical
,	O
which	O
is	O
infrequently	O
reported	O
.	O
CASE	O
:	O
A	O
58	O
-	O
year	O
-	O
old	O
man	O
received	O
an	O
intracarotid	O
injection	O
of	O
carboplatin	B-Chemical
for	O
recurrent	O
glioblastomas	B-Disease
in	O
his	O
left	O
temporal	O
lobe	O
.	O
He	O
complained	O
of	O
pain	B-Disease
and	I-Disease
visual	I-Disease
disturbance	I-Disease
in	I-Disease
the	I-Disease
ipsilateral	I-Disease
eye	I-Disease
30	O
h	O
after	O
the	O
injection	O
.	O
Various	O
ocular	O
symptoms	O
and	O
findings	O
caused	O
by	O
carboplatin	B-Chemical
toxicity	B-Disease
were	O
seen	O
.	O
RESULTS	O
:	O
He	O
was	O
treated	O
with	O
intravenous	O
administration	O
of	O
corticosteroids	O
and	O
glycerin	B-Chemical
for	O
6	O
days	O
after	O
the	O
injection	O
.	O
Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	O
by	O
secondary	O
acute	O
angle	O
-	O
closure	O
glaucoma	B-Disease
decreased	O
and	O
ocular	B-Disease
pain	I-Disease
diminished	O
,	O
inexorable	O
papilledema	B-Disease
and	O
exudative	O
retinal	B-Disease
detachment	I-Disease
continued	O
for	O
3	O
weeks	O
.	O
Finally	O
,	O
6	O
weeks	O
later	O
,	O
diffuse	O
chorioretinal	B-Disease
atrophy	I-Disease
with	O
optic	B-Disease
atrophy	I-Disease
occurred	O
and	O
the	O
vision	O
in	O
his	O
left	O
eye	O
was	O
lost	O
.	O
CONCLUSION	O
:	O
When	O
performing	O
intracarotid	O
injection	O
of	O
carboplatin	B-Chemical
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinding	O
ocular	B-Disease
toxicity	I-Disease
.	O
It	O
is	O
recommended	O
that	O
further	O
studies	O
and	O
investigations	O
are	O
undertaken	O
in	O
the	O
effort	O
to	O
minimize	O
such	O
severe	O
side	O
effects	O
.	O
Visual	B-Disease
hallucinations	I-Disease
associated	O
with	O
zonisamide	B-Chemical
.	O
Zonisamide	B-Chemical
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
used	O
to	O
treat	O
various	O
types	O
of	O
seizures	B-Disease
.	O
Although	O
visual	B-Disease
hallucinations	I-Disease
have	O
not	O
been	O
reported	O
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patients	O
who	O
experienced	O
complex	O
visual	B-Disease
hallucinations	I-Disease
and	O
altered	O
mental	O
status	O
after	O
zonisamide	B-Chemical
treatment	O
was	O
begun	O
or	O
its	O
dosage	O
increased	O
.	O
All	O
three	O
had	O
been	O
diagnosed	O
earlier	O
with	O
epilepsy	B-Disease
,	O
and	O
their	O
electroencephalogram	O
(	O
EEG	O
)	O
findings	O
were	O
abnormal	O
.	O
During	O
monitoring	O
,	O
visual	B-Disease
hallucinations	I-Disease
did	O
not	O
correlate	O
with	O
EEG	O
readings	O
,	O
nor	O
did	O
video	O
recording	O
capture	O
any	O
of	O
the	O
described	O
events	O
.	O
None	O
of	O
the	O
patients	O
had	O
experienced	O
visual	B-Disease
hallucinations	I-Disease
before	O
this	O
event	O
.	O
The	O
only	O
recent	O
change	O
in	O
their	O
treatment	O
was	O
the	O
introduction	O
or	O
increased	O
dosage	O
of	O
zonisamide	B-Chemical
.	O
With	O
either	O
discontinuation	O
or	O
decreased	O
dosage	O
of	O
the	O
drug	O
the	O
symptoms	O
disappeared	O
and	O
did	O
not	O
recur	O
.	O
Further	O
observations	O
and	O
reports	O
will	O
help	O
clarify	O
this	O
adverse	O
effect	O
.	O
Until	O
then	O
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	O
complication	O
associated	O
with	O
zonisamide	B-Chemical
.	O
Anti	O
-	O
epileptic	B-Disease
drugs	O
-	O
induced	O
de	O
novo	O
absence	B-Disease
seizures	I-Disease
.	O
The	O
authors	O
present	O
three	O
patients	O
with	O
de	O
novo	O
absence	B-Disease
epilepsy	I-Disease
after	O
administration	O
of	O
carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
.	O
Despite	O
the	O
underlying	O
diseases	O
,	O
the	O
prognosis	O
for	O
drug	O
-	O
induced	O
de	O
novo	O
absence	B-Disease
seizure	I-Disease
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
discontinuing	O
the	O
use	O
of	O
the	O
offending	O
drugs	O
.	O
The	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
-	O
transmitted	O
thalamocortical	O
circuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurophysiology	O
of	O
the	O
absence	B-Disease
epilepsy	I-Disease
.	O
Because	O
drug	O
-	O
induced	O
de	O
novo	O
absence	B-Disease
seizure	I-Disease
is	O
rare	O
,	O
pro	O
-	O
absence	O
drugs	O
can	O
only	O
be	O
considered	O
a	O
promoting	O
factor	O
.	O
The	O
underlying	O
epileptogenecity	O
of	O
the	O
patients	O
or	O
the	O
synergistic	O
effects	O
of	O
the	O
accompanying	O
drugs	O
is	O
required	O
to	O
trigger	O
the	O
de	O
novo	O
absence	B-Disease
seizure	I-Disease
.	O
The	O
possibility	O
of	O
drug	O
-	O
induced	O
aggravation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
increase	O
in	O
seizure	B-Disease
frequency	O
and	O
/	O
or	O
new	O
seizure	B-Disease
types	O
appear	O
following	O
a	O
change	O
in	O
drug	O
treatment	O
.	O
By	O
understanding	O
the	O
underlying	O
mechanism	O
of	O
absence	B-Disease
epilepsy	I-Disease
,	O
we	O
can	O
avoid	O
the	O
inappropriate	O
use	O
of	O
anticonvulsants	O
in	O
children	O
with	O
epilepsy	B-Disease
and	O
prevent	O
drug	O
-	O
induced	O
absence	B-Disease
seizures	I-Disease
.	O
Prenatal	O
dexamethasone	B-Chemical
programs	O
hypertension	B-Disease
and	O
renal	B-Disease
injury	I-Disease
in	O
the	O
rat	O
.	O
Dexamethasone	O
is	O
frequently	O
administered	O
to	O
the	O
developing	O
fetus	O
to	O
accelerate	O
pulmonary	O
development	O
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
prenatal	O
dexamethasone	B-Chemical
programmed	O
a	O
progressive	O
increase	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
renal	B-Disease
injury	I-Disease
in	O
rats	O
.	O
Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	O
or	O
2	O
daily	O
intraperitoneal	O
injections	O
of	O
dexamethasone	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
gestational	O
days	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O
Offspring	O
of	O
rats	O
administered	O
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
gestation	O
had	O
a	O
20	O
%	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
compared	O
with	O
control	O
at	O
6	O
to	O
9	O
months	O
of	O
age	O
(	O
22	O
527	O
+	O
/	O
-	O
509	O
versus	O
28	O
050	O
+	O
/	O
-	O
561	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
reduction	O
in	O
glomeruli	O
measured	O
at	O
3	O
weeks	O
of	O
age	O
.	O
Six	O
-	O
to	O
9	O
-	O
month	O
old	O
rats	O
receiving	O
prenatal	O
dexamethasone	B-Chemical
on	O
days	O
17	O
and	O
18	O
of	O
gestation	O
had	O
a	O
17	O
%	O
reduction	O
in	O
glomeruli	O
(	O
23	O
380	O
+	O
/	O
-	O
587	O
)	O
compared	O
with	O
control	O
rats	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Male	O
rats	O
that	O
received	O
prenatal	O
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	B-Disease
blood	I-Disease
pressures	I-Disease
at	O
6	O
months	O
of	O
age	O
;	O
the	O
latter	O
group	O
did	O
not	O
have	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
.	O
Adult	O
rats	O
given	O
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
of	O
gestation	O
had	O
more	O
glomeruli	O
with	O
glomerulosclerosis	B-Disease
than	O
control	O
rats	O
.	O
This	O
study	O
shows	O
that	O
prenatal	O
dexamethasone	B-Chemical
in	O
rats	O
results	O
in	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
,	O
glomerulosclerosis	B-Disease
,	O
and	O
hypertension	B-Disease
when	O
administered	O
at	O
specific	O
points	O
during	O
gestation	O
.	O
Hypertension	B-Disease
was	O
observed	O
in	O
animals	O
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
,	O
suggesting	O
that	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
development	O
of	O
hypertension	B-Disease
.	O
Kidney	O
function	O
and	O
morphology	O
after	O
short	O
-	O
term	O
combination	O
therapy	O
with	O
cyclosporine	B-Chemical
A	I-Chemical
,	O
tacrolimus	B-Chemical
and	O
sirolimus	B-Chemical
in	O
the	O
rat	O
.	O
BACKGROUND	O
:	O
Sirolimus	B-Chemical
(	O
SRL	B-Chemical
)	O
may	O
supplement	O
calcineurin	O
inhibitors	O
in	O
clinical	O
organ	O
transplantation	O
.	O
These	O
are	O
nephrotoxic	B-Disease
,	O
but	O
SRL	B-Chemical
seems	O
to	O
act	O
differently	O
displaying	O
only	O
minor	O
nephrotoxic	B-Disease
effects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O
In	O
a	O
number	O
of	O
treatment	O
protocols	O
where	O
SRL	B-Chemical
was	O
combined	O
with	O
a	O
calcineurin	O
inhibitor	O
indications	O
of	O
a	O
synergistic	O
nephrotoxic	B-Disease
effect	O
were	O
described	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
either	O
cyclosporine	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
)	O
,	O
tacrolimus	B-Chemical
(	O
FK506	B-Chemical
)	O
or	O
SRL	B-Chemical
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O
METHODS	O
:	O
For	O
a	O
period	O
of	O
2	O
weeks	O
,	O
CsA	B-Chemical
15	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
,	O
FK506	B-Chemical
3	O
.	O
0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
or	O
SRL	B-Chemical
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
intraperitoneally	O
)	O
was	O
administered	O
once	O
a	O
day	O
as	O
these	O
doses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressive	O
effect	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
.	O
In	O
the	O
'	O
conscious	O
catheterized	O
rat	O
'	O
model	O
,	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
was	O
measured	O
as	O
the	O
clearance	O
of	O
Cr	O
(	O
EDTA	O
)	O
.	O
The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	O
a	O
semi	O
-	O
quantitative	O
scoring	O
system	O
analysing	O
the	O
degree	O
of	O
striped	O
fibrosis	B-Disease
,	O
subcapsular	O
fibrosis	B-Disease
and	O
the	O
number	O
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	O
stereological	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	B-Disease
in	O
the	O
cortex	O
stained	O
with	O
Sirius	O
Red	O
.	O
RESULTS	O
:	O
CsA	B-Chemical
,	O
FK506	B-Chemical
and	O
SRL	B-Chemical
all	O
significantly	O
decreased	O
the	O
GFR	O
.	O
A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	B-Chemical
was	O
combined	O
with	O
either	O
FK506	B-Chemical
or	O
SRL	B-Chemical
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	B-Chemical
plus	O
SRL	B-Chemical
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O
The	O
morphological	O
changes	O
presented	O
a	O
similar	O
pattern	O
.	O
The	O
semi	O
-	O
quantitative	O
scoring	O
was	O
significantly	O
worst	O
in	O
the	O
group	O
treated	O
with	O
CsA	B-Chemical
plus	O
SRL	B-Chemical
(	O
P	O
<	O
0	O
.	O
001	O
compared	O
with	O
controls	O
)	O
and	O
the	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	B-Disease
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O
The	O
FK506	B-Chemical
plus	O
SRL	B-Chemical
combination	O
showed	O
only	O
a	O
marginally	O
higher	O
degree	O
of	O
fibrosis	B-Disease
as	O
compared	O
with	O
controls	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O
CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	B-Disease
effect	O
of	O
CsA	B-Chemical
plus	O
SRL	B-Chemical
,	O
whereas	O
FK506	B-Chemical
plus	O
SRL	B-Chemical
was	O
better	O
tolerated	O
.	O
Evaluation	O
of	O
cardiac	O
troponin	O
I	O
and	O
T	O
levels	O
as	O
markers	O
of	O
myocardial	B-Disease
damage	I-Disease
in	O
doxorubicin	B-Chemical
-	O
induced	O
cardiomyopathy	B-Disease
rats	O
,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings	O
.	O
BACKGROUND	O
:	O
Cardiac	O
troponins	O
I	O
(	O
cTnI	O
)	O
and	O
T	O
(	O
cTnT	O
)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
sensitive	O
and	O
specific	O
markers	O
of	O
myocardial	B-Disease
cell	I-Disease
injury	I-Disease
.	O
We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	B-Disease
damage	I-Disease
in	O
a	O
rat	O
model	O
of	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
induced	O
cardiomyopathy	B-Disease
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	B-Disease
disorders	I-Disease
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O
METHODS	O
:	O
Thirty	O
-	O
five	O
Wistar	O
rats	O
were	O
given	O
1	O
.	O
5	O
mg	O
/	O
kg	O
DOX	B-Chemical
,	O
i	O
.	O
v	O
.	O
,	O
weekly	O
for	O
up	O
to	O
8	O
weeks	O
for	O
a	O
total	O
cumulative	O
dose	O
of	O
12	O
mg	O
/	O
kg	O
BW	O
.	O
Ten	O
rats	O
received	O
saline	O
as	O
a	O
control	O
group	O
.	O
cTnI	O
was	O
measured	O
with	O
Access	O
(	O
R	O
)	O
(	O
ng	O
/	O
ml	O
)	O
and	O
a	O
research	O
immunoassay	O
(	O
pg	O
/	O
ml	O
)	O
,	O
and	O
compared	O
with	O
cTnT	O
,	O
CK	O
-	O
MB	O
mass	O
and	O
CK	O
.	O
By	O
using	O
transthoracic	O
echocardiography	O
,	O
anterior	O
and	O
posterior	O
wall	O
thickness	O
,	O
LV	O
diameters	O
and	O
LV	O
fractional	O
shortening	O
(	O
FS	O
)	O
were	O
measured	O
in	O
all	O
rats	O
before	O
DOX	B-Chemical
or	O
saline	O
,	O
and	O
at	O
weeks	O
6	O
and	O
9	O
after	O
treatment	O
in	O
all	O
surviving	O
rats	O
.	O
Histology	O
was	O
performed	O
in	O
DOX	B-Chemical
-	O
rats	O
at	O
6	O
and	O
9	O
weeks	O
after	O
the	O
last	O
DOX	B-Chemical
dose	O
and	O
in	O
all	O
controls	O
.	O
RESULTS	O
:	O
Eighteen	O
of	O
the	O
DOX	B-Chemical
rats	O
died	O
prematurely	O
of	O
general	O
toxicity	B-Disease
during	O
the	O
9	O
-	O
week	O
period	O
.	O
End	O
-	O
diastolic	O
(	O
ED	O
)	O
and	O
end	O
-	O
systolic	O
(	O
ES	O
)	O
LV	O
diameters	O
/	O
BW	O
significantly	O
increased	O
,	O
whereas	O
LV	O
FS	O
was	O
decreased	O
after	O
9	O
weeks	O
in	O
the	O
DOX	B-Chemical
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
These	O
parameters	O
remained	O
unchanged	O
in	O
controls	O
.	O
Histological	O
evaluation	O
of	O
hearts	O
from	O
all	O
rats	O
given	O
DOX	B-Chemical
revealed	O
significant	O
slight	O
degrees	O
of	O
perivascular	O
and	O
interstitial	O
fibrosis	B-Disease
.	O
In	O
7	O
of	O
the	O
18	O
rats	O
,	O
degeneration	O
and	O
myocyte	O
vacuolisation	O
were	O
found	O
.	O
Only	O
five	O
of	O
the	O
controls	O
exhibited	O
evidence	O
of	O
very	O
slight	O
perivascular	O
fibrosis	B-Disease
.	O
A	O
significant	O
rise	O
in	O
cTnT	O
was	O
found	O
in	O
DOX	B-Chemical
rats	O
after	O
cumulative	O
doses	O
of	O
7	O
.	O
5	O
and	O
12	O
mg	O
/	O
kg	O
in	O
comparison	O
with	O
baseline	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
cTnT	O
found	O
in	O
rats	O
after	O
12	O
mg	O
/	O
kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7	O
.	O
5	O
mg	O
/	O
kg	O
DOX	B-Chemical
.	O
Maximal	O
cTnI	O
(	O
pg	O
/	O
ml	O
)	O
and	O
cTnT	O
levels	O
were	O
significantly	O
increased	O
in	O
DOX	B-Chemical
rats	O
compared	O
with	O
controls	O
(	O
p	O
=	O
0	O
.	O
006	O
,	O
0	O
.	O
007	O
)	O
.	O
cTnI	O
(	O
ng	O
/	O
ml	O
)	O
,	O
CK	O
-	O
MB	O
mass	O
and	O
CK	O
remained	O
unchanged	O
in	O
DOX	B-Chemical
rats	O
compared	O
with	O
controls	O
.	O
All	O
markers	O
remained	O
stable	O
in	O
controls	O
.	O
Analysis	O
of	O
data	O
revealed	O
a	O
significant	O
correlation	O
between	O
maximal	O
cTnT	O
and	O
ED	O
and	O
ES	O
LV	O
diameters	O
/	O
BW	O
(	O
r	O
=	O
0	O
.	O
81	O
and	O
0	O
.	O
65	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O
A	O
significant	O
relationship	O
was	O
observed	O
between	O
maximal	O
cTnT	O
and	O
the	O
extent	O
of	O
myocardial	O
morphological	O
changes	O
,	O
and	O
between	O
LV	O
diameters	O
/	O
BW	O
and	O
histological	O
findings	O
.	O
CONCLUSIONS	O
:	O
Among	O
markers	O
of	O
ischemic	B-Disease
injury	I-Disease
after	O
DOX	B-Chemical
in	O
rats	O
,	O
cTnT	O
showed	O
the	O
greatest	O
ability	O
to	O
detect	O
myocardial	B-Disease
damage	I-Disease
assessed	O
by	O
echocardiographic	O
detection	O
and	O
histological	O
changes	O
.	O
Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	B-Chemical
,	O
probably	O
due	O
to	O
heterogeneity	O
in	O
cross	O
-	O
reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	O
after	O
DOX	B-Chemical
indicates	O
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	O
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	O
marker	O
for	O
the	O
prediction	O
of	O
experimentally	O
induced	O
cardiotoxicity	B-Disease
and	O
possibly	O
for	O
cardioprotective	O
experiments	O
.	O
Octreotide	B-Chemical
-	O
induced	O
hypoxemia	B-Disease
and	O
pulmonary	B-Disease
hypertension	I-Disease
in	O
premature	O
neonates	O
.	O
The	O
authors	O
report	O
2	O
cases	O
of	O
premature	O
neonates	O
who	O
had	O
enterocutaneous	O
fistula	B-Disease
complicating	O
necrotizing	B-Disease
enterocolitis	I-Disease
.	O
Pulmonary	B-Disease
hypertension	I-Disease
developed	O
after	O
administration	O
of	O
a	O
somatostatin	O
analogue	O
,	O
octreotide	B-Chemical
,	O
to	O
enhance	O
resolution	O
of	O
the	O
fistula	B-Disease
.	O
The	O
authors	O
discuss	O
the	O
mechanism	O
of	O
the	O
occurrence	O
of	O
this	O
complication	O
and	O
recommend	O
caution	O
of	O
its	O
use	O
in	O
high	O
-	O
risk	O
premature	O
neonates	O
.	O
The	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
in	O
women	O
prescribed	O
cyproterone	B-Chemical
acetate	I-Chemical
in	O
combination	O
with	O
ethinyl	B-Chemical
estradiol	I-Chemical
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
.	O
BACKGROUND	O
:	O
Cyproterone	B-Chemical
acetate	I-Chemical
combined	O
with	O
ethinyl	B-Chemical
estradiol	I-Chemical
(	O
CPA	B-Chemical
/	O
EE	B-Chemical
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	B-Disease
and	O
hirsutism	B-Disease
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	B-Disease
ovary	I-Disease
syndrome	I-Disease
(	O
PCOS	B-Disease
)	O
.	O
Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	B-Disease
)	O
associated	O
with	O
CPA	B-Chemical
/	O
EE	B-Chemical
compared	O
with	O
conventional	O
combined	O
oral	B-Chemical
contraceptives	I-Chemical
(	O
COCs	O
)	O
.	O
We	O
believe	O
the	O
results	O
of	O
those	O
studies	O
may	O
have	O
been	O
affected	O
by	O
residual	O
confounding	O
.	O
METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	B-Disease
,	O
hirsutism	B-Disease
or	O
PCOS	B-Disease
to	O
estimate	O
the	O
risk	O
of	O
VTE	B-Disease
associated	O
with	O
CPA	B-Chemical
/	O
EE	B-Chemical
.	O
RESULTS	O
:	O
The	O
age	O
-	O
adjusted	O
incidence	O
rate	O
ratio	O
for	O
CPA	B-Chemical
/	O
EE	B-Chemical
versus	O
conventional	O
COCs	O
was	O
2	O
.	O
20	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
35	O
-	O
3	O
.	O
58	O
]	O
.	O
Using	O
as	O
the	O
reference	O
group	O
women	O
who	O
were	O
not	O
using	O
oral	O
contraception	O
,	O
had	O
no	O
recent	O
pregnancy	O
or	O
menopausal	O
symptoms	O
,	O
the	O
case	O
-	O
control	O
analysis	O
gave	O
an	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
(	O
adj	O
)	O
)	O
of	O
7	O
.	O
44	O
(	O
95	O
%	O
CI	O
3	O
.	O
67	O
-	O
15	O
.	O
08	O
)	O
for	O
CPA	B-Chemical
/	O
EE	B-Chemical
use	O
compared	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2	O
.	O
58	O
(	O
95	O
%	O
CI	O
1	O
.	O
60	O
-	O
4	O
.	O
18	O
)	O
for	O
use	O
of	O
conventional	O
COCs	O
.	O
CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	B-Disease
associated	O
with	O
the	O
use	O
of	O
CPA	B-Chemical
/	O
EE	B-Chemical
in	O
women	O
with	O
acne	B-Disease
,	O
hirsutism	B-Disease
or	O
PCOS	B-Disease
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O
The	O
effect	O
of	O
treatment	O
with	O
gum	B-Chemical
Arabic	I-Chemical
on	O
gentamicin	B-Chemical
nephrotoxicity	B-Disease
in	O
rats	O
:	O
a	O
preliminary	O
study	O
.	O
In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	B-Chemical
Arabic	I-Chemical
on	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
induced	O
by	O
gentamicin	B-Chemical
(	O
GM	B-Chemical
)	O
nephrotoxicity	B-Disease
.	O
Rats	O
were	O
treated	O
with	O
the	O
vehicle	O
(	O
2	O
mL	O
/	O
kg	O
of	O
distilled	O
water	O
and	O
5	O
%	O
w	O
/	O
v	O
cellulose	O
,	O
10	O
days	O
)	O
,	O
gum	B-Chemical
Arabic	I-Chemical
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
aqueous	O
suspension	O
of	O
gum	B-Chemical
Arabic	I-Chemical
powder	O
,	O
orally	O
for	O
10	O
days	O
)	O
,	O
or	O
gum	B-Chemical
Arabic	I-Chemical
concomitantly	O
with	O
GM	B-Chemical
(	O
80mg	O
/	O
kg	O
/	O
day	O
intramuscularly	O
,	O
during	O
the	O
last	O
six	O
days	O
of	O
the	O
treatment	O
period	O
)	O
.	O
Nephrotoxicity	B-Disease
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	B-Chemical
and	O
urea	B-Chemical
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O
The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	B-Chemical
Arabic	I-Chemical
and	O
GM	B-Chemical
significantly	O
increased	O
creatinine	B-Chemical
and	O
urea	B-Chemical
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	B-Chemical
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	B-Chemical
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	B-Chemical
group	O
)	O
The	O
GM	B-Chemical
-	O
induced	O
proximal	O
tubular	B-Disease
necrosis	I-Disease
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	B-Chemical
together	O
with	O
gum	B-Chemical
Arabic	I-Chemical
than	O
in	O
those	O
given	O
GM	B-Chemical
and	O
cellulose	O
.	O
It	O
could	O
be	O
inferred	O
that	O
gum	B-Chemical
Arabic	I-Chemical
treatment	O
has	O
induced	O
a	O
modest	O
amelioration	O
of	O
some	O
of	O
the	O
histological	O
and	O
biochemical	O
indices	O
of	O
GM	B-Chemical
nephrotoxicity	B-Disease
.	O
Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	O
of	O
the	O
treatments	O
on	O
renal	O
functional	O
aspects	O
in	O
models	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
,	O
and	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
.	O
Increased	O
frequency	O
of	O
venous	B-Disease
thromboembolism	I-Disease
with	O
the	O
combination	O
of	O
docetaxel	B-Chemical
and	O
thalidomide	B-Chemical
in	O
patients	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
.	O
STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	B-Disease
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
who	O
were	O
treated	O
with	O
docetaxel	B-Chemical
alone	O
or	O
in	O
combination	O
with	O
thalidomide	B-Chemical
.	O
DESIGN	O
:	O
Retrospective	O
analysis	O
of	O
a	O
randomized	O
phase	O
II	O
trial	O
.	O
SETTING	O
:	O
National	O
Institutes	O
of	O
Health	O
clinical	O
research	O
center	O
.	O
PATIENTS	O
:	O
Seventy	O
men	O
,	O
aged	O
50	O
-	O
80	O
years	O
,	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
.	O
INTERVENTION	O
:	O
Each	O
patient	O
received	O
either	O
intravenous	O
docetaxel	B-Chemical
30	O
mg	O
/	O
m2	O
/	O
week	O
for	O
3	O
consecutive	O
weeks	O
,	O
followed	O
by	O
1	O
week	O
off	O
,	O
or	O
the	O
combination	O
of	O
continuous	O
oral	O
thalidomide	B-Chemical
200	O
mg	O
every	O
evening	O
plus	O
the	O
same	O
docetaxel	B-Chemical
regimen	O
.	O
This	O
4	O
-	O
week	O
cycle	O
was	O
repeated	O
until	O
there	O
was	O
evidence	O
of	O
excessive	O
toxicity	B-Disease
or	O
disease	O
progression	O
.	O
MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
patients	O
who	O
received	O
docetaxel	B-Chemical
alone	O
developed	O
VTE	B-Disease
,	O
whereas	O
9	O
of	O
47	O
patients	O
(	O
19	O
%	O
)	O
who	O
received	O
docetaxel	B-Chemical
plus	O
thalidomide	B-Chemical
developed	O
VTE	B-Disease
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O
CONCLUSION	O
:	O
The	O
addition	O
of	O
thalidomide	B-Chemical
to	O
docetaxel	B-Chemical
in	O
the	O
treatment	O
of	O
prostate	B-Disease
cancer	I-Disease
significantly	O
increases	O
the	O
frequency	O
of	O
VTE	B-Disease
.	O
Clinicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
complication	O
when	O
adding	O
thalidomide	B-Chemical
to	O
chemotherapeutic	O
regimens	O
.	O
Ticlopidine	B-Chemical
-	O
induced	O
cholestatic	B-Disease
hepatitis	I-Disease
.	O
OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
ticlopidine	B-Chemical
-	O
induced	O
cholestatic	B-Disease
hepatitis	I-Disease
,	O
investigate	O
its	O
mechanism	O
,	O
and	O
compare	O
the	O
observed	O
main	O
characteristics	O
with	O
those	O
of	O
the	O
published	O
cases	O
.	O
CASE	O
SUMMARIES	O
:	O
Two	O
patients	O
developed	O
prolonged	O
cholestatic	B-Disease
hepatitis	I-Disease
after	O
receiving	O
ticlopidine	B-Chemical
following	O
percutaneous	O
coronary	O
angioplasty	O
,	O
with	O
complete	O
remission	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O
T	O
-	O
cell	O
stimulation	O
by	O
therapeutic	O
concentration	O
of	O
ticlopidine	B-Chemical
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
patients	O
,	O
but	O
not	O
in	O
healthy	O
controls	O
.	O
DISCUSSION	O
:	O
Cholestatic	B-Disease
hepatitis	I-Disease
is	O
a	O
rare	O
complication	O
of	O
the	O
antiplatelet	O
agent	O
ticlopidine	B-Chemical
;	O
several	O
cases	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
English	O
literature	O
.	O
Our	O
patients	O
developed	O
jaundice	B-Disease
following	O
treatment	O
with	O
ticlopidine	B-Chemical
and	O
showed	O
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
cholestatic	B-Disease
hepatitis	I-Disease
,	O
which	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O
Hepatitis	B-Disease
may	O
develop	O
weeks	O
after	O
discontinuation	O
of	O
the	O
drug	O
and	O
may	O
run	O
a	O
prolonged	O
course	O
,	O
but	O
complete	O
remission	O
was	O
observed	O
in	O
all	O
reported	O
cases	O
.	O
An	O
objective	O
causality	O
assessment	O
revealed	O
that	O
the	O
adverse	O
drug	O
event	O
was	O
probably	O
related	O
to	O
the	O
use	O
of	O
ticlopidine	B-Chemical
.	O
The	O
mechanisms	O
of	O
this	O
ticlopidine	B-Chemical
-	O
induced	O
cholestasis	B-Disease
are	O
unclear	O
.	O
Immune	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
drug	O
'	O
s	O
hepatotoxicity	B-Disease
,	O
as	O
suggested	O
by	O
the	O
T	O
-	O
cell	O
stimulation	O
study	O
reported	O
here	O
.	O
CONCLUSIONS	O
:	O
Cholestatic	B-Disease
hepatitis	I-Disease
is	O
a	O
rare	O
adverse	O
effect	O
of	O
ticlopidine	B-Chemical
that	O
may	O
be	O
immune	O
mediated	O
.	O
Patients	O
receiving	O
the	O
drug	O
should	O
be	O
monitored	O
with	O
liver	O
function	O
tests	O
along	O
with	O
complete	O
blood	O
cell	O
counts	O
.	O
This	O
complication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopidine	B-Chemical
is	O
being	O
replaced	O
by	O
the	O
newer	O
antiplatelet	O
agent	O
clopidogrel	B-Chemical
.	O
Epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
)	O
subunit	O
mRNA	O
and	O
protein	O
expression	O
in	O
rats	O
with	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
In	O
experimental	O
nephrotic	B-Disease
syndrome	I-Disease
,	O
urinary	O
sodium	B-Chemical
excretion	O
is	O
decreased	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O
The	O
molecular	O
mechanism	O
(	O
s	O
)	O
leading	O
to	O
salt	O
retention	O
has	O
not	O
been	O
completely	O
elucidated	O
.	O
The	O
rate	O
-	O
limiting	O
constituent	O
of	O
collecting	O
duct	O
sodium	B-Chemical
transport	O
is	O
the	O
epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
)	O
.	O
We	O
examined	O
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
The	O
time	O
courses	O
of	O
urinary	O
sodium	B-Chemical
excretion	O
,	O
plasma	O
aldosterone	B-Chemical
concentration	O
and	O
proteinuria	B-Disease
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
a	O
single	O
dose	O
of	O
either	O
PAN	B-Chemical
or	O
vehicle	O
.	O
The	O
relative	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNAs	O
were	O
determined	O
in	O
kidneys	O
from	O
these	O
rats	O
by	O
real	O
-	O
time	O
quantitative	O
TaqMan	O
PCR	O
,	O
and	O
the	O
amounts	O
of	O
proteins	O
by	O
Western	O
blot	O
.	O
The	O
kinetics	O
of	O
urinary	O
sodium	B-Chemical
excretion	O
and	O
the	O
appearance	O
of	O
proteinuria	B-Disease
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O
Sodium	B-Chemical
retention	O
occurred	O
on	O
days	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	B-Chemical
injection	O
.	O
A	O
significant	O
up	O
-	O
regulation	O
of	O
alphaENaC	O
and	O
betaENaC	O
mRNA	O
abundance	O
on	O
days	O
1	O
and	O
2	O
preceded	O
sodium	B-Chemical
retention	O
on	O
days	O
2	O
and	O
3	O
.	O
Conversely	O
,	O
down	O
-	O
regulation	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	O
expression	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presence	O
of	O
high	O
aldosterone	B-Chemical
concentrations	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
sodium	B-Chemical
excretion	O
to	O
control	O
values	O
.	O
The	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
proteins	O
were	O
not	O
increased	O
during	O
PAN	B-Chemical
-	O
induced	O
sodium	B-Chemical
retention	O
.	O
In	O
conclusion	O
,	O
ENaC	O
mRNA	O
expression	O
,	O
especially	O
alphaENaC	O
,	O
is	O
increased	O
in	O
the	O
very	O
early	O
phase	O
of	O
the	O
experimental	O
model	O
of	O
PAN	B-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
in	O
rats	O
,	O
but	O
appears	O
to	O
escape	O
from	O
the	O
regulation	O
by	O
aldosterone	B-Chemical
after	O
day	O
3	O
.	O
Sub	O
-	O
chronic	O
low	O
dose	O
gamma	B-Chemical
-	I-Chemical
vinyl	I-Chemical
GABA	I-Chemical
(	O
vigabatrin	B-Chemical
)	O
inhibits	O
cocaine	B-Chemical
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
dopamine	B-Chemical
.	O
RATIONALE	O
:	O
gamma	B-Chemical
-	I-Chemical
Vinyl	I-Chemical
GABA	I-Chemical
(	O
GVG	B-Chemical
)	O
irreversibly	O
inhibits	O
GABA	B-Chemical
-	O
transaminase	O
.	O
This	O
non	O
-	O
receptor	O
mediated	O
inhibition	O
requires	O
de	O
novo	O
synthesis	O
for	O
restoration	O
of	O
functional	O
GABA	B-Chemical
catabolism	O
.	O
OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	B-Disease
abuse	I-Disease
and	O
the	O
increased	O
risk	O
of	O
visual	B-Disease
field	I-Disease
defects	I-Disease
(	O
VFD	B-Disease
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	B-Chemical
on	O
cocaine	B-Chemical
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
.	O
METHODS	O
:	O
Using	O
in	O
vivo	O
microdialysis	O
,	O
we	O
compared	O
acute	O
exposure	O
(	O
450	O
mg	O
/	O
kg	O
)	O
to	O
an	O
identical	O
sub	O
-	O
chronic	O
exposure	O
(	O
150	O
mg	O
/	O
kg	O
per	O
day	O
for	O
3	O
days	O
)	O
,	O
followed	O
by	O
1	O
-	O
or	O
3	O
-	O
day	O
washout	O
.	O
Finally	O
,	O
we	O
examined	O
the	O
low	O
dose	O
of	O
150	O
mg	O
/	O
kg	O
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
)	O
using	O
a	O
similar	O
washout	O
period	O
.	O
RESULTS	O
:	O
Sub	O
-	O
chronic	O
GVG	B-Chemical
exposure	O
inhibited	O
the	O
effect	O
of	O
cocaine	B-Chemical
for	O
3	O
days	O
,	O
which	O
exceeded	O
in	O
magnitude	O
and	O
duration	O
the	O
identical	O
acute	O
dose	O
.	O
CONCLUSIONS	O
:	O
Sub	O
-	O
chronic	O
low	O
dose	O
GVG	B-Chemical
potentiates	O
and	O
extends	O
the	O
inhibition	O
of	O
cocaine	B-Chemical
-	O
induced	O
increases	O
in	O
dopamine	B-Chemical
,	O
effectively	O
reducing	O
cumulative	O
exposures	O
and	O
the	O
risk	O
for	O
VFDS	O
.	O
MR	O
imaging	O
with	O
quantitative	O
diffusion	O
mapping	O
of	O
tacrolimus	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
in	O
organ	O
transplant	O
patients	O
.	O
Our	O
objective	O
was	O
to	O
investigate	O
brain	O
MR	O
imaging	O
findings	O
and	O
the	O
utility	O
of	O
diffusion	O
-	O
weighted	O
(	O
DW	O
)	O
imaging	O
in	O
organ	O
transplant	O
patients	O
who	O
developed	O
neurologic	O
symptoms	O
during	O
tacrolimus	B-Chemical
therapy	O
.	O
Brain	O
MR	O
studies	O
,	O
including	O
DW	O
imaging	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
organ	O
transplant	O
patients	O
receiving	O
tacrolimus	B-Chemical
who	O
developed	O
neurologic	B-Disease
complications	I-Disease
.	O
In	O
each	O
patient	O
who	O
had	O
abnormalities	O
on	O
the	O
initial	O
MR	O
study	O
,	O
a	O
follow	O
-	O
up	O
MR	O
study	O
was	O
performed	O
1	O
month	O
later	O
.	O
Apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
values	O
on	O
the	O
initial	O
MR	O
study	O
were	O
correlated	O
with	O
reversibility	O
of	O
the	O
lesions	O
.	O
Of	O
the	O
14	O
patients	O
,	O
5	O
(	O
35	O
.	O
7	O
%	O
)	O
had	O
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
,	O
1	O
(	O
7	O
.	O
1	O
%	O
)	O
had	O
putaminal	B-Disease
hemorrhage	I-Disease
,	O
and	O
8	O
(	O
57	O
.	O
1	O
%	O
)	O
had	O
normal	O
findings	O
on	O
initial	O
MR	O
images	O
.	O
Among	O
the	O
5	O
patients	O
with	O
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
,	O
4	O
patients	O
(	O
80	O
.	O
0	O
%	O
)	O
showed	O
higher	O
than	O
normal	O
ADC	O
values	O
on	O
initial	O
MR	O
images	O
,	O
and	O
all	O
showed	O
complete	O
resolution	O
on	O
follow	O
-	O
up	O
images	O
.	O
The	O
remaining	O
1	O
patient	O
(	O
20	O
.	O
0	O
%	O
)	O
showed	O
lower	O
than	O
normal	O
ADC	O
value	O
and	O
showed	O
incomplete	O
resolution	O
with	O
cortical	B-Disease
laminar	I-Disease
necrosis	I-Disease
.	O
Diffusion	O
-	O
weighted	O
imaging	O
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	O
of	O
the	O
lesions	O
of	O
tacrolimus	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
.	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	O
in	O
humans	O
with	O
cortisol	B-Chemical
-	O
induced	O
hypertension	B-Disease
.	O
A	O
deficient	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
-	O
nitric	B-Chemical
oxide	I-Chemical
system	O
is	O
implicated	O
in	O
cortisol	B-Chemical
-	O
induced	O
hypertension	B-Disease
.	O
We	O
investigate	O
whether	O
abnormalities	O
in	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	O
contribute	O
to	O
this	O
deficiency	O
.	O
Eight	O
healthy	O
men	O
were	O
recruited	O
.	O
Hydrocortisone	B-Chemical
acetate	I-Chemical
(	O
50	O
mg	O
)	O
was	O
given	O
orally	O
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5	O
-	O
day	O
fixed	O
-	O
salt	O
diet	O
(	O
150	O
mmol	O
/	O
d	O
)	O
.	O
Crossover	O
studies	O
were	O
performed	O
2	O
weeks	O
apart	O
.	O
Thirty	O
milliliters	O
of	O
blood	O
was	O
obtained	O
for	O
isolation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
after	O
each	O
treatment	O
period	O
.	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	O
was	O
assessed	O
in	O
mononuclear	O
cells	O
incubated	O
with	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
arginine	I-Chemical
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C	O
.	O
Forearm	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	O
was	O
calculated	O
after	O
infusion	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
into	O
the	O
brachial	O
artery	O
at	O
a	O
rate	O
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
minutes	O
.	O
Deep	O
forearm	O
venous	O
samples	O
were	O
collected	O
for	O
determination	O
of	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	O
.	O
Plasma	O
cortisol	B-Chemical
concentrations	O
were	O
significantly	O
raised	O
during	O
the	O
active	O
phase	O
(	O
323	O
+	O
/	O
-	O
43	O
to	O
1082	O
+	O
/	O
-	O
245	O
mmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Systolic	O
blood	O
pressure	O
was	O
elevated	O
by	O
an	O
average	O
of	O
7	O
mm	O
Hg	O
.	O
Neither	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
concentration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	B-Chemical
treatment	O
;	O
ie	O
,	O
that	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	B-Chemical
treatment	O
.	O
We	O
conclude	O
that	O
cortisol	B-Chemical
-	O
induced	O
increases	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
are	O
not	O
associated	O
with	O
abnormalities	O
in	O
the	O
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	O
system	O
.	O
Amount	O
of	O
bleeding	B-Disease
and	O
hematoma	B-Disease
size	O
in	O
the	O
collagenase	O
-	O
induced	O
intracerebral	B-Disease
hemorrhage	I-Disease
rat	O
model	O
.	O
The	O
aggravated	O
risk	O
on	O
intracerebral	B-Disease
hemorrhage	I-Disease
(	O
ICH	B-Disease
)	O
with	O
drugs	O
used	O
for	O
stroke	B-Disease
patients	O
should	O
be	O
estimated	O
carefully	O
.	O
We	O
therefore	O
established	O
sensitive	O
quantification	O
methods	O
and	O
provided	O
a	O
rat	O
ICH	B-Disease
model	O
for	O
detection	O
of	O
ICH	B-Disease
deterioration	O
.	O
In	O
ICH	B-Disease
intrastriatally	O
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
,	O
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	O
-	O
unit	O
collagenase	O
,	O
the	O
amount	O
of	O
bleeding	B-Disease
was	O
measured	O
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	O
hematoma	B-Disease
volume	O
.	O
The	O
blood	O
amounts	O
and	O
hematoma	B-Disease
volumes	O
were	O
significantly	O
correlated	O
,	O
and	O
the	O
hematoma	B-Disease
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
was	O
adequate	O
to	O
detect	O
ICH	B-Disease
deterioration	O
.	O
In	O
ICH	B-Disease
induction	O
using	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
,	O
heparin	B-Chemical
enhanced	O
the	O
hematoma	B-Disease
volume	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	B-Disease
animals	O
and	O
the	O
bleeding	B-Disease
7	O
.	O
6	O
-	O
fold	O
.	O
Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	O
useful	O
for	O
ICH	B-Disease
detection	O
,	O
and	O
that	O
a	O
model	O
with	O
a	O
small	O
ICH	B-Disease
induced	O
with	O
a	O
low	O
-	O
dose	O
collagenase	O
should	O
be	O
used	O
for	O
evaluation	O
of	O
drugs	O
that	O
may	O
affect	O
ICH	B-Disease
.	O
Estradiol	B-Chemical
reduces	O
seizure	B-Disease
-	O
induced	O
hippocampal	B-Disease
injury	I-Disease
in	O
ovariectomized	O
female	O
but	O
not	O
in	O
male	O
rats	O
.	O
Estrogens	O
protect	O
ovariectomized	O
rats	O
from	O
hippocampal	B-Disease
injury	I-Disease
induced	O
by	O
kainic	B-Chemical
acid	I-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
(	O
SE	B-Disease
)	O
.	O
We	O
compared	O
the	O
effects	O
of	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
in	O
adult	O
male	O
and	O
ovariectomized	O
female	O
rats	O
subjected	O
to	O
lithium	B-Chemical
-	O
pilocarpine	B-Chemical
-	O
induced	O
SE	B-Disease
.	O
Rats	O
received	O
subcutaneous	O
injections	O
of	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
(	O
2	O
microg	O
/	O
rat	O
)	O
or	O
oil	O
once	O
daily	O
for	O
four	O
consecutive	O
days	O
.	O
SE	B-Disease
was	O
induced	O
20	O
h	O
following	O
the	O
second	O
injection	O
and	O
terminated	O
3	O
h	O
later	O
.	O
The	O
extent	O
of	O
silver	B-Chemical
-	O
stained	O
CA3	O
and	O
CA1	O
hippocampal	O
neurons	O
was	O
evaluated	O
2	O
days	O
after	O
SE	B-Disease
.	O
17beta	B-Chemical
-	I-Chemical
Estradiol	I-Chemical
did	O
not	O
alter	O
the	O
onset	O
of	O
first	O
clonus	O
in	O
ovariectomized	O
rats	O
but	O
accelerated	O
it	O
in	O
males	O
.	O
17beta	B-Chemical
-	I-Chemical
Estradiol	I-Chemical
reduced	O
the	O
argyrophilic	O
neurons	O
in	O
the	O
CA1	O
and	O
CA3	O
-	O
C	O
sectors	O
of	O
ovariectomized	O
rats	O
.	O
In	O
males	O
,	O
estradiol	B-Chemical
increased	O
the	O
total	O
damage	O
score	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
effects	O
of	O
estradiol	B-Chemical
on	O
seizure	B-Disease
threshold	O
and	O
damage	O
may	O
be	O
altered	O
by	O
sex	O
-	O
related	O
differences	O
in	O
the	O
hormonal	O
environment	O
.	O
Pseudoacromegaly	B-Disease
induced	O
by	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	B-Chemical
.	O
Acromegaly	B-Disease
is	O
an	O
endocrine	B-Disease
disorder	I-Disease
caused	O
by	O
chronic	O
excessive	O
growth	O
hormone	O
secretion	O
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O
Significant	O
disfiguring	O
changes	O
occur	O
as	O
a	O
result	O
of	O
bone	O
,	O
cartilage	O
,	O
and	O
soft	O
tissue	O
hypertrophy	B-Disease
,	O
including	O
the	O
thickening	O
of	O
the	O
skin	O
,	O
coarsening	O
of	O
facial	O
features	O
,	O
and	O
cutis	B-Disease
verticis	I-Disease
gyrata	I-Disease
.	O
Pseudoacromegaly	B-Disease
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
the	O
presence	O
of	O
similar	O
acromegaloid	O
features	O
in	O
the	O
absence	O
of	O
elevated	O
growth	O
hormone	O
or	O
insulin	O
-	O
like	O
growth	O
factor	O
levels	O
.	O
We	O
present	O
a	O
patient	O
with	O
pseudoacromegaly	B-Disease
that	O
resulted	O
from	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	B-Chemical
at	O
an	O
unusually	O
high	O
dose	O
.	O
This	O
is	O
the	O
first	O
case	O
report	O
of	O
pseudoacromegaly	B-Disease
as	O
a	O
side	O
effect	O
of	O
minoxidil	B-Chemical
use	O
.	O
Combined	O
androgen	O
blockade	O
-	O
induced	O
anemia	B-Disease
in	O
prostate	B-Disease
cancer	I-Disease
patients	O
without	O
bone	O
involvement	O
.	O
BACKGROUND	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
combined	O
androgen	O
blockade	O
(	O
CAB	O
)	O
-	O
induced	O
anemia	B-Disease
in	O
prostate	B-Disease
cancer	I-Disease
patients	O
without	O
bone	O
involvement	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	O
patients	O
with	O
biopsy	O
-	O
proven	O
prostatic	B-Disease
adenocarcinoma	I-Disease
[	O
26	O
with	O
stage	O
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
stage	O
D1	O
(	O
T3N1M0	O
)	O
]	O
were	O
included	O
in	O
this	O
study	O
.	O
All	O
patients	O
received	O
CAB	O
[	O
leuprolide	B-Chemical
acetate	I-Chemical
(	O
LHRH	B-Chemical
-	I-Chemical
A	I-Chemical
)	O
3	O
.	O
75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	B-Chemical
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	O
for	O
anemia	B-Disease
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O
Hb	O
,	O
PSA	O
and	O
Testosterone	B-Chemical
measurements	O
were	O
recorded	O
.	O
Patients	O
with	O
stage	O
D2	O
-	O
3	O
disease	O
,	O
abnormal	O
hemoglobin	O
level	O
or	O
renal	O
and	O
liver	O
function	O
tests	O
that	O
were	O
higher	O
than	O
the	O
upper	O
limits	O
were	O
excluded	O
from	O
the	O
study	O
.	O
The	O
duration	O
of	O
the	O
study	O
was	O
six	O
months	O
.	O
RESULTS	O
:	O
The	O
mean	O
hemoglobin	O
(	O
Hb	O
)	O
levels	O
were	O
significantly	O
declined	O
in	O
all	O
patients	O
from	O
baseline	O
of	O
14	O
.	O
2	O
g	O
/	O
dl	O
to	O
14	O
.	O
0	O
g	O
/	O
dl	O
,	O
13	O
.	O
5	O
g	O
/	O
dl	O
,	O
13	O
.	O
2	O
g	O
/	O
dl	O
and	O
12	O
.	O
7	O
g	O
/	O
dl	O
at	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
,	O
respectively	O
.	O
Severe	O
and	O
clinically	O
evident	O
anemia	B-Disease
of	O
Hb	O
<	O
11	O
g	O
/	O
dl	O
with	O
clinical	O
symptoms	O
was	O
detected	O
in	O
6	O
patients	O
(	O
14	O
.	O
3	O
%	O
)	O
.	O
This	O
CAB	O
-	O
induced	O
anemia	B-Disease
was	O
normochromic	O
and	O
normocytic	O
.	O
At	O
six	O
months	O
post	O
-	O
CAB	O
,	O
patients	O
with	O
severe	O
anemia	B-Disease
had	O
a	O
Hb	O
mean	O
value	O
of	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
dl	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
,	O
whereas	O
the	O
other	O
patients	O
had	O
mild	O
anemia	B-Disease
with	O
Hb	O
mean	O
value	O
of	O
13	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
17	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
.	O
The	O
development	O
of	O
severe	O
anemia	B-Disease
at	O
6	O
months	O
post	O
-	O
CAB	O
was	O
predictable	O
by	O
the	O
reduction	O
of	O
Hb	O
baseline	O
value	O
of	O
more	O
than	O
2	O
.	O
5	O
g	O
/	O
dl	O
after	O
3	O
months	O
of	O
CAB	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O
The	O
development	O
of	O
severe	O
CAB	O
-	O
induced	O
anemia	B-Disease
in	O
prostate	B-Disease
cancer	I-Disease
patients	O
did	O
not	O
correlate	O
with	O
T	O
baseline	O
values	O
(	O
T	O
<	O
3	O
ng	O
/	O
ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng	O
/	O
ml	O
)	O
,	O
with	O
age	O
(	O
<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs	O
)	O
,	O
and	O
clinical	O
stage	O
(	O
stage	O
C	O
versus	O
stage	O
D1	O
)	O
.	O
Severe	O
and	O
clinically	O
evident	O
anemia	B-Disease
was	O
easily	O
corrected	O
by	O
subcutaneous	O
injections	O
(	O
3	O
times	O
/	O
week	O
for	O
1	O
month	O
)	O
of	O
recombinant	O
erythropoietin	O
(	O
rHuEPO	O
-	O
beta	O
)	O
.	O
CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
rHuEPO	O
-	O
beta	O
correctable	O
CAB	O
-	O
induced	O
anemia	B-Disease
occurs	O
in	O
14	O
.	O
3	O
%	O
of	O
prostate	B-Disease
cancer	I-Disease
patients	O
after	O
6	O
months	O
of	O
therapy	O
.	O
Delirium	B-Disease
during	O
clozapine	B-Chemical
treatment	O
:	O
incidence	O
and	O
associated	O
risk	O
factors	O
.	O
BACKGROUND	O
:	O
Incidence	O
and	O
risk	O
factors	O
for	O
delirium	B-Disease
during	O
clozapine	B-Chemical
treatment	O
require	O
further	O
clarification	O
.	O
METHODS	O
:	O
We	O
used	O
computerized	O
pharmacy	O
records	O
to	O
identify	O
all	O
adult	O
psychiatric	B-Disease
inpatients	O
treated	O
with	O
clozapine	B-Chemical
(	O
1995	O
-	O
96	O
)	O
,	O
reviewed	O
their	O
medical	O
records	O
to	O
score	O
incidence	O
and	O
severity	O
of	O
delirium	B-Disease
,	O
and	O
tested	O
associations	O
with	O
potential	O
risk	O
factors	O
.	O
RESULTS	O
:	O
Subjects	O
(	O
n	O
=	O
139	O
)	O
were	O
72	O
women	O
and	O
67	O
men	O
,	O
aged	O
40	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
1	O
years	O
,	O
hospitalized	O
for	O
24	O
.	O
9	O
+	O
/	O
-	O
23	O
.	O
3	O
days	O
,	O
and	O
given	O
clozapine	B-Chemical
,	O
gradually	O
increased	O
to	O
an	O
average	O
daily	O
dose	O
of	O
282	O
+	O
/	O
-	O
203	O
mg	O
(	O
3	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
45	O
mg	O
/	O
kg	O
)	O
for	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
4	O
days	O
.	O
Delirium	B-Disease
was	O
diagnosed	O
in	O
14	O
(	O
10	O
.	O
1	O
%	O
incidence	O
,	O
or	O
1	O
.	O
48	O
cases	O
/	O
person	O
-	O
years	O
of	O
exposure	O
)	O
;	O
71	O
.	O
4	O
%	O
of	O
cases	O
were	O
moderate	O
or	O
severe	O
.	O
Associated	O
factors	O
were	O
co	O
-	O
treatment	O
with	O
other	O
centrally	O
antimuscarinic	O
agents	O
,	O
poor	O
clinical	O
outcome	O
,	O
older	O
age	O
,	O
and	O
longer	O
hospitalization	O
(	O
by	O
17	O
.	O
5	O
days	O
,	O
increasing	O
cost	O
)	O
;	O
sex	O
,	O
diagnosis	O
or	O
medical	O
co	O
-	O
morbidity	O
,	O
and	O
daily	O
clozapine	B-Chemical
dose	O
,	O
which	O
fell	O
with	O
age	O
,	O
were	O
unrelated	O
.	O
CONCLUSIONS	O
:	O
Delirium	B-Disease
was	O
found	O
in	O
10	O
%	O
of	O
clozapine	B-Chemical
-	O
treated	O
inpatients	O
,	O
particularly	O
in	O
older	O
patients	O
exposed	O
to	O
other	O
central	O
anticholinergics	O
.	O
Delirium	B-Disease
was	O
inconsistently	O
recognized	O
clinically	O
in	O
milder	O
cases	O
and	O
was	O
associated	O
with	O
increased	O
length	O
-	O
of	O
-	O
stay	O
and	O
higher	O
costs	O
,	O
and	O
inferior	O
clinical	O
outcome	O
.	O
Neuroprotective	O
action	O
of	O
MPEP	B-Chemical
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	B-Chemical
-	O
induced	O
dopaminergic	O
neurotoxicity	B-Disease
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	B-Chemical
outflow	O
and	O
inhibition	O
of	O
hyperthermia	B-Disease
in	O
rats	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
role	O
of	O
metabotropic	O
glutamate	B-Chemical
receptor	O
5	O
(	O
mGluR5	O
)	O
in	O
the	O
toxic	O
action	O
of	O
methamphetamine	B-Chemical
on	O
dopaminergic	O
neurones	O
in	O
rats	O
.	O
Methamphetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
,	O
administered	O
five	O
times	O
,	O
reduced	O
the	O
levels	O
of	O
dopamine	B-Chemical
and	O
its	O
metabolites	O
in	O
striatal	O
tissue	O
when	O
measured	O
72	O
h	O
after	O
the	O
last	O
injection	O
.	O
A	O
selective	O
antagonist	O
of	O
mGluR5	O
,	O
2	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
(	I-Chemical
phenylethynyl	I-Chemical
)	I-Chemical
pyridine	I-Chemical
(	O
MPEP	B-Chemical
;	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
when	O
administered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	B-Chemical
injection	O
reversed	O
the	O
above	O
-	O
mentioned	O
methamphetamine	B-Chemical
effects	O
.	O
A	O
single	O
MPEP	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	B-Chemical
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	B-Chemical
release	O
stimulated	O
either	O
by	O
methamphetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	B-Chemical
(	O
100	O
microM	O
)	O
.	O
Moreover	O
,	O
it	O
transiently	O
diminished	O
the	O
methamphetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
-	O
induced	O
hyperthermia	B-Disease
and	O
reduced	O
basal	O
body	O
temperature	O
.	O
MPEP	B-Chemical
administered	O
into	O
the	O
striatum	O
at	O
high	O
concentrations	O
(	O
500	O
microM	O
)	O
increased	O
extracellular	O
dopamine	B-Chemical
levels	O
,	O
while	O
lower	O
concentrations	O
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
effect	O
.	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
blockade	O
of	O
mGluR5	O
by	O
MPEP	B-Chemical
may	O
protect	O
dopaminergic	O
neurones	O
against	O
methamphetamine	B-Chemical
-	O
induced	O
toxicity	B-Disease
.	O
Neuroprotection	O
rendered	O
by	O
MPEP	B-Chemical
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	B-Chemical
-	O
induced	O
dopamine	B-Chemical
efflux	O
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	B-Disease
.	O
Protective	O
efficacy	O
of	O
neuroactive	O
steroids	B-Chemical
against	O
cocaine	B-Chemical
kindled	O
-	O
seizures	B-Disease
in	O
mice	O
.	O
Neuroactive	O
steroids	B-Chemical
demonstrate	O
pharmacological	O
actions	O
that	O
have	O
relevance	O
for	O
a	O
host	O
of	O
neurological	B-Disease
and	I-Disease
psychiatric	I-Disease
disorders	I-Disease
.	O
They	O
offer	O
protection	O
against	O
seizures	B-Disease
in	O
a	O
range	O
of	O
models	O
and	O
seem	O
to	O
inhibit	O
certain	O
stages	O
of	O
drug	B-Disease
dependence	I-Disease
in	O
preclinical	O
assessments	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	B-Chemical
that	O
positively	O
modulate	O
the	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
(	O
GABA	B-Chemical
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	B-Chemical
engendered	O
by	O
repeated	O
cocaine	B-Chemical
administration	O
(	O
seizure	B-Disease
kindling	O
)	O
.	O
Allopregnanolone	B-Chemical
(	O
3alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
5alpha	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
,	O
pregnanolone	B-Chemical
(	O
3alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
5beta	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
and	O
ganaxolone	B-Chemical
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	B-Chemical
3alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
3beta	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
5alpha	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	B-Chemical
-	O
kindled	O
seizures	B-Disease
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O
Kindled	O
seizures	B-Disease
were	O
induced	O
by	O
daily	O
administration	O
of	O
60	O
mg	O
/	O
kg	O
cocaine	B-Chemical
for	O
5	O
days	O
.	O
All	O
of	O
these	O
positive	O
GABA	B-Chemical
(	O
A	O
)	O
modulators	O
suppressed	O
the	O
expression	O
of	O
kindled	O
seizures	B-Disease
,	O
whereas	O
only	O
allopregnanolone	B-Chemical
and	O
ganaxolone	B-Chemical
inhibited	O
the	O
development	O
of	O
kindling	O
.	O
Allopregnanolone	B-Chemical
and	O
pregnanolone	B-Chemical
,	O
but	O
not	O
ganaxolone	B-Chemical
,	O
also	O
reduced	O
cumulative	O
lethality	O
associated	O
with	O
kindling	O
.	O
These	O
findings	O
demonstrate	O
that	O
some	O
neuroactive	O
steroids	B-Chemical
attenuate	O
convulsant	O
and	O
sensitizing	O
properties	O
of	O
cocaine	B-Chemical
and	O
add	O
to	O
a	O
growing	O
literature	O
on	O
their	O
potential	O
use	O
in	O
the	O
modulation	O
of	O
effects	O
of	O
drugs	O
of	O
abuse	O
.	O
Effect	O
of	O
humoral	O
modulators	O
of	O
morphine	B-Chemical
-	O
induced	O
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
of	O
mice	O
.	O
The	O
effect	O
of	O
humoral	O
modulators	O
on	O
the	O
morphine	B-Chemical
-	O
induced	O
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
of	O
mice	O
was	O
studied	O
.	O
The	O
subcutaneous	O
administration	O
of	O
10	O
mg	O
/	O
kg	O
of	O
morphine	B-Chemical
-	O
HC1	O
produced	O
a	O
marked	O
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
in	O
mice	O
.	O
The	O
morphine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
was	O
potentiated	O
by	O
scopolamine	B-Chemical
and	O
attenuated	O
by	O
physostigmine	B-Chemical
.	O
In	O
contrast	O
,	O
both	O
methscopolamine	B-Chemical
and	O
neostigmine	B-Chemical
,	O
which	O
do	O
not	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
had	O
no	O
effect	O
on	O
the	O
hyperactivity	B-Disease
produced	O
by	O
morphine	B-Chemical
.	O
Pretreatment	O
of	O
mice	O
with	O
alpha	B-Chemical
-	I-Chemical
methyltyrosine	I-Chemical
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inhibitor	O
of	O
tyrosine	B-Chemical
hydroxylase	O
,	O
significantly	O
decreased	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	B-Chemical
.	O
On	O
the	O
other	O
hand	O
,	O
pretreatment	O
with	O
p	B-Chemical
-	I-Chemical
chlorophenylalamine	I-Chemical
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	B-Chemical
depletor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactivity	B-Disease
.	O
The	O
study	O
suggests	O
that	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	B-Chemical
are	O
mediated	O
by	O
the	O
release	O
of	O
catecholamines	B-Chemical
from	O
adrenergic	O
neurons	O
in	O
the	O
brain	O
.	O
And	O
the	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
morphine	B-Chemical
acts	O
by	O
retarding	O
the	O
release	O
of	O
acetylcholine	B-Chemical
at	O
some	O
central	O
cholinergic	O
synapses	O
.	O
It	O
is	O
also	O
suggested	O
from	O
collected	O
evidence	O
that	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	B-Chemical
in	O
mice	O
are	O
mediated	O
by	O
mechanisms	O
different	O
from	O
those	O
which	O
mediate	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	B-Chemical
in	O
rats	O
.	O
Effects	O
of	O
uninephrectomy	O
and	O
high	O
protein	O
feeding	O
on	O
lithium	B-Chemical
-	O
induced	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
in	O
rats	O
.	O
Rats	O
with	O
lithium	B-Chemical
-	O
induced	O
nephropathy	B-Disease
were	O
subjected	O
to	O
high	O
protein	O
(	O
HP	O
)	O
feeding	O
,	O
uninephrectomy	O
(	O
NX	O
)	O
or	O
a	O
combination	O
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
induce	O
glomerular	O
hyperfiltration	O
and	O
further	O
progression	O
of	O
renal	B-Disease
failure	I-Disease
.	O
Newborn	O
female	O
Wistar	O
rats	O
were	O
fed	O
a	O
lithium	B-Chemical
-	O
containing	O
diet	O
(	O
50	O
mmol	O
/	O
kg	O
)	O
for	O
8	O
weeks	O
and	O
then	O
randomized	O
to	O
normal	O
diet	O
,	O
HP	O
diet	O
(	O
40	O
vs	O
.	O
19	O
%	O
)	O
,	O
NX	O
or	O
HP	O
+	O
NX	O
for	O
another	O
8	O
weeks	O
.	O
Corresponding	O
non	O
-	O
lithium	B-Chemical
pretreated	O
groups	O
were	O
generated	O
.	O
When	O
comparing	O
all	O
lithium	B-Chemical
treated	O
versus	O
non	O
-	O
lithium	B-Chemical
-	O
treated	O
groups	O
,	O
lithium	B-Chemical
caused	O
a	O
reduction	O
in	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
without	O
significant	O
changes	O
in	O
effective	O
renal	O
plasma	O
flow	O
(	O
as	O
determined	O
by	O
a	O
marker	O
secreted	O
into	O
the	O
proximal	O
tubules	O
)	O
or	O
lithium	B-Chemical
clearance	O
.	O
Consequently	O
,	O
lithium	B-Chemical
pretreatment	O
caused	O
a	O
fall	O
in	O
filtration	O
fraction	O
and	O
an	O
increase	O
in	O
fractional	O
Li	B-Chemical
excretion	O
.	O
Lithium	B-Chemical
also	O
caused	O
proteinuria	B-Disease
and	O
systolic	O
hypertension	B-Disease
in	O
absence	O
of	O
glomerulosclerosis	B-Disease
.	O
HP	O
failed	O
to	O
accentuante	O
progression	O
of	O
renal	B-Disease
failure	I-Disease
and	O
in	O
fact	O
tended	O
to	O
increase	O
GFR	O
and	O
decrease	O
plasma	O
creatinine	B-Chemical
levels	O
in	O
lithium	B-Chemical
pretreated	O
rats	O
.	O
NX	O
caused	O
an	O
additive	O
deterioration	O
in	O
GFR	O
which	O
,	O
however	O
,	O
was	O
ameliorated	O
by	O
HP	O
.	O
NX	O
+	O
HP	O
caused	O
a	O
further	O
rise	O
in	O
blood	O
pressure	O
in	O
Li	B-Chemical
-	O
pretreated	O
rats	O
.	O
The	O
results	O
indicate	O
that	O
Li	B-Chemical
-	O
induced	O
nephropathy	B-Disease
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
reduced	O
,	O
is	O
associated	O
with	O
proteinuria	B-Disease
and	O
arterial	O
systolic	O
hypertension	B-Disease
.	O
In	O
this	O
model	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
the	O
decline	O
in	O
GFR	O
is	O
not	O
accompanied	O
by	O
a	O
corresponding	O
fall	O
in	O
effective	O
renal	O
plasma	O
flow	O
,	O
which	O
may	O
be	O
the	O
functional	O
expression	O
of	O
the	O
formation	O
of	O
nonfiltrating	O
atubular	O
glomeruli	O
.	O
The	O
fractional	O
reabsorption	O
of	O
tubular	O
fluid	O
by	O
the	O
proximal	O
tubules	O
is	O
reduced	O
,	O
leaving	O
the	O
distal	O
delivery	O
unchanged	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Treatment	O
of	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
with	O
fusidic	B-Chemical
acid	I-Chemical
:	O
an	O
antibiotic	O
with	O
immunosuppressive	O
properties	O
similar	O
to	O
cyclosporin	B-Chemical
.	O
Fusidic	O
acid	O
is	O
an	O
antibiotic	O
with	O
T	O
-	O
cell	O
specific	O
immunosuppressive	O
effects	O
similar	O
to	O
those	O
of	O
cyclosporin	B-Chemical
.	O
Because	O
of	O
the	O
need	O
for	O
the	O
development	O
of	O
new	O
treatments	O
for	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
,	O
a	O
pilot	O
study	O
was	O
undertaken	O
to	O
estimate	O
the	O
pharmacodynamics	O
and	O
tolerability	O
of	O
fusidic	B-Chemical
acid	I-Chemical
treatment	O
in	O
chronic	O
active	O
,	O
therapy	O
-	O
resistant	O
patients	O
.	O
Eight	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
were	O
included	O
.	O
Fusidic	B-Chemical
acid	I-Chemical
was	O
administered	O
orally	O
in	O
a	O
dose	O
of	O
500	O
mg	O
t	O
.	O
d	O
.	O
s	O
.	O
and	O
the	O
treatment	O
was	O
planned	O
to	O
last	O
8	O
weeks	O
.	O
The	O
disease	O
activity	O
was	O
primarily	O
measured	O
by	O
a	O
modified	O
individual	O
grading	O
score	O
.	O
Five	O
of	O
8	O
patients	O
(	O
63	O
%	O
)	O
improved	O
during	O
fusidic	B-Chemical
acid	I-Chemical
treatment	O
:	O
3	O
at	O
two	O
weeks	O
and	O
2	O
after	O
four	O
weeks	O
.	O
There	O
were	O
no	O
serious	O
clinical	O
side	O
effects	O
,	O
but	O
dose	O
reduction	O
was	O
required	O
in	O
two	O
patients	O
because	O
of	O
nausea	B-Disease
.	O
Biochemically	O
,	O
an	O
increase	O
in	O
alkaline	O
phosphatases	O
was	O
noted	O
in	O
5	O
of	O
8	O
cases	O
(	O
63	O
%	O
)	O
,	O
and	O
the	O
greatest	O
increases	O
were	O
seen	O
in	O
those	O
who	O
had	O
elevated	O
levels	O
prior	O
to	O
treatment	O
.	O
All	O
reversed	O
to	O
pre	O
-	O
treatment	O
levels	O
after	O
cessation	O
of	O
treatment	O
.	O
The	O
results	O
of	O
this	O
pilot	O
study	O
suggest	O
that	O
fusidic	B-Chemical
acid	I-Chemical
may	O
be	O
of	O
benefit	O
in	O
selected	O
chronic	O
active	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
in	O
whom	O
conventional	O
treatment	O
is	O
ineffective	O
.	O
Because	O
there	O
seems	O
to	O
exist	O
a	O
scientific	O
rationale	O
for	O
the	O
use	O
of	O
fusidic	B-Chemical
acid	I-Chemical
at	O
the	O
cytokine	O
level	O
in	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
,	O
we	O
suggest	O
that	O
the	O
role	O
of	O
this	O
treatment	O
should	O
be	O
further	O
investigated	O
.	O
Changes	O
in	O
depressive	B-Disease
status	O
associated	O
with	O
topical	O
beta	O
-	O
blockers	O
.	O
Depression	B-Disease
and	O
sexual	B-Disease
dysfunction	I-Disease
have	O
been	O
related	O
to	O
side	O
effects	O
of	O
topical	O
beta	O
-	O
blockers	O
.	O
We	O
performed	O
a	O
preliminary	O
study	O
in	O
order	O
to	O
determine	O
any	O
difference	O
between	O
a	O
non	O
selective	O
beta	O
-	O
blocker	O
(	O
timolol	B-Chemical
)	O
and	O
a	O
selective	O
beta	O
-	O
blocker	O
(	O
betaxolol	B-Chemical
)	O
regarding	O
CNS	O
side	O
effects	O
.	O
Eight	O
glaucomatous	B-Disease
patients	O
chronically	O
treated	O
with	O
timolol	B-Chemical
0	O
.	O
5	O
%	O
/	O
12h	O
,	O
suffering	O
from	O
depression	B-Disease
diagnosed	O
through	O
DMS	O
-	O
III	O
-	O
R	O
criteria	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O
During	O
the	O
six	O
-	O
month	O
follow	O
up	O
,	O
depression	B-Disease
was	O
quantified	O
through	O
the	O
Beck	O
and	O
Zung	O
-	O
Conde	O
scales	O
every	O
two	O
months	O
.	O
In	O
a	O
double	O
blind	O
cross	O
-	O
over	O
study	O
with	O
control	O
group	O
,	O
the	O
patients	O
under	O
timolol	B-Chemical
treatment	O
presented	O
higher	O
depression	B-Disease
values	O
measured	O
through	O
the	O
Beck	O
and	O
the	O
Zung	O
-	O
Conde	O
scales	O
(	O
p	O
<	O
0	O
.	O
001	O
vs	O
control	O
)	O
.	O
These	O
results	O
suggest	O
that	O
betaxolol	B-Chemical
could	O
be	O
less	O
of	O
a	O
depression	B-Disease
-	O
inducer	O
than	O
timolol	B-Chemical
in	O
predisposed	O
patients	O
.	O
Protection	O
against	O
amphetamine	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
toward	O
striatal	O
dopamine	B-Chemical
neurons	O
in	O
rodents	O
by	O
LY274614	B-Chemical
,	O
an	O
excitatory	O
amino	B-Chemical
acid	I-Chemical
antagonist	O
.	O
LY274614	B-Chemical
,	O
3SR	B-Chemical
,	I-Chemical
4aRS	I-Chemical
,	I-Chemical
6SR	I-Chemical
,	I-Chemical
8aRS	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
[	I-Chemical
phosphonomethyl	I-Chemical
]	I-Chemical
decahydr	I-Chemical
oisoquinoline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylic	I-Chemical
acid	I-Chemical
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
antagonist	O
of	O
the	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
subtype	O
of	O
glutamate	B-Chemical
receptor	O
.	O
Here	O
its	O
ability	O
to	O
antagonize	O
the	O
prolonged	O
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
by	O
amphetamine	B-Chemical
in	O
iprindole	B-Chemical
-	O
treated	O
rats	O
is	O
reported	O
.	O
A	O
single	O
18	O
.	O
4	O
mg	O
/	O
kg	O
(	O
i	O
.	O
p	O
.	O
)	O
dose	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
amphetamine	B-Chemical
hemisulfate	O
,	O
given	O
to	O
rats	O
pretreated	O
with	O
iprindole	B-Chemical
,	O
resulted	O
in	O
persistent	O
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
1	O
week	O
later	O
.	O
This	O
prolonged	O
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
was	O
antagonized	O
by	O
dizocilpine	B-Chemical
(	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
,	O
a	O
non	O
-	O
competitive	O
antagonist	O
of	O
NMDA	B-Chemical
receptors	O
)	O
or	O
by	O
LY274614	B-Chemical
(	O
a	O
competitive	O
antagonist	O
of	O
NMDA	B-Chemical
receptors	O
)	O
.	O
The	O
protective	O
effect	O
of	O
LY274614	B-Chemical
was	O
dose	O
-	O
dependent	O
,	O
being	O
maximum	O
at	O
10	O
-	O
40	O
mgkg	O
(	O
i	O
.	O
p	O
.	O
)	O
.	O
A	O
10	O
mg	O
/	O
kg	O
dose	O
of	O
LY274614	B-Chemical
was	O
effective	O
in	O
antagonizing	O
the	O
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
,	O
when	O
given	O
as	O
long	O
as	O
8	O
hr	O
prior	O
to	O
amphetamine	B-Chemical
but	O
not	O
when	O
given	O
24	O
hr	O
prior	O
to	O
amphetamine	B-Chemical
.	O
Depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
was	O
also	O
antagonized	O
when	O
LY274614	B-Chemical
was	O
given	O
after	O
the	O
injection	O
of	O
amphetamine	B-Chemical
;	O
LY274614	B-Chemical
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amphetamine	B-Chemical
.	O
The	O
prolonged	O
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
in	O
mice	O
,	O
given	O
multiple	O
injections	O
of	O
methamphetamine	B-Chemical
,	O
was	O
also	O
antagonized	O
dose	O
-	O
dependently	O
and	O
completely	O
by	O
LY274614	B-Chemical
.	O
The	O
data	O
strengthen	O
the	O
evidence	O
that	O
the	O
neurotoxic	B-Disease
effect	O
of	O
amphetamine	B-Chemical
and	O
related	O
compounds	O
toward	O
nigrostriatal	O
dopamine	B-Chemical
neurons	O
involves	O
NMDA	B-Chemical
receptors	O
and	O
that	O
LY274614	B-Chemical
is	O
an	O
NMDA	B-Chemical
receptor	O
antagonist	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O
Ketoconazole	B-Chemical
-	O
induced	O
neurologic	B-Disease
sequelae	I-Disease
.	O
A	O
77	O
-	O
y	O
-	O
old	O
patient	O
developed	O
weakness	B-Disease
of	I-Disease
extremities	I-Disease
,	O
legs	B-Disease
paralysis	I-Disease
,	O
dysarthria	B-Disease
and	O
tremor	B-Disease
1	O
h	O
after	O
ingestion	O
of	O
200	O
mg	O
ketoconazole	B-Chemical
for	O
the	O
first	O
time	O
in	O
his	O
life	O
.	O
All	O
complaints	O
faded	O
away	O
within	O
24	O
h	O
.	O
Few	O
days	O
later	O
,	O
the	O
patient	O
used	O
another	O
200	O
mg	O
ketoconazole	B-Chemical
tablet	O
,	O
and	O
within	O
an	O
hour	O
experienced	O
a	O
similar	O
clinical	O
picture	O
,	O
which	O
resolved	O
again	O
spontaneously	O
within	O
hours	O
.	O
Laboratory	O
evaluations	O
,	O
including	O
head	O
CT	O
scan	O
,	O
were	O
normal	O
.	O
This	O
case	O
illustrates	O
the	O
need	O
for	O
close	O
vigilance	O
in	O
adverse	B-Disease
drug	I-Disease
reactions	I-Disease
,	O
particularly	O
in	O
the	O
elderly	O
.	O
Development	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
in	O
parkinsonian	B-Disease
monkeys	O
may	O
depend	O
upon	O
rate	O
of	O
symptom	O
onset	O
and	O
/	O
or	O
duration	O
of	O
symptoms	O
.	O
Levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
(	O
LIDs	B-Disease
)	O
present	O
a	O
major	O
problem	O
for	O
the	O
long	O
-	O
term	O
management	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
patients	O
.	O
Due	O
to	O
the	O
interdependence	O
of	O
risk	O
factors	O
in	O
clinical	O
populations	O
,	O
it	O
is	O
difficult	O
to	O
independently	O
examine	O
factors	O
that	O
may	O
influence	O
the	O
development	O
of	O
LIDs	B-Disease
.	O
Using	O
macaque	O
monkeys	O
with	O
different	O
types	O
of	O
MPTP	B-Chemical
-	O
induced	O
parkinsonism	B-Disease
,	O
the	O
current	O
study	O
evaluated	O
the	O
degree	O
to	O
which	O
rate	O
of	O
symptom	O
progression	O
,	O
symptom	O
severity	O
,	O
and	O
response	O
to	O
and	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
LIDs	B-Disease
.	O
Monkeys	O
with	O
acute	O
(	O
short	O
-	O
term	O
)	O
MPTP	B-Chemical
exposure	O
,	O
rapid	O
symptom	O
onset	O
and	O
short	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	B-Chemical
therapy	O
developed	O
dyskinesia	B-Disease
between	O
11	O
and	O
24	O
days	O
of	O
daily	O
levodopa	B-Chemical
administration	O
.	O
In	O
contrast	O
,	O
monkeys	O
with	O
long	O
-	O
term	O
MPTP	B-Chemical
exposure	O
,	O
slow	O
symptom	O
progression	O
and	O
/	O
or	O
long	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	B-Chemical
therapy	O
were	O
more	O
resistant	O
to	O
developing	O
LIDs	B-Disease
(	O
e	O
.	O
g	O
.	O
,	O
dyskinesia	B-Disease
developed	O
no	O
sooner	O
than	O
146	O
days	O
of	O
chronic	O
levodopa	B-Chemical
administration	O
)	O
.	O
All	O
animals	O
were	O
similarly	O
symptomatic	O
at	O
the	O
start	O
of	O
levodopa	B-Chemical
treatment	O
and	O
had	O
similar	O
therapeutic	O
responses	O
to	O
the	O
drug	O
.	O
These	O
data	O
suggest	O
distinct	O
differences	O
in	O
the	O
propensity	O
to	O
develop	O
LIDs	B-Disease
in	O
monkeys	O
with	O
different	O
rates	O
of	O
symptom	O
progression	O
or	O
symptom	O
durations	O
prior	O
to	O
levodopa	B-Chemical
and	O
demonstrate	O
the	O
value	O
of	O
these	O
models	O
for	O
further	O
studying	O
the	O
pathophysiology	O
of	O
LIDs	B-Disease
.	O
A	O
diet	O
promoting	O
sugar	B-Disease
dependency	I-Disease
causes	O
behavioral	B-Disease
cross	I-Disease
-	I-Disease
sensitization	I-Disease
to	O
a	O
low	O
dose	O
of	O
amphetamine	B-Chemical
.	O
Previous	O
research	O
in	O
this	O
laboratory	O
has	O
shown	O
that	O
a	O
diet	O
of	O
intermittent	O
excessive	O
sugar	O
consumption	O
produces	O
a	O
state	O
with	O
neurochemical	O
and	O
behavioral	O
similarities	O
to	O
drug	B-Disease
dependency	I-Disease
.	O
The	O
present	O
study	O
examined	O
whether	O
female	O
rats	O
on	O
various	O
regimens	O
of	O
sugar	O
access	O
would	O
show	O
behavioral	B-Disease
cross	I-Disease
-	I-Disease
sensitization	I-Disease
to	O
a	O
low	O
dose	O
of	O
amphetamine	B-Chemical
.	O
After	O
a	O
30	O
-	O
min	O
baseline	O
measure	O
of	O
locomotor	O
activity	O
(	O
day	O
0	O
)	O
,	O
animals	O
were	O
maintained	O
on	O
a	O
cyclic	O
diet	O
of	O
12	O
-	O
h	O
deprivation	O
followed	O
by	O
12	O
-	O
h	O
access	O
to	O
10	O
%	O
sucrose	B-Chemical
solution	O
and	O
chow	O
pellets	O
(	O
12	O
h	O
access	O
starting	O
4	O
h	O
after	O
onset	O
of	O
the	O
dark	O
period	O
)	O
for	O
21	O
days	O
.	O
Locomotor	O
activity	O
was	O
measured	O
again	O
for	O
30	O
min	O
at	O
the	O
beginning	O
of	O
days	O
1	O
and	O
21	O
of	O
sugar	O
access	O
.	O
Beginning	O
on	O
day	O
22	O
,	O
all	O
rats	O
were	O
maintained	O
on	O
ad	O
libitum	O
chow	O
.	O
Nine	O
days	O
later	O
locomotor	O
activity	O
was	O
measured	O
in	O
response	O
to	O
a	O
single	O
low	O
dose	O
of	O
amphetamine	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O
The	O
animals	O
that	O
had	O
experienced	O
cyclic	O
sucrose	B-Chemical
and	O
chow	O
were	O
hyperactive	B-Disease
in	O
response	O
to	O
amphetamine	B-Chemical
compared	O
with	O
four	O
control	O
groups	O
(	O
ad	O
libitum	O
10	O
%	O
sucrose	B-Chemical
and	O
chow	O
followed	O
by	O
amphetamine	B-Chemical
injection	O
,	O
cyclic	O
chow	O
followed	O
by	O
amphetamine	B-Chemical
injection	O
,	O
ad	O
libitum	O
chow	O
with	O
amphetamine	B-Chemical
,	O
or	O
cyclic	O
10	O
%	O
sucrose	B-Chemical
and	O
chow	O
with	O
a	O
saline	O
injection	O
)	O
.	O
These	O
results	O
suggest	O
that	O
a	O
diet	O
comprised	O
of	O
alternating	O
deprivation	O
and	O
access	O
to	O
a	O
sugar	O
solution	O
and	O
chow	O
produces	O
bingeing	O
on	O
sugar	O
that	O
leads	O
to	O
a	O
long	O
lasting	O
state	O
of	O
increased	O
sensitivity	O
to	O
amphetamine	B-Chemical
,	O
possibly	O
due	O
to	O
a	O
lasting	O
alteration	O
in	O
the	O
dopamine	B-Chemical
system	O
.	O
Reversible	O
dilated	B-Disease
cardiomyopathy	I-Disease
related	O
to	O
amphotericin	B-Chemical
B	I-Chemical
therapy	O
.	O
We	O
describe	O
a	O
patient	O
who	O
developed	O
dilated	B-Disease
cardiomyopathy	I-Disease
and	O
clinical	O
congestive	O
heart	B-Disease
failure	I-Disease
after	O
2	O
months	O
of	O
therapy	O
with	O
amphotericin	B-Chemical
B	I-Chemical
(	O
AmB	B-Chemical
)	O
for	O
disseminated	O
coccidioidomycosis	B-Disease
.	O
His	O
echocardiographic	O
abnormalities	O
and	O
heart	B-Disease
failure	I-Disease
resolved	O
after	O
posaconazole	B-Chemical
was	O
substituted	O
for	O
AmB	B-Chemical
.	O
It	O
is	O
important	O
to	O
recognize	O
the	O
rare	O
and	O
potentially	O
reversible	O
toxicity	B-Disease
of	O
AmB	B-Chemical
.	O
NO	B-Chemical
-	O
induced	O
migraine	B-Disease
attack	O
:	O
strong	O
increase	O
in	O
plasma	O
calcitonin	B-Chemical
gene	I-Chemical
-	I-Chemical
related	I-Chemical
peptide	I-Chemical
(	O
CGRP	B-Chemical
)	O
concentration	O
and	O
negative	O
correlation	O
with	O
platelet	O
serotonin	B-Chemical
release	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
in	O
the	O
plasma	O
calcitonin	B-Chemical
gene	I-Chemical
-	I-Chemical
related	I-Chemical
peptide	I-Chemical
(	O
CGRP	B-Chemical
)	O
concentration	O
and	O
platelet	O
serotonin	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
hydroxytriptamine	I-Chemical
,	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
content	O
during	O
the	O
immediate	O
headache	B-Disease
and	O
the	O
delayed	O
genuine	O
migraine	B-Disease
attack	O
provoked	O
by	O
nitroglycerin	B-Chemical
.	O
Fifteen	O
female	O
migraineurs	B-Disease
(	I-Disease
without	I-Disease
aura	I-Disease
)	I-Disease
and	O
eight	O
controls	O
participated	O
in	O
the	O
study	O
.	O
Sublingual	O
nitroglycerin	B-Chemical
(	O
0	O
.	O
5	O
mg	O
)	O
was	O
administered	O
.	O
Blood	O
was	O
collected	O
from	O
the	O
antecubital	O
vein	O
four	O
times	O
:	O
60	O
min	O
before	O
and	O
after	O
the	O
nitroglycerin	B-Chemical
application	O
,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	O
of	O
the	O
migraine	B-Disease
attack	O
(	O
mean	O
344	O
and	O
404	O
min	O
;	O
12	O
subjects	O
)	O
.	O
In	O
those	O
subjects	O
who	O
had	O
no	O
migraine	B-Disease
attack	O
(	O
11	O
subjects	O
)	O
a	O
similar	O
time	O
schedule	O
was	O
used	O
.	O
Plasma	O
CGRP	B-Chemical
concentration	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
during	O
the	O
migraine	B-Disease
attack	O
and	O
returned	O
to	O
baseline	O
after	O
the	O
cessation	O
of	O
the	O
migraine	B-Disease
.	O
In	O
addition	O
,	O
both	O
change	O
and	O
peak	O
,	O
showed	O
significant	O
positive	O
correlations	O
with	O
migraine	B-Disease
headache	B-Disease
intensity	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
However	O
,	O
plasma	O
CGRP	B-Chemical
concentrations	O
failed	O
to	O
change	O
during	O
immediate	O
headache	B-Disease
and	O
in	O
the	O
subjects	O
with	O
no	O
migraine	B-Disease
attack	O
.	O
Basal	O
CGRP	B-Chemical
concentration	O
was	O
significantly	O
higher	O
and	O
platelet	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
content	O
tended	O
to	O
be	O
lower	O
in	O
subjects	O
who	O
experienced	O
a	O
migraine	B-Disease
attack	O
.	O
Platelet	O
serotonin	B-Chemical
content	O
decreased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
nitroglycerin	B-Chemical
in	O
subjects	O
with	O
no	O
migraine	B-Disease
attack	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patients	O
with	O
migraine	B-Disease
attack	O
.	O
In	O
conclusion	O
,	O
the	O
fact	O
that	O
plasma	O
CGRP	B-Chemical
concentration	O
correlates	O
with	O
the	O
timing	O
and	O
severity	O
of	O
a	O
migraine	B-Disease
headache	B-Disease
suggests	O
a	O
direct	O
relationship	O
between	O
CGRP	B-Chemical
and	O
migraine	B-Disease
.	O
In	O
contrast	O
,	O
serotonin	B-Chemical
release	O
from	O
platelets	O
does	O
not	O
provoke	O
migraine	B-Disease
,	O
it	O
may	O
even	O
counteract	O
the	O
headache	B-Disease
and	O
the	O
concomitant	O
CGRP	B-Chemical
release	O
in	O
this	O
model	O
.	O
Hyperbaric	O
oxygen	B-Chemical
therapy	O
for	O
control	O
of	O
intractable	O
cyclophosphamide	B-Chemical
-	O
induced	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O
We	O
report	O
a	O
case	O
of	O
intractable	O
hemorrhagic	B-Disease
cystitis	I-Disease
due	O
to	O
cyclophosphamide	B-Chemical
therapy	O
for	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
.	O
Conservative	O
treatment	O
,	O
including	O
bladder	O
irrigation	O
with	O
physiological	O
saline	O
and	O
instillation	O
of	O
prostaglandin	B-Chemical
F2	I-Chemical
alpha	I-Chemical
,	O
failed	O
to	O
totally	O
control	O
hemorrhage	B-Disease
.	O
We	O
then	O
used	O
hyperbaric	O
oxygen	B-Chemical
at	O
an	O
absolute	O
pressure	O
of	O
2	O
atm	O
,	O
5	O
days	O
a	O
week	O
for	O
8	O
consecutive	O
weeks	O
.	O
The	O
bleeding	B-Disease
ceased	O
completely	O
by	O
the	O
end	O
of	O
treatment	O
and	O
the	O
patient	O
remained	O
free	O
of	O
hematuria	B-Disease
thereafter	O
.	O
No	O
side	O
effect	O
was	O
noted	O
during	O
the	O
course	O
of	O
therapy	O
.	O
In	O
future	O
,	O
this	O
form	O
of	O
therapy	O
can	O
offer	O
a	O
safe	O
alternative	O
in	O
the	O
treatment	O
of	O
cyclophosphamide	B-Chemical
-	O
induced	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O
Acute	B-Disease
psychosis	I-Disease
due	O
to	O
treatment	O
with	O
phenytoin	B-Chemical
in	O
a	O
nonepileptic	O
patient	O
.	O
The	O
development	O
of	O
psychosis	B-Disease
related	O
to	O
antiepileptic	O
drug	O
treatment	O
is	O
usually	O
attributed	O
to	O
the	O
interaction	O
between	O
the	O
epileptic	B-Disease
brain	O
substratum	O
and	O
the	O
antiepileptic	O
drugs	O
.	O
The	O
case	O
of	O
a	O
nonepileptic	O
patient	O
who	O
developed	O
psychosis	B-Disease
following	O
phenytoin	B-Chemical
treatment	O
for	O
trigeminal	B-Disease
neuralgia	I-Disease
is	O
described	O
.	O
This	O
case	O
suggests	O
that	O
the	O
psychotic	B-Disease
symptoms	I-Disease
that	O
occur	O
following	O
phenytoin	B-Chemical
treatment	O
in	O
some	O
epileptic	B-Disease
patients	O
may	O
be	O
the	O
direct	O
result	O
of	O
medication	O
,	O
unrelated	O
to	O
seizures	B-Disease
.	O
Risks	O
of	O
the	O
consumption	O
of	O
beverages	O
containing	O
quinine	B-Chemical
.	O
Although	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
banned	O
its	O
use	O
for	O
nocturnal	B-Disease
leg	I-Disease
cramps	I-Disease
due	O
to	O
lack	O
of	O
safety	O
and	O
efficacy	O
,	O
quinine	B-Chemical
is	O
widely	O
available	O
in	O
beverages	O
including	O
tonic	O
water	O
and	O
bitter	O
lemon	O
.	O
Numerous	O
anecdotal	O
reports	O
suggest	O
that	O
products	O
containing	O
quinine	B-Chemical
may	O
produce	O
neurological	B-Disease
complications	I-Disease
,	O
including	O
confusion	B-Disease
,	O
altered	O
mental	O
status	O
,	O
seizures	B-Disease
,	O
and	O
coma	B-Disease
,	O
particularly	O
in	O
older	O
women	O
.	O
Psychologists	O
need	O
to	O
inquire	O
about	O
consumption	O
of	O
quinine	B-Chemical
-	O
containing	O
beverages	O
as	O
part	O
of	O
an	O
evaluation	O
process	O
.	O
Transient	O
platypnea	B-Disease
-	I-Disease
orthodeoxia	I-Disease
-	I-Disease
like	I-Disease
syndrome	I-Disease
induced	O
by	O
propafenone	B-Chemical
overdose	B-Disease
in	O
a	O
young	O
woman	O
with	O
Ebstein	B-Disease
'	I-Disease
s	I-Disease
anomaly	I-Disease
.	O
In	O
this	O
report	O
we	O
describe	O
the	O
case	O
of	O
a	O
37	O
-	O
year	O
-	O
old	O
white	O
woman	O
with	O
Ebstein	B-Disease
'	I-Disease
s	I-Disease
anomaly	I-Disease
,	O
who	O
developed	O
a	O
rare	O
syndrome	O
called	O
platypnea	B-Disease
-	I-Disease
orthodeoxia	I-Disease
,	O
characterized	O
by	O
massive	O
right	O
-	O
to	O
-	O
left	O
interatrial	O
shunting	O
with	O
transient	O
profound	O
hypoxia	B-Disease
and	O
cyanosis	B-Disease
.	O
This	O
shunt	O
of	O
blood	O
via	O
a	O
patent	B-Disease
foramen	I-Disease
ovale	I-Disease
occurred	O
in	O
the	O
presence	O
of	O
a	O
normal	O
pulmonary	O
artery	O
pressure	O
,	O
and	O
was	O
probably	O
precipitated	O
by	O
a	O
propafenone	B-Chemical
overdose	B-Disease
.	O
This	O
drug	O
caused	O
biventricular	B-Disease
dysfunction	I-Disease
,	O
due	O
to	O
its	O
negative	O
inotropic	O
effect	O
,	O
and	O
hypotension	B-Disease
,	O
due	O
to	O
its	O
peripheral	O
vasodilatory	O
effect	O
.	O
These	O
effects	O
gave	O
rise	O
to	O
an	O
increase	O
in	O
the	O
right	O
atrial	O
pressure	O
and	O
a	O
decrease	O
in	O
the	O
left	O
one	O
with	O
a	O
consequent	O
stretching	O
of	O
the	O
foramen	O
ovale	O
and	O
the	O
creation	O
of	O
massive	O
right	O
-	O
to	O
-	O
left	O
shunting	O
.	O
In	O
our	O
case	O
this	O
interatrial	O
shunt	O
was	O
very	O
accurately	O
detected	O
at	O
bubble	O
contrast	O
echocardiography	O
.	O
Noxious	O
chemical	O
stimulation	O
of	O
rat	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
through	O
a	O
trigemino	O
-	O
parasympathetic	O
reflex	O
-	O
-	O
an	O
experimental	O
model	O
for	O
vascular	B-Disease
dysfunctions	I-Disease
in	O
cluster	B-Disease
headache	I-Disease
.	O
Cluster	B-Disease
headache	I-Disease
is	O
characterized	O
by	O
typical	O
autonomic	O
dysfunctions	O
including	O
facial	O
and	O
intracranial	B-Disease
vascular	I-Disease
disturbances	I-Disease
.	O
Both	O
the	O
trigeminal	O
and	O
the	O
cranial	O
parasympathetic	O
systems	O
may	O
be	O
involved	O
in	O
mediating	O
these	O
dysfunctions	O
.	O
An	O
experimental	O
model	O
was	O
developed	O
in	O
the	O
rat	O
to	O
measure	O
changes	O
in	O
lacrimation	O
and	O
intracranial	O
blood	O
flow	O
following	O
noxious	O
chemical	O
stimulation	O
of	O
facial	O
mucosa	O
.	O
Blood	O
flow	O
was	O
monitored	O
in	O
arteries	O
of	O
the	O
exposed	O
cranial	O
dura	O
mater	O
and	O
the	O
parietal	O
cortex	O
using	O
laser	O
Doppler	O
flowmetry	O
.	O
Capsaicin	B-Chemical
(	O
0	O
.	O
01	O
-	O
1	O
mm	O
)	O
applied	O
to	O
oral	O
or	O
nasal	O
mucosa	O
induced	O
increases	B-Disease
in	I-Disease
dural	I-Disease
and	I-Disease
cortical	I-Disease
blood	I-Disease
flow	I-Disease
and	O
provoked	O
lacrimation	O
.	O
These	O
responses	O
were	O
blocked	O
by	O
systemic	O
pre	O
-	O
administration	O
of	O
hexamethonium	B-Chemical
chloride	I-Chemical
(	O
20	O
mg	O
/	O
kg	O
)	O
.	O
The	O
evoked	O
increases	B-Disease
in	I-Disease
dural	I-Disease
blood	I-Disease
flow	I-Disease
were	O
also	O
abolished	O
by	O
topical	O
pre	O
-	O
administration	O
of	O
atropine	B-Chemical
(	O
1	O
mm	O
)	O
and	O
[	O
Lys1	O
,	O
Pro2	O
,	O
5	O
,	O
Arg3	O
,	O
4	O
,	O
Tyr6	O
]	O
-	O
VIP	O
(	O
0	O
.	O
1	O
mm	O
)	O
,	O
a	O
vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
antagonist	O
,	O
onto	O
the	O
exposed	O
dura	O
mater	O
.	O
We	O
conclude	O
that	O
noxious	O
stimulation	O
of	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
and	O
lacrimation	O
via	O
a	O
trigemino	O
-	O
parasympathetic	O
reflex	O
.	O
The	O
blood	O
flow	O
responses	O
seem	O
to	O
be	O
mediated	O
by	O
the	O
release	O
of	O
acetylcholine	B-Chemical
and	O
VIP	O
within	O
the	O
meninges	O
.	O
Similar	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
cluster	B-Disease
headache	I-Disease
.	O
Organophosphate	B-Chemical
-	O
induced	O
convulsions	B-Disease
and	O
prevention	O
of	O
neuropathological	B-Disease
damages	I-Disease
.	O
Such	O
organophosphorus	B-Chemical
(	O
OP	B-Chemical
)	O
compounds	O
as	O
diisopropylfluorophosphate	B-Chemical
(	O
DFP	B-Chemical
)	O
,	O
sarin	B-Chemical
and	O
soman	B-Chemical
are	O
potent	O
inhibitors	O
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
)	O
.	O
The	O
acute	O
toxicity	B-Disease
of	O
OPs	B-Chemical
is	O
the	O
result	O
of	O
their	O
irreversible	O
binding	O
with	O
AChEs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
which	O
elevates	O
acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
levels	O
.	O
The	O
protective	O
action	O
of	O
subcutaneously	O
(	O
SC	O
)	O
administered	O
antidotes	O
or	O
their	O
combinations	O
in	O
DFP	B-Chemical
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
intoxication	O
was	O
studied	O
in	O
9	O
-	O
10	O
-	O
weeks	O
-	O
old	O
Han	O
-	O
Wistar	O
male	O
rats	O
.	O
The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime	B-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
chloride	I-Chemical
(	O
2PAM	B-Chemical
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	B-Chemical
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosine	B-Chemical
receptor	O
agonist	O
N	B-Chemical
(	I-Chemical
6	I-Chemical
)	I-Chemical
-	I-Chemical
cyclopentyl	I-Chemical
adenosine	I-Chemical
(	O
CPA	B-Chemical
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	B-Chemical
-	O
receptor	O
antagonist	O
dizocilpine	B-Chemical
maleate	I-Chemical
(	O
+	O
-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	B-Chemical
sulfate	I-Chemical
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	B-Chemical
.	O
The	O
control	O
rats	O
received	O
atropine	B-Chemical
sulfate	I-Chemical
,	O
but	O
also	O
saline	O
and	O
olive	O
oil	O
instead	O
of	O
other	O
antidotes	O
and	O
DFP	B-Chemical
,	O
respectively	O
.	O
All	O
rats	O
were	O
terminated	O
either	O
24	O
h	O
or	O
3	O
weeks	O
after	O
the	O
DFP	B-Chemical
injection	O
.	O
The	O
rats	O
treated	O
with	O
DFP	B-Chemical
-	O
atropine	B-Chemical
showed	O
severe	O
typical	O
OP	B-Chemical
-	O
induced	O
toxicity	B-Disease
signs	O
.	O
When	O
CPA	B-Chemical
,	O
diazepam	B-Chemical
or	O
2PAM	B-Chemical
was	O
given	O
immediately	O
after	O
DFP	B-Chemical
-	O
atropine	B-Chemical
,	O
these	O
treatments	O
prevented	O
,	O
delayed	O
or	O
shortened	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	B-Disease
.	O
Atropine	B-Chemical
-	O
MK801	B-Chemical
did	O
not	O
offer	O
any	O
additional	O
protection	O
against	O
DFP	B-Chemical
toxicity	B-Disease
.	O
In	O
conclusion	O
,	O
CPA	B-Chemical
,	O
diazepam	B-Chemical
and	O
2PAM	B-Chemical
in	O
combination	O
with	O
atropine	B-Chemical
prevented	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	B-Disease
and	O
thus	O
reduced	O
the	O
toxicity	B-Disease
of	O
DFP	B-Chemical
in	O
rat	O
.	O
A	O
pyridoxine	B-Chemical
-	O
dependent	O
behavioral	B-Disease
disorder	I-Disease
unmasked	O
by	O
isoniazid	B-Chemical
.	O
A	O
3	O
-	O
year	O
-	O
old	O
girl	O
had	O
behavioral	B-Disease
deterioration	I-Disease
,	O
with	O
hyperkinesis	B-Disease
,	O
irritability	B-Disease
,	O
and	O
sleeping	B-Disease
difficulties	I-Disease
after	O
the	O
therapeutic	O
administration	O
of	O
isoniazid	B-Chemical
.	O
The	O
administration	O
of	O
pharmacologic	O
doses	O
of	O
pyridoxine	B-Chemical
hydrochloride	I-Chemical
led	O
to	O
a	O
disappearance	O
of	O
symptoms	O
.	O
After	O
discontinuing	O
isoniazid	B-Chemical
therapy	O
a	O
similar	O
pattern	O
of	O
behavior	O
was	O
noted	O
that	O
was	O
controlled	O
by	O
pyridoxine	B-Chemical
.	O
A	O
placebo	O
had	O
no	O
effect	O
,	O
but	O
niacinamide	B-Chemical
was	O
as	O
effective	O
as	O
pyridoxine	B-Chemical
.	O
Periodic	O
withdrawal	O
of	O
pyridoxine	B-Chemical
was	O
associated	O
with	O
return	O
of	O
the	O
hyperkinesis	B-Disease
.	O
The	O
level	O
of	O
pyridoxal	B-Chemical
in	O
the	O
blood	O
was	O
normal	O
during	O
the	O
periods	O
of	O
relapse	O
.	O
Metabolic	O
studies	O
suggested	O
a	O
block	O
in	O
the	O
kynurenine	B-Chemical
pathway	O
of	O
tryptophan	B-Chemical
metabolism	O
.	O
The	O
patient	O
has	O
been	O
followed	O
for	O
six	O
years	O
and	O
has	O
required	O
pharmacologic	O
doses	O
of	O
pyridoxine	B-Chemical
to	O
control	O
her	O
behavior	O
.	O
Recurrent	O
excitation	O
in	O
the	O
dentate	O
gyrus	O
of	O
a	O
murine	O
model	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O
Similar	O
to	O
rats	O
,	O
systemic	O
pilocarpine	B-Chemical
injection	O
causes	O
status	B-Disease
epilepticus	I-Disease
(	O
SE	B-Disease
)	O
and	O
the	O
eventual	O
development	O
of	O
spontaneous	O
seizures	B-Disease
and	O
mossy	O
fiber	O
sprouting	O
in	O
C57BL	O
/	O
6	O
and	O
CD1	O
mice	O
,	O
but	O
the	O
physiological	O
correlates	O
of	O
these	O
events	O
have	O
not	O
been	O
identified	O
in	O
mice	O
.	O
Population	O
responses	O
in	O
granule	O
cells	O
of	O
the	O
dentate	O
gyrus	O
were	O
examined	O
in	O
transverse	O
slices	O
of	O
the	O
ventral	O
hippocampus	O
from	O
pilocarpine	B-Chemical
-	O
treated	O
and	O
untreated	O
mice	O
.	O
In	O
Mg	B-Chemical
(	O
2	O
+	O
)	O
-	O
free	O
bathing	O
medium	O
containing	O
bicuculline	B-Chemical
,	O
conditions	O
designed	O
to	O
increase	O
excitability	O
in	O
the	O
slices	O
,	O
electrical	O
stimulation	O
of	O
the	O
hilus	O
resulted	O
in	O
a	O
single	O
population	O
spike	O
in	O
granule	O
cells	O
from	O
control	O
mice	O
and	O
pilocarpine	B-Chemical
-	O
treated	O
mice	O
that	O
did	O
not	O
experience	O
SE	B-Disease
.	O
In	O
SE	B-Disease
survivors	O
,	O
similar	O
stimulation	O
resulted	O
in	O
a	O
population	O
spike	O
followed	O
,	O
at	O
a	O
variable	O
latency	O
,	O
by	O
negative	O
DC	O
shifts	O
and	O
repetitive	O
afterdischarges	O
of	O
3	O
-	O
60	O
s	O
duration	O
,	O
which	O
were	O
blocked	O
by	O
ionotropic	O
glutamate	B-Chemical
receptor	O
antagonists	O
.	O
Focal	O
glutamate	B-Chemical
photostimulation	O
of	O
the	O
granule	O
cell	O
layer	O
at	O
sites	O
distant	O
from	O
the	O
recording	O
pipette	O
resulted	O
in	O
population	O
responses	O
of	O
1	O
-	O
30	O
s	O
duration	O
in	O
slices	O
from	O
SE	B-Disease
survivors	O
but	O
not	O
other	O
groups	O
.	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
SE	B-Disease
-	O
induced	O
mossy	O
fiber	O
sprouting	O
and	O
synaptic	O
reorganization	O
are	O
relevant	O
characteristics	O
of	O
seizure	B-Disease
development	O
in	O
these	O
murine	O
strains	O
,	O
resembling	O
rat	O
models	O
of	O
human	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O
Urinary	B-Disease
bladder	I-Disease
cancer	I-Disease
in	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
:	O
risks	O
and	O
relation	O
to	O
cyclophosphamide	B-Chemical
.	O
OBJECTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
,	O
and	O
its	O
relation	O
to	O
cyclophosphamide	B-Chemical
,	O
in	O
patients	O
with	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
.	O
METHODS	O
:	O
In	O
the	O
population	O
based	O
,	O
nationwide	O
Swedish	O
Inpatient	O
Register	O
a	O
cohort	O
of	O
1065	O
patients	O
with	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
,	O
1969	O
-	O
95	O
,	O
was	O
identified	O
.	O
Through	O
linkage	O
with	O
the	O
Swedish	O
Cancer	B-Disease
Register	O
,	O
all	O
subjects	O
in	O
this	O
cohort	O
diagnosed	O
with	O
bladder	B-Disease
cancer	I-Disease
were	O
identified	O
.	O
Nested	O
within	O
the	O
cohort	O
,	O
a	O
matched	O
case	O
-	O
control	O
study	O
was	O
performed	O
to	O
estimate	O
the	O
association	O
between	O
cyclophosphamide	B-Chemical
and	O
bladder	B-Disease
cancer	I-Disease
using	O
odds	O
ratios	O
(	O
ORs	O
)	O
as	O
relative	O
risk	O
.	O
In	O
the	O
cohort	O
the	O
cumulative	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
after	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
,	O
and	O
the	O
relative	O
prevalence	O
of	O
a	O
history	O
of	O
bladder	B-Disease
cancer	I-Disease
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
,	O
were	O
also	O
estimated	O
.	O
RESULTS	O
:	O
The	O
median	O
cumulative	O
doses	O
of	O
cyclophosphamide	B-Chemical
among	O
cases	O
(	O
n	O
=	O
11	O
)	O
and	O
controls	O
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O
The	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
doubled	O
for	O
every	O
10	O
g	O
increment	O
in	O
cyclophosphamide	B-Chemical
(	O
OR	O
=	O
2	O
.	O
0	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
8	O
to	O
4	O
.	O
9	O
)	O
.	O
Treatment	O
duration	O
longer	O
than	O
1	O
year	O
was	O
associated	O
with	O
an	O
eightfold	O
increased	O
risk	O
(	O
OR	O
=	O
7	O
.	O
7	O
,	O
95	O
%	O
CI	O
0	O
.	O
9	O
to	O
69	O
)	O
.	O
The	O
absolute	O
risk	O
for	O
bladder	B-Disease
cancer	I-Disease
in	O
the	O
cohort	O
reached	O
10	O
%	O
16	O
years	O
after	O
diagnosis	O
of	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
,	O
and	O
a	O
history	O
of	O
bladder	B-Disease
cancer	I-Disease
was	O
(	O
non	O
-	O
significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
.	O
CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
dose	O
-	O
response	O
relationship	O
between	O
cyclophosphamide	B-Chemical
and	O
the	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
,	O
high	O
cumulative	O
risks	O
in	O
the	O
entire	O
cohort	O
,	O
and	O
also	O
the	O
possibility	O
of	O
risk	O
factors	O
operating	O
even	O
before	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
.	O
Differential	O
modulation	O
by	O
estrogen	B-Chemical
of	O
alpha2	O
-	O
adrenergic	O
and	O
I1	O
-	O
imidazoline	B-Chemical
receptor	O
-	O
mediated	O
hypotension	B-Disease
in	O
female	O
rats	O
.	O
We	O
have	O
recently	O
shown	O
that	O
estrogen	B-Chemical
negatively	O
modulates	O
the	O
hypotensive	B-Disease
effect	O
of	O
clonidine	B-Chemical
(	O
mixed	O
alpha2	O
-	O
/	O
I1	O
-	O
receptor	O
agonist	O
)	O
in	O
female	O
rats	O
and	O
implicates	O
the	O
cardiovascular	O
autonomic	O
control	O
in	O
this	O
interaction	O
.	O
The	O
present	O
study	O
investigated	O
whether	O
this	O
effect	O
of	O
estrogen	B-Chemical
involves	O
interaction	O
with	O
alpha2	O
-	O
and	O
/	O
or	O
I1	O
-	O
receptors	O
.	O
Changes	O
evoked	O
by	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
rilmenidine	B-Chemical
(	O
600	O
microg	O
/	O
kg	O
)	O
or	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
)	O
,	O
selective	O
I1	O
-	O
and	O
alpha2	O
-	O
receptor	O
agonists	O
,	O
respectively	O
,	O
in	O
blood	O
pressure	O
,	O
hemodynamic	O
variability	O
,	O
and	O
locomotor	O
activity	O
were	O
assessed	O
in	O
radiotelemetered	O
sham	O
-	O
operated	O
and	O
ovariectomized	O
(	O
Ovx	O
)	O
Sprague	O
-	O
Dawley	O
female	O
rats	O
with	O
or	O
without	O
12	O
-	O
wk	O
estrogen	B-Chemical
replacement	O
.	O
Three	O
time	O
domain	O
indexes	O
of	O
hemodynamic	O
variability	O
were	O
employed	O
:	O
the	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
as	O
a	O
measure	O
of	O
blood	O
pressure	O
variability	O
and	O
the	O
standard	O
deviation	O
of	O
beat	O
-	O
to	O
-	O
beat	O
intervals	O
(	O
SDRR	O
)	O
and	O
the	O
root	O
mean	O
square	O
of	O
successive	O
differences	O
in	O
R	O
-	O
wave	O
-	O
to	O
-	O
R	O
-	O
wave	O
intervals	O
as	O
measures	O
of	O
heart	O
rate	O
variability	O
.	O
In	O
sham	O
-	O
operated	O
rats	O
,	O
rilmenidine	B-Chemical
or	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
elicited	O
similar	O
hypotension	B-Disease
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reductions	O
in	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
.	O
SDRR	O
was	O
reduced	O
only	O
by	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
.	O
Ovx	O
significantly	O
enhanced	O
the	O
hypotensive	B-Disease
response	O
to	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
,	O
in	O
contrast	O
to	O
no	O
effect	O
on	O
rilmenidine	B-Chemical
hypotension	B-Disease
.	O
The	O
enhanced	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
hypotension	B-Disease
in	O
Ovx	O
rats	O
was	O
paralleled	O
with	O
further	O
reduction	O
in	O
SDRR	O
and	O
a	B-Disease
reduced	I-Disease
locomotor	I-Disease
activity	I-Disease
.	O
Estrogen	O
replacement	O
(	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
subcutaneous	O
pellet	O
,	O
14	O
.	O
2	O
microg	O
/	O
day	O
,	O
12	O
wk	O
)	O
of	O
Ovx	O
rats	O
restored	O
the	O
hemodynamic	O
and	O
locomotor	O
effects	O
of	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
to	O
sham	O
-	O
operated	O
levels	O
.	O
These	O
findings	O
suggest	O
that	O
estrogen	B-Chemical
downregulates	O
alpha2	O
-	O
but	O
not	O
I1	O
-	O
receptor	O
-	O
mediated	O
hypotension	B-Disease
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiac	O
autonomic	O
control	O
in	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
-	O
estrogen	B-Chemical
interaction	O
.	O
Severe	O
reversible	O
left	B-Disease
ventricular	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
dysfunction	I-Disease
due	O
to	O
accidental	O
iatrogenic	O
epinephrine	B-Chemical
overdose	B-Disease
.	O
Catecholamine	B-Chemical
-	O
induced	O
cardiomyopathy	B-Disease
due	O
to	O
chronic	O
excess	O
of	O
endogenous	O
catecholamines	B-Chemical
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinical	O
phenomenon	O
.	O
In	O
contrast	O
,	O
reports	O
of	O
myocardial	B-Disease
dysfunction	I-Disease
due	O
to	O
acute	O
iatrogenic	O
overdose	B-Disease
are	O
rare	O
.	O
A	O
35	O
-	O
year	O
-	O
old	O
woman	O
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	O
with	O
8	O
mg	O
of	O
epinephrine	B-Chemical
developed	O
myocardial	B-Disease
stunning	I-Disease
that	O
was	O
characterized	O
by	O
severe	O
hemodynamic	O
compromise	O
,	O
profound	O
,	O
albeit	O
transient	O
,	O
left	B-Disease
ventricular	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
dysfunction	I-Disease
,	O
and	O
only	O
modestly	O
elevated	O
biochemical	O
markers	O
of	O
myocardial	B-Disease
necrosis	I-Disease
.	O
Our	O
case	O
illustrates	O
the	O
serious	O
consequences	O
of	O
medical	O
errors	O
that	O
can	O
be	O
avoided	O
through	O
improved	O
medication	O
labeling	O
and	O
staff	O
supervision	O
.	O
Cardioprotective	O
effect	O
of	O
tincture	B-Chemical
of	I-Chemical
Crataegus	I-Chemical
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
Tincture	B-Chemical
of	I-Chemical
Crataegus	I-Chemical
(	O
TCR	B-Chemical
)	O
,	O
an	O
alcoholic	B-Chemical
extract	I-Chemical
of	I-Chemical
the	I-Chemical
berries	I-Chemical
of	I-Chemical
hawthorn	I-Chemical
(	O
Crataegus	B-Chemical
oxycantha	I-Chemical
)	O
,	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	O
.	O
The	O
present	O
study	O
was	O
done	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
TCR	B-Chemical
on	O
experimentally	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
Pretreatment	O
of	O
TCR	B-Chemical
,	O
at	O
a	O
dose	O
of	O
0	O
.	O
5	O
mL	O
/	O
100	O
g	O
bodyweight	O
per	O
day	O
,	O
orally	O
for	O
30	O
days	O
,	O
prevented	O
the	O
increase	O
in	O
lipid	O
peroxidation	O
and	O
activity	O
of	O
marker	O
enzymes	O
observed	O
in	O
isoproterenol	B-Chemical
-	O
induced	O
rats	O
(	O
85	O
mg	O
kg	O
(	O
-	O
1	O
)	O
s	O
.	O
c	O
.	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
)	O
.	O
TCR	B-Chemical
prevented	O
the	O
isoproterenol	B-Chemical
-	O
induced	O
decrease	O
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	O
the	O
rate	O
of	O
ADP	B-Chemical
-	O
stimulated	O
oxygen	B-Chemical
uptake	O
and	O
respiratory	O
coupling	O
ratio	O
.	O
TCR	B-Chemical
protected	O
against	O
pathological	O
changes	O
induced	O
by	O
isoproterenol	B-Chemical
in	O
rat	O
heart	O
.	O
The	O
results	O
show	O
that	O
pretreatment	O
with	O
TCR	B-Chemical
may	O
be	O
useful	O
in	O
preventing	O
the	O
damage	O
induced	O
by	O
isoproterenol	B-Chemical
in	O
rat	O
heart	O
.	O
Treatment	O
of	O
tinnitus	B-Disease
by	O
intratympanic	O
instillation	O
of	O
lignocaine	B-Chemical
(	O
lidocaine	B-Chemical
)	O
2	O
per	O
cent	O
through	O
ventilation	O
tubes	O
.	O
Idiopathic	B-Disease
subjective	I-Disease
tinnitus	I-Disease
(	O
IST	B-Disease
)	O
is	O
one	O
of	O
the	O
most	O
obscure	O
otological	O
pathologies	O
.	O
This	O
paper	O
presents	O
the	O
results	O
of	O
treating	O
IST	B-Disease
by	O
intratympanic	O
instillation	O
of	O
lignocaine	B-Chemical
(	O
lidocaine	B-Chemical
)	O
2	O
per	O
cent	O
through	O
a	O
grommet	O
,	O
for	O
five	O
weekly	O
courses	O
.	O
Fifty	O
-	O
two	O
patients	O
suffering	O
from	O
intractable	O
tinnitus	B-Disease
entered	O
this	O
therapeutic	O
trial	O
,	O
but	O
only	O
nine	O
finished	O
all	O
five	O
courses	O
.	O
In	O
one	O
patient	O
,	O
the	O
tinnitus	B-Disease
was	O
almost	O
completely	O
abolished	O
,	O
but	O
in	O
all	O
the	O
nine	O
patients	O
the	O
decompensated	O
tinnitus	B-Disease
changed	O
to	O
a	O
compensated	O
one	O
.	O
We	O
suggest	O
this	O
mode	O
of	O
treatment	O
for	O
patients	O
that	O
were	O
previously	O
treated	O
by	O
drugs	O
,	O
acupuncture	O
and	O
biofeedback	O
,	O
with	O
disappointing	O
results	O
.	O
Patients	O
should	O
be	O
warned	O
about	O
the	O
side	O
effects	O
of	O
vertigo	B-Disease
and	O
vomiting	B-Disease
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
instillation	O
,	O
and	O
that	O
the	O
tinnitus	B-Disease
may	O
not	O
disappear	O
but	O
will	O
be	O
alleviated	O
,	O
enabling	O
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
disease	O
and	O
lead	O
a	O
more	O
normal	O
life	O
.	O
The	O
alpha3	O
and	O
beta4	O
nicotinic	O
acetylcholine	B-Chemical
receptor	O
subunits	O
are	O
necessary	O
for	O
nicotine	B-Chemical
-	O
induced	O
seizures	B-Disease
and	O
hypolocomotion	B-Disease
in	O
mice	O
.	O
Binding	O
of	O
nicotine	B-Chemical
to	O
nicotinic	O
acetylcholine	B-Chemical
receptors	O
(	O
nAChRs	O
)	O
elicits	O
a	O
series	O
of	O
dose	O
-	O
dependent	O
behaviors	O
that	O
go	O
from	O
altered	O
exploration	O
,	O
sedation	O
,	O
and	O
tremors	B-Disease
,	O
to	O
seizures	B-Disease
and	O
death	B-Disease
.	O
nAChRs	O
are	O
pentameric	O
ion	O
channels	O
usually	O
composed	O
of	O
alpha	O
and	O
beta	O
subunits	O
.	O
A	O
gene	O
cluster	O
comprises	O
the	O
alpha3	O
,	O
alpha5	O
and	O
beta4	O
subunits	O
,	O
which	O
coassemble	O
to	O
form	O
functional	O
receptors	O
.	O
We	O
examined	O
the	O
role	O
of	O
the	O
beta4	O
subunits	O
in	O
nicotine	B-Chemical
-	O
induced	O
seizures	B-Disease
and	O
hypolocomotion	B-Disease
in	O
beta4	O
homozygous	O
(	O
beta4	O
-	O
/	O
-	O
)	O
and	O
alpha3	O
heterozygous	O
(	O
+	O
/	O
-	O
)	O
mice	O
.	O
beta4	O
-	O
/	O
-	O
mice	O
were	O
less	O
sensitive	O
to	O
the	O
effects	O
of	O
nicotine	B-Chemical
both	O
at	O
low	O
doses	O
,	O
measured	O
as	O
decreased	O
exploration	O
in	O
an	O
open	O
field	O
,	O
and	O
at	O
high	O
doses	O
,	O
measured	O
as	O
sensitivity	O
to	O
nicotine	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O
Using	O
in	O
situ	O
hybridization	O
probes	O
for	O
the	O
alpha3	O
and	O
alpha5	O
subunits	O
,	O
we	O
showed	O
that	O
alpha5	O
mRNA	O
levels	O
are	O
unchanged	O
,	O
whereas	O
alpha3	O
mRNA	O
levels	O
are	O
selectively	O
decreased	O
in	O
the	O
mitral	O
cell	O
layer	O
of	O
the	O
olfactory	O
bulb	O
,	O
and	O
the	O
inferior	O
and	O
the	O
superior	O
colliculus	O
of	O
beta4	O
-	O
/	O
-	O
brains	O
.	O
alpha3	O
+	O
/	O
-	O
mice	O
were	O
partially	O
resistant	O
to	O
nicotine	B-Chemical
-	O
induced	O
seizures	B-Disease
when	O
compared	O
to	O
wild	O
-	O
type	O
littermates	O
.	O
mRNA	O
levels	O
for	O
the	O
alpha5	O
and	O
the	O
beta4	O
subunits	O
were	O
unchanged	O
in	O
alpha3	O
+	O
/	O
-	O
brains	O
.	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
beta4	O
and	O
the	O
alpha3	O
subunits	O
are	O
mediators	O
of	O
nicotine	B-Chemical
-	O
induced	O
seizures	B-Disease
and	O
hypolocomotion	B-Disease
.	O
The	O
effects	O
of	O
sevoflurane	B-Chemical
on	O
lidocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
.	O
The	O
influence	O
of	O
sevoflurane	B-Chemical
on	O
lidocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
was	O
studied	O
in	O
cats	O
.	O
The	O
convulsive	B-Disease
threshold	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
was	O
41	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
5	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
with	O
lidocaine	B-Chemical
infusion	O
(	O
6	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
increasing	O
significantly	O
to	O
66	O
.	O
6	O
+	O
/	O
-	O
10	O
.	O
9	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
when	O
the	O
end	O
-	O
tidal	O
concentration	O
of	O
sevoflurane	B-Chemical
was	O
0	O
.	O
8	O
%	O
.	O
However	O
,	O
the	O
threshold	O
(	O
61	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
7	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
during	O
1	O
.	O
6	O
%	O
sevoflurane	B-Chemical
was	O
not	O
significant	O
from	O
that	O
during	O
0	O
.	O
8	O
%	O
sevoflurane	B-Chemical
,	O
indicating	O
a	O
celling	O
effect	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsive	B-Disease
threshold	O
between	O
sevoflurane	B-Chemical
and	O
enflurane	B-Chemical
.	O
The	O
rise	O
in	O
blood	O
pressure	O
became	O
less	O
marked	O
when	O
higher	O
concentrations	O
of	O
sevoflurane	B-Chemical
or	O
enflurane	B-Chemical
were	O
administered	O
and	O
the	O
blood	O
pressure	O
at	O
convulsions	B-Disease
decreased	O
significantly	O
in	O
1	O
.	O
6	O
%	O
sevoflurane	B-Chemical
,	O
and	O
in	O
0	O
.	O
8	O
%	O
and	O
1	O
.	O
6	O
%	O
enflurane	B-Chemical
.	O
However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
lidocaine	B-Chemical
concentrations	O
measured	O
when	O
the	O
systolic	O
blood	O
pressure	O
became	O
70	O
mmHg	O
.	O
Apamin	B-Chemical
,	O
a	O
selective	O
blocker	O
of	O
calcium	B-Chemical
-	O
dependent	O
potassium	B-Chemical
channels	O
,	O
was	O
administered	O
intracerebroventricularly	O
in	O
rats	O
anesthetized	O
with	O
0	O
.	O
8	O
%	O
sevoflurane	B-Chemical
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
anticonvulsive	O
effects	O
.	O
Apamin	B-Chemical
(	O
10	O
ng	O
)	O
had	O
a	O
tendency	O
to	O
decrease	O
the	O
convulsive	B-Disease
threshold	O
(	O
21	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
2	O
to	O
19	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
5	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
but	O
this	O
was	O
not	O
statistically	O
significant	O
.	O
It	O
is	O
suggested	O
that	O
sevoflurane	B-Chemical
reduces	O
the	O
convulsive	B-Disease
effect	O
of	O
lidocaine	B-Chemical
toxicity	B-Disease
but	O
carries	O
some	O
risk	O
due	O
to	O
circulatory	O
depression	B-Disease
.	O
Cardiac	B-Disease
toxicity	I-Disease
observed	O
in	O
association	O
with	O
high	O
-	O
dose	O
cyclophosphamide	B-Chemical
-	O
based	O
chemotherapy	O
for	O
metastatic	O
breast	B-Disease
cancer	I-Disease
.	O
INTRODUCTION	O
:	O
Cyclophosphamide	B-Chemical
is	O
an	O
alkylating	O
agent	O
given	O
frequently	O
as	O
a	O
component	O
of	O
many	O
conditioning	O
regimens	O
.	O
In	O
high	O
doses	O
,	O
its	O
nonhematological	O
dose	O
-	O
limiting	O
toxicity	B-Disease
is	O
cardiomyopathy	B-Disease
.	O
STUDY	O
DESIGN	O
:	O
We	O
combined	O
paclitaxel	B-Chemical
,	O
melphalan	B-Chemical
and	O
high	O
-	O
dose	O
cyclophosphamide	B-Chemical
,	O
thiotepa	B-Chemical
,	O
and	O
carboplatin	B-Chemical
in	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
for	O
patients	O
with	O
metastatic	O
breast	B-Disease
cancer	I-Disease
.	O
Analysis	O
was	O
performed	O
on	O
61	O
women	O
with	O
chemotherapy	O
-	O
responsive	O
metastatic	O
breast	B-Disease
cancer	I-Disease
receiving	O
96	O
-	O
h	O
infusional	O
cyclophosphamide	B-Chemical
as	O
part	O
of	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
to	O
assess	O
association	O
between	O
presence	O
of	O
peritransplant	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
(	O
CHF	B-Disease
)	O
and	O
the	O
following	O
pretreatment	O
characteristics	O
:	O
presence	O
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	O
,	O
age	O
,	O
hypertension	B-Disease
,	O
prior	O
cardiac	O
history	O
,	O
smoking	O
,	O
diabetes	B-Disease
mellitus	I-Disease
,	O
prior	O
use	O
of	O
anthracyclines	B-Chemical
,	O
and	O
left	O
-	O
sided	O
chest	O
irradiation	O
.	O
RESULTS	O
:	O
Six	O
of	O
61	O
women	O
(	O
10	O
%	O
)	O
developed	O
clinically	O
reversible	O
grade	O
3	O
CHF	B-Disease
following	O
infusional	O
cyclophosphamide	B-Chemical
with	O
a	O
median	O
percent	O
decline	O
in	O
ejection	O
fraction	O
of	O
31	O
%	O
.	O
Incidence	O
of	O
transient	O
cyclophosphamide	B-Chemical
-	O
related	O
cardiac	B-Disease
toxicity	I-Disease
(	O
10	O
%	O
)	O
is	O
comparable	O
to	O
previous	O
recorded	O
literature	O
.	O
Older	O
age	O
was	O
significantly	O
correlated	O
with	O
the	O
CHF	B-Disease
development	O
;	O
with	O
median	O
ages	O
for	O
the	O
entire	O
group	O
and	O
for	O
patients	O
developing	O
CHF	B-Disease
of	O
45	O
and	O
59	O
,	O
respectively	O
.	O
No	O
association	O
was	O
found	O
with	O
other	O
pretreatment	O
characteristics	O
.	O
CONCLUSIONS	O
:	O
As	O
a	O
result	O
of	O
these	O
findings	O
,	O
oncologists	O
should	O
carefully	O
monitor	O
fluid	O
balance	O
in	O
older	O
patients	O
.	O
Routine	O
EKG	O
monitoring	O
during	O
infusional	O
cyclophosphamide	B-Chemical
did	O
not	O
predict	O
CHF	B-Disease
development	O
.	O
Tremor	B-Disease
side	O
effects	O
of	O
salbutamol	B-Chemical
,	O
quantified	O
by	O
a	O
laser	O
pointer	O
technique	O
.	O
OBJECTIVE	O
:	O
To	O
study	O
tremor	B-Disease
side	O
effects	O
of	O
salbutamol	B-Chemical
an	O
easily	O
applicable	O
,	O
quick	O
and	O
low	O
-	O
priced	O
method	O
is	O
needed	O
.	O
A	O
new	O
method	O
using	O
a	O
commercially	O
available	O
,	O
pen	O
-	O
shaped	O
laser	O
pointer	O
was	O
developed	O
.	O
Aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
sensitivity	O
,	O
reproducibility	O
,	O
reference	O
values	O
and	O
the	O
agreement	O
with	O
a	O
questionnaire	O
.	O
METHODS	O
:	O
Tremor	B-Disease
was	O
measured	O
using	O
a	O
laser	O
pointer	O
technique	O
.	O
To	O
determine	O
sensitivity	O
we	O
assessed	O
tremor	B-Disease
in	O
44	O
patients	O
with	O
obstructive	B-Disease
lung	I-Disease
disease	I-Disease
after	O
administration	O
of	O
cumulative	O
doses	O
of	O
salbutamol	B-Chemical
.	O
Subjects	O
were	O
asked	O
to	O
aim	O
at	O
the	O
centre	O
of	O
a	O
target	O
,	O
subdivided	O
in	O
concentric	O
circles	O
,	O
from	O
5	O
m	O
distance	O
.	O
The	O
circle	O
in	O
which	O
the	O
participant	O
succeeded	O
to	O
aim	O
was	O
recorded	O
in	O
millimetres	O
radius	O
.	O
In	O
another	O
series	O
of	O
measurements	O
,	O
reproducibility	O
and	O
reference	O
values	O
of	O
the	O
tremor	B-Disease
was	O
assessed	O
in	O
65	O
healthy	O
subjects	O
in	O
three	O
sessions	O
,	O
at	O
9	O
a	O
.	O
m	O
.	O
,	O
4	O
p	O
.	O
m	O
.	O
and	O
9	O
a	O
.	O
m	O
.	O
,	O
respectively	O
,	O
1	O
week	O
later	O
.	O
Postural	O
tremor	B-Disease
was	O
measured	O
with	O
the	O
arm	O
horizontally	O
outstretched	O
rest	O
tremor	B-Disease
with	O
the	O
arm	O
supported	O
by	O
an	O
armrest	O
and	O
finally	O
tremor	B-Disease
was	O
measured	O
after	O
holding	O
a	O
2	O
-	O
kg	O
weight	O
until	O
exhaustion	O
.	O
Inter	O
-	O
observer	O
variability	O
was	O
measured	O
in	O
a	O
series	O
of	O
10	O
healthy	O
subjects	O
.	O
Tremor	B-Disease
was	O
measured	O
simultaneously	O
by	O
two	O
independent	O
observers	O
.	O
RESULTS	O
:	O
Salbutamol	B-Chemical
significantly	O
increased	O
tremor	B-Disease
severity	O
in	O
patients	O
in	O
a	O
dose	O
-	O
dependent	O
way	O
.	O
Within	O
healthy	O
adults	O
no	O
age	O
-	O
dependency	O
could	O
be	O
found	O
(	O
b	O
=	O
0	O
.	O
262	O
mm	O
/	O
year	O
;	O
P	O
=	O
0	O
.	O
72	O
)	O
.	O
There	O
was	O
no	O
agreement	O
between	O
the	O
questionnaire	O
and	O
tremor	B-Disease
severity	O
(	O
r	O
=	O
0	O
.	O
093	O
;	O
P	O
=	O
0	O
.	O
53	O
)	O
.	O
Postural	O
tremor	B-Disease
showed	O
no	O
significant	O
difference	O
between	O
the	O
first	O
and	O
third	O
session	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O
Support	O
of	O
the	O
arm	O
decreased	O
tremor	B-Disease
severity	O
,	O
exhaustion	O
increased	O
tremor	B-Disease
severity	O
significantly	O
.	O
A	O
good	O
agreement	O
was	O
found	O
between	O
two	O
independent	O
observers	O
(	O
interclass	O
correlation	O
coefficient	O
0	O
.	O
72	O
)	O
.	O
DISCUSSION	O
:	O
Quantifying	O
tremor	B-Disease
by	O
using	O
an	O
inexpensive	O
laser	O
pointer	O
is	O
,	O
with	O
the	O
exception	O
of	O
children	O
(	O
<	O
12	O
years	O
)	O
a	O
sensitive	O
and	O
reproducible	O
method	O
.	O
Safety	O
and	O
adverse	O
effects	O
associated	O
with	O
raloxifene	B-Chemical
:	O
multiple	O
outcomes	O
of	O
raloxifene	B-Chemical
evaluation	O
.	O
OBJECTIVE	O
:	O
To	O
examine	O
the	O
effect	O
of	O
raloxifene	B-Chemical
on	O
major	O
adverse	O
events	O
that	O
occur	O
with	O
postmenopausal	O
estrogen	B-Chemical
therapy	O
or	O
tamoxifen	B-Chemical
.	O
METHODS	O
:	O
The	O
Multiple	O
Outcomes	O
of	O
Raloxifene	B-Chemical
Evaluation	O
,	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
,	O
enrolled	O
7	O
,	O
705	O
postmenopausal	O
women	O
with	O
osteoporosis	B-Disease
.	O
Women	O
were	O
randomly	O
assigned	O
to	O
raloxifene	B-Chemical
60	O
mg	O
/	O
d	O
or	O
120	O
mg	O
/	O
d	O
or	O
placebo	O
.	O
Outcomes	O
included	O
venous	B-Disease
thromboembolism	I-Disease
,	O
cataracts	B-Disease
,	O
gallbladder	B-Disease
disease	I-Disease
,	O
and	O
endometrial	B-Disease
hyperplasia	I-Disease
or	I-Disease
cancer	I-Disease
.	O
RESULTS	O
:	O
During	O
a	O
mean	O
follow	O
-	O
up	O
of	O
3	O
.	O
3	O
years	O
,	O
raloxifene	B-Chemical
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	B-Disease
thromboembolism	I-Disease
(	O
relative	O
risk	O
[	O
RR	O
]	O
2	O
.	O
1	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
2	O
-	O
3	O
.	O
8	O
)	O
.	O
The	O
excess	O
event	O
rate	O
was	O
1	O
.	O
8	O
per	O
1	O
,	O
000	O
woman	O
-	O
years	O
(	O
95	O
%	O
CI	O
-	O
0	O
.	O
5	O
-	O
4	O
.	O
1	O
)	O
,	O
and	O
the	O
number	O
needed	O
to	O
treat	O
to	O
cause	O
1	O
event	O
was	O
170	O
(	O
95	O
%	O
CI	O
100	O
-	O
582	O
)	O
over	O
3	O
.	O
3	O
years	O
.	O
Risk	O
in	O
the	O
raloxifene	B-Chemical
group	O
was	O
higher	O
than	O
in	O
the	O
placebo	O
group	O
for	O
the	O
first	O
2	O
years	O
,	O
but	O
decreased	O
to	O
about	O
the	O
same	O
rate	O
as	O
in	O
the	O
placebo	O
group	O
thereafter	O
.	O
Raloxifene	B-Chemical
did	O
not	O
increase	O
risk	O
for	O
cataracts	B-Disease
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
8	O
-	O
1	O
.	O
1	O
)	O
,	O
gallbladder	B-Disease
disease	I-Disease
(	O
RR	O
1	O
.	O
0	O
;	O
95	O
%	O
CI	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
)	O
,	O
endometrial	B-Disease
hyperplasia	I-Disease
(	O
RR	O
1	O
.	O
3	O
;	O
95	O
%	O
CI	O
0	O
.	O
4	O
-	O
5	O
.	O
1	O
)	O
,	O
or	O
endometrial	B-Disease
cancer	I-Disease
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
3	O
-	O
2	O
.	O
7	O
)	O
.	O
CONCLUSION	O
:	O
Raloxifene	B-Chemical
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	B-Disease
thromboembolism	I-Disease
,	O
but	O
there	O
was	O
no	O
increased	O
risk	O
for	O
cataracts	B-Disease
,	O
gallbladder	B-Disease
disease	I-Disease
,	O
endometrial	B-Disease
hyperplasia	I-Disease
,	O
or	O
endometrial	B-Disease
cancer	I-Disease
.	O
LEVEL	O
OF	O
EVIDENCE	O
:	O
I	O
Optimization	O
of	O
levodopa	B-Chemical
therapy	O
.	O
While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
dose	O
for	O
levodopa	B-Chemical
therapy	O
,	O
many	O
individuals	O
can	O
be	O
started	O
on	O
either	O
the	O
25	O
/	O
100	O
or	O
controlled	O
-	O
release	O
formula	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbidopa	B-Chemical
-	O
levodopa	B-Chemical
to	O
the	O
point	O
of	O
""""	O
normality	O
,	O
""""	O
which	O
can	O
lead	O
to	O
toxicity	B-Disease
.	O
The	O
physician	O
should	O
also	O
determine	O
the	O
proper	O
use	O
of	O
any	O
adjunctive	O
medications	O
;	O
such	O
combined	O
therapy	O
has	O
become	O
the	O
standard	O
approach	O
to	O
treatment	O
.	O
Following	O
the	O
initial	O
period	O
of	O
therapy	O
,	O
emerging	O
difficulties	O
require	O
a	O
reassessment	O
of	O
therapeutic	O
approaches	O
,	O
such	O
as	O
dosage	O
adjustment	O
or	O
introduction	O
of	O
a	O
dopamine	B-Chemical
agonist	O
.	O
Other	O
possible	O
adverse	O
effects	O
-	O
-	O
such	O
as	O
gastrointestinal	B-Disease
disorders	I-Disease
,	O
orthostatic	B-Disease
hypotension	I-Disease
,	O
levodopa	B-Chemical
-	O
induced	O
psychosis	B-Disease
,	O
sleep	B-Disease
disturbances	I-Disease
or	O
parasomnias	B-Disease
,	O
or	O
drug	O
interactions	O
-	O
-	O
also	O
require	O
carefully	O
monitored	O
individual	O
treatment	O
.	O
Nonpharmacologic	O
concerns	O
can	O
help	O
the	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patient	O
achieve	O
and	O
maintain	O
optimal	O
functioning	O
,	O
including	O
daily	O
exercise	O
,	O
physical	O
therapy	O
,	O
and	O
involvement	O
with	O
support	O
groups	O
.	O
Long	O
term	O
audiological	O
evaluation	O
of	O
beta	B-Disease
-	I-Disease
thalassemic	I-Disease
patients	O
.	O
OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
incidence	O
and	O
to	O
monitor	O
the	O
progression	O
of	O
hearing	B-Disease
loss	I-Disease
in	O
children	O
and	O
young	O
adults	O
with	O
beta	B-Disease
-	I-Disease
thalassemia	I-Disease
major	O
.	O
METHODS	O
:	O
One	O
hundred	O
and	O
four	O
(	O
104	O
)	O
patients	O
aged	O
6	O
-	O
35	O
years	O
(	O
mean	O
17	O
,	O
2	O
years	O
)	O
participated	O
in	O
the	O
study	O
.	O
All	O
patients	O
were	O
on	O
a	O
regular	O
transfusion	O
-	O
chelation	O
program	O
maintaining	O
a	O
mean	O
hemoglobin	O
level	O
of	O
9	O
.	O
5	O
gr	O
/	O
dl	O
.	O
Subjects	O
were	O
receiving	O
desferrioxamine	B-Chemical
(	O
DFO	B-Chemical
)	O
chelation	O
treatment	O
with	O
a	O
mean	O
daily	O
dose	O
of	O
50	O
-	O
60	O
mg	O
/	O
kg	O
,	O
5	O
-	O
6	O
days	O
a	O
week	O
during	O
the	O
first	O
six	O
years	O
of	O
the	O
study	O
,	O
which	O
was	O
then	O
reduced	O
to	O
40	O
-	O
50	O
mg	O
/	O
kg	O
for	O
the	O
following	O
eight	O
years	O
.	O
Patients	O
were	O
followed	O
for	O
8	O
-	O
14	O
years	O
.	O
RESULTS	O
:	O
Overall	O
,	O
21	O
out	O
of	O
104	O
patients	O
(	O
20	O
.	O
2	O
%	O
)	O
presented	O
with	O
high	O
frequency	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
(	O
SNHL	B-Disease
)	O
,	O
either	O
unilateral	O
or	O
bilateral	O
.	O
No	O
ototoxic	B-Disease
factor	O
,	O
other	O
than	O
DFO	B-Chemical
,	O
was	O
present	O
in	O
any	O
of	O
the	O
patients	O
.	O
Patients	O
with	O
SNHL	B-Disease
presented	O
with	O
relatively	O
lower	O
serum	O
ferritin	O
levels	O
than	O
those	O
with	O
normal	O
hearing	O
,	O
however	O
,	O
no	O
statistically	O
significant	O
difference	O
was	O
observed	O
.	O
Subjects	O
with	O
SNHL	B-Disease
were	O
submitted	O
to	O
DFO	B-Chemical
reduction	O
or	O
temporary	O
withdrawal	O
.	O
Following	O
intervention	O
,	O
7	O
out	O
of	O
21	O
affected	O
patients	O
recovered	O
,	O
10	O
remained	O
stable	O
and	O
4	O
demonstrated	O
aggravation	O
.	O
CONCLUSION	O
:	O
The	O
findings	O
are	O
indicative	O
of	O
DFO	B-Chemical
'	O
s	O
contributing	O
role	O
in	O
the	O
development	O
of	O
hearing	B-Disease
impairment	I-Disease
.	O
Regular	O
audiologic	O
evaluation	O
is	O
imperative	O
in	O
all	O
thalassemic	B-Disease
patients	O
so	O
that	O
early	O
changes	O
may	O
be	O
recognized	O
and	O
treatment	O
may	O
be	O
judiciously	O
adjusted	O
in	O
order	O
to	O
prevent	O
or	O
reverse	O
hearing	B-Disease
impairment	I-Disease
.	O
Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
in	O
healthy	O
rats	O
predict	O
susceptibility	O
to	O
adriamycin	B-Chemical
-	O
induced	O
renal	B-Disease
damage	I-Disease
.	O
BACKGROUND	O
:	O
In	O
man	O
,	O
differences	O
in	O
angiotensin	B-Chemical
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
levels	O
,	O
related	O
to	O
ACE	O
(	O
I	O
/	O
D	O
)	O
genotype	O
,	O
are	O
associated	O
with	O
renal	O
prognosis	O
.	O
This	O
raises	O
the	O
hypothesis	O
that	O
individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
are	O
involved	O
in	O
renal	O
susceptibility	O
to	O
inflicted	O
damage	O
.	O
Therefore	O
,	O
we	O
studied	O
the	O
predictive	O
effect	O
of	O
renal	O
ACE	O
activity	O
for	O
the	O
severity	O
of	O
renal	B-Disease
damage	I-Disease
induced	O
by	O
a	O
single	O
injection	O
of	O
adriamycin	B-Chemical
in	O
rats	O
.	O
METHODS	O
:	O
Renal	O
ACE	O
activity	O
(	O
Hip	B-Chemical
-	I-Chemical
His	I-Chemical
-	I-Chemical
Leu	I-Chemical
cleavage	O
by	O
cortical	O
homogenates	O
)	O
was	O
determined	O
by	O
renal	O
biopsy	O
in	O
27	O
adult	O
male	O
Wistar	O
rats	O
.	O
After	O
1	O
week	O
of	O
recovery	O
,	O
proteinuria	B-Disease
was	O
induced	O
by	O
adriamycin	B-Chemical
[	O
1	O
.	O
5	O
mg	O
/	O
kg	O
intravenously	O
(	O
i	O
.	O
v	O
.	O
)	O
n	O
=	O
18	O
;	O
controls	O
,	O
saline	O
i	O
.	O
v	O
.	O
n	O
=	O
9	O
]	O
.	O
Proteinuria	B-Disease
was	O
measured	O
every	O
2	O
weeks	O
.	O
After	O
12	O
weeks	O
,	O
rats	O
were	O
sacrificed	O
and	O
their	O
kidneys	O
harvested	O
.	O
RESULTS	O
:	O
As	O
anticipated	O
,	O
adriamycin	B-Chemical
elicited	O
nephrotic	B-Disease
range	O
proteinuria	B-Disease
,	O
renal	B-Disease
interstitial	I-Disease
damage	I-Disease
and	O
mild	O
focal	B-Disease
glomerulosclerosis	I-Disease
.	O
Baseline	O
renal	O
ACE	O
positively	O
correlated	O
with	O
the	O
relative	O
rise	O
in	O
proteinuria	B-Disease
after	O
adriamycin	B-Chemical
(	O
r	O
=	O
0	O
.	O
62	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
renal	O
interstitial	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0	O
.	O
49	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
interstitial	O
macrophage	O
influx	O
(	O
r	O
=	O
0	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
interstitial	O
collagen	O
III	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
glomerular	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0	O
.	O
74	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
glomerular	O
desmin	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Baseline	O
renal	O
ACE	O
did	O
not	O
correlate	O
with	O
focal	B-Disease
glomerulosclerosis	I-Disease
(	O
r	O
=	O
0	O
.	O
22	O
,	O
NS	O
)	O
.	O
In	O
controls	O
,	O
no	O
predictive	O
values	O
for	O
renal	O
parameters	O
were	O
observed	O
.	O
CONCLUSION	O
:	O
Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
predict	O
the	O
severity	O
of	O
adriamycin	B-Chemical
-	O
induced	O
renal	B-Disease
damage	I-Disease
in	O
this	O
outbred	O
rat	O
strain	O
.	O
This	O
supports	O
the	O
assumption	O
that	O
differences	O
in	O
renal	O
ACE	O
activity	O
predispose	O
to	O
a	O
less	O
favourable	O
course	O
of	O
renal	B-Disease
damage	I-Disease
.	O
Recurrent	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
induced	O
by	O
azithromycin	B-Chemical
.	O
A	O
14	O
-	O
year	O
-	O
old	O
girl	O
is	O
reported	O
with	O
recurrent	O
,	O
azithromycin	B-Chemical
-	O
induced	O
,	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
.	O
The	O
second	O
episode	O
was	O
more	O
severe	O
than	O
the	O
first	O
;	O
and	O
although	O
both	O
were	O
treated	O
with	O
intensive	O
corticosteroid	O
therapy	O
,	O
renal	O
function	O
remained	O
impaired	O
.	O
Although	O
most	O
cases	O
of	O
antibiotic	O
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
are	O
benign	O
and	O
self	O
-	O
limited	O
,	O
some	O
patients	O
are	O
at	O
risk	O
for	O
permanent	O
renal	B-Disease
injury	I-Disease
.	O
Spironolactone	B-Chemical
-	O
induced	O
renal	B-Disease
insufficiency	I-Disease
and	O
hyperkalemia	B-Disease
in	O
patients	O
with	O
heart	B-Disease
failure	I-Disease
.	O
BACKGROUND	O
:	O
A	O
previous	O
randomized	O
controlled	O
trial	O
evaluating	O
the	O
use	O
of	O
spironolactone	B-Chemical
in	O
heart	B-Disease
failure	I-Disease
patients	O
reported	O
a	O
low	O
risk	O
of	O
hyperkalemia	B-Disease
(	O
2	O
%	O
)	O
and	O
renal	B-Disease
insufficiency	I-Disease
(	O
0	O
%	O
)	O
.	O
Because	O
treatments	O
for	O
heart	B-Disease
failure	I-Disease
have	O
changed	O
since	O
the	O
benefits	O
of	O
spironolactone	B-Chemical
were	O
reported	O
,	O
the	O
prevalence	O
of	O
these	O
complications	O
may	O
differ	O
in	O
current	O
clinical	O
practice	O
.	O
We	O
therefore	O
sought	O
to	O
determine	O
the	O
prevalence	O
and	O
clinical	O
associations	O
of	O
hyperkalemia	B-Disease
and	O
renal	B-Disease
insufficiency	I-Disease
in	O
heart	B-Disease
failure	I-Disease
patients	O
treated	O
with	O
spironolactone	B-Chemical
.	O
METHODS	O
:	O
We	O
performed	O
a	O
case	O
control	O
study	O
of	O
heart	B-Disease
failure	I-Disease
patients	O
treated	O
with	O
spironolactone	B-Chemical
in	O
our	O
clinical	O
practice	O
.	O
Cases	O
were	O
patients	O
who	O
developed	O
hyperkalemia	B-Disease
(	O
K	B-Chemical
(	O
+	O
)	O
>	O
5	O
.	O
0	O
mEq	O
/	O
L	O
)	O
or	O
renal	B-Disease
insufficiency	I-Disease
(	O
Cr	B-Chemical
>	O
or	O
=	O
2	O
.	O
5	O
mg	O
/	O
dL	O
)	O
,	O
and	O
they	O
were	O
compared	O
to	O
2	O
randomly	O
selected	O
controls	O
per	O
case	O
.	O
Clinical	O
characteristics	O
,	O
medications	O
,	O
and	O
serum	O
chemistries	O
at	O
baseline	O
and	O
follow	O
-	O
up	O
time	O
periods	O
were	O
compared	O
.	O
RESULTS	O
:	O
Sixty	O
-	O
seven	O
of	O
926	O
patients	O
(	O
7	O
.	O
2	O
%	O
)	O
required	O
discontinuation	O
of	O
spironolactone	B-Chemical
due	O
to	O
hyperkalemia	B-Disease
(	O
n	O
=	O
33	O
)	O
or	O
renal	B-Disease
failure	I-Disease
(	O
n	O
=	O
34	O
)	O
.	O
Patients	O
who	O
developed	O
hyperkalemia	B-Disease
were	O
older	O
and	O
more	O
likely	O
to	O
have	O
diabetes	B-Disease
,	O
had	O
higher	O
baseline	O
serum	O
potassium	B-Chemical
levels	O
and	O
lower	O
baseline	O
potassium	B-Chemical
supplement	O
doses	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
beta	O
-	O
blockers	O
than	O
controls	O
(	O
n	O
=	O
134	O
)	O
.	O
Patients	O
who	O
developed	O
renal	B-Disease
insufficiency	I-Disease
had	O
lower	O
baseline	O
body	O
weight	O
and	O
higher	O
baseline	O
serum	O
creatinine	B-Chemical
,	O
required	O
higher	O
doses	O
of	O
loop	O
diuretics	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
thiazide	B-Chemical
diuretics	O
than	O
controls	O
.	O
CONCLUSIONS	O
:	O
Spironolactone	B-Chemical
-	O
induced	O
hyperkalemia	B-Disease
and	O
renal	B-Disease
insufficiency	I-Disease
are	O
more	O
common	O
in	O
our	O
clinical	O
experience	O
than	O
reported	O
previously	O
.	O
This	O
difference	O
is	O
explained	O
by	O
patient	O
comorbidities	O
and	O
more	O
frequent	O
use	O
of	O
beta	O
-	O
blockers	O
.	O
Acute	O
reserpine	B-Chemical
and	O
subchronic	O
haloperidol	B-Chemical
treatments	O
change	O
synaptosomal	O
brain	O
glutamate	B-Chemical
uptake	O
and	O
elicit	O
orofacial	B-Disease
dyskinesia	I-Disease
in	O
rats	O
.	O
Reserpine	B-Chemical
-	O
and	O
haloperidol	B-Chemical
-	O
induced	O
orofacial	B-Disease
dyskinesia	I-Disease
are	O
putative	O
animal	O
models	O
of	O
tardive	B-Disease
dyskinesia	I-Disease
(	O
TD	B-Disease
)	O
whose	O
pathophysiology	O
has	O
been	O
related	O
to	O
free	O
radical	O
generation	O
and	O
oxidative	O
stress	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
authors	O
induced	O
orofacial	B-Disease
dyskinesia	I-Disease
by	O
acute	O
reserpine	B-Chemical
and	O
subchronic	O
haloperidol	B-Chemical
administration	O
to	O
rats	O
.	O
Reserpine	B-Chemical
injection	O
(	O
one	O
dose	O
of	O
1	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
every	O
other	O
day	O
for	O
3	O
days	O
caused	O
a	O
significant	O
increase	O
in	O
vacuous	O
chewing	O
,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching	O
,	O
compared	O
to	O
the	O
control	O
.	O
Haloperidol	B-Chemical
administration	O
(	O
one	O
dose	O
of	O
12	O
mg	O
/	O
kg	O
once	O
a	O
week	O
s	O
.	O
c	O
.	O
)	O
for	O
4	O
weeks	O
caused	O
an	O
increase	O
in	O
vacuous	O
chewing	O
,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching	O
observed	O
in	O
four	O
weekly	O
evaluations	O
.	O
After	O
the	O
treatments	O
and	O
behavioral	O
observation	O
,	O
glutamate	B-Chemical
uptake	O
by	O
segments	O
of	O
the	O
brain	O
was	O
analyzed	O
.	O
A	O
decreased	O
glutamate	B-Chemical
uptake	O
was	O
observed	O
in	O
the	O
subcortical	O
parts	O
of	O
animals	O
treated	O
with	O
reserpine	B-Chemical
and	O
haloperidol	B-Chemical
,	O
compared	O
to	O
the	O
control	O
.	O
Importantly	O
,	O
a	O
decrease	O
in	O
glutamate	B-Chemical
uptake	O
correlates	O
negatively	O
with	O
an	O
increase	O
in	O
the	O
incidence	O
of	O
orofacial	B-Disease
diskinesia	I-Disease
.	O
These	O
results	O
indicate	O
that	O
early	O
changes	O
in	O
glutamate	B-Chemical
transport	O
may	O
be	O
related	O
to	O
the	O
development	O
of	O
vacuous	O
chewing	O
movements	O
in	O
rats	O
.	O
Ceftriaxone	B-Chemical
-	O
associated	O
biliary	B-Disease
pseudolithiasis	I-Disease
in	O
paediatric	O
surgical	O
patients	O
.	O
It	O
is	O
well	O
known	O
that	O
ceftriaxone	B-Chemical
leads	O
to	O
pseudolithiasis	B-Disease
in	O
some	O
patients	O
.	O
Clinical	O
and	O
experimental	O
studies	O
also	O
suggest	O
that	O
situations	O
causing	O
gallbladder	B-Disease
dysfunction	I-Disease
,	O
such	O
as	O
fasting	O
,	O
may	O
have	O
a	O
role	O
for	O
the	O
development	O
of	O
pseudolithiasis	B-Disease
.	O
In	O
this	O
study	O
,	O
we	O
prospectively	O
evaluated	O
the	O
incidence	O
and	O
clinical	O
importance	O
of	O
pseudolithiasis	B-Disease
in	O
paediatric	O
surgical	O
patients	O
receiving	O
ceftriaxone	B-Chemical
treatment	O
,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
post	O
-	O
operative	O
period	O
.	O
Fifty	O
children	O
who	O
were	O
given	O
ceftriaxone	B-Chemical
were	O
evaluated	O
by	O
serial	O
abdominal	O
sonograms	O
.	O
Of	O
those	O
,	O
13	O
(	O
26	O
%	O
)	O
developed	O
biliary	O
pathology	O
.	O
Comparison	O
of	O
the	O
patients	O
with	O
or	O
without	O
pseudolithiasis	B-Disease
revealed	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
duration	O
of	O
the	O
treatment	O
and	O
starvation	O
variables	O
.	O
After	O
cessation	O
of	O
the	O
treatment	O
,	O
pseudolithiasis	B-Disease
resolved	O
spontaneously	O
within	O
a	O
short	O
period	O
.	O
The	O
incidence	O
of	O
pseudolithiasis	B-Disease
is	O
not	O
affected	O
by	O
fasting	O
.	O
Coronary	B-Disease
aneurysm	I-Disease
after	O
implantation	O
of	O
a	O
paclitaxel	B-Chemical
-	O
eluting	O
stent	O
.	O
Formation	O
of	O
coronary	B-Disease
aneurysm	I-Disease
is	O
a	O
rare	O
complication	O
of	O
stenting	O
with	O
bare	O
metal	O
stents	O
,	O
but	O
based	O
on	O
experimental	O
studies	O
drug	O
-	O
eluting	O
stents	O
may	O
induce	O
toxic	O
effects	O
on	O
the	O
vessel	O
wall	O
with	O
incomplete	O
stent	O
apposition	O
,	O
aneurysm	B-Disease
formation	O
and	O
with	O
the	O
potential	O
of	O
stent	O
thrombosis	B-Disease
or	O
vessel	B-Disease
rupture	I-Disease
.	O
We	O
present	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
a	O
coronary	B-Disease
aneurysm	I-Disease
in	O
the	O
right	O
coronary	O
artery	O
6	O
months	O
after	O
receiving	O
a	O
paclitaxel	B-Chemical
-	O
eluting	O
stent	O
.	O
The	O
patient	O
was	O
asymptomatic	O
and	O
the	O
aneurysm	B-Disease
was	O
detected	O
in	O
a	O
routine	O
control	O
.	O
Angiography	O
and	O
intracoronary	O
ultrasound	O
demonstrated	O
lack	O
of	O
contact	O
between	O
stent	O
and	O
vessel	O
wall	O
in	O
a	O
15	O
-	O
mm	O
long	O
segment	O
with	O
maximal	O
aneurysm	B-Disease
diameter	O
of	O
6	O
.	O
0	O
mm	O
.	O
The	O
patient	O
was	O
successfully	O
treated	O
with	O
a	O
graft	O
stent	O
.	O
Causes	O
of	O
acute	O
thrombotic	B-Disease
microangiopathy	I-Disease
in	O
patients	O
receiving	O
kidney	O
transplantation	O
.	O
OBJECTIVES	O
:	O
Thrombotic	B-Disease
microangiopathy	I-Disease
is	O
a	O
well	O
-	O
known	O
problem	O
in	O
patients	O
following	O
renal	O
transplantation	O
.	O
In	O
postrenal	O
transplantation	O
,	O
thrombotic	B-Disease
microangiopathy	I-Disease
is	O
often	O
a	O
reflection	O
of	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
.	O
We	O
aimed	O
to	O
determine	O
the	O
causes	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
in	O
a	O
population	O
of	O
renal	O
transplantation	O
recipients	O
and	O
discuss	O
the	O
literature	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
We	O
investigated	O
the	O
causes	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
during	O
a	O
1	O
-	O
year	O
period	O
,	O
from	O
June	O
2003	O
to	O
June	O
2004	O
,	O
at	O
the	O
King	O
Fahad	O
National	O
Guard	O
Hospital	O
in	O
Riyadh	O
,	O
Saudi	O
Arabia	O
,	O
by	O
reviewing	O
the	O
slides	O
of	O
all	O
transplant	O
biopsies	O
(	O
n	O
=	O
25	O
)	O
performed	O
during	O
this	O
interval	O
.	O
Pre	O
-	O
and	O
posttransplant	O
crossmatching	O
was	O
done	O
when	O
possible	O
.	O
RESULTS	O
:	O
Five	O
cases	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
were	O
found	O
.	O
Three	O
of	O
these	O
cases	O
were	O
from	O
the	O
25	O
transplantations	O
performed	O
at	O
King	O
Fahad	O
National	O
Guard	O
Hospital	O
,	O
while	O
the	O
other	O
2	O
transplantations	O
had	O
been	O
performed	O
abroad	O
and	O
were	O
referred	O
to	O
us	O
for	O
follow	O
-	O
up	O
.	O
Three	O
cases	O
were	O
related	O
to	O
cyclosporine	B-Chemical
,	O
and	O
1	O
case	O
was	O
secondary	O
to	O
both	O
cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
.	O
The	O
fifth	O
case	O
had	O
features	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
related	O
to	O
an	O
antiphospholipid	B-Disease
syndrome	I-Disease
in	O
a	O
patient	O
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
.	O
CONCLUSIONS	O
:	O
In	O
the	O
literature	O
,	O
the	O
most	O
-	O
frequent	O
cause	O
of	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
in	O
patients	O
following	O
renal	O
transplantation	O
is	O
recurrence	O
of	O
the	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
.	O
Other	O
causes	O
include	O
drug	O
-	O
related	O
(	O
cyclosporine	B-Chemical
,	O
tacrolimus	B-Chemical
)	O
toxicity	B-Disease
,	O
procoagulant	O
status	O
,	O
and	O
antibody	O
-	O
mediated	O
rejection	O
.	O
We	O
found	O
that	O
the	O
most	O
-	O
frequent	O
cause	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
was	O
drug	O
related	O
,	O
secondary	O
mainly	O
to	O
cyclosporine	B-Chemical
.	O
In	O
the	O
current	O
study	O
,	O
the	O
frequency	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
was	O
similar	O
to	O
the	O
percentage	O
reported	O
in	O
the	O
literature	O
(	O
20	O
%	O
)	O
.	O
Comparison	O
of	O
developmental	O
toxicity	B-Disease
of	O
selective	O
and	O
non	O
-	O
selective	O
cyclooxygenase	O
-	O
2	O
inhibitors	O
in	O
CRL	O
:	O
(	O
WI	O
)	O
WUBR	O
Wistar	O
rats	O
-	O
-	O
DFU	B-Chemical
and	O
piroxicam	B-Chemical
study	O
.	O
BACKGROUND	O
:	O
Cyclooxygenase	O
(	O
COX	O
)	O
inhibitors	O
are	O
one	O
of	O
the	O
most	O
often	O
ingested	O
drugs	O
during	O
pregnancy	O
.	O
Unlike	O
general	O
toxicity	B-Disease
data	O
,	O
their	O
prenatal	O
toxic	O
effects	O
were	O
not	O
extensively	O
studied	O
before	O
.	O
The	O
aim	O
of	O
the	O
experiment	O
was	O
to	O
evaluate	O
the	O
developmental	O
toxicity	B-Disease
of	O
the	O
non	O
-	O
selective	O
(	O
piroxicam	B-Chemical
)	O
and	O
selective	O
(	O
DFU	B-Chemical
;	O
5	B-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
dimethyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluorophenyl	I-Chemical
)	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
methylsulphonyl	I-Chemical
)	I-Chemical
phenyl	I-Chemical
-	I-Chemical
2	I-Chemical
(	I-Chemical
5H	I-Chemical
)	I-Chemical
-	I-Chemical
furanon	I-Chemical
)	O
COX	O
-	O
2	O
inhibitors	O
.	O
METHODS	O
:	O
Drugs	O
were	O
separately	O
,	O
orally	O
once	O
daily	O
dosed	O
to	O
pregnant	O
rats	O
from	O
day	O
8	O
to	O
21	O
(	O
GD1	O
=	O
plug	O
day	O
)	O
.	O
Doses	O
were	O
set	O
at	O
0	O
.	O
3	O
,	O
3	O
.	O
0	O
and	O
30	O
.	O
0mg	O
/	O
kg	O
for	O
piroxicam	B-Chemical
and	O
0	O
.	O
2	O
,	O
2	O
.	O
0	O
and	O
20	O
.	O
0mg	O
/	O
kg	O
for	O
DFU	B-Chemical
.	O
Fetuses	O
were	O
delivered	O
on	O
GD	O
21	O
and	O
routinely	O
examined	O
.	O
Comprehensive	O
clinical	O
and	O
developmental	O
measurements	O
were	O
done	O
.	O
The	O
pooled	O
statistical	O
analysis	O
for	O
ventricular	B-Disease
septal	I-Disease
(	I-Disease
VSD	I-Disease
)	I-Disease
and	I-Disease
midline	I-Disease
(	I-Disease
MD	I-Disease
)	I-Disease
defects	I-Disease
was	O
performed	O
for	O
rat	O
fetuses	O
exposed	O
to	O
piroxicam	B-Chemical
,	O
selective	O
and	O
non	O
-	O
selective	O
COX	O
-	O
2	O
inhibitor	O
based	O
on	O
present	O
and	O
historic	O
data	O
.	O
RESULTS	O
:	O
Maternal	O
toxicity	B-Disease
,	O
intrauterine	B-Disease
growth	I-Disease
retardation	I-Disease
,	O
and	O
increase	B-Disease
of	I-Disease
external	I-Disease
and	I-Disease
skeletal	I-Disease
variations	I-Disease
were	O
found	O
in	O
rats	O
treated	O
with	O
the	O
highest	O
dose	O
of	O
piroxicam	B-Chemical
.	O
Decrease	O
of	O
fetal	O
length	O
was	O
the	O
only	O
signs	O
of	O
the	O
DFU	B-Chemical
developmental	O
toxicity	B-Disease
observed	O
in	O
pups	O
exposed	O
to	O
the	O
highest	O
compound	O
dose	O
.	O
Lack	O
of	O
teratogenicity	O
was	O
found	O
in	O
piroxicam	B-Chemical
and	O
DFU	B-Chemical
-	O
exposed	O
groups	O
.	O
Prenatal	O
exposure	O
to	O
non	O
-	O
selective	O
COX	O
inhibitors	O
increases	O
the	O
risk	O
of	O
VSD	O
and	O
MD	O
when	O
compared	O
to	O
historic	O
control	O
but	O
not	O
with	O
selective	O
COX	O
-	O
2	O
inhibitors	O
.	O
CONCLUSION	O
:	O
Both	O
selective	O
and	O
non	O
-	O
selective	O
COX	O
-	O
2	O
inhibitors	O
were	O
toxic	O
for	O
rats	O
fetuses	O
when	O
administered	O
in	O
the	O
highest	O
dose	O
.	O
Unlike	O
DFU	B-Chemical
,	O
piroxicam	B-Chemical
was	O
also	O
highly	O
toxic	O
to	O
the	O
dams	O
.	O
Prenatal	O
exposure	O
to	O
selective	O
COX	O
-	O
2	O
inhibitors	O
does	O
not	O
increase	O
the	O
risk	O
of	O
ventricular	B-Disease
septal	I-Disease
and	I-Disease
midline	I-Disease
defects	I-Disease
in	O
rat	O
when	O
compared	O
to	O
non	O
-	O
selective	O
drugs	O
and	O
historic	O
control	O
.	O
Lone	O
atrial	B-Disease
fibrillation	I-Disease
associated	O
with	O
creatine	B-Chemical
monohydrate	O
supplementation	O
.	O
Atrial	B-Disease
fibrillation	I-Disease
in	O
young	O
patients	O
without	O
structural	O
heart	B-Disease
disease	I-Disease
is	O
rare	O
.	O
Therefore	O
,	O
when	O
the	O
arrhythmia	B-Disease
is	O
present	O
in	O
this	O
population	O
,	O
reversible	O
causes	O
must	O
be	O
identified	O
and	O
resolved	O
.	O
Thyroid	B-Disease
disorders	I-Disease
,	O
illicit	O
drug	O
or	O
stimulant	O
use	O
,	O
and	O
acute	B-Disease
alcohol	I-Disease
intoxication	I-Disease
are	O
among	O
these	O
causes	O
.	O
We	O
report	O
the	O
case	O
of	O
a	O
30	O
-	O
year	O
-	O
old	O
Caucasian	O
man	O
who	O
came	O
to	O
the	O
emergency	O
department	O
in	O
atrial	B-Disease
fibrillation	I-Disease
with	O
rapid	O
ventricular	O
response	O
.	O
His	O
medical	O
history	O
was	O
unremarkable	O
,	O
except	O
for	O
minor	O
fractures	B-Disease
of	O
the	O
fingers	O
and	O
foot	O
.	O
Thyroid	O
-	O
stimulating	O
hormone	O
,	O
magnesium	B-Chemical
,	O
and	O
potassium	B-Chemical
levels	O
were	O
within	O
normal	O
limits	O
,	O
urine	O
drug	O
screen	O
was	O
negative	O
,	O
and	O
alcohol	B-Chemical
use	O
was	O
denied	O
.	O
However	O
,	O
when	O
the	O
patient	O
was	O
questioned	O
about	O
use	O
of	O
herbal	O
products	O
and	O
supplements	O
,	O
the	O
use	O
of	O
creatine	B-Chemical
monohydrate	O
was	O
revealed	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
,	O
anticoagulated	O
with	O
unfractionated	O
heparin	B-Chemical
,	O
and	O
given	O
intravenous	O
diltiazem	B-Chemical
for	O
rate	O
control	O
and	O
intravenous	O
amiodarone	B-Chemical
for	O
rate	O
and	O
rhythm	O
control	O
.	O
When	O
discharged	O
less	O
than	O
24	O
hours	O
later	O
,	O
he	O
was	O
receiving	O
metoprolol	B-Chemical
and	O
aspirin	B-Chemical
,	O
with	O
follow	O
-	O
up	O
plans	O
for	O
echocardiography	O
and	O
nuclear	O
imaging	O
to	O
assess	O
perfusion	O
.	O
Exogenous	O
creatine	B-Chemical
is	O
used	O
by	O
athletes	O
to	O
theoretically	O
improve	O
exercise	O
performance	O
.	O
Vegetarians	O
may	O
also	O
take	O
creatine	B-Chemical
to	O
replace	O
what	O
they	O
are	O
not	O
consuming	O
from	O
meat	O
,	O
fish	O
,	O
and	O
other	O
animal	O
products	O
.	O
Previous	O
anecdotal	O
reports	O
have	O
linked	O
creatine	B-Chemical
to	O
the	O
development	O
of	O
arrhythmia	B-Disease
.	O
Clinicians	O
must	O
be	O
diligent	O
when	O
interviewing	O
patients	O
about	O
their	O
drug	O
therapy	O
histories	O
and	O
include	O
questions	O
about	O
their	O
use	O
of	O
herbal	O
products	O
and	O
dietary	O
supplements	O
.	O
In	O
addition	O
,	O
it	O
is	O
important	O
to	O
report	O
adverse	O
effects	O
associated	O
with	O
frequently	O
consumed	O
supplements	O
and	O
herbal	O
products	O
to	O
the	O
Food	O
and	O
Drug	O
Administration	O
and	O
in	O
the	O
literature	O
.	O
Seizures	B-Disease
induced	O
by	O
the	O
cocaine	B-Chemical
metabolite	O
benzoylecgonine	B-Chemical
in	O
rats	O
.	O
The	O
half	O
-	O
life	O
(	O
t1	O
/	O
2	O
)	O
of	O
cocaine	B-Chemical
is	O
relatively	O
short	O
,	O
but	O
some	O
of	O
the	O
consequences	O
of	O
its	O
use	O
,	O
such	O
as	O
seizures	B-Disease
and	O
strokes	B-Disease
,	O
can	O
occur	O
hours	O
after	O
exposure	O
.	O
This	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
metabolite	O
of	O
cocaine	B-Chemical
may	O
be	O
responsible	O
for	O
some	O
of	O
those	O
delayed	O
sequelae	O
.	O
We	O
evaluated	O
the	O
potential	O
of	O
the	O
major	O
metabolite	O
of	O
cocaine	B-Chemical
,	O
benzoylecgonine	B-Chemical
(	O
BE	B-Chemical
)	O
,	O
to	O
cause	O
seizures	B-Disease
.	O
Two	O
separate	O
equimolar	O
doses	O
(	O
0	O
.	O
2	O
and	O
0	O
.	O
4	O
mumol	O
)	O
of	O
either	O
cocaine	B-Chemical
or	O
BE	B-Chemical
were	O
injected	O
ventricularly	O
in	O
unanesthetized	O
juvenile	O
rats	O
.	O
Treated	O
rats	O
were	O
then	O
evaluated	O
for	O
incidence	O
,	O
latency	O
,	O
and	O
seizure	B-Disease
pattern	O
or	O
for	O
locomotor	O
activity	O
in	O
animals	O
without	O
seizures	B-Disease
.	O
BE	B-Chemical
-	O
Induced	O
seizures	B-Disease
occurred	O
more	O
frequently	O
and	O
had	O
significantly	O
longer	O
latencies	O
than	O
those	O
induced	O
by	O
equimolar	O
amounts	O
of	O
cocaine	B-Chemical
.	O
Whereas	O
cocaine	B-Chemical
-	O
induced	O
seizures	B-Disease
were	O
best	O
characterized	O
as	O
brief	O
,	O
generalized	O
,	O
and	O
tonic	O
and	O
resulted	O
in	O
death	B-Disease
,	O
those	O
induced	O
by	O
BE	B-Chemical
were	O
prolonged	O
,	O
often	O
multiple	O
and	O
mixed	O
in	O
type	O
,	O
and	O
rarely	O
resulted	O
in	O
death	B-Disease
.	O
Electrical	O
recordings	O
from	O
the	O
hippocampus	O
showed	O
a	O
rhythmic	O
progression	O
in	O
EEG	O
frequency	O
and	O
voltage	O
with	O
clinical	O
seizure	B-Disease
expression	O
.	O
BE	B-Chemical
-	O
Injected	O
rats	O
that	O
did	O
not	O
have	O
seizures	B-Disease
had	O
significantly	O
more	O
locomotor	O
activity	O
than	O
cocaine	B-Chemical
-	O
injected	O
animals	O
without	O
seizures	B-Disease
.	O
The	O
finding	O
that	O
cocaine	B-Chemical
-	O
and	O
BE	B-Chemical
-	O
induced	O
seizures	B-Disease
differ	O
in	O
several	O
respects	O
suggests	O
more	O
than	O
one	O
mechanism	O
for	O
cocaine	B-Chemical
-	O
induced	O
seizures	B-Disease
and	O
emphasizes	O
the	O
importance	O
of	O
a	O
cocaine	B-Chemical
metabolite	O
,	O
BE	B-Chemical
.	O
The	O
selective	O
5	O
-	O
HT6	O
receptor	O
antagonist	O
Ro4368554	B-Chemical
restores	O
memory	O
performance	O
in	O
cholinergic	O
and	O
serotonergic	O
models	O
of	O
memory	B-Disease
deficiency	I-Disease
in	O
the	O
rat	O
.	O
Antagonists	O
at	O
serotonin	B-Chemical
type	O
6	O
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
6	O
)	O
)	O
receptors	O
show	O
activity	O
in	O
models	O
of	O
learning	O
and	O
memory	O
.	O
Although	O
the	O
underlying	O
mechanism	O
(	O
s	O
)	O
are	O
not	O
well	O
understood	O
,	O
these	O
effects	O
may	O
involve	O
an	O
increase	O
in	O
acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
levels	O
.	O
The	O
present	O
study	O
sought	O
to	O
characterize	O
the	O
cognitive	O
-	O
enhancing	O
effects	O
of	O
the	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
6	O
)	O
antagonist	O
Ro4368554	B-Chemical
(	O
3	B-Chemical
-	I-Chemical
benzenesulfonyl	I-Chemical
-	I-Chemical
7	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
piperazin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
1H	I-Chemical
-	I-Chemical
indole	I-Chemical
)	O
in	O
a	O
rat	O
object	O
recognition	O
task	O
employing	O
a	O
cholinergic	O
(	O
scopolamine	B-Chemical
pretreatment	O
)	O
and	O
a	O
serotonergic	O
-	O
(	O
tryptophan	B-Chemical
(	O
TRP	B-Chemical
)	O
depletion	O
)	O
deficient	O
model	O
,	O
and	O
compared	O
its	O
pattern	O
of	O
action	O
with	O
that	O
of	O
the	O
acetylcholinesterase	O
inhibitor	O
metrifonate	B-Chemical
.	O
Initial	O
testing	O
in	O
a	O
time	O
-	O
dependent	O
forgetting	O
task	O
employing	O
a	O
24	O
-	O
h	O
delay	O
between	O
training	O
and	O
testing	O
showed	O
that	O
metrifonate	B-Chemical
improved	O
object	O
recognition	O
(	O
at	O
10	O
and	O
30	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
whereas	O
Ro4368554	B-Chemical
was	O
inactive	O
.	O
Both	O
,	O
Ro4368554	B-Chemical
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
,	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
)	O
and	O
metrifonate	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
reversed	O
memory	B-Disease
deficits	I-Disease
induced	O
by	O
scopolamine	B-Chemical
and	O
TRP	B-Chemical
depletion	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
and	O
3	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
.	O
In	O
conclusion	O
,	O
although	O
Ro4368554	B-Chemical
did	O
not	O
improve	O
a	O
time	O
-	O
related	O
retention	O
deficit	O
,	O
it	O
reversed	O
a	O
cholinergic	O
and	O
a	O
serotonergic	O
memory	B-Disease
deficit	I-Disease
,	O
suggesting	O
that	O
both	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
facilitation	O
of	O
object	O
memory	O
by	O
Ro4368554	B-Chemical
and	O
,	O
possibly	O
,	O
other	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
6	O
)	O
receptor	O
antagonists	O
.	O
Evaluation	O
of	O
the	O
anticocaine	O
monoclonal	O
antibody	O
GNC92H2	B-Chemical
as	O
an	O
immunotherapy	O
for	O
cocaine	B-Disease
overdose	I-Disease
.	O
The	O
illicit	O
use	O
of	O
cocaine	B-Chemical
continues	O
in	O
epidemic	O
proportions	O
and	O
treatment	O
for	O
cocaine	B-Disease
overdose	I-Disease
remains	O
elusive	O
.	O
Current	O
protein	O
-	O
based	O
technology	O
offers	O
a	O
new	O
therapeutic	O
venue	O
by	O
which	O
antibodies	O
bind	O
the	O
drug	O
in	O
the	O
blood	O
stream	O
,	O
inactivating	O
its	O
toxic	O
effects	O
.	O
The	O
therapeutic	O
potential	O
of	O
the	O
anticocaine	O
antibody	O
GNC92H2	B-Chemical
was	O
examined	O
using	O
a	O
model	O
of	O
cocaine	B-Disease
overdose	I-Disease
.	O
Swiss	O
albino	O
mice	O
prepared	O
with	O
intrajugular	O
catheters	O
were	O
tested	O
in	O
photocell	O
cages	O
after	O
administration	O
of	O
93	O
mg	O
/	O
kg	O
(	O
LD50	O
)	O
of	O
cocaine	B-Chemical
and	O
GNC92H2	B-Chemical
infusions	O
ranging	O
from	O
30	O
to	O
190	O
mg	O
/	O
kg	O
.	O
GNC92H2	B-Chemical
was	O
delivered	O
30	O
min	O
before	O
,	O
concomitantly	O
or	O
3	O
min	O
after	O
cocaine	B-Chemical
treatment	O
.	O
Significant	O
blockade	O
of	O
cocaine	B-Chemical
toxicity	B-Disease
was	O
observed	O
with	O
the	O
higher	O
dose	O
of	O
GNC92H2	B-Chemical
(	O
190	O
mg	O
/	O
kg	O
)	O
,	O
where	O
premorbid	O
behaviors	O
were	O
reduced	O
up	O
to	O
40	O
%	O
,	O
seizures	B-Disease
up	O
to	O
77	O
%	O
and	O
death	B-Disease
by	O
72	O
%	O
.	O
Importantly	O
,	O
GNC92H2	B-Chemical
prevented	O
death	B-Disease
even	O
post	O
-	O
cocaine	B-Chemical
injection	O
.	O
The	O
results	O
support	O
the	O
important	O
potential	O
of	O
GNC92H2	B-Chemical
as	O
a	O
therapeutic	O
tool	O
against	O
cocaine	B-Disease
overdose	I-Disease
.	O
Electrocardiographic	O
evidence	O
of	O
myocardial	B-Disease
injury	I-Disease
in	O
psychiatrically	O
hospitalized	O
cocaine	B-Chemical
abusers	O
.	O
The	O
electrocardiograms	O
(	O
ECG	O
)	O
of	O
99	O
cocaine	B-Chemical
-	O
abusing	O
patients	O
were	O
compared	O
with	O
the	O
ECGs	O
of	O
50	O
schizophrenic	B-Disease
controls	O
.	O
Eleven	O
of	O
the	O
cocaine	B-Chemical
abusers	O
and	O
none	O
of	O
the	O
controls	O
had	O
ECG	O
evidence	O
of	O
significant	O
myocardial	B-Disease
injury	I-Disease
defined	O
as	O
myocardial	B-Disease
infarction	I-Disease
,	O
ischemia	B-Disease
,	O
and	O
bundle	B-Disease
branch	I-Disease
block	I-Disease
.	O
Behavioral	O
effects	O
of	O
urotensin	B-Chemical
-	I-Chemical
II	I-Chemical
centrally	O
administered	O
in	O
mice	O
.	O
Urotensin	B-Chemical
-	I-Chemical
II	I-Chemical
(	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
)	O
receptors	O
are	O
widely	O
distributed	O
in	O
the	O
central	O
nervous	O
system	O
.	O
Intracerebroventricular	O
(	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
injection	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
causes	O
hypertension	B-Disease
and	O
bradycardia	B-Disease
and	O
stimulates	O
prolactin	O
and	O
thyrotropin	O
secretion	O
.	O
However	O
,	O
the	O
behavioral	O
effects	O
of	O
centrally	O
administered	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
have	O
received	O
little	O
attention	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
tested	O
the	O
effects	O
of	O
i	O
.	O
c	O
.	O
v	O
.	O
injections	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
on	O
behavioral	O
,	O
metabolic	O
,	O
and	O
endocrine	O
responses	O
in	O
mice	O
.	O
Administration	O
of	O
graded	O
doses	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
(	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
head	O
dips	O
in	O
the	O
hole	O
-	O
board	O
test	O
;	O
(	O
2	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
white	O
chamber	O
in	O
the	O
black	O
-	O
and	O
-	O
white	O
compartment	O
test	O
,	O
and	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
central	O
platform	O
and	O
open	O
arms	O
in	O
the	O
plus	O
-	O
maze	O
test	O
;	O
and	O
(	O
3	O
)	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
the	O
forced	O
-	O
swimming	O
test	O
and	O
tail	O
suspension	O
test	O
.	O
Intracerebroventricular	O
injection	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
also	O
caused	O
an	O
increase	O
in	O
:	O
food	O
intake	O
at	O
doses	O
of	O
100	O
and	O
1	O
,	O
000	O
ng	O
/	O
mouse	O
,	O
water	O
intake	O
at	O
doses	O
of	O
100	O
-	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
,	O
and	O
horizontal	O
locomotion	O
activity	O
at	O
a	O
dose	O
of	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
.	O
Whatever	O
was	O
the	O
dose	O
,	O
the	O
central	O
administration	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
had	O
no	O
effect	O
on	O
body	O
temperature	O
,	O
nociception	O
,	O
apomorphine	B-Chemical
-	O
induced	O
penile	B-Disease
erection	I-Disease
and	O
climbing	O
behavior	O
,	O
and	O
stress	O
-	O
induced	O
plasma	O
corticosterone	B-Chemical
level	O
.	O
Taken	O
together	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
the	O
central	O
injection	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
at	O
doses	O
of	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
induces	O
anxiogenic	O
-	O
and	O
depressant	O
-	O
like	O
effects	O
in	O
mouse	O
.	O
These	O
data	O
suggest	O
that	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psychiatric	B-Disease
disorders	I-Disease
.	O
Learning	O
of	O
rats	O
under	O
amnesia	B-Disease
caused	O
by	O
pentobarbital	B-Chemical
.	O
Dissociated	O
learning	O
of	O
rats	O
in	O
the	O
normal	O
state	O
and	O
the	O
state	O
of	O
amnesia	B-Disease
produced	O
by	O
pentobarbital	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
,	O
ip	O
)	O
was	O
carried	O
out	O
.	O
Rats	O
were	O
trained	O
to	O
approach	O
a	O
shelf	O
where	O
they	O
received	O
food	O
reinforcement	O
.	O
In	O
Group	O
1	O
the	O
rats	O
were	O
trained	O
under	O
the	O
influence	O
of	O
pentobarbital	B-Chemical
to	O
run	O
to	O
the	O
same	O
shelf	O
as	O
in	O
the	O
normal	O
state	O
.	O
In	O
Group	O
2	O
the	O
rats	O
were	O
trained	O
to	O
approach	O
different	O
shelves	O
in	O
different	O
drug	O
states	O
.	O
It	O
was	O
shown	O
that	O
memory	B-Disease
dissociation	I-Disease
occurred	O
in	O
both	O
groups	O
.	O
Differences	O
in	O
the	O
parameters	O
of	O
training	O
under	O
the	O
influence	O
of	O
pentobarbital	B-Chemical
between	O
Groups	O
1	O
and	O
2	O
were	O
revealed	O
.	O
These	O
findings	O
show	O
that	O
the	O
brain	O
-	O
dissociated	O
state	O
induced	O
by	O
pentobarbital	B-Chemical
is	O
formed	O
with	O
the	O
participation	O
of	O
the	O
mechanisms	O
of	O
information	O
perception	O
.	O
The	O
effects	O
of	O
short	O
-	O
term	O
raloxifene	B-Chemical
therapy	O
on	O
fibrinolysis	O
markers	O
:	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI	O
-	O
1	O
.	O
BACKGROUND	O
:	O
Markers	O
of	O
fibrinolysis	O
,	O
thrombin	O
-	O
activatable	O
fibrinolysis	O
inhibitor	O
(	O
TAFI	O
)	O
,	O
tissue	O
-	O
type	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
,	O
and	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
levels	O
were	O
studied	O
for	O
the	O
evaluation	O
of	O
short	O
-	O
term	O
effects	O
of	O
raloxifene	B-Chemical
administration	O
in	O
postmenopausal	O
women	O
.	O
METHODS	O
:	O
Thirty	O
-	O
nine	O
postmenopausal	O
women	O
with	O
osteopenia	B-Disease
or	O
osteoporosis	B-Disease
were	O
included	O
in	O
this	O
prospective	O
,	O
controlled	O
clinical	O
study	O
.	O
Twenty	O
-	O
five	O
women	O
were	O
given	O
raloxifene	B-Chemical
hydrochloride	I-Chemical
(	O
60	O
mg	O
/	O
day	O
)	O
plus	O
calcium	B-Chemical
(	O
500	O
mg	O
/	O
day	O
)	O
.	O
Age	O
-	O
matched	O
controls	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calcium	B-Chemical
.	O
Plasma	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI	O
-	O
1	O
antigen	O
levels	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
3	O
months	O
of	O
treatment	O
by	O
commercially	O
available	O
ELISA	O
kits	O
.	O
Variations	O
of	O
individuals	O
were	O
assessed	O
by	O
Wilcoxon	O
'	O
s	O
test	O
.	O
Relationship	O
between	O
those	O
markers	O
and	O
demographic	O
characteristics	O
were	O
investigated	O
.	O
RESULTS	O
:	O
Three	O
months	O
of	O
raloxifene	B-Chemical
treatment	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
TAFI	O
antigen	O
concentrations	O
(	O
16	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
a	O
significant	O
increase	O
in	O
tPA	O
antigen	O
concentrations	O
(	O
25	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
A	O
significant	O
correlation	O
was	O
found	O
between	O
baseline	O
TAFI	O
antigen	O
concentrations	O
and	O
the	O
duration	O
of	O
amenorrhea	B-Disease
(	O
P	O
<	O
0	O
.	O
05	O
;	O
r	O
=	O
0	O
.	O
33	O
)	O
.	O
CONCLUSION	O
:	O
We	O
suggest	O
that	O
the	O
increased	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
due	O
to	O
raloxifene	B-Chemical
treatment	O
may	O
be	O
related	O
to	O
increased	O
tPA	O
levels	O
,	O
but	O
not	O
TAFI	O
levels	O
.	O
Valproate	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
.	O
Valproate	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
is	O
a	O
rare	O
syndrome	O
that	O
may	O
manifest	O
in	O
otherwise	O
normal	O
epileptic	B-Disease
individuals	O
.	O
It	O
may	O
even	O
present	O
in	O
patients	O
who	O
have	O
tolerated	O
this	O
medicine	O
well	O
in	O
the	O
past	O
.	O
It	O
is	O
usually	O
but	O
not	O
necessarily	O
associated	O
with	O
hyperammonemia	B-Disease
.	O
The	O
EEG	O
shows	O
characteristic	O
triphasic	O
waves	O
in	O
most	O
patients	O
with	O
this	O
complication	O
.	O
A	O
case	O
of	O
valproate	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
is	O
presented	O
.	O
The	O
problems	O
in	O
diagnosing	O
this	O
condition	O
are	O
subsequently	O
discussed	O
.	O
Recurrent	O
dysphonia	B-Disease
and	O
acitretin	B-Chemical
.	O
We	O
report	O
the	O
case	O
of	O
a	O
woman	O
complaining	O
of	O
dysphonia	B-Disease
while	O
she	O
was	O
treated	O
by	O
acitretin	B-Chemical
.	O
Her	O
symptoms	O
totally	O
regressed	O
after	O
drug	O
withdrawal	O
and	O
reappeared	O
when	O
acitretin	B-Chemical
was	O
reintroduced	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
acitretin	B-Chemical
-	O
induced	O
dysphonia	B-Disease
.	O
This	O
effect	O
may	O
be	O
related	O
to	O
the	O
pharmacological	O
effect	O
of	O
this	O
drug	O
on	O
mucous	O
membranes	O
.	O
Nitro	B-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
methyl	I-Chemical
ester	I-Chemical
:	O
a	O
potential	O
protector	O
against	O
gentamicin	B-Chemical
ototoxicity	B-Disease
.	O
The	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
inhibitor	O
nitro	B-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
methyl	I-Chemical
ester	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
)	O
may	O
act	O
as	O
an	O
otoprotectant	O
against	O
high	B-Disease
-	I-Disease
frequency	I-Disease
hearing	I-Disease
loss	I-Disease
caused	O
by	O
gentamicin	B-Chemical
,	O
but	O
further	O
studies	O
are	O
needed	O
to	O
confirm	O
this	O
.	O
Aminoglycoside	B-Chemical
antibiotics	O
are	O
still	O
widely	O
used	O
by	O
virtue	O
of	O
their	O
efficacy	O
and	O
low	O
cost	O
.	O
Their	O
ototoxicity	B-Disease
is	O
a	O
serious	O
health	O
problem	O
and	O
,	O
as	O
their	O
ototoxic	B-Disease
mechanism	O
involves	O
the	O
production	O
of	O
NO	B-Chemical
,	O
we	O
need	O
to	O
assess	O
the	O
use	O
of	O
NO	B-Chemical
inhibitors	O
for	O
the	O
prevention	O
of	O
aminoglycoside	B-Chemical
-	O
induced	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O
In	O
this	O
experimental	O
study	O
we	O
used	O
30	O
Sprague	O
-	O
Dawley	O
rats	O
,	O
27	O
of	O
which	O
had	O
gentamicin	B-Chemical
instilled	O
into	O
the	O
middle	O
ear	O
.	O
The	O
otoprotectant	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
was	O
administered	O
topically	O
to	O
12	O
/	O
27	O
animals	O
.	O
Its	O
effect	O
was	O
determined	O
in	O
terms	O
of	O
attenuation	O
of	O
hearing	B-Disease
loss	I-Disease
,	O
measured	O
by	O
shifts	O
in	O
the	O
auditory	O
brainstem	O
response	O
threshold	O
.	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
reduced	O
gentamicin	B-Chemical
-	O
induced	O
hearing	B-Disease
loss	I-Disease
in	O
the	O
high	O
-	O
frequency	O
range	O
,	O
but	O
gave	O
no	O
protection	O
in	O
the	O
middle	O
or	O
low	O
frequencies	O
.	O
Safety	O
profile	O
of	O
a	O
nicotine	B-Chemical
lozenge	O
compared	O
with	O
that	O
of	O
nicotine	B-Chemical
gum	O
in	O
adult	O
smokers	O
with	O
underlying	O
medical	O
conditions	O
:	O
a	O
12	O
-	O
week	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
.	O
BACKGROUND	O
:	O
Nicotine	B-Chemical
polacrilex	O
lozenges	O
deliver	O
25	O
%	O
to	O
27	O
%	O
more	O
nicotine	B-Chemical
compared	O
with	O
equivalent	O
doses	O
of	O
nicotine	B-Chemical
polacrilex	O
gum	O
.	O
The	O
increased	O
nicotine	B-Chemical
exposure	O
from	O
the	O
lozenge	O
has	O
raised	O
questions	O
about	O
the	O
relative	O
safety	O
of	O
the	O
lozenge	O
and	O
gum	O
.	O
OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
safety	O
profiles	O
of	O
the	O
4	O
-	O
mg	O
nicotine	B-Chemical
lozenge	O
and	O
4	O
-	O
mg	O
nicotine	B-Chemical
gum	O
in	O
smokers	O
with	O
selected	O
label	O
-	O
restricted	O
diseases	O
.	O
METHODS	O
:	O
This	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
in	O
adult	O
smokers	O
with	O
heart	B-Disease
disease	I-Disease
,	O
hypertension	B-Disease
not	O
controlled	O
by	O
medication	O
,	O
and	O
/	O
or	O
diabetes	B-Disease
mellitus	I-Disease
.	O
Patients	O
were	O
randomized	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
the	O
4	O
-	O
mg	O
nicotine	B-Chemical
lozenge	O
or	O
4	O
-	O
mg	O
nicotine	B-Chemical
gum	O
.	O
Safety	O
assessments	O
were	O
made	O
at	O
baseline	O
and	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
12	O
weeks	O
after	O
the	O
start	O
of	O
product	O
use	O
.	O
RESULTS	O
:	O
Nine	O
hundred	O
one	O
patients	O
were	O
randomized	O
to	O
treatment	O
,	O
447	O
who	O
received	O
the	O
lozenge	O
and	O
454	O
who	O
received	O
the	O
gum	O
(	O
safety	O
population	O
)	O
.	O
The	O
majority	O
were	O
women	O
(	O
52	O
.	O
7	O
%	O
)	O
.	O
Patients	O
'	O
mean	O
age	O
was	O
53	O
.	O
9	O
years	O
,	O
their	O
mean	O
weight	O
was	O
193	O
.	O
9	O
pounds	O
,	O
and	O
they	O
smoked	O
a	O
mean	O
of	O
25	O
.	O
2	O
cigarettes	O
per	O
day	O
at	O
baseline	O
.	O
Five	O
hundred	O
fifty	O
-	O
three	O
patients	O
,	O
264	O
taking	O
the	O
lozenge	O
and	O
289	O
taking	O
the	O
gum	O
,	O
used	O
the	O
study	O
product	O
for	O
>	O
or	O
=	O
4	O
days	O
per	O
week	O
during	O
the	O
first	O
2	O
weeks	O
(	O
evaluable	O
population	O
)	O
.	O
The	O
nicotine	B-Chemical
lozenge	O
and	O
nicotine	B-Chemical
gum	O
were	O
equally	O
well	O
tolerated	O
,	O
despite	O
increased	O
nicotine	B-Chemical
exposure	O
from	O
the	O
lozenge	O
.	O
The	O
incidence	O
of	O
adverse	O
events	O
in	O
the	O
2	O
groups	O
was	O
similar	O
during	O
the	O
first	O
2	O
weeks	O
of	O
product	O
use	O
(	O
evaluation	O
population	O
:	O
55	O
.	O
3	O
%	O
lozenge	O
,	O
54	O
.	O
7	O
%	O
gum	O
)	O
,	O
as	O
well	O
as	O
during	O
the	O
entire	O
study	O
(	O
safety	O
population	O
:	O
63	O
.	O
8	O
%	O
and	O
58	O
.	O
6	O
%	O
,	O
respectively	O
)	O
.	O
Stratification	O
of	O
patients	O
by	O
sex	O
,	O
age	O
,	O
extent	O
of	O
concurrent	O
smoking	O
,	O
extent	O
of	O
product	O
use	O
,	O
and	O
severity	O
of	O
adverse	O
events	O
revealed	O
no	O
clinically	O
significant	O
differences	O
between	O
the	O
lozenge	O
and	O
gum	O
.	O
The	O
most	O
common	O
adverse	O
events	O
were	O
nausea	B-Disease
(	O
17	O
.	O
2	O
%	O
and	O
16	O
.	O
1	O
%	O
;	O
95	O
%	O
CI	O
,	O
-	O
3	O
.	O
7	O
to	O
6	O
.	O
0	O
)	O
,	O
hiccups	B-Disease
(	O
10	O
.	O
7	O
%	O
and	O
6	O
.	O
6	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
5	O
to	O
7	O
.	O
8	O
)	O
,	O
and	O
headache	B-Disease
(	O
8	O
.	O
7	O
%	O
and	O
9	O
.	O
9	O
%	O
;	O
95	O
%	O
Cl	O
,	O
-	O
5	O
.	O
0	O
to	O
2	O
.	O
6	O
)	O
.	O
Serious	O
adverse	O
events	O
were	O
reported	O
in	O
11	O
and	O
13	O
patients	O
in	O
the	O
respective	O
groups	O
.	O
Fewer	O
than	O
6	O
%	O
of	O
patients	O
in	O
either	O
group	O
were	O
considered	O
by	O
the	O
investigator	O
to	O
have	O
a	O
worsening	O
of	O
their	O
overall	O
disease	O
condition	O
during	O
the	O
study	O
.	O
The	O
majority	O
of	O
patients	O
(	O
>	O
60	O
%	O
)	O
experienced	O
no	O
change	O
in	O
their	O
disease	O
status	O
from	O
baseline	O
.	O
CONCLUSION	O
:	O
The	O
4	O
-	O
mg	O
nicotine	B-Chemical
lozenge	O
and	O
4	O
-	O
mg	O
nicotine	B-Chemical
gum	O
had	O
comparable	O
safety	O
profiles	O
in	O
these	O
patients	O
with	O
label	O
-	O
restricted	O
medical	O
conditions	O
.	O
Pharmacological	O
modulation	O
of	O
pain	B-Disease
-	O
related	O
brain	O
activity	O
during	O
normal	O
and	O
central	O
sensitization	O
states	O
in	O
humans	O
.	O
Abnormal	O
processing	O
of	O
somatosensory	O
inputs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
central	O
sensitization	O
)	O
is	O
the	O
mechanism	O
accounting	O
for	O
the	O
enhanced	O
pain	B-Disease
sensitivity	O
in	O
the	O
skin	O
surrounding	O
tissue	B-Disease
injury	I-Disease
(	O
secondary	B-Disease
hyperalgesia	I-Disease
)	O
.	O
Secondary	B-Disease
hyperalgesia	I-Disease
shares	O
clinical	O
characteristics	O
with	O
neurogenic	B-Disease
hyperalgesia	I-Disease
in	O
patients	O
with	O
neuropathic	B-Disease
pain	I-Disease
.	O
Abnormal	O
brain	O
responses	O
to	O
somatosensory	O
stimuli	O
have	O
been	O
found	O
in	O
patients	O
with	O
hyperalgesia	B-Disease
as	O
well	O
as	O
in	O
normal	O
subjects	O
during	O
experimental	O
central	O
sensitization	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
gabapentin	B-Chemical
,	O
a	O
drug	O
effective	O
in	O
neuropathic	B-Disease
pain	I-Disease
patients	O
,	O
on	O
brain	O
processing	O
of	O
nociceptive	O
information	O
in	O
normal	O
and	O
central	O
sensitization	O
states	O
.	O
Using	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
in	O
normal	O
volunteers	O
,	O
we	O
studied	O
the	O
gabapentin	B-Chemical
-	O
induced	O
modulation	O
of	O
brain	O
activity	O
in	O
response	O
to	O
nociceptive	O
mechanical	O
stimulation	O
of	O
normal	O
skin	O
and	O
capsaicin	B-Chemical
-	O
induced	O
secondary	B-Disease
hyperalgesia	I-Disease
.	O
The	O
dose	O
of	O
gabapentin	B-Chemical
was	O
1	O
,	O
800	O
mg	O
per	O
os	O
,	O
in	O
a	O
single	O
administration	O
.	O
We	O
found	O
that	O
(	O
i	O
)	O
gabapentin	B-Chemical
reduced	O
the	O
activations	O
in	O
the	O
bilateral	O
operculoinsular	O
cortex	O
,	O
independently	O
of	O
the	O
presence	O
of	O
central	O
sensitization	O
;	O
(	O
ii	O
)	O
gabapentin	B-Chemical
reduced	O
the	O
activation	O
in	O
the	O
brainstem	O
,	O
only	O
during	O
central	O
sensitization	O
;	O
(	O
iii	O
)	O
gabapentin	B-Chemical
suppressed	O
stimulus	O
-	O
induced	O
deactivations	O
,	O
only	O
during	O
central	O
sensitization	O
;	O
this	O
effect	O
was	O
more	O
robust	O
than	O
the	O
effect	O
on	O
brain	O
activation	O
.	O
The	O
observed	O
drug	O
-	O
induced	O
effects	O
were	O
not	O
due	O
to	O
changes	O
in	O
the	O
baseline	O
fMRI	O
signal	O
.	O
These	O
findings	O
indicate	O
that	O
gabapentin	B-Chemical
has	O
a	O
measurable	O
antinociceptive	O
effect	O
and	O
a	O
stronger	O
antihyperalgesic	O
effect	O
most	O
evident	O
in	O
the	O
brain	O
areas	O
undergoing	O
deactivation	O
,	O
thus	O
supporting	O
the	O
concept	O
that	O
gabapentin	B-Chemical
is	O
more	O
effective	O
in	O
modulating	O
nociceptive	O
transmission	O
when	O
central	O
sensitization	O
is	O
present	O
.	O
Investigation	O
of	O
mitochondrial	O
involvement	O
in	O
the	O
experimental	O
model	O
of	O
epilepsy	B-Disease
induced	O
by	O
pilocarpine	B-Chemical
.	O
Mitochondrial	B-Disease
abnormalities	I-Disease
have	O
been	O
associated	O
with	O
several	O
aspects	O
of	O
epileptogenesis	O
,	O
such	O
as	O
energy	O
generation	O
,	O
control	O
of	O
cell	O
death	B-Disease
,	O
neurotransmitter	O
synthesis	O
,	O
and	O
free	O
radical	O
(	O
FR	O
)	O
production	O
.	O
Increased	O
production	O
of	O
FRs	O
may	O
cause	O
mtDNA	O
damage	O
leading	O
to	O
decreased	O
activities	O
of	O
oxidative	O
phosphorylation	O
complexes	O
containing	O
mtDNA	O
-	O
encoded	O
subunits	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
increased	O
generation	O
of	O
FR	O
during	O
status	B-Disease
epilepticus	I-Disease
would	O
be	O
sufficient	O
to	O
provoke	O
abnormalities	O
in	O
mtDNA	O
and	O
in	O
the	O
expression	O
and	O
activity	O
of	O
cytochrome	O
c	O
oxidase	O
(	O
CCO	O
)	O
,	O
complex	O
IV	O
of	O
the	O
respiratory	O
chain	O
,	O
in	O
the	O
chronic	O
phase	O
of	O
the	O
pilocarpine	B-Chemical
model	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O
DNA	O
analysis	O
revealed	O
low	O
amounts	O
of	O
a	O
4	O
.	O
8	O
kb	O
mtDNA	O
deletion	O
but	O
with	O
no	O
differences	O
in	O
frequency	O
or	O
quantity	O
in	O
the	O
control	O
and	O
experimental	O
groups	O
.	O
We	O
did	O
not	O
find	O
abnormalities	O
in	O
the	O
expression	O
and	O
distribution	O
of	O
an	O
mtDNA	O
-	O
encoded	O
subunit	O
of	O
CCO	O
(	O
CCO	O
-	O
I	O
)	O
or	O
a	O
relative	O
decrease	O
in	O
CCO	O
-	O
I	O
when	O
compared	O
with	O
nuclear	O
-	O
encoded	O
subunits	O
(	O
CCO	O
-	O
IV	O
and	O
SDH	O
-	O
fp	O
)	O
.	O
No	O
abnormality	O
in	O
CCO	O
activity	O
was	O
observed	O
through	O
histochemistry	O
.	O
Although	O
evidences	O
of	O
mitochondrial	B-Disease
abnormalities	I-Disease
were	O
found	O
in	O
previously	O
published	O
studies	O
,	O
our	O
results	O
do	O
not	O
suggest	O
that	O
the	O
FRs	O
,	O
generated	O
during	O
the	O
acute	O
phase	O
,	O
determined	O
important	O
abnormalities	O
in	O
mtDNA	O
,	O
in	O
expression	O
of	O
CCO	O
-	O
I	O
,	O
and	O
in	O
CCO	O
activity	O
.	O
Adverse	O
effect	O
of	O
the	O
calcium	B-Chemical
channel	O
blocker	O
nitrendipine	B-Chemical
on	O
nephrosclerosis	B-Disease
in	O
rats	O
with	O
renovascular	B-Disease
hypertension	I-Disease
.	O
The	O
effect	O
of	O
a	O
6	O
-	O
week	O
treatment	O
with	O
the	O
calcium	B-Chemical
channel	O
blocker	O
nitrendipine	B-Chemical
or	O
the	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
enalapril	B-Chemical
on	O
blood	O
pressure	O
,	O
albuminuria	B-Disease
,	O
renal	O
hemodynamics	O
,	O
and	O
morphology	O
of	O
the	O
nonclipped	O
kidney	O
was	O
studied	O
in	O
rats	O
with	O
two	O
-	O
kidney	O
,	O
one	O
clip	O
renovascular	B-Disease
hypertension	I-Disease
.	O
Six	O
weeks	O
after	O
clipping	O
of	O
one	O
renal	O
artery	O
,	O
hypertensive	B-Disease
rats	O
(	O
178	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
)	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
:	O
untreated	O
hypertensive	B-Disease
controls	O
(	O
n	O
=	O
8	O
)	O
,	O
enalapril	B-Chemical
-	O
treated	O
(	O
n	O
=	O
8	O
)	O
,	O
or	O
nitrendipine	B-Chemical
-	O
treated	O
(	O
n	O
=	O
10	O
)	O
.	O
Sham	O
-	O
operated	O
rats	O
served	O
as	O
normotensive	O
controls	O
(	O
128	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
n	O
=	O
8	O
)	O
.	O
After	O
6	O
weeks	O
of	O
treatment	O
,	O
renal	O
hemodynamics	O
(	O
glomerular	O
filtration	O
rate	O
and	O
renal	O
plasma	O
flow	O
)	O
were	O
measured	O
in	O
the	O
anesthetized	O
rats	O
.	O
Renal	O
tissue	O
was	O
obtained	O
for	O
determination	O
of	O
glomerular	O
size	O
and	O
sclerosis	O
.	O
Enalapril	B-Chemical
but	O
not	O
nitrendipine	B-Chemical
reduced	O
blood	O
pressure	O
significantly	O
.	O
After	O
6	O
weeks	O
of	O
therapy	O
,	O
glomerular	O
filtration	O
rate	O
was	O
not	O
different	O
among	O
the	O
studied	O
groups	O
.	O
Renal	O
plasma	O
flow	O
increased	O
,	O
but	O
albumin	O
excretion	O
and	O
glomerulosclerosis	B-Disease
did	O
not	O
change	O
after	O
enalapril	B-Chemical
treatment	O
.	O
In	O
contrast	O
,	O
in	O
the	O
nitrendipine	B-Chemical
-	O
treated	O
group	O
albuminuria	B-Disease
increased	O
from	O
12	O
.	O
8	O
+	O
/	O
-	O
2	O
progressively	O
to	O
163	O
+	O
/	O
-	O
55	O
compared	O
with	O
19	O
.	O
2	O
+	O
/	O
-	O
9	O
mg	O
/	O
24	O
hr	O
in	O
the	O
hypertensive	B-Disease
controls	O
.	O
Furthermore	O
,	O
glomerulosclerosis	B-Disease
index	O
was	O
significantly	O
increased	O
in	O
the	O
nitrendipine	B-Chemical
-	O
treated	O
group	O
compared	O
with	O
the	O
hypertensive	B-Disease
controls	O
(	O
0	O
.	O
38	O
+	O
/	O
-	O
0	O
.	O
1	O
versus	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
04	O
)	O
.	O
In	O
addition	O
,	O
glomerular	O
size	O
was	O
higher	O
in	O
the	O
nitrendipine	B-Chemical
-	O
treated	O
group	O
(	O
14	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
but	O
lower	O
in	O
the	O
enalapril	B-Chemical
-	O
treated	O
group	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
15	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
compared	O
with	O
the	O
hypertensive	B-Disease
controls	O
(	O
12	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Ketoconazole	B-Chemical
induced	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
without	O
concomitant	O
use	O
of	O
QT	O
interval	O
-	O
prolonging	O
drug	O
.	O
Ketoconazole	B-Chemical
is	O
not	O
known	O
to	O
be	O
proarrhythmic	O
without	O
concomitant	O
use	O
of	O
QT	O
interval	O
-	O
prolonging	O
drugs	O
.	O
We	O
report	O
a	O
woman	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
who	O
developed	O
a	O
markedly	O
prolonged	B-Disease
QT	I-Disease
interval	I-Disease
and	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
(	O
TdP	B-Disease
)	O
after	O
taking	O
ketoconazole	B-Chemical
for	O
treatment	O
of	O
fungal	B-Disease
infection	I-Disease
.	O
Her	O
QT	O
interval	O
returned	O
to	O
normal	O
upon	O
withdrawal	O
of	O
ketoconazole	B-Chemical
.	O
Genetic	O
study	O
did	O
not	O
find	O
any	O
mutation	O
in	O
her	O
genes	O
that	O
encode	O
cardiac	O
IKr	O
channel	O
proteins	O
.	O
We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	O
blocking	O
action	O
on	O
IKr	O
,	O
ketoconazole	B-Chemical
alone	O
may	O
prolong	O
QT	O
interval	O
and	O
induce	O
TdP	B-Disease
.	O
This	O
calls	O
for	O
attention	O
when	O
ketoconazole	B-Chemical
is	O
administered	O
to	O
patients	O
with	O
risk	O
factors	O
for	O
acquired	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
.	O
Cerebral	B-Disease
vasculitis	I-Disease
following	O
oral	O
methylphenidate	B-Chemical
intake	O
in	O
an	O
adult	O
:	O
a	O
case	O
report	O
.	O
Methylphenidate	B-Chemical
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
amphetamine	B-Chemical
.	O
Cerebral	B-Disease
vasculitis	I-Disease
associated	O
with	O
amphetamine	B-Disease
abuse	I-Disease
is	O
well	O
documented	O
,	O
and	O
in	O
rare	O
cases	O
ischaemic	B-Disease
stroke	I-Disease
has	O
been	O
reported	O
after	O
methylphenidate	B-Chemical
intake	O
in	O
children	O
.	O
We	O
report	O
the	O
case	O
of	O
a	O
63	O
-	O
year	O
-	O
old	O
female	O
who	O
was	O
treated	O
with	O
methylphenidate	B-Chemical
due	O
to	O
hyperactivity	B-Disease
and	O
suffered	O
from	O
multiple	O
ischaemic	B-Disease
strokes	I-Disease
.	O
We	O
consider	O
drug	O
-	O
induced	O
cerebral	B-Disease
vasculitis	I-Disease
as	O
the	O
most	O
likely	O
cause	O
of	O
recurrent	O
ischaemic	B-Disease
strokes	I-Disease
in	O
the	O
absence	O
of	O
any	O
pathological	O
findings	O
during	O
the	O
diagnostic	O
work	O
-	O
up	O
.	O
We	O
conclude	O
that	O
methylphenidate	B-Chemical
mediated	O
vasculitis	B-Disease
should	O
be	O
considered	O
in	O
patients	O
with	O
neurological	O
symptoms	O
and	O
a	O
history	O
of	O
methylphenidate	B-Chemical
therapy	O
.	O
This	O
potential	O
side	O
-	O
effect	O
,	O
though	O
very	O
rare	O
,	O
represents	O
one	O
more	O
reason	O
to	O
be	O
very	O
restrictive	O
in	O
the	O
use	O
of	O
methylphenidate	B-Chemical
.	O
MDMA	B-Chemical
polydrug	O
users	O
show	O
process	O
-	O
specific	O
central	O
executive	O
impairments	O
coupled	O
with	O
impaired	B-Disease
social	I-Disease
and	I-Disease
emotional	I-Disease
judgement	I-Disease
processes	I-Disease
.	O
In	O
recent	O
years	O
working	O
memory	B-Disease
deficits	I-Disease
have	O
been	O
reported	O
in	O
users	O
of	O
MDMA	B-Chemical
(	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
methylenedioxymethamphetamine	I-Chemical
,	O
ecstasy	B-Chemical
)	O
.	O
The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
MDMA	B-Chemical
use	O
on	O
three	O
separate	O
central	O
executive	O
processes	O
(	O
set	O
shifting	O
,	O
inhibition	O
and	O
memory	O
updating	O
)	O
and	O
also	O
on	O
""""	O
prefrontal	O
""""	O
mediated	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O
Fifteen	O
polydrug	O
ecstasy	B-Chemical
users	O
and	O
15	O
polydrug	O
non	O
-	O
ecstasy	B-Chemical
user	O
controls	O
completed	O
a	O
general	O
drug	O
use	O
questionnaire	O
,	O
the	O
Brixton	O
Spatial	O
Anticipation	O
task	O
(	O
set	O
shifting	O
)	O
,	O
Backward	O
Digit	O
Span	O
procedure	O
(	O
memory	O
updating	O
)	O
,	O
Inhibition	O
of	O
Return	O
(	O
inhibition	O
)	O
,	O
an	O
emotional	O
intelligence	O
scale	O
,	O
the	O
Tromso	O
Social	O
Intelligence	O
Scale	O
and	O
the	O
Dysexecutive	O
Questionnaire	O
(	O
DEX	O
)	O
.	O
Compared	O
with	O
MDMA	B-Chemical
-	O
free	O
polydrug	O
controls	O
,	O
MDMA	B-Chemical
polydrug	O
users	O
showed	O
impairments	O
in	O
set	O
shifting	O
and	O
memory	O
updating	O
,	O
and	O
also	O
in	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O
The	O
latter	O
two	O
deficits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
drug	O
use	O
.	O
These	O
data	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitive	O
processes	O
mediated	O
by	O
the	O
prefrontal	O
cortex	O
may	O
be	O
impaired	O
by	O
recreational	O
ecstasy	B-Chemical
use	O
.	O
Phase	O
II	O
study	O
of	O
the	O
amsacrine	B-Chemical
analogue	O
CI	B-Chemical
-	I-Chemical
921	I-Chemical
(	O
NSC	B-Chemical
343499	I-Chemical
)	O
in	O
non	B-Disease
-	I-Disease
small	I-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
.	O
CI	B-Chemical
-	I-Chemical
921	I-Chemical
(	O
NSC	B-Chemical
343499	I-Chemical
;	O
9	B-Chemical
-	I-Chemical
[	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
[	I-Chemical
(	I-Chemical
methylsulphonyl	I-Chemical
)	I-Chemical
amino	I-Chemical
]	I-Chemical
phenyl	I-Chemical
]	I-Chemical
amino	I-Chemical
]	I-Chemical
-	I-Chemical
N	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
dimethyl	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
acridinecarboxamide	I-Chemical
)	O
is	O
a	O
topoisomerase	O
II	O
poison	O
with	O
high	O
experimental	O
antitumour	O
activity	O
.	O
It	O
was	O
administered	O
by	O
15	O
min	O
infusion	O
to	O
16	O
evaluable	O
patients	O
with	O
non	B-Disease
-	I-Disease
small	I-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
(	O
NSCLC	B-Disease
)	O
(	O
7	O
with	O
no	O
prior	O
treatment	O
,	O
9	O
patients	O
in	O
relapse	O
following	O
surgery	O
/	O
radiotherapy	O
)	O
at	O
a	O
dose	O
(	O
648	O
mg	O
/	O
m2	O
divided	O
over	O
3	O
days	O
,	O
repeated	O
every	O
3	O
weeks	O
)	O
determined	O
by	O
phase	O
I	O
trial	O
.	O
Patients	O
had	O
a	O
median	O
performance	O
status	O
of	O
1	O
(	O
WHO	O
)	O
,	O
and	O
median	O
age	O
of	O
61	O
years	O
.	O
The	O
histology	O
comprised	O
squamous	B-Disease
carcinoma	I-Disease
(	O
11	O
)	O
,	O
adenocarcinoma	B-Disease
(	O
1	O
)	O
,	O
mixed	O
histology	O
(	O
2	O
)	O
,	O
bronchio	B-Disease
-	I-Disease
alveolar	I-Disease
carcinoma	I-Disease
(	O
1	O
)	O
and	O
large	O
cell	O
undifferentiated	B-Disease
carcinoma	I-Disease
(	O
1	O
)	O
.	O
Neutropenia	B-Disease
grade	O
greater	O
than	O
or	O
equal	O
to	O
3	O
was	O
seen	O
in	O
15	O
patients	O
,	O
infections	B-Disease
with	O
recovery	O
in	O
3	O
,	O
and	O
grand	O
mal	O
seizures	B-Disease
in	O
1	O
patient	O
.	O
Grade	O
less	O
than	O
or	O
equal	O
to	O
2	O
nausea	B-Disease
and	O
vomiting	B-Disease
occurred	O
in	O
66	O
%	O
courses	O
and	O
phlebitis	B-Disease
in	O
the	O
infusion	O
arm	O
in	O
37	O
%	O
.	O
1	O
patient	O
with	O
squamous	B-Disease
cell	I-Disease
carcinoma	I-Disease
achieved	O
a	O
partial	O
response	O
lasting	O
5	O
months	O
.	O
Further	O
testing	O
in	O
this	O
and	O
other	O
tumour	B-Disease
types	O
using	O
multiple	O
daily	O
schedules	O
is	O
warranted	O
.	O
Pharmacokinetics	O
of	O
desipramine	B-Chemical
HCl	I-Chemical
when	O
administered	O
with	O
cinacalcet	B-Chemical
HCl	I-Chemical
.	O
OBJECTIVE	O
:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinacalcet	B-Chemical
is	O
a	O
strong	O
inhibitor	O
of	O
cytochrome	O
P450	O
isoenzyme	O
(	O
CYP	O
)	O
2D6	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
cinacalcet	B-Chemical
on	O
CYP2D6	O
activity	O
,	O
using	O
desipramine	B-Chemical
as	O
a	O
probe	O
substrate	O
,	O
in	O
healthy	O
subjects	O
.	O
METHODS	O
:	O
Seventeen	O
subjects	O
who	O
were	O
genotyped	O
as	O
CYP2D6	O
extensive	O
metabolizers	O
were	O
enrolled	O
in	O
this	O
randomized	O
,	O
open	O
-	O
label	O
,	O
crossover	O
study	O
to	O
receive	O
a	O
single	O
oral	O
dose	O
of	O
desipramine	B-Chemical
(	O
50	O
mg	O
)	O
on	O
two	O
separate	O
occasions	O
,	O
once	O
alone	O
and	O
once	O
after	O
multiple	O
doses	O
of	O
cinacalcet	B-Chemical
(	O
90	O
mg	O
for	O
7	O
days	O
)	O
.	O
Blood	O
samples	O
were	O
obtained	O
predose	O
and	O
up	O
to	O
72	O
h	O
postdose	O
.	O
RESULTS	O
:	O
Fourteen	O
subjects	O
completed	O
both	O
treatment	O
arms	O
.	O
Relative	O
to	O
desipramine	B-Chemical
alone	O
,	O
mean	O
AUC	O
and	O
C	O
(	O
max	O
)	O
of	O
desipramine	B-Chemical
increased	O
3	O
.	O
6	O
-	O
and	O
1	O
.	O
8	O
-	O
fold	O
when	O
coadministered	O
with	O
cinacalcet	B-Chemical
.	O
The	O
t	O
(	O
1	O
/	O
2	O
,	O
z	O
)	O
of	O
desipramine	B-Chemical
was	O
longer	O
when	O
desipramine	B-Chemical
was	O
coadministered	O
with	O
cinacalcet	B-Chemical
(	O
21	O
.	O
0	O
versus	O
43	O
.	O
3	O
hs	O
)	O
.	O
The	O
t	O
(	O
max	O
)	O
was	O
similar	O
between	O
the	O
regimens	O
.	O
Fewer	O
subjects	O
reported	O
adverse	O
events	O
following	O
treatment	O
with	O
desipramine	B-Chemical
alone	O
than	O
when	O
receiving	O
desipramine	B-Chemical
with	O
cinacalcet	B-Chemical
(	O
33	O
versus	O
86	O
%	O
)	O
,	O
the	O
most	O
frequent	O
of	O
which	O
(	O
nausea	B-Disease
and	O
headache	B-Disease
)	O
have	O
been	O
reported	O
for	O
patients	O
treated	O
with	O
either	O
desipramine	B-Chemical
or	O
cinacalcet	B-Chemical
.	O
CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
that	O
cinacalcet	B-Chemical
is	O
a	O
strong	O
inhibitor	O
of	O
CYP2D6	O
.	O
These	O
data	O
suggest	O
that	O
during	O
concomitant	O
treatment	O
with	O
cinacalcet	B-Chemical
,	O
dose	O
adjustment	O
may	O
be	O
necessary	O
for	O
drugs	O
that	O
demonstrate	O
a	O
narrow	O
therapeutic	O
index	O
and	O
are	O
metabolized	O
by	O
CYP2D6	O
.	O
Case	O
report	O
:	O
acute	O
unintentional	O
carbachol	B-Chemical
intoxication	O
.	O
INTRODUCTION	O
:	O
Intoxications	O
with	O
carbachol	B-Chemical
,	O
a	O
muscarinic	O
cholinergic	O
receptor	O
agonist	O
are	O
rare	O
.	O
We	O
report	O
an	O
interesting	O
case	O
investigating	O
a	O
(	O
near	O
)	O
fatal	O
poisoning	B-Disease
.	O
METHODS	O
:	O
The	O
son	O
of	O
an	O
84	O
-	O
year	O
-	O
old	O
male	O
discovered	O
a	O
newspaper	O
report	O
stating	O
clinical	O
success	O
with	O
plant	O
extracts	O
in	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
The	O
mode	O
of	O
action	O
was	O
said	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
synthetic	O
compound	O
'	O
carbamylcholin	B-Chemical
'	O
;	O
that	O
is	O
,	O
carbachol	B-Chemical
.	O
He	O
bought	O
25	O
g	O
of	O
carbachol	B-Chemical
as	O
pure	O
substance	O
in	O
a	O
pharmacy	O
,	O
and	O
the	O
father	O
was	O
administered	O
400	O
to	O
500	O
mg	O
.	O
Carbachol	B-Chemical
concentrations	O
in	O
serum	O
and	O
urine	O
on	O
day	O
1	O
and	O
2	O
of	O
hospital	O
admission	O
were	O
analysed	O
by	O
HPLC	O
-	O
mass	O
spectrometry	O
.	O
RESULTS	O
:	O
Minutes	O
after	O
oral	O
administration	O
,	O
the	O
patient	O
developed	O
nausea	B-Disease
,	O
sweating	O
and	O
hypotension	B-Disease
,	O
and	O
finally	O
collapsed	O
.	O
Bradycardia	B-Disease
,	O
cholinergic	O
symptoms	O
and	O
asystole	B-Disease
occurred	O
.	O
Initial	O
cardiopulmonary	O
resuscitation	O
and	O
immediate	O
treatment	O
with	O
adrenaline	B-Chemical
(	O
epinephrine	B-Chemical
)	O
,	O
atropine	B-Chemical
and	O
furosemide	B-Chemical
was	O
successful	O
.	O
On	O
hospital	O
admission	O
,	O
blood	O
pressure	O
of	O
the	O
intubated	O
,	O
bradyarrhythmic	O
patient	O
was	O
100	O
/	O
65	O
mmHg	O
.	O
Further	O
signs	O
were	O
hyperhidrosis	B-Disease
,	O
hypersalivation	B-Disease
,	O
bronchorrhoea	B-Disease
,	O
and	O
severe	O
miosis	B-Disease
;	O
the	O
electrocardiographic	O
finding	O
was	O
atrio	B-Disease
-	I-Disease
ventricular	I-Disease
dissociation	I-Disease
.	O
High	O
doses	O
of	O
atropine	B-Chemical
(	O
up	O
to	O
50	O
mg	O
per	O
24	O
hours	O
)	O
,	O
adrenaline	B-Chemical
and	O
dopamine	B-Chemical
were	O
necessary	O
.	O
The	O
patient	O
was	O
extubated	O
1	O
week	O
later	O
.	O
However	O
,	O
increased	O
dyspnoea	B-Disease
and	O
bronchospasm	B-Disease
necessitated	O
reintubation	O
.	O
Respiratory	B-Disease
insufficiency	I-Disease
was	O
further	O
worsened	O
by	O
Proteus	B-Disease
mirabilis	I-Disease
infection	I-Disease
and	O
severe	O
bronchoconstriction	O
.	O
One	O
week	O
later	O
,	O
the	O
patient	O
was	O
again	O
extubated	O
and	O
3	O
days	O
later	O
was	O
transferred	O
to	O
a	O
peripheral	O
ward	O
.	O
On	O
the	O
next	O
day	O
he	O
died	O
,	O
probably	O
as	O
a	O
result	O
of	O
heart	B-Disease
failure	I-Disease
.	O
Serum	O
samples	O
from	O
the	O
first	O
and	O
second	O
days	O
contained	O
3	O
.	O
6	O
and	O
1	O
.	O
9	O
mg	O
/	O
l	O
carbachol	B-Chemical
,	O
respectively	O
.	O
The	O
corresponding	O
urine	O
concentrations	O
amounted	O
to	O
374	O
and	O
554	O
mg	O
/	O
l	O
.	O
CONCLUSION	O
:	O
This	O
case	O
started	O
with	O
a	O
media	O
report	O
in	O
a	O
popular	O
newspaper	O
,	O
initiated	O
by	O
published	O
,	O
peer	O
-	O
reviewed	O
research	O
on	O
herbals	O
,	O
and	O
involved	O
human	O
failure	O
in	O
a	O
case	O
history	O
,	O
medical	O
examination	O
and	O
clinical	O
treatment	O
.	O
For	O
the	O
first	O
time	O
,	O
an	O
analytical	O
method	O
for	O
the	O
determination	O
of	O
carbachol	B-Chemical
in	O
plasma	O
and	O
urine	O
has	O
been	O
developed	O
.	O
The	O
analysed	O
carbachol	B-Chemical
concentration	O
exceeded	O
the	O
supposed	O
serum	O
level	O
resulting	O
from	O
a	O
therapeutic	O
dose	O
by	O
a	O
factor	O
of	O
130	O
to	O
260	O
.	O
Especially	O
in	O
old	O
patients	O
,	O
intensivists	O
should	O
consider	O
intoxications	O
(	O
with	O
cholinergics	O
)	O
as	O
a	O
cause	O
of	O
acute	B-Disease
cardiovascular	I-Disease
failure	I-Disease
.	O
Pharmacological	O
evidence	O
for	O
the	O
potential	O
of	O
Daucus	O
carota	O
in	O
the	O
management	O
of	O
cognitive	B-Disease
dysfunctions	I-Disease
.	O
The	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
effects	O
of	O
Daucus	O
carota	O
seeds	O
on	O
cognitive	O
functions	O
,	O
total	O
serum	O
cholesterol	B-Chemical
levels	O
and	O
brain	O
cholinesterase	O
activity	O
in	O
mice	O
.	O
The	O
ethanolic	O
extract	B-Chemical
of	I-Chemical
Daucus	I-Chemical
carota	I-Chemical
seeds	I-Chemical
(	O
DCE	B-Chemical
)	O
was	O
administered	O
orally	O
in	O
three	O
doses	O
(	O
100	O
,	O
200	O
,	O
400	O
mg	O
/	O
kg	O
)	O
for	O
seven	O
successive	O
days	O
to	O
different	O
groups	O
of	O
young	O
and	O
aged	O
mice	O
.	O
Elevated	O
plus	O
maze	O
and	O
passive	O
avoidance	O
apparatus	O
served	O
as	O
the	O
exteroceptive	O
behavioral	O
models	O
for	O
testing	O
memory	O
.	O
Diazepam	B-Chemical
-	O
,	O
scopolamine	B-Chemical
-	O
and	O
ageing	O
-	O
induced	O
amnesia	B-Disease
served	O
as	O
the	O
interoceptive	O
behavioral	O
models	O
.	O
DCE	B-Chemical
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
showed	O
significant	O
improvement	O
in	O
memory	O
scores	O
of	O
young	O
and	O
aged	O
mice	O
.	O
The	O
extent	O
of	O
memory	O
improvement	O
evoked	O
by	O
DCE	B-Chemical
was	O
23	O
%	O
at	O
the	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
and	O
35	O
%	O
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
in	O
young	O
mice	O
using	O
elevated	O
plus	O
maze	O
.	O
Similarly	O
,	O
significant	O
improvements	O
in	O
memory	O
scores	O
were	O
observed	O
using	O
passive	O
avoidance	O
apparatus	O
and	O
aged	O
mice	O
.	O
Furthermore	O
,	O
DCE	B-Chemical
reversed	O
the	O
amnesia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
and	O
diazepam	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O
Daucus	B-Chemical
carota	I-Chemical
extract	I-Chemical
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
reduced	O
significantly	O
the	O
brain	O
acetylcholinesterase	O
activity	O
and	O
cholesterol	B-Chemical
levels	O
in	O
young	O
and	O
aged	O
mice	O
.	O
The	O
extent	O
of	O
inhibition	O
of	O
brain	O
cholinesterase	O
activity	O
evoked	O
by	O
DCE	B-Chemical
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
was	O
22	O
%	O
in	O
young	O
and	O
19	O
%	O
in	O
aged	O
mice	O
.	O
There	O
was	O
a	O
remarkable	O
reduction	O
in	O
total	O
cholesterol	B-Chemical
level	O
as	O
well	O
,	O
to	O
the	O
extent	O
of	O
23	O
%	O
in	O
young	O
and	O
21	O
%	O
in	O
aged	O
animals	O
with	O
this	O
dose	O
of	O
DCE	B-Chemical
.	O
Therefore	O
,	O
DCE	B-Chemical
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
management	O
of	O
cognitive	B-Disease
dysfunctions	I-Disease
on	O
account	O
of	O
its	O
multifarious	O
beneficial	O
effects	O
such	O
as	O
,	O
memory	O
improving	O
property	O
,	O
cholesterol	B-Chemical
lowering	O
property	O
and	O
anticholinesterase	O
activity	O
.	O
Valproic	B-Chemical
acid	I-Chemical
induced	O
encephalopathy	B-Disease
-	O
-	O
19	O
new	O
cases	O
in	O
Germany	O
from	O
1994	O
to	O
2003	O
-	O
-	O
a	O
side	O
effect	O
associated	O
to	O
VPA	B-Chemical
-	O
therapy	O
not	O
only	O
in	O
young	O
children	O
.	O
Valproic	B-Chemical
acid	I-Chemical
(	O
VPA	B-Chemical
)	O
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
and	O
is	O
usually	O
well	O
-	O
tolerated	O
.	O
Rare	O
serious	O
complications	O
may	O
occur	O
in	O
some	O
patients	O
,	O
including	O
haemorrhagic	O
pancreatitis	B-Disease
,	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
,	O
VPA	B-Chemical
-	O
induced	O
hepatotoxicity	B-Disease
and	O
VPA	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
.	O
The	O
typical	O
signs	O
of	O
VPA	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
are	O
impaired	B-Disease
consciousness	I-Disease
,	O
sometimes	O
marked	O
EEG	O
background	O
slowing	O
,	O
increased	O
seizure	B-Disease
frequency	O
,	O
with	O
or	O
without	O
hyperammonemia	B-Disease
.	O
There	O
is	O
still	O
no	O
proof	O
of	O
causative	O
effect	O
of	O
VPA	B-Chemical
in	O
patients	O
with	O
encephalopathy	B-Disease
,	O
but	O
only	O
of	O
an	O
association	O
with	O
an	O
assumed	O
causal	O
relation	O
.	O
We	O
report	O
19	O
patients	O
with	O
VPA	B-Chemical
-	O
associated	O
encephalopathy	B-Disease
in	O
Germany	O
from	O
the	O
years	O
1994	O
to	O
2003	O
,	O
none	O
of	O
whom	O
had	O
been	O
published	O
previously	O
.	O
Cerebral	B-Disease
haemorrhage	I-Disease
induced	O
by	O
warfarin	B-Chemical
-	O
the	O
influence	O
of	O
drug	O
-	O
drug	O
interactions	O
.	O
PURPOSE	O
:	O
To	O
evaluate	O
the	O
frequency	O
,	O
severity	O
and	O
preventability	O
of	O
warfarin	B-Chemical
-	O
induced	O
cerebral	B-Disease
haemorrhages	I-Disease
due	O
to	O
warfarin	B-Chemical
and	O
warfarin	B-Chemical
-	O
drug	O
interactions	O
in	O
patients	O
living	O
in	O
the	O
county	O
of	O
Osterg	O
tland	O
,	O
Sweden	O
.	O
METHODS	O
:	O
All	O
patients	O
with	O
a	O
diagnosed	O
cerebral	B-Disease
haemorrhage	I-Disease
at	O
three	O
hospitals	O
during	O
the	O
period	O
2000	O
-	O
2002	O
were	O
identified	O
.	O
Medical	O
records	O
were	O
studied	O
retrospectively	O
to	O
evaluate	O
whether	O
warfarin	B-Chemical
and	O
warfarin	B-Chemical
-	O
drug	O
interactions	O
could	O
have	O
caused	O
the	O
cerebral	B-Disease
haemorrhage	I-Disease
.	O
The	O
proportion	O
of	O
possibly	O
avoidable	O
cases	O
due	O
to	O
drug	O
interactions	O
was	O
estimated	O
.	O
RESULTS	O
:	O
Among	O
593	O
patients	O
with	O
cerebral	B-Disease
haemorrhage	I-Disease
,	O
59	O
(	O
10	O
%	O
)	O
were	O
assessed	O
as	O
related	O
to	O
warfarin	B-Chemical
treatment	O
.	O
This	O
imply	O
an	O
incidence	O
of	O
1	O
.	O
7	O
/	O
100	O
,	O
000	O
treatment	O
years	O
.	O
Of	O
the	O
59	O
cases	O
,	O
26	O
(	O
44	O
%	O
)	O
had	O
a	O
fatal	O
outcome	O
,	O
compared	O
to	O
136	O
(	O
25	O
%	O
)	O
among	O
the	O
non	O
-	O
warfarin	B-Chemical
patients	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
A	O
warfarin	B-Chemical
-	O
drug	O
interaction	O
could	O
have	O
contributed	O
to	O
the	O
haemorrhage	B-Disease
in	O
24	O
(	O
41	O
%	O
)	O
of	O
the	O
warfarin	B-Chemical
patients	O
and	O
in	O
7	O
of	O
these	O
(	O
12	O
%	O
)	O
the	O
bleeding	B-Disease
complication	O
was	O
considered	O
being	O
possible	O
to	O
avoid	O
.	O
CONCLUSIONS	O
:	O
Warfarin	B-Chemical
-	O
induced	O
cerebral	B-Disease
haemorrhages	I-Disease
are	O
a	O
major	O
clinical	O
problem	O
with	O
a	O
high	O
fatality	O
rate	O
.	O
Almost	O
half	O
of	O
the	O
cases	O
was	O
related	O
to	O
a	O
warfarin	B-Chemical
-	O
drug	O
interaction	O
.	O
A	O
significant	O
proportion	O
of	O
warfarin	B-Chemical
-	O
related	O
cerebral	B-Disease
haemorrhages	I-Disease
might	O
have	O
been	O
prevented	O
if	O
greater	O
caution	O
had	O
been	O
taken	O
when	O
prescribing	O
drugs	O
known	O
to	O
interact	O
with	O
warfarin	B-Chemical
.	O
Antipsychotic	O
-	O
like	O
profile	O
of	O
thioperamide	B-Chemical
,	O
a	O
selective	O
H3	O
-	O
receptor	O
antagonist	O
in	O
mice	O
.	O
Experimental	O
and	O
clinical	O
evidence	O
points	O
to	O
a	O
role	O
of	O
central	O
histaminergic	O
system	O
in	O
the	O
pathogenesis	O
of	O
schizophrenia	B-Disease
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
study	O
the	O
effect	O
of	O
histamine	B-Chemical
H	O
(	O
3	O
)	O
-	O
receptor	O
ligands	O
on	O
neuroleptic	O
-	O
induced	O
catalepsy	B-Disease
,	O
apomorphine	B-Chemical
-	O
induced	O
climbing	O
behavior	O
and	O
amphetamine	B-Chemical
-	O
induced	O
locomotor	O
activities	O
in	O
mice	O
.	O
Catalepsy	B-Disease
was	O
induced	O
by	O
haloperidol	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
,	O
while	O
apomorphine	B-Chemical
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
and	O
amphetamine	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
were	O
used	O
for	O
studying	O
climbing	O
behavior	O
and	O
locomotor	O
activities	O
,	O
respectively	O
.	O
(	B-Chemical
R	I-Chemical
)	I-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
methylhistamine	I-Chemical
(	O
RAMH	B-Chemical
)	O
(	O
5	O
microg	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
and	O
thioperamide	B-Chemical
(	O
THP	B-Chemical
)	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
,	O
per	O
se	O
did	O
not	O
cause	O
catalepsy	B-Disease
.	O
Administration	O
of	O
THP	B-Chemical
(	O
3	O
.	O
75	O
,	O
7	O
.	O
5	O
and	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
1	O
h	O
prior	O
to	O
haloperidol	B-Chemical
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
catalepsy	B-Disease
times	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
However	O
,	O
pretreatment	O
with	O
RAMH	B-Chemical
significantly	O
reversed	O
such	O
an	O
effect	O
of	O
THP	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O
RAMH	B-Chemical
per	O
se	O
showed	O
significant	O
reduction	O
in	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
but	O
THP	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
per	O
se	O
had	O
no	O
effect	O
on	O
these	O
parameters	O
.	O
On	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
,	O
THP	B-Chemical
(	O
3	O
.	O
75	O
and	O
7	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
reduced	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Pretreatment	O
with	O
RAMH	B-Chemical
(	O
5	O
microg	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
could	O
partially	O
reverse	O
such	O
effects	O
of	O
THP	B-Chemical
(	O
3	O
.	O
75	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O
Climbing	O
behavior	O
induced	O
by	O
apomorphine	B-Chemical
was	O
reduced	O
in	O
animals	O
treated	O
with	O
THP	B-Chemical
.	O
Such	O
an	O
effect	O
was	O
,	O
however	O
,	O
reversed	O
in	O
presence	O
of	O
RAMH	B-Chemical
.	O
THP	B-Chemical
exhibited	O
an	O
antipsychotic	O
-	O
like	O
profile	O
by	O
potentiating	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
,	O
reducing	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
and	O
reducing	O
apomorphine	B-Chemical
-	O
induced	O
climbing	O
in	O
mice	O
.	O
Such	O
effects	O
of	O
THP	B-Chemical
were	O
reversed	O
by	O
RAMH	B-Chemical
indicating	O
the	O
involvement	O
of	O
histamine	B-Chemical
H	O
(	O
3	O
)	O
-	O
receptors	O
.	O
Findings	O
suggest	O
a	O
potential	O
for	O
H	O
(	O
3	O
)	O
-	O
receptor	O
antagonists	O
in	O
improving	O
the	O
refractory	O
cases	O
of	O
schizophrenia	B-Disease
.	O
Cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
after	O
epidural	O
steroid	B-Chemical
injection	O
:	O
a	O
case	O
report	O
.	O
OBJECTIVE	O
:	O
Conventional	O
treatment	O
methods	O
of	O
lumbusacral	O
radiculopathy	B-Disease
are	O
physical	O
therapy	O
,	O
epidural	O
steroid	B-Chemical
injections	O
,	O
oral	O
medications	O
,	O
and	O
spinal	O
manipulative	O
therapy	O
.	O
Cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
complication	O
of	O
epidural	O
anesthesia	O
.	O
The	O
following	O
case	O
is	O
a	O
report	O
of	O
cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
possibly	O
caused	O
by	O
epidural	O
injection	O
of	O
triamcinolone	B-Chemical
and	O
bupivacaine	B-Chemical
.	O
CLINICAL	O
FEATURES	O
:	O
A	O
50	O
-	O
year	O
-	O
old	O
woman	O
with	O
low	B-Disease
back	I-Disease
and	I-Disease
right	I-Disease
leg	I-Disease
pain	I-Disease
was	O
scheduled	O
for	O
epidural	O
steroid	B-Chemical
injection	O
.	O
INTERVENTION	O
AND	O
OUTCOME	O
:	O
An	O
18	O
-	O
gauge	O
Touhy	O
needle	O
was	O
inserted	O
until	O
loss	O
of	O
resistance	O
occurred	O
at	O
the	O
L4	O
-	O
5	O
level	O
.	O
Spread	O
of	O
the	O
contrast	O
medium	O
within	O
the	O
epidural	O
space	O
was	O
determined	O
by	O
radiographic	O
imaging	O
.	O
After	O
verifying	O
the	O
epidural	O
space	O
,	O
bupivacaine	B-Chemical
and	O
triamcinolone	B-Chemical
diacetate	I-Chemical
were	O
injected	O
.	O
After	O
the	O
injection	O
,	O
there	O
was	O
a	O
reduction	O
in	O
radicular	O
symptoms	O
.	O
Three	O
hours	O
later	O
,	O
she	O
complained	O
of	O
perineal	O
numbness	B-Disease
and	O
lower	B-Disease
extremity	I-Disease
weakness	I-Disease
.	O
The	O
neurologic	O
evaluation	O
revealed	O
loss	B-Disease
of	I-Disease
sensation	I-Disease
in	O
the	O
saddle	O
area	O
and	O
medial	O
aspect	O
of	O
her	O
right	O
leg	O
.	O
There	O
was	O
a	O
decrease	O
in	O
the	O
perception	O
of	O
pinprick	O
test	O
.	O
Deep	O
-	O
tendon	O
reflexes	O
were	O
decreased	O
especially	O
in	O
the	O
right	O
leg	O
.	O
She	O
was	O
unable	O
to	O
urinate	O
.	O
The	O
patient	O
'	O
s	O
symptoms	O
improved	O
slightly	O
over	O
the	O
next	O
few	O
hours	O
.	O
She	O
had	O
a	O
gradual	O
return	O
of	O
motor	O
function	O
and	O
ability	O
of	O
feeling	O
Foley	O
catheter	O
.	O
All	O
of	O
the	O
symptoms	O
were	O
completely	O
resolved	O
over	O
the	O
next	O
8	O
hours	O
.	O
CONCLUSION	O
:	O
Complications	O
associated	O
with	O
epidural	O
steroid	B-Chemical
injections	O
are	O
rare	O
.	O
Clinical	O
examination	O
and	O
continued	O
vigilance	O
for	O
neurologic	B-Disease
deterioration	I-Disease
after	O
epidural	O
steroid	B-Chemical
injections	O
is	O
important	O
.	O
High	O
-	O
dose	O
testosterone	B-Chemical
is	O
associated	O
with	O
atherosclerosis	B-Disease
in	O
postmenopausal	O
women	O
.	O
OBJECTIVES	O
:	O
To	O
study	O
the	O
long	O
-	O
term	O
effects	O
of	O
androgen	O
treatment	O
on	O
atherosclerosis	B-Disease
in	O
postmenopausal	O
women	O
.	O
METHODS	O
:	O
In	O
a	O
population	O
-	O
based	O
study	O
in	O
513	O
naturally	O
postmenopausal	O
women	O
aged	O
54	O
-	O
67	O
years	O
,	O
we	O
studied	O
the	O
association	O
between	O
self	O
-	O
reported	O
intramuscularly	O
administered	O
high	O
-	O
dose	O
estrogen	B-Chemical
-	O
testosterone	B-Chemical
therapy	O
(	O
estradiol	B-Chemical
-	I-Chemical
and	I-Chemical
testosterone	I-Chemical
esters	I-Chemical
)	O
and	O
aortic	O
atherosclerosis	B-Disease
.	O
Aortic	O
atherosclerosis	B-Disease
was	O
diagnosed	O
by	O
radiographic	O
detection	O
of	O
calcified	O
deposits	O
in	O
the	O
abdominal	O
aorta	O
,	O
which	O
have	O
been	O
shown	O
to	O
reflect	O
intima	O
atherosclerosis	B-Disease
.	O
Hormone	O
therapy	O
users	O
were	O
compared	O
with	O
never	O
users	O
.	O
RESULTS	O
:	O
Intramuscular	O
hormone	O
therapy	O
use	O
for	O
1	O
year	O
or	O
longer	O
was	O
reported	O
by	O
25	O
women	O
.	O
In	O
almost	O
half	O
of	O
these	O
women	O
severe	O
atherosclerosis	B-Disease
of	O
the	O
aorta	O
was	O
present	O
(	O
n	O
=	O
11	O
)	O
,	O
while	O
in	O
women	O
without	O
hormone	O
use	O
severe	O
atherosclerosis	B-Disease
of	O
the	O
aorta	O
was	O
present	O
in	O
less	O
than	O
20	O
%	O
(	O
OR	O
3	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
8	O
.	O
5	O
,	O
adjusted	O
for	O
age	O
,	O
years	O
since	O
menopause	O
,	O
smoking	O
,	O
and	O
body	O
mass	O
index	O
)	O
.	O
The	O
association	O
remained	O
after	O
additional	O
adjustment	O
for	O
diabetes	B-Disease
,	O
cholesterol	B-Chemical
level	O
,	O
systolic	O
blood	O
pressure	O
,	O
or	O
alcohol	B-Chemical
use	O
.	O
No	O
association	O
was	O
found	O
for	O
hormone	O
use	O
less	O
than	O
1	O
year	O
.	O
CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
high	O
-	O
dose	O
testosterone	B-Chemical
therapy	O
may	O
adversely	O
affect	O
atherosclerosis	B-Disease
in	O
postmenopausal	O
women	O
and	O
indicate	O
that	O
androgen	O
replacement	O
in	O
these	O
women	O
may	O
not	O
be	O
harmless	O
.	O
Optimising	O
stroke	B-Disease
prevention	O
in	O
non	O
-	O
valvular	O
atrial	B-Disease
fibrillation	I-Disease
.	O
Atrial	B-Disease
fibrillation	I-Disease
is	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
.	O
Pooled	O
data	O
from	O
trials	O
comparing	O
antithrombotic	O
treatment	O
with	O
placebo	O
have	O
shown	O
that	O
warfarin	B-Chemical
reduces	O
the	O
risk	O
of	O
stroke	B-Disease
by	O
62	O
%	O
,	O
and	O
that	O
aspirin	B-Chemical
alone	O
reduces	O
the	O
risk	O
by	O
22	O
%	O
.	O
Overall	O
,	O
in	O
high	O
-	O
risk	O
patients	O
,	O
warfarin	B-Chemical
is	O
superior	O
to	O
aspirin	B-Chemical
in	O
preventing	O
strokes	B-Disease
,	O
with	O
a	O
relative	O
risk	O
reduction	O
of	O
36	O
%	O
.	O
Ximelagatran	B-Chemical
,	O
an	O
oral	O
direct	O
thrombin	O
inhibitor	O
,	O
was	O
found	O
to	O
be	O
as	O
efficient	O
as	O
vitamin	B-Chemical
K	I-Chemical
antagonist	O
drugs	O
in	O
the	O
prevention	O
of	O
embolic	B-Disease
events	I-Disease
,	O
but	O
has	O
been	O
recently	O
withdrawn	O
because	O
of	O
abnormal	B-Disease
liver	I-Disease
function	I-Disease
tests	O
.	O
The	O
ACTIVE	O
-	O
W	O
(	O
Atrial	B-Disease
Fibrillation	I-Disease
Clopidogrel	B-Chemical
Trial	O
with	O
Irbesartan	B-Chemical
for	O
Prevention	O
of	O
Vascular	O
Events	O
)	O
study	O
has	O
demonstrated	O
that	O
warfarin	B-Chemical
is	O
superior	O
to	O
platelet	O
therapy	O
(	O
clopidogrel	B-Chemical
plus	O
aspirin	B-Chemical
)	O
in	O
the	O
prevention	O
af	O
embolic	B-Disease
events	I-Disease
.	O
Idraparinux	B-Chemical
,	O
a	O
Factor	O
Xa	O
inhibitor	O
,	O
is	O
being	O
evaluated	O
in	O
patients	O
with	O
atrial	B-Disease
fibrillation	I-Disease
.	O
Angiotensin	B-Chemical
-	O
converting	O
enzyme	O
inhibitors	O
and	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
-	O
blocking	O
drugs	O
hold	O
promise	O
in	O
atrial	B-Disease
fibrillation	I-Disease
through	O
cardiac	B-Disease
remodelling	I-Disease
.	O
Preliminary	O
studies	O
suggest	O
that	O
statins	B-Chemical
could	O
interfere	O
with	O
the	O
risk	O
of	O
recurrence	O
after	O
electrical	O
cardioversion	O
.	O
Finally	O
,	O
percutaneous	O
methods	O
for	O
the	O
exclusion	O
of	O
left	O
atrial	O
appendage	O
are	O
under	O
investigation	O
in	O
high	O
-	O
risk	O
patients	O
.	O
Anti	O
-	O
oxidant	O
effects	O
of	O
atorvastatin	B-Chemical
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
the	O
rat	O
.	O
1	O
.	O
Dexamethasone	B-Chemical
(	O
Dex	B-Chemical
)	O
-	O
induced	O
hypertension	B-Disease
is	O
characterized	O
by	O
endothelial	O
dysfunction	O
associated	O
with	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
deficiency	O
and	O
increased	O
superoxide	B-Chemical
(	O
O2	B-Chemical
-	I-Chemical
)	O
production	O
.	O
Atorvastatin	B-Chemical
(	O
Ato	B-Chemical
)	O
possesses	O
pleiotropic	O
properties	O
that	O
have	O
been	O
reported	O
to	O
improve	O
endothelial	O
function	O
through	O
increased	O
availability	O
of	O
NO	B-Chemical
and	O
reduced	O
O2	B-Chemical
-	I-Chemical
production	O
in	O
various	O
forms	O
of	O
hypertension	B-Disease
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
50	O
mg	O
/	O
kg	O
per	O
day	O
,	O
p	O
.	O
o	O
.	O
,	O
Ato	B-Chemical
could	O
prevent	O
endothelial	O
NO	B-Chemical
synthase	O
(	O
eNOS	O
)	O
downregulation	O
and	O
the	O
increase	O
in	O
O2	B-Chemical
-	I-Chemical
in	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
,	O
thereby	O
reducing	O
blood	O
pressure	O
.	O
2	O
.	O
Male	O
SD	O
rats	O
(	O
n	O
=	O
30	O
)	O
were	O
treated	O
with	O
Ato	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
in	O
drinking	O
water	O
)	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O
Dexamethasone	B-Chemical
(	O
10	O
microg	O
/	O
kg	O
per	O
day	O
,	O
s	O
.	O
c	O
.	O
)	O
or	O
saline	O
was	O
started	O
after	O
4	O
days	O
in	O
Ato	B-Chemical
-	O
treated	O
and	O
non	O
-	O
treated	O
rats	O
and	O
continued	O
for	O
11	O
-	O
13	O
days	O
.	O
Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
on	O
alternate	O
days	O
using	O
the	O
tail	O
-	O
cuff	O
method	O
.	O
Endothelial	O
function	O
was	O
assessed	O
by	O
acetylcholine	B-Chemical
-	O
induced	O
vasorelaxation	O
and	O
phenylephrine	B-Chemical
-	O
induced	O
vasoconstriction	O
in	O
aortic	O
segments	O
.	O
Vascular	O
eNOS	O
mRNA	O
was	O
assessed	O
by	O
semi	O
-	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O
3	O
.	O
In	O
rats	O
treated	O
with	O
Dex	B-Chemical
alone	O
,	O
SBP	O
was	O
increased	O
from	O
109	O
+	O
/	O
-	O
2	O
to	O
133	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Days	O
4	O
and	O
Day	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
In	O
the	O
Ato	B-Chemical
+	O
Dex	B-Chemical
group	O
,	O
SBP	O
was	O
increased	O
from	O
113	O
+	O
/	O
-	O
2	O
to	O
119	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Days	O
4	O
to	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
was	O
significantly	O
lower	O
than	O
SBP	O
in	O
the	O
group	O
treated	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Endothelial	O
-	O
dependent	O
relaxation	O
and	O
eNOS	O
mRNA	O
expression	O
were	O
greater	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
group	O
than	O
in	O
the	O
Dex	B-Chemical
only	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
and	O
P	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O
Aortic	O
superoxide	B-Chemical
production	O
was	O
lower	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
group	O
compared	O
with	O
the	O
group	O
treated	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
4	O
.	O
Treatment	O
with	O
Ato	B-Chemical
improved	O
endothelial	O
function	O
,	O
reduced	O
superoxide	B-Chemical
production	O
and	O
reduced	O
SBP	O
in	O
Dex	B-Chemical
-	O
treated	O
SD	O
rats	O
.	O
Severe	O
citrate	B-Chemical
toxicity	B-Disease
complicating	O
volunteer	O
apheresis	O
platelet	O
donation	O
.	O
We	O
report	O
a	O
case	O
of	O
severe	O
citrate	B-Chemical
toxicity	B-Disease
during	O
volunteer	O
donor	O
apheresis	O
platelet	O
collection	O
.	O
The	O
donor	O
was	O
a	O
40	O
-	O
year	O
-	O
old	O
female	O
,	O
first	O
-	O
time	O
apheresis	O
platelet	O
donor	O
.	O
Past	O
medical	O
history	O
was	O
remarkable	O
for	O
hypertension	B-Disease
,	O
hyperlipidemia	B-Disease
,	O
and	O
depression	B-Disease
.	O
Reported	O
medications	O
included	O
bumetanide	B-Chemical
,	O
pravastatin	B-Chemical
,	O
and	O
paroxetine	B-Chemical
.	O
Thirty	O
minutes	O
from	O
the	O
start	O
of	O
the	O
procedure	O
,	O
the	O
donor	O
noted	O
tingling	O
around	O
the	O
mouth	O
,	O
hands	O
,	O
and	O
feet	O
.	O
She	O
then	O
very	O
rapidly	O
developed	O
acute	O
onset	O
of	O
severe	O
facial	O
and	O
extremity	O
tetany	B-Disease
.	O
Empirical	O
treatment	O
with	O
intravenous	O
calcium	B-Chemical
gluconate	I-Chemical
was	O
initiated	O
,	O
and	O
muscle	B-Disease
contractions	I-Disease
slowly	O
subsided	O
over	O
approximately	O
10	O
to	O
15	O
minutes	O
.	O
The	O
events	O
are	O
consistent	O
with	O
a	O
severe	O
reaction	O
to	O
calcium	B-Chemical
chelation	O
by	O
sodium	B-Chemical
citrate	I-Chemical
anticoagulant	O
resulting	O
in	O
symptomatic	O
systemic	O
hypocalcemia	B-Disease
.	O
Upon	O
additional	O
retrospective	O
analysis	O
,	O
it	O
was	O
noted	O
that	O
bumetanide	B-Chemical
is	O
a	O
loop	B-Chemical
diuretic	I-Chemical
that	O
may	O
cause	O
significant	O
hypocalcemia	B-Disease
.	O
We	O
conclude	O
that	O
careful	O
screening	O
for	O
medications	O
and	O
underlying	O
conditions	O
predisposing	O
to	O
hypocalcemia	B-Disease
is	O
recommended	O
to	O
help	O
prevent	O
severe	O
reactions	O
due	O
to	O
citrate	B-Chemical
toxicity	B-Disease
.	O
Laboratory	O
measurement	O
of	O
pre	O
-	O
procedure	O
serum	O
calcium	B-Chemical
levels	O
in	O
selected	O
donors	O
may	O
identify	O
cases	O
requiring	O
heightened	O
vigilance	O
.	O
The	O
case	O
also	O
illustrates	O
the	O
importance	O
of	O
maintaining	O
preparedness	O
for	O
managing	O
rare	O
but	O
serious	O
reactions	O
in	O
volunteer	O
apheresis	O
blood	O
donors	O
.	O
Sirolimus	B-Chemical
-	O
associated	O
proteinuria	B-Disease
and	O
renal	B-Disease
dysfunction	I-Disease
.	O
Sirolimus	B-Chemical
is	O
a	O
novel	O
immunosuppressant	O
with	O
potent	O
antiproliferative	O
actions	O
through	O
its	O
ability	O
to	O
inhibit	O
the	O
raptor	O
-	O
containing	O
mammalian	O
target	O
of	O
rapamycin	B-Chemical
protein	O
kinase	O
.	O
Sirolimus	B-Chemical
represents	O
a	O
major	O
therapeutic	O
advance	O
in	O
the	O
prevention	O
of	O
acute	O
renal	O
allograft	O
rejection	O
and	O
chronic	O
allograft	O
nephropathy	B-Disease
.	O
Its	O
role	O
in	O
the	O
therapy	O
of	O
glomerulonephritis	B-Disease
,	O
autoimmunity	B-Disease
,	O
cystic	B-Disease
renal	I-Disease
diseases	I-Disease
and	O
renal	B-Disease
cancer	I-Disease
is	O
under	O
investigation	O
.	O
Because	O
sirolimus	B-Chemical
does	O
not	O
share	O
the	O
vasomotor	O
renal	O
adverse	O
effects	O
exhibited	O
by	O
calcineurin	O
inhibitors	O
,	O
it	O
has	O
been	O
designated	O
a	O
'	O
non	O
-	O
nephrotoxic	B-Disease
drug	O
'	O
.	O
However	O
,	O
clinical	O
reports	O
suggest	O
that	O
,	O
under	O
some	O
circumstances	O
,	O
sirolimus	B-Chemical
is	O
associated	O
with	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
dysfunction	I-Disease
.	O
A	O
common	O
risk	O
factor	O
appears	O
to	O
be	O
presence	O
of	O
pre	O
-	O
existing	O
chronic	B-Disease
renal	I-Disease
damage	I-Disease
.	O
The	O
mechanisms	O
of	O
sirolimus	B-Chemical
-	O
associated	O
proteinuria	B-Disease
are	O
multifactorial	O
and	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
glomerular	O
capillary	O
pressure	O
following	O
calcineurin	O
inhibitor	O
withdrawal	O
.	O
It	O
has	O
also	O
been	O
suggested	O
that	O
sirolimus	B-Chemical
directly	O
causes	O
increased	O
glomerular	O
permeability	O
/	O
injury	O
,	O
but	O
evidence	O
for	O
this	O
mechanism	O
is	O
currently	O
inconclusive	O
.	O
The	O
acute	B-Disease
renal	I-Disease
dysfunction	I-Disease
associated	O
with	O
sirolimus	B-Chemical
(	O
such	O
as	O
in	O
delayed	O
graft	O
function	O
)	O
may	O
be	O
due	O
to	O
suppression	O
of	O
compensatory	O
renal	O
cell	O
proliferation	O
and	O
survival	O
/	O
repair	O
processes	O
.	O
Although	O
these	O
adverse	O
effects	O
occur	O
in	O
some	O
patients	O
,	O
their	O
occurrence	O
could	O
be	O
minimised	O
by	O
knowledge	O
of	O
the	O
molecular	O
effects	O
of	O
sirolimus	B-Chemical
on	O
the	O
kidney	O
,	O
the	O
use	O
of	O
sirolimus	B-Chemical
in	O
appropriate	O
patient	O
populations	O
,	O
close	O
monitoring	O
of	O
proteinuria	B-Disease
and	O
renal	O
function	O
,	O
use	O
of	O
angiotensin	B-Chemical
-	O
converting	O
enzyme	O
inhibitors	O
or	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
blockers	O
if	O
proteinuria	B-Disease
occurs	O
and	O
withdrawal	O
if	O
needed	O
.	O
Further	O
long	O
-	O
term	O
analysis	O
of	O
renal	O
allograft	O
studies	O
using	O
sirolimus	B-Chemical
as	O
de	O
novo	O
immunosuppression	O
along	O
with	O
clinical	O
and	O
laboratory	O
studies	O
will	O
refine	O
these	O
issues	O
in	O
the	O
future	O
.	O
Proteinuria	B-Disease
after	O
conversion	O
to	O
sirolimus	B-Chemical
in	O
renal	O
transplant	O
recipients	O
.	O
Sirolimus	B-Chemical
(	O
SRL	B-Chemical
)	O
is	O
a	O
new	O
,	O
potent	O
immunosuppressive	O
agent	O
.	O
More	O
recently	O
,	O
proteinuria	B-Disease
has	O
been	O
reported	O
as	O
a	O
consequence	O
of	O
sirolimus	B-Chemical
therapy	O
,	O
although	O
the	O
mechanism	O
has	O
remained	O
unclear	O
.	O
We	O
retrospectively	O
examined	O
the	O
records	O
of	O
25	O
renal	O
transplant	O
patients	O
,	O
who	O
developed	O
or	O
displayed	O
increased	O
proteinuria	B-Disease
after	O
SRL	B-Chemical
conversion	O
.	O
The	O
patient	O
cohort	O
(	O
14	O
men	O
,	O
11	O
women	O
)	O
was	O
treated	O
with	O
SRL	B-Chemical
as	O
conversion	O
therapy	O
,	O
due	O
to	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
(	O
CAN	B-Disease
)	O
(	O
n	O
=	O
15	O
)	O
neoplasia	B-Disease
(	O
n	O
=	O
8	O
)	O
;	O
Kaposi	B-Disease
'	I-Disease
s	I-Disease
sarcoma	I-Disease
,	O
Four	O
skin	B-Disease
cancers	I-Disease
,	O
One	O
intestinal	B-Disease
tumors	I-Disease
,	O
One	O
renal	B-Disease
cell	I-Disease
carsinom	I-Disease
)	O
or	O
BK	O
virus	O
nephropathy	B-Disease
(	O
n	O
=	O
2	O
)	O
.	O
SRL	B-Chemical
was	O
started	O
at	O
a	O
mean	O
of	O
78	O
+	O
/	O
-	O
42	O
(	O
15	O
to	O
163	O
)	O
months	O
after	O
transplantation	O
.	O
Mean	O
follow	O
-	O
up	O
on	O
SRL	B-Chemical
therapy	O
was	O
20	O
+	O
/	O
-	O
12	O
(	O
6	O
to	O
43	O
)	O
months	O
.	O
Proteinuria	B-Disease
increased	O
from	O
0	O
.	O
445	O
(	O
0	O
to	O
1	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
conversion	O
to	O
3	O
.	O
2	O
g	O
/	O
dL	O
(	O
0	O
.	O
2	O
to	O
12	O
)	O
after	O
conversion	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O
Before	O
conversion	O
8	O
(	O
32	O
%	O
)	O
patients	O
had	O
no	O
proteinuria	B-Disease
,	O
whereas	O
afterwards	O
all	O
patients	O
had	O
proteinuria	B-Disease
.	O
In	O
28	O
%	O
of	O
patients	O
proteinuria	B-Disease
remained	O
unchanged	O
,	O
whereas	O
it	O
increased	O
in	O
68	O
%	O
of	O
patients	O
.	O
In	O
40	O
%	O
it	O
increased	O
by	O
more	O
than	O
100	O
%	O
.	O
Twenty	O
-	O
eight	O
percent	O
of	O
patients	O
showed	O
increased	O
proteinuria	B-Disease
to	O
the	O
nephrotic	B-Disease
range	O
.	O
Biopsies	O
performed	O
in	O
five	O
patients	O
revealed	O
new	O
pathological	O
changes	O
:	O
One	O
membranoproliferative	B-Disease
glomerulopathy	I-Disease
and	O
interstitial	B-Disease
nephritis	I-Disease
.	O
These	O
patients	O
showed	O
persistently	O
good	O
graft	O
function	O
.	O
Serum	O
creatinine	B-Chemical
values	O
did	O
not	O
change	O
significantly	O
:	O
1	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
8	O
mg	O
/	O
dL	O
before	O
SRL	B-Chemical
therapy	O
and	O
2	O
.	O
53	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
/	O
dL	O
at	O
last	O
follow	O
-	O
up	O
(	O
P	O
=	O
.	O
14	O
)	O
.	O
Five	O
grafts	O
were	O
lost	O
and	O
the	O
patients	O
returned	O
to	O
dialysis	O
.	O
Five	O
patients	O
displayed	O
CAN	B-Disease
and	O
Kaposi	B-Disease
'	I-Disease
s	I-Disease
sarcoma	I-Disease
.	O
Mean	O
urinary	O
protein	O
of	O
patients	O
who	O
returned	O
to	O
dialysis	O
was	O
1	O
.	O
26	O
(	O
0	O
.	O
5	O
to	O
3	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
and	O
4	O
.	O
7	O
(	O
3	O
to	O
12	O
)	O
g	O
/	O
d	O
after	O
conversion	O
(	O
P	O
=	O
.	O
01	O
)	O
.	O
Mean	O
serum	O
creatinine	B-Chemical
level	O
before	O
conversion	O
was	O
2	O
.	O
21	O
mg	O
/	O
dL	O
and	O
thereafter	O
,	O
4	O
.	O
93	O
mg	O
/	O
dL	O
(	O
P	O
=	O
.	O
02	O
)	O
.	O
Heavy	O
proteinuria	B-Disease
was	O
common	O
after	O
the	O
use	O
of	O
SRL	B-Chemical
as	O
rescue	O
therapy	O
for	O
renal	O
transplantation	O
.	O
Therefore	O
,	O
conversion	O
should	O
be	O
considered	O
for	O
patients	O
who	O
have	O
not	O
developed	O
advanced	O
CAN	B-Disease
and	O
proteinuria	B-Disease
.	O
The	O
possibility	O
of	O
de	O
novo	O
glomerular	O
pathology	O
under	O
SRL	B-Chemical
treatment	O
requires	O
further	O
investigation	O
by	O
renal	O
biopsy	O
.	O
Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
ifosfamide	B-Chemical
renal	B-Disease
toxicity	I-Disease
in	O
children	O
treated	O
for	O
malignant	B-Disease
mesenchymal	I-Disease
tumors	I-Disease
:	O
an	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
report	O
.	O
The	O
renal	O
function	O
of	O
74	O
children	O
with	O
malignant	B-Disease
mesenchymal	I-Disease
tumors	I-Disease
in	O
complete	O
remission	O
and	O
who	O
have	O
received	O
the	O
same	O
ifosfamide	B-Chemical
chemotherapy	O
protocol	O
(	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
Malignant	B-Disease
Mesenchymal	I-Disease
Tumor	I-Disease
Study	O
84	O
[	O
SIOP	O
MMT	O
84	O
]	O
)	O
were	O
studied	O
1	O
year	O
after	O
the	O
completion	O
of	O
treatment	O
.	O
Total	O
cumulative	O
doses	O
were	O
36	O
or	O
60	O
g	O
/	O
m2	O
of	O
ifosfamide	B-Chemical
(	O
six	O
or	O
10	O
cycles	O
of	O
ifosfamide	B-Chemical
,	I-Chemical
vincristine	I-Chemical
,	I-Chemical
and	I-Chemical
dactinomycin	I-Chemical
[	O
IVA	B-Chemical
]	O
)	O
.	O
None	O
of	O
them	O
had	O
received	O
cisplatin	B-Chemical
chemotherapy	O
.	O
Ages	O
ranged	O
from	O
4	O
months	O
to	O
17	O
years	O
;	O
58	O
patients	O
were	O
males	O
and	O
42	O
females	O
.	O
The	O
most	O
common	O
primary	O
tumor	B-Disease
site	O
was	O
the	O
head	O
and	O
neck	O
.	O
Renal	O
function	O
was	O
investigated	O
by	O
measuring	O
plasma	O
and	O
urinary	O
electrolytes	O
,	O
glucosuria	B-Disease
,	O
proteinuria	B-Disease
,	O
aminoaciduria	B-Disease
,	O
urinary	O
pH	O
,	O
osmolarity	O
,	O
creatinine	B-Chemical
clearance	O
,	O
phosphate	B-Chemical
tubular	O
reabsorption	O
,	O
beta	O
2	O
microglobulinuria	O
,	O
and	O
lysozymuria	O
.	O
Fifty	O
-	O
eight	O
patients	O
(	O
78	O
%	O
)	O
had	O
normal	O
renal	O
tests	O
,	O
whereas	O
16	O
patients	O
(	O
22	O
%	O
)	O
had	O
renal	B-Disease
abnormalities	I-Disease
.	O
Two	O
subsets	O
of	O
patients	O
were	O
identified	O
from	O
this	O
latter	O
group	O
:	O
the	O
first	O
included	O
four	O
patients	O
(	O
5	O
%	O
of	O
the	O
total	O
population	O
)	O
who	O
developed	O
major	O
toxicity	B-Disease
resulting	O
in	O
Fanconi	B-Disease
'	I-Disease
s	I-Disease
syndrome	I-Disease
(	O
TDFS	B-Disease
)	O
;	O
and	O
the	O
second	O
group	O
included	O
five	O
patients	O
with	O
elevated	O
beta	O
2	O
microglobulinuria	O
and	O
low	O
phosphate	B-Chemical
reabsorption	O
.	O
The	O
remaining	O
seven	O
patients	O
had	O
isolated	O
beta	O
2	O
microglobulinuria	O
.	O
Severe	O
toxicity	B-Disease
was	O
correlated	O
with	O
the	O
higher	O
cumulative	O
dose	O
of	O
60	O
g	O
/	O
m2	O
of	O
ifosfamide	B-Chemical
,	O
a	O
younger	O
age	O
(	O
less	O
than	O
2	O
1	O
/	O
2	O
years	O
old	O
)	O
,	O
and	O
a	O
predominance	O
of	O
vesicoprostatic	O
tumor	B-Disease
involvement	O
.	O
This	O
low	O
percentage	O
(	O
5	O
%	O
)	O
of	O
TDFS	O
must	O
be	O
evaluated	O
with	O
respect	O
to	O
the	O
efficacy	O
of	O
ifosfamide	B-Chemical
in	O
the	O
treatment	O
of	O
mesenchymal	B-Disease
tumors	I-Disease
in	O
children	O
.	O
Progressive	O
myopathy	B-Disease
with	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
associated	O
with	O
statin	B-Chemical
therapy	O
.	O
Statins	B-Chemical
can	O
cause	O
a	O
necrotizing	O
myopathy	B-Disease
and	O
hyperCKaemia	B-Disease
which	O
is	O
reversible	O
on	O
cessation	O
of	O
the	O
drug	O
.	O
What	O
is	O
less	O
well	O
known	O
is	O
a	O
phenomenon	O
whereby	O
statins	B-Chemical
may	O
induce	O
a	O
myopathy	B-Disease
,	O
which	O
persists	O
or	O
may	O
progress	O
after	O
stopping	O
the	O
drug	O
.	O
We	O
investigated	O
the	O
muscle	O
pathology	O
in	O
8	O
such	O
cases	O
.	O
All	O
had	O
myofibre	O
necrosis	B-Disease
but	O
only	O
3	O
had	O
an	O
inflammatory	O
infiltrate	O
.	O
In	O
all	O
cases	O
there	O
was	O
diffuse	O
or	O
multifocal	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
expression	O
even	O
in	O
non	O
-	O
necrotic	B-Disease
fibres	O
.	O
Progressive	O
improvement	O
occurred	O
in	O
7	O
cases	O
after	O
commencement	O
of	O
prednisolone	B-Chemical
and	O
methotrexate	B-Chemical
,	O
and	O
in	O
one	O
case	O
spontaneously	O
.	O
These	O
observations	O
suggest	O
that	O
statins	B-Chemical
may	O
initiate	O
an	O
immune	O
-	O
mediated	O
myopathy	B-Disease
that	O
persists	O
after	O
withdrawal	O
of	O
the	O
drug	O
and	O
responds	O
to	O
immunosuppressive	O
therapy	O
.	O
The	O
mechanism	O
of	O
this	O
myopathy	B-Disease
is	O
uncertain	O
but	O
may	O
involve	O
the	O
induction	O
by	O
statins	B-Chemical
of	O
an	O
endoplasmic	O
reticulum	O
stress	O
response	O
with	O
associated	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
expression	O
and	O
antigen	O
presentation	O
by	O
muscle	O
fibres	O
.	O
Use	O
of	O
chromosome	O
substitution	O
strains	O
to	O
identify	O
seizure	B-Disease
susceptibility	O
loci	O
in	O
mice	O
.	O
Seizure	B-Disease
susceptibility	O
varies	O
among	O
inbred	O
mouse	O
strains	O
.	O
Chromosome	O
substitution	O
strains	O
(	O
CSS	O
)	O
,	O
in	O
which	O
a	O
single	O
chromosome	O
from	O
one	O
inbred	O
strain	O
(	O
donor	O
)	O
has	O
been	O
transferred	O
onto	O
a	O
second	O
strain	O
(	O
host	O
)	O
by	O
repeated	O
backcrossing	O
,	O
may	O
be	O
used	O
to	O
identify	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
that	O
contribute	O
to	O
seizure	B-Disease
susceptibility	O
.	O
QTLs	O
for	O
susceptibility	O
to	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
,	O
a	O
model	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
,	O
have	O
not	O
been	O
reported	O
,	O
and	O
CSS	O
have	O
not	O
previously	O
been	O
used	O
to	O
localize	O
seizure	B-Disease
susceptibility	O
genes	O
.	O
We	O
report	O
QTLs	O
identified	O
using	O
a	O
B6	O
(	O
host	O
)	O
x	O
A	O
/	O
J	O
(	O
donor	O
)	O
CSS	O
panel	O
to	O
localize	O
genes	O
involved	O
in	O
susceptibility	O
to	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O
Three	O
hundred	O
fifty	O
-	O
five	O
adult	O
male	O
CSS	O
mice	O
,	O
58	O
B6	O
,	O
and	O
39	O
A	O
/	O
J	O
were	O
tested	O
for	O
susceptibility	O
to	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O
Highest	O
stage	O
reached	O
and	O
latency	O
to	O
each	O
stage	O
were	O
recorded	O
for	O
all	O
mice	O
.	O
B6	O
mice	O
were	O
resistant	O
to	O
seizures	B-Disease
and	O
slower	O
to	O
reach	O
stages	O
compared	O
to	O
A	O
/	O
J	O
mice	O
.	O
The	O
CSS	O
for	O
Chromosomes	O
10	O
and	O
18	O
progressed	O
to	O
the	O
most	O
severe	O
stages	O
,	O
diverging	O
dramatically	O
from	O
the	O
B6	O
phenotype	O
.	O
Latencies	O
to	O
stages	O
were	O
also	O
significantly	O
shorter	O
for	O
CSS10	O
and	O
CSS18	O
mice	O
.	O
CSS	O
mapping	O
suggests	O
seizure	B-Disease
susceptibility	O
loci	O
on	O
mouse	O
Chromosomes	O
10	O
and	O
18	O
.	O
This	O
approach	O
provides	O
a	O
framework	O
for	O
identifying	O
potentially	O
novel	O
homologous	O
candidate	O
genes	O
for	O
human	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O
In	O
vitro	O
characterization	O
of	O
parasympathetic	O
and	O
sympathetic	O
responses	O
in	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
in	O
the	O
rat	O
.	O
In	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
in	O
the	O
rat	O
,	O
detrusor	O
function	O
is	O
impaired	O
and	O
the	O
expression	O
and	O
effects	O
of	O
muscarinic	O
receptors	O
altered	O
.	O
Whether	O
or	O
not	O
the	O
neuronal	O
transmission	O
may	O
be	O
affected	O
by	O
cystitis	B-Disease
was	O
presently	O
investigated	O
.	O
Responses	O
of	O
urinary	O
strip	O
preparations	O
from	O
control	O
and	O
cyclophosphamide	B-Chemical
-	O
pretreated	O
rats	O
to	O
electrical	O
field	O
stimulation	O
and	O
to	O
agonists	O
were	O
assessed	O
in	O
the	O
absence	O
and	O
presence	O
of	O
muscarinic	O
,	O
adrenergic	O
and	O
purinergic	O
receptor	O
antagonists	O
.	O
Generally	O
,	O
atropine	B-Chemical
reduced	O
contractions	O
,	O
but	O
in	O
contrast	O
to	O
controls	O
,	O
it	O
also	O
reduced	O
responses	O
to	O
low	O
electrical	O
field	O
stimulation	O
intensity	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
inflamed	O
preparations	O
.	O
In	O
both	O
types	O
,	O
purinoceptor	O
desensitization	O
with	O
alpha	B-Chemical
,	I-Chemical
beta	I-Chemical
-	I-Chemical
methylene	I-Chemical
adenosine	I-Chemical
-	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
triphosphate	I-Chemical
(	O
alpha	B-Chemical
,	I-Chemical
beta	I-Chemical
-	I-Chemical
meATP	I-Chemical
)	O
caused	O
further	O
reductions	O
at	O
low	O
frequencies	O
(	O
<	O
10	O
Hz	O
)	O
.	O
The	O
muscarinic	O
receptor	O
antagonists	O
atropine	B-Chemical
,	O
4	B-Chemical
-	I-Chemical
diphenylacetoxy	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
methylpiperidine	I-Chemical
(	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
)	O
(	O
'	O
M	O
(	O
1	O
)	O
/	O
M	O
(	O
3	O
)	O
/	O
M	O
(	O
5	O
)	O
-	O
selective	O
'	O
)	O
,	O
methoctramine	B-Chemical
(	O
'	O
M	O
(	O
2	O
)	O
-	O
selective	O
'	O
)	O
and	O
pirenzepine	B-Chemical
(	O
'	O
M	O
(	O
1	O
)	O
-	O
selective	O
'	O
)	O
antagonized	O
the	O
tonic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contractile	O
response	O
more	O
potently	O
than	O
the	O
phasic	O
component	O
.	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
inhibited	O
the	O
tonic	O
contractions	O
in	O
controls	O
more	O
potently	O
than	O
methoctramine	B-Chemical
and	O
pirenzepine	B-Chemical
.	O
In	O
inflamed	O
preparations	O
,	O
the	O
muscarinic	O
receptor	O
antagonism	O
on	O
the	O
phasic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contraction	O
was	O
decreased	O
and	O
the	O
pirenzepine	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
antagonism	O
on	O
the	O
tonic	O
component	O
was	O
much	O
less	O
efficient	O
than	O
in	O
controls	O
.	O
In	O
contrast	O
to	O
controls	O
,	O
methoctramine	B-Chemical
increased	O
-	O
-	O
instead	O
of	O
decreased	O
-	O
-	O
the	O
tonic	O
responses	O
at	O
high	O
frequencies	O
.	O
While	O
contractions	O
to	O
carbachol	B-Chemical
and	O
ATP	B-Chemical
were	O
the	O
same	O
in	O
inflamed	O
and	O
in	O
control	O
strips	O
when	O
related	O
to	O
a	O
reference	O
potassium	B-Chemical
response	O
,	O
isoprenaline	B-Chemical
-	O
induced	O
relaxations	O
were	O
smaller	O
in	O
inflamed	O
strips	O
.	O
Thus	O
,	O
in	O
cystitis	B-Disease
substantial	O
changes	O
of	O
the	O
efferent	O
functional	O
responses	O
occur	O
.	O
While	O
postjunctional	O
beta	O
-	O
adrenoceptor	O
-	O
mediated	O
relaxations	O
are	O
reduced	O
,	O
effects	O
by	O
prejunctional	O
inhibitory	O
muscarinic	O
receptors	O
may	O
be	O
increased	O
.	O
Direct	O
inhibition	O
of	O
cardiac	O
hyperpolarization	O
-	O
activated	O
cyclic	B-Chemical
nucleotide	I-Chemical
-	O
gated	O
pacemaker	O
channels	O
by	O
clonidine	B-Chemical
.	O
BACKGROUND	O
:	O
Inhibition	O
of	O
cardiac	O
sympathetic	O
tone	O
represents	O
an	O
important	O
strategy	O
for	O
treatment	O
of	O
cardiovascular	B-Disease
disease	I-Disease
,	O
including	O
arrhythmia	B-Disease
,	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
,	O
and	O
chronic	O
heart	B-Disease
failure	I-Disease
.	O
Activation	O
of	O
presynaptic	O
alpha2	O
-	O
adrenoceptors	O
is	O
the	O
most	O
widely	O
accepted	O
mechanism	O
of	O
action	O
of	O
the	O
antisympathetic	O
drug	O
clonidine	B-Chemical
;	O
however	O
,	O
other	O
target	O
proteins	O
have	O
been	O
postulated	O
to	O
contribute	O
to	O
the	O
in	O
vivo	O
actions	O
of	O
clonidine	B-Chemical
.	O
METHODS	O
AND	O
RESULTS	O
:	O
To	O
test	O
whether	O
clonidine	B-Chemical
elicits	O
pharmacological	O
effects	O
independent	O
of	O
alpha2	O
-	O
adrenoceptors	O
,	O
we	O
have	O
generated	O
mice	O
with	O
a	O
targeted	O
deletion	O
of	O
all	O
3	O
alpha2	O
-	O
adrenoceptor	O
subtypes	O
(	O
alpha2ABC	O
-	O
/	O
-	O
)	O
.	O
Alpha2ABC	O
-	O
/	O
-	O
mice	O
were	O
completely	O
unresponsive	O
to	O
the	O
analgesic	O
and	O
hypnotic	O
effects	O
of	O
clonidine	B-Chemical
;	O
however	O
,	O
clonidine	B-Chemical
significantly	O
lowered	O
heart	O
rate	O
in	O
alpha2ABC	O
-	O
/	O
-	O
mice	O
by	O
up	O
to	O
150	O
bpm	O
.	O
Clonidine	B-Chemical
-	O
induced	O
bradycardia	B-Disease
in	O
conscious	O
alpha2ABC	O
-	O
/	O
-	O
mice	O
was	O
32	O
.	O
3	O
%	O
(	O
10	O
microg	O
/	O
kg	O
)	O
and	O
26	O
.	O
6	O
%	O
(	O
100	O
microg	O
/	O
kg	O
)	O
of	O
the	O
effect	O
in	O
wild	O
-	O
type	O
mice	O
.	O
A	O
similar	O
bradycardic	O
effect	O
of	O
clonidine	B-Chemical
was	O
observed	O
in	O
isolated	O
spontaneously	O
beating	O
right	O
atria	O
from	O
alpha2ABC	O
-	O
knockout	O
and	O
wild	O
-	O
type	O
mice	O
.	O
Clonidine	B-Chemical
inhibited	O
the	O
native	O
pacemaker	O
current	O
(	O
I	O
(	O
f	O
)	O
)	O
in	O
isolated	O
sinoatrial	O
node	O
pacemaker	O
cells	O
and	O
the	O
I	O
(	O
f	O
)	O
-	O
generating	O
hyperpolarization	O
-	O
activated	O
cyclic	B-Chemical
nucleotide	I-Chemical
-	O
gated	O
(	O
HCN	O
)	O
2	O
and	O
HCN4	O
channels	O
in	O
transfected	O
HEK293	O
cells	O
.	O
As	O
a	O
consequence	O
of	O
blocking	O
I	O
(	O
f	O
)	O
,	O
clonidine	B-Chemical
reduced	O
the	O
slope	O
of	O
the	O
diastolic	O
depolarization	O
and	O
the	O
frequency	O
of	O
pacemaker	O
potentials	O
in	O
sinoatrial	O
node	O
cells	O
from	O
wild	O
-	O
type	O
and	O
alpha2ABC	O
-	O
knockout	O
mice	O
.	O
CONCLUSIONS	O
:	O
Direct	O
inhibition	O
of	O
cardiac	O
HCN	O
pacemaker	O
channels	O
contributes	O
to	O
the	O
bradycardic	O
effects	O
of	O
clonidine	B-Chemical
gene	O
-	O
targeted	O
mice	O
in	O
vivo	O
,	O
and	O
thus	O
,	O
clonidine	B-Chemical
-	O
like	O
drugs	O
represent	O
novel	O
structures	O
for	O
future	O
HCN	O
channel	O
inhibitors	O
.	O
Granulomatous	B-Disease
hepatitis	I-Disease
due	O
to	O
combination	B-Chemical
of	I-Chemical
amoxicillin	I-Chemical
and	I-Chemical
clavulanic	I-Chemical
acid	I-Chemical
.	O
We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
amoxicillin	B-Chemical
-	I-Chemical
clavulanic	I-Chemical
acid	I-Chemical
-	O
induced	O
hepatitis	B-Disease
with	O
histologic	O
multiple	O
granulomas	B-Disease
.	O
This	O
type	O
of	O
lesion	O
broadens	O
the	O
spectrum	O
of	O
liver	B-Disease
injury	I-Disease
due	O
to	O
this	O
drug	O
combination	O
,	O
mainly	O
represented	O
by	O
a	O
benign	O
cholestatic	B-Disease
syndrome	I-Disease
.	O
The	O
association	O
of	O
granulomas	B-Disease
and	O
eosinophilia	B-Disease
favor	O
an	O
immunoallergic	O
mechanism	O
.	O
As	O
penicillin	B-Chemical
derivatives	O
and	O
amoxicillin	B-Chemical
alone	O
are	O
known	O
to	O
induce	O
such	O
types	O
of	O
lesions	O
,	O
the	O
amoxicillin	B-Chemical
component	O
,	O
with	O
or	O
without	O
a	O
potentiating	O
effect	O
of	O
clavulanic	B-Chemical
acid	I-Chemical
,	O
might	O
have	O
a	O
major	O
role	O
.	O
Dobutamine	B-Chemical
stress	O
echocardiography	O
:	O
a	O
sensitive	O
indicator	O
of	O
diminished	O
myocardial	O
function	O
in	O
asymptomatic	O
doxorubicin	B-Chemical
-	O
treated	O
long	O
-	O
term	O
survivors	O
of	O
childhood	O
cancer	B-Disease
.	O
Doxorubicin	B-Chemical
is	O
an	O
effective	O
anticancer	O
chemotherapeutic	O
agent	O
known	O
to	O
cause	O
acute	O
and	O
chronic	O
cardiomyopathy	B-Disease
.	O
To	O
develop	O
a	O
more	O
sensitive	O
echocardiographic	O
screening	O
test	O
for	O
cardiac	B-Disease
damage	I-Disease
due	O
to	O
doxorubicin	B-Chemical
,	O
a	O
cohort	O
study	O
was	O
performed	O
using	O
dobutamine	B-Chemical
infusion	O
to	O
differentiate	O
asymptomatic	O
long	O
-	O
term	O
survivors	O
of	O
childhood	O
cancer	B-Disease
treated	O
with	O
doxorubicin	B-Chemical
from	O
healthy	O
control	O
subjects	O
.	O
Echocardiographic	O
data	O
from	O
the	O
experimental	O
group	O
of	O
21	O
patients	O
(	O
mean	O
age	O
16	O
+	O
/	O
-	O
5	O
years	O
)	O
treated	O
from	O
1	O
.	O
6	O
to	O
14	O
.	O
3	O
years	O
(	O
median	O
5	O
.	O
3	O
)	O
before	O
this	O
study	O
with	O
27	O
to	O
532	O
mg	O
/	O
m2	O
of	O
doxorubicin	B-Chemical
(	O
mean	O
196	O
)	O
were	O
compared	O
with	O
echocardiographic	O
data	O
from	O
12	O
normal	O
age	O
-	O
matched	O
control	O
subjects	O
.	O
Graded	O
dobutamine	B-Chemical
infusions	O
of	O
0	O
.	O
5	O
,	O
2	O
.	O
5	O
,	O
5	O
and	O
10	O
micrograms	O
/	O
kg	O
per	O
min	O
were	O
administered	O
.	O
Echocardiographic	O
Doppler	O
studies	O
were	O
performed	O
before	O
infusion	O
and	O
after	O
15	O
min	O
of	O
infusion	O
at	O
each	O
rate	O
.	O
Dobutamine	B-Chemical
infusion	O
at	O
10	O
micrograms	O
/	O
kg	O
per	O
min	O
was	O
discontinued	O
after	O
six	O
studies	O
secondary	O
to	O
a	O
50	O
%	O
incidence	O
rate	O
of	O
adverse	O
symptoms	O
.	O
The	O
most	O
important	O
findings	O
were	O
that	O
compared	O
with	O
values	O
in	O
control	O
subjects	O
,	O
end	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
and	O
percent	O
of	O
left	O
ventricular	O
posterior	O
wall	O
thickening	O
in	O
doxorubicin	B-Chemical
-	O
treated	O
patients	O
were	O
decreased	O
at	O
baseline	O
study	O
and	O
these	O
findings	O
were	O
more	O
clearly	O
delineated	O
with	O
dobutamine	B-Chemical
stimulation	O
.	O
End	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
baseline	O
for	O
the	O
doxorubicin	B-Chemical
-	O
treated	O
group	O
was	O
11	O
+	O
/	O
-	O
1	O
.	O
9	O
mm	O
versus	O
13	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
mm	O
for	O
control	O
subjects	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
End	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
the	O
5	O
-	O
micrograms	O
/	O
kg	O
per	O
min	O
dobutamine	B-Chemical
infusion	O
for	O
the	O
doxorubicin	B-Chemical
-	O
treated	O
group	O
was	O
14	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
4	O
mm	O
versus	O
19	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
6	O
mm	O
for	O
control	O
subjects	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Influence	O
of	O
smoking	B-Chemical
on	O
developing	O
cochlea	O
.	O
Does	O
smoking	B-Chemical
during	O
pregnancy	O
affect	O
the	O
amplitudes	O
of	O
transient	O
evoked	O
otoacoustic	O
emissions	O
in	O
newborns	O
?	O
OBJECTIVE	O
:	O
Maternal	O
tobacco	O
smoking	B-Chemical
has	O
negative	O
effects	O
on	O
fetal	O
growth	O
.	O
The	O
influence	O
of	O
smoking	B-Chemical
during	O
pregnancy	O
on	O
the	O
developing	O
cochlea	O
has	O
not	O
been	O
estimated	O
,	O
although	O
smoking	B-Chemical
has	O
been	O
positively	O
associated	O
with	O
hearing	B-Disease
loss	I-Disease
in	O
adults	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
maternal	O
smoking	B-Chemical
on	O
transient	O
evoked	O
otoacoustic	O
emissions	O
(	O
TEOAEs	O
)	O
of	O
healthy	O
neonates	O
.	O
METHODS	O
:	O
This	O
study	O
was	O
undertaken	O
as	O
part	O
of	O
neonatal	O
screening	O
for	O
hearing	B-Disease
impairment	I-Disease
and	O
involved	O
both	O
ears	O
of	O
200	O
newborns	O
.	O
Newborns	O
whose	O
mothers	O
reported	O
smoking	B-Chemical
during	O
pregnancy	O
(	O
n	O
=	O
200	O
ears	O
)	O
were	O
compared	O
to	O
a	O
control	O
group	O
of	O
newborns	O
(	O
n	O
=	O
200	O
ears	O
)	O
,	O
whose	O
mothers	O
were	O
non	O
-	O
smokers	O
.	O
Exposure	O
to	O
tobacco	O
was	O
characterized	O
as	O
low	O
(	O
<	O
5	O
cigarettes	O
per	O
day	O
,	O
n	O
=	O
88	O
ears	O
)	O
,	O
moderate	O
(	O
5	O
<	O
or	O
=	O
cigarettes	O
per	O
day	O
<	O
10	O
,	O
n	O
=	O
76	O
)	O
or	O
high	O
(	O
>	O
or	O
=	O
10	O
cigarettes	O
per	O
day	O
,	O
n	O
=	O
36	O
)	O
.	O
RESULTS	O
:	O
In	O
exposed	O
neonates	O
,	O
TEOAEs	O
mean	O
response	O
(	O
across	O
frequency	O
)	O
and	O
mean	O
amplitude	O
at	O
4000Hz	O
was	O
significantly	O
lower	O
than	O
in	O
non	O
-	O
exposed	O
neonates	O
.	O
Comparisons	O
between	O
exposed	O
newborns	O
'	O
subgroups	O
revealed	O
no	O
significant	O
differences	O
.	O
However	O
,	O
by	O
comparing	O
each	O
subgroup	O
to	O
control	O
group	O
,	O
we	O
found	O
statistically	O
significant	O
decreases	B-Disease
of	I-Disease
TEOAEs	I-Disease
amplitudes	I-Disease
at	O
4000Hz	O
for	O
all	O
three	O
groups	O
.	O
Mean	O
TEOAEs	O
responses	O
of	O
highly	O
exposed	O
newborns	O
were	O
also	O
significantly	O
lower	O
in	O
comparison	O
to	O
our	O
control	O
group	O
.	O
CONCLUSION	O
:	O
In	O
utero	O
,	O
exposure	O
to	O
tobacco	O
smoking	B-Chemical
seems	O
to	O
have	O
a	O
small	O
impact	O
on	O
outer	O
hair	O
cells	O
.	O
These	O
effects	O
seem	O
to	O
be	O
equally	O
true	O
for	O
all	O
exposed	O
newborns	O
,	O
regardless	O
of	O
the	O
degree	O
of	O
exposure	O
.	O
Further	O
studies	O
are	O
needed	O
in	O
order	O
to	O
establish	O
a	O
potential	O
negative	O
effect	O
of	O
maternal	O
smoking	B-Chemical
on	O
the	O
neonate	O
'	O
s	O
hearing	O
acuity	O
.	O
Simvastatin	B-Chemical
-	O
induced	O
bilateral	O
leg	O
compartment	B-Disease
syndrome	I-Disease
and	O
myonecrosis	B-Disease
associated	O
with	O
hypothyroidism	B-Disease
.	O
A	O
54	O
-	O
year	O
-	O
old	O
hypothyroid	B-Disease
male	O
taking	O
thyroxine	B-Chemical
and	O
simvastatin	B-Chemical
presented	O
with	O
bilateral	O
leg	O
compartment	B-Disease
syndrome	I-Disease
and	O
myonecrosis	B-Disease
.	O
Urgent	O
fasciotomies	O
were	O
performed	O
and	O
the	O
patient	O
made	O
an	O
uneventful	O
recovery	O
with	O
the	O
withdrawal	O
of	O
simvastatin	B-Chemical
.	O
It	O
is	O
likely	O
that	O
this	O
complication	O
will	O
be	O
seen	O
more	O
often	O
with	O
the	O
increased	O
worldwide	O
use	O
of	O
this	O
drug	O
and	O
its	O
approval	O
for	O
all	O
arteriopathic	B-Disease
patients	O
.	O
Neuroinflammation	B-Disease
and	O
behavioral	B-Disease
abnormalities	I-Disease
after	O
neonatal	O
terbutaline	B-Chemical
treatment	O
in	O
rats	O
:	O
implications	O
for	O
autism	B-Disease
.	O
Autism	B-Disease
is	O
a	O
neurodevelopmental	B-Disease
disorder	I-Disease
presenting	O
before	O
3	O
years	O
of	O
age	O
with	O
deficits	B-Disease
in	I-Disease
communication	I-Disease
and	I-Disease
social	I-Disease
skills	I-Disease
and	O
repetitive	B-Disease
behaviors	I-Disease
.	O
In	O
addition	O
to	O
genetic	O
influences	O
,	O
recent	O
studies	O
suggest	O
that	O
prenatal	O
drug	O
or	O
chemical	O
exposures	O
are	O
risk	O
factors	O
for	O
autism	B-Disease
.	O
Terbutaline	B-Chemical
,	O
a	O
beta2	O
-	O
adrenoceptor	O
agonist	O
used	O
to	O
arrest	O
preterm	B-Disease
labor	I-Disease
,	O
has	O
been	O
associated	O
with	O
increased	O
concordance	O
for	O
autism	B-Disease
in	O
dizygotic	O
twins	O
.	O
We	O
studied	O
the	O
effects	O
of	O
terbutaline	B-Chemical
on	O
microglial	O
activation	O
in	O
different	O
brain	O
regions	O
and	O
behavioral	O
outcomes	O
in	O
developing	O
rats	O
.	O
Newborn	O
rats	O
were	O
given	O
terbutaline	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
daily	O
on	O
postnatal	O
days	O
(	O
PN	O
)	O
2	O
to	O
5	O
or	O
PN	O
11	O
to	O
14	O
and	O
examined	O
24	O
h	O
after	O
the	O
last	O
dose	O
and	O
at	O
PN	O
30	O
.	O
Immunohistochemical	O
studies	O
showed	O
that	O
administration	O
of	O
terbutaline	B-Chemical
on	O
PN	O
2	O
to	O
5	O
produced	O
a	O
robust	O
increase	O
in	O
microglial	O
activation	O
on	O
PN	O
30	O
in	O
the	O
cerebral	O
cortex	O
,	O
as	O
well	O
as	O
in	O
cerebellar	O
and	O
cerebrocortical	O
white	O
matter	O
.	O
None	O
of	O
these	O
effects	O
occurred	O
in	O
animals	O
given	O
terbutaline	B-Chemical
on	O
PN	O
11	O
to	O
14	O
.	O
In	O
behavioral	O
tests	O
,	O
animals	O
treated	O
with	O
terbutaline	B-Chemical
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	O
patterns	O
of	O
hyper	O
-	O
reactivity	O
to	O
novelty	O
and	O
aversive	O
stimuli	O
when	O
assessed	O
in	O
a	O
novel	O
open	O
field	O
,	O
as	O
well	O
as	O
in	O
the	O
acoustic	O
startle	O
response	O
test	O
.	O
Our	O
findings	O
indicate	O
that	O
beta2	O
-	O
adrenoceptor	O
overstimulation	O
during	O
an	O
early	O
critical	O
period	O
results	O
in	O
microglial	O
activation	O
associated	O
with	O
innate	O
neuroinflammatory	O
pathways	O
and	O
behavioral	B-Disease
abnormalities	I-Disease
,	O
similar	O
to	O
those	O
described	O
in	O
autism	B-Disease
.	O
This	O
study	O
provides	O
a	O
useful	O
animal	O
model	O
for	O
understanding	O
the	O
neuropathological	O
processes	O
underlying	O
autism	B-Disease
spectrum	I-Disease
disorders	I-Disease
.	O
Upregulation	O
of	O
brain	O
expression	O
of	O
P	O
-	O
glycoprotein	O
in	O
MRP2	O
-	O
deficient	O
TR	O
(	O
-	O
)	O
rats	O
resembles	O
seizure	B-Disease
-	O
induced	O
up	O
-	O
regulation	O
of	O
this	O
drug	O
efflux	O
transporter	O
in	O
normal	O
rats	O
.	O
PURPOSE	O
:	O
The	O
multidrug	O
resistance	O
protein	O
2	O
(	O
MRP2	O
)	O
is	O
a	O
drug	O
efflux	O
transporter	O
that	O
is	O
expressed	O
predominantly	O
at	O
the	O
apical	O
domain	O
of	O
hepatocytes	O
but	O
seems	O
also	O
to	O
be	O
expressed	O
at	O
the	O
apical	O
membrane	O
of	O
brain	O
capillary	O
endothelial	O
cells	O
that	O
form	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
.	O
MRP2	O
is	O
absent	O
in	O
the	O
transport	O
-	O
deficient	O
(	O
TR	O
(	O
-	O
)	O
)	O
Wistar	O
rat	O
mutant	O
,	O
so	O
that	O
this	O
rat	O
strain	O
was	O
very	O
helpful	O
in	O
defining	O
substrates	O
of	O
MRP2	O
by	O
comparing	O
tissue	O
concentrations	O
or	O
functional	O
activities	O
of	O
compounds	O
in	O
MRP2	O
-	O
deficient	O
rats	O
with	O
those	O
in	O
transport	O
-	O
competent	O
Wistar	O
rats	O
.	O
By	O
using	O
this	O
strategy	O
to	O
study	O
the	O
involvement	O
of	O
MRP2	O
in	O
brain	O
access	O
of	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
,	O
we	O
recently	O
reported	O
that	O
phenytoin	B-Chemical
is	O
a	O
substrate	O
for	O
MRP2	O
in	O
the	O
BBB	O
.	O
However	O
,	O
one	O
drawback	O
of	O
such	O
studies	O
in	O
genetically	O
deficient	O
rats	O
is	O
the	O
fact	O
that	O
compensatory	O
changes	O
with	O
upregulation	O
of	O
other	O
transporters	O
can	O
occur	O
.	O
This	O
prompted	O
us	O
to	O
study	O
the	O
brain	O
expression	O
of	O
P	O
-	O
glycoprotein	O
(	O
Pgp	O
)	O
,	O
a	O
major	O
drug	O
efflux	O
transporter	O
in	O
many	O
tissues	O
,	O
including	O
the	O
BBB	O
,	O
in	O
TR	O
(	O
-	O
)	O
rats	O
compared	O
with	O
nonmutant	O
(	O
wild	O
-	O
type	O
)	O
Wistar	O
rats	O
.	O
METHODS	O
:	O
The	O
expression	O
of	O
MRP2	O
and	O
Pgp	O
in	O
brain	O
and	O
liver	O
sections	O
of	O
TR	O
(	O
-	O
)	O
rats	O
and	O
normal	O
Wistar	O
rats	O
was	O
determined	O
with	O
immunohistochemistry	O
,	O
by	O
using	O
a	O
novel	O
,	O
highly	O
selective	O
monoclonal	O
MRP2	O
antibody	O
and	O
the	O
monoclonal	O
Pgp	O
antibody	O
C219	O
,	O
respectively	O
.	O
RESULTS	O
:	O
Immunofluorescence	O
staining	O
with	O
the	O
MRP2	O
antibody	O
was	O
found	O
to	O
label	O
a	O
high	O
number	O
of	O
microvessels	O
throughout	O
the	O
brain	O
in	O
normal	O
Wistar	O
rats	O
,	O
whereas	O
such	O
labeling	O
was	O
absent	O
in	O
TR	O
(	O
-	O
)	O
rats	O
.	O
TR	O
(	O
-	O
)	O
rats	O
exhibited	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
Pgp	O
in	O
brain	O
capillary	O
endothelial	O
cells	O
compared	O
with	O
wild	O
-	O
type	O
controls	O
.	O
No	O
such	O
obvious	O
upregulation	O
of	O
Pgp	O
was	O
observed	O
in	O
liver	O
sections	O
.	O
A	O
comparable	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
was	O
obtained	O
after	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
in	O
wild	O
-	O
type	O
Wistar	O
rats	O
.	O
Experiments	O
with	O
systemic	O
administration	O
of	O
the	O
Pgp	O
substrate	O
phenobarbital	B-Chemical
and	O
the	O
selective	O
Pgp	O
inhibitor	O
tariquidar	B-Chemical
in	O
TR	O
(	O
-	O
)	O
rats	O
substantiated	O
that	O
Pgp	O
is	O
functional	O
and	O
compensates	O
for	O
the	O
lack	O
of	O
MRP2	O
in	O
the	O
BBB	O
.	O
CONCLUSIONS	O
:	O
The	O
data	O
on	O
TR	O
(	O
-	O
)	O
rats	O
indicate	O
that	O
Pgp	O
plays	O
an	O
important	O
role	O
in	O
the	O
compensation	O
of	O
MRP2	O
deficiency	O
in	O
the	O
BBB	O
.	O
Because	O
such	O
a	O
compensatory	O
mechanism	O
most	O
likely	O
occurs	O
to	O
reduce	O
injury	B-Disease
to	I-Disease
the	I-Disease
brain	I-Disease
from	O
cytotoxic	O
compounds	O
,	O
the	O
present	O
data	O
substantiate	O
the	O
concept	O
that	O
MRP2	O
performs	O
a	O
protective	O
role	O
in	O
the	O
BBB	O
.	O
Furthermore	O
,	O
our	O
data	O
suggest	O
that	O
TR	O
(	O
-	O
)	O
rats	O
are	O
an	O
interesting	O
tool	O
to	O
study	O
consequences	O
of	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
on	O
access	O
of	O
drugs	O
in	O
the	O
brain	O
,	O
without	O
the	O
need	O
of	O
inducing	O
seizures	B-Disease
or	O
other	O
Pgp	O
-	O
enhancing	O
events	O
for	O
this	O
purpose	O
.	O
Role	O
of	O
xanthine	B-Chemical
oxidase	O
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rats	O
.	O
1	O
.	O
Glucocorticoid	O
-	O
induced	O
hypertension	B-Disease
(	O
GC	O
-	O
HT	B-Disease
)	O
in	O
the	O
rat	O
is	O
associated	O
with	O
nitric	B-Chemical
oxide	I-Chemical
-	O
redox	O
imbalance	O
.	O
2	O
.	O
We	O
studied	O
the	O
role	O
of	O
xanthine	B-Chemical
oxidase	O
(	O
XO	O
)	O
,	O
which	O
is	O
implicated	O
in	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
,	O
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
(	O
dex	B-Chemical
-	O
HT	B-Disease
)	O
.	O
3	O
.	O
Thirty	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
divided	O
randomly	O
into	O
four	O
treatment	O
groups	O
:	O
saline	O
,	O
dexamethasone	B-Chemical
(	O
dex	B-Chemical
)	O
,	O
allopurinol	B-Chemical
plus	O
saline	O
,	O
and	O
allopurinol	B-Chemical
plus	O
dex	B-Chemical
.	O
4	O
.	O
Systolic	O
blood	O
pressures	O
(	O
SBP	O
)	O
and	O
bodyweights	O
were	O
recorded	O
each	O
alternate	O
day	O
.	O
Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	O
activity	O
,	O
and	O
serum	O
urate	B-Chemical
to	O
assess	O
XO	O
inhibition	O
.	O
5	O
.	O
Dex	B-Chemical
increased	B-Disease
SBP	I-Disease
(	O
110	O
+	O
/	O
-	O
2	O
-	O
126	O
+	O
/	O
-	O
3	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
decreased	B-Disease
thymus	I-Disease
(	I-Disease
P	I-Disease
<	I-Disease
0	I-Disease
.	I-Disease
001	I-Disease
)	I-Disease
and	I-Disease
bodyweights	I-Disease
(	O
P	O
""""	O
<	O
0	O
.	O
01	O
)	O
.	O
Allopurinol	B-Chemical
decreased	O
serum	O
urate	B-Chemical
from	O
76	O
+	O
/	O
-	O
5	O
to	O
30	O
+	O
/	O
-	O
3	O
micromol	O
/	O
L	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
saline	O
and	O
from	O
84	O
+	O
/	O
-	O
13	O
to	O
28	O
+	O
/	O
-	O
2	O
micromol	O
/	O
L	O
in	O
dex	B-Chemical
-	O
treated	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
groups	O
.	O
6	O
.	O
Allopurinol	B-Chemical
did	O
not	O
prevent	O
dex	B-Chemical
-	O
HT	B-Disease
.	O
This	O
,	O
together	O
with	O
our	O
previous	O
findings	O
that	O
allopurinol	B-Chemical
failed	O
to	O
prevent	O
adrenocorticotrophic	O
hormone	O
induced	O
hypertension	B-Disease
,	O
suggests	O
that	O
XO	O
activity	O
is	O
not	O
a	O
major	O
determinant	O
of	O
GC	O
-	O
HT	B-Disease
in	O
the	O
rat	O
.	O
Side	O
effects	O
of	O
postoperative	O
administration	O
of	O
methylprednisolone	B-Chemical
and	O
gentamicin	B-Chemical
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
.	O
PURPOSE	O
:	O
To	O
assess	O
the	O
incidence	O
of	O
postoperative	O
emetic	O
side	O
effects	O
after	O
the	O
administration	O
of	O
methylprednisolone	B-Chemical
and	O
gentamicin	B-Chemical
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
at	O
the	O
end	O
of	O
routine	O
cataract	B-Disease
surgery	O
.	O
SETTING	O
:	O
St	O
.	O
Luke	O
'	O
s	O
Hospital	O
,	O
Gwardamangia	O
,	O
Malta	O
.	O
METHODS	O
:	O
A	O
double	O
-	O
blind	O
double	O
-	O
armed	O
prospective	O
study	O
comprised	O
40	O
patients	O
who	O
had	O
uneventful	O
sutureless	O
phacoemulsification	O
under	O
sub	O
-	O
Tenon	O
'	O
s	O
local	O
infiltration	O
of	O
3	O
mL	O
of	O
plain	O
lignocaine	B-Chemical
.	O
At	O
the	O
end	O
of	O
the	O
procedure	O
,	O
Group	O
A	O
(	O
n	O
=	O
20	O
)	O
had	O
20	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
methylprednisolone	B-Chemical
and	O
10	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
gentamicin	B-Chemical
injected	O
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
and	O
Group	O
B	O
(	O
n	O
=	O
20	O
)	O
had	O
the	O
same	O
combination	O
injected	O
into	O
the	O
anterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
.	O
Postoperatively	O
,	O
all	O
patients	O
were	O
assessed	O
for	O
symptoms	O
of	O
nausea	B-Disease
,	I-Disease
vomiting	I-Disease
,	O
and	O
headache	B-Disease
.	O
A	O
chi	O
-	O
square	O
test	O
was	O
used	O
to	O
assess	O
the	O
statistical	O
significance	O
of	O
results	O
.	O
RESULTS	O
:	O
Sixty	O
percent	O
in	O
Group	O
A	O
developed	O
postoperative	B-Disease
emetic	I-Disease
symptoms	I-Disease
,	O
headache	B-Disease
,	O
or	O
both	O
;	O
1	O
patient	O
in	O
Group	O
B	O
developed	O
symptoms	O
.	O
CONCLUSIONS	O
:	O
The	O
administration	O
of	O
methylprednisolone	B-Chemical
and	O
gentamicin	B-Chemical
in	O
the	O
posterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
was	O
related	O
to	O
a	O
high	O
incidence	O
of	O
side	O
effects	O
including	O
nausea	B-Disease
,	I-Disease
vomiting	I-Disease
,	O
and	O
headache	B-Disease
.	O
All	O
adverse	O
effects	O
were	O
self	O
-	O
limiting	O
.	O
Assessment	O
of	O
a	O
new	O
non	O
-	O
invasive	O
index	O
of	O
cardiac	O
performance	O
for	O
detection	O
of	O
dobutamine	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
.	O
BACKGROUND	O
:	O
Electrocardiography	O
has	O
a	O
very	O
low	O
sensitivity	O
in	O
detecting	O
dobutamine	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
.	O
OBJECTIVES	O
:	O
To	O
assess	O
the	O
added	O
diagnostic	O
value	O
of	O
a	O
new	O
cardiac	O
performance	O
index	O
(	O
dP	O
/	O
dtejc	O
)	O
measurement	O
,	O
based	O
on	O
brachial	O
artery	O
flow	O
changes	O
,	O
as	O
compared	O
to	O
standard	O
12	O
-	O
lead	O
ECG	O
,	O
for	O
detecting	O
dobutamine	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
,	O
using	O
Tc99m	B-Chemical
-	I-Chemical
Sestamibi	I-Chemical
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
as	O
the	O
gold	O
standard	O
of	O
comparison	O
to	O
assess	O
the	O
presence	O
or	O
absence	O
of	O
ischemia	B-Disease
.	O
METHODS	O
:	O
The	O
study	O
group	O
comprised	O
40	O
patients	O
undergoing	O
Sestamibi	B-Chemical
-	O
SPECT	O
/	O
dobutamine	B-Chemical
stress	O
test	O
.	O
Simultaneous	O
measurements	O
of	O
ECG	O
and	O
brachial	O
artery	O
dP	O
/	O
dtejc	O
were	O
performed	O
at	O
each	O
dobutamine	B-Chemical
level	O
.	O
In	O
19	O
of	O
the	O
40	O
patients	O
perfusion	O
defects	O
compatible	O
with	O
ischemia	B-Disease
were	O
detected	O
on	O
SPECT	O
.	O
The	O
increase	O
in	O
dP	O
/	O
dtejc	O
during	O
infusion	O
of	O
dobutamine	B-Chemical
in	O
this	O
group	O
was	O
severely	O
impaired	O
as	O
compared	O
to	O
the	O
non	O
-	O
ischemic	O
group	O
.	O
dP	O
/	O
dtejc	O
outcome	O
was	O
combined	O
with	O
the	O
ECG	O
results	O
,	O
giving	O
an	O
ECG	O
-	O
enhanced	O
value	O
,	O
and	O
compared	O
to	O
ECG	O
alone	O
.	O
RESULTS	O
:	O
The	O
sensitivity	O
improved	O
dramatically	O
from	O
16	O
%	O
to	O
79	O
%	O
,	O
positive	O
predictive	O
value	O
increased	O
from	O
60	O
%	O
to	O
68	O
%	O
and	O
negative	O
predictive	O
value	O
from	O
54	O
%	O
to	O
78	O
%	O
,	O
and	O
specificity	O
decreased	O
from	O
90	O
%	O
to	O
67	O
%	O
.	O
CONCLUSIONS	O
:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
specificity	O
,	O
the	O
combination	O
with	O
dP	O
/	O
dtejc	O
improved	O
the	O
sensitivity	O
of	O
the	O
test	O
and	O
could	O
be	O
a	O
cost	O
-	O
savings	O
alternative	O
to	O
cardiac	O
imaging	O
or	O
perfusion	O
studies	O
to	O
detect	O
myocardial	B-Disease
ischemia	I-Disease
,	O
especially	O
in	O
patients	O
unable	O
to	O
exercise	O
.	O
Cocaine	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
:	O
clinical	O
observations	O
and	O
pathogenetic	O
considerations	O
.	O
Clinical	O
and	O
experimental	O
data	O
published	O
to	O
date	O
suggest	O
several	O
possible	O
mechanisms	O
by	O
which	O
cocaine	B-Chemical
may	O
result	O
in	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O
In	O
individuals	O
with	O
preexisting	O
,	O
high	O
-	O
grade	O
coronary	O
arterial	O
narrowing	O
,	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
may	O
result	O
from	O
an	O
increase	O
in	O
myocardial	O
oxygen	B-Chemical
demand	O
associated	O
with	O
cocaine	B-Chemical
-	O
induced	O
increase	O
in	O
rate	O
-	O
pressure	O
product	O
.	O
In	O
other	O
individuals	O
with	O
no	O
underlying	O
atherosclerotic	B-Disease
obstruction	I-Disease
,	O
coronary	B-Disease
occlusion	I-Disease
may	O
be	O
due	O
to	O
spasm	B-Disease
,	O
thrombus	B-Disease
,	O
or	O
both	O
.	O
With	O
regard	O
to	O
spasm	B-Disease
,	O
the	O
clinical	O
findings	O
are	O
largely	O
circumstantial	O
,	O
and	O
the	O
locus	O
of	O
cocaine	B-Chemical
-	O
induced	O
vasoconstriction	O
remains	O
speculative	O
.	O
Although	O
certain	O
clinical	O
and	O
experimental	O
findings	O
support	O
the	O
hypothesis	O
that	O
spasm	B-Disease
involves	O
the	O
epicardial	O
,	O
medium	O
-	O
size	O
vessels	O
,	O
other	O
data	O
suggest	O
intramural	O
vasoconstriction	O
.	O
Diffuse	O
intramural	O
vasoconstriction	O
is	O
not	O
consistent	O
with	O
reports	O
of	O
segmental	O
,	O
discrete	O
infarction	B-Disease
.	O
Whereas	O
certain	O
in	O
vivo	O
data	O
suggest	O
that	O
these	O
effects	O
are	O
alpha	O
-	O
mediated	O
,	O
other	O
in	O
vitro	O
data	O
suggest	O
the	O
opposite	O
.	O
The	O
finding	O
of	O
cocaine	B-Chemical
-	O
induced	O
vasoconstriction	O
in	O
segments	O
of	O
(	O
noninnervated	O
)	O
human	O
umbilical	O
artery	O
suggests	O
that	O
the	O
presence	O
or	O
absence	O
of	O
intact	O
innervation	O
is	O
not	O
sufficient	O
to	O
explain	O
the	O
discrepant	O
data	O
involving	O
the	O
possibility	O
of	O
alpha	O
-	O
mediated	O
effects	O
.	O
Finally	O
,	O
the	O
contribution	O
of	O
a	O
primary	O
,	O
thrombotic	B-Disease
effect	O
of	O
cocaine	B-Chemical
has	O
not	O
been	O
excluded	O
.	O
Proteomic	O
analysis	O
of	O
striatal	O
proteins	O
in	O
the	O
rat	O
model	O
of	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
-	O
induced	O
dyskinesia	B-Disease
.	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
-	O
induced	O
dyskinesia	B-Disease
(	O
LID	B-Disease
)	O
is	O
among	O
the	O
motor	O
complications	O
that	O
arise	O
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
patients	O
after	O
a	O
prolonged	O
treatment	O
with	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
.	O
To	O
this	O
day	O
,	O
transcriptome	O
analysis	O
has	O
been	O
performed	O
in	O
a	O
rat	O
model	O
of	O
LID	B-Disease
[	O
Neurobiol	O
.	O
Dis	O
.	O
,	O
17	O
(	O
2004	O
)	O
,	O
219	O
]	O
but	O
information	O
regarding	O
the	O
proteome	O
is	O
still	O
lacking	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
changes	O
occurring	O
at	O
the	O
protein	O
level	O
in	O
striatal	O
samples	O
obtained	O
from	O
the	O
unilaterally	O
6	B-Chemical
-	I-Chemical
hydroxydopamine	I-Chemical
-	O
lesion	O
rat	O
model	O
of	O
PD	B-Disease
treated	O
with	O
saline	O
,	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
or	O
bromocriptine	B-Chemical
using	O
two	O
-	O
dimensional	O
difference	O
gel	O
electrophoresis	O
and	O
mass	O
spectrometry	O
(	O
MS	O
)	O
.	O
Rats	O
treated	O
with	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
were	O
allocated	O
to	O
two	O
groups	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
LID	B-Disease
.	O
Among	O
the	O
2000	O
spots	O
compared	O
for	O
statistical	O
difference	O
,	O
67	O
spots	O
were	O
significantly	O
changed	O
in	O
abundance	O
and	O
identified	O
using	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
MS	O
,	O
atmospheric	O
pressure	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
and	O
HPLC	O
coupled	O
tandem	O
MS	O
(	O
LC	O
/	O
MS	O
/	O
MS	O
)	O
.	O
Out	O
of	O
these	O
67	O
proteins	O
,	O
LID	B-Disease
significantly	O
changed	O
the	O
expression	O
level	O
of	O
five	O
proteins	O
:	O
alphabeta	O
-	O
crystalin	O
,	O
gamma	O
-	O
enolase	O
,	O
guanidoacetate	O
methyltransferase	O
,	O
vinculin	O
,	O
and	O
proteasome	O
alpha	O
-	O
2	O
subunit	O
.	O
Complementary	O
techniques	O
such	O
as	O
western	O
immunoblotting	O
and	O
immunohistochemistry	O
were	O
performed	O
to	O
investigate	O
the	O
validity	O
of	O
the	O
data	O
obtained	O
using	O
the	O
proteomic	O
approach	O
.	O
In	O
conclusion	O
,	O
this	O
study	O
provides	O
new	O
insights	O
into	O
the	O
protein	O
changes	O
occurring	O
in	O
LID	B-Disease
.	O
Cardiac	O
Angiography	O
in	O
Renally	O
Impaired	O
Patients	O
(	O
CARE	O
)	O
study	O
:	O
a	O
randomized	O
double	O
-	O
blind	O
trial	O
of	O
contrast	O
-	O
induced	O
nephropathy	B-Disease
in	O
patients	O
with	O
chronic	B-Disease
kidney	I-Disease
disease	I-Disease
.	O
BACKGROUND	O
:	O
No	O
direct	O
comparisons	O
exist	O
of	O
the	O
renal	O
tolerability	O
of	O
the	O
low	O
-	O
osmolality	O
contrast	B-Chemical
medium	I-Chemical
iopamidol	B-Chemical
with	O
that	O
of	O
the	O
iso	O
-	O
osmolality	O
contrast	B-Chemical
medium	I-Chemical
iodixanol	B-Chemical
in	O
high	O
-	O
risk	O
patients	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
The	O
present	O
study	O
is	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
comparison	O
of	O
iopamidol	B-Chemical
and	O
iodixanol	B-Chemical
in	O
patients	O
with	O
chronic	B-Disease
kidney	I-Disease
disease	I-Disease
(	O
estimated	O
glomerular	O
filtration	O
rate	O
,	O
20	O
to	O
59	O
mL	O
/	O
min	O
)	O
who	O
underwent	O
cardiac	O
angiography	O
or	O
percutaneous	O
coronary	O
interventions	O
.	O
Serum	O
creatinine	B-Chemical
(	O
SCr	O
)	O
levels	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
assessed	O
at	O
baseline	O
and	O
2	O
to	O
5	O
days	O
after	O
receiving	O
medications	O
.	O
The	O
primary	O
outcome	O
was	O
a	O
postdose	O
SCr	O
increase	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
.	O
2	O
micromol	O
/	O
L	O
)	O
over	O
baseline	O
.	O
Secondary	O
outcomes	O
were	O
a	O
postdose	O
SCr	O
increase	O
>	O
or	O
=	O
25	O
%	O
,	O
a	O
postdose	O
estimated	O
glomerular	O
filtration	O
rate	O
decrease	O
of	O
>	O
or	O
=	O
25	O
%	O
,	O
and	O
the	O
mean	O
peak	O
change	O
in	O
SCr	O
.	O
In	O
414	O
patients	O
,	O
contrast	O
volume	O
,	O
presence	O
of	O
diabetes	B-Disease
mellitus	I-Disease
,	O
use	O
of	O
N	B-Chemical
-	I-Chemical
acetylcysteine	I-Chemical
,	O
mean	O
baseline	O
SCr	O
,	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
comparable	O
in	O
the	O
2	O
groups	O
.	O
SCr	O
increases	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
occurred	O
in	O
4	O
.	O
4	O
%	O
(	O
9	O
of	O
204	O
patients	O
)	O
after	O
iopamidol	B-Chemical
and	O
6	O
.	O
7	O
%	O
(	O
14	O
of	O
210	O
patients	O
)	O
after	O
iodixanol	B-Chemical
(	O
P	O
=	O
0	O
.	O
39	O
)	O
,	O
whereas	O
rates	O
of	O
SCr	O
increases	O
>	O
or	O
=	O
25	O
%	O
were	O
9	O
.	O
8	O
%	O
and	O
12	O
.	O
4	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
44	O
)	O
.	O
In	O
patients	O
with	O
diabetes	B-Disease
,	O
SCr	O
increases	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
were	O
5	O
.	O
1	O
%	O
(	O
4	O
of	O
78	O
patients	O
)	O
with	O
iopamidol	B-Chemical
and	O
13	O
.	O
0	O
%	O
(	O
12	O
of	O
92	O
patients	O
)	O
with	O
iodixanol	B-Chemical
(	O
P	O
=	O
0	O
.	O
11	O
)	O
,	O
whereas	O
SCr	O
increases	O
>	O
or	O
=	O
25	O
%	O
were	O
10	O
.	O
3	O
%	O
and	O
15	O
.	O
2	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
37	O
)	O
.	O
Mean	O
post	O
-	O
SCr	O
increases	O
were	O
significantly	O
less	O
with	O
iopamidol	B-Chemical
(	O
all	O
patients	O
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
12	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
10	O
.	O
6	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
03	O
;	O
patients	O
with	O
diabetes	B-Disease
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
16	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
14	O
.	O
1	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
rate	O
of	O
contrast	O
-	O
induced	O
nephropathy	B-Disease
,	O
defined	O
by	O
multiple	O
end	O
points	O
,	O
is	O
not	O
statistically	O
different	O
after	O
the	O
intraarterial	O
administration	O
of	O
iopamidol	B-Chemical
or	O
iodixanol	B-Chemical
to	O
high	O
-	O
risk	O
patients	O
,	O
with	O
or	O
without	O
diabetes	B-Disease
mellitus	I-Disease
.	O
Any	O
true	O
difference	O
between	O
the	O
agents	O
is	O
small	O
and	O
not	O
likely	O
to	O
be	O
clinically	O
significant	O
.	O
A	O
novel	O
compound	O
,	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
,	O
attenuates	O
cognitive	B-Disease
deficits	I-Disease
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
dementia	B-Disease
models	O
.	O
To	O
develop	O
a	O
novel	O
and	O
effective	O
drug	O
that	O
could	O
enhance	O
cognitive	O
function	O
and	O
neuroprotection	O
,	O
we	O
newly	O
synthesized	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
by	O
the	O
esterification	O
of	O
maltol	B-Chemical
and	O
p	B-Chemical
-	I-Chemical
coumaric	I-Chemical
acid	I-Chemical
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
could	O
improve	O
cognitive	B-Disease
decline	I-Disease
in	O
scopolamine	B-Chemical
-	O
injected	O
rats	O
and	O
in	O
amyloid	B-Chemical
beta	I-Chemical
peptide	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
-	O
infused	O
rats	O
.	O
Maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
was	O
found	O
to	O
attenuate	O
cognitive	B-Disease
deficits	I-Disease
in	O
both	O
rat	O
models	O
using	O
passive	O
avoidance	O
test	O
and	O
to	O
reduce	O
apoptotic	O
cell	O
death	O
observed	O
in	O
the	O
hippocampus	O
of	O
the	O
amyloid	B-Chemical
beta	I-Chemical
peptide	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
-	O
infused	O
rats	O
.	O
We	O
also	O
examined	O
the	O
neuroprotective	O
effects	O
of	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
in	O
vitro	O
using	O
SH	O
-	O
SY5Y	O
cells	O
.	O
Cells	O
were	O
pretreated	O
with	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
,	O
before	O
exposed	O
to	O
amyloid	B-Chemical
beta	I-Chemical
peptide	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
,	O
glutamate	B-Chemical
or	O
H2O2	B-Chemical
.	O
We	O
found	O
that	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
significantly	O
decreased	O
apoptotic	O
cell	O
death	O
and	O
reduced	O
reactive	O
oxygen	O
species	O
,	O
cytochrome	O
c	O
release	O
,	O
and	O
caspase	O
3	O
activation	O
.	O
Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
together	O
,	O
our	O
study	O
suggests	O
that	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
is	O
a	O
potentially	O
effective	O
candidate	O
against	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
that	O
is	O
characterized	O
by	O
wide	O
spread	O
neuronal	B-Disease
death	I-Disease
and	O
progressive	O
decline	B-Disease
of	I-Disease
cognitive	I-Disease
function	I-Disease
.	O
Attenuation	O
of	O
methamphetamine	B-Chemical
-	O
induced	O
nigrostriatal	O
dopaminergic	O
neurotoxicity	B-Disease
in	O
mice	O
by	O
lipopolysaccharide	B-Chemical
pretreatment	O
.	O
Immunological	O
activation	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
methamphetamine	B-Chemical
-	O
induced	O
dopaminergic	B-Disease
terminal	I-Disease
damage	I-Disease
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
lipopolysaccharide	B-Chemical
,	O
a	O
pro	O
-	O
inflammatory	O
and	O
inflammatory	O
factor	O
,	O
treatment	O
in	O
modulating	O
the	O
methamphetamine	B-Chemical
-	O
induced	O
nigrostriatal	O
dopamine	B-Chemical
neurotoxicity	B-Disease
.	O
Lipopolysaccharide	B-Chemical
pretreatment	O
did	O
not	O
affect	O
the	O
basal	O
body	O
temperature	O
or	O
methamphetamine	B-Chemical
-	O
elicited	O
hyperthermia	B-Disease
three	O
days	O
later	O
.	O
Such	O
systemic	O
lipopolysaccharide	B-Chemical
treatment	O
mitigated	O
methamphetamine	B-Chemical
-	O
induced	O
striatal	O
dopamine	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylacetic	I-Chemical
acid	I-Chemical
depletions	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
As	O
the	O
most	O
potent	O
dose	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
lipopolysaccharide	B-Chemical
was	O
administered	O
two	O
weeks	O
,	O
one	O
day	O
before	O
or	O
after	O
the	O
methamphetamine	B-Chemical
dosing	O
regimen	O
,	O
methamphetamine	B-Chemical
-	O
induced	O
striatal	O
dopamine	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylacetic	I-Chemical
acid	I-Chemical
depletions	O
remained	O
unaltered	O
.	O
Moreover	O
,	O
systemic	O
lipopolysaccharide	B-Chemical
pretreatment	O
(	O
1	O
mg	O
/	O
kg	O
)	O
attenuated	O
local	O
methamphetamine	B-Chemical
infusion	O
-	O
produced	O
dopamine	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylacetic	I-Chemical
acid	I-Chemical
depletions	O
in	O
the	O
striatum	O
,	O
indicating	O
that	O
the	O
protective	O
effect	O
of	O
lipopolysaccharide	B-Chemical
is	O
less	O
likely	O
due	O
to	O
interrupted	O
peripheral	O
distribution	O
or	O
metabolism	O
of	O
methamphetamine	B-Chemical
.	O
We	O
concluded	O
a	O
critical	O
time	O
window	O
for	O
systemic	O
lipopolysaccharide	B-Chemical
pretreatment	O
in	O
exerting	O
effective	O
protection	O
against	O
methamphetamine	B-Chemical
-	O
induced	O
nigrostriatal	O
dopamine	B-Chemical
neurotoxicity	B-Disease
.	O
Acute	O
myocarditis	B-Disease
associated	O
with	O
clozapine	B-Chemical
.	O
OBJECTIVE	O
:	O
A	O
case	O
of	O
acute	O
myocarditis	B-Disease
associated	O
with	O
the	O
commencement	O
of	O
clozapine	B-Chemical
is	O
described	O
,	O
highlighting	O
the	O
onset	O
,	O
course	O
and	O
possible	O
contributing	O
factors	O
.	O
There	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
about	O
this	O
potentially	O
fatal	O
complication	O
of	O
clozapine	B-Chemical
use	O
.	O
RESULTS	O
:	O
A	O
20	O
-	O
year	O
-	O
old	O
male	O
with	O
schizophrenia	B-Disease
developed	O
a	O
sudden	O
onset	O
of	O
myocarditis	B-Disease
after	O
commencement	O
of	O
clozapine	B-Chemical
.	O
The	O
patient	O
recovered	O
with	O
intensive	O
medical	O
support	O
.	O
The	O
symptoms	O
occurred	O
around	O
2	O
weeks	O
after	O
starting	O
clozapine	B-Chemical
in	O
an	O
inpatient	O
setting	O
.	O
Possible	O
contributing	O
factors	O
may	O
have	O
been	O
concomitant	O
antidepressant	B-Chemical
use	O
and	O
unaccustomed	O
physical	O
activity	O
.	O
CONCLUSIONS	O
:	O
Myocarditis	B-Disease
is	O
an	O
increasingly	O
recognized	O
complication	O
associated	O
with	O
the	O
use	O
of	O
clozapine	B-Chemical
.	O
It	O
can	O
be	O
fatal	O
if	O
not	O
recognized	O
and	O
treated	O
early	O
.	O
Considering	O
that	O
clozapine	B-Chemical
remains	O
the	O
gold	O
standard	O
in	O
treatment	O
of	O
resistant	O
psychosis	B-Disease
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
among	O
medical	O
and	O
paramedical	O
staff	O
involved	O
in	O
the	O
care	O
of	O
these	O
patients	O
.	O
There	O
are	O
also	O
implications	O
for	O
recommendations	O
and	O
regulations	O
regarding	O
the	O
use	O
of	O
clozapine	B-Chemical
.	O
Severe	O
rhabdomyolysis	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
secondary	O
to	O
concomitant	O
use	O
of	O
simvastatin	B-Chemical
,	O
amiodarone	B-Chemical
,	O
and	O
atazanavir	B-Chemical
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
a	O
severe	O
interaction	O
between	O
simvastatin	B-Chemical
,	O
amiodarone	B-Chemical
,	O
and	O
atazanavir	B-Chemical
resulting	O
in	O
rhabdomyolysis	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O
BACKGROUND	O
:	O
A	O
72	O
-	O
year	O
-	O
old	O
white	O
man	O
with	O
underlying	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
,	O
atrial	B-Disease
fibrillation	I-Disease
,	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
,	O
and	O
hyperlipidemia	B-Disease
presented	O
with	O
generalized	O
pain	B-Disease
,	O
fatigue	B-Disease
,	O
and	O
dark	O
orange	O
urine	O
for	O
3	O
days	O
.	O
The	O
patient	O
was	O
taking	O
80	O
mg	O
simvastatin	B-Chemical
at	O
bedtime	O
(	O
initiated	O
27	O
days	O
earlier	O
)	O
;	O
amiodarone	B-Chemical
at	O
a	O
dose	O
of	O
400	O
mg	O
daily	O
for	O
7	O
days	O
,	O
then	O
200	O
mg	O
daily	O
(	O
initiated	O
19	O
days	O
earlier	O
)	O
;	O
and	O
400	O
mg	O
atazanavir	B-Chemical
daily	O
(	O
initiated	O
at	O
least	O
2	O
years	O
previously	O
)	O
.	O
Laboratory	O
evaluation	O
revealed	O
66	O
,	O
680	O
U	O
/	O
L	O
creatine	B-Chemical
kinase	O
,	O
93	O
mg	O
/	O
dL	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
,	O
4	O
.	O
6	O
mg	O
/	O
dL	O
creatinine	B-Chemical
,	O
1579	O
U	O
/	O
L	O
aspartate	B-Chemical
aminotransferase	O
,	O
and	O
738	O
U	O
/	O
L	O
alanine	B-Chemical
aminotransferase	O
.	O
Simvastatin	B-Chemical
,	O
amiodarone	B-Chemical
,	O
and	O
the	O
patient	O
'	O
s	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
medications	O
were	O
all	O
temporarily	O
discontinued	O
and	O
the	O
patient	O
was	O
given	O
forced	O
alkaline	O
diuresis	O
and	O
started	O
on	O
dialysis	O
.	O
Nine	O
days	O
later	O
the	O
patient	O
'	O
s	O
creatine	B-Chemical
kinase	O
had	O
dropped	O
to	O
1695	O
U	O
/	O
L	O
and	O
creatinine	B-Chemical
was	O
3	O
.	O
3	O
mg	O
/	O
dL	O
.	O
The	O
patient	O
was	O
discharged	O
and	O
continued	O
outpatient	O
dialysis	O
for	O
1	O
month	O
until	O
his	O
renal	O
function	O
recovered	O
.	O
DISCUSSION	O
:	O
The	O
risk	O
of	O
rhabdomyolysis	B-Disease
is	O
increased	O
in	O
the	O
presence	O
of	O
concomitant	O
drugs	O
that	O
inhibit	O
simvastatin	B-Chemical
metabolism	O
.	O
Simvastatin	B-Chemical
is	O
metabolized	O
by	O
CYP3A4	O
.	O
Amiodarone	B-Chemical
and	O
atazanavir	B-Chemical
are	O
recognized	O
CYP3A4	O
inhibitors	O
.	O
CONCLUSIONS	O
:	O
Pharmacokinetic	O
differences	O
in	O
statins	B-Chemical
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
risk	O
of	O
potential	O
drug	O
interactions	O
.	O
In	O
patients	O
requiring	O
the	O
concurrent	O
use	O
of	O
statins	B-Chemical
and	O
CYP3A4	O
inhibitors	O
,	O
pravastatin	B-Chemical
,	O
fluvastatin	B-Chemical
,	O
and	O
rosuvastatin	B-Chemical
carry	O
the	O
lowest	O
risk	O
of	O
drug	O
interactions	O
;	O
atorvastatin	B-Chemical
carries	O
moderate	O
risk	O
,	O
whereas	O
simvastatin	B-Chemical
and	O
lovastatin	B-Chemical
have	O
the	O
highest	O
risk	O
and	O
should	O
be	O
avoided	O
in	O
patients	O
taking	O
concomitant	O
CYP3A4	O
inhibitors	O
.	O
Interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
:	O
case	O
series	O
.	O
Warfarin	B-Chemical
is	O
the	O
most	O
widely	O
used	O
oral	O
anticoagulant	O
and	O
is	O
indicated	O
for	O
many	O
clinical	O
conditions	O
.	O
Levofloxacin	B-Chemical
,	O
a	O
fluoroquinolone	B-Chemical
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescribed	O
antibiotics	O
in	O
clinical	O
practice	O
and	O
is	O
effective	O
against	O
Gram	O
-	O
positive	O
,	O
Gram	O
-	O
negative	O
,	O
and	O
atypical	O
bacteria	O
.	O
While	O
small	O
prospective	O
studies	O
have	O
not	O
revealed	O
any	O
significant	O
drug	O
-	O
drug	O
interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
,	O
several	O
case	O
reports	O
have	O
indicated	O
that	O
levofloxacin	B-Chemical
may	O
significantly	O
potentiate	O
the	O
anticoagulation	O
effect	O
of	O
warfarin	B-Chemical
.	O
We	O
report	O
3	O
cases	O
of	O
serious	O
bleeding	B-Disease
complications	O
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
.	O
Physicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
interaction	O
and	O
use	O
caution	O
when	O
prescribing	O
levofloxacin	B-Chemical
to	O
patients	O
taking	O
warfarin	B-Chemical
.	O
Mutations	O
associated	O
with	O
lamivudine	B-Chemical
-	O
resistance	O
in	O
therapy	O
-	O
na	B-Chemical
ve	O
hepatitis	B-Disease
B	I-Disease
virus	I-Disease
(	I-Disease
HBV	I-Disease
)	I-Disease
infected	I-Disease
patients	O
with	O
and	O
without	O
HIV	B-Disease
co	I-Disease
-	I-Disease
infection	I-Disease
:	O
implications	O
for	O
antiretroviral	O
therapy	O
in	O
HBV	B-Disease
and	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
South	O
African	O
patients	O
.	O
This	O
was	O
an	O
exploratory	O
study	O
to	O
investigate	O
lamivudine	B-Chemical
-	O
resistant	O
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
strains	O
in	O
selected	O
lamivudine	B-Chemical
-	O
na	B-Chemical
ve	O
HBV	O
carriers	O
with	O
and	O
without	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
(	I-Disease
HIV	I-Disease
)	I-Disease
co	I-Disease
-	I-Disease
infection	I-Disease
in	O
South	O
African	O
patients	O
.	O
Thirty	O
-	O
five	O
lamivudine	B-Chemical
-	O
na	B-Chemical
ve	O
HBV	B-Disease
infected	I-Disease
patients	O
with	O
or	O
without	O
HIV	B-Disease
co	I-Disease
-	I-Disease
infection	I-Disease
were	O
studied	O
:	O
15	O
chronic	O
HBV	B-Disease
mono	I-Disease
-	I-Disease
infected	I-Disease
patients	O
and	O
20	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O
The	O
latter	O
group	O
was	O
further	O
sub	O
-	O
divided	O
into	O
13	O
occult	O
HBV	O
(	O
HBsAg	B-Chemical
-	O
negative	O
)	O
and	O
7	O
overt	O
HBV	O
(	O
HBsAg	B-Chemical
-	O
positive	O
)	O
patients	O
.	O
HBsAg	B-Chemical
,	O
anti	O
-	O
HBs	O
,	O
anti	O
-	O
HBc	O
,	O
and	O
anti	O
-	O
HIV	O
1	O
/	O
2	O
were	O
determined	O
as	O
part	O
of	O
routine	O
diagnosis	O
using	O
Axsym	O
assays	O
(	O
Abbott	O
Laboratories	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O
Serum	O
samples	O
were	O
PCR	O
amplified	O
with	O
HBV	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
primers	O
,	O
followed	O
by	O
direct	O
sequencing	O
across	O
the	O
tyrosine	B-Chemical
-	O
methionine	B-Chemical
-	O
aspartate	B-Chemical
-	O
aspartate	B-Chemical
(	O
YMDD	O
)	O
motif	O
of	O
the	O
major	O
catalytic	O
region	O
in	O
the	O
C	O
domain	O
of	O
the	O
HBV	O
RT	O
enzyme	O
.	O
HBV	O
viral	O
load	O
was	O
performed	O
with	O
Amplicor	O
HBV	O
Monitor	O
test	O
v2	O
.	O
0	O
(	O
Roche	O
Diagnostics	O
,	O
Penzberg	O
,	O
Germany	O
)	O
.	O
HBV	O
lamivudine	B-Chemical
-	O
resistant	O
strains	O
were	O
detected	O
in	O
3	O
of	O
15	O
mono	O
-	O
infected	O
chronic	O
hepatitis	B-Disease
B	I-Disease
patients	O
and	O
10	O
of	O
20	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
report	O
of	O
HBV	O
lamivudine	B-Chemical
-	O
resistant	O
strains	O
in	O
therapy	O
-	O
na	B-Chemical
ve	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O
The	O
HBV	O
viral	O
loads	O
for	O
mono	O
-	O
infected	O
and	O
co	O
-	O
infected	O
patients	O
ranged	O
from	O
3	O
.	O
32	O
x	O
10	O
(	O
2	O
)	O
to	O
3	O
.	O
82	O
x	O
10	O
(	O
7	O
)	O
and	O
<	O
200	O
to	O
4	O
.	O
40	O
x	O
10	O
(	O
3	O
)	O
copies	O
/	O
ml	O
,	O
respectively	O
.	O
It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre	O
-	O
existing	O
antiviral	O
mutations	O
could	O
result	O
in	O
widespread	O
emergence	O
of	O
HBV	O
resistant	O
strains	O
when	O
lamivudine	B-Chemical
-	O
containing	O
highly	O
active	O
antiretroviral	O
(	O
ARV	O
)	O
treatment	O
(	O
HAART	O
)	O
regimens	O
become	O
widely	O
applied	O
in	O
South	O
Africa	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potential	O
implications	O
in	O
the	O
management	O
of	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O
Rabbit	B-Disease
syndrome	I-Disease
,	O
antidepressant	B-Chemical
use	O
,	O
and	O
cerebral	O
perfusion	O
SPECT	O
scan	O
findings	O
.	O
The	O
rabbit	B-Disease
syndrome	I-Disease
is	O
an	O
extrapyramidal	O
side	O
effect	O
associated	O
with	O
chronic	O
neuroleptic	O
therapy	O
.	O
Its	O
occurrence	O
in	O
a	O
patient	O
being	O
treated	O
with	O
imipramine	B-Chemical
is	O
described	O
,	O
representing	O
the	O
first	O
reported	O
case	O
of	O
this	O
syndrome	O
in	O
conjunction	O
with	O
antidepressants	B-Chemical
.	O
Repeated	O
cerebral	O
perfusion	O
SPECT	O
scans	O
revealed	O
decreased	B-Disease
basal	I-Disease
ganglia	I-Disease
perfusion	I-Disease
while	O
the	O
movement	B-Disease
disorder	I-Disease
was	O
present	O
,	O
and	O
a	O
return	O
to	O
normal	O
perfusion	O
when	O
the	O
rabbit	B-Disease
syndrome	I-Disease
resolved	O
.	O
Estrogen	O
prevents	O
cholesteryl	B-Chemical
ester	I-Chemical
accumulation	O
in	O
macrophages	O
induced	O
by	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	B-Chemical
.	O
Individuals	O
with	O
HIV	O
can	O
now	O
live	O
long	O
lives	O
with	O
drug	O
therapy	O
that	O
often	O
includes	O
protease	O
inhibitors	O
such	O
as	O
ritonavir	B-Chemical
.	O
Many	O
patients	O
,	O
however	O
,	O
develop	O
negative	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
premature	B-Disease
atherosclerosis	I-Disease
.	O
We	O
have	O
previously	O
demonstrated	O
that	O
ritonavir	B-Chemical
treatment	O
increases	O
atherosclerotic	B-Disease
lesion	I-Disease
formation	O
in	O
male	O
mice	O
to	O
a	O
greater	O
extent	O
than	O
in	O
female	O
mice	O
.	O
Furthermore	O
,	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
ritonavir	B-Chemical
-	O
treated	O
females	O
had	O
less	O
cholesteryl	B-Chemical
ester	I-Chemical
accumulation	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
female	O
hormones	O
influence	O
cholesterol	B-Chemical
metabolism	O
in	O
macrophages	O
in	O
response	O
to	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	B-Chemical
.	O
We	O
have	O
utilized	O
the	O
human	O
monocyte	O
cell	O
line	O
,	O
THP	O
-	O
1	O
as	O
a	O
model	O
to	O
address	O
this	O
question	O
.	O
Briefly	O
,	O
cells	O
were	O
differentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macrophage	O
-	O
like	O
phenotype	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
nM	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
(	O
E2	B-Chemical
)	O
,	O
100	O
nM	O
progesterone	B-Chemical
or	O
vehicle	O
(	O
0	O
.	O
01	O
%	O
ethanol	B-Chemical
)	O
.	O
Cells	O
were	O
then	O
treated	O
with	O
30	O
ng	O
/	O
ml	O
ritonavir	B-Chemical
or	O
vehicle	O
in	O
the	O
presence	O
of	O
aggregated	O
LDL	O
for	O
24	O
h	O
.	O
Cell	O
extracts	O
were	O
harvested	O
,	O
and	O
lipid	O
or	O
total	O
RNA	O
was	O
isolated	O
.	O
E2	B-Chemical
decreased	O
the	O
accumulation	O
of	O
cholesteryl	B-Chemical
esters	I-Chemical
in	O
macrophages	O
following	O
ritonavir	B-Chemical
treatment	O
.	O
Ritonavir	B-Chemical
increased	O
the	O
expression	O
of	O
the	O
scavenger	O
receptor	O
,	O
CD36	O
mRNA	O
,	O
responsible	O
for	O
the	O
uptake	O
of	O
LDL	O
.	O
Additionally	O
,	O
ritonavir	B-Chemical
treatment	O
selectively	O
increased	O
the	O
relative	O
levels	O
of	O
PPARgamma	O
mRNA	O
,	O
a	O
transcription	O
factor	O
responsible	O
for	O
the	O
regulation	O
of	O
CD36	O
mRNA	O
expression	O
.	O
Treatment	O
with	O
E2	B-Chemical
,	O
however	O
,	O
failed	O
to	O
prevent	O
these	O
increases	O
at	O
the	O
mRNA	O
level	O
.	O
E2	B-Chemical
did	O
,	O
however	O
,	O
significantly	O
suppress	O
CD36	O
protein	O
levels	O
as	O
measured	O
by	O
fluorescent	O
immunocytochemistry	O
.	O
This	O
data	O
suggests	O
that	O
E2	B-Chemical
modifies	O
the	O
expression	O
of	O
CD36	O
at	O
the	O
level	O
of	O
protein	O
expression	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
resulting	O
in	O
reduced	O
cholesteryl	B-Chemical
ester	I-Chemical
accumulation	O
following	O
ritonavir	B-Chemical
treatment	O
.	O
Acute	O
hepatitis	B-Disease
attack	O
after	O
exposure	O
to	O
telithromycin	B-Chemical
.	O
INTRODUCTION	O
:	O
Antibiotic	O
-	O
associated	O
hepatotoxicity	B-Disease
is	O
rare	O
.	O
With	O
widespread	O
use	O
of	O
antimicrobial	O
agents	O
,	O
however	O
,	O
hepatic	B-Disease
injury	I-Disease
occurs	O
frequently	O
,	O
and	O
among	O
adverse	B-Disease
drug	I-Disease
reactions	I-Disease
,	O
idiosyncratic	O
reactions	O
are	O
the	O
most	O
serious	O
.	O
CASE	O
SUMMARY	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
male	O
patient	O
,	O
with	O
a	O
height	O
of	O
175	O
cm	O
and	O
weight	O
of	O
72	O
kg	O
presented	O
to	O
Marmara	O
University	O
Hospital	O
Emergency	O
Department	O
,	O
Istanbul	O
,	O
Turkey	O
,	O
with	O
5	O
days	O
'	O
history	O
of	O
jaundice	B-Disease
,	O
malaise	O
,	O
nausea	B-Disease
,	O
and	O
vomiting	B-Disease
.	O
He	O
had	O
been	O
prescribed	O
telithromycin	B-Chemical
400	O
mg	O
/	O
d	O
PO	O
to	O
treat	O
an	O
upper	B-Disease
respiratory	I-Disease
tract	I-Disease
infection	I-Disease
7	O
days	O
prior	O
.	O
Admission	O
laboratory	O
tests	O
were	O
as	O
follows	O
:	O
alanine	B-Chemical
aminotransferase	O
,	O
67	O
U	O
/	O
L	O
(	O
reference	O
range	O
,	O
10	O
-	O
37	O
U	O
/	O
L	O
)	O
;	O
aspartate	B-Chemical
aminotransferase	O
,	O
98	O
U	O
/	O
L	O
(	O
10	O
-	O
40	O
U	O
/	O
L	O
)	O
;	O
alkaline	O
phosphatase	O
,	O
513	O
U	O
/	O
L	O
(	O
0	O
-	O
270	O
U	O
/	O
L	O
)	O
;	O
gamma	O
-	O
glutamyltransferase	O
,	O
32	O
U	O
/	O
L	O
(	O
7	O
-	O
49	O
U	O
/	O
L	O
)	O
;	O
amylase	O
,	O
46	O
U	O
/	O
L	O
(	O
0	O
-	O
220	O
U	O
/	O
L	O
)	O
;	O
total	O
bilirubin	B-Chemical
,	O
20	O
.	O
1	O
mg	O
/	O
dL	O
(	O
0	O
.	O
2	O
-	O
1	O
.	O
0	O
mg	O
/	O
dL	O
)	O
;	O
direct	O
bilirubin	B-Chemical
,	O
14	O
.	O
8	O
mg	O
/	O
dL	O
(	O
0	O
-	O
0	O
.	O
3	O
mg	O
/	O
dL	O
)	O
;	O
and	O
albumin	O
,	O
4	O
.	O
7	O
mg	O
/	O
dL	O
(	O
3	O
.	O
5	O
-	O
5	O
.	O
4	O
mg	O
/	O
dL	O
)	O
.	O
No	O
toxin	O
,	O
alcohol	B-Chemical
,	O
or	O
other	O
drugs	O
were	O
reported	O
.	O
The	O
patient	O
had	O
suffered	O
a	O
previous	O
episode	O
of	O
""""	O
acute	O
hepatitis	B-Disease
of	O
unknown	O
origin	O
,	O
""""	O
that	O
occurred	O
after	O
telithromycin	B-Chemical
usage	O
.	O
Both	O
incidents	O
occurred	O
within	O
a	O
year	O
.	O
DISCUSSION	O
:	O
Telithromycin	B-Chemical
is	O
the	O
first	O
of	O
the	O
ketolide	O
antibacterials	O
to	O
receive	O
US	O
Food	O
and	O
Drug	O
Administration	O
approval	O
for	O
clinical	O
use	O
.	O
It	O
has	O
been	O
associated	O
with	O
infrequent	O
and	O
usually	O
reversible	O
severe	O
hepatic	B-Disease
dysfunction	I-Disease
.	O
Based	O
on	O
a	O
score	O
of	O
8	O
on	O
the	O
Naranjo	O
adverse	B-Disease
drug	I-Disease
reaction	I-Disease
probability	O
scale	O
,	O
telithromycin	B-Chemical
was	O
the	O
probable	O
cause	O
of	O
acute	O
hepatitis	B-Disease
in	O
this	O
patient	O
,	O
and	O
pathological	O
findings	O
suggested	O
drug	O
-	O
induced	O
toxic	B-Disease
hepatitis	I-Disease
.	O
Recurrence	O
of	O
hepatitis	B-Disease
attack	O
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	O
incident	O
had	O
been	O
communicated	O
to	O
the	O
attending	O
physician	O
who	O
prescribed	O
telithromycin	B-Chemical
the	O
second	O
time	O
.	O
CONCLUSION	O
:	O
Here	O
we	O
report	O
a	O
case	O
of	O
acute	O
hepatitis	B-Disease
probably	O
associated	O
with	O
the	O
administration	O
of	O
telithromycin	B-Chemical
.	O
A	O
study	O
on	O
the	O
effect	O
of	O
the	O
duration	O
of	O
subcutaneous	O
heparin	B-Chemical
injection	O
on	O
bruising	B-Disease
and	O
pain	B-Disease
.	O
AIM	O
:	O
This	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
bruising	B-Disease
and	O
pain	B-Disease
following	O
the	O
administration	O
of	O
the	O
subcutaneous	O
injection	O
of	O
heparin	B-Chemical
.	O
BACKGROUND	O
:	O
Although	O
different	O
methods	O
to	O
prevent	O
bruising	B-Disease
and	O
pain	B-Disease
following	O
the	O
subcutaneous	O
injection	O
of	O
heparin	B-Chemical
have	O
been	O
widely	O
studied	O
and	O
described	O
,	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
the	O
occurrence	O
of	O
bruising	B-Disease
and	O
pain	B-Disease
is	O
little	O
documented	O
.	O
DESIGN	O
:	O
This	O
study	O
was	O
designed	O
as	O
within	O
-	O
subject	O
,	O
quasi	O
-	O
experimental	O
research	O
.	O
METHOD	O
:	O
The	O
sample	O
for	O
the	O
study	O
consisted	O
of	O
50	O
patients	O
to	O
whom	O
subcutaneous	O
heparin	B-Chemical
was	O
administered	O
.	O
Heparin	B-Chemical
was	O
injected	O
over	O
10	O
seconds	O
on	O
the	O
right	O
abdominal	O
site	O
and	O
30	O
seconds	O
on	O
the	O
left	O
abdominal	O
site	O
.	O
Injections	O
areas	O
were	O
assessed	O
for	O
the	O
presence	O
of	O
bruising	B-Disease
at	O
48	O
and	O
72	O
hours	O
after	O
each	O
injection	O
.	O
Dimensions	O
of	O
the	O
bruising	B-Disease
on	O
the	O
heparin	B-Chemical
applied	O
areas	O
were	O
measured	O
using	O
transparent	O
millimetric	O
measuring	O
paper	O
.	O
The	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
was	O
used	O
to	O
measure	O
pain	B-Disease
intensity	O
and	O
a	O
stop	O
-	O
watch	O
was	O
used	O
to	O
time	O
the	O
pain	B-Disease
period	O
.	O
Data	O
were	O
analysed	O
using	O
chi	O
-	O
square	O
test	O
,	O
Mann	O
-	O
Whitney	O
U	O
,	O
Wilcoxon	O
signed	O
ranks	O
tests	O
and	O
correlation	O
.	O
RESULTS	O
:	O
The	O
percentage	O
of	O
bruising	B-Disease
occurrence	O
was	O
64	O
%	O
with	O
the	O
injection	O
of	O
10	O
seconds	O
duration	O
and	O
42	O
%	O
in	O
the	O
30	O
-	O
second	O
injection	O
.	O
It	O
was	O
determined	O
that	O
the	O
size	O
of	O
the	O
bruising	B-Disease
was	O
smaller	O
in	O
the	O
30	O
-	O
second	O
injection	O
.	O
Pain	B-Disease
intensity	O
and	O
pain	B-Disease
period	O
were	O
statistically	O
significantly	O
lower	O
for	O
the	O
30	O
-	O
second	O
injection	O
than	O
for	O
the	O
10	O
-	O
second	O
injection	O
.	O
CONCLUSIONS	O
:	O
It	O
was	O
determined	O
that	O
injection	O
duration	O
had	O
an	O
effect	O
on	O
bruising	B-Disease
and	O
pain	B-Disease
following	O
the	O
subcutaneous	O
administration	O
of	O
heparin	B-Chemical
.	O
This	O
study	O
should	O
be	O
repeated	O
on	O
a	O
larger	O
sample	O
.	O
RELEVANCE	O
TO	O
CLINICAL	O
PRACTICE	O
:	O
When	O
administering	O
subcutaneous	O
heparin	B-Chemical
injections	O
,	O
it	O
is	O
important	O
to	O
extend	O
the	O
duration	O
of	O
the	O
injection	O
.	O
Acute	B-Disease
liver	I-Disease
failure	I-Disease
in	O
two	O
patients	O
with	O
regular	O
alcohol	B-Chemical
consumption	O
ingesting	O
paracetamol	B-Chemical
at	O
therapeutic	O
dosage	O
.	O
BACKGROUND	O
:	O
The	O
possible	O
role	O
of	O
alcohol	B-Chemical
in	O
the	O
development	O
of	O
hepatotoxicity	B-Disease
associated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	B-Chemical
(	O
acetaminophen	B-Chemical
)	O
is	O
currently	O
debated	O
.	O
CASE	O
REPORT	O
:	O
We	O
describe	O
2	O
patients	O
who	O
were	O
regular	O
consumers	O
of	O
alcohol	B-Chemical
and	O
who	O
developed	O
liver	B-Disease
failure	I-Disease
within	O
3	O
-	O
5	O
days	O
after	O
hospitalization	O
and	O
stopping	O
alcohol	B-Chemical
consumption	O
while	O
being	O
treated	O
with	O
4	O
g	O
paracetamol	B-Chemical
/	O
day	O
.	O
A	O
paracetamol	B-Chemical
serum	O
level	O
obtained	O
in	O
one	O
of	O
these	O
patients	O
was	O
not	O
in	O
the	O
toxic	O
range	O
.	O
Possible	O
risk	O
factors	O
for	O
the	O
development	O
of	O
hepatotoxicity	B-Disease
in	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	B-Chemical
are	O
discussed	O
.	O
CONCLUSION	O
:	O
In	O
patients	O
with	O
risk	O
factors	O
,	O
e	O
.	O
g	O
.	O
regular	O
consumption	O
of	O
alcohol	B-Chemical
,	O
liver	B-Disease
failure	I-Disease
is	O
possible	O
when	O
therapeutic	O
doses	O
are	O
ingested	O
.	O
We	O
propose	O
that	O
the	O
paracetamol	B-Chemical
dose	O
should	O
not	O
exceed	O
2	O
g	O
/	O
day	O
in	O
such	O
patients	O
and	O
that	O
their	O
liver	O
function	O
should	O
be	O
monitored	O
closely	O
while	O
being	O
treated	O
with	O
paracetamol	B-Chemical
.	O
Associations	O
between	O
use	O
of	O
benzodiazepines	B-Chemical
or	O
related	O
drugs	O
and	O
health	O
,	O
physical	O
abilities	O
and	O
cognitive	O
function	O
:	O
a	O
non	O
-	O
randomised	O
clinical	O
study	O
in	O
the	O
elderly	O
.	O
OBJECTIVE	O
:	O
To	O
describe	O
associations	O
between	O
the	O
use	O
of	O
benzodiazepines	B-Chemical
or	O
related	O
drugs	O
(	O
BZDs	B-Chemical
/	O
RDs	O
)	O
and	O
health	O
,	O
functional	O
abilities	O
and	O
cognitive	O
function	O
in	O
the	O
elderly	O
.	O
METHODS	O
:	O
A	O
non	O
-	O
randomised	O
clinical	O
study	O
of	O
patients	O
aged	O
>	O
or	O
=	O
65	O
years	O
admitted	O
to	O
acute	O
hospital	O
wards	O
during	O
1	O
month	O
.	O
164	O
patients	O
(	O
mean	O
age	O
+	O
/	O
-	O
standard	O
deviation	O
[	O
SD	O
]	O
81	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
8	O
years	O
)	O
were	O
admitted	O
.	O
Of	O
these	O
,	O
nearly	O
half	O
(	O
n	O
=	O
78	O
)	O
had	O
used	O
BZDs	B-Chemical
/	O
RDs	O
before	O
admission	O
,	O
and	O
the	O
remainder	O
(	O
n	O
=	O
86	O
)	O
were	O
non	O
-	O
users	O
.	O
Cognitive	O
ability	O
was	O
assessed	O
by	O
the	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
.	O
Patients	O
scoring	O
>	O
or	O
=	O
20	O
MMSE	O
sum	O
points	O
were	O
interviewed	O
(	O
n	O
=	O
79	O
)	O
and	O
questioned	O
regarding	O
symptoms	O
and	O
functional	O
abilities	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O
Data	O
on	O
use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
before	O
admission	O
,	O
current	O
medications	O
and	O
discharge	O
diagnoses	O
were	O
collected	O
from	O
medical	O
records	O
.	O
Health	O
,	O
physical	O
abilities	O
and	O
cognitive	O
function	O
were	O
compared	O
between	O
BZD	O
/	O
RD	O
users	O
and	O
non	O
-	O
users	O
,	O
and	O
adjustments	O
were	O
made	O
for	O
confounding	O
variables	O
.	O
The	O
residual	O
serum	O
concentrations	O
of	O
oxazepam	B-Chemical
,	O
temazepam	B-Chemical
and	O
zopiclone	B-Chemical
were	O
analysed	O
.	O
RESULTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
duration	O
of	O
BZD	O
/	O
RD	O
use	O
was	O
7	O
+	O
/	O
-	O
7	O
years	O
(	O
range	O
1	O
-	O
31	O
)	O
.	O
Two	O
or	O
three	O
BZDs	B-Chemical
/	O
RDs	O
were	O
concomitantly	O
taken	O
by	O
26	O
%	O
of	O
users	O
(	O
n	O
=	O
20	O
)	O
.	O
Long	O
-	O
term	O
use	O
of	O
these	O
drugs	O
was	O
associated	O
with	O
female	O
sex	O
and	O
use	O
of	O
a	O
higher	O
number	O
of	O
drugs	O
with	O
effects	O
on	O
the	O
CNS	O
,	O
which	O
tended	O
to	O
be	O
related	O
to	O
diagnosed	O
dementia	B-Disease
.	O
After	O
adjustment	O
for	O
these	O
variables	O
as	O
confounders	O
,	O
use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
was	O
not	O
associated	O
with	O
cognitive	O
function	O
as	O
measured	O
by	O
the	O
MMSE	O
.	O
However	O
,	O
use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
was	O
associated	O
with	O
dizziness	B-Disease
,	O
inability	B-Disease
to	I-Disease
sleep	I-Disease
after	O
awaking	O
at	O
night	O
and	O
tiredness	B-Disease
in	O
the	O
mornings	O
during	O
the	O
week	O
prior	O
to	O
admission	O
and	O
with	O
stronger	O
depressive	B-Disease
symptoms	I-Disease
measured	O
at	O
the	O
beginning	O
of	O
the	O
hospital	O
stay	O
.	O
Use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
tended	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
ability	O
to	O
walk	O
and	O
shorter	O
night	O
-	O
time	O
sleep	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O
A	O
higher	O
residual	O
serum	O
concentration	O
of	O
temazepam	B-Chemical
correlated	O
with	O
a	O
lower	O
MMSE	O
sum	O
score	O
after	O
adjustment	O
for	O
confounding	O
variables	O
.	O
CONCLUSIONS	O
:	O
Long	O
-	O
term	O
use	O
and	O
concomitant	O
use	O
of	O
more	O
than	O
one	O
BZD	O
/	O
RD	O
were	O
common	O
in	O
elderly	O
patients	O
hospitalised	O
because	O
of	O
acute	O
illnesses	O
.	O
Long	O
-	O
term	O
use	O
was	O
associated	O
with	O
daytime	O
and	O
night	O
-	O
time	O
symptoms	O
indicative	O
of	O
poorer	O
health	O
and	O
potentially	O
caused	O
by	O
the	O
adverse	O
effects	O
of	O
these	O
drugs	O
.	O
Acute	O
vocal	B-Disease
fold	I-Disease
palsy	I-Disease
after	O
acute	O
disulfiram	B-Chemical
intoxication	O
.	O
Acute	O
peripheral	B-Disease
neuropathy	I-Disease
caused	O
by	O
a	O
disulfiram	B-Chemical
overdose	B-Disease
is	O
very	O
rare	O
and	O
there	O
is	O
no	O
report	O
of	O
it	O
leading	O
to	O
vocal	B-Disease
fold	I-Disease
palsy	I-Disease
.	O
A	O
49	O
-	O
year	O
-	O
old	O
woman	O
was	O
transferred	O
to	O
our	O
department	O
because	O
of	O
quadriparesis	B-Disease
,	O
lancinating	O
pain	B-Disease
,	O
sensory	B-Disease
loss	I-Disease
,	O
and	O
paresthesia	B-Disease
of	O
the	O
distal	O
limbs	O
.	O
One	O
month	O
previously	O
,	O
she	O
had	O
taken	O
a	O
single	O
high	O
dose	O
of	O
disulfiram	B-Chemical
(	O
130	O
tablets	O
of	O
ALCOHOL	B-Chemical
STOP	O
TAB	O
,	O
Shin	O
-	O
Poong	O
Pharm	O
.	O
Co	O
.	O
,	O
Ansan	O
,	O
Korea	O
)	O
in	O
a	O
suicide	O
attempt	O
.	O
She	O
was	O
not	O
an	O
alcoholic	O
.	O
For	O
the	O
first	O
few	O
days	O
after	O
ingestion	O
,	O
she	O
was	O
in	O
a	O
confused	O
state	O
and	O
had	O
mild	O
to	O
moderate	O
ataxia	B-Disease
and	O
giddiness	B-Disease
.	O
She	O
noticed	O
hoarseness	B-Disease
and	O
distally	O
accentuated	O
motor	O
and	O
sensory	O
dysfunction	O
after	O
she	O
had	O
recovered	O
from	O
this	O
state	O
.	O
A	O
nerve	O
conduction	O
study	O
was	O
consistent	O
with	O
severe	O
sensorimotor	O
axonal	O
polyneuropathy	B-Disease
.	O
Laryngeal	O
electromyography	O
(	O
thyroarytenoid	O
muscle	O
)	O
showed	O
ample	O
denervation	O
potentials	O
.	O
Laryngoscopy	O
revealed	O
asymmetric	O
vocal	O
fold	O
movements	O
during	O
phonation	O
.	O
Her	O
vocal	O
change	O
and	O
weakness	O
began	O
to	O
improve	O
spontaneously	O
about	O
3	O
weeks	O
after	O
transfer	O
.	O
This	O
was	O
a	O
case	O
of	O
acute	O
palsy	B-Disease
of	O
the	O
recurrent	O
laryngeal	O
nerve	O
and	O
superimposed	O
severe	O
acute	O
sensorimotor	O
axonal	O
polyneuropathy	B-Disease
caused	O
by	O
high	O
-	O
dose	O
disulfiram	B-Chemical
intoxication	O
.	O
Encephalopathy	B-Disease
induced	O
by	O
levetiracetam	B-Chemical
added	O
to	O
valproate	B-Chemical
.	O
BACKGROUND	O
:	O
We	O
report	O
on	O
the	O
manifestation	O
of	O
a	O
levetiracetam	B-Chemical
(	O
LEV	B-Chemical
)	O
-	O
induced	O
encephalopathy	B-Disease
.	O
FINDINGS	O
:	O
A	O
28	O
-	O
year	O
-	O
old	O
man	O
suffering	O
from	O
idiopathic	B-Disease
epilepsy	I-Disease
with	O
generalized	O
seizures	B-Disease
was	O
treated	O
with	O
LEV	B-Chemical
(	O
3000	O
mg	O
)	O
added	O
to	O
valproate	B-Chemical
(	O
VPA	B-Chemical
)	O
(	O
2000	O
mg	O
)	O
.	O
Frequency	O
of	O
generalized	O
tonic	B-Disease
-	I-Disease
clonic	I-Disease
seizures	I-Disease
increased	O
from	O
one	O
per	O
6	O
months	O
to	O
two	O
per	O
month	O
.	O
Neuropsychological	O
testing	O
showed	O
impaired	B-Disease
word	I-Disease
fluency	I-Disease
,	I-Disease
psychomotor	I-Disease
speed	I-Disease
and	I-Disease
working	I-Disease
memory	I-Disease
.	O
The	O
interictal	O
electroencephalogram	O
(	O
EEG	O
)	O
showed	O
a	O
generalized	O
slowing	O
to	O
5	O
per	O
second	O
theta	O
rhythms	O
with	O
bilateral	O
generalized	O
high	O
-	O
amplitude	O
discharges	O
.	O
OUTCOME	O
:	O
Following	O
discontinuation	O
of	O
LEV	B-Chemical
,	O
EEG	O
and	O
neuropsychological	O
findings	O
improved	O
and	O
seizure	B-Disease
frequency	O
decreased	O
.	O
Norepinephrine	B-Chemical
signaling	O
through	O
beta	O
-	O
adrenergic	O
receptors	O
is	O
critical	O
for	O
expression	O
of	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
.	O
BACKGROUND	O
:	O
Cocaine	B-Chemical
is	O
a	O
widely	O
abused	O
psychostimulant	O
that	O
has	O
both	O
rewarding	O
and	O
aversive	O
properties	O
.	O
While	O
the	O
mechanisms	O
underlying	O
cocaine	B-Chemical
'	O
s	O
rewarding	O
effects	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
attention	O
has	O
been	O
paid	O
to	O
the	O
unpleasant	O
behavioral	O
states	O
induced	O
by	O
cocaine	B-Chemical
,	O
such	O
as	O
anxiety	B-Disease
.	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
performance	O
of	O
dopamine	B-Chemical
beta	O
-	O
hydroxylase	O
knockout	O
(	O
Dbh	O
-	O
/	O
-	O
)	O
mice	O
,	O
which	O
lack	O
norepinephrine	B-Chemical
(	O
NE	B-Chemical
)	O
,	O
in	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
to	O
examine	O
the	O
contribution	O
of	O
noradrenergic	O
signaling	O
to	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
.	O
RESULTS	O
:	O
We	O
found	O
that	O
cocaine	B-Chemical
dose	O
-	O
dependently	O
increased	O
anxiety	B-Disease
-	O
like	O
behavior	O
in	O
control	O
(	O
Dbh	O
+	O
/	O
-	O
)	O
mice	O
,	O
as	O
measured	O
by	O
a	O
decrease	O
in	O
open	O
arm	O
exploration	O
.	O
The	O
Dbh	O
-	O
/	O
-	O
mice	O
had	O
normal	O
baseline	O
performance	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
resistant	O
to	O
the	O
anxiogenic	O
effects	O
of	O
cocaine	B-Chemical
.	O
Cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
was	O
also	O
attenuated	O
in	O
Dbh	O
+	O
/	O
-	O
mice	O
following	O
administration	O
of	O
disulfiram	B-Chemical
,	O
a	O
dopamine	B-Chemical
beta	O
-	O
hydroxylase	O
(	O
DBH	O
)	O
inhibitor	O
.	O
In	O
experiments	O
using	O
specific	O
adrenergic	O
antagonists	O
,	O
we	O
found	O
that	O
pretreatment	O
with	O
the	O
beta	O
-	O
adrenergic	O
receptor	O
antagonist	O
propranolol	B-Chemical
blocked	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
-	O
like	O
behavior	O
in	O
Dbh	O
+	O
/	O
-	O
and	O
wild	O
-	O
type	O
C57BL6	O
/	O
J	O
mice	O
,	O
while	O
the	O
alpha	O
(	O
1	O
)	O
antagonist	O
prazosin	B-Chemical
and	O
the	O
alpha	O
(	O
2	O
)	O
antagonist	O
yohimbine	B-Chemical
had	O
no	O
effect	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
noradrenergic	O
signaling	O
via	O
beta	O
-	O
adrenergic	O
receptors	O
is	O
required	O
for	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
in	O
mice	O
.	O
Hypothalamic	O
prolactin	O
receptor	O
messenger	O
ribonucleic	B-Chemical
acid	I-Chemical
levels	O
,	O
prolactin	O
signaling	O
,	O
and	O
hyperprolactinemic	B-Disease
inhibition	O
of	O
pulsatile	O
luteinizing	O
hormone	O
secretion	O
are	O
dependent	O
on	O
estradiol	B-Chemical
.	O
Hyperprolactinemia	B-Disease
can	O
reduce	O
fertility	O
and	O
libido	O
.	O
Although	O
central	O
prolactin	O
actions	O
are	O
thought	O
to	O
contribute	O
to	O
this	O
,	O
the	O
mechanisms	O
are	O
poorly	O
understood	O
.	O
We	O
first	O
tested	O
whether	O
chronic	O
hyperprolactinemia	B-Disease
inhibited	O
two	O
neuroendocrine	O
parameters	O
necessary	O
for	O
female	O
fertility	O
:	O
pulsatile	O
LH	O
secretion	O
and	O
the	O
estrogen	B-Chemical
-	O
induced	O
LH	O
surge	O
.	O
Chronic	O
hyperprolactinemia	B-Disease
induced	O
by	O
the	O
dopamine	B-Chemical
antagonist	O
sulpiride	B-Chemical
caused	O
a	O
40	O
%	O
reduction	O
LH	O
pulse	O
frequency	O
in	O
ovariectomized	O
rats	O
,	O
but	O
only	O
in	O
the	O
presence	O
of	O
chronic	O
low	O
levels	O
of	O
estradiol	B-Chemical
.	O
Sulpiride	B-Chemical
did	O
not	O
affect	O
the	O
magnitude	O
of	O
a	O
steroid	B-Chemical
-	O
induced	O
LH	O
surge	O
or	O
the	O
percentage	O
of	O
GnRH	O
neurons	O
activated	O
during	O
the	O
surge	O
.	O
Estradiol	B-Chemical
is	O
known	O
to	O
influence	O
expression	O
of	O
the	O
long	O
form	O
of	O
prolactin	O
receptors	O
(	O
PRL	O
-	O
R	O
)	O
and	O
components	O
of	O
prolactin	O
'	O
s	O
signaling	O
pathway	O
.	O
To	O
test	O
the	O
hypothesis	O
that	O
estrogen	B-Chemical
increases	O
PRL	O
-	O
R	O
expression	O
and	O
sensitivity	O
to	O
prolactin	O
,	O
we	O
next	O
demonstrated	O
that	O
estradiol	B-Chemical
greatly	O
augments	O
prolactin	O
-	O
induced	O
STAT5	O
activation	O
.	O
Lastly	O
,	O
we	O
measured	O
PRL	O
-	O
R	O
and	O
suppressor	O
of	O
cytokine	O
signaling	O
(	O
SOCS	O
-	O
1	O
and	O
-	O
3	O
and	O
CIS	O
,	O
which	O
reflect	O
the	O
level	O
of	O
prolactin	O
signaling	O
)	O
mRNAs	O
in	O
response	O
to	O
sulpiride	B-Chemical
and	O
estradiol	B-Chemical
.	O
Sulpiride	B-Chemical
induced	O
only	O
SOCS	O
-	O
1	O
in	O
the	O
medial	O
preoptic	O
area	O
,	O
where	O
GnRH	O
neurons	O
are	O
regulated	O
,	O
but	O
in	O
the	O
arcuate	O
nucleus	O
and	O
choroid	O
plexus	O
,	O
PRL	O
-	O
R	O
,	O
SOCS	O
-	O
3	O
,	O
and	O
CIS	O
mRNA	O
levels	O
were	O
also	O
induced	O
.	O
Estradiol	B-Chemical
enhanced	O
these	O
effects	O
on	O
SOCS	O
-	O
3	O
and	O
CIS	O
.	O
Interestingly	O
,	O
estradiol	B-Chemical
also	O
induced	O
PRL	O
-	O
R	O
,	O
SOCS	O
-	O
3	O
,	O
and	O
CIS	O
mRNA	O
levels	O
independently	O
.	O
These	O
data	O
show	O
that	O
GnRH	O
pulse	O
frequency	O
is	O
inhibited	O
by	O
chronic	O
hyperprolactinemia	B-Disease
in	O
a	O
steroid	B-Chemical
-	O
dependent	O
manner	O
.	O
They	O
also	O
provide	O
evidence	O
for	O
estradiol	B-Chemical
-	O
dependent	O
and	O
brain	O
region	O
-	O
specific	O
regulation	O
of	O
PRL	O
-	O
R	O
expression	O
and	O
signaling	O
responses	O
by	O
prolactin	O
.	O
Clonidine	B-Chemical
for	O
attention	B-Disease
-	I-Disease
deficit	I-Disease
/	I-Disease
hyperactivity	I-Disease
disorder	I-Disease
:	O
II	O
.	O
ECG	O
changes	O
and	O
adverse	O
events	O
analysis	O
.	O
OBJECTIVE	O
:	O
To	O
examine	O
the	O
safety	O
and	O
tolerability	O
of	O
clonidine	B-Chemical
used	O
alone	O
or	O
with	O
methylphenidate	B-Chemical
in	O
children	O
with	O
attention	B-Disease
-	I-Disease
deficit	I-Disease
/	I-Disease
hyperactivity	I-Disease
disorder	I-Disease
(	O
ADHD	B-Disease
)	O
.	O
METHOD	O
:	O
In	O
a	O
16	O
-	O
week	O
multicenter	O
,	O
double	O
-	O
blind	O
trial	O
,	O
122	O
children	O
with	O
ADHD	B-Disease
were	O
randomly	O
assigned	O
to	O
clonidine	B-Chemical
(	O
n	O
=	O
31	O
)	O
,	O
methylphenidate	B-Chemical
(	O
n	O
=	O
29	O
)	O
,	O
clonidine	B-Chemical
and	O
methylphenidate	B-Chemical
(	O
n	O
=	O
32	O
)	O
,	O
or	O
placebo	O
(	O
n	O
=	O
30	O
)	O
.	O
Doses	O
were	O
flexibly	O
titrated	O
up	O
to	O
0	O
.	O
6	O
mg	O
/	O
day	O
for	O
clonidine	B-Chemical
and	O
60	O
mg	O
/	O
day	O
for	O
methylphenidate	B-Chemical
(	O
both	O
with	O
divided	O
dosing	O
)	O
.	O
Groups	O
were	O
compared	O
regarding	O
adverse	O
events	O
and	O
changes	O
from	O
baseline	O
to	O
week	O
16	O
in	O
electrocardiograms	O
and	O
vital	O
signs	O
.	O
RESULTS	O
:	O
There	O
were	O
more	O
incidents	O
of	O
bradycardia	B-Disease
in	O
subjects	O
treated	O
with	O
clonidine	B-Chemical
compared	O
with	O
those	O
not	O
treated	O
with	O
clonidine	B-Chemical
(	O
17	O
.	O
5	O
%	O
versus	O
3	O
.	O
4	O
%	O
;	O
p	O
=	O
.	O
02	O
)	O
,	O
but	O
no	O
other	O
significant	O
group	O
differences	O
regarding	O
electrocardiogram	O
and	O
other	O
cardiovascular	O
outcomes	O
.	O
There	O
were	O
no	O
suggestions	O
of	O
interactions	O
between	O
clonidine	B-Chemical
and	O
methylphenidate	B-Chemical
regarding	O
cardiovascular	O
outcomes	O
.	O
Moderate	O
or	O
severe	O
adverse	O
events	O
were	O
more	O
common	O
in	O
subjects	O
on	O
clonidine	B-Chemical
(	O
79	O
.	O
4	O
%	O
versus	O
49	O
.	O
2	O
%	O
;	O
p	O
=	O
.	O
0006	O
)	O
but	O
not	O
associated	O
with	O
higher	O
rates	O
of	O
early	O
study	O
withdrawal	O
.	O
Drowsiness	B-Disease
was	O
common	O
on	O
clonidine	B-Chemical
,	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
weeks	O
.	O
CONCLUSIONS	O
:	O
Clonidine	B-Chemical
,	O
used	O
alone	O
or	O
with	O
methylphenidate	B-Chemical
,	O
appears	O
safe	O
and	O
well	O
tolerated	O
in	O
childhood	O
ADHD	B-Disease
.	O
Physicians	O
prescribing	O
clonidine	B-Chemical
should	O
monitor	O
for	O
bradycardia	B-Disease
and	O
advise	O
patients	O
about	O
the	O
high	O
likelihood	O
of	O
initial	O
drowsiness	B-Disease
.	O
Renal	B-Disease
Fanconi	I-Disease
syndrome	I-Disease
and	O
myopathy	B-Disease
after	O
liver	O
transplantation	O
:	O
drug	O
-	O
related	O
mitochondrial	B-Disease
cytopathy	I-Disease
?	O
Advances	O
in	O
the	O
field	O
of	O
transplantation	O
provide	O
a	O
better	O
quality	O
of	O
life	O
and	O
allow	O
more	O
favorable	O
conditions	O
for	O
growth	O
and	O
development	O
in	O
children	O
.	O
However	O
,	O
combinations	O
of	O
different	O
therapeutic	O
regimens	O
require	O
consideration	O
of	O
potential	O
adverse	O
reactions	O
.	O
We	O
describe	O
a	O
15	O
-	O
yr	O
-	O
old	O
girl	O
who	O
had	O
orthotopic	O
liver	O
transplantation	O
because	O
of	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
Tacrolimus	B-Chemical
,	O
MMF	B-Chemical
,	O
and	O
steroids	B-Chemical
were	O
given	O
as	O
immunosuppressant	O
.	O
Lamivudine	B-Chemical
was	O
added	O
because	O
of	O
de	O
nova	O
hepatitis	B-Disease
B	I-Disease
infection	I-Disease
during	O
her	O
follow	O
-	O
up	O
.	O
Three	O
yr	O
after	O
transplantation	O
she	O
developed	O
renal	B-Disease
Fanconi	I-Disease
syndrome	I-Disease
with	O
severe	O
metabolic	B-Disease
acidosis	I-Disease
,	O
hypophosphatemia	B-Disease
,	O
glycosuria	B-Disease
,	O
and	O
aminoaciduria	B-Disease
.	O
Although	O
tacrolimus	B-Chemical
was	O
suspected	O
to	O
be	O
the	O
cause	O
of	O
late	O
post	O
-	O
transplant	O
renal	O
acidosis	B-Disease
and	O
was	O
replaced	O
by	O
sirolimus	B-Chemical
,	O
acidosis	B-Disease
,	O
and	O
electrolyte	O
imbalance	O
got	O
worse	O
.	O
Proximal	O
muscle	B-Disease
weakness	I-Disease
has	O
developed	O
during	O
her	O
follow	O
-	O
up	O
.	O
Fanconi	B-Disease
syndrome	I-Disease
,	O
as	O
well	O
as	O
myopathy	B-Disease
,	O
is	O
well	O
recognized	O
in	O
patients	O
with	O
mitochondrial	B-Disease
disorders	I-Disease
and	O
caused	O
by	O
depletion	O
of	O
mtDNA	O
.	O
We	O
suggest	O
that	O
our	O
patient	O
'	O
s	O
tubular	B-Disease
dysfunction	I-Disease
and	O
myopathy	B-Disease
may	O
have	O
resulted	O
from	O
mitochondrial	B-Disease
dysfunction	I-Disease
which	O
is	O
triggered	O
by	O
tacrolimus	B-Chemical
and	O
augmented	O
by	O
lamivudine	B-Chemical
.	O
Higher	O
optical	O
density	O
of	O
an	O
antigen	O
assay	O
predicts	O
thrombosis	B-Disease
in	O
patients	O
with	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
.	O
OBJECTIVES	O
:	O
To	O
correlate	O
optical	O
density	O
and	O
percent	O
inhibition	O
of	O
a	O
two	O
-	O
step	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
(	O
HIT	B-Disease
)	O
antigen	O
assay	O
with	O
thrombosis	B-Disease
;	O
the	O
assay	O
utilizes	O
reaction	O
inhibition	O
characteristics	O
of	O
a	O
high	O
heparin	B-Chemical
concentration	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
more	O
than	O
50	O
%	O
decrease	O
in	O
platelet	O
count	O
or	O
thrombocytopenia	B-Disease
(	O
<	O
150	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
after	O
exposure	O
to	O
heparin	B-Chemical
,	O
who	O
had	O
a	O
positive	O
two	O
-	O
step	O
antigen	O
assay	O
[	O
optical	O
density	O
(	O
OD	O
)	O
>	O
0	O
.	O
4	O
and	O
>	O
50	O
inhibition	O
with	O
high	O
concentration	O
of	O
heparin	B-Chemical
]	O
were	O
included	O
in	O
the	O
study	O
.	O
RESULTS	O
:	O
Forty	O
of	O
94	O
HIT	B-Disease
patients	O
had	O
thrombosis	B-Disease
at	O
diagnosis	O
;	O
54	O
/	O
94	O
had	O
isolated	O
-	O
HIT	B-Disease
without	O
thrombosis	B-Disease
.	O
Eight	O
of	O
the	O
isolated	O
-	O
HIT	B-Disease
patients	O
developed	O
thrombosis	B-Disease
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	O
of	O
48	O
patients	O
had	O
thrombosis	B-Disease
at	O
day	O
30	O
.	O
At	O
diagnosis	O
there	O
was	O
no	O
significant	O
difference	O
in	O
OD	O
between	O
HIT	B-Disease
patients	O
with	O
thrombosis	B-Disease
and	O
those	O
with	O
isolated	O
-	O
HIT	B-Disease
.	O
However	O
,	O
OD	O
was	O
significantly	O
higher	O
in	O
all	O
patients	O
with	O
thrombosis	B-Disease
(	O
n	O
=	O
48	O
,	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
89	O
)	O
,	O
including	O
isolated	O
-	O
HIT	B-Disease
patients	O
who	O
later	O
developed	O
thrombosis	B-Disease
within	O
30	O
d	O
(	O
n	O
=	O
8	O
,	O
1	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
64	O
)	O
as	O
compared	O
to	O
isolated	O
-	O
HIT	B-Disease
patients	O
who	O
did	O
not	O
develop	O
thrombosis	B-Disease
(	O
0	O
.	O
96	O
+	O
/	O
-	O
0	O
.	O
75	O
;	O
P	O
=	O
0	O
.	O
011	O
and	O
P	O
=	O
0	O
.	O
008	O
)	O
.	O
The	O
Receiver	O
Operative	O
Characteristic	O
Curve	O
showed	O
that	O
OD	O
>	O
1	O
.	O
27	O
in	O
the	O
isolated	O
-	O
HIT	B-Disease
group	O
had	O
a	O
significantly	O
higher	O
chance	O
of	O
developing	O
thrombosis	B-Disease
by	O
day	O
30	O
.	O
None	O
of	O
these	O
groups	O
showed	O
significant	O
difference	O
in	O
percent	O
inhibition	O
.	O
Multivariate	O
analysis	O
showed	O
a	O
2	O
.	O
8	O
-	O
fold	O
increased	O
risk	O
of	O
thrombosis	B-Disease
in	O
females	O
.	O
Similarly	O
,	O
thrombotic	B-Disease
risk	O
increased	O
with	O
age	O
and	O
OD	O
values	O
.	O
CONCLUSION	O
:	O
Higher	O
OD	O
is	O
associated	O
with	O
significant	O
risk	O
of	O
subsequent	O
thrombosis	B-Disease
in	O
patients	O
with	O
isolated	O
-	O
HIT	B-Disease
;	O
percent	O
inhibition	O
,	O
however	O
,	O
was	O
not	O
predictive	O
.	O
Thalidomide	B-Chemical
has	O
limited	O
single	O
-	O
agent	O
activity	O
in	O
relapsed	O
or	O
refractory	O
indolent	O
non	B-Disease
-	I-Disease
Hodgkin	I-Disease
lymphomas	I-Disease
:	O
a	O
phase	O
II	O
trial	O
of	O
the	O
Cancer	B-Disease
and	O
Leukemia	B-Disease
Group	O
B	O
.	O
Thalidomide	B-Chemical
is	O
an	O
immunomodulatory	O
agent	O
with	O
demonstrated	O
activity	O
in	O
multiple	B-Disease
myeloma	I-Disease
,	O
mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
and	O
lymphoplasmacytic	B-Disease
lymphoma	I-Disease
.	O
Its	O
activity	O
is	O
believed	O
to	O
be	O
due	O
modulation	O
of	O
the	O
tumour	B-Disease
milieu	O
,	O
including	O
downregulation	O
of	O
angiogenesis	O
and	O
inflammatory	O
cytokines	O
.	O
Between	O
July	O
2001	O
and	O
April	O
2004	O
,	O
24	O
patients	O
with	O
relapsed	O
/	O
refractory	O
indolent	O
lymphomas	B-Disease
received	O
thalidomide	B-Chemical
200	O
mg	O
daily	O
with	O
escalation	O
by	O
100	O
mg	O
daily	O
every	O
1	O
-	O
2	O
weeks	O
as	O
tolerated	O
,	O
up	O
to	O
a	O
maximum	O
of	O
800	O
mg	O
daily	O
.	O
Patients	O
had	O
received	O
a	O
median	O
of	O
2	O
(	O
range	O
,	O
1	O
-	O
4	O
)	O
prior	O
regimens	O
.	O
Of	O
24	O
evaluable	O
patients	O
,	O
two	O
achieved	O
a	O
complete	O
remission	O
and	O
one	O
achieved	O
a	O
partial	O
remission	O
for	O
an	O
overall	O
response	O
rate	O
of	O
12	O
.	O
5	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
2	O
.	O
6	O
-	O
32	O
.	O
4	O
%	O
)	O
.	O
Eleven	O
patients	O
progressed	O
during	O
therapy	O
.	O
Grade	O
3	O
-	O
4	O
adverse	O
effects	O
included	O
myelosuppression	B-Disease
,	O
fatigue	B-Disease
,	O
somnolence	B-Disease
/	O
depressed	B-Disease
mood	I-Disease
,	O
neuropathy	B-Disease
and	O
dyspnea	B-Disease
.	O
Of	O
concern	O
was	O
the	O
occurrence	O
of	O
four	O
thromboembolic	B-Disease
events	O
.	O
Our	O
results	O
failed	O
to	O
demonstrate	O
an	O
important	O
response	O
rate	O
to	O
single	O
agent	O
thalidomide	B-Chemical
in	O
indolent	O
lymphomas	B-Disease
and	O
contrast	O
with	O
the	O
higher	O
activity	O
level	O
reported	O
with	O
the	O
second	O
generation	O
immunomodulatory	O
agent	O
,	O
lenalidomide	B-Chemical
.	O
Sex	O
differences	O
in	O
NMDA	B-Chemical
antagonist	O
enhancement	O
of	O
morphine	B-Chemical
antihyperalgesia	O
in	O
a	O
capsaicin	B-Chemical
model	O
of	O
persistent	O
pain	B-Disease
:	O
comparisons	O
to	O
two	O
models	O
of	O
acute	B-Disease
pain	I-Disease
.	O
In	O
acute	B-Disease
pain	I-Disease
models	O
,	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
antagonists	O
enhance	O
the	O
antinociceptive	O
effects	O
of	O
morphine	B-Chemical
to	O
a	O
greater	O
extent	O
in	O
males	O
than	O
females	O
.	O
The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
extend	O
these	O
findings	O
to	O
a	O
persistent	O
pain	B-Disease
model	O
which	O
could	O
be	O
distinguished	O
from	O
acute	B-Disease
pain	I-Disease
models	O
on	O
the	O
basis	O
of	O
the	O
nociceptive	O
fibers	O
activated	O
,	O
neurochemical	O
substrates	O
,	O
and	O
duration	O
of	O
the	O
nociceptive	O
stimulus	O
.	O
To	O
this	O
end	O
,	O
persistent	O
hyperalgesia	B-Disease
was	O
induced	O
by	O
administration	O
of	O
capsaicin	B-Chemical
in	O
the	O
tail	O
of	O
gonadally	O
intact	O
F344	O
rats	O
,	O
following	O
which	O
the	O
tail	O
was	O
immersed	O
in	O
a	O
mildly	O
noxious	O
thermal	O
stimulus	O
,	O
and	O
tail	O
-	O
withdrawal	O
latencies	O
measured	O
.	O
For	O
comparison	O
,	O
tests	O
were	O
conducted	O
in	O
two	O
acute	B-Disease
pain	I-Disease
models	O
,	O
the	O
hotplate	O
and	O
warm	O
water	O
tail	O
-	O
withdrawal	O
procedures	O
.	O
In	O
males	O
,	O
the	O
non	O
-	O
competitive	O
NMDA	B-Chemical
antagonist	O
dextromethorphan	B-Chemical
enhanced	O
the	O
antihyperalgesic	O
effect	O
of	O
low	O
to	O
moderate	O
doses	O
of	O
morphine	B-Chemical
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O
Across	O
the	O
doses	O
and	O
pretreatment	O
times	O
examined	O
,	O
enhancement	O
was	O
not	O
observed	O
in	O
females	O
.	O
Enhancement	O
of	O
morphine	B-Chemical
antinociception	O
by	O
dextromethorphan	B-Chemical
was	O
seen	O
in	O
both	O
males	O
and	O
females	O
in	O
the	O
acute	B-Disease
pain	I-Disease
models	O
,	O
with	O
the	O
magnitude	O
of	O
this	O
effect	O
being	O
greater	O
in	O
males	O
.	O
These	O
findings	O
demonstrate	O
a	O
sexually	O
-	O
dimorphic	O
interaction	O
between	O
NMDA	B-Chemical
antagonists	O
and	O
morphine	B-Chemical
in	O
a	O
persistent	O
pain	B-Disease
model	O
that	O
can	O
be	O
distinguished	O
from	O
those	O
observed	O
in	O
acute	B-Disease
pain	I-Disease
models	O
.	O
Development	O
of	O
proteinuria	B-Disease
after	O
switch	O
to	O
sirolimus	B-Chemical
-	O
based	O
immunosuppression	O
in	O
long	O
-	O
term	O
cardiac	O
transplant	O
patients	O
.	O
Calcineurin	O
-	O
inhibitor	O
therapy	O
can	O
lead	O
to	O
renal	B-Disease
dysfunction	I-Disease
in	O
heart	O
transplantation	O
patients	O
.	O
The	O
novel	O
immunosuppressive	O
(	O
IS	O
)	O
drug	O
sirolmus	B-Chemical
(	O
Srl	B-Chemical
)	O
lacks	O
nephrotoxic	B-Disease
effects	O
;	O
however	O
,	O
proteinuria	B-Disease
associated	O
with	O
Srl	B-Chemical
has	O
been	O
reported	O
following	O
renal	O
transplantation	O
.	O
In	O
cardiac	O
transplantation	O
,	O
the	O
incidence	O
of	O
proteinuria	B-Disease
associated	O
with	O
Srl	B-Chemical
is	O
unknown	O
.	O
In	O
this	O
study	O
,	O
long	O
-	O
term	O
cardiac	O
transplant	O
patients	O
were	O
switched	O
from	O
cyclosporine	B-Chemical
to	O
Srl	B-Chemical
-	O
based	O
IS	O
.	O
Concomitant	O
IS	O
consisted	O
of	O
mycophenolate	B-Chemical
mofetil	I-Chemical
+	O
/	O
-	O
steroids	B-Chemical
.	O
Proteinuria	O
increased	O
significantly	O
from	O
a	O
median	O
of	O
0	O
.	O
13	O
g	O
/	O
day	O
(	O
range	O
0	O
-	O
5	O
.	O
7	O
)	O
preswitch	O
to	O
0	O
.	O
23	O
g	O
/	O
day	O
(	O
0	O
-	O
9	O
.	O
88	O
)	O
at	O
24	O
months	O
postswitch	O
(	O
p	O
=	O
0	O
.	O
0024	O
)	O
.	O
Before	O
the	O
switch	O
,	O
11	O
.	O
5	O
%	O
of	O
patients	O
had	O
high	O
-	O
grade	O
proteinuria	B-Disease
(	O
>	O
1	O
.	O
0	O
g	O
/	O
day	O
)	O
;	O
this	O
increased	O
to	O
22	O
.	O
9	O
%	O
postswitch	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O
ACE	B-Chemical
inhibitor	I-Chemical
and	O
angiotensin	B-Chemical
-	I-Chemical
releasing	I-Chemical
blocker	I-Chemical
(	O
ARB	B-Chemical
)	O
therapy	O
reduced	O
proteinuria	B-Disease
development	O
.	O
Patients	O
without	O
proteinuria	B-Disease
had	O
increased	O
renal	O
function	O
(	O
median	O
42	O
.	O
5	O
vs	O
.	O
64	O
.	O
1	O
,	O
p	O
=	O
0	O
.	O
25	O
)	O
,	O
whereas	O
patients	O
who	O
developed	O
high	O
-	O
grade	O
proteinuria	B-Disease
showed	O
decreased	O
renal	O
function	O
at	O
the	O
end	O
of	O
follow	O
-	O
up	O
(	O
median	O
39	O
.	O
6	O
vs	O
.	O
29	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
125	O
)	O
.	O
Thus	O
,	O
proteinuria	B-Disease
may	O
develop	O
in	O
cardiac	O
transplant	O
patients	O
after	O
switch	O
to	O
Srl	B-Chemical
,	O
which	O
may	O
have	O
an	O
adverse	O
effect	O
on	O
renal	O
function	O
in	O
these	O
patients	O
.	O
Srl	B-Chemical
should	O
be	O
used	O
with	O
ACEi	B-Chemical
/	O
ARB	B-Chemical
therapy	O
and	O
patients	O
monitored	O
for	O
proteinuria	B-Disease
and	O
increased	O
renal	B-Disease
dysfunction	I-Disease
.	O
Ginsenoside	B-Chemical
Rg1	I-Chemical
restores	O
the	O
impairment	B-Disease
of	I-Disease
learning	I-Disease
induced	O
by	O
chronic	O
morphine	B-Chemical
administration	O
in	O
rats	O
.	O
Rg1	B-Chemical
,	O
as	O
a	O
ginsenoside	B-Chemical
extracted	O
from	O
Panax	O
ginseng	O
,	O
could	O
ameliorate	O
spatial	O
learning	B-Disease
impairment	I-Disease
.	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
Rg1	B-Chemical
might	O
be	O
a	O
useful	O
agent	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
the	O
adverse	O
effects	O
of	O
morphine	B-Chemical
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
Rg1	B-Chemical
on	O
learning	B-Disease
impairment	I-Disease
by	O
chronic	O
morphine	B-Chemical
administration	O
and	O
the	O
mechanism	O
responsible	O
for	O
this	O
effect	O
.	O
Male	O
rats	O
were	O
subcutaneously	O
injected	O
with	O
morphine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
twice	O
a	O
day	O
at	O
12	O
hour	O
intervals	O
for	O
10	O
days	O
,	O
and	O
Rg1	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
was	O
intraperitoneally	O
injected	O
2	O
hours	O
after	O
the	O
second	O
injection	O
of	O
morphine	B-Chemical
once	O
a	O
day	O
for	O
10	O
days	O
.	O
Spatial	O
learning	O
capacity	O
was	O
assessed	O
in	O
the	O
Morris	O
water	O
maze	O
.	O
The	O
results	O
showed	O
that	O
rats	O
treated	O
with	O
Morphine	B-Chemical
/	O
Rg1	B-Chemical
decreased	O
escape	O
latency	O
and	O
increased	O
the	O
time	O
spent	O
in	O
platform	O
quadrant	O
and	O
entering	O
frequency	O
.	O
By	O
implantation	O
of	O
electrodes	O
and	O
electrophysiological	O
recording	O
in	O
vivo	O
,	O
the	O
results	O
showed	O
that	O
Rg1	B-Chemical
restored	O
the	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
impaired	O
by	O
morphine	B-Chemical
in	O
both	O
freely	O
moving	O
and	O
anaesthetised	O
rats	O
.	O
The	O
electrophysiological	O
recording	O
in	O
vitro	O
showed	O
that	O
Rg1	B-Chemical
restored	O
the	O
LTP	O
in	O
slices	O
from	O
the	O
rats	O
treated	O
with	O
morphine	B-Chemical
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
slices	O
from	O
normal	O
saline	O
-	O
or	O
morphine	B-Chemical
/	O
Rg1	B-Chemical
-	O
treated	O
rats	O
;	O
this	O
restoration	O
could	O
be	O
inhibited	O
by	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
receptor	O
antagonist	O
MK801	B-Chemical
.	O
We	O
conclude	O
that	O
Rg1	B-Chemical
may	O
significantly	O
improve	O
the	O
spatial	O
learning	O
capacity	O
impaired	O
by	O
chonic	O
morphine	B-Chemical
administration	O
and	O
restore	O
the	O
morphine	B-Chemical
-	O
inhibited	O
LTP	O
.	O
This	O
effect	O
is	O
NMDA	B-Chemical
receptor	O
dependent	O
.	O
Synthesis	O
of	O
N	B-Chemical
-	I-Chemical
pyrimidinyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
phenoxyacetamides	I-Chemical
as	O
adenosine	B-Chemical
A2A	O
receptor	O
antagonists	O
.	O
A	O
series	O
of	O
N	B-Chemical
-	I-Chemical
pyrimidinyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
phenoxyacetamide	I-Chemical
adenosine	B-Chemical
A	O
(	O
2A	O
)	O
antagonists	O
is	O
described	O
.	O
SAR	O
studies	O
led	O
to	O
compound	O
14	O
with	O
excellent	O
potency	O
(	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
4	O
nM	O
)	O
,	O
selectivity	O
(	O
A	O
(	O
1	O
)	O
/	O
A	O
(	O
2A	O
)	O
>	O
100	O
)	O
,	O
and	O
efficacy	O
(	O
MED	O
10	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
in	O
the	O
rat	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
model	O
for	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
Evidence	O
for	O
an	O
involvement	O
of	O
D1	O
and	O
D2	O
dopamine	B-Chemical
receptors	O
in	O
mediating	O
nicotine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
in	O
rats	O
.	O
Previous	O
studies	O
have	O
suggested	O
that	O
repeated	O
exposure	O
of	O
rats	O
to	O
the	O
drug	O
or	O
to	O
the	O
experimental	O
environment	O
is	O
necessary	O
to	O
observe	O
nicotine	B-Chemical
-	O
induced	O
locomotor	O
stimulation	O
.	O
In	O
the	O
present	O
study	O
the	O
role	O
of	O
habituation	O
to	O
the	O
experimental	O
environment	O
on	O
the	O
stimulant	O
effect	O
of	O
nicotine	B-Chemical
in	O
rats	O
was	O
examined	O
.	O
In	O
addition	O
,	O
the	O
role	O
of	O
dopamine	B-Chemical
receptors	O
in	O
mediating	O
nicotine	B-Chemical
-	O
induced	O
locomotor	O
stimulation	O
was	O
investigated	O
by	O
examining	O
the	O
effects	O
of	O
selective	O
D1	O
and	O
D2	O
dopamine	B-Chemical
receptor	O
antagonists	O
on	O
activity	O
induced	O
by	O
nicotine	B-Chemical
.	O
Locomotor	O
activity	O
was	O
assessed	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
tested	O
in	O
photocell	O
cages	O
.	O
Nicotine	B-Chemical
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
)	O
caused	O
a	O
significant	O
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
in	O
rats	O
that	O
were	O
habituated	O
to	O
the	O
test	O
environment	O
,	O
but	O
had	O
only	O
a	O
weak	O
and	O
delayed	O
stimulant	O
action	O
in	O
rats	O
that	O
were	O
unfamiliar	O
with	O
the	O
test	O
environment	O
.	O
The	O
stimulant	O
action	O
of	O
nicotine	B-Chemical
was	O
blocked	O
by	O
the	O
central	O
nicotinic	O
antagonist	O
mecamylamine	B-Chemical
but	O
not	O
by	O
the	O
peripheral	O
nicotinic	O
blocker	O
hexamethonium	B-Chemical
,	O
indicating	O
that	O
the	O
response	O
is	O
probably	O
mediated	O
by	O
central	O
nicotinic	O
receptors	O
.	O
Nicotine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
was	O
blocked	O
by	O
the	O
selective	O
D1	O
antagonist	O
SCH	B-Chemical
23390	I-Chemical
,	O
the	O
selective	O
D2	O
antagonist	O
raclopride	B-Chemical
and	O
the	O
D1	O
/	O
D2	O
antagonist	O
fluphenazine	B-Chemical
.	O
Pretreatment	O
with	O
the	O
D2	O
agonist	O
PHNO	B-Chemical
enhanced	O
nicotine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
,	O
whereas	O
the	O
D1	O
agonist	O
SKF	B-Chemical
38393	I-Chemical
had	O
no	O
effect	O
.	O
The	O
results	O
indicate	O
that	O
acute	O
nicotine	B-Chemical
injection	O
induces	O
a	O
pronounced	O
hyperactivity	B-Disease
in	O
rats	O
habituated	O
to	O
the	O
test	O
environment	O
.	O
The	O
effect	O
appears	O
to	O
be	O
mediated	O
by	O
central	O
nicotine	B-Chemical
receptors	O
,	O
possibly	O
located	O
on	O
dopaminergic	O
neurons	O
,	O
and	O
also	O
requires	O
the	O
activation	O
of	O
both	O
D1	O
and	O
D2	O
dopamine	B-Chemical
receptors	O
.	O
Central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
associated	O
with	O
clomiphene	B-Chemical
-	O
induced	O
ovulation	O
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
associated	O
with	O
clomiphene	B-Chemical
citrate	I-Chemical
(	O
CC	B-Chemical
)	O
.	O
DESIGN	O
:	O
Case	O
study	O
.	O
SETTING	O
:	O
Ophthalmology	O
clinic	O
of	O
an	O
academic	O
hospital	O
.	O
PATIENT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
year	O
-	O
old	O
woman	O
referred	O
from	O
the	O
infertility	B-Disease
clinic	O
for	O
blurred	B-Disease
vision	I-Disease
.	O
INTERVENTION	O
(	O
S	O
)	O
:	O
Ophthalmic	O
examination	O
after	O
CC	B-Chemical
therapy	O
.	O
MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
:	O
Central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
ovulation	O
induction	O
with	O
CC	B-Chemical
.	O
RESULT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
year	O
-	O
old	O
Chinese	O
woman	O
developed	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
eight	O
courses	O
of	O
CC	B-Chemical
.	O
A	O
search	O
of	O
the	O
literature	O
on	O
the	O
thromboembolic	B-Disease
complications	O
of	O
CC	B-Chemical
does	O
not	O
include	O
this	O
severe	O
ophthalmic	O
complication	O
,	O
although	O
mild	O
visual	B-Disease
disturbance	I-Disease
after	O
CC	B-Chemical
intake	O
is	O
not	O
uncommon	O
.	O
CONCLUSION	O
(	O
S	O
)	O
:	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
treatment	O
with	O
CC	B-Chemical
.	O
Extra	O
caution	O
is	O
warranted	O
in	O
treating	O
infertility	B-Disease
patients	O
with	O
CC	B-Chemical
,	O
and	O
patients	O
should	O
be	O
well	O
informed	O
of	O
this	O
side	O
effect	O
before	O
commencement	O
of	O
therapy	O
.	O
Acute	O
bronchodilating	O
effects	O
of	O
ipratropium	B-Chemical
bromide	I-Chemical
and	O
theophylline	B-Chemical
in	O
chronic	B-Disease
obstructive	I-Disease
pulmonary	I-Disease
disease	I-Disease
.	O
The	O
bronchodilator	O
effects	O
of	O
a	O
single	O
dose	O
of	O
ipratropium	B-Chemical
bromide	I-Chemical
aerosol	O
(	O
36	O
micrograms	O
)	O
and	O
short	O
-	O
acting	O
theophylline	B-Chemical
tablets	O
(	O
dose	O
titrated	O
to	O
produce	O
serum	O
levels	O
of	O
10	O
-	O
20	O
micrograms	O
/	O
mL	O
)	O
were	O
compared	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
crossover	O
study	O
in	O
21	O
patients	O
with	O
stable	O
,	O
chronic	B-Disease
obstructive	I-Disease
pulmonary	I-Disease
disease	I-Disease
.	O
Mean	O
peak	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
increases	O
over	O
baseline	O
and	O
the	O
proportion	O
of	O
patients	O
attaining	O
at	O
least	O
a	O
15	O
%	O
increase	O
in	O
the	O
FEV1	O
(	O
responders	O
)	O
were	O
31	O
%	O
and	O
90	O
%	O
,	O
respectively	O
,	O
for	O
ipratropium	B-Chemical
and	O
17	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
for	O
theophylline	B-Chemical
.	O
The	O
average	O
FEV1	O
increases	O
during	O
the	O
6	O
-	O
hour	O
observation	O
period	O
were	O
18	O
%	O
for	O
ipratropium	B-Chemical
and	O
8	O
%	O
for	O
theophylline	B-Chemical
.	O
The	O
mean	O
duration	O
of	O
action	O
was	O
3	O
.	O
8	O
hours	O
with	O
ipratropium	B-Chemical
and	O
2	O
.	O
4	O
hours	O
with	O
theophylline	B-Chemical
.	O
While	O
side	O
effects	O
were	O
rare	O
,	O
those	O
experienced	O
after	O
theophylline	B-Chemical
use	O
did	O
involve	O
the	O
cardiovascular	B-Disease
and	I-Disease
gastrointestinal	I-Disease
systems	I-Disease
.	O
These	O
results	O
show	O
that	O
ipratropium	B-Chemical
is	O
a	O
more	O
potent	O
bronchodilator	O
than	O
oral	O
theophylline	B-Chemical
in	O
patients	O
with	O
chronic	B-Disease
airflow	I-Disease
obstruction	I-Disease
.	O
Methamphetamine	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
and	O
microglial	O
activation	O
are	O
not	O
mediated	O
by	O
fractalkine	O
receptor	O
signaling	O
.	O
Methamphetamine	B-Chemical
(	O
METH	B-Chemical
)	O
damages	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
nerve	O
endings	O
by	O
a	O
process	O
that	O
has	O
been	O
linked	O
to	O
microglial	O
activation	O
but	O
the	O
signaling	O
pathways	O
that	O
mediate	O
this	O
response	O
have	O
not	O
yet	O
been	O
delineated	O
.	O
Cardona	O
et	O
al	O
.	O
[	O
Nat	O
.	O
Neurosci	O
.	O
9	O
(	O
2006	O
)	O
,	O
917	O
]	O
recently	O
identified	O
the	O
microglial	O
-	O
specific	O
fractalkine	O
receptor	O
(	O
CX3CR1	O
)	O
as	O
an	O
important	O
mediator	O
of	O
MPTP	B-Chemical
-	O
induced	O
neurodegeneration	B-Disease
of	O
DA	B-Chemical
neurons	O
.	O
Because	O
the	O
CNS	B-Disease
damage	I-Disease
caused	O
by	O
METH	B-Chemical
and	O
MPTP	B-Chemical
is	O
highly	O
selective	O
for	O
the	O
DA	B-Chemical
neuronal	O
system	O
in	O
mouse	O
models	O
of	O
neurotoxicity	B-Disease
,	O
we	O
hypothesized	O
that	O
the	O
CX3CR1	O
plays	O
a	O
role	O
in	O
METH	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
and	O
microglial	O
activation	O
.	O
Mice	O
in	O
which	O
the	O
CX3CR1	O
gene	O
has	O
been	O
deleted	O
and	O
replaced	O
with	O
a	O
cDNA	O
encoding	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
eGFP	O
)	O
were	O
treated	O
with	O
METH	B-Chemical
and	O
examined	O
for	O
striatal	O
neurotoxicity	B-Disease
.	O
METH	B-Chemical
depleted	O
DA	B-Chemical
,	O
caused	O
microglial	O
activation	O
,	O
and	O
increased	O
body	O
temperature	O
in	O
CX3CR1	O
knockout	O
mice	O
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
time	O
course	O
seen	O
in	O
wild	O
-	O
type	O
controls	O
.	O
The	O
effects	O
of	O
METH	B-Chemical
in	O
CX3CR1	O
knockout	O
mice	O
were	O
not	O
gender	O
-	O
dependent	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatum	O
.	O
Striatal	O
microglia	O
expressing	O
eGFP	O
constitutively	O
show	O
morphological	O
changes	O
after	O
METH	B-Chemical
that	O
are	O
characteristic	O
of	O
activation	O
.	O
This	O
response	O
was	O
restricted	O
to	O
the	O
striatum	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eGFP	O
-	O
microglia	O
in	O
surrounding	O
brain	O
areas	O
that	O
are	O
not	O
damaged	O
by	O
METH	B-Chemical
.	O
We	O
conclude	O
from	O
these	O
studies	O
that	O
CX3CR1	O
signaling	O
does	O
not	O
modulate	O
METH	B-Chemical
neurotoxicity	B-Disease
or	O
microglial	O
activation	O
.	O
Furthermore	O
,	O
it	O
appears	O
that	O
striatal	O
-	O
resident	O
microglia	O
respond	O
to	O
METH	B-Chemical
with	O
an	O
activation	O
cascade	O
and	O
then	O
return	O
to	O
a	O
surveying	O
state	O
without	O
undergoing	O
apoptosis	O
or	O
migration	O
.	O
Nicotine	B-Chemical
-	O
induced	O
nystagmus	B-Disease
correlates	O
with	O
midpontine	O
activation	O
.	O
The	O
pathomechanism	O
of	O
nicotine	B-Chemical
-	O
induced	O
nystagmus	B-Disease
(	O
NIN	B-Disease
)	O
is	O
unknown	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
delineate	O
brain	O
structures	O
that	O
are	O
involved	O
in	O
NIN	B-Disease
generation	O
.	O
Eight	O
healthy	O
volunteers	O
inhaled	O
nicotine	B-Chemical
in	O
darkness	O
during	O
a	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
experiment	O
;	O
eye	O
movements	O
were	O
registered	O
using	O
video	O
-	O
oculography	O
.	O
NIN	B-Disease
correlated	O
with	O
blood	O
oxygen	B-Chemical
level	O
-	O
dependent	O
(	O
BOLD	O
)	O
activity	O
levels	O
in	O
a	O
midpontine	O
site	O
in	O
the	O
posterior	O
basis	O
pontis	O
.	O
NIN	B-Disease
-	O
induced	O
midpontine	O
activation	O
may	O
correspond	O
to	O
activation	O
of	O
the	O
dorsomedial	O
pontine	O
nuclei	O
and	O
the	O
nucleus	O
reticularis	O
tegmenti	O
pontis	O
,	O
structures	O
known	O
to	O
participate	O
in	O
the	O
generation	O
of	O
multidirectional	O
saccades	O
and	O
smooth	O
pursuit	O
eye	O
movements	O
.	O
Acute	O
effects	O
of	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
propylpentanoyl	I-Chemical
)	I-Chemical
urea	I-Chemical
on	O
hippocampal	O
amino	B-Chemical
acid	I-Chemical
neurotransmitters	O
in	O
pilocarpine	B-Chemical
-	O
induced	O
seizure	B-Disease
in	O
rats	O
.	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
anticonvulsant	O
activity	O
as	O
well	O
as	O
the	O
effects	O
on	O
the	O
level	O
of	O
hippocampal	O
amino	B-Chemical
acid	I-Chemical
neurotransmitters	O
(	O
glutamate	B-Chemical
,	O
aspartate	B-Chemical
,	O
glycine	B-Chemical
and	O
GABA	B-Chemical
)	O
of	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
propylpentanoyl	I-Chemical
)	I-Chemical
urea	I-Chemical
(	O
VPU	B-Chemical
)	O
in	O
comparison	O
to	O
its	O
parent	O
compound	O
,	O
valproic	B-Chemical
acid	I-Chemical
(	O
VPA	B-Chemical
)	O
.	O
VPU	B-Chemical
was	O
more	O
potent	O
than	O
VPA	B-Chemical
,	O
exhibiting	O
the	O
median	O
effective	O
dose	O
(	O
ED	O
(	O
50	O
)	O
)	O
of	O
49	O
mg	O
/	O
kg	O
in	O
protecting	O
rats	O
against	O
pilocarpine	B-Chemical
-	O
induced	O
seizure	B-Disease
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	B-Chemical
was	O
322	O
mg	O
/	O
kg	O
.	O
In	O
vivo	O
microdialysis	O
demonstrated	O
that	O
an	O
intraperitoneal	O
administration	O
of	O
pilocarpine	B-Chemical
induced	O
a	O
pronounced	O
increment	O
of	O
hippocampal	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
level	O
of	O
glycine	B-Chemical
and	O
GABA	B-Chemical
.	O
Pretreatment	O
with	O
either	O
VPU	B-Chemical
(	O
50	O
and	O
100	O
mg	O
/	O
kg	O
)	O
or	O
VPA	B-Chemical
(	O
300	O
and	O
600	O
mg	O
/	O
kg	O
)	O
completely	O
abolished	O
pilocarpine	B-Chemical
-	O
evoked	O
increases	O
in	O
extracellular	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
.	O
In	O
addition	O
,	O
a	O
statistically	O
significant	O
reduction	O
was	O
also	O
observed	O
on	O
the	O
level	O
of	O
GABA	B-Chemical
and	O
glycine	B-Chemical
but	O
less	O
than	O
a	O
drastic	O
reduction	O
of	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
level	O
.	O
Based	O
on	O
the	O
finding	O
that	O
VPU	B-Chemical
and	O
VPA	B-Chemical
could	O
protect	O
the	O
animals	O
against	O
pilocarpine	B-Chemical
-	O
induced	O
seizure	B-Disease
it	O
is	O
suggested	O
that	O
the	O
reduction	O
of	O
inhibitory	O
amino	B-Chemical
acid	I-Chemical
neurotransmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reduction	O
of	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
.	O
Therefore	O
,	O
like	O
VPA	B-Chemical
,	O
the	O
finding	O
that	O
VPU	B-Chemical
could	O
drastically	O
reduce	O
pilocarpine	B-Chemical
-	O
induced	O
increases	O
in	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticonvulsant	O
activity	O
observed	O
in	O
pilocarpine	B-Chemical
-	O
induced	O
seizure	B-Disease
in	O
experimental	O
animals	O
.	O
Some	O
other	O
mechanism	O
than	O
those	O
being	O
reported	O
herein	O
should	O
be	O
further	O
investigated	O
.	O
Protective	O
effect	O
of	O
verapamil	B-Chemical
on	O
gastric	B-Disease
hemorrhagic	I-Disease
ulcers	B-Disease
in	O
severe	O
atherosclerotic	B-Disease
rats	O
.	O
Studies	O
concerning	O
with	O
pathogenesis	O
of	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
mucosal	O
ulceration	O
produced	O
in	O
atherosclerotic	B-Disease
rats	O
are	O
lacking	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
role	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mast	O
cell	O
histamine	B-Chemical
release	O
,	O
lipid	O
peroxide	O
(	O
LPO	O
)	O
generation	O
and	O
mucosal	O
microvascular	O
permeability	O
in	O
modulating	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
ulcer	B-Disease
in	O
rats	O
with	O
atherosclerosis	B-Disease
induced	O
by	O
coadministration	O
of	O
vitamin	B-Chemical
D2	I-Chemical
and	O
cholesterol	B-Chemical
.	O
Additionally	O
,	O
the	O
protective	O
effect	O
of	O
verapamil	B-Chemical
on	O
this	O
ulcer	B-Disease
model	O
was	O
evaluated	O
.	O
Male	O
Wistar	O
rats	O
were	O
challenged	O
intragastrically	O
once	O
daily	O
for	O
9	O
days	O
with	O
1	O
.	O
0	O
ml	O
/	O
kg	O
of	O
corn	O
oil	O
containing	O
vitamin	B-Chemical
D2	I-Chemical
and	O
cholesterol	B-Chemical
to	O
induce	O
atherosclerosis	B-Disease
.	O
Control	O
rats	O
received	O
corn	O
oil	O
only	O
.	O
After	O
gastric	O
surgery	O
,	O
rat	O
stomachs	O
were	O
irrigated	O
for	O
3	O
h	O
with	O
either	O
simulated	O
gastric	O
juice	O
or	O
normal	O
saline	O
.	O
Gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mucosal	O
LPO	O
generation	O
,	O
histamine	B-Chemical
concentration	O
,	O
microvascular	O
permeability	O
,	O
luminal	B-Chemical
hemoglobin	O
content	O
and	O
ulcer	B-Disease
areas	O
were	O
determined	O
.	O
Elevated	O
atherosclerotic	B-Disease
parameters	O
,	O
such	O
as	O
serum	O
calcium	B-Chemical
,	O
total	O
cholesterol	B-Chemical
and	O
low	O
-	O
density	O
lipoprotein	O
concentration	O
were	O
obtained	O
in	O
atherosclerotic	B-Disease
rats	O
.	O
Severe	O
gastric	O
ulcers	B-Disease
accompanied	O
with	O
increased	O
ulcerogenic	O
factors	O
,	O
including	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
histamine	B-Chemical
release	O
,	O
LPO	O
generation	O
and	O
luminal	B-Chemical
hemoglobin	O
content	O
were	O
also	O
observed	O
in	O
these	O
rats	O
.	O
Moreover	O
,	O
a	O
positive	O
correlation	O
of	O
histamine	B-Chemical
to	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
to	O
ulcer	B-Disease
was	O
found	O
in	O
those	O
atherosclerotic	B-Disease
rats	O
.	O
This	O
hemorrhagic	B-Disease
ulcer	B-Disease
and	O
various	O
ulcerogenic	O
parameters	O
were	O
dose	O
-	O
dependently	O
ameliorated	O
by	O
daily	O
intragastric	O
verapamil	B-Chemical
.	O
Atherosclerosis	B-Disease
could	O
produce	O
gastric	B-Disease
hemorrhagic	I-Disease
ulcer	B-Disease
via	O
aggravation	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
LPO	O
generation	O
,	O
histamine	B-Chemical
release	O
and	O
microvascular	O
permeability	O
that	O
could	O
be	O
ameliorated	O
by	O
verapamil	B-Chemical
in	O
rats	O
.	O
Lamivudine	B-Chemical
for	O
the	O
prevention	O
of	O
hepatitis	B-Disease
B	I-Disease
virus	O
reactivation	O
in	O
hepatitis	B-Chemical
-	I-Chemical
B	I-Chemical
surface	I-Chemical
antigen	I-Chemical
(	O
HBSAG	B-Chemical
)	O
seropositive	O
cancer	B-Disease
patients	O
undergoing	O
cytotoxic	O
chemotherapy	O
.	O
Hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
chronic	O
liver	B-Disease
disease	I-Disease
worldwide	O
.	O
Cancer	B-Disease
patients	O
who	O
are	O
chronic	O
carriers	O
of	O
HBV	O
have	O
a	O
higher	O
hepatic	B-Disease
complication	I-Disease
rate	O
while	O
receiving	O
cytotoxic	O
chemotherapy	O
(	O
CT	O
)	O
and	O
this	O
has	O
mainly	O
been	O
attributed	O
to	O
HBV	O
reactivation	O
.	O
In	O
this	O
study	O
,	O
cancer	B-Disease
patients	O
who	O
have	O
solid	O
and	O
hematological	B-Disease
malignancies	I-Disease
with	O
chronic	O
HBV	B-Disease
infection	I-Disease
received	O
the	O
antiviral	O
agent	O
lamivudine	B-Chemical
prior	O
and	O
during	O
CT	O
compared	O
with	O
historical	O
control	O
group	O
who	O
did	O
not	O
receive	O
lamivudine	B-Chemical
.	O
The	O
objectives	O
were	O
to	O
assess	O
the	O
efficacy	O
of	O
lamivudine	B-Chemical
in	O
reducing	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
,	O
and	O
diminishing	O
morbidity	O
and	O
mortality	O
during	O
CT	O
.	O
Two	O
groups	O
were	O
compared	O
in	O
this	O
study	O
.	O
The	O
prophylactic	O
lamivudin	B-Chemical
group	O
consisted	O
of	O
37	O
patients	O
who	O
received	O
prophylactic	O
lamivudine	B-Chemical
treatment	O
.	O
The	O
historical	O
controls	O
consisted	O
of	O
50	O
consecutive	O
patients	O
who	O
underwent	O
CT	O
without	O
prophylactic	O
lamivudine	B-Chemical
.	O
They	O
were	O
followed	O
up	O
during	O
and	O
for	O
8	O
weeks	O
after	O
CT	O
.	O
The	O
outcomes	O
were	O
compared	O
for	O
both	O
groups	O
.	O
Of	O
our	O
control	O
group	O
(	O
n	O
=	O
50	O
)	O
,	O
21	O
patients	O
(	O
42	O
%	O
)	O
were	O
established	O
hepatitis	B-Disease
.	O
Twelve	O
(	O
24	O
%	O
)	O
of	O
them	O
were	O
evaluated	O
as	O
severe	O
hepatitis	B-Disease
.	O
In	O
the	O
prophylactic	O
lamivudine	B-Chemical
group	O
severe	O
hepatitis	B-Disease
were	O
observed	O
only	O
in	O
1	O
patient	O
(	O
2	O
.	O
7	O
%	O
)	O
of	O
37	O
patients	O
(	O
p	O
<	O
0	O
.	O
006	O
)	O
.	O
Comparison	O
of	O
the	O
mean	O
ALT	O
values	O
revealed	O
significantly	O
higher	O
mean	O
alanine	B-Chemical
aminotransferase	O
(	O
ALT	O
)	O
values	O
in	O
the	O
control	O
group	O
than	O
the	O
prophylactic	O
lamivudine	B-Chemical
group	O
;	O
154	O
:	O
64	O
(	O
p	O
<	O
0	O
.	O
32	O
)	O
.	O
Our	O
study	O
suggests	O
that	O
prophylactic	O
lamivudine	B-Chemical
significantly	O
decreases	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
and	O
overall	O
morbidity	O
in	O
cancer	B-Disease
patients	O
during	O
and	O
after	O
immunosuppressive	O
therapy	O
.	O
Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
nucleoside	B-Chemical
or	O
nucleotide	B-Chemical
analogue	O
for	O
antiviral	O
prophylaxis	O
during	O
CT	O
and	O
the	O
optimal	O
duration	O
of	O
administration	O
after	O
completion	O
of	O
CT	O
.	O
Recovery	O
of	O
tacrolimus	B-Chemical
-	O
associated	O
brachial	B-Disease
neuritis	I-Disease
after	O
conversion	O
to	O
everolimus	B-Chemical
in	O
a	O
pediatric	O
renal	O
transplant	O
recipient	O
-	O
-	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O
TAC	B-Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppressive	O
agent	O
for	O
solid	O
organ	O
transplantation	O
in	O
pediatrics	O
.	O
Neurotoxicity	B-Disease
is	O
a	O
potentially	O
serious	O
toxic	O
effect	O
.	O
It	O
is	O
characterized	O
by	O
encephalopathy	B-Disease
,	O
headaches	B-Disease
,	O
seizures	B-Disease
,	O
or	O
neurological	B-Disease
deficits	I-Disease
.	O
Here	O
,	O
we	O
describe	O
an	O
eight	O
-	O
and	O
-	O
a	O
-	O
half	O
-	O
yr	O
-	O
old	O
male	O
renal	O
transplant	O
recipient	O
with	O
right	O
BN	O
.	O
MRI	O
demonstrated	O
hyperintense	O
T2	O
signals	O
in	O
the	O
cervical	O
cord	O
and	O
right	O
brachial	O
plexus	O
roots	O
indicative	O
of	O
both	O
myelitis	B-Disease
and	O
right	O
brachial	B-Disease
plexitis	I-Disease
.	O
Symptoms	O
persisted	O
for	O
three	O
months	O
despite	O
TAC	B-Chemical
dose	O
reduction	O
,	O
administration	O
of	O
IVIG	O
and	O
four	O
doses	O
of	O
methylprednisolone	B-Chemical
pulse	O
therapy	O
.	O
Improvement	O
and	O
eventually	O
full	O
recovery	O
only	O
occurred	O
after	O
TAC	B-Chemical
was	O
completely	O
discontinued	O
and	O
successfully	O
replaced	O
by	O
everolimus	B-Chemical
.	O
Omitting	O
fentanyl	B-Chemical
reduces	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
without	O
increasing	O
pain	B-Disease
,	O
after	O
sevoflurane	B-Chemical
for	O
day	O
surgery	O
.	O
BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Despite	O
advantages	O
of	O
induction	O
and	O
maintenance	O
of	O
anaesthesia	O
with	O
sevoflurane	B-Chemical
,	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
occurs	O
frequently	O
.	O
Fentanyl	B-Chemical
is	O
a	O
commonly	O
used	O
supplement	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
improve	O
analgesia	O
.	O
METHODS	O
:	O
This	O
double	O
-	O
blind	O
study	O
examined	O
the	O
incidence	O
and	O
severity	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
and	O
pain	B-Disease
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurane	B-Chemical
anaesthesia	O
in	O
216	O
adult	O
day	O
surgery	O
patients	O
.	O
Patients	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentanyl	B-Chemical
,	O
while	O
a	O
third	O
group	O
received	O
dexamethasone	B-Chemical
in	O
addition	O
to	O
fentanyl	B-Chemical
.	O
RESULTS	O
:	O
Omission	O
of	O
fentanyl	B-Chemical
did	O
not	O
reduce	O
the	O
overall	O
incidence	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
,	O
but	O
did	O
reduce	O
the	O
incidence	O
of	O
vomiting	B-Disease
and	O
/	O
or	O
moderate	O
to	O
severe	O
nausea	B-Disease
prior	O
to	O
discharge	O
from	O
20	O
%	O
and	O
17	O
%	O
with	O
fentanyl	B-Chemical
and	O
fentanyl	B-Chemical
-	O
dexamethasone	B-Chemical
,	O
respectively	O
,	O
to	O
5	O
%	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O
Antiemetic	O
requirements	O
were	O
reduced	O
from	O
24	O
%	O
and	O
31	O
%	O
to	O
7	O
%	O
(	O
P	O
=	O
0	O
.	O
0012	O
)	O
.	O
Dexamethasone	B-Chemical
had	O
no	O
significant	O
effect	O
on	O
the	O
incidence	O
or	O
severity	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
.	O
Combining	O
the	O
two	O
fentanyl	B-Chemical
groups	O
revealed	O
further	O
significant	O
benefits	O
from	O
the	O
avoidance	O
of	O
opioids	O
,	O
reducing	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
and	O
nausea	B-Disease
prior	O
to	O
discharge	O
from	O
35	O
%	O
and	O
33	O
%	O
to	O
22	O
%	O
and	O
19	O
%	O
(	O
P	O
=	O
0	O
.	O
049	O
and	O
P	O
=	O
0	O
.	O
035	O
)	O
,	O
respectively	O
,	O
while	O
nausea	B-Disease
in	O
the	O
first	O
24	O
h	O
was	O
decreased	O
from	O
42	O
%	O
to	O
27	O
%	O
(	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O
Pain	B-Disease
severity	O
and	O
analgesic	O
requirements	O
were	O
unaffected	O
by	O
the	O
omission	O
of	O
fentanyl	B-Chemical
.	O
Fentanyl	B-Chemical
did	O
reduce	O
minor	O
intraoperative	O
movement	O
but	O
had	O
no	O
sevoflurane	B-Chemical
-	O
sparing	O
effect	O
and	O
increased	O
respiratory	B-Disease
depression	I-Disease
,	O
hypotension	B-Disease
and	O
bradycardia	B-Disease
.	O
CONCLUSION	O
:	O
As	O
fentanyl	B-Chemical
exacerbated	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
without	O
an	O
improvement	O
in	O
postoperative	B-Disease
pain	I-Disease
and	O
also	O
had	O
adverse	O
cardiorespiratory	O
effects	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimental	O
supplement	O
to	O
sevoflurane	B-Chemical
in	O
day	O
surgery	O
.	O
Valvular	B-Disease
heart	I-Disease
disease	I-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
treated	O
with	O
pergolide	B-Chemical
.	O
Course	O
following	O
treatment	O
modifications	O
.	O
Valvular	B-Disease
heart	I-Disease
abnormalities	I-Disease
have	O
been	O
reported	O
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
treated	O
with	O
pergolide	B-Chemical
.	O
However	O
,	O
the	O
incidence	O
and	O
severity	O
of	O
these	O
abnormalities	O
vary	O
from	O
study	O
to	O
study	O
and	O
their	O
course	O
after	O
drug	O
withdrawal	O
has	O
not	O
been	O
systematically	O
assessed	O
.	O
OBJECTIVES	O
:	O
To	O
estimate	O
the	O
frequency	O
and	O
severity	O
of	O
valvular	B-Disease
heart	I-Disease
abnormality	I-Disease
and	O
its	O
possible	O
reversibility	O
after	O
drug	O
withdrawal	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O
METHODS	O
:	O
All	O
PD	B-Disease
patients	O
in	O
the	O
Amiens	O
area	O
treated	O
with	O
pergolide	B-Chemical
were	O
invited	O
to	O
attend	O
a	O
cardiologic	O
assessment	O
including	O
transthoracic	O
echocardiography	O
.	O
Thirty	O
PD	B-Disease
patients	O
participated	O
in	O
the	O
study	O
.	O
A	O
second	O
echocardiography	O
was	O
performed	O
(	O
median	O
interval	O
:	O
13	O
months	O
)	O
after	O
pergolide	B-Chemical
withdrawal	O
(	O
n	O
=	O
10	O
patients	O
)	O
.	O
Controls	O
were	O
age	O
-	O
and	O
sex	O
-	O
matched	O
non	O
-	O
PD	B-Disease
patients	O
referred	O
to	O
the	O
cardiology	O
department	O
.	O
RESULTS	O
:	O
Compared	O
to	O
controls	O
,	O
aortic	B-Disease
regurgitation	I-Disease
(	O
OR	O
:	O
3	O
.	O
1	O
;	O
95	O
%	O
IC	O
:	O
1	O
.	O
1	O
-	O
8	O
.	O
8	O
)	O
and	O
mitral	B-Disease
regurgitation	I-Disease
(	O
OR	O
:	O
10	O
.	O
7	O
;	O
95	O
%	O
IC	O
:	O
2	O
.	O
1	O
-	O
53	O
)	O
were	O
more	O
frequent	O
in	O
PD	B-Disease
patients	O
(	O
tricuspid	O
:	O
NS	O
)	O
.	O
The	O
number	O
of	O
affected	O
valves	O
(	O
n	O
=	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
7	O
)	O
and	O
the	O
sum	O
of	O
regurgitation	O
grades	O
(	O
n	O
=	O
2	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
09	O
)	O
were	O
higher	O
(	O
p	O
=	O
0	O
.	O
008	O
and	O
p	O
=	O
0	O
.	O
006	O
,	O
respectively	O
)	O
in	O
the	O
pergolide	B-Chemical
group	O
.	O
Severity	O
of	O
regurgitation	O
was	O
not	O
correlated	O
with	O
pergolide	B-Chemical
cumulative	O
dose	O
.	O
A	O
restrictive	O
pattern	O
of	O
valvular	B-Disease
regurgitation	I-Disease
,	O
suggestive	O
of	O
the	O
role	O
of	O
pergolide	B-Chemical
,	O
was	O
observed	O
in	O
12	O
/	O
30	O
(	O
40	O
%	O
)	O
patients	O
including	O
two	O
with	O
heart	B-Disease
failure	I-Disease
.	O
Pergolide	B-Chemical
was	O
discontinued	O
in	O
10	O
patients	O
with	O
valvular	B-Disease
heart	I-Disease
disease	I-Disease
,	O
resulting	O
in	O
a	O
lower	O
regurgitation	O
grade	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
at	O
the	O
second	O
transthoracic	O
echocardiography	O
and	O
the	O
two	O
patients	O
with	O
heart	B-Disease
failure	I-Disease
returned	O
to	O
nearly	O
normal	O
clinical	O
examination	O
.	O
This	O
study	O
supports	O
the	O
high	O
frequency	O
of	O
restrictive	O
valve	B-Disease
regurgitation	I-Disease
in	O
PD	B-Disease
patients	O
treated	O
with	O
pergolide	B-Chemical
and	O
reveals	O
that	O
a	O
significant	O
improvement	O
is	O
usual	O
when	O
the	O
treatment	O
is	O
converted	O
to	O
non	O
-	O
ergot	O
dopamine	B-Chemical
agonists	O
.	O
Adriamycin	B-Chemical
-	O
induced	O
autophagic	O
cardiomyocyte	O
death	B-Disease
plays	O
a	O
pathogenic	O
role	O
in	O
a	O
rat	O
model	O
of	O
heart	B-Disease
failure	I-Disease
.	O
BACKGROUND	O
:	O
The	O
mechanisms	O
underlying	O
heart	B-Disease
failure	I-Disease
induced	O
by	O
adriamycin	B-Chemical
are	O
very	O
complicated	O
and	O
still	O
unclear	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
autophagy	O
was	O
involved	O
in	O
the	O
progression	O
of	O
heart	B-Disease
failure	I-Disease
induced	O
by	O
adriamycin	B-Chemical
,	O
so	O
that	O
we	O
can	O
develop	O
a	O
novel	O
treatment	O
strategy	O
for	O
heart	B-Disease
failure	I-Disease
.	O
METHODS	O
:	O
3	B-Chemical
-	I-Chemical
methyladenine	I-Chemical
(	O
3MA	B-Chemical
)	O
,	O
a	O
specific	O
inhibitor	O
on	O
autophagy	O
was	O
used	O
in	O
a	O
heart	B-Disease
failure	I-Disease
model	O
of	O
rats	O
induced	O
by	O
adriamycin	B-Chemical
.	O
Neonatal	O
cardiomyocytes	O
were	O
isolated	O
from	O
Sprague	O
-	O
Dawley	O
rat	O
hearts	O
and	O
randomly	O
divided	O
into	O
controls	O
,	O
an	O
adriamycin	B-Chemical
-	O
treated	O
group	O
,	O
and	O
a	O
3MA	B-Chemical
plus	O
adriamycin	B-Chemical
-	O
treated	O
group	O
.	O
We	O
then	O
examined	O
the	O
morphology	O
,	O
expression	O
of	O
beclin	O
1	O
gene	O
,	O
mitochondrial	O
permeability	O
transition	O
(	O
MPT	O
)	O
,	O
and	O
Na	O
+	O
-	O
K	B-Chemical
+	O
ATPase	O
activity	O
in	O
vivo	O
.	O
We	O
also	O
assessed	O
cell	O
viability	O
,	O
mitochondrial	O
membrane	O
potential	O
changes	O
and	O
counted	O
autophagic	O
vacuoles	O
in	O
cultured	O
cardiomyocytes	O
.	O
In	O
addition	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
autophagy	O
associated	O
gene	O
,	O
beclin	O
1	O
using	O
RT	O
-	O
PCR	O
and	O
Western	O
blotting	O
in	O
an	O
animal	O
model	O
.	O
RESULTS	O
:	O
3MA	B-Chemical
significantly	O
improved	O
cardiac	O
function	O
and	O
reduced	O
mitochondrial	O
injury	O
.	O
Furthermore	O
,	O
adriamycin	B-Chemical
induced	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
,	O
and	O
3MA	B-Chemical
strongly	O
downregulated	O
the	O
expression	O
of	O
beclin	O
1	O
in	O
adriamycin	B-Chemical
-	O
induced	O
failing	O
heart	O
and	O
inhibited	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
.	O
CONCLUSION	O
:	O
Autophagic	O
cardiomyocyte	O
death	B-Disease
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
heart	B-Disease
failure	I-Disease
in	O
rats	O
induced	O
by	O
adriamycin	B-Chemical
.	O
Mitochondrial	O
injury	O
may	O
be	O
involved	O
in	O
the	O
progression	O
of	O
heart	B-Disease
failure	I-Disease
caused	O
by	O
adriamycin	B-Chemical
via	O
the	O
autophagy	O
pathway	O
.	O
mToR	O
inhibitors	O
-	O
induced	O
proteinuria	B-Disease
:	O
mechanisms	O
,	O
significance	O
,	O
and	O
management	O
.	O
Massive	O
urinary	O
protein	O
excretion	O
has	O
been	O
observed	O
after	O
conversion	O
from	O
calcineurin	O
inhibitors	O
to	O
mammalian	O
target	O
of	O
rapamycin	B-Chemical
(	O
mToR	O
)	O
inhibitors	O
,	O
especially	O
sirolimus	B-Chemical
,	O
in	O
renal	O
transplant	O
recipients	O
with	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
.	O
Because	O
proteinuria	B-Disease
is	O
a	O
major	O
predictive	O
factor	O
of	O
poor	O
transplantation	O
outcome	O
,	O
many	O
studies	O
focused	O
on	O
this	O
adverse	O
event	O
during	O
the	O
past	O
years	O
.	O
Whether	O
proteinuria	B-Disease
was	O
due	O
to	O
sirolimus	B-Chemical
or	O
only	O
a	O
consequence	O
of	O
calcineurin	O
inhibitors	O
withdrawal	O
remained	O
unsolved	O
until	O
high	O
range	O
proteinuria	B-Disease
has	O
been	O
observed	O
during	O
sirolimus	B-Chemical
therapy	O
in	O
islet	O
transplantation	O
and	O
in	O
patients	O
who	O
received	O
sirolimus	B-Chemical
de	O
novo	O
.	O
Podocyte	O
injury	O
and	O
focal	O
segmental	O
glomerulosclerosis	B-Disease
have	O
been	O
related	O
to	O
mToR	O
inhibition	O
in	O
some	O
patients	O
,	O
but	O
the	O
pathways	O
underlying	O
these	O
lesions	O
remain	O
hypothetic	O
.	O
We	O
discuss	O
herein	O
the	O
possible	O
mechanisms	O
and	O
the	O
significance	O
of	O
mToR	O
blockade	O
-	O
induced	O
proteinuria	B-Disease
.	O
Neuropsychiatric	O
side	O
effects	O
after	O
the	O
use	O
of	O
mefloquine	B-Chemical
.	O
This	O
study	O
describes	O
neuropsychiatric	O
side	O
effects	O
in	O
patients	O
after	O
treatment	O
with	O
mefloquine	B-Chemical
.	O
Reactions	O
consisted	O
mainly	O
of	O
seizures	B-Disease
,	O
acute	O
psychoses	B-Disease
,	O
anxiety	B-Disease
neurosis	I-Disease
,	O
and	O
major	O
disturbances	B-Disease
of	I-Disease
sleep	I-Disease
-	I-Disease
wake	I-Disease
rhythm	I-Disease
.	O
Side	O
effects	O
occurred	O
after	O
both	O
therapeutic	O
and	O
prophylactic	O
intake	O
and	O
were	O
graded	O
from	O
moderate	O
to	O
severe	O
.	O
In	O
a	O
risk	O
analysis	O
of	O
neuropsychiatric	O
side	O
effects	O
in	O
Germany	O
,	O
it	O
is	O
estimated	O
that	O
one	O
of	O
8	O
,	O
000	O
mefloquine	B-Chemical
users	O
suffers	O
from	O
such	O
reactions	O
.	O
The	O
incidence	O
calculation	O
revealed	O
that	O
one	O
of	O
215	O
therapeutic	O
users	O
had	O
reactions	O
,	O
compared	O
with	O
one	O
of	O
13	O
,	O
000	O
in	O
the	O
prophylaxis	O
group	O
,	O
making	O
the	O
risk	O
of	O
neuropsychiatric	O
reactions	O
after	O
mefloquine	B-Chemical
treatment	O
60	O
times	O
higher	O
than	O
after	O
prophylaxis	O
.	O
Therefore	O
,	O
certain	O
limitations	O
for	O
malaria	B-Disease
prophylaxis	O
and	O
treatment	O
with	O
mefloquine	B-Chemical
are	O
recommended	O
.	O
Prenatal	O
protein	O
deprivation	O
alters	O
dopamine	B-Chemical
-	O
mediated	O
behaviors	O
and	O
dopaminergic	O
and	O
glutamatergic	O
receptor	O
binding	O
.	O
Epidemiological	O
evidence	O
indicates	O
that	O
prenatal	O
nutritional	O
deprivation	O
may	O
increase	O
the	O
risk	O
of	O
schizophrenia	B-Disease
.	O
The	O
goal	O
of	O
these	O
studies	O
was	O
to	O
use	O
an	O
animal	O
model	O
to	O
examine	O
the	O
effects	O
of	O
prenatal	O
protein	O
deprivation	O
on	O
behaviors	O
and	O
receptor	O
binding	O
with	O
relevance	O
to	O
schizophrenia	B-Disease
.	O
We	O
report	O
that	O
prenatally	O
protein	O
deprived	O
(	O
PD	O
)	O
female	O
rats	O
showed	O
an	O
increased	O
stereotypic	O
response	O
to	O
apomorphine	B-Chemical
and	O
an	O
increased	O
locomotor	O
response	O
to	O
amphetamine	B-Chemical
in	O
adulthood	O
.	O
These	O
differences	O
were	O
not	O
observed	O
during	O
puberty	O
.	O
No	O
changes	O
in	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
or	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
-	O
induced	O
locomotion	O
were	O
seen	O
following	O
PD	O
.	O
In	O
addition	O
,	O
PD	O
female	O
rats	O
showed	O
increased	O
(	O
3	O
)	O
H	B-Chemical
-	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
binding	O
in	O
the	O
striatum	O
and	O
hippocampus	O
,	O
but	O
not	O
in	O
the	O
cortex	O
.	O
PD	O
female	O
rats	O
also	O
showed	O
increased	O
(	O
3	O
)	O
H	B-Chemical
-	O
haloperidol	B-Chemical
binding	O
and	O
decreased	O
dopamine	B-Chemical
transporter	O
binding	O
in	O
striatum	O
.	O
No	O
statistically	O
significant	O
changes	O
in	O
behavior	O
or	O
receptor	O
binding	O
were	O
found	O
in	O
PD	O
males	O
with	O
the	O
exception	O
of	O
increased	O
(	O
3	O
)	O
H	B-Chemical
-	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
binding	O
in	O
cortex	O
.	O
This	O
animal	O
model	O
may	O
be	O
useful	O
to	O
explore	O
the	O
mechanisms	O
by	O
which	O
prenatal	O
nutritional	B-Disease
deficiency	I-Disease
enhances	O
risk	O
for	O
schizophrenia	B-Disease
in	O
humans	O
and	O
may	O
also	O
have	O
implications	O
for	O
developmental	O
processes	O
leading	O
to	O
differential	O
sensitivity	O
to	O
drugs	O
of	O
abuse	O
.	O
Adverse	O
effects	O
of	O
topical	O
papaverine	B-Chemical
on	O
auditory	O
nerve	O
function	O
.	O
BACKGROUND	O
:	O
Papaverine	B-Chemical
hydrochloride	I-Chemical
is	O
a	O
direct	O
-	O
acting	O
vasodilator	O
used	O
to	O
manage	O
vasospasm	B-Disease
during	O
various	O
neurosurgical	O
operations	O
.	O
Transient	O
cranial	B-Disease
nerve	I-Disease
dysfunction	I-Disease
has	O
been	O
described	O
in	O
a	O
few	O
cases	O
with	O
topical	O
papaverine	B-Chemical
.	O
This	O
study	O
supports	O
previous	O
reports	O
and	O
provides	O
neurophysiological	O
evidence	O
of	O
an	O
adverse	O
effect	O
on	O
the	O
auditory	O
nerve	O
.	O
METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
review	O
of	O
70	O
consecutive	O
microvascular	O
decompression	O
operations	O
and	O
studied	O
those	O
patients	O
who	O
received	O
topical	O
papaverine	B-Chemical
for	O
vasospasm	B-Disease
.	O
Topical	O
papaverine	B-Chemical
was	O
used	O
as	O
a	O
direct	O
therapeutic	O
action	O
to	O
manage	O
vasospasm	B-Disease
in	O
a	O
total	O
of	O
11	O
patients	O
.	O
The	O
timing	O
of	O
papaverine	B-Chemical
application	O
and	O
ongoing	O
operative	O
events	O
was	O
reviewed	O
relative	O
to	O
changes	O
in	O
neurophysiological	O
recordings	O
.	O
Brainstem	O
auditory	O
evoked	O
potentials	O
(	O
BAEPs	O
)	O
were	O
routinely	O
used	O
to	O
monitor	O
cochlear	O
nerve	O
function	O
during	O
these	O
operations	O
.	O
FINDINGS	O
:	O
A	O
temporal	O
relationship	O
was	O
found	O
between	O
topical	O
papaverine	B-Chemical
and	O
BAEP	O
changes	O
leading	O
to	O
complete	O
waveform	O
loss	O
.	O
The	O
average	O
temporal	O
delay	O
between	O
papaverine	B-Chemical
and	O
the	O
onset	O
of	O
an	O
adverse	O
BAEP	O
change	O
was	O
5	O
min	O
.	O
In	O
10	O
of	O
11	O
patients	O
,	O
BAEP	O
waves	O
II	O
/	O
III	O
-	O
V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	O
after	O
papaverine	B-Chemical
.	O
Eight	O
of	O
these	O
10	O
patients	O
had	O
complete	O
loss	O
of	O
BAEP	O
waveforms	O
within	O
10	O
min	O
.	O
One	O
patient	O
showed	O
no	O
recovery	O
of	O
later	O
waves	O
and	O
a	O
delayed	O
profound	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O
The	O
average	O
recovery	O
time	O
of	O
BAEP	O
waveforms	O
to	O
pre	O
-	O
papaverine	B-Chemical
baseline	O
values	O
was	O
39	O
min	O
.	O
CONCLUSIONS	O
:	O
Topical	O
papaverine	B-Chemical
for	O
the	O
treatment	O
of	O
vasospasm	B-Disease
was	O
associated	O
with	O
the	O
onset	O
of	O
a	O
transient	O
disturbance	O
in	O
neurophysiological	O
function	O
of	O
the	O
ascending	O
auditory	O
brainstem	O
pathway	O
.	O
The	O
complete	O
disappearance	O
of	O
BAEP	O
waveforms	O
with	O
a	O
consistent	O
temporal	O
delay	O
suggests	O
a	O
possible	O
adverse	B-Disease
effect	I-Disease
on	I-Disease
the	I-Disease
proximal	I-Disease
eighth	I-Disease
nerve	I-Disease
.	O
Recommendations	O
to	O
avoid	O
potential	O
cranial	B-Disease
nerve	I-Disease
deficits	I-Disease
from	O
papaverine	B-Chemical
are	O
provided	O
.	O
Simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
-	O
induced	O
hepatic	B-Disease
failure	I-Disease
necessitating	O
liver	O
transplantation	O
.	O
Abstract	O
Serum	O
aminotransferase	O
elevations	O
are	O
a	O
commonly	O
known	O
adverse	O
effect	O
of	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
reductase	O
inhibitor	O
(	O
statin	B-Chemical
)	O
therapy	O
.	O
However	O
,	O
hepatotoxic	B-Disease
events	O
have	O
not	O
been	O
widely	O
published	O
with	O
ezetimibe	B-Chemical
or	O
the	O
combination	O
agent	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
.	O
We	O
describe	O
a	O
70	O
-	O
year	O
-	O
old	O
Hispanic	O
woman	O
who	O
developed	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
necessitating	O
liver	O
transplantation	O
10	O
weeks	O
after	O
conversion	O
from	O
simvastatin	B-Chemical
40	O
mg	O
/	O
day	O
to	O
simvastatin	B-Chemical
10	I-Chemical
mg	I-Chemical
-	I-Chemical
ezetimibe	I-Chemical
40	I-Chemical
mg	I-Chemical
/	O
day	O
.	O
The	O
patient	O
'	O
s	O
lipid	O
panel	O
had	O
been	O
maintained	O
with	O
simvastatin	B-Chemical
for	O
18	O
months	O
before	O
the	O
conversion	O
without	O
evidence	O
of	O
hepatotoxicity	B-Disease
.	O
A	O
routine	O
laboratory	O
work	O
-	O
up	O
10	O
weeks	O
after	O
conversion	O
revealed	O
elevated	O
serum	O
aminotransferase	O
levels	O
.	O
Simvastatinezetimibe	B-Chemical
and	O
escitalopram	B-Chemical
(	O
which	O
she	O
was	O
taking	O
for	O
depression	B-Disease
)	O
were	O
discontinued	O
,	O
and	O
other	O
potential	O
causes	O
of	O
hepatotoxicity	B-Disease
were	O
excluded	O
.	O
A	O
repeat	O
work	O
-	O
up	O
revealed	O
further	O
elevations	O
in	O
aminotransferase	O
levels	O
,	O
and	O
liver	O
biopsy	O
revealed	O
evidence	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
drug	B-Disease
toxicity	I-Disease
.	O
She	O
underwent	O
liver	O
transplantation	O
with	O
an	O
uneventful	O
postoperative	O
course	O
.	O
Her	O
aminotransferase	O
levels	O
returned	O
to	O
normal	O
by	O
postoperative	O
day	O
23	O
,	O
and	O
her	O
2	O
-	O
year	O
follow	O
-	O
up	O
showed	O
no	O
adverse	O
events	O
.	O
Ezetimibe	B-Chemical
undergoes	O
extensive	O
glucuronidation	O
by	O
uridine	B-Chemical
diphosphate	I-Chemical
glucoronosyltransferases	O
(	O
UGT	O
)	O
in	O
the	O
intestine	O
and	O
liver	O
and	O
may	O
have	O
inhibited	O
the	O
glucuronidation	O
of	O
simvastatin	B-Chemical
hydroxy	I-Chemical
acid	I-Chemical
,	O
resulting	O
in	O
increased	O
simvastatin	B-Chemical
exposure	O
and	O
subsequent	O
hepatotoxicity	B-Disease
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
-	O
induced	O
liver	B-Disease
failure	I-Disease
that	O
resulted	O
in	O
liver	O
transplantation	O
.	O
We	O
postulate	O
that	O
the	O
mechanism	O
of	O
the	O
simvastatinezetimibe	B-Chemical
-	O
induced	O
hepatotoxicity	B-Disease
is	O
the	O
increased	O
simvastatin	B-Chemical
exposure	O
by	O
ezetimibe	B-Chemical
inhibition	O
of	O
UGT	O
enzymes	O
.	O
Clinicians	O
should	O
be	O
aware	O
of	O
potential	O
hepatotoxicity	B-Disease
with	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
especially	O
in	O
elderly	O
patients	O
and	O
should	O
carefully	O
monitor	O
serum	O
aminotransferase	O
levels	O
when	O
starting	O
therapy	O
and	O
titrating	O
the	O
dosage	O
.	O
Massive	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
after	O
oral	O
bisphosphonate	B-Chemical
(	O
alendronate	B-Chemical
)	O
administration	O
in	O
a	O
patient	O
with	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
.	O
A	O
61	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
with	O
nephrotic	B-Disease
syndrome	I-Disease
due	O
to	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
was	O
initially	O
responding	O
well	O
to	O
steroid	B-Chemical
therapy	O
.	O
The	O
amount	O
of	O
daily	O
urinary	O
protein	O
decreased	O
from	O
15	O
.	O
6	O
to	O
2	O
.	O
8	O
g	O
.	O
Within	O
14	O
days	O
of	O
the	O
oral	O
bisphosphonate	B-Chemical
(	O
alendronate	B-Chemical
sodium	I-Chemical
)	O
administration	O
,	O
the	O
amount	O
of	O
daily	O
urinary	O
protein	O
increased	O
rapidly	O
up	O
to	O
12	O
.	O
8	O
g	O
with	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O
After	O
discontinuing	O
the	O
oral	O
alendronate	B-Chemical
,	O
the	O
patient	O
underwent	O
six	O
cycles	O
of	O
hemodialysis	O
and	O
four	O
cycles	O
of	O
LDL	O
apheresis	O
.	O
Urinary	O
volume	O
and	O
serum	O
creatinine	B-Chemical
levels	O
recovered	O
to	O
the	O
normal	O
range	O
,	O
with	O
urinary	O
protein	O
disappearing	O
completely	O
within	O
40	O
days	O
.	O
This	O
report	O
demonstrates	O
that	O
not	O
only	O
intravenous	O
,	O
but	O
also	O
oral	O
bisphosphonates	B-Chemical
can	O
aggravate	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O
Serum	O
-	O
and	O
glucocorticoid	O
-	O
inducible	O
kinase	O
1	O
in	O
doxorubicin	B-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
Doxorubicin	B-Chemical
-	O
induced	O
nephropathy	B-Disease
leads	O
to	O
epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
)	O
-	O
dependent	O
volume	B-Disease
retention	I-Disease
and	O
renal	O
fibrosis	B-Disease
.	O
The	O
aldosterone	B-Chemical
-	O
sensitive	O
serum	O
-	O
and	O
glucocorticoid	O
-	O
inducible	O
kinase	O
SGK1	O
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
stimulation	O
of	O
ENaC	O
and	O
to	O
mediate	O
renal	O
fibrosis	B-Disease
following	O
mineralocorticoid	O
and	O
salt	O
excess	O
.	O
The	O
present	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SGK1	O
in	O
the	O
volume	B-Disease
retention	I-Disease
and	O
fibrosis	B-Disease
during	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
To	O
this	O
end	O
,	O
doxorubicin	B-Chemical
(	O
15	O
mug	O
/	O
g	O
body	O
wt	O
)	O
was	O
injected	O
intravenously	O
into	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
(	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
)	O
and	O
their	O
wild	O
-	O
type	O
littermates	O
(	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
)	O
.	O
Doxorubicin	B-Chemical
treatment	O
resulted	O
in	O
heavy	O
proteinuria	B-Disease
(	O
>	O
100	O
mg	O
protein	O
/	O
mg	O
crea	O
)	O
in	O
15	O
/	O
44	O
of	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
and	O
15	O
/	O
44	O
of	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
leading	O
to	O
severe	O
nephrotic	B-Disease
syndrome	I-Disease
with	O
ascites	B-Disease
,	O
lipidemia	B-Disease
,	O
and	O
hypoalbuminemia	B-Disease
in	O
both	O
genotypes	O
.	O
Plasma	O
aldosterone	B-Chemical
levels	O
increased	O
in	O
nephrotic	B-Disease
mice	O
of	O
both	O
genotypes	O
and	O
was	O
followed	O
by	O
increased	O
SGK1	O
protein	O
expression	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mice	O
.	O
Urinary	O
sodium	B-Chemical
excretion	O
reached	O
signficantly	O
lower	O
values	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mice	O
(	O
15	O
+	O
/	O
-	O
5	O
mumol	O
/	O
mg	O
crea	O
)	O
than	O
in	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
(	O
35	O
+	O
/	O
-	O
5	O
mumol	O
/	O
mg	O
crea	O
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
body	O
weight	B-Disease
gain	I-Disease
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
compared	O
with	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
(	O
+	O
6	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
vs	O
.	O
+	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
8	O
g	O
)	O
.	O
During	O
the	O
course	O
of	O
nephrotic	B-Disease
syndrome	I-Disease
,	O
serum	O
urea	B-Chemical
concentrations	O
increased	O
significantly	O
faster	O
in	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
than	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mice	O
leading	O
to	O
uremia	B-Disease
and	O
a	O
reduced	O
median	O
survival	O
in	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
(	O
29	O
vs	O
.	O
40	O
days	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mice	O
)	O
.	O
In	O
conclusion	O
,	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
showed	O
blunted	O
volume	B-Disease
retention	I-Disease
,	O
yet	O
were	O
not	O
protected	O
against	O
renal	O
fibrosis	B-Disease
during	O
experimental	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
Severe	O
thrombocytopenia	B-Disease
and	O
haemolytic	B-Disease
anaemia	I-Disease
associated	O
with	O
ciprofloxacin	B-Chemical
:	O
a	O
case	O
report	O
with	O
fatal	O
outcome	O
.	O
Haematological	O
adverse	O
reactions	O
associated	O
with	O
fatal	O
outcome	O
are	O
rare	O
during	O
treatment	O
with	O
ciprofloxacin	B-Chemical
.	O
A	O
30	O
-	O
year	O
old	O
Caucasian	O
man	O
reported	O
with	O
abdominal	B-Disease
pain	I-Disease
and	O
jaundice	B-Disease
after	O
3	O
-	O
day	O
administration	O
of	O
oral	O
ciprofloxacin	B-Chemical
for	O
a	O
suspect	O
of	O
urinary	B-Disease
tract	I-Disease
infection	I-Disease
.	O
Clinical	O
evaluations	O
suggested	O
an	O
initial	O
diagnosis	O
of	O
severe	O
thrombocytopenia	B-Disease
and	O
haemolysis	B-Disease
.	O
The	O
patient	O
progressively	O
developed	O
petechiae	B-Disease
and	O
purpura	B-Disease
on	O
thorax	O
and	O
lower	O
limbs	O
.	O
Despite	O
pharmacological	O
and	O
supportive	O
interventions	O
,	O
laboratory	O
parameters	O
worsened	O
and	O
the	O
patient	O
died	O
17	O
hours	O
after	O
admission	O
.	O
An	O
accurate	O
autopsy	O
revealed	O
most	O
organs	O
with	O
diffuse	O
petechial	O
haemorrhages	B-Disease
.	O
No	O
signs	O
of	O
bone	B-Disease
marrow	I-Disease
depression	I-Disease
were	O
found	O
.	O
No	O
thrombi	B-Disease
or	O
signs	O
of	O
microangiopathies	B-Disease
were	O
observed	O
in	O
arterial	O
vessels	O
.	O
Blood	O
and	O
urine	O
cultures	O
did	O
not	O
show	O
any	O
bacterial	O
growth	O
.	O
This	O
case	O
report	O
shows	O
that	O
ciprofloxacin	B-Chemical
may	O
precipitate	O
life	O
-	O
threatening	O
thrombocytopenia	B-Disease
and	O
haemolytic	B-Disease
anaemia	I-Disease
,	O
even	O
in	O
the	O
early	O
phases	O
of	O
treatment	O
and	O
without	O
apparent	O
previous	O
exposures	O
.	O
Alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
prevents	O
mitochondrial	B-Disease
damage	I-Disease
and	O
neurotoxicity	B-Disease
in	O
experimental	O
chemotherapy	O
neuropathy	B-Disease
.	O
The	O
study	O
investigates	O
if	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
is	O
neuroprotective	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-Disease
,	O
if	O
mitochondrial	B-Disease
damage	I-Disease
plays	O
a	O
critical	O
role	O
in	O
toxic	B-Disease
neurodegenerative	I-Disease
cascade	I-Disease
,	O
and	O
if	O
neuroprotective	O
effects	O
of	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
depend	O
on	O
mitochondria	O
protection	O
.	O
We	O
used	O
an	O
in	O
vitro	O
model	O
of	O
chemotherapy	O
induced	O
peripheral	B-Disease
neuropathy	I-Disease
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
condition	O
by	O
exposing	O
primary	O
cultures	O
of	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
sensory	O
neurons	O
to	O
paclitaxel	B-Chemical
and	O
cisplatin	B-Chemical
,	O
two	O
widely	O
used	O
and	O
highly	O
effective	O
chemotherapeutic	O
drugs	O
.	O
This	O
approach	O
allowed	O
investigating	O
the	O
efficacy	O
of	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
in	O
preventing	O
axonal	B-Disease
damage	I-Disease
and	O
apoptosis	O
and	O
the	O
function	O
and	O
ultrastructural	O
morphology	O
of	O
mitochondria	O
after	O
exposure	O
to	O
toxic	O
agents	O
and	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
.	O
Our	O
results	O
demonstrate	O
that	O
both	O
cisplatin	B-Chemical
and	O
paclitaxel	B-Chemical
cause	O
early	O
mitochondrial	B-Disease
impairment	I-Disease
with	O
loss	O
of	O
membrane	O
potential	O
and	O
induction	O
of	O
autophagic	O
vacuoles	O
in	O
neurons	O
.	O
Alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
exerts	O
neuroprotective	O
effects	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-Disease
in	O
sensory	O
neurons	O
:	O
it	O
rescues	O
the	O
mitochondrial	B-Disease
toxicity	I-Disease
and	O
induces	O
the	O
expression	O
of	O
frataxin	O
,	O
an	O
essential	O
mitochondrial	O
protein	O
with	O
anti	O
-	O
oxidant	O
and	O
chaperone	O
properties	O
.	O
In	O
conclusion	O
mitochondrial	B-Disease
toxicity	I-Disease
is	O
an	O
early	O
common	O
event	O
both	O
in	O
paclitaxel	B-Chemical
and	O
cisplatin	B-Chemical
induced	O
neurotoxicity	B-Disease
.	O
Alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
protects	O
sensory	O
neurons	O
through	O
its	O
anti	O
-	O
oxidant	O
and	O
mitochondrial	O
regulatory	O
functions	O
,	O
possibly	O
inducing	O
the	O
expression	O
of	O
frataxin	O
.	O
These	O
findings	O
suggest	O
that	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
might	O
reduce	O
the	O
risk	O
of	O
developing	O
peripheral	B-Disease
nerve	I-Disease
toxicity	I-Disease
in	O
patients	O
undergoing	O
chemotherapy	O
and	O
encourage	O
further	O
confirmatory	O
clinical	O
trials	O
.	O
Toxicity	B-Disease
in	O
rhesus	O
monkeys	O
following	O
administration	O
of	O
the	O
8	B-Chemical
-	I-Chemical
aminoquinoline	I-Chemical
8	B-Chemical
-	I-Chemical
[	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
amino	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
methylbutyl	I-Chemical
)	I-Chemical
amino	I-Chemical
]	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
(	I-Chemical
l	I-Chemical
-	I-Chemical
hexyloxy	I-Chemical
)	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methylquinoline	I-Chemical
(	O
WR242511	B-Chemical
)	O
.	O
INTRODUCTION	O
:	O
Many	O
substances	O
that	O
form	O
methemoglobin	O
(	O
MHb	O
)	O
effectively	O
counter	O
cyanide	O
(	O
CN	O
)	O
toxicity	B-Disease
.	O
Although	O
MHb	O
formers	O
are	O
generally	O
applied	O
as	O
treatments	O
for	O
CN	O
poisoning	B-Disease
,	O
it	O
has	O
been	O
proposed	O
that	O
a	O
stable	O
,	O
long	O
-	O
acting	O
MHb	O
former	O
could	O
serve	O
as	O
a	O
CN	O
pretreatment	O
.	O
Using	O
this	O
rationale	O
,	O
the	O
8	B-Chemical
-	I-Chemical
aminoquinoline	I-Chemical
WR242511	B-Chemical
,	O
a	O
potent	O
long	O
-	O
lasting	O
MHb	O
former	O
in	O
rodents	O
and	O
beagle	O
dogs	O
,	O
was	O
studied	O
in	O
the	O
rhesus	O
monkey	O
for	O
advanced	O
development	O
as	O
a	O
potential	O
CN	O
pretreatment	O
.	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
WR242511	B-Chemical
was	O
administered	O
intravenously	O
(	O
IV	O
)	O
in	O
2	O
female	O
and	O
4	O
male	O
rhesus	O
monkeys	O
in	O
doses	O
of	O
3	O
.	O
5	O
and	O
/	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
;	O
a	O
single	O
male	O
also	O
received	O
WR242511	B-Chemical
orally	O
(	O
PO	O
)	O
at	O
7	O
.	O
0	O
mg	O
/	O
kg	O
.	O
Health	O
status	O
and	O
MHb	O
levels	O
were	O
monitored	O
following	O
exposure	O
.	O
RESULTS	O
:	O
The	O
selected	O
doses	O
of	O
WR242511	B-Chemical
,	O
which	O
produced	O
significant	O
methemoglobinemia	B-Disease
in	O
beagle	O
dogs	O
in	O
earlier	O
studies	O
conducted	O
elsewhere	O
,	O
produced	O
very	O
little	O
MHb	O
(	O
mean	O
<	O
2	O
.	O
0	O
%	O
)	O
in	O
the	O
rhesus	O
monkey	O
.	O
Furthermore	O
,	O
transient	O
hemoglobinuria	B-Disease
was	O
noted	O
approximately	O
60	O
minutes	O
postinjection	O
of	O
WR242511	B-Chemical
(	O
3	O
.	O
5	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
)	O
,	O
and	O
2	O
lethalities	O
occurred	O
(	O
one	O
IV	O
and	O
one	O
PO	O
)	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dose	O
.	O
Myoglobinuria	B-Disease
was	O
also	O
observed	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dose	O
.	O
Histopathology	O
analyses	O
in	O
the	O
2	O
animals	O
that	O
died	O
revealed	O
liver	B-Disease
and	I-Disease
kidney	I-Disease
toxicity	I-Disease
,	O
with	O
greater	O
severity	O
in	O
the	O
orally	O
-	O
treated	O
animal	O
.	O
CONCLUSIONS	O
:	O
These	O
data	O
demonstrate	O
direct	O
and	O
/	O
or	O
indirect	O
drug	O
-	O
induced	O
toxicity	B-Disease
.	O
It	O
is	O
concluded	O
that	O
WR242511	B-Chemical
should	O
not	O
be	O
pursued	O
as	O
a	O
pretreatment	O
for	O
CN	O
poisoning	B-Disease
unless	O
the	O
anti	O
-	O
CN	O
characteristics	O
of	O
this	O
compound	O
can	O
be	O
successfully	O
dissociated	O
from	O
those	O
producing	O
undesirable	O
toxicity	B-Disease
.	O
Repetitive	O
transcranial	O
magnetic	O
stimulation	O
for	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
In	O
a	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
blinded	O
,	O
crossover	O
study	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
""""	O
real	O
""""	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
versus	O
""""	O
sham	O
""""	O
rTMS	O
(	O
placebo	O
)	O
on	O
peak	O
dose	O
dyskinesias	B-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
.	O
Ten	O
patients	O
with	O
PD	B-Disease
and	O
prominent	O
dyskinesias	B-Disease
had	O
rTMS	O
(	O
1	O
,	O
800	O
pulses	O
;	O
1	O
Hz	O
rate	O
)	O
delivered	O
over	O
the	O
motor	O
cortex	O
for	O
4	O
consecutive	O
days	O
twice	O
,	O
once	O
real	O
stimuli	O
and	O
once	O
sham	O
stimulation	O
were	O
used	O
;	O
evaluations	O
were	O
done	O
at	O
the	O
baseline	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatment	O
series	O
.	O
Direct	O
comparison	O
between	O
sham	O
and	O
real	O
rTMS	O
effects	O
showed	O
no	O
significant	O
difference	O
in	O
clinician	O
-	O
assessed	O
dyskinesia	B-Disease
severity	O
.	O
However	O
,	O
comparison	O
with	O
the	O
baseline	O
showed	O
small	O
but	O
significant	O
reduction	O
in	O
dyskinesia	B-Disease
severity	O
following	O
real	O
rTMS	O
but	O
not	O
placebo	O
.	O
The	O
major	O
effect	O
was	O
on	O
dystonia	B-Disease
subscore	O
.	O
Similarly	O
,	O
in	O
patient	O
diaries	O
,	O
although	O
both	O
treatments	O
caused	O
reduction	O
in	O
subjective	O
dyskinesia	B-Disease
scores	O
during	O
the	O
days	O
of	O
intervention	O
,	O
the	O
effect	O
was	O
sustained	O
for	O
3	O
days	O
after	O
the	O
intervention	O
for	O
the	O
real	O
rTMS	O
only	O
.	O
Following	O
rTMS	O
,	O
no	O
side	O
effects	O
and	O
no	O
adverse	O
effects	O
on	O
motor	O
function	O
and	O
PD	B-Disease
symptoms	O
were	O
noted	O
.	O
The	O
results	O
suggest	O
the	O
existence	O
of	O
residual	O
beneficial	O
clinical	O
aftereffects	O
of	O
consecutive	O
daily	O
applications	O
of	O
low	O
-	O
frequency	O
rTMS	O
on	O
dyskinesias	B-Disease
in	O
PD	B-Disease
.	O
The	O
effects	O
may	O
be	O
further	O
exploited	O
for	O
potential	O
therapeutic	O
uses	O
.	O
Intracavernous	O
epinephrine	B-Chemical
:	O
a	O
minimally	O
invasive	O
treatment	O
for	O
priapism	B-Disease
in	O
the	O
emergency	O
department	O
.	O
Priapism	B-Disease
is	O
the	O
prolonged	O
erection	O
of	O
the	O
penis	O
in	O
the	O
absence	O
of	O
sexual	O
arousal	O
.	O
A	O
45	O
-	O
year	O
-	O
old	O
man	O
,	O
an	O
admitted	O
frequent	O
cocaine	B-Chemical
user	O
,	O
presented	O
to	O
the	O
Emergency	O
Department	O
(	O
ED	O
)	O
on	O
two	O
separate	O
occasions	O
with	O
a	O
history	O
of	O
priapism	B-Disease
after	O
cocaine	B-Chemical
use	O
.	O
The	O
management	O
options	O
in	O
the	O
ED	O
,	O
as	O
exemplified	O
by	O
four	O
individual	O
case	O
reports	O
,	O
in	O
particular	O
the	O
use	O
of	O
a	O
minimally	O
invasive	O
method	O
of	O
intracorporal	O
epinephrine	B-Chemical
instillation	O
,	O
are	O
discussed	O
.	O
Prophylactic	O
use	O
of	O
lamivudine	B-Chemical
with	O
chronic	O
immunosuppressive	O
therapy	O
for	O
rheumatologic	B-Disease
disorders	I-Disease
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
report	O
our	O
experience	O
concerning	O
the	O
effectiveness	O
of	O
the	O
prophylactic	O
administration	O
of	O
lamivudine	B-Chemical
in	O
hepatitis	B-Chemical
B	I-Chemical
virus	I-Chemical
surface	I-Chemical
antigen	I-Chemical
(	O
HBs	B-Chemical
Ag	I-Chemical
)	O
positive	O
patients	O
with	O
rheumatologic	B-Disease
disease	I-Disease
.	O
From	O
June	O
2004	O
to	O
October	O
2006	O
,	O
11	O
HBs	B-Chemical
Ag	I-Chemical
positive	O
patients	O
with	O
rheumatologic	B-Disease
diseases	I-Disease
,	O
who	O
were	O
on	O
both	O
immunosuppressive	O
and	O
prophylactic	O
lamivudine	B-Chemical
therapies	O
,	O
were	O
retrospectively	O
assessed	O
.	O
Liver	O
function	O
tests	O
,	O
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
serologic	O
markers	O
,	O
and	O
HBV	O
DNA	O
levels	O
of	O
the	O
patients	O
during	O
follow	O
-	O
up	O
were	O
obtained	O
from	O
hospital	O
file	O
records	O
.	O
Eleven	O
patients	O
(	O
six	O
male	O
)	O
with	O
median	O
age	O
47	O
years	O
(	O
range	O
27	O
-	O
73	O
)	O
,	O
median	O
disease	O
duration	O
50	O
months	O
(	O
range	O
9	O
-	O
178	O
)	O
and	O
median	O
follow	O
-	O
up	O
period	O
of	O
patients	O
13	O
.	O
8	O
months	O
(	O
range	O
5	O
-	O
27	O
)	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
Lamivudine	B-Chemical
therapy	O
was	O
started	O
3	O
-	O
7	O
days	O
prior	O
to	O
immunosuppressive	O
therapy	O
in	O
all	O
patients	O
.	O
Baseline	O
,	O
liver	O
function	O
tests	O
were	O
elevated	O
in	O
two	O
patients	O
(	O
fourth	O
patient	O
:	O
ALT	O
:	O
122	O
IU	O
/	O
l	O
,	O
AST	O
:	O
111	O
IU	O
/	O
l	O
,	O
tenth	O
patient	O
:	O
ALT	O
:	O
294	O
IU	O
/	O
l	O
,	O
AST	O
:	O
274	O
IU	O
/	O
l	O
,	O
with	O
minimal	O
changes	O
in	O
the	O
liver	O
biopsy	O
in	O
both	O
)	O
.	O
Shortly	O
after	O
treatment	O
their	O
tests	O
normalized	O
and	O
during	O
follow	O
-	O
up	O
period	O
none	O
of	O
the	O
patients	O
had	O
abnormal	B-Disease
liver	I-Disease
function	I-Disease
tests	O
.	O
In	O
four	O
patients	O
HBV	O
DNA	O
levels	O
were	O
higher	O
than	O
normal	O
at	O
baseline	O
.	O
Two	O
of	O
these	O
normalized	O
and	O
the	O
others	O
increased	O
later	O
.	O
In	O
three	O
additional	O
patients	O
,	O
HBV	O
DNA	O
levels	O
were	O
increased	O
during	O
follow	O
-	O
up	O
.	O
None	O
of	O
the	O
patients	O
had	O
significant	O
clinical	O
sings	O
of	O
HBV	O
activation	O
.	O
Lamivudine	B-Chemical
was	O
well	O
tolerated	O
and	O
was	O
continued	O
in	O
all	O
patients	O
.	O
Prophylactic	O
administration	O
of	O
lamivudine	B-Chemical
in	O
patients	O
who	O
required	O
immunosuppressive	O
therapy	O
seems	O
to	O
be	O
safe	O
,	O
well	O
tolerated	O
and	O
effective	O
in	O
preventing	O
HBV	O
reactivation	O
.	O
Effect	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
combination	O
in	O
isoproterenol	B-Chemical
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
The	O
present	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
combined	O
effects	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
on	O
heart	O
weight	O
,	O
body	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
,	O
endogenous	O
antioxidants	O
and	O
membrane	O
bound	O
ATPases	O
in	O
isoproterenol	B-Chemical
(	O
ISO	B-Chemical
)	O
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
Adult	O
male	O
albino	O
rats	O
,	O
treated	O
with	O
ISO	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
elevation	O
of	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
and	O
Ca	B-Chemical
+	O
2	O
ATPase	O
level	O
whereas	O
there	O
was	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
decrease	O
in	O
body	O
weight	O
,	O
endogenous	O
antioxidants	O
,	O
Na	B-Chemical
+	O
/	O
K	B-Chemical
+	O
ATPase	O
and	O
Mg	B-Chemical
+	O
2	O
ATPase	O
levels	O
.	O
Administration	O
of	O
green	B-Chemical
tea	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
and	O
vitamin	B-Chemical
E	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
together	O
for	O
30	O
consecutive	O
days	O
and	O
challenged	O
with	O
ISO	B-Chemical
on	O
the	O
day	O
29th	O
and	O
30th	O
,	O
showed	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
decrease	O
in	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
,	O
Ca	B-Chemical
+	O
2	O
ATPase	O
and	O
a	O
significant	O
increase	O
in	O
the	O
body	O
weight	O
,	O
endogenous	O
antioxidants	O
,	O
Na	B-Chemical
+	O
/	O
K	B-Chemical
+	O
ATPase	O
and	O
Mg	B-Chemical
+	O
2	O
ATPase	O
when	O
compared	O
with	O
ISO	B-Chemical
treated	O
group	O
and	O
green	B-Chemical
tea	I-Chemical
or	O
vitamin	B-Chemical
E	I-Chemical
alone	O
treated	O
groups	O
.	O
These	O
findings	O
indicate	O
the	O
synergistic	O
protective	O
effect	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
during	O
ISO	B-Chemical
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
Irreversible	O
damage	O
to	O
the	O
medullary	O
interstitium	O
in	O
experimental	O
analgesic	O
nephropathy	B-Disease
in	O
F344	O
rats	O
.	O
Renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
(	O
RPN	B-Disease
)	O
and	O
a	O
decreased	O
urinary	O
concentrating	O
ability	O
developed	O
during	O
continuous	O
long	O
-	O
term	O
treatment	O
with	O
aspirin	B-Chemical
and	O
paracetamol	B-Chemical
in	O
female	O
Fischer	O
344	O
rats	O
.	O
Renal	O
structure	O
and	O
concentrating	O
ability	O
were	O
examined	O
after	O
a	O
recovery	O
period	O
of	O
up	O
to	O
18	O
weeks	O
,	O
when	O
no	O
analgesics	O
were	O
given	O
,	O
to	O
investigate	O
whether	O
the	O
analgesic	O
-	O
induced	O
changes	O
were	O
reversible	O
.	O
There	O
was	O
no	O
evidence	O
of	O
repair	O
to	O
the	O
damaged	O
medullary	O
interstitial	O
matrix	O
,	O
or	O
proliferation	O
of	O
remaining	O
undamaged	O
type	O
1	O
medullary	O
interstitial	O
cells	O
after	O
the	O
recovery	O
period	O
following	O
analgesic	O
treatment	O
.	O
The	O
recovery	O
of	O
urinary	O
concentrating	O
ability	O
was	O
related	O
to	O
the	O
length	O
of	O
analgesic	O
treatment	O
and	O
the	O
extent	O
of	O
the	O
resulting	O
inner	O
medullary	O
structural	O
damage	O
.	O
During	O
the	O
early	O
stages	O
of	O
analgesic	O
treatment	O
,	O
the	O
changes	O
in	O
urinary	O
concentrating	O
ability	O
were	O
reversible	O
,	O
but	O
after	O
prolonged	O
analgesic	O
treatment	O
,	O
maximum	O
urinary	O
concentrating	O
ability	O
failed	O
to	O
recover	O
.	O
This	O
study	O
shows	O
that	O
prolonged	O
analgesic	O
treatment	O
in	O
Fischer	O
344	O
rats	O
causes	O
progressive	O
and	O
irreversible	O
damage	O
to	O
the	O
interstitial	O
matrix	O
and	O
type	O
1	O
interstitial	O
cells	O
leading	O
to	O
RPN	B-Disease
.	O
The	O
associated	O
urinary	O
concentrating	O
defect	O
is	O
reversible	O
only	O
during	O
the	O
early	O
stages	O
of	O
structural	O
damage	O
to	O
the	O
inner	O
medulla	O
.	O
Testosterone	B-Chemical
-	O
dependent	O
hypertension	B-Disease
and	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
in	O
Dahl	O
salt	B-Chemical
-	O
sensitive	O
rats	O
.	O
Blood	O
pressure	O
(	O
BP	O
)	O
is	O
more	O
salt	B-Chemical
sensitive	O
in	O
men	O
than	O
in	O
premenopausal	O
women	O
.	O
In	O
Dahl	O
salt	B-Chemical
-	O
sensitive	O
rats	O
(	O
DS	O
)	O
,	O
high	O
-	O
salt	B-Chemical
(	O
HS	O
)	O
diet	O
increases	O
BP	O
more	O
in	O
males	O
than	O
females	O
.	O
In	O
contrast	O
to	O
the	O
systemic	O
renin	O
-	O
angiotensin	B-Chemical
system	O
,	O
which	O
is	O
suppressed	O
in	O
response	O
to	O
HS	O
in	O
male	O
DS	O
,	O
intrarenal	O
angiotensinogen	O
expression	O
is	O
increased	O
,	O
and	O
intrarenal	O
levels	O
of	O
ANG	O
II	O
are	O
not	O
suppressed	O
.	O
In	O
this	O
study	O
,	O
the	O
hypothesis	O
was	O
tested	O
that	O
there	O
is	O
a	O
sexual	O
dimorphism	O
in	O
HS	O
-	O
induced	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
mediated	O
by	O
testosterone	B-Chemical
that	O
also	O
causes	O
increases	O
in	O
BP	O
and	O
renal	B-Disease
injury	I-Disease
.	O
On	O
a	O
low	O
-	O
salt	B-Chemical
(	O
LS	O
)	O
diet	O
,	O
male	O
DS	O
had	O
higher	O
levels	O
of	O
intrarenal	O
angiotensinogen	O
mRNA	O
than	O
females	O
.	O
HS	O
diet	O
for	O
4	O
wk	O
increased	O
renal	O
cortical	O
angiotensinogen	O
mRNA	O
and	O
protein	O
only	O
in	O
male	O
DS	O
,	O
which	O
was	O
prevented	O
by	O
castration	O
.	O
Ovariectomy	O
of	O
female	O
DS	O
had	O
no	O
effect	O
on	O
intrarenal	O
angiotensinogen	O
expression	O
on	O
either	O
diet	O
.	O
Radiotelemetric	O
BP	O
was	O
similar	O
between	O
males	O
and	O
castrated	O
rats	O
on	O
LS	O
diet	O
.	O
HS	O
diet	O
for	O
4	O
wk	O
caused	O
a	O
progressive	O
increase	O
in	O
BP	O
,	O
protein	O
and	O
albumin	O
excretion	O
,	O
and	O
glomerular	B-Disease
sclerosis	I-Disease
in	O
male	O
DS	O
rats	O
,	O
which	O
were	O
attenuated	O
by	O
castration	O
.	O
Testosterone	B-Chemical
replacement	O
in	O
castrated	O
DS	O
rats	O
increased	O
BP	O
,	O
renal	B-Disease
injury	I-Disease
,	O
and	O
upregulation	O
of	O
renal	O
angiotensinogen	O
associated	O
with	O
HS	O
diet	O
.	O
Testosterone	B-Chemical
contributes	O
to	O
the	O
development	O
of	O
hypertension	B-Disease
and	O
renal	B-Disease
injury	I-Disease
in	O
male	O
DS	O
rats	O
on	O
HS	O
diet	O
possibly	O
through	O
upregulation	O
of	O
the	O
intrarenal	O
renin	O
-	O
angiotensin	B-Chemical
system	O
.	O
Explicit	O
episodic	O
memory	O
for	O
sensory	O
-	O
discriminative	O
components	O
of	O
capsaicin	B-Chemical
-	O
induced	O
pain	B-Disease
:	O
immediate	O
and	O
delayed	O
ratings	O
.	O
Pain	B-Disease
memory	O
is	O
thought	O
to	O
affect	O
future	O
pain	B-Disease
sensitivity	O
and	O
thus	O
contribute	O
to	O
clinical	O
pain	B-Disease
conditions	O
.	O
Systematic	O
investigations	O
of	O
the	O
human	O
capacity	O
to	O
remember	O
sensory	O
features	O
of	O
experimental	O
pain	B-Disease
are	O
sparse	O
.	O
In	O
order	O
to	O
address	O
long	O
-	O
term	O
pain	B-Disease
memory	O
,	O
nine	O
healthy	O
male	O
volunteers	O
received	O
intradermal	O
injections	O
of	O
three	O
doses	O
of	O
capsaicin	B-Chemical
(	O
0	O
.	O
05	O
,	O
1	O
and	O
20	O
microg	O
,	O
separated	O
by	O
15	O
min	O
breaks	O
)	O
,	O
each	O
given	O
three	O
times	O
in	O
a	O
balanced	O
design	O
across	O
three	O
sessions	O
at	O
one	O
week	O
intervals	O
.	O
Pain	B-Disease
rating	O
was	O
performed	O
using	O
a	O
computerized	O
visual	O
analogue	O
scale	O
(	O
0	O
-	O
100	O
)	O
digitized	O
at	O
1	O
/	O
s	O
,	O
either	O
immediately	O
online	O
or	O
one	O
hour	O
or	O
one	O
day	O
after	O
injection	O
.	O
Subjects	O
also	O
recalled	O
their	O
pains	B-Disease
one	O
week	O
later	O
.	O
Capsaicin	B-Chemical
injection	O
reliably	O
induced	O
a	O
dose	O
-	O
dependent	O
flare	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
without	O
any	O
difference	O
within	O
or	O
across	O
sessions	O
.	O
The	O
strong	O
burning	O
pain	B-Disease
decayed	O
exponentially	O
within	O
a	O
few	O
minutes	O
.	O
Subjects	O
were	O
able	O
to	O
reliably	O
discriminate	O
pain	B-Disease
magnitude	O
and	O
duration	O
across	O
capsaicin	B-Chemical
doses	O
(	O
both	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
regardless	O
of	O
whether	O
first	O
-	O
time	O
ratings	O
were	O
requested	O
immediately	O
,	O
after	O
one	O
hour	O
or	O
after	O
one	O
day	O
.	O
Pain	B-Disease
recall	O
after	O
one	O
week	O
was	O
similarly	O
precise	O
(	O
magnitude	O
:	O
p	O
<	O
0	O
.	O
01	O
,	O
duration	O
:	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Correlation	O
with	O
rating	O
recall	O
after	O
one	O
week	O
was	O
best	O
when	O
first	O
-	O
time	O
ratings	O
were	O
requested	O
as	O
late	O
as	O
one	O
day	O
after	O
injection	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
79	O
)	O
indicating	O
that	O
both	O
rating	O
retrievals	O
utilized	O
similar	O
memory	O
traces	O
.	O
These	O
results	O
indicate	O
a	O
reliable	O
memory	O
for	O
magnitude	O
and	O
duration	O
of	O
experimentally	O
induced	O
pain	B-Disease
.	O
The	O
data	O
further	O
suggest	O
that	O
the	O
consolidation	O
of	O
this	O
memory	O
is	O
an	O
important	O
interim	O
stage	O
,	O
and	O
may	O
take	O
up	O
to	O
one	O
day	O
.	O
Severe	O
and	O
long	O
lasting	O
cholestasis	B-Disease
after	O
high	O
-	O
dose	O
co	B-Chemical
-	I-Chemical
trimoxazole	I-Chemical
treatment	O
for	O
Pneumocystis	B-Disease
pneumonia	I-Disease
in	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
patients	O
-	O
-	O
a	O
report	O
of	O
two	O
cases	O
.	O
Pneumocystis	B-Disease
pneumonia	I-Disease
(	O
PCP	B-Disease
)	O
,	O
a	O
common	O
opportunistic	B-Disease
infection	I-Disease
in	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
individuals	O
,	O
is	O
generally	O
treated	O
with	O
high	O
doses	O
of	O
co	B-Chemical
-	I-Chemical
trimoxazole	I-Chemical
.	O
However	O
,	O
treatment	O
is	O
often	O
limited	O
by	O
adverse	O
effects	O
.	O
Here	O
,	O
we	O
report	O
two	O
cases	O
of	O
severely	O
immunocompromised	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
patients	O
who	O
developed	O
severe	O
intrahepatic	B-Disease
cholestasis	I-Disease
,	O
and	O
in	O
one	O
patient	O
lesions	O
mimicking	O
liver	B-Disease
abscess	I-Disease
formation	O
on	O
radiologic	O
exams	O
,	O
during	O
co	B-Chemical
-	I-Chemical
trimoxazole	I-Chemical
treatment	O
for	O
PCP	B-Disease
.	O
Whereas	O
patient	O
1	O
showed	O
lesions	O
of	O
up	O
to	O
1	O
cm	O
readily	O
detectable	O
on	O
magnetic	O
resonance	O
imaging	O
under	O
prolonged	O
co	B-Chemical
-	I-Chemical
trimoxazole	I-Chemical
treatment	O
,	O
therapy	O
of	O
patient	O
2	O
was	O
switched	O
early	O
.	O
Bradykinin	B-Chemical
receptors	O
antagonists	O
and	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
inhibitors	O
in	O
vincristine	B-Chemical
and	O
streptozotocin	B-Chemical
induced	O
hyperalgesia	B-Disease
in	O
chemotherapy	O
and	O
diabetic	B-Disease
neuropathy	I-Disease
rat	O
model	O
.	O
PURPOSE	O
:	O
The	O
influence	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
constitutive	O
NO	B-Chemical
synthase	O
(	O
L	O
-	O
NOArg	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
a	O
relatively	O
selective	O
inhibitor	O
of	O
inducible	O
NO	B-Chemical
synthase	O
(	O
L	O
-	O
NIL	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
and	O
a	O
relatively	O
specific	O
inhibitor	O
of	O
neuronal	O
NO	B-Chemical
synthase	O
(	O
7	O
-	O
NI	O
;	O
0	O
.	O
1	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
on	O
antihyperalgesic	O
action	O
of	O
selective	O
antagonists	O
of	O
B2	O
and	O
B1	O
receptors	O
:	O
D	O
-	O
Arg	O
-	O
[	O
Hyp3	O
,	O
Thi5	O
,	O
D	O
-	O
Tic7	O
,	O
Oic8	O
]	O
bradykinin	B-Chemical
(	O
HOE	B-Chemical
140	I-Chemical
;	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
or	O
des	B-Chemical
Arg10	I-Chemical
HOE	I-Chemical
140	I-Chemical
(	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
respectively	O
,	O
in	O
model	O
of	O
diabetic	B-Disease
(	I-Disease
streptozotocin	I-Disease
-	I-Disease
induced	I-Disease
)	I-Disease
and	I-Disease
toxic	I-Disease
(	I-Disease
vincristine	I-Disease
-	I-Disease
induced	I-Disease
)	I-Disease
neuropathy	I-Disease
was	O
investigated	O
.	O
METHODS	O
:	O
The	O
changes	O
in	O
pain	B-Disease
thresholds	O
were	O
determined	O
using	O
mechanical	O
stimuli	O
-	O
-	O
the	O
modification	O
of	O
the	O
classic	O
paw	O
withdrawal	O
test	O
described	O
by	O
Randall	O
-	O
Selitto	O
.	O
RESULTS	O
:	O
The	O
results	O
of	O
this	O
paper	O
confirm	O
that	O
inhibition	O
of	O
bradykinin	B-Chemical
receptors	O
and	O
inducible	O
NO	B-Chemical
synthase	O
but	O
not	O
neuronal	O
NO	B-Chemical
synthase	O
activity	O
reduces	O
diabetic	B-Disease
hyperalgesia	I-Disease
.	O
Pretreatment	O
with	O
L	O
-	O
NOArg	O
and	O
L	O
-	O
NIL	O
but	O
not	O
7	O
-	O
NI	O
,	O
significantly	O
increases	O
antihyperalgesic	O
activity	O
both	O
HOE	B-Chemical
140	I-Chemical
and	O
des	B-Chemical
Arg10	I-Chemical
HOE	I-Chemical
140	I-Chemical
.	O
It	O
was	O
also	O
shown	O
that	O
both	O
products	O
of	O
inducible	O
NO	B-Chemical
synthase	O
and	O
neuronal	O
NO	B-Chemical
synthase	O
activation	O
as	O
well	O
as	O
bradykinin	B-Chemical
are	O
involved	O
in	O
hyperalgesia	B-Disease
produced	O
by	O
vincristine	B-Chemical
.	O
Moreover	O
,	O
L	O
-	O
NOArg	O
and	O
7	O
-	O
NI	O
but	O
not	O
L	O
-	O
NIL	O
intensify	O
antihyperalgesic	O
activity	O
of	O
HOE	B-Chemical
140	I-Chemical
or	O
des	B-Chemical
-	I-Chemical
Arg10HOE	I-Chemical
140	I-Chemical
in	O
toxic	B-Disease
neuropathy	I-Disease
.	O
CONCLUSIONS	O
:	O
Results	O
of	O
these	O
studies	O
suggest	O
that	O
B1	O
and	O
B2	O
receptors	O
are	O
engaged	O
in	O
transmission	O
of	O
nociceptive	O
stimuli	O
in	O
both	O
diabetic	B-Disease
and	I-Disease
toxic	I-Disease
neuropathy	I-Disease
.	O
In	O
streptozotocin	B-Chemical
-	O
induced	O
hyperalgesia	B-Disease
,	O
inducible	O
NO	B-Chemical
synthase	O
participates	O
in	O
pronociceptive	O
activity	O
of	O
bradykinin	B-Chemical
,	O
whereas	O
in	O
vincristine	B-Chemical
-	O
induced	O
hyperalgesia	B-Disease
bradykinin	B-Chemical
seemed	O
to	O
activate	O
neuronal	O
NO	B-Chemical
synthase	O
pathway	O
.	O
Therefore	O
,	O
concomitant	O
administration	O
of	O
small	O
doses	O
of	O
bradykinin	B-Chemical
receptor	O
antagonists	O
and	O
NO	B-Chemical
synthase	O
inhibitors	O
can	O
be	O
effective	O
in	O
alleviation	O
of	O
neuropathic	B-Disease
pain	I-Disease
,	O
even	O
in	O
hospital	O
care	O
.	O
Confusion	B-Disease
,	O
a	O
rather	O
serious	O
adverse	O
drug	O
reaction	O
with	O
valproic	B-Chemical
acid	I-Chemical
:	O
a	O
review	O
of	O
the	O
French	O
Pharmacovigilance	O
database	O
.	O
INTRODUCTION	O
:	O
Confusion	B-Disease
is	O
an	O
adverse	O
drug	O
reaction	O
frequently	O
observed	O
with	O
valproic	B-Chemical
acid	I-Chemical
.	O
Some	O
case	O
reports	O
are	O
published	O
in	O
the	O
literature	O
but	O
no	O
systematic	O
study	O
from	O
a	O
sample	O
of	O
patients	O
has	O
been	O
published	O
.	O
We	O
performed	O
this	O
study	O
in	O
order	O
to	O
describe	O
the	O
main	O
characteristics	O
of	O
this	O
adverse	O
drug	O
reaction	O
.	O
METHODS	O
:	O
Using	O
the	O
French	O
Pharmacovigilance	O
database	O
,	O
we	O
selected	O
the	O
cases	O
of	O
confusion	B-Disease
reported	O
since	O
1985	O
with	O
valproic	B-Chemical
acid	I-Chemical
.	O
RESULTS	O
:	O
272	O
cases	O
of	O
confusion	B-Disease
were	O
reported	O
with	O
valproic	B-Chemical
acid	I-Chemical
:	O
153	O
women	O
and	O
119	O
men	O
.	O
Confusion	B-Disease
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weeks	O
following	O
valproic	B-Chemical
acid	I-Chemical
exposure	O
(	O
39	O
.	O
7	O
%	O
)	O
.	O
It	O
was	O
""""	O
serious	O
""""	O
for	O
almost	O
2	O
/	O
3	O
of	O
the	O
patients	O
(	O
62	O
.	O
5	O
%	O
)	O
and	O
its	O
outcome	O
favourable	O
in	O
most	O
of	O
the	O
cases	O
(	O
82	O
%	O
)	O
.	O
The	O
occurrence	O
of	O
this	O
ADR	O
was	O
more	O
frequent	O
in	O
patients	O
aged	O
between	O
61	O
and	O
80	O
years	O
.	O
CONCLUSION	O
:	O
This	O
work	O
shows	O
that	O
confusion	B-Disease
with	O
valproic	B-Chemical
acid	I-Chemical
is	O
a	O
serious	O
,	O
rather	O
frequent	O
but	O
reversible	O
adverse	O
drug	O
reaction	O
.	O
It	O
occurs	O
especially	O
in	O
older	O
patients	O
and	O
during	O
the	O
first	O
two	O
weeks	O
of	O
treatment	O
.	O
Reversible	O
inferior	B-Disease
colliculus	I-Disease
lesion	I-Disease
in	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
:	O
magnetic	O
resonance	O
findings	O
on	O
diffusion	O
-	O
weighted	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
imaging	O
.	O
OBJECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
inferior	B-Disease
colliculus	I-Disease
lesions	I-Disease
in	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
,	O
to	O
focus	O
on	O
the	O
diffusion	O
-	O
weighted	O
imaging	O
(	O
DWI	O
)	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
imaging	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
From	O
November	O
2005	O
to	O
September	O
2007	O
,	O
8	O
patients	O
(	O
5	O
men	O
and	O
3	O
women	O
)	O
were	O
diagnosed	O
as	O
having	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
(	O
age	O
range	O
;	O
43	O
-	O
78	O
years	O
)	O
.	O
They	O
had	O
been	O
taking	O
metronidazole	B-Chemical
(	O
total	O
dosage	O
,	O
45	O
-	O
120	O
g	O
;	O
duration	O
,	O
30	O
days	O
to	O
2	O
months	O
)	O
to	O
treat	O
the	O
infection	B-Disease
in	O
various	O
organs	O
.	O
Initial	O
brain	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
were	O
obtained	O
after	O
the	O
hospitalization	O
,	O
including	O
DWI	O
(	O
8	O
/	O
8	O
)	O
,	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
map	O
(	O
4	O
/	O
8	O
)	O
,	O
FLAIR	O
(	O
7	O
/	O
8	O
)	O
,	O
and	O
T2	O
-	O
weighted	O
image	O
(	O
8	O
/	O
8	O
)	O
.	O
Follow	O
-	O
up	O
MRIs	O
were	O
performed	O
on	O
5	O
patients	O
from	O
third	O
to	O
14th	O
days	O
after	O
discontinuation	O
of	O
metronidazole	B-Chemical
administration	O
.	O
Findings	O
of	O
initial	O
and	O
follow	O
-	O
up	O
MRIs	O
were	O
retrospectively	O
evaluated	O
by	O
2	O
neuroradiologists	O
by	O
consensus	O
,	O
to	O
analyze	O
the	O
presence	O
of	O
abnormal	O
signal	O
intensities	O
,	O
their	O
locations	O
,	O
and	O
signal	O
changes	O
on	O
follow	O
-	O
up	O
images	O
.	O
RESULTS	O
:	O
Initial	O
MRIs	O
showed	O
abnormal	O
high	O
signal	O
intensities	O
on	O
DWI	O
and	O
FLAIR	O
(	O
or	O
T2	O
-	O
weighted	O
image	O
)	O
at	O
the	O
dentate	O
nucleus	O
(	O
8	O
/	O
8	O
)	O
,	O
inferior	O
colliculus	O
(	O
6	O
/	O
8	O
)	O
,	O
corpus	O
callosum	O
(	O
2	O
/	O
8	O
)	O
,	O
pons	O
(	O
2	O
/	O
8	O
)	O
,	O
medulla	O
(	O
1	O
/	O
8	O
)	O
,	O
and	O
bilateral	O
cerebral	O
white	O
matter	O
(	O
1	O
/	O
8	O
)	O
.	O
High	O
-	O
signal	O
intensity	O
lesions	O
on	O
DWI	O
tended	O
to	O
show	O
low	O
signal	O
intensity	O
on	O
ADC	O
map	O
(	O
3	O
/	O
4	O
)	O
,	O
but	O
in	O
one	O
patient	O
,	O
high	O
signal	O
intensity	O
was	O
shown	O
at	O
bilateral	O
dentate	O
nuclei	O
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
map	O
.	O
All	O
the	O
lesions	O
in	O
dentate	O
,	O
inferior	O
colliculus	O
,	O
pons	O
,	O
and	O
medullas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MRIs	O
in	O
5	O
patients	O
,	O
but	O
in	O
1	O
patient	O
of	O
them	O
,	O
corpus	O
callosal	B-Disease
lesion	I-Disease
persisted	O
.	O
CONCLUSIONS	O
:	O
Reversible	O
inferior	B-Disease
colliculus	I-Disease
lesions	I-Disease
could	O
be	O
considered	O
as	O
the	O
characteristic	O
for	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
,	O
next	O
to	O
the	O
dentate	O
nucleus	O
involvement	O
.	O
Clinically	O
significant	O
proteinuria	B-Disease
following	O
the	O
administration	O
of	O
sirolimus	B-Chemical
to	O
renal	O
transplant	O
recipients	O
.	O
BACKGROUND	O
:	O
Sirolimus	B-Chemical
is	O
the	O
latest	O
immunosuppressive	O
agent	O
used	O
to	O
prevent	O
rejection	O
,	O
and	O
may	O
have	O
less	O
nephrotoxicity	B-Disease
than	O
calcineurin	O
inhibitor	O
(	O
CNI	O
)	O
-	O
based	O
regimens	O
.	O
To	O
date	O
there	O
has	O
been	O
little	O
documentation	O
of	O
clinically	O
significant	O
proteinuria	B-Disease
linked	O
with	O
the	O
use	O
of	O
sirolimus	B-Chemical
.	O
We	O
have	O
encountered	O
several	O
patients	O
who	O
developed	O
substantial	O
proteinuria	B-Disease
associated	O
with	O
sirolimus	B-Chemical
use	O
.	O
In	O
each	O
patient	O
,	O
the	O
close	O
temporal	O
association	O
between	O
the	O
commencement	O
of	O
sirolimus	B-Chemical
therapy	O
and	O
proteinuria	B-Disease
implicated	O
sirolimus	B-Chemical
as	O
the	O
most	O
likely	O
etiology	O
of	O
the	O
proteinuria	B-Disease
.	O
METHODS	O
:	O
We	O
analyzed	O
the	O
clinical	O
and	O
laboratory	O
information	O
available	O
for	O
all	O
119	O
patients	O
transplanted	O
at	O
the	O
Washington	O
Hospital	O
Center	O
between	O
1999	O
-	O
2003	O
for	O
whom	O
sirolimus	B-Chemical
was	O
a	O
component	O
of	O
their	O
immunosuppressant	O
regimen	O
.	O
In	O
these	O
patients	O
,	O
the	O
magnitude	O
of	O
proteinuria	B-Disease
was	O
assessed	O
on	O
morning	O
urine	O
samples	O
by	O
turbidometric	O
measurement	O
or	O
random	O
urine	O
protein	O
:	O
creatinine	B-Chemical
ratios	O
,	O
an	O
estimate	O
of	O
grams	O
of	O
proteinuria	B-Disease
/	O
day	O
.	O
Laboratory	O
results	O
were	O
compared	O
between	O
prior	O
,	O
during	O
and	O
following	O
sirolimus	B-Chemical
use	O
.	O
RESULTS	O
:	O
Twenty	O
-	O
eight	O
patients	O
(	O
24	O
%	O
)	O
developed	O
increased	O
proteinuria	B-Disease
from	O
baseline	O
during	O
their	O
post	O
-	O
transplantation	O
course	O
.	O
In	O
21	O
patients	O
an	O
alternative	O
cause	O
of	O
proteinuria	B-Disease
was	O
either	O
obvious	O
or	O
insufficient	O
data	O
was	O
available	O
to	O
be	O
conclusive	O
.	O
In	O
7	O
of	O
the	O
28	O
patients	O
there	O
was	O
a	O
striking	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
sirolimus	B-Chemical
and	O
the	O
development	O
of	O
nephrotic	B-Disease
-	O
range	O
proteinuria	B-Disease
.	O
Proteinuria	B-Disease
correlated	O
most	O
strongly	O
with	O
sirolimus	B-Chemical
therapy	O
when	O
compared	O
to	O
other	O
demographic	O
and	O
clinical	O
variables	O
.	O
In	O
most	O
patients	O
,	O
discontinuation	O
of	O
sirolimus	B-Chemical
resulted	O
in	O
a	O
decrease	O
,	O
but	O
not	O
resolution	O
,	O
of	O
proteinuria	B-Disease
.	O
CONCLUSIONS	O
:	O
Sirolimus	B-Chemical
induces	O
or	O
aggravates	O
pre	O
-	O
existing	O
proteinuria	B-Disease
in	O
an	O
unpredictable	O
subset	O
of	O
renal	O
allograft	O
recipients	O
.	O
Proteinuria	B-Disease
may	O
improve	O
,	O
but	O
does	O
not	O
resolve	O
,	O
when	O
sirolimus	B-Chemical
is	O
withdrawn	O
.	O
Components	O
of	O
lemon	O
essential	O
oil	O
attenuate	O
dementia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
.	O
The	O
anti	O
-	O
dementia	B-Disease
effects	O
of	O
s	B-Chemical
-	I-Chemical
limonene	I-Chemical
and	O
s	B-Chemical
-	I-Chemical
perillyl	I-Chemical
alcohol	I-Chemical
were	O
observed	O
using	O
the	O
passive	O
avoidance	O
test	O
(	O
PA	O
)	O
and	O
the	O
open	O
field	O
habituation	O
test	O
(	O
OFH	O
)	O
.	O
These	O
lemon	O
essential	O
oils	O
showed	O
strong	O
ability	O
to	O
improve	O
memory	B-Disease
impaired	I-Disease
by	O
scopolamine	B-Chemical
;	O
however	O
,	O
s	B-Chemical
-	I-Chemical
perillyl	I-Chemical
alcohol	I-Chemical
relieved	O
the	O
deficit	B-Disease
of	I-Disease
associative	I-Disease
memory	I-Disease
in	O
PA	O
only	O
,	O
and	O
did	O
not	O
improve	O
non	O
-	O
associative	O
memory	O
significantly	O
in	O
OFH	O
.	O
Analysis	O
of	O
neurotransmitter	O
concentration	O
in	O
some	O
brain	O
regions	O
on	O
the	O
test	O
day	O
showed	O
that	O
dopamine	B-Chemical
concentration	O
of	O
the	O
vehicle	O
/	O
scopolamine	B-Chemical
group	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
vehicle	O
/	O
vehicle	O
group	O
,	O
but	O
this	O
phenomenon	O
was	O
reversed	O
when	O
s	B-Chemical
-	I-Chemical
limonene	I-Chemical
or	O
s	B-Chemical
-	I-Chemical
perillyl	I-Chemical
alcohol	I-Chemical
were	O
administered	O
before	O
the	O
injection	O
of	O
scopolamine	B-Chemical
.	O
Simultaneously	O
,	O
we	O
found	O
that	O
these	O
two	O
lemon	O
essential	O
oil	O
components	O
could	O
inhibit	O
acetylcholinesterase	O
activity	O
in	O
vitro	O
using	O
the	O
Ellman	O
method	O
.	O
Attentional	O
modulation	O
of	O
perceived	O
pain	B-Disease
intensity	O
in	O
capsaicin	B-Chemical
-	O
induced	O
secondary	O
hyperalgesia	B-Disease
.	O
Perceived	O
pain	B-Disease
intensity	O
is	O
modulated	O
by	O
attention	O
.	O
However	O
,	O
it	O
is	O
not	O
known	O
that	O
how	O
pain	B-Disease
intensity	O
ratings	O
are	O
affected	O
by	O
attention	O
in	O
capsaicin	B-Chemical
-	O
induced	O
secondary	O
hyperalgesia	B-Disease
.	O
Here	O
we	O
show	O
that	O
perceived	O
pain	B-Disease
intensity	O
in	O
secondary	O
hyperalgesia	B-Disease
is	O
decreased	O
when	O
attention	O
is	O
distracted	O
away	O
from	O
the	O
painful	O
pinprick	O
stimulus	O
with	O
a	O
visual	O
task	O
.	O
Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
magnitude	O
of	O
attentional	O
modulation	O
in	O
secondary	O
hyperalgesia	B-Disease
is	O
very	O
similar	O
to	O
that	O
of	O
capsaicin	B-Chemical
-	O
untreated	O
,	O
control	O
condition	O
.	O
Our	O
findings	O
,	O
showing	O
no	O
interaction	O
between	O
capsaicin	B-Chemical
treatment	O
and	O
attentional	O
modulation	O
suggest	O
that	O
capsaicin	B-Chemical
-	O
induced	O
secondary	O
hyperalgesia	B-Disease
and	O
attention	O
might	O
affect	O
mechanical	O
pain	B-Disease
through	O
independent	O
mechanisms	O
.	O
Cardioprotective	O
effect	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
cardioprotective	O
potential	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
Hemodynamic	O
parameters	O
and	O
lead	O
II	O
electrocardiograph	O
were	O
monitored	O
and	O
recorded	O
continuously	O
.	O
Cardiac	O
marker	O
enzymes	O
and	O
antioxidative	O
parameters	O
in	O
serum	O
and	O
heart	O
tissues	O
were	O
measured	O
.	O
Assay	O
for	O
mitochondrial	O
respiratory	O
function	O
and	O
histopathological	O
examination	O
of	O
heart	O
tissues	O
were	O
performed	O
.	O
Isoproterenol	B-Chemical
-	O
treated	O
rats	O
showed	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
lactate	B-Chemical
dehydrogenase	O
,	O
aspartate	B-Chemical
transaminase	O
,	O
creatine	B-Chemical
kinase	O
and	O
malondialdehyde	B-Chemical
and	O
significant	O
decreases	O
in	O
the	O
activities	O
of	O
superoxide	B-Chemical
dismutase	O
,	O
catalase	O
and	O
glutathione	B-Chemical
peroxidase	O
in	O
serum	O
and	O
heart	O
.	O
These	O
rats	O
also	O
showed	O
declines	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
,	O
maximum	O
and	O
minimum	O
rate	O
of	O
developed	O
left	O
ventricular	O
pressure	O
,	O
and	O
elevation	O
of	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
ST	O
-	O
segment	O
.	O
In	O
addition	O
,	O
mitochondrial	O
respiratory	B-Disease
dysfunction	I-Disease
characterized	O
by	O
decreased	O
respiratory	O
control	O
ratio	O
and	O
ADP	B-Chemical
/	O
O	O
was	O
observed	O
in	O
isoproterenol	B-Chemical
-	O
treated	O
rats	O
.	O
Administration	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
for	O
a	O
period	O
of	O
8	O
days	O
significantly	O
attenuated	O
isoproterenol	B-Chemical
-	O
induced	O
cardiac	B-Disease
dysfunction	I-Disease
and	O
myocardial	B-Disease
injury	I-Disease
and	O
improved	O
mitochondrial	O
respiratory	O
function	O
.	O
The	O
protective	O
role	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
against	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
damage	I-Disease
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O
The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
possessing	O
antioxidant	O
activity	O
has	O
a	O
significant	O
protective	O
effect	O
against	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
.	O
Long	O
-	O
term	O
glutamate	B-Chemical
supplementation	O
failed	O
to	O
protect	O
against	O
peripheral	B-Disease
neurotoxicity	I-Disease
of	O
paclitaxel	B-Chemical
.	O
Toxic	O
peripheral	B-Disease
neuropathy	I-Disease
is	O
still	O
a	O
significant	O
limiting	O
factor	O
for	O
chemotherapy	O
with	O
paclitaxel	B-Chemical
(	O
PAC	B-Chemical
)	O
,	O
although	O
glutamate	B-Chemical
and	O
its	O
closely	O
related	O
amino	B-Chemical
acid	I-Chemical
glutamine	B-Chemical
were	O
claimed	O
to	O
ameliorate	O
PAC	B-Chemical
neurotoxicity	B-Disease
.	O
This	O
pilot	O
trial	O
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
glutamate	B-Chemical
supplementation	O
for	O
preventing	O
PAC	B-Chemical
-	O
induced	O
peripheral	B-Disease
neuropathy	I-Disease
in	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blinded	O
clinical	O
and	O
electro	O
-	O
diagnostic	O
study	O
.	O
Forty	O
-	O
three	O
ovarian	B-Disease
cancer	I-Disease
patients	O
were	O
available	O
for	O
analysis	O
following	O
six	O
cycles	O
of	O
the	O
same	O
PAC	B-Chemical
-	O
containing	O
regimen	O
:	O
23	O
had	O
been	O
supplemented	O
by	O
glutamate	B-Chemical
all	O
along	O
the	O
treatment	O
period	O
,	O
at	O
a	O
daily	O
dose	O
of	O
three	O
times	O
500	O
mg	O
(	O
group	O
G	O
)	O
,	O
and	O
20	O
had	O
received	O
a	O
placebo	O
(	O
group	O
P	O
)	O
.	O
Patients	O
were	O
evaluated	O
by	O
neurological	O
examinations	O
,	O
questionnaires	O
and	O
sensory	O
-	O
motor	O
nerve	O
conduction	O
studies	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
signs	O
or	O
symptoms	O
between	O
the	O
two	O
groups	O
although	O
neurotoxicity	B-Disease
symptoms	O
presented	O
mostly	O
with	O
lower	O
scores	O
of	O
severity	O
in	O
group	O
G	O
.	O
However	O
,	O
this	O
difference	O
reached	O
statistical	O
significance	O
only	O
with	O
regard	O
to	O
reported	O
pain	B-Disease
sensation	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O
Also	O
the	O
frequency	O
of	O
abnormal	O
electro	O
-	O
diagnostic	O
findings	O
showed	O
similarity	O
between	O
the	O
two	O
groups	O
(	O
G	O
:	O
7	O
/	O
23	O
=	O
30	O
.	O
4	O
%	O
;	O
P	O
:	O
6	O
/	O
20	O
=	O
30	O
%	O
)	O
.	O
This	O
pilot	O
study	O
leads	O
to	O
the	O
conclusion	O
that	O
glutamate	B-Chemical
supplementation	O
at	O
the	O
chosen	O
regimen	O
fails	O
to	O
protect	O
against	O
peripheral	B-Disease
neurotoxicity	I-Disease
of	O
PAC	B-Chemical
.	O
Development	O
of	O
ocular	B-Disease
myasthenia	I-Disease
during	O
pegylated	B-Chemical
interferon	I-Chemical
and	O
ribavirin	B-Chemical
treatment	O
for	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
.	O
A	O
63	O
-	O
year	O
-	O
old	O
male	O
experienced	O
sudden	O
diplopia	B-Disease
after	O
9	O
weeks	O
of	O
administration	O
of	O
pegylated	B-Chemical
interferon	I-Chemical
(	I-Chemical
IFN	I-Chemical
)	I-Chemical
alpha	I-Chemical
-	I-Chemical
2b	I-Chemical
and	O
ribavirin	B-Chemical
for	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
(	O
CHC	B-Disease
)	O
.	O
Ophthalmologic	O
examinations	O
showed	O
ptosis	B-Disease
on	I-Disease
the	I-Disease
right	I-Disease
upper	I-Disease
lid	I-Disease
and	O
restricted	B-Disease
right	I-Disease
eye	I-Disease
movement	I-Disease
without	O
any	O
other	O
neurological	O
signs	O
.	O
A	O
brain	O
imaging	O
study	O
and	O
repetitive	O
nerve	O
stimulation	O
test	O
indicated	O
no	O
abnormality	O
.	O
The	O
acetylcholine	B-Chemical
receptor	O
antibody	O
titer	O
and	O
response	O
to	O
acetylcholinesterase	O
inhibitors	O
were	O
negative	O
,	O
and	O
the	O
results	O
of	O
thyroid	O
function	O
tests	O
were	O
normal	O
.	O
The	O
patient	O
'	O
s	O
ophthalmological	O
symptoms	O
improved	O
rapidly	O
3	O
weeks	O
after	O
discontinuation	O
of	O
pegylated	B-Chemical
IFN	I-Chemical
alpha	I-Chemical
-	I-Chemical
2b	I-Chemical
and	O
ribavirin	B-Chemical
.	O
The	O
ocular	B-Disease
myasthenia	I-Disease
associated	O
with	O
combination	O
therapy	O
of	O
pegylated	B-Chemical
IFN	I-Chemical
alpha	I-Chemical
-	I-Chemical
2b	I-Chemical
and	O
ribavirin	B-Chemical
for	O
CHC	B-Disease
is	O
very	O
rarely	O
reported	O
;	O
therefore	O
,	O
we	O
present	O
this	O
case	O
with	O
a	O
review	O
of	O
the	O
various	O
eye	O
complications	O
of	O
IFN	B-Chemical
therapy	O
.	O
Learning	B-Disease
and	I-Disease
memory	I-Disease
deficits	I-Disease
in	O
ecstasy	B-Chemical
users	O
and	O
their	O
neural	O
correlates	O
during	O
a	O
face	O
-	O
learning	O
task	O
.	O
It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstasy	B-Chemical
users	O
display	O
impairments	B-Disease
in	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
performance	O
.	O
In	O
addition	O
,	O
working	O
memory	O
processing	O
in	O
ecstasy	B-Chemical
users	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neural	O
alterations	O
in	O
hippocampal	O
and	O
/	O
or	O
cortical	O
regions	O
as	O
measured	O
by	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
.	O
Using	O
functional	O
imaging	O
and	O
a	O
face	O
-	O
learning	O
task	O
,	O
we	O
investigated	O
neural	O
correlates	O
of	O
encoding	O
and	O
recalling	O
face	O
-	O
name	O
associations	O
in	O
20	O
recreational	O
drug	O
users	O
whose	O
predominant	O
drug	O
use	O
was	O
ecstasy	B-Chemical
and	O
20	O
controls	O
.	O
To	O
address	O
the	O
potential	O
confounding	O
effects	O
of	O
the	O
cannabis	B-Chemical
use	O
of	O
the	O
ecstasy	B-Chemical
using	O
group	O
,	O
a	O
second	O
analysis	O
included	O
14	O
previously	O
tested	O
cannabis	B-Chemical
users	O
(	O
Nestor	O
,	O
L	O
.	O
,	O
Roberts	O
,	O
G	O
.	O
,	O
Garavan	O
,	O
H	O
.	O
,	O
Hester	O
,	O
R	O
.	O
,	O
2008	O
.	O
Deficits	B-Disease
in	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
:	O
parahippocampal	O
hyperactivity	B-Disease
and	O
frontocortical	O
hypoactivity	O
in	O
cannabis	B-Chemical
users	O
.	O
Neuroimage	O
40	O
,	O
1328	O
-	O
1339	O
)	O
.	O
Ecstasy	B-Chemical
users	O
performed	O
significantly	O
worse	O
in	O
learning	O
and	O
memory	O
compared	O
to	O
controls	O
and	O
cannabis	B-Chemical
users	O
.	O
A	O
conjunction	O
analysis	O
of	O
the	O
encode	O
and	O
recall	O
phases	O
of	O
the	O
task	O
revealed	O
ecstasy	B-Chemical
-	O
specific	O
hyperactivity	B-Disease
in	O
bilateral	O
frontal	O
regions	O
,	O
left	O
temporal	O
,	O
right	O
parietal	O
,	O
bilateral	O
temporal	O
,	O
and	O
bilateral	O
occipital	O
brain	O
regions	O
.	O
Ecstasy	B-Chemical
-	O
specific	O
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	O
anterior	O
cingulated	O
cortex	O
(	O
ACC	O
)	O
and	O
left	O
posterior	O
cingulated	O
cortex	O
.	O
In	O
both	O
ecstasy	B-Chemical
and	O
cannabis	B-Chemical
groups	O
brain	O
activation	O
was	O
decreased	O
in	O
the	O
right	O
medial	O
frontal	O
gyrus	O
,	O
left	O
parahippocampal	O
gyrus	O
,	O
left	O
dorsal	O
cingulate	O
gyrus	O
,	O
and	O
left	O
caudate	O
.	O
These	O
results	O
elucidated	O
ecstasy	B-Chemical
-	O
related	O
deficits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabis	B-Chemical
use	O
.	O
These	O
ecstasy	B-Chemical
-	O
specific	O
effects	O
may	O
be	O
related	O
to	O
the	O
vulnerability	O
of	O
isocortical	O
and	O
allocortical	O
regions	O
to	O
the	O
neurotoxic	B-Disease
effects	O
of	O
ecstasy	B-Chemical
.	O
Disulfiram	B-Chemical
-	O
like	O
syndrome	O
after	O
hydrogen	B-Chemical
cyanamide	I-Chemical
professional	O
skin	O
exposure	O
:	O
two	O
case	O
reports	O
in	O
France	O
.	O
Hydrogen	B-Chemical
cyanamide	I-Chemical
is	O
a	O
plant	O
growth	O
regulator	O
used	O
in	O
agriculture	O
to	O
induce	O
bud	O
break	O
in	O
fruit	O
trees	O
.	O
Contact	O
with	O
the	O
skin	O
can	O
result	O
in	O
percutaneous	O
absorption	O
of	O
the	O
substance	O
that	O
inhibits	O
aldehyde	B-Chemical
dehydrogenase	O
and	O
can	O
induce	O
acetaldehyde	B-Chemical
syndrome	O
in	O
case	O
of	O
alcohol	B-Chemical
use	O
.	O
The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
describe	O
two	O
cases	O
of	O
a	O
disulfiram	B-Chemical
-	O
like	O
syndrome	O
following	O
occupational	O
exposure	O
to	O
hydrogen	B-Chemical
cyanamide	I-Chemical
.	O
The	O
first	O
case	O
involved	O
a	O
59	O
-	O
year	O
-	O
old	O
man	O
who	O
used	O
Dormex	B-Chemical
,	O
which	O
contains	O
hydrogen	B-Chemical
cyanamide	I-Chemical
,	O
without	O
protection	O
after	O
consuming	O
a	O
large	O
amount	O
of	O
alcohol	B-Chemical
during	O
a	O
meal	O
.	O
In	O
less	O
than	O
1	O
hour	O
after	O
the	O
ingestion	O
of	O
alcohol	B-Chemical
,	O
he	O
developed	O
malaise	O
with	O
flushing	B-Disease
of	I-Disease
the	I-Disease
face	I-Disease
,	O
tachycardia	B-Disease
,	O
and	O
dyspnea	B-Disease
.	O
Manifestations	O
regressed	O
spontaneously	O
under	O
surveillance	O
in	O
the	O
hospital	O
.	O
The	O
second	O
case	O
occurred	O
in	O
a	O
55	O
-	O
year	O
-	O
old	O
farmer	O
following	O
cutaneous	O
contact	O
with	O
Dormex	B-Chemical
.	O
Five	O
hours	O
after	O
exposure	O
,	O
he	O
developed	O
disulfiram	B-Chemical
-	O
like	O
syndrome	O
with	O
flushing	B-Disease
,	O
tachycardia	B-Disease
,	O
and	O
arterial	B-Disease
hypotension	I-Disease
after	O
consuming	O
three	O
glasses	O
of	O
wine	O
.	O
The	O
patient	O
recovered	O
spontaneously	O
in	O
3	O
hours	O
under	O
surveillance	O
in	O
the	O
hospital	O
.	O
These	O
cases	O
confirm	O
the	O
necessity	O
of	O
avoiding	O
alcohol	B-Chemical
consumption	O
as	O
recommended	O
in	O
the	O
instructions	O
for	O
use	O
of	O
Dormex	B-Chemical
and	O
of	O
preventing	O
cutaneous	O
contact	O
during	O
use	O
.	O
Sulpiride	B-Chemical
-	O
induced	O
tardive	B-Disease
dystonia	I-Disease
.	O
Sulpiride	B-Chemical
is	O
a	O
selective	O
D2	O
-	O
receptor	O
antagonist	O
with	O
antipsychotic	O
and	O
antidepressant	B-Chemical
properties	O
.	O
Although	O
initially	O
thought	O
to	O
be	O
free	O
of	O
extrapyramidal	O
side	O
effects	O
,	O
sulpiride	B-Chemical
-	O
induced	O
tardive	B-Disease
dyskinesia	I-Disease
and	O
parkinsonism	B-Disease
have	O
been	O
reported	O
occasionally	O
.	O
We	O
studied	O
a	O
37	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
persistent	O
segmental	O
dystonia	B-Disease
within	O
2	O
months	O
after	O
starting	O
sulpiride	B-Chemical
therapy	O
.	O
We	O
could	O
not	O
find	O
any	O
previous	O
reports	O
of	O
sulpiride	B-Chemical
-	O
induced	O
tardive	B-Disease
dystonia	I-Disease
.	O
Comparative	O
cognitive	O
and	O
subjective	O
side	O
effects	O
of	O
immediate	O
-	O
release	O
oxycodone	B-Chemical
in	O
healthy	O
middle	O
-	O
aged	O
and	O
older	O
adults	O
.	O
This	O
study	O
measured	O
the	O
objective	O
and	O
subjective	O
neurocognitive	O
effects	O
of	O
a	O
single	O
10	O
-	O
mg	O
dose	O
of	O
immediate	O
-	O
release	O
oxycodone	B-Chemical
in	O
healthy	O
,	O
older	O
(	O
>	O
65	O
years	O
)	O
,	O
and	O
middle	O
-	O
aged	O
(	O
35	O
to	O
55	O
years	O
)	O
adults	O
who	O
were	O
not	O
suffering	O
from	O
chronic	O
or	O
significant	O
daily	O
pain	B-Disease
.	O
Seventy	O
-	O
one	O
participants	O
completed	O
2	O
separate	O
study	O
days	O
and	O
were	O
blind	O
to	O
medication	O
condition	O
(	O
placebo	O
,	O
10	O
-	O
mg	O
oxycodone	B-Chemical
)	O
.	O
Plasma	O
oxycodone	B-Chemical
concentration	O
peaked	O
between	O
60	O
and	O
90	O
minutes	O
postdose	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
pupil	O
size	O
,	O
an	O
indication	O
of	O
physiological	O
effects	O
of	O
the	O
medication	O
,	O
peaked	O
at	O
approximately	O
90	O
to	O
120	O
minutes	O
postdose	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O
Significant	O
declines	B-Disease
in	I-Disease
simple	I-Disease
and	I-Disease
sustained	I-Disease
attention	I-Disease
,	I-Disease
working	I-Disease
memory	I-Disease
,	I-Disease
and	I-Disease
verbal	I-Disease
memory	I-Disease
were	O
observed	O
at	O
1	O
hour	O
postdose	O
compared	O
to	O
baseline	O
for	O
both	O
age	O
groups	O
with	O
a	O
trend	O
toward	O
return	O
to	O
baseline	O
by	O
5	O
hours	O
postdose	O
.	O
For	O
almost	O
all	O
cognitive	O
measures	O
,	O
there	O
were	O
no	O
medication	O
by	O
age	O
-	O
interaction	O
effects	O
,	O
which	O
indicates	O
that	O
the	O
2	O
age	O
groups	O
exhibited	O
similar	O
responses	O
to	O
the	O
medication	O
challenge	O
.	O
This	O
study	O
suggests	O
that	O
for	O
healthy	O
older	O
adults	O
who	O
are	O
not	O
suffering	O
from	O
chronic	B-Disease
pain	I-Disease
,	O
neurocognitive	O
and	O
pharmacodynamic	O
changes	O
in	O
response	O
to	O
a	O
10	O
-	O
mg	O
dose	O
of	O
immediate	O
-	O
release	O
oxycodone	B-Chemical
are	O
similar	O
to	O
those	O
observed	O
for	O
middle	O
-	O
aged	O
adults	O
.	O
PERSPECTIVE	O
:	O
Study	O
findings	O
indicate	O
that	O
the	O
metabolism	O
,	O
neurocognitive	O
effects	O
,	O
and	O
physical	O
side	O
effects	O
of	O
oral	O
oxycodone	B-Chemical
are	O
similar	O
for	O
healthy	O
middle	O
-	O
aged	O
and	O
older	O
adults	O
.	O
Therefore	O
,	O
clinicians	O
should	O
not	O
avoid	O
prescribing	O
oral	O
opioids	O
to	O
older	O
adults	O
based	O
on	O
the	O
belief	O
that	O
older	O
adults	O
are	O
at	O
higher	O
risk	O
for	O
side	O
effects	O
than	O
younger	O
adults	O
.	O
The	O
glycine	B-Chemical
transporter	O
-	O
1	O
inhibitor	O
SSR103800	B-Chemical
displays	O
a	O
selective	O
and	O
specific	O
antipsychotic	O
-	O
like	O
profile	O
in	O
normal	O
and	O
transgenic	O
mice	O
.	O
Schizophrenia	B-Disease
has	O
been	O
initially	O
associated	O
with	O
dysfunction	O
in	O
dopamine	B-Chemical
neurotransmission	O
.	O
However	O
,	O
the	O
observation	O
that	O
antagonists	O
of	O
the	O
glutamate	B-Chemical
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
receptor	O
produce	O
schizophrenic	B-Disease
-	O
like	O
symptoms	O
in	O
humans	O
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunctioning	O
of	O
the	O
glutamatergic	O
system	O
via	O
its	O
NMDA	B-Chemical
receptor	O
.	O
As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
development	O
of	O
pharmacological	O
agents	O
with	O
potential	O
antipsychotic	O
properties	O
that	O
enhance	O
the	O
activity	O
of	O
the	O
glutamatergic	O
system	O
via	O
a	O
modulation	O
of	O
the	O
NMDA	B-Chemical
receptor	O
.	O
Among	O
them	O
are	O
glycine	B-Chemical
transporter	O
-	O
1	O
(	O
GlyT1	O
)	O
inhibitors	O
such	O
as	O
SSR103800	B-Chemical
,	O
which	O
indirectly	O
enhance	O
NMDA	B-Chemical
receptor	O
function	O
by	O
increasing	O
the	O
glycine	B-Chemical
(	O
a	O
co	O
-	O
agonist	O
for	O
the	O
NMDA	B-Chemical
receptor	O
)	O
levels	O
in	O
the	O
synapse	O
.	O
This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic	O
-	O
like	O
properties	O
of	O
SSR103800	B-Chemical
,	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	B-Disease
,	O
involving	O
either	O
drug	O
challenge	O
(	O
ie	O
,	O
amphetamine	B-Chemical
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
)	O
or	O
transgenic	O
mice	O
(	O
ie	O
,	O
NMDA	B-Chemical
Nr1	O
(	O
neo	O
-	O
/	O
-	O
)	O
and	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
.	O
Results	O
showed	O
that	O
SSR103800	B-Chemical
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
blocked	O
hyperactivity	B-Disease
induced	O
by	O
the	O
non	O
-	O
competitive	O
NMDA	B-Chemical
receptor	O
antagonist	O
,	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
and	O
partially	O
reversed	O
spontaneous	O
hyperactivity	B-Disease
of	O
NMDA	B-Chemical
Nr1	O
(	O
neo	O
-	O
/	O
-	O
)	O
mice	O
.	O
In	O
contrast	O
,	O
SSR103800	B-Chemical
failed	O
to	O
affect	O
hyperactivity	B-Disease
induced	O
by	O
amphetamine	B-Chemical
or	O
naturally	O
observed	O
in	O
dopamine	B-Chemical
transporter	O
(	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
knockout	O
mice	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
.	O
Importantly	O
,	O
both	O
classical	O
(	O
haloperidol	B-Chemical
)	O
and	O
atypical	O
(	O
olanzapine	B-Chemical
,	O
clozapine	B-Chemical
and	O
aripiprazole	B-Chemical
)	O
antipsychotics	O
were	O
effective	O
in	O
all	O
these	O
models	O
of	O
hyperactivity	B-Disease
.	O
However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	B-Chemical
did	O
not	O
produce	O
catalepsy	B-Disease
(	O
retention	O
on	O
the	O
bar	O
test	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
Together	O
these	O
findings	O
show	O
that	O
the	O
GlyT1	O
inhibitor	O
,	O
SSR103800	B-Chemical
,	O
produces	O
antipsychotic	O
-	O
like	O
effects	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compounds	O
primarily	O
targeting	O
the	O
dopaminergic	O
system	O
,	O
and	O
has	O
a	O
reduced	O
side	O
-	O
effect	O
potential	O
as	O
compared	O
with	O
these	O
latter	O
drugs	O
.	O
Pyrrolidine	B-Chemical
dithiocarbamate	I-Chemical
protects	O
the	O
piriform	O
cortex	O
in	O
the	O
pilocarpine	B-Chemical
status	B-Disease
epilepticus	I-Disease
model	O
.	O
Pyrrolidine	B-Chemical
dithiocarbamate	I-Chemical
(	O
PDTC	B-Chemical
)	O
has	O
a	O
dual	O
mechanism	O
of	O
action	O
as	O
an	O
antioxidant	O
and	O
an	O
inhibitor	O
of	O
the	O
transcription	O
factor	O
kappa	O
-	O
beta	O
.	O
Both	O
,	O
production	O
of	O
reactive	O
oxygen	B-Chemical
species	O
as	O
well	O
as	O
activation	O
of	O
NF	O
-	O
kappaB	O
have	O
been	O
implicated	O
in	O
severe	O
neuronal	B-Disease
damage	I-Disease
in	O
different	O
sub	O
-	O
regions	O
of	O
the	O
hippocampus	O
as	O
well	O
as	O
in	O
the	O
surrounding	O
cortices	O
.	O
The	O
effect	O
of	O
PDTC	B-Chemical
on	O
status	B-Disease
epilepticus	I-Disease
-	O
associated	O
cell	O
loss	O
in	O
the	O
hippocampus	O
and	O
piriform	O
cortex	O
was	O
evaluated	O
in	O
the	O
rat	O
fractionated	O
pilocarpine	B-Chemical
model	O
.	O
Treatment	O
with	O
150	O
mg	O
/	O
kg	O
PDTC	B-Chemical
before	O
and	O
following	O
status	B-Disease
epilepticus	I-Disease
significantly	O
increased	O
the	O
mortality	O
rate	O
to	O
100	O
%	O
.	O
Administration	O
of	O
50	O
mg	O
/	O
kg	O
PDTC	B-Chemical
(	O
low	O
-	O
dose	O
)	O
did	O
not	O
exert	O
major	O
effects	O
on	O
the	O
development	O
of	O
a	O
status	B-Disease
epilepticus	I-Disease
or	O
the	O
mortality	O
rate	O
.	O
In	O
vehicle	O
-	O
treated	O
rats	O
,	O
status	B-Disease
epilepticus	I-Disease
caused	O
pronounced	O
neuronal	B-Disease
damage	I-Disease
in	O
the	O
piriform	O
cortex	O
comprising	O
both	O
pyramidal	O
cells	O
and	O
interneurons	O
.	O
Low	O
-	O
dose	O
PDTC	B-Chemical
treatment	O
almost	O
completely	O
protected	O
from	O
lesions	O
in	O
the	O
piriform	O
cortex	O
.	O
A	O
significant	O
decrease	O
in	O
neuronal	O
density	O
of	O
the	O
hippocampal	O
hilar	O
formation	O
was	O
identified	O
in	O
vehicle	O
-	O
and	O
PDTC	B-Chemical
-	O
treated	O
rats	O
following	O
status	B-Disease
epilepticus	I-Disease
.	O
In	O
conclusion	O
,	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
and	O
antioxidant	O
PDTC	B-Chemical
protected	O
the	O
piriform	O
cortex	O
,	O
whereas	O
it	O
did	O
not	O
affect	O
hilar	O
neuronal	B-Disease
loss	I-Disease
.	O
These	O
data	O
might	O
indicate	O
that	O
the	O
generation	O
of	O
reactive	O
oxygen	B-Chemical
species	O
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
plays	O
a	O
more	O
central	O
role	O
in	O
seizure	B-Disease
-	O
associated	O
neuronal	B-Disease
damage	I-Disease
in	O
the	O
temporal	O
cortex	O
as	O
compared	O
to	O
the	O
hippocampal	O
hilus	O
.	O
However	O
,	O
future	O
investigations	O
are	O
necessary	O
to	O
exactly	O
analyze	O
the	O
biochemical	O
mechanisms	O
by	O
which	O
PDTC	B-Chemical
exerted	O
its	O
beneficial	O
effects	O
in	O
the	O
piriform	O
cortex	O
.	O
Anaesthetists	O
'	O
nightmare	O
:	O
masseter	B-Disease
spasm	I-Disease
after	O
induction	O
in	O
an	O
undiagnosed	O
case	O
of	O
myotonia	B-Disease
congenita	I-Disease
.	O
We	O
report	O
an	O
undiagnosed	O
case	O
of	O
myotonia	B-Disease
congenita	I-Disease
in	O
a	O
24	O
-	O
year	O
-	O
old	O
previously	O
healthy	O
primigravida	O
,	O
who	O
developed	O
life	O
threatening	O
masseter	B-Disease
spasm	I-Disease
following	O
a	O
standard	O
dose	O
of	O
intravenous	O
suxamethonium	B-Chemical
for	O
induction	O
of	O
anaesthesia	O
.	O
Neither	O
the	O
patient	O
nor	O
the	O
anaesthetist	O
was	O
aware	O
of	O
the	O
diagnosis	O
before	O
this	O
potentially	O
lethal	O
complication	O
occurred	O
.	O
Twin	O
preterm	O
neonates	O
with	O
cardiac	B-Disease
toxicity	I-Disease
related	O
to	O
lopinavir	B-Chemical
/	I-Chemical
ritonavir	I-Chemical
therapy	O
.	O
We	O
report	O
twin	O
neonates	O
who	O
were	O
born	O
prematurely	O
at	O
32	O
weeks	O
of	O
gestation	O
to	O
a	O
mother	O
with	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
infection	I-Disease
.	O
One	O
of	O
the	O
twins	O
developed	O
complete	O
heart	B-Disease
block	I-Disease
and	O
dilated	B-Disease
cardiomyopathy	I-Disease
related	O
to	O
lopinavir	B-Chemical
/	I-Chemical
ritonavir	I-Chemical
therapy	O
,	O
a	O
boosted	O
protease	O
-	O
inhibitor	O
agent	O
,	O
while	O
the	O
other	O
twin	O
developed	O
mild	O
bradycardia	B-Disease
.	O
We	O
recommend	O
caution	O
in	O
the	O
use	O
of	O
lopinavir	B-Chemical
/	I-Chemical
ritonavir	I-Chemical
in	O
the	O
immediate	O
neonatal	O
period	O
.	O
When	O
drugs	O
disappear	O
from	O
the	O
patient	O
:	O
elimination	O
of	O
intravenous	O
medication	O
by	O
hemodiafiltration	O
.	O
Twenty	O
-	O
three	O
hours	O
after	O
heart	O
transplantation	O
,	O
life	O
-	O
threatening	O
acute	O
right	B-Disease
heart	I-Disease
failure	I-Disease
was	O
diagnosed	O
in	O
a	O
patient	O
requiring	O
continuous	O
venovenous	O
hemodiafiltration	O
(	O
CVVHDF	O
)	O
.	O
Increasing	O
doses	O
of	O
catecholamines	B-Chemical
,	O
sedatives	O
,	O
and	O
muscle	O
relaxants	O
administered	O
through	O
a	O
central	O
venous	O
catheter	O
were	O
ineffective	O
.	O
However	O
,	O
a	O
bolus	O
of	O
epinephrine	B-Chemical
injected	O
through	O
an	O
alternative	O
catheter	O
provoked	O
a	O
hypertensive	B-Disease
crisis	O
.	O
Thus	O
,	O
interference	O
with	O
the	O
central	O
venous	O
infusion	O
by	O
the	O
dialysis	O
catheter	O
was	O
suspected	O
.	O
The	O
catheters	O
were	O
changed	O
,	O
and	O
hemodynamics	O
stabilized	O
at	O
lower	O
catecholamine	B-Chemical
doses	O
.	O
When	O
the	O
effects	O
of	O
IV	O
drugs	O
are	O
inadequate	O
in	O
patients	O
receiving	O
CVVHDF	O
,	O
interference	O
with	O
adjacent	O
catheters	O
resulting	O
in	O
elimination	O
of	O
the	O
drug	O
by	O
CVVHDF	O
should	O
be	O
suspected	O
.	O
Less	O
frequent	O
lithium	B-Chemical
administration	O
and	O
lower	O
urine	O
volume	O
.	O
OBJECTIVE	O
:	O
This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
patients	O
maintained	O
on	O
a	O
regimen	O
of	O
lithium	B-Chemical
on	O
a	O
once	O
-	O
per	O
-	O
day	O
schedule	O
have	O
lower	O
urine	O
volumes	O
than	O
do	O
patients	O
receiving	O
multiple	O
doses	O
per	O
day	O
.	O
METHOD	O
:	O
This	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
85	O
patients	O
from	O
a	O
lithium	B-Chemical
clinic	O
who	O
received	O
different	O
dose	O
schedules	O
.	O
Patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
measurement	O
of	O
lithium	B-Chemical
level	O
,	O
creatinine	B-Chemical
clearance	O
,	O
urine	O
volume	O
,	O
and	O
maximum	O
osmolality	O
.	O
RESULTS	O
:	O
Multiple	O
daily	O
doses	O
of	O
lithium	B-Chemical
were	O
associated	O
with	O
higher	O
urine	O
volumes	O
.	O
The	O
dosing	O
schedule	O
,	O
duration	O
of	O
lithium	B-Chemical
treatment	O
,	O
and	O
daily	O
dose	O
of	O
lithium	B-Chemical
did	O
not	O
affect	O
maximum	O
osmolality	O
or	O
creatinine	B-Chemical
clearance	O
.	O
CONCLUSIONS	O
:	O
Urine	O
volume	O
can	O
be	O
reduced	O
by	O
giving	O
lithium	B-Chemical
once	O
daily	O
and	O
/	O
or	O
by	O
lowering	O
the	O
total	O
daily	O
dose	O
.	O
Lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
seems	O
to	O
be	O
related	O
to	O
extrarenal	O
as	O
well	O
as	O
to	O
renal	O
effects	O
.	O
Antibacterial	O
medication	O
use	O
during	O
pregnancy	O
and	O
risk	O
of	O
birth	B-Disease
defects	I-Disease
:	O
National	O
Birth	B-Disease
Defects	I-Disease
Prevention	O
Study	O
.	O
OBJECTIVE	O
:	O
To	O
estimate	O
the	O
association	O
between	O
antibacterial	O
medications	O
and	O
selected	O
birth	B-Disease
defects	I-Disease
.	O
DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
:	O
Population	O
-	O
based	O
,	O
multisite	O
,	O
case	O
-	O
control	O
study	O
of	O
women	O
who	O
had	O
pregnancies	O
affected	O
by	O
1	O
of	O
more	O
than	O
30	O
eligible	O
major	O
birth	B-Disease
defects	I-Disease
identified	O
via	O
birth	B-Disease
defect	I-Disease
surveillance	O
programs	O
in	O
10	O
states	O
(	O
n	O
=	O
13	O
155	O
)	O
and	O
control	O
women	O
randomly	O
selected	O
from	O
the	O
same	O
geographical	O
regions	O
(	O
n	O
=	O
4941	O
)	O
.	O
MAIN	O
EXPOSURE	O
:	O
Reported	O
maternal	O
use	O
of	O
antibacterials	O
(	O
1	O
month	O
before	O
pregnancy	O
through	O
the	O
end	O
of	O
the	O
first	O
trimester	O
)	O
.	O
MAIN	O
OUTCOME	O
MEASURE	O
:	O
Odds	O
ratios	O
(	O
ORs	O
)	O
measuring	O
the	O
association	O
between	O
antibacterial	O
use	O
and	O
selected	O
birth	B-Disease
defects	I-Disease
adjusted	O
for	O
potential	O
confounders	O
.	O
RESULTS	O
:	O
The	O
reported	O
use	O
of	O
antibacterials	O
increased	O
during	O
pregnancy	O
,	O
peaking	O
during	O
the	O
third	O
month	O
.	O
Sulfonamides	B-Chemical
were	O
associated	O
with	O
anencephaly	B-Disease
(	O
adjusted	O
OR	O
[	O
AOR	O
]	O
=	O
3	O
.	O
4	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
3	O
-	O
8	O
.	O
8	O
)	O
,	O
hypoplastic	B-Disease
left	I-Disease
heart	I-Disease
syndrome	I-Disease
(	O
AOR	O
=	O
3	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
7	O
.	O
6	O
)	O
,	O
coarctation	B-Disease
of	I-Disease
the	I-Disease
aorta	I-Disease
(	O
AOR	O
=	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
5	O
.	O
6	O
)	O
,	O
choanal	B-Disease
atresia	I-Disease
(	O
AOR	O
=	O
8	O
.	O
0	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
7	O
-	O
23	O
.	O
5	O
)	O
,	O
transverse	B-Disease
limb	I-Disease
deficiency	I-Disease
(	O
AOR	O
=	O
2	O
.	O
5	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
0	O
-	O
5	O
.	O
9	O
)	O
,	O
and	O
diaphragmatic	B-Disease
hernia	I-Disease
(	O
AOR	O
=	O
2	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
5	O
.	O
4	O
)	O
.	O
Nitrofurantoins	B-Chemical
were	O
associated	O
with	O
anophthalmia	B-Disease
or	O
microphthalmos	B-Disease
(	O
AOR	O
=	O
3	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
12	O
.	O
2	O
)	O
,	O
hypoplastic	B-Disease
left	I-Disease
heart	I-Disease
syndrome	I-Disease
(	O
AOR	O
=	O
4	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
9	O
-	O
9	O
.	O
1	O
)	O
,	O
atrial	B-Disease
septal	I-Disease
defects	I-Disease
(	O
AOR	O
=	O
1	O
.	O
9	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
3	O
.	O
4	O
)	O
,	O
and	O
cleft	B-Disease
lip	I-Disease
with	O
cleft	B-Disease
palate	I-Disease
(	O
AOR	O
=	O
2	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
3	O
.	O
9	O
)	O
.	O
Other	O
antibacterial	O
agents	O
that	O
showed	O
associations	O
included	O
erythromycins	B-Chemical
(	O
2	O
defects	O
)	O
,	O
penicillins	B-Chemical
(	O
1	O
defect	O
)	O
,	O
cephalosporins	B-Chemical
(	O
1	O
defect	O
)	O
,	O
and	O
quinolones	B-Chemical
(	O
1	O
defect	O
)	O
.	O
CONCLUSIONS	O
:	O
Reassuringly	O
,	O
penicillins	B-Chemical
,	O
erythromycins	B-Chemical
,	O
and	O
cephalosporins	B-Chemical
,	O
although	O
used	O
commonly	O
by	O
pregnant	O
women	O
,	O
were	O
not	O
associated	O
with	O
many	O
birth	B-Disease
defects	I-Disease
.	O
Sulfonamides	B-Chemical
and	O
nitrofurantoins	B-Chemical
were	O
associated	O
with	O
several	O
birth	B-Disease
defects	I-Disease
,	O
indicating	O
a	O
need	O
for	O
additional	O
scrutiny	O
.	O
Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	O
and	O
P120T	O
on	O
the	O
replication	O
of	O
lamivudine	B-Chemical
-	O
resistant	O
hepatitis	B-Chemical
B	I-Chemical
virus	I-Chemical
e	I-Chemical
antigen	I-Chemical
-	O
positive	O
and	O
-	O
negative	O
strains	O
.	O
Immune	O
escape	O
variants	O
of	O
the	O
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
represent	O
an	O
emerging	O
clinical	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccine	O
escape	O
,	O
HBV	O
reactivation	O
,	O
and	O
failure	O
of	O
diagnostic	O
tests	O
.	O
Recent	O
data	O
suggest	O
a	O
preferential	O
selection	O
of	O
immune	O
escape	O
mutants	O
in	O
distinct	O
peripheral	O
blood	O
leukocyte	O
compartments	O
of	O
infected	O
individuals	O
.	O
We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	O
impact	O
of	O
the	O
most	O
prevalent	O
immune	O
escape	O
variants	O
,	O
the	O
sG145R	O
and	O
sP120T	O
mutants	O
,	O
on	O
the	O
viral	O
replication	O
efficacy	O
and	O
antiviral	O
drug	O
susceptibility	O
of	O
common	O
treatment	O
-	O
associated	O
mutants	O
with	O
resistance	O
to	O
lamivudine	B-Chemical
(	O
LAM	B-Chemical
)	O
and	O
/	O
or	O
HBeAg	B-Chemical
negativity	O
.	O
Replication	O
-	O
competent	O
HBV	O
strains	O
with	O
sG145R	O
or	O
sP120T	O
and	O
LAM	B-Chemical
resistance	O
(	O
rtM204I	O
or	O
rtL180M	O
/	O
rtM204V	O
)	O
were	O
generated	O
on	O
an	O
HBeAg	B-Chemical
-	O
positive	O
and	O
an	O
HBeAg	B-Chemical
-	O
negative	O
background	O
with	O
precore	O
(	O
PC	O
)	O
and	O
basal	O
core	O
promoter	O
(	O
BCP	O
)	O
mutants	O
.	O
The	O
sG145R	O
mutation	O
strongly	O
reduced	O
HBsAg	B-Chemical
levels	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
impaired	O
replication	O
of	O
LAM	B-Chemical
-	O
resistant	O
HBV	O
mutants	O
to	O
the	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
,	O
and	O
PC	O
or	O
BCP	O
mutations	O
further	O
enhanced	O
viral	O
replication	O
.	O
Although	O
the	O
sP120T	O
substitution	O
also	O
impaired	O
HBsAg	B-Chemical
secretion	O
,	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM	B-Chemical
-	O
resistant	O
clones	O
.	O
However	O
,	O
the	O
concomitant	O
occurrence	O
of	O
HBeAg	B-Chemical
negativity	O
(	O
PC	O
/	O
BCP	O
)	O
,	O
sP120T	O
,	O
and	O
LAM	B-Chemical
resistance	O
resulted	O
in	O
the	O
restoration	O
of	O
replication	O
to	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
.	O
In	O
all	O
clones	O
with	O
combined	O
immune	O
escape	O
and	O
LAM	B-Chemical
resistance	O
mutations	O
,	O
the	O
nucleotide	B-Chemical
analogues	O
adefovir	B-Chemical
and	O
tenofovir	B-Chemical
remained	O
effective	O
in	O
suppressing	O
viral	O
replication	O
in	O
vitro	O
.	O
These	O
findings	O
reveal	O
the	O
differential	O
impact	O
of	O
immune	O
escape	O
variants	O
on	O
the	O
replication	O
and	O
drug	O
susceptibility	O
of	O
complex	O
HBV	O
mutants	O
,	O
supporting	O
the	O
need	O
of	O
close	O
surveillance	O
and	O
treatment	O
adjustment	O
in	O
response	O
to	O
the	O
selection	O
of	O
distinct	O
mutational	O
patterns	O
.	O
Hemolytic	B-Disease
anemia	I-Disease
associated	O
with	O
the	O
use	O
of	O
omeprazole	B-Chemical
.	O
Omeprazole	B-Chemical
is	O
the	O
first	O
drug	O
designed	O
to	O
block	O
the	O
final	O
step	O
in	O
the	O
acid	O
secretory	O
process	O
within	O
the	O
parietal	O
cell	O
.	O
It	O
has	O
been	O
shown	O
to	O
be	O
extremely	O
effective	O
in	O
the	O
treatment	O
of	O
peptic	B-Disease
ulcer	I-Disease
disease	I-Disease
,	O
reflux	B-Disease
esophagitis	I-Disease
,	O
and	O
the	O
Zollinger	B-Disease
-	I-Disease
Ellison	I-Disease
syndrome	I-Disease
.	O
Although	O
clinical	O
experience	O
with	O
omeprazole	B-Chemical
is	O
still	O
limited	O
,	O
many	O
controlled	O
studies	O
have	O
established	O
the	O
short	O
-	O
term	O
safety	O
of	O
this	O
drug	O
.	O
We	O
report	O
the	O
first	O
case	O
of	O
a	O
serious	O
short	O
-	O
term	O
adverse	O
reaction	O
with	O
the	O
use	O
of	O
omeprazole	B-Chemical
:	O
hemolytic	B-Disease
anemia	I-Disease
.	O
The	O
patient	O
developed	O
weakness	O
,	O
lethargy	B-Disease
,	O
and	O
shortness	B-Disease
of	I-Disease
breath	I-Disease
2	O
days	O
after	O
starting	O
therapy	O
with	O
omeprazole	B-Chemical
.	O
Two	O
weeks	O
after	O
the	O
initiation	O
of	O
therapy	O
,	O
her	O
hematocrit	O
had	O
decreased	O
from	O
44	O
.	O
1	O
%	O
to	O
20	O
.	O
4	O
%	O
,	O
and	O
she	O
had	O
a	O
positive	O
direct	O
Coombs	O
antiglobulin	O
test	O
and	O
an	O
elevated	O
indirect	O
bilirubin	B-Chemical
.	O
After	O
she	O
discontinued	O
the	O
omeprazole	B-Chemical
,	O
her	O
hemoglobin	O
and	O
hematocrit	O
gradually	O
returned	O
to	O
normal	O
.	O
The	O
mechanism	O
by	O
which	O
omeprazole	B-Chemical
caused	O
the	O
patient	O
'	O
s	O
hemolytic	B-Disease
anemia	I-Disease
is	O
uncertain	O
,	O
but	O
physicians	O
should	O
be	O
alerted	O
to	O
this	O
possible	O
adverse	O
effect	O
.	O
Phenylephrine	B-Chemical
but	O
not	O
ephedrine	B-Chemical
reduces	B-Disease
frontal	I-Disease
lobe	I-Disease
oxygenation	I-Disease
following	O
anesthesia	O
-	O
induced	O
hypotension	B-Disease
.	O
BACKGROUND	O
:	O
Vasopressor	O
agents	O
are	O
used	O
to	O
correct	O
anesthesia	O
-	O
induced	O
hypotension	B-Disease
.	O
We	O
describe	O
the	O
effect	O
of	O
phenylephrine	B-Chemical
and	O
ephedrine	B-Chemical
on	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
following	O
anesthesia	O
-	O
induced	O
hypotension	B-Disease
.	O
METHODS	O
:	O
Following	O
induction	O
of	O
anesthesia	O
by	O
fentanyl	B-Chemical
(	O
0	O
.	O
15	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
and	O
propofol	B-Chemical
(	O
2	O
.	O
0	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
13	O
patients	O
received	O
phenylephrine	B-Chemical
(	O
0	O
.	O
1	O
mg	O
iv	O
)	O
and	O
12	O
patients	O
received	O
ephedrine	B-Chemical
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
.	O
Heart	O
rate	O
(	O
HR	O
)	O
,	O
MAP	O
,	O
stroke	B-Disease
volume	O
(	O
SV	O
)	O
,	O
cardiac	O
output	O
(	O
CO	O
)	O
,	O
and	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
were	O
registered	O
.	O
RESULTS	O
:	O
Induction	O
of	O
anesthesia	O
was	O
followed	O
by	O
a	B-Disease
decrease	I-Disease
in	I-Disease
MAP	I-Disease
,	I-Disease
HR	I-Disease
,	I-Disease
SV	I-Disease
,	I-Disease
and	I-Disease
CO	I-Disease
concomitant	O
with	O
an	O
elevation	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O
After	O
administration	O
of	O
phenylephrine	B-Chemical
,	O
MAP	O
increased	O
(	O
51	O
+	O
/	O
-	O
12	O
to	O
81	O
+	O
/	O
-	O
13	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O
However	O
,	O
a	O
14	O
%	O
(	O
from	O
70	O
+	O
/	O
-	O
8	O
%	O
to	O
60	O
+	O
/	O
-	O
7	O
%	O
)	O
reduction	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
followed	O
with	O
no	O
change	O
in	O
CO	O
(	O
3	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
to	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O
The	O
administration	O
of	O
ephedrine	B-Chemical
led	O
to	O
a	O
similar	O
increase	O
in	O
MAP	O
(	O
53	O
+	O
/	O
-	O
9	O
to	O
79	O
+	O
/	O
-	O
8	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
restored	O
CO	O
(	O
3	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
to	O
5	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
3	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
preserved	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
utilization	O
of	O
phenylephrine	B-Chemical
to	O
correct	O
hypotension	B-Disease
induced	O
by	O
anesthesia	O
has	O
a	O
negative	O
impact	O
on	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
while	O
ephedrine	B-Chemical
maintains	O
frontal	O
lobe	O
oxygenation	O
potentially	O
related	O
to	O
an	O
increase	O
in	O
CO	O
.	O
Prolonged	O
elevation	O
of	O
plasma	O
argatroban	B-Chemical
in	O
a	O
cardiac	O
transplant	O
patient	O
with	O
a	O
suspected	O
history	O
of	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
with	O
thrombosis	B-Disease
.	O
BACKGROUND	O
:	O
Direct	O
thrombin	O
inhibitors	O
(	O
DTIs	O
)	O
provide	O
an	O
alternative	O
method	O
of	O
anticoagulation	O
for	O
patients	O
with	O
a	O
history	O
of	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
(	O
HIT	B-Disease
)	O
or	O
HIT	B-Disease
with	O
thrombosis	B-Disease
(	O
HITT	B-Disease
)	O
undergoing	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
.	O
In	O
the	O
following	O
report	O
,	O
a	O
65	O
-	O
year	O
-	O
old	O
critically	B-Disease
ill	I-Disease
patient	O
with	O
a	O
suspected	O
history	O
of	O
HITT	B-Disease
was	O
administered	O
argatroban	B-Chemical
for	O
anticoagulation	O
on	O
bypass	O
during	O
heart	O
transplantation	O
.	O
The	O
patient	O
required	O
massive	O
transfusion	O
support	O
(	O
55	O
units	O
of	O
red	O
blood	O
cells	O
,	O
42	O
units	O
of	O
fresh	O
-	O
frozen	O
plasma	O
,	O
40	O
units	O
of	O
cryoprecipitate	O
,	O
40	O
units	O
of	O
platelets	O
,	O
and	O
three	O
doses	O
of	O
recombinant	O
Factor	O
VIIa	O
)	O
for	O
severe	O
intraoperative	B-Disease
and	I-Disease
postoperative	I-Disease
bleeding	I-Disease
.	O
STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
Plasma	O
samples	O
from	O
before	O
and	O
after	O
CPB	O
were	O
analyzed	O
postoperatively	O
for	O
argatroban	B-Chemical
concentration	O
using	O
a	O
modified	O
ecarin	O
clotting	O
time	O
(	O
ECT	O
)	O
assay	O
.	O
RESULTS	O
:	O
Unexpectedly	O
high	O
concentrations	O
of	O
argatroban	B-Chemical
were	O
measured	O
in	O
these	O
samples	O
(	O
range	O
,	O
0	O
-	O
32	O
microg	O
/	O
mL	O
)	O
,	O
and	O
a	O
prolonged	O
plasma	O
argatroban	B-Chemical
half	O
life	O
(	O
t	O
(	O
1	O
/	O
2	O
)	O
)	O
of	O
514	O
minutes	O
was	O
observed	O
(	O
published	O
elimination	O
t	O
(	O
1	O
/	O
2	O
)	O
is	O
39	O
-	O
51	O
minutes	O
[	O
<	O
or	O
=	O
181	O
minutes	O
with	O
hepatic	B-Disease
impairment	I-Disease
]	O
)	O
.	O
CONCLUSIONS	O
:	O
Correlation	O
of	O
plasma	O
argatroban	B-Chemical
concentration	O
versus	O
the	O
patient	O
'	O
s	O
coagulation	O
variables	O
and	O
clinical	O
course	O
suggest	O
that	O
prolonged	O
elevated	O
levels	O
of	O
plasma	O
argatroban	B-Chemical
may	O
have	O
contributed	O
to	O
the	O
patient	O
'	O
s	O
extended	O
coagulopathy	B-Disease
.	O
Because	O
DTIs	O
do	O
not	O
have	O
reversal	O
agents	O
,	O
surgical	O
teams	O
and	O
transfusion	O
services	O
should	O
remain	O
aware	O
of	O
the	O
possibility	O
of	O
massive	O
transfusion	O
events	O
during	O
anticoagulation	O
with	O
these	O
agents	O
.	O
This	O
is	O
the	O
first	O
report	O
to	O
measure	O
plasma	O
argatroban	B-Chemical
concentration	O
in	O
the	O
context	O
of	O
CPB	O
and	O
extended	O
coagulopathy	B-Disease
.	O
The	O
effects	O
of	O
the	O
adjunctive	O
bupropion	B-Chemical
on	O
male	O
sexual	B-Disease
dysfunction	I-Disease
induced	O
by	O
a	O
selective	B-Chemical
serotonin	I-Chemical
reuptake	I-Chemical
inhibitor	I-Chemical
:	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
and	O
randomized	O
study	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
adjunctive	O
bupropion	B-Chemical
sustained	O
-	O
release	O
(	O
SR	O
)	O
on	O
male	O
sexual	B-Disease
dysfunction	I-Disease
(	O
SD	B-Disease
)	O
induced	O
by	O
a	O
selective	B-Chemical
serotonin	I-Chemical
reuptake	I-Chemical
inhibitor	I-Chemical
(	O
SSRI	B-Chemical
)	O
,	O
as	O
SD	B-Disease
is	O
a	O
common	O
side	O
-	O
effect	O
of	O
SSRIs	B-Chemical
and	O
the	O
most	O
effective	O
treatments	O
have	O
yet	O
to	O
be	O
determined	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
The	O
randomized	O
sample	O
consisted	O
of	O
234	O
euthymic	O
men	O
who	O
were	O
receiving	O
some	O
type	O
of	O
SSRI	B-Chemical
.	O
The	O
men	O
were	O
randomly	O
assigned	O
to	O
bupropion	B-Chemical
SR	O
(	O
150	O
mg	O
twice	O
daily	O
,	O
117	O
)	O
or	O
placebo	O
(	O
twice	O
daily	O
,	O
117	O
)	O
for	O
12	O
weeks	O
.	O
Efficacy	O
was	O
evaluated	O
using	O
the	O
Clinical	O
Global	O
Impression	O
-	O
Sexual	O
Function	O
(	O
CGI	O
-	O
SF	O
;	O
the	O
primary	O
outcome	O
measure	O
)	O
,	O
the	O
International	O
Index	O
of	O
Erectile	O
Function	O
(	O
IIEF	O
)	O
,	O
Arizona	O
Sexual	O
Experience	O
Scale	O
(	O
ASEX	O
)	O
,	O
and	O
Erectile	B-Disease
Dysfunction	I-Disease
Inventory	O
of	O
Treatment	O
Satisfaction	O
(	O
EDITS	O
)	O
(	O
secondary	O
outcome	O
measures	O
)	O
.	O
Participants	O
were	O
followed	O
biweekly	O
during	O
study	O
period	O
.	O
RESULTS	O
:	O
After	O
12	O
weeks	O
of	O
treatment	O
,	O
the	O
mean	O
(	O
sd	O
)	O
scores	O
for	O
CGI	O
-	O
SF	O
were	O
significantly	O
lower	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
in	O
patients	O
on	O
bupropion	B-Chemical
SR	O
,	O
at	O
2	O
.	O
4	O
(	O
1	O
.	O
2	O
)	O
,	O
than	O
in	O
the	O
placebo	O
group	O
,	O
at	O
3	O
.	O
9	O
(	O
1	O
.	O
1	O
)	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O
Men	O
who	O
received	O
bupropion	B-Chemical
had	O
a	O
significant	O
increase	O
in	O
the	O
total	O
IIEF	O
score	O
(	O
54	O
.	O
4	O
%	O
vs	O
1	O
.	O
2	O
%	O
;	O
P	O
=	O
0	O
.	O
003	O
)	O
,	O
and	O
in	O
the	O
five	O
different	O
domains	O
of	O
the	O
IIEF	O
.	O
Total	O
ASEX	O
scores	O
were	O
significantly	O
lower	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
among	O
men	O
who	O
received	O
bupropion	B-Chemical
than	O
placebo	O
,	O
at	O
15	O
.	O
5	O
(	O
4	O
.	O
3	O
)	O
vs	O
21	O
.	O
5	O
(	O
4	O
.	O
7	O
)	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O
The	O
EDITS	O
scores	O
were	O
67	O
.	O
4	O
(	O
10	O
.	O
2	O
)	O
for	O
the	O
bupropion	B-Chemical
and	O
36	O
.	O
3	O
(	O
11	O
.	O
7	O
)	O
for	O
the	O
placebo	O
group	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O
The	O
ASEX	O
score	O
and	O
CGI	O
-	O
SF	O
score	O
were	O
correlated	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
.	O
In	O
linear	O
regression	O
analyses	O
the	O
CGI	O
-	O
SF	O
score	O
was	O
not	O
affected	O
significantly	O
by	O
the	O
duration	O
of	O
SD	B-Disease
,	O
type	O
of	O
SSRI	B-Chemical
used	O
and	O
age	O
.	O
CONCLUSIONS	O
:	O
Bupropion	B-Chemical
is	O
an	O
effective	O
treatment	O
for	O
male	O
SD	B-Disease
induced	O
by	O
SSRIs	B-Chemical
.	O
These	O
results	O
provide	O
empirical	O
support	O
for	O
conducting	O
a	O
further	O
study	O
of	O
bupropion	B-Chemical
.	O
Prevention	O
of	O
seizures	B-Disease
and	O
reorganization	O
of	O
hippocampal	O
functions	O
by	O
transplantation	O
of	O
bone	O
marrow	O
cells	O
in	O
the	O
acute	O
phase	O
of	O
experimental	O
epilepsy	B-Disease
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
therapeutic	O
potential	O
of	O
bone	O
marrow	O
mononuclear	O
cells	O
(	O
BMCs	O
)	O
in	O
a	O
model	O
of	O
epilepsy	B-Disease
induced	O
by	O
pilocarpine	B-Chemical
in	O
rats	O
.	O
BMCs	O
obtained	O
from	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
transgenic	O
mice	O
or	O
rats	O
were	O
transplanted	O
intravenously	O
after	O
induction	O
of	O
status	B-Disease
epilepticus	I-Disease
(	O
SE	B-Disease
)	O
.	O
Spontaneous	B-Disease
recurrent	I-Disease
seizures	I-Disease
(	O
SRS	B-Disease
)	O
were	O
monitored	O
using	O
Racine	O
'	O
s	O
seizure	B-Disease
severity	O
scale	O
.	O
All	O
of	O
the	O
rats	O
in	O
the	O
saline	O
-	O
treated	O
epileptic	B-Disease
control	O
group	O
developed	O
SRS	B-Disease
,	O
whereas	O
none	O
of	O
the	O
BMC	O
-	O
treated	O
epileptic	B-Disease
animals	O
had	O
seizures	B-Disease
in	O
the	O
short	O
term	O
(	O
15	O
days	O
after	O
transplantation	O
)	O
,	O
regardless	O
of	O
the	O
BMC	O
source	O
.	O
Over	O
the	O
long	O
-	O
term	O
chronic	O
phase	O
(	O
120	O
days	O
after	O
transplantation	O
)	O
,	O
only	O
25	O
%	O
of	O
BMC	O
-	O
treated	O
epileptic	B-Disease
animals	O
had	O
seizures	B-Disease
,	O
but	O
with	O
a	O
lower	O
frequency	O
and	O
duration	O
compared	O
to	O
the	O
epileptic	B-Disease
control	O
group	O
.	O
The	O
density	O
of	O
hippocampal	O
neurons	O
in	O
the	O
brains	O
of	O
animals	O
treated	O
with	O
BMCs	O
was	O
markedly	O
preserved	O
.	O
At	O
hippocampal	O
Schaeffer	O
collateral	O
-	O
CA1	O
synapses	O
,	O
long	O
-	O
term	O
potentiation	O
was	O
preserved	O
in	O
BMC	O
-	O
transplanted	O
rats	O
compared	O
to	O
epileptic	B-Disease
controls	O
.	O
The	O
donor	O
-	O
derived	O
GFP	O
(	O
+	O
)	O
cells	O
were	O
rarely	O
found	O
in	O
the	O
brains	O
of	O
transplanted	O
epileptic	B-Disease
rats	O
.	O
In	O
conclusion	O
,	O
treatment	O
with	O
BMCs	O
can	O
prevent	O
the	O
development	O
of	O
chronic	O
seizures	B-Disease
,	O
reduce	O
neuronal	B-Disease
loss	I-Disease
,	O
and	O
influence	O
the	O
reorganization	O
of	O
the	O
hippocampal	O
neuronal	O
network	O
.	O
Normalizing	O
effects	O
of	O
modafinil	B-Chemical
on	O
sleep	O
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O
OBJECTIVE	O
:	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
morning	O
-	O
dosed	O
modafinil	B-Chemical
on	O
sleep	O
and	O
daytime	B-Disease
sleepiness	I-Disease
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O
METHOD	O
:	O
Twenty	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
modafinil	B-Chemical
,	O
400	O
mg	O
(	O
N	O
=	O
10	O
)	O
,	O
or	O
placebo	O
(	O
N	O
=	O
10	O
)	O
every	O
morning	O
at	O
7	O
:	O
30	O
a	O
.	O
m	O
.	O
for	O
16	O
days	O
in	O
an	O
inpatient	O
,	O
double	O
-	O
blind	O
randomized	O
trial	O
.	O
Participants	O
underwent	O
polysomnographic	O
sleep	O
recordings	O
on	O
days	O
1	O
to	O
3	O
,	O
7	O
to	O
9	O
,	O
and	O
14	O
to	O
16	O
(	O
first	O
,	O
second	O
,	O
and	O
third	O
weeks	O
of	O
abstinence	O
)	O
.	O
The	O
Multiple	O
Sleep	O
Latency	O
Test	O
was	O
performed	O
at	O
11	O
:	O
30	O
a	O
.	O
m	O
.	O
,	O
2	O
:	O
00	O
p	O
.	O
m	O
.	O
,	O
and	O
4	O
:	O
30	O
p	O
.	O
m	O
.	O
on	O
days	O
2	O
,	O
8	O
,	O
and	O
15	O
.	O
For	O
comparison	O
of	O
sleep	O
architecture	O
variables	O
,	O
12	O
healthy	O
comparison	O
participants	O
underwent	O
a	O
single	O
night	O
of	O
experimental	O
polysomnography	O
that	O
followed	O
1	O
night	O
of	O
accommodation	O
polysomnography	O
.	O
RESULTS	O
:	O
Progressive	O
abstinence	O
from	O
cocaine	B-Chemical
was	O
associated	O
with	O
worsening	O
of	O
all	O
measured	O
polysomnographic	O
sleep	O
outcomes	O
.	O
Compared	O
with	O
placebo	O
,	O
modafinil	B-Chemical
decreased	O
nighttime	O
sleep	O
latency	O
and	O
increased	O
slow	O
-	O
wave	O
sleep	O
time	O
in	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
.	O
The	O
effect	O
of	O
modafinil	B-Chemical
interacted	O
with	O
the	O
abstinence	O
week	O
and	O
was	O
associated	O
with	O
longer	O
total	O
sleep	O
time	O
and	O
shorter	O
REM	O
sleep	O
latency	O
in	O
the	O
third	O
week	O
of	O
abstinence	O
.	O
Comparison	O
of	O
slow	O
-	O
wave	O
sleep	O
time	O
,	O
total	O
sleep	O
time	O
,	O
and	O
sleep	O
latency	O
in	O
cocaine	B-Chemical
-	O
dependent	O
and	O
healthy	O
participants	O
revealed	O
a	O
normalizing	O
effect	O
of	O
modafinil	B-Chemical
in	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
.	O
Modafinil	B-Chemical
was	O
associated	O
with	O
increased	O
daytime	O
sleep	O
latency	O
,	O
as	O
measured	O
by	O
the	O
Multiple	O
Sleep	O
Latency	O
Test	O
,	O
and	O
a	O
nearly	O
significant	O
decrease	O
in	O
subjective	O
daytime	B-Disease
sleepiness	I-Disease
.	O
CONCLUSIONS	O
:	O
Morning	O
-	O
dosed	O
modafinil	B-Chemical
promotes	O
nocturnal	O
sleep	O
,	O
normalizes	O
sleep	O
architecture	O
,	O
and	O
decreases	O
daytime	B-Disease
sleepiness	I-Disease
in	O
abstinent	O
cocaine	B-Chemical
users	O
.	O
These	O
effects	O
may	O
be	O
relevant	O
in	O
the	O
treatment	O
of	O
cocaine	B-Chemical
dependence	O
.	O
Safety	O
of	O
transesophageal	O
echocardiography	O
in	O
adults	O
:	O
study	O
in	O
a	O
multidisciplinary	O
hospital	O
.	O
BACKGROUND	O
:	O
TEE	O
is	O
a	O
semi	O
-	O
invasive	O
tool	O
broadly	O
used	O
and	O
its	O
utilization	O
associated	O
to	O
sedatives	O
drugs	O
might	O
to	O
affect	O
the	O
procedure	O
safety	O
.	O
OBJECTIVE	O
:	O
to	O
analyze	O
aspects	O
of	O
TEE	O
safety	O
associated	O
to	O
the	O
use	O
of	O
Midazolan	B-Chemical
(	O
MZ	B-Chemical
)	O
and	O
Flumazenil	B-Chemical
(	O
FL	B-Chemical
)	O
and	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
on	O
the	O
event	O
rate	O
.	O
METHOD	O
:	O
prospective	O
study	O
with	O
137	O
patients	O
that	O
underwent	O
TEE	O
with	O
MZ	B-Chemical
associated	O
to	O
moderate	O
sedation	O
.	O
We	O
analyzed	O
the	O
following	O
events	O
:	O
complications	O
related	O
with	O
the	O
topical	O
anesthesia	O
,	O
with	O
MZ	B-Chemical
use	O
and	O
with	O
the	O
procedure	O
.	O
Uni	O
-	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
test	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
:	O
age	O
,	O
sex	O
,	O
stroke	B-Disease
,	O
myocardiopathy	B-Disease
(	O
MP	B-Disease
)	O
,	O
duration	O
of	O
the	O
test	O
,	O
mitral	B-Disease
regurgitation	I-Disease
(	O
MR	B-Disease
)	O
and	O
the	O
MZ	B-Chemical
dose	O
.	O
RESULTS	O
:	O
All	O
patients	O
(	O
65	O
+	O
/	O
-	O
16	O
yrs	O
;	O
58	O
%	O
males	O
)	O
finished	O
the	O
examination	O
.	O
The	O
mean	O
doses	O
of	O
MZ	B-Chemical
and	O
FL	B-Chemical
were	O
4	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
and	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
,	O
respectively	O
.	O
The	O
duration	O
of	O
the	O
examination	O
and	O
the	O
mean	O
ejection	O
fraction	O
(	O
EF	O
)	O
were	O
16	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
1	O
minutes	O
and	O
60	O
+	O
/	O
-	O
9	O
%	O
,	O
respectively	O
.	O
Mild	O
hypoxia	B-Disease
(	O
SO2	O
<	O
90	O
%	O
)	O
was	O
the	O
most	O
common	O
event	O
(	O
11	O
patients	O
)	O
;	O
3	O
patients	O
(	O
2	O
%	O
)	O
presented	O
transient	O
hypoxia	B-Disease
due	O
to	O
upper	O
airway	B-Disease
obstruction	I-Disease
by	O
probe	O
introduction	O
and	O
8	O
(	O
5	O
.	O
8	O
%	O
)	O
due	O
to	O
hypoxia	B-Disease
caused	O
by	O
MZ	B-Chemical
use	O
.	O
Transient	O
hypotension	B-Disease
(	O
SAP	O
<	O
90mmHg	O
)	O
occurred	O
in	O
1	O
patient	O
(	O
0	O
.	O
7	O
%	O
)	O
.	O
The	O
multivariate	O
analysis	O
showed	O
that	O
severe	O
MR	B-Disease
,	O
MP	B-Disease
(	O
EF	O
<	O
45	O
%	O
)	O
and	O
high	O
doses	O
of	O
MZ	B-Chemical
(	O
>	O
5mg	O
)	O
were	O
associated	O
with	O
events	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
The	O
EF	O
was	O
40	O
%	O
,	O
in	O
the	O
group	O
with	O
MP	B-Disease
and	O
44	O
%	O
in	O
the	O
group	O
with	O
severe	O
MR	B-Disease
and	O
it	O
can	O
be	O
a	O
factor	O
associated	O
with	O
clinical	O
events	O
in	O
the	O
last	O
group	O
.	O
CONCLUSION	O
:	O
TEE	O
with	O
sedation	O
presents	O
a	O
low	O
rate	O
of	O
events	O
.	O
There	O
were	O
no	O
severe	O
events	O
and	O
there	O
was	O
no	O
need	O
to	O
interrupt	O
the	O
examinations	O
.	O
Effect	O
of	O
direct	O
intracoronary	O
administration	O
of	O
methylergonovine	B-Chemical
in	O
patients	O
with	O
and	O
without	O
variant	B-Disease
angina	I-Disease
.	O
The	O
effects	O
of	O
intracoronary	O
administration	O
of	O
methylergonovine	B-Chemical
were	O
studied	O
in	O
21	O
patients	O
with	O
variant	B-Disease
angina	I-Disease
and	O
22	O
patients	O
with	O
atypical	O
chest	B-Disease
pain	I-Disease
and	O
in	O
others	O
without	O
angina	B-Disease
pectoris	I-Disease
(	O
control	O
group	O
)	O
.	O
Methylergonovine	B-Chemical
was	O
administered	O
continuously	O
at	O
a	O
rate	O
of	O
10	O
micrograms	O
/	O
min	O
up	O
to	O
50	O
micrograms	O
.	O
In	O
all	O
patients	O
with	O
variant	B-Disease
angina	I-Disease
,	O
coronary	B-Disease
spasm	I-Disease
was	O
provoked	O
at	O
a	O
mean	O
dose	O
of	O
28	O
+	O
/	O
-	O
13	O
micrograms	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O
In	O
the	O
control	O
group	O
neither	O
ischemic	O
ST	O
change	O
nor	O
localized	O
spasm	B-Disease
occurred	O
.	O
The	O
basal	O
tone	O
of	O
the	O
right	O
coronary	O
artery	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
left	O
coronary	O
artery	O
.	O
The	O
percentage	O
of	O
vasoconstriction	O
of	O
the	O
right	O
coronary	O
artery	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
left	O
coronary	O
artery	O
.	O
These	O
results	O
suggest	O
that	O
spasm	B-Disease
provocation	O
tests	O
,	O
which	O
use	O
an	O
intracoronary	O
injection	O
of	O
a	O
relatively	O
low	O
dose	O
of	O
methylergonovine	B-Chemical
,	O
have	O
a	O
high	O
sensitivity	O
in	O
variant	B-Disease
angina	I-Disease
and	O
the	O
vasoreactivity	O
of	O
the	O
right	O
coronary	O
artery	O
may	O
be	O
greater	O
than	O
that	O
of	O
the	O
other	O
coronary	O
arteries	O
.	O
Oral	O
manifestations	O
of	O
""""	O
meth	B-Disease
mouth	I-Disease
""""	O
:	O
a	O
case	O
report	O
.	O
AIM	O
:	O
The	O
aim	O
of	O
the	O
documentation	O
of	O
this	O
clinical	O
case	O
is	O
to	O
make	O
clinicians	O
aware	O
of	O
""""	O
meth	B-Disease
mouth	I-Disease
""""	O
and	O
the	O
medical	O
risks	O
associated	O
with	O
this	O
serious	O
condition	O
.	O
BACKGROUND	O
:	O
Methamphetamine	B-Chemical
is	O
a	O
very	O
addictive	O
,	O
powerful	O
stimulant	O
that	O
increases	O
wakefulness	O
and	O
physical	O
activity	O
and	O
can	O
produce	O
other	O
effects	O
such	O
as	O
cardiac	B-Disease
dysrhythmias	I-Disease
,	O
hypertension	B-Disease
,	O
hallucinations	B-Disease
,	O
and	O
violent	B-Disease
behavior	I-Disease
.	O
Dental	O
patients	O
abusing	O
methamphetamine	B-Chemical
can	O
present	O
with	O
poor	O
oral	O
hygiene	O
,	O
xerostomia	B-Disease
,	O
rampant	O
caries	B-Disease
(	O
""""	O
meth	B-Disease
mouth	I-Disease
""""	O
)	O
,	O
and	O
excessive	O
tooth	B-Disease
wear	I-Disease
.	O
Oral	O
rehabilitation	O
of	O
patients	O
using	O
methamphetamine	B-Chemical
can	O
be	O
challenging	O
.	O
CASE	O
DESCRIPTION	O
:	O
A	O
30	O
-	O
year	O
-	O
old	O
Caucasian	O
woman	O
presented	O
with	O
dental	O
pain	B-Disease
,	O
bad	B-Disease
breath	I-Disease
,	O
and	O
self	O
-	O
reported	O
poor	O
esthetics	O
.	O
A	O
comprehensive	O
examination	O
including	O
her	O
medical	O
history	O
,	O
panoramic	O
radiograph	O
,	O
and	O
intraoral	O
examination	O
revealed	O
19	O
carious	B-Disease
lesions	I-Disease
,	O
which	O
is	O
not	O
very	O
common	O
for	O
a	O
healthy	O
adult	O
.	O
She	O
reported	O
her	O
use	O
of	O
methamphetamine	B-Chemical
for	O
five	O
years	O
and	O
had	O
not	O
experienced	O
any	O
major	O
carious	B-Disease
episodes	I-Disease
before	O
she	O
started	O
using	O
the	O
drug	O
.	O
SUMMARY	O
:	O
The	O
patient	O
'	O
s	O
medical	O
and	O
dental	O
histories	O
along	O
with	O
radiographic	O
and	O
clinical	O
findings	O
lead	O
to	O
a	O
diagnosis	O
of	O
""""	O
meth	B-Disease
mouth	I-Disease
.	O
""""	O
Although	O
three	O
different	O
dental	O
treatment	O
modalities	O
(	O
either	O
conventional	O
or	O
implant	O
-	O
supported	O
)	O
have	O
been	O
offered	O
to	O
the	O
patient	O
since	O
August	O
2007	O
,	O
the	O
patient	O
has	O
yet	O
to	O
initiate	O
any	O
treatment	O
.	O
CLINICAL	O
SIGNIFICANCE	O
:	O
This	O
clinical	O
case	O
showing	O
oral	O
manifestations	O
of	O
meth	B-Disease
mouth	I-Disease
was	O
presented	O
to	O
help	O
dental	O
practitioners	O
recognize	O
and	O
manage	O
patients	O
who	O
may	O
be	O
abusing	O
methamphetamines	B-Chemical
.	O
Dental	O
practitioners	O
also	O
may	O
be	O
skeptical	O
about	O
the	O
reliability	O
of	O
appointment	O
keeping	O
by	O
these	O
patients	O
,	O
as	O
they	O
frequently	O
miss	O
their	O
appointments	O
without	O
reasonable	O
justification	O
.	O
Antituberculosis	B-Chemical
therapy	O
-	O
induced	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
:	O
magnitude	O
,	O
profile	O
,	O
prognosis	O
,	O
and	O
predictors	O
of	O
outcome	O
.	O
Antituberculosis	B-Chemical
therapy	O
(	O
ATT	O
)	O
-	O
associated	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
(	O
ATT	O
-	O
ALF	B-Disease
)	O
is	O
the	O
commonest	O
drug	O
-	O
induced	O
ALF	B-Disease
in	O
South	O
Asia	O
.	O
Prospective	O
studies	O
on	O
ATT	O
-	O
ALF	B-Disease
are	O
lacking	O
.	O
The	O
current	O
study	O
prospectively	O
evaluated	O
the	O
magnitude	O
,	O
clinical	O
course	O
,	O
outcome	O
,	O
and	O
prognostic	O
factors	O
in	O
ATT	O
-	O
ALF	B-Disease
.	O
From	O
January	O
1986	O
to	O
January	O
2009	O
,	O
1223	O
consecutive	O
ALF	B-Disease
patients	O
were	O
evaluated	O
:	O
ATT	O
alone	O
was	O
the	O
cause	O
in	O
70	O
(	O
5	O
.	O
7	O
%	O
)	O
patients	O
.	O
Another	O
15	O
(	O
1	O
.	O
2	O
%	O
)	O
had	O
ATT	O
and	O
simultaneous	O
hepatitis	B-Disease
virus	I-Disease
infection	I-Disease
.	O
In	O
44	O
(	O
62	O
.	O
8	O
%	O
)	O
patients	O
,	O
ATT	O
was	O
prescribed	O
empirically	O
without	O
definitive	O
evidence	O
of	O
tuberculosis	B-Disease
.	O
ATT	O
-	O
ALF	B-Disease
patients	O
were	O
younger	O
(	O
32	O
.	O
87	O
[	O
+	O
/	O
-	O
15	O
.	O
8	O
]	O
years	O
)	O
,	O
and	O
49	O
(	O
70	O
%	O
)	O
of	O
them	O
were	O
women	O
.	O
Most	O
had	O
hyperacute	O
presentation	O
;	O
the	O
median	O
icterus	B-Disease
encephalopathy	B-Disease
interval	O
was	O
4	O
.	O
5	O
(	O
0	O
-	O
30	O
)	O
days	O
.	O
The	O
median	O
duration	O
of	O
ATT	O
before	O
ALF	B-Disease
was	O
30	O
(	O
7	O
-	O
350	O
)	O
days	O
.	O
At	O
presentation	O
,	O
advanced	O
encephalopathy	B-Disease
and	O
cerebral	B-Disease
edema	I-Disease
were	O
present	O
in	O
51	O
(	O
76	O
%	O
)	O
and	O
29	O
(	O
41	O
.	O
4	O
%	O
)	O
patients	O
,	O
respectively	O
.	O
Gastrointestinal	B-Disease
bleed	I-Disease
,	O
seizures	B-Disease
,	O
infection	B-Disease
,	O
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
were	O
documented	O
in	O
seven	O
(	O
10	O
%	O
)	O
,	O
five	O
(	O
7	O
.	O
1	O
%	O
)	O
,	O
26	O
(	O
37	O
.	O
1	O
%	O
)	O
,	O
and	O
seven	O
(	O
10	O
%	O
)	O
patients	O
,	O
respectively	O
.	O
Compared	O
with	O
hepatitis	B-Disease
E	I-Disease
virus	O
(	O
HEV	O
)	O
and	O
non	O
-	O
A	O
non	O
-	O
E	O
-	O
induced	O
ALF	B-Disease
,	O
ATT	O
-	O
ALF	B-Disease
patients	O
had	O
nearly	O
similar	O
presentations	O
except	O
for	O
older	O
age	O
and	O
less	O
elevation	O
of	O
liver	O
enzymes	O
.	O
The	O
mortality	O
rate	O
among	O
patients	O
with	O
ATT	O
-	O
ALF	B-Disease
was	O
high	O
(	O
67	O
.	O
1	O
%	O
,	O
n	O
=	O
47	O
)	O
,	O
and	O
only	O
23	O
(	O
32	O
.	O
9	O
%	O
)	O
patients	O
recovered	O
with	O
medical	O
treatment	O
.	O
In	O
multivariate	O
analysis	O
,	O
three	O
factors	O
independently	O
predicted	O
mortality	O
:	O
serum	O
bilirubin	B-Chemical
(	O
>	O
or	O
=	O
10	O
.	O
8	O
mg	O
/	O
dL	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
prolongation	O
(	O
>	O
or	O
=	O
26	O
seconds	O
)	O
,	O
and	O
grade	O
III	O
/	O
IV	O
encephalopathy	B-Disease
at	O
presentation	O
.	O
CONCLUSION	O
:	O
ATT	O
-	O
ALF	B-Disease
constituted	O
5	O
.	O
7	O
%	O
of	O
ALF	B-Disease
at	O
our	O
center	O
and	O
had	O
a	O
high	O
mortality	O
rate	O
.	O
Because	O
the	O
mortality	O
rate	O
is	O
so	O
high	O
,	O
determining	O
which	O
factors	O
are	O
predictors	O
is	O
less	O
important	O
.	O
A	O
high	O
proportion	O
of	O
patients	O
had	O
consumed	O
ATT	O
empirically	O
,	O
which	O
could	O
have	O
been	O
prevented	O
.	O
Design	O
and	O
analysis	O
of	O
the	O
HYPREN	O
-	O
trial	O
:	O
safety	O
of	O
enalapril	B-Chemical
and	O
prazosin	B-Chemical
in	O
the	O
initial	O
treatment	O
phase	O
of	O
patients	O
with	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
.	O
Since	O
the	O
introduction	O
of	O
angiotensin	B-Chemical
converting	I-Chemical
enzyme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhibitors	I-Chemical
into	O
the	O
adjunctive	O
treatment	O
of	O
patients	O
with	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
,	O
cases	O
of	O
severe	O
hypotension	B-Disease
,	O
especially	O
on	O
the	O
first	O
day	O
of	O
treatment	O
,	O
have	O
occasionally	O
been	O
reported	O
.	O
To	O
assess	O
the	O
safety	O
of	O
the	O
ACE	B-Chemical
inhibitor	I-Chemical
enalapril	B-Chemical
a	O
multicenter	O
,	O
randomized	O
,	O
prazosin	B-Chemical
-	O
controlled	O
trial	O
was	O
designed	O
that	O
compared	O
the	O
incidence	O
and	O
severity	O
of	O
symptomatic	O
hypotension	B-Disease
on	O
the	O
first	O
day	O
of	O
treatment	O
.	O
Trial	O
medication	O
was	O
2	O
.	O
5	O
mg	O
enalapril	B-Chemical
or	O
0	O
.	O
5	O
prazosin	B-Chemical
.	O
Subjects	O
were	O
1210	O
inpatients	O
with	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
functional	O
class	O
II	O
and	O
III	O
.	O
Patients	O
who	O
received	O
enalapril	B-Chemical
experienced	O
clinically	O
and	O
statistically	O
significantly	O
less	O
symptomatic	O
hypotension	B-Disease
(	O
5	O
.	O
2	O
%	O
)	O
than	O
the	O
patients	O
who	O
received	O
prazosin	B-Chemical
(	O
12	O
.	O
9	O
%	O
)	O
.	O
All	O
patients	O
recovered	O
.	O
It	O
was	O
concluded	O
that	O
treatment	O
with	O
enalapril	B-Chemical
was	O
well	O
tolerated	O
and	O
it	O
is	O
,	O
therefore	O
,	O
unreasonable	O
to	O
restrict	O
the	O
initiation	O
of	O
treatment	O
with	O
enalapril	B-Chemical
to	O
inpatients	O
.	O
Central	B-Disease
nervous	I-Disease
system	I-Disease
complications	I-Disease
during	O
treatment	O
of	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
in	O
a	O
single	O
pediatric	O
institution	O
.	O
Central	B-Disease
nervous	I-Disease
system	I-Disease
(	I-Disease
CNS	I-Disease
)	I-Disease
complications	I-Disease
during	O
treatment	O
of	O
childhood	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
(	O
ALL	B-Disease
)	O
remain	O
a	O
challenging	O
clinical	O
problem	O
.	O
Outcome	O
improvement	O
with	O
more	O
intensive	O
chemotherapy	O
has	O
significantly	O
increased	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	O
events	O
.	O
This	O
study	O
analyzed	O
the	O
incidence	O
of	O
neurological	B-Disease
complications	I-Disease
during	O
ALL	B-Disease
treatment	O
in	O
a	O
single	O
pediatric	O
institution	O
,	O
focusing	O
on	O
clinical	O
,	O
radiological	O
,	O
and	O
electrophysiological	O
findings	O
.	O
Exclusion	O
criteria	O
included	O
CNS	O
leukemic	B-Disease
infiltration	I-Disease
at	O
diagnosis	O
,	O
therapy	O
-	O
related	O
peripheral	B-Disease
neuropathy	I-Disease
,	O
late	O
-	O
onset	O
encephalopathy	B-Disease
,	O
or	O
long	O
-	O
term	O
neurocognitive	B-Disease
defects	I-Disease
.	O
During	O
a	O
9	O
-	O
year	O
period	O
,	O
we	O
retrospectively	O
collected	O
27	O
neurological	O
events	O
(	O
11	O
%	O
)	O
in	O
as	O
many	O
patients	O
,	O
from	O
253	O
children	O
enrolled	O
in	O
the	O
ALL	B-Disease
front	O
-	O
line	O
protocol	O
.	O
CNS	O
complications	O
included	O
posterior	O
reversible	O
leukoencephalopathy	B-Disease
syndrome	O
(	O
n	O
=	O
10	O
)	O
,	O
stroke	B-Disease
(	O
n	O
=	O
5	O
)	O
,	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
(	O
n	O
=	O
2	O
)	O
,	O
high	O
-	O
dose	O
methotrexate	B-Chemical
toxicity	B-Disease
(	O
n	O
=	O
2	O
)	O
,	O
syndrome	O
of	O
inappropriate	B-Disease
antidiuretic	I-Disease
hormone	I-Disease
secretion	I-Disease
(	O
n	O
=	O
1	O
)	O
,	O
and	O
other	O
unclassified	O
events	O
(	O
n	O
=	O
7	O
)	O
.	O
In	O
conclusion	O
,	O
CNS	O
complications	O
are	O
frequent	O
events	O
during	O
ALL	B-Disease
therapy	O
,	O
and	O
require	O
rapid	O
detection	O
and	O
prompt	O
treatment	O
to	O
limit	O
permanent	O
damage	O
.	O
Cocaine	B-Chemical
causes	O
memory	B-Disease
and	I-Disease
learning	I-Disease
impairments	I-Disease
in	O
rats	O
:	O
involvement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
and	O
oxidative	O
stress	O
,	O
and	O
prevention	O
by	O
topiramate	B-Chemical
.	O
Different	O
mechanisms	O
have	O
been	O
suggested	O
for	O
cocaine	B-Chemical
toxicity	B-Disease
including	O
an	O
increase	O
in	O
oxidative	O
stress	O
but	O
the	O
association	O
between	O
oxidative	O
status	O
in	O
the	O
brain	O
and	O
cocaine	B-Chemical
induced	O
-	O
behaviour	O
is	O
poorly	O
understood	O
.	O
Nuclear	O
factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
is	O
a	O
sensor	O
of	O
oxidative	O
stress	O
and	O
participates	O
in	O
memory	O
formation	O
that	O
could	O
be	O
involved	O
in	O
drug	O
toxicity	B-Disease
and	O
addiction	O
mechanisms	O
.	O
Therefore	O
NFkappaB	O
activity	O
,	O
oxidative	O
stress	O
,	O
neuronal	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
(	O
nNOS	O
)	O
activity	O
,	O
spatial	O
learning	O
and	O
memory	O
as	O
well	O
as	O
the	O
effect	O
of	O
topiramate	B-Chemical
,	O
a	O
previously	O
proposed	O
therapy	O
for	O
cocaine	B-Disease
addiction	I-Disease
,	O
were	O
evaluated	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	B-Chemical
administration	O
in	O
rats	O
.	O
NFkappaB	O
activity	O
was	O
decreased	O
in	O
the	O
frontal	O
cortex	O
of	O
cocaine	B-Chemical
treated	O
rats	O
,	O
as	O
well	O
as	O
GSH	B-Chemical
concentration	O
and	O
glutathione	B-Chemical
peroxidase	O
activity	O
in	O
the	O
hippocampus	O
,	O
whereas	O
nNOS	O
activity	O
in	O
the	O
hippocampus	O
was	O
increased	O
.	O
Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	B-Chemical
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	O
activity	O
in	O
the	O
frontal	O
cortex	O
.	O
In	O
contrast	O
,	O
learning	O
of	O
new	O
tasks	O
was	O
enhanced	O
and	O
correlated	O
with	O
the	O
increase	O
of	O
nNOS	O
activity	O
and	O
the	O
decrease	O
of	O
glutathione	B-Chemical
peroxidase	O
.	O
These	O
results	O
provide	O
evidence	O
for	O
a	O
possible	O
mechanistic	O
role	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
and	O
NFkappaB	O
in	O
the	O
alterations	O
induced	O
by	O
cocaine	B-Chemical
.	O
Topiramate	B-Chemical
prevented	O
all	O
the	O
alterations	O
observed	O
,	O
showing	O
novel	O
neuroprotective	O
properties	O
.	O
Efficacy	O
and	O
safety	O
of	O
asenapine	B-Chemical
in	O
a	O
placebo	O
-	O
and	O
haloperidol	B-Chemical
-	O
controlled	O
trial	O
in	O
patients	O
with	O
acute	O
exacerbation	O
of	O
schizophrenia	B-Disease
.	O
Asenapine	B-Chemical
is	O
approved	O
by	O
the	O
Food	O
and	O
Drugs	O
Administration	O
in	O
adults	O
for	O
acute	O
treatment	O
of	O
schizophrenia	B-Disease
or	O
of	O
manic	B-Disease
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	B-Disease
I	I-Disease
disorder	I-Disease
with	O
or	O
without	O
psychotic	B-Disease
features	O
.	O
In	O
a	O
double	O
-	O
blind	O
6	O
-	O
week	O
trial	O
,	O
458	O
patients	O
with	O
acute	O
schizophrenia	B-Disease
were	O
randomly	O
assigned	O
to	O
fixed	O
-	O
dose	O
treatment	O
with	O
asenapine	B-Chemical
at	O
5	O
mg	O
twice	O
daily	O
(	O
BID	O
)	O
,	O
asenapine	B-Chemical
at	O
10	O
mg	O
BID	O
,	O
placebo	O
,	O
or	O
haloperidol	B-Chemical
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
assay	O
sensitivity	O
)	O
.	O
With	O
last	O
observations	O
carried	O
forward	O
(	O
LOCF	O
)	O
,	O
mean	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
total	O
score	O
reductions	O
from	O
baseline	O
to	O
endpoint	O
were	O
significantly	O
greater	O
with	O
asenapine	B-Chemical
at	O
5	O
mg	O
BID	O
(	O
-	O
16	O
.	O
2	O
)	O
and	O
haloperidol	B-Chemical
(	O
-	O
15	O
.	O
4	O
)	O
than	O
placebo	O
(	O
-	O
10	O
.	O
7	O
;	O
both	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
using	O
mixed	O
model	O
for	O
repeated	O
measures	O
(	O
MMRM	O
)	O
,	O
changes	O
at	O
day	O
42	O
were	O
significantly	O
greater	O
with	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
(	O
-	O
21	O
.	O
3	O
and	O
-	O
19	O
.	O
4	O
,	O
respectively	O
)	O
and	O
haloperidol	B-Chemical
(	O
-	O
20	O
.	O
0	O
)	O
than	O
placebo	O
(	O
-	O
14	O
.	O
6	O
;	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
On	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
positive	O
subscale	O
,	O
all	O
treatments	O
were	O
superior	O
to	O
placebo	O
with	O
LOCF	O
and	O
MMRM	O
;	O
asenapine	B-Chemical
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
placebo	O
on	O
the	O
negative	O
subscale	O
with	O
MMRM	O
and	O
on	O
the	O
general	O
psychopathology	O
subscale	O
with	O
LOCF	O
and	O
MMRM	O
.	O
Treatment	O
-	O
related	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-Chemical
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O
Extrapyramidal	B-Disease
symptoms	I-Disease
reported	O
as	O
AEs	O
occurred	O
in	O
15	O
%	O
and	O
18	O
%	O
,	O
34	O
%	O
,	O
and	O
10	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-Chemical
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O
Across	O
all	O
groups	O
,	O
no	O
more	O
than	O
5	O
%	O
of	O
patients	O
had	O
clinically	O
significant	O
weight	O
change	O
.	O
Post	O
hoc	O
analyses	O
indicated	O
that	O
efficacy	O
was	O
similar	O
with	O
asenapine	B-Chemical
and	O
haloperidol	B-Chemical
;	O
greater	O
contrasts	O
were	O
seen	O
in	O
AEs	O
,	O
especially	O
extrapyramidal	B-Disease
symptoms	I-Disease
.	O
Salvage	O
therapy	O
with	O
nelarabine	B-Chemical
,	O
etoposide	B-Chemical
,	O
and	O
cyclophosphamide	B-Chemical
in	O
relapsed	O
/	O
refractory	O
paediatric	O
T	B-Disease
-	I-Disease
cell	I-Disease
lymphoblastic	I-Disease
leukaemia	I-Disease
and	I-Disease
lymphoma	I-Disease
.	O
A	O
combination	O
of	O
5	O
d	O
of	O
nelarabine	B-Chemical
(	O
AraG	B-Chemical
)	O
with	O
5	O
d	O
of	O
etoposide	B-Chemical
(	O
VP	B-Chemical
)	O
and	O
cyclophosphamide	B-Chemical
(	O
CPM	B-Chemical
)	O
and	O
prophylactic	O
intrathecal	O
chemotherapy	O
was	O
used	O
as	O
salvage	O
therapy	O
in	O
seven	O
children	O
with	O
refractory	O
or	O
relapsed	O
T	B-Disease
-	I-Disease
cell	I-Disease
leukaemia	I-Disease
or	I-Disease
lymphoma	I-Disease
.	O
The	O
most	O
common	O
side	O
effects	O
attributable	O
to	O
the	O
AraG	B-Chemical
included	O
Grade	O
2	O
and	O
3	O
sensory	O
and	O
motor	O
neuropathy	B-Disease
and	O
musculoskeletal	B-Disease
pain	I-Disease
.	O
Haematological	B-Disease
toxicity	I-Disease
was	O
greater	O
for	O
the	O
combination	O
than	O
AraG	B-Chemical
alone	O
,	O
although	O
median	O
time	O
to	O
neutrophil	O
and	O
platelet	O
recovery	O
was	O
consistent	O
with	O
other	O
salvage	O
therapies	O
.	O
All	O
patients	O
had	O
some	O
response	O
to	O
the	O
combined	O
therapy	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
remission	O
after	O
one	O
or	O
two	O
courses	O
of	O
AraG	B-Chemical
/	O
VP	B-Chemical
/	O
CPM	B-Chemical
.	O
Our	O
experience	O
supports	O
the	O
safety	O
of	O
giving	O
AraG	B-Chemical
as	O
salvage	O
therapy	O
in	O
synchrony	O
with	O
etoposide	B-Chemical
and	O
cyclophosphamide	B-Chemical
,	O
although	O
neurological	B-Disease
toxicity	I-Disease
must	O
be	O
closely	O
monitored	O
.	O
Effect	O
of	O
adriamycin	B-Chemical
combined	O
with	O
whole	O
body	O
hyperthermia	B-Disease
on	O
tumor	B-Disease
and	O
normal	O
tissues	O
.	O
Thermal	O
enhancement	O
of	O
Adriamycin	B-Chemical
-	O
mediated	O
antitumor	O
activity	O
and	O
normal	O
tissue	O
toxicities	B-Disease
by	O
whole	O
body	O
hyperthermia	B-Disease
were	O
compared	O
using	O
a	O
F344	O
rat	O
model	O
.	O
Antitumor	O
activity	O
was	O
studied	O
using	O
a	O
tumor	B-Disease
growth	O
delay	O
assay	O
.	O
Acute	O
normal	O
tissue	O
toxicities	B-Disease
(	O
i	O
.	O
e	O
.	O
,	O
leukopenia	B-Disease
and	O
thrombocytopenia	B-Disease
)	O
and	O
late	O
normal	O
tissue	O
toxicities	B-Disease
(	O
i	O
.	O
e	O
.	O
,	O
myocardial	B-Disease
and	I-Disease
kidney	I-Disease
injury	I-Disease
)	O
were	O
evaluated	O
by	O
functional	O
/	O
physiological	O
assays	O
and	O
by	O
morphological	O
techniques	O
.	O
Whole	O
body	O
hyperthermia	B-Disease
(	O
120	O
min	O
at	O
41	O
.	O
5	O
degrees	O
C	O
)	O
enhanced	O
both	O
Adriamycin	B-Chemical
-	O
mediated	O
antitumor	O
activity	O
and	O
toxic	O
side	O
effects	O
.	O
The	O
thermal	O
enhancement	O
ratio	O
calculated	O
for	O
antitumor	O
activity	O
was	O
1	O
.	O
6	O
.	O
Thermal	O
enhancement	O
ratios	O
estimated	O
for	O
""""	O
acute	O
""""	O
hematological	O
changes	O
were	O
1	O
.	O
3	O
,	O
whereas	O
those	O
estimated	O
for	O
""""	O
late	O
""""	O
damage	O
(	O
based	O
on	O
morphological	O
cardiac	B-Disease
and	I-Disease
renal	I-Disease
lesions	I-Disease
)	O
varied	O
between	O
2	O
.	O
4	O
and	O
4	O
.	O
3	O
.	O
Thus	O
,	O
while	O
whole	O
body	O
hyperthermia	B-Disease
enhances	O
Adriamycin	B-Chemical
-	O
mediated	O
antitumor	O
effect	O
,	O
normal	O
tissue	O
toxicity	B-Disease
is	O
also	O
increased	O
,	O
and	O
the	O
potential	O
therapeutic	O
gain	O
of	O
the	O
combined	O
modality	O
treatment	O
is	O
eroded	O
.	O
Permeability	O
,	O
ultrastructural	O
changes	O
,	O
and	O
distribution	O
of	O
novel	O
proteins	O
in	O
the	O
glomerular	O
barrier	O
in	O
early	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
.	O
BACKGROUND	O
/	O
AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	B-Disease
starts	O
.	O
Using	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
(	O
PAN	O
)	O
rats	O
,	O
we	O
studied	O
early	O
ultrastructural	O
and	O
permeability	O
changes	O
in	O
relation	O
to	O
the	O
expression	O
of	O
the	O
podocyte	O
-	O
associated	O
molecules	O
nephrin	O
,	O
a	O
-	O
actinin	O
,	O
dendrin	O
,	O
and	O
plekhh2	O
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocytes	O
.	O
METHODS	O
:	O
Using	O
immune	O
stainings	O
,	O
semiquantitative	O
measurement	O
was	O
performed	O
under	O
the	O
electron	O
microscope	O
.	O
Permeability	O
was	O
assessed	O
using	O
isolated	O
kidney	O
perfusion	O
with	O
tracers	O
.	O
Possible	O
effects	O
of	O
ACE	O
inhibition	O
were	O
tested	O
.	O
RESULTS	O
:	O
By	O
day	O
2	O
,	O
some	O
patchy	O
foot	O
process	O
effacement	O
,	O
but	O
no	O
proteinuria	B-Disease
,	O
appeared	O
.	O
The	O
amount	O
of	O
nephrin	O
was	O
reduced	O
in	O
both	O
diseased	O
and	O
normal	O
areas	O
.	O
The	O
other	O
proteins	O
showed	O
few	O
changes	O
,	O
which	O
were	O
limited	O
to	O
diseased	O
areas	O
.	O
By	O
day	O
4	O
,	O
foot	O
process	O
effacement	O
was	O
complete	O
and	O
proteinuria	B-Disease
appeared	O
in	O
parallel	O
with	O
signs	O
of	O
size	O
barrier	O
damage	O
.	O
Nephrin	O
decreased	O
further	O
,	O
while	O
dendrin	O
and	O
plekhh2	O
also	O
decreased	O
but	O
a	O
-	O
actinin	O
remained	O
unchanged	O
.	O
ACE	O
inhibition	O
had	O
no	O
significant	O
protective	O
effect	O
.	O
CONCLUSIONS	O
:	O
PAN	O
glomeruli	O
already	O
showed	O
significant	O
pathology	O
by	O
day	O
4	O
,	O
despite	O
relatively	O
mild	O
proteinuria	B-Disease
.	O
This	O
was	O
preceded	O
by	O
altered	O
nephrin	O
expression	O
,	O
supporting	O
its	O
pivotal	O
role	O
in	O
podocyte	O
morphology	O
.	O
The	O
novel	O
proteins	O
dendrin	O
and	O
plekhh2	O
were	O
both	O
reduced	O
,	O
suggesting	O
roles	O
in	O
PAN	O
,	O
whereas	O
a	O
-	O
actinin	O
was	O
unchanged	O
.	O
A	O
novel	O
,	O
multiple	O
symptom	O
model	O
of	O
obsessive	B-Disease
-	I-Disease
compulsive	I-Disease
-	I-Disease
like	I-Disease
behaviors	I-Disease
in	O
animals	O
.	O
BACKGROUND	O
:	O
Current	O
animal	O
models	O
of	O
obsessive	B-Disease
-	I-Disease
compulsive	I-Disease
disorder	I-Disease
(	O
OCD	B-Disease
)	O
typically	O
involve	O
acute	O
,	O
drug	O
-	O
induced	O
symptom	O
provocation	O
or	O
a	O
genetic	O
association	O
with	O
stereotypies	O
or	O
anxiety	B-Disease
.	O
None	O
of	O
these	O
current	O
models	O
demonstrate	O
multiple	O
OCD	B-Disease
-	O
like	O
behaviors	O
.	O
METHODS	O
:	O
Neonatal	O
rats	O
were	O
treated	O
with	O
the	O
tricyclic	O
antidepressant	B-Chemical
clomipramine	B-Chemical
or	O
vehicle	O
between	O
days	O
9	O
and	O
16	O
twice	O
daily	O
and	O
behaviorally	O
tested	O
in	O
adulthood	O
.	O
RESULTS	O
:	O
Clomipramine	B-Chemical
exposure	O
in	O
immature	O
rats	O
produced	O
significant	O
behavioral	O
and	O
biochemical	O
changes	O
that	O
include	O
enhanced	O
anxiety	B-Disease
(	O
elevated	O
plus	O
maze	O
and	O
marble	O
burying	O
)	O
,	O
behavioral	B-Disease
inflexibility	I-Disease
(	O
perseveration	O
in	O
the	O
spontaneous	O
alternation	O
task	O
and	O
impaired	O
reversal	O
learning	O
)	O
,	O
working	O
memory	B-Disease
impairment	I-Disease
(	O
e	O
.	O
g	O
.	O
,	O
win	O
-	O
shift	O
paradigm	O
)	O
,	O
hoarding	B-Disease
,	O
and	O
corticostriatal	B-Disease
dysfunction	I-Disease
.	O
Dopamine	B-Chemical
D2	O
receptors	O
were	O
elevated	O
in	O
the	O
striatum	O
,	O
whereas	O
serotonin	B-Chemical
2C	O
,	O
but	O
not	O
serotonin	B-Chemical
1A	O
,	O
receptors	O
were	O
elevated	O
in	O
the	O
orbital	O
frontal	O
cortex	O
.	O
CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
multiple	O
symptoms	O
consistent	O
with	O
an	O
OCD	B-Disease
-	O
like	O
profile	O
in	O
animals	O
.	O
Moreover	O
,	O
these	O
behaviors	O
are	O
accompanied	O
by	O
biochemical	O
changes	O
in	O
brain	O
regions	O
previously	O
identified	O
as	O
relevant	O
to	O
OCD	B-Disease
.	O
This	O
novel	O
model	O
of	O
OCD	B-Disease
demonstrates	O
that	O
drug	O
exposure	O
during	O
a	O
sensitive	O
period	O
can	O
program	O
disease	O
-	O
like	O
systems	O
permanently	O
,	O
which	O
could	O
have	O
implications	O
for	O
current	O
and	O
future	O
therapeutic	O
strategies	O
for	O
this	O
and	O
other	O
psychiatric	B-Disease
disorders	I-Disease
.	O
Elevation	O
of	O
ADAM10	O
,	O
ADAM17	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
expression	O
with	O
media	O
degeneration	O
features	O
CaCl2	B-Chemical
-	O
induced	O
thoracic	B-Disease
aortic	I-Disease
aneurysm	I-Disease
in	O
a	O
rat	O
model	O
.	O
PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
establish	O
a	O
rat	O
model	O
of	O
thoracic	B-Disease
aortic	I-Disease
aneurysm	I-Disease
(	O
TAA	B-Disease
)	O
by	O
calcium	B-Chemical
chloride	I-Chemical
(	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
)	O
-	O
induced	O
arterial	B-Disease
injury	I-Disease
and	O
to	O
explore	O
the	O
potential	O
role	O
of	O
a	O
disintegrin	O
and	O
metalloproteinase	O
(	O
ADAM	O
)	O
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
their	O
endogenous	O
inhibitors	O
(	O
TIMPs	O
)	O
in	O
TAA	B-Disease
formation	O
.	O
METHODS	O
:	O
Thoracic	O
aorta	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
was	O
exposed	O
to	O
0	O
.	O
5M	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
or	O
normal	O
saline	O
(	O
NaCl	B-Chemical
)	O
.	O
After	O
12weeks	O
,	O
animals	O
were	O
euthanized	O
,	O
and	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
,	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
untreated	O
(	O
n	O
=	O
12	O
)	O
and	O
NaCl	B-Chemical
-	O
treated	O
aortic	O
segments	O
(	O
n	O
=	O
12	O
)	O
were	O
collected	O
for	O
histological	O
and	O
molecular	O
assessments	O
.	O
MMP	O
-	O
TIMP	O
and	O
ADAM	O
mRNAs	O
were	O
semi	O
-	O
quantitatively	O
analyzed	O
and	O
protein	O
expressions	O
were	O
determined	O
by	O
immunohistochemistry	O
.	O
RESULTS	O
:	O
Despite	O
similar	O
external	O
diameters	O
among	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
,	O
non	O
-	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
and	O
NaCl	B-Chemical
-	O
treated	O
segments	O
,	O
aneurymal	O
alteration	O
(	O
n	O
=	O
6	O
,	O
50	O
%	O
)	O
,	O
media	O
degeneration	O
with	O
regional	O
disruption	O
,	O
fragmentation	O
of	O
elastic	O
fiber	O
,	O
and	O
increased	O
collagen	O
deposition	O
(	O
n	O
=	O
12	O
,	O
100	O
%	O
)	O
were	O
demonstrated	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
segments	O
.	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM	O
-	O
10	O
and	O
ADAM	O
-	O
17	O
mRNA	O
levels	O
were	O
increased	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
segments	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
with	O
trends	O
of	O
elevation	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
untreated	O
segments	O
,	O
as	O
compared	O
with	O
NaCl	B-Chemical
-	O
treated	O
segments	O
.	O
Immunohistochemistry	O
displayed	O
significantly	O
increased	O
expressions	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM	O
-	O
10	O
and	O
ADAM	O
-	O
17	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
intima	O
and	O
media	O
for	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
segments	O
.	O
TIMP	O
mRNA	O
and	O
tissue	O
levels	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
aortic	O
segments	O
.	O
CONCLUSION	O
:	O
This	O
study	O
establishes	O
a	O
TAA	B-Disease
model	O
by	O
periarterial	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
exposure	O
in	O
rats	O
,	O
and	O
demonstrates	O
a	O
significant	O
elevation	O
of	O
expression	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM10	O
and	O
ADAM17	O
in	O
the	O
pathogenesis	O
of	O
vascular	O
remodeling	O
.	O
Suxamethonium	B-Chemical
induced	O
prolonged	O
apnea	B-Disease
in	O
a	O
patient	O
receiving	O
electroconvulsive	O
therapy	O
.	O
Suxamethonium	B-Chemical
causes	O
prolonged	O
apnea	B-Disease
in	O
patients	O
in	O
whom	O
pseudocholinesterase	O
enzyme	O
gets	O
deactivated	O
by	O
organophosphorus	B-Chemical
(	I-Chemical
OP	I-Chemical
)	I-Chemical
poisons	I-Chemical
.	O
Here	O
,	O
we	O
present	O
a	O
similar	O
incident	O
in	O
a	O
severely	O
depressed	B-Disease
patient	O
who	O
received	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
.	O
Prolonged	O
apnea	B-Disease
in	O
our	O
case	O
ensued	O
because	O
the	O
information	O
about	O
suicidal	O
attempt	O
by	O
OP	B-Chemical
compound	I-Chemical
was	O
concealed	O
from	O
the	O
treating	O
team	O
.	O
Curcumin	B-Chemical
ameliorates	O
cognitive	B-Disease
dysfunction	I-Disease
and	O
oxidative	O
damage	O
in	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
administered	O
rats	O
.	O
The	O
antiepileptic	O
drugs	O
,	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
are	O
well	O
known	O
to	O
cause	O
cognitive	B-Disease
impairment	I-Disease
on	O
chronic	O
use	O
.	O
The	O
increase	O
in	O
free	O
radical	O
generation	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mechanisms	O
of	O
cognitive	B-Disease
impairment	I-Disease
by	O
antiepileptic	O
drugs	O
.	O
Curcumin	B-Chemical
has	O
shown	O
antioxidant	O
,	O
anti	O
-	O
inflammatory	O
and	O
neuro	O
-	O
protective	O
properties	O
.	O
Therefore	O
,	O
the	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
effect	O
of	O
chronic	O
curcumin	B-Chemical
administration	O
on	O
phenobarbitone	B-Chemical
-	O
and	O
carbamazepine	B-Chemical
-	O
induced	O
cognitive	B-Disease
impairment	I-Disease
and	O
oxidative	O
stress	O
in	O
rats	O
.	O
Pharmacokinetic	O
interactions	O
of	O
curcumin	B-Chemical
with	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
were	O
also	O
studied	O
.	O
Vehicle	O
/	O
drugs	O
were	O
administered	O
daily	O
for	O
21days	O
to	O
male	O
Wistar	O
rats	O
.	O
Passive	O
avoidance	O
paradigm	O
and	O
elevated	O
plus	O
maze	O
test	O
were	O
used	O
to	O
assess	O
cognitive	O
function	O
.	O
At	O
the	O
end	O
of	O
study	O
period	O
,	O
serum	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
,	O
whole	O
brain	O
malondialdehyde	B-Chemical
and	O
reduced	O
glutathione	B-Chemical
levels	O
were	O
estimated	O
.	O
The	O
administration	O
of	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
for	O
21days	O
caused	O
a	O
significant	O
impairment	B-Disease
of	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
as	O
well	O
as	O
an	O
increased	O
oxidative	O
stress	O
.	O
Concomitant	O
curcumin	B-Chemical
administration	O
prevented	O
the	O
cognitive	B-Disease
impairment	I-Disease
and	O
decreased	O
the	O
increased	O
oxidative	O
stress	O
induced	O
by	O
these	O
antiepileptic	O
drugs	O
.	O
Curcumin	B-Chemical
co	O
-	O
administration	O
did	O
not	O
cause	O
any	O
significant	O
alteration	O
in	O
the	O
serum	O
concentrations	O
of	O
both	O
phenobarbitone	B-Chemical
as	O
well	O
as	O
carbamazepine	B-Chemical
.	O
These	O
results	O
show	O
that	O
curcumin	B-Chemical
has	O
beneficial	O
effect	O
in	O
mitigating	O
the	O
deterioration	B-Disease
of	I-Disease
cognitive	I-Disease
functions	I-Disease
and	O
oxidative	O
damage	O
in	O
rats	O
treated	O
with	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
without	O
significantly	O
altering	O
their	O
serum	O
concentrations	O
.	O
The	O
findings	O
suggest	O
that	O
curcumin	B-Chemical
can	O
be	O
considered	O
as	O
a	O
potential	O
safe	O
and	O
effective	O
adjuvant	O
to	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
therapy	O
in	O
preventing	O
cognitive	B-Disease
impairment	I-Disease
associated	O
with	O
these	O
drugs	O
.	O
Can	O
angiogenesis	O
be	O
a	O
target	O
of	O
treatment	O
for	O
ribavirin	B-Chemical
associated	O
hemolytic	B-Disease
anemia	I-Disease
?	O
BACKGROUND	O
/	O
AIMS	O
:	O
Recently	O
ribavirin	B-Chemical
has	O
been	O
found	O
to	O
inhibit	O
angiogenesis	O
and	O
a	O
number	O
of	O
angiogenesis	O
inhibitors	O
such	O
as	O
sunitinib	B-Chemical
and	O
sorafenib	B-Chemical
have	O
been	O
found	O
to	O
cause	O
acute	O
hemolysis	B-Disease
.	O
We	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
a	O
relation	O
between	O
hemoglobin	O
,	O
haptoglobin	O
and	O
angiogenesis	O
soluble	O
markers	O
which	O
are	O
modifiable	O
and	O
can	O
help	O
in	O
developing	O
strategies	O
against	O
anemia	B-Disease
.	O
METHODS	O
:	O
Fourteen	O
patients	O
chronically	B-Disease
infected	I-Disease
with	I-Disease
hepatitis	I-Disease
C	I-Disease
virus	I-Disease
were	O
treated	O
by	O
pegylated	B-Chemical
interferon	I-Chemical
alpha	I-Chemical
2a	I-Chemical
and	O
ribavirin	B-Chemical
.	O
Serum	O
hemoglobin	O
,	O
haptoglobin	O
and	O
angiogenesis	O
markers	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
angiopoetin	O
-	O
2	O
were	O
investigated	O
before	O
and	O
after	O
therapy	O
.	O
RESULTS	O
:	O
We	O
observed	O
a	O
significant	O
decrease	O
in	O
haptoglobin	O
levels	O
at	O
the	O
end	O
of	O
the	O
treatment	O
period	O
.	O
Hemoglobin	O
levels	O
also	O
decreased	O
but	O
insignificantly	O
by	O
treatment	O
.	O
In	O
contrast	O
with	O
the	O
literature	O
,	O
serum	O
levels	O
of	O
angiogenesis	O
factors	O
did	O
not	O
change	O
significantly	O
by	O
pegylated	B-Chemical
interferon	I-Chemical
and	O
ribavirin	B-Chemical
therapy	O
.	O
We	O
found	O
no	O
correlation	O
of	O
angiogenesis	O
soluble	O
markers	O
with	O
either	O
hemoglobin	O
or	O
haptoglobin	O
.	O
CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
study	O
in	O
the	O
literature	O
investigating	O
a	O
link	O
between	O
angiogenesis	O
soluble	O
markers	O
and	O
ribavirin	B-Chemical
induced	O
anemia	B-Disease
in	O
patients	O
with	O
hepatitis	B-Disease
C	I-Disease
and	O
we	O
could	O
not	O
find	O
any	O
relation	O
.	O
Future	O
research	O
with	O
larger	O
number	O
of	O
patients	O
is	O
needed	O
to	O
find	O
out	O
modifiable	O
factors	O
that	O
will	O
improve	O
the	O
safety	O
of	O
ribavirin	B-Chemical
therapy	O
.	O
Reduction	O
in	O
injection	O
pain	B-Disease
using	O
buffered	O
lidocaine	B-Chemical
as	O
a	O
local	O
anesthetic	O
before	O
cardiac	O
catheterization	O
.	O
Previous	O
reports	O
have	O
suggested	O
that	O
pain	B-Disease
associated	O
with	O
the	O
injection	O
of	O
lidocaine	B-Chemical
is	O
related	O
to	O
the	O
acidic	O
pH	O
of	O
the	O
solution	O
.	O
To	O
determine	O
if	O
the	O
addition	O
of	O
a	O
buffering	O
solution	O
to	O
adjust	O
the	O
pH	O
of	O
lidocaine	B-Chemical
into	O
the	O
physiologic	O
range	O
would	O
reduce	O
pain	B-Disease
during	O
injection	O
,	O
we	O
performed	O
a	O
blinded	O
randomized	O
study	O
in	O
patients	O
undergoing	O
cardiac	O
catheterization	O
.	O
Twenty	O
patients	O
were	O
asked	O
to	O
quantify	O
the	O
severity	O
of	O
pain	B-Disease
after	O
receiving	O
standard	O
lidocaine	B-Chemical
in	O
one	O
femoral	O
area	O
and	O
buffered	O
lidocaine	B-Chemical
in	O
the	O
opposite	O
femoral	O
area	O
.	O
The	O
mean	O
pain	B-Disease
score	O
for	O
buffered	O
lidocaine	B-Chemical
was	O
significantly	O
lower	O
than	O
the	O
mean	O
score	O
for	O
standard	O
lidocaine	B-Chemical
(	O
2	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
vs	O
.	O
3	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O
The	O
pH	O
adjustment	O
of	O
standard	O
lidocaine	B-Chemical
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheterization	O
laboratory	O
before	O
injection	O
and	O
results	O
in	O
a	O
reduction	O
of	O
the	O
pain	B-Disease
occurring	O
during	O
the	O
infiltration	O
of	O
tissues	O
.	O
Effect	O
of	O
L	B-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
glyceryl	I-Chemical
-	I-Chemical
phosphorylcholine	I-Chemical
on	O
amnesia	B-Disease
caused	O
by	O
scopolamine	B-Chemical
.	O
The	O
present	O
study	O
was	O
carried	O
out	O
to	O
test	O
the	O
effects	O
of	O
L	B-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
glycerylphosphorylcholine	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
GFC	I-Chemical
)	O
on	O
memory	B-Disease
impairment	I-Disease
induced	O
by	O
scopolamine	B-Chemical
in	O
man	O
.	O
Thirty	O
-	O
two	O
healthy	O
young	O
volunteers	O
were	O
randomly	O
allocated	O
to	O
four	O
different	O
groups	O
.	O
They	O
were	O
given	O
a	O
ten	O
day	O
pretreatment	O
with	O
either	O
L	B-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
GFC	I-Chemical
or	O
placebo	O
,	O
p	O
.	O
o	O
.	O
,	O
and	O
on	O
the	O
eleventh	O
day	O
either	O
scopolamine	B-Chemical
or	O
placebo	O
,	O
i	O
.	O
m	O
.	O
Before	O
and	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
6	O
h	O
after	O
injection	O
the	O
subjects	O
were	O
given	O
attention	O
and	O
mnemonic	O
tests	O
.	O
The	O
findings	O
of	O
this	O
study	O
indicate	O
that	O
the	O
drug	O
is	O
able	O
to	O
antagonize	O
impairment	B-Disease
of	I-Disease
attention	I-Disease
and	I-Disease
memory	I-Disease
induced	O
by	O
scopolamine	B-Chemical
.	O
Safety	O
of	O
capecitabine	B-Chemical
:	O
a	O
review	O
.	O
IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
Fluoropyrimidines	B-Chemical
,	O
in	O
particular	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
treatment	O
for	O
several	O
solid	O
tumors	B-Disease
,	O
including	O
colorectal	B-Disease
,	I-Disease
breast	I-Disease
and	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
cancers	I-Disease
,	O
for	O
>	O
40	O
years	O
.	O
AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
This	O
article	O
reviews	O
the	O
pharmacology	O
and	O
efficacy	O
of	O
capecitabine	B-Chemical
with	O
a	O
special	O
emphasis	O
on	O
its	O
safety	O
.	O
WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safety	O
of	O
capecitabine	B-Chemical
in	O
special	O
populations	O
such	O
as	O
patients	O
with	O
advanced	O
age	O
,	O
renal	B-Disease
and	I-Disease
kidney	I-Disease
disease	I-Disease
.	O
We	O
also	O
explore	O
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	B-Chemical
administration	O
.	O
TAKE	O
HOME	O
MESSAGE	O
:	O
Capecitabine	B-Chemical
is	O
an	O
oral	O
prodrug	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
therapy	O
and	O
provide	O
an	O
improved	O
safety	O
/	O
efficacy	O
profile	O
.	O
It	O
has	O
shown	O
promising	O
results	O
alone	O
or	O
in	O
combination	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
colorectal	B-Disease
,	I-Disease
breast	I-Disease
,	I-Disease
pancreaticobiliary	I-Disease
,	I-Disease
gastric	I-Disease
,	I-Disease
renal	I-Disease
cell	I-Disease
and	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
cancers	I-Disease
.	O
The	O
most	O
commonly	O
reported	O
toxic	O
effects	O
of	O
capecitabine	B-Chemical
are	O
diarrhea	B-Disease
,	O
nausea	B-Disease
,	O
vomiting	B-Disease
,	O
stomatitis	B-Disease
and	O
hand	B-Disease
-	I-Disease
foot	I-Disease
syndrome	I-Disease
.	O
Capecitabine	B-Chemical
has	O
a	O
well	O
-	O
established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	O
with	O
advanced	O
age	O
,	O
hepatic	B-Disease
and	I-Disease
renal	I-Disease
dysfunctions	I-Disease
.	O
Levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
:	O
filling	O
the	O
bench	O
-	O
to	O
-	O
bedside	O
gap	O
.	O
Levodopa	B-Chemical
is	O
the	O
most	O
effective	O
drug	O
for	O
the	O
treatment	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
However	O
,	O
the	O
long	O
-	O
term	O
use	O
of	O
this	O
dopamine	B-Chemical
precursor	O
is	O
complicated	O
by	O
highly	O
disabling	O
fluctuations	O
and	O
dyskinesias	B-Disease
.	O
Although	O
preclinical	O
and	O
clinical	O
findings	O
suggest	O
pulsatile	O
stimulation	O
of	O
striatal	O
postsynaptic	O
receptors	O
as	O
a	O
key	O
mechanism	O
underlying	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
,	O
their	O
pathogenesis	O
is	O
still	O
unclear	O
.	O
In	O
recent	O
years	O
,	O
evidence	O
from	O
animal	O
models	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
has	O
provided	O
important	O
information	O
to	O
understand	O
the	O
effect	O
of	O
specific	O
receptor	O
and	O
post	O
-	O
receptor	O
molecular	O
mechanisms	O
underlying	O
the	O
development	O
of	O
dyskinetic	B-Disease
movements	I-Disease
.	O
Recent	O
preclinical	O
and	O
clinical	O
data	O
from	O
promising	O
lines	O
of	O
research	O
focus	O
on	O
the	O
differential	O
role	O
of	O
presynaptic	O
versus	O
postsynaptic	O
mechanisms	O
,	O
dopamine	B-Chemical
receptor	O
subtypes	O
,	O
ionotropic	O
and	O
metabotropic	O
glutamate	B-Chemical
receptors	O
,	O
and	O
non	O
-	O
dopaminergic	O
neurotransmitter	O
systems	O
in	O
the	O
pathophysiology	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
.	O
Effects	O
of	O
pallidal	O
neurotensin	B-Chemical
on	O
haloperidol	B-Chemical
-	O
induced	O
parkinsonian	B-Disease
catalepsy	I-Disease
:	O
behavioral	O
and	O
electrophysiological	O
studies	O
.	O
OBJECTIVE	O
:	O
The	O
globus	O
pallidus	O
plays	O
a	O
critical	O
role	O
in	O
movement	O
regulation	O
.	O
Previous	O
studies	O
have	O
indicated	O
that	O
the	O
globus	O
pallidus	O
receives	O
neurotensinergic	O
innervation	O
from	O
the	O
striatum	O
,	O
and	O
systemic	O
administration	O
of	O
a	O
neurotensin	B-Chemical
analog	O
could	O
produce	O
antiparkinsonian	O
effects	O
.	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
pallidal	O
neurotensin	B-Chemical
on	O
haloperidol	B-Chemical
-	O
induced	O
parkinsonian	B-Disease
symptoms	I-Disease
.	O
METHODS	O
:	O
Behavioral	O
experiments	O
and	O
electrophysiological	O
recordings	O
were	O
performed	O
in	O
the	O
present	O
study	O
.	O
RESULTS	O
:	O
Bilateral	O
infusions	O
of	O
neurotensin	B-Chemical
into	O
the	O
globus	O
pallidus	O
reversed	O
haloperidol	B-Chemical
-	O
induced	O
parkinsonian	B-Disease
catalepsy	I-Disease
in	O
rats	O
.	O
Electrophysiological	O
recordings	O
showed	O
that	O
microinjection	O
of	O
neurotensin	B-Chemical
induced	O
excitation	O
of	O
pallidal	O
neurons	O
in	O
the	O
presence	O
of	O
systemic	O
haloperidol	B-Chemical
administration	O
.	O
The	O
neurotensin	B-Chemical
type	I-Chemical
-	I-Chemical
1	I-Chemical
receptor	I-Chemical
antagonist	I-Chemical
SR48692	B-Chemical
blocked	O
both	O
the	O
behavioral	O
and	O
the	O
electrophysiological	O
effects	O
induced	O
by	O
neurotensin	B-Chemical
.	O
CONCLUSION	O
:	O
Activation	O
of	O
pallidal	O
neurotensin	B-Chemical
receptors	O
may	O
be	O
involved	O
in	O
neurotensin	B-Chemical
-	O
induced	O
antiparkinsonian	O
effects	O
.	O
Carmofur	B-Chemical
-	O
induced	O
organic	B-Disease
mental	I-Disease
disorders	I-Disease
.	O
Organic	B-Disease
mental	I-Disease
disorder	I-Disease
was	O
observed	O
in	O
a	O
29	O
-	O
year	O
-	O
old	O
female	O
in	O
the	O
prognostic	O
period	O
after	O
the	O
onset	O
of	O
carmofur	B-Chemical
-	O
induced	O
leukoencephalopathy	B-Disease
.	O
Symptoms	O
such	O
as	O
euphoria	O
,	O
emotional	O
lability	O
and	O
puerile	O
attitude	O
noted	O
in	O
the	O
patient	O
were	O
diagnosed	O
as	O
organic	B-Disease
personality	I-Disease
syndrome	I-Disease
according	O
to	O
the	O
criteria	O
defined	O
in	O
the	O
DSM	O
-	O
III	O
-	O
R	O
.	O
It	O
is	O
referred	O
to	O
as	O
a	O
frontal	B-Disease
lobe	I-Disease
syndrome	I-Disease
.	O
Brain	O
CT	O
revealed	O
a	O
periventricular	O
low	O
density	O
area	O
in	O
the	O
frontal	O
white	O
matter	O
and	O
moderate	O
dilatation	O
of	O
the	O
lateral	O
ventricles	O
especially	O
at	O
the	O
bilateral	O
anterior	O
horns	O
.	O
Consequently	O
,	O
carmofur	B-Chemical
-	O
induced	O
leukoencephalopathy	B-Disease
may	O
uncommonly	O
result	O
in	O
organic	B-Disease
personality	I-Disease
syndrome	I-Disease
in	O
the	O
residual	O
state	O
.	O
It	O
may	O
be	O
attributed	O
to	O
the	O
structural	B-Disease
damage	I-Disease
to	I-Disease
the	I-Disease
frontal	I-Disease
lobe	I-Disease
.	O
Butyrylcholinesterase	O
gene	O
mutations	O
in	O
patients	O
with	O
prolonged	O
apnea	B-Disease
after	O
succinylcholine	B-Chemical
for	O
electroconvulsive	O
therapy	O
.	O
BACKGROUND	O
:	O
patients	O
undergoing	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
often	O
receive	O
succinylcholine	B-Chemical
as	O
part	O
of	O
the	O
anesthetic	O
procedure	O
.	O
The	O
duration	O
of	O
action	O
may	O
be	O
prolonged	O
in	O
patients	O
with	O
genetic	O
variants	O
of	O
the	O
butyrylcholinesterase	O
enzyme	O
(	O
BChE	O
)	O
,	O
the	O
most	O
common	O
being	O
the	O
K	O
-	O
and	O
the	O
A	O
-	O
variants	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
significance	O
of	O
genetic	O
variants	O
in	O
butyrylcholinesterase	O
gene	O
(	O
BCHE	O
)	O
in	O
patients	O
with	O
a	O
suspected	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	B-Chemical
after	O
ECT	O
.	O
METHODS	O
:	O
a	O
total	O
of	O
13	O
patients	O
were	O
referred	O
to	O
the	O
Danish	O
Cholinesterase	O
Research	O
Unit	O
after	O
ECT	O
during	O
38	O
months	O
.	O
We	O
determined	O
the	O
BChE	O
activity	O
and	O
the	O
BCHE	O
genotype	O
using	O
molecular	O
genetic	O
methods	O
,	O
the	O
duration	O
of	O
apnea	B-Disease
,	O
time	O
to	O
sufficient	O
spontaneous	O
ventilation	O
and	O
whether	O
neuromuscular	O
monitoring	O
was	O
used	O
.	O
The	O
duration	O
of	O
apnea	B-Disease
was	O
compared	O
with	O
published	O
data	O
on	O
normal	O
subjects	O
.	O
RESULTS	O
:	O
in	O
11	O
patients	O
,	O
mutations	O
were	O
found	O
in	O
the	O
BCHE	O
gene	O
,	O
the	O
K	O
-	O
variant	O
being	O
the	O
most	O
frequent	O
.	O
The	O
duration	O
of	O
apnea	B-Disease
was	O
5	O
-	O
15	O
min	O
compared	O
with	O
3	O
-	O
5	O
.	O
3	O
min	O
from	O
the	O
literature	O
.	O
Severe	O
distress	O
was	O
noted	O
in	O
the	O
recovery	O
phase	O
in	O
two	O
patients	O
.	O
Neuromuscular	O
monitoring	O
was	O
used	O
in	O
two	O
patients	O
.	O
CONCLUSION	O
:	O
eleven	O
of	O
13	O
patients	O
with	O
a	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	B-Chemical
had	O
mutations	O
in	O
BCHE	O
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
prolonged	O
period	O
of	O
apnea	B-Disease
.	O
We	O
recommend	O
objective	O
neuromuscular	O
monitoring	O
during	O
the	O
first	O
ECT	O
.	O
Perhexiline	B-Chemical
maleate	I-Chemical
and	O
peripheral	B-Disease
neuropathy	I-Disease
.	O
Peripheral	B-Disease
neuropathy	I-Disease
has	O
been	O
noted	O
as	O
a	O
complication	O
of	O
therapy	O
with	O
perhexiline	B-Chemical
maleate	I-Chemical
,	O
a	O
drug	O
widely	O
used	O
in	O
France	O
(	O
and	O
in	O
clinical	O
trials	O
in	O
the	O
United	O
States	O
)	O
for	O
the	O
prophylactic	O
treatment	O
of	O
angina	B-Disease
pectoris	I-Disease
.	O
In	O
24	O
patients	O
with	O
this	O
complication	O
,	O
the	O
marked	O
slowing	O
of	O
motor	O
nerve	O
conduction	O
velocity	O
and	O
the	O
electromyographic	O
changes	O
imply	O
mainly	O
a	O
demyelinating	B-Disease
disorder	I-Disease
.	O
Improvement	O
was	O
noted	O
with	O
cessation	O
of	O
therapy	O
.	O
In	O
a	O
few	O
cases	O
the	O
presence	O
of	O
active	O
denervation	O
signified	O
a	O
poor	O
prognosis	O
,	O
with	O
only	O
slight	O
improvement	O
.	O
The	O
underlying	O
mechanism	O
causing	O
the	O
neuropathy	B-Disease
is	O
not	O
yet	O
fully	O
known	O
,	O
although	O
some	O
evidence	O
indicates	O
that	O
it	O
may	O
be	O
a	O
lipid	O
storage	O
process	O
.	O
A	O
phase	O
I	O
study	O
of	O
4	B-Chemical
'	I-Chemical
-	I-Chemical
0	I-Chemical
-	I-Chemical
tetrahydropyranyladriamycin	I-Chemical
.	O
Clinical	O
pharmacology	O
and	O
pharmacokinetics	O
.	O
A	O
Phase	O
I	O
study	O
of	O
intravenous	O
(	O
IV	O
)	O
bolus	O
4	B-Chemical
'	I-Chemical
-	I-Chemical
0	I-Chemical
-	I-Chemical
tetrahydropyranyladriamycin	I-Chemical
(	O
Pirarubicin	B-Chemical
)	O
was	O
done	O
in	O
55	O
patients	O
in	O
good	O
performance	O
status	O
with	O
refractory	O
tumors	B-Disease
.	O
Twenty	O
-	O
six	O
had	O
minimal	O
prior	O
therapy	O
(	O
good	O
risk	O
)	O
,	O
23	O
had	O
extensive	O
prior	O
therapy	O
(	O
poor	O
risk	O
)	O
,	O
and	O
six	O
had	O
renal	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
hepatic	I-Disease
dysfunction	I-Disease
.	O
A	O
total	O
of	O
167	O
courses	O
at	O
doses	O
of	O
15	O
to	O
70	O
mg	O
/	O
m2	O
were	O
evaluable	O
.	O
Maximum	O
tolerated	O
dose	O
in	O
good	O
-	O
risk	O
patients	O
was	O
70	O
mg	O
/	O
m2	O
,	O
and	O
in	O
poor	O
-	O
risk	O
patients	O
,	O
60	O
mg	O
/	O
m2	O
.	O
The	O
dose	O
-	O
limiting	O
toxic	O
effect	O
was	O
transient	O
noncumulative	O
granulocytopenia	B-Disease
.	O
Granulocyte	O
nadir	O
was	O
on	O
day	O
14	O
(	O
range	O
,	O
4	O
-	O
22	O
)	O
.	O
Less	O
frequent	O
toxic	O
effects	O
included	O
thrombocytopenia	B-Disease
,	O
anemia	B-Disease
,	O
nausea	B-Disease
,	O
mild	O
alopecia	B-Disease
,	O
phlebitis	B-Disease
,	O
and	O
mucositis	B-Disease
.	O
Myelosuppression	B-Disease
was	O
more	O
in	O
patients	O
with	O
hepatic	B-Disease
dysfunction	I-Disease
.	O
Pharmacokinetic	O
analyses	O
in	O
21	O
patients	O
revealed	O
Pirarubicin	B-Chemical
plasma	O
T	O
1	O
/	O
2	O
alpha	O
(	O
+	O
/	O
-	O
SE	O
)	O
of	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
85	O
minutes	O
,	O
T	O
beta	O
1	O
/	O
2	O
of	O
25	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
5	O
minutes	O
,	O
and	O
T	O
1	O
/	O
2	O
gamma	O
of	O
23	O
.	O
6	O
+	O
/	O
-	O
7	O
.	O
6	O
hours	O
.	O
The	O
area	O
under	O
the	O
curve	O
was	O
537	O
+	O
/	O
-	O
149	O
ng	O
/	O
ml	O
x	O
hours	O
,	O
volume	O
of	O
distribution	O
(	O
Vd	O
)	O
3504	O
+	O
/	O
-	O
644	O
l	O
/	O
m2	O
,	O
and	O
total	O
clearance	O
(	O
ClT	O
)	O
was	O
204	O
+	O
39	O
.	O
3	O
l	O
/	O
hour	O
/	O
m2	O
.	O
Adriamycinol	B-Chemical
,	O
doxorubicin	B-Chemical
,	O
adriamycinone	B-Chemical
,	O
and	O
tetrahydropyranyladriamycinol	B-Chemical
were	O
the	O
metabolites	O
detected	O
in	O
plasma	O
and	O
the	O
amount	O
of	O
doxorubicin	B-Chemical
was	O
less	O
than	O
or	O
equal	O
to	O
10	O
%	O
of	O
the	O
total	O
metabolites	O
.	O
Urinary	O
excretion	O
of	O
Pirarubicin	B-Chemical
in	O
the	O
first	O
24	O
hours	O
was	O
less	O
than	O
or	O
equal	O
to	O
10	O
%	O
.	O
Activity	O
was	O
noted	O
in	O
mesothelioma	B-Disease
,	O
leiomyosarcoma	B-Disease
,	O
and	O
basal	B-Disease
cell	I-Disease
carcinoma	I-Disease
.	O
The	O
recommended	O
starting	O
dose	O
for	O
Phase	O
II	O
trials	O
is	O
60	O
mg	O
/	O
m2	O
IV	O
bolus	O
every	O
3	O
weeks	O
.	O
Ocular	B-Disease
and	I-Disease
auditory	I-Disease
toxicity	I-Disease
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	B-Chemical
.	O
During	O
an	O
18	O
-	O
month	O
period	O
of	O
study	O
41	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	B-Chemical
(	O
10	O
-	O
40	O
mg	O
/	O
kg	O
BW	O
/	O
3	O
times	O
weekly	O
)	O
for	O
the	O
first	O
time	O
were	O
monitored	O
for	O
detection	O
of	O
audiovisual	B-Disease
toxicity	I-Disease
.	O
6	O
patients	O
presented	O
clinical	O
symptoms	O
of	O
visual	B-Disease
or	I-Disease
auditory	I-Disease
toxicity	I-Disease
.	O
Moreover	O
,	O
detailed	O
ophthalmologic	O
and	O
audiologic	O
studies	O
disclosed	O
abnormalities	O
in	O
7	O
more	O
asymptomatic	O
patients	O
.	O
Visual	B-Disease
toxicity	I-Disease
was	O
of	O
retinal	O
origin	O
and	O
was	O
characterized	O
by	O
a	O
tritan	O
-	O
type	O
dyschromatopsy	B-Disease
,	O
sometimes	O
associated	O
with	O
a	B-Disease
loss	I-Disease
of	I-Disease
visual	I-Disease
acuity	I-Disease
and	O
pigmentary	B-Disease
retinal	I-Disease
deposits	I-Disease
.	O
Auditory	B-Disease
toxicity	I-Disease
was	O
characterized	O
by	O
a	O
mid	O
-	O
to	O
high	O
-	O
frequency	O
neurosensorial	B-Disease
hearing	I-Disease
loss	I-Disease
and	O
the	O
lesion	O
was	O
of	O
the	O
cochlear	O
type	O
.	O
Desferrioxamine	B-Chemical
withdrawal	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
visual	O
function	O
in	O
1	O
patient	O
and	O
partial	O
recovery	O
in	O
3	O
,	O
and	O
a	O
complete	O
reversal	O
of	O
hearing	B-Disease
loss	I-Disease
in	O
3	O
patients	O
and	O
partial	O
recovery	O
in	O
3	O
.	O
This	O
toxicity	B-Disease
appeared	O
in	O
patients	O
receiving	O
the	O
higher	O
doses	O
of	O
desferrioxamine	B-Chemical
or	O
coincided	O
with	O
the	O
normalization	O
of	O
ferritin	O
or	O
aluminium	B-Chemical
serum	O
levels	O
.	O
The	O
data	O
indicate	O
that	O
audiovisual	B-Disease
toxicity	I-Disease
is	O
not	O
an	O
infrequent	O
complication	O
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	B-Chemical
.	O
Periodical	O
audiovisual	O
monitoring	O
should	O
be	O
performed	O
on	O
hemodialyzed	O
patients	O
receiving	O
the	O
drug	O
in	O
order	O
to	O
detect	O
adverse	O
effects	O
as	O
early	O
as	O
possible	O
.	O
Serial	O
epilepsy	B-Disease
caused	O
by	O
levodopa	B-Chemical
/	I-Chemical
carbidopa	I-Chemical
administration	O
in	O
two	O
patients	O
on	O
hemodialysis	O
.	O
Two	O
patients	O
with	O
similar	O
clinical	O
features	O
are	O
presented	O
:	O
both	O
patients	O
had	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
,	O
on	O
hemodialysis	O
for	O
many	O
years	O
but	O
recently	O
begun	O
on	O
a	O
high	O
-	O
flux	O
dialyzer	O
;	O
both	O
had	O
been	O
receiving	O
a	O
carbidopa	B-Chemical
/	I-Chemical
levodopa	I-Chemical
preparation	O
;	O
and	O
both	O
had	O
the	O
onset	O
of	O
hallucinosis	B-Disease
and	O
recurrent	O
seizures	B-Disease
,	O
which	O
were	O
refractory	O
to	O
anticonvulsants	O
.	O
The	O
first	O
patient	O
died	O
without	O
a	O
diagnosis	O
;	O
the	O
second	O
patient	O
had	O
a	O
dramatic	O
recovery	O
following	O
the	O
administration	O
of	O
vitamin	B-Chemical
B6	I-Chemical
.	O
Neither	O
patient	O
was	O
considered	O
to	O
have	O
a	O
renal	O
state	O
sufficiently	O
severe	O
enough	O
to	O
explain	O
their	O
presentation	O
.	O
Randomized	O
,	O
double	O
-	O
blind	O
trial	O
of	O
mazindol	B-Chemical
in	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O
There	O
is	O
evidence	O
that	O
growth	O
hormone	O
may	O
be	O
related	O
to	O
the	O
progression	O
of	O
weakness	B-Disease
in	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O
We	O
conducted	O
a	O
12	O
-	O
month	O
controlled	O
trial	O
of	O
mazindol	B-Chemical
,	O
a	O
putative	O
growth	O
hormone	O
secretion	O
inhibitor	O
,	O
in	O
83	O
boys	O
with	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O
Muscle	O
strength	O
,	O
contractures	O
,	O
functional	O
ability	O
and	O
pulmonary	O
function	O
were	O
tested	O
at	O
baseline	O
,	O
and	O
6	O
and	O
12	O
months	O
after	O
treatment	O
with	O
mazindol	B-Chemical
(	O
3	O
mg	O
/	O
d	O
)	O
or	O
placebo	O
.	O
The	O
study	O
was	O
designed	O
to	O
have	O
a	O
power	O
of	O
greater	O
than	O
0	O
.	O
90	O
to	O
detect	O
a	O
slowing	O
to	O
25	O
%	O
of	O
the	O
expected	O
rate	O
of	O
progression	O
of	O
weakness	B-Disease
at	O
P	O
less	O
than	O
0	O
.	O
05	O
.	O
Mazindol	B-Chemical
did	O
not	O
benefit	O
strength	O
at	O
any	O
point	O
in	O
the	O
study	O
.	O
Side	O
effects	O
attributable	O
to	O
mazindol	B-Chemical
included	O
decreased	B-Disease
appetite	I-Disease
(	O
36	O
%	O
)	O
,	O
dry	B-Disease
mouth	I-Disease
(	O
10	O
%	O
)	O
,	O
behavioral	O
change	O
(	O
22	O
%	O
)	O
,	O
and	O
gastrointestinal	B-Disease
symptoms	I-Disease
(	O
18	O
%	O
)	O
;	O
mazindol	B-Chemical
dosage	O
was	O
reduced	O
in	O
43	O
%	O
of	O
patients	O
.	O
The	O
effect	O
of	O
mazindol	B-Chemical
on	O
GH	O
secretion	O
was	O
estimated	O
indirectly	O
by	O
comparing	O
the	O
postabsorptive	O
IGF	O
-	O
I	O
levels	O
obtained	O
following	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
in	O
the	O
mazindol	B-Chemical
treated	O
to	O
those	O
in	O
the	O
placebo	O
groups	O
.	O
Although	O
mazindol	B-Chemical
-	O
treated	O
patients	O
gained	O
less	O
weight	O
and	O
height	O
than	O
placebo	O
-	O
treated	O
patients	O
,	O
no	O
significant	O
effect	O
on	O
IGF	O
-	O
I	O
levels	O
was	O
observed	O
.	O
Mazindol	B-Chemical
doses	O
not	O
slow	O
the	O
progression	O
of	O
weakness	B-Disease
in	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O
Facilitation	O
of	O
memory	O
retrieval	O
by	O
pre	O
-	O
test	O
morphine	B-Chemical
and	O
its	O
state	O
dependency	O
in	O
the	O
step	O
-	O
through	O
type	O
passive	O
avoidance	O
learning	O
test	O
in	O
mice	O
.	O
Amnesia	B-Disease
produced	O
by	O
scopolamine	B-Chemical
and	O
cycloheximide	B-Chemical
were	O
reversed	O
by	O
morphine	B-Chemical
given	O
30	O
min	O
before	O
the	O
test	O
trial	O
(	O
pre	O
-	O
test	O
)	O
,	O
and	O
pre	O
-	O
test	O
morphine	B-Chemical
also	O
facilitated	O
the	O
memory	O
retrieval	O
in	O
the	O
animals	O
administered	O
naloxone	B-Chemical
during	O
the	O
training	O
trial	O
.	O
Similarly	O
,	O
pre	O
-	O
test	O
scopolamine	B-Chemical
partially	O
reversed	O
the	O
scopolamine	B-Chemical
-	O
induced	O
amnesia	B-Disease
,	O
but	O
not	O
significantly	O
;	O
and	O
pre	O
-	O
test	O
cycloheximide	B-Chemical
failed	O
to	O
reverse	O
the	O
cycloheximide	B-Chemical
-	O
induced	O
amnesia	B-Disease
.	O
These	O
results	O
suggest	O
that	O
the	O
facilitation	O
of	O
memory	O
retrieval	O
by	O
pre	O
-	O
test	O
morphine	B-Chemical
might	O
be	O
the	O
direct	O
action	O
of	O
morphine	B-Chemical
rather	O
than	O
a	O
state	O
dependent	O
effect	O
.	O
Naloxone	B-Chemical
reverses	O
the	O
antihypertensive	O
effect	O
of	O
clonidine	B-Chemical
.	O
In	O
unanesthetized	O
,	O
spontaneously	O
hypertensive	B-Disease
rats	O
the	O
decrease	O
in	O
blood	O
pressure	O
and	O
heart	O
rate	O
produced	O
by	O
intravenous	O
clonidine	B-Chemical
,	O
5	O
to	O
20	O
micrograms	O
/	O
kg	O
,	O
was	O
inhibited	O
or	O
reversed	O
by	O
nalozone	B-Chemical
,	O
0	O
.	O
2	O
to	O
2	O
mg	O
/	O
kg	O
.	O
The	O
hypotensive	B-Disease
effect	O
of	O
100	O
mg	O
/	O
kg	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
was	O
also	O
partially	O
reversed	O
by	O
naloxone	B-Chemical
.	O
Naloxone	B-Chemical
alone	O
did	O
not	O
affect	O
either	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O
In	O
brain	O
membranes	O
from	O
spontaneously	O
hypertensive	B-Disease
rats	O
clonidine	B-Chemical
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
did	O
not	O
influence	O
stereoselective	O
binding	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
naloxone	I-Chemical
(	O
8	O
nM	O
)	O
,	O
and	O
naloxone	B-Chemical
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
4	O
)	O
M	O
,	O
did	O
not	O
influence	O
clonidine	B-Chemical
-	O
suppressible	O
binding	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
dihydroergocryptine	I-Chemical
(	O
1	O
nM	O
)	O
.	O
These	O
findings	O
indicate	O
that	O
in	O
spontaneously	O
hypertensive	B-Disease
rats	O
the	O
effects	O
of	O
central	O
alpha	O
-	O
adrenoceptor	O
stimulation	O
involve	O
activation	O
of	O
opiate	O
receptors	O
.	O
As	O
naloxone	B-Chemical
and	O
clonidine	B-Chemical
do	O
not	O
appear	O
to	O
interact	O
with	O
the	O
same	O
receptor	O
site	O
,	O
the	O
observed	O
functional	O
antagonism	O
suggests	O
the	O
release	O
of	O
an	O
endogenous	O
opiate	O
by	O
clonidine	B-Chemical
or	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
and	O
the	O
possible	O
role	O
of	O
the	O
opiate	O
in	O
the	O
central	O
control	O
of	O
sympathetic	O
tone	O
.	O
Neurotoxicity	B-Disease
of	O
halogenated	B-Chemical
hydroxyquinolines	I-Chemical
:	O
clinical	O
analysis	O
of	O
cases	O
reported	O
outside	O
Japan	O
.	O
An	O
analysis	O
is	O
presented	O
of	O
220	O
cases	O
of	O
possible	O
neurotoxic	B-Disease
reactions	O
to	O
halogenated	B-Chemical
hydroxyquinolines	I-Chemical
reported	O
from	O
outside	O
Japan	O
.	O
In	O
80	O
cases	O
insufficient	O
information	O
was	O
available	O
for	O
adequate	O
comment	O
and	O
in	O
29	O
a	O
relationship	O
to	O
the	O
administration	O
of	O
clioquinol	B-Chemical
could	O
be	O
excluded	O
.	O
Of	O
the	O
remainder	O
,	O
a	O
relationship	O
to	O
clioquinol	B-Chemical
was	O
considered	O
probable	O
in	O
42	O
and	O
possible	O
in	O
69	O
cases	O
.	O
In	O
six	O
of	O
the	O
probable	O
cases	O
the	O
neurological	B-Disease
disturbance	I-Disease
consisted	O
of	O
an	O
acute	O
reversible	O
encephalopathy	B-Disease
usually	O
related	O
to	O
the	O
ingestion	O
of	O
a	O
high	O
dose	O
of	O
clioquinol	B-Chemical
over	O
a	O
short	O
period	O
.	O
The	O
most	O
common	O
manifestation	O
,	O
observed	O
in	O
15	O
further	O
cases	O
,	O
was	O
isolated	O
optic	B-Disease
atrophy	I-Disease
.	O
This	O
was	O
most	O
frequently	O
found	O
in	O
children	O
,	O
many	O
of	O
whom	O
had	O
received	O
clioquinol	B-Chemical
as	O
treatment	O
for	O
acrodermatitis	B-Disease
enteropathica	I-Disease
.	O
In	O
the	O
remaining	O
cases	O
,	O
a	O
combination	O
of	O
myelopathy	B-Disease
,	O
visual	B-Disease
disturbance	I-Disease
,	O
and	O
peripheral	B-Disease
neuropathy	I-Disease
was	O
the	O
most	O
common	O
manifestation	O
.	O
Isolated	O
myelopathy	B-Disease
or	O
peripheral	B-Disease
neuropathy	I-Disease
,	O
or	O
these	O
manifestations	O
occurring	O
together	O
,	O
were	O
infrequent	O
.	O
The	O
onset	O
of	O
all	O
manifestations	O
(	O
except	O
toxic	O
encephalopathy	B-Disease
)	O
was	O
usually	O
subacute	O
,	O
with	O
subsequent	O
partial	O
recovery	O
.	O
Older	O
subjects	O
tended	O
to	O
display	O
more	O
side	O
effects	O
.	O
The	O
full	O
syndrome	O
of	O
subacute	O
myelo	B-Disease
-	I-Disease
optic	I-Disease
neuropathy	I-Disease
was	O
more	O
frequent	O
in	O
women	O
,	O
but	O
they	O
tended	O
to	O
have	O
taken	O
greater	O
quantities	O
of	O
the	O
drug	O
.	O
Prazosin	B-Chemical
-	O
induced	O
stress	B-Disease
incontinence	I-Disease
.	O
A	O
case	O
of	O
genuine	O
stress	B-Disease
incontinence	I-Disease
due	O
to	O
prazosin	B-Chemical
,	O
a	O
common	O
antihypertensive	O
drug	O
,	O
is	O
presented	O
.	O
Prazosin	B-Chemical
exerts	O
its	O
antihypertensive	O
effects	O
through	O
vasodilatation	O
caused	O
by	O
selective	O
blockade	O
of	O
postsynaptic	O
alpha	O
-	O
1	O
adrenergic	O
receptors	O
.	O
As	O
an	O
alpha	O
-	O
blocker	O
,	O
it	O
also	O
exerts	O
a	O
significant	O
relaxant	O
effect	O
on	O
the	O
bladder	O
neck	O
and	O
urethra	O
.	O
The	O
patient	O
'	O
s	O
clinical	O
course	O
is	O
described	O
and	O
correlated	O
with	O
initial	O
urodynamic	O
studies	O
while	O
on	O
prazosin	B-Chemical
and	O
subsequent	O
studies	O
while	O
taking	O
verapamil	B-Chemical
.	O
Her	O
incontinence	B-Disease
resolved	O
with	O
the	O
change	O
of	O
medication	O
.	O
The	O
restoration	O
of	O
continence	O
was	O
accompanied	O
by	O
a	O
substantial	O
rise	O
in	O
maximum	O
urethral	O
pressure	O
,	O
maximum	O
urethral	O
closure	O
pressure	O
,	O
and	O
functional	O
urethral	O
length	O
.	O
Patients	O
who	O
present	O
with	O
stress	B-Disease
incontinence	I-Disease
while	O
taking	O
prazosin	B-Chemical
should	O
change	O
their	O
antihypertensive	O
medication	O
before	O
considering	O
surgery	O
,	O
because	O
their	O
incontinence	B-Disease
may	O
resolve	O
spontaneously	O
with	O
a	O
change	O
in	O
drug	O
therapy	O
.	O
Myocardial	B-Disease
infarction	I-Disease
following	O
sublingual	O
administration	O
of	O
isosorbide	B-Chemical
dinitrate	I-Chemical
.	O
A	O
78	O
-	O
year	O
-	O
old	O
with	O
healed	O
septal	O
necrosis	B-Disease
suffered	O
a	O
recurrent	O
myocardial	B-Disease
infarction	I-Disease
of	O
the	O
anterior	O
wall	O
following	O
the	O
administration	O
of	O
isosorbide	B-Chemical
dinitrate	I-Chemical
5	O
mg	O
sublingually	O
.	O
After	O
detailing	O
the	O
course	O
of	O
events	O
,	O
we	O
discuss	O
the	O
role	O
of	O
paradoxical	O
coronary	O
spasm	B-Disease
and	O
hypotension	B-Disease
-	O
mediated	O
myocardial	B-Disease
ischemia	I-Disease
occurring	O
downstream	O
to	O
significant	O
coronary	B-Disease
arterial	I-Disease
stenosis	I-Disease
in	O
the	O
pathophysiology	O
of	O
acute	B-Disease
coronary	I-Disease
insufficiency	I-Disease
.	O
Comparison	O
of	O
the	O
respiratory	O
effects	O
of	O
i	O
.	O
v	O
.	O
infusions	O
of	O
morphine	B-Chemical
and	O
regional	O
analgesia	O
by	O
extradural	O
block	O
.	O
The	O
incidence	O
of	O
postoperative	O
respiratory	O
apnoea	B-Disease
was	O
compared	O
between	O
five	O
patients	O
receiving	O
a	O
continuous	O
i	O
.	O
v	O
.	O
infusion	O
of	O
morphine	B-Chemical
(	O
mean	O
73	O
.	O
6	O
mg	O
)	O
and	O
five	O
patients	O
receiving	O
a	O
continuous	O
extradural	O
infusion	O
of	O
0	O
.	O
25	O
%	O
bupivacaine	B-Chemical
(	O
mean	O
192	O
mg	O
)	O
in	O
the	O
24	O
-	O
h	O
period	O
following	O
upper	O
abdominal	O
surgery	O
.	O
Monitoring	O
consisted	O
of	O
airflow	O
detection	O
by	O
a	O
carbon	B-Chemical
dioxide	I-Chemical
analyser	O
,	O
chest	O
wall	O
movement	O
detected	O
by	O
pneumatic	O
capsules	O
,	O
and	O
continuous	O
electrocardiograph	O
recorded	O
with	O
a	O
Holter	O
ambulatory	O
monitor	O
.	O
Both	O
obstructive	B-Disease
(	I-Disease
P	I-Disease
less	I-Disease
than	I-Disease
0	I-Disease
.	I-Disease
05	I-Disease
)	I-Disease
and	I-Disease
central	I-Disease
apnoea	I-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
occurred	O
more	O
frequently	O
in	O
patients	O
who	O
had	O
a	O
morphine	B-Chemical
infusion	O
.	O
There	O
was	O
also	O
a	O
higher	O
incidence	O
of	O
tachyarrhythmias	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
ventricular	B-Disease
ectopic	I-Disease
beats	I-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
the	O
morphine	B-Chemical
infusion	O
group	O
.	O
Effects	O
of	O
aminophylline	B-Chemical
on	O
the	O
threshold	O
for	O
initiating	O
ventricular	B-Disease
fibrillation	I-Disease
during	O
respiratory	B-Disease
failure	I-Disease
.	O
Cardiac	B-Disease
arrhythmias	I-Disease
have	O
frequently	O
been	O
reported	O
in	O
association	O
with	O
respiratory	B-Disease
failure	I-Disease
.	O
The	O
possible	O
additive	O
role	O
of	O
pharmacologic	O
agents	O
in	O
precipitating	O
cardiac	B-Disease
disturbances	I-Disease
in	O
patients	O
with	O
respiratory	B-Disease
failure	I-Disease
has	O
only	O
recently	O
been	O
emphasized	O
.	O
The	O
effects	O
of	O
aminophylline	B-Chemical
on	O
the	O
ventricular	B-Disease
fibrillation	I-Disease
threshold	O
during	O
normal	O
acid	O
-	O
base	O
conditions	O
and	O
during	O
respiratory	B-Disease
failure	I-Disease
were	O
studied	O
in	O
anesthetized	O
open	O
chest	O
dogs	O
.	O
The	O
ventricular	B-Disease
fibrillation	I-Disease
threshold	O
was	O
measured	O
by	O
passing	O
a	O
gated	O
train	O
of	O
12	O
constant	O
current	O
pulses	O
through	O
the	O
ventricular	O
myocardium	O
during	O
the	O
vulnerable	O
period	O
of	O
the	O
cardiac	O
cycle	O
.	O
During	O
the	O
infusion	O
of	O
aminophylline	B-Chemical
,	O
the	O
ventricular	B-Disease
fibrillation	I-Disease
threshold	O
was	O
reduced	O
by	O
30	O
to	O
40	O
percent	O
of	O
the	O
control	O
when	O
pH	O
and	O
partial	O
pressures	O
of	O
oxygen	B-Chemical
(	O
PO2	B-Chemical
)	O
and	O
carbon	B-Chemical
dioxide	I-Chemical
(	O
CO2	B-Chemical
)	O
were	O
kept	O
within	O
normal	O
limits	O
.	O
When	O
respiratory	B-Disease
failure	I-Disease
was	O
produced	O
by	O
hypoventilation	B-Disease
(	O
pH	O
7	O
.	O
05	O
to	O
7	O
.	O
25	O
;	O
PC02	O
70	O
to	O
100	O
mm	O
Hg	O
:	O
P02	O
20	O
to	O
40	O
mm	O
Hg	O
)	O
,	O
infusion	O
of	O
aminophylline	B-Chemical
resulted	O
in	O
an	O
even	O
greater	O
decrease	O
in	O
ventricular	B-Disease
fibrillation	I-Disease
threshold	O
to	O
60	O
percent	O
of	O
the	O
control	O
level	O
.	O
These	O
experiments	O
suggest	O
that	O
although	O
many	O
factors	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
ventricular	B-Disease
arrhythmias	I-Disease
in	O
respiratory	B-Disease
failure	I-Disease
,	O
pharmacologic	O
agents	O
,	O
particularly	O
aminophylline	B-Chemical
,	O
may	O
play	O
a	O
significant	O
role	O
.	O
Pentoxifylline	B-Chemical
(	O
Trental	B-Chemical
)	O
does	O
not	O
inhibit	O
dipyridamole	B-Chemical
-	O
induced	O
coronary	O
hyperemia	B-Disease
:	O
implications	O
for	O
dipyridamole	B-Chemical
-	O
thallium	B-Chemical
-	O
201	O
myocardial	O
imaging	O
.	O
Dipyridamole	B-Chemical
-	O
thallium	B-Chemical
-	O
201	O
imaging	O
is	O
often	O
performed	O
in	O
patients	O
unable	O
to	O
exercise	O
because	O
of	O
peripheral	B-Disease
vascular	I-Disease
disease	I-Disease
.	O
Many	O
of	O
these	O
patients	O
are	O
taking	O
pentoxifylline	B-Chemical
(	O
Trental	B-Chemical
)	O
,	O
a	O
methylxanthine	B-Chemical
derivative	O
which	O
may	O
improve	O
intermittent	B-Disease
claudication	I-Disease
.	O
Whether	O
pentoxifylline	B-Chemical
inhibits	O
dipyridamole	B-Chemical
-	O
induced	O
coronary	O
hyperemia	B-Disease
like	O
other	O
methylxanthines	B-Chemical
such	O
as	O
theophylline	B-Chemical
and	O
should	O
be	O
stopped	O
prior	O
to	O
dipyridamole	B-Chemical
-	O
thallium	B-Chemical
-	O
201	O
imaging	O
is	O
unknown	O
.	O
Therefore	O
,	O
we	O
studied	O
the	O
hyperemic	O
response	O
to	O
dipyridamole	B-Chemical
in	O
seven	O
open	O
-	O
chest	O
anesthetized	O
dogs	O
after	O
pretreatment	O
with	O
either	O
pentoxifylline	B-Chemical
(	O
0	O
,	O
7	O
.	O
5	O
,	O
or	O
15	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
or	O
theophylline	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
.	O
Baseline	O
circumflex	O
coronary	O
blood	O
flows	O
did	O
not	O
differ	O
significantly	O
among	O
treatment	O
groups	O
.	O
Dipyridamole	B-Chemical
significantly	O
increased	O
coronary	O
blood	O
flow	O
before	O
and	O
after	O
7	O
.	O
5	O
or	O
15	O
mm	O
/	O
kg	O
i	O
.	O
v	O
.	O
pentoxifylline	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
002	O
)	O
.	O
Neither	O
dose	O
of	O
pentoxifylline	B-Chemical
significantly	O
decreased	O
the	O
dipyridamole	B-Chemical
-	O
induced	O
hyperemia	B-Disease
,	O
while	O
peak	O
coronary	O
blood	O
flow	O
was	O
significantly	O
lower	O
after	O
theophylline	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
We	O
conclude	O
that	O
pentoxyifylline	B-Chemical
does	O
not	O
inhibit	O
dipyridamole	B-Chemical
-	O
induced	O
coronary	O
hyperemia	B-Disease
even	O
at	O
high	O
doses	O
.	O
Cause	O
of	O
death	B-Disease
among	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
:	O
a	O
rare	O
mortality	O
due	O
to	O
cerebral	B-Disease
haemorrhage	I-Disease
.	O
Causes	O
of	O
death	B-Disease
,	O
with	O
special	O
reference	O
to	O
cerebral	B-Disease
haemorrhage	I-Disease
,	O
among	O
240	O
patients	O
with	O
pathologically	O
verified	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
were	O
investigated	O
using	O
the	O
Annuals	O
of	O
the	O
Pathological	O
Autopsy	O
Cases	O
in	O
Japan	O
from	O
1981	O
to	O
1985	O
.	O
The	O
leading	O
causes	O
of	O
death	B-Disease
were	O
pneumonia	B-Disease
and	O
bronchitis	B-Disease
(	O
44	O
.	O
1	O
%	O
)	O
,	O
malignant	O
neoplasms	B-Disease
(	O
11	O
.	O
6	O
%	O
)	O
,	O
heart	B-Disease
diseases	I-Disease
(	O
4	O
.	O
1	O
%	O
)	O
,	O
cerebral	B-Disease
infarction	I-Disease
(	O
3	O
.	O
7	O
%	O
)	O
and	O
septicaemia	B-Disease
(	O
3	O
.	O
3	O
%	O
)	O
.	O
Cerebral	B-Disease
haemorrhage	I-Disease
was	O
the	O
11th	O
most	O
frequent	O
cause	O
of	O
death	B-Disease
,	O
accounting	O
for	O
only	O
0	O
.	O
8	O
%	O
of	O
deaths	B-Disease
among	O
the	O
patients	O
,	O
whereas	O
it	O
was	O
the	O
5th	O
most	O
common	O
cause	O
of	O
death	B-Disease
among	O
the	O
Japanese	O
general	O
population	O
in	O
1985	O
.	O
The	O
low	O
incidence	O
of	O
cerebral	B-Disease
haemorrhage	I-Disease
as	O
a	O
cause	O
of	O
death	B-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
may	O
reflect	O
the	O
hypotensive	B-Disease
effect	O
of	O
levodopa	B-Chemical
and	O
a	O
hypotensive	B-Disease
mechanism	O
due	O
to	O
reduced	O
noradrenaline	B-Chemical
levels	O
in	O
the	O
parkinsonian	B-Disease
brain	O
.	O
Possible	O
intramuscular	O
midazolam	B-Chemical
-	O
associated	O
cardiorespiratory	B-Disease
arrest	I-Disease
and	O
death	B-Disease
.	O
Midazolam	B-Chemical
hydrochloride	I-Chemical
is	O
commonly	O
used	O
for	O
dental	O
or	O
endoscopic	O
procedures	O
.	O
Although	O
generally	O
consisted	O
safe	O
when	O
given	O
intramuscularly	O
,	O
intravenous	O
administration	O
is	O
known	O
to	O
cause	O
respiratory	B-Disease
and	I-Disease
cardiovascular	I-Disease
depression	I-Disease
.	O
This	O
report	O
describes	O
the	O
first	O
published	O
case	O
of	O
cardiorespiratory	B-Disease
arrest	I-Disease
and	O
death	B-Disease
associated	O
with	O
intramuscular	O
administration	O
of	O
midazolam	B-Chemical
.	O
Information	O
regarding	O
midazolam	B-Chemical
use	O
is	O
reviewed	O
to	O
provide	O
recommendation	O
for	O
safe	O
administration	O
.	O
Myasthenia	B-Disease
gravis	I-Disease
presenting	O
as	O
weakness	O
after	O
magnesium	B-Chemical
administration	O
.	O
We	O
studied	O
a	O
patient	O
with	O
no	O
prior	O
history	O
of	O
neuromuscular	B-Disease
disease	I-Disease
who	O
became	O
virtually	O
quadriplegic	B-Disease
after	O
parenteral	O
magnesium	B-Chemical
administration	O
for	O
preeclampsia	B-Disease
.	O
The	O
serum	O
magnesium	B-Chemical
concentration	O
was	O
3	O
.	O
0	O
mEq	O
/	O
L	O
,	O
which	O
is	O
usually	O
well	O
tolerated	O
.	O
The	O
magnesium	B-Chemical
was	O
stopped	O
and	O
she	O
recovered	O
over	O
a	O
few	O
days	O
.	O
While	O
she	O
was	O
weak	O
,	O
2	O
-	O
Hz	O
repetitive	O
stimulation	O
revealed	O
a	O
decrement	O
without	O
significant	O
facilitation	O
at	O
rapid	O
rates	O
or	O
after	O
exercise	O
,	O
suggesting	O
postsynaptic	B-Disease
neuromuscular	I-Disease
blockade	I-Disease
.	O
After	O
her	O
strength	O
returned	O
,	O
repetitive	O
stimulation	O
was	O
normal	O
,	O
but	O
single	O
fiber	O
EMG	O
revealed	O
increased	O
jitter	O
and	O
blocking	O
.	O
Her	O
acetylcholine	B-Chemical
receptor	O
antibody	O
level	O
was	O
markedly	O
elevated	O
.	O
Although	O
paralysis	B-Disease
after	O
magnesium	B-Chemical
administration	O
has	O
been	O
described	O
in	O
patients	O
with	O
known	O
myasthenia	B-Disease
gravis	I-Disease
,	O
it	O
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
the	O
initial	O
or	O
only	O
manifestation	O
of	O
the	O
disease	O
.	O
Patients	O
who	O
are	O
unusually	O
sensitive	O
to	O
the	O
neuromuscular	O
effects	O
of	O
magnesium	B-Chemical
should	O
be	O
suspected	O
of	O
having	O
an	O
underlying	O
disorder	B-Disease
of	I-Disease
neuromuscular	I-Disease
transmission	I-Disease
.	O
No	O
enhancement	O
by	O
phenobarbital	B-Chemical
of	O
the	O
hepatocarcinogenicity	O
of	O
a	O
choline	B-Chemical
-	O
devoid	O
diet	O
in	O
the	O
rat	O
.	O
An	O
experiment	O
was	O
performed	O
to	O
test	O
whether	O
inclusion	O
of	O
phenobarbital	B-Chemical
in	O
a	O
choline	B-Chemical
-	O
devoid	O
diet	O
would	O
increase	O
the	O
hepatocarcinogenicity	O
of	O
the	O
diet	O
.	O
Groups	O
of	O
5	O
-	O
week	O
old	O
male	O
Fischer	O
-	O
344	O
rats	O
were	O
fed	O
for	O
7	O
-	O
25	O
months	O
semipurified	O
choline	B-Chemical
-	O
devoid	O
or	O
choline	B-Chemical
-	O
supplemented	O
diets	O
,	O
containing	O
or	O
not	O
0	O
.	O
06	O
%	O
phenobarbital	B-Chemical
.	O
No	O
hepatic	O
preneoplastic	O
nodules	O
or	O
hepatocellular	B-Disease
carcinomas	I-Disease
developed	O
in	O
rats	O
fed	O
the	O
plain	O
choline	B-Chemical
-	O
supplemented	O
diet	O
,	O
while	O
one	O
preneoplastic	O
nodule	O
and	O
one	O
hepatocellular	B-Disease
carcinoma	I-Disease
developed	O
in	O
two	O
rats	O
fed	O
the	O
same	O
diet	O
containing	O
phenobarbital	B-Chemical
.	O
The	O
incidence	O
of	O
preneoplastic	O
nodules	O
and	O
of	O
hepatocellular	B-Disease
carcinomas	I-Disease
was	O
10	O
%	O
and	O
37	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
fed	O
the	O
plain	O
choline	B-Chemical
-	O
devoid	O
diet	O
,	O
and	O
17	O
%	O
and	O
30	O
%	O
,	O
in	O
rats	O
fed	O
the	O
phenobarbital	B-Chemical
-	O
containing	O
choline	B-Chemical
-	O
devoid	O
diet	O
.	O
The	O
results	O
evinced	O
no	O
enhancement	O
of	O
the	O
hepatocarcinogenicity	O
of	O
the	O
choline	B-Chemical
-	O
devoid	O
diet	O
by	O
phenobarbital	B-Chemical
.	O
Sporadic	O
neoplastic	O
lesions	O
were	O
observed	O
in	O
organs	O
other	O
than	O
the	O
liver	O
of	O
some	O
of	O
the	O
animals	O
,	O
irrespective	O
of	O
the	O
diet	O
fed	O
.	O
On	O
two	O
paradoxical	O
side	O
-	O
effects	O
of	O
prednisolone	B-Chemical
in	O
rats	O
,	O
ribosomal	O
RNA	O
biosyntheses	O
,	O
and	O
a	O
mechanism	O
of	O
action	O
.	O
Liver	B-Disease
enlargement	I-Disease
and	O
muscle	B-Disease
wastage	I-Disease
occurred	O
in	O
Wistar	O
rats	O
following	O
the	O
subcutaneous	O
administration	O
of	O
prednisolone	B-Chemical
.	O
In	O
the	O
liver	O
both	O
the	O
content	O
of	O
RNA	O
and	O
the	O
biosynthesis	O
of	O
ribosomal	O
RNA	O
increased	O
while	O
both	O
the	O
RNA	O
content	O
and	O
ribosomal	O
RNA	O
biosynthesis	O
were	O
reduced	O
in	O
the	O
gastrocnemius	O
muscle	O
.	O
It	O
is	O
suggested	O
that	O
the	O
drug	O
acted	O
in	O
a	O
selective	O
and	O
tissue	O
-	O
specific	O
manner	O
to	O
enhance	O
ribosomal	O
RNA	O
synthesis	O
in	O
the	O
liver	O
and	O
depress	O
such	O
synthesis	O
in	O
the	O
muscle	O
.	O
This	O
view	O
supports	O
the	O
contention	O
that	O
the	O
liver	O
and	O
muscle	O
are	O
independent	O
sites	O
of	O
prednisolone	B-Chemical
action	O
.	O
Differential	O
effects	O
of	O
gamma	B-Chemical
-	I-Chemical
hexachlorocyclohexane	I-Chemical
(	O
lindane	B-Chemical
)	O
on	O
pharmacologically	O
-	O
induced	O
seizures	B-Disease
.	O
Gamma	B-Chemical
-	I-Chemical
hexachlorocyclohexane	I-Chemical
(	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
)	O
,	O
the	O
active	O
ingredient	O
of	O
the	O
insecticide	O
lindane	B-Chemical
,	O
has	O
been	O
shown	O
to	O
decrease	O
seizure	B-Disease
threshold	O
to	O
pentylenetrazol	O
(	O
PTZ	B-Chemical
)	O
3	O
h	O
after	O
exposure	O
to	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
and	O
conversely	O
increase	O
threshold	O
to	O
PTZ	B-Chemical
-	O
induced	O
seizures	B-Disease
24	O
h	O
after	O
exposure	O
to	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
(	O
Vohland	O
et	O
al	O
.	O
1981	O
)	O
.	O
In	O
this	O
study	O
,	O
the	O
severity	O
of	O
response	O
to	O
other	O
seizure	B-Disease
-	O
inducing	O
agents	O
was	O
tested	O
in	O
mice	O
1	O
and	O
24	O
h	O
after	O
intraperitoneal	O
administration	O
of	O
80	O
mg	O
/	O
kg	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
.	O
One	O
hour	O
after	O
the	O
administration	O
of	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
the	O
activity	O
of	O
seizure	B-Disease
-	O
inducing	O
agents	O
was	O
increased	O
,	O
regardless	O
of	O
their	O
mechanism	O
,	O
while	O
24	O
h	O
after	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
a	O
differential	O
response	O
was	O
observed	O
.	O
Seizure	B-Disease
activity	O
due	O
to	O
PTZ	B-Chemical
and	O
picrotoxin	B-Chemical
(	O
PTX	B-Chemical
)	O
was	O
significantly	O
decreased	O
;	O
however	O
,	O
seizure	B-Disease
activity	O
due	O
to	O
3	B-Chemical
-	I-Chemical
mercaptopropionic	I-Chemical
acid	I-Chemical
(	O
MPA	B-Chemical
)	O
,	O
bicuculline	B-Chemical
(	O
BCC	B-Chemical
)	O
,	O
methyl	B-Chemical
6	I-Chemical
,	I-Chemical
7	I-Chemical
-	I-Chemical
dimethoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
ethyl	I-Chemical
-	I-Chemical
B	I-Chemical
-	I-Chemical
carboline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
DMCM	B-Chemical
)	O
,	O
or	O
strychnine	B-Chemical
(	O
STR	B-Chemical
)	O
was	O
not	O
different	O
from	O
control	O
.	O
In	O
vitro	O
,	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
pentylenetetrazol	B-Chemical
and	O
picrotoxin	B-Chemical
were	O
shown	O
to	O
inhibit	O
3H	B-Chemical
-	I-Chemical
TBOB	I-Chemical
binding	O
in	O
mouse	O
whole	O
brain	O
,	O
with	O
IC50	O
values	O
of	O
4	O
.	O
6	O
,	O
404	O
and	O
9	O
.	O
4	O
microM	O
,	O
respectively	O
.	O
MPA	B-Chemical
,	O
BCC	B-Chemical
,	O
DMCM	B-Chemical
,	O
and	O
STR	B-Chemical
showed	O
no	O
inhibition	O
of	O
3H	B-Chemical
-	I-Chemical
TBOB	I-Chemical
(	O
t	B-Chemical
-	I-Chemical
butyl	I-Chemical
bicyclo	I-Chemical
-	I-Chemical
orthobenzoate	I-Chemical
)	O
binding	O
at	O
concentrations	O
of	O
100	O
micron	O
.	O
The	O
pharmacological	O
challenge	O
data	O
suggest	O
that	O
tolerance	O
may	O
occur	O
to	O
seizure	B-Disease
activity	O
induced	O
by	O
PTZ	B-Chemical
and	O
PTX	B-Chemical
24	O
h	O
after	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
since	O
the	O
response	O
to	O
only	O
these	O
two	O
seizure	B-Disease
-	O
inducing	O
agents	O
is	O
decreased	O
.	O
The	O
in	O
vitro	O
data	O
suggest	O
that	O
the	O
site	O
responsible	O
for	O
the	O
decrease	O
in	O
seizure	B-Disease
activity	O
24	O
h	O
after	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
may	O
be	O
the	O
GABA	B-Chemical
-	O
A	O
receptor	O
-	O
linked	O
chloride	O
channel	O
.	O
Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	B-Chemical
in	O
patients	O
with	O
Argentine	B-Disease
hemorrhagic	I-Disease
fever	I-Disease
.	O
Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	B-Chemical
was	O
studied	O
in	O
6	O
patients	O
with	O
Argentine	B-Disease
hemorrhagic	I-Disease
fever	I-Disease
(	O
AHF	B-Disease
)	O
of	O
more	O
than	O
8	O
days	O
of	O
evolution	O
.	O
Administration	O
of	O
ribavirin	B-Chemical
resulted	O
in	O
a	O
neutralization	O
of	O
viremia	B-Disease
and	O
a	O
drop	O
of	O
endogenous	O
interferon	O
titers	O
.	O
The	O
average	O
time	O
of	O
death	B-Disease
was	O
delayed	O
.	O
A	O
reversible	O
anemia	B-Disease
was	O
the	O
only	O
adverse	O
effect	O
observed	O
.	O
From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
ribavirin	B-Chemical
has	O
an	O
antiviral	O
effect	O
in	O
advanced	O
cases	O
of	O
AHF	B-Disease
,	O
and	O
that	O
anemia	B-Disease
,	O
the	O
only	O
secondary	O
reaction	O
observed	O
,	O
can	O
be	O
easily	O
managed	O
.	O
The	O
possible	O
beneficial	O
effect	O
of	O
ribavirin	B-Chemical
during	O
the	O
initial	O
days	O
of	O
AHF	B-Disease
is	O
discussed	O
.	O
Is	O
the	O
treatment	O
of	O
scabies	B-Disease
hazardous	O
?	O
Treatment	O
for	O
scabies	B-Disease
is	O
usually	O
initiated	O
by	O
general	O
practitioners	O
;	O
most	O
consider	O
lindane	B-Chemical
(	O
gamma	B-Chemical
benzene	I-Chemical
hexachloride	I-Chemical
)	O
the	O
treatment	O
of	O
choice	O
.	O
Lindane	B-Chemical
is	O
also	O
widely	O
used	O
as	O
an	O
agricultural	O
and	O
industrial	O
pesticide	O
,	O
and	O
as	O
a	O
result	O
the	O
toxic	O
profile	O
of	O
this	O
insecticide	O
is	O
well	O
understood	O
.	O
Evidence	O
is	O
accumulating	O
that	O
lindane	B-Chemical
can	O
be	O
toxic	B-Disease
to	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
and	O
may	O
be	O
associated	O
with	O
aplastic	B-Disease
anaemia	I-Disease
.	O
Preparations	O
containing	O
lindane	B-Chemical
continue	O
to	O
be	O
sold	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
hazard	O
to	O
poorly	O
informed	O
patients	O
.	O
This	O
literature	O
review	O
suggests	O
that	O
general	O
practitioners	O
should	O
prescribe	O
scabicides	O
with	O
increased	O
caution	O
for	O
certain	O
at	O
-	O
risk	O
groups	O
,	O
and	O
give	O
adequate	O
warnings	O
regarding	O
potential	O
toxicity	B-Disease
.	O
Mouse	O
strain	O
-	O
dependent	O
effect	O
of	O
amantadine	B-Chemical
on	O
motility	O
and	O
brain	O
biogenic	O
amines	B-Chemical
.	O
The	O
effect	O
of	O
amantadine	B-Chemical
hydrochloride	I-Chemical
,	O
injected	O
i	O
.	O
p	O
.	O
in	O
6	O
increments	O
of	O
100	O
mg	O
/	O
kg	O
each	O
over	O
30	O
hr	O
,	O
on	O
mouse	O
motility	O
and	O
whole	O
brain	O
content	O
of	O
selected	O
biogenic	O
amines	B-Chemical
and	O
major	O
metabolites	O
was	O
studied	O
in	O
4	O
strains	O
of	O
mice	O
.	O
These	O
were	O
the	O
albino	O
Sprague	O
-	O
Dawley	O
ICR	O
and	O
BALB	O
/	O
C	O
,	O
the	O
black	O
C57BL	O
/	O
6	O
and	O
the	O
brown	O
CDF	O
-	O
I	O
mouse	O
strains	O
.	O
Amantadine	B-Chemical
treatment	O
produced	O
a	O
biphasic	O
effect	O
on	O
mouse	O
motility	O
.	O
The	O
initial	O
dose	O
of	O
amantadine	B-Chemical
depressed	B-Disease
locomotor	O
activity	O
in	O
all	O
mouse	O
strains	O
studied	O
with	O
the	O
BALB	O
/	O
C	O
mice	O
being	O
the	O
most	O
sensitive	O
.	O
Subsequent	O
amantadine	B-Chemical
treatments	O
produced	O
enhancement	O
of	O
motility	O
from	O
corresponding	O
control	O
in	O
all	O
mouse	O
strains	O
with	O
the	O
BALB	O
/	O
C	O
mice	O
being	O
the	O
least	O
sensitive	O
.	O
The	O
locomotor	O
activity	O
was	O
decreased	O
from	O
corresponding	O
controls	O
in	O
all	O
strains	O
studied	O
,	O
except	O
for	O
the	O
ICR	O
mice	O
,	O
during	O
an	O
overnight	O
drug	O
-	O
free	O
period	O
following	O
the	O
fourth	O
amantadine	B-Chemical
treatment	O
.	O
Readministration	O
of	O
amantadine	B-Chemical
,	O
after	O
a	O
drug	O
-	O
free	O
overnight	O
period	O
,	O
increased	O
motility	O
from	O
respective	O
saline	O
control	O
in	O
all	O
strains	O
with	O
exception	O
of	O
the	O
BALB	O
/	O
C	O
mice	O
where	O
suppression	B-Disease
of	I-Disease
motility	I-Disease
occurred	O
.	O
Treatment	O
with	O
amantadine	B-Chemical
did	O
not	O
alter	O
whole	O
brain	O
dopamine	B-Chemical
levels	O
but	O
decreased	O
the	O
amounts	O
of	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylacetic	I-Chemical
acid	I-Chemical
in	O
the	O
BALB	O
/	O
C	O
mice	O
compared	O
to	O
saline	O
control	O
.	O
Conversely	O
,	O
brain	O
normetanephrine	B-Chemical
concentration	O
was	O
increased	O
from	O
saline	O
control	O
by	O
amantadine	B-Chemical
in	O
the	O
BALB	O
/	O
C	O
mice	O
.	O
The	O
results	O
suggest	O
a	O
strain	O
-	O
dependent	O
effect	O
of	O
amantadine	B-Chemical
on	O
motility	O
and	O
indicate	O
a	O
differential	O
response	O
to	O
the	O
acute	O
and	O
multiple	O
dose	O
regimens	O
used	O
.	O
The	O
BALB	O
/	O
C	O
mouse	O
was	O
the	O
most	O
sensitive	O
strain	O
and	O
could	O
serve	O
as	O
the	O
strain	O
of	O
choice	O
for	O
evaluating	O
the	O
side	O
effects	O
of	O
amantadine	B-Chemical
.	O
The	O
biochemical	O
results	O
of	O
brain	O
biogenic	O
amines	B-Chemical
of	O
BALB	O
/	O
C	O
mouse	O
strain	O
suggest	O
a	O
probable	O
decrease	O
of	O
catecholamine	B-Chemical
turnover	O
rate	O
and	O
/	O
or	O
metabolism	O
by	O
monoamine	O
oxidase	O
and	O
a	O
resulting	O
increase	O
in	O
O	O
-	O
methylation	O
of	O
norepinephrine	B-Chemical
which	O
may	O
account	O
for	O
a	O
behavioral	B-Disease
depression	I-Disease
caused	O
by	O
amantadine	B-Chemical
in	O
the	O
BALB	O
/	O
C	O
mice	O
.	O
Chloroacetaldehyde	B-Chemical
and	O
its	O
contribution	O
to	O
urotoxicity	O
during	O
treatment	O
with	O
cyclophosphamide	B-Chemical
or	O
ifosfamide	B-Chemical
.	O
An	O
experimental	O
study	O
/	O
short	O
communication	O
.	O
Based	O
on	O
clinical	O
data	O
,	O
indicating	O
that	O
chloroacetaldehyde	B-Chemical
(	O
CAA	B-Chemical
)	O
is	O
an	O
important	O
metabolite	O
of	O
oxazaphosphorine	O
cytostatics	O
,	O
an	O
experimental	O
study	O
was	O
carried	O
out	O
in	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
CAA	B-Chemical
in	O
the	O
development	O
of	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O
The	O
data	O
demonstrate	O
that	O
CAA	B-Chemical
after	O
i	O
.	O
v	O
.	O
administration	O
does	O
not	O
contribute	O
to	O
bladder	B-Disease
damage	I-Disease
.	O
When	O
instilled	O
directly	O
into	O
the	O
bladder	O
,	O
CAA	B-Chemical
exerts	O
urotoxic	O
effects	O
,	O
it	O
is	O
,	O
however	O
,	O
susceptible	O
to	O
detoxification	O
with	O
mesna	B-Chemical
.	O
Source	O
of	O
pain	B-Disease
and	O
primitive	O
dysfunction	O
in	O
migraine	B-Disease
:	O
an	O
identical	O
site	O
?	O
Twenty	O
common	O
migraine	B-Disease
patients	O
received	O
a	O
one	O
sided	O
frontotemporal	O
application	O
of	O
nitroglycerin	B-Chemical
(	O
10	O
patients	O
)	O
or	O
placebo	O
ointment	O
(	O
10	O
patients	O
)	O
in	O
a	O
double	O
blind	O
study	O
.	O
Early	O
onset	O
migraine	B-Disease
attacks	O
were	O
induced	O
by	O
nitroglycerin	B-Chemical
in	O
seven	O
out	O
of	O
10	O
patients	O
versus	O
no	O
patient	O
in	O
the	O
placebo	O
group	O
.	O
Subsequently	O
20	O
migraine	B-Disease
patients	O
,	O
who	O
developed	O
an	O
early	O
onset	O
attack	O
with	O
frontotemporal	O
nitroglycerin	B-Chemical
,	O
received	O
the	O
drug	O
in	O
a	O
second	O
induction	O
test	O
at	O
other	O
body	O
areas	O
.	O
No	O
early	O
onset	O
migraine	B-Disease
was	O
observed	O
.	O
Thus	O
the	O
migraine	B-Disease
-	O
inducing	O
effect	O
of	O
nitroglycerin	B-Chemical
seems	O
to	O
depend	O
on	O
direct	O
stimulation	O
of	O
the	O
habitual	O
site	O
of	O
pain	B-Disease
,	O
suggesting	O
that	O
the	O
frontotemporal	O
region	O
is	O
of	O
crucial	O
importance	O
in	O
the	O
development	O
of	O
a	O
migraine	B-Disease
crisis	O
.	O
This	O
is	O
not	O
consistent	O
with	O
a	O
CNS	O
origin	O
of	O
migraine	B-Disease
attack	O
.	O
Hypersensitivity	B-Disease
to	O
carbamazepine	B-Chemical
presenting	O
with	O
a	O
leukemoid	B-Disease
reaction	I-Disease
,	O
eosinophilia	B-Disease
,	O
erythroderma	B-Disease
,	O
and	O
renal	B-Disease
failure	I-Disease
.	O
We	O
report	O
a	O
patient	O
in	O
whom	O
hypersensitivity	B-Disease
to	O
carbamazepine	B-Chemical
presented	O
with	O
generalized	O
erythroderma	B-Disease
,	O
a	O
severe	O
leukemoid	B-Disease
reaction	I-Disease
,	O
eosinophilia	B-Disease
,	O
hyponatremia	B-Disease
,	O
and	O
renal	B-Disease
failure	I-Disease
.	O
This	O
is	O
the	O
first	O
report	O
of	O
such	O
an	O
unusual	O
reaction	O
to	O
carbamazepine	B-Chemical
.	O
Fluoxetine	B-Chemical
-	O
induced	O
akathisia	B-Disease
:	O
clinical	O
and	O
theoretical	O
implications	O
.	O
Five	O
patients	O
receiving	O
fluoxetine	B-Chemical
for	O
the	O
treatment	O
of	O
obsessive	B-Disease
compulsive	I-Disease
disorder	I-Disease
or	O
major	B-Disease
depression	I-Disease
developed	O
akathisia	B-Disease
.	O
The	O
typical	O
fluoxetine	B-Chemical
-	O
induced	O
symptoms	O
of	O
restlessness	O
,	O
constant	O
pacing	O
,	O
purposeless	O
movements	O
of	O
the	O
feet	O
and	O
legs	O
,	O
and	O
marked	O
anxiety	B-Disease
were	O
indistinguishable	O
from	O
those	O
of	O
neuroleptic	O
-	O
induced	O
akathisia	B-Disease
.	O
Three	O
patients	O
who	O
had	O
experienced	O
neuroleptic	O
-	O
induced	O
akathisia	B-Disease
in	O
the	O
past	O
reported	O
that	O
the	O
symptoms	O
of	O
fluoxetine	B-Chemical
-	O
induced	O
akathisia	B-Disease
were	O
identical	O
,	O
although	O
somewhat	O
milder	O
.	O
Akathisia	B-Disease
appeared	O
to	O
be	O
a	O
common	O
side	O
effect	O
of	O
fluoxetine	B-Chemical
and	O
generally	O
responded	O
well	O
to	O
treatment	O
with	O
the	O
beta	O
-	O
adrenergic	O
antagonist	O
propranolol	B-Chemical
,	O
dose	O
reduction	O
,	O
or	O
both	O
.	O
The	O
authors	O
suggest	O
that	O
fluoxetine	B-Chemical
-	O
induced	O
akathisia	B-Disease
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibition	O
of	O
dopaminergic	O
neurotransmission	O
and	O
that	O
the	O
pathophysiology	O
of	O
fluoxetine	B-Chemical
-	O
induced	O
akathisia	B-Disease
and	O
tricyclic	O
antidepressant	B-Chemical
-	O
induced	O
""""	O
jitteriness	O
""""	O
may	O
be	O
identical	O
.	O
Effect	O
of	O
converting	O
enzyme	O
inhibition	O
on	O
the	O
course	O
of	O
adriamycin	B-Chemical
-	O
induced	O
nephropathy	B-Disease
.	O
The	O
effect	O
of	O
the	O
converting	O
enzyme	O
inhibitor	O
(	O
CEI	O
)	O
enalapril	B-Chemical
was	O
assessed	O
in	O
Munich	O
-	O
Wistar	O
rats	O
with	O
established	O
adriamycin	B-Chemical
nephrosis	B-Disease
.	O
Rats	O
were	O
given	O
a	O
single	O
dose	O
of	O
adriamycin	B-Chemical
and	O
one	O
month	O
later	O
divided	O
into	O
four	O
groups	O
matched	O
for	O
albuminuria	B-Disease
,	O
blood	O
pressure	O
,	O
and	O
plasma	O
albumin	O
concentration	O
.	O
Groups	O
1	O
and	O
3	O
remained	O
untreated	O
while	O
groups	O
2	O
and	O
4	O
received	O
enalapril	B-Chemical
.	O
Groups	O
1	O
and	O
2	O
underwent	O
micropuncture	O
studies	O
after	O
10	O
days	O
.	O
These	O
short	O
-	O
term	O
studies	O
showed	O
that	O
enalapril	B-Chemical
reduced	O
arterial	O
blood	O
pressure	O
(	O
101	O
+	O
/	O
-	O
2	O
vs	O
.	O
124	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
group	O
2	O
vs	O
.	O
1	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
glomerular	O
capillary	O
pressure	O
(	O
54	O
+	O
/	O
-	O
1	O
vs	O
.	O
61	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
without	O
reducing	O
albuminuria	B-Disease
(	O
617	O
+	O
/	O
-	O
50	O
vs	O
.	O
570	O
+	O
/	O
-	O
47	O
mg	O
/	O
day	O
)	O
or	O
GFR	O
(	O
1	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
04	O
vs	O
.	O
1	O
.	O
04	O
+	O
/	O
-	O
0	O
.	O
11	O
ml	O
/	O
min	O
)	O
.	O
Groups	O
3	O
and	O
4	O
were	O
studied	O
at	O
four	O
and	O
at	O
six	O
months	O
to	O
assess	O
the	O
effect	O
of	O
enalapril	B-Chemical
on	O
progression	O
of	O
renal	B-Disease
injury	I-Disease
in	O
adriamycin	B-Chemical
nephrosis	B-Disease
.	O
Chronic	O
enalapril	B-Chemical
treatment	O
reduced	O
blood	O
pressure	O
without	O
reducing	O
albuminuria	B-Disease
in	O
group	O
4	O
.	O
Untreated	O
group	O
3	O
rats	O
exhibited	O
a	O
progressive	O
reduction	O
in	O
GFR	O
(	O
0	O
.	O
35	O
+	O
/	O
-	O
0	O
.	O
08	O
ml	O
/	O
min	O
at	O
4	O
months	O
,	O
0	O
.	O
27	O
+	O
/	O
-	O
0	O
.	O
07	O
ml	O
/	O
min	O
at	O
6	O
months	O
)	O
.	O
Enalapril	B-Chemical
treatment	O
blunted	O
but	O
did	O
not	O
prevent	O
reduction	O
in	O
GFR	O
in	O
group	O
4	O
(	O
0	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
15	O
ml	O
/	O
min	O
at	O
4	O
months	O
,	O
0	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
13	O
ml	O
/	O
min	O
at	O
6	O
months	O
,	O
both	O
P	O
less	O
than	O
0	O
.	O
05	O
vs	O
.	O
group	O
3	O
)	O
.	O
Reduction	O
in	O
GFR	O
was	O
associated	O
with	O
the	O
development	O
of	O
glomerular	B-Disease
sclerosis	I-Disease
in	O
both	O
treated	O
and	O
untreated	O
rats	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Clotiazepam	B-Chemical
-	O
induced	O
acute	O
hepatitis	B-Disease
.	O
We	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
acute	O
hepatitis	B-Disease
with	O
extensive	B-Disease
hepatocellular	I-Disease
necrosis	I-Disease
,	O
7	O
months	O
after	O
the	O
onset	O
of	O
administration	O
of	O
clotiazepam	B-Chemical
,	O
a	O
thienodiazepine	B-Chemical
derivative	O
.	O
Clotiazepam	B-Chemical
withdrawal	O
was	O
followed	O
by	O
prompt	O
recovery	O
.	O
The	O
administration	O
of	O
several	O
benzodiazepines	B-Chemical
,	O
chemically	O
related	O
to	O
clotiazepam	B-Chemical
,	O
did	O
not	O
interfere	O
with	O
recovery	O
and	O
did	O
not	O
induce	O
any	O
relapse	O
of	O
hepatitis	B-Disease
.	O
This	O
observation	O
shows	O
that	O
clotiazepam	B-Chemical
can	O
induce	O
acute	O
hepatitis	B-Disease
and	O
suggests	O
that	O
there	O
is	O
no	O
cross	O
hepatotoxicity	B-Disease
between	O
clotiazepam	B-Chemical
and	O
several	O
benzodiazepines	B-Chemical
.	O
5	B-Chemical
-	I-Chemical
azacytidine	I-Chemical
potentiates	O
initiation	B-Disease
induced	I-Disease
by	I-Disease
carcinogens	I-Disease
in	O
rat	O
liver	O
.	O
To	O
test	O
the	O
validity	O
of	O
the	O
hypothesis	O
that	O
hypomethylation	O
of	O
DNA	O
plays	O
an	O
important	O
role	O
in	O
the	O
initiation	B-Disease
of	I-Disease
carcinogenic	I-Disease
process	I-Disease
,	O
5	B-Chemical
-	I-Chemical
azacytidine	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
)	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhibitor	O
of	O
DNA	O
methylation	O
,	O
was	O
given	O
to	O
rats	O
during	O
the	O
phase	O
of	O
repair	O
synthesis	O
induced	O
by	O
the	O
three	O
carcinogens	O
,	O
benzo	B-Chemical
[	I-Chemical
a	I-Chemical
]	I-Chemical
-	I-Chemical
pyrene	I-Chemical
(	O
200	O
mg	O
/	O
kg	O
)	O
,	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
nitrosourea	I-Chemical
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
1	B-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
dimethylhydrazine	I-Chemical
(	O
1	B-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
DMH	I-Chemical
)	O
(	O
100	O
mg	O
/	O
kg	O
)	O
.	O
The	O
initiated	O
hepatocytes	O
in	O
the	O
liver	O
were	O
assayed	O
as	O
the	O
gamma	O
-	O
glutamyltransferase	O
(	O
gamma	O
-	O
GT	O
)	O
positive	O
foci	O
formed	O
following	O
a	O
2	O
-	O
week	O
selection	O
regimen	O
consisting	O
of	O
dietary	O
0	O
.	O
02	O
%	O
2	B-Chemical
-	I-Chemical
acetylaminofluorene	I-Chemical
coupled	O
with	O
a	O
necrogenic	O
dose	O
of	O
CCl4	B-Chemical
.	O
The	O
results	O
obtained	O
indicate	O
that	O
with	O
all	O
three	O
carcinogens	O
,	O
administration	O
of	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
during	O
repair	O
synthesis	O
increased	O
the	O
incidence	O
of	O
initiated	O
hepatocytes	O
,	O
for	O
example	O
10	O
-	O
20	O
foci	O
/	O
cm2	O
in	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
and	O
carcinogen	O
-	O
treated	O
rats	O
compared	O
with	O
3	O
-	O
5	O
foci	O
/	O
cm2	O
in	O
rats	O
treated	O
with	O
carcinogen	O
only	O
.	O
Administration	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
azadeoxycytidine	I-Chemical
during	O
the	O
repair	O
synthesis	O
induced	O
by	O
1	B-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
DMH	I-Chemical
further	O
showed	O
that	O
0	O
.	O
019	O
mol	O
%	O
of	O
cytosine	B-Chemical
residues	O
in	O
DNA	O
were	O
substituted	O
by	O
the	O
analogue	O
,	O
indicating	O
that	O
incorporation	O
of	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
occurs	O
during	O
repair	O
synthesis	O
.	O
In	O
the	O
absence	O
of	O
the	O
carcinogen	O
,	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
given	O
after	O
a	O
two	O
thirds	O
partial	O
hepatectomy	O
,	O
when	O
its	O
incorporation	O
should	O
be	O
maximum	O
,	O
failed	O
to	O
induce	O
any	O
gamma	O
-	O
GT	O
positive	O
foci	O
.	O
The	O
results	O
suggest	O
that	O
hypomethylation	O
of	O
DNA	O
per	O
se	O
may	O
not	O
be	O
sufficient	O
for	O
initiation	O
.	O
Perhaps	O
two	O
events	O
might	O
be	O
necessary	O
for	O
initiation	O
,	O
the	O
first	O
caused	O
by	O
the	O
carcinogen	O
and	O
a	O
second	O
involving	O
hypomethylation	O
of	O
DNA	O
.	O
Antihypertensive	O
drugs	O
and	O
depression	B-Disease
:	O
a	O
reappraisal	O
.	O
Eighty	O
-	O
nine	O
new	O
referral	O
hypertensive	B-Disease
out	O
-	O
patients	O
and	O
46	O
new	O
referral	O
non	O
-	O
hypertensive	B-Disease
chronically	O
physically	O
ill	O
out	O
-	O
patients	O
completed	O
a	O
mood	O
rating	O
scale	O
at	O
regular	O
intervals	O
for	O
one	O
year	O
.	O
The	O
results	O
showed	O
a	O
high	O
prevalence	O
of	O
depression	B-Disease
in	O
both	O
groups	O
of	O
patients	O
,	O
with	O
no	O
preponderance	O
in	O
the	O
hypertensive	B-Disease
group	O
.	O
Hypertensive	B-Disease
patients	O
with	O
psychiatric	B-Disease
histories	O
had	O
a	O
higher	O
prevalence	O
of	O
depression	B-Disease
than	O
the	O
comparison	O
patients	O
.	O
This	O
was	O
accounted	O
for	O
by	O
a	O
significant	O
number	O
of	O
depressions	B-Disease
occurring	O
in	O
methyl	B-Chemical
dopa	I-Chemical
treated	O
patients	O
with	O
psychiatric	B-Disease
histories	O
.	O
Chronic	B-Disease
active	I-Disease
hepatitis	I-Disease
associated	O
with	O
diclofenac	B-Chemical
sodium	I-Chemical
therapy	O
.	O
Diclofenac	B-Chemical
sodium	I-Chemical
(	O
Voltarol	B-Chemical
,	O
Geigy	O
Pharmaceuticals	O
)	O
is	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
derivative	O
of	O
phenylacetic	B-Chemical
acid	I-Chemical
.	O
Although	O
generally	O
well	O
-	O
tolerated	O
,	O
asymptomatic	O
abnormalities	B-Disease
of	I-Disease
liver	I-Disease
function	I-Disease
have	O
been	O
recorded	O
and	O
,	O
less	O
commonly	O
,	O
severe	O
hepatitis	B-Disease
induced	O
by	O
diclofenac	B-Chemical
.	O
The	O
patient	O
described	O
developed	O
chronic	B-Disease
active	I-Disease
hepatitis	I-Disease
after	O
six	O
months	O
therapy	O
with	O
diclofenac	B-Chemical
sodium	I-Chemical
which	O
progressed	O
despite	O
the	O
withdrawal	O
of	O
the	O
drug	O
,	O
a	O
finding	O
not	O
previously	O
reported	O
.	O
Arterial	O
hypertension	B-Disease
as	O
a	O
complication	O
of	O
prolonged	O
ketoconazole	B-Chemical
treatment	O
.	O
Two	O
of	O
14	O
patients	O
with	O
Cushing	B-Disease
'	I-Disease
s	I-Disease
syndrome	I-Disease
treated	O
on	O
a	O
long	O
-	O
term	O
basis	O
with	O
ketoconazole	B-Chemical
developed	O
sustained	O
hypertension	B-Disease
.	O
In	O
both	O
cases	O
normal	O
plasma	O
and	O
urinary	O
free	O
cortisol	B-Chemical
levels	O
had	O
been	O
achieved	O
following	O
ketoconazole	B-Chemical
therapy	O
,	O
yet	O
continuous	O
blood	O
pressure	O
monitoring	O
demonstrated	O
hypertension	B-Disease
31	O
(	O
patient	O
1	O
)	O
and	O
52	O
weeks	O
(	O
patient	O
2	O
)	O
after	O
treatment	O
.	O
In	O
patient	O
1	O
,	O
plasma	O
levels	O
of	O
deoxycorticosterone	B-Chemical
and	O
11	B-Chemical
-	I-Chemical
deoxycortisol	I-Chemical
were	O
elevated	O
.	O
In	O
patient	O
2	O
,	O
in	O
addition	O
to	O
an	O
increase	O
in	O
both	O
deoxycorticosterone	B-Chemical
and	O
11	B-Chemical
-	I-Chemical
deoxycortisol	I-Chemical
levels	O
,	O
plasma	O
aldosterone	B-Chemical
values	O
were	O
raised	O
,	O
with	O
a	O
concomitant	O
suppression	O
of	O
renin	O
levels	O
.	O
Our	O
findings	O
show	O
that	O
long	O
-	O
term	O
treatment	O
with	O
high	O
doses	O
of	O
ketoconazole	B-Chemical
may	O
induce	O
enzyme	O
blockade	O
leading	O
to	O
mineralocorticoid	O
-	O
related	O
hypertension	B-Disease
.	O
Effects	O
of	O
an	O
inhibitor	O
of	O
angiotensin	B-Chemical
converting	O
enzyme	O
(	O
Captopril	B-Chemical
)	O
on	O
pulmonary	B-Disease
and	I-Disease
renal	I-Disease
insufficiency	I-Disease
due	O
to	O
intravascular	B-Disease
coagulation	I-Disease
in	O
the	O
rat	O
.	O
Induction	O
of	O
intravascular	B-Disease
coagulation	I-Disease
and	O
inhibition	O
of	O
fibrinolysis	O
by	O
injection	O
of	O
thrombin	O
and	O
tranexamic	B-Chemical
acid	I-Chemical
(	O
AMCA	B-Chemical
)	O
in	O
the	O
rat	O
gives	O
rise	O
to	O
pulmonary	B-Disease
and	I-Disease
renal	I-Disease
insufficiency	I-Disease
resembling	O
that	O
occurring	O
after	O
trauma	B-Disease
or	O
sepsis	B-Disease
in	O
man	O
.	O
Injection	O
of	O
Captopril	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhibitor	O
of	O
angiotensin	B-Chemical
converting	O
enzyme	O
(	O
ACE	O
)	O
,	O
reduced	O
both	O
pulmonary	B-Disease
and	I-Disease
renal	I-Disease
insufficiency	I-Disease
in	O
this	O
rat	O
model	O
.	O
The	O
lung	O
weights	O
were	O
lower	O
and	O
PaO2	O
was	O
improved	O
in	O
rats	O
given	O
this	O
enzyme	O
-	O
blocking	O
agent	O
.	O
The	O
contents	O
of	O
albumin	O
in	O
the	O
lungs	O
were	O
not	O
changed	O
,	O
indicating	O
that	O
Captopril	B-Chemical
did	O
not	O
influence	O
the	O
extravasation	O
of	O
protein	O
.	O
Renal	B-Disease
damage	I-Disease
as	O
reflected	O
by	O
an	O
increase	O
in	O
serum	O
urea	B-Chemical
and	O
in	O
kidney	O
weight	O
was	O
prevented	O
by	O
Captopril	B-Chemical
.	O
The	O
amount	O
of	O
fibrin	O
in	O
the	O
kidneys	O
was	O
also	O
considerably	O
lower	O
than	O
in	O
animals	O
which	O
received	O
thrombin	O
and	O
AMCA	B-Chemical
alone	O
.	O
It	O
is	O
suggested	O
that	O
the	O
effects	O
of	O
Captopril	B-Chemical
on	O
the	O
lungs	O
may	O
be	O
attributable	O
to	O
a	O
vasodilatory	O
effect	O
due	O
to	O
a	O
reduction	O
in	O
the	O
circulating	O
level	O
of	O
Angiotension	B-Chemical
II	I-Chemical
and	O
an	O
increase	O
in	O
prostacyclin	B-Chemical
(	O
secondary	O
to	O
an	O
increase	O
in	O
bradykinin	B-Chemical
)	O
.	O
Captopril	B-Chemical
may	O
,	O
by	O
the	O
same	O
mechanism	O
,	O
reduce	O
the	O
increase	O
in	O
glomerular	O
filtration	O
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
injection	O
of	O
thrombin	O
,	O
thereby	O
diminishing	O
the	O
aggregation	O
of	O
fibrin	O
monomers	O
in	O
the	O
glomeruli	O
,	O
with	O
the	O
result	O
that	O
less	O
fibrin	O
will	O
be	O
deposited	O
and	O
thus	O
less	O
kidney	B-Disease
damage	I-Disease
will	O
be	O
produced	O
.	O
Stroke	B-Disease
associated	O
with	O
cocaine	B-Chemical
use	O
.	O
We	O
describe	O
eight	O
patients	O
in	O
whom	O
cocaine	B-Chemical
use	O
was	O
related	O
to	O
stroke	B-Disease
and	O
review	O
39	O
cases	O
from	O
the	O
literature	O
.	O
Among	O
these	O
47	O
patients	O
the	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
age	O
was	O
32	O
.	O
5	O
+	O
/	O
-	O
12	O
.	O
1	O
years	O
;	O
76	O
%	O
(	O
34	O
/	O
45	O
)	O
were	O
men	O
.	O
Stroke	B-Disease
followed	O
cocaine	B-Chemical
use	O
by	O
inhalation	O
,	O
intranasal	O
,	O
intravenous	O
,	O
and	O
intramuscular	O
routes	O
.	O
Intracranial	B-Disease
aneurysms	I-Disease
or	O
arteriovenous	B-Disease
malformations	I-Disease
were	O
present	O
in	O
17	O
of	O
32	O
patients	O
studied	O
angiographically	O
or	O
at	O
autopsy	O
;	O
cerebral	B-Disease
vasculitis	I-Disease
was	O
present	O
in	O
two	O
patients	O
.	O
Cerebral	B-Disease
infarction	I-Disease
occurred	O
in	O
10	O
patients	O
(	O
22	O
%	O
)	O
,	O
intracerebral	B-Disease
hemorrhage	I-Disease
in	O
22	O
(	O
49	O
%	O
)	O
,	O
and	O
subarachnoid	B-Disease
hemorrhage	I-Disease
in	O
13	O
(	O
29	O
%	O
)	O
.	O
These	O
data	O
indicate	O
that	O
(	O
1	O
)	O
the	O
apparent	O
incidence	O
of	O
stroke	B-Disease
related	O
to	O
cocaine	B-Chemical
use	O
is	O
increasing	O
;	O
(	O
2	O
)	O
cocaine	B-Chemical
-	O
associated	O
stroke	B-Disease
occurs	O
primarily	O
in	O
young	O
adults	O
;	O
(	O
3	O
)	O
stroke	B-Disease
may	O
follow	O
any	O
route	O
of	O
cocaine	B-Chemical
administration	O
;	O
(	O
4	O
)	O
stroke	B-Disease
after	O
cocaine	B-Chemical
use	O
is	O
frequently	O
associated	O
with	O
intracranial	B-Disease
aneurysms	I-Disease
and	O
arteriovenous	B-Disease
malformations	I-Disease
;	O
and	O
(	O
5	O
)	O
in	O
cocaine	B-Chemical
-	O
associated	O
stroke	B-Disease
,	O
the	O
frequency	O
of	O
intracranial	B-Disease
hemorrhage	I-Disease
exceeds	O
that	O
of	O
cerebral	B-Disease
infarction	I-Disease
.	O
A	O
randomized	O
comparison	O
of	O
labetalol	B-Chemical
and	O
nitroprusside	B-Chemical
for	O
induced	O
hypotension	B-Disease
.	O
In	O
a	O
randomized	O
study	O
,	O
labetalol	B-Chemical
-	O
induced	O
hypotension	B-Disease
and	O
nitroprusside	B-Chemical
-	O
induced	O
hypotension	B-Disease
were	O
compared	O
in	O
20	O
patients	O
(	O
10	O
in	O
each	O
group	O
)	O
scheduled	O
for	O
major	O
orthopedic	O
procedures	O
.	O
Each	O
patient	O
was	O
subjected	O
to	O
an	O
identical	O
anesthetic	O
protocol	O
and	O
similar	O
drug	O
-	O
induced	O
reductions	B-Disease
in	I-Disease
mean	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
(	O
BP	O
)	O
(	O
50	O
to	O
55	O
mmHg	O
)	O
.	O
Nitroprusside	O
infusion	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
increase	B-Disease
in	I-Disease
heart	I-Disease
rate	I-Disease
and	I-Disease
cardiac	I-Disease
output	I-Disease
;	O
rebound	O
hypertension	B-Disease
was	O
observed	O
in	O
three	O
patients	O
after	O
discontinuation	O
of	O
nitroprusside	B-Chemical
.	O
Labetalol	B-Chemical
administration	O
was	O
not	O
associated	O
with	O
any	O
of	O
these	O
findings	O
.	O
Arterial	O
PO2	B-Chemical
decreased	O
in	O
both	O
groups	O
.	O
It	O
was	O
concluded	O
that	O
labetalol	B-Chemical
offers	O
advantages	O
over	O
nitroprusside	B-Chemical
.	O
Sodium	B-Chemical
status	O
influences	O
chronic	O
amphotericin	B-Chemical
B	I-Chemical
nephrotoxicity	B-Disease
in	O
rats	O
.	O
The	O
nephrotoxic	B-Disease
potential	O
of	O
amphotericin	B-Chemical
B	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
per	O
day	O
intraperitoneally	O
for	O
3	O
weeks	O
)	O
has	O
been	O
investigated	O
in	O
salt	O
-	O
depleted	O
,	O
normal	O
-	O
salt	O
,	O
and	O
salt	O
-	O
loaded	O
rats	O
.	O
In	O
salt	O
-	O
depleted	O
rats	O
,	O
amphotericin	B-Chemical
B	I-Chemical
decreased	O
creatinine	B-Chemical
clearance	O
linearly	O
with	O
time	O
,	O
with	O
an	O
85	O
%	O
reduction	O
by	O
week	O
3	O
.	O
In	O
contrast	O
,	O
in	O
normal	O
-	O
salt	O
rats	O
creatinine	B-Chemical
clearance	O
was	O
decreased	O
but	O
to	O
a	O
lesser	O
extent	O
at	O
week	O
2	O
and	O
3	O
,	O
and	O
in	O
salt	O
-	O
loaded	O
rats	O
creatinine	B-Chemical
clearance	O
did	O
not	O
change	O
for	O
2	O
weeks	O
and	O
was	O
decreased	O
by	O
43	O
%	O
at	O
week	O
3	O
.	O
All	O
rats	O
in	O
the	O
sodium	B-Chemical
-	O
depleted	O
group	O
had	O
histopathological	O
evidence	O
of	O
patchy	O
tubular	O
cytoplasmic	O
degeneration	O
in	O
tubules	O
that	O
was	O
not	O
observed	O
in	O
any	O
normal	O
-	O
salt	O
or	O
salt	O
-	O
loaded	O
rat	O
.	O
Concentrations	O
of	O
amphotericin	B-Chemical
B	I-Chemical
in	O
plasma	O
were	O
not	O
significantly	O
different	O
among	O
the	O
three	O
groups	O
at	O
any	O
time	O
during	O
the	O
study	O
.	O
However	O
,	O
at	O
the	O
end	O
of	O
3	O
weeks	O
,	O
amphotericin	B-Chemical
B	I-Chemical
levels	O
in	O
the	O
kidneys	O
and	O
liver	O
were	O
significantly	O
higher	O
in	O
salt	O
-	O
depleted	O
and	O
normal	O
-	O
salt	O
rats	O
than	O
those	O
in	O
salt	O
-	O
loaded	O
rats	O
,	O
with	O
plasma	O
/	O
kidney	O
ratios	O
of	O
21	O
,	O
14	O
,	O
and	O
8	O
in	O
salt	O
-	O
depleted	O
,	O
normal	O
-	O
salt	O
,	O
and	O
salt	O
-	O
loaded	O
rats	O
,	O
respectively	O
.	O
In	O
conclusion	O
,	O
reductions	O
in	O
creatinine	B-Chemical
clearance	O
and	O
renal	O
amphotericin	B-Chemical
B	I-Chemical
accumulation	O
after	O
chronic	O
amphotericin	B-Chemical
B	I-Chemical
administration	O
were	O
enhanced	O
by	O
salt	O
depletion	O
and	O
attenuated	O
by	O
sodium	B-Chemical
loading	O
in	O
rats	O
.	O
Flestolol	B-Chemical
:	O
an	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
.	O
Flestolol	B-Chemical
(	O
ACC	B-Chemical
-	I-Chemical
9089	I-Chemical
)	O
is	O
a	O
nonselective	O
,	O
competitive	O
,	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
,	O
without	O
any	O
intrinsic	O
sympathomimetic	O
activity	O
.	O
Flestolol	B-Chemical
is	O
metabolized	O
by	O
plasma	O
esterases	O
and	O
has	O
an	O
elimination	O
half	O
-	O
life	O
of	O
approximately	O
6	O
.	O
5	O
minutes	O
.	O
This	O
agent	O
was	O
well	O
tolerated	O
in	O
healthy	O
volunteers	O
at	O
doses	O
up	O
to	O
100	O
micrograms	O
/	O
kg	O
/	O
min	O
.	O
In	O
long	O
-	O
term	O
infusion	O
studies	O
,	O
flestolol	B-Chemical
was	O
well	O
tolerated	O
at	O
the	O
effective	O
beta	O
-	O
blocking	O
dose	O
(	O
5	O
micrograms	O
/	O
kg	O
/	O
min	O
)	O
for	O
up	O
to	O
seven	O
days	O
.	O
Flestolol	B-Chemical
blood	O
concentrations	O
increased	O
linearly	O
with	O
increasing	O
dose	O
and	O
good	O
correlation	O
exists	O
between	O
blood	O
concentrations	O
of	O
flestolol	B-Chemical
and	O
beta	O
-	O
adrenergic	O
blockade	O
.	O
Flestolol	B-Chemical
produced	O
a	O
dose	O
-	O
dependent	O
attenuation	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
tachycardia	B-Disease
.	O
Electrophysiologic	O
and	O
hemodynamic	O
effects	O
of	O
flestolol	B-Chemical
are	O
similar	O
to	O
those	O
of	O
other	O
beta	O
blockers	O
.	O
In	O
contrast	O
with	O
other	O
beta	O
blockers	O
,	O
flestolol	B-Chemical
-	O
induced	O
effects	O
reverse	O
rapidly	O
(	O
within	O
30	O
minutes	O
)	O
following	O
discontinuation	O
because	O
of	O
its	O
short	O
half	O
-	O
life	O
.	O
Flestolol	B-Chemical
effectively	O
reduced	O
heart	O
rate	O
in	O
patients	O
with	O
supraventricular	B-Disease
tachyarrhythmia	I-Disease
.	O
In	O
patients	O
with	O
unstable	B-Disease
angina	I-Disease
,	O
flestolol	B-Chemical
infusion	O
was	O
found	O
to	O
be	O
safe	O
and	O
effective	O
in	O
controlling	O
chest	B-Disease
pain	I-Disease
.	O
It	O
is	O
concluded	O
that	O
flestolol	B-Chemical
is	O
a	O
potent	O
,	O
well	O
-	O
tolerated	O
,	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
.	O
Use	O
of	O
flestolol	B-Chemical
in	O
the	O
critical	O
care	O
setting	O
is	O
currently	O
undergoing	O
investigation	O
.	O
Immunohistochemical	O
,	O
electron	O
microscopic	O
and	O
morphometric	O
studies	O
of	O
estrogen	B-Chemical
-	O
induced	O
rat	O
prolactinomas	B-Disease
after	O
bromocriptine	B-Chemical
treatment	O
.	O
To	O
clarify	O
the	O
effects	O
of	O
bromocriptine	B-Chemical
on	O
prolactinoma	B-Disease
cells	O
in	O
vivo	O
,	O
immunohistochemical	O
,	O
ultrastructural	O
and	O
morphometrical	O
analyses	O
were	O
applied	O
to	O
estrogen	B-Chemical
-	O
induced	O
rat	O
prolactinoma	B-Disease
cells	O
1	O
h	O
and	O
6	O
h	O
after	O
injection	O
of	O
bromocriptine	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
of	O
body	O
weight	O
)	O
.	O
One	O
h	O
after	O
treatment	O
,	O
serum	O
prolactin	O
levels	O
decreased	O
markedly	O
.	O
Electron	O
microscopy	O
disclosed	O
many	O
secretory	O
granules	O
,	O
slightly	O
distorted	O
rough	O
endoplasmic	O
reticulum	O
,	O
and	O
partially	O
dilated	O
Golgi	O
cisternae	O
in	O
the	O
prolactinoma	B-Disease
cells	O
.	O
Morphometric	O
analysis	O
revealed	O
that	O
the	O
volume	O
density	O
of	O
secretory	O
granules	O
increased	O
,	O
while	O
the	O
volume	O
density	O
of	O
cytoplasmic	O
microtubules	O
decreased	O
.	O
These	O
findings	O
suggest	O
that	O
lowered	O
serum	O
prolactin	O
levels	O
in	O
the	O
early	O
phase	O
of	O
bromocriptine	B-Chemical
treatment	O
may	O
result	O
from	O
an	O
impaired	O
secretion	O
of	O
prolactin	O
due	O
to	O
decreasing	O
numbers	O
of	O
cytoplasmic	O
microtubules	O
.	O
At	O
6	O
h	O
after	O
injection	O
,	O
serum	O
prolactin	O
levels	O
were	O
still	O
considerably	O
lower	O
than	O
in	O
controls	O
.	O
The	O
prolactinoma	B-Disease
cells	O
at	O
this	O
time	O
were	O
well	O
granulated	O
,	O
with	O
vesiculated	O
rough	O
endoplasmic	O
reticulum	O
and	O
markedly	O
dilated	O
Golgi	O
cisternae	O
.	O
Electron	O
microscopical	O
immunohistochemistry	O
revealed	O
positive	O
reaction	O
products	O
noted	O
on	O
the	O
secretory	O
granules	O
,	O
Golgi	O
cisternae	O
,	O
and	O
endoplasmic	O
reticulum	O
of	O
the	O
untreated	O
rat	O
prolactinoma	B-Disease
cells	O
.	O
However	O
,	O
only	O
secretory	O
granules	O
showed	O
the	O
positive	O
reaction	O
products	O
for	O
prolactin	O
6	O
h	O
after	O
bromocriptine	B-Chemical
treatment	O
of	O
the	O
adenoma	B-Disease
cells	O
.	O
An	O
increase	O
in	O
the	O
volume	O
density	O
of	O
secretory	O
granules	O
and	O
a	O
decrease	O
in	O
the	O
volume	O
densities	O
of	O
rough	O
endoplasmic	O
reticulum	O
and	O
microtubules	O
was	O
determined	O
by	O
morphometric	O
analysis	O
,	O
suggesting	O
that	O
bromocriptine	B-Chemical
inhibits	O
protein	O
synthesis	O
as	O
well	O
as	O
bringing	O
about	O
a	O
disturbance	O
of	O
the	O
prolactin	O
secretion	O
.	O
Sulfasalazine	B-Chemical
-	O
induced	O
lupus	B-Disease
erythematosus	I-Disease
.	O
Pneumonitis	B-Disease
,	O
bilateral	O
pleural	B-Disease
effusions	I-Disease
,	O
echocardiographic	O
evidence	O
of	O
cardiac	B-Disease
tamponade	I-Disease
,	O
and	O
positive	O
autoantibodies	O
developed	O
in	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
,	O
who	O
was	O
receiving	O
long	O
-	O
term	O
sulfasalazine	B-Chemical
therapy	O
for	O
chronic	O
ulcerative	B-Disease
colitis	I-Disease
.	O
After	O
cessation	O
of	O
the	O
sulfasalazine	B-Chemical
and	O
completion	O
of	O
a	O
six	O
-	O
week	O
course	O
of	O
corticosteroids	O
,	O
these	O
problems	O
resolved	O
over	O
a	O
period	O
of	O
four	O
to	O
six	O
months	O
.	O
It	O
is	O
suggested	O
that	O
the	O
patient	O
had	O
sulfasalazine	B-Chemical
-	O
induced	O
lupus	B-Disease
,	O
which	O
manifested	O
with	O
serositis	B-Disease
and	O
pulmonary	O
parenchymal	O
involvement	O
in	O
the	O
absence	O
of	O
joint	O
symptoms	O
.	O
Physicians	O
who	O
use	O
sulfasalazine	B-Chemical
to	O
treat	O
patients	O
with	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
should	O
be	O
aware	O
of	O
the	O
signs	O
of	O
sulfasalazine	B-Chemical
-	O
induced	O
lupus	B-Disease
syndrome	I-Disease
.	O
Chronic	O
carbamazepine	B-Chemical
treatment	O
in	O
the	O
rat	O
:	O
efficacy	O
,	O
toxicity	B-Disease
,	O
and	O
effect	O
on	O
plasma	O
and	O
tissue	O
folate	B-Chemical
concentrations	O
.	O
Folate	B-Chemical
depletion	O
has	O
often	O
been	O
a	O
problem	O
in	O
chronic	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
therapy	O
.	O
Carbamazepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
,	O
a	O
commonly	O
used	O
AED	O
,	O
has	O
been	O
implicated	O
in	O
some	O
clinical	O
studies	O
.	O
A	O
rat	O
model	O
was	O
developed	O
to	O
examine	O
the	O
effects	O
of	O
chronic	O
CBZ	B-Chemical
treatment	O
on	O
folate	B-Chemical
concentrations	O
in	O
the	O
rat	O
.	O
In	O
the	O
course	O
of	O
developing	O
this	O
model	O
,	O
a	O
common	O
vehicle	O
,	O
propylene	B-Chemical
glycol	I-Chemical
,	O
by	O
itself	O
in	O
high	O
doses	O
,	O
was	O
found	O
to	O
exhibit	O
protective	O
properties	O
against	O
induced	O
seizures	B-Disease
and	O
inhibited	O
weight	B-Disease
gain	I-Disease
.	O
Seizures	B-Disease
induced	O
by	O
hexafluorodiethyl	B-Chemical
ether	I-Chemical
(	O
HFDE	B-Chemical
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
sensitive	O
measure	O
of	O
protection	O
by	O
CBZ	B-Chemical
than	O
seizures	B-Disease
induced	O
by	O
maximal	O
electroshock	O
(	O
MES	O
)	O
.	O
Oral	O
administration	O
of	O
CBZ	B-Chemical
as	O
an	O
aqueous	O
suspension	O
every	O
8	O
h	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
was	O
continuously	O
protective	O
against	O
HFDE	B-Chemical
-	O
induced	O
seizures	B-Disease
and	O
was	O
minimally	O
toxic	O
as	O
measured	O
by	O
weight	B-Disease
gain	I-Disease
over	O
8	O
weeks	O
of	O
treatment	O
.	O
The	O
CBZ	B-Chemical
levels	O
measured	O
in	O
plasma	O
and	O
brain	O
of	O
these	O
animals	O
,	O
however	O
,	O
were	O
below	O
those	O
normally	O
considered	O
protective	O
.	O
This	O
treatment	O
with	O
CBZ	B-Chemical
had	O
no	O
apparent	O
adverse	O
effect	O
on	O
folate	B-Chemical
concentrations	O
in	O
the	O
rat	O
,	O
and	O
,	O
indeed	O
,	O
the	O
folate	B-Chemical
concentration	O
increased	O
in	O
liver	O
after	O
6	O
weeks	O
of	O
treatment	O
and	O
in	O
plasma	O
at	O
8	O
weeks	O
of	O
treatment	O
.	O
Dipyridamole	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
.	O
Angina	B-Disease
and	O
ischemic	O
electrocardiographic	O
changes	O
occurred	O
after	O
administration	O
of	O
oral	O
dipyridamole	B-Chemical
in	O
four	O
patients	O
awaiting	O
urgent	O
myocardial	O
revascularization	O
procedures	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
has	O
not	O
previously	O
been	O
reported	O
as	O
a	O
side	O
effect	O
of	O
preoperative	O
dipyridamole	B-Chemical
therapy	O
,	O
although	O
dipyridamole	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
has	O
been	O
demonstrated	O
to	O
occur	O
in	O
animals	O
and	O
humans	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
.	O
Epicardial	O
coronary	O
collateral	O
vessels	O
were	O
demonstrated	O
in	O
all	O
four	O
patients	O
;	O
a	O
coronary	O
""""	O
steal	O
""""	O
phenomenon	O
may	O
be	O
the	O
mechanism	O
of	O
the	O
dipyridamole	B-Chemical
-	O
induced	O
ischemia	B-Disease
observed	O
.	O
Inhibition	O
of	O
sympathoadrenal	O
activity	O
by	O
atrial	O
natriuretic	O
factor	O
in	O
dogs	O
.	O
In	O
six	O
conscious	O
,	O
trained	O
dogs	O
,	O
maintained	O
on	O
a	O
normal	O
sodium	B-Chemical
intake	O
of	O
2	O
to	O
4	O
mEq	O
/	O
kg	O
/	O
day	O
,	O
sympathetic	O
activity	O
was	O
assessed	O
as	O
the	O
release	O
rate	O
of	O
norepinephrine	B-Chemical
and	O
epinephrine	B-Chemical
during	O
15	O
-	O
minute	O
i	O
.	O
v	O
.	O
infusions	O
of	O
human	O
alpha	O
-	O
atrial	O
natriuretic	O
factor	O
.	O
Mean	O
arterial	O
pressure	O
(	O
as	O
a	O
percentage	O
of	O
control	O
+	O
/	O
-	O
SEM	O
)	O
during	O
randomized	O
infusions	O
of	O
0	O
.	O
03	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
3	O
,	O
or	O
1	O
.	O
0	O
microgram	O
/	O
kg	O
/	O
min	O
was	O
99	O
+	O
/	O
-	O
1	O
,	O
95	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
93	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
or	O
79	O
+	O
/	O
-	O
6	O
%	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
respectively	O
,	O
but	O
no	O
tachycardia	B-Disease
and	O
no	O
augmentation	O
of	O
the	O
norepinephrine	B-Chemical
release	O
rate	O
(	O
up	O
to	O
0	O
.	O
3	O
microgram	O
/	O
kg	O
/	O
min	O
)	O
were	O
observed	O
,	O
which	O
is	O
in	O
contrast	O
to	O
comparable	O
hypotension	B-Disease
induced	O
by	O
hydralazine	B-Chemical
or	O
nitroglycerin	B-Chemical
.	O
The	O
release	O
rate	O
of	O
epinephrine	B-Chemical
(	O
control	O
,	O
6	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
ng	O
/	O
kg	O
/	O
min	O
)	O
declined	O
immediately	O
during	O
infusions	O
of	O
atrial	O
natriuretic	O
factor	O
to	O
a	O
minimum	O
of	O
49	O
+	O
/	O
-	O
5	O
%	O
of	O
control	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
during	O
0	O
.	O
1	O
microgram	O
/	O
kg	O
/	O
min	O
and	O
to	O
63	O
+	O
/	O
-	O
5	O
%	O
(	O
0	O
.	O
1	O
greater	O
than	O
p	O
greater	O
than	O
0	O
.	O
05	O
)	O
or	O
95	O
+	O
/	O
-	O
13	O
%	O
(	O
not	O
significant	O
)	O
during	O
0	O
.	O
3	O
or	O
1	O
.	O
0	O
microgram	O
/	O
kg	O
/	O
min	O
.	O
Steady	O
state	O
arterial	O
plasma	O
concentrations	O
of	O
atrial	O
natriuretic	O
factor	O
were	O
39	O
+	O
/	O
-	O
10	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
during	O
infusions	O
of	O
saline	O
and	O
284	O
+	O
/	O
-	O
24	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
and	O
1520	O
+	O
/	O
-	O
300	O
pg	O
/	O
ml	O
(	O
n	O
=	O
9	O
)	O
during	O
0	O
.	O
03	O
and	O
0	O
.	O
1	O
microgram	O
/	O
kg	O
/	O
min	O
infusions	O
of	O
the	O
factor	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Inhibition	O
of	O
immunoreactive	O
corticotropin	O
-	O
releasing	O
factor	O
secretion	O
into	O
the	O
hypophysial	O
-	O
portal	O
circulation	O
by	O
delayed	O
glucocorticoid	O
feedback	O
.	O
Nitroprusside	B-Chemical
-	O
induced	O
hypotension	B-Disease
evokes	O
ACTH	O
secretion	O
which	O
is	O
primarily	O
mediated	O
by	O
enhanced	O
secretion	O
of	O
immunoreactive	O
corticotropin	O
-	O
releasing	O
factor	O
(	O
irCRF	O
)	O
into	O
the	O
hypophysial	O
-	O
portal	O
circulation	O
.	O
Portal	O
plasma	O
concentrations	O
of	O
neither	O
arginine	B-Chemical
vasopressin	I-Chemical
nor	O
oxytocin	B-Chemical
are	O
significantly	O
altered	O
in	O
this	O
paradigm	O
.	O
Application	O
of	O
a	O
delayed	O
feedback	O
signal	O
,	O
in	O
the	O
form	O
of	O
a	O
2	O
-	O
h	O
systemic	O
corticosterone	B-Chemical
infusion	O
in	O
urethane	B-Chemical
-	O
anesthetized	O
rats	O
with	O
pharmacological	O
blockade	O
of	O
glucocorticoid	O
synthesis	O
,	O
is	O
without	O
effect	O
on	O
the	O
resting	O
secretion	O
of	O
arginine	B-Chemical
vasopressin	I-Chemical
and	O
oxytocin	B-Chemical
at	O
any	O
corticosterone	B-Chemical
feedback	O
dose	O
tested	O
.	O
Resting	O
irCRF	O
levels	O
are	O
suppressed	O
only	O
at	O
the	O
highest	O
corticosterone	B-Chemical
infusion	O
rate	O
,	O
which	O
resulted	O
in	O
systemic	O
corticosterone	B-Chemical
levels	O
of	O
40	O
micrograms	O
/	O
dl	O
.	O
Suppression	O
of	O
irCRF	O
secretion	O
in	O
response	O
to	O
nitroprusside	B-Chemical
-	O
induced	O
hypotension	B-Disease
is	O
observed	O
and	O
occurs	O
at	O
a	O
plasma	O
corticosterone	B-Chemical
level	O
between	O
8	O
-	O
12	O
micrograms	O
/	O
dl	O
.	O
These	O
studies	O
provide	O
further	O
evidence	O
for	O
a	O
strong	O
central	O
component	O
of	O
the	O
delayed	O
feedback	O
process	O
which	O
is	O
mediated	O
by	O
modulation	O
of	O
irCRF	O
release	O
.	O
Noradrenergic	O
involvement	O
in	O
catalepsy	B-Disease
induced	O
by	O
delta	B-Chemical
9	I-Chemical
-	I-Chemical
tetrahydrocannabinol	I-Chemical
.	O
In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
the	O
catecholaminergic	O
system	O
in	O
the	O
cataleptogenic	O
effect	O
of	O
delta	B-Chemical
9	I-Chemical
-	I-Chemical
tetrahydrocannabinol	I-Chemical
(	O
THC	B-Chemical
)	O
,	O
the	O
effect	O
of	O
pretreatment	O
with	O
6	B-Chemical
-	I-Chemical
hydroxydopamine	I-Chemical
(	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
)	O
or	O
with	O
desipramine	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
and	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
were	O
investigated	O
in	O
rats	O
.	O
The	O
cataleptogenic	O
effect	O
of	O
THC	B-Chemical
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
and	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
but	O
not	O
in	O
rats	O
treated	O
with	O
desipramine	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
,	O
as	O
compared	O
with	O
control	O
rats	O
.	O
On	O
the	O
contrary	O
,	O
the	O
cataleptogenic	O
effect	O
of	O
haloperidol	B-Chemical
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
desipramine	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
but	O
not	O
in	O
rats	O
treated	O
with	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
or	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
.	O
These	O
results	O
indicate	O
that	O
noradrenergic	O
neurons	O
have	O
an	O
important	O
role	O
in	O
the	O
manifestation	O
of	O
catalepsy	B-Disease
induced	O
by	O
THC	B-Chemical
,	O
whereas	O
dopaminergic	O
neurons	O
are	O
important	O
in	O
catalepsy	B-Disease
induced	O
by	O
haloperidol	B-Chemical
.	O
Reversibility	O
of	O
captopril	B-Chemical
-	O
induced	O
renal	B-Disease
insufficiency	I-Disease
after	O
prolonged	O
use	O
in	O
an	O
unusual	O
case	O
of	O
renovascular	B-Disease
hypertension	I-Disease
.	O
We	O
report	O
a	O
case	O
of	O
severe	O
hypertension	B-Disease
with	O
an	O
occluded	O
renal	O
artery	O
to	O
a	O
solitary	O
kidney	O
,	O
who	O
developed	O
sudden	B-Disease
deterioration	I-Disease
of	I-Disease
renal	I-Disease
function	I-Disease
following	O
treatment	O
with	O
captopril	B-Chemical
.	O
His	O
renal	O
function	O
remained	O
impaired	O
but	O
stable	O
during	O
2	O
years	O
'	O
treatment	O
with	O
captopril	B-Chemical
but	O
returned	O
to	O
pre	O
-	O
treatment	O
levels	O
soon	O
after	O
cessation	O
of	O
the	O
drug	O
.	O
This	O
indicates	O
reversibility	O
in	O
captopril	B-Chemical
-	O
induced	O
renal	B-Disease
failure	I-Disease
even	O
after	O
its	O
prolonged	O
use	O
and	O
suggests	O
that	O
no	O
organic	O
damage	O
occurs	O
to	O
glomerular	O
arterioles	O
following	O
chronic	O
ACE	O
inhibition	O
.	O
HMG	O
CoA	O
reductase	O
inhibitors	O
.	O
Current	O
clinical	O
experience	O
.	O
Lovastatin	B-Chemical
and	O
simvastatin	B-Chemical
are	O
the	O
2	O
best	O
-	O
known	O
members	O
of	O
the	O
class	O
of	O
hypolipidaemic	O
agents	O
known	O
as	O
HMG	O
CoA	O
reductase	O
inhibitors	O
.	O
Clinical	O
experience	O
with	O
lovastatin	B-Chemical
includes	O
over	O
5000	O
patients	O
,	O
700	O
of	O
whom	O
have	O
been	O
treated	O
for	O
2	O
years	O
or	O
more	O
,	O
and	O
experience	O
with	O
simvastatin	B-Chemical
includes	O
over	O
3500	O
patients	O
,	O
of	O
whom	O
350	O
have	O
been	O
treated	O
for	O
18	O
months	O
or	O
more	O
.	O
Lovastatin	B-Chemical
has	O
been	O
marketed	O
in	O
the	O
United	O
States	O
for	O
over	O
6	O
months	O
.	O
Both	O
agents	O
show	O
substantial	O
clinical	O
efficacy	O
,	O
with	O
reductions	O
in	O
total	O
cholesterol	B-Chemical
of	O
over	O
30	O
%	O
and	O
in	O
LDL	O
-	O
cholesterol	B-Chemical
of	O
40	O
%	O
in	O
clinical	O
studies	O
.	O
Modest	O
increases	O
in	O
HDL	O
-	O
cholesterol	B-Chemical
levels	O
of	O
about	O
10	O
%	O
are	O
also	O
reported	O
.	O
Clinical	O
tolerability	O
of	O
both	O
agents	O
has	O
been	O
good	O
,	O
with	O
fewer	O
than	O
3	O
%	O
of	O
patients	O
withdrawn	O
from	O
treatment	O
because	O
of	O
clinical	O
adverse	O
experiences	O
.	O
Ophthalmological	O
examinations	O
in	O
over	O
1100	O
patients	O
treated	O
with	O
one	O
or	O
the	O
other	O
agent	O
have	O
revealed	O
no	O
evidence	O
of	O
significant	O
short	O
term	O
(	O
up	O
to	O
2	O
years	O
)	O
cataractogenic	O
potential	O
.	O
One	O
to	O
2	O
%	O
of	O
patients	O
have	O
elevations	O
of	O
serum	O
transaminases	O
to	O
greater	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O
These	O
episodes	O
are	O
asymptomatic	O
and	O
reversible	O
when	O
therapy	O
is	O
discontinued	O
.	O
Minor	O
elevations	O
of	O
creatine	B-Chemical
kinase	O
levels	O
are	O
reported	O
in	O
about	O
5	O
%	O
of	O
patients	O
.	O
Myopathy	B-Disease
,	O
associated	O
in	O
some	O
cases	O
with	O
myoglobinuria	B-Disease
,	O
and	O
in	O
2	O
cases	O
with	O
transient	O
renal	B-Disease
failure	I-Disease
,	O
has	O
been	O
rarely	O
reported	O
with	O
lovastatin	B-Chemical
,	O
especially	O
in	O
patients	O
concomitantly	O
treated	O
with	O
cyclosporin	B-Chemical
,	O
gemfibrozil	B-Chemical
or	O
niacin	B-Chemical
.	O
Lovastatin	B-Chemical
and	O
simvastatin	B-Chemical
are	O
both	O
effective	O
and	O
well	O
-	O
tolerated	O
agents	O
for	O
lowering	O
elevated	O
levels	O
of	O
serum	O
cholesterol	B-Chemical
.	O
As	O
wider	O
use	O
confirms	O
their	O
safety	O
profile	O
,	O
they	O
will	O
gain	O
increasing	O
importance	O
in	O
the	O
therapeutic	O
approach	O
to	O
hypercholesterolaemia	B-Disease
and	O
its	O
consequences	O
.	O
Hepatic	O
reactions	O
associated	O
with	O
ketoconazole	B-Chemical
in	O
the	O
United	O
Kingdom	O
.	O
Ketoconazole	B-Chemical
was	O
introduced	O
in	O
the	O
United	O
Kingdom	O
in	O
1981	O
.	O
By	O
November	O
1984	O
the	O
Committee	O
on	O
Safety	O
of	O
Medicines	O
had	O
received	O
82	O
reports	O
of	O
possible	O
hepatotoxicity	B-Disease
associated	O
with	O
the	O
drug	O
,	O
including	O
five	O
deaths	B-Disease
.	O
An	O
analysis	O
of	O
the	O
75	O
cases	O
that	O
had	O
been	O
adequately	O
followed	O
up	O
suggested	O
that	O
16	O
,	O
including	O
three	O
deaths	B-Disease
,	O
were	O
probably	O
related	O
to	O
treatment	O
with	O
the	O
drug	O
.	O
Of	O
the	O
remainder	O
,	O
48	O
were	O
possibly	O
related	O
to	O
treatment	O
,	O
five	O
were	O
unlikely	O
to	O
be	O
so	O
,	O
and	O
six	O
were	O
unclassifiable	O
.	O
The	O
mean	O
age	O
of	O
patients	O
in	O
the	O
16	O
probable	O
cases	O
was	O
57	O
.	O
9	O
,	O
with	O
hepatotoxicity	B-Disease
being	O
more	O
common	O
in	O
women	O
.	O
The	O
average	O
duration	O
of	O
treatment	O
before	O
the	O
onset	O
of	O
jaundice	B-Disease
was	O
61	O
days	O
.	O
None	O
of	O
these	O
well	O
validated	O
cases	O
occurred	O
within	O
the	O
first	O
10	O
days	O
after	O
treatment	O
.	O
The	O
results	O
of	O
serum	O
liver	O
function	O
tests	O
suggested	O
hepatocellular	B-Disease
injury	I-Disease
in	O
10	O
(	O
63	O
%	O
)	O
;	O
the	O
rest	O
showed	O
a	O
mixed	O
pattern	O
.	O
In	O
contrast	O
,	O
the	O
results	O
of	O
histological	O
examination	O
of	O
the	O
liver	O
often	O
showed	O
evidence	O
of	O
cholestasis	B-Disease
.	O
The	O
characteristics	O
of	O
the	O
48	O
patients	O
in	O
the	O
possible	O
cases	O
were	O
similar	O
.	O
Allergic	O
manifestations	O
such	O
as	O
rash	B-Disease
and	O
eosinophilia	B-Disease
were	O
rare	O
.	O
Hepatitis	B-Disease
was	O
usually	O
reversible	O
when	O
treatment	O
was	O
stopped	O
,	O
with	O
the	O
results	O
of	O
liver	O
function	O
tests	O
returning	O
to	O
normal	O
after	O
an	O
average	O
of	O
3	O
.	O
1	O
months	O
.	O
In	O
two	O
of	O
the	O
three	O
deaths	B-Disease
probably	O
associated	O
with	O
ketoconazole	B-Chemical
treatment	O
the	O
drug	O
had	O
been	O
continued	O
after	O
the	O
onset	O
of	O
jaundice	B-Disease
and	O
other	O
symptoms	O
of	O
hepatitis	B-Disease
.	O
Clinical	O
and	O
biochemical	O
monitoring	O
at	O
regular	O
intervals	O
for	O
evidence	O
of	O
hepatitis	B-Disease
is	O
advised	O
during	O
long	O
term	O
treatment	O
with	O
ketoconazole	B-Chemical
to	O
prevent	O
possible	O
serious	O
hepatic	B-Disease
injury	I-Disease
.	O
Glyburide	B-Chemical
-	O
induced	O
hepatitis	B-Disease
.	O
Drug	O
-	O
induced	O
hepatotoxicity	B-Disease
,	O
although	O
common	O
,	O
has	O
been	O
reported	O
only	O
infrequently	O
with	O
sulfonylureas	B-Chemical
.	O
For	O
glyburide	B-Chemical
,	O
a	O
second	O
-	O
generation	O
sulfonylurea	B-Chemical
,	O
only	O
two	O
brief	O
reports	O
of	O
hepatotoxicity	B-Disease
exist	O
.	O
Two	O
patients	O
with	O
type	B-Disease
II	I-Disease
diabetes	I-Disease
mellitus	I-Disease
developed	O
an	O
acute	B-Disease
hepatitis	I-Disease
-	I-Disease
like	I-Disease
syndrome	I-Disease
soon	O
after	O
initiation	O
of	O
glyburide	B-Chemical
therapy	O
.	O
There	O
was	O
no	O
serologic	O
evidence	O
of	O
viral	B-Disease
infection	I-Disease
,	O
and	O
a	O
liver	O
biopsy	O
sample	O
showed	O
a	O
histologic	O
pattern	O
consistent	O
with	O
drug	B-Disease
-	I-Disease
induced	I-Disease
hepatitis	I-Disease
.	O
Both	O
patients	O
recovered	O
quickly	O
after	O
stopping	O
glyburide	B-Chemical
therapy	O
and	O
have	O
remained	O
well	O
for	O
a	O
follow	O
-	O
up	O
period	O
of	O
1	O
year	O
.	O
Glyburide	B-Chemical
can	O
produce	O
an	O
acute	B-Disease
hepatitis	I-Disease
-	I-Disease
like	I-Disease
illness	I-Disease
in	O
some	O
persons	O
.	O
Intracranial	O
pressure	O
increases	O
during	O
alfentanil	B-Chemical
-	O
induced	O
rigidity	B-Disease
.	O
Intracranial	O
pressure	O
(	O
ICP	O
)	O
was	O
measured	O
during	O
alfentanil	B-Chemical
-	O
induced	O
rigidity	B-Disease
in	O
rats	O
.	O
Ten	O
rats	O
had	O
arterial	O
,	O
central	O
venous	O
(	O
CVP	O
)	O
,	O
and	O
subdural	O
cannulae	O
inserted	O
under	O
halothane	B-Chemical
anesthesia	O
.	O
The	O
animals	O
were	O
mechanically	O
ventilated	O
to	O
achieve	O
normocarbia	O
(	O
PCO2	O
=	O
42	O
+	O
/	O
-	O
1	O
mmHg	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
.	O
Following	O
instrumentation	O
,	O
halothane	B-Chemical
was	O
discontinued	O
and	O
alfentanil	B-Chemical
(	O
125	O
mu	O
/	O
kg	O
)	O
administered	O
iv	O
during	O
emergence	O
from	O
halothane	B-Chemical
anesthesia	O
.	O
In	O
the	O
five	O
rats	O
that	O
developed	O
somatic	B-Disease
rigidity	I-Disease
,	O
ICP	O
and	O
CVP	O
increased	O
significantly	O
above	O
baseline	O
(	O
delta	O
ICP	O
7	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
0	O
mmHg	O
,	O
delta	O
CVP	O
5	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
3	O
mmHg	O
)	O
.	O
These	O
variables	O
returned	O
to	O
baseline	O
when	O
rigidity	B-Disease
was	O
abolished	O
with	O
metocurine	B-Chemical
.	O
In	O
five	O
rats	O
that	O
did	O
not	O
become	O
rigid	O
,	O
ICP	O
and	O
CVP	O
did	O
not	O
change	O
following	O
alfentanil	B-Chemical
.	O
These	O
observations	O
suggest	O
that	O
rigidity	B-Disease
should	O
be	O
prevented	O
when	O
alfentanil	B-Chemical
,	O
and	O
,	O
presumably	O
,	O
other	O
opiates	O
,	O
are	O
used	O
in	O
the	O
anesthetic	O
management	O
of	O
patients	O
with	O
ICP	O
problems	O
.	O
Verapamil	B-Chemical
withdrawal	O
as	O
a	O
possible	O
cause	O
of	O
myocardial	B-Disease
infarction	I-Disease
in	O
a	O
hypertensive	B-Disease
woman	O
with	O
a	O
normal	O
coronary	O
angiogram	O
.	O
Verapamil	B-Chemical
is	O
an	O
effective	O
and	O
relatively	O
-	O
safe	O
antihypertensive	O
drug	O
.	O
Serious	O
adverse	O
effects	O
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
depression	B-Disease
of	O
cardiac	O
contractility	O
and	O
conduction	O
,	O
especially	O
when	O
the	O
drug	O
is	O
combined	O
with	O
beta	O
-	O
blocking	O
agents	O
.	O
We	O
report	O
a	O
case	O
in	O
which	O
myocardial	B-Disease
infarction	I-Disease
coincided	O
with	O
the	O
introduction	O
of	O
captopril	B-Chemical
and	O
the	O
withdrawal	O
of	O
verapamil	B-Chemical
in	O
a	O
previously	O
asymptomatic	O
woman	O
with	O
severe	O
hypertension	B-Disease
.	O
Possible	O
mechanisms	O
that	O
involve	O
a	O
verapamil	B-Chemical
-	O
related	O
increase	O
in	O
platelet	O
and	O
/	O
or	O
vascular	O
alpha	O
2	O
-	O
adrenoreceptor	O
affinity	O
for	O
catecholamines	B-Chemical
are	O
discussed	O
.	O
Haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
after	O
treatment	O
with	O
metronidazole	B-Chemical
.	O
This	O
paper	O
describes	O
the	O
clinical	O
features	O
of	O
six	O
children	O
who	O
developed	O
the	O
haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
after	O
treatment	O
with	O
metronidazole	B-Chemical
.	O
These	O
children	O
were	O
older	O
and	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
recent	O
bowel	O
surgery	O
than	O
are	O
other	O
children	O
with	O
this	O
condition	O
.	O
While	O
the	O
involvement	O
of	O
metronidazole	B-Chemical
in	O
the	O
aetiology	O
of	O
the	O
haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
is	O
not	O
established	O
firmly	O
,	O
the	O
action	O
of	O
this	O
drug	O
in	O
sensitizing	O
tissues	O
to	O
oxidation	O
injury	O
and	O
the	O
reported	O
evidence	O
of	O
oxidation	O
changes	O
in	O
the	O
haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
suggest	O
a	O
possible	O
link	O
between	O
metronidazole	B-Chemical
treatment	O
and	O
some	O
cases	O
of	O
the	O
haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
.	O
Adverse	O
cardiac	O
effects	O
during	O
induction	O
chemotherapy	O
treatment	O
with	O
cis	B-Chemical
-	I-Chemical
platin	I-Chemical
and	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
.	O
Survival	O
for	O
patients	O
with	O
advanced	O
head	B-Disease
and	I-Disease
neck	I-Disease
carcinoma	I-Disease
and	O
esophageal	B-Disease
carcinoma	I-Disease
is	O
poor	O
with	O
radiotherapy	O
and	O
/	O
or	O
surgery	O
.	O
Obviously	O
,	O
there	O
is	O
a	O
need	O
for	O
effective	O
chemotherapy	O
.	O
In	O
the	O
present	O
study	O
,	O
cis	B-Chemical
-	I-Chemical
platin	I-Chemical
(	O
80	O
-	O
120	O
mg	O
/	O
m2BSA	O
)	O
and	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
1000	O
mg	O
/	O
m2BSA	O
daily	O
as	O
a	O
continuous	O
infusion	O
during	O
5	O
days	O
)	O
were	O
given	O
to	O
76	O
patients	O
before	O
radiotherapy	O
and	O
surgery	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
clarify	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	O
cardiac	O
effects	O
to	O
this	O
treatment	O
.	O
Before	O
treatment	O
all	O
patients	O
had	O
a	O
cardiac	O
evaluation	O
and	O
during	O
treatment	O
serial	O
ECG	O
recordings	O
were	O
performed	O
.	O
In	O
the	O
pre	O
-	O
treatment	O
evaluation	O
,	O
signs	O
of	O
cardiovascular	B-Disease
disease	I-Disease
were	O
found	O
in	O
33	O
patients	O
(	O
43	O
%	O
)	O
.	O
During	O
treatment	O
,	O
adverse	O
cardiac	O
effects	O
were	O
observed	O
in	O
14	O
patients	O
(	O
18	O
%	O
)	O
.	O
The	O
mean	O
age	O
of	O
these	O
patients	O
was	O
the	O
same	O
as	O
for	O
the	O
entire	O
group	O
,	O
64	O
years	O
.	O
The	O
incidence	O
of	O
cardiotoxicity	B-Disease
was	O
not	O
higher	O
in	O
patients	O
with	O
signs	O
of	O
cardiovascular	B-Disease
disease	I-Disease
than	O
in	O
those	O
without	O
in	O
the	O
pre	O
-	O
treatment	O
evaluation	O
.	O
The	O
most	O
common	O
signs	O
of	O
cardiotoxicity	B-Disease
were	O
chest	B-Disease
pain	I-Disease
,	O
ST	O
-	O
T	O
wave	O
changes	O
and	O
atrial	B-Disease
fibrillation	I-Disease
.	O
This	O
was	O
followed	O
by	O
ventricular	B-Disease
fibrillation	I-Disease
in	O
one	O
patient	O
and	O
sudden	B-Disease
death	I-Disease
in	O
another	O
.	O
It	O
is	O
concluded	O
that	O
patients	O
on	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
treatment	O
should	O
be	O
under	O
close	O
supervision	O
and	O
that	O
the	O
treatment	O
should	O
be	O
discontinued	O
if	O
chest	B-Disease
pain	I-Disease
or	O
tachyarrhythmia	B-Disease
is	O
observed	O
.	O
Death	B-Disease
from	O
chemotherapy	O
in	O
gestational	B-Disease
trophoblastic	I-Disease
disease	I-Disease
.	O
Multiple	O
cytotoxic	O
drug	O
administration	O
is	O
the	O
generally	O
accepted	O
treatment	O
of	O
patients	O
with	O
a	O
high	O
-	O
risk	O
stage	O
of	O
choriocarcinoma	B-Disease
.	O
Based	O
on	O
this	O
principle	O
a	O
27	O
-	O
year	O
old	O
woman	O
,	O
classified	O
as	O
being	O
in	O
the	O
high	O
-	O
risk	O
group	O
(	O
Goldstein	O
and	O
Berkowitz	O
score	O
:	O
11	O
)	O
,	O
was	O
treated	O
with	O
multiple	O
cytotoxic	O
drugs	O
.	O
The	O
multiple	O
drug	O
schema	O
consisted	O
of	O
:	O
Etoposide	B-Chemical
16	O
.	O
213	O
,	O
Methotrexate	B-Chemical
,	O
Cyclophosphamide	B-Chemical
,	O
Actomycin	B-Chemical
-	I-Chemical
D	I-Chemical
,	O
and	O
Cisplatin	B-Chemical
.	O
On	O
the	O
first	O
day	O
of	O
the	O
schedule	O
,	O
moderate	O
high	O
doses	O
of	O
Methotrexate	B-Chemical
,	O
Etoposide	B-Chemical
and	O
Cyclophosphamide	B-Chemical
were	O
administered	O
.	O
Within	O
8	O
hours	O
after	O
initiation	O
of	O
therapy	O
the	O
patient	O
died	O
with	O
a	O
clinical	O
picture	O
resembling	O
massive	O
pulmonary	B-Disease
obstruction	I-Disease
due	O
to	O
choriocarcinomic	O
tissue	O
plugs	O
,	O
probably	O
originating	O
from	O
the	O
uterus	O
.	O
Formation	O
of	O
these	O
plugs	O
was	O
probably	O
due	O
to	O
extensive	O
tumor	B-Disease
necrosis	B-Disease
at	O
the	O
level	O
of	O
the	O
walls	O
of	O
the	O
major	O
uterine	O
veins	O
,	O
which	O
resulted	O
in	O
an	O
open	O
exchange	O
of	O
tumor	B-Disease
plugs	O
to	O
the	O
vascular	O
spaces	O
;	O
decrease	O
in	O
tumor	B-Disease
tissue	O
coherence	O
secondary	O
to	O
chemotherapy	O
may	O
have	O
further	O
contributed	O
to	O
the	O
formation	O
of	O
tumor	B-Disease
emboli	O
.	O
In	O
view	O
of	O
the	O
close	O
time	O
association	O
between	O
the	O
start	O
of	O
chemotherapy	O
and	O
the	O
acute	O
onset	O
of	O
massive	O
embolism	B-Disease
other	O
explanations	O
,	O
such	O
as	O
spontaneous	O
necrosis	B-Disease
,	O
must	O
be	O
considered	O
less	O
likely	O
.	O
Patients	O
with	O
large	O
pelvic	B-Disease
tumor	I-Disease
loads	O
are	O
,	O
according	O
to	O
existing	O
classifications	O
,	O
at	O
high	O
risk	O
to	O
die	O
and	O
to	O
develop	O
drug	O
resistance	O
.	O
Notwithstanding	O
these	O
facts	O
our	O
findings	O
suggest	O
that	O
these	O
patients	O
might	O
benefit	O
from	O
relatively	O
mild	O
initial	O
treatment	O
,	O
especially	O
true	O
for	O
patients	O
not	O
previously	O
exposed	O
to	O
this	O
drug	O
.	O
Close	O
observation	O
of	O
the	O
response	O
status	O
both	O
clinically	O
and	O
with	O
beta	O
-	O
hCG	O
values	O
may	O
indicate	O
whether	O
and	O
when	O
more	O
agressive	O
combination	O
chemotherapy	O
should	O
be	O
started	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Pulmonary	O
shunt	O
and	O
cardiovascular	O
responses	O
to	O
CPAP	O
during	O
nitroprusside	B-Chemical
-	O
induced	O
hypotension	B-Disease
.	O
The	O
effects	O
of	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
on	O
cardiovascular	O
dynamics	O
and	O
pulmonary	O
shunt	O
(	O
QS	O
/	O
QT	O
)	O
were	O
investigated	O
in	O
12	O
dogs	O
before	O
and	O
during	O
sodium	B-Chemical
nitroprusside	I-Chemical
infusion	O
that	O
decreased	O
mean	O
arterial	O
blood	O
pressure	O
40	O
-	O
50	O
per	O
cent	O
.	O
Before	O
nitroprusside	B-Chemical
infusion	O
,	O
5	O
cm	O
H2O	B-Chemical
CPAP	O
significantly	O
,	O
P	O
less	O
than	O
.	O
05	O
,	O
decreased	O
arterial	O
blood	O
pressure	O
,	O
but	O
did	O
not	O
significantly	O
alter	O
heart	O
rate	O
,	O
cardiac	O
output	O
,	O
systemic	O
vascular	O
resistance	O
,	O
or	O
QS	O
/	O
QT	O
.	O
Ten	O
cm	O
H2O	B-Chemical
CPAP	O
before	O
nitroprusside	B-Chemical
infusion	O
produced	O
a	O
further	O
decrease	B-Disease
in	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
significantly	O
increased	O
heart	O
rate	O
and	O
decreased	B-Disease
cardiac	I-Disease
output	I-Disease
and	O
QS	O
/	O
QT	O
.	O
Nitroprusside	B-Chemical
caused	O
significant	O
decreases	B-Disease
in	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
systemic	O
vascular	O
resistance	O
and	O
increases	O
in	O
heart	O
rate	O
,	O
but	O
did	O
not	O
change	O
cardiac	O
output	O
or	O
QS	O
/	O
QT	O
.	O
Five	O
cm	O
H2O	B-Chemical
CPAP	O
during	O
nitroprusside	B-Chemical
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above	O
-	O
mentioned	O
variables	O
.	O
However	O
,	O
10	O
cm	O
H2O	B-Chemical
CPAP	O
decreased	O
arterial	O
blood	O
pressure	O
,	O
cardiac	O
output	O
,	O
and	O
QS	O
/	O
QT	O
.	O
These	O
data	O
indicate	O
that	O
nitroprusside	B-Chemical
infusion	O
rates	O
that	O
decrease	O
mean	O
arterial	O
blood	O
pressure	O
by	O
40	O
-	O
50	O
per	O
cent	O
do	O
not	O
change	O
cardiac	O
output	O
or	O
QS	O
/	O
QT	O
.	O
During	O
nitroprusside	B-Chemical
infusion	O
low	O
levels	O
of	O
CPAP	O
do	O
not	O
markedly	O
alter	O
cardiovascular	O
dynamics	O
,	O
but	O
high	O
levels	O
of	O
CPAP	O
(	O
10	O
cm	O
H2O	B-Chemical
)	O
,	O
while	O
decreasing	O
QS	O
/	O
QT	O
,	O
produce	O
marked	O
decreases	B-Disease
in	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
and	I-Disease
cardiac	I-Disease
output	I-Disease
.	O
Systolic	O
pressure	O
variation	O
is	O
greater	O
during	O
hemorrhage	B-Disease
than	O
during	O
sodium	B-Chemical
nitroprusside	I-Chemical
-	O
induced	O
hypotension	B-Disease
in	O
ventilated	O
dogs	O
.	O
The	O
systolic	O
pressure	O
variation	O
(	O
SPV	O
)	O
,	O
which	O
is	O
the	O
difference	O
between	O
the	O
maximal	O
and	O
minimal	O
values	O
of	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
after	O
one	O
positive	O
-	O
pressure	O
breath	O
,	O
was	O
studied	O
in	O
ventilated	O
dogs	O
subjected	O
to	O
hypotension	B-Disease
.	O
Mean	O
arterial	O
pressure	O
was	O
decreased	O
to	O
50	O
mm	O
Hg	O
for	O
30	O
minutes	O
either	O
by	O
hemorrhage	B-Disease
(	O
HEM	B-Disease
,	O
n	O
=	O
7	O
)	O
or	O
by	O
continuous	O
infusion	O
of	O
sodium	B-Chemical
nitroprusside	I-Chemical
(	O
SNP	B-Chemical
,	O
n	O
=	O
7	O
)	O
.	O
During	O
HEM	B-Disease
-	O
induced	O
hypotension	B-Disease
the	O
cardiac	O
output	O
was	O
significantly	O
lower	O
and	O
systemic	O
vascular	O
resistance	O
higher	O
compared	O
with	O
that	O
in	O
the	O
SNP	B-Chemical
group	O
.	O
The	O
systemic	O
,	O
central	O
venous	O
,	O
pulmonary	O
capillary	O
wedge	O
pressures	O
,	O
and	O
heart	O
rates	O
,	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O
Analysis	O
of	O
the	O
respiratory	O
changes	O
in	O
the	O
arterial	O
pressure	O
waveform	O
enabled	O
differentiation	O
between	O
the	O
two	O
groups	O
.	O
The	O
SPV	O
during	O
hypotension	B-Disease
was	O
15	O
.	O
7	O
+	O
/	O
-	O
6	O
.	O
7	O
mm	O
Hg	O
in	O
the	O
HEM	B-Disease
group	O
,	O
compared	O
with	O
9	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
0	O
mm	O
Hg	O
in	O
the	O
SNP	B-Chemical
group	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O
The	O
delta	O
down	O
,	O
which	O
is	O
the	O
measure	O
of	O
decrease	O
of	O
SBP	O
after	O
a	O
mechanical	O
breath	O
,	O
was	O
20	O
.	O
3	O
+	O
/	O
-	O
8	O
.	O
4	O
and	O
10	O
.	O
1	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
in	O
the	O
HEM	B-Disease
and	O
SNP	B-Chemical
groups	O
,	O
respectively	O
,	O
during	O
hypotension	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O
It	O
is	O
concluded	O
that	O
increases	O
in	O
the	O
SPV	O
and	O
the	O
delta	O
down	O
are	O
characteristic	O
of	O
a	O
hypotensive	B-Disease
state	O
due	O
to	O
a	O
predominant	O
decrease	O
in	O
preload	O
.	O
They	O
are	O
thus	O
more	O
important	O
during	O
absolute	O
hypovolemia	B-Disease
than	O
during	O
deliberate	O
hypotension	B-Disease
.	O
Ventricular	B-Disease
tachyarrhythmias	I-Disease
during	O
cesarean	O
section	O
after	O
ritodrine	B-Chemical
therapy	O
:	O
interaction	O
with	O
anesthetics	O
.	O
This	O
case	O
illustrates	O
that	O
patients	O
receiving	O
ritodrine	B-Chemical
for	O
preterm	B-Disease
labor	I-Disease
may	O
risk	O
interactions	O
between	O
the	O
residual	O
betamimetic	O
effects	O
of	O
ritodrine	B-Chemical
and	O
the	O
effects	O
of	O
anesthetics	O
during	O
cesarean	O
section	O
.	O
Such	O
interactions	O
may	O
result	O
in	O
serious	O
cardiovascular	B-Disease
complications	I-Disease
even	O
after	O
cessation	O
of	O
an	O
infusion	O
of	O
ritodrine	B-Chemical
.	O
Preoperative	O
assessment	O
should	O
focus	O
on	O
cardiovascular	O
status	O
and	O
serum	O
potassium	B-Chemical
level	O
.	O
Delaying	O
induction	O
of	O
anesthesia	O
should	O
be	O
considered	O
whenever	O
possible	O
.	O
Careful	O
fluid	O
administration	O
and	O
cautious	O
use	O
of	O
titrated	O
doses	O
of	O
ephedrine	B-Chemical
are	O
advised	O
.	O
After	O
delivery	O
of	O
the	O
infant	O
,	O
there	O
should	O
be	O
no	O
contraindication	O
to	O
the	O
use	O
of	O
an	O
alpha	O
-	O
adrenergic	O
vasopressor	O
such	O
as	O
phenylephrine	B-Chemical
to	O
treat	O
hypotensive	B-Disease
patients	O
with	O
tachycardia	B-Disease
.	O
Verapamil	B-Chemical
-	O
induced	O
carbamazepine	B-Chemical
neurotoxicity	B-Disease
.	O
A	O
report	O
of	O
two	O
cases	O
.	O
Two	O
patients	O
with	O
signs	O
of	O
carbamazepine	B-Chemical
neurotoxicity	B-Disease
after	O
combined	O
treatment	O
with	O
verapamil	B-Chemical
showed	O
complete	O
recovery	O
after	O
discontinuation	O
of	O
the	O
calcium	B-Chemical
entry	O
blocker	O
.	O
Use	O
of	O
verapamil	B-Chemical
in	O
combination	O
with	O
carbamazepine	B-Chemical
should	O
either	O
be	O
avoided	O
or	O
prescribed	O
only	O
with	O
appropriate	O
adjustment	O
of	O
the	O
carbamazepine	B-Chemical
dose	O
(	O
usually	O
reduction	O
of	O
the	O
carbamazepine	B-Chemical
dose	O
by	O
one	O
half	O
)	O
.	O
Paracetamol	B-Chemical
-	O
associated	O
coma	B-Disease
,	O
metabolic	B-Disease
acidosis	I-Disease
,	O
renal	B-Disease
and	I-Disease
hepatic	I-Disease
failure	I-Disease
.	O
A	O
case	O
of	O
metabolic	B-Disease
acidosis	I-Disease
,	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
and	I-Disease
hepatic	I-Disease
failure	I-Disease
following	O
paracetamol	B-Chemical
ingestion	O
is	O
presented	O
.	O
The	O
diagnostic	O
difficulty	O
at	O
presentation	O
is	O
highlighted	O
.	O
Continuous	O
arteriovenous	O
haemofiltration	O
proved	O
a	O
valuable	O
means	O
of	O
maintaining	O
fluid	O
and	O
electrolyte	O
balance	O
.	O
The	O
patient	O
recovered	O
.	O
Sexual	B-Disease
dysfunction	I-Disease
among	O
patients	O
with	O
arthritis	B-Disease
.	O
The	O
relationship	O
of	O
arthritis	B-Disease
and	O
sexual	B-Disease
dysfunction	I-Disease
was	O
investigated	O
among	O
169	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
,	O
osteoarthritis	B-Disease
and	O
spondyloarthropathy	B-Disease
,	O
130	O
of	O
whom	O
were	O
pair	O
-	O
matched	O
to	O
controls	O
.	O
Assessments	O
of	O
marital	O
happiness	O
and	O
depressed	B-Disease
mood	I-Disease
were	O
also	O
made	O
using	O
the	O
CES	O
-	O
D	O
and	O
the	O
Azrin	O
Marital	O
Happiness	O
Scale	O
(	O
AMHS	O
)	O
.	O
Sexual	B-Disease
dysfunctions	I-Disease
were	O
found	O
to	O
be	O
common	O
among	O
patients	O
and	O
controls	O
,	O
the	O
majority	O
in	O
both	O
groups	O
reporting	O
one	O
or	O
more	O
dysfunctions	O
.	O
Impotence	B-Disease
was	O
more	O
common	O
among	O
male	O
patients	O
than	O
controls	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
co	O
-	O
morbidity	O
and	O
the	O
taking	O
of	O
methotrexate	B-Chemical
.	O
Depressed	B-Disease
mood	I-Disease
was	O
more	O
common	O
among	O
patients	O
and	O
was	O
associated	O
with	O
certain	O
sexual	O
difficulties	O
,	O
but	O
not	O
with	O
impotence	B-Disease
.	O
Marital	O
unhappiness	O
,	O
as	O
indicated	O
by	O
AMHS	O
scores	O
,	O
was	O
not	O
associated	O
with	O
arthritis	B-Disease
but	O
was	O
associated	O
with	O
sexual	B-Disease
dysfunction	I-Disease
,	O
sexual	O
dissatisfaction	O
and	O
being	O
female	O
.	O
Does	O
paracetamol	B-Chemical
cause	O
urothelial	B-Disease
cancer	I-Disease
or	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
?	O
The	O
risk	O
of	O
developing	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
or	O
cancer	B-Disease
of	I-Disease
the	I-Disease
renal	I-Disease
pelvis	I-Disease
,	I-Disease
ureter	I-Disease
or	I-Disease
bladder	I-Disease
associated	O
with	O
consumption	O
of	O
either	O
phenacetin	B-Chemical
or	O
paracetamol	B-Chemical
was	O
calculated	O
from	O
data	O
acquired	O
by	O
questionnaire	O
from	O
381	O
cases	O
and	O
808	O
controls	O
.	O
The	O
risk	O
of	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
was	O
increased	O
nearly	O
20	O
-	O
fold	O
by	O
consumption	O
of	O
phenacetin	B-Chemical
,	O
which	O
also	O
increased	O
the	O
risk	O
for	O
cancer	B-Disease
of	I-Disease
the	I-Disease
renal	I-Disease
pelvis	I-Disease
and	I-Disease
bladder	I-Disease
but	O
not	O
for	O
ureteric	B-Disease
cancer	I-Disease
.	O
By	O
contrast	O
,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
increased	O
risk	O
from	O
paracetamol	B-Chemical
consumption	O
for	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
or	O
any	O
of	O
these	O
cancers	B-Disease
although	O
there	O
was	O
a	O
suggestion	O
of	O
an	O
association	O
with	O
cancer	B-Disease
of	I-Disease
the	I-Disease
ureter	I-Disease
.	O
Dapsone	B-Chemical
-	O
associated	O
Heinz	O
body	O
hemolytic	B-Disease
anemia	I-Disease
in	O
a	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
.	O
A	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
(	O
AE	O
)	O
and	O
leprosy	B-Disease
developed	O
a	O
Heinz	O
body	O
hemolytic	B-Disease
anemia	I-Disease
while	O
taking	O
a	O
dose	O
of	O
dapsone	B-Chemical
(	O
50	O
mg	O
/	O
day	O
)	O
not	O
usually	O
associated	O
with	O
clinical	O
hemolysis	B-Disease
.	O
Her	O
red	O
blood	O
cells	O
(	O
RBCs	O
)	O
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
decreased	O
reduced	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
)	O
,	O
and	O
decreased	O
GSH	B-Chemical
stability	O
.	O
The	O
pentose	B-Chemical
phosphate	I-Chemical
shunt	O
activity	O
of	O
the	O
dapsone	B-Chemical
-	O
exposed	O
AE	O
RBCs	O
was	O
increased	O
compared	O
to	O
normal	O
RBCs	O
.	O
Although	O
the	O
AE	O
RBCs	O
from	O
an	O
individual	O
not	O
taking	O
dapsone	B-Chemical
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
the	O
GSH	B-Chemical
content	O
and	O
GSH	B-Chemical
stability	O
were	O
normal	O
.	O
The	O
pentose	B-Chemical
phosphate	I-Chemical
shunt	O
activity	O
of	O
the	O
non	O
-	O
dapsone	B-Chemical
-	O
exposed	O
AE	O
RBCs	O
was	O
decreased	O
compared	O
to	O
normal	O
RBCs	O
.	O
Thus	O
,	O
AE	O
RBCs	O
appear	O
to	O
have	O
an	O
increased	O
sensitivity	O
to	O
oxidant	O
stress	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
dapsone	B-Chemical
does	O
not	O
cause	O
hemolytic	B-Disease
anemia	I-Disease
at	O
this	O
dose	O
in	O
hematologically	O
normal	O
individuals	O
.	O
Given	O
the	O
influx	O
of	O
Southeast	O
Asians	O
into	O
the	O
United	O
States	O
,	O
oxidant	O
medications	O
should	O
be	O
used	O
with	O
caution	O
,	O
especially	O
if	O
an	O
infection	B-Disease
is	O
present	O
,	O
in	O
individuals	O
of	O
ethnic	O
backgrounds	O
that	O
have	O
an	O
increased	O
prevalence	O
of	O
hemoglobin	O
E	O
.	O
Severe	O
complications	O
of	O
antianginal	O
drug	O
therapy	O
in	O
a	O
patient	O
identified	O
as	O
a	O
poor	O
metabolizer	O
of	O
metoprolol	B-Chemical
,	O
propafenone	B-Chemical
,	O
diltiazem	B-Chemical
,	O
and	O
sparteine	B-Chemical
.	O
A	O
47	O
-	O
year	O
-	O
old	O
patient	O
suffering	O
from	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
was	O
admitted	O
to	O
the	O
CCU	O
in	O
shock	B-Disease
with	O
III	O
.	O
AV	B-Disease
block	I-Disease
,	O
severe	O
hypotension	B-Disease
,	O
and	O
impairment	B-Disease
of	I-Disease
ventricular	I-Disease
function	I-Disease
.	O
One	O
week	O
prior	O
to	O
admission	O
a	O
therapy	O
with	O
standard	O
doses	O
of	O
metoprolol	B-Chemical
(	O
100	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
and	O
then	O
100	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
had	O
been	O
initiated	O
.	O
Two	O
days	O
before	O
admission	O
diltiazem	B-Chemical
(	O
60	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
was	O
prescribed	O
in	O
addition	O
.	O
Analyses	O
of	O
a	O
blood	O
sample	O
revealed	O
unusually	O
high	O
plasma	O
concentrations	O
of	O
metoprolol	B-Chemical
(	O
greater	O
than	O
3000	O
ng	O
/	O
ml	O
)	O
and	O
diltiazem	B-Chemical
(	O
526	O
ng	O
/	O
ml	O
)	O
.	O
The	O
patient	O
recovered	O
within	O
1	O
week	O
following	O
discontinuation	O
of	O
antianginal	O
therapy	O
.	O
Three	O
months	O
later	O
the	O
patient	O
was	O
exposed	O
to	O
a	O
single	O
dose	O
of	O
metoprolol	B-Chemical
,	O
diltiazem	B-Chemical
,	O
propafenone	B-Chemical
(	O
since	O
he	O
had	O
received	O
this	O
drug	O
in	O
the	O
past	O
)	O
,	O
and	O
sparteine	B-Chemical
(	O
as	O
a	O
probe	O
for	O
the	O
debrisoquine	B-Chemical
/	O
sparteine	B-Chemical
type	O
polymorphism	O
of	O
oxidative	O
drug	O
metabolism	O
)	O
.	O
It	O
was	O
found	O
that	O
he	O
was	O
a	O
poor	O
metabolizer	O
of	O
all	O
four	O
drugs	O
,	O
indicating	O
that	O
their	O
metabolism	O
is	O
under	O
the	O
same	O
genetic	O
control	O
.	O
Therefore	O
,	O
patients	O
belonging	O
to	O
the	O
poor	O
-	O
metabolizer	O
phenotype	O
of	O
sparteine	B-Chemical
/	O
debrisoquine	B-Chemical
polymorphism	O
in	O
drug	O
metabolism	O
,	O
which	O
constitutes	O
6	O
.	O
4	O
%	O
of	O
the	O
German	O
population	O
,	O
may	O
experience	O
adverse	B-Disease
drug	I-Disease
reactions	I-Disease
when	O
treated	O
with	O
standard	O
doses	O
of	O
one	O
of	O
these	O
drugs	O
alone	O
.	O
Moreover	O
,	O
the	O
coadministration	O
of	O
these	O
frequently	O
used	O
drugs	O
is	O
expected	O
to	O
be	O
especially	O
harmful	O
in	O
this	O
subgroup	O
of	O
patients	O
.	O
Clinical	O
experiences	O
in	O
an	O
open	O
and	O
a	O
double	O
-	O
blind	O
trial	O
.	O
A	O
total	O
of	O
sixty	O
patients	O
were	O
trated	O
with	O
bromperidol	B-Chemical
first	O
in	O
open	O
conditions	O
(	O
20	O
patients	O
)	O
,	O
then	O
on	O
a	O
double	O
blind	O
basis	O
(	O
40	O
patients	O
)	O
with	O
haloperidol	B-Chemical
as	O
the	O
reference	O
substance	O
.	O
The	O
open	O
study	O
lasted	O
for	O
four	O
weeks	O
;	O
the	O
drug	O
was	O
administrated	O
in	O
the	O
form	O
of	O
1	O
mg	O
tablets	O
.	O
The	O
daily	O
dose	O
(	O
initial	O
dose	O
:	O
1	O
mg	O
;	O
mean	O
dose	O
at	O
the	O
end	O
of	O
the	O
trial	O
:	O
4	O
.	O
47	O
mg	O
)	O
was	O
always	O
administered	O
in	O
one	O
single	O
dose	O
.	O
Nineteen	O
patients	O
finished	O
the	O
trial	O
,	O
and	O
in	O
18	O
cases	O
the	O
therapeutic	O
result	O
was	O
considered	O
very	O
good	O
to	O
good	O
.	O
These	O
results	O
were	O
confirmed	O
by	O
statistical	O
analysis	O
.	O
Nine	O
patients	O
exhibited	O
mild	O
to	O
moderate	O
extrapyramidal	B-Disease
concomitant	I-Disease
symptoms	I-Disease
;	O
no	O
other	O
side	O
effects	O
were	O
observed	O
.	O
The	O
results	O
of	O
detailed	O
laboratory	O
tests	O
and	O
evaluations	O
of	O
various	O
quantitative	O
and	O
qualitative	O
tolerability	O
parameters	O
were	O
not	O
indicative	O
of	O
toxic	O
effects	O
.	O
In	O
the	O
double	O
blind	O
study	O
with	O
haloperidol	B-Chemical
,	O
both	O
substances	O
were	O
found	O
to	O
be	O
highly	O
effective	O
in	O
the	O
treatment	O
of	O
psychotic	B-Disease
syndromes	I-Disease
belonging	I-Disease
predominantly	I-Disease
to	I-Disease
the	I-Disease
schizophrenia	I-Disease
group	I-Disease
.	O
Certain	O
clues	O
,	O
including	O
the	O
onset	O
of	O
action	O
,	O
seem	O
to	O
be	O
indicative	O
of	O
the	O
superiority	O
of	O
bromperidol	B-Chemical
.	O
No	O
differences	O
were	O
observed	O
with	O
respect	O
to	O
side	O
effects	O
and	O
general	O
tolerability	O
.	O
Prolonged	O
cholestasis	B-Disease
after	O
troleandomycin	B-Chemical
-	O
induced	O
acute	O
hepatitis	B-Disease
.	O
We	O
report	O
the	O
case	O
of	O
a	O
patient	O
in	O
whom	O
troleandomycin	B-Chemical
-	O
induced	O
hepatitis	B-Disease
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	B-Disease
.	O
Jaundice	B-Disease
occurred	O
after	O
administration	O
of	O
troleandomycin	B-Chemical
for	O
7	O
days	O
and	O
was	O
associated	O
with	O
hypereosinophilia	B-Disease
.	O
Jaundice	B-Disease
disappeared	O
within	O
3	O
months	O
but	O
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	B-Disease
marked	O
by	O
pruritus	B-Disease
and	O
high	O
levels	O
of	O
alkaline	O
phosphatase	O
and	O
gammaglutamyltransferase	O
activities	O
.	O
Finally	O
,	O
pruritus	B-Disease
disappeared	O
within	O
19	O
months	O
,	O
and	O
liver	O
tests	O
returned	O
to	O
normal	O
27	O
months	O
after	O
the	O
onset	O
of	O
hepatitis	B-Disease
.	O
This	O
observation	O
demonstrates	O
that	O
prolonged	O
cholestasis	B-Disease
can	O
follow	O
troleandomycin	B-Chemical
-	O
induced	O
acute	O
hepatitis	B-Disease
.	O
Serial	O
studies	O
of	O
auditory	B-Disease
neurotoxicity	I-Disease
in	O
patients	O
receiving	O
deferoxamine	B-Chemical
therapy	O
.	O
Visual	B-Disease
and	I-Disease
auditory	I-Disease
neurotoxicity	I-Disease
was	O
previously	O
documented	O
in	O
42	O
of	O
89	O
patients	O
with	O
transfusion	O
-	O
dependent	O
anemia	B-Disease
who	O
were	O
receiving	O
iron	B-Chemical
chelation	O
therapy	O
with	O
daily	O
subcutaneous	O
deferoxamine	B-Chemical
.	O
Twenty	O
-	O
two	O
patients	O
in	O
the	O
affected	O
group	O
had	O
abnormal	B-Disease
audiograms	I-Disease
with	I-Disease
deficits	I-Disease
mostly	I-Disease
in	I-Disease
the	I-Disease
high	I-Disease
frequency	I-Disease
range	I-Disease
of	I-Disease
4	I-Disease
,	I-Disease
000	I-Disease
to	I-Disease
8	I-Disease
,	I-Disease
000	I-Disease
Hz	I-Disease
and	O
in	O
the	O
hearing	O
threshold	O
levels	O
of	O
30	O
to	O
100	O
decibels	O
.	O
When	O
deferoxamine	B-Chemical
therapy	O
was	O
discontinued	O
and	O
serial	O
studies	O
were	O
performed	O
,	O
audiograms	O
in	O
seven	O
cases	O
reverted	O
to	O
normal	O
or	O
near	O
normal	O
within	O
two	O
to	O
three	O
weeks	O
,	O
and	O
nine	O
of	O
13	O
patients	O
with	O
symptoms	O
became	O
asymptomatic	O
.	O
Audiograms	O
from	O
15	O
patients	O
remained	O
abnormal	O
and	O
four	O
patients	O
required	O
hearing	O
aids	O
because	O
of	O
permanent	B-Disease
disability	I-Disease
.	O
Since	O
18	O
of	O
the	O
22	O
patients	O
were	O
initially	O
receiving	O
deferoxamine	B-Chemical
doses	O
in	O
excess	O
of	O
the	O
commonly	O
recommended	O
50	O
mg	O
/	O
kg	O
per	O
dose	O
,	O
therapy	O
was	O
restarted	O
with	O
lower	O
doses	O
,	O
usually	O
50	O
mg	O
/	O
kg	O
per	O
dose	O
or	O
less	O
depending	O
on	O
the	O
degree	O
of	O
auditory	B-Disease
abnormality	I-Disease
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
cases	O
no	O
further	O
toxicity	B-Disease
was	O
demonstrated	O
.	O
Auditory	O
deterioration	O
and	O
improvement	O
,	O
demonstrated	O
serially	O
in	O
individual	O
patients	O
receiving	O
and	O
not	O
receiving	O
deferoxamine	B-Chemical
,	O
respectively	O
,	O
provided	O
convincing	O
evidence	O
for	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relation	O
between	O
deferoxamine	B-Chemical
administration	O
and	O
ototoxicity	B-Disease
.	O
Based	O
on	O
these	O
data	O
,	O
a	O
plan	O
of	O
management	O
was	O
developed	O
that	O
allows	O
effective	O
yet	O
safe	O
administration	O
of	O
deferoxamine	B-Chemical
.	O
A	O
dose	O
of	O
50	O
mg	O
/	O
kg	O
is	O
recommended	O
in	O
those	O
without	O
audiogram	O
abnormalities	O
.	O
With	O
mild	O
toxicity	B-Disease
,	O
a	O
reduction	O
to	O
30	O
or	O
40	O
mg	O
/	O
kg	O
per	O
dose	O
should	O
result	O
in	O
a	O
reversal	O
of	O
the	O
abnormal	O
results	O
to	O
normal	O
within	O
four	O
weeks	O
.	O
Moderate	O
abnormalities	O
require	O
a	O
reduction	O
of	O
deferoxamine	B-Chemical
to	O
25	O
mg	O
/	O
kg	O
per	O
dose	O
with	O
careful	O
monitoring	O
.	O
In	O
those	O
with	O
symptoms	O
of	O
hearing	B-Disease
loss	I-Disease
,	O
the	O
drug	O
should	O
be	O
stopped	O
for	O
four	O
weeks	O
,	O
and	O
when	O
the	O
audiogram	O
is	O
stable	O
or	O
improved	O
,	O
therapy	O
should	O
be	O
restarted	O
at	O
10	O
to	O
25	O
mg	O
/	O
kg	O
per	O
dose	O
.	O
Serial	O
audiograms	O
should	O
be	O
performed	O
every	O
six	O
months	O
in	O
those	O
without	O
problems	O
and	O
more	O
frequently	O
in	O
young	O
patients	O
with	O
normal	O
serum	O
ferritin	O
values	O
and	O
in	O
those	O
with	O
auditory	B-Disease
dysfunction	I-Disease
.	O
Lidocaine	B-Chemical
-	O
induced	O
cardiac	B-Disease
asystole	I-Disease
.	O
Intravenous	O
administration	O
of	O
a	O
single	O
50	O
-	O
mg	O
bolus	O
of	O
lidocaine	B-Chemical
in	O
a	O
67	O
-	O
year	O
-	O
old	O
man	O
resulted	O
in	O
profound	O
depression	B-Disease
of	O
the	O
activity	O
of	O
the	O
sinoatrial	O
and	O
atrioventricular	O
nodal	O
pacemakers	O
.	O
The	O
patient	O
had	O
no	O
apparent	O
associated	O
conditions	O
which	O
might	O
have	O
predisposed	O
him	O
to	O
the	O
development	O
of	O
bradyarrhythmias	B-Disease
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idiosyncrasy	O
to	O
lidocaine	B-Chemical
.	O
Flurbiprofen	B-Chemical
in	O
the	O
treatment	O
of	O
juvenile	B-Disease
rheumatoid	I-Disease
arthritis	I-Disease
.	O
Thirty	O
-	O
four	O
patients	O
with	O
juvenile	B-Disease
rheumatoid	I-Disease
arthritis	I-Disease
,	O
who	O
were	O
treated	O
with	O
flurbiprofen	B-Chemical
at	O
a	O
maximum	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
/	O
day	O
,	O
had	O
statistically	O
significant	O
decreases	O
from	O
baseline	O
in	O
6	O
arthritis	B-Disease
indices	O
after	O
12	O
weeks	O
of	O
treatment	O
.	O
Improvements	O
were	O
seen	O
in	O
the	O
number	O
of	O
tender	B-Disease
joints	I-Disease
,	O
the	O
severity	O
of	O
swelling	B-Disease
and	O
tenderness	B-Disease
,	O
the	O
time	O
of	O
walk	O
50	O
feet	O
,	O
the	O
duration	O
of	O
morning	B-Disease
stiffness	I-Disease
and	O
the	O
circumference	O
of	O
the	O
left	O
knee	O
.	O
The	O
most	O
frequently	O
observed	O
side	O
effect	O
was	O
fecal	B-Disease
occult	I-Disease
blood	I-Disease
(	O
25	O
%	O
of	O
patients	O
)	O
;	O
however	O
,	O
there	O
was	O
no	O
other	O
evidence	O
of	O
gastrointestinal	B-Disease
(	I-Disease
GI	I-Disease
)	I-Disease
bleeding	I-Disease
in	O
these	O
patients	O
.	O
One	O
patient	O
was	O
prematurely	O
discontinued	O
from	O
the	O
study	O
for	O
severe	O
headache	B-Disease
and	O
abdominal	B-Disease
pain	I-Disease
.	O
Most	O
side	O
effects	O
were	O
mild	O
and	O
related	O
to	O
the	O
GI	O
tract	O
.	O
Hyperkalemia	B-Disease
associated	O
with	O
sulindac	B-Chemical
therapy	O
.	O
Hyperkalemia	B-Disease
has	O
recently	O
been	O
recognized	O
as	O
a	O
complication	O
of	O
nonsteroidal	O
antiinflammatory	O
agents	O
(	O
NSAID	O
)	O
such	O
as	O
indomethacin	B-Chemical
.	O
Several	O
recent	O
studies	O
have	O
stressed	O
the	O
renal	O
sparing	O
features	O
of	O
sulindac	B-Chemical
,	O
owing	O
to	O
its	O
lack	O
of	O
interference	O
with	O
renal	O
prostacyclin	B-Chemical
synthesis	O
.	O
We	O
describe	O
4	O
patients	O
in	O
whom	O
hyperkalemia	B-Disease
ranging	O
from	O
6	O
.	O
1	O
to	O
6	O
.	O
9	O
mEq	O
/	O
l	O
developed	O
within	O
3	O
to	O
8	O
days	O
of	O
sulindac	B-Chemical
administration	O
.	O
In	O
all	O
of	O
them	O
normal	O
serum	O
potassium	B-Chemical
levels	O
reached	O
within	O
2	O
to	O
4	O
days	O
of	O
stopping	O
sulindac	B-Chemical
.	O
As	O
no	O
other	O
medications	O
known	O
to	O
effect	O
serum	O
potassium	B-Chemical
had	O
been	O
given	O
concomitantly	O
,	O
this	O
course	O
of	O
events	O
is	O
suggestive	O
of	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
between	O
sulindac	B-Chemical
and	O
hyperkalemia	B-Disease
.	O
These	O
observations	O
indicate	O
that	O
initial	O
hopes	O
that	O
sulindac	B-Chemical
may	O
not	O
be	O
associated	O
with	O
the	O
adverse	O
renal	O
effects	O
of	O
other	O
NSAID	O
are	O
probably	O
not	O
justified	O
.	O
Drug	O
-	O
induced	O
arterial	O
spasm	B-Disease
relieved	O
by	O
lidocaine	B-Chemical
.	O
Case	O
report	O
.	O
Following	O
major	O
intracranial	O
surgery	O
in	O
a	O
35	O
-	O
year	O
-	O
old	O
man	O
,	O
sodium	B-Chemical
pentothal	I-Chemical
was	O
intravenously	O
infused	O
to	O
minimize	O
cerebral	B-Disease
ischaemia	I-Disease
.	O
Intense	O
vasospasm	B-Disease
with	O
threatened	O
gangrene	B-Disease
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
infusion	O
.	O
Since	O
the	O
cranial	O
condition	O
precluded	O
use	O
of	O
more	O
usual	O
methods	O
,	O
lidocaine	B-Chemical
was	O
given	O
intra	O
-	O
arterially	O
,	O
with	O
careful	O
cardiovascular	O
monitoring	O
,	O
to	O
counteract	O
the	O
vasospasm	B-Disease
.	O
The	O
treatment	O
was	O
rapidly	O
successful	O
.	O
Regional	O
localization	O
of	O
the	O
antagonism	O
of	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
by	O
intracerebral	O
calcitonin	B-Chemical
injections	O
.	O
Calcitonin	B-Chemical
receptors	O
are	O
found	O
in	O
the	O
brain	O
,	O
and	O
intracerebral	O
infusions	O
of	O
calcitonin	B-Chemical
can	O
produce	O
behavioral	O
effects	O
.	O
Among	O
these	O
behavioral	O
effects	O
are	O
decreases	O
in	O
food	O
intake	O
and	O
decreases	O
in	O
amphetamine	B-Chemical
-	O
induced	O
locomotor	O
activity	O
.	O
In	O
previous	O
experiments	O
we	O
found	O
that	O
decreases	O
in	O
food	O
intake	O
were	O
induced	O
by	O
local	O
administration	O
of	O
calcitonin	B-Chemical
into	O
several	O
hypothalamic	O
sites	O
and	O
into	O
the	O
nucleus	O
accumbens	O
.	O
In	O
the	O
present	O
experiment	O
calcitonin	B-Chemical
decreased	O
locomotor	O
activity	O
when	O
locally	O
injected	O
into	O
the	O
same	O
sites	O
where	O
it	O
decreases	O
food	O
intake	O
.	O
The	O
areas	O
where	O
calcitonin	B-Chemical
is	O
most	O
effective	O
in	O
decreasing	O
locomotor	O
activity	O
are	O
located	O
in	O
the	O
hypothalamus	O
and	O
nucleus	O
accumbens	O
,	O
suggesting	O
that	O
these	O
areas	O
are	O
the	O
major	O
sites	O
of	O
action	O
of	O
calcitonin	B-Chemical
in	O
inhibiting	O
amphetamine	B-Chemical
-	O
induced	O
locomotor	O
activity	O
.	O
The	O
hematologic	O
effects	O
of	O
cefonicid	B-Chemical
and	O
cefazedone	B-Chemical
in	O
the	O
dog	O
:	O
a	O
potential	O
model	O
of	O
cephalosporin	B-Chemical
hematotoxicity	B-Disease
in	O
man	O
.	O
Cephalosporin	B-Chemical
antibiotics	O
cause	O
a	O
variety	O
of	O
hematologic	B-Disease
disturbances	I-Disease
in	O
man	O
,	O
the	O
pathogeneses	O
and	O
hematopathology	O
of	O
which	O
remain	O
poorly	O
characterized	O
.	O
There	O
is	O
a	O
need	O
for	O
a	O
well	O
-	O
defined	O
animal	O
model	O
in	O
which	O
these	O
blood	B-Disease
dyscrasias	I-Disease
can	O
be	O
studied	O
.	O
In	O
four	O
subacute	O
toxicity	B-Disease
studies	O
,	O
the	O
intravenous	O
administration	O
of	O
cefonicid	B-Chemical
or	O
cefazedone	B-Chemical
to	O
beagle	O
dogs	O
caused	O
a	O
dose	O
-	O
dependent	O
incidence	O
of	O
anemia	B-Disease
,	O
neutropenia	B-Disease
,	O
and	O
thrombocytopenia	B-Disease
after	O
1	O
-	O
3	O
months	O
of	O
treatment	O
.	O
A	O
nonregenerative	O
anemia	B-Disease
was	O
the	O
most	O
compromising	O
of	O
the	O
cytopenias	B-Disease
and	O
occurred	O
in	O
approximately	O
50	O
%	O
of	O
dogs	O
receiving	O
400	O
-	O
500	O
mg	O
/	O
kg	O
cefonicid	B-Chemical
or	O
540	O
-	O
840	O
mg	O
/	O
kg	O
cefazedone	B-Chemical
.	O
All	O
three	O
cytopenias	B-Disease
were	O
completely	O
reversible	O
following	O
cessation	O
of	O
treatment	O
;	O
the	O
time	O
required	O
for	O
recovery	O
of	O
the	O
erythron	O
(	O
approximately	O
1	O
month	O
)	O
was	O
considerably	O
longer	O
than	O
that	O
of	O
the	O
granulocytes	O
and	O
platelets	O
(	O
hours	O
to	O
a	O
few	O
days	O
)	O
.	O
Upon	O
rechallenge	O
with	O
either	O
cephalosporin	B-Chemical
,	O
the	O
hematologic	B-Disease
syndrome	I-Disease
was	O
reproduced	O
in	O
most	O
dogs	O
tested	O
;	O
cefonicid	B-Chemical
(	O
but	O
not	O
cefazedone	B-Chemical
)	O
-	O
treated	O
dogs	O
showed	O
a	O
substantially	O
reduced	O
induction	O
period	O
(	O
15	O
+	O
/	O
-	O
5	O
days	O
)	O
compared	O
to	O
that	O
of	O
the	O
first	O
exposure	O
to	O
the	O
drug	O
(	O
61	O
+	O
/	O
-	O
24	O
days	O
)	O
.	O
This	O
observation	O
,	O
along	O
with	O
the	O
rapid	O
rate	O
of	O
decline	O
in	O
red	O
cell	O
mass	O
parameters	O
of	O
affected	O
dogs	O
,	O
suggests	O
that	O
a	O
hemolytic	B-Disease
component	O
complicated	O
the	O
red	O
cell	O
production	O
problem	O
and	O
that	O
multiple	O
toxicologic	O
mechanisms	O
contributed	O
to	O
the	O
cytopenia	B-Disease
.	O
We	O
conclude	O
that	O
the	O
administration	O
of	O
high	O
doses	O
of	O
cefonicid	B-Chemical
or	O
cefazedone	B-Chemical
to	O
dogs	O
can	O
induce	O
hematotoxicity	B-Disease
similar	O
to	O
the	O
cephalosporin	B-Chemical
-	O
induced	O
blood	B-Disease
dyscrasias	I-Disease
described	O
in	O
man	O
and	O
thus	O
provides	O
a	O
useful	O
model	O
for	O
studying	O
the	O
mechanisms	O
of	O
these	O
disorders	O
.	O
Cerebral	O
blood	O
flow	O
and	O
metabolism	O
during	O
isoflurane	B-Chemical
-	O
induced	O
hypotension	B-Disease
in	O
patients	O
subjected	O
to	O
surgery	O
for	O
cerebral	B-Disease
aneurysms	I-Disease
.	O
Cerebral	O
blood	O
flow	O
and	O
cerebral	O
metabolic	O
rate	O
for	O
oxygen	B-Chemical
were	O
measured	O
during	O
isoflurane	B-Chemical
-	O
induced	O
hypotension	B-Disease
in	O
10	O
patients	O
subjected	O
to	O
craniotomy	O
for	O
clipping	O
of	O
a	O
cerebral	B-Disease
aneurysm	I-Disease
.	O
Flow	O
and	O
metabolism	O
were	O
measured	O
5	O
-	O
13	O
days	O
after	O
the	O
subarachnoid	B-Disease
haemorrhage	I-Disease
by	O
a	O
modification	O
of	O
the	O
classical	O
Kety	O
-	O
Schmidt	O
technique	O
using	O
xenon	B-Chemical
-	O
133	O
i	O
.	O
v	O
.	O
Anaesthesia	O
was	O
maintained	O
with	O
an	O
inspired	O
isoflurane	B-Chemical
concentration	O
of	O
0	O
.	O
75	O
%	O
(	O
plus	O
67	O
%	O
nitrous	B-Chemical
oxide	I-Chemical
in	O
oxygen	B-Chemical
)	O
,	O
during	O
which	O
CBF	O
and	O
CMRO2	O
were	O
34	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
1	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
and	O
2	O
.	O
32	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
at	O
PaCO2	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
.	O
Controlled	O
hypotension	B-Disease
to	O
an	O
average	O
MAP	O
of	O
50	O
-	O
55	O
mm	O
Hg	B-Chemical
was	O
induced	O
by	O
increasing	O
the	O
dose	O
of	O
isoflurane	B-Chemical
,	O
and	O
maintained	O
at	O
an	O
inspired	O
concentration	O
of	O
2	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
%	O
.	O
This	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
CMRO2	O
(	O
to	O
1	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
)	O
,	O
while	O
CBF	O
was	O
unchanged	O
.	O
After	O
the	O
clipping	O
of	O
the	O
aneurysm	B-Disease
the	O
isoflurane	B-Chemical
concentration	O
was	O
reduced	O
to	O
0	O
.	O
75	O
%	O
.	O
There	O
was	O
a	O
significant	O
increase	O
in	O
CBF	O
,	O
although	O
CMRO2	O
was	O
unchanged	O
,	O
compared	O
with	O
pre	O
-	O
hypotensive	B-Disease
values	O
.	O
These	O
changes	O
might	O
offer	O
protection	O
to	O
brain	O
tissue	O
during	O
periods	O
of	O
induced	O
hypotension	B-Disease
.	O
Triazolam	B-Chemical
-	O
induced	O
brief	O
episodes	O
of	O
secondary	O
mania	B-Disease
in	O
a	O
depressed	B-Disease
patient	O
.	O
Large	O
doses	O
of	O
triazolam	B-Chemical
repeatedly	O
induced	O
brief	O
episodes	O
of	O
mania	B-Disease
in	O
a	O
depressed	B-Disease
elderly	O
woman	O
.	O
Features	O
of	O
organic	B-Disease
mental	I-Disease
disorder	I-Disease
(	O
delirium	B-Disease
)	O
were	O
not	O
present	O
.	O
Manic	B-Disease
excitement	O
was	O
coincident	O
with	O
the	O
duration	O
of	O
action	O
of	O
triazolam	B-Chemical
.	O
The	O
possible	O
contribution	O
of	O
the	O
triazolo	B-Chemical
group	O
to	O
changes	O
in	O
affective	O
status	O
is	O
discussed	O
.	O
The	O
correlation	O
between	O
neurotoxic	B-Disease
esterase	O
inhibition	O
and	O
mipafox	B-Chemical
-	O
induced	O
neuropathic	B-Disease
damage	I-Disease
in	O
rats	O
.	O
The	O
correlation	O
between	O
neuropathic	B-Disease
damage	I-Disease
and	O
inhibition	O
of	O
neurotoxic	B-Disease
esterase	O
or	O
neuropathy	B-Disease
target	O
enzyme	O
(	O
NTE	O
)	O
was	O
examined	O
in	O
rats	O
acutely	O
exposed	O
to	O
Mipafox	B-Chemical
(	O
N	B-Chemical
,	I-Chemical
N	I-Chemical
'	I-Chemical
-	I-Chemical
diisopropylphosphorodiamidofluoridate	I-Chemical
)	O
,	O
a	O
neurotoxic	B-Disease
organophosphate	B-Chemical
.	O
Brain	O
and	O
spinal	O
cord	O
NTE	O
activities	O
were	O
measured	O
in	O
Long	O
-	O
Evans	O
male	O
rats	O
1	O
hr	O
post	O
-	O
exposure	O
to	O
various	O
dosages	O
of	O
Mipafox	B-Chemical
(	O
ip	O
,	O
1	O
-	O
15	O
mg	O
/	O
kg	O
)	O
.	O
These	O
data	O
were	O
correlated	O
with	O
histologically	O
scored	O
cervical	O
cord	B-Disease
damage	I-Disease
in	O
a	O
separate	O
group	O
of	O
similarly	O
dosed	O
rats	O
sampled	O
14	O
-	O
21	O
days	O
post	O
-	O
exposure	O
.	O
Those	O
dosages	O
(	O
greater	O
than	O
or	O
equal	O
to	O
10	O
mg	O
/	O
kg	O
)	O
that	O
inhibited	O
mean	O
NTE	O
activity	O
in	O
the	O
spinal	O
cord	O
greater	O
than	O
or	O
equal	O
to	O
73	O
%	O
and	O
brain	O
greater	O
than	O
or	O
equal	O
to	O
67	O
%	O
of	O
control	O
values	O
produced	O
severe	O
(	O
greater	O
than	O
or	O
equal	O
to	O
3	O
)	O
cervical	O
cord	O
pathology	O
in	O
85	O
%	O
of	O
the	O
rats	O
.	O
In	O
contrast	O
,	O
dosages	O
of	O
Mipafox	B-Chemical
(	O
less	O
than	O
or	O
equal	O
to	O
5	O
mg	O
/	O
kg	O
)	O
which	O
inhibited	O
mean	O
NTE	O
activity	O
in	O
spinal	O
cord	O
less	O
than	O
or	O
equal	O
to	O
61	O
%	O
and	O
brain	O
less	O
than	O
or	O
equal	O
to	O
60	O
%	O
produced	O
this	O
degree	O
of	O
cord	B-Disease
damage	I-Disease
in	O
only	O
9	O
%	O
of	O
the	O
animals	O
.	O
These	O
data	O
indicate	O
that	O
a	O
critical	O
percentage	O
of	O
NTE	O
inhibition	O
in	O
brain	O
and	O
spinal	O
cord	O
sampled	O
shortly	O
after	O
Mipafox	B-Chemical
exposure	O
can	O
predict	O
neuropathic	B-Disease
damage	I-Disease
in	O
rats	O
several	O
weeks	O
later	O
.	O
Allergic	B-Disease
reaction	I-Disease
to	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
infusion	O
.	O
An	O
allergic	B-Disease
reaction	I-Disease
consisting	O
of	O
angioneurotic	B-Disease
edema	I-Disease
secondary	O
to	O
continuous	O
infusion	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
occurred	O
in	O
a	O
patient	O
with	O
recurrent	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
oral	I-Disease
cavity	I-Disease
,	O
cirrhosis	B-Disease
,	O
and	O
cisplatin	B-Chemical
-	O
induced	O
impaired	B-Disease
renal	I-Disease
function	I-Disease
.	O
This	O
reaction	O
occurred	O
during	O
the	O
sixth	O
and	O
seventh	O
courses	O
of	O
infusional	O
chemotherapy	O
.	O
Oral	O
diphenhydramine	B-Chemical
and	O
prednisone	B-Chemical
were	O
ineffective	O
in	O
preventing	O
the	O
recurrence	O
of	O
the	O
allergic	B-Disease
reaction	I-Disease
.	O
Discontinuance	O
of	O
effective	O
chemotherapy	O
in	O
this	O
patient	O
during	O
partial	O
remission	O
resulted	O
in	O
fatal	O
disease	O
progression	O
.	O
Myasthenia	B-Disease
gravis	I-Disease
caused	O
by	O
penicillamine	B-Chemical
and	O
chloroquine	B-Chemical
therapy	O
for	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O
We	O
have	O
described	O
a	O
unique	O
patient	O
who	O
had	O
reversible	O
and	O
dose	O
-	O
related	O
myasthenia	B-Disease
gravis	I-Disease
after	O
penicillamine	B-Chemical
and	O
chloroquine	B-Chemical
therapy	O
for	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O
Although	O
acetylcholine	B-Chemical
receptor	O
antibodies	O
were	O
not	O
detectable	O
,	O
the	O
time	O
course	O
was	O
consistent	O
with	O
an	O
autoimmune	O
process	O
.	O
On	O
the	O
mechanisms	O
of	O
the	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	B-Disease
rigidity	I-Disease
produced	O
by	O
morphine	B-Chemical
in	O
rats	O
.	O
The	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	B-Disease
rigidity	I-Disease
produced	O
by	O
morphine	B-Chemical
was	O
studied	O
in	O
rats	O
.	O
Saline	O
-	O
pretreated	O
controls	O
given	O
a	O
test	O
dose	O
of	O
morphine	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
showed	O
a	O
pronounced	O
rigidity	B-Disease
recorded	O
as	O
tonic	O
activity	O
in	O
the	O
electromyogram	O
.	O
Rats	O
treated	O
for	O
11	O
days	O
with	O
morphine	B-Chemical
and	O
withdrawn	O
for	O
36	O
-	O
40	O
h	O
showed	O
differences	O
in	O
the	O
development	O
of	O
tolerance	O
:	O
about	O
half	O
of	O
the	O
animals	O
showed	O
a	O
rigidity	B-Disease
after	O
the	O
test	O
dose	O
of	O
morphine	B-Chemical
that	O
was	O
not	O
significantly	O
less	O
than	O
in	O
the	O
controls	O
and	O
were	O
akinetic	B-Disease
(	O
A	O
group	O
)	O
.	O
The	O
other	O
rats	O
showed	O
a	O
strong	O
decrease	O
in	O
the	O
rigidity	B-Disease
and	O
the	O
occurrence	O
of	O
stereotyped	O
(	O
S	O
)	O
licking	O
and	O
/	O
or	O
gnawing	O
in	O
presence	O
of	O
akinetic	B-Disease
or	O
hyperkinetic	B-Disease
(	O
K	O
)	O
behaviour	O
(	O
AS	O
/	O
KS	O
group	O
)	O
,	O
suggesting	O
signs	O
of	O
dopaminergic	O
activation	O
.	O
The	O
rigidity	B-Disease
was	O
considerably	O
decreased	O
in	O
both	O
groups	O
after	O
20	O
days	O
'	O
treatment	O
.	O
In	O
a	O
further	O
series	O
of	O
experiments	O
,	O
haloperidol	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
was	O
used	O
in	O
order	O
to	O
block	O
the	O
dopaminergic	O
activation	O
and	O
to	O
estimate	O
the	O
real	O
degree	O
of	O
the	O
tolerance	O
to	O
the	O
rigidity	B-Disease
without	O
any	O
dopaminergic	O
interference	O
.	O
Haloperidol	B-Chemical
enhanced	O
the	O
rigidity	B-Disease
in	O
the	O
A	O
group	O
.	O
However	O
,	O
the	O
level	O
in	O
the	O
AS	O
/	O
KS	O
group	O
remained	O
considerably	O
lower	O
than	O
in	O
the	O
A	O
group	O
.	O
The	O
results	O
suggest	O
that	O
rigidity	B-Disease
,	O
which	O
is	O
assumed	O
to	O
be	O
due	O
to	O
an	O
action	O
of	O
morphine	B-Chemical
in	O
the	O
striatum	O
,	O
can	O
be	O
antagonized	O
by	O
another	O
process	O
leading	O
to	O
dopaminergic	O
activation	O
in	O
the	O
striatum	O
.	O
Nevertheless	O
,	O
there	O
occurs	O
some	O
real	O
tolerance	O
to	O
this	O
effect	O
.	O
The	O
rapid	O
alternations	O
of	O
rigidity	B-Disease
and	O
the	O
signs	O
of	O
dopaminergic	O
activation	O
observed	O
in	O
the	O
animals	O
of	O
the	O
AS	O
/	O
KS	O
group	O
might	O
be	O
due	O
to	O
rapid	O
shifts	O
in	O
the	O
predominance	O
of	O
various	O
DA	O
-	O
innervated	O
structures	O
.	O
A	O
case	O
of	O
massive	O
rhabdomyolysis	B-Disease
following	O
molindone	B-Chemical
administration	O
.	O
Rhabdomyolysis	B-Disease
is	O
a	O
potentially	O
lethal	O
syndrome	O
that	O
psychiatric	B-Disease
patients	O
seem	O
predisposed	O
to	O
develop	O
.	O
The	O
clinical	O
signs	O
and	O
symptoms	O
,	O
typical	O
laboratory	O
features	O
,	O
and	O
complications	O
of	O
rhabdomyolysis	B-Disease
are	O
presented	O
.	O
The	O
case	O
of	O
a	O
schizophrenic	B-Disease
patient	O
is	O
reported	O
to	O
illustrate	O
massive	O
rhabdomyolysis	B-Disease
and	O
subsequent	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
following	O
molindone	B-Chemical
administration	O
.	O
Physicians	O
who	O
prescribe	O
molindone	B-Chemical
should	O
be	O
aware	O
of	O
this	O
reaction	O
.	O
Compression	B-Disease
neuropathy	I-Disease
of	I-Disease
the	I-Disease
radial	I-Disease
nerve	I-Disease
due	O
to	O
pentazocine	B-Chemical
-	O
induced	O
fibrous	B-Disease
myopathy	I-Disease
.	O
Fibrous	B-Disease
myopathy	I-Disease
is	O
a	O
common	O
,	O
well	O
-	O
known	O
side	O
effect	O
of	O
repeated	O
pentazocine	B-Chemical
injection	O
.	O
However	O
,	O
compression	B-Disease
neuropathy	I-Disease
due	O
to	O
fibrotic	O
muscle	O
affected	O
by	O
pentazocine	B-Chemical
-	O
induced	O
myopathy	B-Disease
has	O
not	O
previously	O
been	O
reported	O
.	O
In	O
a	O
37	O
-	O
year	O
-	O
old	O
woman	O
with	O
documented	O
pentazocine	B-Chemical
-	O
induced	O
fibrous	B-Disease
myopathy	I-Disease
of	O
triceps	O
and	O
deltoid	O
muscles	O
bilaterally	O
and	O
a	O
three	O
-	O
week	O
history	O
of	O
right	O
wrist	O
drop	O
,	O
electrodiagnostic	O
examination	O
showed	O
a	O
severe	O
but	O
partial	O
lesion	O
of	O
the	O
right	O
radial	O
nerve	O
distal	O
to	O
the	O
branches	O
to	O
the	O
triceps	O
,	O
in	O
addition	O
to	O
the	O
fibrous	B-Disease
myopathy	I-Disease
.	O
Surgery	O
revealed	O
the	O
right	O
radial	O
nerve	O
to	O
be	O
severely	O
compressed	O
by	O
the	O
densely	O
fibrotic	O
lateral	O
head	O
of	O
the	O
triceps	O
.	O
Decompression	O
and	O
neurolysis	O
were	O
performed	O
with	O
good	O
subsequent	O
recovery	O
of	O
function	O
.	O
Recurrent	O
reversible	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
from	O
amphotericin	B-Chemical
.	O
A	O
patient	O
with	O
cryptogenic	O
cirrhosis	B-Disease
and	O
disseminated	O
sporotrichosis	B-Disease
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
immediately	O
following	O
the	O
administration	O
of	O
amphotericin	B-Chemical
B	I-Chemical
on	O
four	O
separate	O
occasions	O
.	O
The	O
abruptness	O
of	O
the	O
renal	B-Disease
failure	I-Disease
and	O
its	O
reversibility	O
within	O
days	O
suggests	O
that	O
there	O
was	O
a	O
functional	O
component	O
to	O
the	O
renal	B-Disease
dysfunction	I-Disease
.	O
We	O
propose	O
that	O
amphotericin	B-Chemical
,	O
in	O
the	O
setting	O
of	O
reduced	O
effective	O
arterial	O
volume	O
,	O
may	O
activate	O
tubuloglomerular	O
feedback	O
,	O
thereby	O
contributing	O
to	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O
Cerebral	B-Disease
infarction	I-Disease
with	O
a	O
single	O
oral	O
dose	O
of	O
phenylpropanolamine	B-Chemical
.	O
Phenylpropanolamine	B-Chemical
(	O
PPA	B-Chemical
)	O
,	O
a	O
synthetic	O
sympathomimetic	O
that	O
is	O
structurally	O
similar	O
to	O
amphetamine	B-Chemical
,	O
is	O
available	O
over	O
the	O
counter	O
in	O
anorectics	O
,	O
nasal	O
congestants	O
,	O
and	O
cold	O
preparations	O
.	O
Its	O
prolonged	O
use	O
or	O
overuse	O
has	O
been	O
associated	O
with	O
seizures	B-Disease
,	O
intracerebral	B-Disease
hemorrhage	I-Disease
,	O
neuropsychiatric	B-Disease
symptoms	I-Disease
,	O
and	O
nonhemorrhagic	O
cerebral	B-Disease
infarction	I-Disease
.	O
We	O
report	O
the	O
case	O
of	O
a	O
young	O
woman	O
who	O
suffered	O
a	O
cerebral	B-Disease
infarction	I-Disease
after	O
taking	O
a	O
single	O
oral	O
dose	O
of	O
PPA	B-Chemical
.	O
Remission	O
induction	O
of	O
meningeal	B-Disease
leukemia	I-Disease
with	O
high	O
-	O
dose	O
intravenous	O
methotrexate	B-Chemical
.	O
Twenty	O
children	O
with	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
who	O
developed	O
meningeal	B-Disease
disease	I-Disease
were	O
treated	O
with	O
a	O
high	O
-	O
dose	O
intravenous	O
methotrexate	B-Chemical
regimen	O
that	O
was	O
designed	O
to	O
achieve	O
and	O
maintain	O
CSF	O
methotrexate	B-Chemical
concentrations	O
of	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
without	O
the	O
need	O
for	O
concomitant	O
intrathecal	O
dosing	O
.	O
The	O
methotrexate	B-Chemical
was	O
administered	O
as	O
a	O
loading	O
dose	O
of	O
6	O
,	O
000	O
mg	O
/	O
m2	O
for	O
a	O
period	O
of	O
one	O
hour	O
followed	O
by	O
an	O
infusion	O
of	O
1	O
,	O
200	O
mg	O
/	O
m2	O
/	O
h	O
for	O
23	O
hours	O
.	O
Leucovorin	B-Chemical
rescue	O
was	O
initiated	O
12	O
hours	O
after	O
the	O
end	O
of	O
the	O
infusion	O
with	O
a	O
loading	O
dose	O
of	O
200	O
mg	O
/	O
m2	O
followed	O
by	O
12	O
mg	O
/	O
m2	O
every	O
three	O
hours	O
for	O
six	O
doses	O
and	O
then	O
every	O
six	O
hours	O
until	O
the	O
plasma	O
methotrexate	B-Chemical
level	O
decreased	O
to	O
less	O
than	O
1	O
X	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
.	O
The	O
mean	O
steady	O
-	O
state	O
plasma	O
and	O
CSF	O
methotrexate	B-Chemical
concentrations	O
achieved	O
were	O
1	O
.	O
1	O
X	O
10	O
(	O
-	O
3	O
)	O
mol	O
/	O
L	O
and	O
3	O
.	O
6	O
X	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
,	O
respectively	O
.	O
All	O
20	O
patients	O
responded	O
to	O
this	O
regimen	O
,	O
16	O
/	O
20	O
(	O
80	O
%	O
)	O
achieved	O
a	O
complete	O
remission	O
,	O
and	O
20	O
%	O
obtained	O
a	O
partial	O
remission	O
.	O
The	O
most	O
common	O
toxicities	B-Disease
encountered	O
were	O
transient	O
serum	O
transaminase	O
and	O
bilirubin	B-Chemical
elevations	O
,	O
neutropenia	B-Disease
,	O
and	O
mucositis	B-Disease
.	O
One	O
patient	O
had	O
focal	O
seizures	B-Disease
and	O
transient	B-Disease
hemiparesis	I-Disease
but	O
recovered	O
completely	O
.	O
High	O
-	O
dose	O
intravenous	O
methotrexate	B-Chemical
is	O
an	O
effective	O
treatment	O
for	O
the	O
induction	O
of	O
remission	O
after	O
meningeal	O
relapse	O
in	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
.	O
Interaction	O
of	O
cyclosporin	B-Chemical
A	I-Chemical
with	O
antineoplastic	O
agents	O
.	O
A	O
synergistic	O
effect	O
of	O
etoposide	B-Chemical
and	O
cyclosporin	B-Chemical
A	I-Chemical
was	O
observed	O
in	O
a	O
patient	O
with	O
acute	B-Disease
T	I-Disease
-	I-Disease
lymphocytic	I-Disease
leukemia	I-Disease
in	O
relapse	O
.	O
The	O
concomitant	O
administration	O
of	O
etoposide	B-Chemical
and	O
cyclosporin	B-Chemical
A	I-Chemical
resulted	O
in	O
eradication	O
of	O
hitherto	O
refractory	O
leukemic	B-Disease
infiltration	I-Disease
of	O
bone	O
marrow	O
.	O
Severe	O
side	O
effects	O
in	O
terms	O
of	O
mental	O
confusion	B-Disease
and	O
progressive	O
hyperbilirubinemia	B-Disease
,	O
however	O
,	O
point	O
to	O
an	O
enhancement	O
not	O
only	O
of	O
antineoplastic	O
effects	O
but	O
also	O
of	O
toxicity	B-Disease
in	O
normal	O
tissues	O
.	O
This	O
report	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
the	O
pharmacodynamic	O
properties	O
of	O
cyclosporin	B-Chemical
A	I-Chemical
may	O
not	O
be	O
confined	O
strictly	O
to	O
suppression	O
of	O
normal	O
T	O
-	O
cell	O
functions	O
.	O
Incidence	O
of	O
neoplasms	B-Disease
in	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
exposed	O
to	O
different	O
treatment	O
regimens	O
.	O
Immunosuppressive	O
drugs	O
have	O
been	O
used	O
during	O
the	O
last	O
30	O
years	O
in	O
treatment	O
of	O
patients	O
with	O
severe	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O
The	O
drugs	O
commonly	O
used	O
are	O
cyclophosphamide	B-Chemical
and	O
chlorambucil	B-Chemical
(	O
alkylating	B-Chemical
agents	I-Chemical
)	O
,	O
azathioprine	B-Chemical
(	O
purine	B-Chemical
analogue	O
)	O
,	O
and	O
methotrexate	B-Chemical
(	O
folic	B-Chemical
acid	I-Chemical
analogue	O
)	O
.	O
There	O
is	O
evidence	O
that	O
all	O
four	O
immunosuppressive	O
drugs	O
can	O
reduce	O
synovitis	B-Disease
,	O
but	O
disease	O
activity	O
almost	O
always	O
recurs	O
after	O
therapy	O
is	O
stopped	O
.	O
Since	O
adverse	O
reactions	O
are	O
frequent	O
,	O
less	O
than	O
50	O
percent	O
of	O
patients	O
are	O
able	O
to	O
continue	O
a	O
particular	O
drug	O
for	O
more	O
than	O
one	O
year	O
.	O
Since	O
it	O
takes	O
three	O
to	O
12	O
months	O
to	O
achieve	O
maximal	O
effects	O
,	O
those	O
patients	O
who	O
are	O
unable	O
to	O
continue	O
the	O
drug	O
receive	O
little	O
benefit	O
from	O
it	O
.	O
Patients	O
treated	O
with	O
alkylating	B-Chemical
agents	I-Chemical
have	O
an	O
increased	O
risk	O
of	O
development	O
of	O
acute	B-Disease
nonlymphocytic	I-Disease
leukemia	I-Disease
,	O
and	O
both	O
alkylating	B-Chemical
agents	I-Chemical
and	O
azathioprine	B-Chemical
are	O
associated	O
with	O
the	O
development	O
of	O
non	B-Disease
-	I-Disease
Hodgkin	I-Disease
'	I-Disease
s	I-Disease
lymphoma	I-Disease
.	O
Cyclophosphamide	B-Chemical
therapy	O
increases	O
the	O
risk	O
of	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
bladder	I-Disease
.	O
There	O
have	O
been	O
several	O
long	O
-	O
term	O
studies	O
of	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
treated	O
with	O
azathioprine	B-Chemical
and	O
cyclophosphamide	B-Chemical
and	O
the	O
incidence	O
of	O
most	O
of	O
the	O
common	O
cancers	B-Disease
is	O
not	O
increased	O
.	O
Data	O
on	O
the	O
possible	O
increased	O
risk	O
of	O
malignancy	B-Disease
in	O
rheumatoid	B-Disease
arthritis	I-Disease
are	O
still	O
being	O
collected	O
,	O
and	O
until	O
further	O
information	O
is	O
available	O
,	O
the	O
use	O
of	O
immunosuppressive	O
drugs	O
,	O
particularly	O
alkylating	B-Chemical
agents	I-Chemical
,	O
in	O
the	O
treatment	O
of	O
rheumatoid	B-Disease
arthritis	I-Disease
should	O
be	O
reserved	O
for	O
patients	O
with	O
severe	O
progressive	O
disease	O
or	O
life	O
-	O
threatening	O
complications	O
.	O
Warfarin	B-Chemical
-	O
induced	O
iliopsoas	O
hemorrhage	B-Disease
with	O
subsequent	O
femoral	B-Disease
nerve	I-Disease
palsy	I-Disease
.	O
We	O
present	O
the	O
case	O
of	O
a	O
28	O
-	O
year	O
-	O
old	O
man	O
on	O
chronic	O
warfarin	B-Chemical
therapy	O
who	O
sustained	O
a	O
minor	O
muscle	B-Disease
tear	I-Disease
and	O
developed	O
increasing	O
pain	B-Disease
and	O
a	O
flexure	O
contracture	B-Disease
of	O
the	O
right	O
hip	O
.	O
Surgical	O
exploration	O
revealed	O
an	O
iliopsoas	O
hematoma	B-Disease
and	O
femoral	O
nerve	B-Disease
entrapment	I-Disease
,	O
resulting	O
in	O
a	O
femoral	B-Disease
nerve	I-Disease
palsy	I-Disease
and	O
partial	B-Disease
loss	I-Disease
of	I-Disease
quadriceps	I-Disease
functions	I-Disease
.	O
Anticoagulant	O
-	O
induced	O
femoral	B-Disease
nerve	I-Disease
palsy	I-Disease
represents	O
the	O
most	O
common	O
form	O
of	O
warfarin	B-Chemical
-	O
induced	O
peripheral	B-Disease
neuropathy	I-Disease
;	O
it	O
is	O
characterized	O
by	O
severe	O
pain	B-Disease
in	O
the	O
inguinal	O
region	O
,	O
varying	O
degrees	O
of	O
motor	B-Disease
and	I-Disease
sensory	I-Disease
impairment	I-Disease
,	O
and	O
flexure	O
contracture	B-Disease
of	O
the	O
involved	O
extremity	O
.	O
Pneumonitis	O
with	O
pleural	B-Disease
and	I-Disease
pericardial	I-Disease
effusion	I-Disease
and	O
neuropathy	B-Disease
during	O
amiodarone	B-Chemical
therapy	O
.	O
A	O
patient	O
with	O
sinuatrial	B-Disease
disease	I-Disease
and	O
implanted	O
pacemaker	O
was	O
treated	O
with	O
amiodarone	B-Chemical
(	O
maximum	O
dose	O
1000	O
mg	O
,	O
maintenance	O
dose	O
800	O
mg	O
daily	O
)	O
for	O
10	O
months	O
,	O
for	O
control	O
of	O
supraventricular	B-Disease
tachyarrhythmias	I-Disease
.	O
He	O
developed	O
pneumonitis	B-Disease
,	O
pleural	B-Disease
and	I-Disease
pericardial	I-Disease
effusions	I-Disease
,	O
and	O
a	O
predominantly	O
proximal	B-Disease
motor	I-Disease
neuropathy	I-Disease
.	O
Immediate	O
but	O
gradual	O
improvement	O
followed	O
withdrawal	O
of	O
amiodarone	B-Chemical
and	O
treatment	O
with	O
prednisolone	B-Chemical
.	O
Review	O
of	O
this	O
and	O
previously	O
reported	O
cases	O
indicates	O
the	O
need	O
for	O
early	O
diagnosis	O
of	O
amiodarone	B-Chemical
pneumonitis	B-Disease
,	O
immediate	O
withdrawal	O
of	O
amiodarone	B-Chemical
,	O
and	O
prompt	O
but	O
continued	O
steroid	B-Chemical
therapy	O
to	O
ensure	O
full	O
recovery	O
.	O
Amiodarone	B-Chemical
-	O
induced	O
sinoatrial	B-Disease
block	I-Disease
.	O
We	O
observed	O
sinoatrial	B-Disease
block	I-Disease
due	O
to	O
chronic	O
amiodarone	B-Chemical
administration	O
in	O
a	O
5	O
-	O
year	O
-	O
old	O
boy	O
with	O
primary	B-Disease
cardiomyopathy	I-Disease
,	O
Wolff	B-Disease
-	I-Disease
Parkinson	I-Disease
-	I-Disease
White	I-Disease
syndrome	I-Disease
and	O
supraventricular	B-Disease
tachycardia	I-Disease
.	O
Reduction	O
in	O
the	O
dosage	O
of	O
amiodarone	B-Chemical
resulted	O
in	O
the	O
disappearance	O
of	O
the	O
sinoatrial	B-Disease
block	I-Disease
and	O
the	O
persistence	O
of	O
asymptomatic	O
sinus	B-Disease
bradycardia	I-Disease
.	O
Desipramine	B-Chemical
-	O
induced	O
delirium	B-Disease
at	O
""""	O
subtherapeutic	O
""""	O
concentrations	O
:	O
a	O
case	O
report	O
.	O
An	O
elderly	O
patient	O
treated	O
with	O
low	O
dose	O
Desipramine	B-Chemical
developed	O
a	O
delirium	B-Disease
while	O
her	O
plasma	O
level	O
was	O
in	O
the	O
""""	O
subtherapeutic	O
""""	O
range	O
.	O
Delirium	B-Disease
,	O
which	O
may	O
be	O
induced	O
by	O
tricyclic	O
drug	O
therapy	O
in	O
the	O
elderly	O
,	O
can	O
be	O
caused	O
by	O
tricyclics	O
with	O
low	O
anticholinergic	O
potency	O
.	O
Therapeutic	O
ranges	O
for	O
antidepressants	B-Chemical
that	O
have	O
been	O
derived	O
from	O
general	O
adult	O
population	O
studies	O
may	O
not	O
be	O
appropriate	O
for	O
the	O
elderly	O
.	O
Further	O
studies	O
of	O
specifically	O
elderly	O
patients	O
are	O
now	O
required	O
to	O
establish	O
safer	O
and	O
more	O
appropriate	O
guidelines	O
for	O
drug	O
therapy	O
.	O
Indomethacin	B-Chemical
-	O
induced	O
renal	B-Disease
insufficiency	I-Disease
:	O
recurrence	O
on	O
rechallenge	O
.	O
We	O
have	O
reported	O
a	O
case	O
of	O
acute	O
oliguric	O
renal	B-Disease
failure	I-Disease
with	O
hyperkalemia	B-Disease
in	O
a	O
patient	O
with	O
cirrhosis	B-Disease
,	O
ascites	B-Disease
,	O
and	O
cor	B-Disease
pulmonale	I-Disease
after	O
indomethacin	B-Chemical
therapy	O
.	O
Prompt	O
restoration	O
of	O
renal	O
function	O
followed	O
drug	O
withdrawal	O
,	O
while	O
re	O
-	O
exposure	O
to	O
a	O
single	O
dose	O
of	O
indomethacin	B-Chemical
caused	O
recurrence	O
of	O
acute	O
reversible	O
oliguria	B-Disease
.	O
Our	O
case	O
supports	O
the	O
hypothesis	O
that	O
endogenous	O
renal	O
prostaglandins	B-Chemical
play	O
a	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
blood	O
flow	O
when	O
circulating	O
plasma	O
volume	O
is	O
diminished	O
.	O
Since	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
agents	O
interfere	O
with	O
this	O
compensatory	O
mechanism	O
and	O
may	O
cause	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
in	O
such	O
patients	O
.	O
Patterns	O
of	O
hepatic	B-Disease
injury	I-Disease
induced	O
by	O
methyldopa	B-Chemical
.	O
Twelve	O
patients	O
with	O
liver	B-Disease
disease	I-Disease
related	O
to	O
methyldopa	B-Chemical
were	O
seen	O
between	O
1967	O
and	O
1977	O
.	O
Illness	O
occurred	O
within	O
1	O
-	O
-	O
9	O
weeks	O
of	O
commencement	O
of	O
therapy	O
in	O
9	O
patients	O
,	O
the	O
remaining	O
3	O
patients	O
having	O
received	O
the	O
drug	O
for	O
13	O
months	O
,	O
15	O
months	O
and	O
7	O
years	O
before	O
experiencing	O
symptoms	O
.	O
Jaundice	B-Disease
with	O
tender	O
hepatomegaly	B-Disease
,	O
usually	O
preceded	O
by	O
symptoms	O
of	O
malaise	O
,	O
anorexia	B-Disease
,	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
and	O
associated	O
with	O
upper	O
abdominal	B-Disease
pain	I-Disease
,	O
was	O
an	O
invariable	O
finding	O
in	O
all	O
patients	O
.	O
Biochemical	O
liver	O
function	O
tests	O
indicated	O
hepatocellular	O
necrosis	B-Disease
and	O
correlated	O
with	O
histopathological	O
evidence	O
of	O
hepatic	B-Disease
injury	I-Disease
,	O
the	O
spectrum	O
of	O
which	O
ranged	O
from	O
fatty	B-Disease
change	I-Disease
and	O
focal	O
hepatocellular	O
necrosis	B-Disease
to	O
massive	B-Disease
hepatic	I-Disease
necrosis	I-Disease
.	O
Most	O
patients	O
showed	O
moderate	O
to	O
severe	O
acute	B-Disease
hepatitis	I-Disease
or	O
chronic	B-Disease
active	I-Disease
hepatitis	I-Disease
with	O
associated	O
cholestasis	B-Disease
.	O
The	O
drug	O
was	O
withdrawn	O
on	O
presentation	O
to	O
hospital	O
in	O
11	O
patients	O
,	O
with	O
rapid	O
clinical	O
improvement	O
in	O
9	O
.	O
One	O
patient	O
died	O
,	O
having	O
presented	O
in	O
hepatic	B-Disease
failure	I-Disease
,	O
and	O
another	O
,	O
who	O
had	O
been	O
taking	O
methyldopa	B-Chemical
for	O
7	O
years	O
,	O
showed	O
slower	O
clinical	O
and	O
biochemical	O
resolution	O
over	O
a	O
period	O
of	O
several	O
months	O
.	O
The	O
remaining	O
patient	O
in	O
the	O
series	O
developed	O
fulminant	B-Disease
hepatitis	I-Disease
when	O
the	O
drug	O
was	O
accidentally	O
recommenced	O
1	O
year	O
after	O
a	O
prior	O
episode	O
of	O
methyldopa	B-Chemical
-	O
induced	O
hepatitis	B-Disease
.	O
In	O
this	O
latter	O
patient	O
,	O
and	O
in	O
2	O
others	O
,	O
the	O
causal	O
relationship	O
between	O
methyldopa	B-Chemical
and	O
hepatic	B-Disease
dysfunction	I-Disease
was	O
proved	O
with	O
the	O
recurrence	O
of	O
hepatitis	B-Disease
within	O
2	O
weeks	O
of	O
re	O
-	O
exposure	O
to	O
the	O
drug	O
.	O
Suxamethonium	B-Chemical
infusion	O
rate	O
and	O
observed	O
fasciculations	B-Disease
.	O
A	O
dose	O
-	O
response	O
study	O
.	O
Suxamethonium	B-Chemical
chloride	I-Chemical
(	O
Sch	B-Chemical
)	O
was	O
administered	O
i	O
.	O
v	O
.	O
to	O
36	O
adult	O
males	O
at	O
six	O
rates	O
:	O
0	O
.	O
25	O
mg	O
s	O
-	O
1	O
to	O
20	O
mg	O
s	O
-	O
1	O
.	O
The	O
infusion	O
was	O
discontinued	O
either	O
when	O
there	O
was	O
no	O
muscular	O
response	O
to	O
tetanic	B-Disease
stimulation	O
of	O
the	O
ulnar	O
nerve	O
or	O
when	O
Sch	B-Chemical
120	O
mg	O
was	O
exceeded	O
.	O
Six	O
additional	O
patients	O
received	O
a	O
30	O
-	O
mg	O
i	O
.	O
v	O
.	O
bolus	O
dose	O
.	O
Fasciculations	B-Disease
in	O
six	O
areas	O
of	O
the	O
body	O
were	O
scored	O
from	O
0	O
to	O
3	O
and	O
summated	O
as	O
a	O
total	O
fasciculation	B-Disease
score	O
.	O
The	O
times	O
to	O
first	O
fasciculation	B-Disease
,	O
twitch	B-Disease
suppression	O
and	O
tetanus	B-Disease
suppression	O
were	O
inversely	O
related	O
to	O
the	O
infusion	O
rates	O
.	O
Fasciculations	B-Disease
in	O
the	O
six	O
areas	O
and	O
the	O
total	O
fasciculation	B-Disease
score	O
were	O
related	O
directly	O
to	O
the	O
rate	O
of	O
infusion	O
.	O
Total	O
fasciculation	B-Disease
scores	O
in	O
the	O
30	O
-	O
mg	O
bolus	O
group	O
and	O
the	O
5	O
-	O
mg	O
s	O
-	O
1	O
and	O
20	O
-	O
mg	O
s	O
-	O
1	O
infusion	O
groups	O
were	O
not	O
significantly	O
different	O
.	O
Treatment	O
of	O
psoriasis	B-Disease
with	O
azathioprine	B-Chemical
.	O
Azathioprine	B-Chemical
treatment	O
benefited	O
19	O
(	O
66	O
%	O
)	O
out	O
of	O
29	O
patients	O
suffering	O
from	O
severe	O
psoriasis	B-Disease
.	O
Haematological	O
complications	O
were	O
not	O
troublesome	O
and	O
results	O
of	O
biochemical	O
liver	O
function	O
tests	O
remained	O
normal	O
.	O
Minimal	O
cholestasis	B-Disease
was	O
seen	O
in	O
two	O
cases	O
and	O
portal	O
fibrosis	B-Disease
of	O
a	O
reversible	O
degree	O
in	O
eight	O
.	O
Liver	O
biopsies	O
should	O
be	O
undertaken	O
at	O
regular	O
intervals	O
if	O
azathioprine	B-Chemical
therapy	O
is	O
continued	O
so	O
that	O
structural	O
liver	B-Disease
damage	I-Disease
may	O
be	O
detected	O
at	O
an	O
early	O
and	O
reversible	O
stage	O
.	O
Angiosarcoma	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
associated	O
with	O
diethylstilbestrol	B-Chemical
.	O
Angiosarcoma	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
occurred	O
in	O
a	O
76	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
been	O
treated	O
for	O
a	O
well	O
-	O
differentiated	O
adenocarcinoma	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
with	O
diethylstilbestrol	B-Chemical
for	O
13	O
years	O
.	O
Angiosarcoma	B-Disease
was	O
also	O
present	O
within	O
pulmonary	O
and	O
renal	O
arteries	O
.	O
The	O
possibility	O
that	O
the	O
intraarterial	B-Disease
lesions	I-Disease
might	O
represent	O
independent	O
primary	O
tumors	B-Disease
is	O
considered	O
.	O
Galanthamine	B-Chemical
hydrobromide	I-Chemical
,	O
a	O
longer	O
acting	O
anticholinesterase	O
drug	O
,	O
in	O
the	O
treatment	O
of	O
the	O
central	O
effects	O
of	O
scopolamine	B-Chemical
(	O
Hyoscine	B-Chemical
)	O
.	O
Galanthamine	B-Chemical
hydrobromide	I-Chemical
,	O
an	O
anticholinesterase	O
drug	O
capable	O
of	O
penetrating	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
was	O
used	O
in	O
a	O
patient	O
demonstrating	O
central	O
effects	O
of	O
scopolamine	B-Chemical
(	O
hyoscine	B-Chemical
)	O
overdosage	B-Disease
.	O
It	O
is	O
longer	O
acting	O
than	O
physostigmine	B-Chemical
and	O
is	O
used	O
in	O
anaesthesia	O
to	O
reverse	O
the	O
non	O
-	O
depolarizing	O
neuromuscular	O
block	O
.	O
However	O
,	O
studies	O
into	O
the	O
dose	O
necessary	O
to	O
combating	O
scopolamine	B-Chemical
intoxication	O
are	O
indicated	O
.	O
Comparison	O
of	O
the	O
subjective	O
effects	O
and	O
plasma	O
concentrations	O
following	O
oral	O
and	O
i	O
.	O
m	O
.	O
administration	O
of	O
flunitrazepam	B-Chemical
in	O
volunteers	O
.	O
Flunitrazepam	B-Chemical
0	O
.	O
5	O
,	O
1	O
.	O
0	O
or	O
2	O
.	O
0	O
mg	O
was	O
given	O
by	O
the	O
oral	O
or	O
i	O
.	O
m	O
.	O
routes	O
to	O
groups	O
of	O
volunteers	O
and	O
its	O
effects	O
compared	O
.	O
Plasma	O
concentrations	O
of	O
the	O
drug	O
were	O
estimated	O
by	O
gas	O
-	O
liquid	O
chromatography	O
,	O
in	O
a	O
smaller	O
number	O
of	O
the	O
subjects	O
.	O
The	O
most	O
striking	O
effect	O
was	O
sedation	O
which	O
increased	O
with	O
the	O
dose	O
,	O
2	O
mg	O
producing	O
deep	O
sleep	O
although	O
the	O
subjects	O
could	O
still	O
be	O
aroused	O
.	O
The	O
effects	O
of	O
i	O
.	O
m	O
.	O
administration	O
were	O
apparent	O
earlier	O
and	O
sometimes	O
lasted	O
longer	O
than	O
those	O
following	O
oral	O
administration	O
.	O
Dizziness	B-Disease
was	O
less	O
marked	O
than	O
sedation	O
,	O
but	O
increased	O
with	O
the	O
dose	O
.	O
There	O
was	O
pain	B-Disease
on	O
i	O
.	O
m	O
.	O
injection	O
of	O
flunitrazepam	B-Chemical
significantly	O
more	O
often	O
than	O
with	O
isotonic	O
saline	O
.	O
Plasma	O
concentrations	O
varied	O
with	O
dose	O
and	O
route	O
and	O
corresponded	O
qualitatively	O
with	O
the	O
subjective	O
effects	O
.	O
The	O
drug	O
was	O
still	O
present	O
in	O
measurable	O
quantities	O
after	O
24	O
h	O
even	O
with	O
the	O
smallest	O
dose	O
.	O
Possible	O
teratogenicity	O
of	O
sulphasalazine	B-Chemical
.	O
Three	O
infants	O
,	O
born	O
of	O
two	O
mothers	O
with	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
who	O
received	O
treatment	O
with	O
sulphasalazine	B-Chemical
throughout	O
pregnancy	O
,	O
were	O
found	O
to	O
have	O
major	O
congenital	B-Disease
anomalies	I-Disease
.	O
In	O
the	O
singleton	O
pregnancy	O
,	O
the	O
mother	O
had	O
ulcerative	B-Disease
colitis	I-Disease
,	O
and	O
the	O
infant	O
,	O
a	O
male	O
,	O
had	O
coarctation	B-Disease
of	I-Disease
the	I-Disease
aorta	I-Disease
and	O
a	O
ventricular	B-Disease
septal	I-Disease
defect	I-Disease
.	O
In	O
the	O
twin	O
pregnancy	O
,	O
the	O
mother	O
had	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
The	O
first	O
twin	O
,	O
a	O
female	O
,	O
had	O
a	O
left	O
Potter	B-Disease
-	I-Disease
type	I-Disease
IIa	I-Disease
polycystic	I-Disease
kidney	I-Disease
and	O
a	O
rudimentary	B-Disease
left	I-Disease
uterine	I-Disease
cornu	I-Disease
.	O
The	O
second	O
twin	O
,	O
a	O
male	O
,	O
had	O
some	O
features	O
of	O
Potter	B-Disease
'	I-Disease
s	I-Disease
facies	I-Disease
,	O
hypoplastic	B-Disease
lungs	I-Disease
,	O
absent	B-Disease
kidneys	I-Disease
and	I-Disease
ureters	I-Disease
,	O
and	O
talipes	B-Disease
equinovarus	I-Disease
.	O
Despite	O
reports	O
to	O
the	O
contrary	O
,	O
it	O
is	O
suggested	O
that	O
sulphasalazine	B-Chemical
may	O
be	O
teratogenic	O
.	O
Thrombotic	B-Disease
microangiopathy	I-Disease
and	O
renal	B-Disease
failure	I-Disease
associated	O
with	O
antineoplastic	O
chemotherapy	O
.	O
Five	O
patients	O
with	O
carcinoma	B-Disease
developed	O
thrombotic	B-Disease
microangiopathy	I-Disease
(	O
characterized	O
by	O
renal	B-Disease
insufficiency	I-Disease
,	O
microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
and	O
usually	O
thrombocytopenia	B-Disease
)	O
after	O
treatment	O
with	O
cisplatin	B-Chemical
,	O
bleomycin	B-Chemical
,	O
and	O
a	O
vinca	B-Chemical
alkaloid	I-Chemical
.	O
One	O
patient	O
had	O
thrombotic	B-Disease
thrombocytopenic	I-Disease
purpura	I-Disease
,	O
three	O
the	O
hemolytic	B-Disease
-	I-Disease
uremic	I-Disease
syndrome	I-Disease
,	O
and	O
one	O
an	O
apparent	O
forme	O
fruste	O
of	O
one	O
of	O
these	O
disorders	O
.	O
Histologic	O
examination	O
of	O
the	O
renal	O
tissue	O
showed	O
evidence	O
of	O
intravascular	B-Disease
coagulation	I-Disease
,	O
primarily	O
affecting	O
the	O
small	O
arteries	O
,	O
arterioles	O
,	O
and	O
glomeruli	O
.	O
Because	O
each	O
patient	O
was	O
tumor	B-Disease
-	O
free	O
or	O
had	O
only	O
a	O
small	O
tumor	B-Disease
at	O
the	O
onset	O
of	O
this	O
syndrome	O
,	O
the	O
thrombotic	B-Disease
microangiopathy	I-Disease
may	O
have	O
been	O
induced	O
by	O
chemotherapy	O
.	O
Diagnosis	O
of	O
this	O
potentially	O
fatal	O
complication	O
may	O
be	O
delayed	O
or	O
missed	O
if	O
renal	O
tissue	O
or	O
the	O
peripheral	O
blood	O
smear	O
is	O
not	O
examined	O
,	O
because	O
renal	B-Disease
failure	I-Disease
may	O
be	O
ascribed	O
to	O
cisplatin	B-Chemical
nephrotoxicity	B-Disease
and	O
the	O
anemia	B-Disease
and	O
thrombocytopenia	B-Disease
to	O
drug	O
-	O
induced	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
.	O
International	O
mexiletine	B-Chemical
and	O
placebo	O
antiarrhythmic	O
coronary	O
trial	O
:	O
I	O
.	O
Report	O
on	O
arrhythmia	B-Disease
and	O
other	O
findings	O
.	O
Impact	O
Research	O
Group	O
.	O
The	O
antiarrhythmic	O
effects	O
of	O
the	O
sustained	O
release	O
form	O
of	O
mexiletine	B-Chemical
(	O
Mexitil	B-Chemical
-	I-Chemical
Perlongets	I-Chemical
)	O
were	O
evaluated	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
trial	O
in	O
630	O
patients	O
with	O
recent	O
documented	O
myocardial	B-Disease
infarction	I-Disease
.	O
The	O
primary	O
response	O
variable	O
was	O
based	O
on	O
central	O
reading	O
of	O
24	O
hour	O
ambulatory	O
electrocardiographic	O
recordings	O
and	O
was	O
defined	O
as	O
the	O
occurrence	O
of	O
30	O
or	O
more	O
single	O
premature	O
ventricular	O
complexes	O
in	O
any	O
two	O
consecutive	O
30	O
minute	O
blocks	O
or	O
one	O
or	O
more	O
runs	O
of	O
two	O
or	O
more	O
premature	O
ventricular	O
complexes	O
in	O
the	O
entire	O
24	O
hour	O
electrocardiographic	O
recording	O
.	O
Large	O
differences	O
,	O
regarded	O
as	O
statistically	O
significant	O
,	O
between	O
the	O
mexiletine	B-Chemical
and	O
placebo	O
groups	O
were	O
noted	O
in	O
that	O
end	O
point	O
at	O
months	O
1	O
and	O
4	O
,	O
but	O
only	O
trends	O
were	O
observed	O
at	O
month	O
12	O
.	O
These	O
differences	O
were	O
observed	O
even	O
though	O
the	O
serum	O
mexiletine	B-Chemical
levels	O
obtained	O
in	O
this	O
study	O
were	O
generally	O
lower	O
than	O
those	O
observed	O
in	O
studies	O
that	O
have	O
used	O
the	O
regular	O
form	O
of	O
the	O
drug	O
.	O
There	O
were	O
more	O
deaths	B-Disease
in	O
the	O
mexiletine	B-Chemical
group	O
(	O
7	O
.	O
6	O
%	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
4	O
.	O
8	O
%	O
)	O
;	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O
The	O
incidence	O
of	O
coronary	O
events	O
was	O
similar	O
in	O
both	O
groups	O
.	O
Previously	O
recognized	O
side	O
effects	O
,	O
particularly	O
tremor	B-Disease
and	O
gastrointestinal	B-Disease
problems	I-Disease
,	O
were	O
more	O
frequent	O
in	O
the	O
mexiletine	B-Chemical
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O
Changes	O
in	O
heart	O
size	O
during	O
long	O
-	O
term	O
timolol	B-Chemical
treatment	O
after	O
myocardial	B-Disease
infarction	I-Disease
.	O
The	O
effect	O
of	O
long	O
-	O
term	O
timolol	B-Chemical
treatment	O
on	O
heart	O
size	O
after	O
myocardial	B-Disease
infarction	I-Disease
was	O
evaluated	O
by	O
X	O
-	O
ray	O
in	O
a	O
double	O
-	O
blind	O
study	O
including	O
241	O
patients	O
(	O
placebo	O
126	O
,	O
timolol	B-Chemical
115	O
)	O
.	O
The	O
follow	O
-	O
up	O
period	O
was	O
12	O
months	O
.	O
The	O
timolol	B-Chemical
-	O
treated	O
patients	O
showed	O
a	O
small	O
but	O
significant	O
increase	O
in	O
heart	O
size	O
from	O
baseline	O
in	O
contrast	O
to	O
a	O
decrease	O
in	O
the	O
placebo	O
group	O
.	O
These	O
differences	O
may	O
be	O
caused	O
by	O
timolol	B-Chemical
-	O
induced	O
bradycardia	B-Disease
and	O
a	O
compensatory	O
increase	O
in	O
end	O
-	O
diastolic	O
volume	O
.	O
The	O
timolol	B-Chemical
-	O
related	O
increase	O
in	O
heart	O
size	O
was	O
observed	O
only	O
in	O
patients	O
with	O
normal	O
and	O
borderline	O
heart	O
size	O
.	O
In	O
patients	O
with	O
cardiomegaly	B-Disease
,	O
the	O
increase	O
in	O
heart	O
size	O
was	O
similar	O
in	O
both	O
groups	O
.	O
After	O
re	O
-	O
infarction	B-Disease
,	O
heart	O
size	O
increased	O
in	O
the	O
placebo	O
group	O
and	O
remained	O
unchanged	O
in	O
the	O
timolol	B-Chemical
group	O
.	O
Vitamin	B-Chemical
D3	I-Chemical
toxicity	B-Disease
in	O
dairy	O
cows	O
.	O
Large	O
parenteral	O
doses	O
of	O
vitamin	B-Chemical
D3	I-Chemical
(	O
15	O
to	O
17	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
IU	O
vitamin	B-Chemical
D3	I-Chemical
)	O
were	O
associated	O
with	O
prolonged	O
hypercalcemia	B-Disease
,	O
hyperphosphatemia	B-Disease
,	O
and	O
large	O
increases	O
of	O
vitamin	B-Chemical
D3	I-Chemical
and	O
its	O
metabolites	O
in	O
the	O
blood	O
plasma	O
of	O
nonlactating	O
nonpregnant	O
and	O
pregnant	O
Jersey	O
cows	O
.	O
Calcium	B-Chemical
concentrations	O
1	O
day	O
postpartum	O
were	O
higher	O
in	O
cows	O
treated	O
with	O
vitamin	B-Chemical
D3	I-Chemical
about	O
32	O
days	O
prepartum	O
(	O
8	O
.	O
8	O
mg	O
/	O
100	O
ml	O
)	O
than	O
in	O
control	O
cows	O
(	O
5	O
.	O
5	O
mg	O
/	O
100	O
ml	O
)	O
.	O
None	O
of	O
the	O
cows	O
treated	O
with	O
vitamin	B-Chemical
D3	I-Chemical
showed	O
signs	O
of	O
milk	B-Disease
fever	I-Disease
during	O
the	O
peripartal	O
period	O
;	O
however	O
,	O
22	O
%	O
of	O
the	O
control	O
cows	O
developed	O
clinical	O
signs	O
of	O
milk	B-Disease
fever	I-Disease
during	O
this	O
period	O
.	O
Signs	O
of	O
vitamin	B-Chemical
D3	I-Chemical
toxicity	B-Disease
were	O
not	O
observed	O
in	O
nonlactating	O
nonpregnant	O
cows	O
;	O
however	O
,	O
pregnant	O
cows	O
commonly	O
developed	O
severe	O
signs	O
of	O
vitamin	B-Chemical
D3	I-Chemical
toxicity	B-Disease
and	O
10	O
of	O
17	O
cows	O
died	O
.	O
There	O
was	O
widespread	O
metastatic	O
calcification	O
in	O
the	O
cows	O
that	O
died	O
.	O
Because	O
of	O
the	O
extreme	O
toxicity	B-Disease
of	O
vitamin	B-Chemical
D3	I-Chemical
in	O
pregnant	O
Jersey	O
cows	O
and	O
the	O
low	O
margin	O
of	O
safety	O
between	O
doses	O
of	O
vitamin	B-Chemical
D3	I-Chemical
that	O
prevent	O
milk	B-Disease
fever	I-Disease
and	O
doses	O
that	O
induce	O
milk	B-Disease
fever	I-Disease
,	O
we	O
concluded	O
that	O
vitamin	B-Chemical
D3	I-Chemical
cannot	O
be	O
used	O
practically	O
to	O
prevent	O
milk	B-Disease
fever	I-Disease
when	O
injected	O
several	O
weeks	O
prepartum	O
.	O
Diseases	B-Disease
of	I-Disease
peripheral	I-Disease
nerves	I-Disease
as	O
seen	O
in	O
the	O
Nigerian	O
African	O
.	O
The	O
anatomical	O
and	O
aetiological	O
diagnoses	O
of	O
peripheral	B-Disease
nerve	I-Disease
disease	I-Disease
excluding	O
its	O
primary	O
benign	O
and	O
malignant	O
disorders	O
,	O
as	O
seen	O
in	O
358	O
Nigerians	O
are	O
presented	O
.	O
There	O
is	O
a	O
male	O
preponderance	O
and	O
the	O
peak	O
incidence	O
is	O
in	O
the	O
fourth	O
decade	O
.	O
Sensori	B-Disease
-	I-Disease
motor	I-Disease
neuropathy	I-Disease
was	O
the	O
commonest	O
presentation	O
(	O
50	O
%	O
)	O
.	O
Guillain	B-Disease
-	I-Disease
Barr	I-Disease
syndrome	I-Disease
was	O
the	O
commonest	O
identifiable	O
cause	O
(	O
15	O
.	O
6	O
%	O
)	O
,	O
accounting	O
for	O
half	O
of	O
the	O
cases	O
with	O
motor	B-Disease
neuropathy	I-Disease
.	O
Peripheral	B-Disease
neuropathy	I-Disease
due	O
to	O
nutritional	B-Disease
deficiency	I-Disease
of	O
thiamine	B-Chemical
and	O
riboflavin	B-Chemical
was	O
common	O
(	O
10	O
.	O
1	O
%	O
)	O
and	O
presented	O
mainly	O
as	O
sensory	O
and	O
sensori	B-Disease
-	I-Disease
motor	I-Disease
neuropathy	I-Disease
.	O
Diabetes	B-Disease
mellitus	I-Disease
was	O
the	O
major	O
cause	O
of	O
autonomic	B-Disease
neuropathy	I-Disease
.	O
Isoniazid	B-Chemical
was	O
the	O
most	O
frequent	O
agent	O
in	O
drug	O
-	O
induced	O
neuropathy	B-Disease
.	O
Migraine	B-Disease
(	O
20	O
%	O
)	O
was	O
not	O
an	O
uncommon	O
cause	O
of	O
cranial	B-Disease
neuropathy	I-Disease
although	O
malignancies	B-Disease
arising	O
from	O
the	O
reticuloendothelial	O
system	O
or	O
related	O
structures	O
of	O
the	O
head	O
and	O
neck	O
were	O
more	O
frequent	O
(	O
26	O
%	O
)	O
.	O
In	O
26	O
.	O
5	O
%	O
of	O
all	O
the	O
cases	O
,	O
the	O
aetiology	O
of	O
the	O
neuropathy	B-Disease
was	O
undetermined	O
.	O
Heredofamilial	O
and	O
connective	B-Disease
tissue	I-Disease
disorders	I-Disease
were	O
rare	O
.	O
Some	O
of	O
the	O
factors	O
related	O
to	O
the	O
clinical	O
presentation	O
and	O
pathogenesis	O
of	O
the	O
neuropathies	B-Disease
are	O
briefly	O
discussed	O
.	O
Reduction	O
in	O
caffeine	B-Chemical
toxicity	B-Disease
by	O
acetaminophen	B-Chemical
.	O
A	O
patient	O
who	O
allegedly	O
consumed	O
100	O
tablets	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
analgesic	O
containing	O
sodium	B-Chemical
acetylsalicylate	I-Chemical
,	O
caffeine	B-Chemical
,	O
and	O
acetaminophen	B-Chemical
displayed	O
no	O
significant	O
CNS	O
stimulation	O
despite	O
the	O
presence	O
of	O
175	O
micrograms	O
of	O
caffeine	B-Chemical
per	O
mL	O
of	O
serum	O
.	O
Because	O
salicylates	O
have	O
been	O
reported	O
to	O
augment	O
the	O
stimulatory	O
effects	O
of	O
caffeine	B-Chemical
on	O
the	O
CNS	O
,	O
attention	O
was	O
focused	O
on	O
the	O
possibility	O
that	O
the	O
presence	O
of	O
acetaminophen	B-Chemical
(	O
52	O
micrograms	O
/	O
mL	O
)	O
reduced	O
the	O
CNS	O
toxicity	B-Disease
of	O
caffeine	B-Chemical
.	O
Studies	O
in	O
DBA	O
/	O
2J	O
mice	O
showed	O
that	O
:	O
1	O
)	O
pretreatment	O
with	O
acetaminophen	B-Chemical
(	O
100	O
mg	O
/	O
kg	O
)	O
increased	O
the	O
interval	O
between	O
the	O
administration	O
of	O
caffeine	B-Chemical
(	O
300	O
to	O
450	O
mg	O
/	O
kg	O
IP	O
)	O
and	O
the	O
onset	O
of	O
fatal	O
convulsions	B-Disease
by	O
a	O
factor	O
of	O
about	O
two	O
;	O
and	O
2	O
)	O
pretreatment	O
with	O
acetaminophen	B-Chemical
(	O
75	O
mg	O
/	O
kg	O
)	O
reduced	O
the	O
incidence	O
of	O
audiogenic	O
seizures	B-Disease
produced	O
in	O
the	O
presence	O
of	O
caffeine	B-Chemical
(	O
12	O
.	O
5	O
to	O
75	O
mg	O
/	O
kg	O
IP	O
)	O
.	O
The	O
frequency	O
of	O
sound	O
-	O
induced	O
seizures	B-Disease
after	O
12	O
.	O
5	O
or	O
25	O
mg	O
/	O
kg	O
caffeine	B-Chemical
was	O
reduced	O
from	O
50	O
to	O
5	O
%	O
by	O
acetaminophen	B-Chemical
.	O
In	O
the	O
absence	O
of	O
caffeine	B-Chemical
,	O
acetaminophen	B-Chemical
(	O
up	O
to	O
300	O
mg	O
/	O
kg	O
)	O
did	O
not	O
modify	O
the	O
seizures	B-Disease
induced	O
by	O
maximal	O
electroshock	O
and	O
did	O
not	O
alter	O
the	O
convulsant	O
dose	O
of	O
pentylenetetrezol	B-Chemical
in	O
mice	O
(	O
tests	O
performed	O
by	O
the	O
Anticonvulsant	O
Screening	O
Project	O
of	O
NINCDS	O
)	O
.	O
Acetaminophen	B-Chemical
(	O
up	O
to	O
150	O
micrograms	O
/	O
mL	O
)	O
did	O
not	O
retard	O
the	O
incorporation	O
of	O
radioactive	O
adenosine	B-Chemical
into	O
ATP	B-Chemical
in	O
slices	O
of	O
rat	O
cerebral	O
cortex	O
.	O
Thus	O
the	O
mechanism	O
by	O
which	O
acetaminophen	B-Chemical
antagonizes	O
the	O
actions	O
of	O
caffeine	B-Chemical
in	O
the	O
CNS	O
remains	O
unknown	O
.	O
A	O
double	O
-	O
blind	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
dothiepin	B-Chemical
hydrochloride	I-Chemical
in	O
the	O
treatment	O
of	O
major	O
depressive	B-Disease
disorder	I-Disease
.	O
In	O
a	O
6	O
-	O
week	O
double	O
-	O
blind	O
parallel	O
treatment	O
study	O
,	O
dothiepin	B-Chemical
and	O
amitriptyline	B-Chemical
were	O
compared	O
to	O
placebo	O
in	O
the	O
treatment	O
of	O
33	O
depressed	B-Disease
outpatients	O
.	O
Dothiepin	B-Chemical
and	O
amitriptyline	B-Chemical
were	O
equally	O
effective	O
in	O
alleviating	O
the	O
symptoms	O
of	O
depressive	B-Disease
illness	I-Disease
,	O
and	O
both	O
were	O
significantly	O
superior	O
to	O
placebo	O
.	O
The	O
overall	O
incidence	O
of	O
side	O
effects	O
and	O
the	O
frequency	O
and	O
severity	O
of	O
blurred	B-Disease
vision	I-Disease
,	O
dry	B-Disease
mouth	I-Disease
,	O
and	O
drowsiness	O
were	O
significantly	O
less	O
with	O
dothiepin	B-Chemical
than	O
with	O
amitriptyline	B-Chemical
.	O
Dothiepin	B-Chemical
also	O
produced	O
fewer	O
CNS	O
and	O
cardiovascular	O
effects	O
.	O
There	O
were	O
no	O
clinically	O
important	O
changes	O
in	O
laboratory	O
parameters	O
.	O
Dothiepin	B-Chemical
thus	O
was	O
found	O
to	O
be	O
an	O
effective	O
antidepressant	B-Chemical
drug	O
associated	O
with	O
fewer	O
side	O
effects	O
than	O
amitriptyline	B-Chemical
in	O
the	O
treatment	O
of	O
depressed	B-Disease
outpatients	O
.	O
Behavioral	O
effects	O
of	O
diazepam	B-Chemical
and	O
propranolol	B-Chemical
in	O
patients	O
with	O
panic	B-Disease
disorder	I-Disease
and	O
agoraphobia	B-Disease
.	O
The	O
effects	O
of	O
oral	O
doses	O
of	O
diazepam	B-Chemical
(	O
single	O
dose	O
of	O
10	O
mg	O
and	O
a	O
median	O
dose	O
of	O
30	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
and	O
propranolol	B-Chemical
(	O
single	O
dose	O
of	O
80	O
mg	O
and	O
a	O
median	O
dose	O
of	O
240	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
on	O
psychological	O
performance	O
of	O
patients	O
with	O
panic	B-Disease
disorders	I-Disease
and	O
agoraphobia	B-Disease
were	O
investigated	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
and	O
crossover	O
design	O
.	O
Both	O
drugs	O
impaired	B-Disease
immediate	I-Disease
free	I-Disease
recall	I-Disease
but	O
the	O
decrease	O
was	O
greater	O
for	O
diazepam	B-Chemical
than	O
propranolol	B-Chemical
.	O
Delayed	B-Disease
free	I-Disease
recall	I-Disease
was	I-Disease
also	I-Disease
impaired	I-Disease
but	O
the	O
two	O
drugs	O
did	O
not	O
differ	O
.	O
Patients	O
tapped	O
faster	O
after	O
propranolol	B-Chemical
than	O
diazepam	B-Chemical
and	O
they	O
were	O
more	O
sedated	O
after	O
diazepam	B-Chemical
than	O
propranolol	B-Chemical
.	O
After	O
2	O
weeks	O
of	O
treatment	O
,	O
patients	O
tested	O
5	O
-	O
8	O
h	O
after	O
the	O
last	O
dose	O
of	O
medication	O
did	O
not	O
show	O
any	O
decrement	O
of	O
performance	O
.	O
These	O
results	O
are	O
similar	O
to	O
those	O
previously	O
found	O
in	O
healthy	O
subjects	O
.	O
Accumulation	O
of	O
drugs	O
was	O
not	O
reflected	O
in	O
prolonged	O
behavioral	B-Disease
impairment	I-Disease
.	O
Comparison	O
of	O
i	O
.	O
v	O
.	O
glycopyrrolate	B-Chemical
and	O
atropine	B-Chemical
in	O
the	O
prevention	O
of	O
bradycardia	B-Disease
and	O
arrhythmias	B-Disease
following	O
repeated	O
doses	O
of	O
suxamethonium	B-Chemical
in	O
children	O
.	O
The	O
effectiveness	O
of	O
administration	O
of	O
glycopyrrolate	B-Chemical
5	O
and	O
10	O
micrograms	O
kg	O
-	O
1	O
and	O
atropine	B-Chemical
10	O
and	O
20	O
micrograms	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
immediately	O
before	O
the	O
induction	O
of	O
anaesthesia	O
,	O
to	O
prevent	O
arrhythmia	B-Disease
and	O
bradycardia	B-Disease
following	O
repeated	O
doses	O
of	O
suxamethonium	B-Chemical
in	O
children	O
,	O
was	O
studied	O
.	O
A	O
control	O
group	O
was	O
included	O
for	O
comparison	O
with	O
the	O
lower	O
dose	O
range	O
of	O
glycopyrrolate	B-Chemical
and	O
atropine	B-Chemical
.	O
A	O
frequency	O
of	O
bradycardia	B-Disease
of	O
50	O
%	O
was	O
noted	O
in	O
the	O
control	O
group	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
frequency	O
with	O
the	O
active	O
drugs	O
.	O
Bradycardia	B-Disease
(	O
defined	O
as	O
a	O
decrease	O
in	O
heart	O
rate	O
to	O
less	O
than	O
50	O
beat	O
min	O
-	O
1	O
)	O
was	O
prevented	O
when	O
the	O
larger	O
dose	O
of	O
either	O
active	O
drug	O
was	O
used	O
.	O
It	O
is	O
recommended	O
that	O
either	O
glycopyrrolate	B-Chemical
10	O
micrograms	O
kg	O
-	O
1	O
or	O
atropine	B-Chemical
20	O
micrograms	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
should	O
immediately	O
precede	O
induction	O
of	O
anaesthesia	O
,	O
in	O
children	O
,	O
if	O
the	O
repeated	O
administration	O
of	O
suxamethonium	B-Chemical
is	O
anticipated	O
.	O
Veno	B-Disease
-	I-Disease
occlusive	I-Disease
liver	I-Disease
disease	I-Disease
after	O
dacarbazine	B-Chemical
therapy	O
(	O
DTIC	B-Chemical
)	O
for	O
melanoma	B-Disease
.	O
A	O
case	O
of	O
veno	B-Disease
-	I-Disease
occlusive	I-Disease
disease	I-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
with	O
fatal	O
outcome	O
after	O
dacarbazine	B-Chemical
(	O
DTIC	B-Chemical
)	O
therapy	O
for	O
melanoma	B-Disease
is	O
reported	O
.	O
There	O
was	O
a	O
fulminant	O
clinical	O
course	O
from	O
start	O
of	O
symptoms	O
until	O
death	B-Disease
.	O
At	O
autopsy	O
the	O
liver	O
was	O
enlarged	O
and	O
firm	O
with	O
signs	O
of	O
venous	B-Disease
congestion	I-Disease
.	O
Small	O
-	O
and	O
medium	O
-	O
sized	O
hepatic	O
veins	O
were	O
blocked	O
by	O
thrombosis	B-Disease
.	O
Eosinophilic	O
infiltrations	O
were	O
found	O
around	O
the	O
vessels	O
.	O
Published	O
cases	O
from	O
the	O
literature	O
are	O
reviewed	O
and	O
pertinent	O
features	O
discussed	O
.	O
Maternal	O
lithium	B-Chemical
and	O
neonatal	O
Ebstein	B-Disease
'	I-Disease
s	I-Disease
anomaly	I-Disease
:	O
evaluation	O
with	O
cross	O
-	O
sectional	O
echocardiography	O
.	O
Cross	O
-	O
sectional	O
echocardiography	O
was	O
used	O
to	O
evaluate	O
two	O
neonates	O
whose	O
mothers	O
ingested	O
lithium	B-Chemical
during	O
pregnancy	O
.	O
In	O
one	O
infant	O
,	O
Ebstein	B-Disease
'	I-Disease
s	I-Disease
anomaly	I-Disease
of	O
the	O
tricuspid	O
valve	O
was	O
identified	O
.	O
In	O
the	O
other	O
infant	O
cross	O
-	O
sectional	O
echocardiography	O
provided	O
reassurance	O
that	O
the	O
infant	O
did	O
not	O
have	O
Ebstein	B-Disease
'	I-Disease
s	I-Disease
anomaly	I-Disease
.	O
Cross	O
-	O
sectional	O
echocardiographic	O
screening	O
of	O
newborns	O
exposed	O
to	O
lithium	B-Chemical
during	O
gestation	O
can	O
provide	O
highly	O
accurate	O
,	O
noninvasive	O
assessment	O
of	O
the	O
presence	O
or	O
absence	O
of	O
lithium	B-Chemical
-	O
induced	O
cardiac	B-Disease
malformations	I-Disease
.	O
Effects	O
of	O
training	O
on	O
the	O
extent	O
of	O
experimental	O
myocardial	B-Disease
infarction	I-Disease
in	O
aging	O
rats	O
.	O
The	O
effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
were	O
studied	O
in	O
female	O
albino	O
rats	O
of	O
20	O
,	O
40	O
,	O
60	O
and	O
80	O
weeks	O
of	O
age	O
.	O
The	O
rats	O
were	O
trained	O
to	O
swim	O
for	O
a	O
specific	O
duration	O
and	O
for	O
a	O
particular	O
period	O
.	O
The	O
occurrence	O
of	O
infarcts	B-Disease
were	O
confirmed	O
by	O
histological	O
methods	O
.	O
Elevations	O
in	O
the	O
serum	O
GOT	O
and	O
GPT	O
were	O
maximum	O
in	O
the	O
sedentary	O
-	O
isoproterenols	B-Chemical
and	O
minimum	O
in	O
the	O
exercise	O
-	O
controls	O
.	O
These	O
changes	O
in	O
the	O
serum	O
transaminases	O
were	O
associated	O
with	O
corresponding	O
depletions	O
in	O
the	O
cardiac	O
GOT	O
and	O
GPT	O
.	O
However	O
,	O
age	O
was	O
seen	O
to	O
interfere	O
with	O
the	O
responses	O
exhibited	O
by	O
the	O
young	O
and	O
old	O
rats	O
.	O
Studies	O
dealing	O
with	O
myocardial	B-Disease
infarction	I-Disease
are	O
more	O
informative	O
when	O
dealt	O
with	O
age	O
.	O
Effect	O
of	O
polyethylene	B-Chemical
glycol	I-Chemical
400	I-Chemical
on	O
adriamycin	B-Chemical
toxicity	B-Disease
in	O
mice	O
.	O
The	O
effect	O
of	O
a	O
widely	O
used	O
organic	O
solvent	O
,	O
polyethylene	B-Chemical
glycol	I-Chemical
400	I-Chemical
(	O
PEG	B-Chemical
400	I-Chemical
)	O
,	O
on	O
the	O
toxic	O
action	O
of	O
an	O
acute	O
or	O
chronic	O
treatment	O
with	O
adriamycin	B-Chemical
(	O
ADR	B-Chemical
)	O
was	O
evaluated	O
in	O
mice	O
.	O
PEG	B-Chemical
400	I-Chemical
impressively	O
decreased	O
both	O
acute	O
high	O
-	O
dose	O
and	O
chronic	O
low	O
-	O
dose	O
-	O
ADR	B-Chemical
-	O
associated	O
lethality	O
.	O
Light	O
microscopic	O
analysis	O
showed	O
a	O
significant	O
protection	O
against	O
ADR	B-Chemical
-	O
induced	O
cardiac	B-Disease
morphological	I-Disease
alterations	I-Disease
.	O
Such	O
treatment	O
did	O
not	O
diminish	O
the	O
ADR	B-Chemical
antitumor	O
activity	O
in	O
L1210	B-Disease
leukemia	I-Disease
and	O
in	O
Ehrlich	B-Disease
ascites	I-Disease
tumor	I-Disease
.	O
Sublingual	O
absorption	O
of	O
the	O
quaternary	B-Chemical
ammonium	I-Chemical
antiarrhythmic	O
agent	O
,	O
UM	B-Chemical
-	I-Chemical
272	I-Chemical
.	O
UM	B-Chemical
-	I-Chemical
272	I-Chemical
(	O
N	B-Chemical
,	I-Chemical
N	I-Chemical
-	I-Chemical
dimethylpropranolol	I-Chemical
)	O
,	O
a	O
quaternary	O
antiarrhythmic	O
agent	O
,	O
was	O
administered	O
sublingually	O
to	O
dogs	O
with	O
ouabain	B-Chemical
-	O
induced	O
ventricular	B-Disease
tachycardias	I-Disease
.	O
Both	O
anti	O
-	O
arrhythmic	O
efficacy	O
and	O
bioavailability	O
were	O
compared	O
to	O
oral	O
drug	O
.	O
Sublingual	O
UM	B-Chemical
-	I-Chemical
272	I-Chemical
converted	O
ventricular	B-Disease
tachycardia	I-Disease
to	O
sinus	O
rhythm	O
in	O
all	O
5	O
dogs	O
.	O
The	O
area	O
under	O
the	O
plasma	O
concentration	O
time	O
curve	O
at	O
90	O
min	O
was	O
4	O
-	O
12	O
times	O
greater	O
than	O
for	O
oral	O
drug	O
,	O
suggesting	O
the	O
existence	O
of	O
an	O
absorption	O
-	O
limiting	O
process	O
in	O
the	O
intestine	O
,	O
and	O
providing	O
an	O
alternate	O
form	O
of	O
administration	O
for	O
quaternary	O
drugs	O
.	O
Early	O
adjuvant	O
adriamycin	B-Chemical
in	O
superficial	O
bladder	B-Disease
carcinoma	I-Disease
.	O
A	O
multicenter	O
study	O
was	O
performed	O
in	O
110	O
patients	O
with	O
superficial	O
transitional	O
cell	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
bladder	I-Disease
.	O
Adriamycin	B-Chemical
(	O
50	O
mg	O
/	O
50	O
ml	O
)	O
was	O
administered	O
intravesically	O
within	O
24	O
h	O
after	O
transurethral	O
resection	O
of	O
TA	O
-	O
T1	O
(	O
O	O
-	O
A	O
)	O
bladder	B-Disease
tumors	I-Disease
.	O
Instillation	O
was	O
repeated	O
twice	O
during	O
the	O
first	O
week	O
,	O
then	O
weekly	O
during	O
the	O
first	O
month	O
and	O
afterwards	O
monthly	O
for	O
1	O
year	O
.	O
The	O
tolerance	O
was	O
evaluated	O
in	O
these	O
110	O
patients	O
,	O
and	O
29	O
patients	O
presented	O
with	O
local	O
side	O
-	O
effects	O
.	O
In	O
24	O
of	O
these	O
patients	O
chemical	O
cystitis	B-Disease
was	O
severe	O
enough	O
for	O
them	O
to	O
drop	O
out	O
of	O
the	O
study	O
.	O
No	O
systemic	O
side	O
-	O
effects	O
were	O
observed	O
.	O
Recurrence	O
was	O
studied	O
in	O
82	O
evaluable	O
patients	O
after	O
1	O
year	O
of	O
follow	O
-	O
up	O
and	O
in	O
72	O
patients	O
followed	O
for	O
2	O
-	O
3	O
years	O
(	O
mean	O
32	O
months	O
)	O
.	O
Of	O
the	O
82	O
patients	O
studied	O
after	O
1	O
year	O
,	O
23	O
had	O
primary	O
and	O
59	O
recurrent	O
disease	O
.	O
Of	O
the	O
82	O
evaluable	O
patients	O
,	O
50	O
did	O
not	O
show	O
any	O
recurrence	O
after	O
1	O
year	O
(	O
61	O
%	O
)	O
,	O
while	O
32	O
presented	O
with	O
one	O
or	O
more	O
recurrences	O
(	O
39	O
%	O
)	O
.	O
Of	O
these	O
recurrences	O
,	O
27	O
were	O
T1	O
tumors	B-Disease
while	O
five	O
progressed	O
to	O
more	O
highly	O
invasive	O
lesions	O
.	O
In	O
patients	O
that	O
were	O
free	O
of	O
recurrence	O
during	O
the	O
first	O
year	O
,	O
80	O
%	O
remained	O
tumor	B-Disease
-	O
free	O
during	O
the	O
2	O
-	O
to	O
3	O
-	O
year	O
follow	O
-	O
up	O
period	O
.	O
Of	O
the	O
patients	O
developing	O
one	O
or	O
more	O
recurrences	O
during	O
the	O
first	O
year	O
,	O
only	O
50	O
%	O
presented	O
with	O
further	O
recurrence	O
once	O
the	O
instillations	O
were	O
stopped	O
.	O
The	O
beneficial	O
effect	O
of	O
Adriamycin	B-Chemical
appears	O
obvious	O
and	O
might	O
be	O
related	O
to	O
the	O
drug	O
itself	O
,	O
the	O
early	O
and	O
repeated	O
instillations	O
after	O
TUR	O
,	O
or	O
both	O
.	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
-	O
induced	O
angiopathy	B-Disease
in	O
rats	O
.	O
The	O
effect	O
of	O
high	O
dose	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
treatment	O
on	O
aortic	O
permeability	O
to	O
albumin	O
and	O
on	O
the	O
ultrastructure	O
of	O
the	O
vessel	O
.	O
Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
with	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
(	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
)	O
500	O
mg	O
/	O
kg	O
/	O
day	O
for	O
10	O
or	O
42	O
days	O
.	O
Pair	O
fed	O
rats	O
served	O
as	O
controls	O
.	O
Changes	O
in	O
aortic	O
morphology	O
were	O
examined	O
by	O
light	O
-	O
and	O
transmission	O
-	O
electron	O
microscopy	O
(	O
TEM	O
)	O
.	O
In	O
addition	O
,	O
the	O
endothelial	O
permeability	O
and	O
the	O
penetration	O
through	O
the	O
aortic	O
wall	O
of	O
albumin	O
were	O
studied	O
10	O
minutes	O
,	O
24	O
and	O
48	O
hours	O
after	O
i	O
.	O
v	O
.	O
injection	O
of	O
human	O
serum	O
131I	O
-	O
albumin	O
(	O
131I	O
-	O
HSA	O
)	O
.	O
TEM	O
revealed	O
extensive	O
elastolysis	O
in	O
the	O
arterial	O
wall	O
of	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
-	O
treated	O
rats	O
,	O
consistent	O
with	O
an	O
inhibitory	O
effect	O
on	O
crosslink	O
formation	O
.	O
In	O
experimental	O
animals	O
excess	O
deposition	O
of	O
collagen	O
and	O
glycoaminoglycans	O
was	O
observed	O
in	O
the	O
subendothelial	O
and	O
medial	O
layer	O
of	O
the	O
aortic	O
wall	O
,	O
together	O
with	O
prominent	O
basal	O
membrane	O
substance	O
around	O
aortic	O
smooth	O
muscle	O
cells	O
.	O
The	O
aorta	O
/	O
serum	O
-	O
ratio	O
and	O
the	O
radioactive	O
build	O
-	O
up	O
24	O
and	O
48	O
hours	O
after	O
injection	O
of	O
131I	O
-	O
HSA	O
was	O
reduced	O
in	O
animals	O
treated	O
with	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
for	O
42	O
days	O
,	O
indicating	O
an	O
impeded	O
transmural	O
transport	O
of	O
tracer	O
which	O
may	O
be	O
caused	O
by	O
a	O
steric	O
exclusion	O
effect	O
of	O
abundant	O
hyaluronate	B-Chemical
.	O
The	O
endothelial	O
ultrastructure	O
was	O
unaffected	O
by	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
,	O
and	O
no	O
differences	O
in	O
aortic	O
131I	O
-	O
HSA	O
radioactivity	O
or	O
aorta	O
/	O
serum	O
-	O
ratio	O
were	O
recorded	O
between	O
experimental	O
and	O
control	O
groups	O
10	O
minutes	O
after	O
tracer	O
injection	O
,	O
indicating	O
that	O
the	O
permeability	O
of	O
the	O
endothelial	O
barrier	O
to	O
albumin	O
remained	O
unaffected	O
by	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
treatment	O
.	O
These	O
observations	O
support	O
the	O
hypothesis	O
that	O
treatment	O
with	O
high	O
doses	O
of	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
may	O
induce	O
a	O
fibroproliferative	O
response	O
in	O
rat	O
aorta	O
,	O
possibly	O
by	O
an	O
inhibitory	O
effect	O
on	O
the	O
cross	O
-	O
linking	O
of	O
collagen	O
and	O
elastin	O
.	O
Effect	O
of	O
aspirin	B-Chemical
on	O
N	B-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
5	I-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
furyl	I-Chemical
)	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
thiazolyl	I-Chemical
]	I-Chemical
-	I-Chemical
formamide	I-Chemical
-	O
induced	O
epithelial	O
proliferation	O
in	O
the	O
urinary	O
bladder	O
and	O
forestomach	O
of	O
the	O
rat	O
.	O
The	O
co	O
-	O
administration	O
of	O
aspirin	B-Chemical
with	O
N	B-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
5	I-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
furyl	I-Chemical
)	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
thiazolyl	I-Chemical
]	I-Chemical
-	I-Chemical
formamide	I-Chemical
(	O
FANFT	B-Chemical
)	O
to	O
rats	O
resulted	O
in	O
a	O
reduced	O
incidence	O
of	O
FANFT	B-Chemical
-	O
induced	O
bladder	B-Disease
carcinomas	I-Disease
but	O
a	O
concomitant	O
induction	O
of	O
forestomach	B-Disease
tumors	I-Disease
.	O
An	O
autoradiographic	O
study	O
was	O
performed	O
on	O
male	O
F	O
-	O
344	O
rats	O
fed	O
diet	O
containing	O
FANFT	B-Chemical
at	O
a	O
level	O
of	O
0	O
.	O
2	O
%	O
and	O
/	O
or	O
aspirin	B-Chemical
at	O
a	O
level	O
of	O
0	O
.	O
5	O
%	O
to	O
evaluate	O
the	O
effect	O
of	O
aspirin	B-Chemical
on	O
the	O
increased	O
cell	O
proliferation	O
induced	O
by	O
FANFT	B-Chemical
in	O
the	O
forestomach	O
and	O
bladder	O
.	O
FANFT	B-Chemical
-	O
induced	O
cell	O
proliferation	O
in	O
the	O
bladder	O
was	O
significantly	O
suppressed	O
by	O
aspirin	B-Chemical
co	O
-	O
administration	O
after	O
4	O
weeks	O
but	O
not	O
after	O
12	O
weeks	O
.	O
In	O
the	O
forestomach	O
,	O
and	O
also	O
in	O
the	O
liver	O
,	O
aspirin	B-Chemical
did	O
not	O
affect	O
the	O
FANFT	B-Chemical
-	O
induced	O
increase	O
in	O
labeling	O
index	O
.	O
The	O
present	O
results	O
are	O
consistent	O
with	O
the	O
carcinogenicity	O
experiment	O
suggesting	O
that	O
different	O
mechanisms	O
are	O
involved	O
in	O
FANFT	B-Chemical
carcinogenesis	B-Disease
in	O
the	O
bladder	O
and	O
forestomach	O
,	O
and	O
that	O
aspirin	B-Chemical
'	O
s	O
effect	O
on	O
FANFT	B-Chemical
in	O
the	O
forestomach	O
is	O
not	O
due	O
to	O
an	O
irritant	O
effect	O
associated	O
with	O
increased	O
cell	O
proliferation	O
.	O
Also	O
,	O
there	O
appears	O
to	O
be	O
an	O
adaptation	O
by	O
the	O
rats	O
to	O
the	O
chronic	O
ingestion	O
of	O
aspirin	B-Chemical
.	O
A	O
case	O
of	O
tardive	B-Disease
dyskinesia	I-Disease
caused	O
by	O
metoclopramide	B-Chemical
.	O
Abnormal	B-Disease
involuntary	I-Disease
movements	I-Disease
appeared	O
in	O
the	O
mouth	O
,	O
tongue	O
,	O
neck	O
and	O
abdomen	O
of	O
a	O
64	O
-	O
year	O
-	O
old	O
male	O
patient	O
after	O
he	O
took	O
metoclopramide	B-Chemical
for	O
gastrointestinal	B-Disease
disorder	I-Disease
in	O
a	O
regimen	O
of	O
30	O
mg	O
per	O
day	O
for	O
a	O
total	O
of	O
about	O
260	O
days	O
.	O
The	O
symptoms	O
exacerbated	O
to	O
a	O
maximum	O
in	O
a	O
month	O
.	O
When	O
the	O
metoclopramide	B-Chemical
administration	O
was	O
discontinued	O
,	O
the	O
abnormal	B-Disease
movements	I-Disease
gradually	O
improved	O
to	O
a	O
considerable	O
extent	O
.	O
Attention	O
to	O
the	O
possible	O
induction	O
of	O
specific	O
tardive	B-Disease
dyskinesia	I-Disease
is	O
called	O
for	O
in	O
the	O
use	O
of	O
this	O
drug	O
.	O
Intra	O
-	O
arterial	O
BCNU	B-Chemical
chemotherapy	O
for	O
treatment	O
of	O
malignant	B-Disease
gliomas	I-Disease
of	O
the	O
central	O
nervous	O
system	O
.	O
Because	O
of	O
the	O
rapid	O
systemic	O
clearance	O
of	O
BCNU	B-Chemical
(	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
bis	I-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
chloroethyl	I-Chemical
)	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
nitrosourea	I-Chemical
)	O
,	O
intra	O
-	O
arterial	O
administration	O
should	O
provide	O
a	O
substantial	O
advantage	O
over	O
intravenous	O
administration	O
for	O
the	O
treatment	O
of	O
malignant	B-Disease
gliomas	I-Disease
.	O
Thirty	O
-	O
six	O
patients	O
were	O
treated	O
with	O
BCNU	B-Chemical
every	O
6	O
to	O
8	O
weeks	O
,	O
either	O
by	O
transfemoral	O
catheterization	O
of	O
the	O
internal	O
carotid	O
or	O
vertebral	O
artery	O
or	O
through	O
a	O
fully	O
implantable	O
intracarotid	O
drug	O
delivery	O
system	O
,	O
beginning	O
with	O
a	O
dose	O
of	O
200	O
mg	O
/	O
sq	O
m	O
body	O
surface	O
area	O
.	O
Twelve	O
patients	O
with	O
Grade	O
III	O
or	O
IV	O
astrocytomas	B-Disease
were	O
treated	O
after	O
partial	O
resection	O
of	O
the	O
tumor	B-Disease
without	O
prior	O
radiation	O
therapy	O
.	O
After	O
two	O
to	O
seven	O
cycles	O
of	O
chemotherapy	O
,	O
nine	O
patients	O
showed	O
a	O
decrease	O
in	O
tumor	B-Disease
size	O
and	O
surrounding	O
edema	B-Disease
on	O
contrast	O
-	O
enhanced	O
computerized	O
tomography	O
scans	O
.	O
In	O
the	O
nine	O
responders	O
,	O
median	O
duration	O
of	O
chemotherapy	O
response	O
from	O
the	O
time	O
of	O
operation	O
was	O
25	O
weeks	O
(	O
range	O
12	O
to	O
more	O
than	O
91	O
weeks	O
)	O
.	O
The	O
median	O
duration	O
of	O
survival	O
in	O
the	O
12	O
patients	O
was	O
54	O
weeks	O
(	O
range	O
21	O
to	O
more	O
than	O
156	O
weeks	O
)	O
,	O
with	O
an	O
18	O
-	O
month	O
survival	O
rate	O
of	O
42	O
%	O
.	O
Twenty	O
-	O
four	O
patients	O
with	O
recurrent	O
Grade	O
I	O
to	O
IV	O
astrocytomas	B-Disease
,	O
whose	O
resection	O
and	O
irradiation	O
therapy	O
had	O
failed	O
,	O
received	O
two	O
to	O
eight	O
courses	O
of	O
intra	O
-	O
arterial	O
BCNU	B-Chemical
therapy	O
.	O
Seventeen	O
of	O
these	O
had	O
a	O
response	O
or	O
were	O
stable	O
for	O
a	O
median	O
of	O
20	O
weeks	O
(	O
range	O
6	O
to	O
more	O
than	O
66	O
weeks	O
)	O
.	O
The	O
catheterization	O
procedure	O
is	O
safe	O
,	O
with	O
no	O
immediate	O
complication	O
in	O
111	O
infusions	O
of	O
BCNU	B-Chemical
.	O
A	O
delayed	O
complication	O
in	O
nine	O
patients	O
has	O
been	O
unilateral	O
loss	B-Disease
of	I-Disease
vision	I-Disease
secondary	O
to	O
a	O
retinal	B-Disease
vasculitis	I-Disease
.	O
The	O
frequency	O
of	O
visual	B-Disease
loss	I-Disease
decreased	O
after	O
the	O
concentration	O
of	O
the	O
ethanol	B-Chemical
diluent	O
was	O
lowered	O
.	O
Provocation	O
of	O
postural	O
hypotension	B-Disease
by	O
nitroglycerin	B-Chemical
in	O
diabetic	B-Disease
autonomic	I-Disease
neuropathy	I-Disease
?	O
The	O
effect	O
of	O
nitroglycerin	B-Chemical
on	O
heart	O
rate	O
and	O
systolic	O
blood	O
pressure	O
was	O
compared	O
in	O
5	O
normal	O
subjects	O
,	O
12	O
diabetic	B-Disease
subjects	O
without	O
autonomic	B-Disease
neuropathy	I-Disease
,	O
and	O
5	O
diabetic	B-Disease
subjects	O
with	O
autonomic	B-Disease
neuropathy	I-Disease
.	O
The	O
magnitude	O
and	O
time	O
course	O
of	O
the	O
increase	O
in	O
heart	O
rate	O
and	O
the	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
after	O
nitroglycerin	B-Chemical
were	O
similar	O
in	O
the	O
normal	O
and	O
diabetic	B-Disease
subjects	O
without	O
autonomic	B-Disease
neuropathy	I-Disease
,	O
whereas	O
a	O
lesser	O
increase	O
in	O
heart	O
rate	O
and	O
a	O
greater	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
occurred	O
in	O
the	O
diabetic	B-Disease
subjects	O
with	O
autonomic	B-Disease
neuropathy	I-Disease
.	O
It	O
is	O
therefore	O
suggested	O
that	O
caution	O
should	O
be	O
exercised	O
when	O
prescribing	O
vasodilator	O
drugs	O
in	O
diabetic	B-Disease
patients	O
,	O
particularly	O
those	O
with	O
autonomic	B-Disease
neuropathy	I-Disease
.	O
Blood	O
pressure	O
response	O
to	O
chronic	O
low	O
-	O
dose	O
intrarenal	O
noradrenaline	B-Chemical
infusion	O
in	O
conscious	O
rats	O
.	O
Sodium	B-Chemical
chloride	I-Chemical
solution	O
(	O
0	O
.	O
9	O
%	O
)	O
or	O
noradrenaline	B-Chemical
in	O
doses	O
of	O
4	O
,	O
12	O
and	O
36	O
micrograms	O
h	O
-	O
1	O
kg	O
-	O
1	O
was	O
infused	O
for	O
five	O
consecutive	O
days	O
,	O
either	O
intrarenally	O
(	O
by	O
a	O
new	O
technique	O
)	O
or	O
intravenously	O
into	O
rats	O
with	O
one	O
kidney	O
removed	O
.	O
Intrarenal	O
infusion	O
of	O
noradrenaline	B-Chemical
caused	O
hypertension	B-Disease
at	O
doses	O
which	O
did	O
not	O
do	O
so	O
when	O
infused	O
intravenously	O
.	O
Intrarenal	O
compared	O
with	O
intravenous	O
infusion	O
of	O
noradrenaline	B-Chemical
caused	O
higher	O
plasma	O
noradrenaline	B-Chemical
concentrations	O
and	O
a	O
shift	O
of	O
the	O
plasma	O
noradrenaline	B-Chemical
concentration	O
-	O
blood	O
pressure	O
effect	O
curve	O
towards	O
lower	O
plasma	O
noradrenaline	B-Chemical
levels	O
.	O
These	O
results	O
suggest	O
that	O
hypertension	B-Disease
after	O
chronic	O
intrarenal	O
noradrenaline	B-Chemical
infusion	O
is	O
produced	O
by	O
relatively	O
higher	O
levels	O
of	O
circulating	O
noradrenaline	B-Chemical
and	O
by	O
triggering	O
of	O
an	O
additional	O
intrarenal	O
pressor	O
mechanism	O
.	O
Characterization	O
of	O
estrogen	B-Chemical
-	O
induced	O
adenohypophyseal	B-Disease
tumors	I-Disease
in	O
the	O
Fischer	O
344	O
rat	O
.	O
Pituitary	B-Disease
tumors	I-Disease
were	O
induced	O
in	O
F344	O
female	O
rats	O
by	O
chronic	O
treatment	O
with	O
diethylstilbestrol	B-Chemical
(	O
DES	B-Chemical
,	O
8	O
-	O
10	O
mg	O
)	O
implanted	O
subcutaneously	O
in	O
silastic	O
capsules	O
.	O
Over	O
a	O
range	O
of	O
1	O
-	O
150	O
days	O
of	O
DES	B-Chemical
treatment	O
,	O
pairs	O
of	O
control	O
and	O
DES	B-Chemical
-	O
treated	O
rats	O
were	O
sacrificed	O
,	O
and	O
their	O
pituitaries	O
dissociated	O
enzymatically	O
into	O
single	O
-	O
cell	O
preparations	O
.	O
The	O
cell	O
populations	O
were	O
examined	O
regarding	O
total	O
cell	O
recovery	O
correlated	O
with	O
gland	O
weight	O
,	O
intracellular	O
prolactin	O
(	O
PRL	O
)	O
content	O
and	O
subsequent	O
release	O
in	O
primary	O
culture	O
,	O
immunocytochemical	O
PRL	O
staining	O
,	O
density	O
and	O
/	O
or	O
size	O
alterations	O
via	O
separation	O
on	O
Ficoll	O
-	O
Hypaque	O
and	O
by	O
unit	O
gravity	O
sedimentation	O
,	O
and	O
cell	O
cycle	O
analysis	O
,	O
after	O
acriflavine	B-Chemical
DNA	O
staining	O
,	O
by	O
laser	O
flow	O
cytometry	O
.	O
Total	O
cell	O
yields	O
from	O
DES	B-Chemical
-	O
treated	O
pituitaries	O
increased	O
from	O
1	O
.	O
3	O
times	O
control	O
yields	O
at	O
8	O
days	O
of	O
treatment	O
to	O
58	O
.	O
9	O
times	O
control	O
values	O
by	O
day	O
150	O
.	O
Intracellular	O
PRL	O
content	O
ranged	O
from	O
1	O
.	O
9	O
to	O
9	O
.	O
4	O
times	O
control	O
levels	O
,	O
and	O
PRL	O
release	O
in	O
vitro	O
was	O
significantly	O
and	O
consistently	O
higher	O
than	O
controls	O
,	O
after	O
at	O
least	O
8	O
days	O
of	O
DES	B-Chemical
exposure	O
.	O
Beyond	O
8	O
days	O
of	O
DES	B-Chemical
exposure	O
,	O
the	O
immunochemically	O
PRL	O
-	O
positive	O
proportion	O
of	O
cells	O
increased	O
to	O
over	O
50	O
%	O
of	O
the	O
total	O
population	O
.	O
Increased	O
density	O
and	O
/	O
or	O
size	O
and	O
PRL	O
content	O
were	O
indicated	O
for	O
the	O
majority	O
of	O
the	O
PRL	O
cell	O
population	O
in	O
both	O
types	O
of	O
separation	O
protocols	O
.	O
All	O
these	O
effects	O
of	O
DES	B-Chemical
were	O
more	O
pronounced	O
among	O
previously	O
ovariectomized	O
animals	O
.	O
The	O
data	O
extend	O
the	O
findings	O
of	O
other	O
investigators	O
,	O
further	O
establishing	O
the	O
DES	B-Chemical
-	O
induced	O
tumor	B-Disease
as	O
a	O
model	O
for	O
study	O
of	O
PRL	O
cellular	O
control	O
mechanisms	O
.	O
Age	O
and	O
renal	O
clearance	O
of	O
cimetidine	B-Chemical
.	O
In	O
35	O
patients	O
(	O
ages	O
20	O
to	O
86	O
yr	O
)	O
receiving	O
cimetidine	B-Chemical
therapeutically	O
two	O
serum	O
samples	O
and	O
all	O
urine	O
formed	O
in	O
the	O
interim	O
were	O
collected	O
for	O
analysis	O
of	O
cimetidine	B-Chemical
by	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
and	O
for	O
creatinine	B-Chemical
.	O
Cimetidine	B-Chemical
clearance	O
decreased	O
with	O
age	O
.	O
The	O
extrapolated	O
6	O
-	O
hr	O
serum	O
concentration	O
of	O
cimetidine	B-Chemical
per	O
unit	O
dose	O
,	O
after	O
intravenous	O
cimetidine	B-Chemical
,	O
increased	O
with	O
age	O
of	O
the	O
patients	O
.	O
The	O
ratio	O
of	O
cimetidine	B-Chemical
clearance	O
to	O
creatinine	B-Chemical
clearance	O
(	O
Rc	O
)	O
averaged	O
4	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
0	O
,	O
indicating	O
net	O
tubular	O
secretion	O
for	O
cimetidine	B-Chemical
.	O
Rc	O
seemed	O
to	O
be	O
independent	O
of	O
age	O
and	O
decreased	O
with	O
increasing	O
serum	O
concentration	O
of	O
cimetidine	B-Chemical
,	O
suggesting	O
that	O
secretion	O
of	O
cimetidine	B-Chemical
is	O
a	O
saturable	O
process	O
.	O
There	O
was	O
only	O
one	O
case	O
of	O
dementia	B-Disease
possibly	O
due	O
to	O
cimetidine	B-Chemical
(	O
with	O
a	O
drug	O
level	O
of	O
1	O
.	O
9	O
microgram	O
/	O
ml	O
6	O
hr	O
after	O
a	O
dose	O
)	O
in	O
a	O
group	O
of	O
13	O
patients	O
without	O
liver	B-Disease
or	I-Disease
kidney	I-Disease
disease	I-Disease
who	O
had	O
cimetidine	B-Chemical
levels	O
above	O
1	O
.	O
25	O
microgram	O
/	O
ml	O
.	O
Thus	O
,	O
high	O
cimetidine	B-Chemical
levels	O
alone	O
do	O
not	O
always	O
induce	O
dementia	B-Disease
.	O
Further	O
observations	O
on	O
the	O
electrophysiologic	O
effects	O
of	O
oral	O
amiodarone	B-Chemical
therapy	O
.	O
A	O
case	O
is	O
presented	O
of	O
a	O
reversible	O
intra	B-Disease
-	I-Disease
Hisian	I-Disease
block	I-Disease
occurring	O
under	O
amiodarone	B-Chemical
treatment	O
for	O
atrial	B-Disease
tachycardia	I-Disease
in	O
a	O
patient	O
without	O
clear	O
intraventricular	B-Disease
conduction	I-Disease
abnormalities	I-Disease
.	O
His	O
bundle	O
recordings	O
showed	O
an	O
atrial	B-Disease
tachycardia	I-Disease
with	O
intermittent	O
exit	O
block	O
and	O
greatly	O
prolonged	O
BH	O
and	O
HV	O
intervals	O
(	O
40	O
and	O
100	O
msec	O
,	O
respectively	O
)	O
.	O
Thirty	O
days	O
after	O
amiodarone	B-Chemical
discontinuation	O
,	O
His	O
bundle	O
electrograms	O
showed	O
atrial	B-Disease
flutter	I-Disease
without	O
intra	O
-	O
Hisian	O
or	O
infra	O
-	O
Hisian	O
delay	O
.	O
Amiodarone	B-Chemical
should	O
be	O
used	O
with	O
caution	O
during	O
long	O
-	O
term	O
oral	O
therapy	O
in	O
patients	O
with	O
or	O
without	O
clear	O
intraventricular	O
conduction	O
defects	O
.	O
Development	O
of	O
clear	B-Disease
cell	I-Disease
adenocarcinoma	I-Disease
in	O
DES	B-Chemical
-	O
exposed	O
offspring	O
under	O
observation	O
.	O
Two	O
cases	O
of	O
clear	B-Disease
cell	I-Disease
adenocarcinoma	I-Disease
of	I-Disease
the	I-Disease
vagina	I-Disease
detected	O
at	O
follow	O
-	O
up	O
in	O
young	O
women	O
exposed	O
in	O
utero	O
to	O
diethylstilbestrol	B-Chemical
are	O
reported	O
.	O
One	O
patient	O
,	O
aged	O
23	O
,	O
had	O
been	O
followed	O
for	O
2	O
years	O
before	O
carcinoma	B-Disease
was	O
diagnosed	O
;	O
the	O
second	O
patient	O
,	O
aged	O
22	O
,	O
had	O
been	O
seen	O
on	O
a	O
regular	O
basis	O
for	O
5	O
years	O
,	O
8	O
months	O
.	O
In	O
both	O
instances	O
,	O
suspicion	O
of	O
the	O
presence	O
of	O
carcinoma	B-Disease
was	O
aroused	O
by	O
the	O
palpation	O
of	O
a	O
small	O
nodule	O
in	O
the	O
vaginal	O
fornix	O
.	O
Hysterosalpingography	O
was	O
performed	O
on	O
both	O
patients	O
and	O
,	O
in	O
1	O
instance	O
,	O
an	O
abnormal	O
x	O
-	O
ray	O
film	O
was	O
reflected	O
by	O
the	O
gross	O
appearance	O
of	O
the	O
uterine	O
cavity	O
found	O
in	O
the	O
surgical	O
specimen	O
.	O
Neurologic	O
effects	O
of	O
subarachnoid	O
administration	O
of	O
2	B-Chemical
-	I-Chemical
chloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
,	O
bupivacaine	B-Chemical
,	O
and	O
low	O
pH	O
normal	O
saline	O
in	O
dogs	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
neurologic	O
consequences	O
of	O
deliberate	O
subarachnoid	O
injection	O
of	O
large	O
volumes	O
of	O
2	B-Chemical
-	I-Chemical
chloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
in	O
experimental	O
animals	O
.	O
The	O
possible	O
role	O
of	O
low	O
pH	O
as	O
well	O
as	O
total	O
volume	O
as	O
potential	O
factors	O
in	O
causing	O
neurotoxicity	B-Disease
was	O
evaluated	O
.	O
The	O
65	O
dogs	O
in	O
the	O
study	O
received	O
injections	O
in	O
the	O
subarachnoid	O
space	O
as	O
follows	O
:	O
6	O
to	O
8	O
ml	O
of	O
bupivacaine	B-Chemical
(	O
N	O
=	O
15	O
)	O
,	O
2	B-Chemical
-	I-Chemical
chloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
(	O
N	O
=	O
20	O
)	O
,	O
low	O
pH	O
normal	O
saline	O
(	O
pH	O
3	O
.	O
0	O
)	O
(	O
N	O
=	O
20	O
)	O
,	O
or	O
normal	O
saline	O
(	O
N	O
=	O
10	O
)	O
.	O
Of	O
the	O
20	O
animals	O
that	O
received	O
subarachnoid	O
injection	O
of	O
2	B-Chemical
-	I-Chemical
chloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
seven	O
(	O
35	O
%	O
)	O
developed	O
hind	O
-	O
limb	O
paralysis	B-Disease
.	O
None	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	B-Chemical
,	O
normal	O
saline	O
,	O
or	O
normal	O
saline	O
titrated	O
to	O
a	O
pH	O
3	O
.	O
0	O
developed	O
hind	O
-	O
limb	O
paralysis	B-Disease
.	O
Of	O
the	O
15	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
2	B-Chemical
-	I-Chemical
chloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
,	O
13	O
showed	O
subpial	B-Disease
necrosis	I-Disease
;	O
the	O
nerve	O
roots	O
and	O
subarachnoid	O
vessels	O
were	O
normal	O
.	O
The	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	B-Chemical
,	O
low	O
pH	O
normal	O
saline	O
(	O
pH	O
3	O
.	O
0	O
)	O
,	O
or	O
normal	O
saline	O
did	O
not	O
show	O
abnormal	O
findings	O
.	O
Procainamide	B-Chemical
-	O
induced	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
.	O
Seven	O
cases	O
of	O
procainamide	B-Chemical
-	O
induced	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
are	O
presented	O
.	O
In	O
four	O
patients	O
,	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
appeared	O
after	O
intravenous	O
administration	O
of	O
200	O
to	O
400	O
mg	O
of	O
procainamide	B-Chemical
for	O
the	O
treatment	O
of	O
sustained	O
ventricular	B-Disease
tachycardia	I-Disease
.	O
In	O
the	O
remaining	O
three	O
patients	O
,	O
procainamide	B-Chemical
was	O
administered	O
orally	O
for	O
treatment	O
of	O
chronic	O
premature	B-Disease
ventricular	I-Disease
contractions	I-Disease
or	O
atrial	B-Disease
flutter	I-Disease
.	O
These	O
patients	O
had	O
Q	B-Disease
-	I-Disease
T	I-Disease
prolongation	I-Disease
and	O
recurrent	O
syncope	B-Disease
due	O
to	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
.	O
In	O
four	O
patients	O
,	O
the	O
arrhythmia	B-Disease
was	O
rapidly	O
diagnosed	O
and	O
treated	O
with	O
disappearance	O
of	O
further	O
episodes	O
of	O
the	O
arrhythmia	B-Disease
.	O
In	O
two	O
patients	O
,	O
the	O
arrhythmia	B-Disease
degenerated	O
into	O
irreversible	O
ventricular	B-Disease
fibrillation	I-Disease
and	O
both	O
patients	O
died	O
.	O
In	O
the	O
seventh	O
patient	O
,	O
a	O
permanent	O
ventricular	O
pacemaker	O
was	O
inserted	O
and	O
,	O
despite	O
continuation	O
of	O
procainamide	B-Chemical
therapy	O
,	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
did	O
not	O
reoccur	O
.	O
These	O
seven	O
cases	O
demonstrate	O
that	O
procainamide	B-Chemical
can	O
produce	O
an	O
acquired	O
prolonged	B-Disease
Q	I-Disease
-	I-Disease
T	I-Disease
syndrome	I-Disease
with	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
.	O
Phenobarbitone	B-Chemical
-	O
induced	O
enlargement	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
in	O
the	O
rat	O
:	O
its	O
relationship	O
to	O
carbon	B-Chemical
tetrachloride	I-Chemical
-	O
induced	O
cirrhosis	B-Disease
.	O
The	O
yield	O
of	O
severe	O
cirrhosis	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
(	O
defined	O
as	O
a	O
shrunken	O
finely	O
nodular	O
liver	O
with	O
micronodular	O
histology	O
,	O
ascites	B-Disease
greater	O
than	O
30	O
ml	O
,	O
plasma	O
albumin	O
less	O
than	O
2	O
.	O
2	O
g	O
/	O
dl	O
,	O
splenomegaly	B-Disease
2	O
-	O
3	O
times	O
normal	O
,	O
and	O
testicular	O
atrophy	B-Disease
approximately	O
half	O
normal	O
weight	O
)	O
after	O
12	O
doses	O
of	O
carbon	B-Chemical
tetrachloride	I-Chemical
given	O
intragastrically	O
in	O
the	O
phenobarbitone	B-Chemical
-	O
primed	O
rat	O
was	O
increased	O
from	O
25	O
%	O
to	O
56	O
%	O
by	O
giving	O
the	O
initial	O
""""	O
calibrating	O
""""	O
dose	O
of	O
carbon	B-Chemical
tetrachloride	I-Chemical
at	O
the	O
peak	O
of	O
the	O
phenobarbitone	B-Chemical
-	O
induced	O
enlargement	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
.	O
At	O
this	O
point	O
it	O
was	O
assumed	O
that	O
the	O
cytochrome	O
P450	O
/	O
CCl4	B-Chemical
toxic	O
state	O
was	O
both	O
maximal	O
and	O
stable	O
.	O
The	O
optimal	O
rat	O
size	O
to	O
begin	O
phenobarbitone	B-Chemical
was	O
determined	O
as	O
100	O
g	O
,	O
and	O
this	O
size	O
as	O
a	O
group	O
had	O
a	O
mean	O
maximum	O
relative	O
liver	O
weight	O
increase	O
47	O
%	O
greater	O
than	O
normal	O
rats	O
of	O
the	O
same	O
body	O
weight	O
.	O
The	O
optimal	O
time	O
for	O
the	O
initial	O
dose	O
of	O
carbon	B-Chemical
tetrachloride	I-Chemical
was	O
after	O
14	O
days	O
on	O
phenobarbitone	B-Chemical
.	O
Triamterene	B-Chemical
nephrolithiasis	B-Disease
complicating	O
dyazide	B-Chemical
therapy	O
.	O
A	O
case	O
of	O
triamterene	B-Chemical
nephrolithiasis	B-Disease
is	O
reported	O
in	O
a	O
man	O
after	O
4	O
years	O
of	O
hydrochlorothiazide	B-Chemical
-	I-Chemical
triamterene	I-Chemical
therapy	O
for	O
hypertension	B-Disease
.	O
The	O
stone	O
passed	O
spontaneously	O
and	O
was	O
found	O
to	O
contain	O
a	O
triamterene	B-Chemical
metabolite	O
admixed	O
with	O
uric	B-Chemical
acid	I-Chemical
salts	I-Chemical
.	O
Factors	O
affecting	O
triamterene	B-Chemical
nephrolithiasis	B-Disease
are	O
discussed	O
and	O
2	O
previously	O
reported	O
cases	O
are	O
reviewed	O
.	O
Busulfan	B-Chemical
-	O
induced	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O
A	O
case	O
of	O
a	O
busulfan	B-Chemical
-	O
induced	O
hemorrhage	B-Disease
cystitis	I-Disease
is	O
reported	O
.	O
Spontaneous	O
resolution	O
occurred	O
following	O
cessation	O
of	O
the	O
drug	O
.	O
The	O
similarity	O
between	O
the	O
histologic	O
appearances	O
of	O
busulfan	B-Chemical
cystitis	B-Disease
and	O
both	O
radiation	O
and	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
is	O
discussed	O
and	O
the	O
world	O
literature	O
reviewed	O
.	O
In	O
view	O
of	O
the	O
known	O
tendency	O
of	O
busulfan	B-Chemical
to	O
induce	O
cellular	O
atypia	O
and	O
carcinoma	B-Disease
in	O
other	O
sites	O
,	O
periodic	O
urinary	O
cytology	O
is	O
suggested	O
in	O
patients	O
on	O
long	O
-	O
term	O
therapy	O
.	O
Variant	O
ventricular	B-Disease
tachycardia	I-Disease
in	O
desipramine	B-Chemical
toxicity	B-Disease
.	O
We	O
report	O
a	O
case	O
of	O
variant	O
ventricular	B-Disease
tachycardia	I-Disease
induced	O
by	O
desipramine	B-Chemical
toxicity	B-Disease
.	O
Unusual	O
features	O
of	O
the	O
arrhythmia	B-Disease
are	O
repetitive	O
group	O
beating	O
,	O
progressive	O
shortening	O
of	O
the	O
R	O
-	O
R	O
interval	O
,	O
progressive	O
widening	O
of	O
the	O
QRS	O
complex	O
with	O
eventual	O
failure	O
of	O
intraventricular	O
conduction	O
,	O
and	O
changes	O
in	O
direction	O
of	O
the	O
QRS	O
axis	O
.	O
Recognition	O
of	O
variant	O
ventricular	B-Disease
tachycardia	I-Disease
is	O
important	O
because	O
therapy	O
differs	O
from	O
that	O
of	O
classic	O
ventricular	B-Disease
tachycardia	I-Disease
.	O
Rebound	O
hypertensive	B-Disease
after	O
sodium	B-Chemical
nitroprusside	I-Chemical
prevented	O
by	O
saralasin	B-Chemical
in	O
rats	O
.	O
The	O
role	O
of	O
the	O
renin	O
-	O
-	O
angiotensin	B-Chemical
system	O
in	O
the	O
maintenance	O
of	O
blood	O
pressure	O
during	O
halothane	B-Chemical
anesthesia	O
and	O
sodium	B-Chemical
nitroprusside	I-Chemical
(	O
SNP	B-Chemical
)	O
-	O
induced	O
hypotension	B-Disease
was	O
evaluated	O
.	O
Control	O
rats	O
received	O
halothane	B-Chemical
anesthesia	O
(	O
1	O
MAC	O
)	O
for	O
one	O
hour	O
,	O
followed	O
by	O
SNP	B-Chemical
infusion	O
,	O
40	O
microgram	O
/	O
kg	O
/	O
min	O
,	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
30	O
-	O
min	O
recovery	O
period	O
.	O
A	O
second	O
group	O
of	O
rats	O
was	O
treated	O
identically	O
and	O
,	O
in	O
addition	O
,	O
received	O
an	O
infusion	O
of	O
saralasin	B-Chemical
(	O
a	O
competitive	O
inhibitor	O
of	O
angiotensin	B-Chemical
II	I-Chemical
)	O
throughout	O
the	O
experimental	O
period	O
.	O
In	O
each	O
group	O
,	O
SNP	B-Chemical
infusion	O
resulted	O
in	O
an	O
initial	O
decrease	O
in	O
blood	O
pressure	O
from	O
86	O
torr	O
and	O
83	O
torr	O
,	O
respectively	O
,	O
to	O
48	O
torr	O
.	O
During	O
the	O
SNP	B-Chemical
infusion	O
the	O
control	O
animals	O
demonstrated	O
a	O
progressive	O
increase	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
to	O
61	O
torr	O
,	O
whereas	O
the	O
saralasin	B-Chemical
-	O
treated	O
animals	O
showed	O
no	O
change	O
.	O
Following	O
discontinuation	O
of	O
SNP	B-Chemical
,	O
blood	O
pressure	O
in	O
the	O
control	O
animals	O
rebounded	O
to	O
94	O
torr	O
,	O
as	O
compared	O
with	O
78	O
torr	O
in	O
the	O
saralasin	B-Chemical
-	O
treated	O
rats	O
.	O
This	O
study	O
indicates	O
that	O
with	O
stable	O
halothane	B-Chemical
anesthesia	O
,	O
the	O
partial	O
recovery	O
of	O
blood	O
pressure	O
during	O
SNP	B-Chemical
infusion	O
and	O
the	O
post	O
-	O
SNP	B-Chemical
rebound	O
of	O
blood	O
pressure	O
can	O
be	O
completely	O
blocked	O
by	O
saralasin	B-Chemical
.	O
This	O
demonstrates	O
the	O
participation	O
of	O
the	O
renin	O
-	O
-	O
angiotensin	B-Chemical
system	O
in	O
antagonizing	O
the	O
combined	O
hypotensive	B-Disease
effects	O
of	O
halothane	B-Chemical
and	O
SNP	B-Chemical
.	O
Clinical	O
nephrotoxicity	B-Disease
of	O
tobramycin	B-Chemical
and	O
gentamicin	B-Chemical
.	O
A	O
prospective	O
study	O
.	O
Nearly	O
3	O
.	O
2	O
million	O
people	O
in	O
this	O
country	O
receive	O
aminoglycoside	B-Chemical
antibiotics	O
annually	O
.	O
Gentamicin	B-Chemical
sulfate	I-Chemical
and	O
tobramycin	B-Chemical
sulfate	I-Chemical
continue	O
to	O
demonstrate	O
ototoxicity	B-Disease
and	O
nephrotoxicity	B-Disease
in	O
both	O
animal	O
and	O
clinical	O
studies	O
.	O
In	O
this	O
study	O
,	O
62	O
patients	O
with	O
confirmed	O
initial	O
normal	O
renal	O
function	O
and	O
treated	O
with	O
2	O
to	O
5	O
mg	O
/	O
kg	O
/	O
day	O
of	O
gentamicin	B-Chemical
sulfate	I-Chemical
or	O
tobramycin	B-Chemical
sulfate	I-Chemical
for	O
a	O
minimum	O
of	O
seven	O
days	O
were	O
followed	O
up	O
prospectively	O
for	O
the	O
development	O
of	O
aminoglycoside	B-Chemical
-	O
related	O
renal	B-Disease
failure	I-Disease
,	O
defined	O
as	O
at	O
least	O
a	O
one	O
-	O
third	O
reduction	O
in	O
renal	O
function	O
.	O
In	O
these	O
62	O
patients	O
,	O
no	O
other	O
causes	O
for	O
renal	B-Disease
failure	I-Disease
could	O
be	O
identified	O
.	O
Five	O
of	O
33	O
(	O
15	O
%	O
)	O
of	O
the	O
tobramycin	B-Chemical
-	O
treated	O
patients	O
and	O
16	O
of	O
29	O
(	O
55	O
.	O
2	O
%	O
)	O
of	O
the	O
gentamicin	B-Chemical
-	O
treated	O
patients	O
had	O
renal	B-Disease
failure	I-Disease
.	O
Thus	O
,	O
gentamicin	B-Chemical
was	O
associated	O
with	O
renal	B-Disease
failure	I-Disease
more	O
than	O
three	O
times	O
as	O
often	O
as	O
was	O
tobramycin	B-Chemical
.	O
Metabolic	O
involvement	O
in	O
adriamycin	B-Chemical
cardiotoxicity	B-Disease
.	O
The	O
cardiotoxic	B-Disease
effects	O
of	O
adriamycin	B-Chemical
were	O
studied	O
in	O
mammalian	O
myocardial	O
cells	O
in	O
culture	O
as	O
a	O
model	O
system	O
.	O
Adriamycin	B-Chemical
inhibited	O
cell	O
growth	O
and	O
the	O
rhythmic	O
contractions	O
characteristic	O
of	O
myocardial	O
cells	O
in	O
culture	O
.	O
A	O
possible	O
involvement	O
of	O
energy	O
metabolism	O
was	O
suggested	O
previously	O
,	O
and	O
in	O
this	O
study	O
the	O
adenylate	O
energy	O
charge	O
and	O
phosphorylcreatine	B-Chemical
mole	O
fraction	O
were	O
determined	O
in	O
the	O
adriamycin	B-Chemical
-	O
treated	O
cells	O
.	O
The	O
adenylate	O
energy	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
decreased	O
,	O
while	O
the	O
phophorylcreatine	B-Chemical
mole	O
fraction	O
was	O
unchanged	O
.	O
Such	O
disparity	O
suggests	O
an	O
inhibition	O
of	O
creatine	B-Chemical
phosphokinase	O
.	O
The	O
addition	O
of	O
1	O
mM	O
adenosine	B-Chemical
to	O
the	O
myocardial	O
cell	O
cultures	O
markedly	O
increases	O
the	O
ATP	B-Chemical
concentration	O
through	O
a	O
pathway	O
reportedly	O
leading	O
to	O
a	O
compartmentalized	O
ATP	B-Chemical
pool	O
.	O
In	O
the	O
adriamycin	B-Chemical
-	O
treated	O
cells	O
,	O
the	O
addition	O
of	O
adenosine	B-Chemical
increased	O
the	O
adenylate	O
charge	O
and	O
,	O
concomitant	O
with	O
this	O
inrcease	O
,	O
the	O
cells	O
'	O
functional	O
integrity	O
,	O
in	O
terms	O
of	O
percentage	O
of	O
beating	O
cells	O
and	O
rate	O
of	O
contractions	O
,	O
was	O
maintained	O
.	O
Age	O
-	O
dependent	O
sensitivity	O
of	O
the	O
rat	O
to	O
neurotoxic	B-Disease
effects	O
of	O
streptomycin	B-Chemical
.	O
Streptomycin	B-Chemical
sulfate	O
(	O
300	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
was	O
injected	O
for	O
various	O
periods	O
into	O
preweanling	O
rats	O
and	O
for	O
3	O
weeks	O
into	O
weanling	O
rats	O
.	O
Beginning	O
at	O
8	O
days	O
of	O
age	O
,	O
body	O
movement	O
and	O
hearing	O
were	O
examined	O
for	O
6	O
and	O
up	O
to	O
17	O
weeks	O
,	O
respectively	O
.	O
Abnormal	B-Disease
movements	I-Disease
and	O
deafness	B-Disease
occurred	O
only	O
in	O
rats	O
treated	O
during	O
the	O
preweaning	O
period	O
;	O
within	O
this	O
period	O
the	O
greatest	O
sensitivities	O
for	O
these	O
abnormalities	O
occurred	O
from	O
2	O
to	O
11	O
-	O
17	O
and	O
5	O
to	O
11	O
days	O
of	O
age	O
,	O
respectively	O
,	O
indicating	O
that	O
the	O
cochlea	O
is	O
more	O
sensitive	O
to	O
streptomycin	B-Chemical
than	O
the	O
site	O
(	O
vestibular	O
or	O
central	O
)	O
responsible	O
for	O
the	O
dyskinesias	B-Disease
.	O
Late	O
,	O
late	O
doxorubicin	B-Chemical
cardiotoxicity	B-Disease
.	O
Cardiac	B-Disease
toxicity	I-Disease
is	O
a	O
major	O
complication	O
which	O
limits	O
the	O
use	O
of	O
adriamycin	B-Chemical
as	O
a	O
chemotherapeutic	O
agent	O
.	O
Cardiomyopathy	B-Disease
is	O
frequent	O
when	O
the	O
total	O
dose	O
exceeds	O
600	O
mg	O
/	O
m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
months	O
after	O
cessation	O
of	O
therapy	O
.	O
A	O
patient	O
is	O
reported	O
who	O
developed	O
progressive	O
cardiomyopathy	B-Disease
two	O
and	O
one	O
-	O
half	O
years	O
after	O
receiving	O
580	O
mg	O
/	O
m2	O
which	O
apparently	O
represents	O
late	O
,	O
late	O
cardiotoxicity	B-Disease
.	O
Attenuation	O
of	O
the	O
lithium	B-Chemical
-	O
induced	O
diabetes	B-Disease
-	I-Disease
insipidus	I-Disease
-	I-Disease
like	I-Disease
syndrome	I-Disease
by	O
amiloride	B-Chemical
in	O
rats	O
.	O
The	O
effect	O
of	O
amiloride	B-Chemical
on	O
lithium	B-Chemical
-	O
induced	O
polydipsia	B-Disease
and	O
polyuria	B-Disease
and	O
on	O
the	O
lithium	B-Chemical
concentration	O
in	O
the	O
plasma	O
,	O
brain	O
,	O
kidney	O
,	O
thyroid	O
and	O
red	O
blood	O
cells	O
was	O
investigated	O
in	O
rats	O
,	O
chronically	O
treated	O
with	O
LiCl	B-Chemical
.	O
Amiloride	B-Chemical
reduced	O
the	O
drinking	O
and	O
urine	O
volume	O
of	O
rats	O
in	O
an	O
acute	O
(	O
6	O
or	O
12	O
h	O
)	O
and	O
a	O
subacute	O
(	O
3	O
days	O
)	O
experiment	O
.	O
6	O
h	O
after	O
the	O
administration	O
of	O
amiloride	B-Chemical
,	O
a	O
reduction	O
was	O
observed	O
in	O
the	O
lithium	B-Chemical
content	O
of	O
the	O
renal	O
medulla	O
but	O
not	O
in	O
the	O
other	O
organs	O
studied	O
.	O
At	O
12	O
h	O
,	O
all	O
the	O
tissues	O
showed	O
a	O
slight	O
increase	O
in	O
lithium	B-Chemical
levels	O
.	O
After	O
3	O
days	O
of	O
combined	O
treatment	O
,	O
a	O
marked	O
elevation	O
in	O
plasma	O
and	O
tissue	O
lithium	B-Chemical
levels	O
accompanied	O
a	O
reduction	O
in	O
water	O
intake	O
.	O
In	O
all	O
the	O
experiments	O
,	O
the	O
attenuation	O
of	O
the	O
lithium	B-Chemical
-	O
induced	O
diabetes	B-Disease
-	I-Disease
insipidus	I-Disease
-	I-Disease
like	I-Disease
syndrome	I-Disease
by	O
amiloride	B-Chemical
was	O
accompanied	O
by	O
a	O
reduction	O
of	O
the	O
ratio	O
between	O
the	O
lithium	B-Chemical
concentration	O
in	O
the	O
renal	O
medulla	O
and	O
its	O
levels	O
in	O
the	O
blood	O
and	O
an	O
elevation	O
in	O
the	O
plasma	O
potassium	B-Chemical
level	O
.	O
It	O
is	O
concluded	O
that	O
acute	O
amiloride	B-Chemical
administration	O
to	O
lithium	B-Chemical
-	O
treated	O
patients	O
suffering	O
from	O
polydipsia	B-Disease
and	O
polyuria	B-Disease
might	O
relieve	O
these	O
patients	O
but	O
prolonged	O
amiloride	B-Chemical
supplementation	O
would	O
result	O
in	O
elevated	O
lithium	B-Chemical
levels	O
and	O
might	O
be	O
hazardous	O
.	O
Cardiovascular	B-Disease
complications	I-Disease
associated	O
with	O
terbutaline	B-Chemical
treatment	O
for	O
preterm	B-Disease
labor	I-Disease
.	O
Severe	O
cardiovascular	B-Disease
complications	I-Disease
occurred	O
in	O
eight	O
of	O
160	O
patients	O
treated	O
with	O
terbutaline	B-Chemical
for	O
preterm	B-Disease
labor	I-Disease
.	O
Associated	O
corticosteroid	O
therapy	O
and	O
twin	O
gestations	O
appear	O
to	O
be	O
predisposing	O
factors	O
.	O
Potential	O
mechanisms	O
of	O
the	O
pathophysiology	O
are	O
briefly	O
discussed	O
.	O
Toxic	B-Disease
hepatitis	I-Disease
induced	O
by	O
antithyroid	O
drugs	O
:	O
four	O
cases	O
including	O
one	O
with	O
cross	O
-	O
reactivity	O
between	O
carbimazole	B-Chemical
and	O
benzylthiouracil	B-Chemical
.	O
OBJECTIVE	O
:	O
This	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
occurrence	O
of	O
hepatic	B-Disease
adverse	I-Disease
effects	I-Disease
encountered	O
with	O
antithyroid	O
drugs	O
.	O
METHODS	O
:	O
Retrospective	O
review	O
of	O
medical	O
records	O
of	O
236	O
patients	O
with	O
hyperthyroidism	B-Disease
admitted	O
in	O
our	O
department	O
(	O
in	O
-	O
or	O
out	O
-	O
patients	O
)	O
from	O
1986	O
to	O
1992	O
.	O
RESULTS	O
:	O
Four	O
patients	O
(	O
1	O
.	O
7	O
%	O
)	O
were	O
identified	O
with	O
toxic	B-Disease
hepatitis	I-Disease
which	O
could	O
reasonably	O
be	O
attributed	O
to	O
the	O
use	O
of	O
antithyroid	O
agent	O
.	O
Two	O
patients	O
had	O
a	O
cholestatic	B-Disease
hepatitis	I-Disease
induced	O
by	O
carbimazole	B-Chemical
(	O
N	B-Chemical
omercazole	I-Chemical
)	O
.	O
Two	O
others	O
had	O
a	O
mixed	O
(	O
cholestatic	B-Disease
and	O
cytolytic	O
)	O
hepatitis	B-Disease
following	O
carbimazole	B-Chemical
.	O
One	O
of	O
the	O
latter	O
two	O
patients	O
further	O
experienced	O
a	O
cytolytic	O
hepatitis	B-Disease
which	O
appeared	O
after	O
Benzylthiouracil	B-Chemical
(	O
Basd	B-Chemical
ne	I-Chemical
)	O
had	O
replaced	O
carbimazole	B-Chemical
.	O
Biological	O
features	O
of	O
hepatitis	B-Disease
disappeared	O
in	O
all	O
cases	O
after	O
cessation	O
of	O
the	O
incriminated	O
drug	O
,	O
while	O
biliary	O
,	O
viral	O
and	O
immunological	O
searches	O
were	O
negative	O
.	O
Only	O
2	O
patients	O
of	O
our	O
retrospective	O
study	O
experienced	O
a	O
mild	O
or	O
severe	O
neutropenia	B-Disease
.	O
CONCLUSION	O
:	O
Toxic	B-Disease
hepatitis	I-Disease
is	O
a	O
potential	O
adverse	O
effect	O
of	O
antithyroid	O
drugs	O
which	O
warrants	O
,	O
as	O
for	O
haematological	O
disturbances	O
,	O
a	O
pre	O
-	O
therapeutic	O
determination	O
and	O
a	O
careful	O
follow	O
-	O
up	O
of	O
relevant	O
biological	O
markers	O
.	O
Moreover	O
,	O
hepatotoxicity	B-Disease
may	O
not	O
be	O
restricted	O
to	O
one	O
class	O
of	O
antithyroid	O
agents	O
.	O
Interactive	O
effects	O
of	O
variations	O
in	O
[	O
Na	B-Chemical
]	O
o	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
on	O
rat	O
atrial	O
spontaneous	O
frequency	O
.	O
The	O
effects	O
of	O
varying	O
the	O
extracellular	O
concentrations	O
of	O
Na	B-Chemical
and	O
Ca	B-Chemical
(	O
[	O
Na	B-Chemical
]	O
o	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
)	O
on	O
both	O
,	O
the	O
spontaneous	O
beating	O
and	O
the	O
negative	O
chronotropic	O
action	O
of	O
verapamil	B-Chemical
,	O
were	O
studied	O
in	O
the	O
isolated	O
rat	O
atria	O
.	O
Basal	O
frequency	O
(	O
BF	O
)	O
evaluated	O
by	O
surface	O
electrogram	O
was	O
223	O
+	O
/	O
-	O
4	O
beats	O
/	O
min	O
.	O
in	O
control	O
Krebs	O
-	O
Ringer	O
containing	O
137	O
mM	O
Na	B-Chemical
and	O
1	O
.	O
35	O
mM	O
Ca	B-Chemical
(	O
N	O
)	O
.	O
It	O
decreased	O
by	O
16	O
+	O
/	O
-	O
3	O
%	O
by	O
lowering	O
[	O
Na	B-Chemical
]	O
o	O
to	O
78	O
mM	O
(	O
LNa	O
)	O
,	O
23	O
+	O
/	O
-	O
2	O
%	O
by	O
lowering	O
simultaneously	O
[	O
Na	B-Chemical
]	O
o	O
to	O
78	O
mM	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
to	O
0	O
.	O
675	O
mM	O
(	O
LNa	O
+	O
LCa	O
)	O
and	O
31	O
+	O
/	O
-	O
5	O
%	O
by	O
lowering	O
[	O
Na	B-Chemical
]	O
o	O
to	O
78	O
mM	O
plus	O
increasing	O
[	O
Ca	B-Chemical
]	O
o	O
to	O
3	O
.	O
6	O
mM	O
(	O
LNa	O
+	O
HCa	O
)	O
.	O
At	O
normal	O
[	O
Na	B-Chemical
]	O
o	O
,	O
decrease	O
(	O
0	O
.	O
675	O
mM	O
)	O
or	O
increase	O
(	O
3	O
.	O
6	O
mM	O
)	O
of	O
[	O
Ca	B-Chemical
]	O
o	O
did	O
not	O
modify	O
BF	O
;	O
a	O
reduction	O
of	O
ten	O
times	O
(	O
0	O
.	O
135	O
mM	O
of	O
normal	O
[	O
Ca	B-Chemical
]	O
o	O
was	O
effective	O
to	O
reduce	O
BF	O
by	O
40	O
+	O
/	O
-	O
13	O
%	O
.	O
All	O
negative	O
chronotropic	O
effects	O
were	O
BF	O
-	O
dependent	O
.	O
Dose	O
-	O
dependent	O
bradycardia	B-Disease
induced	O
by	O
verapamil	B-Chemical
was	O
potentiated	O
by	O
LNa	O
,	O
LCa	O
,	O
and	O
HCa	O
.	O
Independent	O
but	O
not	O
additive	O
effects	O
of	O
Na	B-Chemical
and	O
Ca	B-Chemical
are	O
shown	O
by	O
decreases	O
in	O
the	O
values	O
of	O
[	O
verapamil	B-Chemical
]	O
o	O
needed	O
to	O
reduce	O
BF	O
by	O
30	O
%	O
(	O
IC30	O
)	O
with	O
the	O
following	O
order	O
of	O
inhibitory	O
potency	O
:	O
LNa	O
>	O
LCa	O
>	O
HCa	O
>	O
N	O
,	O
resulting	O
LNa	O
+	O
HCa	O
similar	O
to	O
LNa	O
.	O
The	O
[	O
verapamil	B-Chemical
]	O
o	O
that	O
arrested	O
atrial	O
beating	O
(	O
AC	O
)	O
was	O
also	O
potentiated	O
with	O
the	O
order	O
LNa	O
=	O
LNa	O
+	O
LCa	O
=	O
LNa	O
+	O
HCa	O
=	O
LCa	O
>	O
HCa	O
=	O
N	O
.	O
The	O
results	O
indicate	O
that	O
rat	O
atrial	O
spontaneous	O
beating	O
is	O
more	O
dependent	O
on	O
[	O
Na	B-Chemical
]	O
o	O
than	O
on	O
[	O
Ca	B-Chemical
]	O
o	O
in	O
a	O
range	O
of	O
+	O
/	O
-	O
50	O
%	O
of	O
their	O
normal	O
concentration	O
.	O
Also	O
the	O
enhancement	O
of	O
verapamil	B-Chemical
effects	O
on	O
atrial	O
beating	O
was	O
more	O
pronounced	O
at	O
LNa	O
than	O
at	O
LCa	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Pseudo	O
-	O
allergic	B-Disease
reactions	I-Disease
to	O
corticosteroids	B-Chemical
:	O
diagnosis	O
and	O
alternatives	O
.	O
Two	O
patients	O
treated	O
with	O
parenteral	O
paramethasone	B-Chemical
(	O
Triniol	O
)	O
and	O
dexamethasone	B-Chemical
(	O
Sedionbel	O
)	O
are	O
described	O
.	O
A	O
few	O
minutes	O
after	O
administration	O
of	O
the	O
drugs	O
,	O
they	O
presented	O
urticaria	B-Disease
(	O
patients	O
1	O
and	O
2	O
)	O
and	O
conjunctivitis	B-Disease
(	O
patient	O
1	O
)	O
.	O
The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
determine	O
the	O
cause	O
of	O
the	O
patients	O
'	O
reactions	O
,	O
the	O
immunological	O
mechanisms	O
involved	O
and	O
whether	O
these	O
patients	O
would	O
be	O
able	O
to	O
tolerate	O
any	O
kind	O
of	O
corticoid	O
.	O
Clinical	O
examinations	O
and	O
skin	O
,	O
oral	O
and	O
parenteral	O
challenges	O
with	O
different	O
corticosteroids	B-Chemical
and	O
ELISA	O
tests	O
were	O
performed	O
.	O
In	O
the	O
two	O
patients	O
,	O
skin	O
and	O
ELISA	O
tests	O
with	O
paramethasone	B-Chemical
were	O
negative	O
,	O
as	O
was	O
the	O
prick	O
test	O
with	O
each	O
of	O
its	O
excipients	O
.	O
A	O
single	O
-	O
blind	O
parenteral	O
challenge	O
with	O
Triniol	O
was	O
positive	O
in	O
both	O
patients	O
after	O
the	O
administration	O
of	O
1	O
ml	O
of	O
the	O
drug	O
,	O
and	O
negative	O
with	O
its	O
excipients	O
.	O
We	O
also	O
carried	O
out	O
oral	O
and	O
parenteral	O
challenges	O
with	O
other	O
corticosteroids	B-Chemical
and	O
found	O
intolerance	O
to	O
some	O
of	O
them	O
.	O
These	O
results	O
suggest	O
that	O
paramethasone	B-Chemical
caused	O
pseudoallergic	O
reactions	O
in	O
our	O
patients	O
.	O
Corticosteroids	O
different	O
from	O
paramethasone	B-Chemical
also	O
produced	O
hypersensitivity	B-Disease
reactions	O
in	O
these	O
patients	O
;	O
however	O
,	O
a	O
few	O
of	O
them	O
were	O
tolerated	O
.	O
The	O
basic	O
mechanisms	O
of	O
those	O
reactions	O
are	O
not	O
yet	O
fully	O
understood	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
pseudo	O
-	O
allergy	B-Disease
caused	O
by	O
paramethasone	B-Chemical
.	O
Study	O
of	O
the	O
role	O
of	O
vitamin	B-Chemical
B12	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
supplementation	O
in	O
preventing	O
hematologic	O
toxicity	B-Disease
of	O
zidovudine	B-Chemical
.	O
A	O
prospective	O
,	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
role	O
of	O
vitamin	B-Chemical
B12	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
supplementation	O
in	O
preventing	O
zidovudine	B-Chemical
(	O
ZDV	B-Chemical
)	O
-	O
induced	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
.	O
Seventy	O
-	O
five	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
(	I-Disease
HIV	I-Disease
)	I-Disease
-	I-Disease
infected	I-Disease
patients	O
with	O
CD4	O
+	O
cell	O
counts	O
<	O
500	O
/	O
mm3	O
were	O
randomized	O
to	O
receive	O
either	O
ZDV	B-Chemical
(	O
500	O
mg	O
daily	O
)	O
alone	O
(	O
group	O
I	O
,	O
n	O
=	O
38	O
)	O
or	O
in	O
combination	O
with	O
folinic	B-Chemical
acid	I-Chemical
(	O
15	O
mg	O
daily	O
)	O
and	O
intramascular	O
vitamin	B-Chemical
B12	I-Chemical
(	O
1000	O
micrograms	O
monthly	O
)	O
(	O
group	O
II	O
,	O
n	O
=	O
37	O
)	O
.	O
Finally	O
,	O
15	O
patients	O
were	O
excluded	O
from	O
the	O
study	O
(	O
noncompliance	O
14	O
,	O
death	B-Disease
1	O
)	O
;	O
thus	O
,	O
60	O
patients	O
(	O
31	O
in	O
group	O
I	O
and	O
29	O
in	O
group	O
II	O
)	O
were	O
eligible	O
for	O
analysis	O
.	O
No	O
significant	O
differences	O
between	O
groups	O
were	O
found	O
at	O
enrollment	O
.	O
During	O
the	O
study	O
,	O
vitamin	B-Chemical
B12	I-Chemical
and	O
folate	B-Chemical
levels	O
were	O
significantly	O
higher	O
in	O
group	O
II	O
patients	O
;	O
however	O
,	O
no	O
differences	O
in	O
hemoglobin	O
,	O
hematocrit	O
,	O
mean	O
corpuscular	O
volume	O
,	O
and	O
white	O
-	O
cell	O
,	O
neutrophil	O
and	O
platelet	O
counts	O
were	O
observed	O
between	O
groups	O
at	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
.	O
Severe	O
hematologic	O
toxicity	B-Disease
(	O
neutrophil	O
count	O
<	O
1000	O
/	O
mm3	O
and	O
/	O
or	O
hemoglobin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
patients	O
assigned	O
to	O
group	O
I	O
and	O
7	O
assigned	O
to	O
group	O
II	O
.	O
There	O
was	O
no	O
correlation	O
between	O
vitamin	B-Chemical
B12	I-Chemical
or	O
folate	B-Chemical
levels	O
and	O
development	O
of	O
myelosuppression	B-Disease
.	O
Vitamin	B-Chemical
B12	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
supplementation	O
of	O
ZDV	B-Chemical
therapy	O
does	O
not	O
seem	O
useful	O
in	O
preventing	O
or	O
reducing	O
ZDV	B-Chemical
-	O
induced	O
myelotoxicity	B-Disease
in	O
the	O
overall	O
treated	O
population	O
,	O
although	O
a	O
beneficial	O
effect	O
in	O
certain	O
subgroups	O
of	O
patients	O
cannot	O
be	O
excluded	O
.	O
Safety	O
and	O
side	O
-	O
effects	O
of	O
alprazolam	B-Chemical
.	O
Controlled	O
study	O
in	O
agoraphobia	B-Disease
with	O
panic	B-Disease
disorder	I-Disease
.	O
BACKGROUND	O
:	O
The	O
widespread	O
use	O
of	O
benzodiazepines	B-Chemical
has	O
led	O
to	O
increasing	O
recognition	O
of	O
their	O
unwanted	O
effects	O
.	O
The	O
efficacy	O
of	O
alprazolam	B-Chemical
and	O
placebo	O
in	O
panic	B-Disease
disorder	I-Disease
with	O
agoraphobia	B-Disease
,	O
and	O
the	O
side	O
-	O
effect	O
and	O
adverse	O
effect	O
profiles	O
of	O
both	O
drug	O
groups	O
were	O
measured	O
.	O
METHOD	O
:	O
In	O
London	O
and	O
Toronto	O
154	O
patients	O
who	O
met	O
DSM	O
-	O
III	O
criteria	O
for	O
panic	B-Disease
disorder	I-Disease
with	O
agoraphobia	B-Disease
were	O
randomised	O
to	O
alprazolam	B-Chemical
or	O
placebo	O
.	O
Subjects	O
in	O
each	O
drug	O
group	O
also	O
received	O
either	O
exposure	O
or	O
relaxation	O
.	O
Treatment	O
was	O
from	O
weeks	O
0	O
to	O
8	O
and	O
was	O
then	O
tapered	O
from	O
weeks	O
8	O
to	O
16	O
.	O
RESULTS	O
:	O
Mean	O
alprazolam	B-Chemical
dose	O
was	O
5	O
mg	O
daily	O
.	O
Compared	O
with	O
placebo	O
subjects	O
,	O
alprazolam	B-Chemical
patients	O
developed	O
more	O
adverse	O
reactions	O
(	O
21	O
%	O
v	O
.	O
0	O
%	O
)	O
of	O
depression	B-Disease
,	O
enuresis	B-Disease
,	O
disinhibition	O
and	O
aggression	B-Disease
;	O
and	O
more	O
side	O
-	O
effects	O
,	O
particularly	O
sedation	O
,	O
irritability	B-Disease
,	O
impaired	B-Disease
memory	I-Disease
,	O
weight	B-Disease
loss	I-Disease
and	O
ataxia	B-Disease
.	O
Side	O
-	O
effects	O
tended	O
to	O
diminish	O
during	O
treatment	O
but	O
remained	O
significant	O
at	O
week	O
8	O
.	O
Despite	O
this	O
,	O
the	O
drop	O
-	O
out	O
rate	O
was	O
low	O
.	O
CONCLUSIONS	O
:	O
Alprazolam	B-Chemical
caused	O
side	O
-	O
effects	O
and	O
adverse	O
effects	O
during	O
treatment	O
but	O
many	O
patients	O
were	O
willing	O
to	O
accept	O
these	O
.	O
Crescentic	O
fibrillary	O
glomerulonephritis	B-Disease
associated	O
with	O
intermittent	O
rifampin	B-Chemical
therapy	O
for	O
pulmonary	B-Disease
tuberculosis	I-Disease
.	O
This	O
case	O
study	O
reveals	O
an	O
unusual	O
finding	O
of	O
rapidly	O
proliferative	O
crescentic	O
glomerulonephritis	B-Disease
in	O
a	O
patient	O
treated	O
with	O
rifampin	B-Chemical
who	O
had	O
no	O
other	O
identifiable	O
causes	O
for	O
developing	O
this	O
disease	O
.	O
This	O
patient	O
underwent	O
a	O
10	O
-	O
month	O
regimen	O
of	O
rifampin	B-Chemical
and	O
isoniazid	B-Chemical
for	O
pulmonary	B-Disease
tuberculosis	I-Disease
and	O
was	O
discovered	O
to	O
have	O
developed	O
signs	O
of	O
severe	O
renal	B-Disease
failure	I-Disease
five	O
weeks	O
after	O
completion	O
of	O
therapy	O
.	O
Renal	O
biopsy	O
revealed	O
severe	O
glomerulonephritis	B-Disease
with	O
crescents	O
,	O
electron	O
dense	O
fibrillar	O
deposits	O
and	O
moderate	O
lymphocytic	O
interstitial	O
infiltrate	O
.	O
Other	O
possible	O
causes	O
of	O
rapidly	O
progressive	O
glomerulonephritis	B-Disease
were	O
investigated	O
and	O
ruled	O
out	O
.	O
This	O
report	O
documents	O
the	O
unusual	O
occurrence	O
of	O
rapidly	O
progressive	O
glomerulonephritis	B-Disease
with	O
crescents	O
and	O
fibrillar	O
glomerulonephritis	B-Disease
in	O
a	O
patient	O
treated	O
with	O
rifampin	B-Chemical
.	O
Acute	O
confusion	B-Disease
induced	O
by	O
a	O
high	O
-	O
dose	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
.	O
A	O
61	O
-	O
year	O
-	O
old	O
man	O
was	O
treated	O
with	O
combination	O
chemotherapy	O
incorporating	O
cisplatinum	B-Chemical
,	O
etoposide	B-Chemical
,	O
high	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
2	O
,	O
250	O
mg	O
/	O
m2	O
/	O
24	O
hours	O
)	O
and	O
folinic	B-Chemical
acid	I-Chemical
for	O
an	O
inoperable	O
gastric	B-Disease
adenocarcinoma	I-Disease
.	O
He	O
developed	O
acute	O
neurologic	O
symptoms	O
of	O
mental	O
confusion	B-Disease
,	O
disorientation	B-Disease
and	O
irritability	B-Disease
,	O
and	O
then	O
lapsed	O
into	O
a	O
deep	O
coma	B-Disease
,	O
lasting	O
for	O
approximately	O
40	O
hours	O
during	O
the	O
first	O
dose	O
(	O
day	O
2	O
)	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
infusion	O
.	O
This	O
complication	O
reappeared	O
on	O
day	O
25	O
during	O
the	O
second	O
dose	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
,	O
which	O
were	O
then	O
the	O
only	O
drugs	O
given	O
.	O
Because	O
folinic	B-Chemical
acid	I-Chemical
was	O
unlikely	O
to	O
be	O
associated	O
with	O
this	O
condition	O
,	O
neurotoxicity	B-Disease
due	O
to	O
high	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
was	O
highly	O
suspected	O
.	O
The	O
pathogenesis	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
neurotoxicity	B-Disease
may	O
be	O
due	O
to	O
a	O
Krebs	O
cycle	O
blockade	O
by	O
fluoroacetate	B-Chemical
and	O
fluorocitrate	B-Chemical
,	O
thiamine	B-Chemical
deficiency	O
,	O
or	O
dihydrouracil	B-Chemical
dehydrogenase	O
deficiency	O
.	O
High	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
/	O
folinic	B-Chemical
acid	I-Chemical
infusion	O
therapy	O
has	O
recently	O
become	O
a	O
popular	O
regimen	O
for	O
various	O
cancers	B-Disease
.	O
It	O
is	O
necessary	O
that	O
both	O
oncologists	O
and	O
neurologists	O
be	O
fully	O
aware	O
of	O
this	O
unusual	O
complication	O
.	O
Effect	O
of	O
switching	O
carbamazepine	B-Chemical
to	O
oxcarbazepine	B-Chemical
on	O
the	O
plasma	O
levels	O
of	O
neuroleptics	O
.	O
A	O
case	O
report	O
.	O
Carbamazepine	B-Chemical
was	O
switched	O
to	O
its	O
10	O
-	O
keto	O
analogue	O
oxcarbazepine	B-Chemical
among	O
six	O
difficult	O
-	O
to	O
-	O
treat	O
schizophrenic	B-Disease
or	O
organic	B-Disease
psychotic	I-Disease
patients	O
using	O
concomitantly	O
haloperidol	B-Chemical
,	O
chlorpromazine	B-Chemical
or	O
clozapine	B-Chemical
.	O
This	O
change	O
resulted	O
within	O
2	O
-	O
4	O
weeks	O
in	O
the	O
50	O
-	O
200	O
%	O
increase	O
in	O
the	O
plasma	O
levels	O
of	O
these	O
neuroleptics	O
and	O
the	O
appearance	O
of	O
extrapyramidal	B-Disease
symptoms	I-Disease
.	O
None	O
of	O
the	O
patients	O
showed	O
any	O
clinical	O
deteriotation	O
during	O
the	O
following	O
3	O
-	O
6	O
months	O
.	O
The	O
results	O
of	O
this	O
case	O
report	O
support	O
the	O
idea	O
that	O
in	O
contrast	O
with	O
carbamazepine	B-Chemical
oxcarbazepine	B-Chemical
does	O
not	O
induce	O
the	O
hepatic	O
microsomal	O
enzyme	O
systems	O
regulating	O
the	O
inactivation	O
of	O
antipsychotic	O
drugs	O
.	O
Time	O
course	O
of	O
lipid	O
peroxidation	O
in	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephropathy	B-Disease
.	O
Reactive	O
oxygen	B-Chemical
species	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
-	O
induced	O
nephropathy	B-Disease
,	O
with	O
antioxidants	O
significantly	O
reducing	O
the	O
proteinuria	B-Disease
.	O
The	O
temporal	O
relationship	O
between	O
lipid	O
peroxidation	O
in	O
the	O
kidney	O
and	O
proteinuria	B-Disease
was	O
examined	O
in	O
this	O
study	O
.	O
Rats	O
were	O
treated	O
with	O
a	O
single	O
IV	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
,	O
(	O
PAN	B-Chemical
,	O
7	O
.	O
5	O
mg	O
/	O
kg	O
)	O
and	O
24	O
hour	O
urine	O
samples	O
were	O
obtained	O
prior	O
to	O
sacrifice	O
on	O
days	O
3	O
,	O
5	O
,	O
7	O
,	O
10	O
,	O
17	O
,	O
27	O
,	O
41	O
(	O
N	O
=	O
5	O
-	O
10	O
per	O
group	O
)	O
.	O
The	O
kidneys	O
were	O
removed	O
,	O
flushed	O
with	O
ice	O
cold	O
TRIS	O
buffer	O
.	O
Kidney	O
cortices	O
from	O
each	O
animal	O
were	O
used	O
to	O
prepare	O
homogenates	O
.	O
Tissue	O
lipid	O
peroxidation	O
was	O
measured	O
in	O
whole	O
homogenates	O
as	O
well	O
as	O
in	O
lipid	O
extracts	O
from	O
homogenates	O
as	O
thiobarbituric	B-Chemical
acid	I-Chemical
reactive	O
substances	O
.	O
Proteinuria	B-Disease
was	O
evident	O
at	O
day	O
5	O
,	O
peaked	O
at	O
day	O
7	O
and	O
persisted	O
to	O
day	O
27	O
.	O
Lipid	O
peroxidation	O
in	O
homogenates	O
was	O
maximal	O
at	O
day	O
3	O
and	O
declined	O
rapidly	O
to	O
control	O
levels	O
by	O
day	O
17	O
.	O
This	O
study	O
supports	O
the	O
role	O
of	O
lipid	O
peroxidation	O
in	O
mediating	O
the	O
proteinuric	B-Disease
injury	I-Disease
in	O
PAN	B-Chemical
nephropathy	B-Disease
.	O
Composition	O
of	O
gall	B-Disease
bladder	I-Disease
stones	I-Disease
associated	O
with	O
octreotide	B-Chemical
:	O
response	O
to	O
oral	O
ursodeoxycholic	B-Chemical
acid	I-Chemical
.	O
Octreotide	B-Chemical
,	O
an	O
effective	O
treatment	O
for	O
acromegaly	B-Disease
,	O
induces	O
gall	B-Disease
bladder	I-Disease
stones	I-Disease
in	O
13	O
-	O
60	O
%	O
of	O
patients	O
.	O
Because	O
knowledge	O
of	O
stone	O
composition	O
is	O
essential	O
for	O
studies	O
of	O
their	O
pathogenesis	O
,	O
treatment	O
,	O
and	O
prevention	O
,	O
this	O
was	O
investigated	O
by	O
direct	O
and	O
indirect	O
methods	O
in	O
14	O
octreotide	B-Chemical
treated	O
acromegalic	B-Disease
patients	O
with	O
gall	B-Disease
stones	I-Disease
.	O
Chemical	O
analysis	O
of	O
gall	B-Disease
stones	I-Disease
retrieved	O
at	O
cholecystectomy	O
from	O
two	O
patients	O
,	O
showed	O
that	O
they	O
contained	O
71	O
%	O
and	O
87	O
%	O
cholesterol	B-Chemical
by	O
weight	O
.	O
In	O
the	O
remaining	O
12	O
patients	O
,	O
localised	O
computed	O
tomography	O
of	O
the	O
gall	O
bladder	O
showed	O
that	O
eight	O
had	O
stones	O
with	O
maximum	O
attenuation	O
scores	O
of	O
<	O
100	O
Hounsfield	O
units	O
(	O
values	O
of	O
<	O
100	O
HU	O
predict	O
cholesterol	B-Chemical
rich	O
,	O
dissolvable	O
stones	O
)	O
.	O
Gall	O
bladder	O
bile	O
was	O
obtained	O
by	O
ultrasound	O
guided	O
,	O
fine	O
needle	O
puncture	O
from	O
six	O
patients	O
.	O
All	O
six	O
patients	O
had	O
supersaturated	O
bile	O
(	O
mean	O
(	O
SEM	O
)	O
cholesterol	B-Chemical
saturation	O
index	O
of	O
1	O
.	O
19	O
(	O
0	O
.	O
08	O
)	O
(	O
range	O
1	O
.	O
01	O
-	O
1	O
.	O
53	O
)	O
)	O
and	O
all	O
had	O
abnormally	O
rapid	O
cholesterol	B-Chemical
microcrystal	O
nucleation	O
times	O
(	O
<	O
4	O
days	O
(	O
range	O
1	O
-	O
4	O
)	O
)	O
,	O
whilst	O
in	O
four	O
,	O
the	O
bile	O
contained	O
cholesterol	B-Chemical
microcrystals	O
immediately	O
after	O
sampling	O
.	O
Of	O
the	O
12	O
patients	O
considered	O
for	O
oral	O
ursodeoxycholic	B-Chemical
acid	I-Chemical
(	O
UDCA	B-Chemical
)	O
treatment	O
,	O
two	O
had	O
a	O
blocked	O
cystic	O
duct	O
and	O
were	O
not	O
started	O
on	O
UDCA	B-Chemical
while	O
one	O
was	O
lost	O
to	O
follow	O
up	O
.	O
After	O
one	O
year	O
of	O
treatment	O
,	O
five	O
of	O
the	O
remaining	O
nine	O
patients	O
showed	O
either	O
partial	O
(	O
n	O
=	O
3	O
)	O
or	O
complete	O
(	O
n	O
=	O
2	O
)	O
gall	B-Disease
stone	I-Disease
dissolution	O
,	O
suggesting	O
that	O
their	O
stones	O
were	O
cholesterol	B-Chemical
rich	O
.	O
This	O
corresponds	O
,	O
by	O
actuarial	O
(	O
life	O
table	O
)	O
analysis	O
,	O
to	O
a	O
combined	O
gall	B-Disease
stone	I-Disease
dissolution	O
rate	O
of	O
58	O
.	O
3	O
(	O
15	O
.	O
9	O
%	O
)	O
.	O
In	O
conclusion	O
,	O
octreotide	B-Chemical
induced	O
gall	B-Disease
stones	I-Disease
are	O
generally	O
small	O
,	O
multiple	O
,	O
and	O
cholesterol	B-Chemical
rich	O
although	O
,	O
in	O
common	O
with	O
spontaneous	O
gall	B-Disease
stone	I-Disease
disease	I-Disease
,	O
at	O
presentation	O
some	O
patients	O
will	O
have	O
a	O
blocked	O
cystic	O
duct	O
and	O
some	O
gall	B-Disease
stones	I-Disease
containing	O
calcium	B-Chemical
.	O
Erythema	B-Disease
multiforme	I-Disease
and	O
hypersensitivity	B-Disease
myocarditis	I-Disease
caused	O
by	O
ampicillin	B-Chemical
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
erythema	B-Disease
multiforme	I-Disease
and	O
hypersensitivity	B-Disease
myocarditis	I-Disease
caused	O
by	O
ampicillin	B-Chemical
.	O
CASE	O
SUMMARY	O
:	O
A	O
13	O
-	O
year	O
-	O
old	O
boy	O
was	O
treated	O
with	O
ampicillin	B-Chemical
and	O
gentamicin	B-Chemical
because	O
of	O
suspected	O
septicemia	B-Disease
.	O
Medications	O
were	O
discontinued	O
when	O
erythema	B-Disease
multiforme	I-Disease
and	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
caused	O
by	O
myocarditis	B-Disease
occurred	O
.	O
The	O
patient	O
was	O
treated	O
with	O
methylprednisolone	B-Chemical
and	O
gradually	O
improved	O
.	O
Macrophage	O
-	O
migration	O
inhibition	O
(	O
MIF	O
)	O
test	O
with	O
ampicillin	B-Chemical
was	O
positive	O
.	O
DISCUSSION	O
:	O
After	O
most	O
infections	B-Disease
causing	O
erythema	B-Disease
multiforme	I-Disease
and	O
myocarditis	B-Disease
were	O
ruled	O
out	O
,	O
a	O
drug	B-Disease
-	I-Disease
induced	I-Disease
allergic	I-Disease
reaction	I-Disease
was	O
suspected	O
.	O
Positive	O
MIF	O
test	O
for	O
ampicillin	B-Chemical
showed	O
sensitization	O
of	O
the	O
patient	O
'	O
s	O
lymphocytes	O
to	O
ampicillin	B-Chemical
.	O
CONCLUSIONS	O
:	O
Hypersensitivity	B-Disease
myocarditis	I-Disease
is	O
a	O
rare	O
and	O
dangerous	O
manifestation	O
of	O
allergy	B-Disease
to	O
penicillins	B-Chemical
.	O
Clomipramine	B-Chemical
-	O
induced	O
sleep	B-Disease
disturbance	I-Disease
does	O
not	O
impair	O
its	O
prolactin	O
-	O
releasing	O
action	O
.	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
examine	O
the	O
role	O
of	O
sleep	B-Disease
disturbance	I-Disease
,	O
induced	O
by	O
clomipramine	B-Chemical
administration	O
,	O
on	O
the	O
secretory	O
rate	O
of	O
prolactin	O
(	O
PRL	O
)	O
in	O
addition	O
to	O
the	O
direct	O
drug	O
effect	O
.	O
Two	O
groups	O
of	O
supine	O
subjects	O
were	O
studied	O
under	O
placebo	O
-	O
controlled	O
conditions	O
,	O
one	O
during	O
the	O
night	O
,	O
when	O
sleeping	O
(	O
n	O
=	O
7	O
)	O
and	O
the	O
other	O
at	O
daytime	O
,	O
when	O
awake	O
(	O
n	O
=	O
6	O
)	O
.	O
Each	O
subject	O
received	O
a	O
single	O
50	O
mg	O
dose	O
of	O
clomipramine	B-Chemical
given	O
orally	O
2	O
hours	O
before	O
blood	O
collection	O
.	O
Plasma	O
PRL	O
concentrations	O
were	O
analysed	O
at	O
10	O
min	O
intervals	O
and	O
underlying	O
secretory	O
rates	O
calculated	O
by	O
a	O
deconvolution	O
procedure	O
.	O
For	O
both	O
experiments	O
the	O
drug	O
intake	O
led	O
to	O
significant	O
increases	O
in	O
PRL	O
secretion	O
,	O
acting	O
preferentially	O
on	O
tonic	O
secretion	O
as	O
pulse	O
amplitude	O
and	O
frequency	O
did	O
not	O
differ	O
significantly	O
from	O
corresponding	O
control	O
values	O
.	O
During	O
the	O
night	O
clomipramine	B-Chemical
ingestion	O
altered	O
the	O
complete	O
sleep	O
architecture	O
in	O
that	O
it	O
suppressed	O
REM	O
sleep	O
and	O
the	O
sleep	O
cycles	O
and	O
induced	O
increased	O
wakefulness	O
.	O
As	O
the	O
relative	O
increase	O
in	O
PRL	O
secretion	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
mean	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
night	O
and	O
day	O
time	O
studies	O
(	O
46	O
+	O
/	O
-	O
19	O
%	O
vs	O
34	O
+	O
/	O
-	O
10	O
%	O
)	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
sleep	B-Disease
disturbance	I-Disease
did	O
not	O
interfere	O
with	O
the	O
drug	O
action	O
per	O
se	O
.	O
The	O
presence	O
of	O
REM	O
sleep	O
was	O
shown	O
not	O
to	O
be	O
a	O
determining	O
factor	O
either	O
for	O
secretory	O
pulse	O
amplitude	O
and	O
frequency	O
,	O
as	O
,	O
for	O
both	O
,	O
mean	O
nocturnal	O
values	O
were	O
similar	O
with	O
and	O
without	O
prior	O
clomipramine	B-Chemical
ingestion	O
.	O
Survey	O
of	O
complications	O
of	O
indocyanine	B-Chemical
green	I-Chemical
angiography	O
in	O
Japan	O
.	O
PURPOSE	O
:	O
We	O
evaluated	O
the	O
safety	O
of	O
indocyanine	B-Chemical
green	I-Chemical
for	O
use	O
in	O
fundus	O
angiography	O
.	O
METHODS	O
:	O
We	O
sent	O
a	O
questionnaire	O
concerning	O
complications	O
of	O
indocyanine	B-Chemical
green	I-Chemical
to	O
32	O
institutions	O
in	O
Japan	O
,	O
which	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
client	O
list	O
from	O
the	O
Topcon	O
Company	O
,	O
which	O
manufactures	O
the	O
indocyanine	B-Chemical
green	I-Chemical
fundus	O
camera	O
.	O
RESULTS	O
:	O
Ophthalmologists	O
at	O
15	O
institutions	O
responded	O
,	O
reporting	O
a	O
total	O
of	O
3	O
,	O
774	O
indocyanine	B-Chemical
green	I-Chemical
angiograms	O
performed	O
on	O
2	O
,	O
820	O
patients	O
between	O
June	O
1984	O
and	O
September	O
1992	O
.	O
Before	O
angiography	O
,	O
intradermal	O
or	O
intravenous	O
indocyanine	B-Chemical
green	I-Chemical
testing	O
,	O
or	O
both	O
was	O
performed	O
at	O
13	O
of	O
15	O
institutions	O
.	O
For	O
three	O
patients	O
,	O
the	O
decision	O
was	O
made	O
not	O
to	O
proceed	O
with	O
angiography	O
after	O
positive	O
preangiographic	O
testing	O
.	O
The	O
dosage	O
of	O
indocyanine	B-Chemical
green	I-Chemical
used	O
for	O
angiography	O
varied	O
from	O
25	O
to	O
75	O
mg	O
,	O
depending	O
upon	O
the	O
institution	O
.	O
There	O
were	O
13	O
cases	O
of	O
adverse	O
reactions	O
(	O
0	O
.	O
34	O
%	O
)	O
,	O
ten	O
of	O
which	O
were	O
mild	O
reactions	O
such	O
as	O
nausea	B-Disease
,	O
exanthema	B-Disease
,	O
urtication	B-Disease
,	O
itchiness	B-Disease
,	O
and	O
urgency	O
to	O
defecate	O
,	O
and	O
did	O
not	O
require	O
treatment	O
.	O
Also	O
recorded	O
were	O
one	O
case	O
of	O
pain	B-Disease
of	O
the	O
vein	O
,	O
which	O
required	O
treatment	O
,	O
and	O
two	O
cases	O
of	O
hypotension	B-Disease
.	O
The	O
two	O
hypotensive	B-Disease
patients	O
required	O
treatment	O
for	O
shock	B-Disease
.	O
CONCLUSIONS	O
:	O
A	O
comparison	O
of	O
frequency	O
of	O
adverse	O
reactions	O
to	O
indocyanine	B-Chemical
green	I-Chemical
with	O
the	O
previously	O
reported	O
frequency	O
of	O
such	O
reactions	O
to	O
fluorescein	B-Chemical
sodium	I-Chemical
indicated	O
that	O
indocyanine	B-Chemical
green	I-Chemical
is	O
a	O
safe	O
as	O
fluorescein	B-Chemical
for	O
use	O
in	O
angiography	O
.	O
Angioedema	B-Disease
following	O
the	O
intravenous	O
administration	O
of	O
metoprolol	B-Chemical
.	O
A	O
72	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
""""	O
flash	O
""""	O
pulmonary	B-Disease
edema	I-Disease
,	O
preceded	O
by	O
chest	B-Disease
pain	I-Disease
,	O
requiring	O
intubation	O
.	O
Her	O
medical	O
history	O
included	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
with	O
previous	O
myocardial	B-Disease
infarctions	I-Disease
,	O
hypertension	B-Disease
,	O
and	O
diabetes	B-Disease
mellitus	I-Disease
.	O
A	O
history	O
of	O
angioedema	B-Disease
secondary	O
to	O
lisinopril	B-Chemical
therapy	O
was	O
elicited	O
.	O
Current	O
medications	O
did	O
not	O
include	O
angiotensin	B-Chemical
-	O
converting	O
enzyme	O
inhibitors	O
or	O
beta	O
-	O
blockers	O
.	O
She	O
had	O
no	O
previous	O
beta	O
-	O
blocking	O
drug	O
exposure	O
.	O
During	O
the	O
first	O
day	O
of	O
hospitalization	O
(	O
while	O
intubated	O
)	O
,	O
intravenous	O
metoprolol	B-Chemical
was	O
given	O
,	O
resulting	O
in	O
severe	O
angioedema	B-Disease
.	O
The	O
angioedema	B-Disease
resolved	O
after	O
therapy	O
with	O
intravenous	O
steroids	B-Chemical
and	O
diphenhydramine	B-Chemical
hydrochloride	O
.	O
Effect	O
of	O
coniine	B-Chemical
on	O
the	O
developing	O
chick	O
embryo	O
.	O
Coniine	B-Chemical
,	O
an	O
alkaloid	O
from	O
Conium	O
maculatum	O
(	O
poison	O
hemlock	O
)	O
,	O
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
livestock	O
.	O
The	O
major	O
teratogenic	O
outcome	O
is	O
arthrogryposis	B-Disease
,	O
presumably	O
due	O
to	O
nicotinic	O
receptor	O
blockade	O
.	O
However	O
,	O
coniine	B-Chemical
has	O
failed	O
to	O
produce	O
arthrogryposis	B-Disease
in	O
rats	O
or	O
mice	O
and	O
is	O
only	O
weakly	O
teratogenic	O
in	O
rabbits	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
compare	O
the	O
effects	O
of	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
in	O
the	O
developing	O
chick	O
.	O
Concentrations	O
of	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
sulfate	O
were	O
0	O
.	O
015	O
%	O
,	O
0	O
.	O
03	O
%	O
,	O
0	O
.	O
075	O
%	O
,	O
0	O
.	O
15	O
%	O
,	O
0	O
.	O
75	O
%	O
,	O
1	O
.	O
5	O
%	O
,	O
3	O
%	O
,	O
and	O
6	O
%	O
and	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
,	O
respectively	O
.	O
Both	O
compounds	O
caused	O
deformations	B-Disease
and	O
lethality	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
All	O
concentrations	O
of	O
nicotine	B-Chemical
sulfate	O
caused	O
some	O
lethality	O
but	O
a	O
no	O
effect	O
level	O
for	O
coniine	B-Chemical
lethality	O
was	O
0	O
.	O
75	O
%	O
.	O
The	O
deformations	B-Disease
caused	O
by	O
both	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
sulfate	O
were	O
excessive	B-Disease
flexion	I-Disease
or	I-Disease
extension	I-Disease
of	I-Disease
one	I-Disease
or	I-Disease
more	I-Disease
toes	I-Disease
.	O
No	O
histopathological	O
alterations	O
or	O
differences	O
in	O
bone	O
formation	O
were	O
seen	O
in	O
the	O
limbs	O
or	O
toes	O
of	O
any	O
chicks	O
from	O
any	O
group	O
;	O
however	O
,	O
extensive	O
cranial	B-Disease
hemorrhage	I-Disease
occurred	O
in	O
all	O
nicotine	B-Chemical
sulfate	O
-	O
treated	O
chicks	O
.	O
There	O
was	O
a	O
statistically	O
significant	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
decrease	O
in	O
movement	O
in	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
sulfate	O
treated	O
chicks	O
as	O
determined	O
by	O
ultrasound	O
.	O
Control	O
chicks	O
were	O
in	O
motion	O
an	O
average	O
of	O
33	O
.	O
67	O
%	O
of	O
the	O
time	O
,	O
while	O
coniine	B-Chemical
-	O
treated	O
chicks	O
were	O
only	O
moving	O
8	O
.	O
95	O
%	O
of	O
a	O
5	O
-	O
min	O
interval	O
,	O
and	O
no	O
movement	O
was	O
observed	O
for	O
nicotine	B-Chemical
sulfate	O
treated	O
chicks	O
.	O
In	O
summary	O
,	O
the	O
chick	O
embryo	O
provides	O
a	O
reliable	O
and	O
simple	O
experimental	O
animal	O
model	O
of	O
coniine	B-Chemical
-	O
induced	O
arthrogryposis	B-Disease
.	O
Data	O
from	O
this	O
model	O
support	O
a	O
mechanism	O
involving	O
nicotinic	O
receptor	O
blockade	O
with	O
subsequent	O
decreased	O
fetal	O
movement	O
.	O
Immediate	O
allergic	B-Disease
reactions	I-Disease
to	O
amoxicillin	B-Chemical
.	O
A	O
large	O
group	O
of	O
patients	O
with	O
suspected	O
allergic	B-Disease
reactions	I-Disease
to	O
beta	B-Chemical
-	I-Chemical
lactam	I-Chemical
antibiotics	O
was	O
evaluated	O
.	O
A	O
detailed	O
clinical	O
history	O
,	O
together	O
with	O
skin	O
tests	O
,	O
RAST	O
(	O
radioallergosorbent	O
test	O
)	O
,	O
and	O
controlled	O
challenge	O
tests	O
,	O
was	O
used	O
to	O
establish	O
whether	O
patients	O
allergic	B-Disease
to	O
beta	B-Chemical
-	I-Chemical
lactam	I-Chemical
antibiotics	O
had	O
selective	O
immediate	O
allergic	B-Disease
responses	O
to	O
amoxicillin	B-Chemical
(	O
AX	B-Chemical
)	O
or	O
were	O
cross	O
-	O
reacting	O
with	O
other	O
penicillin	B-Chemical
derivatives	O
.	O
Skin	O
tests	O
were	O
performed	O
with	O
benzylpenicilloyl	B-Chemical
-	I-Chemical
poly	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
lysine	I-Chemical
(	O
BPO	B-Chemical
-	I-Chemical
PLL	I-Chemical
)	O
,	O
benzylpenicilloate	B-Chemical
,	O
benzylpenicillin	B-Chemical
(	O
PG	B-Chemical
)	O
,	O
ampicillin	B-Chemical
(	O
AMP	B-Chemical
)	O
,	O
and	O
AX	B-Chemical
.	O
RAST	O
for	O
BPO	B-Chemical
-	I-Chemical
PLL	I-Chemical
and	O
AX	B-Chemical
-	O
PLL	O
was	O
done	O
.	O
When	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
BPO	B-Chemical
were	O
negative	O
,	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
challenge	O
tests	O
were	O
done	O
to	O
ensure	O
tolerance	O
of	O
PG	B-Chemical
or	O
sensitivity	O
to	O
AX	B-Chemical
.	O
A	O
total	O
of	O
177	O
patients	O
were	O
diagnosed	O
as	O
allergic	B-Disease
to	O
beta	B-Chemical
-	I-Chemical
lactam	I-Chemical
antibiotics	O
.	O
We	O
selected	O
the	O
54	O
(	O
30	O
.	O
5	O
%	O
)	O
cases	O
of	O
immediate	O
AX	B-Chemical
allergy	B-Disease
with	O
good	O
tolerance	O
of	O
PG	B-Chemical
.	O
Anaphylaxis	B-Disease
was	O
seen	O
in	O
37	O
patients	O
(	O
69	O
%	O
)	O
,	O
the	O
other	O
17	O
(	O
31	O
%	O
)	O
having	O
urticaria	B-Disease
and	O
/	O
or	O
angioedema	B-Disease
.	O
All	O
the	O
patients	O
were	O
skin	O
test	O
negative	O
to	O
BPO	B-Chemical
;	O
49	O
of	O
51	O
(	O
96	O
%	O
)	O
were	O
also	O
negative	O
to	O
MDM	B-Disease
,	O
and	O
44	O
of	O
46	O
(	O
96	O
%	O
)	O
to	O
PG	B-Chemical
.	O
Skin	O
tests	O
with	O
AX	B-Chemical
were	O
positive	O
in	O
34	O
(	O
63	O
%	O
)	O
patients	O
.	O
RAST	O
was	O
positive	O
for	O
AX	B-Chemical
in	O
22	O
patients	O
(	O
41	O
%	O
)	O
and	O
to	O
BPO	B-Chemical
in	O
just	O
5	O
(	O
9	O
%	O
)	O
.	O
None	O
of	O
the	O
sera	O
with	O
negative	O
RAST	O
for	O
AX	B-Chemical
were	O
positive	O
to	O
BPO	B-Chemical
.	O
Challenge	O
tests	O
with	O
AX	B-Chemical
were	O
performed	O
in	O
23	O
subjects	O
(	O
43	O
%	O
)	O
to	O
establish	O
the	O
diagnosis	O
of	O
immediate	O
allergic	B-Disease
reaction	I-Disease
to	O
AX	B-Chemical
,	O
and	O
in	O
15	O
cases	O
(	O
28	O
%	O
)	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
AX	B-Chemical
were	O
negative	O
.	O
PG	B-Chemical
was	O
well	O
tolerated	O
by	O
all	O
54	O
patients	O
.	O
We	O
describe	O
the	O
largest	O
group	O
of	O
AX	B-Chemical
-	O
allergic	B-Disease
patients	O
who	O
have	O
tolerated	O
PG	B-Chemical
reported	O
so	O
far	O
.	O
Diagnosis	O
of	O
these	O
patients	O
can	O
be	O
achieved	O
only	O
if	O
specific	O
AX	B-Chemical
-	O
related	O
reagents	O
are	O
employed	O
.	O
Further	O
studies	O
are	O
necessary	O
to	O
determine	O
the	O
exact	O
extent	O
of	O
this	O
problem	O
and	O
to	O
improve	O
the	O
efficacy	O
of	O
diagnostic	O
methods	O
.	O
Reversal	O
by	O
phenylephrine	B-Chemical
of	O
the	O
beneficial	O
effects	O
of	O
intravenous	O
nitroglycerin	B-Chemical
in	O
patients	O
with	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O
Nitroglycerin	B-Chemical
has	O
been	O
shown	O
to	O
reduce	O
ST	O
-	O
segment	O
elevation	O
during	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
,	O
an	O
effect	O
potentiated	O
in	O
the	O
dog	O
by	O
agents	O
that	O
reverse	O
nitroglycerin	B-Chemical
-	O
induced	O
hypotension	B-Disease
.	O
Our	O
study	O
was	O
designed	O
to	O
determine	O
the	O
effects	O
of	O
combined	O
nitroglycerin	B-Chemical
and	O
phenylephrine	B-Chemical
therapy	O
.	O
Ten	O
patients	O
with	O
acute	O
transmural	O
myocardial	B-Disease
infarctions	I-Disease
received	O
intravenous	O
nitroglycerin	B-Chemical
,	O
sufficient	O
to	O
reduce	O
mean	O
arterial	O
pressure	O
from	O
107	O
+	O
/	O
-	O
6	O
to	O
85	O
+	O
/	O
-	O
6	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
for	O
60	O
minutes	O
.	O
Left	O
ventricular	O
filling	O
pressure	O
decreased	O
from	O
19	O
+	O
/	O
-	O
2	O
to	O
11	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
SigmaST	O
,	O
the	O
sum	O
of	O
ST	O
-	O
segment	O
elevations	O
in	O
16	O
precordial	O
leads	O
,	O
decreased	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
with	O
intravenous	O
nitroglycerin	B-Chemical
.	O
Subsequent	O
addition	O
of	O
phenylephrine	B-Chemical
infusion	O
,	O
sufficient	O
to	O
re	O
-	O
elevate	O
mean	O
arterial	O
pressure	O
to	O
106	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
for	O
30	O
minutes	O
,	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
to	O
17	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
also	O
significantly	O
increased	O
sigmaST	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
Our	O
results	O
suggest	O
that	O
addition	O
of	O
phenylephrine	B-Chemical
to	O
nitroglycerin	B-Chemical
is	O
not	O
beneficial	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O
Acetazolamide	B-Chemical
-	O
induced	O
nephrolithiasis	B-Disease
:	O
implications	O
for	O
treatment	O
of	O
neuromuscular	B-Disease
disorders	I-Disease
.	O
Carbonic	O
anhydrase	O
inhibitors	O
can	O
cause	O
nephrolithiasis	B-Disease
.	O
We	O
studied	O
20	O
patients	O
receiving	O
long	O
-	O
term	O
carbonic	O
anhydrase	O
inhibitor	O
treatment	O
for	O
periodic	O
paralysis	B-Disease
and	O
myotonia	B-Disease
.	O
Three	O
patients	O
on	O
acetazolamide	B-Chemical
(	O
15	O
%	O
)	O
developed	O
renal	B-Disease
calculi	I-Disease
.	O
Extracorporeal	O
lithotripsy	O
successfully	O
removed	O
a	O
renal	B-Disease
calculus	I-Disease
in	O
one	O
patient	O
and	O
surgery	O
removed	O
a	O
staghorn	O
calculus	B-Disease
in	O
another	O
,	O
permitting	O
continued	O
treatment	O
.	O
Renal	O
function	O
remained	O
normal	O
in	O
all	O
patients	O
.	O
Nephrolithiasis	B-Disease
is	O
a	O
complication	O
of	O
acetazolamide	B-Chemical
but	O
does	O
not	O
preclude	O
its	O
use	O
.	O
Effects	O
of	O
calcium	B-Chemical
channel	O
blockers	O
on	O
bupivacaine	B-Chemical
-	O
induced	O
toxicity	B-Disease
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
influence	O
of	O
calcium	B-Chemical
channel	O
blockers	O
on	O
bupivacaine	B-Chemical
-	O
induced	O
acute	O
toxicity	B-Disease
.	O
For	O
each	O
of	O
the	O
three	O
tested	O
calcium	B-Chemical
channel	O
blockers	O
(	O
diltiazem	B-Chemical
,	O
verapamil	B-Chemical
and	O
bepridil	B-Chemical
)	O
6	O
groups	O
of	O
mice	O
were	O
treated	O
by	O
two	O
different	O
doses	O
,	O
i	O
.	O
e	O
.	O
2	O
and	O
10	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
,	O
or	O
an	O
equal	O
volume	O
of	O
saline	O
for	O
the	O
control	O
group	O
(	O
n	O
=	O
20	O
)	O
;	O
15	O
minutes	O
later	O
,	O
all	O
the	O
animals	O
were	O
injected	O
with	O
a	O
single	O
50	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
dose	O
of	O
bupivacaine	B-Chemical
.	O
The	O
convulsant	O
activity	O
,	O
the	O
time	O
of	O
latency	O
to	O
convulse	O
and	O
the	O
mortality	O
rate	O
were	O
assessed	O
in	O
each	O
group	O
.	O
The	O
local	O
anesthetic	O
-	O
induced	O
mortality	O
was	O
significantly	O
increased	O
by	O
the	O
three	O
different	O
calcium	B-Chemical
channel	O
blockers	O
.	O
The	O
convulsant	O
activity	O
of	O
bupivacaine	B-Chemical
was	O
not	O
significantly	O
modified	O
but	O
calcium	B-Chemical
channel	O
blockers	O
decreased	O
the	O
time	O
of	O
latency	O
to	O
obtain	O
bupivacaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
;	O
this	O
effect	O
was	O
less	O
pronounced	O
with	O
bepridil	B-Chemical
.	O
Epidural	O
blood	O
flow	O
during	O
prostaglandin	B-Chemical
E1	I-Chemical
or	O
trimethaphan	B-Chemical
induced	O
hypotension	B-Disease
.	O
To	O
evaluate	O
the	O
effect	O
of	O
prostaglandin	B-Chemical
E1	I-Chemical
(	O
PGE1	B-Chemical
)	O
or	O
trimethaphan	B-Chemical
(	O
TMP	B-Chemical
)	O
induced	O
hypotension	B-Disease
on	O
epidural	O
blood	O
flow	O
(	O
EBF	O
)	O
during	O
spinal	O
surgery	O
,	O
EBF	O
was	O
measured	O
using	O
the	O
heat	O
clearance	O
method	O
in	O
30	O
patients	O
who	O
underwent	O
postero	O
-	O
lateral	O
interbody	O
fusion	O
under	O
isoflurane	B-Chemical
anaesthesia	O
.	O
An	O
initial	O
dose	O
of	O
0	O
.	O
1	O
microgram	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
PGE1	B-Chemical
(	O
15	O
patients	O
)	O
,	O
or	O
10	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
TMP	B-Chemical
(	O
15	O
patients	O
)	O
was	O
administered	O
intravenously	O
after	O
the	O
dural	O
opening	O
and	O
the	O
dose	O
was	O
adjusted	O
to	O
maintain	O
the	O
mean	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
at	O
about	O
60	O
mmHg	O
.	O
The	O
hypotensive	B-Disease
drug	O
was	O
discontinued	O
at	O
the	O
completion	O
of	O
the	O
operative	O
procedure	O
.	O
After	O
starting	O
PGE1	B-Chemical
or	O
TMP	B-Chemical
,	O
MAP	O
and	O
rate	O
pressure	O
product	O
(	O
RPP	O
)	O
decreased	O
significantly	O
compared	O
with	O
preinfusion	O
values	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
the	O
degree	O
of	O
hypotension	B-Disease
due	O
to	O
PGE1	B-Chemical
remained	O
constant	O
until	O
60	O
min	O
after	O
its	O
discontinuation	O
.	O
Heart	O
rate	O
(	O
HR	O
)	O
did	O
not	O
change	O
in	O
either	O
group	O
.	O
EBFF	O
did	O
not	O
change	O
during	O
PGE1	B-Chemical
infusion	O
whereas	O
in	O
the	O
TMP	B-Chemical
group	O
,	O
EBF	O
decreased	O
significantly	O
at	O
30	O
and	O
60	O
min	O
after	O
the	O
start	O
of	O
TMP	B-Chemical
(	O
preinfusion	O
:	O
45	O
.	O
9	O
+	O
/	O
-	O
13	O
.	O
9	O
ml	O
/	O
100g	O
/	O
min	O
.	O
30	O
min	O
:	O
32	O
.	O
3	O
+	O
/	O
-	O
9	O
.	O
9	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
60	O
min	O
:	O
30	O
+	O
/	O
-	O
7	O
.	O
5	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
)	O
.	O
These	O
results	O
suggest	O
that	O
PGE1	B-Chemical
may	O
be	O
preferable	O
to	O
TMP	B-Chemical
for	O
hypotensive	B-Disease
anaesthesia	O
in	O
spinal	O
surgery	O
because	O
TMP	B-Chemical
decreased	O
EBF	O
.	O
Dup	B-Chemical
753	I-Chemical
prevents	O
the	O
development	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrosis	B-Disease
.	O
The	O
appearance	O
of	O
nephrotic	B-Disease
syndromes	I-Disease
such	O
as	O
proteinuria	B-Disease
,	O
hypoalbuminemia	B-Disease
,	O
hypercholesterolemia	B-Disease
and	O
increase	O
in	O
blood	B-Chemical
nitrogen	I-Chemical
urea	I-Chemical
,	O
induced	O
in	O
rats	O
by	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
was	O
markedly	O
inhibited	O
by	O
oral	O
administration	O
of	O
Dup	B-Chemical
753	I-Chemical
(	O
losartan	B-Chemical
)	O
,	O
a	O
novel	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
antagonist	O
,	O
at	O
a	O
dose	O
of	O
1	O
or	O
2	O
mg	O
/	O
kg	O
per	O
day	O
.	O
The	O
results	O
suggest	O
a	O
possible	O
involvement	O
of	O
the	O
renin	O
-	O
angiotensin	B-Chemical
system	O
in	O
the	O
development	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrosis	B-Disease
.	O
Neuroplasticity	O
of	O
the	O
adult	O
primate	O
auditory	O
cortex	O
following	O
cochlear	O
hearing	B-Disease
loss	I-Disease
.	O
Tonotopic	O
organization	O
is	O
an	O
essential	O
feature	O
of	O
the	O
primary	O
auditory	O
area	O
(	O
A1	O
)	O
of	O
primate	O
cortex	O
.	O
In	O
A1	O
of	O
macaque	O
monkeys	O
,	O
low	O
frequencies	O
are	O
represented	O
rostrolaterally	O
and	O
high	O
frequencies	O
are	O
represented	O
caudomedially	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
changes	O
occur	O
in	O
this	O
tonotopic	O
organization	O
following	O
cochlear	O
hearing	B-Disease
loss	I-Disease
.	O
Under	O
anesthesia	O
,	O
the	O
superior	O
temporal	O
gyrus	O
of	O
adult	O
macaque	O
monkeys	O
was	O
exposed	O
,	O
and	O
the	O
tonotopic	O
organization	O
of	O
A1	O
was	O
mapped	O
using	O
conventional	O
microelectrode	O
recording	O
techniques	O
.	O
Following	O
recovery	O
,	O
the	O
monkeys	O
were	O
selectively	O
deafened	O
for	O
high	O
frequencies	O
using	O
kanamycin	B-Chemical
and	O
furosemide	B-Chemical
.	O
The	O
actual	O
frequencies	O
deafened	O
were	O
determined	O
by	O
the	O
loss	O
of	O
tone	O
-	O
burst	O
elicited	O
auditory	O
brainstem	O
responses	O
.	O
Three	O
months	O
after	O
deafening	O
,	O
A1	O
was	O
remapped	O
.	O
Postmortem	O
cytoarchitectural	O
features	O
identifying	O
A1	O
were	O
correlated	O
with	O
the	O
electrophysiologic	O
data	O
.	O
The	O
results	O
indicate	O
that	O
the	O
deprived	O
area	O
of	O
A1	O
undergoes	O
extensive	O
reorganization	O
and	O
becomes	O
responsive	O
to	O
intact	O
cochlear	O
frequencies	O
.	O
The	O
region	O
of	O
cortex	O
that	O
represents	O
the	O
low	O
frequencies	O
was	O
not	O
obviously	O
affected	O
by	O
the	O
cochlear	O
hearing	B-Disease
loss	I-Disease
.	O
Sodium	B-Chemical
bicarbonate	I-Chemical
alleviates	O
penile	B-Disease
pain	I-Disease
induced	O
by	O
intracavernous	O
injections	O
for	O
erectile	B-Disease
dysfunction	I-Disease
.	O
In	O
an	O
attempt	O
to	O
determine	O
whether	O
penile	B-Disease
pain	I-Disease
associated	O
with	O
intracorporeal	O
injections	O
could	O
be	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
we	O
performed	O
a	O
randomized	O
study	O
comparing	O
the	O
incidence	O
of	O
penile	B-Disease
pain	I-Disease
following	O
intracorporeal	O
injections	O
with	O
or	O
without	O
the	O
addition	O
of	O
sodium	B-Chemical
bicarbonate	I-Chemical
to	O
the	O
intracorporeal	O
medications	O
.	O
A	O
total	O
of	O
38	O
consecutive	O
patients	O
who	O
presented	O
to	O
our	O
clinic	O
with	O
impotence	B-Disease
received	O
0	O
.	O
2	O
ml	O
.	O
of	O
a	O
combination	O
of	O
3	O
drugs	O
:	O
6	O
mg	O
.	O
papaverine	B-Chemical
,	O
100	O
micrograms	O
.	O
phentolamine	B-Chemical
and	O
10	O
micrograms	O
.	O
prostaglandin	B-Chemical
E1	I-Chemical
with	O
(	O
pH	O
7	O
.	O
05	O
)	O
or	O
without	O
(	O
pH	O
4	O
.	O
17	O
)	O
the	O
addition	O
of	O
sodium	B-Chemical
bicarbonate	I-Chemical
(	O
0	O
.	O
03	O
mEq	O
.	O
)	O
.	O
Of	O
the	O
19	O
patients	O
without	O
sodium	B-Chemical
bicarbonate	I-Chemical
added	O
to	O
the	O
medication	O
11	O
(	O
58	O
%	O
)	O
complained	O
of	O
penile	B-Disease
pain	I-Disease
due	O
to	O
the	O
medication	O
,	O
while	O
only	O
1	O
of	O
the	O
19	O
men	O
(	O
5	O
%	O
)	O
who	O
received	O
sodium	B-Chemical
bicarbonate	I-Chemical
complained	O
of	O
penile	B-Disease
pain	I-Disease
.	O
From	O
these	O
data	O
we	O
conclude	O
that	O
the	O
penile	B-Disease
pain	I-Disease
following	O
intracorporeal	O
injections	O
is	O
most	O
likely	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
which	O
can	O
be	O
overcome	O
by	O
elevating	O
the	O
pH	O
to	O
a	O
neutral	O
level	O
.	O
The	O
use	O
and	O
toxicity	B-Disease
of	O
didanosine	B-Chemical
(	O
ddI	B-Chemical
)	O
in	O
HIV	B-Disease
antibody	I-Disease
-	I-Disease
positive	I-Disease
individuals	O
intolerant	O
to	O
zidovudine	B-Chemical
(	O
AZT	B-Chemical
)	O
One	O
hundred	O
and	O
fifty	O
-	O
one	O
patients	O
intolerant	O
to	O
zidovudine	B-Chemical
(	O
AZT	B-Chemical
)	O
received	O
didanosine	B-Chemical
(	O
ddI	B-Chemical
)	O
to	O
a	O
maximum	O
dose	O
of	O
12	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
.	O
Patient	O
response	O
was	O
assessed	O
using	O
changes	O
in	O
CD4	O
+	O
lymphocyte	O
subset	O
count	O
,	O
HIV	O
p24	O
antigen	O
,	O
weight	O
,	O
and	O
quality	O
of	O
life	O
.	O
Seventy	O
patients	O
developed	O
major	O
opportunistic	B-Disease
infections	I-Disease
whilst	O
on	O
therapy	O
;	O
this	O
was	O
the	O
first	O
AIDS	B-Disease
diagnosis	O
in	O
17	O
.	O
Only	O
minor	O
changes	O
in	O
CD4	O
+	O
lymphocyte	O
subset	O
count	O
were	O
observed	O
in	O
AIDS	B-Disease
patients	O
,	O
although	O
a	O
more	O
significant	O
rise	O
occurred	O
in	O
those	O
with	O
earlier	O
stages	O
of	O
disease	O
.	O
Of	O
those	O
positive	O
for	O
p24	O
antigen	O
at	O
the	O
commencement	O
of	O
the	O
study	O
67	O
%	O
showed	O
a	O
positive	O
response	O
,	O
and	O
this	O
was	O
most	O
likely	O
in	O
those	O
with	O
CD4	O
+	O
lymphocyte	O
subset	O
counts	O
above	O
100	O
mm3	O
.	O
A	O
positive	O
weight	O
response	O
was	O
seen	O
in	O
16	O
%	O
of	O
patients	O
.	O
Most	O
patients	O
showed	O
improvement	O
in	O
individual	O
parameters	O
and	O
global	O
score	O
of	O
quality	O
of	O
life	O
.	O
Adverse	O
reactions	O
possibly	O
attributable	O
to	O
didanosine	B-Chemical
were	O
common	O
.	O
The	O
most	O
common	O
side	O
-	O
effect	O
was	O
diarrhoea	B-Disease
,	O
which	O
resulted	O
in	O
cessation	O
of	O
therapy	O
in	O
19	O
individuals	O
.	O
Peripheral	B-Disease
neuropathy	I-Disease
occurred	O
in	O
12	O
patients	O
and	O
pancreatitis	B-Disease
in	O
six	O
.	O
Thirteen	O
patients	O
developed	O
a	O
raised	O
serum	O
amylase	O
without	O
abdominal	B-Disease
pain	I-Disease
.	O
Seven	O
patients	O
developed	O
glucose	B-Disease
tolerance	I-Disease
curves	I-Disease
characteristic	O
of	O
diabetes	B-Disease
but	O
these	O
were	O
mild	O
,	O
did	O
not	O
require	O
treatment	O
and	O
returned	O
to	O
normal	O
on	O
ceasing	O
didanosine	B-Chemical
.	O
Immunohistochemical	O
studies	O
with	O
antibodies	O
to	O
neurofilament	O
proteins	O
on	O
axonal	B-Disease
damage	I-Disease
in	O
experimental	O
focal	O
lesions	O
in	O
rat	O
.	O
Immunohistochemistry	O
with	O
monoclonal	O
antibodies	O
against	O
neurofilament	O
(	O
NF	O
)	O
proteins	O
of	O
middle	O
and	O
high	O
molecular	O
weight	O
class	O
,	O
NF	O
-	O
M	O
and	O
NF	O
-	O
H	O
,	O
was	O
used	O
to	O
study	O
axonal	B-Disease
injury	I-Disease
in	O
the	O
borderzone	O
of	O
focal	O
lesions	O
in	O
rats	O
.	O
Focal	O
injury	B-Disease
in	I-Disease
the	I-Disease
cortex	I-Disease
was	O
produced	O
by	O
infusion	O
of	O
lactate	B-Chemical
at	O
acid	O
pH	O
or	O
by	O
stab	O
caused	O
by	O
needle	O
insertion	O
.	O
Infarcts	B-Disease
in	I-Disease
substantia	I-Disease
nigra	I-Disease
pars	I-Disease
reticulata	I-Disease
were	O
evoked	O
by	O
prolonged	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
.	O
Immunohistochemical	O
staining	O
for	O
NFs	O
showed	O
characteristic	O
terminal	O
clubs	O
of	O
axons	O
in	O
the	O
borderzone	O
of	O
lesions	O
.	O
Differences	O
in	O
the	O
labelling	O
pattern	O
occurred	O
with	O
different	O
antibodies	O
which	O
apparently	O
depended	O
on	O
molecular	O
weight	O
class	O
of	O
NFs	O
and	O
phosphorylation	O
state	O
.	O
These	O
immunohistochemical	O
changes	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
marker	O
for	O
axonal	B-Disease
damage	I-Disease
in	O
various	O
experimental	O
traumatic	B-Disease
or	O
ischemic	O
lesions	O
.	O
Pharmacokinetic	O
and	O
clinical	O
studies	O
in	O
patients	O
with	O
cimetidine	B-Chemical
-	O
associated	O
mental	O
confusion	B-Disease
.	O
15	O
cases	O
of	O
cimetidine	B-Chemical
-	O
associated	O
mental	O
confusion	B-Disease
have	O
been	O
reported	O
.	O
In	O
order	O
that	O
this	O
syndrome	O
might	O
be	O
investigated	O
changes	O
in	O
mental	O
status	O
(	O
M	O
.	O
S	O
.	O
)	O
were	O
correlated	O
with	O
serum	O
concentrations	O
and	O
renal	O
and	O
hepatic	O
function	O
in	O
36	O
patients	O
,	O
30	O
patients	O
had	O
no	O
M	O
.	O
S	O
.	O
change	O
on	O
cimetidine	B-Chemical
and	O
6	O
had	O
moderate	O
to	O
severe	O
changes	O
.	O
These	O
6	O
patients	O
had	O
both	O
renal	B-Disease
and	I-Disease
liver	I-Disease
dysfunction	I-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
as	O
well	O
as	O
cimetidine	B-Chemical
trough	O
-	O
concentrations	O
of	O
more	O
than	O
1	O
.	O
25	O
microgram	O
/	O
ml	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
The	O
severity	O
of	O
M	O
.	O
S	O
.	O
changes	O
increased	O
as	O
trough	O
-	O
concentrations	O
rose	O
,	O
5	O
patients	O
had	O
lumbar	O
puncture	O
.	O
The	O
cerebrospinal	O
fluid	O
:	O
serum	O
ratio	O
of	O
cimetidine	B-Chemical
concentrations	O
was	O
0	O
.	O
24	O
:	O
1	O
and	O
indicates	O
that	O
cimetidine	B-Chemical
passes	O
the	O
blood	O
-	O
brain	O
barrier	O
;	O
it	O
also	O
raises	O
the	O
possibility	O
that	O
M	O
.	O
S	O
.	O
changes	O
are	O
due	O
to	O
blockade	O
of	O
histamine	B-Chemical
H2	O
-	O
receptors	O
in	O
the	O
central	O
nervous	O
system	O
.	O
Patients	O
likely	O
to	O
have	O
both	O
raised	O
trough	O
-	O
concentrations	O
and	O
mental	O
confusion	B-Disease
are	O
those	O
with	O
both	O
severe	O
renal	B-Disease
and	I-Disease
hepatic	I-Disease
dysfunction	I-Disease
.	O
They	O
should	O
be	O
closely	O
observed	O
and	O
should	O
be	O
given	O
reduced	O
doses	O
of	O
cimetidine	B-Chemical
.	O
Prospective	O
study	O
of	O
the	O
long	O
-	O
term	O
effects	O
of	O
somatostatin	O
analog	O
(	O
octreotide	B-Chemical
)	O
on	O
gallbladder	O
function	O
and	O
gallstone	B-Disease
formation	O
in	O
Chinese	O
acromegalic	B-Disease
patients	O
.	O
This	O
article	O
reports	O
the	O
changes	O
in	O
gallbladder	O
function	O
examined	O
by	O
ultrasonography	O
in	O
20	O
Chinese	O
patients	O
with	O
active	O
acromegaly	B-Disease
treated	O
with	O
sc	O
injection	O
of	O
the	O
somatostatin	O
analog	O
octreotide	B-Chemical
in	O
dosages	O
of	O
300	O
-	O
1500	O
micrograms	O
/	O
day	O
for	O
a	O
mean	O
of	O
24	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
9	O
months	O
.	O
During	O
treatment	O
with	O
octreotide	B-Chemical
,	O
17	O
patients	O
developed	O
sludge	O
,	O
10	O
had	O
gallstones	B-Disease
,	O
and	O
1	O
developed	O
acute	B-Disease
cholecystitis	I-Disease
requiring	O
surgery	O
.	O
In	O
all	O
of	O
7	O
patients	O
examined	O
acutely	O
,	O
gallbladder	O
contractility	O
was	O
inhibited	O
after	O
a	O
single	O
100	O
-	O
micrograms	O
injection	O
.	O
In	O
8	O
patients	O
followed	O
for	O
24	O
weeks	O
,	O
gallbladder	O
contractility	O
remained	O
depressed	B-Disease
throughout	O
therapy	O
.	O
After	O
withdrawal	O
of	O
octreotide	B-Chemical
in	O
10	O
patients	O
without	O
gallstones	B-Disease
,	O
8	O
patients	O
assessed	O
had	O
return	O
of	O
normal	O
gallbladder	O
contractility	O
within	O
1	O
month	O
.	O
In	O
8	O
of	O
the	O
remaining	O
10	O
patients	O
who	O
developed	O
gallstones	B-Disease
during	O
treatment	O
,	O
gallbladder	O
contractility	O
normalized	O
in	O
5	O
patients	O
(	O
3	O
of	O
whom	O
has	O
disappearance	O
of	O
their	O
stones	O
within	O
3	O
weeks	O
)	O
,	O
and	O
remained	O
depressed	B-Disease
in	O
3	O
(	O
2	O
of	O
whom	O
had	O
stones	O
present	O
at	O
6	O
months	O
)	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
gallbladder	O
contractility	O
is	O
the	O
cause	O
of	O
the	O
successive	O
formation	O
of	O
bile	O
sludge	O
,	O
gallstones	B-Disease
,	O
and	O
cholecystitis	B-Disease
during	O
octreotide	B-Chemical
therapy	O
in	O
Chinese	O
acromegalic	B-Disease
patients	O
.	O
It	O
is	O
therefore	O
very	O
important	O
to	O
follow	O
the	O
changes	O
of	O
gallbladder	O
function	O
during	O
long	O
-	O
term	O
octreotide	B-Chemical
therapy	O
of	O
acromegalic	B-Disease
patients	O
.	O
Increase	O
of	O
Parkinson	B-Disease
disability	I-Disease
after	O
fluoxetine	B-Chemical
medication	O
.	O
Depression	B-Disease
is	O
a	O
major	O
clinical	O
feature	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
We	O
report	O
the	O
increased	O
amount	O
of	O
motor	B-Disease
disability	I-Disease
in	O
four	O
patients	O
with	O
idiopathic	B-Disease
Parkinson	I-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
after	O
exposure	O
to	O
the	O
antidepressant	B-Chemical
fluoxetine	B-Chemical
.	O
The	O
possibility	O
of	O
a	O
clinically	O
relevant	O
dopamine	B-Chemical
-	O
antagonistic	O
capacity	O
of	O
fluoxetine	B-Chemical
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
must	O
be	O
considered	O
.	O
Sinus	B-Disease
arrest	I-Disease
associated	O
with	O
continuous	O
-	O
infusion	O
cimetidine	B-Chemical
.	O
The	O
administration	O
of	O
intermittent	O
intravenous	O
infusions	O
of	O
cimetidine	B-Chemical
is	O
infrequently	O
associated	O
with	O
the	O
development	O
of	O
bradyarrhythmias	B-Disease
.	O
A	O
40	O
-	O
year	O
-	O
old	O
man	O
with	O
leukemia	B-Disease
and	O
no	O
history	O
of	O
cardiac	B-Disease
disease	I-Disease
developed	O
recurrent	O
,	O
brief	O
episodes	O
of	O
apparent	O
sinus	B-Disease
arrest	I-Disease
while	O
receiving	O
continuous	O
-	O
infusion	O
cimetidine	B-Chemical
50	O
mg	O
/	O
hour	O
.	O
The	O
arrhythmias	B-Disease
were	O
temporally	O
related	O
to	O
cimetidine	B-Chemical
administration	O
,	O
disappeared	O
after	O
dechallenge	O
,	O
and	O
did	O
not	O
recur	O
during	O
ranitidine	B-Chemical
treatment	O
.	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
sinus	B-Disease
arrest	I-Disease
associated	O
with	O
continuous	O
-	O
infusion	O
cimetidine	B-Chemical
.	O
Phase	O
II	O
trial	O
of	O
vinorelbine	B-Chemical
in	O
metastatic	O
squamous	B-Disease
cell	I-Disease
esophageal	I-Disease
carcinoma	I-Disease
.	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	B-Disease
Gastrointestinal	O
Treat	O
Cancer	B-Disease
Cooperative	O
Group	O
.	O
PURPOSE	O
:	O
To	O
evaluate	O
the	O
response	O
rate	O
and	O
toxic	O
effects	O
of	O
vinorelbine	B-Chemical
(	O
VNB	B-Chemical
)	O
administered	O
as	O
a	O
single	O
agent	O
in	O
metastatic	O
squamous	B-Disease
cell	I-Disease
esophageal	I-Disease
carcinoma	I-Disease
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
six	O
eligible	O
patients	O
with	O
measurable	O
lesions	O
were	O
included	O
and	O
were	O
stratified	O
according	O
to	O
previous	O
chemotherapy	O
.	O
Thirty	O
patients	O
without	O
prior	O
chemotherapy	O
and	O
16	O
pretreated	O
with	O
cisplatin	B-Chemical
-	O
based	O
chemotherapy	O
were	O
assessable	O
for	O
toxicity	B-Disease
and	O
response	O
.	O
VNB	B-Chemical
was	O
administered	O
weekly	O
as	O
a	O
25	O
-	O
mg	O
/	O
m2	O
short	O
intravenous	O
(	O
i	O
.	O
v	O
.	O
)	O
infusion	O
.	O
RESULTS	O
:	O
Six	O
of	O
30	O
patients	O
(	O
20	O
%	O
)	O
without	O
prior	O
chemotherapy	O
achieved	O
a	O
partial	O
response	O
(	O
PR	O
)	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
8	O
%	O
to	O
39	O
%	O
)	O
.	O
The	O
median	O
duration	O
of	O
response	O
was	O
21	O
weeks	O
(	O
range	O
,	O
17	O
to	O
28	O
)	O
.	O
One	O
of	O
16	O
patients	O
(	O
6	O
%	O
)	O
with	O
prior	O
chemotherapy	O
had	O
a	O
complete	O
response	O
(	O
CR	O
)	O
of	O
31	O
weeks	O
'	O
duration	O
(	O
95	O
%	O
CI	O
,	O
0	O
%	O
to	O
30	O
%	O
)	O
.	O
The	O
overall	O
response	O
rate	O
(	O
World	O
Health	O
Organization	O
[	O
WHO	O
]	O
criteria	O
)	O
was	O
15	O
%	O
(	O
CR	O
,	O
2	O
%	O
;	O
PR	O
13	O
%	O
;	O
95	O
%	O
CI	O
,	O
6	O
%	O
to	O
29	O
%	O
)	O
.	O
The	O
median	O
dose	O
-	O
intensity	O
(	O
DI	O
)	O
was	O
20	O
mg	O
/	O
m2	O
/	O
wk	O
.	O
VNB	B-Chemical
was	O
well	O
tolerated	O
and	O
zero	O
instances	O
of	O
WHO	O
grade	O
4	O
nonhematologic	O
toxicity	B-Disease
occurred	O
.	O
At	O
least	O
one	O
episode	O
of	O
grade	O
3	O
or	O
4	O
granulocytopenia	B-Disease
was	O
seen	O
in	O
59	O
%	O
of	O
patients	O
.	O
A	O
grade	O
2	O
or	O
3	O
infection	B-Disease
occurred	O
in	O
16	O
%	O
of	O
patients	O
,	O
but	O
no	O
toxic	O
deaths	B-Disease
occurred	O
.	O
Other	O
side	O
effects	O
were	O
rare	O
,	O
and	O
peripheral	B-Disease
neurotoxicity	I-Disease
has	O
been	O
minor	O
(	O
26	O
%	O
grade	O
1	O
)	O
.	O
CONCLUSION	O
:	O
These	O
data	O
indicate	O
that	O
VNB	B-Chemical
is	O
an	O
active	O
agent	O
in	O
metastatic	O
esophageal	B-Disease
squamous	I-Disease
cell	I-Disease
carcinoma	I-Disease
.	O
Given	O
its	O
excellent	O
tolerance	O
profile	O
and	O
low	O
toxicity	B-Disease
,	O
further	O
evaluation	O
of	O
VNB	B-Chemical
in	O
combination	O
therapy	O
is	O
warranted	O
.	O
Evaluation	O
of	O
adverse	O
reactions	O
of	O
aponidine	B-Chemical
hydrochloride	I-Chemical
ophthalmic	O
solution	O
.	O
We	O
prospectively	O
evaluated	O
the	O
adverse	O
reactions	O
of	O
apraclonidine	B-Chemical
in	O
20	O
normal	O
volunteers	O
by	O
instilling	O
a	O
single	O
drop	O
of	O
1	O
%	O
apraclonidine	B-Chemical
in	O
their	O
right	O
eyes	O
.	O
Examinations	O
,	O
including	O
blood	O
pressure	O
,	O
pulse	O
rate	O
,	O
conjunctiva	O
and	O
cornea	O
,	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
,	O
pupil	O
diameter	O
,	O
basal	O
tear	O
secretion	O
and	O
margin	O
reflex	O
distance	O
of	O
both	O
upper	O
and	O
lower	O
eyelids	O
,	O
were	O
performed	O
prior	O
to	O
entry	O
and	O
at	O
1	O
,	O
3	O
,	O
5	O
and	O
7	O
hours	O
after	O
instillation	O
.	O
The	O
ocular	B-Disease
hypotensive	I-Disease
effects	O
were	O
statistically	O
significant	O
for	O
apraclonidine	B-Chemical
-	O
treated	O
eyes	O
throughout	O
the	O
study	O
and	O
also	O
statistically	O
significant	O
for	O
contralateral	O
eyes	O
from	O
three	O
hours	O
after	O
topical	O
administration	O
of	O
1	O
%	O
apraclonidine	B-Chemical
.	O
Decreases	B-Disease
in	I-Disease
systolic	I-Disease
blood	I-Disease
pressure	I-Disease
were	O
statistically	O
,	O
but	O
not	O
clinically	O
,	O
significant	O
.	O
No	O
significant	O
changes	O
in	O
diastolic	O
blood	O
pressure	O
,	O
pulse	O
rate	O
and	O
basal	O
tear	O
secretion	O
were	O
noted	O
.	O
Conjunctival	B-Disease
blanching	I-Disease
and	O
mydriasis	B-Disease
were	O
commonly	O
found	O
.	O
Upper	O
lid	O
retraction	O
was	O
frequently	O
noted	O
.	O
While	O
the	O
elevations	O
of	O
the	O
upper	O
lid	O
margin	O
in	O
most	O
subjects	O
were	O
not	O
more	O
than	O
2	O
mm	O
and	O
did	O
not	O
cause	O
noticeable	O
change	O
in	O
appearance	O
,	O
one	O
subject	O
suffered	O
from	O
mechanical	O
entropion	B-Disease
and	O
marked	O
corneal	B-Disease
abrasion	I-Disease
3	O
hours	O
after	O
instillation	O
of	O
the	O
medication	O
.	O
This	O
may	O
well	O
be	O
a	O
particularly	O
notable	O
finding	O
in	O
Asian	O
people	O
.	O
Thiopentone	B-Chemical
pretreatment	O
for	O
propofol	B-Chemical
injection	O
pain	B-Disease
in	O
ambulatory	O
patients	O
.	O
This	O
study	O
investigated	O
propofol	B-Chemical
injection	O
pain	B-Disease
in	O
patients	O
undergoing	O
ambulatory	O
anaesthesia	O
.	O
In	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
,	O
90	O
women	O
were	O
allocated	O
to	O
receive	O
one	O
of	O
three	O
treatments	O
prior	O
to	O
induction	O
of	O
anaesthesia	O
with	O
propofol	B-Chemical
.	O
Patients	O
in	O
Group	O
C	O
received	O
2	O
ml	O
normal	O
saline	O
,	O
Group	O
L	O
,	O
2	O
ml	O
,	O
lidocaine	B-Chemical
2	O
%	O
(	O
40	O
mg	O
)	O
and	O
Group	O
T	O
,	O
2	O
ml	O
thiopentone	B-Chemical
2	O
.	O
5	O
%	O
(	O
50	O
mg	O
)	O
.	O
Venous	O
discomfort	O
was	O
assessed	O
with	O
a	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
5	O
-	O
15	O
sec	O
after	O
commencing	O
propofol	B-Chemical
administration	O
using	O
an	O
infusion	O
pump	O
(	O
rate	O
1000	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
)	O
.	O
Loss	B-Disease
of	I-Disease
consciousness	I-Disease
occurred	O
in	O
60	O
-	O
90	O
sec	O
.	O
Visual	O
analogue	O
scores	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
during	O
induction	O
were	O
lower	O
in	O
Groups	O
L	O
(	O
3	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
)	O
and	O
T	O
(	O
4	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
7	O
)	O
than	O
in	O
Group	O
C	O
(	O
5	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
3	O
)	O
;	O
P	O
=	O
0	O
.	O
0031	O
.	O
The	O
incidence	O
of	O
venous	O
discomfort	O
was	O
lower	O
in	O
Group	O
L	O
(	O
76	O
.	O
6	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
in	O
Group	O
C	O
(	O
100	O
%	O
)	O
but	O
not	O
different	O
from	O
Group	O
T	O
(	O
90	O
%	O
)	O
.	O
The	O
VAS	O
scores	O
for	O
recall	O
of	O
pain	B-Disease
in	O
the	O
recovery	O
room	O
were	O
correlated	O
with	O
the	O
VAS	O
scores	O
during	O
induction	O
(	O
r	O
=	O
0	O
.	O
7045	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
Recovery	O
room	O
discharge	O
times	O
were	O
similar	O
:	O
C	O
(	O
75	O
.	O
9	O
+	O
/	O
-	O
19	O
.	O
4	O
min	O
)	O
;	O
L	O
73	O
.	O
6	O
+	O
/	O
-	O
21	O
.	O
6	O
min	O
)	O
;	O
T	O
(	O
77	O
.	O
1	O
+	O
/	O
-	O
18	O
.	O
9	O
min	O
)	O
.	O
Assessing	O
their	O
overall	O
satisfaction	O
,	O
89	O
.	O
7	O
%	O
would	O
choose	O
propofol	B-Chemical
anaesthesia	O
again	O
.	O
We	O
conclude	O
that	O
lidocaine	B-Chemical
reduces	O
the	O
incidence	O
and	O
severity	O
of	O
propofol	B-Chemical
injection	O
pain	B-Disease
in	O
ambulatory	O
patients	O
whereas	O
thiopentone	B-Chemical
only	O
reduces	O
its	O
severity	O
.	O
Persistent	O
paralysis	B-Disease
after	O
prolonged	O
use	O
of	O
atracurium	B-Chemical
in	O
the	O
absence	O
of	O
corticosteroids	O
.	O
Neuromuscular	O
blocking	O
agents	O
(	O
NMBAs	O
)	O
are	O
often	O
used	O
for	O
patients	O
requiring	O
prolonged	O
mechanical	O
ventilation	O
.	O
Reports	O
of	O
persistent	O
paralysis	B-Disease
after	O
the	O
discontinuance	O
of	O
these	O
drugs	O
have	O
most	O
often	O
involved	O
aminosteroid	O
-	O
based	O
NMBAs	O
such	O
as	O
vecuronium	B-Chemical
bromide	I-Chemical
,	O
especially	O
when	O
used	O
in	O
conjunction	O
with	O
corticosteroids	O
.	O
Atracurium	B-Chemical
besylate	I-Chemical
,	O
a	O
short	O
-	O
acting	O
benzylisoquinolinium	B-Chemical
NMBA	O
that	O
is	O
eliminated	O
independently	O
of	O
renal	O
or	O
hepatic	O
function	O
,	O
has	O
also	O
been	O
associated	O
with	O
persistent	O
paralysis	B-Disease
,	O
but	O
only	O
when	O
used	O
with	O
corticosteroids	O
.	O
We	O
report	O
a	O
case	O
of	O
atracurium	B-Chemical
-	O
related	O
paralysis	B-Disease
persisting	O
for	O
approximately	O
50	O
hours	O
in	O
a	O
patient	O
who	O
was	O
not	O
treated	O
with	O
corticosteroids	O
.	O
A	O
phase	O
I	O
/	O
II	O
study	O
of	O
paclitaxel	B-Chemical
plus	O
cisplatin	B-Chemical
as	O
first	O
-	O
line	O
therapy	O
for	O
head	B-Disease
and	I-Disease
neck	I-Disease
cancers	I-Disease
:	O
preliminary	O
results	O
.	O
Improved	O
outcomes	O
among	O
patients	O
with	O
head	B-Disease
and	I-Disease
neck	I-Disease
carcinomas	I-Disease
require	O
investigations	O
of	O
new	O
drugs	O
for	O
induction	O
therapy	O
.	O
Preliminary	O
results	O
of	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
of	O
single	O
-	O
agent	O
paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
reported	O
a	O
37	O
%	O
response	O
rate	O
in	O
patients	O
with	O
head	B-Disease
and	I-Disease
neck	I-Disease
cancer	I-Disease
,	O
and	O
the	O
paclitaxel	B-Chemical
/	O
cisplatin	B-Chemical
combination	O
has	O
been	O
used	O
successfully	O
and	O
has	O
significantly	O
improved	O
median	O
response	O
duration	O
in	O
ovarian	B-Disease
cancer	I-Disease
patients	O
.	O
We	O
initiated	O
a	O
phase	O
I	O
/	O
II	O
trial	O
to	O
determine	O
the	O
response	O
and	O
toxicity	B-Disease
of	O
escalating	O
paclitaxel	B-Chemical
doses	O
combined	O
with	O
fixed	O
-	O
dose	O
cisplatin	B-Chemical
with	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
support	O
in	O
patients	O
with	O
untreated	O
locally	O
advanced	O
inoperable	O
head	B-Disease
and	I-Disease
neck	I-Disease
carcinoma	I-Disease
.	O
To	O
date	O
,	O
23	O
men	O
with	O
a	O
median	O
age	O
of	O
50	O
years	O
and	O
good	O
performance	O
status	O
have	O
entered	O
the	O
trial	O
.	O
Primary	O
tumor	B-Disease
sites	O
were	O
oropharynx	O
,	O
10	O
patients	O
;	O
hypopharynx	O
,	O
four	O
;	O
larynx	O
,	O
two	O
;	O
oral	O
cavity	O
,	O
three	O
;	O
unknown	O
primary	O
,	O
two	O
;	O
and	O
nasal	O
cavity	O
and	O
parotid	O
gland	O
,	O
one	O
each	O
.	O
Of	O
20	O
patients	O
evaluable	O
for	O
toxicity	B-Disease
,	O
four	O
had	O
stage	O
III	O
and	O
16	O
had	O
stage	O
IV	O
disease	O
.	O
Treatment	O
,	O
given	O
every	O
21	O
days	O
for	O
a	O
maximum	O
of	O
three	O
cycles	O
,	O
consisted	O
of	O
paclitaxel	B-Chemical
by	O
3	O
-	O
hour	O
infusion	O
followed	O
the	O
next	O
day	O
by	O
a	O
fixed	O
dose	O
of	O
cisplatin	B-Chemical
(	O
75	O
mg	O
/	O
m2	O
)	O
.	O
The	O
dose	O
levels	O
incorporate	O
escalating	O
paclitaxel	B-Chemical
doses	O
,	O
and	O
intrapatient	O
escalations	O
within	O
a	O
given	O
dose	O
level	O
are	O
permitted	O
if	O
toxicity	B-Disease
permits	O
.	O
At	O
the	O
time	O
of	O
this	O
writing	O
,	O
dose	O
level	O
4	O
(	O
260	O
,	O
270	O
,	O
and	O
280	O
mg	O
/	O
m2	O
)	O
is	O
being	O
evaluated	O
;	O
three	O
patients	O
from	O
this	O
level	O
are	O
evaluable	O
.	O
With	O
paclitaxel	B-Chemical
doses	O
of	O
200	O
mg	O
/	O
m2	O
and	O
higher	O
,	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
5	O
micrograms	O
/	O
kg	O
/	O
d	O
is	O
given	O
(	O
days	O
4	O
through	O
12	O
)	O
.	O
Of	O
18	O
patients	O
evaluable	O
for	O
response	O
,	O
seven	O
(	O
39	O
%	O
)	O
achieved	O
a	O
complete	O
response	O
and	O
six	O
(	O
33	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
.	O
Three	O
patients	O
had	O
no	O
change	O
and	O
disease	O
progressed	O
in	O
two	O
.	O
The	O
overall	O
response	O
rate	O
is	O
72	O
%	O
.	O
Eleven	O
responding	O
patients	O
had	O
subsequent	O
surgery	O
/	O
radiotherapy	O
or	O
radical	O
radiotherapy	O
.	O
Two	O
pathologic	O
complete	O
responses	O
were	O
observed	O
in	O
patients	O
who	O
had	O
achieved	O
clinical	O
complete	O
responses	O
.	O
Alopecia	B-Disease
,	O
paresthesias	B-Disease
,	O
and	O
arthralgias	B-Disease
/	O
myalgias	B-Disease
have	O
occurred	O
frequently	O
,	O
but	O
with	O
one	O
exception	O
(	O
a	O
grade	O
3	O
myalgia	B-Disease
)	O
they	O
have	O
been	O
grade	O
1	O
or	O
2	O
.	O
No	O
dose	O
-	O
limiting	O
hematologic	O
toxicity	B-Disease
has	O
been	O
seen	O
.	O
Paclitaxel	B-Chemical
/	O
cisplatin	B-Chemical
is	O
an	O
effective	O
first	O
-	O
line	O
regimen	O
for	O
locoregionally	O
advanced	O
head	B-Disease
and	I-Disease
neck	I-Disease
cancer	I-Disease
and	O
continued	O
study	O
is	O
warranted	O
.	O
Results	O
thus	O
far	O
suggest	O
no	O
dose	O
-	O
response	O
effect	O
for	O
paclitaxel	B-Chemical
doses	O
above	O
200	O
mg	O
/	O
m2	O
.	O
Improvement	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesia	B-Disease
by	O
propranolol	B-Chemical
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
Seven	O
patients	O
suffering	O
from	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
with	O
severely	O
disabling	O
dyskinesia	B-Disease
received	O
low	O
-	O
dose	O
propranolol	B-Chemical
as	O
an	O
adjunct	O
to	O
the	O
currently	O
used	O
medical	O
treatment	O
.	O
There	O
was	O
a	O
significant	O
40	O
%	O
improvement	O
in	O
the	O
dyskinesia	B-Disease
score	O
without	O
increase	O
of	O
parkinsonian	B-Disease
motor	B-Disease
disability	I-Disease
.	O
Ballistic	O
and	O
choreic	O
dyskinesia	B-Disease
were	O
markedly	O
ameliorated	O
,	O
whereas	O
dystonia	B-Disease
was	O
not	O
.	O
This	O
study	O
suggests	O
that	O
administration	O
of	O
low	O
doses	O
of	O
beta	O
-	O
blockers	O
may	O
improve	O
levodopa	B-Chemical
-	O
induced	O
ballistic	O
and	O
choreic	O
dyskinesia	B-Disease
in	O
PD	B-Disease
.	O
Habitual	O
use	O
of	O
acetaminophen	B-Chemical
as	O
a	O
risk	O
factor	O
for	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
:	O
a	O
comparison	O
with	O
phenacetin	B-Chemical
.	O
Six	O
epidemiologic	O
studies	O
in	O
the	O
United	O
States	O
and	O
Europe	O
indicate	O
that	O
habitual	O
use	O
of	O
phenacetin	B-Chemical
is	O
associated	O
with	O
the	O
development	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
and	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
4	O
to	O
19	O
.	O
As	O
a	O
result	O
of	O
these	O
and	O
other	O
studies	O
,	O
phenacetin	B-Chemical
has	O
now	O
been	O
withdrawn	O
from	O
the	O
market	O
in	O
most	O
countries	O
.	O
However	O
,	O
three	O
case	O
control	O
studies	O
,	O
one	O
each	O
in	O
North	O
Carolina	O
,	O
northern	O
Maryland	O
,	O
and	O
West	O
Berlin	O
,	O
Germany	O
,	O
showed	O
that	O
habitual	O
use	O
of	O
acetaminophen	B-Chemical
is	O
also	O
associated	O
with	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
and	O
ESRD	B-Disease
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
2	O
to	O
4	O
.	O
These	O
studies	O
suggest	O
that	O
both	O
phenacetin	B-Chemical
and	O
acetaminophen	B-Chemical
may	O
contribute	O
to	O
the	O
burden	O
of	O
ESRD	B-Disease
,	O
with	O
the	O
risk	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O
This	O
apparent	O
difference	O
in	O
risk	O
may	O
not	O
be	O
due	O
to	O
differences	O
in	O
nephrotoxic	B-Disease
potential	O
of	O
the	O
drugs	O
themselves	O
.	O
A	O
lower	O
relative	O
risk	O
would	O
be	O
expected	O
for	O
acetaminophen	B-Chemical
if	O
the	O
risk	O
of	O
both	O
drugs	O
in	O
combination	O
with	O
other	O
analgesics	O
was	O
higher	O
than	O
the	O
risk	O
of	O
either	O
agent	O
alone	O
.	O
Thus	O
,	O
acetaminophen	B-Chemical
has	O
been	O
used	O
both	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
other	O
analgesics	O
,	O
whereas	O
phenacetin	B-Chemical
was	O
available	O
only	O
in	O
combinations	O
.	O
The	O
possibility	O
that	O
habitual	O
use	O
of	O
acetaminophen	B-Chemical
alone	O
increases	O
the	O
risk	O
of	O
ESRD	B-Disease
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
cannot	O
be	O
dismissed	O
.	O
Acetaminophen	B-Chemical
-	O
induced	O
hypotension	B-Disease
.	O
Through	O
30	O
years	O
of	O
widespread	O
use	O
,	O
acetaminophen	B-Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
medication	O
in	O
therapeutic	O
dosages	O
.	O
The	O
potential	O
for	O
acetaminophen	B-Chemical
to	O
produce	O
cardiovascular	B-Disease
toxicities	I-Disease
is	O
very	O
low	O
.	O
However	O
,	O
acetaminophen	B-Chemical
has	O
been	O
demonstrated	O
to	O
produce	O
symptoms	O
of	O
anaphylaxis	B-Disease
,	O
including	O
hypotension	B-Disease
,	O
in	O
sensitive	O
individuals	O
.	O
This	O
article	O
describes	O
two	O
critically	B-Disease
ill	I-Disease
patients	O
in	O
whom	O
transient	O
episodes	O
of	O
hypotension	B-Disease
reproducibly	O
developed	O
after	O
administration	O
of	O
acetaminophen	B-Chemical
.	O
Other	O
symptoms	O
of	O
allergic	B-Disease
reactions	I-Disease
were	O
not	O
clinically	O
detectable	O
.	O
The	O
hypotensive	B-Disease
episodes	O
were	O
severe	O
enough	O
to	O
require	O
vasopressor	O
administration	O
.	O
The	O
reports	O
illustrate	O
the	O
need	O
for	O
clinicians	O
to	O
consider	O
acetaminophen	B-Chemical
in	O
patients	O
with	O
hypotension	B-Disease
of	O
unknown	O
origin	O
.	O
Reduction	O
of	O
heparan	B-Chemical
sulphate	I-Chemical
-	O
associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
of	O
rats	O
with	O
streptozotocin	B-Chemical
-	O
induced	O
diabetic	B-Disease
nephropathy	I-Disease
.	O
Heparan	B-Chemical
sulphate	I-Chemical
-	O
associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
were	O
studied	O
in	O
rats	O
8	O
months	O
after	O
induction	O
of	O
diabetes	B-Disease
by	O
streptozotocin	B-Chemical
and	O
in	O
age	O
-	O
adn	O
sex	O
-	O
matched	O
control	O
rats	O
,	O
employing	O
the	O
cationic	O
dye	O
cuprolinic	B-Chemical
blue	I-Chemical
.	O
Morphometric	O
analysis	O
at	O
the	O
ultrastructural	O
level	O
was	O
performed	O
using	O
a	O
computerized	O
image	O
processor	O
.	O
The	O
heparan	B-Chemical
sulphate	I-Chemical
specificity	O
of	O
the	O
cuprolinic	B-Chemical
blue	I-Chemical
staining	O
was	O
demonstrated	O
by	O
glycosaminoglycan	B-Chemical
-	O
degrading	O
enzymes	O
,	O
showing	O
that	O
pretreatment	O
of	O
the	O
sections	O
with	O
heparitinase	O
abolished	O
all	O
staining	O
,	O
whereas	O
chondroitinase	O
ABC	O
had	O
no	O
effect	O
.	O
The	O
majority	O
of	O
anionic	O
sites	O
(	O
74	O
%	O
in	O
diabetic	B-Disease
and	O
81	O
%	O
in	O
control	O
rats	O
)	O
were	O
found	O
within	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O
A	O
minority	O
of	O
anionic	O
sites	O
were	O
scattered	O
throughout	O
the	O
lamina	O
densa	O
and	O
lamina	O
rara	O
interna	O
,	O
and	O
were	O
significantly	O
smaller	O
than	O
those	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(	O
p	O
<	O
0	O
.	O
001	O
and	O
p	O
<	O
0	O
.	O
01	O
for	O
diabetic	B-Disease
and	O
control	O
rats	O
,	O
respectively	O
)	O
.	O
Diabetic	B-Disease
rats	O
progressively	O
developed	O
albuminuria	B-Disease
reaching	O
40	O
.	O
3	O
(	O
32	O
.	O
2	O
-	O
62	O
.	O
0	O
)	O
mg	O
/	O
24	O
h	O
after	O
8	O
months	O
in	O
contrast	O
to	O
the	O
control	O
animals	O
(	O
0	O
.	O
8	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
9	O
)	O
mg	O
/	O
24	O
h	O
,	O
p	O
<	O
0	O
.	O
002	O
)	O
.	O
At	O
the	O
same	O
time	O
,	O
the	O
number	O
of	O
heparan	B-Chemical
sulphate	I-Chemical
anionic	O
sites	O
and	O
the	O
total	O
anionic	O
site	O
surface	O
(	O
number	O
of	O
anionic	O
sites	O
x	O
mean	O
anionic	O
site	O
surface	O
)	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
was	O
reduced	O
by	O
19	O
%	O
(	O
p	O
<	O
0	O
.	O
021	O
)	O
and	O
by	O
26	O
%	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
,	O
respectively	O
.	O
Number	O
and	O
total	O
anionic	O
site	O
surface	O
in	O
the	O
remaining	O
part	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(	O
lamina	O
densa	O
and	O
lamina	O
rara	O
interna	O
)	O
were	O
not	O
significantly	O
changed	O
.	O
We	O
conclude	O
that	O
in	O
streptozotocin	B-Chemical
-	O
diabetic	B-Disease
rats	O
with	O
an	O
increased	O
urinary	O
albumin	O
excretion	O
,	O
a	O
reduced	O
heparan	B-Chemical
sulphate	I-Chemical
charge	O
barrier	O
/	O
density	O
is	O
found	O
at	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O
Mediation	O
of	O
enhanced	O
reflex	O
vagal	O
bradycardia	B-Disease
by	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
via	O
central	O
dopamine	B-Chemical
formation	O
in	O
dogs	O
.	O
L	B-Chemical
-	I-Chemical
Dopa	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
after	O
extracerebral	O
decarboxylase	O
inhibition	O
with	O
MK	B-Chemical
-	I-Chemical
486	I-Chemical
(	O
25	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
in	O
anesthetize	O
MAO	B-Chemical
-	O
inhibited	O
dogs	O
.	O
In	O
addition	O
,	O
reflex	O
bradycardia	B-Disease
caused	O
by	O
injected	O
norepinephrine	B-Chemical
was	O
significantly	O
enhanced	O
by	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
,	O
DL	B-Chemical
-	I-Chemical
Threo	I-Chemical
-	I-Chemical
dihydroxyphenylserine	I-Chemical
had	O
no	O
effect	O
on	O
blood	O
pressure	O
,	O
heart	O
rate	O
or	O
reflex	O
responses	O
to	O
norepinephrine	B-Chemical
.	O
FLA	B-Chemical
-	I-Chemical
63	I-Chemical
,	O
a	O
dopamine	B-Chemical
-	O
beta	O
-	O
oxidase	O
inhibitor	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
the	O
hypotension	B-Disease
,	O
bradycardia	B-Disease
or	O
reflex	O
-	O
enhancing	O
effect	O
of	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
.	O
Pimozide	B-Chemical
did	O
not	O
affect	O
the	O
actions	O
of	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
on	O
blood	O
pressure	O
and	O
heart	O
rate	O
but	O
completely	O
blocked	O
the	O
enhancement	O
of	O
reflexes	O
.	O
Removal	O
of	O
the	O
carotid	O
sinuses	O
caused	O
an	O
elevation	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
abolished	O
the	O
negative	O
chronotropic	O
effect	O
of	O
norepinephrine	B-Chemical
.	O
However	O
,	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
restored	O
the	O
bradycardia	B-Disease
caused	O
by	O
norepinephrine	B-Chemical
in	O
addition	O
to	O
decreasing	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O
5	B-Chemical
-	I-Chemical
HTP	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
decreased	O
the	O
reflex	O
bradycardia	B-Disease
to	O
norepinephrine	B-Chemical
.	O
It	O
is	O
concluded	O
that	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
enhances	O
reflex	O
bradycardia	B-Disease
through	O
central	O
alpha	O
-	O
receptor	O
stimulation	O
.	O
Furthermore	O
,	O
the	O
effects	O
are	O
mediated	O
through	O
dopamine	B-Chemical
rather	O
than	O
norepinephrine	B-Chemical
and	O
do	O
not	O
require	O
the	O
carotid	O
sinus	O
baroreceptors	O
.	O
Microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
complicating	O
FK506	B-Chemical
(	O
tacrolimus	B-Chemical
)	O
therapy	O
.	O
We	O
describe	O
3	O
episodes	O
of	O
microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
MAHA	B-Disease
)	O
in	O
2	O
solid	O
organ	O
recipients	O
under	O
FK506	B-Chemical
(	O
tacrolimus	B-Chemical
)	O
therapy	O
.	O
In	O
both	O
cases	O
,	O
discontinuation	O
of	O
FK506	B-Chemical
and	O
treatment	O
with	O
plasma	O
exchange	O
,	O
fresh	O
frozen	O
plasma	O
replacement	O
,	O
corticosteroids	B-Chemical
,	O
aspirin	B-Chemical
,	O
and	O
dipyridamole	B-Chemical
led	O
to	O
resolution	O
of	O
MAHA	B-Disease
.	O
In	O
one	O
patient	O
,	O
reintroduction	O
of	O
FK506	B-Chemical
led	O
to	O
rapid	O
recurrence	O
of	O
MAHA	B-Disease
.	O
FK506	B-Chemical
-	O
associated	O
MAHA	B-Disease
is	O
probably	O
rare	O
but	O
physicians	O
must	O
be	O
aware	O
of	O
this	O
severe	O
complication	O
.	O
In	O
our	O
experience	O
and	O
according	O
to	O
the	O
literature	O
,	O
FK506	B-Chemical
does	O
not	O
seem	O
to	O
cross	O
-	O
react	O
with	O
cyclosporin	B-Chemical
A	I-Chemical
(	O
CyA	B-Chemical
)	O
,	O
an	O
immuno	O
-	O
suppressive	O
drug	O
already	O
known	O
to	O
induce	O
MAHA	B-Disease
.	O
Effect	O
of	O
some	O
anticancer	O
drugs	O
and	O
combined	O
chemotherapy	O
on	O
renal	B-Disease
toxicity	I-Disease
.	O
The	O
nephrotoxic	B-Disease
action	O
of	O
anticancer	O
drugs	O
such	O
as	O
nitrogranulogen	B-Chemical
(	O
NG	B-Chemical
)	O
,	O
methotrexate	B-Chemical
(	O
MTX	B-Chemical
)	O
,	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
and	O
cyclophosphamide	B-Chemical
(	O
CY	B-Chemical
)	O
administered	O
alone	O
or	O
in	O
combination	O
[	O
MTX	B-Chemical
+	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
+	O
CY	B-Chemical
(	O
CMF	O
)	O
]	O
was	O
evaluated	O
in	O
experiments	O
on	O
Wistar	O
rats	O
.	O
After	O
drug	O
administration	O
,	O
creatinine	B-Chemical
concentrations	O
in	O
the	O
plasma	O
and	O
in	O
the	O
urine	O
of	O
the	O
rats	O
were	O
determined	O
,	O
as	O
well	O
as	O
creatinine	B-Chemical
clearance	O
.	O
Histopathologic	O
evaluation	O
of	O
the	O
kidneys	O
was	O
also	O
performed	O
.	O
After	O
MTX	B-Chemical
administration	O
a	O
significant	O
increase	O
(	O
p	O
=	O
0	O
.	O
0228	O
)	O
in	O
the	O
plasma	O
creatinine	B-Chemical
concentration	O
and	O
a	O
significant	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
decrease	O
in	O
creatinine	B-Chemical
clearance	O
was	O
noted	O
compared	O
to	O
controls	O
.	O
After	O
the	O
administration	O
of	O
NG	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
CY	B-Chemical
neither	O
a	O
statistically	O
significant	O
increase	O
in	O
creatinine	B-Chemical
concentration	O
nor	O
an	O
increase	O
in	O
creatinine	B-Chemical
clearance	O
was	O
observed	O
compared	O
to	O
the	O
group	O
receiving	O
no	O
cytostatics	O
.	O
Following	O
polytherapy	O
according	O
to	O
the	O
CMF	O
regimen	O
,	O
a	O
statistically	O
significant	O
decrease	O
(	O
p	O
=	O
0	O
.	O
0343	O
)	O
in	O
creatinine	B-Chemical
clearance	O
was	O
found	O
,	O
but	O
creatinine	B-Chemical
concentration	O
did	O
not	O
increase	O
significantly	O
compared	O
to	O
controls	O
.	O
CY	B-Chemical
caused	O
hemorrhagic	B-Disease
cystitis	I-Disease
in	O
40	O
%	O
of	O
rats	O
,	O
but	O
it	O
did	O
not	O
cause	O
this	O
complication	O
when	O
combined	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
MTX	B-Chemical
.	O
Histologic	O
changes	O
were	O
found	O
in	O
rat	O
kidneys	O
after	O
administration	O
of	O
MTX	B-Chemical
,	O
CY	B-Chemical
and	O
NG	B-Chemical
,	O
while	O
no	O
such	O
change	O
was	O
observed	O
after	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
joint	O
administration	O
of	O
MTX	B-Chemical
+	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
+	O
CY	B-Chemical
compared	O
to	O
controls	O
.	O
Our	O
studies	O
indicate	O
that	O
nephrotoxicity	B-Disease
of	O
MTX	B-Chemical
+	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
+	O
CY	B-Chemical
administered	O
jointly	O
is	O
lower	O
than	O
in	O
monotherapy	O
.	O
The	O
interpeduncular	O
nucleus	O
regulates	O
nicotine	B-Chemical
'	O
s	O
effects	O
on	O
free	O
-	O
field	O
activity	O
.	O
Partial	O
lesions	O
were	O
made	O
with	O
kainic	B-Chemical
acid	I-Chemical
in	O
the	O
interpeduncular	O
nucleus	O
of	O
the	O
ventral	O
midbrain	O
of	O
the	O
rat	O
.	O
Compared	O
with	O
sham	O
-	O
operated	O
controls	O
,	O
lesions	O
significantly	O
(	O
p	O
<	O
0	O
.	O
25	O
)	O
blunted	O
the	O
early	O
(	O
<	O
60	O
min	O
)	O
free	O
-	O
field	O
locomotor	B-Disease
hypoactivity	I-Disease
caused	O
by	O
nicotine	B-Chemical
(	O
0	O
.	O
5	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
i	O
.	O
m	O
.	O
)	O
,	O
enhanced	O
the	O
later	O
(	O
60	O
-	O
120	O
min	O
)	O
nicotine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
,	O
and	O
raised	O
spontaneous	O
nocturnal	O
activity	O
.	O
Lesions	O
reduced	O
the	O
extent	O
of	O
immunohistological	O
staining	O
for	O
choline	B-Chemical
acetyltransferase	O
in	O
the	O
interpeduncular	O
nucleus	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
,	O
but	O
not	O
for	O
tyrosine	B-Chemical
hydroxylase	O
in	O
the	O
surrounding	O
catecholaminergic	O
A10	O
region	O
.	O
We	O
conclude	O
that	O
the	O
interpeduncular	O
nucleus	O
mediates	O
nicotinic	O
depression	B-Disease
of	O
locomotor	O
activity	O
and	O
dampens	O
nicotinic	O
arousal	O
mechanisms	O
located	O
elsewhere	O
in	O
the	O
brain	O
.	O
Lithium	B-Chemical
-	O
associated	O
cognitive	B-Disease
and	I-Disease
functional	I-Disease
deficits	I-Disease
reduced	O
by	O
a	O
switch	O
to	O
divalproex	B-Chemical
sodium	I-Chemical
:	O
a	O
case	O
series	O
.	O
BACKGROUND	O
:	O
Lithium	B-Chemical
remains	O
a	O
first	O
-	O
line	O
treatment	O
for	O
the	O
acute	O
and	O
maintenance	O
treatment	O
of	O
bipolar	B-Disease
disorder	I-Disease
.	O
Although	O
much	O
has	O
been	O
written	O
about	O
the	O
management	O
of	O
the	O
more	O
common	O
adverse	O
effects	O
of	O
lithium	B-Chemical
,	O
such	O
as	O
polyuria	B-Disease
and	O
tremor	B-Disease
,	O
more	O
subtle	O
lithium	B-Chemical
side	O
effects	O
such	O
as	O
cognitive	B-Disease
deficits	I-Disease
,	O
loss	B-Disease
of	I-Disease
creativity	I-Disease
,	O
and	O
functional	B-Disease
impairments	I-Disease
remain	O
understudied	O
.	O
This	O
report	O
summarizes	O
our	O
experience	O
in	O
switching	O
bipolar	B-Disease
patients	O
from	O
lithium	B-Chemical
to	O
divalproex	B-Chemical
sodium	I-Chemical
to	O
alleviate	O
such	O
cognitive	B-Disease
and	I-Disease
functional	I-Disease
impairments	I-Disease
.	O
METHOD	O
:	O
Open	O
,	O
case	O
series	O
design	O
.	O
RESULTS	O
:	O
We	O
report	O
seven	O
cases	O
where	O
substitution	O
of	O
lithium	B-Chemical
,	O
either	O
fully	O
or	O
partially	O
,	O
with	O
divalproex	B-Chemical
sodium	I-Chemical
was	O
extremely	O
helpful	O
in	O
reducing	O
the	O
cognitive	B-Disease
,	I-Disease
motivational	I-Disease
,	I-Disease
or	I-Disease
creative	I-Disease
deficits	I-Disease
attributed	O
to	O
lithium	B-Chemical
in	O
our	O
bipolar	B-Disease
patients	O
.	O
CONCLUSION	O
:	O
In	O
this	O
preliminary	O
report	O
,	O
divalproex	B-Chemical
sodium	I-Chemical
was	O
a	O
superior	O
alternative	O
to	O
lithium	B-Chemical
in	O
bipolar	B-Disease
patients	O
experiencing	O
cognitive	B-Disease
deficits	I-Disease
,	O
loss	B-Disease
of	I-Disease
creativity	I-Disease
,	O
and	O
functional	B-Disease
impairments	I-Disease
.	O
Effect	O
of	O
nifedipine	B-Chemical
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
receiving	O
tacrolimus	B-Chemical
.	O
The	O
effect	O
of	O
nifedipine	B-Chemical
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
who	O
were	O
receiving	O
tacrolimus	B-Chemical
was	O
evaluated	O
between	O
January	O
1992	O
and	O
January	O
1996	O
.	O
Two	O
groups	O
of	O
patients	O
receiving	O
tacrolimus	B-Chemical
were	O
compared	O
over	O
a	O
period	O
of	O
1	O
year	O
,	O
one	O
group	O
comprising	O
hypertensive	B-Disease
patients	O
who	O
were	O
receiving	O
nifedipine	B-Chemical
,	O
and	O
the	O
other	O
comprising	O
nonhypertensive	O
patients	O
not	O
receiving	O
nifedipine	B-Chemical
.	O
The	O
time	O
from	O
transplant	O
to	O
baseline	O
was	O
similar	O
in	O
all	O
patients	O
.	O
Nifedipine	B-Chemical
significantly	O
improved	O
kidney	O
function	O
as	O
indicated	O
by	O
a	O
significant	O
lowering	O
of	O
serum	O
creatinine	B-Chemical
levels	O
at	O
6	O
and	O
12	O
months	O
.	O
The	O
observed	O
positive	O
impact	O
of	O
nifedipine	B-Chemical
on	O
reducing	O
the	O
nephrotoxicity	B-Disease
associated	O
with	O
tacrolimus	B-Chemical
in	O
liver	O
transplant	O
recipients	O
should	O
be	O
an	O
important	O
factor	O
in	O
selecting	O
an	O
agent	O
to	O
treat	O
hypertension	B-Disease
in	O
this	O
population	O
.	O
Alpha	O
and	O
beta	O
coma	B-Disease
in	O
drug	O
intoxication	O
uncomplicated	O
by	O
cerebral	B-Disease
hypoxia	I-Disease
.	O
Four	O
patients	O
who	O
were	O
rendered	O
comatose	B-Disease
or	O
stuporous	B-Disease
by	O
drug	O
intoxication	O
,	O
but	O
who	O
were	O
not	O
hypoxic	O
,	O
are	O
described	O
.	O
Three	O
patients	O
received	O
high	O
doses	O
of	O
chlormethiazole	B-Chemical
for	O
alcohol	B-Chemical
withdrawal	B-Disease
symptoms	I-Disease
,	O
and	O
one	O
took	O
a	O
suicidal	O
overdose	B-Disease
of	O
nitrazepam	B-Chemical
.	O
The	O
patient	O
with	O
nitrazepam	B-Chemical
overdose	B-Disease
and	O
two	O
of	O
those	O
with	O
chlormethiazole	B-Chemical
intoxication	O
conformed	O
to	O
the	O
criteria	O
of	O
'	O
alpha	O
coma	B-Disease
'	O
,	O
showing	O
non	O
-	O
reactive	O
generalized	O
or	O
frontally	O
predominant	O
alpha	O
activity	O
in	O
the	O
EEG	O
.	O
The	O
fourth	O
patient	O
who	O
was	O
unconscious	O
after	O
chlormethiazole	B-Chemical
administration	O
exhibite	O
generalized	O
non	O
-	O
reactive	O
activity	O
in	O
the	O
slow	O
beta	O
range	O
.	O
All	O
four	O
recovered	O
completely	O
without	O
neurological	B-Disease
sequelae	I-Disease
following	O
the	O
withdrawal	O
of	O
the	O
offending	O
agents	O
.	O
The	O
similarities	O
between	O
the	O
effects	O
of	O
structural	O
lesions	O
and	O
pharmacological	O
depression	B-Disease
of	O
the	O
brain	O
stem	O
reticular	O
formation	O
are	O
discussed	O
.	O
It	O
is	O
suggested	O
that	O
in	O
both	O
situations	O
disturbed	O
reticulo	O
-	O
thalamic	O
interactions	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
alpha	O
coma	B-Disease
.	O
It	O
is	O
concluded	O
that	O
when	O
this	O
electroencephalographic	O
and	O
behavioural	O
picture	O
is	O
seen	O
in	O
drug	O
intoxication	O
,	O
in	O
the	O
absence	O
of	O
significant	O
hypoxaemia	B-Disease
,	O
a	O
favourable	O
outcome	O
may	O
be	O
anticipated	O
.	O
Magnetic	O
resonance	O
volumetry	O
of	O
the	O
cerebellum	O
in	O
epileptic	B-Disease
patients	O
after	O
phenytoin	B-Chemical
overdosages	B-Disease
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
between	O
phenytoin	B-Chemical
medication	O
and	O
cerebellar	B-Disease
atrophy	I-Disease
in	O
patients	O
who	O
had	O
experienced	O
clinical	O
intoxication	O
.	O
Five	O
females	O
and	O
6	O
males	O
,	O
21	O
-	O
59	O
years	O
of	O
age	O
,	O
were	O
examined	O
with	O
a	O
1	O
.	O
5	O
-	O
T	O
whole	O
-	O
body	O
system	O
using	O
a	O
circular	O
polarized	O
head	O
coil	O
.	O
Conventional	O
spin	O
echo	O
images	O
were	O
acquired	O
in	O
the	O
sagittal	O
and	O
transverse	O
orientation	O
.	O
In	O
addition	O
,	O
we	O
performed	O
a	O
high	O
-	O
resolution	O
3D	O
gradient	O
echo	O
,	O
T1	O
-	O
weighted	O
sequences	O
at	O
a	O
1	O
-	O
mm	O
slice	O
thickness	O
.	O
The	O
images	O
were	O
subsequently	O
processed	O
to	O
obtain	O
volumetric	O
data	O
for	O
the	O
cerebellum	O
.	O
Cerebellar	O
volume	O
for	O
the	O
patient	O
group	O
ranged	O
between	O
67	O
.	O
66	O
and	O
131	O
.	O
08	O
ml	O
(	O
mean	O
108	O
.	O
9	O
ml	O
)	O
.	O
In	O
addition	O
3D	O
gradient	O
echo	O
data	O
sets	O
from	O
10	O
healthy	O
male	O
and	O
10	O
healthy	O
female	O
age	O
-	O
matched	O
volunteers	O
were	O
used	O
to	O
compare	O
cerebellar	O
volumes	O
.	O
Using	O
linear	O
regression	O
we	O
found	O
that	O
no	O
correlation	O
exists	O
between	O
seizure	B-Disease
duration	O
,	O
elevation	O
of	O
phenytoin	B-Chemical
serum	O
levels	O
and	O
cerebellar	O
volume	O
.	O
However	O
,	O
multiple	O
regression	O
for	O
the	O
daily	O
dosage	O
,	O
duration	O
of	O
phenytoin	B-Chemical
treatment	O
and	O
cerebellar	O
volume	O
revealed	O
a	O
correlation	O
of	O
these	O
parameters	O
.	O
We	O
conclude	O
that	O
phenytoin	B-Chemical
overdosage	B-Disease
does	O
not	O
necessarily	O
result	O
in	O
cerebellar	B-Disease
atrophy	I-Disease
and	O
it	O
is	O
unlikely	O
that	O
phenytoin	B-Chemical
medication	O
was	O
the	O
only	O
cause	O
of	O
cerebellar	B-Disease
atrophy	I-Disease
in	O
the	O
remaining	O
patients	O
.	O
Quantitative	O
morphometric	O
studies	O
of	O
the	O
cerebellum	O
provide	O
valuable	O
insights	O
into	O
the	O
pathogenesis	O
of	O
cerebellar	B-Disease
disorders	I-Disease
.	O
Late	O
recovery	O
of	O
renal	O
function	O
in	O
a	O
woman	O
with	O
the	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
.	O
A	O
case	O
is	O
reported	O
of	O
the	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
(	O
HUS	B-Disease
)	O
in	O
a	O
woman	O
taking	O
oral	B-Chemical
contraceptives	I-Chemical
.	O
She	O
was	O
treated	O
with	O
heparin	B-Chemical
,	O
dipyridamole	B-Chemical
and	O
hemodialysis	O
;	O
and	O
after	O
more	O
than	O
three	O
months	O
,	O
her	O
urinary	O
output	O
rose	O
above	O
500	O
ml	O
;	O
and	O
six	O
months	O
after	O
the	O
onset	O
of	O
anuria	B-Disease
,	O
dialysis	O
treatment	O
was	O
stopped	O
.	O
This	O
case	O
emphasizes	O
the	O
possibility	O
that	O
HUS	B-Disease
in	O
adults	O
is	O
not	O
invariably	O
irreversible	O
and	O
that	O
,	O
despite	O
prolonged	O
oliguria	B-Disease
,	O
recovery	O
of	O
renal	O
function	O
can	O
be	O
obtained	O
.	O
Therefore	O
,	O
in	O
adult	O
patients	O
affected	O
by	O
HUS	B-Disease
,	O
dialysis	O
should	O
not	O
be	O
discontinued	O
prematurely	O
;	O
moreover	O
,	O
bilateral	O
nephrectomy	O
,	O
for	O
treatment	O
of	O
severe	O
hypertension	B-Disease
and	O
microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
should	O
be	O
performed	O
with	O
caution	O
.	O
Morphological	O
features	O
of	O
encephalopathy	B-Disease
after	O
chronic	O
administration	O
of	O
the	O
antiepileptic	O
drug	O
valproate	B-Chemical
to	O
rats	O
.	O
A	O
transmission	O
electron	O
microscopic	O
study	O
of	O
capillaries	O
in	O
the	O
cerebellar	O
cortex	O
.	O
Long	O
-	O
term	O
intragastric	O
application	O
of	O
the	O
antiepileptic	O
drug	O
sodium	B-Chemical
valproate	I-Chemical
(	O
Vupral	O
""""	O
Polfa	O
""""	O
)	O
at	O
the	O
effective	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
once	O
daily	O
to	O
rats	O
for	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
revealed	O
neurological	B-Disease
disorders	I-Disease
indicating	O
cerebellum	B-Disease
damage	I-Disease
(	O
""""	O
valproate	B-Chemical
encephalopathy	B-Disease
""""	O
)	O
.	O
The	O
first	O
ultrastructural	O
changes	O
in	O
structural	O
elements	O
of	O
the	O
blood	O
-	O
brain	O
-	O
barrier	O
(	O
BBB	O
)	O
in	O
the	O
cerebellar	O
cortex	O
were	O
detectable	O
after	O
3	O
months	O
of	O
the	O
experiment	O
.	O
They	O
became	O
more	O
severe	O
in	O
the	O
later	O
months	O
of	O
the	O
experiment	O
,	O
and	O
were	O
most	O
severe	O
after	O
12	O
months	O
,	O
located	O
mainly	O
in	O
the	O
molecular	O
layer	O
of	O
the	O
cerebellar	O
cortex	O
.	O
Lesions	O
of	O
the	O
capillary	O
included	O
necrosis	B-Disease
of	O
endothelial	O
cells	O
.	O
Organelles	O
of	O
these	O
cells	O
,	O
in	O
particular	O
the	O
mitochondria	O
(	O
increased	O
number	O
and	O
size	O
,	O
distinct	O
degeneration	O
of	O
their	O
matrix	O
and	O
cristae	O
)	O
and	O
Golgi	O
apparatus	O
were	O
altered	O
.	O
Reduced	O
size	O
of	O
capillary	O
lumen	O
and	O
occlusion	O
were	O
caused	O
by	O
swollen	O
endothelial	O
cells	O
which	O
had	O
luminal	B-Chemical
protrusions	O
and	O
swollen	O
microvilli	O
.	O
Pressure	O
on	O
the	O
vessel	O
wall	O
was	O
produced	O
by	O
enlarged	O
perivascular	O
astrocytic	O
processes	O
.	O
Fragments	O
of	O
necrotic	B-Disease
endothelial	O
cells	O
were	O
in	O
the	O
vascular	O
lumens	O
and	O
in	O
these	O
there	O
was	O
loosening	O
and	O
breaking	O
of	O
tight	O
cellular	O
junctions	O
.	O
Damage	O
to	O
the	O
vascular	O
basement	O
lamina	O
was	O
also	O
observed	O
.	O
Damage	O
to	O
the	O
capillary	O
was	O
accompanied	O
by	O
marked	O
damage	O
to	O
neuroglial	O
cells	O
,	O
mainly	O
to	O
perivascular	O
processes	O
of	O
astrocytes	O
.	O
The	O
proliferation	O
of	O
astrocytes	O
(	O
Bergmann	O
'	O
s	O
in	O
particular	O
)	O
and	O
occasionally	O
of	O
oligodendrocytes	O
was	O
found	O
.	O
Alterations	O
in	O
the	O
structural	O
elements	O
of	O
the	O
BBB	O
coexisted	O
with	O
marked	O
lesions	O
of	O
neurons	O
of	O
the	O
cerebellum	O
(	O
Purkinje	O
cells	O
are	O
earliest	O
)	O
.	O
In	O
electron	O
micrographs	O
both	O
luminal	B-Chemical
and	O
antiluminal	O
sides	O
of	O
the	O
BBB	O
of	O
the	O
cerebellar	O
cortex	O
had	O
similar	O
lesions	O
.	O
The	O
possible	O
influence	O
of	O
the	O
hepatic	B-Disease
damage	I-Disease
,	O
mainly	O
hyperammonemia	B-Disease
,	O
upon	O
the	O
development	O
of	O
valproate	B-Chemical
encephalopathy	B-Disease
is	O
discussed	O
.	O
Fatal	O
intracranial	B-Disease
bleeding	I-Disease
associated	O
with	O
prehospital	O
use	O
of	O
epinephrine	B-Chemical
.	O
We	O
present	O
a	O
case	O
of	O
paramedic	O
misjudgment	O
in	O
the	O
execution	O
of	O
a	O
protocol	O
for	O
the	O
treatment	O
of	O
allergic	B-Disease
reaction	I-Disease
in	O
a	O
case	O
of	O
pulmonary	B-Disease
edema	I-Disease
with	O
wheezing	B-Disease
.	O
The	O
sudden	O
onset	O
of	O
respiratory	B-Disease
distress	I-Disease
,	O
rash	B-Disease
,	O
and	O
a	O
history	O
of	O
a	O
new	O
medicine	O
led	O
the	O
two	O
paramedics	O
on	O
the	O
scene	O
to	O
administer	O
subcutaneous	O
epinephrine	B-Chemical
.	O
Subsequently	O
,	O
acute	O
cardiac	B-Disease
arrest	I-Disease
and	O
fatal	O
subarachnoid	B-Disease
hemorrhage	I-Disease
occurred	O
.	O
Epinephrine	B-Chemical
has	O
a	O
proven	O
role	O
in	O
cardiac	B-Disease
arrest	I-Disease
in	O
prehospital	O
care	O
;	O
however	O
,	O
use	O
by	O
paramedics	O
in	O
patients	O
with	O
suspected	O
allergic	B-Disease
reaction	I-Disease
and	O
severe	O
hypertension	B-Disease
should	O
be	O
viewed	O
with	O
caution	O
.	O
Role	O
of	O
activation	O
of	O
bradykinin	B-Chemical
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
.	O
Cellular	O
mechanisms	O
which	O
account	O
for	O
disruption	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
are	O
not	O
clear	O
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
synthesis	O
/	O
release	O
of	O
bradykinin	B-Chemical
to	O
activate	O
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
.	O
Permeability	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
was	O
quantitated	O
by	O
clearance	O
of	O
fluorescent	O
-	O
labeled	O
dextran	B-Chemical
before	O
and	O
during	O
phenylephrine	B-Chemical
-	O
induced	O
acute	O
hypertension	B-Disease
in	O
rats	O
treated	O
with	O
vehicle	O
and	O
Hoe	B-Chemical
-	I-Chemical
140	I-Chemical
(	O
0	O
.	O
1	O
microM	O
)	O
.	O
Phenylephrine	B-Chemical
infusion	O
increased	O
arterial	O
pressure	O
,	O
arteriolar	O
diameter	O
and	O
clearance	O
of	O
fluorescent	O
dextran	B-Chemical
by	O
a	O
similar	O
magnitude	O
in	O
both	O
groups	O
.	O
These	O
findings	O
suggest	O
that	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
is	O
not	O
related	O
to	O
the	O
synthesis	O
/	O
release	O
of	O
bradykinin	B-Chemical
to	O
activate	O
B2	O
receptors	O
.	O
Risk	O
factors	O
of	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
in	O
preterm	O
infants	O
.	O
Among	O
547	O
preterm	O
infants	O
of	O
<	O
or	O
=	O
34	O
weeks	O
gestation	O
born	O
between	O
1987	O
and	O
1991	O
,	O
8	O
children	O
(	O
1	O
.	O
46	O
%	O
)	O
developed	O
severe	O
progressive	O
and	O
bilateral	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O
Perinatal	O
risk	O
factors	O
of	O
infants	O
with	O
hearing	B-Disease
loss	I-Disease
were	O
compared	O
with	O
those	O
of	O
two	O
control	O
groups	O
matched	O
for	O
gestation	O
and	O
birth	O
weight	O
and	O
for	O
perinatal	O
complications	O
.	O
Our	O
observations	O
demonstrated	O
an	O
association	O
of	O
hearing	B-Disease
loss	I-Disease
with	O
a	O
higher	O
incidence	O
of	O
perinatal	O
complications	O
.	O
Ototoxicity	B-Disease
appeared	O
closely	O
related	O
to	O
a	O
prolonged	O
administration	O
and	O
higher	O
total	O
dose	O
of	O
ototoxic	B-Disease
drugs	O
,	O
particularly	O
aminoglycosides	B-Chemical
and	O
furosemide	B-Chemical
.	O
Finally	O
,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
audiologic	O
assessment	O
in	O
sick	O
preterm	O
children	O
as	O
hearing	B-Disease
loss	I-Disease
is	O
of	O
delayed	O
onset	O
and	O
in	O
most	O
cases	O
bilateral	O
and	O
severe	O
.	O
Seizure	B-Disease
resulting	O
from	O
a	O
venlafaxine	B-Chemical
overdose	B-Disease
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
venlafaxine	B-Chemical
overdose	B-Disease
.	O
CASE	O
SUMMARY	O
:	O
A	O
40	O
-	O
year	O
-	O
old	O
woman	O
with	O
major	B-Disease
depression	I-Disease
took	O
an	O
overdose	B-Disease
of	O
venlafaxine	B-Chemical
in	O
an	O
apparent	O
suicide	O
attempt	O
.	O
After	O
the	O
ingestion	O
of	O
26	O
venlafaxine	B-Chemical
50	O
-	O
mg	O
tablets	O
,	O
the	O
patient	O
experienced	O
a	O
witnessed	O
generalized	O
seizure	B-Disease
.	O
She	O
was	O
admitted	O
to	O
the	O
medical	O
intensive	O
care	O
unit	O
,	O
venlafaxine	B-Chemical
was	O
discontinued	O
,	O
and	O
no	O
further	O
sequelae	O
were	O
seen	O
.	O
DISCUSSION	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
venlafaxine	B-Chemical
overdose	B-Disease
that	O
resulted	O
in	O
a	O
generalized	O
seizure	B-Disease
.	O
Based	O
on	O
nonoverdose	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
venlafaxine	B-Chemical
and	O
the	O
potential	O
risks	O
of	O
available	O
interventions	O
,	O
no	O
emergent	O
therapy	O
was	O
instituted	O
.	O
CONCLUSIONS	O
:	O
The	O
venlafaxine	B-Chemical
overdose	B-Disease
in	O
our	O
patient	O
resulted	O
in	O
a	O
single	O
episode	O
of	O
generalized	O
seizure	B-Disease
but	O
elicited	O
no	O
further	O
sequelae	O
.	O
Combined	O
effects	O
of	O
prolonged	O
prostaglandin	B-Chemical
E1	I-Chemical
-	O
induced	O
hypotension	B-Disease
and	O
haemodilution	B-Disease
on	O
human	O
hepatic	O
function	O
.	O
Combined	O
effects	O
of	O
prolonged	O
prostaglandin	B-Chemical
E1	I-Chemical
(	O
PGE1	B-Chemical
)	O
-	O
induced	O
hypotension	B-Disease
and	O
haemodilution	B-Disease
on	O
hepatic	O
function	O
were	O
studied	O
in	O
30	O
patients	O
undergoing	O
hip	O
surgery	O
.	O
The	O
patients	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
groups	O
;	O
those	O
in	O
group	O
A	O
(	O
n	O
=	O
10	O
)	O
were	O
subjected	O
to	O
controlled	O
hypotension	B-Disease
alone	O
,	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
10	O
)	O
to	O
haemodilution	B-Disease
alone	O
and	O
those	O
in	O
group	O
C	O
(	O
n	O
=	O
10	O
)	O
to	O
both	O
controlled	O
hypotension	B-Disease
and	O
haemodilution	B-Disease
.	O
Haemodilution	B-Disease
in	O
groups	O
B	O
and	O
C	O
was	O
produced	O
by	O
withdrawing	O
approximately	O
1000	O
mL	O
of	O
blood	O
and	O
replacing	O
it	O
with	O
the	O
same	O
amount	O
of	O
dextran	B-Chemical
solution	O
,	O
and	O
final	O
haematocrit	O
values	O
were	O
21	O
or	O
22	O
%	O
.	O
Controlled	O
hypotension	B-Disease
in	O
groups	O
A	O
and	O
C	O
was	O
induced	O
with	O
PGE1	B-Chemical
to	O
maintain	O
mean	O
arterial	O
blood	O
pressure	O
at	O
55	O
mmHg	O
for	O
180	O
min	O
.	O
Measurements	O
included	O
arterial	O
ketone	O
body	O
ratio	O
(	O
AKBR	O
,	O
aceto	B-Chemical
-	I-Chemical
acetate	I-Chemical
/	O
3	B-Chemical
-	I-Chemical
hydroxybutyrate	I-Chemical
)	O
and	O
clinical	O
hepatic	O
function	O
parameters	O
.	O
AKBR	O
and	O
biological	O
hepatic	O
function	O
tests	O
showed	O
no	O
change	O
throughout	O
the	O
time	O
course	O
in	O
groups	O
A	O
and	O
B	O
.	O
In	O
group	O
C	O
,	O
AKBR	O
showed	O
a	O
significant	O
decrease	O
at	O
120	O
min	O
(	O
-	O
40	O
%	O
)	O
and	O
at	O
180	O
min	O
(	O
-	O
49	O
%	O
)	O
after	O
the	O
start	O
of	O
hypotension	B-Disease
and	O
at	O
60	O
min	O
(	O
-	O
32	O
%	O
)	O
after	O
recovery	O
of	O
normotension	O
,	O
and	O
SGOT	O
,	O
SGPT	O
,	O
LDH	O
and	O
total	O
bilirubin	B-Chemical
showed	O
significant	O
increases	O
after	O
operation	O
.	O
The	O
results	O
suggest	O
that	O
a	O
prolonged	O
combination	O
of	O
more	O
than	O
120	O
min	O
of	O
PGE1	B-Chemical
-	O
induced	O
hypotension	B-Disease
and	O
moderate	O
haemodilution	B-Disease
would	O
cause	O
impairment	B-Disease
of	I-Disease
hepatic	I-Disease
function	I-Disease
.	O
Cardiovascular	B-Disease
alterations	I-Disease
in	O
rat	O
fetuses	O
exposed	O
to	O
calcium	B-Chemical
channel	O
blockers	O
.	O
Preclinical	O
toxicologic	O
investigation	O
suggested	O
that	O
a	O
new	O
calcium	B-Chemical
channel	O
blocker	O
,	O
Ro	B-Chemical
40	I-Chemical
-	I-Chemical
5967	I-Chemical
,	O
induced	O
cardiovascular	B-Disease
alterations	I-Disease
in	O
rat	O
fetuses	O
exposed	O
to	O
this	O
agent	O
during	O
organogenesis	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
hypothesis	O
that	O
calcium	B-Chemical
channel	O
blockers	O
in	O
general	O
induce	O
cardiovascular	B-Disease
malformations	I-Disease
indicating	O
a	O
pharmacologic	O
class	O
effect	O
.	O
We	O
studied	O
three	O
calcium	B-Chemical
channel	O
blockers	O
of	O
different	O
structure	O
,	O
nifedipine	B-Chemical
,	O
diltiazem	B-Chemical
,	O
and	O
verapamil	B-Chemical
,	O
along	O
with	O
the	O
new	O
agent	O
.	O
Pregnant	O
rats	O
were	O
administered	O
one	O
of	O
these	O
calcium	B-Chemical
channel	O
blockers	O
during	O
the	O
period	O
of	O
cardiac	O
morphogenesis	O
and	O
the	O
offspring	O
examined	O
on	O
day	O
20	O
of	O
gestation	O
for	O
cardiovascular	B-Disease
malformations	I-Disease
.	O
A	O
low	O
incidence	O
of	O
cardiovascular	B-Disease
malformations	I-Disease
was	O
observed	O
after	O
exposure	O
to	O
each	O
of	O
the	O
four	O
calcium	B-Chemical
channel	O
blockers	O
,	O
but	O
this	O
incidence	O
was	O
statistically	O
significant	O
only	O
for	O
verapamil	B-Chemical
and	O
nifedipine	B-Chemical
.	O
All	O
four	O
agents	O
were	O
associated	O
with	O
aortic	O
arch	O
branching	O
variants	O
,	O
although	O
significantly	O
increased	O
only	O
for	O
Ro	B-Chemical
40	I-Chemical
-	I-Chemical
5967	I-Chemical
and	O
verapamil	B-Chemical
.	O
The	O
site	O
of	O
common	O
side	O
effects	O
of	O
sumatriptan	B-Chemical
.	O
Atypical	B-Disease
sensations	I-Disease
following	O
the	O
use	O
of	O
subcutaneous	O
sumatriptan	B-Chemical
are	O
common	O
,	O
but	O
of	O
uncertain	O
origin	O
.	O
They	O
are	O
almost	O
always	O
benign	O
,	O
but	O
can	O
be	O
mistaken	O
for	O
a	O
serious	O
adverse	O
event	O
by	O
the	O
patient	O
.	O
Two	O
patients	O
are	O
presented	O
with	O
tingling	B-Disease
or	I-Disease
burning	I-Disease
sensations	I-Disease
limited	O
to	O
areas	O
of	O
heat	O
exposure	O
or	O
sunburn	B-Disease
.	O
In	O
these	O
individuals	O
,	O
side	O
effects	O
are	O
most	O
likely	O
generated	O
superficially	O
in	O
the	O
skin	O
.	O
Macula	O
toxicity	B-Disease
after	O
intravitreal	O
amikacin	B-Chemical
.	O
BACKGROUND	O
:	O
Although	O
intravitreal	O
aminoglycosides	B-Chemical
have	O
substantially	O
improved	O
visual	O
prognosis	O
in	O
endophthalmitis	B-Disease
,	O
macular	O
infarction	B-Disease
may	O
impair	O
full	O
visual	O
recovery	O
.	O
METHODS	O
:	O
We	O
present	O
a	O
case	O
of	O
presumed	O
amikacin	B-Chemical
retinal	B-Disease
toxicity	I-Disease
following	O
treatment	O
with	O
amikacin	B-Chemical
and	O
vancomycin	B-Chemical
for	O
alpha	O
-	O
haemolytic	O
streptococcal	B-Disease
endophthalmitis	I-Disease
.	O
RESULTS	O
:	O
Endophthalmitis	B-Disease
resolved	O
with	O
improvement	O
in	O
visual	O
acuity	O
to	O
6	O
/	O
24	O
at	O
three	O
months	O
.	O
Fundus	O
fluorescein	B-Chemical
angiography	O
confirmed	O
macular	O
capillary	O
closure	O
and	O
telangiectasis	B-Disease
.	O
CONCLUSIONS	O
:	O
Currently	O
accepted	O
intravitreal	O
antibiotic	O
regimens	O
may	O
cause	O
retinal	B-Disease
toxicity	I-Disease
and	O
macular	O
ischaemia	B-Disease
.	O
Treatment	O
strategies	O
aimed	O
at	O
avoiding	O
retinal	B-Disease
toxicity	I-Disease
are	O
discussed	O
.	O
The	O
role	O
of	O
nicotine	B-Chemical
in	O
smoking	O
-	O
related	O
cardiovascular	B-Disease
disease	I-Disease
.	O
Nicotine	B-Chemical
activates	O
the	O
sympathetic	O
nervous	O
system	O
and	O
in	O
this	O
way	O
could	O
contribute	O
to	O
cardiovascular	B-Disease
disease	I-Disease
.	O
Animal	O
studies	O
and	O
mechanistic	O
studies	O
indicate	O
that	O
nicotine	B-Chemical
could	O
play	O
a	O
role	O
in	O
accelerating	O
atherosclerosis	B-Disease
,	O
but	O
evidence	O
among	O
humans	O
is	O
too	O
inadequate	O
to	O
be	O
definitive	O
about	O
such	O
an	O
effect	O
.	O
Almost	O
certainly	O
,	O
nicotine	B-Chemical
via	O
its	O
hemodynamic	O
effects	O
contributes	O
to	O
acute	O
cardiovascular	O
events	O
,	O
although	O
current	O
evidence	O
suggests	O
that	O
the	O
effects	O
of	O
nicotine	B-Chemical
are	O
much	O
less	O
important	O
than	O
are	O
the	O
prothrombotic	O
effects	O
of	O
cigarette	O
smoking	O
or	O
the	O
effects	O
of	O
carbon	B-Chemical
monoxide	I-Chemical
.	O
Nicotine	B-Chemical
does	O
not	O
appear	O
to	O
enhance	O
thrombosis	B-Disease
among	O
humans	O
.	O
Clinical	O
studies	O
of	O
pipe	O
smokers	O
and	O
people	O
using	O
transdermal	O
nicotine	B-Chemical
support	O
the	O
idea	O
that	O
toxins	O
other	O
than	O
nicotine	B-Chemical
are	O
the	O
most	O
important	O
causes	O
of	O
acute	O
cardiovascular	O
events	O
.	O
Finally	O
,	O
the	O
dose	O
response	O
for	O
cardiovascular	O
events	O
of	O
nicotine	B-Chemical
appears	O
to	O
be	O
flat	O
,	O
suggesting	O
that	O
if	O
nicotine	B-Chemical
is	O
involved	O
,	O
adverse	O
effects	O
might	O
be	O
seen	O
with	O
relatively	O
low	O
-	O
level	O
cigarette	O
exposures	O
.	O
Iatrogenically	O
induced	O
intractable	O
atrioventricular	B-Disease
reentrant	I-Disease
tachycardia	I-Disease
after	O
verapamil	B-Chemical
and	O
catheter	O
ablation	O
in	O
a	O
patient	O
with	O
Wolff	B-Disease
-	I-Disease
Parkinson	I-Disease
-	I-Disease
White	I-Disease
syndrome	I-Disease
and	O
idiopathic	B-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
.	O
In	O
a	O
patient	O
with	O
WPW	B-Disease
syndrome	I-Disease
and	O
idiopathic	B-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
,	O
intractable	O
atrioventricular	B-Disease
reentrant	I-Disease
tachycardia	I-Disease
(	O
AVRT	B-Disease
)	O
was	O
iatrogenically	O
induced	O
.	O
QRS	O
without	O
preexcitation	O
,	O
caused	O
by	O
junctional	O
escape	O
beats	O
after	O
verapamil	B-Chemical
or	O
unidirectional	O
antegrade	O
block	O
of	O
accessory	O
pathway	O
after	O
catheter	O
ablation	O
,	O
established	O
frequent	O
AVRT	B-Disease
attack	O
.	O
Epidemic	O
of	O
liver	B-Disease
disease	I-Disease
caused	O
by	O
hydrochlorofluorocarbons	B-Chemical
used	O
as	O
ozone	B-Chemical
-	O
sparing	O
substitutes	O
of	O
chlorofluorocarbons	B-Chemical
.	O
BACKGROUND	O
:	O
Hydrochlorofluorocarbons	B-Chemical
(	O
HCFCs	B-Chemical
)	O
are	O
used	O
increasingly	O
in	O
industry	O
as	O
substitutes	O
for	O
ozone	B-Chemical
-	O
depleting	O
chlorofluorocarbons	B-Chemical
(	O
CFCs	B-Chemical
)	O
.	O
Limited	O
studies	O
in	O
animals	O
indicate	O
potential	O
hepatotoxicity	B-Disease
of	O
some	O
of	O
these	O
compounds	O
.	O
We	O
investigated	O
an	O
epidemic	O
of	O
liver	B-Disease
disease	I-Disease
in	O
nine	O
industrial	O
workers	O
who	O
had	O
had	O
repeated	O
accidental	O
exposure	O
to	O
a	O
mixture	O
of	O
1	B-Chemical
,	I-Chemical
1	I-Chemical
-	I-Chemical
dichloro	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
trifluoroethane	I-Chemical
(	O
HCFC	B-Chemical
123	I-Chemical
)	O
and	O
1	B-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
tetrafluoroethane	I-Chemical
(	O
HCFC	B-Chemical
124	I-Chemical
)	O
.	O
All	O
nine	O
exposed	O
workers	O
were	O
affected	O
to	O
various	O
degrees	O
.	O
Both	O
compounds	O
are	O
metabolised	O
in	O
the	O
same	O
way	O
as	O
1	B-Chemical
-	I-Chemical
bromo	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
trifluoroethane	I-Chemical
(	O
halothane	B-Chemical
)	O
to	O
form	O
reactive	O
trifluoroacetyl	B-Chemical
halide	O
intermediates	O
,	O
which	O
have	O
been	O
implicated	O
in	O
the	O
hepatotoxicity	B-Disease
of	O
halothane	B-Chemical
.	O
We	O
aimed	O
to	O
test	O
whether	O
HCFCs	B-Chemical
123	I-Chemical
and	I-Chemical
124	I-Chemical
can	O
result	O
in	O
serious	O
liver	B-Disease
disease	I-Disease
.	O
METHODS	O
:	O
For	O
one	O
severely	O
affected	O
worker	O
liver	O
biopsy	O
and	O
immunohistochemical	O
stainings	O
for	O
the	O
presence	O
of	O
trifluoroacetyl	B-Chemical
protein	O
adducts	O
were	O
done	O
.	O
The	O
serum	O
of	O
six	O
affected	O
workers	O
and	O
five	O
controls	O
was	O
tested	O
for	O
autoantibodies	O
that	O
react	O
with	O
human	O
liver	O
cytochrome	O
-	O
P450	O
2E1	O
(	O
P450	O
2E1	O
)	O
and	O
P58	O
protein	O
disulphide	O
isomerase	O
isoform	O
(	O
P58	O
)	O
.	O
FINDINGS	O
:	O
The	O
liver	O
biopsy	O
sample	O
showed	O
hepatocellular	O
necrosis	B-Disease
which	O
was	O
prominent	O
in	O
perivenular	O
zone	O
three	O
and	O
extended	O
focally	O
from	O
portal	O
tracts	O
to	O
portal	O
tracts	O
and	O
centrilobular	O
areas	O
(	O
bridging	O
necrosis	B-Disease
)	O
.	O
Trifluoroacetyl	B-Chemical
-	O
adducted	O
proteins	O
were	O
detected	O
in	O
surviving	O
hepatocytes	O
.	O
Autoantibodies	O
against	O
P450	O
2E1	O
or	O
P58	O
,	O
previously	O
associated	O
with	O
halothane	B-Disease
hepatitis	I-Disease
,	O
were	O
detected	O
in	O
the	O
serum	O
of	O
five	O
affected	O
workers	O
.	O
INTERPRETATION	O
:	O
Repeated	O
exposure	O
of	O
human	O
beings	O
to	O
HCFCs	B-Chemical
123	I-Chemical
and	I-Chemical
124	I-Chemical
can	O
result	O
in	O
serious	O
liver	B-Disease
injury	I-Disease
in	O
a	O
large	O
proportion	O
of	O
the	O
exposed	O
population	O
.	O
Although	O
the	O
exact	O
mechanism	O
of	O
hepatotoxicity	B-Disease
of	O
these	O
agents	O
is	O
not	O
known	O
,	O
the	O
results	O
suggest	O
that	O
trifluoroacetyl	B-Chemical
-	O
altered	O
liver	O
proteins	O
are	O
involved	O
.	O
In	O
view	O
of	O
the	O
potentially	O
widespread	O
use	O
of	O
these	O
compounds	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
safer	O
alternatives	O
.	O
Bile	B-Disease
duct	I-Disease
hamartoma	I-Disease
occurring	O
in	O
association	O
with	O
long	O
-	O
term	O
treatment	O
with	O
danazol	B-Chemical
.	O
We	O
report	O
a	O
case	O
of	O
bile	B-Disease
duct	I-Disease
hamartoma	I-Disease
which	O
developed	O
in	O
a	O
patient	O
who	O
had	O
been	O
on	O
long	O
-	O
term	O
danazol	B-Chemical
treatment	O
.	O
Such	O
patients	O
should	O
be	O
under	O
close	O
follow	O
-	O
up	O
,	O
preferably	O
with	O
periodic	O
ultrasound	O
examination	O
of	O
the	O
liver	O
.	O
If	O
the	O
patient	O
develops	O
a	O
liver	B-Disease
mass	I-Disease
,	O
because	O
of	O
non	O
-	O
specific	O
clinical	O
features	O
and	O
imaging	O
appearances	O
,	O
biopsy	O
may	O
be	O
the	O
only	O
way	O
to	O
achieve	O
a	O
definitive	O
diagnosis	O
.	O
Endocrine	O
screening	O
in	O
1	O
,	O
022	O
men	O
with	O
erectile	B-Disease
dysfunction	I-Disease
:	O
clinical	O
significance	O
and	O
cost	O
-	O
effective	O
strategy	O
.	O
PURPOSE	O
:	O
We	O
reviewed	O
the	O
results	O
of	O
serum	O
testosterone	B-Chemical
and	O
prolactin	O
determination	O
in	O
1	O
,	O
022	O
patients	O
referred	O
because	O
of	O
erectile	B-Disease
dysfunction	I-Disease
and	O
compared	O
the	O
data	O
with	O
history	O
,	O
results	O
of	O
physical	O
examination	O
,	O
other	O
etiological	O
investigations	O
and	O
effects	O
of	O
endocrine	O
therapy	O
to	O
refine	O
the	O
rules	O
of	O
cost	O
-	O
effective	O
endocrine	O
screening	O
and	O
to	O
pinpoint	O
actual	O
responsibility	O
for	O
hormonal	O
abnormalities	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Testosterone	B-Chemical
and	O
prolactin	O
were	O
determined	O
by	O
radioimmunoassay	O
.	O
Every	O
patient	O
was	O
screened	O
for	O
testosterone	B-Chemical
and	O
451	O
were	O
screened	O
for	O
prolactin	O
on	O
the	O
basis	O
of	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
,	O
gynecomastia	B-Disease
or	O
testosterone	B-Chemical
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O
Determination	O
was	O
repeated	O
in	O
case	O
of	O
abnormal	O
first	O
results	O
.	O
Prolactin	O
results	O
were	O
compared	O
with	O
those	O
of	O
a	O
previous	O
personal	O
cohort	O
of	O
1	O
,	O
340	O
patients	O
with	O
erectile	B-Disease
dysfunction	I-Disease
and	O
systematic	O
prolactin	O
determination	O
.	O
Main	O
clinical	O
criteria	O
tested	O
regarding	O
efficiency	O
in	O
hormone	O
determination	O
were	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
,	O
small	O
testes	O
and	O
gynecomastia	B-Disease
.	O
Endocrine	O
therapy	O
consisted	O
of	O
testosterone	B-Chemical
heptylate	I-Chemical
or	O
human	O
chorionic	O
gonadotropin	O
for	O
hypogonadism	B-Disease
and	O
bromocriptine	B-Chemical
for	O
hyperprolactinemia	B-Disease
.	O
RESULTS	O
:	O
Testosterone	B-Chemical
was	O
less	O
than	O
3	O
ng	O
.	O
/	O
ml	O
.	O
in	O
107	O
patients	O
but	O
normal	O
in	O
40	O
%	O
at	O
repeat	O
determination	O
.	O
The	O
prevalence	O
of	O
repeatedly	O
low	O
testosterone	B-Chemical
increased	O
with	O
age	O
(	O
4	O
%	O
before	O
age	O
50	O
years	O
and	O
9	O
%	O
50	O
years	O
or	O
older	O
)	O
.	O
Two	O
pituitary	B-Disease
tumors	I-Disease
were	O
discovered	O
after	O
testosterone	B-Chemical
determination	O
.	O
Most	O
of	O
the	O
other	O
low	O
testosterone	B-Chemical
levels	O
seemed	O
to	O
result	O
from	O
nonorganic	O
hypothalamic	B-Disease
dysfunction	I-Disease
because	O
of	O
normal	O
serum	O
luteinizing	O
hormone	O
and	O
prolactin	O
and	O
to	O
have	O
only	O
a	O
small	O
role	O
in	O
erectile	B-Disease
dysfunction	I-Disease
(	O
definite	O
improvement	O
in	O
only	O
16	O
of	O
44	O
[	O
36	O
%	O
]	O
after	O
androgen	O
therapy	O
,	O
normal	O
morning	O
or	O
nocturnal	O
erections	O
in	O
30	O
%	O
and	O
definite	O
vasculogenic	O
contributions	O
in	O
42	O
%	O
)	O
.	O
Determining	O
testosterone	B-Chemical
only	O
in	O
cases	O
of	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
or	O
abnormal	O
physical	O
examination	O
would	O
have	O
missed	O
40	O
%	O
of	O
the	O
cases	O
with	O
low	O
testosterone	B-Chemical
,	O
including	O
37	O
%	O
of	O
those	O
subsequently	O
improved	O
by	O
androgen	O
therapy	O
.	O
Prolactin	O
exceeded	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
5	O
men	O
and	O
was	O
normal	O
in	O
2	O
at	O
repeat	O
determination	O
.	O
Only	O
1	O
prolactinoma	B-Disease
was	O
discovered	O
.	O
These	O
data	O
are	O
lower	O
than	O
those	O
we	O
found	O
during	O
the	O
last	O
2	O
decades	O
(	O
overall	O
prolactin	O
greater	O
than	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
1	O
.	O
86	O
%	O
of	O
1	O
,	O
821	O
patients	O
,	O
prolactinomas	B-Disease
in	O
7	O
,	O
0	O
.	O
38	O
%	O
)	O
.	O
Bromocriptine	B-Chemical
was	O
definitely	O
effective	O
in	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O
(	O
8	O
of	O
12	O
compared	O
to	O
only	O
9	O
of	O
22	O
cases	O
with	O
prolactin	O
between	O
20	O
and	O
35	O
ng	O
.	O
/	O
ml	O
.	O
)	O
.	O
Testosterone	B-Chemical
was	O
low	O
in	O
less	O
than	O
50	O
%	O
of	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O
CONCLUSIONS	O
:	O
Low	O
prevalences	O
and	O
effects	O
of	O
low	O
testosterone	B-Chemical
and	O
high	O
prolactin	O
in	O
erectile	B-Disease
dysfunction	I-Disease
cannot	O
justify	O
their	O
routine	O
determination	O
.	O
However	O
,	O
cost	O
-	O
effective	O
screening	O
strategies	O
recommended	O
so	O
far	O
missed	O
40	O
to	O
50	O
%	O
of	O
cases	O
improved	O
with	O
endocrine	O
therapy	O
and	O
the	O
pituitary	B-Disease
tumors	I-Disease
.	O
We	O
now	O
advocate	O
that	O
before	O
age	O
50	O
years	O
testosterone	B-Chemical
be	O
determined	O
only	O
in	O
cases	O
of	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
and	O
abnormal	O
physical	O
examination	O
but	O
that	O
it	O
be	O
measured	O
in	O
all	O
men	O
older	O
than	O
50	O
years	O
.	O
Prolactin	O
should	O
be	O
determined	O
only	O
in	O
cases	O
of	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
,	O
gynecomastia	B-Disease
and	O
/	O
or	O
testosterone	B-Chemical
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O
Extrapyramidal	O
side	O
effects	O
with	O
risperidone	B-Chemical
and	O
haloperidol	B-Chemical
at	O
comparable	O
D2	O
receptor	O
occupancy	O
levels	O
.	O
Risperidone	B-Chemical
is	O
an	O
antipsychotic	O
drug	O
with	O
high	O
affinity	O
at	O
dopamine	B-Chemical
D2	O
and	O
serotonin	B-Chemical
5	I-Chemical
-	I-Chemical
HT2	I-Chemical
receptors	O
.	O
Previous	O
clinical	O
studies	O
have	O
proposed	O
that	O
risperidone	B-Chemical
'	O
s	O
pharmacologic	O
profile	O
may	O
produce	O
improved	O
efficacy	O
for	O
negative	O
psychotic	B-Disease
symptoms	I-Disease
and	O
decreased	O
propensity	O
for	O
extrapyramidal	O
side	O
effects	O
;	O
features	O
shared	O
by	O
so	O
-	O
called	O
'	O
atypical	O
'	O
neuroleptics	O
.	O
To	O
determine	O
if	O
routine	O
risperidone	B-Chemical
treatment	O
is	O
associated	O
with	O
a	O
unique	O
degree	O
of	O
D2	O
receptor	O
occupancy	O
and	O
pattern	O
of	O
clinical	O
effects	O
,	O
we	O
used	O
[	O
123I	O
]	O
IBZM	O
SPECT	O
to	O
determine	O
D2	O
occupancy	O
in	O
subjects	O
treated	O
with	O
routine	O
clinical	O
doses	O
of	O
risperidone	B-Chemical
(	O
n	O
=	O
12	O
)	O
or	O
haloperidol	B-Chemical
(	O
n	O
=	O
7	O
)	O
.	O
Both	O
risperidone	B-Chemical
and	O
haloperidol	B-Chemical
produced	O
D2	O
occupancy	O
levels	O
between	O
approximately	O
60	O
and	O
90	O
%	O
at	O
standard	O
clinical	O
doses	O
.	O
There	O
was	O
no	O
significant	O
difference	O
between	O
occupancy	O
levels	O
obtained	O
with	O
haloperidol	B-Chemical
or	O
risperidone	B-Chemical
.	O
Drug	B-Disease
-	I-Disease
induced	I-Disease
parkinsonism	I-Disease
was	O
observed	O
in	O
subjects	O
treated	O
with	O
risperidone	B-Chemical
(	O
42	O
%	O
)	O
and	O
haloperidol	B-Chemical
(	O
29	O
%	O
)	O
and	O
was	O
observed	O
at	O
occupancy	O
levels	O
above	O
60	O
%	O
.	O
Based	O
on	O
these	O
observations	O
,	O
it	O
is	O
concluded	O
that	O
5	O
-	O
HT2	O
blockade	O
obtained	O
with	O
risperidone	B-Chemical
at	O
D2	O
occupancy	O
rates	O
of	O
60	O
%	O
and	O
above	O
does	O
not	O
appear	O
to	O
protect	O
against	O
the	O
risk	O
for	O
extrapyramidal	O
side	O
effects	O
.	O
Treatment	O
of	O
previously	O
treated	O
metastatic	O
breast	B-Disease
cancer	I-Disease
by	O
mitoxantrone	B-Chemical
and	O
48	O
-	O
hour	O
continuous	O
infusion	O
of	O
high	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
leucovorin	B-Chemical
(	O
MFL	B-Chemical
)	O
:	O
low	O
palliative	O
benefit	O
and	O
high	O
treatment	O
-	O
related	O
toxicity	B-Disease
.	O
For	O
previously	O
treated	O
advanced	O
breast	B-Disease
cancer	I-Disease
,	O
there	O
is	O
no	O
standard	O
second	O
-	O
line	O
therapy	O
.	O
Combination	O
chemotherapy	O
with	O
mitoxantrone	B-Chemical
,	O
high	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
and	O
leucovorin	B-Chemical
(	O
MFL	B-Chemical
regimen	I-Chemical
)	O
had	O
been	O
reported	O
as	O
an	O
effective	O
and	O
well	O
tolerated	O
regimen	O
.	O
From	O
October	O
1993	O
to	O
November	O
1995	O
,	O
we	O
treated	O
13	O
patients	O
with	O
previously	O
chemotherapy	O
-	O
treated	O
metastatic	O
breast	B-Disease
cancer	I-Disease
by	O
mitoxantrone	B-Chemical
,	O
12	O
mg	O
/	O
m2	O
,	O
on	O
day	O
1	O
and	O
continuous	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
,	O
3000	O
mg	O
/	O
m2	O
,	O
together	O
with	O
leucovorin	B-Chemical
,	O
300	O
mg	O
/	O
m2	O
,	O
for	O
48	O
h	O
from	O
day	O
1	O
to	O
2	O
.	O
Each	O
course	O
of	O
chemotherapy	O
was	O
given	O
every	O
4	O
weeks	O
.	O
Most	O
of	O
these	O
patients	O
had	O
more	O
than	O
two	O
metastatic	O
sites	O
,	O
with	O
lung	O
metastasis	O
predominant	O
.	O
Seven	O
patients	O
had	O
been	O
treated	O
with	O
anthracycline	B-Chemical
.	O
Seven	O
patients	O
had	O
previously	O
received	O
radiotherapy	O
and	O
seven	O
had	O
received	O
hormone	O
therapy	O
.	O
Median	O
number	O
of	O
courses	O
of	O
MFL	B-Chemical
regimen	I-Chemical
given	O
was	O
six	O
and	O
the	O
median	O
cumulative	O
dose	O
of	O
mitoxantrone	B-Chemical
was	O
68	O
.	O
35	O
mg	O
/	O
m2	O
.	O
One	O
patient	O
had	O
complete	O
response	O
,	O
seven	O
had	O
stable	O
disease	O
,	O
none	O
had	O
partial	O
response	O
and	O
five	O
had	O
progressive	O
disease	O
.	O
The	O
overall	O
objective	O
response	O
rate	O
was	O
7	O
.	O
6	O
%	O
.	O
The	O
median	O
follow	O
-	O
up	O
period	O
was	O
14	O
months	O
.	O
Median	O
survival	O
was	O
16	O
months	O
.	O
Median	O
progression	O
-	O
free	O
survival	O
was	O
5	O
months	O
.	O
A	O
complete	O
responder	O
had	O
relapse	O
-	O
free	O
survival	O
up	O
to	O
17	O
months	O
.	O
Major	O
toxicities	B-Disease
were	O
cardiotoxicity	B-Disease
and	O
leukopenia	B-Disease
.	O
Eight	O
patients	O
were	O
dead	O
in	O
the	O
last	O
follow	O
-	O
up	O
;	O
two	O
of	O
them	O
died	O
of	O
treatment	O
-	O
related	O
toxicity	B-Disease
.	O
The	O
MFL	B-Chemical
regimen	I-Chemical
achieves	O
little	O
palliative	O
benefit	O
and	O
induces	O
severe	O
toxicity	B-Disease
at	O
a	O
fairly	O
high	O
rate	O
.	O
Administration	O
of	O
this	O
regimen	O
to	O
breast	B-Disease
cancer	I-Disease
patients	O
who	O
have	O
been	O
treated	O
by	O
chemotherapy	O
and	O
those	O
with	O
impaired	B-Disease
heart	I-Disease
function	I-Disease
requires	O
careful	O
attention	O
.	O
Ticlopidine	B-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
:	O
report	O
of	O
three	O
Chinese	O
patients	O
and	O
review	O
of	O
the	O
literature	O
.	O
In	O
this	O
study	O
,	O
three	O
Chinese	O
patients	O
with	O
ticlopidine	B-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
were	O
reported	O
and	O
another	O
13	O
patients	O
in	O
the	O
English	O
literature	O
were	O
reviewed	O
.	O
We	O
attempted	O
to	O
find	O
underlying	O
similarities	O
,	O
evaluate	O
the	O
risk	O
factors	O
,	O
and	O
identify	O
appropriate	O
treatment	O
for	O
this	O
complication	O
.	O
All	O
but	O
one	O
of	O
the	O
patients	O
were	O
over	O
60	O
years	O
old	O
,	O
and	O
the	O
6	O
who	O
died	O
were	O
all	O
older	O
than	O
65	O
.	O
Therefore	O
,	O
old	O
age	O
may	O
be	O
a	O
risk	O
factor	O
for	O
developing	O
this	O
complication	O
.	O
Agranulocytosis	B-Disease
occurred	O
3	O
-	O
20	O
weeks	O
after	O
initiation	O
of	O
ticlopidine	B-Chemical
,	O
so	O
frequent	O
examination	O
of	O
white	O
cell	O
count	O
during	O
treatment	O
is	O
recommended	O
.	O
There	O
seemed	O
to	O
be	O
no	O
direct	O
correlation	O
between	O
the	O
dose	O
or	O
duration	O
used	O
and	O
the	O
severity	O
of	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
.	O
Treatment	O
for	O
ticlopidine	B-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
with	O
colony	O
-	O
stimulating	O
factors	O
seemed	O
to	O
have	O
little	O
effect	O
.	O
The	O
fact	O
that	O
5	O
of	O
the	O
6	O
patients	O
who	O
received	O
concurrent	O
calcium	B-Chemical
channel	O
blockers	O
died	O
,	O
should	O
alert	O
clinicians	O
to	O
be	O
more	O
cautious	O
when	O
using	O
these	O
two	O
drugs	O
simultaneously	O
.	O
Upregulation	O
of	O
the	O
expression	O
of	O
vasopressin	B-Chemical
gene	O
in	O
the	O
paraventricular	O
and	O
supraoptic	O
nuclei	O
of	O
the	O
lithium	B-Chemical
-	O
induced	O
diabetes	B-Disease
insipidus	I-Disease
rat	O
.	O
The	O
expression	O
of	O
arginine	B-Chemical
vasopressin	I-Chemical
(	O
AVP	B-Chemical
)	O
gene	O
in	O
the	O
paraventricular	O
(	O
PVN	O
)	O
and	O
supraoptic	O
nuclei	O
(	O
SON	O
)	O
was	O
investigated	O
in	O
rats	O
with	O
lithium	B-Chemical
(	O
Li	B-Chemical
)	O
-	O
induced	O
polyuria	B-Disease
,	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
and	O
radioimmunoassay	O
.	O
The	O
male	O
Wistar	O
rats	O
consuming	O
a	O
diet	O
that	O
contained	O
LiCl	B-Chemical
(	O
60	O
mmol	O
/	O
kg	O
)	O
for	O
4	O
weeks	O
developed	O
marked	O
polyuria	B-Disease
.	O
The	O
Li	B-Chemical
-	O
treated	O
rats	O
produced	O
a	O
large	O
volume	O
of	O
hypotonic	O
urine	O
with	O
low	O
ionic	O
concentrations	O
.	O
Plasma	O
sodium	B-Chemical
concentrations	O
were	O
found	O
to	O
be	O
slightly	O
increased	O
in	O
the	O
Li	B-Chemical
-	O
treated	O
rats	O
compared	O
with	O
those	O
in	O
controls	O
.	O
Plasma	O
concentration	O
of	O
AVP	B-Chemical
and	O
transcripts	O
of	O
AVP	B-Chemical
gene	O
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	O
increased	O
in	O
the	O
Li	B-Chemical
-	O
treated	O
rats	O
compared	O
with	O
controls	O
.	O
These	O
results	O
suggest	O
that	O
dehydration	B-Disease
and	O
/	O
or	O
the	O
activation	O
of	O
visceral	O
afferent	O
inputs	O
may	O
contribute	O
to	O
the	O
elevation	O
of	O
plasma	O
AVP	B-Chemical
and	O
the	O
upregulation	O
of	O
AVP	B-Chemical
gene	O
expression	O
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
Li	B-Chemical
-	O
induced	O
diabetes	B-Disease
insipidus	I-Disease
rat	O
.	O
Antinociceptive	O
and	O
antiamnesic	O
properties	O
of	O
the	O
presynaptic	O
cholinergic	O
amplifier	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
.	O
The	O
antinociceptive	O
effect	O
of	O
3	B-Chemical
alpha	I-Chemical
-	I-Chemical
tropyl	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
bromophenyl	I-Chemical
)	I-Chemical
propionate	I-Chemical
[	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
]	O
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
s	O
.	O
c	O
.	O
;	O
30	O
-	O
60	O
mg	O
kg	O
-	O
1	O
p	O
.	O
o	O
.	O
;	O
10	O
-	O
30	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
;	O
10	O
-	O
30	O
micrograms	O
/	O
mouse	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
examined	O
in	O
mice	O
,	O
rats	O
and	O
guinea	O
pigs	O
by	O
use	O
of	O
the	O
hot	O
-	O
plate	O
,	O
abdominal	O
-	O
constriction	O
,	O
tail	O
-	O
flick	O
and	O
paw	O
-	O
pressure	O
tests	O
.	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
antinociception	O
peaked	O
15	O
min	O
after	O
injection	O
and	O
then	O
slowly	O
diminished	O
.	O
The	O
antinociception	O
produced	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
was	O
prevented	O
by	O
the	O
unselective	O
muscarinic	O
antagonist	O
atropine	B-Chemical
,	O
the	O
M1	O
-	O
selective	O
antagonists	O
pirenzepine	B-Chemical
and	O
dicyclomine	B-Chemical
and	O
the	O
acetylcholine	B-Chemical
depletor	O
hemicholinium	B-Chemical
-	I-Chemical
3	I-Chemical
,	O
but	O
not	O
by	O
the	O
opioid	O
antagonist	O
naloxone	B-Chemical
,	O
the	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acidB	I-Chemical
antagonist	O
3	B-Chemical
-	I-Chemical
aminopropyl	I-Chemical
-	I-Chemical
diethoxy	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
phosphinic	I-Chemical
acid	I-Chemical
,	O
the	O
H3	O
agonist	O
R	B-Chemical
-	I-Chemical
(	I-Chemical
alpha	I-Chemical
)	I-Chemical
-	I-Chemical
methylhistamine	I-Chemical
,	O
the	O
D2	O
antagonist	O
quinpirole	B-Chemical
,	O
the	O
5	B-Chemical
-	I-Chemical
hydroxytryptamine4	I-Chemical
antagonist	O
2	B-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
amino	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
chlorobenzoic	I-Chemical
acid	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
diethylamino	I-Chemical
)	I-Chemical
ethyl	I-Chemical
ester	I-Chemical
hydrochloride	O
,	O
the	O
5	B-Chemical
-	I-Chemical
hydroxytryptamin1A	I-Chemical
antagonist	O
1	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
methoxyphenyl	I-Chemical
)	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
phthalimido	I-Chemical
)	I-Chemical
butyl	I-Chemical
]	I-Chemical
piperazine	I-Chemical
hydrobromide	O
and	O
the	O
polyamines	O
depletor	O
reserpine	B-Chemical
.	O
Based	O
on	O
these	O
data	O
,	O
it	O
can	O
be	O
postulated	O
that	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
exerted	O
an	O
antinociceptive	O
effect	O
mediated	O
by	O
a	O
central	O
potentiation	O
of	O
cholinergic	O
transmission	O
.	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
was	O
able	O
to	O
prevent	O
amnesia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
(	O
1	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
and	O
dicyclomine	B-Chemical
(	O
2	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
in	O
the	O
mouse	O
passive	O
-	O
avoidance	O
test	O
.	O
Affinity	O
profiles	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
for	O
muscarinic	O
receptor	O
subtypes	O
,	O
determined	O
by	O
functional	O
studies	O
(	O
rabbit	O
vas	O
deferens	O
for	O
M1	O
,	O
guinea	O
pig	O
atrium	O
for	O
M2	O
,	O
guinea	O
pig	O
ileum	O
for	O
M3	O
and	O
immature	O
guinea	O
pig	O
uterus	O
for	O
putative	O
M4	O
)	O
,	O
have	O
shown	O
an	O
M4	O
/	O
M1	O
selectivity	O
ratio	O
of	O
10	O
.	O
2	O
that	O
might	O
be	O
responsible	O
for	O
the	O
antinociception	O
and	O
the	O
anti	O
-	O
amnesic	B-Disease
effect	O
induced	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
through	O
an	O
increase	O
in	O
acetylcholine	B-Chemical
extracellular	O
levels	O
.	O
In	O
the	O
antinociceptive	O
and	O
antiamnesic	O
dose	O
range	O
,	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
did	O
not	O
impair	O
mouse	O
performance	O
evaluated	O
by	O
the	O
rota	O
-	O
rod	O
test	O
and	O
Animex	O
apparatus	O
.	O
The	O
effect	O
of	O
different	O
anaesthetic	O
agents	O
in	O
hearing	B-Disease
loss	I-Disease
following	O
spinal	O
anaesthesia	O
.	O
The	O
cause	O
of	O
hearing	B-Disease
loss	I-Disease
after	O
spinal	O
anaesthesia	O
is	O
unknown	O
.	O
Up	O
until	O
now	O
,	O
the	O
only	O
factor	O
studied	O
has	O
been	O
the	O
effect	O
of	O
the	O
diameter	O
of	O
the	O
spinal	O
needle	O
on	O
post	O
-	O
operative	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
this	O
hearing	B-Disease
loss	I-Disease
and	O
to	O
investigate	O
other	O
factors	O
influencing	O
the	O
degree	O
of	O
hearing	B-Disease
loss	I-Disease
.	O
Two	O
groups	O
of	O
22	O
similar	O
patients	O
were	O
studied	O
:	O
one	O
group	O
received	O
6	O
mL	O
prilocaine	B-Chemical
2	O
%	O
;	O
and	O
the	O
other	O
received	O
3	O
mL	O
bupivacaine	B-Chemical
0	O
.	O
5	O
%	O
.	O
Patients	O
given	O
prilocaine	B-Chemical
were	O
more	O
likely	O
to	O
develop	O
hearing	B-Disease
loss	I-Disease
(	O
10	O
out	O
of	O
22	O
)	O
than	O
those	O
given	O
bupivacaine	B-Chemical
(	O
4	O
out	O
of	O
22	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
The	O
average	O
hearing	B-Disease
loss	I-Disease
for	O
speech	O
frequencies	O
was	O
about	O
10	O
dB	O
after	O
prilocaine	B-Chemical
and	O
15	O
dB	O
after	O
bupivacaine	B-Chemical
.	O
None	O
of	O
the	O
patients	O
complained	O
of	O
subjective	O
hearing	B-Disease
loss	I-Disease
.	O
Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
the	O
patients	O
was	O
not	O
possible	O
.	O
A	O
transient	O
neurological	B-Disease
deficit	I-Disease
following	O
intrathecal	O
injection	O
of	O
1	O
%	O
hyperbaric	O
bupivacaine	B-Chemical
for	O
unilateral	O
spinal	O
anaesthesia	O
.	O
We	O
describe	O
a	O
case	O
of	O
transient	O
neurological	B-Disease
deficit	I-Disease
that	O
occurred	O
after	O
unilateral	O
spinal	O
anaesthesia	O
with	O
8	O
mg	O
of	O
1	O
%	O
hyperbaric	O
bupivacaine	B-Chemical
slowly	O
injected	O
through	O
a	O
25	O
-	O
gauge	O
pencil	O
-	O
point	O
spinal	O
needle	O
.	O
The	O
surgery	O
and	O
anaesthesia	O
were	O
uneventful	O
,	O
but	O
3	O
days	O
after	O
surgery	O
,	O
the	O
patient	O
reported	O
an	O
area	O
of	O
hypoaesthesia	O
over	O
L3	O
-	O
L4	O
dermatomes	O
of	O
the	O
leg	O
which	O
had	O
been	O
operated	O
on	O
(	O
loss	B-Disease
of	I-Disease
pinprick	I-Disease
sensation	I-Disease
)	O
without	O
reduction	O
in	O
muscular	O
strength	O
.	O
Sensation	O
in	O
this	O
area	O
returned	O
to	O
normal	O
over	O
the	O
following	O
2	O
weeks	O
.	O
Prospective	O
multicentre	O
studies	O
with	O
a	O
large	O
population	O
and	O
a	O
long	O
follow	O
-	O
up	O
should	O
be	O
performed	O
in	O
order	O
to	O
evaluate	O
the	O
incidence	O
of	O
this	O
unusual	O
side	O
effect	O
.	O
However	O
,	O
we	O
suggest	O
that	O
a	O
low	O
solution	O
concentration	O
should	O
be	O
preferred	O
for	O
unilateral	O
spinal	O
anaesthesia	O
with	O
a	O
hyperbaric	O
anaesthetic	O
solution	O
(	O
if	O
pencil	O
-	O
point	O
needle	O
and	O
slow	O
injection	O
rate	O
are	O
employed	O
)	O
,	O
in	O
order	O
to	O
minimize	O
the	O
risk	O
of	O
a	O
localized	O
high	O
peak	O
anaesthetic	O
concentration	O
,	O
which	O
might	O
lead	O
to	O
a	O
transient	O
neurological	B-Disease
deficit	I-Disease
.	O
Transient	B-Disease
neurologic	I-Disease
symptoms	I-Disease
after	O
spinal	O
anesthesia	O
:	O
a	O
lower	O
incidence	O
with	O
prilocaine	B-Chemical
and	O
bupivacaine	B-Chemical
than	O
with	O
lidocaine	B-Chemical
.	O
BACKGROUND	O
:	O
Recent	O
evidence	O
suggests	O
that	O
transient	B-Disease
neurologic	I-Disease
symptoms	I-Disease
(	O
TNSs	B-Disease
)	O
frequently	O
follow	O
lidocaine	B-Chemical
spinal	O
anesthesia	O
but	O
are	O
infrequent	O
with	O
bupivacaine	B-Chemical
.	O
However	O
,	O
identification	O
of	O
a	O
short	O
-	O
acting	O
local	O
anesthetic	O
to	O
substitute	O
for	O
lidocaine	B-Chemical
for	O
brief	O
surgical	O
procedures	O
remains	O
an	O
important	O
goal	O
.	O
Prilocaine	B-Chemical
is	O
an	O
amide	O
local	O
anesthetic	O
with	O
a	O
duration	O
of	O
action	O
similar	O
to	O
that	O
of	O
lidocaine	B-Chemical
.	O
Accordingly	O
,	O
the	O
present	O
,	O
prospective	O
double	O
-	O
blind	O
study	O
compares	O
prilocaine	B-Chemical
with	O
lidocaine	B-Chemical
and	O
bupivacaine	B-Chemical
with	O
respect	O
to	O
duration	O
of	O
action	O
and	O
relative	O
risk	O
of	O
TNSs	B-Disease
.	O
METHODS	O
:	O
Ninety	O
patients	O
classified	O
as	O
American	O
Society	O
of	O
Anesthesiologists	O
physical	O
status	O
I	O
or	O
II	O
who	O
were	O
scheduled	O
for	O
short	O
gynecologic	O
procedures	O
under	O
spinal	O
anesthesia	O
were	O
randomly	O
allocated	O
to	O
receive	O
2	O
.	O
5	O
ml	O
2	O
%	O
lidocaine	B-Chemical
in	O
7	O
.	O
5	O
%	O
glucose	B-Chemical
,	O
2	O
%	O
prilocaine	B-Chemical
in	O
7	O
.	O
5	O
%	O
glucose	B-Chemical
,	O
or	O
0	O
.	O
5	O
%	O
bupivacaine	B-Chemical
in	O
7	O
.	O
5	O
%	O
glucose	B-Chemical
.	O
All	O
solutions	O
were	O
provided	O
in	O
blinded	O
vials	O
by	O
the	O
hospital	O
pharmacy	O
.	O
Details	O
of	O
spinal	O
puncture	O
,	O
extension	O
and	O
regression	O
of	O
spinal	O
block	O
,	O
and	O
the	O
times	O
to	O
reach	O
discharge	O
criteria	O
were	O
noted	O
.	O
In	O
the	O
evening	O
of	O
postoperative	O
day	O
1	O
,	O
patients	O
were	O
evaluated	O
for	O
TNSs	B-Disease
by	O
a	O
physician	O
unaware	O
of	O
the	O
drug	O
administered	O
and	O
the	O
details	O
of	O
the	O
anesthetic	O
procedure	O
.	O
RESULTS	O
:	O
Nine	O
of	O
30	O
patients	O
receiving	O
lidocaine	B-Chemical
experienced	O
TNSs	B-Disease
,	O
1	O
of	O
30	O
patients	O
receiving	O
prilocaine	B-Chemical
(	O
P	O
=	O
0	O
.	O
03	O
)	O
had	O
them	O
,	O
and	O
none	O
of	O
30	O
patients	O
receiving	O
bupivacaine	B-Chemical
had	O
TNSs	B-Disease
.	O
Times	O
to	O
ambulate	O
and	O
to	O
void	O
were	O
similar	O
after	O
lidocaine	B-Chemical
and	O
prilocaine	B-Chemical
(	O
150	O
vs	O
.	O
165	O
min	O
and	O
238	O
vs	O
.	O
253	O
min	O
,	O
respectively	O
)	O
but	O
prolonged	O
after	O
bupivacaine	B-Chemical
(	O
200	O
and	O
299	O
min	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
CONCLUSIONS	O
:	O
Prilocaine	B-Chemical
may	O
be	O
preferable	O
to	O
lidocaine	B-Chemical
for	O
short	O
surgical	O
procedures	O
because	O
it	O
has	O
a	O
similar	O
duration	O
of	O
action	O
but	O
a	O
lower	O
incidence	O
of	O
TNSs	B-Disease
.	O
Suxamethonium	B-Chemical
-	O
induced	O
cardiac	B-Disease
arrest	I-Disease
and	O
death	B-Disease
following	O
5	O
days	O
of	O
immobilization	O
.	O
The	O
present	O
report	O
describes	O
a	O
case	O
of	O
cardiac	B-Disease
arrest	I-Disease
and	O
subsequent	O
death	B-Disease
as	O
a	O
result	O
of	O
hyperkalaemia	B-Disease
following	O
the	O
use	O
of	O
suxamethonium	B-Chemical
in	O
a	O
23	O
-	O
year	O
-	O
old	O
Malawian	O
woman	O
.	O
Five	O
days	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
of	O
meningitis	B-Disease
,	O
the	O
patient	O
aspirated	O
stomach	O
contents	O
and	O
needed	O
endotracheal	O
intubation	O
.	O
Forty	O
seconds	O
after	O
injection	O
of	O
suxamethonium	B-Chemical
,	O
bradycardia	B-Disease
and	O
cardiac	B-Disease
arrest	I-Disease
occurred	O
.	O
Attempts	O
to	O
resuscitate	O
the	O
patient	O
were	O
not	O
successful	O
.	O
The	O
serum	O
level	O
of	O
potassium	B-Chemical
was	O
observed	O
to	O
be	O
8	O
.	O
4	O
mequiv	O
L	O
-	O
1	O
.	O
Apart	O
from	O
the	O
reduction	O
in	O
the	O
patient	O
'	O
s	O
level	O
of	O
consciousness	O
,	O
there	O
were	O
no	O
signs	O
of	O
motor	O
neurone	O
damage	O
or	O
of	O
any	O
of	O
the	O
other	O
known	O
predisposing	O
conditions	O
for	O
hyperkalaemia	B-Disease
following	O
the	O
administration	O
of	O
suxamethonium	B-Chemical
.	O
It	O
is	O
postulated	O
that	O
her	O
death	B-Disease
was	O
caused	O
by	O
hypersensitivity	B-Disease
to	O
suxamethonium	B-Chemical
,	O
associated	O
with	O
her	O
5	O
-	O
day	O
immobilization	O
.	O
Acute	O
hepatitis	B-Disease
,	O
autoimmune	B-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
and	O
erythroblastocytopenia	B-Disease
induced	O
by	O
ceftriaxone	B-Chemical
.	O
An	O
80	O
-	O
yr	O
-	O
old	O
man	O
developed	O
acute	O
hepatitis	B-Disease
shortly	O
after	O
ingesting	O
oral	O
ceftriaxone	B-Chemical
.	O
Although	O
the	O
transaminases	O
gradually	O
returned	O
to	O
baseline	O
after	O
withholding	O
the	O
beta	B-Chemical
lactam	I-Chemical
antibiotic	O
,	O
there	O
was	O
a	O
gradual	O
increase	O
in	O
serum	O
bilirubin	B-Chemical
and	O
a	O
decrease	O
in	O
hemoglobin	O
concentration	O
caused	O
by	O
an	O
autoimmune	B-Disease
hemolytic	I-Disease
anemia	I-Disease
and	O
erythroblastocytopenia	B-Disease
.	O
These	O
responded	O
to	O
systemic	O
steroids	B-Chemical
and	O
immunoglobulins	O
.	O
Despite	O
the	O
widespread	O
use	O
of	O
these	O
agents	O
this	O
triad	O
of	O
side	O
effects	O
has	O
not	O
previously	O
been	O
reported	O
in	O
connection	O
with	O
beta	B-Chemical
lactam	I-Chemical
antibiotics	O
.	O
Thyroxine	B-Chemical
abuse	O
:	O
an	O
unusual	O
case	O
of	O
thyrotoxicosis	B-Disease
in	O
pregnancy	O
.	O
Eating	B-Disease
disorders	I-Disease
and	O
the	O
associated	O
behavioural	O
problems	O
and	O
drug	B-Disease
abuse	I-Disease
are	O
uncommon	O
in	O
pregnancy	O
.	O
When	O
they	O
do	O
occur	O
they	O
are	O
often	O
unrecognized	O
because	O
of	O
denial	O
but	O
when	O
significant	O
may	O
pose	O
a	O
risk	O
to	O
both	O
the	O
mother	O
and	O
her	O
fetus	O
.	O
This	O
case	O
illustrates	O
a	O
number	O
of	O
problems	O
that	O
may	O
be	O
encountered	O
in	O
women	O
with	O
eating	B-Disease
disorders	I-Disease
in	O
pregnancy	O
,	O
including	O
prolonged	O
and	O
recurrent	O
metabolic	O
disturbances	O
and	O
diuretic	O
abuse	O
.	O
In	O
particular	O
it	O
illustrates	O
the	O
derangements	O
of	O
thyroid	O
function	O
seen	O
in	O
pregnant	O
women	O
with	O
eating	B-Disease
disorders	I-Disease
and	O
reminds	O
us	O
that	O
when	O
a	O
cause	O
for	O
thyrotoxicosis	B-Disease
remains	O
obscure	O
,	O
thyroxine	B-Chemical
abuse	O
should	O
be	O
considered	O
and	O
explored	O
.	O
Repeated	O
trimipramine	B-Chemical
induces	O
dopamine	B-Chemical
D2	O
/	O
D3	O
and	O
alpha1	O
-	O
adrenergic	O
up	O
-	O
regulation	O
.	O
Trimipramine	B-Chemical
(	O
TRI	B-Chemical
)	O
,	O
which	O
shows	O
a	O
clinical	O
antidepressant	B-Chemical
activity	O
,	O
is	O
chemically	O
related	O
to	O
imipramine	B-Chemical
but	O
does	O
not	O
inhibit	O
the	O
reuptake	O
of	O
noradrenaline	B-Chemical
and	O
5	B-Chemical
-	I-Chemical
hydroxytryptamine	I-Chemical
,	O
nor	O
does	O
it	O
induce	O
beta	O
-	O
adrenergic	O
down	O
-	O
regulation	O
.	O
The	O
mechanism	O
of	O
its	O
antidepressant	B-Chemical
activity	O
is	O
still	O
unknown	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
find	O
out	O
whether	O
TRI	B-Chemical
given	O
repeatedly	O
was	O
able	O
to	O
induce	O
adaptive	O
changes	O
in	O
the	O
dopaminergic	O
and	O
alpha1	O
-	O
adrenergic	O
systems	O
,	O
demonstrated	O
by	O
us	O
previously	O
for	O
various	O
antidepressants	B-Chemical
.	O
TRI	B-Chemical
was	O
given	O
to	O
male	O
Wistar	O
rats	O
and	O
male	O
Albino	O
Swiss	O
mice	O
perorally	O
twice	O
daily	O
for	O
14	O
days	O
.	O
In	O
the	O
acute	O
experiment	O
TRI	B-Chemical
(	O
given	O
i	O
.	O
p	O
.	O
)	O
does	O
not	O
antagonize	O
the	O
reserpine	B-Chemical
hypothermia	B-Disease
in	O
mice	O
and	O
does	O
not	O
potentiate	O
the	O
5	B-Chemical
-	I-Chemical
hydroxytryptophan	I-Chemical
head	O
twitches	O
in	O
rats	O
.	O
TRI	B-Chemical
given	O
repeatedly	O
to	O
rats	O
increases	O
the	O
locomotor	O
hyperactivity	B-Disease
induced	O
by	O
d	B-Chemical
-	I-Chemical
amphetamine	I-Chemical
,	O
quinpirole	B-Chemical
and	O
(	O
+	O
)	O
-	O
7	O
-	O
hydroxy	O
-	O
dipropyloaminotetralin	O
(	O
dopamine	B-Chemical
D2	O
and	O
D3	O
effects	O
)	O
.	O
The	O
stereotypies	O
induced	O
by	O
d	B-Chemical
-	I-Chemical
amphetamine	I-Chemical
or	O
apomorphine	B-Chemical
are	O
not	O
potentiated	O
by	O
TRI	B-Chemical
.	O
It	O
increases	O
the	O
behaviour	O
stimulation	O
evoked	O
by	O
phenylephrine	B-Chemical
(	O
given	O
intraventricularly	O
)	O
in	O
rats	O
,	O
evaluated	O
in	O
the	O
open	O
field	O
test	O
as	O
well	O
as	O
the	O
aggressiveness	B-Disease
evoked	O
by	O
clonidine	B-Chemical
in	O
mice	O
,	O
both	O
these	O
effects	O
being	O
mediated	O
by	O
an	O
alpha1	O
-	O
adrenergic	O
receptor	O
.	O
It	O
may	O
be	O
concluded	O
that	O
,	O
like	O
other	O
tricyclic	O
antidepressants	B-Chemical
studied	O
previously	O
,	O
TRI	B-Chemical
given	O
repeatedly	O
increases	O
the	O
responsiveness	O
of	O
brain	O
dopamine	B-Chemical
D2	O
and	O
D3	O
(	O
locomotor	O
activity	O
but	O
not	O
stereotypy	O
)	O
as	O
well	O
as	O
alpha1	O
-	O
adrenergic	O
receptors	O
to	O
their	O
agonists	O
.	O
A	O
question	O
arises	O
whether	O
the	O
reuptake	O
inhibition	O
is	O
of	O
any	O
importance	O
to	O
the	O
adaptive	O
changes	O
induced	O
by	O
repeated	O
antidepressants	B-Chemical
,	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
antidepressant	B-Chemical
activity	O
.	O
Pethidine	B-Chemical
-	O
associated	O
seizure	B-Disease
in	O
a	O
healthy	O
adolescent	O
receiving	O
pethidine	B-Chemical
for	O
postoperative	B-Disease
pain	I-Disease
control	O
.	O
A	O
healthy	O
17	O
-	O
year	O
-	O
old	O
male	O
received	O
standard	O
intermittent	O
doses	O
of	O
pethidine	B-Chemical
via	O
a	O
patient	O
-	O
controlled	O
analgesia	O
(	O
PCA	O
)	O
pump	O
for	O
management	O
of	O
postoperative	B-Disease
pain	I-Disease
control	O
.	O
Twenty	O
-	O
three	O
h	O
postoperatively	O
he	O
developed	O
a	O
brief	O
self	O
-	O
limited	O
seizure	B-Disease
.	O
Both	O
plasma	O
pethidine	B-Chemical
and	O
norpethidine	B-Chemical
were	O
elevated	O
in	O
the	O
range	O
associated	O
with	O
clinical	O
manifestations	O
of	O
central	O
nervous	O
system	O
excitation	O
.	O
No	O
other	O
risk	O
factors	O
for	O
CNS	O
toxicity	B-Disease
were	O
identified	O
.	O
This	O
method	O
allowed	O
frequent	O
self	O
-	O
dosing	O
of	O
pethidine	B-Chemical
at	O
short	O
time	O
intervals	O
and	O
rapid	O
accumulation	O
of	O
pethidine	B-Chemical
and	O
norpethidine	B-Chemical
.	O
The	O
routine	O
use	O
of	O
pethidine	B-Chemical
via	O
PCA	O
even	O
for	O
a	O
brief	O
postoperative	O
analgesia	O
should	O
be	O
reconsidered	O
.	O
An	O
unusual	O
toxic	O
reaction	O
to	O
axillary	O
block	O
by	O
mepivacaine	B-Chemical
with	O
adrenaline	B-Chemical
.	O
An	O
increase	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
,	O
accompanied	O
by	O
atrial	B-Disease
fibrillation	I-Disease
,	O
agitation	B-Disease
,	O
incomprehensible	B-Disease
shouts	I-Disease
and	O
loss	B-Disease
of	I-Disease
consciousness	I-Disease
,	O
was	O
observed	O
in	O
an	O
elderly	O
,	O
ASA	O
classification	O
group	O
II	O
,	O
cardiovascularly	O
medicated	O
male	O
,	O
12	O
min	O
after	O
performance	O
of	O
axillary	O
block	O
with	O
mepivacaine	B-Chemical
850	O
mg	O
containing	O
adrenaline	B-Chemical
0	O
.	O
225	O
mg	O
,	O
for	O
correction	O
of	O
Dupuytren	B-Disease
'	I-Disease
s	I-Disease
contracture	I-Disease
.	O
After	O
intravenous	O
administration	O
of	O
labetalol	B-Chemical
,	O
metoprolol	B-Chemical
and	O
midazolam	B-Chemical
the	O
patient	O
'	O
s	O
condition	O
improved	O
,	O
and	O
15	O
min	O
later	O
he	O
woke	O
up	O
.	O
The	O
block	O
was	O
successful	O
and	O
surgery	O
was	O
conducted	O
as	O
scheduled	O
despite	O
persisting	O
atrial	B-Disease
fibrillation	I-Disease
.	O
Postoperatively	O
,	O
the	O
patient	O
refused	O
DC	O
cardioversion	O
and	O
was	O
treated	O
medically	O
.	O
Both	O
the	O
temporal	O
relationship	O
of	O
events	O
and	O
the	O
response	O
to	O
treatment	O
suggest	O
that	O
a	O
rapid	O
systemic	O
absorption	O
of	O
mepivacaine	B-Chemical
with	O
adrenaline	B-Chemical
and	O
/	O
or	O
interaction	O
of	O
these	O
drugs	O
with	O
the	O
patient	O
'	O
s	O
cardiovascular	O
medications	O
were	O
responsible	O
for	O
the	O
perioperative	O
complications	O
.	O
Drug	O
-	O
associated	O
acute	O
-	O
onset	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
and	O
Stevens	B-Disease
-	I-Disease
Johnson	I-Disease
syndromes	I-Disease
in	O
a	O
child	O
.	O
Acute	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
syndrome	O
is	O
a	O
rare	O
but	O
established	O
cause	O
of	O
progressive	O
cholestasis	B-Disease
in	O
adults	O
,	O
is	O
most	O
often	O
drug	O
or	O
toxin	O
related	O
,	O
and	O
is	O
of	O
unknown	O
pathogenesis	O
.	O
It	O
has	O
not	O
been	O
reported	O
previously	O
in	O
children	O
.	O
Stevens	B-Disease
-	I-Disease
Johnson	I-Disease
syndrome	I-Disease
is	O
a	O
well	O
-	O
recognized	O
immune	O
complex	O
-	O
mediated	O
hypersensitivity	B-Disease
reaction	O
that	O
affects	O
all	O
age	O
groups	O
,	O
is	O
drug	O
or	O
infection	B-Disease
induced	O
,	O
and	O
has	O
classic	O
systemic	O
,	O
mucosal	O
,	O
and	O
dermatologic	O
manifestations	O
.	O
A	O
previously	O
healthy	O
child	O
who	O
developed	O
acute	O
,	O
severe	O
,	O
rapidly	O
progressive	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
syndrome	I-Disease
shortly	O
after	O
Stevens	B-Disease
-	I-Disease
Johnson	I-Disease
syndrome	I-Disease
is	O
described	O
;	O
this	O
was	O
temporally	O
associated	O
with	O
ibuprofen	B-Chemical
use	O
.	O
Despite	O
therapy	O
with	O
ursodeoxycholic	B-Chemical
acid	I-Chemical
,	O
prednisone	B-Chemical
,	O
and	O
then	O
tacrolimus	B-Chemical
,	O
her	O
cholestatic	B-Disease
disease	I-Disease
was	O
unrelenting	O
,	O
with	O
cirrhosis	B-Disease
shown	O
by	O
biopsy	O
6	O
months	O
after	O
presentation	O
.	O
This	O
case	O
documents	O
acute	O
drug	O
-	O
related	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
syndrome	I-Disease
in	O
the	O
pediatric	O
age	O
group	O
and	O
suggests	O
shared	O
immune	O
mechanisms	O
in	O
the	O
pathogenesis	O
of	O
both	O
Stevens	B-Disease
-	I-Disease
Johnson	I-Disease
syndrome	I-Disease
and	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
syndrome	I-Disease
.	O
High	O
incidence	O
of	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
associated	O
with	O
appetite	B-Chemical
suppressants	I-Chemical
in	O
Belgium	O
.	O
Primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
is	O
a	O
rare	O
,	O
progressive	O
and	O
incurable	O
disease	O
,	O
which	O
has	O
been	O
associated	O
with	O
the	O
intake	O
of	O
appetite	B-Chemical
suppressant	I-Chemical
drugs	O
.	O
The	O
importance	O
of	O
this	O
association	O
was	O
evaluated	O
in	O
Belgium	O
while	O
this	O
country	O
still	O
had	O
no	O
restriction	O
on	O
the	O
prescription	O
of	O
appetite	B-Chemical
suppressants	I-Chemical
.	O
Thirty	O
-	O
five	O
patients	O
with	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
and	O
85	O
matched	O
controls	O
were	O
recruited	O
over	O
32	O
months	O
(	O
1992	O
-	O
1994	O
)	O
in	O
Belgium	O
.	O
Exposure	O
to	O
appetite	B-Chemical
-	I-Chemical
suppressants	I-Chemical
was	O
assessed	O
on	O
the	O
basis	O
of	O
hospital	O
records	O
and	O
standardized	O
interview	O
.	O
Twenty	O
-	O
three	O
of	O
the	O
patients	O
had	O
previously	O
taken	O
appetite	B-Chemical
suppressants	I-Chemical
,	O
mainly	O
fenfluramines	B-Chemical
,	O
as	O
compared	O
with	O
only	O
5	O
of	O
the	O
controls	O
(	O
66	O
versus	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O
Five	O
patients	O
died	O
before	O
the	O
interview	O
,	O
all	O
of	O
them	O
had	O
taken	O
appetite	B-Chemical
suppressants	I-Chemical
.	O
In	O
8	O
patients	O
the	O
diagnosis	O
of	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
was	O
uncertain	O
,	O
5	O
of	O
them	O
had	O
taken	O
appetite	B-Chemical
suppressants	I-Chemical
.	O
The	O
patients	O
who	O
had	O
been	O
exposed	O
to	O
appetite	B-Chemical
suppressants	I-Chemical
tended	O
to	O
be	O
on	O
average	O
more	O
severely	O
ill	O
,	O
and	O
to	O
have	O
a	O
shorter	O
median	O
delay	O
between	O
onset	O
of	O
symptoms	O
and	O
diagnosis	O
.	O
A	O
policy	O
of	O
unrestricted	O
prescription	O
of	O
appetite	B-Chemical
suppressants	I-Chemical
may	O
lead	O
to	O
a	O
high	O
incidence	O
of	O
associated	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
.	O
Intake	O
of	O
appetite	B-Chemical
suppressants	I-Chemical
may	O
accelerate	O
the	O
progression	O
of	O
the	O
disease	O
.	O
Inappropriate	O
use	O
of	O
carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
in	O
typical	O
absence	B-Disease
seizures	I-Disease
.	O
Carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
are	O
contraindicated	O
in	O
typical	O
absence	B-Disease
seizures	I-Disease
.	O
Of	O
18	O
consecutive	O
referrals	O
of	O
children	O
with	O
resistant	O
typical	O
absences	O
only	O
,	O
eight	O
were	O
erroneously	O
treated	O
with	O
carbamazepine	B-Chemical
either	O
as	O
monotherapy	O
or	O
as	O
an	O
add	O
-	O
on	O
.	O
Vigabatrin	B-Chemical
was	O
also	O
used	O
in	O
the	O
treatment	O
of	O
two	O
children	O
.	O
Frequency	O
of	O
absences	O
increased	O
in	O
four	O
children	O
treated	O
with	O
carbamazepine	B-Chemical
and	O
two	O
of	O
these	O
developed	O
myoclonic	B-Disease
jerks	I-Disease
,	O
which	O
resolved	O
on	O
withdrawal	O
of	O
carbamazepine	B-Chemical
.	O
Absences	O
were	O
aggravated	O
in	O
both	O
cases	O
where	O
vigabatrin	B-Chemical
was	O
added	O
on	O
to	O
concurrent	O
treatment	O
.	O
Optimal	O
control	O
of	O
the	O
absences	O
was	O
achieved	O
with	O
sodium	B-Chemical
valproate	I-Chemical
,	O
lamotrigine	B-Chemical
,	O
or	O
ethosuximide	B-Chemical
alone	O
or	O
in	O
combination	O
.	O
Choreoathetoid	B-Disease
movements	I-Disease
associated	O
with	O
rapid	O
adjustment	O
to	O
methadone	B-Chemical
.	O
Choreatiform	B-Disease
hyperkinesias	I-Disease
are	O
known	O
to	O
be	O
occasional	O
movement	B-Disease
abnormalities	I-Disease
during	O
intoxications	O
with	O
cocaine	B-Chemical
but	O
not	O
opiates	O
.	O
This	O
is	O
a	O
case	O
report	O
of	O
euphoria	O
and	O
choreoathetoid	B-Disease
movements	I-Disease
both	O
transiently	O
induced	O
by	O
rapid	O
adjustment	O
to	O
the	O
selective	O
mu	O
-	O
opioid	O
receptor	O
agonist	O
methadone	B-Chemical
in	O
an	O
inpatient	O
previously	O
abusing	O
heroine	B-Chemical
and	O
cocaine	B-Chemical
.	O
In	O
addition	O
,	O
minor	O
EEG	O
abnormalities	O
occurred	O
.	O
Possible	O
underlying	O
neurobiological	O
phenomena	O
are	O
discussed	O
.	O
Adverse	O
effects	O
of	O
the	O
atypical	O
antipsychotics	O
.	O
Collaborative	O
Working	O
Group	O
on	O
Clinical	O
Trial	O
Evaluations	O
.	O
Adverse	O
effects	O
of	O
antipsychotics	O
often	O
lead	O
to	O
noncompliance	O
.	O
Thus	O
,	O
clinicians	O
should	O
address	O
patients	O
'	O
concerns	O
about	O
adverse	O
effects	O
and	O
attempt	O
to	O
choose	O
medications	O
that	O
will	O
improve	O
their	O
patients	O
'	O
quality	O
of	O
life	O
as	O
well	O
as	O
overall	O
health	O
.	O
The	O
side	O
effect	O
profiles	O
of	O
the	O
atypical	O
antipsychotics	O
are	O
more	O
advantageous	O
than	O
those	O
of	O
the	O
conventional	O
neuroleptics	O
.	O
Conventional	O
agents	O
are	O
associated	O
with	O
unwanted	O
central	O
nervous	O
system	O
effects	O
,	O
including	O
extrapyramidal	B-Disease
symptoms	I-Disease
(	O
EPS	B-Disease
)	O
,	O
tardive	B-Disease
dyskinesia	I-Disease
,	O
sedation	O
,	O
and	O
possible	O
impairment	O
of	O
some	O
cognitive	O
measures	O
,	O
as	O
well	O
as	O
cardiac	O
effects	O
,	O
orthostatic	B-Disease
hypotension	I-Disease
,	O
hepatic	O
changes	O
,	O
anticholinergic	O
side	O
effects	O
,	O
sexual	B-Disease
dysfunction	I-Disease
,	O
and	O
weight	B-Disease
gain	I-Disease
.	O
The	O
newer	O
atypical	O
agents	O
have	O
a	O
lower	O
risk	O
of	O
EPS	B-Disease
,	O
but	O
are	O
associated	O
in	O
varying	O
degrees	O
with	O
sedation	O
,	O
cardiovascular	O
effects	O
,	O
anticholinergic	O
effects	O
,	O
weight	B-Disease
gain	I-Disease
,	O
sexual	B-Disease
dysfunction	I-Disease
,	O
hepatic	O
effects	O
,	O
lowered	O
seizure	B-Disease
threshold	O
(	O
primarily	O
clozapine	B-Chemical
)	O
,	O
and	O
agranulocytosis	B-Disease
(	O
clozapine	B-Chemical
only	O
)	O
.	O
Since	O
the	O
incidence	O
and	O
severity	O
of	O
specific	O
adverse	O
effects	O
differ	O
among	O
the	O
various	O
atypicals	O
,	O
the	O
clinician	O
should	O
carefully	O
consider	O
which	O
side	O
effects	O
are	O
most	O
likely	O
to	O
lead	O
to	O
the	O
individual	O
'	O
s	O
dissatisfaction	O
and	O
noncompliance	O
before	O
choosing	O
an	O
antipsychotic	O
for	O
a	O
particular	O
patient	O
.	O
A	O
randomized	O
,	O
placebo	O
-	O
controlled	O
dose	O
-	O
comparison	O
trial	O
of	O
haloperidol	B-Chemical
for	O
psychosis	B-Disease
and	O
disruptive	B-Disease
behaviors	I-Disease
in	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
OBJECTIVE	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
side	O
effects	O
of	O
two	O
doses	O
of	O
haloperidol	B-Chemical
and	O
placebo	O
in	O
the	O
treatment	O
of	O
psychosis	B-Disease
and	O
disruptive	B-Disease
behaviors	I-Disease
in	O
patients	O
with	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
METHOD	O
:	O
In	O
a	O
6	O
-	O
week	O
random	O
-	O
assignment	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
(	O
phase	O
A	O
)	O
,	O
haloperidol	B-Chemical
,	O
2	O
-	O
3	O
mg	O
/	O
day	O
(	O
standard	O
dose	O
)	O
,	O
and	O
haloperidol	B-Chemical
,	O
0	O
.	O
50	O
-	O
0	O
.	O
75	O
mg	O
/	O
day	O
(	O
low	O
dose	O
)	O
,	O
were	O
compared	O
in	O
71	O
outpatients	O
with	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
For	O
the	O
subsequent	O
6	O
-	O
week	O
double	O
-	O
blind	O
crossover	O
phase	O
(	O
phase	O
B	O
)	O
,	O
patients	O
taking	O
standard	O
-	O
or	O
low	O
-	O
dose	O
haloperidol	B-Chemical
were	O
switched	O
to	O
placebo	O
,	O
and	O
patients	O
taking	O
placebo	O
were	O
randomly	O
assigned	O
to	O
standard	O
-	O
or	O
low	O
-	O
dose	O
haloperidol	B-Chemical
.	O
RESULTS	O
:	O
For	O
the	O
60	O
patients	O
who	O
completed	O
phase	O
A	O
,	O
standard	O
-	O
dose	O
haloperidol	B-Chemical
was	O
efficacious	O
and	O
superior	O
to	O
both	O
low	O
-	O
dose	O
haloperidol	B-Chemical
and	O
placebo	O
for	O
scores	O
on	O
the	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
psychosis	B-Disease
factor	O
and	O
on	O
psychomotor	B-Disease
agitation	I-Disease
.	O
Response	O
rates	O
according	O
to	O
three	O
sets	O
of	O
criteria	O
were	O
greater	O
with	O
the	O
standard	O
dose	O
(	O
55	O
%	O
-	O
60	O
%	O
)	O
than	O
the	O
low	O
dose	O
(	O
25	O
%	O
-	O
35	O
%	O
)	O
and	O
placebo	O
(	O
25	O
%	O
-	O
30	O
%	O
)	O
.	O
The	O
advantage	O
of	O
standard	O
dose	O
over	O
low	O
dose	O
was	O
replicated	O
in	O
phase	O
B	O
.	O
In	O
phase	O
A	O
,	O
extrapyramidal	B-Disease
signs	I-Disease
tended	O
to	O
be	O
greater	O
with	O
the	O
standard	O
dose	O
than	O
in	O
the	O
other	O
two	O
conditions	O
,	O
primarily	O
because	O
of	O
a	O
subgroup	O
(	O
20	O
%	O
)	O
who	O
developed	O
moderate	O
to	O
severe	O
signs	O
.	O
Low	O
-	O
dose	O
haloperidol	B-Chemical
did	O
not	O
differ	O
from	O
placebo	O
on	O
any	O
measure	O
of	O
efficacy	O
or	O
side	O
effects	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
indicated	O
a	O
favorable	O
therapeutic	O
profile	O
for	O
haloperidol	B-Chemical
in	O
doses	O
of	O
2	O
-	O
3	O
mg	O
/	O
day	O
,	O
although	O
a	O
subgroup	O
developed	O
moderate	O
to	O
severe	O
extrapyramidal	B-Disease
signs	I-Disease
.	O
A	O
starting	O
dose	O
of	O
1	O
mg	O
/	O
day	O
with	O
gradual	O
,	O
upward	O
dose	O
titration	O
is	O
recommended	O
.	O
The	O
narrow	O
therapeutic	O
window	O
observed	O
with	O
haloperidol	B-Chemical
may	O
also	O
apply	O
to	O
other	O
neuroleptics	O
used	O
in	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
with	O
psychosis	B-Disease
and	O
disruptive	B-Disease
behaviors	I-Disease
.	O
Effects	O
of	O
acetylsalicylic	B-Chemical
acid	I-Chemical
,	O
dipyridamole	B-Chemical
,	O
and	O
hydrocortisone	B-Chemical
on	O
epinephrine	B-Chemical
-	O
induced	O
myocardial	B-Disease
injury	I-Disease
in	O
dogs	O
.	O
A	O
reproducible	O
model	O
for	O
producing	O
diffuse	O
myocardial	B-Disease
injury	I-Disease
(	O
epinephrine	B-Chemical
infusion	O
)	O
has	O
been	O
developed	O
to	O
study	O
the	O
cardioprotective	O
effects	O
of	O
agents	O
or	O
maneuvers	O
which	O
might	O
alter	O
the	O
evolution	O
of	O
acute	O
myocardial	B-Disease
infarction	I-Disease
.	O
Infusions	O
of	O
epinephrine	B-Chemical
(	O
4	O
mug	O
per	O
kilogram	O
per	O
minute	O
for	O
6	O
hours	O
)	O
increased	O
radiocalcium	B-Chemical
uptakes	O
into	O
intact	O
myocardium	O
and	O
each	O
of	O
its	O
subcellular	O
components	O
with	O
the	O
mitochondrial	O
fraction	O
showing	O
the	O
most	O
consistent	O
changes	O
when	O
compared	O
to	O
saline	O
-	O
infused	O
control	O
animals	O
(	O
4	O
,	O
957	O
vs	O
.	O
827	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
tissue	O
or	O
fraction	O
)	O
.	O
Myocardial	O
concentrations	O
of	O
calcium	B-Chemical
also	O
increased	O
significantly	O
(	O
12	O
.	O
0	O
vs	O
.	O
5	O
.	O
0	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
weight	O
)	O
.	O
Infusions	O
of	O
calcium	B-Chemical
chloride	I-Chemical
sufficient	O
to	O
raise	O
serum	O
calcium	B-Chemical
concentrations	O
2	O
mEq	O
.	O
per	O
liter	O
failed	O
to	O
increase	O
calcium	B-Chemical
influx	O
into	O
the	O
myocardial	O
cell	O
.	O
Mitochondrial	O
radiocalcium	B-Chemical
uptakes	O
were	O
significantly	O
decreased	O
in	O
animals	O
pretreated	O
with	O
acetylsalicylic	B-Chemical
acid	I-Chemical
or	O
dipyridamole	B-Chemical
or	O
when	O
hydrocortisone	B-Chemical
was	O
added	O
to	O
the	O
epinephrine	B-Chemical
infusion	O
(	O
2	O
,	O
682	O
,	O
2	O
,	O
803	O
,	O
and	O
3	O
,	O
424	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
fraction	O
,	O
respectively	O
)	O
.	O
Myocardial	O
calcium	B-Chemical
concentrations	O
also	O
were	O
decreased	O
(	O
11	O
.	O
2	O
,	O
8	O
.	O
3	O
,	O
and	O
8	O
.	O
9	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
weight	O
,	O
respectively	O
)	O
in	O
the	O
three	O
treatment	O
groups	O
,	O
being	O
significantly	O
decreased	O
only	O
in	O
the	O
last	O
two	O
.	O
Evidence	O
of	O
microscopic	O
damage	O
was	O
graded	O
as	O
less	O
severe	O
in	O
the	O
three	O
treatment	O
groups	O
.	O
Acetylsalicylic	B-Chemical
acid	I-Chemical
,	O
dipyridamole	B-Chemical
,	O
and	O
hydrocortisone	B-Chemical
all	O
appear	O
to	O
have	O
cardioprotective	O
effects	O
when	O
tested	O
in	O
this	O
model	O
.	O
Clinical	O
and	O
histopathologic	O
examination	O
of	O
renal	O
allografts	O
treated	O
with	O
tacrolimus	B-Chemical
(	O
FK506	B-Chemical
)	O
for	O
at	O
least	O
one	O
year	O
.	O
BACKGROUND	O
:	O
We	O
clinically	O
and	O
pathologically	O
analyzed	O
renal	O
allografts	O
from	O
1	O
9	O
renal	O
transplant	O
patients	O
treated	O
with	O
tacrolimus	B-Chemical
(	O
FK506	B-Chemical
)	O
for	O
more	O
than	O
1	O
year	O
.	O
METHODS	O
:	O
Twenty	O
-	O
six	O
renal	O
allograft	O
biopsy	O
specimens	O
from	O
1	O
9	O
renal	O
transplant	O
patients	O
who	O
underwent	O
transplantations	O
between	O
1991	O
and	O
1993	O
were	O
evaluated	O
.	O
Thirteen	O
biopsies	O
were	O
performed	O
from	O
stable	O
functioning	O
renal	O
allografts	O
with	O
informed	O
consent	O
(	O
nonepisode	O
biopsy	O
)	O
and	O
the	O
other	O
13	O
were	O
from	O
dysfunctional	O
renal	O
allografts	O
with	O
a	O
clinical	O
indication	O
for	O
biopsy	O
(	O
episode	O
biopsy	O
)	O
.	O
RESULTS	O
:	O
The	O
main	O
pathologic	O
diagnoses	O
(	O
some	O
overlap	O
)	O
were	O
acute	O
rejection	O
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
chronic	O
rejection	O
(	O
CR	O
;	O
n	O
=	O
5	O
)	O
,	O
AR	O
+	O
CR	O
(	O
n	O
=	O
4	O
)	O
,	O
recurrent	O
IgA	B-Disease
nephropathy	I-Disease
(	O
n	O
=	O
5	O
)	O
,	O
normal	O
findings	O
(	O
n	O
=	O
2	O
)	O
,	O
minimal	O
-	O
type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
(	O
n	O
=	O
9	O
)	O
,	O
and	O
mild	O
-	O
type	O
FK506	B-Chemical
nephropathy	B-Disease
(	O
n	O
=	O
11	O
)	O
.	O
Of	O
the	O
nonepisode	O
biopsies	O
,	O
7	O
and	O
4	O
biopsies	O
showed	O
minimal	O
-	O
type	O
and	O
mild	O
-	O
type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
,	O
respectively	O
.	O
Chronic	O
FK506	B-Chemical
nephropathy	B-Disease
consisted	O
of	O
rough	O
and	O
foamy	O
tubular	O
vacuolization	O
(	O
5	O
biopsies	O
)	O
,	O
arteriolopathy	O
(	O
angiodegeneration	O
of	O
the	O
arteriolar	O
wall	O
;	O
20	O
biopsies	O
)	O
,	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
(	O
4	O
biopsies	O
)	O
and	O
the	O
striped	O
form	O
of	O
interstitial	B-Disease
fibrosis	I-Disease
(	O
11	O
biopsies	O
)	O
.	O
The	O
serum	O
creatinine	B-Chemical
levels	O
of	O
patients	O
in	O
the	O
mild	O
-	O
type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
group	O
,	O
which	O
included	O
7	O
episode	O
biopsies	O
,	O
were	O
statistically	O
higher	O
than	O
those	O
in	O
the	O
minimum	O
-	O
type	O
chronic	O
FK506	B-Chemical
-	O
nephropathy	B-Disease
group	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
consists	O
primarily	O
of	O
arteriolopathy	O
manifesting	O
as	O
insudative	O
hyalinosis	O
of	O
the	O
arteriolar	O
wall	O
,	O
and	O
suggests	O
that	O
mild	O
-	O
type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
is	O
a	O
condition	O
which	O
may	O
lead	O
to	O
deterioration	O
of	O
renal	O
allograft	O
function	O
.	O
Different	O
lobular	O
distributions	O
of	O
altered	O
hepatocyte	O
tight	O
junctions	O
in	O
rat	O
models	O
of	O
intrahepatic	B-Disease
and	I-Disease
extrahepatic	I-Disease
cholestasis	I-Disease
.	O
Hepatocyte	O
tight	O
junctions	O
(	O
TJs	O
)	O
,	O
the	O
only	O
intercellular	O
barrier	O
between	O
the	O
sinusoidal	O
and	O
the	O
canalicular	O
spaces	O
,	O
play	O
a	O
key	O
role	O
in	O
bile	O
formation	O
.	O
Although	O
hepatocyte	O
TJs	O
are	O
impaired	O
in	O
cholestasis	B-Disease
,	O
attempts	O
to	O
localize	O
the	O
precise	O
site	O
of	O
hepatocyte	O
TJ	O
damage	O
by	O
freeze	O
-	O
fracture	O
electron	O
microscopy	O
have	O
produced	O
limited	O
information	O
.	O
Recently	O
,	O
several	O
TJ	O
-	O
associated	O
proteins	O
like	O
ZO	O
-	O
1	O
and	O
7H6	O
have	O
been	O
identified	O
and	O
characterized	O
.	O
Immunolocalization	O
of	O
7H6	O
appears	O
to	O
closely	O
correlate	O
with	O
paracellular	O
permeability	O
.	O
We	O
used	O
rat	O
models	O
of	O
intrahepatic	B-Disease
cholestasis	I-Disease
by	O
ethinyl	B-Chemical
estradiol	I-Chemical
(	O
EE	B-Chemical
)	O
treatment	O
and	O
extrahepatic	B-Disease
cholestasis	I-Disease
by	O
bile	O
duct	O
ligation	O
(	O
BDL	O
)	O
to	O
precisely	O
determine	O
the	O
site	O
of	O
TJ	O
damage	O
.	O
Alterations	O
in	O
hepatocyte	O
TJs	O
were	O
assessed	O
by	O
double	O
-	O
immunolabeling	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
using	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
.	O
In	O
control	O
rats	O
,	O
immunostaining	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
colocalized	O
to	O
outline	O
bile	O
canaliculi	O
in	O
a	O
continuous	O
fashion	O
.	O
In	O
contrast	O
,	O
7H6	O
and	O
ZO	O
-	O
1	O
immunostaining	O
was	O
more	O
discontinuous	O
,	O
outlining	O
the	O
bile	O
canaliculi	O
after	O
BDL	O
.	O
Immunostaining	O
for	O
7H6	O
,	O
not	O
ZO	O
-	O
1	O
,	O
decreased	O
and	O
predominantly	O
appeared	O
as	O
discrete	O
signals	O
in	O
the	O
submembranous	O
cytoplasm	O
of	O
periportal	O
hepatocytes	O
after	O
BDL	O
.	O
After	O
EE	B-Chemical
treatment	O
,	O
changes	O
in	O
immunostaining	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
were	O
similar	O
to	O
those	O
seen	O
in	O
periportal	O
hepatocytes	O
after	O
BDL	O
,	O
but	O
distributed	O
more	O
diffusely	O
throughout	O
the	O
lobule	O
.	O
This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
impairment	O
of	O
hepatocyte	O
TJs	O
occurs	O
heterogenously	O
in	O
the	O
liver	O
lobule	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	B-Chemical
treatments	O
produce	O
different	O
lobular	O
distributions	O
of	O
increased	O
paracellular	O
permeability	O
.	O
Memory	O
facilitation	O
and	O
stimulation	O
of	O
endogenous	O
nerve	O
growth	O
factor	O
synthesis	O
by	O
the	O
acetylcholine	B-Chemical
releaser	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
.	O
The	O
effects	O
of	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
3alpha	B-Chemical
-	I-Chemical
tropyl	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
bromophenyl	I-Chemical
)	I-Chemical
propionate	I-Chemical
)	O
,	O
the	O
acetylcholine	B-Chemical
releaser	O
,	O
on	O
memory	O
processes	O
and	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
synthesis	O
were	O
evaluated	O
.	O
In	O
the	O
mouse	O
passive	O
-	O
avoidance	O
test	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
administered	O
20	O
min	O
before	O
the	O
training	O
session	O
,	O
prevented	O
amnesia	B-Disease
induced	O
by	O
both	O
the	O
non	O
selective	O
antimuscarinic	O
drug	O
scopolamine	B-Chemical
and	O
the	O
M1	O
-	O
selective	O
antagonist	O
S	B-Chemical
-	I-Chemical
(	I-Chemical
-	I-Chemical
)	I-Chemical
-	I-Chemical
ET	I-Chemical
-	I-Chemical
126	I-Chemical
.	O
In	O
the	O
same	O
experimental	O
conditions	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
5	O
-	O
20	O
microg	O
per	O
mouse	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
also	O
able	O
to	O
prevent	O
antimuscarine	O
-	O
induced	O
amnesia	B-Disease
,	O
demonstrating	O
a	O
central	O
localization	O
of	O
the	O
activity	O
.	O
At	O
the	O
highest	O
effective	O
doses	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
did	O
not	O
produce	O
any	O
collateral	O
symptoms	O
as	O
revealed	O
by	O
the	O
Irwin	O
test	O
,	O
and	O
it	O
did	O
not	O
modify	O
spontaneous	O
motility	O
and	O
inspection	O
activity	O
,	O
as	O
revealed	O
by	O
the	O
hole	O
-	O
board	O
test	O
.	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
was	O
also	O
able	O
to	O
increase	O
the	O
amount	O
of	O
NGF	O
secreted	O
in	O
vitro	O
by	O
astrocytes	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
The	O
maximal	O
NGF	O
contents	O
obtained	O
by	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
were	O
17	O
.	O
6	O
-	O
fold	O
of	O
the	O
control	O
value	O
.	O
During	O
culture	O
,	O
no	O
morphological	O
changes	O
were	O
found	O
at	O
effective	O
concentrations	O
of	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
.	O
The	O
current	O
work	O
indicates	O
the	O
ability	O
of	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
to	O
induce	O
beneficial	O
effects	O
on	O
cognitive	O
processes	O
and	O
stimulate	O
activity	O
of	O
NGF	O
synthesis	O
in	O
astroglial	O
cells	O
.	O
Therefore	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
could	O
represent	O
a	O
potential	O
useful	O
drug	O
able	O
to	O
improve	O
the	O
function	O
of	O
impaired	O
cognitive	O
processes	O
.	O
Mechanisms	O
of	O
FK	B-Chemical
506	I-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
the	O
rat	O
.	O
-	O
Tacrolimus	B-Chemical
(	O
FK	B-Chemical
506	I-Chemical
)	O
is	O
a	O
powerful	O
,	O
widely	O
used	O
immunosuppressant	O
.	O
The	O
clinical	O
utility	O
of	O
FK	B-Chemical
506	I-Chemical
is	O
complicated	O
by	O
substantial	O
hypertension	B-Disease
and	O
nephrotoxicity	B-Disease
.	O
To	O
clarify	O
the	O
mechanisms	O
of	O
FK	B-Chemical
506	I-Chemical
-	O
induced	O
hypertension	B-Disease
,	O
we	O
studied	O
the	O
chronic	O
effects	O
of	O
FK	B-Chemical
506	I-Chemical
on	O
the	O
synthesis	O
of	O
endothelin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
,	O
the	O
expression	O
of	O
mRNA	O
of	O
ET	O
-	O
1	O
and	O
endothelin	O
-	O
converting	O
enzyme	O
-	O
1	O
(	O
ECE	O
-	O
1	O
)	O
,	O
the	O
endothelial	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
(	O
eNOS	O
)	O
activity	O
,	O
and	O
the	O
expression	O
of	O
mRNA	O
of	O
eNOS	O
and	O
C	O
-	O
type	O
natriuretic	O
peptide	O
(	O
CNP	O
)	O
in	O
rat	O
blood	O
vessels	O
.	O
In	O
addition	O
,	O
the	O
effect	O
of	O
the	O
specific	O
endothelin	O
type	O
A	O
receptor	O
antagonist	O
FR	B-Chemical
139317	I-Chemical
on	O
FK	B-Chemical
506	I-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rats	O
was	O
studied	O
.	O
FK	B-Chemical
506	I-Chemical
,	O
5	O
mg	O
.	O
kg	O
-	O
1	O
.	O
d	O
-	O
1	O
given	O
for	O
4	O
weeks	O
,	O
elevated	O
blood	O
pressure	O
from	O
102	O
+	O
/	O
-	O
13	O
to	O
152	O
+	O
/	O
-	O
15	O
mm	O
Hg	O
and	O
increased	O
the	O
synthesis	O
of	O
ET	O
-	O
1	O
and	O
the	O
levels	O
of	O
ET	O
-	O
1	O
mRNA	O
in	O
the	O
mesenteric	O
artery	O
(	O
240	O
%	O
and	O
230	O
%	O
,	O
respectively	O
)	O
.	O
Little	O
change	O
was	O
observed	O
in	O
the	O
expression	O
of	O
ECE	O
-	O
1	O
mRNA	O
and	O
CNP	O
mRNA	O
.	O
FK	B-Chemical
506	I-Chemical
decreased	O
eNOS	O
activity	O
and	O
the	O
levels	O
of	O
eNOS	O
mRNA	O
in	O
the	O
aorta	O
(	O
48	O
%	O
and	O
55	O
%	O
,	O
respectively	O
)	O
.	O
The	O
administration	O
of	O
FR	B-Chemical
139317	I-Chemical
(	O
10	O
mg	O
.	O
kg	O
-	O
1	O
.	O
d	O
-	O
1	O
)	O
prevented	O
FK	B-Chemical
506	I-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rats	O
.	O
These	O
results	O
indicate	O
that	O
FK	B-Chemical
506	I-Chemical
may	O
increase	O
blood	O
pressure	O
not	O
only	O
by	O
increasing	O
ET	O
-	O
1	O
production	O
but	O
also	O
by	O
decreasing	O
NO	B-Chemical
synthesis	O
in	O
the	O
vasculature	O
.	O
